site,doi,date,link,title,authors,affiliations,abstract,category,match_type,author_similarity,affiliation_similarity
medRxiv,10.1101/2023.05.31.23290774,2023-06-05,https://medrxiv.org/cgi/content/short/2023.05.31.23290774,POST-COVID ORTHOPAEDIC ELECTIVE RESOURCE PLANNING USING SIMULATION MODELLING,Alison Harper; Thomas Monks; Rebecca Wilson; Maria Theresa Redaniel; Emily Eyles; Timothy Jones; Chris Penfold; Andrew Elliott; Tim Keen; Martin Pitt; Ashley Blom; Michael Whitehouse; Andrew Judge,University of Exeter; University of Exeter; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; North Bristol NHS Foundation Trust; North Bristol NHS Foundation Trust; University of Exeter; University of Sheffield; University of Bristol; University of Bristol,"ObjectivesTo develop a simulation model to support orthopaedic elective capacity planning.

MethodsAn open-source, generalisable discrete-event simulation was developed, including a web-based application. The model used anonymised patient records between 2016-2019 of elective orthopaedic procedures from an NHS Trust in England. In this paper, it is used to investigate scenarios including resourcing (beds and theatres) and productivity (lengths-of-stay, delayed discharges, theatre activity) to support planning for meeting new NHS targets aimed at reducing elective orthopaedic surgical backlogs in a proposed ring fenced orthopaedic surgical facility. The simulation is interactive and intended for use by health service planners and clinicians.

ResultsA higher number of beds (65-70) than the proposed number (40 beds) will be required if lengths-of-stay and delayed discharge rates remain unchanged. Reducing lengths-of-stay in line with national benchmarks reduces bed utilisation to an estimated 60%, allowing for additional theatre activity such as weekend working. Further, reducing the proportion of patients with a delayed discharge by 75% reduces bed utilisation to below 40%, even with weekend working. A range of other scenarios can also be investigated directly by NHS planners using the interactive web app.

ConclusionsThe simulation model is intended to support capacity planning of orthopaedic elective services by identifying a balance of capacity across theatres and beds and predicting the impact of productivity measures on capacity requirements. It is applicable beyond the study site and can be adapted for other specialties.

Strengths and Limitations of this studyO_LIThe simulation model provides rapid quantitative estimates to support post-COVID elective services recovery toward medium-term elective targets.
C_LIO_LIParameter combinations include changes to both resourcing and productivity.
C_LIO_LIThe interactive web app enables intuitive parameter changes by users while underlying source code can be adapted or re-used for similar applications.
C_LIO_LIPatient attributes such as complexity are not included in the model but are reflected in variables such as length-of-stay and delayed discharge rates.
C_LIO_LITheatre schedules are simplified, incorporating the five key orthopaedic elective surgical procedures.
C_LI",orthopedics,fuzzy,100,100
medRxiv,10.1101/2023.05.23.23290354,2023-05-28,https://medrxiv.org/cgi/content/short/2023.05.23.23290354,Long COVID and financial outcomes: Evidence from four longitudinal population surveys,Rebecca Rhead; Jacques Wels; Bettina Moltrecht; Richard John Shaw; Richard John Silverwood; Jingmin Zhu; Alun Hughes; Nishi Chaturvedi; Evangelia Demou; Srinivasa Vittal Katikireddi; George Ploubidis,King's College London Institute of Psychiatry Psychology and Neuroscience; University College London; University College London; University of Glasgow; University College London; University College London; UCL; University College London; University of Glasgow; University of Glasgow; University College London,"BackgroundLong-term sequelae of COVID-19 (long COVID) include muscle weakness, fatigue, breathing difficulties and sleep disturbance over weeks or months. Using UK longitudinal data, we assessed the relationship between long COVID and financial disruption.

MethodsWe estimated associations between long COVID (derived using self-reported length of COVID-19 symptoms) and measures of financial disruption (subjective financial well-being, new benefit claims, changes in household income) by analysing data from four longitudinal population studies, gathered during the first year of the pandemic. We employed modified Poisson regression in a pooled analysis of the four cohorts adjusting for a range of potential confounders, including pre-pandemic (pre-long COVID) factors.

ResultsAmong 20,112 observations across four population surveys, 13% reported having COVID-19 with symptoms that impeded their ability to function normally - 10.7% had such symptoms for <4 weeks (acute COVID-19), 1.2% had such symptoms for 4-12 weeks (ongoing symptomatic COVID-19) and 0.6% had such symptoms for >12 weeks (post-COVID-19 syndrome). We found that post-COVID-19 syndrome was associated with worse subjective financial well-being (adjusted relative risk ratios (aRRR)=1.57, 95% confidence interval (CI)=1.25, 1.96) and new benefit claims (aRRR=1.79, CI=1.27, 2.53). Associations were broadly similar across sexes and education levels. These results were not meaningfully altered when scaled to represent the population by age.

ConclusionsLong COVID was associated with financial disruption in the UK. If our findings reflect causal effects, extending employment protection and financial support to people with long COVID may be warranted.",public and global health,fuzzy,100,100
bioRxiv,10.1101/2023.05.24.541920,2023-05-25,https://biorxiv.org/cgi/content/short/2023.05.24.541920,"Dichotomy of neutralizing antibody, B cell and T cell responses to SARS-CoV-2 vaccination and protection in healthy adults",Edward J Carr; Hermaleigh Townsley; Mary Y Wu; Katalin A Wilkinson; Philip S Hobson; Dina Levi; Sina Namjou; Harriet V Mears; Agnieszka Hobbs; Martina Ragno; Lou S Herman; Ruth Harvey; Chris Bailey; Ashley S Fowler; Emine Hatipoglu; Yenting Ngai; Bobbi Clayton; Murad Miah; Philip Bawumia; Mauro Miranda; Callie Smith; Chelsea Sawyer; Gavin Kelly; Viyaasan Mahalingasivam; Bang Zheng; Stephen JW Evans; Vincenzo Libri; Andrew Riddell; Jerome Nicod; Nicola O'Reilly; Michael Howell; Bryan Williams; Robert J Wilkinson; George Kassiotis; Charles Swanton; Sonia Gandhi; Rupert CL Beale; David LV Bauer; Emma C Wall,The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; Worldwide Influenza Centre; The Francis Crick Institute; The Francis Crick Institute; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; UCL; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute,"Heterogeneity in SARS-CoV-2 vaccine responses is not understood. Here, we identify four patterns of live-virus neutralizing antibody responses: individuals with hybrid immunity (with confirmed prior infection); rare individuals with low responses (paucity of S1-binding antibodies); and surprisingly, two further groups with distinct serological repertoires. One group - broad responders - neutralize a range of SARS-CoV-2 variants, whereas the other - narrow responders - neutralize fewer, less divergent variants. This heterogeneity does not correlate with Ancestral S1-binding antibody, rather the quality of the serological response. Furthermore, IgDlowCD27-CD137+ B cells and CCR6+ CD4+ T cells are enriched in broad responders before dose 3. Notably, broad responders have significantly longer infection-free time after their third dose. Understanding the control and persistence of these serological profiles could allow personalized approaches to enhance serological breadth after vaccination.",immunology,fuzzy,100,100
medRxiv,10.1101/2023.05.23.23289798,2023-05-24,https://medrxiv.org/cgi/content/short/2023.05.23.23289798,Primary Care Post-COVID syndrome Diagnosis and Referral Coding,Robert Willans; Gail Allsopp; Pall Jonsson; Fiona Glen; Felix Greaves; John Macleod; Yinghui Wei; Sebastian Bacon; Amir Mehrkar; Alex Walker; Brian MacKenna; Louis Fisher; Ben Goldacre; - The OpenSAFELY Collaborative; - The CONVALESCENCE Collaborative,"National Institute of Health and Care Excellence; Royal College of General Practitioners; National Institute of Health and Care Excellence; National Institute of Health and Care Excellence; National Institute of Health and Care Excellence; University of Bristol; University of Plymouth; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford; ; ","IntroductionGuidelines for diagnosing and managing Post-COVID syndrome have been rapidly developed. Consistency of the application of these guidelines in primary care is unknown. Electronic health records provide an opportunity to review the use of codes relating to Post-COVID syndrome. This paper explores the use of primary care records as a surrogate uptake measure for NICEs rapid guideline ""managing the long-term effects of COVID-19"" by measuring the use of Post-COVID syndrome diagnosis and referral codes in the pathway.

MethodWith the approval of NHS England we used routine clinical data from the OpenSafely-EMIS/-TPP platforms. Counts of Post-COVID syndrome diagnosis and referral codes were generated from a cohort of all adults, establishing numbers of diagnoses and referrals following diagnosis. The relationship between Post-COVID syndrome diagnosis and referral codes was explored with reference to NICEs rapid guideline.

ResultsOf over 45 million patients, 69,220 (0.15%) had a Post-COVID syndrome diagnostic code, and 67,741 (0.15%) had a referral code. 78% of referral codes did not have an associated diagnosis code. 79% of diagnosis codes had no subsequent referral code. Only 18,633 (0.04%) had both. There were higher rates of both diagnosis and referral in those who were more deprived, female and some ethnic groups.

DiscussionThis study demonstrates variation in diagnosis and referral coding rates for Post-COVID syndrome across different patient groups. The results, with limited crossover of referral and diagnostic codes, suggest only one type of code is usually recorded. Recording one code limits the use of routine data for monitoring Post-COVID syndrome diagnosis and management, but suggests several areas for improvement in coding. Post-COVID syndrome coding, particularly diagnosis coding, needs to improve before administrators and researchers can use it to evaluate care pathways.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.05.17.23290105,2023-05-24,https://medrxiv.org/cgi/content/short/2023.05.17.23290105,Within-host SARS-CoV-2 viral kinetics informed by complex life course exposures reveals different intrinsic properties of Omicron and Delta variants,Timothy W Russell; Hermaleigh Townsley; Sam Abbott; Joel Hellewell; Edward J Carr; Lloyd Chapman; Rachael Pung; Billy J Quilty; David Hodgson; Ashley Fowler; Lorin Adams; Christopher Bailey; Harriet V Mears; Ruth Harvey; Bobbi Clayton; Nicola O'Reilly; Yenting Ngai; Jerome Nicod; Steve Gamblin; Bryan Williams; Sonia Gandhi; Charles Swanton; Rupert Beale; David LV Bauer; Emma C Wall; Adam Kucharski,London School of Hygiene and Tropical Medicine; The Francis Crick Institute; London School of Hygiene and Tropical Medicine; European Molecular Biology Laboratory; The Francis Crick Institute; Lancaster University; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; National Institute for Health Research (NIHR) University College London Hospitals (UCLH); The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; The Francis Crick Institute; London School of Hygiene and Tropical Medicine,"The emergence of successive SARS-CoV-2 variants of concern (VOC) during 2020-22, each exhibiting increased epidemic growth relative to earlier circulating variants, has created a need to understand the drivers of such growth. However, both pathogen biology and changing host characteristics - such as varying levels of immunity - can combine to influence replication and transmission of SARS-CoV-2 within and between hosts. Disentangling the role of variant and host in individual-level viral shedding of VOCs is essential to inform COVID-19 planning and response, and interpret past epidemic trends. Using data from a prospective observational cohort study of healthy adult volunteers undergoing weekly occupational health PCR screening, we developed a Bayesian hierarchical model to reconstruct individual-level viral kinetics and estimate how different factors shaped viral dynamics, measured by PCR cycle threshold (Ct) values over time. Jointly accounting for both inter-individual variation in Ct values and complex host characteristics - such as vaccination status, exposure history and age - we found that age and number of prior exposures had a strong influence on peak viral replication. Older individuals and those who had at least five prior antigen exposures to vaccination and/or infection typically had much lower levels of shedding. Moreover, we found evidence of a correlation between the speed of early shedding and duration of incubation period when comparing different VOCs and age groups. Our findings illustrate the value of linking information on participant characteristics, symptom profile and infecting variant with prospective PCR sampling, and the importance of accounting for increasingly complex population exposure landscapes when analysing the viral kinetics of VOCs.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.05.08.23289442,2023-05-11,https://medrxiv.org/cgi/content/short/2023.05.08.23289442,Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID),Omer Elneima; Hamish J C McAuley; Olivia C Leavy; James D Chalmers; Alex Horsley; Ling-Pei Ho; Michael Marks; Krisnah Poinasamy; Betty Raman; Aarti Shikotra; Amisha Singapuri; Marco Sereno; Victoria C Harris; Linzy Houchen-Wolloff; Ruth M Saunders; Neil J Greening; Matthew Richardson; Jennifer K Quint; Andrew Briggs; Annemarie B Docherty; Steven Kerr; Ewen M Harrison; Nazir I Lone; Mathew Thorpe; Liam G Heaney; Keir E Lewis; Raminder Aul; Paul Beirne; Charlotte E Bolton; Jeremy S Brown; Gourab Choudhury; Nawar Diar Bakerly; Nicholas Easom; Carlos Echevarria; Jonathan Fuld; Nick Hart; John R Hurst; Mark G Jones; Dhruv Parekh; Paul E Pfeffer; Najib M Rahman; Sarah L Rowland-Jones; AA Roger Thompson; Caroline Jolley; Ajay M Shah; Dan G Wootton; Trudie Chalder; Melanie J Davies; Anthony De Soyza; John R Geddes; William Greenhalf; Simon Heller; Luke S Howard; Joseph Jacob; R Gisli Jenkins; Janet M Lord; William D-C Man; Gerry P McCann; Stefan Neubauer; Peter JM Openshaw; Joanna C Porter; Matthew J Rowland; Janet T Scott; Malcolm G Semple; Sally J Singh; David C Thomas; Mark Toshner; Aziz Sheikh; Chris E Brightling; Louise v Wain; Rachael A Evans; - on behalf of the PHOSP-COVID Collaborative Group,"The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; Department of Population Health Sciences, University of Leicester, Leicester, UK; University of Dundee, Ninewells Hospital and Medical School, Dundee, UK; Division of Infection, Immunity & Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; MRC Human Immunology Unit, University of Oxford, Oxford, UK; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; Asthma and Lung UK, London, UK; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre- Respiratory, University of Leicester, Leicester, UK; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; National Heart and Lung Institute, Imperial College London, London, UK; London School of Hygiene & Tropical Medicine, London, UK; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK; The Roslin Institute, University of Edinburgh, Edinburgh, UK; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK; Wellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, Belfast, UK; Hywel Dda University Health Board, Wales, UK; St George's University Hospitals NHS Foundation Trust, London, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK; NIHR Nottingham Biomedical Research Centre, University of Nottingham, Nottingham, UK; UCL Respiratory, Department of Medicine, University College London, London, UK; Centre for Inflammation Research, University of Edinburgh, Edinburgh, UK; Salford Royal NHS Foundation Trust, Manchester, UK; Infection Research Group, Hull University Teaching Hospitals, Hull, UK; Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK; Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Lane Fox Respiratory Unit, Guy's and St Thomas' NHS Foundation Trust, London, UK; Royal Free London NHS Foundation Trust, London, UK; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; NIHR Oxford Biomedical Research Centre, Oxford, UK; University of Sheffield, Sheffield, UK; University of Sheffield, Sheffield, UK; Centre for Human & Applied Physiological Sciences, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine, King's College London, London, UK; King's College London British Heart Foundation Centre, London, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK; NIHR Oxford Health Biomedical Research Centre, University of Oxford, Oxford, UK; The CRUK Liverpool Experimental Cancer Medicine Centre, Liverpool, UK; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK; Imperial College Healthcare NHS Trust, London, UK; Centre for Medical Image Computing, University College London, London, UK; National Heart and Lung Institute, Imperial College London, London, UK; MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; Royal Brompton & Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, UK; Department of Cardiovascular Sciences, University of Leicester and the NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester; NIHR Oxford Biomedical Research Centre, Oxford, UK; National Heart and Lung Institute, Imperial College London, London, UK; UCL Respiratory, Department of Medicine, University College London, London, UK; Kadoorie Centre for Critical Care Research, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; MRC-University of Glasgow Center for Virus research; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, UK; Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; Department of Immunology and Inflammation, Imperial College London, London, UK; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; Department of Population Health Sciences, University of Leicester, Leicester, UK; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; ","O_LIPHOSP-COVID is a national UK multi-centre cohort study of patients who were hospitalised for COVID-19 and subsequently discharged.
C_LIO_LIPHOSP-COVID was established to investigate the medium- and long-term sequelae of severe COVID-19 requiring hospitalisation, understand the underlying mechanisms of these sequelae, evaluate the medium- and long-term effects of COVID-19 treatments, and to serve as a platform to enable future studies, including clinical trials.
C_LIO_LIData collected covered a wide range of physical measures, biological samples, and Patient Reported Outcome Measures (PROMs).
C_LIO_LIParticipants could join the cohort either in Tier 1 only with remote data collection using hospital records, a PROMs app and postal saliva sample for DNA, or in Tier 2 where they were invited to attend two specific research visits for further data collection and biological research sampling. These research visits occurred at five (range 2-7) months and 12 (range 10-14) months post-discharge. Participants could also participate in specific nested studies (Tier 3) at selected sites.
C_LIO_LIAll participants were asked to consent to further follow-up for 25 years via linkage to their electronic healthcare records and to be re-contacted for further research.
C_LIO_LIIn total, 7935 participants were recruited from 83 UK sites: 5238 to Tier 1 and 2697 to Tier 2, between August 2020 and March 2022.
C_LIO_LICohort data are held in a Trusted Research Environment and samples stored in a central biobank. Data and samples can be accessed upon request and subject to approvals.
C_LI",respiratory medicine,fuzzy,100,100
medRxiv,10.1101/2023.05.08.23289637,2023-05-08,https://medrxiv.org/cgi/content/short/2023.05.08.23289637,SARS-CoV-2 Infection Biomarkers Reveal an Extended RSAD2 Dependant Metabolic Pathway,Samuele Sala; Philipp Nitschke; Reika Masuda; Nicola Gray; Nathan Lawler; James M. Wood; Georgy Berezhnoy; Alejandro Bolanos; Berin A. Boughton; Caterina Lonati; Titus Roessler; Yogesh Singh; Ian D. Wilson; Samantha Lodge; Aude-Claire Morillon; Ruey Leng Loo; Drew Hall; Luke Whiley; Gary B. Evans; Tyler L. Grove; Steven C. Almo; Lawrence D. Harris; Elaine Holmes; Uta Merle; Christoph Trautwein; Jeremy K. Nicholson; Julien Wist,"The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; Ferrier Research Institute, Victoria University of Wellington, Wellington 6012, New Zealand ;The Maurice Wilkins Centre for Molecular Biodiscovery, The Universi; Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, University Hospital Tuebingen, Tuebingen, Germany; Chemistry Department, Universidad del Valle, Cali 76001, Colombia; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; Center for Preclinical Research, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy; Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, University Hospital Tuebingen, Tuebingen, Germany; Institute of Medical Genetics and Applied Genomics, University Hospital Tuebingen, Germany; Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College, Burlington Danes Building, Du Cane Road, London W12 0NN, U; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; Ferrier Research Institute, Victoria University of Wellington, Wellington 6012, New Zealand ;The Maurice Wilkins Centre for Molecular Biodiscovery, The Universi; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, United States; Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York 10461, United States; Ferrier Research Institute, Victoria University of Wellington, Wellington 6012, New Zealand ;The Maurice Wilkins Centre for Molecular Biodiscovery, The Universi; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany; Department of Preclinical Imaging and Radiopharmacy, Werner Siemens Imaging Center, University Hospital Tuebingen, Tuebingen, Germany; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust; The Australian National Phenome Centre and Computational and Systems Medicine, Health Futures Institute, Murdoch University, Harry Perkins Building, Perth, Aust","We present compelling evidence for the existence of an evolutionary adaptive response to viral agents such as SARS-CoV-2, that results in the human in vivo biosynthesis of a family of compounds with potential antiviral activity. Using nuclear magnetic resonance (NMR) spectroscopy, we detected a characteristic spin-system motif indicative of the presence of an extended panel of urinary and serum metabolites during the acute viral phase. The structure of eight of nucleoside analogues was elucidated (six of which have not previously been reported in human urine), and subsequently confirmed by total-synthesis and matrix spiking. The molecular structures of the nucleoside analogues and their correlation with an array of serum cytokines, including IFN-2, IFN-{gamma} and IL-10, suggest an association with the viperin enzyme contributing to an endogenous innate immune defense mechanism against viral infection.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2023.04.24.23289043,2023-04-24,https://medrxiv.org/cgi/content/short/2023.04.24.23289043,LONG-TERM PHYSICAL AND MENTAL HEALTH IMPACT OF COVID-19 ON ADULTS IN ENGLAND: FOLLOW UP OF A LARGE RANDOM COMMUNITY SAMPLE,Christina J Atchison; Bethan Davies; Emily Cooper; Adam Lound; Matthew Whitaker; Adam Hampshire; Adriana Azor; Christl A Donnelly; Marc Chadeau-Hyam; Graham Cooke; Helen Ward; Paul Elliott,Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London School of Public Health,"BackgroundThe COVID-19 pandemic is having a lasting impact on health and well-being. We compare current self-reported health, quality of life and symptom profiles for people with ongoing symptoms following COVID-19 to those who have never had COVID-19 or have recovered.

MethodsA cohort study was established with participants from the REACT programme. A sample (N=800,000) of adults were contacted between August and December 2022 to complete a questionnaire about their current health and COVID-19 history. We used logistic regression to identify predictors of persistent symptoms lasting [&ge;]12 weeks following COVID-19. We fitted Accelerated Failure Time models to assess factors associated with rate of recovery from persistent symptoms.

FindingsOverall, 276,840/800,000 (34.6%) of invited participants completed the questionnaire. Median duration of COVID-related symptoms (N=130,251) was 1.3 weeks (inter-quartile range 6 days to 2 weeks), with 7.5% and 5.2% reporting ongoing symptoms [&ge;]12 weeks and [&ge;]52 weeks respectively. Female sex, having [&ge;]1 comorbidity, more severe symptoms at time of COVID-19 and being infected when Wild-type variant was dominant were associated with higher probability of symptoms lasting [&ge;]12 weeks. Longer time to recovery in those with persistent symptoms was found for females, people with comorbidities, living in more deprived areas, current smokers and for Wild-type compared to later variants. Mental health and health-related quality of life were significantly worse among participants with ongoing persistent COVID-19 symptoms compared with those who had never had COVID-19 or had recovered.

InterpretationAlthough COVID-19 is usually of short duration, some adults experience persistent and burdensome illness.

FundingThis work is independent research funded by the National Institute for Health and Care Research (NIHR) (REACT Long COVID (REACT-LC) (COV-LT-0040)). This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (UKRI) (MC_PC_20029). The views expressed in this publication are those of the author(s) and not necessarily those of NIHR or UKRI.",public and global health,fuzzy,100,100
medRxiv,10.1101/2023.04.13.23288469,2023-04-19,https://medrxiv.org/cgi/content/short/2023.04.13.23288469,"Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial",Peter W Horby; Natalie Staplin; Leon Peto; Jonathan R Emberson; Mark Campbell; Guilherme Pessoa-Amorim; Buddha Basnyat; Louise Thwaites; Rogier Van Doorn; Raph L Hamers; Jeremy Nel; John Amuasi; Manisha Rawal; Dipansu Ghosh; Jonathan Douse; Fergus Hamilton; Anthony Kerry; Pinky Thu-Ta; John Widdrington; Chris Green; Purav Desai; Richard Stewart; Nguyen Thanh Phong; J Kenneth Baillie; Maya H Buch; Saul N Faust; Thomas Jaki; Katie Jeffery; Edmund Juszczak; Marian Knight; Wei Shen Lim; Alan Montgomery; Aparna Mukherjee; Andrew Mumford; Kathryn Rowan; Guy Thwaites; Marion Mafham; Richard Haynes; Martin J Landray,"Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; OUCRU-Nepal, Patan Adademy of Health Sciences, Kathmandu, Nepal; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; Division of Infectious Diseases, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa; Kumasi Center for Collaborative Research in Tropic Medicine, Kumasi, Ghana; Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal; Leeds Teaching Hospitals NHS Foundation Trust, Leeds, United Kingdom; East Suffolk and North Essex NHS Foundation Trust; University Hospital of Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom; Great Western Hospitals Foundation Trust, Swindon, United Kingdom; Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom; Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United Kingdom; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, United Kingdom; Milton Keynes University Hospital, Milton Keynes, United Kingdom; Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Respiratory Medicine Department, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Indian Council of Medical Research, New Delhi, India; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Intensive Care National Audit and Research Centre, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","BackgroundEmpagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic and haemodynamic effects.

MethodsIn this randomised, controlled, open-label trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care alone or usual standard of care plus empagliflozin 10mg once daily for 28 days or until discharge using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28-day mortality. On 3 March the independent data monitoring committee recommended that the investigators review the data and recruitment was consequently stopped on 7 March. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

FindingsBetween 8 July 2021 and 6 March 2023, 4271 patients were randomly allocated to receive either empagliflozin (2113 patients) or usual care alone (2158 patients). Overall, 289 (14%) patients allocated to empagliflozin and 307 (14%) patients allocated to usual care died within 28 days (rate ratio 0.96; 95% confidence interval [CI] 0.82-1.13; p=0.64). There was no evidence of significant differences in duration of hospitalisation (median 8 days vs. 8 days) or the proportion of patients discharged from hospital alive within 28 days (79% vs. 78%; rate ratio 1.03; 95% CI 0.96-1.10; p=0.44). Among those not on invasive mechanical ventilation at baseline, there was no evidence of a significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (16% vs. 17%; risk ratio 0.95; 95% CI 0.84-1.08; p=0.44).

InterpretationIn adults hospitalised with COVID-19, empagliflozin was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

FundingUK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056), and Wellcome Trust (Grant Ref: 222406/Z/20/Z).

Trial registrationClinicalTrials.gov NCT04381936 https://clinicaltrials.gov/ct2/show/NCT04381936

ISRCTN50189673 http://www.isrctn.com/ISRCTN50189673",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2023.04.13.23288522,2023-04-17,https://medrxiv.org/cgi/content/short/2023.04.13.23288522,Risk of new-onset Long Covid following reinfection with SARS-CoV-2: community-based cohort study,Matthew L Bosworth; Boran Shenhuy; A. Sarah Walker; Vah√© Nafilyan; Nisreen A Alwan; Margaret E O'Hara; Daniel Ayoubkhani,Office for National Statistics; Office for National Statistics; University of Oxford; Office for National Statistics; University of Southampton; Long Covid Support; University of Leicester; Office for National Statistics,"BackgroundLittle is known about the risk of Long Covid following reinfection with SARS-CoV-2. We estimated the likelihood of new-onset, self-reported Long Covid after a second SARS-CoV-2 infection, and compared to a first infection.

MethodsWe included UK COVID-19 Infection Survey participants who tested positive for SARS-CoV-2 between 1 November 2021 and 8 October 2022. The primary outcome was self-reported Long Covid 12 to 20 weeks after each infection. Separate analyses were performed for those <16 years and [&ge;]16 years. We estimated adjusted odds ratios (aORs) for new-onset Long Covid using logistic regression, comparing second to first infections, controlling for socio-demographic characteristics and calendar date of infection, plus vaccination status in those [&ge;]16 years.

ResultsOverall, Long Covid was reported by those [&ge;]16 years after 4.0% and 2.4% of first and second infections, respectively; the corresponding estimates among those <16 years were 1.0% and 0.6%. The aOR for Long Covid after second compared to first infections was 0.72 (95% confidence interval: 0.63-0.81) for those [&ge;]16 years and 0.93 (0.57-1.53) for those <16 years.

ConclusionsThe risk of new-onset Long Covid after a second SARS-CoV-2 infection is lower than that after a first infection for those [&ge;]16 years, though there is no evidence of a difference in risk for those <16 years. However, there remains some risk of new-onset Long Covid after a second infection, with around 1 in 40 of those [&ge;]16 years and 1 in 165 of those <16 years reporting Long Covid after a second infection.",public and global health,fuzzy,100,100
medRxiv,10.1101/2023.03.24.23287700,2023-03-26,https://medrxiv.org/cgi/content/short/2023.03.24.23287700,The potential contribution of vaccination uptake to occupational differences in risk of SARS-CoV-2: Analysis of the ONS COVID-19 Infection Survey,Jack D Wilkinson; Evangelia Demou; Mark Cherrie; Rhiannon Edge; Matthew Gittins; Srinivasa Vittal Katikireddi; Theocharis Kromydas; WIll Mueller; Neil Pearce; Martie van Tongeren; Sarah Rhodes,University of Manchester; University of Glasgow; Institute of Occupational Medicine; University of Lancaster; University of Manchester; University of Glasgow; University of Glasgow; Institute for Occupational Medicine; London School of Hygiene and Tropical Medicine; University of Manchester; University of Manchester,"ObjectivesTo assess variation in vaccination uptake across occupational groups as a potential explanation for variation in risk of SARS-CoV-2 infection.

DesignWe analysed data from the UK Office of National Statistics COVID-19 Infection Survey linked to vaccination data from the National Immunisation Management System in England from December 1st 2020 to 11th May 2022. We analysed vaccination uptake and SARS-CoV-2 infection risk by occupational group and assessed whether adjustment for vaccination reduced the variation in risk between occupational groups.

Setting

ResultsEstimated rates of triple-vaccination were high across all occupational groups (80% or above), but were lowest for food processing (80%), personal care (82%), hospitality (83%), manual occupations (84%), and retail (85%). High rates were observed for individuals working in health (95% for office-based, 92% for those in patient-facing roles) and education (91%) and office-based workers not included in other categories (90%). The impact of adjusting for vaccination when estimating relative risks of infection was generally modest (ratio of hazard ratios reduced from 1.38 to 1.32), but was consistent with the hypothesis that low vaccination rates contribute to elevated risk in some groups. Conversely, estimated relative risk for some occupational groups, such as people working in education, remained high despite high vaccine coverage.

ConclusionsVariation in vaccination coverage might account for a modest proportion of occupational differences in infection risk. Vaccination rates were uniformly very high in this cohort, which may suggest that the participants are not representative of the general population. Accordingly, these results should be considered tentative pending the accumulation of additional evidence.",occupational and environmental health,fuzzy,100,100
medRxiv,10.1101/2023.03.24.23287666,2023-03-24,https://medrxiv.org/cgi/content/short/2023.03.24.23287666,Occupational differences in the prevalence and severity of long-COVID: Analysis of the ONS Coronavirus (COVID-19) Infection Survey,Theocharis Kromydas; Evangelia Demou; Rhiannon Edge; Matthew Gittins; Srinivasa Vittal Katikireddi; Neil Pearce; Martie van Tongeren; Jack Wilkinson; Sarah Rhodes,University of Glasgow; University of Glasgow; Lancaster University; University of Manchester; University of Glasgow; London School of Hygiene and Tropical Medicine; University of Manchester; University of Manchester; University of Manchester,"ObjectivesTo establish whether prevalence and severity of long-COVID symptoms vary by industry and occupation.

MethodsWe utilised ONS Coronavirus Infection Survey (CIS) data (February 2021-April 2022) of working-age participants (16-65 years). Exposures were industrial sector, occupation and major Standard Occupational Classification (SOC) group. Outcomes were self-reported: (1) long-COVID symptoms; and (2) reduced function due to long-COVID. Binary (outcome 1) and ordered (outcome 2) logistic regression were used to estimate odds ratios (OR) and prevalence (marginal means) for all exposures.

ResultsPublic facing industries, including teaching and education, social care, healthcare, civil service, retail and transport industries and occupations had highest odds ratios for long-COVID. By major SOC group, those in caring, leisure and other services (OR 1.44, CIs: 1.38-1.52) had substantially elevated odds than average. For almost all exposures, the pattern of odds ratios for long-COVID symptoms followed that for SARS-CoV-2 infections, except for professional occupations (OR<1 for infection; OR>1 for long-COVID). The probability of reporting long-COVID for industry ranged from 7.7% (financial services) to 11.6% (teaching and education); whereas the prevalence of reduced function by  a lot ranged from 17.1% (arts, entertainment and recreation) to 22-23% (teaching and education and armed forces) and to 27% (those not working).

ConclusionsThe risk and prevalence of long-COVID differs across industries and occupations. Generally, it appears that likelihood of developing long-COVID symptoms follows likelihood of SARS-CoV-2 infection, except for professional occupations. These findings highlight sectors and occupations where further research is needed to understand the occupational factors resulting in long-COVID.

Key messages

What is already known on this topicO_LISARS-CoV-2 infection and COVID-19 mortality in the UK varied by occupational group; yet it is not known if any occupational groups are more susceptible to long-COVID than others.
C_LI

What this study addsO_LIThis is the first study to examine how prevalence of long-COVID and its impacts on functional capacity differ by industrial sector and occupational groups.
C_LIO_LIPrevalence of self-reported long-COVID increased with time across all exposure groups and mostly followed SARS-CoV-2 infection trends; with the exception of Professional occupations that demonstrated notable differences in the direction of odds of long-covid when compared to odds of SARS-CoV-2 infection.
C_LIO_LIThose working in Teaching and education, and social care industries showed the highest likelihood of having long-COVID symptoms. The exact same pattern was observed when analysis was performed using occupational groups. When we used SOC groups the likelihood was higher in Caring, leisure and other services.
C_LI

How this study might affect research, practice or policyO_LIThe findings contribute to the evidence base that long-COVID differences occur across industries and occupations, provides insights for employees, employers, occupational and healthcare for the industries and occupations that may need additional support for return- to-work policies and highlights sectors and occupations where further research is needed to understand the mechanisms resulting in long-COVID and how occupational factors influence the risk of developing long-COVID or interact with long-COVID to increase the impact on activities.
C_LI",public and global health,fuzzy,100,100
medRxiv,10.1101/2023.03.21.23287524,2023-03-22,https://medrxiv.org/cgi/content/short/2023.03.21.23287524,Employment outcomes of people with Long Covid symptoms: community-based cohort study,Daniel Ayoubkhani; Francesco Zaccardi; Koen B Pouwels; Ann Sarah Walker; Donald Houston; Nisreen A Alwan; Josh Martin; Kamlesh Khunti; Vahe Nafilyan,Office for National Statistics; University of Leicester; University of Oxford; University of Oxford; University of Portsmouth; University of Southampton; Bank of England; University of Leicester; Office for National Statistics,"BackgroundEvidence on the long-term employment consequences of SARS-CoV-2 infection is lacking. We used data from a large, community-based sample in the UK to estimate associations between Long Covid and subsequent employment outcomes.

MethodsThis was an observational, longitudinal study using a pre-post design. We included UK COVID-19 Infection Survey participants who completed questionnaires on Long Covid from 3 February 2021 to 30 September 2022 when they were aged 16 to 64 years and not in full-time education. We used conditional logit modelling to explore the time-varying relationship between Long Covid status [&ge;]12 weeks after a first test-confirmed SARS-CoV-2 infection (reference: pre-infection) and labour market inactivity (neither working nor looking for work) or workplace absence lasting [&ge;]4 weeks.

ResultsOf 206,299 included participants (mean age 45 years, 54% female, 92% white), 15% were ever inactive in the labour market and 10% were ever long-term absent during follow-up. Compared with pre-infection, inactivity was higher in participants reporting Long Covid 30 to <40 weeks (adjusted odds ratio (aOR): 1.45; 95% CI: 1.17 to 1.81) or 40 to <52 weeks (1.34; 1.05 to 1.72) post-infection. Compared with pre-infection, reporting Long Covid was also associated with increased odds of long-term absence 18 to <24 weeks (1.40; 1.04 to 1.90) and 24 to <30 weeks (1.45; 1.03 to 2.04) post-infection, but not beyond 30 weeks. Combining with official statistics on Long Covid prevalence, our estimates translate to 27,000 (95% CI: 6,000 to 47,000) working-age adults in the UK being inactive because of their Long Covid symptoms in July 2022.

ConclusionsLong Covid is likely to have contributed to reduced levels of participation in the UK labour market, though it is unlikely to be the sole driver. Further research is required to quantify the contribution of other factors, such as indirect health effects of the pandemic.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.03.15.23287300,2023-03-19,https://medrxiv.org/cgi/content/short/2023.03.15.23287300,Risk factors for SARS-CoV-2 infection: A test-negative case-control study with additional population controls,Marjut Sarjomaa; Chi Zhang; Yngvar Tveten; Hege Kersten; Harald Reiso; Randi Eikeland; Johny Kongerud; Kristine  Karlsrud Berg; Carina Thilesen; Svein Arne Nordbo; Ingeborg Aaberge; Jan Vandenbroucke; Neil Pearce; Anne Kristin Fell,Telemark Hospital: Sykehuset Telemark HF; Norwegian Institute of Public Health: Folkehelseinstituttet; Telemark Hospital: Sykehuset Telemark HF; Telemark Hospital: Sykehuset Telemark HF; Sorlandet Hospital; Sorlandet Hospital; University of Oslo; Sorlandet Sykehus HF; Unilabs Laboratory Medicine; St Olavs Hospital; Norwegian Institute of Public Health; Leiden University Medical Center; London School of Hygiene and Tropical Medicine; Telemark Hospital: Sykehuset Telemark HF,"ObjectivesTo assess risk factors for SARS-CoV-2 infection by first comparing positive cases with negative controls as determined by polymerase chain reaction (PCR) testing and then comparing these two groups with an additional population control group.

Design and settingTest-negative design (TND), multicentre case-control study with additional population controls in South Eastern Norway.

ParticipantsAdults who underwent SARS-CoV-2 PCR testing between February and December 2020. PCR-positive cases, PCR-negative controls, and additional age-matched population controls.

Primary outcome measuresThe associations between various risk factors based on self-reported questionnaire and SARS-CoV-2 infection comparing PCR positive cases and PCR-negative controls. Using subgroup analysis, the risk factors were then compared with a population control group. Univariate and multivariate regression analyses were performed.

ResultsIn total, 400 SARS-CoV-2 PCR-positive cases, 719 PCR-negative controls, and 14,509 population controls were included. Male sex was associated with the risk of SARS-CoV-2 infection when PCR-positive cases were compared with PCR-negative controls (OR 1.9, 95% CI 1.4 to 2.6). Age, education level, comorbidities (asthma, diabetes, hypertension), an exercise were not associated with the risk of SARS-CoV-2 infection when PCR-positive cases were compared with PCR-negative controls. In the subgroup analysis comparing PCR-positive cases with age-matched population controls, asthma was associated with the risk of SARS-CoV-2 infection (OR 1.6, 95% CI 1.1 to 2.1). Daily or occasional smoking was negatively associated with the risk of SARS-CoV-2 infection in both analyses (OR 0.5, 95% CI 0.3 to 0.8 and OR 0.55, 95% CI 0.35, to 0.82, respectively).

ConclusionsMale sex was a possible risk factor, whereas smoking was negatively associated with the risk of SARS-CoV-2 infection, when comparing PCR-positive cases and PCR-negative controls. Asthma was associated with the risk of SARS-CoV-2 infection when PCR-positive cases were compared with population controls.

ARTICLE SUMMARYO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LIThe test-negative design (TND) was an important strength of this study. The design can reduce confounding from healthcare-seeking bias because PCR-controls are likely to have similar healthcare-seeking attitudes as PCR+ cases.
C_LIO_LIThis study mostly included non-hospitalised patients, which can improve the generalisability of the findings to the general public.
C_LIO_LIThe use of an additional control group from the general public for comparison with the findings from the test-negative controls provides further information on the similarities and differences in risk factors for COVID-19 and other respiratory tract infections.
C_LIO_LIIn the subgroup analyses, PCR+ cases and PCR- controls were compared with the population controls to assess the risk factors for those aged 18-55 years. Hence, the results may not be generalisable to patients older than 55 years.
C_LIO_LIPCR test results, rather than symptoms, were used to categorise the participants into cases or controls, and therefore risk factors for SARS-CoV-2 infection and not COVID-19 disease were assessed.
C_LI",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2023.03.15.23287292,2023-03-15,https://medrxiv.org/cgi/content/short/2023.03.15.23287292,Living alone and mental health: parallel analyses in longitudinal population surveys and electronic health records prior to and during the COVID-19 pandemic,Eoin McElroy; Emily Herrett; Kishan Patel; Dominik M Piehlmaier; Giorgio Di Gessa; Charlotte Huggins; Michael J Green; Alex SF Kwong; Ellen J Thompson; Jingmin Zhu; Kathryn E Mansfield; Richard J Silverwood; Rosie Mansfield; Jane Maddock; Rohini Mathur; Ruth E Costello; Anthony A Matthews; John Tazare; Alasdair Henderson; Kevin Wing; Lucy Bridges; Sebastian Bacon; Amir Mehrkar; - OpenSafely Collaborative; Richard John Shaw; Jacques Wels; Srinivasa Vittal Katikireddi; Nishi Chaturvedi; Laurie Tomlinson; Praveetha Patalay,"School of Psychology, Ulster University, Coleraine, UK; London School of Hygiene and Tropical Medicine, London, UK; MRC Unit for Lifelong Health and Ageing, University College London, London, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford; University of Sussex Business Sch; Department of Epidemiology & Public Health, University College London, London, UK; Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK; MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK; MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK; Division of Psychiatry, University of Edinburgh, Edinburgh, UK; Department of Twin Research and Genetic Epidemiology, Kings College London; Department of Epidemiology & Public Health, University College London, London, UK; London School of Hygiene and Tropical Medicine, London, UK; Centre for Longitudinal Studies, University College London, London, UK; Centre for Longitudinal Studies, University College London, London, UK; MRC Unit for Lifelong Health and Ageing, University College London, London, UK; Centre for Primary Care, Wolfson Insitute of Population Health, Queen Mary, University of London, London; London School of Hygiene and Tropical Medicine, London, UK; Karolinska Institutet, Stockholm, Sweden; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford; ; MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK; MRC Unit for Lifelong Health and Ageing, University College London, London, UK; MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK; MRC Unit for Lifelong Health and Ageing, University College London, London, UK; London School of Hygiene and Tropical Medicine, London, UK; MRC Unit for Lifelong Health and Ageing, University College London, London, UK; Centre for Longitudinal Studies, University College London, London, UK","ObjectivesTo describe the mental health gap between those who live alone and those who live with others, and to examine whether the COVID-19 pandemic had an impact on this gap.

DesignTen population based prospective cohort studies, and a retrospective descriptive cohort study based on electronic health records (EHRs).

SettingUK Longitudinal population-based surveys (LPS), and primary and secondary care records within the OpenSAFELY-TPP database.

ParticipantsParticipants from the LPS were included if they had information on living status in early 2020, valid data on mental ill-health at the closest pre-pandemic assessment and at least once during the pandemic, and valid data on a key minimum set of covariates. The EHR dataset included 16 million adults registered with primary care practices in England using TPP SystmOne software on 1st February 2020, with at least three months of registration, valid address data, and living in households of <16 people.

Main outcome measuresIn the LPS, self-reported survey measures of psychological distress and life satisfaction were assessed in the nearest pre-pandemic sweep and three periods during the pandemic: April-June 2020, July-October 2020, and November 2020-March 2021. In the EHR analyses, outcomes were morbidity codes recorded in primary or secondary care between March 2018 and January 2022 reflecting the diagnoses of depression, self-harm, anxiety, obsessive compulsive disorder, eating disorders, and severe mental illnesses.

ResultsThe LPS consisted of 37,544 participants (15.2% living alone) and we found greater psychological distress (SMD: 0.09 (95% CI: 0.04, 0.14) and lower life satisfaction (SMD: -0.22 (95% CI: -0.30, -0.15) in those living alone pre-pandemic, and the gap between the two groups stayed similar after the onset of the pandemic. In the EHR analysis of almost 16 million records (21.4% living alone), codes indicating mental health conditions were more common in those who lived alone compared to those who lived with others (e.g., depression 26 and severe mental illness 58 cases more per 100,000). Recording of mental health conditions fell during the pandemic for common mental health disorders and the gap between the two groups narrowed.

ConclusionsMultiple sources of data indicate that those who live alone experience greater levels of common and severe mental illnesses, and lower life satisfaction. During the pandemic this gap in need remained, however, there was a narrowing of the gap in service use, suggesting greater barriers to healthcare access for those who live alone.

Summary BoxO_ST_ABSWhat is already known on the topic?C_ST_ABSHouseholds with one individual are an increasing demographic, comprising over a quarter of all households in the UK in 2021. However, the mental health gap between those who live alone compared to those who live with others is not well described and even less is known about the relative gaps in need and healthcare-seeking and access. The pandemic and associated restrictive measures further increased the likelihood of isolation for this group, which may have impacted mental health.

What this study adds?We present comprehensive evidence from both population-based surveys and electronic health records regarding the greater levels of mental health symptoms and in recorded diagnoses for common (anxiety, depression) and less common (OCD, eating disorders, SMIs) mental health conditions for people living alone compared to those living with others.

Our analyses indicate that mental health conditions are more common among those who live alone compared to those who live with others. Although levels of reported distress increased for both groups during the pandemic, healthcare-seeking dropped in both groups, and the rates of healthcare-seeking among those who live alone converged with those who live with others for common mental health conditions. This suggests greater barriers for treatment access among those that live alone.

The findings have implications for mental health service planning and efforts to reduce barriers to treatment access, especially for individuals who live on their own.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2023.02.26.23286474,2023-03-06,https://medrxiv.org/cgi/content/short/2023.02.26.23286474,Improving the representativeness of UKs national COVID-19 Infection Survey through spatio-temporal regression and post-stratification,Koen B Pouwels; David W Eyre; Thomas House; Ben Aspey; Philippa C Matthews; Nicole Stoesser; John Newton; Ian Diamond; Ruth Studley; Nick Taylor; John Bell; Jeremy Farrar; Jaison Kolenchery; Brian Marsden; Sarah Hoosdally; Yvonne Jones; David Stuart; Derrick Crook; tim E peto; Ann Sarah Walker; - COVID-19 Infection Survey Team,University of Oxford; University of Oxford; University of Manchester; Office for National Statistics; The Francis Crick Institute; University of Oxford; University of Exeter; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Wellcome Trust; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; oxford university; University of Oxford; -,"Population-representative estimates of SARS-CoV-2 infection prevalence and antibody levels in specific geographic areas at different time points are needed to optimise policy responses. However, even population-wide surveys are potentially impacted by biases arising from differences in participation rates across key groups. Here, we use spatio-temporal regression and post-stratification models to UKs national COVID-19 Infection Survey (CIS) to obtain representative estimates of PCR positivity (6,496,052 tests) and antibody prevalence (1,941,333 tests) for different regions, ages and ethnicities (7-December-2020 to 4-May-2022). Not accounting for vaccination status through post-stratification led to small underestimation of PCR positivity, but more substantial overestimations of antibody levels in the population (up to 21%), particularly in groups with low vaccine uptake in the general population. There was marked variation in the relative contribution of different areas and age-groups to each wave. Future analyses of infectious disease surveys should take into account major drivers of outcomes of interest that may also influence participation, with vaccination being an important factor to consider.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2023.03.01.23286627,2023-03-03,https://medrxiv.org/cgi/content/short/2023.03.01.23286627,Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of Long-Term Care Facilities in the VIVALDI study,Oliver Stirrup; Madhumita Shrotri; Natalie L. Adams; Maria Krutikov; Borscha Azmi; Igor Monakhov; Gokhan Tut; Paul Moss; Andrew Hayward; Andrew Copas; Laura Shallcross,University College London; University College London; University College London; University College London; University College London; UK Health Security Agency; University of Birmingham; University of Birmingham; University College London; University College London; University College London,"We evaluated the effectiveness of 1-3 booster vaccinations against SARS-CoV-2 related mortality among a cohort of 13407 older residents of long-term care facilities (LTCFs) participating in the VIVALDI study in England in 2022. Cox regression was used to estimate relative hazards of SARS-CoV-2 related death following booster vaccination relative to 2 doses (after 84+ days), stratified by previous SARS-CoV-2 infection and adjusting for age, sex and LTCF capacity. Each booster provided additional short-term protection relative to primary vaccination, with consistent pattern of waning to 45-75% reduction in risk beyond 112 days.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2023.03.01.23286624,2023-03-03,https://medrxiv.org/cgi/content/short/2023.03.01.23286624,Risk of cardiovascular events following COVID-19 in people with and without pre-existing chronic respiratory disease,Hannah Whittaker; Costantinos Kallis; Angela Wood; Thomas Bolton; Samantha Walker; Aziz Sheikh; Alex Brownrigg; Ashley Akbari; Kamil Sterniczuk; Jennifer K Quint,"Imperial College London; Imperial College London; Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, United Kingdom; Health Data Research UK; Asthm + Lung; The University of Edinburgh College of Medicine and Veterinary Medicine; Health Data Research UK BREATHE; Swansea University; Health Data Research UK BREATHE; Imperial College London","BackgroundCOVID-19 is associated with a higher risk of cardiovascular outcomes in the general population. People with chronic respiratory disease have a higher risk of cardiovascular disease than the general population therefore, we investigated the association between pre-existing chronic respiratory disease and risk of cardiovascular events following COVID-19 using routinely collected data from 56 million people in England.

MethodsPrimary and secondary care data from the English National Health Service and COVID-19-specific linked data were used to define a population of adults with COVID-19 between 01/01/2020-30/11/2021. Start of follow-up was from first COVID-19 diagnosis. Pre-existing chronic respiratory disease included asthma, chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis, or pulmonary fibrosis prior to COVID-19 diagnosis. Adjusted Cox Proportional Hazard regression was used to investigate the association between pre-existing chronic respiratory disease and risk of cardiovascular events. Secondary objectives investigated the impact of COVID-19 hospitalisation and vaccine dose on risk of cardiovascular outcomes.

FindingsA total of 3,670,455 people were included. People with pre-existing respiratory disease had a higher risk of cardiovascular events (adjusted HR 1.11, 95% confidence intervals 1.07-1.14), heart failure (1.15, 1.09-1.21), and pulmonary embolism (1.20, 1.11-1.30) compared with those without pre-existing respiratory disease. Regardless of pre-existing respiratory disease, the risk of cardiovascular events was lower with increasing COVID-19 vaccine dose.

InterpretationPeople with chronic respiratory disease have a higher risk of some cardiovascular outcomes but the risk might be explained by the underlying respiratory condition. Risk of cardiovascular events was lower with increasing COVID-19 vaccine doses regardless of pre-existing chronic respiratory disease.

FundingThis work was funded by the British Heart Foundation Data Science Centre.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.02.28.23286559,2023-03-01,https://medrxiv.org/cgi/content/short/2023.02.28.23286559,Elevated symptoms of depression and anxiety among family members and friends of critically ill COVID-19 patients - An observational study of five cohorts across four countries,Anik√≥ Lovik; Juan Gonz√°lez-Hij√≥n; Asle Hoffart; Chloe Fawns-Ritchie; Ingibj√∂rg Magn√∫sd√≥ttir; Li Lu; Anna B√°ra Unnarsd√≥ttir; Anna K. K√§hler; Archie Campbell; Arna Hauksd√≥ttir; Charilaos Chourpiliadis; Daniel L McCartney; Edda Bj√∂rk Thordard√≥ttir; Emily E. Joyce; Emma M. Frans; J√≥hanna Jakobsd√≥ttir; Lill Trogstad; Ole A. Andreassen; Per Magnus; Sverre Urnes Johnson; Patrick F. Sullivan; Thor Aspelund; David J. Porteous; Helga Ask; Omid V. Ebrahimi; Unnur Anna Valdimarsd√≥ttir; Fang Fang,Karolinska Institutet and Leiden University; Karolinska Institutet; University of Oslo; University of Edinburgh; University of Iceland; University of Oslo; University of Iceland; Karolinska Institutet; University of Edinburgh; University of Iceland; Karolinska Institutet; University of Edinburgh; University of Iceland; Karolinska Institutet; Karolinska Institutet; University of Iceland; Norwegian Institute of Public Health; University of Oslo; Norwegian Institute of Public Health; University of Oslo; Karolinska Institutet; University of Iceland; University of Edinburgh; University of Oslo; University of Oslo; Karolinska Institutet; Karolinska Institutet,"BackgroundLittle is known regarding the mental health impact of having a significant person (family member and/or close friend) with COVID-19 of different severity.

MethodsThe study included five prospective cohorts from four countries (Iceland, Norway, Sweden, and the UK) with self-reported data on COVID-19 and symptoms of depression and anxiety during March 2020-March 2022. We calculated the prevalence ratio (PR) of depression and anxiety in relation to having a significant person with COVID-19 and performed a longitudinal analysis in the Swedish cohort to describe the temporal patterns of the results.

Results162,237 and 168,783 individuals were included in the analysis of depression and anxiety, respectively, of whom 24,718 and 27,003 reported a significant person with COVID-19. Overall, the PR was 1.07 (95% CI: 1.05-1.10) for depression and 1.08 (95% CI: 1.03-1.13) for anxiety among significant others of COVID-19 patients. The respective PRs for depression and anxiety were 1.04 (95% CI: 1.01-1.07) and 1.03 (95% CI: 0.98-1.07) if the significant person was never hospitalized, 1.15 (95% CI: 1.08-1.23) and 1.24 (95% CI: 1.14-1.34) if the patient was hospitalized, 1.42 (95% CI: 1.27-1.57) and 1.45 (95% CI: 1.31-1.60) if admitted to the ICU, and 1.34 (95% CI: 1.22-1.46) and 1.36 (95% CI: 1.22-1.51) if the significant person died. Individuals of hospitalized, ICU admitted, or deceased patients showed higher prevalence of depression and anxiety during the entire 12 months after the COVID-19 diagnosis of the significant person.

ConclusionsClose friends and family members of critically ill COVID-19 patients show elevated prevalence of depression and anxiety throughout the first year after the diagnosis.",public and global health,fuzzy,100,100
medRxiv,10.1101/2023.02.17.23286079,2023-02-23,https://medrxiv.org/cgi/content/short/2023.02.17.23286079,"Surface sampling for SARS-CoV-2 in workplace outbreak settings in the UK, 2021-22.",Ian George Nicholls; Antony Spencer; Yiqun Chen; Allan Bennett; Barry Atkinson,UK Health Security Agency; UK Health Security Agency; Health and Safety Executive; UK Health Security Agency; UK Health Security Agency,"AimsTo utilise environmental surface sampling to evaluate areas of SARS-CoV-2 contamination within workplaces to identify trends and improve local COVID-control measures.

Methods and ResultsSurface sampling was undertaken at 12 workplaces that experienced a cluster of COVID-19 cases in the workforce between March 2021 and March 2022. 7.4% (61/829) of samples collected were positive for SARS-CoV-2 RNA by qPCR with only 1.8% (15/829) of samples identified with crossing threshold (Ct) values below 35.0. No sample returned whole genome sequence inferring RNA detected was degraded.

ConclusionsFew workplace surface samples were positive for SARS-CoV-2 RNA and positive samples typically contained low levels of nucleic acid. Although these data may infer a low probability of fomite transmission or other forms of transmission within the workplace, Ct values may have been lower at the time of contamination. Workplace environmental sampling identified lapses in COVID-control measures within individual sites and showed trends through the pandemic.

Significance and Impact of the StudyPrior to this study, few published reports investigated SARS-CoV-2 RNA contamination within workplaces experiencing cases of COVID-19. This report provides extensive data on environmental sampling identifying trends across workplaces and through the pandemic.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.02.18.23286127,2023-02-19,https://medrxiv.org/cgi/content/short/2023.02.18.23286127,Antipsychotic prescribing and mortality in people with dementia before and during the COVID-19 pandemic: retrospective cohort study,Christian Schnier; Aoife McCarthy; Daniel R Morales; Ashley Akbari; Reecha Sofat; Caroline Dale; Rohan Takhar; Mamas Mamas; Kamlesh Khunti; Francesco Zaccardi; Cathie  LM Sudlow; Tim Wilkinson,University of Edinburgh; University of Edinburgh; University of Dundee; Swansea University; University of Liverpool; University of Liverpool; University College London; Keele University; University of Leicester; University of Leicester; University of Edinburgh; University of Edinburgh,"BackgroundAntipsychotic drugs have been associated with increased mortality, stroke and myocardial infarction in people with dementia. Concerns have been raised that antipsychotic prescribing may have increased during the COVID-19 pandemic due to social restrictions imposed to limit the spread of the virus. We used multisource, routinely-collected healthcare data from Wales, UK, to investigate prescribing and mortality trends in people with dementia before and during the COVID-19 pandemic.

MethodsWe used individual-level, anonymised, population-scale linked health data to identify adults aged [&ge;]60 years with a diagnosis of dementia in Wales, UK. We explored antipsychotic prescribing trends over 67 months between 1st January 2016 and 1st August 2021, overall and stratified by age and dementia subtype. We used time series analyses to examine all-cause, myocardial infarction (MI) and stroke mortality over the study period and identified the leading causes of death in people with dementia.

FindingsOf 57,396 people with dementia, 11,929 (21%) were prescribed an antipsychotic at any point during follow-up. Accounting for seasonality, antipsychotic prescribing increased during the second half of 2019 and throughout 2020. However, the absolute difference in prescribing rates was small, ranging from 1253 to 1305 per 10,000 person-months. Prescribing in the 60-64 age group and those with Alzheimers disease increased throughout the 5-year period. All-cause and stroke mortality increased in the second half of 2019 and throughout 2020 but MI mortality declined. From January 2020, COVID-19 was the second commonest underlying cause of death in people with dementia.

InterpretationDuring the COVID-19 pandemic there was a small increase in antipsychotic prescribing in people with dementia. The long-term increase in antipsychotic prescribing in younger people and in those with Alzheimers disease warrants further investigation.

FundingBritish Heart Foundation (BHF) (SP/19/3/34678) via the BHF Data Science Centre led by HDR UK, and the Scottish Neurological Research Fund.

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSWe searched Ovid MEDLINE for studies describing antipsychotic prescribing trends in people with dementia during the COVID-19 pandemic, published between 1st January 2020 and 22nd March 2022. The following search terms were used: (exp Antipsychotic Agents/ OR antipsychotic.mp OR neuroleptic.mp OR risperidone.mp OR exp Risperidone/ OR quetiapine.mp OR exp Quetiapine Fumarate/ OR olanzapine.mp OR exp Olanzapine/ OR exp Psychotropic Drugs/ or psychotropic.mp) AND (exp Dementia/ OR exp Alzheimer Disease/ or alzheimer.mp) AND (prescri*.mp OR exp Prescriptions/ OR exp Electronic Prescribing/ OR trend*.mp OR time series.mp). The search identified 128 published studies, of which three were eligible for inclusion. Two studies, based on data from England and the USA, compared antipsychotic prescribing in people with dementia before and during the COVID-19 pandemic. Both reported an increase in the proportion of patients prescribed an antipsychotic after the onset of the pandemic. A third study, based in the Netherlands, reported antipsychotic prescription trends in nursing home residents with dementia during the first four months of the pandemic, comparing prescribing rates to the timings of lifting of social restrictions, showing that antipsychotic prescribing rates remained constant throughout this period.

Added value of this studyWe conducted age-standardised time series analyses using comprehensive, linked, anonymised, individual-level routinely-collected, population-scale health data for the population of Wales, UK. By accounting for seasonal variations in prescribing and mortality, we demonstrated that the absolute increase in antipsychotic prescribing in people with dementia of any cause during the COVID-19 pandemic was small. In contrast, antipsychotic prescribing in the youngest age group (60-64 years) and in people with a subtype diagnosis of Alzheimers disease increased throughout the five-year study period. Accounting for seasonal variation, all-cause mortality rates in people with dementia began to increase in late 2019 and increased sharply during the first few months of the pandemic. COVID-19 became the leading non-dementia cause of death in people with dementia from 2020 to 2021. Stroke mortality increased during the pandemic, following a similar pattern to that of all-cause mortality, whereas myocardial infarction rates decreased.

Implications of all the available evidenceDuring COVID-19 we observed a large increase in all-cause and stroke mortality in people with dementia. When seasonal variations are accounted for, antipsychotic prescribing rates in all-cause dementia increased by a small amount before and during the pandemic in the UK. The increased prescribing rates in younger age groups and in people with Alzheimers disease warrants further investigation.",neurology,fuzzy,100,100
medRxiv,10.1101/2023.02.16.23286017,2023-02-18,https://medrxiv.org/cgi/content/short/2023.02.16.23286017,Long-term outdoor air pollution and COVID-19 mortality in London: an individual-level analysis,Loes Charlton; Chris Gale; Jasper Morgan; Myer Glickman; Sean Beevers; Anna L Hansell; Vah√© Nafilyan,Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Imperial College London; University of Leicester; Office for National Statistics,"BackgroundThe risk of COVID-19 severity and mortality differs markedly by age, socio-demographic characteristics and pre-existing health status. Various studies have suggested that higher air pollution exposures also increase the likelihood of dying from COVID-19.

Objectives: To assess the association between long-term outdoor air pollution (NO2, NOx, PM10 and PM2.5) concentrations and the risk of death involving COVID-19, using a large individual-level dataset.

MethodsWe used comprehensive individual-level data from the Office for National Statistics Public Health Data Asset for September 2020 to January 2022 and London Air Quality Network modelled air pollution concentrations available for 2016. Using Cox proportional hazard regression models, we adjusted for potential confounders including age, sex, vaccination status, dominant virus variants, geographical factors (such as population density), ethnicity, area and household-level deprivation, and health comorbidities.

ResultsThere were 737,356 confirmed COVID-19 cases including 9,315 COVID-related deaths. When only adjusting for age, sex, and vaccination status, there was an increased risk of dying from COVID-19 with increased exposure to all air pollutants studied (NO2: HR 1.07 [95% confidence interval: 1.04-1.12] per 10 g/m3; NOx: 1.05[1.02-1.09] per 20 g/m3; PM10: 1.32[1.15-1.51] per 10 g/m3; PM2.5: 1.29[1.12-1.49] per 5 g/m3). However, after adjustment including ethnicity and socio-economic factors the HRs were close to unity (NO2: 0.98[0.90-1.06]; NOx: 0.99[0.94-1.04]; PM10: 0.95[0.74-1.22]; PM2.5: 0.90[0.67-1.20]). Additional adjustment for dominant variant or pre-existing health comorbidities did not alter the results.

ConclusionsObserved associations between long-term outdoor air pollution exposure and COVID-19 mortality in London are strongly confounded by geography, ethnicity and deprivation.

SummaryUsing a large individual-level dataset, we found that a positive association between long-term outdoor air pollution and COVID-19 mortality in London did not persist after adjusting for confounders including population density, ethnicity and deprivation.",respiratory medicine,fuzzy,100,100
medRxiv,10.1101/2023.02.10.23285717,2023-02-14,https://medrxiv.org/cgi/content/short/2023.02.10.23285717,The long COVID evidence gap: comparing self-reporting and clinical coding of long COVID using longitudinal study data linked to healthcare records.,Anika Knuppel; Andy Boyd; John Macleod; Nishi Chaturvedi; Dylan M Williams,"MRC Unit of Lifelong Health and Ageing at UCL, University College London, London W1E 7HB, London, United Kingdom; Institute of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, United Kingdom; Institute of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2BN, United Kingdom; MRC Unit of Lifelong Health and Ageing at UCL, University College London, London W1E 7HB, London, United Kingdom; MRC Unit of Lifelong Health and Ageing at UCL, University College London, London W1E 7HB, London, United Kingdom","The term ""long COVID"" (LC) was coined in spring 2020 by individuals with ongoing symptoms following COVID-19, but it took until December 2020 for clinical codes to be created in order to record persistent post-COVID-19 illness and referrals within electronic health records (EHRs). Analysis of whole-population EHR databases have helped understand the epidemiology of LC; yet concerns exist about the completeness of accessible EHRs for LC. UK longitudinal population studies (LPS) collected self-reported data on COVID-19 and LC from early 2020 and deposited these data in the UK Longitudinal Linkage Collaboration (UK LLC) research database where they are systematically linked to the participants EHRs. Comparisons of LPS reported LC with recorded LC in the EHRs of the same individuals may be helpful in understanding the epidemiology of emerging conditions such as LC. We used data from 10 UK LPS in the UK LLC to investigate whether participants self-reporting LC had a LC diagnosis or referral code in their English EHR after 10 to 22 months of follow up. Of 6412 participants with COVID-19 symptom duration data and linkage to health records, 898 (14.0%) self-reported LC of any severity in LPS surveys. Among these, just 42 (4.7%; 95% CI: 3.5, 6.3) were identified with LC-related codes in EHRs. In individuals reporting debilitating LC, this proportion was only marginally higher (5.6%; 95% CI: 3.7, 8.3). Our data show a striking discrepancy between LC as perceived and reported by participants in LPS and evidence of LC recorded in their EHRs; and that this discrepancy was patterned by ethnicity and possibly by indicators of deprivation. Self-reported symptoms may not be reflected in coded EHRs due to factors including variations in individuals help seeking behaviours, clinician coding practices and the availability of appropriate codes. However, these considerations appear unlikely to provide a complete explanation for the substantial observed reporting discrepancy. These results may indicate substantial unmet clinical need, in keeping with patient reports of difficulties accessing healthcare and sub-optimal recognition of, and response to, their illness when they do. They may also indicate potential shortcomings of epidemiological research on LC based on EHR- or LPS-based ascertainment alone and illustrate the value of triangulation between LPS and EHR data where linked and made available through resources such as the UK LLC.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.02.09.23285649,2023-02-14,https://medrxiv.org/cgi/content/short/2023.02.09.23285649,"Antibody prevalence after 3 or more COVID-19 vaccine doses in 23,000 immunosuppressed individuals: a cross-sectional study from MELODY",Fiona A Pearce; Sean Hua Lim; Mary Bythell; Peter Lanyon; Rachel Hog; Adam Taylor; Gillian Powter; Graham Cooke; Helen Ward; Joseph Chilcot; Helen Thomas; Lisa Mumford; Stephen P McAdoo; Gavin J Pettigrew; Liz Lightstone; Michelle Willicombe,"Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK; Centre for Cancer Immunology, University of Southampton, Southampton, UK; National Disease Registration Service, NHS Digital; Department of Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham, UK; Statistics and Clinical Research, NHS Blood and Transplant, Bristol, UK; Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, UK; NHS Blood and Transplant Clinical Trials Unit, Oxford, UK; Imperial College; Imperial College London; Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK; Statistics and Clinical Research, NHS Blood and Transplant, Bristol, UK; Statistics and Clinical Research, NHS Blood and Transplant, Bristol, UK; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, Du Cane Road, London, UK.; Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, Du Cane Road, London, UK.; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, Du Cane Road, London, UK.","ObjectivesTo investigate the prevalence of spike-protein antibodies following at least 3 COVID-19 vaccine doses in immunocompromised individuals.

DesignCross-sectional study using UK national disease registries of individuals with solid organ transplants (SOT), rare autoimmune rheumatic diseases (RAIRD) and lymphoid malignancies (LM).

SettingParticipants were identified, invited and recruited at home by accessing the NHS Blood and Transplant Registry for those UK individuals who had received a SOT; and the National Disease Registration Service at NHS Digital for identifying individuals within England with RAIRD or LM.

Participants101972 people were invited, 28411 recruited, and 23036 provided serological data, comprising 9927 SOT recipients, 6516 with RAIRD, and 6593 with LM.

InterventionsParticipants received a lateral flow immunoassay for spike-protein antibodies to perform at home together with an online questionnaire.

Main outcome measuresOdds of detectable IgG spike-protein antibodies in immunosuppressed cohorts following at least three COVID-19 vaccine doses by participant demographic, disease type, and treatment related characteristics

ResultsIgG spike-protein antibodies were undetectable in 23.3%, 14.1% and 20.7% of the SOT, RAIRD and LM cohorts, respectively. Participants had received three, four or [&ge;]five vaccine doses at the time of testing in 28.5%, 61.8%, and 9.6%, respectively. In all groups, seropositivity was associated with younger age, higher number of vaccine doses and previous COVID-19 infection. Immunosuppressive medication reduced the likelihood of seropositivity: the lowest odds of seropositivity were found in SOT recipients receiving an anti-proliferative agent, calcineurin inhibitor and steroid concurrently, and those treated with anti-CD20 in the RAIRD and LM cohorts.

ConclusionsApproximately one in five individuals with SOT, RAIRD and LM have no detectable IgG spike-protein antibodies despite three or more vaccines, but this proportion reduces with sequential booster doses. Choice of immunosuppressant and disease-type is strongly associated with serological response. Antibody testing could enable rapid identification of individuals who are most likely to benefit from additional COVID-19 interventions.

Trial registrationClinicaltrials.gov, NCT05148806",public and global health,fuzzy,100,100
medRxiv,10.1101/2023.02.06.23285513,2023-02-06,https://medrxiv.org/cgi/content/short/2023.02.06.23285513,A Rapid review on the COVID-19 Pandemic's Global Impact on Breast Cancer Screening Participation Rates and Volumes from January-December 2020,"Reagan Lee; - UNCOVER; Wei Xu; - International Partnership for Resilience in Cancer Systems (I-PaRCS), Breast Cancer Working Group 2; Marshall Dozier; Ruth McQuillan; Evropi Theodoratou; Jonine Figueroa",University of Edinburgh; -; University of Edinburgh; -; University of Edinburgh; University of Edinburgh; The University of Edinburgh; University of Edinburgh,"BackgroundCOVID-19 has strained population breast mammography screening programs that aim to diagnose and treat breast cancers earlier. As the pandemic has affected countries differently, we aimed to quantify changes in breast screening volume and uptake during the first year of the COVID-19 pandemic.

MethodsWe systematically searched Medline, the WHO (World Health Organization) COVID-19 database, and governmental databases. Studies covering January 2020 to March 2022 were included. We extracted and analyzed data regarding study methodology, screening volume and uptake. To assess for risk-of-bias, we used the Joanna Briggs Institute Critical Appraisal tool.

ResultsTwenty-six cross-sectional descriptive studies were included out of 935 independent records. Reductions in screening volume and uptake rates were observed among eight countries. Changes in screening participation volume in five countries with national population-based screening ranged from -13% to -31%. Among two countries with limited population-based programs the decline ranged from -61% to -41%. Within the USA, population participation volumes varied ranging from +18% to -39% with suggestion of differences by insurance status (HMO, Medicare, and low-income programs). Almost all studies had high risk-of-bias due to insufficient statistical analysis and confounding factors.

Discussion and ConclusionExtent of COVID-19-induced reduction in breast screening participation volume differed by region and data suggested potential differences by healthcare setting (e.g., national health insurance vs private health care). Recovery efforts should monitor access to screening and early diagnosis to determine if prevention services need strengthening to increase coverage of marginalized groups and reduce disparities.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.02.01.23285333,2023-02-02,https://medrxiv.org/cgi/content/short/2023.02.01.23285333,Associations between reported healthcare disruption due to COVID-19 and avoidable hospitalisation: Evidence from seven linked longitudinal studies for England,Mark A Green; Martin McKee; Olivia Hamilton; Richard Shaw; John MacLeod; Andrew Boyd; - The LH&W NCS Collaborative; Srinivasa Vittal Katikireddi,University of Liverpool; London School of Hygiene and Tropical Medicine; University of Glasgow; University of Glasgow; University of Bristol; University of Bristol; ; University of Glasgow,"BackgroundHealth services across the UK struggled to cope during the COVID-19 pandemic. Many treatments were postponed or cancelled, although the impact was mitigated by new models of delivery. While the scale of disruption has been studied, much less is known about if this disruption impacted health outcomes. The aim of our paper is to examine whether there is an association between individuals experiencing disrupted access to healthcare during the pandemic and risk of an avoidable hospitalisation.

MethodsWe used individual-level data for England from seven longitudinal cohort studies linked to electronic health records from NHS Digital (n = 29 276) within the UK Longitudinal Linkage Collaboration trusted research environment. Avoidable hospitalisations were defined as emergency hospital admissions for ambulatory care sensitive and emergency urgent care sensitive conditions (1st March 2020 to 25th August 2022). Self-reported measures of whether people had experienced disruption during the pandemic to appointments (e.g., visiting their GP or an outpatient department), procedures (e.g., surgery, cancer treatment) or medications were used as our exposures. Logistic regression models examined associations.

Results35% of people experienced some form of disrupted access to healthcare. Those whose access was disrupted were at increased risk of any (Odds Ratio (OR) = 1.80, 95% Confidence Intervals (CIs) = 1.34-2.41), acute (OR = 1.68, CIs = 1.13-2.53) and chronic (OR = 1.93, CIs = 1.40-2.64) ambulatory care sensitive hospital admissions. There were positive associations between disrupted access to appointments and procedures to measures of avoidable hospitalisations as well.

ConclusionsOur study presents novel evidence from linked individual-level data showing that people whose access to healthcare was disrupted were more likely to have an avoidable or potentially preventable hospitalisation. Our findings highlight the need to increase healthcare investment to tackle the short- and long-term implications of the pandemic beyond directly dealing with SARS-CoV-2 infections.",public and global health,fuzzy,100,100
medRxiv,10.1101/2023.01.31.23285232,2023-02-01,https://medrxiv.org/cgi/content/short/2023.01.31.23285232,"Cohort profile: Virus Watch: Understanding community incidence, symptom profiles, and transmission of COVID-19 in relation to population movement and behaviour",Thomas Edward Byrne; Jana Kovar; Sarah Beale; Isobel Braithwaite; Ellen Fragaszy; Wing Lam Erica Fong; Cyril Geismar; Susan J Hoskins; Annalan Mathew Dwight Navaratnam; Vincent Nguyen; Parth Patel; Madhumita Shrotri; Alexei Yavlinsky; Pia Hardelid; Linda Wijlaars; Eleni Nastouli; Moira Spyer; Anna Ayree; Ingemar Cox; Vasileios Lampos; Rachel A McKendry; Tao Cheng; Anne M Johnson; Susan Fiona Michie; Jo Gibbs; Richard Gilson; Alison Rodger; Ibrahim Abubakar; Andrew Hayward; Robert W Aldridge,University College London; University College London; University College London; University College London; UCL; University College London; University College London; Univerity College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; UCLH; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; UCL,"Key FeaturesO_LIVirus Watch is a national community cohort study of COVID-19 in households in England and Wales, established in June 2020. The study aims to provide evidence on which public health approaches are most effective in reducing transmission, and investigate community incidence, symptoms, and transmission of COVID-19 in relation to population movement and behaviours.
C_LIO_LI28,527 households and 58,628 participants of age (0-98 years, mean age 48), were recruited between June 2020 - July 2022
C_LIO_LIData collected include demographics, details on occupation, co-morbidities, medications, and infection-prevention behaviours. Households are followed up weekly with illness surveys capturing symptoms and their severity, activities in the week prior to symptom onset and any COVID-19 test results. Monthly surveys capture household finance, employment, mental health, access to healthcare, vaccination uptake, activities and contacts. Data have been linked to Hospital Episode Statistics (HES), inpatient and critical care episodes, outpatient visits, emergency care contacts, mortality, virology testing and vaccination data held by NHS Digital.
C_LIO_LINested within Virus Watch are a serology & PCR cohort study (n=12,877) and a vaccine evaluation study (n=19,555).
C_LIO_LIStudy data are deposited in the Office of National Statistics (ONS) Secure Research Service (SRS). Survey data are available under restricted access upon request to ONS SRS.
C_LI",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.01.29.23285160,2023-01-30,https://medrxiv.org/cgi/content/short/2023.01.29.23285160,High number of SARS-CoV-2 persistent infections uncovered through genetic analysis of samples from a large community-based surveillance study,Mahan Ghafari; Matthew Hall; Tanya Golubchik; Daniel Ayoubkhani; Thomas House; George MacIntyre-Cockett; Helen Fryer; Laura Thomson; Anel Nurtay; David Buck; Angie Green; Amy Trebes; Paolo Piazza; Lorne J Lonie; Ruth Studley; Emma Rourke; Darren Smith; Matthew Bashton; Andrew Nelson; Matthew Crown; Clare McCann; Gregory R Young; Rui Andre Nunes de Santos; Zack Richards; Adnan Tariq; Roberto Cahuantzi; - Wellcome Sanger Institute COVID-19 Surveillance Team; - COVID-19 Infection Survey Group; - The COVID-19 Genomics UK (COG-UK) consortium; Jeff Barrett; Christophe Fraser; David Bonsall; Sarah Walker; Katrina A Lythgoe,University of Oxford; University of Oxford; University of Oxford; Office for National Statistics; University of Manchester; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Office for National Statistics; Office for National Statistics; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Office for National Statistics; -; -; -; Wellcome Sanger Institute; University of Oxford; University of Oxford; University of Oxford; University of Oxford,"Persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections may act as viral reservoirs that could seed future outbreaks 1-5, give rise to highly divergent lineages 6-8, and contribute to cases with post-acute Coronavirus disease 2019 (COVID-19) sequelae (Long Covid) 9,10. However, the population prevalence of persistent infections, their viral load kinetics, and evolutionary dynamics over the course of infections remain largely unknown. We identified 381 infections lasting at least 30 days, of which 54 lasted at least 60 days. These persistently infected individuals had more than 50% higher odds of self-reporting Long Covid compared to the infected controls, and we estimate that 0.09-0.5% of SARS-CoV-2 infections can become persistent and last for at least 60 days. In nearly 70% of the persistent infections we identified, there were long periods during which there were no consensus changes in virus sequences, consistent with prolonged presence of non-replicating virus. Our findings also suggest reinfections with the same major lineage are rare and that many persistent infections are characterised by relapsing viral load dynamics. Furthermore, we found a strong signal for positive selection during persistent infections, with multiple amino acid substitutions in the Spike and ORF1ab genes emerging independently in different individuals, including mutations that are lineage-defining for SARS-CoV-2 variants, at target sites for several monoclonal antibodies, and commonly found in immunocompromised patients 11-14. This work has significant implications for understanding and characterising SARS-CoV-2 infection, epidemiology, and evolution.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.01.24.23284906,2023-01-25,https://medrxiv.org/cgi/content/short/2023.01.24.23284906,The impact of COVID-19 lockdown on a cohort of adults with recurrent major depressive disorder from Catalonia: a decentralized longitudinal study using remote measurement technology,Raffaele Lavalle Sr.; Elena Condominas; Josep Maria Haro; Iago Gine-Vazquez; Raquel Bailon; Estela Laporta; Ester Garcia; Spyridon Kontaxis; Gemma Riquelme; Federica Lombardini; Antonio Preti; Maria Teresa Penarrubia Maria; Marta Coromina; Belen Arranz; Elisabet Vilella; Elena Rubio Abadal; Faith Matcham; Femke Lamers; Matthew Hotopf; Brenda W.J.H Penninx; Peter Annas; Vaibhav Narayan; Sara Katherine Simblett; Sara Siddi,"Dipartimento di neuroscienze, Universita degli studi di Torino, Italia; Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM,Universitat de Barcelona, Barcelona, Spain; Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM,Universitat de Barcelona, Barcelona, Spain; Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM,Universitat de Barcelona, Barcelona, Spain; Aragon Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain; Centros de investigacion biomedica en red en el area de bioingenieria, biomateriales y nanomedicina (CIBER BBN), Madrid, Spain; Microelectronica y Sistemas Electronicos, Universidad Autonoma de Barcelona, Spain; Centros de Investigacion Biomedica en Red en el Area de Bioingenieria, Biomateriales y Nanomedicina (CIBER BBN), 28029 Madrid, Spain; Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain; Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM,Universitat de Barcelona, Barcelona, Spain; Dipartimento di neuroscienze, Universita degli studi di Torino, Italia; Health Technology Assessment in Primary Care and Mental Health (PRISMA) Research Group, Parc Sanitari Sant Joan de Deu, Institut de Recerca Sant Joan de Deu, St; Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM,Universitat de Barcelona, Barcelona, Spain; Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM,Universitat de Barcelona, Barcelona, Spain; Hospital Universitari Institut Pere Mata, Reus, Spain Institut d'Investigacio Sanitaria Pere Virgili CERCA, Reus, Spain; Universitat Rovira i Virgili, Reus, Spa; Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM,Universitat de Barcelona, Barcelona, Spain; King's College London: London, GB; VU medisch centrum: Amsterdam, Noord-Holland, NL; Kings College London, Institute of Psychiatry, Psychology and Neuroscience, UK; Amsterdam UMC location Vrije Universiteit Amsterdam, Department of Psychiatry, Boelelaan 1117, Amsterdam, The Netherlands; H. Lundbeck A/S, Valby, Denmark; Research and Development Information Technology, Janssen Research & Development, LLC, Titusville, NJ, USA; Kings College London, Institute of Psychiatry, Psychology and Neuroscience, UK; Parc Sanitari Sant Joan de Deu, Fundacio Sant Joan de Deu, CIBERSAM,Universitat de Barcelona, Barcelona, Spain","BackgroundThe present study analyzes the effects of each containment phase of the first COVID-19 wave on depression levels in a cohort of adults with a history of major depressive disorder (MDD).

MethodsThis analysis is part of the Remote Assessment of Disease and Relapse-MDD (RADAR-MDD) study. Individuals included had a diagnosis of DSM-5 major depressive disorder (MDD), at least two episodes of major depression (MDE), one of them in the previous two years. Depression was evaluated with the Patient Health Questionnaire-8 (PHQ-8) and anxiety with the Generalized Anxiety Disorder-7 (GAD-7). A total of 121 participants recruited from Catalonia were registered from November 1, 2019, to October 16, 2020. Levels of depression were explored across the phases (pre-lockdown, lockdown, four post-lockdown phases) of the restrictions imposed by the Spanish/Catalan governments. Then, a mixed model was fitted to estimate how depression varied over the phases.

ResultsA small but statistically significant rise in the depressive severity was found during the lockdown and phase 0 (early post-lockdown), as compared with the pre-lockdown phase in this sample with a history of MDD. Those with low pre-lockdown depression experienced an increase in depression levels during the ""new normality"". We observed a significant decrease in the depression levels during the ""new normality"" in those with high pre-lockdown depression, compared to the pre-lockdown period.

ConclusionThese findings suggest that COVID-19 restrictions impacted on the depression of individuals diagnosed with MDD, depending on their pre-lockdown depression severity. Furthermore, these subjects worsened when the restrictions were harder, during the lockdown and the early post-lockdown.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.01.24.23284916,2023-01-25,https://medrxiv.org/cgi/content/short/2023.01.24.23284916,"Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study",Andrew Evans; Cathy Qi; Lolu Adebayo; Jonathan Underwood; James Coulson; Rowena Bailey; Gareth John; Alison Cooper; Ashley Akbari; Ronan Lyons; Adrian Edwards,"Welsh Government; Swansea University Medical School; Swansea University Medical School; School of Medicine, Cardiff University; School of Medicine, Cardiff University,; Swansea University Medical School; Digital Health and Care Wales; Wales COVID-19 Evidence Centre; Swansea University; Swansea University; Wales COVID-19 Evidence Centre","ObjectiveTo compare the effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab with no treatment in preventing hospital admission or death in higher-risk patients infected with SARS-CoV-2 in the community.

DesignRetrospective cohort study of non-hospitalised adult patients with COVID-19 using the Secure Anonymised Information Linkage (SAIL) Databank.

SettingA real-world cohort study was conducted within the SAIL Databank (a secure trusted research environment containing anonymised, individual, population-scale electronic health record (EHR) data) for the population of Wales, UK.

ParticipantsAdult patients with COVID-19 in the community, at higher risk of hospitalisation and death, testing positive for SARS-CoV-2 between 16th December 2021 and 22nd April 2022.

InterventionsMolnupiravir, nirmatrelvir-ritonavir, and sotrovimab given in the community by local health boards and the National Antiviral Service in Wales.

Main outcome measuresAll-cause admission to hospital or death within 28 days of a positive test for SARS-CoV-2.

Statistical analysisCox proportional hazard model with treatment status (treated/untreated) as a time-dependent covariate and adjusted for age, sex, number of comorbidities, Welsh Index of Multiple Deprivation, and vaccination status. Secondary subgroup analyses were by treatment type, number of comorbidities, and before and on or after 20th February 2022, when omicron BA.1 and omicron BA.2 were the dominant subvariants in Wales.

ResultsBetween 16th December 2021 and 22nd April 2022, 7,103 higher-risk patients were eligible for inclusion in the study. Of these, 2,040 received treatment with molnupiravir (359, 17.6%), nirmatrelvir-ritonavir (602, 29.5%), or sotrovimab (1,079, 52.9%). Patients in the treatment group were younger (mean age 53 vs 57 years), had fewer comorbidities, and a higher proportion had received four or more doses of the COVID-19 vaccine (36.3% vs 17.6%).

Within 28 days of a positive test, 628 (9.0%) patients were admitted to hospital or died (84 treated and 544 untreated). The primary analysis indicated a lower risk of hospitalisation or death at any point within 28 days in treated participants compared to those not receiving treatment. The adjusted hazard rate was 35% (95% CI: 18-49%) lower in treated than untreated participants. There was no indication of the superiority of one treatment over another and no evidence of a reduction in risk of hospitalisation or death within 28 days for patients with no or only one comorbidity. In patients treated with sotrovimab, the event rates before and on or after 20th February 2022 were similar (5.0% vs 4.9%) with no significant difference in the hazard ratios for sotrovimab between the time periods.

ConclusionsIn higher-risk adult patients in the community with COVID-19, those who received treatment with molnupiravir, nirmatrelvir-ritonavir, or sotrovimab were at lower risk of hospitalisation or death than those not receiving treatment.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2023.01.06.22283653,2023-01-07,https://medrxiv.org/cgi/content/short/2023.01.06.22283653,The incidence of COVID-19-related hospitalisation in migrants in the UK: Findings from the Virus Watch prospective community cohort study,Wing Lam Erica Fong; Vincent G Nguyen; Rachel Burns; Yamina Boukari; Sarah Beale; Isobel Braithwaite; Thomas E Byrne; Cyril Geismar; Ellen Fragaszy; Susan Hoskins; Jana Kovar; Annalan MD Navaratnam; Youssof Oskrochi; Parth Patel; Sam Tweed; Alexei Yavlinsky; Andrew C Hayward; Robert W Aldridge,"Institute of Health Informatics, University College London; Institute of Health Informatics, University College London; Institute of Epidemiology and Health Care, University College London; Department of Population, Poli; Institute of Health Informatics, University College London; Institute of Health Informatics, University College London; Institute of Health Informatics, University College London; Institute of Epidemiology and Health Care, University College London;; Institute of Health Informatics, University College London; Institute of Health Informatics, University College London; MRC Centre for Global Infectious Disease Analysis, Department of Infectious Disease Epidemiology, School of Public Health, Imperial College London; Institute of; Institute of Health Informatics, University College London; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine; Institute of Epidemiology and Health Care, University College London; Institute of Health Informatics, University College London; Institute of Health Informatics, University College London; Institute of Epidemiology and Health Care, University College London; Institute of Health Informatics, University College London; Institute of Health Informatics, University College London; Institute of Health Informatics, University College London; Institute of Health Informatics, University College London; Institute of Epidemiology and Health Care, University College London; Institute of Health Informatics, University College London","BackgroundMigrants in the UK may be at higher risk of SARS-CoV-2 exposure; however, little is known about their risk of COVID-19-related hospitalisation during waves 1-3 of the pandemic.

MethodsWe analysed secondary care data linked to Virus Watch study data for adults and estimated COVID-19-related hospitalisation incidence rates by migration status. To estimate the total effect of migration status on COVID-19 hospitalisation rates, we ran fixed-effect Poisson regression for wave 1 (01/03/2020-31/08/2020; wildtype), and fixed-effect negative binomial regressions for waves 2 (01/09/2020-31/05/2021; Alpha) and 3 (01/06/2020-31/11/2021; Delta). Results of all models were then meta-analysed.

ResultsOf 30,276 adults in the analyses, 26,492 (87.5%) were UK-born and 3,784 (12.5%) were migrants. COVID-19-related hospitalisation incidence rates for UK-born and migrant individuals across waves 1-3 were 2.7 [95% CI 2.2-3.2], and 4.6 [3.1-6.7] per 1,000 person-years, respectively. Pooled incidence rate ratios across waves suggested increased rate of COVID-19-related hospitalisation in migrants compared to UK-born individuals in unadjusted 1.68 [1.08-2.60] and adjusted analyses 1.35 [0.71-2.60].

ConclusionOur findings suggest migration populations in the UK have excess risk of COVID-19-related hospitalisations and underscore the need for more equitable interventions particularly aimed at COVID-19 vaccination uptake among migrants.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.01.04.22283762,2023-01-05,https://medrxiv.org/cgi/content/short/2023.01.04.22283762,Challenges in estimating waning effectiveness of two doses of BNT162b2 and ChAdOx1 COVID-19 vaccines beyond six months: an OpenSAFELY cohort study using linked electronic health records,Elsie MF Horne; William J Hulme; Ruth H Keogh; Tom M Palmer; Elizabeth Williamson; Edward PK Parker; Venexia M Walker; Rochelle Knight; Yinghui Wei; Kurt Taylor; Louis Fisher; Jessica Morley; Amir Mehrkar; Iain Dillingham; Sebastian CJ Bacon; Ben Goldacre; Jonathan AC Sterne; - The OpenSAFELY Collaborative,University of Bristol; University of Oxford; London School of Hygiene and Tropical Medicine; University of Bristol; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Bristol; University of Bristol; University of Plymouth; University of Bristol; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Bristol; -,"Quantifying the waning effectiveness of second COVID-19 vaccination beyond six months and against the omicron variant is important for scheduling subsequent doses. With the approval of NHS England, we estimated effectiveness up to one year after second dose, but found that bias in such estimates may be substantial.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2023.01.04.23284174,2023-01-05,https://medrxiv.org/cgi/content/short/2023.01.04.23284174,Ethnic differences in the indirect impacts of the COVID-19 pandemic on clinical monitoring and hospitalisations for non-COVID conditions in England: An observational cohort study using OpenSAFELY,Ruth E Costello; John Tazare; Dominik Piehlmaier; Emily Herrett; Edward PK Parker; Bang Zheng; Kathryn E Mansfield; Alasdair D Henderson; Helena Carreira; Patrick Bidulka; Angel YS Wong; Charlotte Warren-Gash; Joseph F Hayes; Jennifer K Quint; Brian MacKenna; Rosalind M Eggo; Srinivasa Vittal Katikireddi; Laurie Tomlinson; Sinead M Langan; Rohini Mathur; - The longitudinal health and wellbeing; - The OpenSAFELYcollaborative,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Sussex; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; UCL; Imperial College London; University of Oxford; London School of Hygiene & Tropical Medicine; University of Glasgow; LSHTM; London School of Hygiene and Tropical Medicine; Queen Mary University of London; ; ,"BackgroundThe COVID-19 pandemic disrupted healthcare and may have impacted ethnic inequalities in healthcare. We aimed to describe the impact of pandemic-related disruption on ethnic differences in clinical monitoring and hospital admissions for non-COVID conditions in England.

MethodsWe conducted a cohort study using OpenSAFELY (2018-2022). We grouped ethnicity (exposure), into five categories: White, South Asian, Black, Other, Mixed. We used interrupted time-series regression to estimate ethnic differences in clinical monitoring frequency (e.g., blood pressure measurements) before and after 23rd March 2020. We used multivariable Cox regression to quantify ethnic differences in hospitalisations related to: diabetes, cardiovascular disease, respiratory disease, and mental health before and after 23rd March 2020.

FindingsOf 14,930,356 adults in 2020 with known ethnicity (92% of sample): 86.6% were White, 7.3% Asian, 2.6% Black, 1.4% Mixed ethnicity, and 2.2% Other ethnicities. Clinical monitoring did not return to pre-pandemic levels for any ethnic group. Ethnic differences were apparent pre-pandemic, except for diabetes monitoring, and remained unchanged, except for blood pressure monitoring in those with mental health conditions where differences narrowed during the pandemic. For those of Black ethnicity, there were seven additional admissions for diabetic ketoacidosis per month during the pandemic, and relative ethnic differences narrowed during the pandemic compared to White. There was increased admissions for heart failure during the pandemic for all ethnic groups, though highest in White ethnicity. Relatively, ethnic differences narrowed for heart failure admission in those of Asian and Black ethnicity compared to White. For other outcomes the pandemic had minimal impact on ethnic differences.

InterpretationOur study suggests ethnic differences in clinical monitoring and hospitalisations remained largely unchanged during the pandemic for most conditions. Key exceptions were hospitalisations for diabetic ketoacidosis and heart failure, which warrant further investigation to understand the causes.

FundingLSHTM COVID-19 Response Grant (DONAT15912).

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched MEDLINE from inception to 7th September 2022, for articles published in English, including the title/abstract search terms (healthcare disruption OR indirect impact OR miss* diagnos* OR delayed diagnos* OR service disruption) AND (sars-cov-2 OR covid-19 OR pandemic OR lockdown) AND (ethnic*). Of the seven studies identified, two broadly investigated the indirect impacts of the pandemic on non-COVID outcomes and reported ethnic differences. However, these two only included data until January 2021 at the latest. Other studies investigated just one disease area such as dementia or diabetes and frequently did not have the power to investigate specific ethnic groups.

Added value of this studyThis is one of the largest studies to describe how the pandemic impacted ethnic differences in clinical monitoring at primary care and hospital admissions for non-COVID conditions (across four disease areas: cardiovascular disease, diabetes mellitus, respiratory disease and mental health) in England. A study population of nearly 15 million people, allowed the examination of five ethnic groups, and data until April 2022 allowed the evaluation of impacts for a longer period than previous studies.We showed that clinical monitoring had still not returned to pre-pandemic levels even by April 2022. Ethnic differences in clinical monitoring were seen pre-pandemic, though not in diabetes measures, these differences were either not impacted or reduced during the pandemic. We also showed that there were ethnic differences in hospital admissions, for many outcomes the pandemic did not impact these differences but there were some exceptions, in particular for diabetic ketoacidosis admissions in those of Black ethnicity and heart failure admissions for those of Black and Asian ethnicities.

Implications of all the available evidenceWe found that the pandemic reduced ethnic inequalities for some outcomes (in hospitalisations for diabetic ketoacidosis and heart failure). However, these were driven by greater absolute increases in admissions for black and asian groups (diabetic ketoacidosis) and white groups (heart failure), which warrant further investigation to understand the underlying causes.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.12.21.22283794,2022-12-22,https://medrxiv.org/cgi/content/short/2022.12.21.22283794,SARS-CoV-2 infections in migrants and the role of household overcrowding: A causal mediation analysis of Virus Watch data,Yamina Boukari; Sarah Beale; Vincent Nguyen; Wing Lam Erica Fong; Rachel Burns; Alexei Yavlinsky; Susan J Hoskins; Kate Marie Lewis; Cyril Geismar; Annalan Mathew Dwight Navaratnam; Isobel Braithwaite; Thomas Edward Byrne; Youssof Oskrochi; Sam Tweed; Jana Kovar; Parth Patel; Andrew Hayward; Robert W Aldridge,University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London,"BackgroundMigrants are over-represented in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections globally; however, evidence is limited for migrants in England and Wales. Household overcrowding is a risk factor for SARS-CoV-2 infection, with migrants more likely to live in overcrowded households than UK-born individuals. We aimed to estimate the total effect of migration status on SARS-CoV-2 infection and to what extent household overcrowding mediated this effect.

MethodsWe included a sub-cohort of individuals from the Virus Watch prospective cohort study during the second SARS-CoV-2 wave (1st September 2020-30th April 2021) who were aged [&ge;]18 years, self-reported the number of rooms in their household and had no evidence of SARS-CoV-2 infection pre-September 2020. We estimated total, indirect and direct effects using Buis logistic decomposition regression controlling for age, sex, ethnicity, clinical vulnerability, occupation, income and whether they lived with children.

ResultsIn total, 23,478 individuals were included. 9.07% (187/2,062) of migrants had evidence of infection during the study period versus 6.27% (1,342/21,416) of UK-born individuals. Migrants had 22% higher odds of infection during the second wave (total effect; OR:1.22, 95%CI:1.01-1.47). Household overcrowding accounted for approximately 32% of these increased odds (indirect effect, OR:1.07, 95%CI:1.03-1.12; proportion accounted for: indirect effect[7]/total effect[22]=0.32).

ConclusionMigrants had higher odds of SARS-CoV-2 infection during the second wave compared with UK-born individuals and household overcrowding explained 32% of these increased odds. Policy interventions to reduce household overcrowding for migrants are needed as part of efforts to tackle health inequalities during the pandemic and beyond.

Key messagesO_ST_ABSWhat is already known on this topicC_ST_ABSO_LIMigrants in England and Wales may be at greater risk of exposure to SARS-CoV-2 due to unique risk factors, including over-representation in front-line jobs, an increased likelihood of living in multigenerational households and difficulties in accessing primary care. Research shows that migrants in high-income countries have been disproportionally infected with SARS-CoV-2. It is likely that, due to their pre-existing vulnerabilities, this is similarly the case for migrants in England and Wales; however, quantitative evidence addressing this is lacking.
C_LI

What this study addsO_LIWe investigated the effect of being a migrant on SARS-CoV-2 infection during the second wave of the pandemic in a cohort in England and Wales. We also determined the proportion of the effect mediated by household overcrowding after controlling for age, sex, ethnicity, clinical vulnerability, occupation, income and the presence of children in the household. Migrants had 22% higher odds of being infected with SARS-CoV-2 than their UK-born counterparts, and household overcrowding accounted for approximately 32% of these increased odds.
C_LI

How this study might affect research, practice or policyO_LIOur findings highlight the role of household overcrowding in the disproportionate impact of SARS-CoV-2 infections on migrants. They also demonstrate the urgent need for policy interventions that improve housing conditions as part of efforts to reduce health inequalities. Further research investigating other causes of migrants over-representation in infection cases is also needed to inform further targeted policy interventions.
C_LI",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.12.15.22283507,2022-12-20,https://medrxiv.org/cgi/content/short/2022.12.15.22283507,Antidepressant drug prescription and incidence of COVID-19: a retrospective cohort study,Oleg O Glebov; Christoph Mueller; Robert Stewart; Dag Aarsland; Gayan Perera,"Qingdao University Medical School; King's College London; Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK; South London and Maudsley NHS Foundation Trust, London, UK.; Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London; South London and Maudsley NHS Foundation Trust, London, UK.; Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK; Centre for Age-related research, Stavanger University Hospital, Stavange; Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK; South London and Maudsley NHS Foundation Trust, London, UK.","While antidepressant drugs (ADs) have shown some efficacy in treatment of COVID-19, their preventative potential remains unexplored. To investigate association between AD and COVID-19 incidence in the community, we analysed data from community-living, non-hospitalized adults admitted to inpatient care of the South London&Maudsley (SLaM) NHS Foundation Trust during the 1st wave of COVID-19 pandemic in the UK. Prescription of ADs within the period of 1 to 3 months before admission was associated with an approximately 40% decrease in positive COVID-19 test results when adjusted for socioeconomic parameters and physical health. This association was specifically observed for ADs of the Selective Serotonin Reuptake Inhibitor (SSRI) class. These results suggest that ADs, specifically SSRIs, may help prevent COVID-19 infection in the community. Definitive determination of AD preventative potential warrants prospective studies in the wider general population.

Key pointsO_ST_ABSQuestionC_ST_ABSIs there an association between prescription of antidepressants and incidence of COVID-19 in the general population?

FindingsIn this retrospective cohort study of mental health outpatients with a recent (1-3 months) antidepressant prescription, there was a statistically significant 40% decrease in positive COVID-19 tests. This association was specifically observed for the most commonly prescribed antidepressant class, Selective Serotonin Reuptake Inhibitors, and remained when adjusted for socioeconomic parameters and physical health.

MeaningAntidepressant prescription was associated with lower incidence of COVID-19 in the community, warranting further investigation as prophylactics in prospective clinical studies.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.12.19.22283660,2022-12-19,https://medrxiv.org/cgi/content/short/2022.12.19.22283660,"Analysis of uptake, effectiveness and safety of COVID-19 vaccinations in pregnancy using the QResearch database: research protocol and statistical analysis plan",Emma Copland; Jennifer A Hirst; Tom Ranger; Winnie Xue Mei; Sharon Dixon; Carol Coupland; Kenneth Hodson; Jonathan Luke Richardson; Anthony Harnden; Aziz Sheikh; Carol Dezateux; Brenda Kelly; Marian Knight; Jonathan Van Tam; Alessandra Morelli; Joanne Enstone; Julia Hippisley-Cox,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Newcastle upon Tyne Hospitals NHS Foundation Trust; Newcastle upon Tyne Hospitals NHS Foundation Trust; University of Oxford; The University of Edinburgh College of Medicine and Veterinary Medicine; Queen Mary University of London; University of Oxford; University of Oxford; University of Nottingham; University of Oxford; Leicester City Clinical Commissioning Group; University of Oxford,"BackgroundThe COVID-19 pandemic has affected millions of people globally with major health, social and economic consequences, prompting development of vaccines for use in the general population. However, vaccination uptake is lower in some groups, including in pregnant women, because of concerns regarding vaccine safety. There is evidence of increased risk of adverse pregnancy and neonatal outcomes associated with SARS-CoV-2 infection, but fear of vaccine-associated adverse events on the baby both in short and longer term is one of the main drivers of low uptake for this group. Other vaccines commonly used in pregnancy include influenza and pertussis. These both have reportedly higher uptake compared with COVID-19 vaccination, which may be because they are perceived to be safer. In this study, we will undertake an independent evaluation of the uptake, effectiveness and safety of COVID-19 vaccinations in pregnant women using the QResearch primary care database in England.

ObjectivesO_LITo determine COVID-19 vaccine uptake in pregnant women compared to uptake of influenza and pertussis vaccinations.
C_LIO_LITo estimate COVID-19 vaccine effectiveness in pregnant women by evaluating the risk of severe COVID-19 outcomes following vaccination.
C_LIO_LITo assess the safety of COVID-19 vaccination in pregnancy by evaluating the risks of adverse pregnancy and perinatal outcomes and adverse events of special interest for vaccine safety after COVID-19 vaccination compared with influenza and pertussis vaccinations.
C_LI

MethodsThis population-based study uses the QResearch(R) database of primary health care records, linked to individual-level data on hospital admissions, mortality, COVID-19 vaccination, SARS-CoV-2 testing data and congenital anomalies. We will include women aged 16 to 49 years with at least one pregnancy during the study period of 30th December 2020 to the latest date available. Babies born during the study period will be identified and linked to the mothers record, where possible.

We will describe vaccine uptake in pregnant women by trimester and population subgroups defined by demographics and other characteristics. Cox proportional hazards multivariable regression will be used to identify factors associated with vaccine uptake. The effectiveness of COVID-19 vaccines in pregnant women will be assessed using time varying Royston-Palmar regression analyses to determine unadjusted and adjusted hazard ratios for the occurrence of severe COVID-19 outcomes after each vaccine dose compared with unvaccinated individuals. For the safety analysis, we will we use logistic regression analyses to determine unadjusted and adjusted odds ratios for the occurrence of maternal (e.g. miscarriage, ectopic pregnancy and gestational diabetes) and perinatal outcomes (e.g. stillbirth, small for gestational age and congenital anomalies) by vaccination status compared to unvaccinated individuals. For the adverse events of special interest for vaccine safety (e.g. venous thromboembolism, myocarditis and Guillain Barre syndrome), we will use time varying Royston-Palmar regression analyses to determine unadjusted and adjusted hazard ratios for the occurrence of each outcome by vaccination status to unvaccinated individuals.

Ethics and disseminationQResearch is a Research Ethics Approved Research Database with ongoing approval from the East Midlands Multi-Centre Research Ethics Committee (Ref: 18/EM/0400). This study was approved by the QResearch Scientific Committee on 9th June 2022. This research protocol has been developed with support from a patient and public involvement panel, who will continue to provide input throughout the duration of the study. Research findings will be submitted to pre-print servers such as MedRxIv, academic publication and disseminated more broadly through media releases and community groups and conference presentations.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.12.16.22283578,2022-12-17,https://medrxiv.org/cgi/content/short/2022.12.16.22283578,"Higher dose corticosteroids in hospitalised COVID-19 patients with hypoxia but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial",Peter W Horby; Jonathan R Emberson; Buddha Basnyat; Mark Campbell; Leon Peto; Guilherme Pessoa-Amorim; Natalie Staplin; Raph L Hamers; John Amuasi; Jeremy Nel; Evelyne Kestelyn; Manisha Rawal; Roshan Kumar Jha; Nguyen Thanh Phong; Uun Samardi; Damodar Paudel; Pham Ngoc Thach; Nasronudin Nasronudin; Emma Stratton; Louise Mew; Rahuldeb Sarkar; J Kenneth Baillie; Maya H Buch; Jeremy N Day; Saul N Faust; Thomas Jaki; Katie Jeffery; Edmund Juszczak; Marian Knight; Wei Shen Lim; Marion Mafham; Alan Montgomery; Andrew Mumford; Kathryn Rowan; Guy Thwaites; Richard Haynes; Martin J Landray,"Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; OUCRU-Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; Kumasi Center for Collaborative Research in Tropic Medicine, Kumasi, Ghana; Division of Infectious Diseases, Department of Medicine, University of the Witwatersrand, Johannesburg, South Africa; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; Sukraraj Tropical and Infectious Disease Hospital, Kathmandu, Nepal; Medicine Department, Nepal Armed Police Force Hospital, Chandragiri, Kathmandu, Nepal; Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; RSUP Dr Hasan Sadikin Hospital, Bandung, West Java, Indonesia; Department of Medicine, Nepal Police Hospital, Maharajgunj, Kathmandu, Nepal; National Hospital for Tropical Diseases, Hanoi, Vietnam; University of Airlangga Teaching Hospital, Surabaya, Indonesia; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom; Milton Keynes University Hospital, Milton Keynes, United Kingdom; Faculty of Life Sciences and Medicine, King's College, London, United Kingdom; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Respiratory Medicine Department, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Intensive Care National Audit and Research Centre, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","BackgroundLow-dose corticosteroids have been shown to reduce mortality for hypoxic COVID-19 patients requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation or extra-corporeal membrane oxygenation). We evaluated the use of a higher dose of corticosteroids in this patient group.

MethodsThis randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting adult patients with clinical evidence of hypoxia (i.e. receiving oxygen or with oxygen saturation <92% on room air) were randomly allocated (1:1) to either usual care with higher dose corticosteroids (dexamethasone 20 mg once daily for 5 days followed by 10 mg once daily for 5 days or until discharge if sooner) or usual standard of care alone (which includes dexamethasone 6 mg once daily for 10 days or until discharge if sooner). The primary outcome was 28-day mortality. On 11 May 2022, the independent Data Monitoring Committee recommended stopping recruitment of patients receiving no oxygen or simple oxygen only to this comparison due to safety concerns. We report the results for these participants only. Recruitment of patients receiving ventilatory support continues. The RECOVERY trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

FindingsBetween 25 May 2021 and 12 May 2022, 1272 COVID-19 patients with hypoxia and receiving no oxygen (1%) or simple oxygen only (99%) were randomly allocated to receive usual care plus higher dose corticosteroids versus usual care alone (of whom 87% received low dose corticosteroids during the follow-up period). Of those randomised, 745 (59%) were in Asia, 512 (40%) in the UK and 15 (1%) in Africa. 248 (19%) had diabetes mellitus. Overall, 121 (18%) of 659 patients allocated to higher dose corticosteroids versus 75 (12%) of 613 patients allocated to usual care died within 28 days (rate ratio [RR] 1{middle dot}56; 95% CI 1{middle dot}18-2{middle dot}06; p=0{middle dot}0020). There was also an excess of pneumonia reported to be due to non-COVID infection (10% vs. 6%; absolute difference 3.7%; 95% CI 0.7-6.6) and an increase in hyperglycaemia requiring increased insulin dose (22% vs. 14%; absolute difference 7.4%; 95% CI 3.2-11.5).

InterpretationIn patients hospitalised for COVID-19 with clinical hypoxia but requiring either no oxygen or simple oxygen only, higher dose corticosteroids significantly increased the risk of death compared to usual care, which included low dose corticosteroids. The RECOVERY trial continues to assess the effects of higher dose corticosteroids in patients hospitalised with COVID-19 who require non-invasive ventilation, invasive mechanical ventilation or extra-corporeal membrane oxygenation.

FundingUK Research and Innovation (Medical Research Council) and National Institute of Health and Care Research (Grant ref: MC_PC_19056), and Wellcome Trust (Grant Ref: 222406/Z/20/Z).",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.12.12.22283200,2022-12-14,https://medrxiv.org/cgi/content/short/2022.12.12.22283200,"COVID-19 Vaccination in Pregnancy: The Impact of Multimorbidity and Smoking Status on Vaccine Hesitancy, a Cohort Study of 25,111 Women in Wales, UK",Mohamed Mhereeg; Hope Jones; Jonathan Kennedy; Mike Seaborne; Michael Parker; Natasha Kennedy; Ashley Akbari; Luisa Zuccolo; Amaya Azcoaga-Lorenzo; Alisha Davies; Krishnarajah Nirantharakumar; Sinead Brophy,"National Centre for Population Health and Wellbeing Research, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, Wales, U; National Centre for Population Health and Wellbeing Research, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, Wales, U; National Centre for Population Health and Wellbeing Research, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, Wales, U; National Centre for Population Health and Wellbeing Research, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, Wales, U; National Centre for Population Health and Wellbeing Research, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, Wales, U; National Centre for Population Health and Wellbeing Research, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, Wales, U; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, Wales, UK; Health Data Science Centre, Fondazione Human Technopole, Milan, Italy; School of Medicine, University of St Andrews, Scotland, UK and Hospital Rey Juan Carlos. Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz. Madrid. Sp; Research and Evaluation Division, Public Health Wales, UK.; Institute of Applied Health Research, Birmingham University, Birmingham, UK.; National Centre for Population Health and Wellbeing Research, Swansea University Medical School, Faculty of Medicine, Health and Life Science, Swansea, Wales, U","BackgroundMultimorbidity and pregnancy are two risk factors for more severe outcomes after a SARS-CoV-2 infection, thus vaccination uptake is important for pregnant women living with multimorbidity. This study aimed to examine the impact of multimorbidity, smoking status, and demographics (age, ethnic group, area of deprivation) on vaccine hesitancy among pregnant women in Wales using electronic health records (EHR) linkage.

MethodsThis cohort study utilised routinely collected, individual-level, anonymised population-scale linked data within the Secure Anonymised Information Linkage (SAIL) Databank. Pregnant women were identified from 13th April 2021 to 31st December 2021. Survival analysis was utilised to examine and compare the length of time to vaccination uptake in pregnancy by multimorbidity and smoking status, as well as depression, diabetes, asthma, and cardiovascular conditions independently. Variation in uptake by; multimorbidity, smoking status, and demographics was examined jointly and separately for the independent conditions using hazard ratios (HR) from the Cox regression model. A bootstrapping internal validation was conducted to assess the performance of the models.

ResultsWithin the population cohort, 8,203 (32.7%) received at least one dose of the COVID-19 vaccine during pregnancy, with 8,572 (34.1%) remaining unvaccinated throughout the follow-up period, and 8,336 (33.2%) receiving the vaccine postpartum. Women aged 30 years or older were more likely to have the vaccine in pregnancy. Those who had depression were slightly but significantly more likely to have the vaccine compared to those without depression (HR = 1.08, 95% CI 1.03 to 1.14, p = 0.02). Women living with multimorbidity (> 1 health condition) were 1.12 times more likely to have the vaccine compared to those living without multimorbidity (HR = 1.12, 95% CI 1.04 to 1.19, p = 0.001). Vaccine uptakes were significantly lower among both current smokers and former smokers compared to never smokers (HR = 0.87, 95% CI 0.81 to 0.94, p < 0.001 and HR = 0.92, 95% CI 0.85 to 0.98, p = 0.015 respectively). Uptake was also lower among those living in the most deprived areas compared to those living in the most affluent areas (HR = 0.89, 95% CI 0.83 to 0.96, p = 0.002). The validated model had similar performance and revealed that multimorbidity, smoking status, age, and deprivation level together have a significant impact on vaccine hesitancy (p < 0.05 for all).

ConclusionYounger women, living without multimorbidity (zero or only one health condition), current and former smokers, and those living in the more deprived areas are less likely to have the vaccine, thus, a targeted approach to vaccinations may be required for these groups. Women living with multimorbidity are slightly but significantly less likely to be hesitant about COVID-19 vaccination when pregnant.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.12.14.22283458,2022-12-14,https://medrxiv.org/cgi/content/short/2022.12.14.22283458,Trends in inequalities in avoidable hospitalisations across the COVID-19 pandemic: A cohort study of 23.5 million people in England,Mark A Green; Martin McKee; Jon Massey; Brain MacKenna; Amir Mehrkar; Sebastian Bacon; John Macleod; Syed Ahmar Shah; Aziz Sheikh; - The OpenSAFELY Consortium; - The LH&W NCS Collaborative; Srinivasa Vittal Katikireddi,University of Liverpool; London School of Hygiene and Tropical Medicine; University of Oxford; NHS England; University of Oxford; University of Oxford; University of Bristol; University of Edinburgh; University of Edinburgh; ; ; University of Glasgow,"BackgroundThe COVID-19 pandemic and associated national lockdowns created unprecedented disruption to healthcare, with reduced access to services and planned clinical encounters postponed or cancelled. It was widely anticipated that failure to obtain timely treatment would cause progression of illness and increased hospital admissions. Additional concerns were that social and spatial inequalities would widen given the disproportionate impacts of COVID-19 directly. The aim of our study is to determine whether this was observable in England.

MethodsWith the approval of NHS England we utilised individual-level electronic health records from OpenSAFELY, which covered [~]40% of general practices in England (mean monthly population size 23.5 million people). We estimated crude and directly age-standardised rates for potentially preventable unplanned hospital admissions: ambulatory care sensitive conditions and urgent emergency sensitive conditions. We considered how trends in these outcomes varied by three measures of social and spatial inequality: neighbourhood socioeconomic deprivation, ethnicity, and geographical region.

FindingsThere were large declines in avoidable hospitalisations during the first national lockdown, which then reversed post-lockdown albeit never reaching pre-pandemic levels. While trends were consistent by each measure of inequality, absolute levels of inequalities narrowed throughout 2020 (especially during the first national lockdown) and remained lower than pre-pandemic trends. While the scale of inequalities remained similar into 2021 for deprivation and ethnicity, we found evidence of widening absolute and relative inequalities by geographic region in 2021 and 2022.

InterpretationThe anticipation that healthcare disruption from the COVID-19 pandemic and lockdowns would result in more (avoidable) hospitalisations and widening social inequalities was wrong. However, the recent growing gap between geographic regions suggests that the effects of the pandemic has reinforced spatial inequalities.",public and global health,fuzzy,100,100
medRxiv,10.1101/2022.12.13.22283391,2022-12-14,https://medrxiv.org/cgi/content/short/2022.12.13.22283391,The effects of sleep disturbance on dyspnoea and impaired lung function following COVID-19 hospitalisation: a prospective multi-centre cohort study,Callum Jackson; Iain Stewart; Tatiana Plekhanova; Peter Cunningham; Andrew L. Hazel; Bashar Al-Sheklly; Raminder Aul; Charlotte E. Bolton; Trudie Chalder; James D. Chalmers; Nazia Chaudhuri; Annemaire B. Docherty; Gavin Donaldson; Charlotte L. Edwardson; Omer Elneima; Neil J Greening; Neil A. Hanley; Victoria C. Harris; Ewen M. Harrison; Ling-Pei Ho; Linzy Houchen-Wolloff; Luke S. Howard; Caroline J. Jolley; Mark G. Jones; Olivia C. Leavy; Keir E. Lewis; Nazir I. Lone; Michael Marks; Hamish J. C. McAuley; Melitta A. McNarry; Brijesh Patel; Karen Piper-Hanley; Krisnah Poinasamy; Betty Raman; Matthew Richardson; Pilar Rivera-Ortega; Sarah L. Rowland-Jones; Alex V. Rowlands; Ruth M. Saunders; Janet T Scott; Marco Sereno; Ajay M. Shah; Aarti Shikotra; Amisha Singapuri; Stefan C. Stanel; Mathew Thorpe; Daniel G. Wootton; Thomas Yates; R Gisli Jenkins; Sally Singh; William D-C. Man; Chris E. Brightling; Louise V. Wain; Joanna C. Porter; A. A. Roger Thompson; Alexander Horsley; Phil L. Molyneaux; Rachael E. Evans; Samuel E. Jones; Martin K. Rutter; John F. Blaikley,"Department of Mathematics, The University of Manchester, Oxford Road, Manchester M13 9PL, United Kingdom; National Heart & Lung Institute, Imperial College London, London, UK; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, LE5 4PW, UK; Faculty of Biology, Medicine and Health,  The University of Manchester, Oxford Road, Manchester M13 9PL United Kingdom; Department of Mathematics, The University of Manchester, Oxford Road, Manchester M13 9PL, United Kingdom; Manchester University NHS Foundation Trust & University of Manchester; St Georges Univeristy Hospitals NHS Foundation Trust, London, UK; NIHR Nottingham BRC respiratory theme, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom; University of Dundee, Ninewells Hospital and Medical School, Dundee, UK; University Hospital of South Manchester NHS Foundation Trust; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK; National Heart & Lung Institute, Imperial College London, London, UK; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, LE5 4PW, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; Manchester University NHS Foundation Trust; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK; Oxford University Hospitals NHS Foundation Trust & University of Oxford; Centre for Exercise and Rehabilitation Science, NIHR Leicester Biomedical Research Centre-Respiratory, University of Leicester, Leicester, UK; National Heart & Lung Institute, Imperial College London, London, UK; King's College London; Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Health Sciences, Univeristy of Leicester, Leicester, UK; Swansea University, Swansea Welsh Network, Hywel Dda University Health Board; Usher Institute, University of Edinburgh, Edinburgh, UK; Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; Swansea University, Swansea Welsh Network, Hywel Dda University Health Board; Royal Brompton and Harefield Clinical Group, Guys and St Thomas NHS Foundation trust; Manchester University NHS Foundation Trust & University of Manchester; Asthma UK and British Lung Foundation, London, UK; Oxford University Hospitals NHS Foundation Trust & University of Oxford; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; Manchester University NHS Foundation Trust; University of Sheffield, Sheffield, UK; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, LE5 4PW, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; MRC - University of Glasgow Centre for Virus Research, Glasgow, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; King's College Hospital NHS Foundation Trust & Kings College London; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; Interstitial Lung Disease Unit, North West Lung Centre, Wythenshawe Hospital, Southmoor Rd, Wythenshawe, Manchester M23 9LT, UK; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, UK; Liverpool University Hospitals NHS Foundation Trust & University of Liverpool; Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, LE5 4PW, UK; National Heart & Lung Institute, Imperial College London, London, UK; University Hospitals of Leicester NHS Trust & University of Leicester; National Heart & Lung Institute, Imperial College London, London, UK; University Hospitals of Leicester NHS Trust & University of Leicester; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; Department of Respiratory Medicine, University College London WC1E 2JF; Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield UK; Faculty of Biology, Medicine and Health,  The University of Manchester, Oxford Road, Manchester M13 9PL United Kingdom; National Heart & Lung Institute, Imperial College London, London, UK; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK; Institute for Molecular Medicine Finland, FIMM, HiLIFE, University of Helsinki, Helsinki, Finland; Faculty of Biology, Medicine and Health,  The University of Manchester, Oxford Road, Manchester M13 9PL United Kingdom; The University of Manchester","BackgroundSleep disturbance is common following hospitalisation both for COVID-19 and other causes. The clinical associations are poorly understood, despite it altering pathophysiology in other scenarios. We, therefore, investigated whether sleep disturbance is associated with dyspnoea along with relevant mediation pathways.

MethodsSleep parameters were assessed in a prospective cohort of patients (n=2,468) hospitalised for COVID-19 in the United Kingdom in 39 centres using both subjective and device-based measures. Results were compared to a matched UK biobank cohort and associations were evaluated using multivariable linear regression.

Findings64% (456/714) of participants reported poor sleep quality; 56% felt their sleep quality had deteriorated for at least 1-year following hospitalisation. Compared to the matched cohort, both sleep regularity (44.5 vs 59.2, p<0.001) and sleep efficiency (85.4% vs 88.5%, p<0.001) were lower whilst sleep period duration was longer (8.25h vs 7.32h, p<0.001). Overall sleep quality (effect estimate 4.2 (3.0-5.5)), deterioration in sleep quality following hospitalisation (effect estimate 3.2 (2.0-4.5)), and sleep regularity (effect estimate 5.9 (3.7-8.1)) were associated with both dyspnoea and impaired lung function (FEV1 and FVC). Depending on the sleep metric, anxiety mediated 13-42% of the effect of sleep disturbance on dyspnoea and muscle weakness mediated 29-43% of this effect.

InterpretationSleep disturbance is associated with dyspnoea, anxiety and muscle weakness following COVID-19 hospitalisation. It could have similar effects for other causes of hospitalisation where sleep disturbance is prevalent.

FundingUK Research and Innovation, National Institute for Health Research, and Engineering and Physical Sciences Research Council.",respiratory medicine,fuzzy,100,100
medRxiv,10.1101/2022.12.09.22283280,2022-12-13,https://medrxiv.org/cgi/content/short/2022.12.09.22283280,Identification of a protein expression signature distinguishing early from organising diffuse alveolar damage in COVID-19 patients.,Helen Ashwin; Luke Milross; Julie Wilson; Joaquim Majo; Jimmy T. H. Lee; Grant Calder; Bethany Hunter; Sally James; Dimitris Lagos; Nathalie Signoret; Andrew Filby; Omer Ali Bayraktar; Andrew J Fisher; Paul M Kaye,University of York; Newcastle University; University of York; Newcastle upon Tyne Hospitals NHS Foundation Trust; Sanger Institute; University of York; Newcastle University; University of York; University of York; University of York; Newcastle University; Sanger Institute; Newcastle University; University of York,"Diffuse alveolar damage (DAD) is a histopathological finding associated with severe viral infections, including SARS-CoV-2. However, the mechanisms mediating progression of DAD are poorly understood. Applying protein digital spatial profiling to lung tissue obtained from a cohort of 27 COVID-19 autopsy cases from the UK, we identified a protein signature (ARG1, CD127, GZMB, IDO1, Ki67, phospho-PRAS40 (T246), and VISTA that distinguishes early / exudative DAD from late / organising DAD with good predictive accuracy. These proteins warrant further investigation as potential immunotherapeutic targets to modulate DAD progression and improve patient outcome.",pathology,fuzzy,92,100
medRxiv,10.1101/2022.11.29.22282883,2022-12-12,https://medrxiv.org/cgi/content/short/2022.11.29.22282883,"The protection gap under a social health protection initiative in the COVID-19 pandemic: A case study from Khyber Pakhtunkhwa, Pakistan.",Sheraz  Ahmad Khan; Kathrin Cresswell; Aziz Sheikh,The University of Edinburgh; The University of Edinburgh College of Medicine and Veterinary Medicine; The University of Edinburgh College of Medicine and Veterinary Medicine,"BackgroundSehat Sahulat Programme (SSP) is a Social Health Protection (SHP) initiative by the Government of Khyber Pakhtunkhwa (GoKP), covering inpatient services for 100% of the provinces population. In this paper, we describe SSPs role in GoKPs COVID-19 response and draw inferences for similar programmes in Pakistan.

Methodology and methodsWe conceptualised SSP as an instrumental case study and collected three complementary data sources. First, we studied GoKPs official documents to understand SSPs benefits package. Then we undertook in-depth interviews and collected non-participant observations at the SSP policy and implementation levels. We recruited participants through direct (verbal and email) and indirect (invitation posters) methods.

Use of maximum variation sampling enabled us to understand contrasting views from various stakeholders on SSPs policy dimensions (i.e., coverage and financing), tensions between the policy directions (i.e., whether or not to cover COVID-19) and how policy decisions were made and implemented. We collected data from March 2021 to December 2021. Thematic analysis was conducted with the help of Nvivo12.

FindingsThroughout 2020, SSP did not cover COVID-19 treatment. The insurer and GoKP officials considered the pandemic a standard exclusion to insurance coverage. One SSP official said: ""COVID-19 is not covered and not relevant to us"". GoKP had stopped non-emergency services at all hospitals. When routine services restarted, the insurer did not cover COVID-19 screening tests, which were mandatory prior to hospital admission.

In 2021, GoKP engaged 10 private SSP hospitals for COVID-19 treatment. The SSP Reserve Fund, rather than insurance pooled money, was used. The Reserve Fund was originally meant to cover high-cost organ transplants. In 2021, SSP had 1,002 COVID-19-related admissions, which represented 0.2% of all hospital admissions (N=544,841).

An advocacy group representative called the COVID-19 care under SSP ""too little too late"". In contrast, SSP officials suggested their insurance database and funds flow mechanism could help GoKP in future health emergencies.

ConclusionThe commercially focused interpretation of SHP arrangements led to a protection gap in the context of COVID-19. SSP and similar programmes in other provinces of Pakistan should emphasise the notion of protection and not let commercial interests lead to protection gaps.",health policy,fuzzy,100,100
medRxiv,10.1101/2022.12.03.22282974,2022-12-07,https://medrxiv.org/cgi/content/short/2022.12.03.22282974,Non-generalizability of biomarkers for mortality in SARS-CoV-2: a meta-analyses series,ME Rahman Shuvo; Max Schweining; Felipe Soares; Oliver Feng; Susana Abreu; Niki Veale; William Thomas; AA Roger Thompson; Richard Samworth; Nicholas W Morrell; Stefan Marciniak; Elaine Soon,Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; University of Sheffield; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; University of Sheffield; University of Cambridge; University of Cambridge; University of Cambridge; University Of Cambridge,"ObjectivesSophisticated scores have been proposed for prognostication of mortality due to SARS-CoV-2 but perform inconsistently. We conducted these meta-analyses to uncover why and to pragmatically seek a single dependable biomarker for mortality.

DesignWe searched the PubMed database for the keywords  SARS-CoV-2 with  biomarker name and  mortality. All studies published from 01st December 2019 to 30th June 2021 were surveyed. To aggregate the data, the meta library in R was used to report overall mean values and 95% confidence intervals. We fitted a random effects model to obtain pooled AUCs and associated 95% confidence intervals for the European/North American, Asian, and overall datasets.

Setting and ParticipantsData was collected from 131 studies on SARS-CoV-2 PCR-positive general hospital adult admissions (n=76,169 patients in total).

Main Outcome MeasuresWe planned a comparison of pooled area under curves (AUCs) from Receiver Operator Characteristic curves plotted for admission D-dimer, CRP, urea, troponin and interleukin-6 levels.

Main ResultsBiomarker effectiveness varies significantly in different regions of the world. Admission CRP levels are a good prognostic marker for mortality due to SARS-CoV-2 in Asian countries, with a pooled area under curve (AUC) of 0.83 (95% CI 0.80-0.85), but only an average predictor of mortality in Europe/North America, with a pooled AUC of 0.67 (95% CI 0.63-0.71, P<0.0001). We observed the same pattern for D-dimer and IL-6. This variability explains why the proposed prognostic scores did not perform evenly. Notably, urea and troponin had pooled AUCs [&ge;] 0.78 regardless of location, implying that end-organ damage at presentation is a key prognostic factor. These differences might be due to age, genetic backgrounds, or different modes of death (younger patients in Asia dying of cytokine storm while older patients die of multi-organ failure).

ConclusionsBiomarker effectiveness for prognosticating SARS-CoV-2 mortality varies significantly by geographical location. We propose that biomarkers and by extension prognostic scores need to be tailored for specific populations. This also implies that validation of commonly used prognostic scores for other conditions should occur before they are used in different populations.

Summary boxO_ST_ABSSection 1: What is already known on this topicC_ST_ABSBiomarkers such as CRP, D-dimer, and interleukin-6 have been proven to have prognostic value in SARS-CoV-2. However prognostic scores using these as building blocks perform unevenly in different locations.

Section 2: What this study addsCommonly used biomarkers for SARS-CoV-2 have different efficacy in different parts of the world. For example, admission CRP and interleukin-6 levels are good prognostic markers for mortality in Asian countries but only average in Europe and North America. Prognostic markers and scores cannot be  transplanted from one region to another. This has implications not just for SARS-CoV-2 but also for scores in other conditions.",respiratory medicine,fuzzy,100,100
medRxiv,10.1101/2022.12.07.22283175,2022-12-07,https://medrxiv.org/cgi/content/short/2022.12.07.22283175,"Apixaban following discharge in hospitalised adults with COVID-19: Preliminary results from a multicentre, open-label, randomised controlled platform clinical trial.",Mark R Toshner; Carrol Gamble; J Kenneth Baillie; Ashley Best; Emma Bedson; Judy Bradley; Melanie Calvert; Elin Haf Davies; Annemarie B Docherty; Efstathia Gkioni; Dyfrig A Hughes; Thomas Jaki; R Gisli Jenkins; Ashley Jones; Martin J Landray; Jonathan Mant; Daniel F McAuley; Peter JM Openshaw; Duncan Richards; Paul Wicks; - HEAL-COVID Collaboration; Charlotte Summers,"University of Cambridge; University of Liverpool; Roslin Institute, University of Edinburgh; University of Liverpool; University of Liverpool; Queen's University, Belfast; University of Birmingham; Aparito Limited; University of Edinburgh; University of Liverpool; Bangor University; MRC Biostatistics Unit, University of Cambridge; Imperial College London; University of Liverpool; University of Oxford; University of Cambridge; Queen's University Belfast; Imperial College London; University of Oxford; Wicks Digital Health; -; University of Cambridge","BackgroundThe role of thromboprophylaxis in the post-acute phase of COVID-19 is uncertain due to conflicting results from randomised controlled trials and observational studies. We aimed to determine the effectiveness of post-hospital apixaban in reducing the rate of death and hospital readmission of hospitalised adults with COVID-19.

MethodsHEAL COVID is an adaptive randomised open label multicentre platform trial recruiting participants from National Health Service Hospitals in the United Kingdom. Here we report the preliminary results of apixaban comparison of HEAL-COVID. Participants with a hospital admission related to confirmed COVID-19 and an expected date of discharge in the subsequent five days were randomised to either apixaban 2.5 mg twice daily or standard care (no anticoagulation) for 14 days. The primary outcome was hospital free survival at 12 months obtained through routine data sources. The trial was prospectively registered with ISRCTN (15851697) and Clincialtrials.gov (NCT04801940).

FindingsBetween 19 May 2021 and 21 November 2022, 402 participants from 109 sites were randomised to apixaban and 399 to standard care. Seven participants withdrew from the apixaban group and one from the standard care group. Analysis was undertaken on an intention-to-treat basis.

The apixaban arm was stopped on the recommendation of the oversight committees following an interim analysis due to no indication of benefit. Of the 402 participants randomised to apixaban, 117 experienced death or rehospitalisation during a median follow-up of 344{middle dot}5 days (IQR 125 to 365), and 123 participants receiving standard care experienced death or rehospitalisation during a median follow-up of 349 days (IQR 124 to 365). There was no statistical difference in the rate of death and rehospitalisation (HR: 0{middle dot}96 99%CI 0{middle dot}69-1{middle dot}34; p=0{middle dot}75). Three participants in the apixaban arm experienced clinically significant bleeding during treatment.

InterpretationFourteen days of post-hospital anticoagulation with the direct oral anticoagulant apixaban did not reduce the rate of death or rehospitalisation of adults hospitalised with COVID-19. These data do not support the use of prophylactic post-hospital anticoagulation in adults with COVID-19.

FundingHEAL-COVID is funded by the National Institute for Health and Care Research [NIHR133788] and the NIHR Cambridge Biomedical Research Centre [BRC-1215-20014*].",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.12.02.22283049,2022-12-04,https://medrxiv.org/cgi/content/short/2022.12.02.22283049,Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients on kidney replacement therapy: observational cohort study using the OpenSAFELY-UKRR linked platform and SRR database,- The OpenSAFELY Collaborative; Bang Zheng; Jacqueline Campbell; Edward J Carr; John Tazare; Linda Nab; Viyaasan Mahalingasivam; Amir Mehrkar; Shalini Santhakumaran; Retha Steenkamp; Fiona Loud; Susan Lyon; Miranda Scanlon; William J Hulme; Amelia CA Green; Helen J Curtis; Louis Fisher; Edward Parker; Ben Goldacre; Ian Douglas; Stephen Evans; Brian MacKenna; Samira Bell; Laurie Tomlinson; Dorothea Nitsch; - The LH&W NCS (or CONVALESCENCE) Collaborative,"; London School of Hygiene and Tropical Medicine; The Scottish Renal Registry, Scottish Health Audits, Public Health Scotland; Francis Crick Institute; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; UK Renal Registry; UK Renal Registry; Kidney Care UK; Patient Council, UK Kidney Association; Kidney Research UK; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Dundee; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; ","BackgroundPatients on kidney replacement therapy (KRT; dialysis and kidney transplantation) are at the highest risk of severe outcomes from COVID-19. Due to limited inclusion of patients on KRT in clinical trials, information is limited on the effectiveness of sotrovimab (a neutralising monoclonal antibody). We sought to address this by comparing its effectiveness against molnupiravir (an antiviral) in preventing severe COVID-19 outcomes in non-hospitalised adults with symptomatic COVID-19.

MethodsWith the approval of NHS England we used routine clinical data from 24 million patients in England linked to the UK Renal Registry (UKRR) to identify patients on KRT, and data on antiviral treatments, COVID-19 test results, hospitalisation events and death from the OpenSAFELY-TPP data resource. Cox proportional hazards models (stratified for region) were used to estimate hazard ratios of sotrovimab vs. molnupiravir with regards to COVID-19 related hospitalisation or deaths in the subsequent 28 days (as the primary outcome). Further analyses were conducted using propensity score weighting (adjusted for region) and to investigate robustness of results with regards to different time periods, missing data, and adjustment variables. We also conducted a complementary analysis using data from patients in the Scottish Renal Registry (SRR) treated with sotrovimab or molnupiravir, following similar analytical approaches.

ResultsAmong the 2367 renal patients treated with sotrovimab (n=1852) or molnupiravir (n=515) between December 16, 2021 and August 1, 2022 in England, 38 cases (1.6%) of COVID-19 related hospitalisations/deaths were observed during the 28 days of follow-up after treatment initiation, with 21 (1.1%) in the sotrovimab group and 17 (3.3%) in the molnupiravir group. In multiple-adjusted analysis sotrovimab was associated with substantially lower risk of 28-day COVID-19 related hospitalisation/death than treatment with molnupiravir (hazard ratio, HR=0.35, 95% CI: 0.17 to 0.71; P=0.004), with results remaining robust in sensitivity analyses. In the SRR cohort, there were 19 cases (1.9%) of COVID-19 related hospitalisations/deaths during the 28 days of follow-up after treatment initiation of sotrovimab (n=723) or molnupiravir (n=270). In multiple-adjusted analysis, sotrovimab showed a trend toward lower risk of 28-day COVID-19 related hospitalisation/death than treatment with molnupiravir (HR=0.39, 95% CI: 0.13 to 1.21; P=0.106). In both datasets, sotrovimab had no evidence of association with other hospitalisation/death compared with molnupiravir (HRs ranging from 0.73-1.29; P>0.05).

ConclusionsIn routine care of non-hospitalised patients with COVID-19 on kidney replacement therapy, those who received sotrovimab had substantially lower risk of severe COVID-19 outcomes than those receiving molnupiravir.",epidemiology,fuzzy,92,100
medRxiv,10.1101/2022.11.29.22282916,2022-11-30,https://medrxiv.org/cgi/content/short/2022.11.29.22282916,Correlates of protection against SARS-CoV-2 Omicron variant and anti-spike antibody responses after a third/booster vaccination or breakthrough infection in the UK general population,Jia Wei; Philippa C Matthews; Nicole Stoesser; John Newton; Ian Diamond; Ruth Studley; Nick Taylor; John Bell; Jeremy Farrar; Brian Marsden; Jaison Kolenchery; Sarah Hoosdally; Yvonne Jones; David Stuart; Derrick Crook; Tim E Peto; Ann Sarah Walker; Koen Pouwels; David W Eyre,University of Oxford; University of Oxford; University of Oxford; Public Health England; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Wellcome Trust; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford,"Following primary SARS-CoV-2 vaccination, understanding the relative extent of protection against SARS-CoV-2 infection from boosters or from breakthrough infections (i.e. infection in the context of previous vaccination) has important implications for vaccine policy. In this study, we investigated correlates of protection against Omicron BA.4/5 infections and anti-spike IgG antibody trajectories after a third/booster vaccination or breakthrough infection following second vaccination in 154,149 adults [&ge;]18y from the United Kingdom general population. We found that higher anti-spike IgG antibody levels were associated with increased protection against Omicron BA.4/5 infection and that breakthrough infections were associated with higher levels of protection at any given antibody level than booster vaccinations. Breakthrough infections generated similar antibody levels to third/booster vaccinations, and the subsequent declines in antibody levels were similar to or slightly slower than those after third/booster vaccinations. Taken together our findings show that breakthrough infection provides longer lasting protection against further infections than booster vaccinations. For example, considering antibody levels associated with 67% protection against infection, a third/booster vaccination did not provide long-lasting protection, while a Delta/Omicron BA.1 breakthrough infection could provide 5-10 months of protection against Omicron BA.4/5 reinfection. 50-60% of the vaccinated UK population with a breakthrough infection would still be protected by the end of 2022, compared to <15% of the triple-vaccinated UK population without previous infection. Although there are societal impacts and risks to some individuals associated with ongoing transmission, breakthrough infection could be an efficient immune-boosting mechanism for subgroups of the population, including younger healthy adults, who have low risks of adverse consequences from infection.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.11.29.22282899,2022-11-29,https://medrxiv.org/cgi/content/short/2022.11.29.22282899,"Performance of antigen lateral flow devices in the United Kingdom during the Alpha, Delta, and Omicron waves of the SARS-CoV-2 pandemic",David W Eyre; Matthias Futschik; Sarah Tunkel; Jia Wei; Joanna Cole-Hamilton; Rida Saquib; Nick Germanacos; Andrew Dodgson; Paul E Klapper; Malur Sudhanva; Chris Kenny; Peter Marks; Edward Blandford; Susan Hopkins; Tim Peto; Tom Fowler,University of Oxford; UK Health Security Agency; UK Health Security Agency; University of Oxford; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; University of Manchester; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; University of Oxford; UK Health Security Agency,"BackgroundAntigen lateral flow devices (LFDs) have been widely used to control SARS-CoV-2. Changes in LFD sensitivity and detection of infectious individuals during the pandemic with successive variants, vaccination, and changes in LFD use are incompletely understood.

MethodsPaired LFD and PCR tests were collected from asymptomatic and symptomatic participants, across multiple settings in the UK between 04-November-2020 and 21-March-2022. Multivariable logistic regression was used to analyse LFD sensitivity and specificity, adjusting for viral load, LFD manufacturer, setting, age, sex, assistance, symptoms, vaccination, and variant. National contact tracing data were used to estimate the proportion of transmitting index cases (with [&ge;]1 PCR/LFD-positive contact) potentially detectable by LFDs over time, accounting for viral load, variant, and symptom status.

Findings4131/75,382 (5.5%) participants were PCR-positive. Sensitivity vs. PCR was 63.2% (95%CI 61.7-64.6%) and specificity 99.71% (99.66-99.74%). Increased viral load was independently associated with being LFD-positive. There was no evidence LFD sensitivity differed between Delta vs. Alpha/pre-Alpha infections, but Omicron infections were more likely to be LFD positive. Sensitivity was higher in symptomatic participants, 68.7% (66.9-70.4%) than in asymptomatic participants, 52.8% (50.1-55.4%). 79.4% (68.6-81.3%) of index cases resulting in probable onward transmission with were estimated to have been detectable using LFDs, this proportion was relatively stable over time/variants, but lower in asymptomatic vs. symptomatic cases.

InterpretationLFDs remained able to detect most SARS-CoV-2 infections throughout vaccine roll-out and different variants. LFDs can potentially detect most infections that transmit to others and reduce risks. However, performance is lower in asymptomatic compared to symptomatic individuals.

FundingUK Government.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSLateral flow devices (LFDs; i.e. rapid antigen detection devices) have been widely used for SARS-CoV-2 testing. However, due to their imperfect sensitivity when compared to PCR and a lack of a widely available gold standard proxy for infectiousness, the performance and use of LFDs has been a source of debate. We conducted a literature review in PubMed and bioRxiv/medRxiv for all studies examining the performance of lateral flow devices between 01 January 2020 and 31 October 2022. We used the search terms  SARS-CoV-2/COVID-19 and  antigen/lateral flow test/lateral flow device. Multiple studies have examined the sensitivity and specificity of LFDs, including several systematic reviews. However, the majority of the studies are based on pre-Alpha infections. Large studies examining the test accuracy for different variants, including Delta and Omicron, and following vaccination are limited.

Added value of this studyIn this large national LFD evaluation programme, we compared the performance of three different LFDs relative to PCR in various settings. Compared to PCR testing, sensitivity was 63.2% (95%CI 61.7-64.6%) overall, and 71.6% (95%CI 69.8-73.4%) in unselected communitybased testing. Specificity was 99.71% (99.66-99.74%). LFDs were more likely to be positive as viral loads increased. LFD sensitivity was similar during Alpha/pre-Alpha and Delta periods but increased during the Omicron period. There was no association between sensitivity and vaccination status. Sensitivity was higher in symptomatic participants, 68.7% (66.9-70.4%) than in asymptomatic participants, 52.8% (50.1-55.4%). Using national contact tracing data, we estimated that 79.4% (68.6-81.3%) of index cases resulting in probable onward transmission (i.e. with [&ge;]1 PCR/LFD-positive contact) were detectable using LFDs. Symptomatic index cases were more likely to be detected than asymptomatic index cases due to higher viral loads and better LFD performance at a given viral load. The proportion of index cases detected remained relatively stable over time and with successive variants, with a slight increase in the proportion of asymptomatic index cases detected during Omicron.

Implications of all the available evidenceOur data show that LFDs detect most SARS-CoV-2 infections, with findings broadly similar to those summarised in previous meta-analyses. We show that LFD performance has been relatively consistent throughout different variant-dominant phases of the pandemic and following the roll-out of vaccination. LFDs can detect most infections that transmit to others and can therefore be used as part of a risk reduction strategy. However, performance is lower in asymptomatic compared to symptomatic individuals and this needs to be considered when designing testing programmes.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.11.16.22282396,2022-11-18,https://medrxiv.org/cgi/content/short/2022.11.16.22282396,Comparative effectiveness of two- and three-dose schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study,- The OpenSAFELY Collaborative; Edward PK Parker; Elsie MF Horne; William J Hulme; John Tazare; Bang Zheng; Edward J Carr; Fiona Loud; Susan Lyon; Viyaasan Mahalingasivam; Brian MacKenna; Amir Mehrkar; Miranda Scanlon; Shalini Santhakumaran; Retha Steenkamp; Ben Goldacre; Jonathan AC Sterne; Dorothea Nitsch; Laurie A Tomlinson; - The LH&W NCS (or CONVALESCENCE) Collaborative,"; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; The Francis Crick Institute, London, NW1 1AT, UK; Kidney Care UK, Alton, UK; Patient Council, UK Kidney Association, Bristol, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; Kidney Research UK, Peterborough, UK; UK Renal Registry, Bristol, UK; UK Renal Registry, Bristol, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; ","BackgroundKidney disease is a key risk factor for COVID-19-related mortality and suboptimal vaccine response. Optimising vaccination strategies is essential to reduce the disease burden in this vulnerable population.

MethodsWith the approval of NHS England, we performed a retrospective cohort study to estimate the comparative effectiveness of schedules involving AZD1222 (AZ; ChAdOx1-S) and BNT162b2 (BNT) among people with kidney disease. Using linked primary care and UK Renal Registry records in the OpenSAFELY-TPP platform, we identified adults with stage 3- 5 chronic kidney disease, dialysis recipients, and kidney transplant recipients. We used Cox proportional hazards models to compare COVID-19-related outcomes and non-COVID-19 death after two-dose (AZ-AZ vs BNT-BNT) and three-dose (AZ-AZ-BNT vs BNT-BNT- BNT) schedules.

FindingsAfter two doses, incidence during the Delta wave was higher in AZ-AZ (n=257,580) than BNT-BNT recipients (n=169,205; adjusted hazard ratios [95% CIs] 1{middle dot}43 [1{middle dot}37-1{middle dot}50], 1{middle dot}59 [1{middle dot}43-1{middle dot}77], 1{middle dot}44 [1{middle dot}12-1{middle dot}85], and 1{middle dot}09 [1{middle dot}02-1{middle dot}17] for SARS-CoV-2 infection, COVID-19-related hospitalisation, COVID-19-related death, and non-COVID-19 death, respectively). Findings were consistent across disease subgroups, including dialysis and transplant recipients. After three doses, there was little evidence of differences between AZ- AZ-BNT (n=220,330) and BNT-BNT-BNT recipients (n=157,065) for any outcome during a period of Omicron dominance.

InterpretationAmong individuals with moderate-to-severe kidney disease, two doses of BNT conferred stronger protection than AZ against SARS-CoV-2 infection and severe disease. A subsequent BNT dose levelled the playing field, emphasising the value of heterologous RNA doses in vulnerable populations.

FundingNational Core Studies, Wellcome Trust, MRC, and Health Data Research UK.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched Medline for studies published between 1st December 2020 and 7th September 2022 using the following term: ""(coronavir* or covid* or sars*) and (vaccin* or immunis* or immuniz*) and (kidney or dialysis or h?emodialysis or transplant or renal) and (efficacy or effectiveness)"". We identified studies reporting on the effectiveness of various COVID-19 vaccines in individuals with chronic kidney disease (CKD) or end-stage renal disease. Several studies have reported no clear differences in effectiveness against outcomes of varying severity after two doses of BNT162b2 or AZD1222 compared to unvaccinated controls, which is contrary to the significantly higher antibody levels observed after BNT162b2 in immunogenicity studies. One study also showed that a third dose of RNA vaccine restored some protection against the Omicron variant among BNT162b2- and AZD1222-primed individuals, with no clear differences between these groups. This finding is consistent with immunogenicity data suggesting that a third dose of BNT162b2 may reduce the gap in antibody levels observed after two of AZD1222 versus BNT162b2. Notably, we found few studies directly comparing effectiveness in BNT162b2 versus AZD1222 recipients, which reduces biases associated with comparison to a small and potentially unrepresentative group of unvaccinated controls. We also found no studies exploring COVID-19 vaccine effectiveness in kidney disease groups of varying severity (CKD, dialysis, and kidney transplant).

Added value of this studyThis is the largest study to compare the effectiveness of two- and three-dose regimens involving AZD1222 and BNT162b2 among people with moderate-to-severe kidney disease. We compared effectiveness after two and three doses in 426,780 and 377,395 individuals, respectively, and harnessed unique data linkages between primary care records and UK Renal Registry data to identify people with CKD and end-stage renal disease (including dialysis and kidney transplant recipients) with high accuracy. During the Delta wave of infection, we observed a higher risk of COVID-19-related outcomes of varying severity after two doses of AZD1222 versus BNT162b2, with consistent findings in CKD, dialysis, and transplant subgroups. After a third dose of BNT162b2, AZD1222- and BNT162b2-primed individuals had similar rates of COVID-19-related outcomes during a period of Omicron dominance.

Implications of all the available evidence

A growing body of immunogenicity and effectiveness data - including the present study - suggest that two doses of BNT162b2 confers stronger protection than AZD1222 among people with moderate-to-severe kidney disease. However, a third dose of BNT162b2 appears to compensate for this immunity deficit, providing equivalent protection in BNT162b2- and AZD1222-primed individuals. Achieving high coverage with additional RNA vaccine doses (whether homologous or heterologous) has the capacity to reduce the burden of disease in this vulnerable population.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.11.16.22282338,2022-11-18,https://medrxiv.org/cgi/content/short/2022.11.16.22282338,Proteomic analysis of circulating immune cells identifies novel cellular phenotypes associated with COVID-19 severity,Martin Potts; Alice Fletcher-Etherington; Katie Nightingale; Federica Mescia; Laura Bergamaschi; Fernando J Calero-Nieto; Robin Antrobus; James Williamson; - CITIID-NIHR COVID BioResource Collaboration; Nathalie Kingston; Berthold Gottgens; John R Bradley; Paul J Lehner; Nicholas J Matheson; Kenneth GC Smith; Mark R Wills; Paul A Lyons; Michael P Weekes,"Cambridge Institute for Medical Research, University of Cambridge; Department of Medicine, University of Cambridge; Cambridge Institute for Medical Research, University of Cambridge; Department of Medicine, University of Cambridge; Cambridge Institute for Medical Research, University of Cambridge; Department of Medicine, University of Cambridge; Department of Medicine, University of Cambridge; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Universi; Department of Medicine, University of Cambridge; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Universi; Department of Medicine, University of Cambridge; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Universi; Cambridge Institute for Medical Research, University of Cambridge; Department of Medicine, University of Cambridge; Department of Medicine, University of Cambridge; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Universi; ; NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge; Department of Haematology, University of Cambridge; Wellcome - MRC Cambridge Stem Cell Institute, University of Cambridge; Department of Medicine, University of Cambridge; NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge; Department of Medicine, University of Cambridge; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Universi; Department of Medicine, University of Cambridge; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Universi; Department of Medicine, University of Cambridge; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Universi; Department of Medicine, University of Cambridge; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Universi; Department of Medicine, University of Cambridge; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Universi; Cambridge Institute for Medical Research, University of Cambridge; Department of Medicine, University of Cambridge","Certain serum proteins, including CRP and D-dimer, have prognostic value in patients with SARS-CoV-2 infection. Nonetheless, these factors are non-specific, and provide limited mechanistic insight into the peripheral blood mononuclear cell (PBMC) populations which drive the pathogenesis of severe COVID-19. To identify novel cellular phenotypes associated with disease progression, we here describe a comprehensive, unbiased analysis of the total and plasma membrane proteomes of PBMCs from a cohort of 40 unvaccinated individuals with SARS-CoV-2 infection, spanning the whole spectrum of disease severity. Combined with RNA-seq and flow cytometry data from the same donors, we define a comprehensive multi-omic profile for each severity level, revealing cumulative immune cell dysregulation in progressive disease. In particular, the cell surface proteins CEACAMs1, 6 and 8, CD177, CD63 and CD89 are strongly associated with severe COVID-19, corresponding to the emergence of atypical CD3+CD4+CD177+ and CD16+CEACAM1/6/8+ mononuclear cells. Utilisation of these markers may facilitate real-time patient assessment by flow cytometry, and identify immune cell populations that could be targeted to ameliorate immunopathology.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.10.19.22281254,2022-10-21,https://medrxiv.org/cgi/content/short/2022.10.19.22281254,Socioeconomic inequalities of Long COVID: findings from a population-based survey in the United Kingdom,Sharmin Shabnam; Cameron Razieh; Hajira Dambha-Miller; Thomas Yates; Clare Gillies; Yogini V Chudasama; Manish Pareek; Amitava Banerjee; Ichiro Kawachi; Ben Lacey; Eva JA Morris; Martin White; Francesco Zaccardi; Kamlesh Khunti; Nazrul Islam,"Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, LE5 4PW, UK; Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, LE5 4PW, UK; Office for National Statistics, Newport, NP10 8XG; Primary Care Research Centre, University of Southampton; NIHR Leicester Biomedical Research Centre (BRC), University Hospitals of Leicester NHS Trust and University of Leicester, Leicester, LE5 4PW, UK; Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, LE5 4PW, UK; Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, LE5 4PW, UK; Department of Respiratory Sciences, University of Leicester, Leicester, LE1 9HN, UK; Institute of Health Informatics, University College London, London, NW1 2DA, UK; Harvard TH Chan School of Public Health, Harvard University, Boston, MA, 02115, USA; Oxford Population Health, Big Data Institute, University of Oxford, Oxford, OX3 7LF, UK; Oxford Population Health, Big Data Institute, University of Oxford, Oxford, OX3 7LF, UK; MRC Epidemiology Unit, University of Cambridge; Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, LE5 4PW, UK; Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, LE5 4PW, UK; Oxford Population Health, Big Data Institute, University of Oxford, Oxford, OX3 7LF, UK; Faculty of Medicine, University of Southampton, Southampton, SO17 1BJ, ","ObjectiveTo estimate the risk of Long COVID by socioeconomic deprivation and to further examine the socioeconomic inequalities in Long COVID by sex and occupational groups.

DesignWe analysed data from the COVID-19 Infection Survey conducted by the Office for National Statistics between 26/04/2020 and 31/01/2022. This is the largest and nationally representative survey of COVID-19 in the UK and provides uniquely rich, contemporaneous, and longitudinal data on occupation, health status, COVID-19 exposure, and Long COVID symptoms.

SettingCommunity-based longitudinal survey of COVID-19 in the UK.

ParticipantsWe included 201,799 participants in our analysis who were aged between 16 and 64 years and had a confirmed SARS-CoV-2 infection.

Main outcome measuresWe used multivariable logistic regression models to estimate the risk of Long COVID at least 4 weeks after acute SARS-CoV-2 infection by deciles of index of multiple deprivation (IMD) and adjusted for a range of demographic and spatiotemporal factors. We further examined the modifying effects of socioeconomic deprivation by sex and occupational groups.

ResultsA total of 19,315 (9.6%) participants reported having Long COVID symptoms. Compared to the least deprived IMD decile, participants in the most deprived decile had a higher adjusted risk of Long COVID (11.4% vs 8.2%; adjusted OR: 1.45; 95% confidence interval [CI]: 1.33, 1.57). There were particularly significantly higher inequalities (most vs least deprived decile) of Long COVID in healthcare and patient facing roles (aOR: 1.76; 1.27, 2.44), and in the education sector (aOR: 1.62; 1.26, 2.08). The inequality of Long COVID was higher in females (aOR: 1.54; 1.38, 1.71) than males (OR: 1.32; 1.15, 1.51).

ConclusionsParticipants living in the most socioeconomically deprived areas had a higher risk of Long COVID. The inequality gap was wider in females and certain public facing occupations (e.g., healthcare and education). These findings will help inform public health policies and interventions in adopting a social justice and health inequality lens.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.10.14.22281081,2022-10-19,https://medrxiv.org/cgi/content/short/2022.10.14.22281081,A spatio-temporal framework for modelling wastewater concentration during the COVID-19 pandemic,Guangquan Li; Hubert Denise; Peter Diggle; Jasmine Grimsley; Chris Holmes; Daniel James; Radka Jersakova; Callum Mole; George Nicholson; Camila Rangel Smith; Sylvia Richardson; William Rowe; Barry Rowlingson; Fatemeh Torabi; Matthew J Wade; Marta Blangiardo,Northumbria University; UKHSA; Lancaster University; UKHSA; Oxford University; UKHSA; Alan Turing Institute; Alan Turing Institute; Oxford University; Alan Turing Institute; MRC Biostatistics Unit; UKHSA; Lancaster University; Swansea University; UKHSA; Imperial College,"The potential utility of wastewater-based epidemiology as an early warning tool has been explored widely across the globe during the current COVID-19 pandemic. Methods to detect the presence of SARS-CoV-2 RNA in wastewater were developed early in the pandemic, and extensive work has been conducted to evaluate the relationship between viral concentration and COVID-19 case numbers at the catchment areas of sewage treatment works (STWs) over time. However, no attempt has been made to develop a model that predicts wastewater concentration at fine spatio-temporal resolutions covering an entire country, a necessary step towards using wastewater monitoring for the early detection of local outbreaks.

We consider weekly averages of flow-normalised viral concentration, reported as the number of SARS-CoV-2 N1 gene copies per litre (gc/L) of wastewater available at 303 STWs over the period between 1 June 2021 and 30 March 2022. We specify a spatially continuous statistical model that quantifies the relationship between weekly viral concentration and a collection of covariates covering socio-demographics, land cover and virus-associated genomic characteristics at STW catchment areas while accounting for spatial and temporal correlation.

We evaluate the models predictive performance at the catchment level through 10-fold cross-validation. We predict the weekly viral concentration at the population-weighted centroid of the 32,844 lower super output areas (LSOAs) in England, then aggregate these LSOA predictions to the Lower Tier Local Authority level (LTLA), a geography that is more relevant to public health policy-making. We also use the model outputs to quantify the probability of local changes of direction (increases or decreases) in viral concentration over short periods (e.g. two consecutive weeks).

The proposed statistical framework is able to predict SARS-CoV-2 viral concentration in wastewater at high spatio-temporal resolution across England. Additionally, the probabilistic quantification of local changes can be used as an early warning tool for public health surveillance.",public and global health,fuzzy,100,100
medRxiv,10.1101/2022.10.13.22281031,2022-10-17,https://medrxiv.org/cgi/content/short/2022.10.13.22281031,Indirect effects of the first two years of the COVID-19 pandemic on secondary care for cardiovascular disease in the UK: an electronic health record analysis across three countries.,F Lucy Wright; Kate Cheema; Raph Goldacre; Nick Hall; Naomi Herz; Nazrul Islam; Zainab Karim; David Moreno-Martos; Daniel R Morales; Daniel O'Connell; Enti Spata; Ashley Akbari; Mark Ashworth; Mark Barber; Norman Briffa; Dexter Canoy; Spiros Denaxas; Kamlesh Khunti; Amanj Kurdi; Mamas Mamas; Rouven Priedon; Cathie Sudlow; Eva JA Morris; Ben Lacey; Amitava Banerjee,University of Oxford; British Heart Foundation; University of Oxford; University of Oxford; British Heart Foundation; University of Southampton; British Heart Foundation; University of Dundee; University of Dundee; British Heart Foundation; University of Oxford; Swansea University; King's College London; Public Health Scotland; University of Sheffield; University of Oxford; University College London; University of Leicester; University of Strathclyde; Keele University; British Heart Foundation Data Science Centre; Health Data Research UK; University of Oxford; University of Oxford; University College London,"BackgroundAlthough morbidity and mortality from COVID-19 have been widely reported, the indirect effects of the pandemic beyond 2020 on other major diseases and health service activity have not been well described.

MethodsAnalyses used national administrative electronic hospital records in England, Scotland and Wales for 2016-2021. Admissions and procedures during the pandemic (2020-2021) related to six major cardiovascular conditions (acute coronary syndrome, heart failure, stroke/transient ischaemic attack, peripheral arterial disease, aortic aneurysm, and venous thromboembolism) were compared to the annual average in the pre-pandemic period (2016-2019). Differences were assessed by time period and urgency of care.

ResultsIn 2020, there were 31,064 (-6%) fewer hospital admissions (14,506 [-4%] fewer emergencies, 16,560 [-23%] fewer elective admissions) compared to 2016-2019 for the six major cardiovascular diseases combined. The proportional reduction in admissions was similar in all three countries. Overall, hospital admissions returned to pre-pandemic levels in 2021. Elective admissions remained substantially below expected levels for almost all conditions in all three countries (-10,996 [-15%] fewer admissions). However, these reductions were offset by higher than expected total emergency admissions (+25,878 [+6%] higher admissions), notably for heart failure and stroke in England, and for venous thromboembolism in all three countries. Analyses for procedures showed similar temporal variations to admissions.

ConclusionThis study highlights increasing emergency cardiovascular admissions as a result of the pandemic, in the context of a substantial and sustained reduction in elective admissions and procedures. This is likely to increase further the demands on cardiovascular services over the coming years.

Key QuestionWhat is the impact in 2020 and 2021 of the COVID-19 pandemic on hospital admissions and procedures for six major cardiovascular diseases in England, Scotland and Wales?

Key FindingIn 2020, there were 6% fewer hospital admissions (emergency: -4%, elective: -23%) compared to 2016-2019 for six major cardiovascular diseases, across three UK countries. Overall, admissions returned to pre-pandemic levels in 2021, but elective admissions remained below expected levels.

Take-home MessageThere was increasing emergency cardiovascular admissions as a result of the pandemic, with substantial and sustained reduction in elective admissions and procedures. This is likely to increase further the demands on cardiovascular services over the coming years.",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2022.10.12.22281016,2022-10-13,https://medrxiv.org/cgi/content/short/2022.10.12.22281016,Quantifying changes in the IFR and IHR over 23 months of the SARS-CoV-2 pandemic in England,Oliver Eales; David Haw; Haowei Wang; Christina Atchison; Deborah Ashby; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Christl A Donnelly; Marc Chadeau-Hyam; Paul Elliott; Steven Riley,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Environment and Health, School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc","BackgroundThe relationship between prevalence of infection and severe outcomes such as hospitalisation and death changed over the course of the COVID-19 pandemic. The REal-time Assessment of Community Transmission-1 (REACT-1) study estimated swab positivity in England approximately monthly from May 2020 to 31 March 2022. This period covers widespread circulation of the original strain, the emergence of the Alpha, Delta and Omicron variants and the rollout of Englands mass vaccination campaign.

MethodsHere, we explore this changing relationship between prevalence of swab positivity and the infection fatality rate (IFR) and infection hospitalisation rate (IHR) over 23 months of the pandemic in England, using publicly available data for the daily number of deaths and hospitalisations, REACT-1 swab positivity data, time-delay models and Bayesian P-spline models. We analyse data for all age groups together, as well as in two sub-groups: those aged 65 and over and those aged 64 and under.

ResultsDuring 2020, we estimated the IFR to be 0.67% and the IHR to be 2.6%. By late-2021/early-2022 the IFR and IHR had both decreased to 0.097% and 0.76% respectively. Continuous estimates of the IFR and IHR of the virus were observed to increase during the periods of Alpha and Deltas emergence. During periods of vaccination rollout, and the emergence of the Omicron variant, the IFR and IHR of the virus decreased. During 2020, we estimated a time-lag of 19 days between hospitalisation and swab positivity, and 26 days between deaths and swab positivity. By late-2021/early-2022 these time-lags had decreased to 7 days for hospitalisations, and 18 days for deaths.

ConclusionEven though many populations have high levels of immunity to SARS-CoV-2 from vaccination and natural infection, waning of immunity and variant emergence will continue to be an upwards pressure on IHR and IFR. As investments in community surveillance are scaled back, alternative methods should be developed to accurately track the ever changing relationship between infection, hospitalisation and death.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.10.13.22281024,2022-10-13,https://medrxiv.org/cgi/content/short/2022.10.13.22281024,Atypical B cells and impaired SARS-CoV-2 neutralisation following booster vaccination in the elderly.,Isabella A.T.M. Ferreira; Colin Y.C. Lee; William Foster; Adam Abdullahi; Zewen K. Tuong; Benjamin J Stewart; John R Ferdinand; Stephane Guillaume; Martin O. P. Potts; Marianne Perera; Benjamin A Krishna; Ana P Alonso; Mia Cabantous; Steven A Kemp; Lourdes Ceron-Gutierrez; Soraya Ebrahimi; - The CITIID- NIHR BioResource COVID-19 Collaboration; Paul Lyons; Kenneth G. C. Smith; John Bradley; Dami A Collier; Sarah A Teichmann; Laura E McCoy; Paul A MacAry; Rainer Doffinger; Mark R Wills; Michelle Linterman; Menna R Clatworthy; Ravindra K Gupta,"University of Cambridge; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.; Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge, UK.; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.; Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.; Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK.; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.; Department of Clinical Biochemistry and Immunology, Cambridge University Hospital NHS Trust, Cambridge, UK.; Department of Clinical Biochemistry and Immunology, Cambridge University Hospital NHS Trust, Cambridge, UK.; -; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.; Wellcome Sanger Institute, Cambridge, UK.; Division of infection and immunity, UCL, London, UK; National University of Singapore, Singapore; Department of Clinical Biochemistry and Immunology, Cambridge University Hospital NHS Trust, Cambridge, UK.; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.; Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge, UK.; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.; Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK.","Age is a major risk factor for hospitalization and death after SARS-CoV-2 infection, even in vaccinees. Suboptimal responses to a primary vaccination course have been reported in the elderly, but there is little information regarding the impact of age on responses to booster third doses. Here we show that individuals 70 or older who received a primary two dose schedule with AZD1222 and booster third dose with mRNA vaccine achieved significantly lower neutralizing antibody responses against SARS-CoV-2 spike pseudotyped virus compared to those younger than 70. One month after the booster neither the concentration of serum binding anti spike IgG antibody, nor the frequency of spike-specific B cells showed differences by age grouping. However, the impaired neutralization potency and breadth post-third dose in the elderly was associated with enrichment of circulating ""atypical"" spike-specific B cells expressing CD11c and FCRL5. Single cell RNA sequencing confirmed an expansion of TBX21-, ITGAX-expressing B cells in the elderly that enriched for B cell activation/receptor signalling pathway genes. Importantly we also observed impaired T cell responses to SARS-CoV-2 spike peptides in the elderly post-booster, both in terms of IFNgamma and IL2 secretion, as well as a decrease in T cell receptor signalling pathway genes. This expansion of atypical B cells and impaired T cell responses may contribute to the generation of less affinity-matured antibodies, with lower neutralizing capacity post-third dose in the elderly. Altogether, our data reveal the extent and potential mechanistic underpinning of the impaired vaccine responses present in the elderly after a booster dose, contributing to their increased susceptibility to COVID-19 infection.",infectious diseases,fuzzy,100,100
bioRxiv,10.1101/2022.09.27.509649,2022-09-28,https://biorxiv.org/cgi/content/short/2022.09.27.509649,Mutational spectra distinguish SARS-CoV-2 replication niches,Chris Ruis; Thomas P Peacock; Luis Mariano Polo; Diego Masone; Maria Soledad Alvarez; Angie S Hinrichs; Yatish Turakhia; Cheng Ye; Jakob McBroome; Russ Corbett-Detig; Julian Parkhill; Rodrigo Andres Floto,University of Cambridge; University College London (UCL); Universidad Nacional de Cuyo; CONICET; Universidad Nacional de Cuyo; University of California at Santa Cruz; University of California San Diego; University of California San Deigo; UC Santa Cruz; UC Santa Cruz; Department of Veterinary Medicine; University of Cambridge,"Exposure to different mutagens leaves distinct mutational patterns that can allow prediction of pathogen replication niches (Ruis 2022). We therefore hypothesised that analysis of SARS-CoV-2 mutational spectra might show lineage-specific differences, dependant on the dominant site(s) of replication and onwards transmission, and could therefore rapidly infer virulence of emergent variants of concern (VOC; Konings 2021). Through mutational spectrum analysis, we found a significant reduction in G>T mutations in Omicron, which replicates in the upper respiratory tract (URT), compared to other lineages, which replicate in both upper and lower respiratory tracts (LRT). Mutational analysis of other viruses and bacteria indicates a robust, generalisable association of high G>T mutations with replication within the LRT. Monitoring G>T mutation rates over time, we found early separation of Omicron from Beta, Gamma and Delta, while the mutational burden in Alpha varied consistent with changes in transmission source as social restrictions were lifted. This supports the use of mutational spectra to infer niches of established and emergent pathogens.",microbiology,fuzzy,100,100
medRxiv,10.1101/2022.09.27.22280397,2022-09-27,https://medrxiv.org/cgi/content/short/2022.09.27.22280397,Vaccine effectiveness for preventing COVID-19 hospital admission during pregnancy: a population-based cohort study in England during the Alpha and Delta waves of the SARS-CoV-2 pandemic,Matthew L Bosworth; Ryan Schofield; Daniel Ayoubkhani; Loes Charlton; Vah√© Nafilyan; Kamlesh Khunti; Francesco Zaccardi; Clare Gillies; Ashley Akbari; Marian Knight; Rachael Wood; Pia Hardelid; Luisa Zuccolo; Camille Harrison,Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Leicester; Office for National Statistics; Office for National Statistics; University of Leicester; University of Leicester; University of Leicester; Swansea Univeristy; University of Oxford; Public Health Scotland; University of Edinburgh; University College London; Fondazione Human Technopole; University of Bristol; Office for National Statistics,"ObjectiveTo estimate vaccine effectiveness (VE) for preventing COVID-19 hospital admission in women first infected with SARS-CoV-2 during pregnancy, and assess how this compares to VE among women of reproductive age who were not pregnant when first infected.

DesignPopulation-based cohort study using national, linked Census and administrative data.

SettingEngland, United Kingdom, from 8th December 2020 to 31st August 2021.

Participants815,4777 women aged 18 to 45 years (mean age, 30.4 years) who had documented evidence of a first SARS-CoV-2 infection in NHS Test and Trace data or Hospital Episode Statistics.

Main outcome measuresA hospital inpatient episode where COVID-19 was recorded as the primary diagnosis. Cox proportional hazards models, adjusted for calendar time of infection and sociodemographic factors related to vaccine uptake and risk of severe COVID-19, were used to estimate VE as the complement of the hazard ratio for COVID-19 hospital admission.

ResultsCompared with unvaccinated pregnant women, the adjusted rate of COVID-19 hospital admission was 76% (95% confidence interval 69% to 82%) lower for single-vaccinated pregnant women and 83% (75% to 88%) lower for double-vaccinated pregnant women. These estimates were similar to those found for non-pregnant women: 79% (76% to 81%) for single-vaccinated and 82% (80% to 83%) for double-vaccinated. Among those vaccinated more than 90 days before infection, being double-vaccinated was associated with a greater reduction in risk than being single-vaccinated.

ConclusionsCOVID-19 vaccination is associated with reduced rates of severe illness in pregnant women infected with SARS-CoV-2, and the reduction in risk is similar to that for non-pregnant women. Waning of vaccine effectiveness occurs more quickly after one dose of a vaccine than two doses.

What is already known on this topicBeing pregnant is a risk factor for severe illness and mortality following infection with SARS-CoV-2.

Existing evidence suggests that COVID-19 vaccines are effective for preventing severe outcomes in pregnant women.

However, research directly comparing vaccine effectiveness between pregnant and non-pregnant women of reproductive age at the population level are lacking.

What this study addsOur study provides real-world evidence that COVID-19 vaccination reduces the risk of hospital admission by a similar amount for both women infected with SARS-CoV-2 during pregnancy and women who were not pregnant when infected, during the Alpha and Delta dominant periods in England.",public and global health,fuzzy,100,100
medRxiv,10.1101/2022.09.23.22280285,2022-09-25,https://medrxiv.org/cgi/content/short/2022.09.23.22280285,"Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial",- RECOVERY Collaborative Group; Peter W Horby; Leon Peto; Natalie Staplin; Mark Campbell; Guilherme Pessoa-Amorim; Marion Mafham; Jonathan R Emberson; Richard Stewart; Benjamin Prudon; Alison Uriel; Christopher A Green; Devesh J Dhasmana; Flora Malein; Jaydip Majumdar; Paul Collini; Jack Shurmer; Bryan Yates; J Kenneth Baillie; Maya H Buch; Jeremy N Day; Saul N Faust; Thomas Jaki; Katie Jeffery; Edmund Juszczak; Marian Knight; Wei Shen Lim; Alan Montgomery; Andrew Mumford; Kathryn Rowan; Guy Thwaites; Richard Haynes; Martin Landray,"; Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, University of Oxford, Oxford, United Kingdom; Milton Keynes University Hospital NHS Foundation Trust; North Tees and Hartlepool NHS Foundation Trust; Manchester University NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; Victoria Hospital Kirkcaldy, NHS Fife; Liverpool University Hospitals NHS Foundation Trust; Mid Cheshire Hospitals NHS Foundation Trust; Sheffield Teaching Hospitals NHS Foundation Trust; Bolton NHS Foundation Trust; Northumbria Healthcare NHS Foundation Trust; Roslin Institute, University of Edinburgh; Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Southampton, Southampton, United Kingdom; University of Regensburg, Germany; Oxford University Hospitals NHS Foundation Trust; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Intensive Care National Audit & Research Centre, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam; MRC Population Health Research Unit, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","BackgroundDimethyl fumarate (DMF) is an anti-inflammatory drug that has been proposed as a treatment for patients hospitalised with COVID-19

MethodsThis randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised for COVID-19. In this initial assessment of DMF, performed at 27 UK hospitals, eligible and consenting adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF 120mg twice daily for 2 days followed by 240mg twice daily for 8 days, or until discharge if sooner. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale, assessed using a proportional odds model. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

FindingsBetween 2 March 2021 and 18 November 2021, 713 patients were enrolled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients were receiving corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.85-1.46; p=0.42). There was no significant effect of DMF on any secondary outcome. As expected, DMF caused flushing and gastrointestinal symptoms, each in around 6% of patients, but no new adverse effects were identified.

InterpretationIn adults hospitalised with COVID-19, DMF was not associated with an improvement in clinical outcomes.

FundingUK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056).",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.09.21.22280191,2022-09-21,https://medrxiv.org/cgi/content/short/2022.09.21.22280191,Exploring the relationship between job characteristics and infection: Application of a COVID-19 Job Exposure Matrix to SARS-CoV-2 infection data in the United Kingdom,Sarah Rhodes; Sarah Beale; Jack Wilkinson; Karin Van-Veldhoven; Ioannis Basinas; Will Mueller; Karen Oedehengel; Alex Burdorf; Susan Peters; Zara Stokholm; Vivi Schlunssen; Henrik Kolstad; Anjoeka Pronk; Neil Pearce; Andrew Hayward; Martie van Tongeren,University of Manchester; University College London; University of Manchester; London School of Hygiene and Tropical Medicine; University of Manchester; Institute of Occupational Medicine; Netherlands Organization for Applied Scientific Research; Erasmus Medical Center Rotterdam; Utrecht University; Aarhus University Hospital; Aarhus University; Aarhus University Hospital; Dutch Institution of Applied Science; London School of Hygiene and Tropical Medicine; UCL; University of Manchester,"ObjectivesTo assess whether workplace exposures as estimated via a COVID-19 Job Exposure Matrix (JEM) are associated with SARS-CoV-2.

MethodsData on 244,470 participants were available from the ONS Coronavirus Infection Survey (CIS) and 16,801 participants from the Virus Watch Cohort, restricted to workers aged 20 to 64. Analysis used logistic regression models with SARS-CoV-2 as the dependent variable for eight individual JEM domains (number of workers, nature of contacts, contact via surfaces, indoor or outdoor location, ability to social distance, use of face covering, job insecurity, migrant workers) with adjustment for age, sex, ethnicity, Index of Multiple Deprivation (IMD), region, household size, urban vs rural area, and health conditions. Analyses were repeated for three time periods (i) February 2020 (Virus Watch)/April 2020 (CIS) to May 2021), (ii)June 2021 to November 2021, (iii) December 2021 to January 2022.

ResultsOverall, higher risk classifications for the first six domains tended to be associated with an increased risk of infection, with little evidence of a relationship for domains relating to proportion of workers with job insecurity or migrant workers. By time there was a clear exposure-response relationship for these domains in the first period only. Results were largely consistent across the two cohorts.

ConclusionsAn exposure-response relationship exists in the early phase of the COVID-19 pandemic for number of contacts, nature of contacts, contacts via surfaces, indoor or outdoor location, ability to social distance and use of face coverings. These associations appear to have diminished over time.",occupational and environmental health,fuzzy,100,100
medRxiv,10.1101/2022.09.16.22279985,2022-09-17,https://medrxiv.org/cgi/content/short/2022.09.16.22279985,Bayesian Prediction of Severe Outcomes in the LabMarCS: Laboratory Markers of COVID-19 Severity - Bristol Cohort,Brian Sullivan; Edward Barker; Philip Williams; Louis MacGregor; Ranjeet Bhamber; Matt Thomas; Stefan Gurney; Catherine Hyams; Alastair Whiteway; Jennifer A Cooper; Chris McWilliams; Katy Turner; Andrew W Dowsey; Mahableshwar Albur,"University of Bristol; University of Bristol; University Hospitals Bristol and Weston NHS Trust; University of Bristol; University of Bristol; Southmead Hospital, North Bristol NHS Trust; University Hospitals Bristol and Weston NHS Trust; Southmead Hospital, North Bristol NHS Trust; Southmead Hospital, North Bristol NHS Trust; University of Bristol; University of Bristol; University of Bristol; University of Bristol; Southmead Hospital, North Bristol NHS Trust","We describe several regression models to predict severe outcomes in COVID-19 and challenges present in complex observational medical data. We demonstrate best practices for data curation, cross-validated statistical modelling, and variable selection emphasizing recent Bayesian methods. The study follows a retrospective observational cohort design using multicentre records across National Health Service (NHS) trusts in southwest England, UK. Participants included hospitalised adult patients positive for SARS-CoV 2 during March to October 2020, totalling 843 patients (mean age 71, 45% female, 32% died or needed ICU stay), split into training (n=590) and validation groups (n=253). Models were fit to predict severe outcomes (ICU admission or death within 28-days of admission to hospital for COVID-19, or a positive PCR result if already admitted) using demographic data and initial results from 30 biomarker tests collected within 3 days of admission or testing positive if already admitted. Cross-validation results showed standard logistic regression had an internal validation median AUC of 0.74 (95% Interval [0.62,0.83]), and external validation AUC of 0.68 [0.61, 0.71]; a Bayesian logistic regression (with horseshoe prior) internal AUC of 0.79 [0.71, 0.87], and external AUC of 0.70 [0.68, 0.71]. Variable selection performed using Bayesian predictive projection determined a four variable model using Age, Urea, Prothrombin time and Neutrophil-Lymphocyte ratio, with a median internal AUC of 0.79 [0.78, 0.80], and external AUC of 0.67 [0.65, 0.69]. We illustrate best-practices protocol for conventional and Bayesian prediction modelling on complex clinical data and reiterate the predictive value of previously identified biomarkers for COVID-19 severity assessment.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.09.14.22279931,2022-09-15,https://medrxiv.org/cgi/content/short/2022.09.14.22279931,Detecting changes in population trends in infection surveillance using community SARS-CoV-2 prevalence as an exemplar,Emma Elizabeth Pritchard; Karina-Doris Vihta; David W Eyre; Susan Hopkins; Tim EA Peto; Philippa C Matthews; Nicole Stoesser; Ruth Studley; Emma Rourke; Ian Diamond; Koen B Pouwels; Ann Sarah Walker,"University of Oxford; University of Oxford; University of Oxford; UK Health Security Agency; University of Oxford; The Francis Crick Institute, London; University of Oxford; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; University of Oxford","BackgroundMonitoring infection trends is vital to informing public health strategy. Detecting and quantifying changes in growth rates can inform policymakers rationale for implementing or continuing interventions aimed at reducing impact. Substantial changes in SARS-CoV-2 prevalence with emergence of variants provides opportunity to investigate different methods to do this.

MethodsWe included PCR results from all participants in the UKs COVID-19 Infection Survey between 1 August 2020-30 June 2022. Change-points for growth rates were identified using iterative sequential regression (ISR) and second derivatives of generalised additive models (GAMs).

Consistency between methods and timeliness of detection were compared.

FindingsOf 8,799,079 visits, 147,278 (1{middle dot}7%) were PCR-positive. Over the time period, change-points associated with emergence of major variants were estimated to occur a median 4 days earlier (IQR 0-8) in GAMs versus ISR, with only 2/48 change-points identified by only one method. Estimating recent change-points using successive data periods, four change-points (4/96) identified by GAMs were not found when adding later data or by ISR; 77% (74/96) of change-points identified by successive GAMs were identified by ISR. Change-points were detected 3-5 weeks after they occurred in both methods but could be detected earlier within specific subgroups.

InterpretationChange-points in growth rates of SARS-CoV-2 can be detected in near real-time using ISR and second derivatives of GAMs. To increase certainty about changes in epidemic trajectories both methods could be run in parallel. Running either method in near real-time on different infection surveillance data streams could provide timely warnings of changing underlying epidemiology.

FundingUK Health Security Agency, Department of Health and Social Care (UK), Welsh Government, Department of Health (on behalf of the Northern Ireland Government), Scottish Government, National Institute for Health Research.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.09.11.22279823,2022-09-12,https://medrxiv.org/cgi/content/short/2022.09.11.22279823,Effects of the COVID-19 pandemic on the mental health of clinically extremely vulnerable children and children living with clinically extremely vulnerable people in Wales: A data linkage study,Laura Elizabeth Cowley; Karen Hodgson; Jiao Song; Tony Whiffen; Jacinta Tan; Ann John; Amrita Bandyopadhyay; Alisha R Davies,Swansea University; Public Health Wales; Public Health Wales; Welsh Government; University of Oxford; Swansea University; Swansea University; Public Health Wales,"ObjectivesTo determine whether clinically extremely vulnerable (CEV) children or children living with a CEV person in Wales were at greater risk of presenting with anxiety or depression in primary or secondary care during the COVID-19 pandemic compared with children in the general population, and to compare patterns of anxiety and depression during the pandemic (23rd March 2020-31st January 2021, referred to as 2020/21) and before the pandemic (March 23rd 2019-January 31st 2020, referred to as 2019/20), between CEV children and the general population.

DesignPopulation-based cross-sectional cohort study using anonymised, linked, routinely collected health and administrative data held in the Secure Anonymised Information Linkage Databank. CEV individuals were identified using the COVID-19 Shielded Patient List.

SettingPrimary and secondary healthcare settings covering 80% of the population of Wales.

ParticipantsChildren aged 2-17 in Wales: CEV (3,769); living with a CEV person (20,033); or neither (415,009).

Primary outcome measureFirst record of anxiety or depression in primary or secondary healthcare in 2019/20 and 2020/21, identified using Read and ICD-10 codes.

ResultsA Cox regression model adjusted for demographics and history of anxiety or depression revealed that only CEV children were at greater risk of presenting with anxiety or depression during the pandemic compared with the general population (Hazard Ratio=2.27, 95% Confidence Interval=1.94-2.66, p<0.001). Compared with the general population, the risk amongst CEV children was higher in 2020/21 (Risk Ratio 3.04) compared with 2019/20 (Risk Ratio 1.90). In 2020/21, the cumulative incidence of anxiety or depression increased slightly amongst CEV children, but declined amongst the general population.

ConclusionsDifferences in the cumulative incidences of recorded anxiety or depression in healthcare between CEV children and the general population were largely driven by a reduction in presentations to healthcare services by children in the general population during the pandemic.

Strengths and limitations of this studyO_LIStrengths of this study include its novelty, national focus and clinical relevance; to date this is the first population-based study examining the effects of the COVID-19 pandemic on healthcare use for anxiety or depression amongst clinically extremely vulnerable (CEV) children and children living with a CEV person in Wales
C_LIO_LIWe compared 2020/21 data with pre-pandemic 2019/20 data for CEV children and children in the general population, to place the impact of the COVID-19 pandemic in the context of longer-term patterns of healthcare use
C_LIO_LIWe used a novel approach and linked multiple datasets to identify a cohort of children living with a CEV person in Wales during the COVID-19 pandemic
C_LIO_LIThere was heterogeneity within the Shielded Patient List that was used to create the cohorts of children identified as CEV or living with a CEV person, in terms of the type and severity of individuals underlying conditions; the manner in which people were added to the list; the time point that people were added to the list; and the extent to which people followed the shielding guidance
C_LIO_LIRoutinely collected healthcare data does not capture self-reported health, and is likely to underestimate the burden of common mental disorders in the population
C_LI",pediatrics,fuzzy,100,100
medRxiv,10.1101/2022.09.09.22279754,2022-09-09,https://medrxiv.org/cgi/content/short/2022.09.09.22279754,Contact patterns of UK home delivery drivers and their use of protective measures during the COVID-19 pandemic: a cross-sectional study,Jessica R E Bridgen; Hua Wei; Carl A Whitfield; Yang Han; Ian Hall; Chris Jewell; Martie JA van Tongeren; Jonathan M Read,Lancaster University; The University of Manchester; University of Manchester; University of Manchester; University of Manchester; Lancaster University; University of Manchester; Lancaster University,"ObjectivesTo quantify contact patterns of UK home delivery drivers and identify protective measures adopted during the pandemic.

MethodsWe conducted a cross-sectional online survey to measure the interactions of 170 UK delivery drivers during a working shift between 7 December 2020 and 31 March 2021.

ResultsDelivery drivers had a mean number of 71.6 (95% Confidence Interval (CI) 61.0 to 84.1) customer contacts per shift and 15.0 (95%CI 11.19 to 19.20) depot contacts per shift. Maintaining physical distancing with customers was more common than at delivery depots. Prolonged contact (more than 5 minutes) with customers was reported by 5.4% of drivers on their last shift. We found 3.0% of drivers had tested positive for SARS-CoV-2 since the start of the pandemic and 16.8% of drivers had self-isolated due to a suspected or confirmed case of COVID-19. Additionally, 5.3% (95%CI 2.3% to 10.2%) of participants reported having worked whilst ill with COVID-19 symptoms, or with a member of their household having a suspected or confirmed case of COVID-19.

ConclusionDelivery drivers had a large number of face-to-face customer and depot contacts per shift compared to other working adults during this time. However, transmission risk may be curtailed as contact with customers was of short duration. Most drivers were unable to maintain physical distance with customers and at depots at all times. Usage of protective items such as face masks and hand sanitizer was widespread.",occupational and environmental health,fuzzy,100,100
medRxiv,10.1101/2022.09.01.22279473,2022-09-02,https://medrxiv.org/cgi/content/short/2022.09.01.22279473,Rebound in asthma exacerbations following relaxation of COVID-19 restrictions: a longitudinal population-based study (COVIDENCE UK),Florence Tydeman; Paul Pfeffer; Giulia Vivaldi; Hayley Holt; Mohammad Talaei; David Jolliffe; Gwyneth Davies; Ronan Lyons; Chris Griffiths; Frank Kee; Aziz Sheikh; Seif Shaheen; Adrian R Martineau,Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Swansea University; Swansea University; Queen Mary University of London; Queen's University Belfast; Edinburgh University; Queen Mary University of London; Queen Mary University of London,"BackgroundThe imposition of restrictions on social mixing early in the COVID-19 pandemic was followed by a reduction in asthma exacerbations in multiple settings internationally. Temporal trends in social mixing, incident acute respiratory infections (ARI) and asthma exacerbations following relaxation of COVID-19 restrictions have not yet been described.

MethodsWe conducted a population-based longitudinal study in 2,312 UK adults with asthma between November 2020 and April 2022. Details of face covering use, social mixing, incident ARI and moderate/severe asthma exacerbations were collected via monthly on-line questionnaires. Temporal changes in these parameters were visualised using Poisson generalised additive models. Multilevel logistic regression was used to test for associations between incident ARI and risk of asthma exacerbations, adjusting for potential confounders.

ResultsRelaxation of COVID-19 restrictions from April 2021 coincided with reduced face covering use (p<0.001), increased frequency of indoor visits to public places and other households (p<0.001) and rising incidence of COVID-19 (p<0.001), non-COVID-19 ARI (p<0.001) and moderate/severe asthma exacerbations (p=0.007). Incident non-COVID-19 ARI associated independently with increased risk of asthma exacerbation (adjusted odds ratio 5.75, 95% CI 4.75 to 6.97) as did incident COVID-19, both prior to emergence of the omicron variant of SARS-CoV-2 (5.89, 3.45 to 10.04) and subsequently (5.69, 3.89 to 8.31).

ConclusionsRelaxation of COVID-19 restrictions coincided with decreased face covering use, increased social mixing and a rebound in ARI and asthma exacerbations. Associations between incident ARI and risk of moderate/severe asthma exacerbation were similar for non-COVID-19 ARI and COVID-19, both before and after emergence of the SARS-CoV-2 omicron variant.

FundingBarts Charity, UKRI",respiratory medicine,fuzzy,100,100
medRxiv,10.1101/2022.08.29.22279359,2022-08-31,https://medrxiv.org/cgi/content/short/2022.08.29.22279359,Prophylactic Treatment of COVID-19 in Care Homes Trial (PROTECT-CH),Philip M Bath; Jonathan Ball; Matthew Boyd; Heather Gage; Matthew Glover; Maureen Godfrey; Bruce Guthrie; Jonathan Hewitt; Robert Howard; Thomas Jaki; Edmund Juszczak; Daniel Lasserson; Paul Leighton; Val Leyland; Wei Shen Lim; Pip Logan; Garry Meakin; Alan Montgomery; Reuben Ogollah; Peter Passmore; Philip Quinlan; Caroline Rick; Simon Royal; Susan D Shenkin; Clare Upton; Adam L Gordon; - PROTECT-CH Trialists,University of Nottingham; University of Nottingham; University of Nottingham; University of Surrey; University of Surrey; Private person; University of Edinburgh; Llandough Hospital; University College London; University of Cambridge; University of Nottingham; University of Warwick; University of Nottingham; Private person; Nottingham University Hospitals NHS Trust; University of Nottingham; University of Nottingham; University of Nottingham; University of Nottingham; Queen's University Belfast; University of Nottingham; University of Nottingham; Cripps Health Centre; University of Edinburgh; University of Nottingham; University of Nottingham; ,"BackgroundCoronavirus disease 2019 (COVID-19) is associated with significant mortality and morbidity in care homes. Novel or repurposed antiviral drugs may reduce infection and disease severity through reducing viral replication and inflammation.

ObjectiveTo compare the safety and efficacy of antiviral agents (ciclesonide, niclosamide) for preventing SARS-CoV-2 infection and COVID-19 severity in care home residents.

DesignCluster-randomised open-label blinded endpoint platform clinical trial testing antiviral agents in a post-exposure prophylaxis paradigm.

SettingCare homes across all four United Kingdom member countries.

ParticipantsCare home residents 65 years of age or older.

InterventionsCare homes were to be allocated at random by computer to 42 days of antiviral agent plus standard care versus standard of care and followed for 60 days after randomisation.

Main outcome measuresThe primary four-level ordered categorical outcome with participants classified according to the most serious of all-cause mortality, all-cause hospitalisation, SARS-CoV-2 infection and no infection. Analysis using ordinal logistic regression was by intention to treat. Other outcomes included the components of the primary outcome and transmission.

ResultsDelays in contracting between NIHR and the manufacturers of potential antiviral agents significantly delayed any potential start date. Having set up the trial (protocol, approvals, insurance, website, database, routine data algorithms, training materials), the trial was stopped in September 2021 prior to contracting of care homes and general practitioners in view of the success of vaccination in care homes with significantly reduced infections, hospitalisations and deaths. As a result, the sample size target (based on COVID-19 rates and deaths occurring in February-June 2020) became unfeasible.

LimitationsCare home residents were not approached about the trial and so were not consented and did not receive treatment. Hence, the feasibility of screening, consent, treatment and data acquisition, and potential benefit of post exposure prophylaxis were never tested. Further, contracting between the University of Nottingham and the PIs, GPs and care homes was not completed, so the feasibility of contracting with all the different groups at the scale needed was not tested.

ConclusionsThe role of post exposure prophylaxis of COVID-19 in care home residents was not tested because of changes in COVID-19 incidence, prevalence and virulence as a consequence of the vaccination programme that rendered the study unfeasible. Significant progress was made in describing and developing the infrastructure necessary for a large scale Clinical Trial of Investigational Medicinal Products in care homes in all four UK nations.

Future workThe role of post-exposure prophylaxis of COVID-19 in care home residents remains to be defined. Significant logistical barriers to conducting research in care homes during a pandemic need to be removed before such studies are possible in the required short timescale.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.08.29.22279333,2022-08-30,https://medrxiv.org/cgi/content/short/2022.08.29.22279333,A case-crossover study of the effect of vaccination on SARS-CoV-2 transmission relevant behaviours during a period of national lockdown in England and Wales,Aimee Serisier; Sarah Beale; Yamina I Boukari; Susan J Hoskins; Vincent Nguyen; Thomas Edward Byrne; Wing Lam Erica Fong; Ellen Fragaszy; Cyril Geismar; Jana Kovar; Alexei Yavlinsky; Andrew Hayward; Robert W Aldridge,University College London; University College London; University College London; Univerity College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London,"BackgroundStudies of COVID-19 vaccine effectiveness show increases in COVID-19 cases within 14 days of a first dose, potentially reflecting post-vaccination behaviour changes associated with SARS-CoV-2 transmission before vaccine protection. However, direct evidence for a relationship between vaccination and behaviour is lacking. We aimed to examine the association between vaccination status and self-reported non-household contacts and non-essential activities during a national lockdown in England and Wales.

MethodsParticipants (n=1,154) who had received the first dose of a COVID-19 vaccine reported non-household contacts and non-essential activities from February to March 2021 in monthly surveys during a national lockdown in England and Wales. We used a case-crossover study design and conditional logistic regression to examine the association between vaccination status (pre-vaccination vs. 14 days post-vaccination) and self-reported contacts and activities within individuals. Stratified subgroup analyses examined potential effect heterogeneity by sociodemographic characteristics such as sex, household income or age group.

Results457/1,154 (39.60%) participants reported non-household contacts post-vaccination compared with 371/1,154 (32.15%) participants pre-vaccination. 100/1,154 (8.67%) participants reported use of non-essential shops or services post-vaccination compared with 74/1,154 (6.41%) participants pre-vaccination. Post-vaccination status was associated with increased odds of reporting non-household contacts (OR 1.65, 95% CI 1.31-2.06, p<0.001) and use of non-essential shops or services (OR 1.50, 95% CI 1.03-2.17, p=0.032). This effect varied between men and women and different age groups.

ConclusionParticipants had higher odds of reporting non-household contacts and use of non-essential shops or services within 14 days of their first COVID-19 vaccine compared to pre-vaccination. Public health emphasis on maintaining protective behaviours during this post-vaccination time period when individuals have yet to develop full protection from vaccination could reduce risk of SARS-CoV-2 infection.",public and global health,fuzzy,100,100
medRxiv,10.1101/2022.08.24.22278954,2022-08-25,https://medrxiv.org/cgi/content/short/2022.08.24.22278954,"Long Covid active case finding: a co-produced community-based pilot within the STIMULATE-ICP study (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways)",Nisreen A Alwan; Donna Clutterbuck; Marija Pantelic; Jasmine Hayer; Lere Fisher; Lyth Hishmeh; Melissa Heightman; Gail Allsopp; Dan Wootton; Asad Khan; Claire Hastie; Monique Jackson; Clare Rayner; Darren Brown; Emily Parrett; Geraint Jones; Kerry Smith; Rowan Clarke; Sammie Mcfarland; Mark Gabbay; Amitava Banerjee,University of Southampton; University of Southampton; Brighton and Sussex Medical School; PPI co-applicant STIMULATE-ICP; PPI co-applicant STIMULATE-ICP; PPI co-applicant STIMULATE-ICP; UCLH; RCGP; University of Liverpool; Member of the Community Advisory Board as person with lived experience of Long Covid; Member of the Community Advisory Board as person with lived experience of Long Covid; Member of the Community Advisory Board as person with lived experience of Long Covid; Member of the Community Advisory Board as person with lived experience of Long Covid; Member of the Community Advisory Board as person with lived experience of Long Covid; Member of the Community Advisory Board as person with lived experience of Long Covid; Member of the Community Advisory Board as person with lived experience of Long Covid; Member of the Community Advisory Board as person with lived experience of Long Covid; Member of the Community Advisory Board as person with lived experience of Long Covid; Member of the Community Advisory Board as person with lived experience of Long Covid; University of Liverpool; UCL,"Background and aimLong Covid is a significant public health concern with potentially negative implications for health inequalities. We know that those who are already socially disadvantaged in society are more exposed to COVID-19, experience the worst health outcomes and are more likely to suffer economically. We also know that these groups are more likely to experience stigma and discrimination and have negative healthcare experiences even before the pandemic. However, little is known about disadvantaged groups experiences of Long Covid and preliminary evidence suggests they may be under-represented in those who access formal care.

We will conduct a pilot study in a defined geographical area (Camden, London, UK) to test the feasibility of a community-based approach of identifying Long Covid cases that have not been formally clinically diagnosed and have not been referred to Long Covid Specialist services. We will explore the barriers to accessing recognition, care and support, as well as experiences of stigma and perceived discrimination.

MethodsThis protocol and study materials were co-produced with a Community Advisory Board (CAB) made up primarily of people living with Long Covid. Working with voluntary organisations, promotional material are co-developed and will be distributed in the local community with engagement from key community organisations and leaders to highlight Long Covid symptoms and invite those experiencing them to participate in the study if they are not formally diagnosed and accessing care. Awareness of Long Covid and symptoms, experiences of trying to access care, as well as stigma and discrimination will be explored through qualitative interviews with participants. Upon completion of the interviews, participants will be offered referral to the local social prescribing team to receive support that is personalised to them potentially including, but not restricted to, liaising with their primary care provider and the regional Long Covid clinic run by University College London Hospitals (UCLH).

Ethics and disseminationEthical approval has been obtained from the Faculty of Medicine Ethics Committee and Research Integrity and Governance, University of Southampton. (reference number 72400). Findings will be reported in a report and submitted for peer-reviewed publication. Definitive methods of dissemination will be decided by the CAB. Summaries of the findings will also be shared on the STIMULATE-ICP website, locally in the study area and through social media. We will specifically target policy makers and those responsible for shaping and commissioning Long Covid healthcare services and social support such as NHSE England Long Covid Group.",public and global health,fuzzy,100,100
medRxiv,10.1101/2022.08.22.22278973,2022-08-24,https://medrxiv.org/cgi/content/short/2022.08.22.22278973,The Impact of SARS-CoV-2 Vaccine Dose Separation and Dose Targeting on Hospital Admissions and Deaths from COVID-19 in England,Matt J Keeling; Sam Moore; Bridget Penman; Edward M Hill,University of Warwick; University of Warwick; University of Warwick; University of Warwick,"In late 2020, the JCVI (the Joint Committee on Vaccination and Immunisation, which provides advice to the Department of Health and Social Care, England) made two important recommendations for the initial roll-out of the COVID-19 vaccine. The first was that vaccines should be targeted to the elderly and vulnerable, with the aim of maximally preventing disease rather than infection. The second was to increase the interval between first and second doses from 3 to 12 weeks. Here, we re-examine these recommendations through a mathematical model of SARS-CoV-2 infection in England. We show that targeting the most vulnerable had the biggest immediate impact (compared to targeting younger individuals who may be more responsible for transmission). The 12-week delay was also highly beneficial, estimated to have averted between 32-72 thousand hospital admissions and 4-9 thousand deaths over the first ten months of the campaign (December 2020 - September 2021) depending on the assumed interaction between dose interval and efficacy.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.08.17.22278893,2022-08-18,https://medrxiv.org/cgi/content/short/2022.08.17.22278893,Uptake of Sotrovimab for prevention of severe COVID-19 and its safety in the community in England,Martina Patone; Holly Tibble; Andrew JHL Snelling; Carol Coupland; Aziz Sheikh; Julia Hippisley-Cox,University of Oxford; University of Edinburgh; University of Oxford; University of Oxford; University of Edinburgh; University of Oxford,"Sotrovimab is a neutralising monoclonal antibody (nMAB), currently administrated in England to treat extremely clinically vulnerable COVID-19 patients. Trials have shown it to have mild or moderate side effects, however safety in real-world settings has not been yet evaluated. We used national databases to investigate its uptake and safety in community patients across England. We used a cohort study to describe uptake and a self-controlled case series design to evaluate the risks of 49 pre-specified suspected adverse events in the 2-28 days post-treatment. Between December 11, 2021 and May 24, 2022, there were 172,860 COVID-19 patients eligible for treatment. Of the 22,815 people who received Sotrovimab, 21,487 (94.2%) had a positive SARS-CoV-2 test and 5,999 (26.3%) were not on the eligible list. Between treated and untreated eligible individuals, the mean age (54.6, SD: 16.1 vs 54.1, SD: 18.3) and sex distribution (women: 60.9% vs 58.1%; men: 38.9% vs 41.1%) were similar. There were marked variations in uptake between ethnic groups, which was higher amongst Indian (15.0%; 95%CI 13.8, 16.3), Other Asian (13.7%; 95%CI 11.9, 15.8), White (13.4%; 95%CI 13.3, 13.6), and Bangladeshi (11.4%; 95%CI 8.8, 14.6); and lower amongst Black Caribbean individuals (6.4%; 95%CI 5.4, 7.5) and Black Africans (4.7%; 95%CI 4.1, 5.4). We found no increased risk of any of the suspected adverse events in the overall period of 2-28 days post-treatment, but an increased risk of rheumatoid arthritis (IRR 3.08, 95% CI 1.44, 6.58) and of systematic lupus erythematosus (IRR 5.15, 95% CI 1.60, 16.60) in the 2-3 days post-treatment, when we narrowed the risk period.

FundingNational Institute of Health Research (Grant reference 135561)",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.08.13.22278733,2022-08-16,https://medrxiv.org/cgi/content/short/2022.08.13.22278733,QCovid 4 - Predicting risk of death or hospitalisation from COVID-19 in adults testing positive for SARS-CoV-2 infection during the Omicron wave in England,Julia Hippisley-Cox; Kamlesh Khunti; Aziz Sheikh; Jonathan Nguyen-Van-Tam; Carol Coupland,University of Oxford; University of Leicester; University of Edinburgh; University of Nottingham; University of Oxford,"ObjectivesTo (a) derive and validate risk prediction algorithms (QCovid4) to estimate risk of COVID-19 mortality and hospitalisation in UK adults with a SARS-CoV-2 positive test during the  Omicron pandemic wave in England and (b) evaluate performance with earlier versions of algorithms developed in previous pandemic waves and the high-risk cohort identified by NHS Digital in England.

DesignPopulation-based cohort study using the QResearch database linked to national data on COVID-19 vaccination, high risk patients prioritised for COVID-19 therapeutics, SARS-CoV-2 results, hospitalisation, cancer registry, systemic anticancer treatment, radiotherapy and the national death registry.

Settings and study period1.3 million adults in the derivation cohort and 0.15 million adults in the validation cohort aged 18-100 years with a SARS-CoV-2 positive test between 11th December 2021 and 31st March 2022 with follow up to 30th June 2022.

Main outcome measuresOur primary outcome was COVID-19 death. The secondary outcome of interest was COVID-19 hospital admission. Models fitted in the derivation cohort to derive risk equations using a range of predictor variables. Performance evaluated in a separate validation cohort.

ResultsOf 1,297,984 people with a SARS-CoV-2 positive test in the derivation cohort, 18,756 (1.45%) had a COVID-19 related hospital admission and 3,878 (0.3%) had a COVID-19 death during follow-up. Of the 145,404 people in the validation cohort, there were 2,124 (1.46%) COVID-19 admissions and 461 (0.3%) COVID-19 deaths.

The COVID-19 mortality rate in men increased with age and deprivation. In the QCovid4 model in men hazard ratios were highest for those with the following conditions (for 95% CI see Figure 1): kidney transplant (6.1-fold increase); Downs syndrome (4.9-fold); radiotherapy (3.1-fold); type 1 diabetes (3.4-fold); chemotherapy grade A (3.8-fold), grade B (5.8-fold); grade C (10.9-fold); solid organ transplant ever (2.4-fold); dementia (1.62-fold); Parkinsons disease (2.2-fold); liver cirrhosis (2.5-fold). Other conditions associated with increased COVID-19 mortality included learning disability, chronic kidney disease (stages 4 and 5), blood cancer, respiratory cancer, immunosuppressants, oral steroids, COPD, coronary heart disease, stroke, atrial fibrillation, heart failure, thromboembolism, rheumatoid/SLE, schizophrenia/bipolar disease sickle cell/HIV/SCID; type 2 diabetes. Results were similar in the model in women.

O_FIG O_LINKSMALLFIG WIDTH=100 HEIGHT=200 SRC=""FIGDIR/small/22278733v1_fig1.gif"" ALT=""Figure 1"">
View larger version (35K):
org.highwire.dtl.DTLVardef@4e93b7org.highwire.dtl.DTLVardef@c3e600org.highwire.dtl.DTLVardef@1311bd4org.highwire.dtl.DTLVardef@11a3246_HPS_FORMAT_FIGEXP  M_FIG O_FLOATNOFigure 1C_FLOATNO QCOVID4 (mortality): Adjusted hazard ratios for COVID-19 death in men mutually adjusted and also adjusted for fractional polynomial terms for age and BMI

C_FIG COVID-19 mortality risk was lower among those who had received COVID-19 vaccination compared with unvaccinated individuals with evidence of a dose response relationship. The reduced mortality rates associated with prior SARS-CoV-2 infection were similar in men (adjusted hazard ratio (HR) 0.51 (95% CI 0.40, 0.64)) and women (adjusted HR 0.55 (95%CI 0.45, 0.67)).

The QCOVID4 algorithm explained 76.6% (95%CI 74.4 to 78.8) of the variation in time to COVID-19 death (R2) in women. The D statistic was 3.70 (95%CI 3.48 to 3.93) and the Harrells C statistic was 0.965 (95%CI 0.951 to 0.978). The corresponding results for COVID-19 death in men were similar with R2 76.0% (95% 73.9 to 78.2); D statistic 3.65 (95%CI 3.43 to 3.86) and C statistic of 0.970 (95%CI 0.962 to 0.979). QCOVID4 discrimination for mortality was slightly higher than that for QCOVID1 and QCOVID2, but calibration was much improved.

ConclusionThe QCovid4 risk algorithm modelled from data during the UKs Omicron wave now includes vaccination dose and prior SARS-CoV-2 infection and predicts COVID-19 mortality among people with a positive test. It has excellent performance and could be used for targeting COVID-19 vaccination and therapeutics. Although large disparities in risks of severe COVID-19 outcomes among ethnic minority groups were observed during the early waves of the pandemic, these are much reduced now with no increased risk of mortality by ethnic group.

What is knownO_LIThe QCOVID risk assessment algorithm for predicting risk of COVID-19 death or hospital admission based on individual characteristics has been used in England to identify people at high risk of severe COVID-19 outcomes, adding an additional 1.5 million people to the national shielded patient list in England and in the UK for prioritising people for COVID-19 vaccination.
C_LIO_LIThere are ethnic disparities in severe COVID-19 outcomes which were most marked in the first pandemic wave in 2020.
C_LIO_LICOVID-19 vaccinations and therapeutics (monoclonal antibodies and antivirals) are available but need to be targeted to those at highest risk of severe outcomes.
C_LI

What this study addsO_LIThe QCOVID4 risk algorithm using data from the Omicron wave now includes number of vaccination doses and prior SARS-CoV-2 infection. It has excellent performance both for ranking individuals (discrimination) and predicting levels of absolute risk (calibration) and can be used for targeting COVID-19 vaccination and therapeutics as well as individualised risk assessment.
C_LIO_LIQCOVID4 more accurately identifies individuals at highest levels of absolute risk for targeted interventions than the  conditions-based approach adopted by NHS Digital based on relative risk of a list of medical conditions.
C_LIO_LIAlthough large disparities in risks of severe COVID-19 outcomes among ethnic minority groups were observed during the early waves of the pandemic, these are much reduced now with no increased risk of mortality by ethnic group.
C_LI",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.08.08.22278532,2022-08-09,https://medrxiv.org/cgi/content/short/2022.08.08.22278532,Clinical effectiveness of SARS-CoV-2 booster vaccine against Omicron infection in residents and staff of Long-Term Care Facilities: a prospective cohort study (VIVALDI),Oliver Stirrup; Madhumita Shrotri; Natalie L Adams; Maria Krutikov; Hadjer Nacer-Laidi; Borscha Azmi; Tom Palmer; Christopher Fuller; Aidan Irwin-Singer; Verity Baynton; Gokhan Tut; Paul Moss; Andrew Hayward; Andrew Copas; Laura Shallcross,University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; Department of Health and Social Care; Department of Health and Social Care; University of Birmingham; University of Birmingham; University College London; University College London; University College London,"BackgroundSuccessive SARS-CoV-2 variants have caused severe disease in long-term care facility (LTCF) residents. Primary vaccination provides strong short-term protection, but data are limited on duration of protection following booster vaccines, particularly against the Omicron variant. We investigated effectiveness of booster vaccination against infections, hospitalisations and deaths among LTCF residents and staff in England.

MethodsWe included residents and staff of LTCFs within the VIVALDI study (ISRCTN 14447421) who underwent routine, asymptomatic testing (December 12 2021-March 31 2022). Cox regression was used to estimate relative hazards of SARS-CoV-2 infection, and associated hospitalisation and death at 0-13, 14-48, 49-83 and 84 days after dose 3 of SARS-CoV-2 vaccination compared to 2 doses (after 84+ days), stratified by previous SARS-CoV-2 infection and adjusting for age, sex, LTCF capacity and local SARS-CoV-2 incidence.

Results14175 residents and 19973 staff were included. In residents without prior SARS-CoV-2 infection, infection risk was reduced 0-83 days after first booster, but no protection was apparent after 84 days. Additional protection following booster vaccination waned, but was still present at 84+ days for COVID-associated hospitalisation (aHR: 0.47, 0.24-0.89) and death (aHR: 0.37, 0.21-0.62). Most residents (64.4%) had received primary course of AstraZeneca, but this did not impact on pre- or post-booster risks. Staff showed a similar pattern of waning booster effectiveness against infection, with few hospitalisations and no deaths.

ConclusionsBooster vaccination provides sustained protection against severe outcomes following infection with the Omicron variant, but no protection against infection from 3 months onwards. Ongoing surveillance for SARS-CoV-2 in LTCFs is crucial.

SummaryThe COVID-19 pandemic has severely impacted residents in long-term care facilities (LTCFs). Booster vaccination provides sustained moderate protection against severe outcomes, but no protection against infection was apparent from around 3 months onwards. Ongoing surveillance in LTCFs is crucial.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.08.07.22278510,2022-08-09,https://medrxiv.org/cgi/content/short/2022.08.07.22278510,Metabolomic and gut microbiome profiles across the spectrum of community-based COVID and non-COVID disease: A COVID-19 Biobank study.,Marc F √ñsterdahl; Ronan Whiston; Carole H Sudre; Francesco Asnicar; Nathan J Cheetham; Aitor Blanco Miguez; Vicky Bowyer; Michela Antonelli; Olivia Snell; Liane dos Santos Canas; Christina Hu; Jonathan Wolf; Cristina Menni; Michael Malim; Deborah Hart; Tim Spector; Sarah Berry; Nicola Segata; Katie Doores; Sebastien Ourselin; Emma L Duncan; Claire J Steves,King's College London; King's College London; King's College London; University of Trento; King's College London; University of Trento; King's College London; King's College London; King's College London; King's College London; ZOE Global Ltd.; ZOE Global Ltd.; King's College London; King's College London; King's College London; King's College London; King's College London; University of Trento; King's College London; King's College London; King's College London; King's College London,"Whilst many with SARS-CoV-2 infection have mild disease, managed in the community, individuals with cardiovascular risk factors experienced often more severe acute disease, requiring hospitalisation. Increasing concern has also developed over long symptom duration in many individuals, including the majority who managed acutely in the community. Risk factors for long symptom duration, including biological variables, are still poorly defined.

We examine post-illness metabolomic and gut-microbiome profiles, in community-dwelling participants with SARS-CoV-2, ranging from asymptomatic illness to Post-COVID Syndrome, and participants with prolonged non-COVID-19 illnesses. We also assess a pre-established metabolomic biomarker score for its association with illness duration.

We found an atherogenic-dyslipidaemic metabolic profile, and greater biomarker scores, associated with longer illness, both in individuals with and without SARS-CoV-2 infection. We found no association between illness duration and gut microbiome in convalescence.

Findings highlight the potential role of cardiometabolic dysfunction to the experience of long illness duration, including after COVID-19.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.08.08.22278493,2022-08-09,https://medrxiv.org/cgi/content/short/2022.08.08.22278493,Inequalities in colorectal cancer screening uptake in Wales: examination of the impact of the temporary suspension of the screening programme during the COVID-19 pandemic,Diana Bright; Sharon Hillier; Jiao Song; Dyfed W Huws; Giles Greene; Karen Hodgson; Ashley Akbari; Rowena Griffiths; Alisha R Davies,"Public Health Wales; Public Health Wales; Public Health Wales; Public Health Wales; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, Wales; Public Health Wales; Public Health Wales; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, Wales; Population Data Science, Swansea University Medical School, Faculty of Medicine, Health & Life Science, Swansea University, Swansea, Wales; Public Health Wales","BackgroundResponse to the early stages of the COVID-19 pandemic resulted in the temporary disruption of cancer screening in the UK, and strong public messaging to stay safe and to protect NHS capacity. Following reintroduction in services, we explored the impact on inequalities in uptake of the Bowel Screening Wales (BSW) programme to identify groups who may benefit from tailored interventions.

MethodsRecords within the BSW were linked to electronic health records (EHR) and administrative data within the Secured Anonymised Information Linkage (SAIL) Databank. Ethnic group was obtained from a linked data method available within SAIL. We examined uptake for the first 3 months of invitations (August to October) following the reintroduction of BSW programme in 2020, compared to the same period in the preceding 3 years. Uptake was measured across a 6 month follow-up period. Logistic models were conducted to analyse variations in uptake by sex, age group, income deprivation quintile, urban/rural location, ethnic group, and clinically extremely vulnerable (CEV) status in each period; and to compare uptake within sociodemographic groups between different periods.

ResultsUptake during August to October 2020 (period 2020/21; 60.4%) declined compared to the same period in 2019/20 (62.7%) but remained above the 60% Welsh standard. Variation by sex, age, income deprivation, and ethnic groups was observed in all periods studied. Compared to the pre-pandemic period in 2019/20, uptake declined for most demographic groups, except for older individuals (70-74 years) and those in the most income deprived group. Uptake continues to be lower in males, younger individuals, people living in the most income deprived areas and those of Asian and unknown ethnic backgrounds.

ConclusionsOur findings are encouraging with overall uptake achieving the 60% Welsh standard during the first three months after the programme restarted in 2020 despite the disruption. Inequalities did not worsen after the programme resumed activities but variations in CRC screening in Wales associated with sex, age, deprivation and ethnicity remain. This needs to be considered in targeting strategies to improve uptake and informed choice in CRC screening to avoid exacerbating disparities in CRC outcomes as screening services recover from the pandemic.",public and global health,fuzzy,100,100
medRxiv,10.1101/2022.07.30.22278161,2022-08-02,https://medrxiv.org/cgi/content/short/2022.07.30.22278161,Changes in COVID-19-related mortality across key demographic and clinical subgroups: an observational cohort study using the OpenSAFELY platform on 18 million adults in England,- The OpenSAFELY Collaborative; Linda Nab; Edward P K Parker; Colm D Andrews; William J Hulme; Louis Fisher; Jessica Morley; Amir Mehrkar; Brian MacKenna; Peter Inglesby; Caroline E Morton; Sebastian CJ Bacon; George Hickman; David Evans; Tom Ward; Rebecca M Smith; Simon Davy; Iain Dillingham; Steven Maude; Ben FC Butler-Cole; Thomas O'Dwyer; Catherine L Stables; Lucy Bridges; Christopher Bates; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Bang Zheng; Elizabeth J Williamson; Rosalind M Eggo; Stephen JW Evans; Ben Goldacre; Laurie A Tomlinson; Alex J Walker,"-; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG","ObjectivesTo quantify in absolute and relative terms how population-level COVID-19 death rates have changed in demographic and clinical subgroups.

DesignRetrospective cohort study on behalf of NHS England.

SettingLinked primary care and death registry data from the OpenSAFELY-TPP platform, covering the first three pandemic waves in England (wave 1: March 23 to May 30, 2020; wave 2: September 7, 2020 to April 24, 2021; and wave 3, delta: May 28 to December 14, 2021).

ParticipantsIn total, 18.7, 18.8, and 18.7 million adults were included for waves 1, 2, and 3 respectively.

Main outcome measuresCOVID-19-related mortality based on linked death registry records.

ResultsThe crude absolute COVID-19-related death rate per 1,000 person-years decreased from 4.48 in wave 1 (95%CI 4.41;4.55), to 2.70 in wave 2 (95%CI 2.67;2.73), to 0.64 in wave 3 (95%CI 0.63;0.66). The absolute death rate decreased by 90% between waves 1 and 3 in patients aged 80+, but by only 20% in patients aged 18-39. This higher proportional reduction in age- and sex-standardised death rates was also seen for other groups, such as neurological disease, learning disability and severe mental illness. Conversely, standardised death rates in transplant recipients stayed constant across successive waves at 10 per 1,000 person-years. There was also only a small decrease in death rates between waves in people with kidney disease, haematological malignancies or conditions associated with immunosuppression. Consequently, the relative hazard of COVID-19-related death decreased over time for some variables (e.g. age), remained similar for some (e.g. sex, ethnicity), and increased for others (e.g. transplant).

ConclusionsCOVID-19 death rates decreased over the first three pandemic waves. An especially large decrease was seen in older age groups and people with neurological disease, learning disability or severe mental illness. Some demographic inequalities in death rates persisted over time. Groups more likely to experience impaired vaccine effectiveness did not see the same benefit in COVID-19 mortality reduction.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.07.28.22278152,2022-07-31,https://medrxiv.org/cgi/content/short/2022.07.28.22278152,"Confirmed SARS-CoV-2 infection in Scottish neonates 2020-2022: a national, population-based cohort study",Anna Goulding; Fiona McQuaid; Laura Lindsay; Utkarsh Agrawal; Bonnie Auyeung; Clara Calvert; Jade Carruthers; Cheryl Denny; Jack Donaghy; Sam Hillman; Lisa Hopcroft; Leanne Hopkins; Colin McCowan; Terry Mclaughlin; Emily Moore; Lewis Ritchie; Colin R Simpson; Bob Taylor; Lynda Fenton; Louisa Pollock; Christopher Gale; Jenny J Kurinczuk; Chris Robertson; Aziz Sheikh; Sarah Stock; Rachael Wood,Public Health Scotland; University of Edinburgh; Public Health Scotland; University of St Andrews; University of Edinburgh; University of Edinburgh; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; University of Oxford; University of Edinburgh; University of St Andrews; Public Health Scotland; Public Health Scotland; University of Aberdeen; Victoria University of Wellington; Public Health Scotland; Public Health Scotland; University of Glasgow; Imperial College London; University of Oxford; University of Strathclyde; University of Edinburgh; University of Edinburgh; Public Health Scotland,"ObjectiveTo examine infants in Scotland aged 0-27 days with confirmed SARS-CoV-2 infection; the risk of neonatal infection by factors including maternal infection status and gestation at birth; and the need for hospital admission among infected neonates.

DesignPopulation-based cohort study.

Setting and populationAll live births in Scotland, 1 March 2020 to 31 January 2022.

ResultsThere were 141 neonates with confirmed SARS-CoV-2 infection over the study period, giving an overall infection rate of 153 per 100,000 live births (141/92,009). Among infants born to women with confirmed infection around the time of birth, the infection rate was 1,811 per 100,000 live births (15/828). Nearly two-thirds (92/141, 65.2%) of babies with confirmed neonatal infection had an associated admission to neonatal or (more commonly) paediatric care. Of those admitted to hospital, 6/92 (6.5%) infants were admitted to neonatal or paediatric intensive care, however none of these six had COVID-19 recorded as the main diagnosis underlying their admission. There were no neonatal deaths among babies with confirmed infection.

Implications and relevanceConfirmed neonatal SARS-CoV-2 infection is uncommon. Secular trends in the neonatal infection rate broadly follow those seen in the general population, albeit at a lower level. Maternal infection at birth increases the risk of neonatal infection, but most babies with neonatal infection are born to women without confirmed infection. A high proportion of neonates with confirmed infection are admitted to hospital, with resulting implications for the baby, family, and services, although their outcomes are generally good.

Key messagesO_ST_ABSWhat is already known on this topicC_ST_ABSO_LIThe incidence of SARS-CoV-2 infection in neonates is low, but some studies have suggested that age under 1 month is a risk factor for severe infection requiring admission to intensive care.
C_LIO_LIAlmost all the studies of neonatal SARS-CoV-2 have focused on the transmission risk from SARS-CoV-2 positive women to their offspring and data are lacking on the level of neonatal SARS-CoV-2 infection in the whole population.
C_LI

What this study addsO_LIThis study includes all babies with confirmed SARS-CoV-2 in the neonatal period in Scotland during the first 22 months of the COVID-19 pandemic.
C_LIO_LIConfirmed neonatal SARS-CoV-2 infection is uncommon, but a high proportion of neonates with confirmed infection are admitted to hospital.
C_LIO_LIConfirmed maternal SARS-CoV-2 infection around the time of birth substantially increases the risk of neonatal infection, although the absolute risk of neonatal infection remains low (<2%) and most babies with neonatal infection are born to women without confirmed infection.
C_LIO_LIOutcomes for neonates with confirmed SARS-CoV-2 infection are good; only 6.5% (6/92) of admitted neonates required intensive care, and COVID-19 was not the primary diagnosis recorded for these babies. There were no neonatal deaths among babies with confirmed infection.
C_LI",pediatrics,fuzzy,100,100
medRxiv,10.1101/2022.07.28.22278159,2022-07-31,https://medrxiv.org/cgi/content/short/2022.07.28.22278159,Profiling post-COVID syndrome across different variants of SARS-CoV-2,Liane S Canas PhD; Erika Molteni PhD; Jie Deng PhD; Carole H. Sudre PhD; Benjamin Murray MSc; Eric Kerfoot PhD; Michela Antonelli PhD; Liyuan Chen MSc; Khaled Rjoob PhD; Joan Capdevila Pujol PhD; Lorenzo Polidori MSc; Anna May MSc; Marc F. Osterdahl PhD; Ronan Whiston PhD; Nathan J. Cheetham PhD; Vicky Bowyer MSc; Tim D. Spector Prof; Alexander Hammers PhD; Emma L. Duncan Prof; Sebastien Ourselin Prof; Claire J. Steves PhD; Marc Modat PhD,"School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK; MRC Unit for Lifelong Health and Ageing, Department of Population Health Sciences, University College London, London, UK; Centre for Medical Image Computing, De; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK; MRC Unit for Lifelong Health and Ageing, Department of Population Health Sciences, University College London, London, UK; ZOE Limited London, UK; ZOE Limited London, UK; ZOE Limited London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Endocrinology, Guys and St Thomas NHS Foundation Trust, Lo; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK","AbstractO_ST_ABSBackgroundC_ST_ABSSelf-reported symptom studies rapidly increased our understanding of SARS-CoV-2 during the pandemic and enabled the monitoring of long-term effects of COVID-19 outside the hospital setting. It is now evident that post-COVID syndrome presents with heterogeneous profiles, which need characterisation to enable personalised care among the most affected survivors. This study describes post-COVID profiles, and how they relate to different viral variants and vaccination status.

MethodsIn this prospective longitudinal cohort study, we analysed data from 336,652 subjects, with regular health reports through the Covid Symptom Study (CSS) smartphone application. These subjects had reported feeling physically normal for at least 30 days before testing positive for SARS-CoV-2. 9,323 individuals subsequently developed Long-COVID, defined as symptoms lasting longer than 28 days. 1,459 had post-COVID syndrome, defined as more than 12 weeks of symptoms. Clustering analysis of the time-series data was performed to identify distinct symptom profiles for post-COVID patients, across variants of SARS-CoV-2 and vaccination status at the time of infection. Clusters were then characterised based on symptom prevalence, duration, demography, and prior conditions (comorbidities).

Using an independent testing sample with additional data (n=140), we investigated the impact of post-COVID symptom clusters on the lives of affected individuals.

FindingsWe identified distinct profiles of symptoms for post-COVID syndrome within and across variants: four endotypes were identified for infections due to the wild-type variant; seven for the alpha variant; and five for delta. Across all variants, a cardiorespiratory cluster of symptoms was identified. A second cluster related to central neurological, and a third to cases with the most severe and debilitating multi-organ symptoms. Gastrointestinal symptoms clustered in no more than two specific phenotypes per viral variant. The three main clusters were confirmed in an independent testing sample, and their functional impact was assessed.

InterpretationUnsupervised analysis identified different post-COVID profiles, characterised by differing symptom combinations, durations, and functional outcomes. Phenotypes were at least partially concordant with individuals reported experiences.

Our classification may be useful to understand distinct mechanisms of the post-COVID syndrome, as well as subgroups of individuals at risk of prolonged debilitation.

FundingUK Government Department of Health and Social Care, Chronic Disease Research Foundation, The Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation and Alzheimers Society, and ZOE Limited, UK.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe conducted a search in the PubMed Central database, with keywords: (""Long-COVID*"" OR ""post?covid*"" OR ""post?COVID*"" OR postCOVID* OR postCovid*) AND (cluster* OR endotype* OR phenotype* OR sub?type* OR subtype).

On 15 June 2022, 161 documents were identified, of which 24 either provided descriptions of sub-types or proposed phenotypes of Long-COVID or post-COVID syndrome(s). These included 16 studies attempting manual sub-grouping of phenotypes, 6 deployments of unsupervised methods for patient clustering and automatic semantic phenotyping (unsupervised k-means=2; random forest classification=1; other=2), and two reports of uncommon presentations of Long-COVID/post-COVID syndrome. Overall, two to eight symptom profiles (clusters) were identified, with three recurring clusters. A cardiopulmonary syndrome was the predominant observation, manifesting with exertional intolerance and dyspnoea (n=10), fatigue (n=8), autonomic dysfunction, tachycardia or palpitations (n=5), lung radiological abnormalities including fibrosis (n=2), and chest pain (n=1). A second common presentation consisted in persistent general autoimmune activation and proinflammatory state (n=2), comprising multi-organ mild sequelae (n=2), gastrointestinal symptoms (n=2), dermatological symptoms (n=2), and/or fever (n=1). A third syndrome was reported, with neurological or neuropsychiatric symptoms: brain fog or dizziness (n=2), poor memory or cognition (n=2), and other mental health issues including mood disorders (n=5), headache (n=2), central sensitization (n=1), paresthesia (n=1), autonomic dysfunction (n=1), fibromyalgia (n=2), and chronic pain or myalgias (n=6). Unsupervised clustering methods identified two to six different post-COVID phenotypes, mapping to the ones described above.

14 further documents focused on possible causes and/or mechanisms of disease underlying one or more manifestations of Long-COVID or post-COVID and identifying immune response dysregulation as a potential common element. All the other documents were beyond the scope of this work.

To our knowledge, there are no studies examining the symptom profile of post-COVID syndrome between different variants and vaccination status. Also, no studies reported the modelling of longitudinally collected symptoms, as time-series data, aiming at the characterisation of post-COVID syndrome.

Added-value of this studyOur study aimed to identify symptom profiles for post-COVID syndrome across the dominant variants in 2020 and 2021, and across vaccination status at the time of infection, using a large sample with prospectively collected longitudinal self-reports of symptoms. For individuals developing 12 weeks or more of symptoms, we identified three main symptom profiles which were consistent across variants and by vaccination status, differing only in the ratio of individuals affected by each profile and symptom duration overall.

Implications of all the available evidenceWe demonstrate the existence of different post-COVID syndromes, which share commonalities across SARS-CoV-2 variant types in both symptoms themselves and how they evolved through the illness. We describe subgroups of patients with specific post-COVID presentations which might reflect different underlying pathophysiological mechanisms. Given the time-series component, our study is relevant for post-COVID prognostication, indicating how long certain symptoms last. These insights could aid in the development of personalised diagnosis and treatment, as well as helping policymakers plan for the delivery of care for people living with post-COVID syndrome.",health informatics,fuzzy,100,100
medRxiv,10.1101/2022.07.29.22278186,2022-07-30,https://medrxiv.org/cgi/content/short/2022.07.29.22278186,Comparative effectiveness of BNT162b2 versus mRNA-1273 boosting in England: a cohort study in OpenSAFELY-TPP,WIlliam J Hulme; Elsie M F Horne; Edward P K Parker; Ruth H Keogh; Elizabeth J Williamson; Venexia Walker; Tom Palmer; Helen J Curtis; Alex Walker; Amir Mehrkar; Jessica Morley; Brian MacKenna; Sebastian C J Bacon; Ben Goldacre; Miguel A Hernan; Jonathan A C Sterne,"The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; MRC Integrative Epidemiology Unit, Bristol Medical Scho; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; MRC Integrative Epidemiology Unit, Bristol Medical Scho; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; CAUSALab, Harvard T.H. Chan School of Public Health, Boston, MA 02115; Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health,; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK; H","IntroductionThe COVID-19 booster vaccination programme in England used both BNT162b2 and mRNA-1273 vaccines. Direct comparisons of the effectiveness against severe COVID-19 of these two vaccines for boosting have not been made in trials or observational data.

MethodsOn behalf of NHS England, we used the OpenSAFELY-TPP database to match adult recipients of each vaccine type on date of vaccination, primary vaccine course, age, and other characteristics. Recipients were eligible if boosted between 29 October 2021 and 31 January 2022, and followed up for 12 weeks. Outcomes were positive SARS-CoV-2 test, COVID-19 hospitalisation, and COVID-19 death. We estimated the cumulative incidence of each outcome, and quantified comparative effectiveness using risk differences (RD) and hazard ratios (HRs).

Results1,528,431 people were matched in each group, contributing a total 23,150,504 person-weeks of follow-up. The 12-week risks per 1,000 people of positive SARS-CoV-2 test were 103.2 (95%CI 102.4 to 104.0) for BNT162b2 and 96.0 (95.2 to 96.8) for mRNA-1273: the HR comparing mRNA-1273 with BNT162b2 was 0.92 (95%CI 0.91 to 0.92). For COVID-19 hospitalisations the 12-week risks per 1,000 were 0.65 (95%CI 0.56 to 0.75) and 0.44 (0.36 to 0.54): HR 0.67 (95%CI 0.58 to 0.78). COVID-19 deaths were rare: the 12-week risks per 1,000 were 0.03 (95%CI 0.02 to 0.06) and 0.01 (0.01 to 0.02): HR 1.23 (95%CI 0.59 to 2.56). Comparative effectiveness was generally similar within subgroups defined by the primary course vaccine brand, age, prior SARS-CoV-2 infection and clinical vulnerability.

ConclusionBooster vaccination with mRNA-1273 COVID-19 vaccine was more effective than BNT162b2 in preventing SARS-CoV-2 infection and COVID-19 hospitalisation during the first 12 weeks after vaccination, during a period of Delta followed by Omicron variant dominance.",epidemiology,fuzzy,100,100
bioRxiv,10.1101/2022.07.26.501570,2022-07-26,https://biorxiv.org/cgi/content/short/2022.07.26.501570,Primary Omicron infection elicits weak antibody response but robust cellularimmunity in children,Alexander C Dowell; Tara Lancaster; Rachel Bruton; Georgina Ireland; Christopher Bentley; Panagiota Sylla; Jianmin Zuo; Sam Scott; Azar Jardin; Jusnara Begum; Thomas Roberts; Christine Stephens; Shabana Ditta; Rebecca Shepherdson; Annable Powell; Andrew Brent; Bernadette Brent; Frances Baawuah; Ifeanyichukwu Okike; Joanna Beckmann; Shazaad Ahmad; Felicity Aiano; Joanna Garstang; Mary Ramsay; Rafaq Azad; Dagmar Waiblinger; Brian Willet; John Wright; Shamez Ladhani; Paul Moss,"Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; MRC-University of Glasgow Centre for Virus Research, 464 Bearsden Road, Glasgow G61-1QH, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK.; Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK.; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford OX3 7HE; Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford OX3 7HE; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom; East London NHS Foundation Trust, 9 Allie Street, London E1 8DE, UK; Manchester University NHS Foundation Trust, Oxford Road, Manchester M13 9WL, UK; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom; Birmingham Community Healthcare NHS Trust, Holt Street, Aston B7 4BN, UK; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom; Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK.; Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK.; MRC-University of Glasgow Centre for Virus Research, 464 Bearsden Road, Glasgow G61-1QH, UK; Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, BD9 6RJ, UK.; Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK","Omicron variants of SARS-CoV-2 are globally dominant and infection rates are very high in children. We determined immune responses following Omicron BA.1/2 infection in children aged 6-14 years and related this to prior and subsequent SARS-CoV-2 infection or vaccination. Primary Omicron infection elicited a weak antibody response with poor functional neutralizing antibodies. Subsequent Omicron reinfection or COVID-19 vaccination elicited increased antibody titres with broad neutralisation of Omicron subvariants. Prior pre-Omicron SARS-CoV-2 virus infection or vaccination primed for robust antibody responses following Omicron infection but these remained primarily focussed against ancestral variants. Primary Omicron infection thus elicits a weak antibody response in children which is boosted after reinfection or vaccination. Cellular responses were robust and broadly equivalent in all groups, providing protection against severe disease irrespective of SARS-CoV-2 variant. Immunological imprinting is likely to act as an important determinant of long-term humoral immunity, the future clinical importance of which is unknown.",immunology,fuzzy,100,100
medRxiv,10.1101/2022.07.20.22277838,2022-07-21,https://medrxiv.org/cgi/content/short/2022.07.20.22277838,"National and regional prevalence of SARS-CoV-2 antibodies in primary and secondary school children in England: the School Infection Survey, a national open cohort study, November 2021",Annabel A Powell; Georgina Ireland; Rebecca Leeson; Andrea Lacey; Ben Ford; John Poh; Samreen Ijaz; Justin Shute; Peter Cherepanov; Richard Tedder; Christian Bottomley; Fiona Dawe; Punam Mangtani; Peter Jones; Patrick Nguipdop-Djomo; Shamez Ladhani,UK Health Security Agency; UK Health Security Agency; Office for National Statistics; Office for National Statistics; Office for National Statistics; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; Imperial College London; Francis Crick Institute; London School of Hygiene & Tropical Medicine; Office for National Statistics; London School of Hygiene & Tropical Medicine; Office for National Statistics; London School of Hygiene & Tropical Medicine; UK Health Security Agency,"BackgroundRisk factors for infection and, therefore, antibody positivity rates will be different in children compared to adults. We aim to estimate national and regional prevalence of SARS-CoV-2 antibodies in primary (4-11-year-olds) and secondary (11-15-year-olds) school children between 10 November and 10 December 2021.

MethodsCross-sectional surveillance in England using two stage sampling, firstly stratifying into regions and selecting local authorities, then selecting schools according to a stratified sample within selected local authorities. Participants were sampled using a novel oral fluid validated assay for SARS-CoV-2 spike and nucleocapsid IgG antibodies.

Results4,980 students from 117 state-funded schools (2,706 from 83 primary schools, 2,274 from 34 secondary schools) provided a valid sample. After weighting for age, sex and ethnicity, and adjusting for assay accuracy, the national prevalence of SARS-CoV-2 antibodies in primary school students, who were all unvaccinated, was 40.1% (95%CI; 37.3-43.0). Antibody prevalence increased with age (p<0.001) and were higher in urban than rural schools (p=0.01). In secondary school students, the adjusted, weighted national prevalence of SARS-CoV-2 antibodies was 82.4% (95%CI; 79.5-85.1); including 57.5% (95%CI; 53.9-61.1) in unvaccinated and 97.5% (95%CI; 96.1-98.5) in vaccinated students. Antibody prevalence increased with age (p<0.001), and was not significantly different in urban versus rural students (p=0.1).

ConclusionsUsing a validated oral fluid assay, we estimated national and regional seroprevalence of SARS-CoV-2 antibodies in primary and secondary school students. In November 2021, 40% of primary school students and nearly all secondary school students in England had SARS-CoV2 antibodies through a combination of natural infection and vaccination.",epidemiology,fuzzy,92,100
medRxiv,10.1101/2022.07.21.22277893,2022-07-21,https://medrxiv.org/cgi/content/short/2022.07.21.22277893,"STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: a structured protocol",Denise Forshaw; Emma  C Wall; Gordon Prescott; Hakim-Moulay Dehbi; Angela Green; Emily Attree; Lyth Hismeh; William  D Strain; Michael  G Crooks; Caroline Watkins; Chris Robson; Rajarshi Banerjee; Paula Lorgelly; Melissa Heightman; Amitava Banerjee; - the STIMULATE-ICP trial team,University of Central Lancashire; The Francis Crick Institute; University of Central Lancashire; University College London; Hull University Teaching Hospitals NHS Trust; STIMULATE-ICP study; STIMULATE-ICP study; University of Exeter; University of Hull; University of Central Lancashire; Living with; Perspectum Ltd; The University of Auckland; University College London Hospitals NHS Foundation Trust; University College London; -,"IntroductionLong COVID (LC), the persistent symptoms [&ge;]12 weeks following acute COVID-19, presents major threats to individual and public health across countries, affecting over 1.5 million people in the UK alone. Evidence-based interventions are urgently required and an integrated care pathway (ICP) approach in pragmatic trials, which include investigations, treatments and rehabilitation for LC, could provide scalable and generalisable solutions at pace.

Methods and analysisThis is a pragmatic, multi-centre, cluster-randomised clinical trial of two components of an ICP (Coverscan, a multi-organ MRI, and Living with COVID Recovery, a digitally enabled rehabilitation platform) with a nested, Phase III, open label, platform randomised drug trial in individuals with LC. Cluster randomisation is at level of primary care networks so that ICP interventions are delivered as ""standard of care"" in that area. The drug trial randomisation is at individual level and initial arms are rivaroxaban, colchicine, famotidine/loratadine, compared with no drugs, with potential to add in further drug arms. The trial is being carried out in 6-10 NHS LC clinics in the UK and is evaluating the effectiveness of a pathway of care for adults with LC in reducing fatigue and other physical, psychological and functional outcomes (e.g. EQ-5D-5L, GAD-7, PHQ-9, WSAS, PDQ-5, CFQ, SF-12, MRC Dyspnoea score) at 3 months. The trial also includes an economic evaluation which will be described separately.

Ethics and disseminationThe protocol was reviewed by South Central - Berkshire Research Ethics Committee (reference: 21/SC/0416). All participating sites obtained local approvals prior to recruitment. Coverscan has UKCA certification (752965). The first participant was recruited in July 2022 and interim/final results will be disseminated in 2023, in a plan co-developed with public and patient representatives. The results will be presented at national and international conferences, published in peer reviewed medical journals, and shared via media (mainstream and social) and patient support organisations.

Trial registration numberISRCTN10665760",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.07.14.22277638,2022-07-15,https://medrxiv.org/cgi/content/short/2022.07.14.22277638,Therapeutic potential of IL6R blockade for the treatment of sepsis and sepsis-related death: Findings from a Mendelian randomisation study,Fergus W Hamilton; Matt Thomas; David T Arnold; Tom M Palmer; Ed Moran; Alexander J Mentzer; Nick A Maskell; J Kenneth Baillie; Charlotte Summers; Aroon Dinesh Hingorani; Alasdair P MacGowan; Golam M Khandaker; Ruth E Mitchell; George Davey Smith; Peter Ghazal; Nicholas J Timpson,"University of Bristol; North Bristol NHS Trust; University of Bristol; University of Bristol; North Bristol NHS Trust; University of Oxford; University; Roslin Institute, University of Edinburgh; University of Cambridge; University College London; North Bristol NHS Trust; University of Bristol; University of Bristol; University of Bristol; Cardiff University; University of Bristol","IntroductionSepsis is characterised by dysregulated, life-threatening immune responses, which are thought to be driven by cytokines such as interleukin-6 (IL-6). Genetic variants in IL6R known to downregulate IL-6 signalling are associated with improved COVID-19 outcomes, a finding later confirmed in randomised trials of IL-6 receptor antagonists (IL6RA). We hypothesised that blockade of IL6R could also improve outcomes in sepsis.

MethodsWe performed a Mendelian randomisation analysis using single nucleotide polymorphisms (SNPs) in and near IL6R to evaluate the likely causal effects of IL6R blockade on sepsis, sepsis severity, other infections, and COVID-19. We weighted SNPs by their effect on CRP and combined results across them in inverse variance weighted meta-analysis, proxying the effect of IL6RA. Our outcomes were measured in UK Biobank, FinnGen, the COVID-19 Host Genetics Initiative (HGI), and the GenOSept and GainS consortium. We performed several sensitivity analyses to test assumptions of our methods, including utilising variants around CRP in a similar analysis.

ResultsIn the UK Biobank cohort (N=485,825, including 11,643 with sepsis), IL6R blockade was associated with a decreased risk of sepsis (OR=0.80; 95% CI 0.66-0.96, per unit of natural log transformed CRP decrease). The size of this effect increased with severity, with larger effects on 28-day sepsis mortality (OR=0.74; 95% CI 0.38-0.70); critical care admission with sepsis (OR=0.48, 95% CI 0.30-0.78) and critical care death with sepsis (OR=0.37, 95% CI 0.14 - 0.98) Similar associations were seen with severe respiratory infection: OR for pneumonia in critical care 0.69 (95% CI 0.49 - 0.97) and for sepsis survival in critical care (OR=0.22; 95% CI 0.04- 1.31) in the GainS and GenOSept consortium. We also confirm the previously reported protective effect of IL6R blockade on severe COVID-19 (OR=0.69, 95% 0.57 - 0.84) in the COVID-19 HGI, which was of similar magnitude to that seen in sepsis. Sensitivity analyses did not alter our primary results.

ConclusionsIL6R blockade is causally associated with reduced incidence of sepsis, sepsis related critical care admission, and sepsis related mortality. These effects are comparable in size to the effect seen in severe COVID-19, where IL-6 receptor antagonists were shown to improve survival. This data suggests a randomised trial of IL-6 receptor antagonists in sepsis should be considered.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.07.07.22277367,2022-07-10,https://medrxiv.org/cgi/content/short/2022.07.07.22277367,"Non-hospitalised, vaccinated adults with COVID-19 caused by Omicron BA.1 and BA.2 present with changing symptom profiles compared to those with Delta despite similar viral kinetics",Hermaleigh Townsley; Joshua Gahir; Timothy W Russell; Edward J Carr; Matala Dyke; Murad Miah; Bobbi Clayton; Callie Smith; Mauro Miranda; Nicola O'Reilly; Lorin Adams; Harriet V Mears; Christopher Bailey; James RM Black; Ashley S Fowler; Katalin Wilkinson; Matthew Hutchinson; Ruth Harvey; Bobbi Clayton; Gavin Kelly; Rupert Beale; Padmasayee Papineni; Tumena Corrah; Simon Caidan; Jerome Nicod; Steve Gamblin; George Kassiotis; Vincenzo Libri; Bryan Williams; Sonia Gandhi; Adam J Kucharski; Charles Swanton; David LV Bauer; Emma C Wall,"Francis Crick Institute, National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clini; Francis Crick Institute, National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clini; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK; Francis Crick Institute; Francis Crick Institute, National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clini; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute, Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London, UK; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute, Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London, UK; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute, Genotype-to-Phenotype UK National Virology Consortium (G2P-UK); London Northwest University Healthcare NHS Trust, London; London Northwest University Healthcare NHS Trust, London; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute; Francis Crick Institute, Department of Infectious Disease, St Mary's Hospital, Imperial College London, London; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, Lo; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, Lo; Francis Crick Institute, University College London, Gower Street, London; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK; Francis Crick Institute, University College London, Gower Street, London; Francis Crick Institute, Genotype-to-Phenotype UK National Virology Consortium (G2P-UK); Francis Crick Institute, National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clini","BackgroundSARS-CoV-2 variant Omicron rapidly evolved over 2022, causing three waves of infection due to sub-variants BA.1, BA.2 and BA.4/5. We sought to characterise symptoms and viral loads over the course of COVID-19 infection with these sub-variants in otherwise-healthy, vaccinated, non-hospitalised adults, and compared data to infections with the preceding Delta variant of concern (VOC).

MethodsIn a prospective, observational cohort study, healthy vaccinated UK adults who reported a positive PCR or lateral flow test, self-swabbed on alternate days until day 10. We compared symptoms and viral load trajectories between infections caused by VOCs Delta and Omicron (sub-variants BA.1, BA.2 and BA.4/5), and tested for relationships between vaccine dose, symptoms and PCR Ct value as a proxy for viral load.

Results555 infection episodes were reported among 483 participants. Across VOCs, symptom burden and duration were similar, however symptom profiles differed among infections caused by Delta compared to Omicron sub-variants; symptoms of all Omicron sub-variants BA.1, BA.2 and BA.4/5 were very similar. Anosmia was reported in 7-13% of participants with Omicron sub-variants, compared to 25/60 (42%) with Delta infection (P= 1.31e-08 or 1.03e-05 or 5.63e-05; {chi}2 test d2+Delta vs. Omicron BA.1 or vs. BA.2, or BA.5, respectively), fever was more common with Omicron BA.5 (30/55, 55%) than Delta (20/60, 33%) (p 0.03). Amongst infections with all Omicron sub-variants, symptoms of coryza, fatigue, cough and myalgia predominated. Viral load trajectories and peaks did not differ between Delta, and Omicron, irrespective of symptom severity (including asymptomatic participants), VOC or vaccination status. Ct values were negatively associated with time since vaccination in participants infected with BA.1; however, this trend was not observed in BA.2/BA.4/5 infections.

ConclusionOur study emphasises both the changing symptom profile of COVID-19 infections in the Omicron era, and ongoing transmission risk of Omicron sub-variants in vaccinated adults.

Trial registrationNCT04750356",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.06.15.22276446,2022-06-21,https://medrxiv.org/cgi/content/short/2022.06.15.22276446,Experiences of mental health and wellbeing support for NHS staff during the COVID-19 pandemic: a reflexive thematic analysis,Corinne Clarkson; Hannah Scott; Siobhan Hegarty; Emilia Soulios; Rupa Bhundia; Sam Gnanapragasam; Mary Jane Docherty; Rosalind Raine; Sharon Stevelink; Neil Greenberg; Matthew Hotopf; Simon Wessely; Ira Madan; Anne Marie Rafferty; Danielle Lamb,University College London; King's College London; King's College London; King's College London; King's College London; King's College London; South London and Maudsley NHS Foundation Trust; University College London; King's College London; King's College London; King's College London; King's College London; Guy's and St Thomas' NHS Foundation Trust; King's College London; UCL,"Staff in the National Health Service (NHS) have been placed under considerable strain during the COVID-19 pandemic; whilst NHS Trusts provide a variety of health and wellbeing support services, there has been little research investigating staff perceptions of these services. Moreover, the research that does exist typically includes only clinical staff, despite a large proportion of patient-facing NHS workers being in non-clinical roles. We interviewed forty-eight clinical and non-clinical healthcare workers from eighteen NHS Trusts in England about their experiences of workplace health and wellbeing support during the pandemic. Reflexive thematic analysis identified that perceived stigma around help-seeking, and staffing shortages due to wider socio-political contexts such as austerity, were barriers to using support services. Visible, caring leadership at all levels (CEO to line managers), peer support, easily accessible services, and clear communication about support offers were enablers. Our evidence suggests Trusts should have active strategies to improve help-seeking. This could involve providing all staff with regular reminders about support options, in a variety of formats (e.g. email, posters, mentioned in meetings), and easily remembered single points of access, delivered by a mix of in-house and externally-provided services, to cater for those more and less concerned about stigma and confidentiality. In addition, managers at all levels should be trained and supported to feel confident to speak about mental health with staff, with formal peer support facilitated by building in time for this during working hours. As others have pointed out, this will require long-term strategic planning to address workforce shortages.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2022.06.20.22276205,2022-06-20,https://medrxiv.org/cgi/content/short/2022.06.20.22276205,Cohort Profile: Longitudinal population-based study of COVID-19 in UK adults (COVIDENCE UK),Hayley Holt; Clare Relton; Mohammad Talaei; Jane Symons; Molly R Davies; David A Jolliffe; Giulia Vivaldi; Florence Tydeman; Anne Williamson; Paul E Pfeffer; Christopher Orton; David Ford; Gwyneth A Davies; Ronan A Lyons; Chris J Griffiths; Frank Kee; Aziz Sheikh; Gerome Breen; Seif Shaheen; Adrian R Martineau,Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Jane Symons Media; King's College London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Blizard Institute; Barts Health NHS Trust; Swansea University; Swansea University; Swansea University; Swansea University; Queen Mary University of London; Queen's University Belfast; University of Edinburgh; King's College London; Queen Mary University of London; Queen Mary University of London,"BackgroundCoronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is estimated to have caused more than 18 million deaths worldwide as of end-May 2022.

MethodsCOVIDENCE UK is a longitudinal population-based study that investigates risk factors for, and impacts of, COVID-19 in UK residents aged [&ge;]16 years. A unique feature is the capacity to support trial-within-cohort studies to evaluate interventions for prevention of COVID-19 and other acute respiratory illnesses. Participants complete a detailed online baseline questionnaire capturing self-reported information relating to their socio-demographic characteristics, occupation, lifestyle, quality of life, weight, height, longstanding medical conditions, medication use, vaccination status, diet and supplemental micronutrient intake. Follow-up on-line questionnaires capturing incident symptoms of COVID-19 and other acute respiratory infections, incident swab test-confirmed COVID-19, doses of SARS-CoV-2 vaccine received, and quality of life are completed at monthly intervals.

ResultsThe study was launched on 1st May 2020 and closed to recruitment on 6th October 2021. A total of 19,981 participants enrolled and consented to 5-year follow-up with medical record linkage. Their mean age was 59.1 years (range 16.0 to 94.4 years), 70.2% were female, and 93.7% identified their ethnic origin as White. Analyses conducted to date have provided key insights into risk factors for SARS-CoV-2 infection and COVID-19 disease, determinants of SARS-CoV-2 vaccine immunogenicity and efficacy, and impacts of COVID-19 on health economic outcomes. The cohort has also supported conduct of a Phase 3 randomised trial-within-cohort study (CORONAVIT) evaluating implementation of a test-and-treat approach to correcting sub-optimal vitamin D status on incidence and severity of acute respiratory infections, including COVID-19.

ConclusionsThe COVIDENCE UK dataset represents a valuable resource containing granular information on factors influencing susceptibility to, and impacts of, COVID-19 in UK adults. Researchers wishing to access anonymised participant-level data should contacting the corresponding author for further information.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.06.20.22275994,2022-06-20,https://medrxiv.org/cgi/content/short/2022.06.20.22275994,Characterising patterns of COVID-19 and long COVID symptoms: Evidence from nine UK longitudinal studies,Ruth C E Bowyer; Charlotte Huggins; Renin Toms; Richard John Shaw; Bo Hou; Ellen J Thompson; Alex Siu Fung Kwong; Dylan M Williams; Milla Kibble; George B Ploubidis; Nicholas J Timpson; Jonathan A C Sterne; Nishi Chaturvedi; Claire J Steves; Kate Tilling; Richard J Silverwood,King's College London; University of Edinburgh; University of Bristol; University of Glasgow; Bradford Institute for Health Research; King's College London; University of Bristol; UCL; King's College London; University College London; University of Bristol; University of Bristol; University College London; King's College London; University of Bristol; University College London,"Multiple studies across global populations have established the primary symptoms characterising COVID-19 (Coronavirus Disease 2019) and long COVID. However, as symptoms may also occur in the absence of COVID-19, a lack of appropriate controls has often meant that specificity of symptoms to acute COVID-19 or long COVID could not be examined. We aimed to characterise patterns of COVID-19 and long COVID symptoms across nine UK longitudinal studies, totalling over 42,000 participants. Conducting latent class analyses separately in three groups ( no COVID-19,  COVID-19 in last 12 weeks,  COVID-19 > 12 weeks ago), the data did not support the presence of more than two distinct symptom patterns, representing high and low symptom burden, in each group. Comparing the high symptom burden classes between the  COVID-19 in last 12 weeks and  no COVID-19 groups we identified symptoms characteristic of acute COVID-19, including loss of taste and smell, fatigue, cough, shortness of breath and muscle pains or aches. Comparing the high symptom burden classes between the  COVID-19 > 12 weeks ago and  no COVID-19 groups we identified symptoms characteristic of long COVID, including fatigue, shortness of breath, muscle pain or aches, difficulty concentrating and chest tightness. The identified symptom patterns among individuals with COVID-19 > 12 weeks ago were strongly associated with self-reported length of time unable to function as normal due to COVID-19 symptoms, suggesting that the symptom pattern identified corresponds to long COVID. Building the evidence base regarding typical long COVID symptoms will improve diagnosis of this condition and the ability to elicit underlying biological mechanisms, leading to better patient access to treatment and services.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.06.18.22276437,2022-06-19,https://medrxiv.org/cgi/content/short/2022.06.18.22276437,A patient-centric characterization of systemic recovery from SARS-CoV-2 infection,H√©l√®ne Ruffieux; Aimee Hanson; Samantha Lodge; Nathan Lawler; Luke Whiley; Nicola Gray; Tui Nolan; Laura Bergamaschi; Federica Mescia; - CITIID-NIHR COVID BioResource Collaboration; Nathalie Kingston; John Bradley; Elaine Holmes; Julien Wist; Jeremy Nicholson; Paul Lyons; Kenneth Smith; Sylvia Richardson; Glenn Bantug; Christoph Hess,University of Cambridge; University of Cambridge; Murdoch University; Murdoch University; Murdoch University; Murdoch University; University of Cambridge; University of Cambridge; University of Cambridge; ; University of Cambridge; University of Cambridge; Murdoch University; Murdoch University; Murdoch University; University of Cambridge; University of Cambridge; University of Cambridge; University and University Hospital Basel; University of Cambridge,"The biology driving individual patient responses to SARS-CoV-2 infection remains ill understood. Here, we developed a patient-centric framework leveraging detailed longitudinal phenotyping data, covering a year post disease onset, from 215 SARS-CoV-2 infected subjects with differing disease severities. Our analyses revealed distinct ""systemic recovery"" profiles with specific progression and resolution of the inflammatory, immune, metabolic and clinical responses, over weeks to several months after infection. In particular, we found a strong intra-patient temporal covariation of innate immune cell numbers, kynurenine- and host lipid-metabolites, which suggested candidate immunometabolic pathways putatively influencing restoration of homeostasis, the risk of death and of long COVID. Based on these data, we identified a composite signature predictive of systemic recovery on the patient level, using a joint model on cellular and molecular parameters measured soon after disease onset. New predictions can be generated using the online tool http://shiny.mrc-bsu.cam.ac.uk/apps/covid-systemic-recovery-prediction-app, designed to test our findings prospectively.

Graphical abstract

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=122 SRC=""FIGDIR/small/22276437v1_ufig1.gif"" ALT=""Figure 1"">
View larger version (38K):
org.highwire.dtl.DTLVardef@12b0afborg.highwire.dtl.DTLVardef@ddf3b2org.highwire.dtl.DTLVardef@1aa670forg.highwire.dtl.DTLVardef@5415ec_HPS_FORMAT_FIGEXP  M_FIG C_FIG",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.06.17.22276433,2022-06-17,https://medrxiv.org/cgi/content/short/2022.06.17.22276433,It hurts your heart: frontline healthcare worker experiences of moral injury during the COVID-19 pandemic,Siobhan Hegarty; Danielle Lamb; Sharon Stevelink; Rupa Bhundia; Rosalind Raine; Mary Jane Docherty; Hannah Rachel Scott; Anne Marie Rafferty; Victoria Williamson; Sarah Dorrington; Matthew hotopf; Reza Razavi; Neil Greenberg; Simon Wessely,King's College London; UCL; King's College London; King's College London; University College London; South London and Maudsley NHS Foundation Trust; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London,"BackgroundMoral injury is defined as the strong emotional and cognitive reactions following events which clash with someones moral code, values or expectations. During the COVID-19 pandemic, increased exposure to potentially morally injurious events (PMIEs) has placed healthcare workers (HCWs) at risk of moral injury. Yet little is known about the lived experience of cumulative PMIE exposure and how NHS staff respond to this.

ObjectiveWe sought to rectify this knowledge gap by qualitatively exploring the lived experiences and perspectives of clinical frontline NHS staff who responded to COVID-19.

MethodsWe recruited a diverse sample of 30 clinical frontline HCWs from the NHS CHECK study cohort, for single time point qualitative interviews. All participants endorsed at least one item on the 9-item Moral Injury Events Scale (MIES) (Nash et al., 2013) at six month follow up. Interviews followed a semi-structured guide and were analysed using reflexive thematic analysis.

ResultsHCWs described being routinely exposed to ethical conflicts, created by exacerbations of pre-existing systemic issues including inadequate staffing and resourcing. We found that HCWs experienced a range of mental health symptoms primarily related to perceptions of institutional betrayal as well as feeling unable to fulfil their duty of care towards patients.

ConclusionThese results suggest that a multi-facetted organisational strategy is warranted to prepare for PMIE exposure, promote opportunities for resolution of symptoms associated with moral injury and prevent organisational disengagement.

HighlightsO_LIClinical frontline healthcare workers (HCWs) have been exposed to an accumulation of potentially morally injurious events (PMIEs) throughout the COVID-19 pandemic, including feeling betrayed by both government and NHS leaders as well as feeling unable to provide duty of care to patients
C_LIO_LIHCWs described the significant adverse impact of this exposure on their mental health, including increased anxiety and depression symptoms and sleep disturbance
C_LIO_LIMost HCWs interviewed believed that organisational change within the NHS was necessary to prevent excess PMIE exposure and promote resolution of moral distress
C_LI",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2022.06.16.22276479,2022-06-16,https://medrxiv.org/cgi/content/short/2022.06.16.22276479,Mental health of healthcare workers in England during the COVID-19 pandemic: a longitudinal cohort study,Danielle Lamb; Rafael Gafoor; Hannah Scott; Ewan Carr; Sharon Stevelink; Rosalind Raine; Matthew Hotopf; Neil Greenberg; Siobhan Hegarty; Ira Madan; Paul Moran; Richard Morriss; Dominic Murphy; Anne Marie Rafferty; Scott Weich; Sarah Dorrington; Simon Wessely,UCL; University College London; King's College London; King's College London; King's College London; University College London; King's College London; King's College London; King's College London; Guy's and St Thomas' NHS Foundation Trust; University of Bristol; University of Nottingham; Combat Stress; King's College London; University of Sheffield; King's College London; King's College London,"ObjectiveTo examine variations in impact of the COVID-19 pandemic on the mental health of all types of healthcare workers (HCWs) in England over the first 17 months of the pandemic.

MethodWe undertook a prospective cohort study of 22,501 HCWs from 18 English acute and mental health NHS Trusts, collecting online survey data on common mental disorders (CMDs), depression, anxiety, alcohol use, and PTSD, from April 2020 to August 2021. We analysed these data cross-sectionally by time period (corresponding to periods the NHS was under most pressure), and longitudinally. Data were weighted to better represent Trust population demographics.

ResultsThe proportion of those with probable CMDs was greater during periods when the NHS was under most pressure (measured by average monthly deaths). For example, 55% (95%CI 53%, 58%) of participants reported symptoms of CMDs in April-June 2020 versus 47% (95%CI 46%, 48%) July-October 2020. Contrary to expectation, there were no major differences between professional groups (i.e. clinical and non-clinical staff). Younger, female, lower paid staff, who felt poorly supported by colleagues/managers, and who experienced potentially morally injurious events were most at risk of negative mental health outcomes.

ConclusionAmong HCWs, the prevalence of probable CMDs increased during periods of escalating pressure on the NHS, suggesting staff support should be increased at such points in the future, and staff should be better prepared for such situations via training. All staff, regardless of role, experienced poorer mental health during these periods, suggesting that support should be provided for all staff groups.

Key messagesO_ST_ABSWhat is already known on this topicC_ST_ABSExisting evidence about the mental health of healthcare workers (HCWs) through the COVID-19 pandemic comes mainly from cross-sectional studies using unrepresentative convenience samples, typically focussing on clinical staff rather than all HCWs. Such studies show high prevalence of symptoms of mental disorders, but the strength of this evidence is uncertain.

What this study addsUsing a defined sampling frame, with longitudinal, weighted data, we show that during periods of greater pressure on the NHS (as indicated by average monthly national COVID-19 death rates), prevalence of mental disorder symptoms increased, and, importantly, that this effect was seen in non-clinical as well as clinical staff.

How this study might affect research, practice or policyThese findings indicate that provision of support for HCWs should not only focus on those providing clinical care, but also on non-clinical staff such as porters, cleaners, and administrative staff, and additional support should be provided during higher pressure periods. Better preparation of staff for such situations is also suggested.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2022.06.16.22276487,2022-06-16,https://medrxiv.org/cgi/content/short/2022.06.16.22276487,"Capturing the experiences of UK healthcare workers during the COVID-19 pandemic: A structural topic modelling analysis of 7,412 free-text survey responses",Danielle Lamb; Liam Wright; Hannah Scott; Bethany Croak; Sam Gnanapragasam; Mary Jane Docherty; Neil Greenberg; Matthew Hotopf; Sharon Stevelink; Rosalind Raine; Simon Wessely,UCL; University College London; King's College London; King's College London; King's College London; South London and Maudsley NHS Foundation Trust; King's College London; King's College London; King's College London; University College London; King's College London,"BackgroundHealthcare workers (HCWs) have provided vital services during the COVID-19 pandemic, but existing research consists of quantitative surveys (lacking in depth or context) or qualitative interviews (with limited generalisability). Structural Topic Modelling (STM) of large-scale free-text survey data offers a way of capturing the perspectives of a wide range of HCWs in their own words about their experiences of the pandemic.

MethodsIn an online survey distributed to all staff at 18 geographically dispersed NHS Trusts, we asked respondents, ""Is there anything else you think we should know about your experiences of the COVID-19 pandemic?"". We used STM on 7,412 responses to identify topics, and thematic analysis on the resultant topics and text excerpts.

ResultsWe identified 33 topics, grouped into two domains, each containing four themes. Our findings emphasise: the deleterious effect of increased workloads, lack of PPE, inconsistent advice/guidance, and lack of autonomy; differing experiences of home working as negative/positive; and the benefits of supportive leadership and peers in ameliorating challenges. Themes varied by demographics and time: discussion of home working decreasing over time, while discussion of workplace challenges increased. Discussion of mental health was lowest between September-November 2020, between the first and second waves of COVID-19 in the UK.

DiscussionOur findings represent the most salient experiences of HCWs through the pandemic. STM enabled statistical examination of how the qualitative themes raised differed according to participant characteristics. This relatively underutilised methodology in healthcare research can provide more nuanced, yet generalisable, evidence than that available via surveys or small interview studies, and should be used in future research.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2022.06.16.22276476,2022-06-16,https://medrxiv.org/cgi/content/short/2022.06.16.22276476,Moral injury and psychological wellbeing in UK healthcare staff,Victoria Williamson; Danielle Lamb; Matthew Hotopf; Rosalind Raine; Sharon Stevelink; Simon Wessely; Mary Jane Docherty; Ira Madan; Dominic Murphy; Neil Greenberg,King's College London; UCL; King's College London; King's College London; King's College London; King's College London; South London and Maudsley NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust; King's College London; King's College London,"BackgroundPotentially morally injurious events (PMIEs) can negatively impact mental health. The COVID-19 pandemic may have placed healthcare staff at risk of moral injury.

AimTo examine the impact of PMIE on healthcare staff wellbeing.

Method12,965 healthcare staff (clinical and non-clinical) were recruited from 18 NHS-England trusts into a survey of PMIE exposure and wellbeing.

ResultsPMIEs were significantly associated with adverse mental health symptoms across healthcare staff. Specific work factors were significantly associated with experiences of moral injury, including being redeployed, lack of PPE, and having a colleague die of COVID-19. Nurses who reported symptoms of mental disorders were more likely to report all forms of PMIEs than those without symptoms (AOR 2.7; 95% CI 2.2, 3.3). Doctors who reported symptoms were only more likely to report betrayal events, such as breach of trust by colleagues (AOR 2.7, 95% CI 1.5, 4.9).

ConclusionsA considerable proportion of NHS healthcare staff in both clinical and non-clinical roles report exposure to PMIEs during the COVID-19 pandemic. Prospective research is needed to identify the direction of causation between moral injury and mental disorder as well as continuing to monitor the longer term outcomes of exposure to PMIEs.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2022.06.14.22276391,2022-06-16,https://medrxiv.org/cgi/content/short/2022.06.14.22276391,Factors associated with COVID-19 vaccine uptake in people with kidney disease: an OpenSAFELY cohort study,- The OpenSAFELY Collaborative; Edward PK Parker; John Tazare; William J Hulme; Christopher Bates; Rupert Beale; Edward J Carr; Jonathan Cockburn; Helen J Curtis; Louis Fisher; Amelia CA Green; Sam Harper; Frank Hester; Elsie MF Horne; Fiona Loud; Susan Lyon; Viyaasan Mahalingasivam; Amir Mehrkar; Linda Nab; John Parry; Shalini Santhakumaran; Retha Steenkamp; Jonathan AC Sterne; Alex J Walker; Elizabeth J Williamson; Michelle Willicombe; Bang Zheng; Ben Goldacre; Dorothea Nitsch; Laurie A Tomlinson,"-; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX, UK; The Francis Crick Institute, London, NW1 1AT, UK; UCL Department of Renal Medicine, Royal Free Hospital, London, UK; The Francis Crick Institute, London, NW1 1AT, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX, UK; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK; Kidney Care UK, Alton, UK; Patient Council, UK Kidney Association, Bristol, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX, UK; UK Renal Registry, Bristol, UK; UK Renal Registry, Bristol, UK; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK; H; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, Du Cane Road London, W12 0NN, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX2 6GG, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; UK Renal Registry, Bristol, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK","BackgroundKidney disease is a significant risk factor for COVID-19-related mortality. Achieving high COVID-19 vaccine coverage among people with kidney disease is therefore a public health priority.

MethodsWith the approval of NHS England, we performed a retrospective cohort study using the OpenSAFELY-TPP platform. Individual-level routine clinical data from 24 million people in England were included. A cohort of individuals with stage 3-5 chronic kidney disease (CKD) or receiving renal replacement therapy (RRT) at the start of the COVID-19 vaccine roll-out was identified based on evidence of reduced estimated glomerular filtration rate or inclusion in the UK Renal Registry. Individual-level factors associated with vaccine uptake were explored via Cox proportional hazards models.

Results948,845 people with stage 3-5 CKD or receiving RRT were included. Cumulative vaccine coverage as of 11th May 2022 was 97.5%, 97.0%, and 93.5% for doses 1, 2, and 3, respectively, and 61.1% among individuals with one or more indications for receipt of a fourth dose. Delayed 3-dose vaccine uptake was associated with non-White ethnicity, social deprivation, and severe mental illness - associations that were consistent across CKD stages and in RRT recipients. Similar associations were observed for 4-dose uptake, which was also delayed among care home residents.

ConclusionAlthough high primary and booster dose coverage has been achieved among people with kidney disease in England, key disparities in vaccine uptake remain across demographic groups. Identifying how to address these disparities remains a priority to reduce the risk of severe disease in this vulnerable patient group.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.06.09.22276232,2022-06-14,https://medrxiv.org/cgi/content/short/2022.06.09.22276232,"HEALTHCARE UTILISATION IN PATIENTS WITH LONG-TERM CONDITIONS DURING THE COVID-19 PANDEMIC: A POPULATION BASED STUDY ACROSS GREATER MANCHESTER, UK",Camilla Sammut-Powell; Richard Williams; Matthew Sperrin; Owain Thomas; Niels Peek; Stuart W Grant,"Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Langworthy Medical Practice, Salford, UK; Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; 6.	Division of Cardiovascular Sciences, University of Manchester, ERC, Manchester University Hospitals Foundation Trust, Manchester, M23 9LT, UK.","BackgroundThe COVID-19 pandemic has placed an unprecedented demand on global healthcare resources. Data on whole population healthcare utilisation (HCU) across both primary and secondary care during the COVID-19 pandemic are lacking.

AimTo describe primary and secondary HCU stratified by LTCs and deprivation, during the first 19 months of COVID-19 pandemic across a large urban area in the United Kingdom.

MethodsObservational HCU data between 30th-December-2019 and 1st-August-2021 were extracted from the Greater Manchester Care Record. Primary care HCU (incident prescribing and recording of healthcare information) and secondary care HCU (planned and unplanned admissions) were assessed.

ResultsThe first national lockdown was associated with reductions in all primary HCU measures, ranging from 24.7% (24.0% to 25.5%) for incident prescribing to 84.9% (84.2% to 85.5%) for cholesterol monitoring. Secondary HCU also dropped significantly for planned (47% (42.9% to 51.5%)) and unplanned admissions (35.0% (28.3% to 41.6%)). Only secondary care had significant reductions in HCU during the second national lockdown. Primary HCU measures had not recovered to pre-pandemic levels by the end of the study. The secondary admission rate ratio between multi-morbid patients and those without LTCs increased during the first lockdown by a factor of 2.4 (2.0 to 2.9;p<0.001) for planned admissions and by 1.3 (1.1 to 1.5;p=0.006) for unplanned admissions. No significant changes in this ratio were observed in primary HCU. Different patterns in secondary care HCU were observed by LTC group.

ConclusionMajor changes in primary and secondary HCU have been observed during the COVID-19 pandemic. Secondary HCU reduced more in those without LTCs and the ratio of utilisation between the most and least deprived increased for the majority of HCU measures. Overall primary HCU measures and secondary care HCU for some LTC groups had not returned to pre-pandemic levels by the end of the study.",epidemiology,fuzzy,100,92
medRxiv,10.1101/2022.06.09.22276196,2022-06-14,https://medrxiv.org/cgi/content/short/2022.06.09.22276196,Accelerated waning of the humoral response to SARS-CoV-2 vaccines in obesity,"Agatha A. van der Klaauw MD, PhD; Emily C. Horner BSc; Pehuen Pereyra-Gerber PhD; Utkarsh Agrawal PhD; William S. Foster BSc, MRes,; Sarah Spencer MD, BSc; Bensi Vergese BSc Hons.; Miriam E. Smith BSc PhD; Elana Henning B.Soc.Sc; Isobel D. Ramsay MA BM BCh; Jack A. Smith BSc MBiol; Stephane M. Guillaume BSc; Hayley J. Sharpe BSc, PhD; Iain M. Hay BSc, PhD; Sam Thompson BSc; Silvia Innocentin BSc., Ph.D; Lucy H Booth BSc; Chris Robertson Ph.D.; Colin McCowan Ph.D.; Thomas E Mulroney PhD; Martin J O'Reilly; Thevinya P Guragama; Lihinya P Guragama; Maria A Rust BSc; Alex Ferreira; Soraya Ebrahimi MSc; Lourdes Ceron-Gutierrez MSc.; Jacopo Scotucci MD; Barbara Kronsteiner Ph.D.; Susanna J. Dunachie MD., Ph.D.; Paul Klenerman MD., Ph.D.; - PITCH Consortium; Adrian J. Park MD PhD; Francesco Rubino MD.,; Hannah Stark BSc; Nathalie Kingson PhD; Rainer Doffinger PhD; Michelle A. Linterman BBmedSc (H; Nicholas J. Matheson MA BM BCh; Aziz Sheikh MD; I. Sadaf Farooqi MD, PhD; James E. Thaventhiran MD, PhD","University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Meta; Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR; Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, UK; Department of Medi; School of Medicine, University of St. Andrews; Immunology, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT; Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR; University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Meta; University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Meta; University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Meta; 1. Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, UK 2. Department of; 1. Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, UK 2. Department of; Immunology, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT; Signalling, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT; Signalling, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT; Cambridge Institute for Medical Research, Cambridge UK.; Flow cytometry core, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT; Babraham Institute, Babraham Research Campus, Cambridge; Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR; Department of Mathematics and Statistics, University of Strathclyde; School of Medicine, University of St. Andrews; Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR; Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR; Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR; Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR; Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR; Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR; NIHR Cambridge Clinical Research Facility, Departments of Immunology and Clinical Biochemistry; NIHR Cambridge Clinical Research Facility, Departments of Immunology and Clinical Biochemistry; University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Meta; Nuffield Department of Clinical Medicine, University of Oxford; Nuffield Department of Clinical Medicine, University of Oxford; Nuffield Department of Clinical Medicine, University of Oxford; ; Cambridge University Hospitals NHS Foundation Trust, Department of Clinical Biochemistry, Cambridge, United Kingdom; Kings College London, Department of Diabetes, School of Life Course Science, London; NIHR BioResource; NIHR BioResource; NIHR Cambridge Clinical Research Facility, Departments of Immunology, Clinical Biochemistry; Immunology, Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT; 1. Cambridge Institute for Therapeutic Immunology and Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, University of Cambridge, UK 2. Department of; Usher Institute, University of Edinburgh; University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Meta; Medical Research Council Toxicology Unit, University of Cambridge, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR","Obesity is associated with an increased risk of severe Covid-19. However, the effectiveness of SARS-CoV-2 vaccines in people with obesity is unknown. Here we studied the relationship between body mass index (BMI), hospitalization and mortality due to Covid-19 amongst 3.5 million people in Scotland. Vaccinated people with severe obesity (BMI>40 kg/m2) were significantly more likely to experience hospitalization or death from Covid-19. Excess risk increased with time since vaccination. To investigate the underlying mechanisms, we conducted a prospective longitudinal study of the immune response in a clinical cohort of vaccinated people with severe obesity. Compared with normal weight people, six months after their second vaccine dose, significantly more people with severe obesity had unquantifiable titres of neutralizing antibody against authentic SARS-CoV-2 virus, reduced frequencies of antigen-experienced SARS-CoV-2 Spike-binding B cells, and a dissociation between anti-Spike antibody levels and neutralizing capacity. Neutralizing capacity was restored by a third dose of vaccine, but again declined more rapidly in people with severe obesity. We demonstrate that waning of SARS-CoV-2 vaccine-induced humoral immunity is accelerated in people with severe obesity and associated with increased hospitalization and mortality from breakthrough infections. Given the prevalence of obesity, our findings have significant implications for global public health.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.06.08.22276134,2022-06-14,https://medrxiv.org/cgi/content/short/2022.06.08.22276134,Implementation of a digital early warning score (NEWS2) in a cardiac specialist and general hospital settings in the COVID-19 pandemic: A qualitative study.,Baneen Alhmoud; Timothy Bonicci; Riyaz Patel; Daniel Melley; Louise Hicks; Amitava Banerjee,"University College London, University College London Hospital, Barts Health Trust.; University College London, University College London Hospital; University College London, University College London Hospital.; Barts Health Trust; Barts Health Trust; University College London, University College London Hospital, Barts Health Trust.","ObjectivesTo evaluate implementation of EHR-integrated NEWS2 in a cardiac care setting and a general hospital setting in the COVID-19 pandemic.

DesignThematic analysis of qualitative semi-structured interviews with purposefully sampled nurses and managers, as well as online surveys.

SettingsSpecialist cardiac hospital (St Bartholomews Hospital) and General teaching hospital (University College London Hospital).

ParticipantsEleven nurses and managers from cardiology, cardiac surgery, oncology, and intensive care wards (St Bartholomews) and medical, haematology and intensive care wards (UCLH) were interviewed and sixty-seven were surveyed online.

ResultsThree main themes emerged: (i) Implementing NEWS2 challenges and supports; (ii) Value of NEWS2 to alarm, escalate, particularly during the pandemic; and (iii) Digitalisation: EHR integration and automation. The value of NEWS2 was partly positive in escalation, yet there were concerns by nurses who undervalued NEWS2 particularly in cardiac care. Challenges, like clinicians behaviours, lack of resources and training and the perception of NEWS2 value, limit the success of this implementation. Changes in guidelines in the pandemic have led to overlooking NEWS2. EHR integration and automated monitoring are improvement solutions that are not fully employed yet.

ConclusionWhether in specialist or general medical settings, the health professionals implementing EWS in healthcare face cultural and systems related challenges to adopting NEWS2 and digital solutions. The validity of NEWS2 in specialised settings and complex conditions is not yet apparent and requires comprehensive validation. EHRs integration and automation are powerful tools to facilitate NEWS2 if its principles are reviewed and rectified, and resources and training are accessible. Further examination of implementation from the cultural and automation domains are needed.",health informatics,fuzzy,100,100
medRxiv,10.1101/2022.06.13.22276316,2022-06-13,https://medrxiv.org/cgi/content/short/2022.06.13.22276316,Patterns of Reported Infection and Reinfection of SARS-CoV-2 in England,Matt J Keeling,University of Warwick,"One of the key features of any infectious disease is whether infection generates long-lasting immunity or whether repeated reinfection is common. In the former, the long-term dynamics are driven by the birth of susceptible individuals while in the latter the dynamics are governed by the speed of waning immunity. Between these two extremes a range of scenarios is possible. During the early waves of SARS-CoV-2, the underlying paradigm was for long-lasting immunity, but more recent data and in particular the 2022 Omicron waves have shown that reinfection can be relatively common. Here we investigate reported SARS-CoV-2 cases in England, partitioning the data into four main waves, and consider the temporal distribution of first and second reports of infection. We show that a simple low-dimensional statistical model of random (but scaled) reinfection captures much of the observed dynamics, with the value of this scaling, k, providing information of underlying epidemiological patterns. We conclude that there is considerable heterogeneity in risk of reporting reinfection by wave, age-group and location. The high levels of reinfection in the Omicron wave (we estimate that 18% of all Omicron cases had been previously infected, although not necessarily previously reported infection) point to reinfection events dominating future COVID-19 dynamics.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.06.12.22276307,2022-06-13,https://medrxiv.org/cgi/content/short/2022.06.12.22276307,"Occupation, Worker Vulnerability, and COVID-19 Vaccination Uptake: Analysis of the Virus Watch prospective cohort study",Sarah Beale; Rachel Burns; Isobel Braithwaite; Thomas Edward Byrne; Wing Lam Erica Fong; Ellen Fragaszy; Cyril Geismar; Susan J Hoskins; Jana Kovar; Annalan Mathew Dwight Navaratnam; Parth Patel; Alexei Yavlinsky; Martie J Van Tongeren; Robert W Aldridge; Andrew Hayward,University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University of Manchester; University College London; University College London,"BackgroundOccupational disparities in COVID-19 vaccine uptake can impact the effectiveness of vaccination programmes and introduce particular risk for vulnerable workers and those with high workplace exposure. This study aimed to investigate COVID-19 vaccine uptake by occupation, including for vulnerable groups and by occupational exposure status.

MethodsWe used data from employed or self-employed adults who provided occupational information as part of the Virus Watch prospective cohort study (n=19,595) and linked this to study-obtained information about vulnerability-relevant characteristics (age, medical conditions, obesity status) and work-related COVID-19 exposure based on the Job Exposure Matrix. Participant vaccination status for the first, second, and third dose of any COVID-19 vaccine was obtained based on linkage to national records and study records. We calculated proportions and Sison-Glaz multinomial 95% confidence intervals for vaccine uptake by occupation overall, by vulnerability-relevant characteristics, and by job exposure.

FindingsVaccination uptake across occupations ranged from 89-96% for the first dose, 87-94% for the second dose, and 75-86% for the third dose, with transport, trade, service and sales workers persistently demonstrating the lowest uptake. Vulnerable workers tended to demonstrate fewer between-occupational differences in uptake than non-vulnerable workers, although clinically vulnerable transport workers (76%-89% across doses) had lower uptake than several other occupational groups (maximum across doses 86-96%). Workers with low SARS-CoV-2 exposure risk had higher vaccine uptake (86%-96% across doses) than those with elevated or high risk (81-94% across doses).

InterpretationDifferential vaccination uptake by occupation, particularly amongst vulnerable and highly-exposed workers, is likely to worsen occupational and related socioeconomic inequalities in infection outcomes. Further investigation into occupational and non-occupational factors influencing differential uptake is required to inform relevant interventions for future COVID-19 booster rollouts and similar vaccination programmes.",public and global health,fuzzy,100,100
medRxiv,10.1101/2022.06.08.22276154,2022-06-09,https://medrxiv.org/cgi/content/short/2022.06.08.22276154,Validity of self-testing at home with rapid SARS-CoV-2 antibody detection by lateral flow immunoassay,Christina J Atchison; Maya Moshe; Jonathan C Brown; Matthew Whitaker; Nathan C K Wong; Anil A Bharath; Rachel A McKendry; Ara Darzi; Deborah Ashby; Christl A. Donnelly; Steven Riley; Paul Elliott; Wendy S Barclay; Graham Cooke; Helen Ward,"Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; University College London; Imperial College London; Imperial College London; Imperial College London; Dept Inf Dis Epi, Imperial College; Imperial College London School of Public Health; Imperial College London; Imperial College; Imperial College London","BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow immunoassays (LFIA) can be carried out in the home and have been used as an affordable and practical approach to large-scale antibody prevalence studies. However, assay performance differs from that of high-throughput laboratory-based assays which can be highly sensitive. We explore LFIA performance under field conditions compared to laboratory-based ELISA and assess the potential of LFIAs to identify people who lack functional antibodies following infection or vaccination.

MethodsField evaluation of a self-administered LFIA test (Fortress, NI) among 3758 participants from the REal-time Assessment of Community Transmission-2 (REACT-2) study in England selected based on vaccination history and previous LFIA result to ensure a range of antibody titres. In July 2021, participants performed, at home, a self-administered LFIA on finger-prick blood, reported and submitted a photograph of the result, and provided a self-collected capillary blood sample (Tasso-SST) for serological assessment of IgG antibodies to the spike protein using the Roche Elecsys(R) Anti-SARS-CoV-2 assay. We compared the self-administered and reported LFIA result to the quantitative Roche assay and checked the reading of the LFIA result with an automated image analysis (ALFA). In a subsample of 250 participants, we compared the results to live virus neutralisation.

ResultsAlmost all participants (3593/3758, 95.6%) had been vaccinated or reported prior infection, with most having received one (862, 22.9%) or two (2430, 64.7%) COVID-19 vaccine doses. Overall, 2777/3758 (73.9%) were positive on self-reported LFIA, 2811/3457 (81.3%) positive by LFIA when ALFA-reported, and 3622/3758 (96.4%) positive on Roche anti-S (using the manufacturer reference standard threshold for positivity of 0.8 U ml-1). Live virus neutralisation was detected in 169 of 250 randomly selected samples (67.6%); 133/169 were positive with self-reported LFIA (sensitivity 78.7%; 95% CI 71.8, 84.6), 142/155 (91.6%; 86.1, 95.5) with ALFA, and 169 (100%; 97.8, 100.0) with Roche anti-S. There were 81 samples with no detectable virus neutralisation; 47/81 were negative with self-reported LFIA (specificity 58.0%; 95% CI 46.5, 68.9), 34/75 (45.3%; 33.8, 57.3) with ALFA, and 0/81 (0%; 0.0, 4.5) with Roche anti-S. All 250 samples remained positive with Roche anti-S when the threshold was increased to 1000U ml-1.

ConclusionsSelf-administered LFIA can provide insights into population patterns of infection and vaccine response, and sensitivity can be improved with automated reading of the result. The LFIA is less sensitive than a quantitative antibody test, but the positivity in LFIA correlates better than the quantitative ELISA with virus neutralisation.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.06.06.22275997,2022-06-08,https://medrxiv.org/cgi/content/short/2022.06.06.22275997,Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity,Satoshi Yoshiji; Guillaume Butler-Laporte; Tianyuan Lu; Julian Daniel Sunday Willett; Chen-Yang Su; Tomoko Nakanishi; David R Morrison; Yiheng Chen; Kevin Liang; Michael Hultstr√∂m; Yann Ilboudo; Zaman Afrasiabi; Shanshan Lan; Naomi Duggan; Chantal DeLuca; Mitra Vaezi; Chris Tselios; Xiaoqing Xue; Meriem Bouab; Fangyi Shi; Laetitia Laurent; Hans Markus Munter; Marc Afilalo; Jonathan Afilalo; Vincent Mooser; Nicholas J Timpson; Hugo J Zeberg; Sirui Zhou; Vincenzo Forgetta; Yossi Farjoun; J. Brent Richards,"Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Uppsala University; McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; McGill University and Genome Quebec Innovation Centre; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; McGill University; University of Bristol; Karolinska Institutet; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University; Lady Davis Institute, Jewish General Hospital, McGill University","Obesity is a major risk factor for COVID-19 severity; however, the mechanisms underlying this relationship are not fully understood. Since obesity influences the plasma proteome, we sought to identify circulating proteins mediating the effects of obesity on COVID-19 severity in humans. Here, we screened 4,907 plasma proteins to identify proteins influenced by body mass index (BMI) using Mendelian randomization (MR). This yielded 1,216 proteins, whose effect on COVID-19 severity was assessed, again using MR. We found that a standard deviation increase in nephronectin (NPNT) was associated with increased odds of critically ill COVID-19 (OR = 1.71, P = 1.63 x 10-10). The effect was driven by an NPNT splice isoform. Mediation analyses supported NPNT as a mediator. In single-cell RNA-sequencing, NPNT was expressed in alveolar cells and fibroblasts of the lung in individuals who died of COVID-19. Finally, decreasing body fat mass and increasing fat-free mass were found to lower NPNT levels. These findings provide actionable insights into how obesity influences COVID-19 severity.",genetic and genomic medicine,fuzzy,100,100
medRxiv,10.1101/2022.06.06.22276026,2022-06-06,https://medrxiv.org/cgi/content/short/2022.06.06.22276026,Effectiveness of BNT162b2 booster doses in England: an observational study in OpenSAFELY-TPP,William J Hulme; Elizabeth J Williamson; Elsie Horne; Amelia CA Green; Linda Nab; Ruth Keogh; Edward PK Parker; Venexia M Walker; Tom M Palmer; Helen J Curtis; Milan Wiedemann; Christine Cunningham; Alex J Walker; Louis Fisher; Brian MacKenna; Christopher T Rentsch; Anna Schultze; Krishnan Bhaskaran; John Tazare; Laurie A Tomlinson; Helen I McDonald; Caroline E Morton; Richard Croker; Colm D Andrews; Lisa EM Hopcroft; Robin Y Park; Jon Massey; Amir Mehrkar; Jessica Morley; Sebastian CJ Bacon; David Evans; Peter Inglesby; George Hickman; Simon Davy; Iaim Dillingham; Tom Ward; Viyaasan Mahalingasivam; Bang Zheng; Ian J Douglas; Stephen JW Evans; Christopher Bates; Jonathan AC Sterne; Miguel A Hernan; Ben Goldacre,"The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; MRC Integrative Epidemiology Unit, Bristol Medical Scho; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; MRC Integrative Epidemiology Unit, Bristol Medical Scho; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; Population Health Sciences, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, UK; NIHR Bristol Biomedical Research Centre, Bristol, UK; H; CAUSALab, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, ; The Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG, UK","BackgroundThe UK COVID-19 vaccination programme delivered its first ""booster"" doses in September 2021, initially in groups at high risk of severe disease then across the adult population. The BNT162b2 Pfizer-BioNTech vaccine was used initially, with Moderna mRNA-1273 subsequently also used.

MethodsWe used the OpenSAFELY-TPP database, covering 40% of English primary care practices and linked to national coronavirus surveillance, hospital episodes, and death registry data, to estimate the effectiveness of boosting with BNT162b2 compared with no boosting in eligible adults who had received two primary course vaccine doses between 16 September and 16 December 2021 when the Delta variant of SARS-CoV-2 was dominant. Follow up was for up to 10 weeks. Each booster recipient was matched with an unboosted control on factors relating to booster priority status and prior immunisation. Additional factors were adjusted for in Cox models estimating hazard ratios (HRs). Outcomes were positive SARS-CoV-2 test, COVID-19 hospitalisation, COVID-19 death and non-COVID-9 death. Booster vaccine effectiveness was defined as 1-HR.

ResultsAmong 4,352,417 BNT162b2 booster recipients matched with unboosted controls, estimated effectiveness of a booster dose compared with two doses only was 50.7% (95% CI 50.1-51.3) for positive SARS-CoV-2 test, 80.1% (78.3-81.8) for COVID-19 hospitalisation, 88.5% (85.0-91.1) for COVID-19 death, and 80.3% (79.0-81.5) for non-COVID-19 death.

Estimated effectiveness was similar among those who had received a BNT162b2 or ChAdOx1-S two-dose primary vaccination course, but effectiveness against severe COVID-19 was slightly lower in those classified as clinically extremely vulnerable (76.3% (73.1-79.1) for COVID-19 hospitalisation, and 85.1% (79.6-89.1) for COVID-19 death). Estimated effectiveness against each outcome was lower in those aged 18-65 years than in those aged 65 and over.

ConclusionOur findings are consistent with strong protection of BNT162b2 boosting against positive SARS-CoV-2 test, COVID-19 hospitalisation, and COVID-19 death.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.06.02.22275900,2022-06-02,https://medrxiv.org/cgi/content/short/2022.06.02.22275900,"Trends in SARS-CoV-2 infection prevalence during England's roadmap out of lockdown, January to July 2021",Oliver Eales; Haowei Wang; David Haw; Kylie E.C. Ainslie; Caroline E. Walters; Christina Atchison; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Deborah Ashby; Christl A Donnelly; Paul Elliott; Steven Riley,"Imperial College London; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc","BackgroundFollowing rapidly rising COVID-19 case numbers, England entered a national lockdown on 6 January 2021, with staged relaxations of restrictions from 8 March 2021 onwards.

AimWe characterise how the lockdown and subsequent easing of restrictions affected trends in SARS-CoV-2 infection prevalence.

MethodsOn average, risk of infection is proportional to infection prevalence. The REal-time Assessment of Community Transmission-1 (REACT-1) study is a repeat cross-sectional study of over 98,000 people every round (rounds approximately monthly) that estimates infection prevalence in England. We used Bayesian P-splines to estimate prevalence and the time-varying reproduction number (Rt) nationally, regionally and by age group from round 8 (beginning 6 January 2021) to round 13 (ending 12 July 2021) of REACT-1. As a comparator, a separate segmented-exponential model was used to quantify the impact on Rt of each relaxation of restrictions.

ResultsFollowing an initial plateau of 1.54% until mid-January, infection prevalence decreased until 13 May when it reached a minimum of 0.09%, before increasing until the end of the study to 0.76%. Following the first easing of restrictions, which included schools reopening, the reproduction number Rt increased by 82% (55%, 108%), but then decreased by 61% (82%, 53%) at the second easing of restrictions, which was timed to match the Easter school holidays. Following further relaxations of restrictions, the observed Rt increased steadily, though the increase due to these restrictions being relaxed was masked by the effects of vaccination and the rapid rise of Delta. There was a high degree of synchrony in the temporal patterns of prevalence between regions and age groups.

ConclusionHigh-resolution prevalence data fitted to P-splines allowed us to show that the lockdown was highly effective at reducing risk of infection with school holidays/closures playing a significant part.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.05.23.22275458,2022-05-25,https://medrxiv.org/cgi/content/short/2022.05.23.22275458,Covid-19 is a leading cause of death in children and young people ages 0-19 years in the United States,Seth Flaxman; Charles Whittaker; Elizaveta Semenova; Theo Rashid; Robbie Parks; Alexandra Blenkinsop; H Juliette T Unwin; Swapnil Mishra; Samir Bhatt; Deepti Gurdasani; Oliver Ratmann,"Oxford; Imperial College London; AstraZeneca; Imperial College London; Columbia University; Imperial College London; Imperial College London; University of Copenhagen; University of Copenhagen, Imperial College London; Queen Mary University of London; Imperial College London","Covid-19 has caused more than 1 million deaths in the US, including at least 1,204 deaths among children and young people (CYP) aged 0-19 years, with 796 occurring in the one year period April 1, 2021 - March 31, 2022. Deaths among US CYP are rare in general, and so we argue here that the mortality burden of Covid-19 in CYP is best understood in the context of all other causes of CYP death. Using publicly available data from CDC WONDER on NCHSs 113 Selected Causes of Death, and comparing to mortality in 2019, the immediate pre-pandemic period, we find that Covid-19 mortality is among the 10 leading causes of death in CYP aged 0-19 years in the US, ranking 8th among all causes of deaths, 5th in disease-related causes of deaths (excluding accidents, assault and suicide), and 1st in deaths caused by infectious or respiratory diseases. Covid-19 deaths constitute 2.3% of the 10 leading causes of death in this age group. Covid-19 caused substantially more deaths in CYP than major vaccine-preventable diseases did historically in the period before vaccines became available. Various factors including underreporting and Covid-19s role as a contributing cause of death from other diseases mean that our estimates may understate the true mortality burden of Covid-19. Our findings underscore the public health relevance of Covid-19 to CYP. In the likely future context of sustained SARS-CoV-2 circulation, pharmaceutical and non-pharmaceutical interventions will continue to play an important role in limiting transmission of the virus in CYP and mitigating severe disease.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.05.22.22275417,2022-05-23,https://medrxiv.org/cgi/content/short/2022.05.22.22275417,Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe COVID-19 outcomes in non-hospitalised patients: an observational cohort study using the OpenSAFELY platform,Bang Zheng; Amelia CA Green; John Tazare; Helen J Curtis; Louis Fisher; Linda Nab; Anna Schultze; Viyaasan Mahalingasivam; Edward Parker; William J Hulme; Sebastian CJ Bacon; Nicholas J DeVito; Christopher Bates; David Evans; Peter Inglesby; Henry Drysdale; Simon Davy; Jonathan Cockburn; Caroline E Morton; George Hickman; Tom Ward; Rebecca M Smith; John Parry; Frank Hester; Sam Harper; Amir Mehrkar; Rosalind M Eggo; Alex J Walker; Stephen JW Evans; Ian J Douglas; Brian MacKenna; Ben Goldacre; Laurie A Tomlinson,London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Trop. Med.; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; TPP; TPP; University of Oxford; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine,"ObjectiveTo compare the effectiveness of sotrovimab (a neutralising monoclonal antibody) vs. molnupiravir (an antiviral) in preventing severe COVID-19 outcomes in non-hospitalised high-risk COVID-19 adult patients.

DesignWith the approval of NHS England, we conducted a real-world cohort study using the OpenSAFELY-TPP platform.

SettingPatient-level electronic health record data were obtained from 24 million people registered with a general practice in England that uses TPP software. The primary care data were securely linked with data on COVID-19 infection and therapeutics, hospital admission, and death within the OpenSAFELY-TPP platform, covering a period where both medications were frequently prescribed in community settings.

ParticipantsNon-hospitalised adult COVID-19 patients at high risk of severe outcomes treated with sotrovimab or molnupiravir since December 16, 2021.

InterventionsSotrovimab or molnupiravir administered in the community by COVID-19 Medicine Delivery Units.

Main outcome measureCOVID-19 related hospitalisation or COVID-19 related death within 28 days after treatment initiation.

ResultsBetween December 16, 2021 and February 10, 2022, 3331 and 2689 patients were treated with sotrovimab and molnupiravir, with no substantial differences in their baseline characteristics. The mean age of all 6020 patients was 52 (SD=16) years; 59% were female, 89% White and 88% had three or more COVID-19 vaccinations. Within 28 days after treatment initiation, 87 (1.4%) COVID-19 related hospitalisations/deaths were observed (32 treated with sotrovimab and 55 with molnupiravir). Cox proportional hazards models stratified by area showed that after adjusting for demographics, high-risk cohort categories, vaccination status, calendar time, body mass index and other comorbidities, treatment with sotrovimab was associated with a substantially lower risk than treatment with molnupiravir (hazard ratio, HR=0.54, 95% CI: 0.33 to 0.88; P=0.014). Consistent results were obtained from propensity score weighted Cox models (HR=0.50, 95% CI: 0.31 to 0.81; P=0.005) and when restricted to fully vaccinated people (HR=0.53, 95% CI: 0.31 to 0.90; P=0.019). No substantial effect modifications by other characteristics were detected (all P values for interaction>0.10). Findings were similar in an exploratory analysis of patients treated between February 16 and May 1, 2022 when the Omicron BA.2 variant was dominant in England.

ConclusionIn routine care of non-hospitalised high-risk adult patients with COVID-19 in England, those who received sotrovimab were at lower risk of severe COVID-19 outcomes than those receiving molnupiravir.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.05.21.22275368,2022-05-23,https://medrxiv.org/cgi/content/short/2022.05.21.22275368,"Variant-specific symptoms of COVID-19 among 1,542,510 people in England",Matthew Whitaker; Joshua Elliott; Barbara Bodinier; Wendy S Barclay; Helen Ward; Graham Cooke; Christl A Donnelly; Marc Chadeau-Hyam; Paul Elliott,Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health,"Infection with SARS-CoV-2 virus is associated with a wide range of symptoms. The REal-time Assessment of Community Transmission -1 (REACT-1) study has been monitoring the spread and clinical manifestation of SARS-CoV-2 among random samples of the population in England from 1 May 2020 to 31 March 2022. We show changing symptom profiles associated with the different variants over that period, with lower reporting of loss of sense of smell and taste for Omicron compared to previous variants, and higher reporting of cold-like and influenza-like symptoms, controlling for vaccination status. Contrary to the perception that recent variants have become successively milder, Omicron BA.2 was associated with reporting more symptoms, with greater disruption to daily activities, than BA.1. With restrictions lifted and routine testing limited in many countries, monitoring the changing symptom profiles associated with SARS-CoV-2 infection and induced changes in daily activities will become increasingly important.",infectious diseases,fuzzy,96,100
medRxiv,10.1101/2022.05.19.22275214,2022-05-22,https://medrxiv.org/cgi/content/short/2022.05.19.22275214,Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors,Nathan J Cheetham; Milla Kibble; Andrew Wong; Richard J Silverwood; Anika Knuppel; Dylan M Williams; Olivia K L Hamilton; Paul H Lee; Charis Bridger Staatz; Giorgio Di Gessa; Jingmin Zhu; Srinivasa Vittal Katikireddi; George B Ploubidis; Ellen J Thompson; Ruth C E Bowyer; Xinyuan Zhang; Golboo Abbasian; Maria Paz Garcia; Deborah Hart; Jeffrew Seow; Carl Graham; Neophytos Kouphou; Sam Acors; Michael H Malim; Ruth E Mitchell; Kate Northstone; Daniel Major-Smith; Sarah Matthews; Thomas Breeze; Michael Crawford; Lynn Molloy; Alex Siu Fung Kwong; Katie J Doores; Nishi Chaturvedi; Emma L Duncan; Nicholas J Timpson; Claire J Steves,King's College London; University of Cambridge; University College London; University College London; University College London; University College London; University of Glasgow; University of Leicester; University College London; University College London; University College London; University of Glasgow; University College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; King's College London; University College London; King's College London; University of Bristol; King's College London,"SARS-CoV-2 antibody levels can be used to assess humoral immune responses following SARS-CoV-2 infection or vaccination, and may predict risk of future infection. From cross-sectional antibody testing of 9,361 individuals from TwinsUK and ALSPAC UK population-based longitudinal studies (jointly in April-May 2021, and TwinsUK only in November 2021-January 2022), we tested associations between antibody levels following vaccination and: (1) SARS-CoV-2 infection following vaccination(s); (2) health, socio-demographic, SARS-CoV-2 infection and SARS-CoV-2 vaccination variables.

Within TwinsUK, single-vaccinated individuals with the lowest 20% of anti-Spike antibody levels at initial testing had 3-fold greater odds of SARS-CoV-2 infection over the next six to nine months, compared to the top 20%. In TwinsUK and ALSPAC, individuals identified as at increased risk of COVID-19 complication through the UK ""Shielded Patient List"" had consistently greater odds (2 to 4-fold) of having antibody levels in the lowest 10%. Third vaccination increased absolute antibody levels for almost all individuals, and reduced relative disparities compared with earlier vaccinations.

These findings quantify the association between antibody level and risk of subsequent infection, and support a policy of triple vaccination for the generation of protective antibodies.

Lay summaryIn this study, we analysed blood samples from 9,361 participants from two studies in the UK: an adult twin registry, TwinsUK (4,739 individuals); and the Avon Longitudinal Study of Parents and Children, ALSPAC (4,622 individuals). We did this work as part of the UK Government National Core Studies initiative researching COVID-19. We measured blood antibodies which are specific to SARS-CoV-2 (which causes COVID-19). Having a third COVID-19 vaccination boosted antibody levels. More than 90% of people from TwinsUK had levels after third vaccination that were greater than the average level after second vaccination. Importantly, this was the case even in individuals on the UK ""Shielded Patient List"". We found that people with lower antibody levels after first vaccination were more likely to report having COVID-19 later on, compared to people with higher antibody levels. People on the UK ""Shielded Patient List"", and individuals who reported that they had poorer general health, were more likely to have lower antibody levels after vaccination. In contrast, people who had had a previous COVID-19 infection were more likely to have higher antibody levels following vaccination compared to people without infection. People receiving the Oxford/AstraZeneca rather than the Pfizer BioNTech vaccine had lower antibody levels after one or two vaccinations. However, after a third vaccination, there was no difference in antibody levels between those who had Oxford/AstraZeneca and Pfizer BioNTech vaccines for their first two doses. These findings support having a third COVID-19 vaccination to boost antibodies.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.05.11.22274964,2022-05-16,https://medrxiv.org/cgi/content/short/2022.05.11.22274964,Mental health outcomes following COVID-19 infection: Evidence from 11 UK longitudinal population studies,Ellen J Thompson; Jean Stafford; Bettina Moltrecht; Charlotte F Huggins; Alex S F Kwong; Richard J Shaw; Paola Zaninotto; Kishan Patel; Richard J Silverwood; Eoin McElroy; Matthias Pierce; Michael J Green; Ruth Bowyer; Jane Maddock; Kate Tilling; Srinivasa Vittal Katikireddi; George B Ploubidis; Professor D Porteous; Nicholas J Timpson; Nish Chaturvedi; Claire Steves; Praveetha Patalay,"Department of Twin Research and Genetic Epidemiology Kings College London; MRC Unit for Lifelong Health and Ageing, UCL; Centre for Longitudinal Studies UCL Social Research Institute University College London; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh; Division of Psychiatry, University of Edinburgh; Population Health Sciences, University of Bristol; MRC/CSO Social & Public Health Sciences Unit, Institute of Health & Wellbeing, University of Glasgow; Department of Epidemiology and Public Health UCL; MRC Unit for Lifelong Health and Ageing UCL; Centre for Longitudinal Studies UCL Social Research Institute  University College London; School of Psychology Ulster University; Division of Psychology & Mental Health The University of Manchester; MRC CSO Social and Public Health Sciences Unit University of Glasgow; Department of Twin Research and Genetic Epidemiology King's College London; MRC Unit for Lifelong Health and Ageing UCL; MRC Integrative Epidemiology Unit University of Bristol; MRC CSO Social and Public Health Sciences UnitUniversity of Glasgow; Centre for Longitudinal Studies UCL Social Research Institute  University College London; Centre for Genomic and Experimental Medicine University of Edinburgh; MRC Integrative Epidemiology Unit University of Bristol; MRC Unit for Lifelong Health and Ageing UCL; Department of Twin Research and Genetic Epidemiology King's College London; Centre for Longitudinal Studies and MRC Unit for Lifelong Health and Ageing University College London","BackgroundEvidence on associations between COVID-19 illness and mental health is mixed. We examined longitudinal associations between COVID-19 and mental health while considering: 1) pre-pandemic mental health, 2) time since infection; 3) subgroup differences; and 4) confirmation of infection via self-reported test, and serology data.

MethodsUsing data from 11 UK longitudinal studies, involving 54,442 participants, with 2 to 8 repeated measures of mental health and COVID-19 between April 2020 and April 2021, we standardised continuous mental health scales within each study across time. We investigated associations between COVID-19 (self-report, test-confirmed, serology-confirmed) and mental health using multilevel generalised estimating equations. We examined whether associations varied by age, sex, ethnicity, education and pre-pandemic mental health. Effect-sizes were pooled in random-effects meta-analyses.

OutcomesPooled estimates of the standardized difference in outcome between those with and without self-reported COVID-19 suggested associations with subsequent psychological distress (0.10 [95%CI: 0.06; 0.13], I2=42.8%), depression (0.08 [0.05; 0.10], I2=20.8%), anxiety (0.08 [0.05; 0.10], I2=0%), and lower life satisfaction (-0.06 [-0.08; -0.04], I2=29.2%). Associations did not vary by time since infection until 3+ months and were present in all age groups, with some evidence of stronger effects in those aged 50+. Self-reported COVID-19, whether suspected or test-confirmed and irrespective of serology status, was associated with poorer mental health.

InterpretationSelf-reporting COVID-19 was longitudinally associated with deterioration in mental health and life satisfaction. Our findings have important implications for mental health service provision, given the substantial prevalence of COVID-19 in the UK and worldwide.

FundingMRC and NIHR",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2022.05.09.22274769,2022-05-11,https://medrxiv.org/cgi/content/short/2022.05.09.22274769,"COVID-19 vaccination in pregnancy: views and vaccination uptake rates in pregnancy, a mixed methods analysis from the Born In Wales study",Mohamed Mhereeg; Hope Jones; Jonathan Kennedy; Michael Seaborne; Michael Parker; Natasha Kennedy; Sarah Beeson; Luisa Zuccolo; Alisha Davies; Sinead Brophy,"Swansea University Medical School, Swansea, Wales, UK; Swansea University Medical School, Swansea, Wales, UK.; Swansea University Medical School, Swansea, Wales, UK.; Swansea University Medical School, Swansea, Wales, UK.; Swansea University Medical School, Swansea, Wales, UK.; Swansea University Medical School, Swansea, Wales, UK.; Swansea University Medical School, Swansea, Wales, UK.; Bristol Medical School, University of Bristol, Bristol, England, UK.; Public Health Wales, UK; Swansea University Medical School, Swansea, Wales, UK","BackgroundVaccine hesitancy amongst pregnant women has been found to be a concern during past epidemics.

ObjectivesThe aims of this study were to 1) estimate COVID-19 vaccination rates among pregnant women in Wales and their association with age, ethnicity, and area of deprivation, using electronic health records (EHR) linkage, and 2) explore pregnant womens views on receiving the COVID-19 vaccine during pregnancy using data from a survey recruiting via social media (Facebook, Twitter), through midwives, and posters in hospitals (Born in Wales Cohort).

DesignA mixed methods study utilising routinely collected linked data from the Secure Anonymised Information Linkage (SAIL) (Objective 1) and the Born In Wales Birth Cohort participants (Objective 2). SAIL combines data from general practice, hospital admissions, the national community child health dataset, maternal indicators dataset, and COVID-19 vaccination databases.

Setting and participantsObjective 1) All women documented as being pregnant on or after 13th April 2021, aged 18 years or older, and eligible for COVID-19 vaccination were identified in routine health care. They were linked to the vaccination data up to and including 31st December 2021. Objective 2) Separately, a cross-section of pregnant women in Wales were invited to complete an online survey via social media advertising. The survey asked what their views were on having the COVID-19 vaccination during pregnancy, and if they had already received, or intended to receive, the COVID-19 vaccination during their pregnancies. They were also asked to give reasons for their decisions.

Outcomes1 (a). Rate of vaccination uptake per month during pregnancy among women eligible for vaccination. 1 (b). Survival analysis was utilised to examine and compare the length of time to vaccination uptake in pregnancy, and variation in uptake by; age, ethnicity, and deprivation area was examined using hazard ratios (HR) from Cox regression. 2.Expectant mothers views of the COVID-19 vaccination during pregnancy.

Results

Population-level data linkage (objective 1)Within the population cohort, 32.7% (n = 8,203) were vaccinated (at least one dose of the vaccine) during pregnancy, 34.1% (n = 8,572) remained unvaccinated throughout follow-up period, and 33.2% (n = 8,336) received the vaccine postpartum. Younger women (<30 years) were less likely to have the vaccine and those living in areas of high deprivation were also less likely to have the vaccine (HR=0.88, 95% CI 0.82 to 0.95). Asian and other ethnic groups were 1.12 and 1.18 times more likely to have the vaccine in pregnancy compared to women of White ethnicity (HR=1.12, 95% CI 1.00 to 1.25) and (HR=1.18, 95% CI 1.03 to 1.37) respectively.

Survey responses (objective 2)69% of participants stated that they would be happy to have the vaccine during pregnancy (n = 207). The remainder, 31%, indicated that they would not have the vaccine during pregnancy (n = 94). Reasons for having the vaccine related to protecting self and baby, perceived risk level, and receipt of sufficient evidence and advice. Reasons for vaccine refusal included lack of research about long-term outcomes for the baby, anxiety about vaccines, inconsistent advice/information, and preference to wait until after the pregnancy.

ConclusionPotentially only 1 in 3 pregnant women would have the COVID-19 vaccine during pregnancy, even though 2 in 3 reported they would have the vaccination, thus it is critical to develop tailored strategies to increase its acceptance rate and to decrease vaccine hesitancy. A targeted approach to vaccinations may be required for groups such as younger people and those living in higher deprivation level areas.",public and global health,fuzzy,100,100
bioRxiv,10.1101/2022.05.07.491004,2022-05-10,https://biorxiv.org/cgi/content/short/2022.05.07.491004,SARS-CoV-2 Spike N-Terminal Domain modulates TMPRSS2-dependent viral entry and fusogenicity,Bo Meng; Rawlings Datir; Jinwook Choi; - CITIID-NIHR BioResource COVID-19 Collaboration; John Bradley; Kenneth GC Smith; Joo Hyeon Lee; Ravindra K Gupta,University of Cambridge; University of Cambridge; University of Cambridge; -; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge,"Over 20 mutations have been identified in the N-Terminal Domain (NTD) of SARS-CoV-2 spike and yet few of them are fully characterised. Here we first examined the contribution of the NTD to infection and cell-cell fusion by constructing different VOC-based chimeric spikes bearing B.1617 lineage (Delta and Kappa variants) NTDs and generating spike pseudotyped lentivirus (PV). We found the Delta NTD on a Kappa or WT background increased spike S1/S2 cleavage efficiency and virus entry, specifically in Calu-3 lung cells and airway organoids, through use of TMPRSS2. We have previously shown Delta spike confers rapid cell-cell fusion kinetics; here we show that increased fusogenicity can be conferred to WT and Kappa variant spikes by transfer of the Delta NTD. Moving to contemporary variants, we found that BA.2 had higher entry efficiency in a range of cell types as compared to BA.1. BA.2 showed higher fusogenic activity than BA.1, but the BA.2 NTD could not confer higher fusion to BA.1 spike. There was low efficiency of TMPRSS2 usage by both BA.1 and BA.2, and chimeras of Omicron BA.1 and BA.2 spikes with a Delta NTD did not result in more efficient use of TMRPSS2 or cell-cell fusogenicity. We conclude that the NTD allosterically modulates S1/S2 cleavage and spike-mediated functions such as entry and cell-cell fusion in a spike context dependent manner, and allosteric interactions may be lost when combining regions from more distantly related spike proteins. These data may explain the lack of successful SARS-CoV-2 inter-variant recombinants bearing breakpoints within spike.",microbiology,fuzzy,100,100
medRxiv,10.1101/2022.05.10.22274890,2022-05-10,https://medrxiv.org/cgi/content/short/2022.05.10.22274890,Biopsychosocial response to the COVID-19 lockdown in people with major depressive disorder and multiple sclerosis.,Sara Siddi; Iago Gine Vazquez; Raquel Bailon; Faith Matcham; Femke Lamers; Spyridon Kontaxis; Estela Laporta Puyal; Esther Garcia; Belen Arranz; Gloria Dallacosta; Anna Isabel Guerrero Perez; Anna Zabalza; Mathias Buron; Giancarlo Comi; Letizia Leocani; Peter Annas; Matthew Hotopf; Brenda Penninx; Melinda Magyari; Per Sorensen; Xavier Montalban; Grace Lavalle; Alina Ivan; Carolin Oetzmann; Katie White; Sonia Difrancesco; Patrick Locatelli; Jordi Aguilo; Vaibhav Narayan; Amos Folarin; Richard Dobson; Judith Anne Dineley; Daniel Leightley; Nicholas Cummins; Yarharth Ranjan; Zulqarnain Rashid; Aki Rintala; Giovanni De Girolamo; Antonio Preti; Sara Simblett; Til Wykes; Inez Myin-Germeys; Josep Maria Haro,"Parc Sanitari Sant Joan de Deu Cibersam; Parc Sanitari Sant Joan de Deu Cibersam; Universidad de Zaragoza; King's College London; Amsterdam UMC Locatie AMC, Amsterdam, North Holland, NL; Universidad de Zaragoza; Universidad de Zaragoza; Universitat Autonoma de Barcelona; Parc Sanitari Sant Joan de Deu Cibersam; Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele Milano; Vall d'Hebron Institut de Recerca; Vall d'Hebron Institut de Recerca; Copenhagen University Hospital Kobenhavn; Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele Milano; Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele Milano; H Lundbeck AS Valby; Institute of Psychiatry, Psychological Medicine; Amsterdam UMC Locatie AMC, Amsterdam, North Holland, NL; Copenhagen University Hospital Kobenhavn; Copenhagen University Hospital Kobenhavn; Vall d'Hebron Institut de Recerca; King's College London; King's College London; King's College London; King's College London; Amsterdam UMC Locatie AMC, Amsterdam, North Holland, NL; University of Bergamo; Universitat Autonoma de Barcelona; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Katholieke Universiteit Leuven; Centro San Giovanni di Dio Fatebenefratelli; Universita degli Studi di Torino; King's College London; King's College London; KU Leuven; Parc Sanitari Sant Joan de Deu Cibersam","BackgroundChanges in lifestyle, finances and work status during COVID-19 lockdowns may have led to biopsychosocial changes in people with pre-existing vulnerabilities such as Major Depressive Disorders (MDD) and Multiple Sclerosis (MS).

MethodsData were collected as a part of the RADAR-CNS (Remote Assessment of Disease and Relapse - Central Nervous System) programme. We analyzed the following data from long-term participants in a decentralized multinational study: symptoms of depression, heart rate (HR) during the day and night; social activity; sedentary state, steps and physical activity of varying intensity. Linear mixed-effects regression analyses with repeated measures were fitted to assess the changes among three time periods (pre, during and post-lockdown) across the groups, adjusting for depression severity before the pandemic and gender.

ResultsParticipants with MDD (N=255) and MS (N=214) were included in the analyses. Overall, depressive symptoms remained stable across the three periods in both groups. Lower mean HR and HR variation were observed between pre and during lockdown during the day for MDD and during the night for MS. HR variation during rest periods also decreased between pre-and post-lockdown in both clinical conditions. We observed a reduction of physical activity for MDD and MS upon the introduction of lockdowns. The group with MDD exhibited a net increase in social interaction via social network apps over the three periods.

ConclusionsBehavioral response to the lockdown measured by social activity, physical activity and HR may reflect changes in stress in people with MDD and MS.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2022.05.09.22274846,2022-05-10,https://medrxiv.org/cgi/content/short/2022.05.09.22274846,"Assessing the impacts of timing on the health benefits, cost-effectiveness and relative affordability of COVID-19 vaccination programmes in 27 African Countries",Yang Liu; Carl AB Pearson; Andres Madriz Montero; Sergio Torres-Rueda; Elias Asfaw; Benjamin Uzochukwu; Tom Drake; Eleanor Bergren; Rosalind M Eggo; Francis Ruiz; Nicaise Ndembi; Justice Nonvignon; Mark Jit; Anna Vassall,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Africa Centres for Disease Control and Prevention; University of Nigeria Nsukka; Centre for Global Development; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Institute of Human Virology Nigeria; Africa Centres for Disease Control and Prevention; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine,"BackgroundThe COVID-19 vaccine supply shortage in 2021 constrained rollout efforts in Africa while populations experienced waves of epidemics. As supply picks up, a key question becomes if vaccination remains an impactful and cost-effective strategy given changes in the timing of implementation.

MethodsWe assessed the impact of timing using an epidemiological and economic model. We fitted our mathematical epidemiological model to reported COVID-19 deaths in 27 African countries to estimate the existing immunity (resulting from infection) before substantial vaccine rollout. We then projected health outcomes for different programme start dates (2021-01-01 to 2021-12-01, n = 12) and roll-out rates (slow, medium, fast; 275, 826, and 2066 doses/ million population-day, respectively) for viral vector and mRNA vaccines. Rollout rates used were derived from observed uptake trajectories. We collected data on vaccine delivery costs by country income group. Lastly, we calculated incremental cost-effectiveness ratios and relative affordability.

FindingsVaccination programmes with early start dates incur the most health benefits and are most cost-effective. While incurring the most health benefits, fast vaccine roll-outs are not always the most cost-effective. At a willingness-to-pay threshold of 0.5xGDP per capita, vaccine programmes starting in August 2021 using mRNA and viral vector vaccines were cost-effective in 6-10 and 17-18 of 27 countries, respectively.

InterpretationAfrican countries with large proportions of their populations unvaccinated by late 2021 may find vaccination programmes less cost-effective than they could have been earlier in 2021. Lower vaccine purchasing costs and/or the emergence of new variants may improve cost-effectiveness.

FundingBill and Melinda Gates Foundation, World Health Organization, National Institute of Health Research (UK), Health Data Research (UK)",health economics,fuzzy,100,100
medRxiv,10.1101/2022.05.06.22274658,2022-05-07,https://medrxiv.org/cgi/content/short/2022.05.06.22274658,"STIMULATE-ICP-CAREINEQUAL - Defining usual care and examining inequalities in Long Covid support: protocol for a mixed-methods study (part of STIMULATE-ICP: Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways).",Mel Ramasawmy; Yi Mu; Donna Clutterbuck; Marija Pantelic; Gregory Y.H. Lip; Christina Van der Feltz-Cornelis; Dan Wootton; Nefyn H Williams; Hugh Montgomery; Rita Mallinson Cookson; Emily Attree; Mark Gabbay; Melissa J Heightman; Nisreen A Alwan; Amitava Banerjee; Paula Lorgelly; - STIMULATE-ICP consortium,"Institute of Health Informatics, University College London; Institute of Health Informatics, University College London; School of Primary Care, Population Sciences and Medical Education, University of Southampton; Brighton and Sussex Medical School, University of Sussex; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Department of Clinical; Department of Health Sciences, HYMS, University of York, and Institute of Health Informatics, University College London; Institute of Infection Veterinary and Ecological Sciences, University of Liverpool; Department of Primary Care and Mental Health, University of Liverpool; Centre for Human Health and Performance, Department of Medicine, University College London; PPIE Representative; PPIE Representative; Department of Primary Care and Mental Health, University of Liverpool; University College London Hospitals NHS Trust; School of Primary Care, Population Sciences and Medical Education, University of Southampton; NIHR Southampton Biomedical Research Centre, University of Southam; Institute of Health Informatics, University College London; School of Population Health and Department of Economics, University of Auckland; ","IntroductionIndividuals with Long Covid represent a new and growing patient population. In England, fewer than 90 Long Covid clinics deliver assessment and treatment informed by NICE guidelines. However, a paucity of clinical trials or longitudinal cohort studies means that the epidemiology, clinical trajectory, healthcare utilisation and effectiveness of current Long Covid care are poorly documented, and that neither evidence-based treatments nor rehabilitation strategies exist. In addition, and in part due to pre-pandemic health inequalities, access to referral and care varies, and patient experience of the Long Covid care pathways can be poor.

In a mixed methods study, we therefore aim to: (1) describe the usual healthcare, outcomes and resource utilisation of individuals with Long Covid; (2) assess the extent of inequalities in access to Long Covid care, and specifically to understand Long Covid patients experiences of stigma and discrimination.

Methods and analysisA mixed methods study will address our aims. Qualitative data collection from patients and health professionals will be achieved through surveys, interviews and focus group discussions, to understand their experience and document the function of clinics. A patient cohort study will provide an understanding of outcomes and costs of care. Accessible data will be further analysed to understand the nature of Long Covid, and the care received.

Ethics and disseminationEthical approval was obtained from South Central - Berkshire Research Ethics Committee (reference 303958). The dissemination plan will be decided by the patient and public involvement and engagement (PPIE) group members and study Co-Is, but will target 1) policy makers, and those responsible for commissioning and delivering Long Covid services, 2) patients and the public, and 3) academics.",health systems and quality improvement,fuzzy,100,100
medRxiv,10.1101/2022.05.05.22273234,2022-05-07,https://medrxiv.org/cgi/content/short/2022.05.05.22273234,Changes in English medication safety indicators throughout the COVID-19 pandemic: a federated analysis of 57 million patients' primary care records in situ using OpenSAFELY,Louis Fisher; Lisa E M Hopcroft; Sarah Rodgers; James Barrett; Kerry Oliver; Anthony J Avery; Dai Evans; Helen Curtis; Richard Croker; Orla Macdonald; Jessica Morley; Amir Mehrkar; Seb Bacon; Simon Davy; Iain Dillingham; David Evans; George Hickman; Peter Inglesby; Caroline E Morton; Becky Smith; Tom Ward; William Hulme; Amelia Green; Jon Massey; Alex J Walker; Chris Bates; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Shaun O'Hanlon; Alex Eavis; Richard Jarvis; Dima Avramov; Paul Griffiths; Aaron Fowles; Nasreen Parkes; Ben Goldacre; Brian MacKenna,"Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; PRIMIS, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK; PRIMIS, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK; PRIMIS, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK; Centre for Academic Primary Care, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK; PRIMIS, School of Medicine, Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, UK; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; EMIS Health, Fulford Grange, Micklefield Lane, Rawdon, Leeds, LS19 6BA; EMIS Health, Fulford Grange, Micklefield Lane, Rawdon, Leeds, LS19 6BA; EMIS Health, Fulford Grange, Micklefield Lane, Rawdon, Leeds, LS19 6BA; EMIS Health, Fulford Grange, Micklefield Lane, Rawdon, Leeds, LS19 6BA; EMIS Health, Fulford Grange, Micklefield Lane, Rawdon, Leeds, LS19 6BA; EMIS Health, Fulford Grange, Micklefield Lane, Rawdon, Leeds, LS19 6BA; EMIS Health, Fulford Grange, Micklefield Lane, Rawdon, Leeds, LS19 6BA; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Bennett Institute of Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG","ObjectiveTo describe the impact of the COVID-19 pandemic on safe prescribing, using the PINCER prescribing indicators; to implement complex prescribing indicators at national scale using GP data.

DesignPopulation based cohort study, with the approval of NHS England using the OpenSAFELY platform.

SettingElectronic health record data from 56.8 million NHS patients general practice records.

ParticipantsAll NHS patients registered at a GP practice using TPP or EMIS computer systems and recorded as at risk of at least one potentially hazardous PINCER indicator between September 2019 and September 2021.

Main outcome measureMonthly trends and between-practice variation for compliance with 13 PINCER measures between September 2019 and September 2021.

ResultsThe indicators were successfully implemented across GP data in OpenSAFELY. Hazardous prescribing remained largely unchanged during the COVID-19 pandemic, with only small reductions in achievement of the PINCER indicators. There were transient delays in blood test monitoring for some medications, particularly ACE inhibitors. All indicators exhibited substantial recovery by September 2021. We identified 1,813,058 patients at risk of at least one hazardous prescribing event.

ConclusionGood performance was maintained during the COVID-19 pandemic across a diverse range of widely evaluated measures of safe prescribing.

Summary box O_TEXTBOXWHAT IS ALREADY KNOWN ON THIS TOPICO_LIPrimary care services were substantially disrupted by the COVID-19 pandemic.
C_LIO_LIDisruption to safe prescribing during the pandemic has not previously been evaluated.
C_LIO_LIPINCER is a nationally adopted programme of activities that aims to identify and correct hazardous prescribing in GP practices, by conducting manual audit on subgroups of practices.
C_LI

WHAT THIS STUDY ADDSO_LIFor the first time, we were able to successfully generate data on PINCER indicators for almost the whole population of England, in a single analysis.
C_LIO_LIOur study is the most comprehensive assessment of medication safety during the COVID-19 pandemic in England, covering 95% of the population using well-validated measures.
C_LIO_LIGood performance was maintained across many PINCER indicators throughout the pandemic.
C_LIO_LIDelays in delivering some medication-related blood test monitoring were evident though considerable recovery was made by the end of the study period.
C_LI

C_TEXTBOX",primary care research,fuzzy,100,100
medRxiv,10.1101/2022.05.03.22274395,2022-05-05,https://medrxiv.org/cgi/content/short/2022.05.03.22274395,Development and evaluation of low-volume tests to detect and characterise antibodies to SARS-CoV-2,Alice Halliday; Anna E Long; Holly E Baum; Amy C Thomas; Kathryn L Shelley; Elizabeth Oliver; Kapil Gupta; Ore Francis; Maia Kavanagh Williamson; Natalie Di Bartolo; Matthew J Randell; Yassin Ben Khoud; Ilana Kelland; Georgina Mortimer; Olivia Ball; Charlie Plumptre; Kyla Chandler; Ulrike Obst; Massimiliano Secchi; Lorenzo Piemonti; Vito Lampasona; Joyce Smith; Michaela Gregorova; Lea Knezevic; Jane Metz; Rachael Barr; Begonia Morales-Aza; Jennifer Oliver; Lucy Collingwood; Benjamin Hitchings; Susan Ring; Linda Wooldridge; Laura Rivino; Nicholas J Timpson; Jorgen McKernon; Peter Muir; Fergus W Hamilton; David Arnold; Derek N Woolfson; Anu Goenka; Andrew D Davidson; Ashley Mark Toye; Imre Berger; Mick Bailey; Kathleen M Gillespie; Alistair JK Williams; Adam Finn,"University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; IRCCS Ospedale San Raffaele; IRCCS Ospedale San Raffaele; IRCCS Ospedale San Raffaele; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; National Infection Service, UK Health Security Agency, Southmead Hospital, Bristol, UK; National Infection Service, UK Health Security Agency, Southmead Hospital, Bristol, UK; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol","Low-volume antibody assays can be used to track SARS-CoV-2 infection rates in settings where active testing for virus is limited and remote sampling is optimal. We developed 12 ELISAs detecting total or antibody isotypes to SARS-CoV-2 nucleocapsid, spike protein or its receptor binding domain (RBD), 3 anti-RBD isotype specific luciferase immunoprecipitation system (LIPS) assays and a novel Spike-RBD bridging LIPS total-antibody assay. We utilised pre-pandemic (n=984) and confirmed/suspected recent COVID-19 sera taken pre-vaccination rollout in 2020 (n=269). Assays measuring total antibody discriminated best between pre-pandemic and COVID-19 sera and were selected for diagnostic evaluation. In the blind evaluation, two of these assays (Spike Pan ELISA and Spike-RBD Bridging LIPS assay) demonstrated >97% specificity and >92% sensitivity for samples from COVID- 19 patients taken >21 days post symptom onset or PCR test. These assays offered better sensitivity for the detection of COVID-19 cases than a commercial assay which requires 100-fold larger serum volumes. This study demonstrates that low-volume in- house antibody assays can provide good diagnostic performance, and highlights the importance of using well-characterised samples and controls for all stages of assay development and evaluation. These cost-effective assays may be particularly useful for seroprevalence studies in low and middle-income countries.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.05.03.22274602,2022-05-03,https://medrxiv.org/cgi/content/short/2022.05.03.22274602,Accident and emergency (AE) attendance in England following infection with SARS-CoV-2 Omicron or Delta,Daniel J Grint; Kevin Wing; Hamish P Gibbs; Stephen JW Evans; Elizabeth J Williamson; Krishnan Bhaskaran; Helen I McDonald; Alex J Walker; David Evans; George Hickman; Rohini Mathur; Anna Schultze; Christopher T Rentsch; John Tazare; Ian J Douglas; Helen J Curtis; Caroline E Morton; Sebastian CJ Bacon; Simon Davy; Brian MacKenna; Peter Inglesby; Richard Croker; John Parry; Frank Hester; Sam Harper; Nicholas J DeVito; William J Hulme; Christopher Bates; Jonathan Cockburn; Amir Mehrkar; Ben Goldacre; Rosalind M Eggo; Laurie Tomlinson,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; TPP; TPP; University of Oxford; University of Oxford; TPP; TPP; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine,"The SARS-CoV-2 Omicron variant is increasing in prevalence around the world. Accurate estimation of disease severity associated with Omicron is critical for pandemic planning. We found lower risk of accident and emergency (AE) attendance following SARS-CoV-2 infection with Omicron compared to Delta (HR: 0.39 (95% CI: 0.30 - 0.51; P<.0001). For AE attendances that lead to hospital admission, Omicron was associated with an 85% lower hazard compared with Delta (HR: 0.14 (95% CI: 0.09 - 0.24; P<.0001)).

Conflicts of InterestsNothing to declare.

Funding statementThis work was supported by the Medical Research Council MR/V015737/1. TPP provided technical expertise and infrastructure within their data centre pro bono in the context of a national emergency. Rosalind Eggo is funded by HDR UK (grant: MR/S003975/1), MRC (grant: MC_PC 19065), NIHR (grant: NIHR200908).",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.04.29.22274267,2022-05-01,https://medrxiv.org/cgi/content/short/2022.04.29.22274267,Multi-omics identify LRRC15 as a COVID-19 severity predictor and persistent pro-thrombotic signals in convalescence,Jack S Gisby; Norzawani B Buang; Artemis Papadaki; Candice L Clarke; Talat H Malik; Nicholas Medjeral-Thomas; Damiola Pinheiro; Paige M Mortimer; Shanice Lewis; Eleanor Sandhu; Stephen P McAdoo; Maria F Prendecki; Michelle Willicombe; Matthew C Pickering; Marina Botto; David C Thomas; James E Peters,Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London,"Patients with end-stage kidney disease (ESKD) are at high risk of severe COVID-19. Here, we performed longitudinal blood sampling of ESKD haemodialysis patients with COVID-19, collecting samples pre-infection, serially during infection, and after clinical recovery. Using plasma proteomics, and RNA-sequencing and flow cytometry of immune cells, we identified transcriptomic and proteomic signatures of COVID-19 severity, and found distinct temporal molecular profiles in patients with severe disease. Supervised learning revealed that the plasma proteome was a superior indicator of clinical severity than the PBMC transcriptome. We showed that both the levels and trajectory of plasma LRRC15, a proposed co-receptor for SARS-CoV-2, are the strongest predictors of clinical outcome. Strikingly, we observed that two months after the acute infection, patients still display dysregulated gene expression related to vascular, platelet and coagulation pathways, including PF4 (platelet factor 4), which may explain the prolonged thrombotic risk following COVID-19.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.04.28.22273177,2022-04-29,https://medrxiv.org/cgi/content/short/2022.04.28.22273177,Occupational differences in SARS-CoV-2 infection: Analysis of the UK ONS Coronavirus (COVID-19) Infection Survey,Sarah Rhodes; Jack Wilkinson; Neil Pearce; Will Mueller; Mark Cherrie; Katie Stocking; Matthew Gittins; Srinivasa Vittal Katikireddi; Martie van Tongeren,University of Manchester; University of Manchester; London School of Hygiene and Tropical Medicine; Institute of Occupational Medicine; Institute of Occupational Medicine; University of Manchester; University of Manchester; University of Glasgow; University of Manchester,"BackgroundConsiderable concern remains about how occupational SARS-CoV-2 risk has evolved during the COVID-19 pandemic. We aimed to ascertain which occupations had the greatest risk of SARS-CoV-2 infection and explore how relative differences varied over the pandemic.

MethodsAnalysis of cohort data from the UK Office of National Statistics Coronavirus (COVID-19) Infection Survey from April 2020 to November 2021. This survey is designed to be representative of the UK population and uses regular PCR testing. Cox and multilevel logistic regression to compare SARS-CoV-2 infection between occupational/sector groups, overall and by four time periods with interactions, adjusted for age, sex, ethnicity, deprivation, region, household size, urban/rural neighbourhood and current health conditions.

ResultsBased on 3,910,311 observations from 312,304 working age adults, elevated risks of infection can be seen overall for social care (HR 1.14; 95% CI 1.04 to 1.24), education (HR 1.31; 95% CI 1.23 to 1.39), bus and coach drivers (1.43; 95% CI 1.03 to 1.97) and police and protective services (HR 1.45; 95% CI 1.29 to 1.62) when compared to non-essential workers. By time period, relative differences were more pronounced early in the pandemic. For healthcare elevated odds in the early waves switched to a reduction in the later stages. Education saw raises after the initial lockdown and this has persisted. Adjustment for covariates made very little difference to effect estimates.

ConclusionsElevated risks among healthcare workers have diminished over time but education workers have had persistently higher risks. Long-term mitigation measures in certain workplaces may be warranted.

What is already known on this topicSome occupational groups have observed increased rates of disease and mortality relating to COVID-19.

What this study addsRelative differences between occupational groups have varied during different stages of the COVID-19 pandemic with risks for healthcare workers diminishing over time and workers in the education sector seeing persistent elevated risks.

How this study might affect research, practice or policyIncreased long term mitigation such as ventilation should be considered in sectors with a persistent elevated risk. It is important for workplace policy to be responsive to evolving pandemic risks.",occupational and environmental health,fuzzy,100,100
medRxiv,10.1101/2022.04.26.22274332,2022-04-27,https://medrxiv.org/cgi/content/short/2022.04.26.22274332,"Community factors and excess mortality in the COVID-19 pandemic in England, Italy and Sweden",Brandon Parkes; Massimo Stafoggia; Daniela Fecht; Bethan Davies; Carl Bonander; Francesca de'Donato; Paola Michelozzi; Fr√©d√©ric B. Piel; Ulf Str√∂mberg; Marta Blangiardo,Imperial College London; Lazio Regional Health Service; Imperial College London; Imperial College London; University of Gothenburg; Lazio Regional Health Service; Lazio Regional Health Service; Imperial College London; University of Gothenburg; Imperial College London,"BackgroundAnalyses of COVID-19 suggest specific risk factors make communities more or less vulnerable to pandemic related deaths within countries. What is unclear is whether the characteristics affecting vulnerability of small communities within countries produce similar patterns of excess mortality across countries with different demographics and public health responses to the pandemic. Our aim is to quantify community-level variations in excess mortality within England, Italy and Sweden and identify how such spatial variability was driven by community-level characteristics.

MethodsWe applied a two-stage Bayesian model to quantify inequalities in excess mortality in people aged 40 years and older at the community level in England, Italy and Sweden during the first year of the pandemic (March 2020-February 2021). We used community characteristics measuring deprivation, air pollution, living conditions, population density and movement of people as covariates to quantify their associations with excess mortality.

ResultsWe found just under half of communities in England (48.1%) and Italy (45.8%) had an excess mortality of over 300 per 100,000 males over the age of 40, while for Sweden that covered 23.1% of communities. We showed that deprivation is a strong predictor of excess mortality across the three countries, and communities with high levels of overcrowding were associated with higher excess mortality in England and Sweden.

ConclusionThese results highlight some international similarities in factors affecting mortality that will help policy makers target public health measures to increase resilience to the mortality impacts of this and future pandemics.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.04.21.22274152,2022-04-27,https://medrxiv.org/cgi/content/short/2022.04.21.22274152,"Health care use attributable to COVID-19: A propensity matched national electronic health records cohort study of 249,390 people in Wales, UK.",Jonathan Kennedy; Michael Parker; Michael Seaborne; Mohamed Mhereeg; Alex J Walker; Venexia Walker; Spiros Denaxas; Natasha Kennedy; Srinivasa Vittal Katikireddi; Sinead Brophy,"Swansea University; Swansea University; Swansea University; Swansea University; Datalab, Nuffield Dept of Primary Care Health Science, Radcliffe Primary Care Building, Oxford, OX2 6GG.; University of Bristol; University College London; Swansea University; University of Glasgow; Swansea University","BackgroundTo determine the extent and nature of changes in infected patients healthcare utilization, we studied healthcare contact in the 1-4 weeks and 5-24 weeks following a COVID-19 diagnosis compared to propensity matched controls.

MethodsSurvival analysis was used for time to death and first clinical outcomes including clinical terminology concepts for post-viral illness, fatigue, embolism, respiratory conditions, mental and developmental conditions, fit note, or hospital attendance. Increased instantaneous risk for the occurrence of an outcome for positive individuals was quantified using hazard ratios (HR) from Cox Regression and absolute risk was quantified using relative risk (RR) from life table analysis.

ResultsCompared to matched individuals testing negative, surviving positive community-tested patients had a higher risk of post-viral illness (HR: 4.57, 95%CI: 1.77-11.80, p=0.002), fatigue (HR: 1.47, 95%CI: 1.24-1.75, p<0.001) and embolism (HR: 1.51, 95%CI: 1.13-2.02, p=0.005) at 5-24 weeks post-diagnosis. In the four weeks after COVID-19 higher rates of sick notes were being issued for community-tested (HR: 3.04, 95%CI: 0.88 to 10.50, p<0.079); the risk was reduced after four weeks, compared to controls. Overall healthcare attendance for anxiety, depression was less likely in those with COVID-19 in the first four weeks (HR: 0.83, 95%CI: 0.73-1.06, p=0.007). After four weeks, anxiety, depression is less likely to occur for the positive community-tested individuals (HR: 0.87, 95%CI: 0.77-1.00, p=0.048), but more likely for positive hospital-tested individuals (HR: 1.16, 95%CI: 1.00-1.45, p=0.053). Although statistical associations between positive infection and post-infection healthcare use are clear, the absolute use of healthcare is very.

ConclusionsCommunity COVID-19 disease is associated with increased risks of post-viral illness, fatigue, embolism, depression, anxiety and respiratory conditions. Despite these elevated risks, the absolute healthcare burden is low. Either very small proportions of people experience adverse outcomes following COVID-19 or they are not presenting to healthcare.

Trial registrationData held in SAIL databank are anonymised and therefore, no ethical approval is required. All data in SAIL has the permission from the relevant Caldicott Guardian or Data Protection Officer and SAIL-related projects are required to obtain Information Governance Review Panel (IGRP) approval. The IGRP approval number for this study is 1259.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.04.21.22274150,2022-04-22,https://medrxiv.org/cgi/content/short/2022.04.21.22274150,Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya,Stacey Orangi; John Ojal; Samuel P.C. Brand; Cameline Orlendo; Angela Kairu; Rabia Aziza; Morris Ogero; Ambrose Agweyu; George M Warimwe; Sophie Uyoga; Edward Otieno; Lynette I Ochola-Oyier; Charles N Agoti; Kadondi Kasera; Patrick Amoth; Mercy Mwangangi; Rashid Aman; Wangari Ng'ang'a; Ifedayo M. O Adetifa; J Anthony G Scott; Philip Bejon; Matt J. Keeling; Stefan Flasche; D. James Nokes; Edwine Barasa,"Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, UK.; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya; The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, UK.; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Ministry of Health, Government of Kenya, Nairobi, Kenya; Ministry of Health, Government of Kenya, Nairobi, Kenya; Ministry of Health, Government of Kenya, Nairobi, Kenya; Ministry of Health, Government of Kenya, Nairobi, Kenya; Presidential Policy & Strategy Unit, The Presidency, Government of Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, UK.; The Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya","BackgroundFew studies have assessed the benefits of COVID-19 vaccines in settings where most of the population had been exposed to SARS-CoV-2 infection.

MethodsWe conducted a cost-effectiveness analysis of COVID-19 vaccine in Kenya from a societal perspective over a 1.5-year time frame. An age-structured transmission model assumed at least 80% of the population to have prior natural immunity when an immune escape variant was introduced. We examine the effect of slow (18 months) or rapid (6 months) vaccine roll-out with vaccine coverage of 30%, 50% or 70% of the adult (> 18 years) population prioritizing roll-out in over 50-year olds (80% uptake in all scenarios). Cost data were obtained from primary analyses. We assumed vaccine procurement at $7 per dose and vaccine delivery costs of $3.90-$6.11 per dose. The cost-effectiveness threshold was USD 919.

FindingsSlow roll-out at 30% coverage largely targets over 50-year-olds and resulted in 54% fewer deaths (8,132(7,914 to 8,373)) than no vaccination and was cost-saving (ICER=US$-1,343 (-1,345 to - 1,341) per DALY averted). Increasing coverage to 50% and 70%, further reduced deaths by 12% (810 (757 to 872) and 5% (282 (251 to 317) but was not cost-effective, using Kenyas cost-effectiveness threshold ($ 919.11). Rapid roll-out with 30% coverage averted 63% more deaths and was more cost-saving (ICER=$-1,607 (-1,609 to -1,604) per DALY averted) compared to slow roll-out at the same coverage level, but 50% and 70% coverage scenarios were not cost-effective.

InterpretationWith prior exposure partially protecting much of the Kenyan population, vaccination of young adults may no longer be cost-effective.

KEY QUESTIONSO_ST_ABSWhat is already known?C_ST_ABSO_LIThe COVID-19 pandemic has led to a substantial number of cases and deaths in low-and middle-income countries.
C_LIO_LICOVID-19 vaccines are considered the main strategy of curtailing the pandemic. However, many African nations are still at the early phase of vaccination.
C_LIO_LIEvidence on the cost-effectiveness of COVID-19 vaccines are useful in estimating value for money and illustrate opportunity costs. However, there is a need to balance these economic outcomes against the potential impact of vaccination.
C_LI

What are the new findings?O_LIIn Kenya, a targeted vaccination strategy that prioritizes those of an older age and is deployed at a rapid rollout speed achieves greater marginal health impacts and is better value for money.
C_LIO_LIGiven the existing high-level population protection to COVID-19 due to prior exposure, vaccination of younger adults is less cost-effective in Kenya.
C_LI

What do the new findings imply?O_LIRapid deployment of vaccines during a pandemic averts more cases, hospitalisations, and deaths and is more cost-effective.
C_LIO_LIAgainst a context of constrained fiscal space for health, it is likely more prudent for Kenya to target those at severe risk of disease and possibly other vulnerable populations rather than to the whole population.
C_LI",health economics,fuzzy,100,100
medRxiv,10.1101/2022.04.22.22274176,2022-04-22,https://medrxiv.org/cgi/content/short/2022.04.22.22274176,Association between household composition and severe COVID-19 outcomes in older people by ethnicity: an observational cohort study using the OpenSAFELY platform,Kevin Wing; Daniel J Grint; Rohini Mathur; Hamish Gibbs; George Hickman; Emily Nightingale; Anna Schultze; Harriet Forbes; Vahe Nafilyan; Krishnan Bhaskaran; Elizabeth Williamson; Thomas House; Lorenzo Pellis; Emily Herrett; Nileesa Gautam; Helen J Curtis; Christopher T. Rentsch; Angel Wong; Brian MacKenna; Amir Mehrkar; Seb Bacon; Ian J Douglas; Stephen Evans; Laurie Tomlinson; Ben Goldacre; Rosalind M Eggo,"London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Trop. Med.; University of Bristol; Office for National Statistics; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Manchester; The University of Manchester; London School of Hygiene & Tropical Medicine; Aetion Inc; University of Oxford; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene & Tropical Medicine","Ethnic differences in the risk of severe COVID-19 may be linked to household composition. We quantified the association between household composition and risk of severe COVID-19 by ethnicity for older individuals. With the approval of NHS England, we analysed ethnic differences in the association between household composition and severe COVID-19 in people aged 67 or over in England. We defined households by number of generations living together, and used multivariable Cox regression stratified by location and wave of the pandemic and accounted for age, sex, comorbidities, smoking, obesity, housing density and deprivation. We included 2 692 223 people over 67 years in wave 1 (01/02/2020-31/08/2020) and 2 731 427 in wave 2 (01/09/2020-31/01/2021). Multigenerational living was associated with increased risk of severe COVID-19 for White and South Asian older people in both waves (e.g. wave 2, 67+ living with 3 other generations vs 67+ year olds only: White HR 1{middle dot}61 95% CI 1{middle dot}38-1{middle dot}87, South Asian HR 1{middle dot}76 95% CI 1{middle dot}48-2{middle dot}10), with a trend for increased risks of severe COVID-19 with increasing generations in wave 2. Multigenerational living was associated with severe COVID-19 in older adults. Older South Asian people are over-represented within multigenerational households in England, especially in the most deprived settings. The number of generations in a household, number of occupants, ethnicity and deprivation status are important considerations in the continued roll-out of COVID-19 vaccination and targeting of interventions for future pandemics.

FundingThis research was funded in part, by the Wellcome Trust. For the purpose of open access, the author has applied a CC-BY public copyright licence to any Author Accepted Manuscript version arising from this submission.",epidemiology,fuzzy,100,100
bioRxiv,10.1101/2022.04.20.488895,2022-04-20,https://biorxiv.org/cgi/content/short/2022.04.20.488895,Emergence of new subgenomic mRNAs in SARS-CoV-2,Harriet V Mears; George R Young; Theo Sanderson; Ruth Harvey; Margaret Crawford; Daniel M Snell; Ashley S Fowler; Saira Hussain; Jerome Nicod; Edward Emmott; Katja Finsterbusch; Jakub Luptak; Emma Wall; Bryan Williams; Sonia Gandhi; Charles Swanton; David LV Bauer,"RNA Virus Replication Laboratory, The Francis Crick Institute, London, UK; RNA Virus Replication Laboratory & Bioinformatics and Biostatistics STP, The Francis Crick Institute, London, UK; Malaria Biochemistry Laboratory, The Francis Crick Institute, London, UK; Worldwide Influenza Centre, The Francis Crick Institute, London, UK; Advanced Sequencing Facility, The Francis Crick Institute, London, UK; Advanced Sequencing Facility, The Francis Crick Institute, London, UK; Advanced Sequencing Facility, The Francis Crick Institute, London, UK; RNA Virus Replication Laboratory, The Francis Crick Institute, London, UK; Advanced Sequencing Facility, The Francis Crick Institute, London, UK; Centre for Proteome Research, Department of Biochemistry & Systems Biology, Institute of Systems Molecular & Integrative Biology, University of Liverpool, Liver; Immunoregulation Laboratory, The Francis Crick Institute, London, UK; MRC Laboratory of Molecular Biology, Cambridge, UK; Crick/UCLH Legacy Study, The Francis Crick Institute, London, UK; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) B; University College London; and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre, London, UK; Neurodegeneration Biology Laboratory, The Francis Crick Institute, London, UK; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; RNA Virus Replication Laboratory, The Francis Crick Institute, London, UK","Two mutations occurred in SARS-CoV-2 early during the COVID-19 pandemic that have come to define circulating virus lineages1: first a change in the spike protein (D614G) that defines the B.1 lineage and second, a double substitution in the nucleocapsid protein (R203K, G204R) that defines the B.1.1 lineage, which has subsequently given rise to three Variants of Concern: Alpha, Gamma and Omicron. While the latter mutations appear unremarkable at the protein level, there are dramatic implications at the nucleotide level: the GGG[-&gt;]AAC substitution generates a new Transcription Regulatory Sequence (TRS) motif, driving SARS-CoV-2 to express a novel subgenomic mRNA (sgmRNA) encoding a truncated C-terminal portion of nucleocapsid (N.iORF3), which is an inhibitor of type I interferon production. We find that N.iORF3 also emerged independently within the Iota variant, and further show that additional TRS motifs have convergently evolved to express novel sgmRNAs; notably upstream of Spike within the nsp16 coding region of ORF1b, which is expressed during human infection. Our findings demonstrate that SARS-CoV-2 is undergoing evolutionary changes at the functional RNA level in addition to the amino acid level, reminiscent of eukaryotic evolution. Greater attention to this aspect in the assessment of emerging strains of SARS-CoV-2 is warranted.",microbiology,fuzzy,100,100
medRxiv,10.1101/2022.04.14.22273903,2022-04-20,https://medrxiv.org/cgi/content/short/2022.04.14.22273903,Effects of COVID-19 in Care Homes - A Mixed Methods Review,C Heneghan; M Dietrich; J Brassey; T Jefferson,The University of Oxford; Collateral Global; Trip Database Ltd; The University of Oxford,"IntroductionThe report provides an up-to-date review of the global effects of the COVID-19 pandemic in care homes. We used a mixed methods approach to assess care home mortality by country, how the deaths compared with previous periods, and how excess deaths may be explained. We retrieved national datasets for 25 countries on mortality, 17 cohort studies assessing deaths compared to a previous period, and 16 cohort studies reporting interventions or factors associated with excess mortality.

The COVID-19 pandemic disproportionately impacted those living in care homes at the highest risk for severe outcomes. However, the pandemic only highlighted and exacerbated a long-running problem: underfunding, poor structural layout, undertraining, under-skilling, under-equipping, and finally, lack of humanity in dealing with the most vulnerable members of society.

The 17 cohort studies point to excess mortality worsening during the pandemic. Despite involving vast numbers of care homes around the globe, the quality of the evidence is not good. For example, the majority of the studies infer the cause of extra deaths from the observation window (mainly the spring of 2020) rather than through detailed investigations. This is why we do not draw any clear conclusions about the specific causes of death, apart from noting their significantly high numbers. In addition, we did not review all policy actions since 2020 but note there has been a scarcity of studies since then - an indicator that interest in this problem has waned and likely not been addressed.

Analysis of national datasets for 25 countries shows that care home deaths were, on average, 30% of the total COVID-19 deaths (range: 9-64%). The quality of the current evidence base is limited, short term, and lacks standardised methods to prevent robust countrywide comparisons. Residual excess deaths were also observed, with excess mortality being reported for both COVID-19 positive and negative patients.

Several reported interventions or factors suggest the potential to mitigate the risk in care homes substantially. Interventions that could reduce mortality include improving the care home quality, increasing staffing levels, reducing the number of beds in the facility, employing staff confinement strategies with residents, and improving clinical care such as implementing daily examinations. Some care home solutions like US  Green House homes, which usually have fewer than 12 beds, may provide crucial insights into the care home problem compared with larger homes. Furthermore, care home residents faced barriers accessing emergency treatments during the pandemic waves. Finally, interventions targeting care homes should be subject to smaller trials given large effect sizes in some studies.

Approximately one per cent of the global population resides in care homes, while care home residents account for nearly one-third of deaths attributed to COVID-19 in the 25 countries studied. Reducing this ratio requires analysing current care home infrastructures, funding models, and incentives for providing high-quality care. The scale of the problem in care homes requires robust evaluation and coordinated strategies to improve outcomes for those most vulnerable to COVID-19. Failure to address these systemic problems could mean global care home populations will be similarly affected by future crises and pandemics.",public and global health,fuzzy,90,100
medRxiv,10.1101/2022.04.11.22273690,2022-04-17,https://medrxiv.org/cgi/content/short/2022.04.11.22273690,Evaluation of isotype specific salivary antibody assays for detecting previous SARS-CoV-2 infection in children and adults,Amy C Thomas; Elizabeth Oliver; Holly Baum; Kapil Gupter; Kathryn Shelley; Anna Long; Hayley Jones; Joyce Smith; Benjamin Hitchings; Natalie di Bartolo; Kate Vasileiou; Fruzsina Rabi; Hanin Alamir; Malak Eghleilib; Ore Francis; Jennifer Oliver; Begonia Morales-Aza; Ulrike Obst; Debbie Shattock; Rachael Barr; Lucy Collingwood; Kaltun Duale; Niall Grace; Guillaume Gonnage Livera; Lindsay Bishop; Harriet Downing; Fernanda Rodrigues; Nicholas J Timpson; Caroline J Relton; Ashley Mark Toye; Derek N Woolfson; Imre Berger; Anu Goenka; Andrew  D. Mark Davidson; Kathleen M Gillespie; Alistair JK Williams; Mick Bailey; Ellen Brooks-Pollock; Adam Finn; Alice Halliday; - CoMMinS Study Team,University of Bristol; University of Bristol; University of Bristol; University of Bristol and Imophoron Ltd.; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; Universidade de Coimbra; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; -,"Saliva is easily obtainable non-invasively and potentially suitable for detecting both current and previous SARS-CoV-2 infection. We established 6 standardised enzyme linked immunosorbent assays (ELISA) capable of detecting IgA and IgG antibodies to whole SARS-CoV-2 spike protein, to its receptor binding domain region and to nucleocapsid protein in saliva. In test accuracy (n=320), we found that spike IgG performed best (ROC AUC: 95.0%, 92.8-97.3%), followed by spike IgA (ROC AUC: 89.9%, 86.5-93.2%) for discriminating between pre-pandemic and post COVID-19 saliva samples. Using machine learning, diagnostic performance was improved when a combination of tests was used. As expected, salivary IgA was poorly correlated with serum, indicating an oral mucosal response whereas salivary IgG responses were predictive of those in serum. When deployed to 20 household outbreaks undergoing Delta and Omicron infection, antibody responses were heterogeneous but remained a reliable indicator of recent infection. Intriguingly, unvaccinated children showed evidence of exposure almost exclusively through specific IgA responses in the absence of evidence of viral infection. We have provided robust standardisation, evaluation, and field-testing of salivary antibody assays as tools for monitoring SARS-CoV-2 immune responses. Future work should focus on investigating salivary antibody responses following infection and vaccination to understand patterns of SARS-CoV-2 transmission and inform ongoing vaccination strategies.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.04.14.22272888,2022-04-14,https://medrxiv.org/cgi/content/short/2022.04.14.22272888,Anti-inflammatory therapy with nebulised dornase alfa in patients with severe COVID-19 pneumonia,Joanna Porter; Jamie Inshaw; Vincente Joel Solis; Emma Denneny; Rebecca Evans; Mia I. Temkin; Nathalia De Vasconcelos; Iker Valle Aramburu; Dennis Hoving; Donna Basire; Tracey Crissell; Jesusa Guinto; Alison Webb; Hanif Esmail; Victoria Johnston; Anna Last; Thomas Rampling; Bryan Williams; Aiden Flynn; Pauline Lukey; Veronique Birault; Venizelos Papayannopoulos,"UCL Respiratory, University College London, UK; Exploristics, Belfast, N. Ireland; University College London Hospitals NHS Trust, London, UK; University College London Hospitals NHS Trust, London, UK; University College London Hospitals NHS Trust, London, UK; Antimicrobial Defence lab, The Francis Crick Institute, London, UK; Antimicrobial Defence lab, The Francis Crick Institute, London, UK; Antimicrobial Defence lab, The Francis Crick Institute, London, UK; Antimicrobial Defence lab, The Francis Crick Institute, London, UK; UCL Respiratory, University College London, UK; University College London Hospitals NHS Trust, London, UK; University College London Hospitals NHS Trust, London, UK; University College London Hospitals NHS Trust, London, UK; National Institute for Health Research, University College London Hospital Biomedical Research Centre, UK; National Institute for Health Research, University College London Hospital Biomedical Research Centre, UK; Clinical Research Department, London School of Hygiene and Tropical Medicine, London, UK; National Institute for Health Research, University College London Hospital Biomedical Research Centre, UK; National Institute for Health Research, University College London Hospital Biomedical Research Centre, UK; Exploristics, Belfast, N. Ireland; Target to Treatment Consulting Ltd, Stevenage, UK; Translation, The Francis Crick Institute, London, UK; Antimicrobial Defence lab, The Francis Crick Institute, London, UK","BackgroundSARS-CoV2 infection causes severe, life-threatening pneumonia. Hyper-inflammation, coagulopathy and lymphopenia are associated with pathology and poor outcomes in these patients. Cell-free (cf) DNA is prominent in COVID-19 patients, amplifies inflammation and promotes coagulopathy and immune dysfunction. We hypothesized that cf-DNA clearance by nebulised dornase alfa may reduce inflammation and improve disease outcomes. Here, we evaluated the efficacy of nebulized dornase alfa in patients hospitalised with severe COVID-19 pneumonia.

MethodsIn this randomised controlled single-centre phase 2 proof-of-concept trial, we recruited adult patients admitted to hospital that exhibited stable oxygen saturation ([&ge;]94%) on supplementary oxygen and a C-reactive protein (CRP) level [&ge;]30mg/L post dexamethasone treatment. Participants were randomized at a 3:1 ratio to receive twice-daily nebulised dornase alfa in addition to best available care (BAC) or BAC alone for seven days or until hospital discharge. A 2:1 ratio of historical controls to treated individuals (HC, 2:1) were included as the primary endpoint comparators. The primary outcome was a reduction in systemic inflammation measured by blood CRP levels over 7 days post-randomisation, or to discharge if sooner. Secondary and exploratory outcomes included time to discharge, time on oxygen, D-dimer levels, lymphocyte counts and levels of circulating cf-DNA.

ResultsWe screened 75 patients and enrolled 39 participants out of which 30 in dornase alfa arm, and 9 in BAC group. We also matched the recruited patients in the treated group (N=30) to historical controls in the BAC group (N=60). For the the primary outcome, 30 patients in the dornase alfa were compared to 69 patients in the BAC group. Dornase alfa treatment reduced CRP by 33% compared to the BAC group at 7-days (P=0.01). The dornase alfa group least squares mean CRP was 23.23 mg/L (95% CI 17.71 to 30.46) and the BAC group 34.82 mg/L (95% CI 28.55 to 42.47). A significant difference was also observed when only randomised participants were compared. Furthermore, compared to the BAC group, the chance of live discharge was increased by 63% in the dornase alfa group (HR 1.63, 95% CI 1.01 to 2.61, P=0.03), lymphocyte counts were improved (least-square mean: 1.08 vs 0.87, P=0.02) and markers of coagulopathy such as D-dimer were diminished (least-square mean: 570.78 vs 1656.96g/mL, P=0.004). Moreover, the dornase alfa group exhibited lower circulating cf-DNA levels that correlated with CRP changes over the course of treatment. No differences were recorded in the rates and length of stay in the ICU or the time on oxygen between the groups. Dornase alfa was well-tolerated with no serious adverse events reported.

ConclusionsIn this proof-of-concept study in patients with severe COVID-19 pneumonia, treatment with nebulised dornase alfa resulted in a significant reduction in inflammation, markers of immune pathology and time to discharge. The effectiveness of dornase alfa in patients with acute respiratory infection and inflammation should be investigated further in larger trials.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.04.12.22273752,2022-04-13,https://medrxiv.org/cgi/content/short/2022.04.12.22273752,Protection conferred by vaccine plus previous infection (hybrid immunity) with vaccines of three different platforms during the Omicron variant period in Brazil,Thiago Cerqueira-Silva; Vinicius de Ara√∫jo Oliveira; Enny S. Paix√£o; Pilar Florentino; Gerson O. Penna; Neil Pearce; Guilherme L. Werneck; Maur√≠cio L. Barreto; Viviane S. Boaventura; Manoel Barral-Netto,"Faculdade de Medicina - Universidade Federal da Bahia; Center of Data and Knowledge Integration for Health (CIDACS), Instituto Gon√ßalo Moniz, Fiocruz, Salvador, Bahia, Brazil; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; Instituto de Ci√™ncias Biom√©dicas, Universidade de S√£o Paulo, S√£o Paulo, Brazil; Nu√∫cleo de Medicina Tropical, Universidade de Brasi√≠lia. Escola Fiocruz de Governo, Fiocruz, DF, Brazil; London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK; Universidade Federal do Rio de Janeiro, Rio de Janeiro,Brazil; Instituto de Sa√∫de Coletiva - Universidade Federal da Bahia; Faculdade de Medicina - Universidade Federal da Bahia; Faculdade de Medicina - Universidade Federal da Bahia","Hybrid immunity (infection plus vaccination) provided high protection against infection and severe disease in the periods of delta and gamma variants of concern. However, the protection of hybrid immunity in the Omicron era remains unknown. We performed a test-negative study using Brazilian national databases between January 01 and March 22, 2022, a period of predominant circulation of the Omicron variant in Brazil. Hybrid immunity offered low protection against infection, with rapid waning, compared to unvaccinated with or without previous infection. For severe illness (hospitalisation or death), the protection, although already high for unvaccinated pre-infected increased regardless of the type of vaccine (Ad26.COV2.S, BNT162b2, ChAdOx-1 or CoronaVac).

In conclusion, during the Omicron-dominant period in Brazil, hybrid immunity offered high protection against severe illness and low protection against infection.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.04.06.22273514,2022-04-07,https://medrxiv.org/cgi/content/short/2022.04.06.22273514,"STIMULATE-ICP-Delphi (Symptoms, Trajectory, Inequalities and Management: Understanding Long-COVID to Address and Transform Existing Integrated Care Pathways Delphi): Study Protocol.",Christina M. van der Feltz-Cornelis; Jennifer Sweetman; Gail Allsopp; Emily Attree; Michael G. Crooks; Daniel J. Cuthbertson; Denise Forshaw; Mark Gabbay; Angela Green; Melissa Heightman; Toby Hillman; Lyth Hishmeh; Kamlesh Khunti; Gregory Y.H. Lip; Paula Lorgelly; Hugh Montgomery; W. David Strain; Emma Wall; Caroline Watkins; Nefyn Williams; Dan G. Wootton; Amitava Banerjee,"Dept of Health Sciences, University of York, York, United Kingdom; Hull York Medical School, (HYMS), University of York, York, United Kingdom; Institute of Heal; Dept of Health Sciences, University of York, York, United Kingdom; Royal College of General Practitioners, London, United Kingdom; National Institute of Health and Care Excellence, United Kingdom; CCG NHS Camden, London, United Kingdom; Hull York Medical School, University of Hull, Hull, United Kingdom; Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom; Institute of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, UK; Lancashire Clinical Trials Unit, University of Central Lancashire, Preston, United Kingdom; Department of Primary Care & Mental Health, University of Liverpool, Liverpool, United Kingdom; NIHR ARC NWC, Liverpool, United Kingdom; Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom; Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom; Department of Respiratory Medicine, University College London Hospitals NHS Foundation Trust, London, United Kingdom; UCL Respiratory, University College London; Long COVID SOS, Oxford, United Kingdom; Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester, United Kingdom; Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; Department of Clinical Med; School of Population Health and Department of Economics, University of Auckland, New Zealand; Institute of Epidemiology and Health Care, University College Lond; Department of Medicine, University College London, London, United Kingdom; Diabetes and Vascular Medicine Research Centre, Institute of Biomedical and Clinical Science and College of Medicine and Health, University of Exeter, Exeter, U; Francis Crick Institute, 1, Midland Road, London, United Kingdom; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biome; Lancashire Clinical Trials Unit, University of Central Lancashire, Preston, United Kingdom; Faculty of Health and Care, University of Central Lancashire, Presto; Department of Primary Care and Mental Health, University of Liverpool, Liverpool, United Kingdom; Institute of Infection Veterinary and Ecological Sciences and NIHR HPRU in Emerging and Zoonotic Infections, University of Liverpool, United Kingdom; Liverpool ; Institute of Health Informatics, University College London, London, United Kingdom; Department of Cardiology, University College London Hospitals NHS Trust, Lon","IntroductionAs mortality rates from COVID-19 disease fall, the high prevalence of long-term sequelae (Long COVID) is becoming increasingly widespread, challenging healthcare systems globally. Traditional pathways of care for Long Term Conditions (LTCs) have tended to be managed by disease-specific specialties, an approach that has been ineffective in delivering care for patients with multi-morbidity. The multi-system nature of Long COVID and its impact on physical and psychological health demands a more effective model of holistic, integrated care. The evolution of integrated care systems (ICSs) in the UK presents an important opportunity to explore areas of mutual benefit to LTC, multi-morbidity and Long COVID care. There may be benefits in comparing and contrasting ICPs for Long COVID with ICPs for other LTCs.

Methods and analysisThis study aims to evaluate health services requirements for ICPs for Long COVID and their applicability to other LTCs including multi-morbidity and the overlap with medically not yet explained symptoms (MNYES). The study will follow a Delphi design and involve an expert panel of stakeholders including people with lived experience, as well as clinicians with expertise in Long COVID and other LTCs. Study processes will include expert panel and moderator panel meetings, surveys, and interviews. The Delphi process is part of the overall STIMULATE-ICP programme, aimed at improving integrated care for people with Long COVID.

Ethics and disseminationEthical approval for this Delphi study has been obtained (Research Governance Board of the University of York) as have approvals for the other STIMULATE-ICP studies. Study outcomes are likely to inform policy for ICPs across LTCs. Results will be disseminated through scientific publication, conference presentation and communications with patients and stakeholders involved in care of other LTCs and Long COVID.

RegistrationResearchregistry: https://www.researchregistry.com/browse-the-registry#home/registrationdetails/6246bfeeeaaed6001f08dadc/.",health systems and quality improvement,fuzzy,100,100
medRxiv,10.1101/2022.04.04.22273427,2022-04-05,https://medrxiv.org/cgi/content/short/2022.04.04.22273427,Sustained patient use and improved outcomes with digital transformation of a COPD service: RECEIVER trial and DYNAMIC-SCOT COVID-19 scale-up response.,Anna Taylor; Andrew Cushing; Morgan Dow; Jacqueline Anderson; Grace McDowell; Maureen Manthe; Sandosh Padmanabhan; Shane Burns; Paul McGineess; David J Lowe; Christopher M Carlin,"Queen Elizabeth University Hospital, Glasgow; LenusHealth, Edinburgh; LenusHealth, Edinburgh; Queen Elizabeth University Hospital, Glasgow; Queen Elizabeth University Hospital, Glasgow; Queen Elizabeth University Hospital, Glasgow; Institute of Cardiovascular and Medical Sciences, University of Glasgow; LenusHealth, Edinburgh; LenusHealth, Edinburgh; Queen Elizabeth University Hospital, Glasgow; Queen Elizabeth University Hospital, Glasgow","IntroductionLenusCOPD has been co-designed to enable digital transformation of COPD services for proactive preventative care. Patient-facing progressive web application, clinician dashboard and support website integrate patient-reported outcomes (PROs), self-management resources, structured clinical summary, wearable and home NIV data with asynchronous patient-clinician messaging. We commenced the implementation-effectiveness observational cohort RECEIVER trial in September 2019, with the primary endpoint of sustained patient usage and secondary endpoints including admissions, mortality, exacerbations, service workload and quality of life. We paused recruitment in March 2021 and provided LenusCOPD as routine care in the ""DYNAMIC-SCOT"" COVID-19 response service scale-up.

Methods83 RECEIVER trial participants and 142 DYNAMIC-SCOT participants had completed minimum 1 year follow-up when we censored data on 31st August 2021. We established a control cohort with 5 patients matched per RECEIVER participant from de-identified contemporary routine clinical data.

ResultsSustained patient app utilisation was noted in both cohorts. Median time to admission or death was 43 days in control, 338 days in RECEIVER and 400 days in DYNAMIC-SCOT participants who had had a respiratory-related admission in the preceding year. The 12-month risk of admission or death was 74% in control patients, 53% in RECEIVER and 47% in the DYNAMIC-SCOT sub-cohort participants. There was a median of 2.5 COPD exacerbations per patient per year with stable quality of life across follow up and a manageable workload for clinical users.

ConclusionsA high proportion of people continued to use the co-designed LenusCOPD application during extended follow-up. Outcome data supports scale-up of this digital service transformation.

Key messages

What is the key question?Can sustained patient interaction and improved patient outcomes be achieved with digital transformation of a COPD service?

What is the bottom line?Participants continue to use the LenusCOPD patient app, with an average of 3-3.5 interactions per person per week sustained >1-year post-onboarding. COPD- related hospital admissions and occupied bed days were reduced following LenusCOPD onboarding in participants with a history of a severe exacerbation in the previous year, with a median time to readmission of 380 days compared with 50 days in a contemporary matched control patient cohort.

Why read on?Feasibility and utility results support scale-up adoption of these digital tools, to support optimised co-management of COPD and other long-term conditions within a continuous implementation-evaluation framework. This will establish a test-bed infrastructure for additional innovations including artificial intelligence-insights for MDT decision support.",respiratory medicine,fuzzy,100,91
medRxiv,10.1101/2022.04.03.22272610,2022-04-04,https://medrxiv.org/cgi/content/short/2022.04.03.22272610,Cardiac impairment in Long Covid 1-year post-SARS-CoV-2 infection,Adriana Roca-Fernandez; Malgorzata Wamil; Alison Telford; Valentina Carapella; Alessandra Borlotti; David Monteiro; Helena Thomaides-Brears; Matthew D Kelly; Andrea Dennis; Rajarshi Banerjee; Matthew Robson; Michael Brady; Gregory Lip; Sacha Bull; Melissa J Heightman; Ntobeko Ntusi; Amitava Banerjee,"Perspectum Diagnostics; Great Western Hospital Foundation NHS Trust, Swindon, UK; Perspectum Ltd; Perspectum Ltd; Perspectum Ltd; Perspectum Ltd; Perspectum Ltd; Perspectum Ltd; Perspectum Ltd; Perspectum Ltd; Perspectum Ltd; Perspectum Ltd; University of Liverpool; Royal Berkshire Hospital, Reading; UCLH; University of Cape Town, Cape Town, South Africa; University College London","BackgroundLong Covid is associated with multiple symptoms and impairment in multiple organs. Cardiac impairment has been reported to varying degrees by varying methodologies in cross-sectional studies. Using cardiac magnetic resonance (CMR), we investigated the 12-month trajectory of cardiac impairment in individuals with Long Covid.

Methods534 individuals with Long Covid underwent baseline CMR (T1 and T2 mapping, cardiac mass, volumes, function, and strain) and multi-organ MRI at 6 months (IQR 4.3,7.3) since first post-COVID-19 symptoms and 330 were rescanned at 12.6 (IQR 11.4, 14.2) months if abnormal findings were reported at baseline. Symptoms, standardised questionnaires, and blood samples were collected at both timepoints. Cardiac impairment was defined as one or more of: low left or right ventricular ejection fraction (LVEF and RVEF), high left or right ventricular end diastolic volume (LVEDV and RVEDV), low 3D left ventricular global longitudinal strain (GLS), or elevated native T1 in [&ge;]3 cardiac segments. A significant change over time was reported by comparison with 92 healthy controls.

ResultsThe technical success of this multiorgan assessment in non-acute settings was 99.1% at baseline, and 98.3% at follow up, with 99.6% and 98.8% for CMR respectively. Of individuals with Long Covid, 102/534 [19%] had cardiac impairment at baseline; 71/102 had complete paired data at 12 months. Of those, 58% presented with ongoing cardiac impairment at 12 months. High sensitivity cardiac troponin I and B-type natriuretic peptide were not predictive of CMR findings, symptoms, or clinical outcomes. At baseline, low LVEF, high RVEDV and low GLS were associated with cardiac impairment. Low LVEF at baseline was associated with persistent cardiac impairment at 12 months.

ConclusionCardiac impairment, other than myocarditis, is present in 1 in 5 individuals with Long Covid at 6 months, persisting in over half of those at 12 months. Cardiac-related blood biomarkers are unable to identify cardiac impairment in Long COVID. Subtypes of disease (based on symptoms, examination, and investigations) and predictive biomarkers are yet to be established. Interventional trials with pre-specified subgroup analyses are required to inform therapeutic options.",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2022.03.29.22272997,2022-04-04,https://medrxiv.org/cgi/content/short/2022.03.29.22272997,Glasses and risk of COVID-19 transmission - analysis of the Virus Watch Community Cohort study.,Annalan Mathew Dwight Navaratnam; Chris O'Callaghan; Sarah Beale; Vincent Nguyen; Anna Aryee; Isobel Braithwaite; Thomas E Byrne; Wing Lam Erica Fong; Ellen Fragaszy; Cyril Geismar; Susan Hoskins; Jana Kovar; Parth Patel; Madhumita Shrotri; Sophie Weber; Alexei Yavlinsky; Robert W Aldridge; Andrew C Hayward,University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London,"BackgroundRespiratory viruses, including SARS-CoV-2, can infect the eyes or pass into the nose via the nasolacrimal duct. The importance of transmission via the eyes is unknown but might plausibly be reduced in those who wear glasses. Previous studies have mainly focussed on protective eyewear in healthcare settings.

MethodsParticipants from the Virus Watch prospective community cohort study in England and Wales responded to a questionnaire on the use of glasses and contact lenses. This included frequency of use, purpose, and likelihood of wearing a mask with glasses. Infection was confirmed through data linkage with Second Generation Surveillance System (Pillar 1 and Pillar 2), weekly questionnaires to self-report positive polymerase chain reaction or lateral flow results, and, for a subgroup, monthly capillary blood testing for antibodies (nucleocapsid and spike). A multivariable logistic regression model, controlling for age, sex, income and occupation, was used to identify odds of infection depending on the frequency and purpose of using glasses or contact lenses.

Findings19,166 Virus Watch participants responded to the questionnaire, with 13,681 (71.3%, CI 70.7-72.0) reporting they wore glasses. A multivariable logistic regression model showed a 15% lower odds of infection for those who reported using glasses always for general use (OR 0.85, 95% 0.77-0.95, p = 0.002) compared to those who never wore glasses. The protective effect was reduced in those who said that wearing glasses interfered with mask wearing. No protective effect was seen for contact lens wearers.

InterpretationPeople who wear glasses have a moderate reduction in risk of COVID-19 infection highlighting the importance of the eye as a route of infection. Eye protection may make a valuable contribution to the reduction of transmission in community and healthcare settings.

FundingThe research costs for the study have been supported by the MRC Grant Ref: MC_PC 19070 awarded to UCL on 30 March 2020 and MRC Grant Ref: MR/V028375/1 awarded on 17 August 2020. The study also received $15,000 of Facebook advertising credit to support a pilot social media recruitment campaign on 18th August 2020. The study also received funding from the UK Government Department of Health and Social Cares Vaccine Evaluation Programme to provide monthly Thriva antibody tests to adult participants. This study was supported by the Wellcome Trust through a Wellcome Clinical Research Career Development Fellowship to RA [206602]. Funding from the HSE Protect study, GOSH Childrens Charity and the Great Ormond Street Hospital BRC supported the involvement of CO in the project.

Research in contextO_ST_ABSEvidence before the studyC_ST_ABSDespite the risk of SARS-CoV-2 transmission via the eyes, very few countries have advocated eye protection to reduce transmission amongst the public and, except when providing close care for those known or suspected to be infected, is variable and based on case-by-case assessment of exposure risk. The mechanism, but not the extent, of the transmission route through the eyes is well described in the literature, with several studies reporting detection of SARS-CoV-2 RNA in the tear film, conjunctiva and conjunctival sac. There have been a small number of hospital based observational studies suggesting that eye protection may help prevent COVID-19 infection. A literature search was carried out on 23rd February 2022 across Medline and Embase using the search terms  eyewear,  glasses,  SARS-CoV-2,  COVID-19,  SARS,  transmission and  infectivity, providing 105 manuscripts. Of these, only eight investigated the risk of infection associated with eye protection, all in hospital settings or followed a cohort of healthcare workers. Among the studies was a systematic review that identified 5 observational studies from 898 articles that were screened. The cohort study with the largest sample size, 345 healthcare professionals, demonstrated a relative risk of 10.25 (95% CI 1.28-82.39; P = 0.009) for infection when not using eye protection. No studies of the potential protective effect of glasses wearing, for visual correction, in community settings were identified.

Added value of this studyThe Virus Watch study is a prospective community household study across England and Wales. 19,166 participants responded to the monthly questionnaire on glasses and contact lens use, assessing reported frequency, the purpose of use and how likely they were to wear a mask with glasses. Infections were identified in data linked to the Second Generation Surveillance System (Pillar 1 and Pillar 2 testing), weekly surveys seeking self-reports of polymerase chain reaction or lateral flow device results and, in a subset of 11,701, self-collected capillary blood testing for antibodies (nucleocapsid and spike - nucleocapsid antibodies were taken as evidence of prior infection as these are unaffected by vaccination). Our multivariable logistic regression model, controlling for age, sex, household income and occupation, demonstrated 15% lower odds of infection for those who reported always using glasses for general use compared to those who never wear glasses. The protective effect was not observed in those who strongly agreed with the statement,  I am less likely to wear a face covering when I have my glasses on because my glasses steam up. Counterfactual analysis of contact lenses did not suggest a protective effect regardless of frequency of use.

Implications of all the available evidenceThe findings of this study demonstrate a moderate reduction in risk of SARS-CoV-2 infection in those who always wear glasses compared to never. Unlike other studies, our results are representative of a community setting, adjust for potential confounders and provide a counterfactual analysis with contact lenses. This extends the current evidence to community settings and validates proposed biological mechanisms of eye protection reducing the risk of SARS-CoV-2 transmission.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.03.29.22273042,2022-04-04,https://medrxiv.org/cgi/content/short/2022.03.29.22273042,The new normal? Dynamics and scale of the SARS-CoV-2 variant Omicron epidemic in England,Oliver Eales; Leonardo de Oliveira Martins; Andrew Page; Haowei Wang; Barbara Bodinier; David Tang; David Haw; Jakob Jonnerby; Christina Atchison; Deborah Ashby; Wendy Barclay; Graham Taylor; Graham Cooke; Helen Ward; Ara Darzi; Steven Riley; Paul Elliott; Christl A Donnelly; Marc Chadeau-Hyam,"Imperial College London; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Environment and Health, School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Environment and Health, School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Environment and Health, School of Public Health, Imperial College London, UK","The SARS-CoV-2 pandemic has been characterised by the regular emergence of genomic variants which have led to substantial changes in the epidemiology of the virus. With natural and vaccine-induced population immunity at high levels, evolutionary pressure favours variants better able to evade SARS-CoV-2 neutralising antibodies. The Omicron variant was first detected in late November 2021 and exhibited a high degree of immune evasion, leading to increased infection rates in many countries. However, estimates of the magnitude of the Omicron wave have relied mainly on routine testing data, which are prone to several biases. Here we infer the dynamics of the Omicron wave in England using PCR testing and genomic sequencing obtained by the REal-time Assessment of Community Transmission-1 (REACT-1) study, a series of cross-sectional surveys testing random samples of the population of England. We estimate an initial peak in national Omicron prevalence of 6.89% (5.34%, 10.61%) during January 2022, followed by a resurgence in SARS-CoV-2 infections in England during February-March 2022 as the more transmissible Omicron sub-lineage, BA.2 replaced BA.1 and BA.1.1. Assuming the emergence of further distinct genomic variants, intermittent epidemics of similar magnitude as the Omicron wave may become the  new normal.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.03.24.22272899,2022-03-25,https://medrxiv.org/cgi/content/short/2022.03.24.22272899,Tracking population mental health before and across stages of the COVID-19 pandemic in young adults,Alex Siu Fung Kwong; Kate Northstone; Rebecca M Pearson; Andrew M McIntosh; Nicholas J Timpson,University of Bristol; University of Bristol; University of Bristol; University of Edinburgh; University of Bristol,"The SARS-CoV-2 (COVID-19) pandemic has been associated with worsening mental health. Longitudinal studies have monitored changes in mental health from pre-pandemic levels, identifying critical points for mental health as COVID-19 restrictions evolve. Here we highlight changes in depression and anxiety in the UK from pre-pandemic across four pandemic occasions: April and June 2020, January, and July 2021 - corresponding to changes in COVID-19 restrictions. Data were from >5,000 27-29-year-olds from the Avon Longitudinal Study of Parents and Children (ALSPAC). We found that anxiety almost doubled throughout the pandemic compared to pre-pandemic levels and remained high until July 2021 when COVID-19 restrictions were fully lifted. Depression was lower than pre-pandemic levels in April 2020 but increased as the pandemic evolved until July 2021. Women, those with existing mental/physical health conditions and those with economic hardship were most at risk of sustained poorer mental health across the pandemic. Our results highlight the importance of longitudinal studies for tracking mental health during the COVID-19 pandemic and across virus suppression policy changes.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2022.03.22.22271707,2022-03-23,https://medrxiv.org/cgi/content/short/2022.03.22.22271707,Vitamin D Supplements for Prevention of Covid-19 or other Acute Respiratory Infections: a Phase 3 Randomized Controlled Trial (CORONAVIT),David Jolliffe; Hayley Holt; Matthew Greenig; Mohammad Talaei; Natalia Perdek; Paul Pfeffer; Giulia Vivaldi; Sheena Maltby; Jane Symons; Nicola Barlow; Alexa Normandale; Rajvinder Garcha; Alex Richter; Sian Faustini; Christopher Orton; David Ford; Ronan Lyons; Gwyneth Davies; Frank Kee; Christopher Griffiths; John Norrie; Aziz Sheikh; Seif Shaheen; Clare Relton; Adrian Martineau,Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Jane Symons Media; City Hospital Birmingham; City Hospital Birmingham; City Hospital Birmingham; University of Birmingham; University of Birmingham; Swansea University; Swansea University; Swansea University; Swansea University; Queen's University Belfast; Queen Mary University of London; University of Edinburgh; University of Edinburgh; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London,"OBJECTIVESTo determine whether population-level implementation of a test-and- treat approach to correction of sub-optimal vitamin D status (25-hydroxyvitamin D [25(OH)D] <75 nmol/L) influences risk of all-cause acute respiratory infection (ARI) or coronavirus disease 2019 (COVID-19).

DESIGNPhase 3 open-label randomised controlled trial (CORONAVIT) utilising trials-within-cohorts (TwiCs) methodology.

SETTINGUnited Kingdom.

PARTICIPANTS6200 adults aged 16 years or older, who were not already taking vitamin D supplements at baseline.

INTERVENTIONSOffer of a postal finger-prick test of blood 25(OH)D concentration with provision of a 6-month supply of higher-dose vitamin D (3200 IU/day, n=1550) or lower-dose vitamin D (800 IU/day, n=1550) to those with blood 25(OH)D concentration <75 nmol/L, vs. no offer of testing or supplementation (n=3100). Follow-up was from 17th December 2020 to 16th June 2021.

MAIN OUTCOME MEASURESThe primary outcome was the proportion of participants experiencing at least one doctor- or swab test-confirmed ARI of any cause. Secondary outcomes included the proportion of participants developing swab test-confirmed COVID-19. Logistic regression was used to calculate odds ratios and associated 95% confidence intervals.

RESULTSOf 3100 participants offered 25(OH)D testing, 2958 (95.4%) accepted, and 2690 (86.8%) had 25(OH)D <75 nmol/L and were sent vitamin D supplements (1356 higher-dose, 1334 lower-dose). 76 (5.0%) vs. 87 (5.7%) vs. 136 (4.6%) participants in higher-dose vs. lower-dose vs. no offer groups experienced at least one ARI of any cause (odds ratio [OR] for higher-dose vs. no offer 1.09, 95% CI 0.82-1.46; lower-dose vs. no offer 1.26, 0.96-1.66). 45 (3.0%) vs. 55 (3.6%) vs. 78 (2.6%) participants in higher-dose vs. lower-dose vs. no offer groups developed COVID-19 (OR for higher-dose vs. no offer 1.13, 0.78-1.63; lower-dose vs. no offer 1.39, 0.98-1.97).

CONCLUSIONSAmong adults with a high baseline prevalence of sub-optimal vitamin D status, implementation of a population-level test-and-treat approach to vitamin D replacement did not reduce risk of all-cause ARI or COVID-19.

TRIAL REGISTRATIONClinicalTrials.gov no. NCT04579640

SUMMARY BOXO_ST_ABSWhat is already known on this topic?C_ST_ABSVitamin D metabolites support innate immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other respiratory pathogens. Sub-optimal vitamin D status (25-hydroxyvitamin D <75 nmol/L) associates with increased susceptibility to all-cause acute respiratory infections (ARI) and coronavirus disease 2019 (COVID-19). Phase 3 randomised controlled trials of vitamin D to prevent COVID-19 have not yet reported.

What this study addsThis phase 3 randomised controlled trial, including 6200 participants, shows that implementation of a population-level test-and-treat approach to oral vitamin D replacement at a dose of 800 IU or 3200 IU per day did not reduce risk of all-cause ARI or COVID-19 among adults with a high baseline prevalence of sub-optimal vitamin D status.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.03.22.22272775,2022-03-23,https://medrxiv.org/cgi/content/short/2022.03.22.22272775,Risk of death following SARS-CoV-2 infection or COVID-19 vaccination in young people in England: a self-controlled case series study,Vahe Nafilyan; Charlotte Bermingham; Isobel L Ward; Jasper Morgan; Francesco Zaccardi; Kamlesh Khunti; Julie Stanborough; Amitava Banerjee,"Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Real World Evidence Unit, Diabetes Research Centre, University of Leicester; Real World Evidence Unit, Diabetes Research Centre, University of Leicester; Office for National Statistics; Institute of Health Informatics, University College London","ObjectivesTo assess whether there is a change in the incidence of cardiac and all-cause death in young people following COVID-19 vaccination or SARS-CoV-2 infection in unvaccinated individuals.

DesignSelf-controlled case series.

SettingNational, linked electronic health record data in England.

Study populationIndividuals aged 12-29 who had received at least one dose of COVID-19 vaccination and died between 8 December 2020 and 2 February 2022 and registered by 16 February 2022 within 12 weeks of COVID-19 vaccination; Individuals aged 12-29 who died within 12 weeks of testing positive for SARS-CoV-2.

Main outcome measuresCardiac and all-cause deaths occurring within 12 weeks of vaccination or SARS-CoV-2 infection.

ResultsCompared to the baseline period, there was no evidence of a change in the incidence of cardiac death in the six weeks after vaccination, whether for each of weeks 1 to 6 or the whole six-week period. There was a decrease in the risk of all-cause death in the first week after vaccination and no change in each of weeks 2 to 6 after vaccination or whole six-week period after vaccination. Subgroup analyses by sex, age, vaccine type, and last dose also showed no change in the risk of death in the first six weeks after vaccination. There was a large increase in the incidence of cardiac and all-cause death in the overall risk period after SARS-CoV-2 infection among the unvaccinated.

ConclusionThere is no evidence of an association between COVID-19 vaccination and an increased risk of death in young people. By contrast, SARS-CoV-2 infection was associated with substantially higher risk of cardiac related death and all-cause death.

What is already known on this topicSeveral studies have highlighted the association between COVID-19 vaccination and the risk of myocarditis, myopericarditis, and other cardiac problems, especially in young people, but associated risk of mortality is unclear. Since younger people have lower risk of COVID-19 hospitalisation and mortality, the mortality risk associated with vaccination is potentially more important to them in balancing the risk and benefit of vaccination.

What this study addsAlthough there is a risk of myocarditis or myopericarditis with COVID-19, there is no evidence of increased risk of cardiac or all-cause mortality following COVID-19 vaccination in young people aged 12 to 29. Given the increased risk of mortality following SARS-CoV-2 infection in this group, the risk-benefit analysis favours COVID-19 vaccination for this age group.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.03.23.22272804,2022-03-23,https://medrxiv.org/cgi/content/short/2022.03.23.22272804,Waning effectiveness of BNT162b2 and ChAdOx1 COVID-19 vaccines over six months since second dose: a cohort study using linked electronic health records,Elsie MF Horne; William J Hulme; Ruth H Keogh; Tom M Palmer; Elizabeth J Williamson; Edward PK Parker; Amelia Green; Venexia Walker; Alex J Walker; Helen Curtis; Louis Fisher; Brian MacKenna; Richard Croker; Lisa Hopcroft; Robin Y Park; Jon Massey; Jessica Morely; Amir Mehrkar; Sebastian Bacon; David Evans; Peter Inglesby; Caroline E Morton; George Hickman; Simon Davy; Tom Ward; Iain Dillingham; Ben Goldacre; Miguel A Hernan; Jonathan AC Sterne,University of Bristol; Univeristy of Oxford; London School of Hygiene and Tropical Medicine; University of Bristol; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Univeristy of Oxford; University of Bristol; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Univeristy of Oxford; Harvard University; University of Bristol,"BackgroundThe rate at which COVID-19 vaccine effectiveness wanes over time is crucial for vaccination policies, but is incompletely understood with conflicting results from different studies.

MethodsThis cohort study, using the OpenSAFELY-TPP database and approved by NHS England, included individuals without prior SARS-CoV-2 infection assigned to vaccines priority groups 2-12 defined by the UK Joint Committee on Vaccination and Immunisation. We compared individuals who had received two doses of BNT162b2 or ChAdOx1 with unvaccinated individuals during six 4-week comparison periods, separately for subgroups aged 65+ years; 16-64 years and clinically vulnerable; 40-64 years and 18-39 years. We used Cox regression, stratified by first dose eligibility and geographical region and controlled for calendar time, to estimate adjusted hazard ratios (aHRs) comparing vaccinated with unvaccinated individuals, and quantified waning vaccine effectiveness as ratios of aHRs per-4-week period. The outcomes were COVID-19 hospitalisation, COVID-19 death, positive SARS-CoV-2 test, and non-COVID-19 death.

FindingsThe BNT162b2, ChAdOx1 and unvaccinated groups comprised 1,773,970, 2,961,011 and 2,433,988 individuals, respectively. Waning of vaccine effectiveness was similar across outcomes and vaccine brands: e.g. in the 65+ years subgroup ratios of aHRs versus unvaccinated for COVID-19 hospitalisation, COVID-19 death and positive SARS-CoV-2 test ranged from 1.23 (95% CI 1.15-1.32) to 1.27 (1.20-1.34) for BNT162b2 and 1.16 (0.98-1.37) to 1.20 (1.14-1.27) for ChAdOx1. Despite waning, rates of COVID-19 hospitalisation and COVID-19 death were substantially lower among vaccinated individuals compared to unvaccinated individuals up to 26 weeks after second dose, with estimated aHRs <0.20 (>80% vaccine effectiveness) for BNT162b2, and <0.26 (>74%) for ChAdOx1. By weeks 23-26, rates of SARS-CoV-2 infection in fully vaccinated individuals were similar to or higher than those in unvaccinated individuals: aHRs ranged from 0.85 (0.78-0.92) to 1.53 (1.07-2.18) for BNT162b2, and 1.21 (1.13-1.30) to 1.99 (1.94-2.05) for ChAdOx1.

InterpretationThe rate at which estimated vaccine effectiveness waned was strikingly consistent for COVID-19 hospitalisation, COVID-19 death and positive SARS-CoV-2 test, and similar across subgroups defined by age and clinical vulnerability. If sustained to outcomes of infection with the Omicron variant and to booster vaccination, these findings will facilitate scheduling of booster vaccination doses.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.03.18.22272607,2022-03-21,https://medrxiv.org/cgi/content/short/2022.03.18.22272607,"Multi-organ impairment and Long COVID: a 1-year prospective, longitudinal cohort study",Andrea Dennis; Daniel J Cuthbertson; Dan Wootton; Michael Crooks; Mark Gabbay; Nicole Eichert; Sofia Mouchti; Michele Pansini; Adriana Roca-Fernandez; Helena Thomaides-Brears; Matt Kelly; Matthew Robson; Lyth Hishmeh; Emily Attree; Melissa J Heightman; Rajarshi Banerjee; Amitava Banerjee,Perspectum Ltd; University of Liverpool; University of Liverpool; University of Hull; University of Liverpool; Perspectum Ltd; Perspectum Ltd; Perspectum Ltd; Perspectum Diagnostics; Perspectum Ltd; Perspectum Ltd; Perspectum Ltd; Long COVID SoS; UKDoctors#Longcovid; UCLH; Perspectum Ltd; University College London,"ImportanceMulti-organ impairment associated with Long COVID is a significant burden to individuals, populations and health systems, presenting challenges for diagnosis and care provision. Standardised assessment across multiple organs over time is lacking, particularly in non-hospitalised individuals.

ObjectiveTo determine the prevalence of organ impairment in Long COVID patients at 6 and at 12 months after initial symptoms and to explore links to clinical presentation.

DesignThis was a prospective, longitudinal study in individuals following recovery from acute COVID-19. We assessed symptoms, health status, and multi-organ tissue characterisation and function, using consensus definitions for single and multi-organ impairment. Physiological and biochemical investigations were performed at baseline on all individuals and those with organ impairment were reassessed, including multi-organ MRI, 6 months later.

SettingTwo non-acute settings (Oxford and London).

Participants536 individuals (mean 45 years, 73% female, 89% white, 32% healthcare workers, 13% acute COVID-19 hospitalisation) completed baseline assessment (median: 6 months post-COVID-19). 331 (62%) with organ impairment or incidental findings had follow up, with reduced symptom burden from baseline (median number of symptoms: 10 and 3, at 6 and 12 months).

ExposureSARS-CoV-2 infection 6 months prior to first assessment.

Main outcomePrevalence of single and multi-organ impairment at 6 and 12 months post-COVID-19.

ResultsExtreme breathlessness (36% and 30%), cognitive dysfunction (50% and 38%) and poor health-related quality of life (EQ-5D-5L<0.7; 55% and 45%) were common at 6 and 12 months, and associated with female gender, younger age and single organ impairment. At baseline, there was fibro-inflammation in the heart (9%), pancreas (9%), kidney (15%) and liver (11%); increased volume in liver (7%), spleen (8%) and kidney (9%); decreased capacity in lungs (2%); and excessive fat deposition in the liver (25%) and pancreas (15%). Single and multi-organ impairment were present in 59% and 23% at baseline, persisting in 59% and 27% at follow-up.

Conclusion and RelevanceOrgan impairment was present in 59% of individuals at 6 months post-COVID-19, persisting in 59% of those followed up at 1 year, with implications for symptoms, quality of life and longer-term health, signalling need for prevention and integrated care of Long COVID.

Trial RegistrationClinicalTrials.gov Identifier: NCT04369807

Key pointsO_LIQuestion: What is the prevalence of organ impairment in Long COVID at 6- and 12-months post-COVID-19?
C_LIO_LIFindings: In a prospective study of 536 mainly non-hospitalised individuals, symptom burden decreased, but single organ impairment persisted in 59% at 12 months post-COVID-19.
C_LIO_LIMeaning: Organ impairment in Long COVID has implications for symptoms, quality of life and longer-term health, signalling need for prevention and integrated care of Long COVID.
C_LI",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.03.17.22272414,2022-03-18,https://medrxiv.org/cgi/content/short/2022.03.17.22272414,Modelling the impact of non-pharmaceutical interventions on workplace transmission of SARS-CoV-2 in the home-delivery sector,Carl A Whitfield; Martie Van Tongeren; Yang Han; Hua Wei; Sarah A Daniels; Martyn Regan; David W Denning; Arpana Verma; Lorenzo Pellis; - University of Manchester COVID-19 Modelling Group; Ian Hall,University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchaster; University of Manchester; University of Manchester; ; University of Manchester,"ObjectiveWe aimed to use mathematical models of SARS-COV-2 to assess the potential efficacy of non-pharmaceutical interventions on transmission in the parcel delivery and logistics sector.

MethodsWe developed a network-based model of workplace contacts based on data and consultations from companies in the parcel delivery and logistics sectors. We used these in stochastic simulations of disease transmission to predict the probability of workplace outbreaks in this settings. Individuals in the model have different viral load trajectories based on SARS-CoV-2 in-host dynamics, which couple to their infectiousness and test positive probability over time, in order to determine the impact of testing and isolation measures.

ResultsThe baseline model (without any interventions) showed different workplace infection rates for staff in different job roles. Based on our assumptions of contact patterns in the parcel delivery work setting we found that when a delivery driver was the index case, on average they infect only 0.14 other employees, while for warehouse and office workers this went up to 0.65 and 2.24 respectively. In the LIDD setting this was predicted to be 1.40, 0.98, and 1.34 respectively. Nonetheless, the vast majority of simulations resulted in 0 secondary cases among customers (even without contact-free delivery). Our results showed that a combination of social distancing, office staff working from home, and fixed driver pairings (all interventions carried out by the companies we consulted) reduce the risk of workplace outbreaks by 3-4 times.

ConclusionThis work suggests that, without interventions, significant transmission could have occured in these workplaces, but that these posed minimal risk to customers. We found that identifying and isolating regular close-contacts of infectious individuals (i.e. house-share, carpools, or delivery pairs) is an efficient measure for stopping workplace outbreaks. Regular testing can make these isolation measures even more effective but also increases the number of staff isolating at one time. It is therefore more efficient to use these isolation measures in addition to social distancing and contact reduction interventions, rather than instead of, as these reduce both transmission and the number of people needing to isolate at one time.

Author summaryDuring the COVID-19 pandemic the home-delivery sector was vital to maintaining peoples access to certain goods, and sustaining levels of economic activity for a variety of businesses. However, this important work necessarily involved contact with a large number of customers as well as colleagues. This means that questions have often been raised about whether enough was being done to keep customers and staff safe. Estimating the potential risk to customers and staff is complex, but here we tackle this problem by building a model of workplace and customer contacts, from which we simulate SARS-CoV-2 transmission. By involving industry representatives in the development of this model, we have simulated interventions that have either been applied or considered, and so the findings of this study are relevant to decisions made in that sector. Furthermore, we can learn generic lessons from this specific case study which apply to many types of shared workplace as well as highlighting implications of the highly stochastic nature of disease transmission in small populations.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.03.17.22272535,2022-03-18,https://medrxiv.org/cgi/content/short/2022.03.17.22272535,Comparison of the 2021 COVID-19 'Roadmap' Projections against Public Health Data,Matt J Keeling; Louise J Dyson; Michael Tildesley; Edward M Hill; Sam M Moore,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"Control and mitigation of the COVID-19 pandemic in England has relied on a combination of vaccination and non-pharmaceutical interventions (NPIs). Some of these NPIs are extremely costly (economically and socially), so it was important to relax these promptly without overwhelming already burdened health services. The eventual policy was a Roadmap of four relaxation steps throughout 2021, taking England from lock-down to the cessation of all restrictions on social interaction. In a series of six Roadmap documents generated throughout 2021, models assessed the potential risk of each relaxation step. Here we show that the model projections generated a reliable estimation of medium-term hospital admission trends, with the data points up to September 2021 generally lying within our 95% prediction intervals. The greatest uncertainties in the modelled scenarios came from vaccine efficacy estimates against novel variants, and from assumptions about human behaviour in the face of changing restrictions and risk.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.03.15.22272362,2022-03-16,https://medrxiv.org/cgi/content/short/2022.03.15.22272362,Community-level characteristics of COVID-19 vaccine hesitancy in England: A nationwide cross-sectional study,Georges Bucyibaruta; Marta Blangialdo; Garyfallos Konstantinoudis,Imperial College London; Imperial College London; Imperial College London,"One year after the start of the COVID-19 vaccination programme in England, more than 43 million people older than 12 years old had received at least a first dose. Nevertheless, geographical differences persist, and vaccine hesitancy is still a major public health concern; understanding its determinants is crucial to managing the COVID-19 pandemic and preparing for future ones. In this cross-sectional population-based study we used cumulative data on the first dose of vaccine received by 01-01-2022 at Middle Super Output Area level in England. We used Bayesian hierarchical spatial models and investigated if the geographical differences in vaccination uptake can be explained by a range of community-level characteristics covering socio-demographics, political view, COVID-19 health risk awareness and targeting of high risk groups and accessibility. Deprivation is the covariate most strongly associated with vaccine uptake (Odds Ratio 0.55, 95%CI 0.54-0.57; most versus least deprived areas). The most ethnically diverse areas have a 38% (95%CI 36-40%) lower odds of vaccine uptake compared with those least diverse. Areas with the highest proportion of population between 12 and 24 years old had lower odds of vaccination (0.87, 95%CI 0.85-0.89). Finally increase in vaccine accessibility is associated with higher COVID-19 uptake (OR 1.07, 95%CI 1.03-1.12). Our results suggest that one year after the start of the vaccination programme, there is still evidence of inequalities in uptake, affecting particularly minorities and marginalised groups. Strategies including prioritising active outreach across communities and removing practical barriers and factors that make vaccines less accessible are needed to level up the differences.",epidemiology,fuzzy,94,100
medRxiv,10.1101/2022.03.14.22272283,2022-03-14,https://medrxiv.org/cgi/content/short/2022.03.14.22272283,Migrants' primary care utilisation before and during the COVID-19 pandemic in England: An interrupted time series,Claire X Zhang; Yamina Boukari; Neha Pathak; Rohini Mathur; Srinivasa Vittal Katikireddi; Parth Patel; In√™s Campos-Matos; Dan Lewer; Vincent Nguyen; Greg Hugenholtz; Rachel Burns; Amy R Mulick; Alasdair Henderson; Robert W Aldridge,UCL; University College London; University College London; London School of Hygiene and Tropical Medicine; University of Glasgow; University College London; Department of Health and Social Care; University College London; University College London; University College London; University College London; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; UCL,"BackgroundHow international migrants access and use primary care in England is poorly understood. We aimed to compare primary care consultation rates between international migrants and non-migrants in England before and during the COVID-19 pandemic (2015- 2020).

MethodsUsing linked data from the Clinical Practice Research Datalink (CPRD) GOLD and the Office for National Statistics, we identified migrants using country-of-birth, visa-status or other codes indicating international migration. We ran a controlled interrupted time series (ITS) using negative binomial regression to compare rates before and during the pandemic.

FindingsIn 262,644 individuals, pre-pandemic consultation rates per person-year were 4.35 (4.34-4.36) for migrants and 4.6 (4.59-4.6) for non-migrants (RR:0.94 [0.92-0.96]). Between 29 March and 26 December 2020, rates reduced to 3.54 (3.52-3.57) for migrants and 4.2 (4.17-4.23) for non-migrants (RR:0.84 [0.8-0.88]). Overall, this represents an 11% widening of the pre-pandemic difference in consultation rates between migrants and non-migrants during the first year of the pandemic (RR:0.89, 95%CI:0.84-0.94). This widening was greater for children, individuals whose first language was not English, and individuals of White British, White non-British and Black/African/Caribbean/Black British ethnicities.

InterpretationMigrants were less likely to use primary care before the pandemic and the first year of the pandemic exacerbated this difference. As GP practices retain remote and hybrid models of service delivery, they must improve services and ensure they are accessible and responsive to migrants healthcare needs.

FundingThis study was funded by the Medical Research Council (MR/V028375/1) and Wellcome Clinical Research Career Development Fellowship (206602).",primary care research,fuzzy,100,100
medRxiv,10.1101/2022.03.10.22272177,2022-03-13,https://medrxiv.org/cgi/content/short/2022.03.10.22272177,The Omicron SARS-CoV-2 epidemic in England during February 2022,Marc Chadeau-Hyam; David Tang; Oliver Eales; Barbara Bodinier; Haowei Wang; Jakob Jonnerby; Matthew Whitaker; Joshua Elliott; David Haw; Caroline E. Walters; Christina Atchinson; Peter J. Diggle; Andrew J. Page; Deborah Ashby; Wendy Barclay; Graham Taylor; Graham Cooke; Helen Ward; Ara Darzi; Christl A Donnelly; Paul Elliott,"School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UK; Imperial College Healthcare NHS Trust, UKDepartment of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; Quadram Institute, Norwich, UK; School of Public Health, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UKImperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical; School of Public Health, Imperial College London, UKImperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical Research; Imperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical Research Centre, UKInstitute of Global Health Innovation at ; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UKImperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical Research","BackgroundThe third wave of COVID-19 in England peaked in January 2022 resulting from the rapid transmission of the Omicron variant. However, rates of hospitalisations and deaths were substantially lower than in the first and second waves

MethodsIn the REal-time Assessment of Community Transmission-1 (REACT-1) study we obtained data from a random sample of 94,950 participants with valid throat and nose swab results by RT-PCR during round 18 (8 February to 1 March 2022).

FindingsWe estimated a weighted mean SARS-CoV-2 prevalence of 2.88% (95% credible interval [CrI] 2.76-3.00), with a within-round reproduction number (R) overall of 0.94 (0{middle dot}91-0.96). While within-round weighted prevalence fell among children (aged 5 to 17 years) and adults aged 18 to 54 years, we observed a level or increasing weighted prevalence among those aged 55 years and older with an R of 1.04 (1.00-1.09). Among 1,195 positive samples with sublineages determined, only one (0.1% [0.0-0.5]) corresponded to AY.39 Delta sublineage and the remainder were Omicron: N=390, 32.7% (30.0-35.4) were BA.1; N=473, 39.6% (36.8-42.5) were BA.1.1; and N=331, 27.7% (25.2-30.4) were BA.2. We estimated an R additive advantage for BA.2 (vs BA.1 or BA.1.1) of 0.40 (0.36-0.43). The highest proportion of BA.2 among positives was found in London.

InterpretationIn February 2022, infection prevalence in England remained high with level or increasing rates of infection in older people and an uptick in hospitalisations. Ongoing surveillance of both survey and hospitalisations data is required.

FundingDepartment of Health and Social Care, England.

O_TEXTBOXResearch in contextO_ST_ABSEvidence before this studyC_ST_ABSA search of PubMed using title or abstract terms (""Omicron"" or ""BA.1"" or ""BA.2"") and ""prevalence"" without language or other restrictions, identified 51 results (with no duplicates). All 51 results were evaluated, with 18 deemed relevant. One study focused on Omicron case rates in South Africa during the early stage after the discovery of the new variant (November 2021), one described genomic surveillance of SARS-CoV-2 in the USA (June - December 2021), one analysed clinical outcomes based on health records (January - December 2021), one described the results of whole-genome sequencing of SARS-CoV-2 samples collected in North Africa (March - December 2021), and one was from a previous REACT survey round (November - December 2021). The others focused on the mutation distribution of Omicron, disease severity, immune response, vaccine effectiveness, and prevalence in animal hosts.

Added value of this studyWe analysed data from throat and nose swabs collected at home by a randomly selected sample of residents of England, aged 5 years and older, obtained during round 18 (8 February to 1 March 2022) of the REal-time Assessment of Community Transmission-1 (REACT-1) study. We estimated a weighted prevalence of SARS-CoV-2 of 2.88% (95% CrI 2.76-3.00) in England in February 2022, which was substantially lower than that estimated in January 2022 (4.41% [4.25-4.56]). The within-round dynamics differed by age group with weighted prevalence falling among children (aged 5 to 17 years) with an R of 0.79 (0.74-0.84) and adults aged 18 to 54 years with an R of 0.92 (0.89-0.96), in contrast to the level or increasing weighted prevalence among those aged 55 years and older with an R of 1.04 (1.00-1.09). Exponential models estimated a daily growth rate advantage of 0.12 (0.11-0.13) in the odds of BA.2 (vs BA.1 or BA.1.1) corresponding to an R additive advantage of 0.40 (0.36-0.43).

Implications of all the available evidenceRandom community surveys of SARS-CoV-2 provide robust insights into transmission dynamics and identify groups at heightened risk of infection based on estimates of population prevalence that are unbiased by test-seeking behaviour or availability of tests. In England, replacement by BA.2 of other Omicron sublineages, the level or increasing rates of infection in older people and the uptick in hospitalisations in England toward the end of February 2022 require ongoing surveillance, both to monitor the levels of current (and future) SARS-CoV-2 variants and the risks of severe disease.

C_TEXTBOX",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.03.11.22272276,2022-03-13,https://medrxiv.org/cgi/content/short/2022.03.11.22272276,Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT1262b2 and after booster vaccination with BNT1262b2 or mRNA-1273: a population-based cohort study (COVIDENCE UK),Giulia Vivaldi; David A Jolliffe; Hayley Holt; Florence Tydeman; Mohammad Talaei; Gwyneth A Davies; Ronan A Lyons; Chris J Griffiths; Frank Kee; Aziz Sheikh; Seif O Shaheen; Adrian R Martineau,"Blizard Institute and Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Blizard Institute and Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Blizard Institute and Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, and Asthma UK Centre for Applied Research, ; Blizard Institute and Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Population Data Science, Swansea University Medical School, Singleton Park, Swansea, UK; Population Data Science, Swansea University Medical School, Singleton Park, Swansea, UK; Asthma UK Centre for Applied Research, Queen Mary University of London, London, UK; Centre for Public Health Research (NI), Queen's University Belfast, Belfast, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Blizard Institute and Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, and Asthma UK Centre for Applied Research, ","BackgroundLittle is known about the relative influence of demographic, behavioural, and vaccine-related factors on risk of post-vaccination SARS-CoV-2 infection. We aimed to identify risk factors for SARS-CoV-2 infection after primary and booster vaccinations.

MethodsWe undertook a prospective population-based study in UK adults ([&ge;]16 years) vaccinated against SARS-CoV-2, including data from Jan 12, 2021, to Feb 21, 2022. We modelled risk of post-vaccination SARS-CoV-2 infection separately for participants who had completed a primary course of vaccination (two-dose or, in the immunosuppressed, three-dose course of either ChAdOx1 nCoV-19 [ChAdOx1] or BNT1262b2) and for those who had additionally received a booster dose (BNT1262b2 or mRNA-1273). Cox regression models were used to explore associations between sociodemographic, behavioural, clinical, pharmacological, and nutritional factors and breakthrough infection, defined as a self-reported positive result on a lateral flow or reverse transcription PCR (RT-PCR) test for SARS-CoV-2. Models were further adjusted for weekly SARS-CoV-2 incidence at the local (lower tier local authority) level.

Findings14,713 participants were included in the post-primary analysis and 10,665 in the post-booster analysis, with a median follow-up of 203 days (IQR 195-216) in the post-primary cohort and 85 days (66-103) in the post-booster cohort. 1051 (7.1%) participants in the post-primary cohort and 1009 (9.4%) participants in the post-booster cohort reported a breakthrough SARS-CoV-2 infection. A primary course of ChAdOx1 (vs BNT182b2) was associated with higher risk of infection, both in the post-primary cohort (adjusted hazard ratio 1.63, 95% CI 1.41-1.88) and in the post-booster cohort after boosting with mRNA-1273 (1.29 [1.03-1.61] vs BNT162b2 primary plus BNT162b2 booster). A lower risk of breakthrough infection was associated with older age (post-primary: 0.96 [0.96-0.97] per year; post-booster: 0.97 [0.96-0.98]), whereas a higher risk of breakthrough infection was associated with lower levels of education (post-primary: 1.66 [1.35-2.06] for primary or secondary vs postgraduate; post-booster: 1.36 [1.08-1.71]) and at least three weekly visits to indoor public places (post-primary: 1.38 [1.15-1.66] vs none; post-booster: 1.33 [1.10-1.60]).

ConclusionsVaccine type, socioeconomic status, age, and behaviours affect risk of breakthrough SARS-CoV-2 infection following a primary schedule and a booster dose.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed, medRxiv, and Google Scholar for papers published up to Feb 18, 2022, using the search terms (breakthrough OR post-vaccin*) AND (SARS-CoV-2 OR COVID) AND (disease OR infection) AND (determinant OR ""risk factor"" OR associat*), with no language restrictions. Existing studies on risk factors for breakthrough SARS-CoV-2 infection among vaccinated individuals have found associations with age, comorbidities, vaccine type, and previous infection; however, findings have been inconsistent across studies. Most studies have been limited to specific subgroups or have focused on severe outcomes, and very few have considered breakthrough infections after a booster dose or have adjusted for behaviours affecting exposure to other people.

Added value of this studyThis study is among the first to provide a detailed analysis of a wide range of risk factors for breakthrough SARS-CoV-2 infection, both after the primary course of vaccination and after a booster dose. Our large study size and detailed data have allowed us to investigate associations with various sociodemographic, clinical, pharmacological, and nutritional factors. Monthly follow-up data have additionally given us the opportunity to consider the effects of behaviours that may have changed across the pandemic, while adjusting for local SARS-CoV-2 incidence.

Implications of all the available evidenceOur findings add to growing evidence that risk factors for SARS-CoV-2 infection after primary or booster vaccinations can differ to those in unvaccinated populations, with effects attenuated for previously observed risk factors such as body-mass index and Asian ethnicity. The clear difference we observed between the efficacies of ChAdOx1 and BNT162b2 as the primary course of vaccination appears to have been reduced by the use of BNT162b2 boosters, but not by mNRA-1273 boosters. As more countries introduce booster vaccinations, future population-based studies with longer follow-up will be needed to investigate our findings further.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.03.13.22272176,2022-03-13,https://medrxiv.org/cgi/content/short/2022.03.13.22272176,Vaccination against SARS-CoV-2 in UK school-aged children and young people decreases infection rates and reduces COVID-19 symptoms,Erika Molteni; Liane S Canas; Kerstin Klaser; Jie Deng; Sunil S Bhopal; Robert C Hughes; Liyuan Chen; Benjamin Murray; Eric Kerfoot; Michela Antonelli; Carole Helene Sudre; Joan Capdevila Pujol; Lorenzo Polidori; Anna May; Alexander Hammers; Jonathan Wolf; Timothy Spector; Claire J Steves; Sebastien Ourselin; Michael Absoud; Marc Modat; Emma L Duncan,"King's College London; King's College London; King's College London; King's College London; Newcastle University; London School of Hygiene & Tropical Medicine, London; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Limited, London, UK; Zoe Limited, London, UK; Zoe Limited, London, UK; King's College London; Zoe Limited, London, UK; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London","BackgroundWe aimed to explore the effectiveness of one-dose BNT162b2 vaccination upon SARS-CoV-2 infection, its effect on COVID-19 presentation, and post-vaccination symptoms in children and young people (CYP) in the UK during periods of Delta and Omicron variant predominance.

MethodsIn this prospective longitudinal cohort study, we analysed data from 115,775 CYP aged 12-17 years, proxy-reported through the Covid Symptom Study (CSS) smartphone application. We calculated post-vaccination infection risk after one dose of BNT162b2, and described the illness profile of CYP with post-vaccination SARS- CoV-2 infection, compared to unvaccinated CYP, and post-vaccination side-effects.

FindingsBetween August 5, 2021 and February 14, 2022, 25,971 UK CYP aged 12-17 years received one dose of BNT162b2 vaccine. Vaccination reduced (proxy-reported) infection risk (-80{middle dot}4% and -53{middle dot}7% at 14-30 days with Delta and Omicron variants respectively, and -61{middle dot}5% and -63{middle dot}7% after 61-90 days). The probability of remaining infection-free diverged soon after vaccination, and was greater in CYP with prior SARS-CoV-2 infection. Vaccinated CYP who contracted SARS-CoV-2 during the Delta period had milder disease than unvaccinated CYP; during the Omicron period this was only evident in children aged 12-15 years. Overall disease profile was similar in both vaccinated and unvaccinated CYP. Post-vaccination local side-effects were common, systemic side-effects were uncommon, and both resolved quickly.

InterpretationOne dose of BNT162b2 vaccine reduced risk of SARS-CoV-2 infection for at least 90 days in CYP aged 12-17 years. Vaccine protection varied for SARS-CoV-2 variant type (lower for Omicron than Delta variant), and was enhanced by pre-vaccination SARS-CoV-2 infection. Severity of COVID-19 presentation after vaccination was generally milder, although unvaccinated CYP also had generally mild disease. Overall, vaccination was well-tolerated.

FundingUK Government Department of Health and Social Care, Chronic Disease Research Foundation, The Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation and Alzheimers Society, and ZOE Limited.

Research in context

Evidence before this studyWe searched PubMed database for peer-reviewed articles and medRxiv for preprint papers, published between January 1, 2021 and February 15, 2022 using keywords (""SARS-CoV-2"" OR ""COVID-19"") AND (child* OR p?ediatric* OR teenager*) AND (""vaccin*"" OR ""immunization campaign"") AND (""efficacy"" OR ""effectiveness"" OR ""symptoms"") AND (""delta"" or ""omicron"" OR ""B.1.617.2"" OR ""B.1.1.529""). The PubMed search retrieved 36 studies, of which fewer than 30% specifically investigated individuals <18 years.

Eleven studies explored SARS-CoV-2 viral transmission: seroprevalence in children (n=4), including age-dependency of susceptibility to SARS-CoV-2 infection (n=1), SARS-CoV-2 transmission in schools (n=5), and the effect of school closure on viral transmission (n=1).

Eighteen documents reported clinical aspects, including manifestation of infection (n=13), symptomatology, disease duration, and severity in children. Other studies estimated emergency department visits, hospitalization, need for intensive care, and/or deaths in children (n=4), and explored prognostic factors (n=1).

Thirteen studies explored vaccination-related aspects, including vaccination of children within specific paediatric co-morbidity groups (e.g., children with Down syndrome, inflammatory bowel disease, and cancer survivors, n=4), mRNA vaccine efficacy in children and adolescents from the general population (n=7), and the relation between vaccination and severity of disease and hospitalization cases (n=2). Four clinical trials were conducted using mRNA vaccines in minors, also exploring side effects. Sixty percent of children were found to have side effects after BNT162b2 vaccination, and especially after the second dose; however, most symptoms were mild and transient apart from rare uncomplicated skin ulcers. Two studies focused on severe adverse effects and safety of SARS-CoV-2 vaccines in children, reporting on myocarditis episodes and two cases of Guillain-Barre syndrome. All other studies were beyond the scope of our research.

Added value of this studyWe assessed multiple components of the UK vaccination campaign in a cohort of children and young people (CYP) aged 12-17 years drawn from a large UK community-based citizen-science study, who received a first dose of BNT162b2 vaccine. We describe a variant-dependent protective effect of the first dose against both Delta and Omicron, with additional protective effect of pre-vaccination SARS- CoV-2 infection on post-vaccination re-infection. We compare the illness profile in CYP infected post-vaccination with that of unvaccinated CYP, demonstrating overall milder disease with fewer symptoms for vaccinated CYP. We describe local and systemic side-effects during the first week following first-dose vaccination, confirming that local symptoms are common, systemic symptoms uncommon, and both usually transient.

Implications of all the available evidenceOur data confirm that first dose BNT162b2 vaccination in CYP reduces risk of infection by SARS-CoV-2 variants, with generally local and brief side-effects. If infected after vaccination, COVID-19 is milder, if manifest at all. The study aims to contribute quantitative evidence to the risk-benefit evaluation of vaccination in CYP to inform discussion regarding rationale for their vaccination and the designing of national immunisation campaigns for this age group; and applies citizen-science approaches in the conduct of epidemiological surveillance and data collection in the UK community.

Importantly, this study was conducted during Delta and Omicron predominance in UK; specificity of vaccine efficacy to variants is also illustrated; and results may not be generalizable to future SARS-CoV-2 strains.",epidemiology,fuzzy,94,100
medRxiv,10.1101/2022.03.10.22272081,2022-03-12,https://medrxiv.org/cgi/content/short/2022.03.10.22272081,Interstitial lung damage following COVID-19 hospitalisation: an interim analysis of the UKILD Post-COVID study.,I Stewart; J Jacob; PM George; PL Molyneaux; JC Porter; RJ Allen; JK Baillie; SL Barratt; P Beirne; SM Bianchi; JF Blaikley; J Chalmers; RC Chambers; N Chadhuri; C Coleman; G Collier; EK Denneny; A Docherty; O Elneima; RA Evans; L Fabbri; MA Gibbons; FV Gleeson; B Gooptu; NJ Greening; B Guillen Guio; IP Hall; NA Hanley; V Harris; E Harrison; M Heightman; TE Hillman; A Horsley; L Houchen-Wolloff; I Jarrold; SR Johnson; MG Jones; F Khan; R Lawson; OC Leavy; N Lone; M Marks; H McAuley; P Mehta; E Omer; D Parekh; K Piper Hanley; M Plate; J Pearl; K Poinasamy; JK Quint; B Raman; M Richardson; P Rivera-Ortega; L Saunders; R Saunders; MG Semple; M Sereno; A Shikotra; AJ Simpson; A Singapuri; DJF Smith; M Spears; LG Spencer; S Stanel; D Thickett; AAR Thompson; M Thorpe; R Thwaites; SLF Walsh; S Walker; ND Weatherley; M Weeks; JM Wild; DG Wootton; CE Brightling; LP Ho; LV Wain; RG Jenkins,"National Heart & Lung Institute, Imperial College London; Respiratory Medicine, University College London; Royal Brompton and Harefield NHS Foundation Trust; National Heart & Lung Institute, Imperial College London; University College London; University of Leicester; University of Edinburgh; North Bristol NHS Trust; Leeds Teaching Hospitals & University of Leeds; Sheffield Teaching Hospitals NHS Foundation Trust; University of Manchester; University of Dundee; Respiratory Medicine, University College London; University of Manchester; University of Nottingham; University of Sheffield; University College London; University of Edinburgh; University Hospitals of Leicester NHS Trust; University Hospitals of Leicester NHS Trust; National Heart & Lung Institute, Imperial College London; Royal Devon and Exeter NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; University of Leicester; University of Leicester; University of Leicester; University of Nottingham; University of Manchester; University Hospitals of Leicester NHS Trust; University of Edinburgh; University College London Hospital; University College London Hospital; University of Manchester; University Hospitals of Leicester NHS Trust; Asthma UK British Lung Foundation; University of Nottingham; Faculty of Medicine, University of Southampton; University of Nottingham; Sheffield Teaching Hospitals NHS Foundation Trust; University of Leicester; Usher Institute, University of Edinburgh; University College London Hospital; University of Leicester; University College London Hospital; University of Leicester; University of Birmingham; University of Manchester; University College London Hospital; University of Leicester; British Lung Foundation; National Heart & Lung Institute, Imperial College London; University of Oxford; University of Leicester; University of Manchester; University of Sheffield; University of Leicester; Liverpool University; University of Leicester; University Hospitals of Leicester NHS Trust; Newcastle University; University of Leicester; Royal Brompton and Harefield NHS Foundation Trust; Perth Royal Infirmary, NHS Tayside; Liverpool University Hospitals NHS Foundation Trust; University of Manchester; University of Birmingham; University of Sheffield; University of Edinburgh; National Heart & Lung Institute, Imperial College London; National Heart & Lung Institute, Imperial College London; Sheffield Teaching NHS Foundation Trust; Sheffield Teaching NHS Foundation Trust; National Heart & Lung Institute, Imperial College London; Sheffield Teaching NHS Foundation Trust; University of Liverpool; University Hospitals of Leicester NHS Trust; University of Oxford; University of Leicester; National Heart & Lung Institute, Imperial College London","IntroductionShared characteristics between COVID-19 and pulmonary fibrosis, including symptoms, genetic architecture, and circulating biomarkers, suggests interstitial lung disease (ILD) development may be associated with SARS-CoV-2 infection.

MethodsThe UKILD Post-COVID study planned interim analysis was designed to stratify risk groups and estimate the prevalence of Post-COVID Interstitial Lung Damage (ILDam) using the Post-HOSPitalisation COVID-19 (PHOSP-COVID) Study. Demographics, radiological patterns and missing data were assessed descriptively. Bayes binomial regression was used to estimate the risk ratio of persistent lung damage >10% involvement in linked, clinically indicated CT scans. Indexing thresholds of percent predicted DLco, chest X-ray findings and severity of admission were used to generate risk strata. Number of cases within strata were used to estimate the amount of suspected Post-COVID ILDam.

ResultsA total 3702 people were included in the UKILD interim cohort, 2406 completed an early follow-up research visit within 240 days of discharge and 1296 had follow-up through routine clinical review. We linked the cohort to 87 clinically indicated CTs with visually scored radiological patterns (median 119 days from discharge; interquartile range 83 to 155, max 240), of which 74 people had ILDam. ILDam was associated with abnormal chest X-ray (RR 1.21 95%CrI 1.05; 1.40), percent predicted DLco<80% (RR 1.25 95%CrI 1.00; 1.56) and severe admission (RR 1.27 95%CrI 1.07; 1.55). A risk index based on these features suggested 6.9% of the interim cohort had moderate to very-high risk of Post-COVID ILDam. Comparable radiological patterns were observed in repeat scans >90 days in a subset of participants.

ConclusionThese interim data highlight that ILDam was not uncommon in clinically indicated thoracic CT up to 8 months following SARS-CoV-2 hospitalisation. Whether the ILDam will progress to ILD is currently unknown, however health services should radiologically and physiologically monitor individuals who have Post-COVID ILDam risk factors.",respiratory medicine,fuzzy,91,100
medRxiv,10.1101/2022.03.09.22272098,2022-03-12,https://medrxiv.org/cgi/content/short/2022.03.09.22272098,"Duration of vaccine effectiveness against SARS-CoV2 infection, hospitalisation, and death in residents and staff of Long-Term Care Facilities (VIVALDI): a prospective cohort study, England, Dec 2020-Dec 2021",Madhumita Shrotri; Maria Krutikov; Hadjer Nacer-Laidi; Borscha Azmi; Tom Palmer; Rebecca Giddings; Chris Fuller; Aidan Irwin-Singer; Verity Baynton; Gokhan Tut; Paul Moss; Andrew Hayward; Andrew Copas; Laura Shallcross,"University College London; University College London; University College London; University College London; University College London; University College London; University College London; UK Government Department of Health & Social Care; UK Government Department of Health & Social Care; University of Birmingham, Medical School; University of Birmingham; UCL; University College London; UCL","BackgroundLong-term care facilities (LTCF) have been prioritised for vaccination, but data on potential waning of vaccine effectiveness (VE) and the impact of booster doses in this vulnerable population remains scarce.

MethodsWe included residents and staff from 331 LTCFs enrolled in VIVALDI (ISRCTN 14447421), who underwent routine PCR testing between Dec 8, 2020 - Dec 11, 2021 in a Cox proportional hazards regression, estimating VE against SARS-CoV2 infection, COVID-19-related hospitalisation, and COVID-19-related death after 1-3 vaccine doses, stratifying by previous SARS-CoV2 exposure.

ResultsFor 15,518 older residents, VE declined from 50{middle dot}7% (15{middle dot}5, 71{middle dot}3) to 17{middle dot}2% ([~]23{middle dot}9, 44{middle dot}6) against infection; from 85{middle dot}4% (60{middle dot}7, 94{middle dot}.6) to 54{middle dot}3% (26{middle dot}2, 71{middle dot}7) against hospitalisation; and from 94{middle dot}4% (76{middle dot}4, 98{middle dot}7) to 62{middle dot}8% (32{middle dot}9, 79{middle dot}4) against death, when comparing 2-12 weeks and [&ge;]12 weeks after two doses. For 19,515 staff, VE against infection declined slightly from 50{middle dot}3% (32{middle dot}7, 63{middle dot}3) to 42{middle dot}1% 29{middle dot}5, 52{middle dot}4). High VE was restored following a third dose, with VE of 71{middle dot}6% (53{middle dot}5, 82{middle dot}7) and 78{middle dot}3% (70{middle dot}1, 84{middle dot}3) against infection and 89{middle dot}9% (80{middle dot}0, 94{middle dot}6) and 95{middle dot}8% (50{middle dot}4, 99{middle dot}6) against hospitalisation, for residents and staff respectively; and 97{middle dot}5% (88{middle dot}1, 99{middle dot}5) against death for residents.

InterpretationSubstantial waning of VE is observed against all outcomes in residents from 12 weeks after a primary course of AstraZeneca or mRNA vaccines. Boosters restore protection, and maximise immunity across all outcomes. These findings demonstrate the importance of boosting and the need for ongoing surveillance of VE in this vulnerable cohort.

FundingUK Government Department of Health and Social Care.

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSWe searched MEDLINE and medRxiv for studies reporting vaccine effectiveness (VE) over time after two or three doses against SARS-CoV2 infection, COVID-19-related hospitalisation, or COVID-19-related death amongst staff or residents of long-term care facilities (LTCFs), that were published between Jan 1, 2020, and December 21, 2021. We used variations of the search terms ""COVID-19"" OR ""SARS-CoV-2"" AND ""vaccine effectiveness"" OR ""vaccine efficacy"" AND ""care homes"" OR ""long term care facilities"".

We identified 8 articles reporting two-dose data from LTCFs, including 1 peer-reviewed paper from Israel, 1 preprint from Denmark, 1 preprint from Norway, 1 peer-reviewed paper from France, two peer-reviewed papers from Spain, 1 peer-reviewed paper from the USA, and 1 preprint from England; however none of these studies examined waning of protection over time after two doses. Five studies (mRNA vaccines 3-4 weeks interval) reported short-term two-dose VE of 49-71% in residents, and 82-90% in staff. Two-dose VE was reported to be 75-88% against hospitalisation, 87-97% against death, and 86% against either outcome. An English study of residents (Pfizer or AstraZeneca, 8-12 week interval) reported 73% VE against infection and noted VE waning from 7 weeks after the first dose, but did not examine waning after the second dose. All of these studies were set prior to emergence of the Delta variant and did not examine waning of immunity due to short lengths of follow-up after Dose 2. Only one study (USA) compared Pfizer/Moderna two-dose VE against infection in LTCF residents before (67{middle dot}5% [60{middle dot}1-73{middle dot}5%]) and during (53{middle dot}1% [49{middle dot}1-56{middle dot}7%]) Delta variant predominance; however, authors could not access vaccination dates therefore did not account for any waning of immunity over time; they also did not examine any severe clinical outcomes.

We identified only one correspondence piece from Israel (Pfizer 3-4 week interval) describing the benefit of a third  booster dose in LTCFs; it reported relative rate reductions of 71% for infection and 80%, for hospitalisation in the period after booster roll-out. However, individual-level VE estimates by time since vaccination were not reported, and adjustment for prior infection was not undertaken.

Overall, there was a paucity of data on non-mRNA vaccines, waning of immunity over time after two doses, and VE following a third (booster) dose in LTCF populations, which we address in this study.

Added value of this studyWe report findings from a prospective cohort study that includes 15,518 residents and 19,515 staff from 331 LTCFs across England, who underwent routine PCR testing 2-3 times per month, looking at SARS-CoV2 vaccine effectiveness over 12 months (Dec 8, 2020-Dec 11, 2021), which is the longest duration of follow-up of any study within this vulnerable cohort. We evaluated the effectiveness of first, second, and booster vaccine doses of AstraZeneca, Pfizer, and Moderna against infection, hospitalisation, and death over the 12 months when the Alpha and Delta variants were dominant. Our findings affirm that complete vaccination with two doses of AstraZeneca or mRNA vaccines offers moderate protection against infection, and high protection against severe clinical outcomes, however this protection declines over time, particularly for residents. A third booster dose of an mRNA vaccine restores, and indeed maximises, VE to 71{middle dot}6% (53{middle dot}5, 82{middle dot}7) and 78{middle dot}3% (70{middle dot}1, 84{middle dot}3) against infection, and 89{middle dot}9% (80{middle dot}0, 94{middle dot}6) and 95{middle dot}8% (50{middle dot}4, 99{middle dot}6) against hospitalisation, for residents and staff respectively, and to 97{middle dot}5% (88{middle dot}1, 99{middle dot}5) against death for residents, with similar protection offered after the third dose irrespective of primary course type.

This is the first study to examine and describe waning of immunity over a one-year period, as well as vaccine effectiveness of a booster dose, in a large cohort of LTCF staff and residents.

Implications of all the available evidenceTaken together, our findings indicate high short-term immunity against SARS-CoV2 infection and very high immunity against severe clinical outcomes of COVID-19 for LTCF residents and staff following vaccination. However substantial waning in vaccine-derived immunity is seen beyond 3 months, irrespective of vaccine type, suggesting the need for regular boosting to maintain protection in this vulnerable cohort. Although this analysis took place in the pre-Omicron period, these trends of waning immunity over time are likely to be generalisable across variants, carrying important implications for long-term vaccination policy in LTCFs. Ongoing surveillance in this vulnerable cohort remains crucial, in order to describe further changes in vaccine-induced immunity, particularly in the context of new variants.",infectious diseases,fuzzy,100,100
bioRxiv,10.1101/2022.03.08.481609,2022-03-08,https://biorxiv.org/cgi/content/short/2022.03.08.481609,The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK,Verity Hill; Louis du Plessis; Thomas P Alexander Peacock; Dinesh Aggarwal; Alessandro Carabelli; Rachel Colquhoun; Nicholas Ellaby; Eileen Gallagher; Natalie Groves; Ben Jackson; JT McCrone; Anna Price; Theo Sanderson; Emily Scher; Joel Alexander Southgate; Erik Volz; - The COVID-19 genomics UK (COG-UK) consortium; Wendy S Barclay; Jeffrey Barrett; Meera Chand; Thomas R Connor; Ian G. Goodfellow; Ravindra K Gupta; Ewan Harrison; Nicholas Loman; Richard Myers; David L Robertson; Oliver Pybus; Andrew Rambaut,The University of Edinburgh; University of Oxford; University College London (UCL); University of Cambridge; University of Cambridge; University of Edinburgh; UK Health Security Agency; Uk Health Security Agency; UK Health Security Agency; University of Edinburgh; University of Edinburgh; Cardiff University; Sanger Institute; University of Edinburgh; Cardiff University; Imperial College London; -; Imperial College London; Sanger Institute; UK Health Security Agency; Cardiff University; University of Cambridge; University of Cambridge; Sanger Institute; University of Birmingham; UK Health Security Agency; University of Glasgow; University of Oxford; University of Edinburgh,"The first SARS-CoV-2 variant of concern (VOC) to be designated was lineage B.1.1.7, later labelled by the World Health Organisation (WHO) as Alpha. Originating in early Autumn but discovered in December 2020, it spread rapidly and caused large waves of infections worldwide. The Alpha variant is notable for being defined by a long ancestral phylogenetic branch with an increased evolutionary rate, along which only two sequences have been sampled. Alpha genomes comprise a well-supported monophyletic clade within which the evolutionary rate is more typical of SARS-CoV-2. The Alpha epidemic continued to grow despite the continued restrictions on social mixing across the UK, and the imposition of new restrictions, in particular the English national lockdown in November 2020. While these interventions succeeded in reducing the absolute number of cases, the impact of these non-pharmaceutical interventions was predominantly to drive the decline of the SARS-CoV-2 lineages which preceded Alpha. We investigate the only two sampled sequences that fall on the branch ancestral to Alpha. We find that one is likely to be a true intermediate sequence, providing information about the order of mutational events that led to Alpha. We explore alternate hypotheses that can explain how Alpha acquired a large number of mutations yet remained largely unobserved in a region of high genomic surveillance: an under-sampled geographical location, a non-human animal population, or a chronically-infected individual. We conclude that the last hypothesis provides the best explanation of the observed behaviour and dynamics of the variant, although we find that the individual need not be immunocompromised, as persistently-infected immunocompetent hosts also display a higher within-host rate of evolution. Finally, we compare the ancestral branches and mutation profiles of other VOCs to each other, and identify that Delta appears to be an outlier both in terms of the genomic locations of its defining mutations, and its lack of rapid evolutionary rate on the ancestral branch. As new variants, such as Omicron, continue to evolve (potentially through similar mechanisms) it remains important to investigate the origins of other variants to identify ways to potentially disrupt their evolution and emergence.",evolutionary biology,fuzzy,100,100
medRxiv,10.1101/2022.03.06.21267462,2022-03-08,https://medrxiv.org/cgi/content/short/2022.03.06.21267462,Risk of myocarditis and pericarditis following COVID-19 vaccination in England and Wales,Samanatha Ip; Fatemeh Torabi; Spiros Denaxas; Ashley Akbari; Hoda Abbasizanjani; Rochelle Knight; Jennifer Anne Cooper; Rachel Denholm; Spencer Keene; Thomas Bolton; Sam Hollings; Efosa Omigi; Teri-Louise North; Arun Karthikeyan Suseeladevi; Emanuele Di Angelantonio; Kamlesh Khunti; Jonathan A C Sterne; Cathie Sudlow; William Whiteley; Angela Wood; Venexia Walker; - British Heart Foundation Data Science Centre (HDR UK) CVD-COVID-UK/COVID-IMPACT Consortium; - UK Covid-19 Longitudinal Health and Wellbeing National Core Study; - UK Covid-19 Data and Connectivity National Core Study,University of Cambridge; Swansea University; University College London; Swansea University; Swansea University; University of Bristol; University of Bristol; University of Bristol; University of Cambridge; Health Data Research UK; NHS Digital; NHS Digital; University of Bristol; University of Bristol; University of Cambridge; University of Leicester; University of Bristol; Health Data Research UK; University of Edinburgh; University of Cambridge; University of Bristol; ; ; ,"We describe our analyses of data from over 49.7 million people in England, representing near-complete coverage of the relevant population, to assess the risk of myocarditis and pericarditis following BNT162b2 and ChAdOx1 COVID-19 vaccination. A self-controlled case series (SCCS) design has previously reported increased risk of myocarditis after first ChAdOx1, BNT162b2, and mRNA-1273 dose and after second doses of mRNA COVID-19 vaccines in England. Here, we use a cohort design to estimate hazard ratios for hospitalised or fatal myocarditis/pericarditis after first and second doses of BNT162b2 and ChAdOx1 vaccinations. SCCS and cohort designs are subject to different assumptions and biases and therefore provide the opportunity for triangulation of evidence. In contrast to the findings from the SCCS approach previously reported for England, we found evidence for lower incidence of hospitalised or fatal myocarditis/pericarditis after first ChAdOx1 and BNT162b2 vaccination, as well as little evidence to suggest higher incidence of these events after second dose of either vaccination.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.03.02.22271762,2022-03-04,https://medrxiv.org/cgi/content/short/2022.03.02.22271762,"Disparities in SARS-CoV-2 case rates by ethnicity, religion, measures of socio-economic position, English proficiency, and self-reported disability: cohort study of 39 million people in England during the Alpha and Delta waves",Tim Larsen; Matthew L Bosworth; Daniel Ayoubkhani; Ryan Schofield; Raghib Ali; Kamlesh Khunti; Ann Sarah Walker; Myer Glickman; Vahe Nafilyan,Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Cambridge; University of Leicester; University of Oxford; Office for National Statistics; Office for National Statistics,"ObjectiveTo examine socio-demographic disparities in SARS-CoV-2 case rates during the second (Alpha) and third (Delta) waves of the COVID-19 pandemic.

DesignRetrospective, population-based cohort study.

SettingResident population of England.

Participants39,006,194 people aged 10 years and over who were enumerated at the 2011 Census, registered with the National Health Service (NHS) and alive on 1 September 2020.

Main outcome measuresTesting positive for SARS-CoV-2 during the second wave (1 September 2020 to 22 May 2021) or third wave (23 May to 10 December 2021) of the pandemic. We calculated age-standardised case rates by socio-demographic characteristics and used logistic regression models to estimate adjusted odds ratios (ORs).

ResultsDuring the study period, 5,767,584 individuals tested positive for SARS-CoV-2. In the second wave, the fully-adjusted odds of having a positive test, relative to the White British group, were highest for the Bangladeshi (OR: 1.88, 95% CI 1.86 to 1.90) and Pakistani (1.81, 1.79 to 1.82) ethnic groups. Relative to the Christian group, Muslim and Sikh religious groups had fully-adjusted ORs of 1.58 (1.57 to 1.59) and 1.74 (1.72 to 1.76), respectively. Greater area deprivation, disadvantaged socio-economic position, living in a care home and low English language proficiency were also associated with higher odds of having a positive test. However, the disparities between groups varied over time. Being Christian, White British, non-disabled, and from a more advantaged socio-economic position were all associated with increased odds of testing positive during the third wave.

ConclusionThere are large socio-demographic disparities on SARS-CoV-2 cases which have varied between different waves of the pandemic. Research is now urgently needed to understand why these disparities exist to inform policy interventions in future waves or pandemics.

What is already known on this topicPeople with pre-existing health conditions or disability, ethnic minority groups, the elderly, some religious groups, people with low socio-economic status, and those living in deprived areas have been disproportionately affected by the COVID-19 pandemic in terms of risk of infection and adverse outcomes.

What this study addsUsing linked data on 39 million people in England, we found that during the second wave, COVID-19 case rates were highest among the Bangladeshi and Pakistani ethnic groups, the Muslim religious group, individuals from deprived areas and of low socio-economic position; during the third wave, being Christian, White British, non-disabled, and from a more advantaged socio-economic position were all associated with increased odds of receiving a positive test

Adjusting for geographical factors, socio-demographic characteristics, and pre-pandemic health status explained some, but not all, of the excess risk

When stratifying the dataset by broad age groups, the odds of receiving a positive test remained higher among the Bangladeshi and Pakistani ethnic groups aged 65 years and over during the third wave, which may partly explain the continued elevated mortality rates in these groups",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.03.02.22271623,2022-03-03,https://medrxiv.org/cgi/content/short/2022.03.02.22271623,"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis",Peter W Horby; Jonathan R Emberson; Marion Mafham; Mark Campbell; Leon Peto; Guilherme Pessoa-Amorim; Enti Spata; Natalie Staplin; Catherine Lowe; David R Chadwick; Christopher Brightling; Richard Stewart; Paul Collini; Abdul Ashish; Christopher A Green; Benjamin Prudon; Tim Felton; Anthony Kerry; J Kenneth Baillie; Maya H Buch; Jeremy N Day; Saul N Faust; Thomas Jaki; Katie Jeffery; Edmund Juszczak; Marian Knight; Wei Shen Lim; Alan Montgomery; Andrew Mumford; Kathryn Rowan; Guy Thwaites; Richard Haynes; Martin J Landray,"Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Liverpool University Hospitals NHS Foundation Trust; Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United Kingdom; Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; Milton Keynes University Hospital, Milton Keynes, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, United Kingdom; Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, United Kingdom; University Hospitals Birmingham NHS Foundation Trust; North Tees and Hartlepool NHS Foundation Trust, Hartlepool, United Kingdom; Manchester University NHS Foundation Trust; Great Western Hospitals Foundation Trust, Swindon, United Kingdom; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Respiratory Medicine Department, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Intensive Care National Audit and Research Centre, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","BackgroundWe evaluated the use of baricitinib, a Janus kinase (JAK) 1/2 inhibitor, for the treatment of patients admitted to hospital because of COVID-19.

MethodsThis randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple possible treatments in patients hospitalised for COVID-19. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus baricitinib 4 mg once daily by mouth for 10 days or until discharge if sooner (baricitinib group). The primary outcome was 28-day mortality assessed in the intention-to-treat population. A meta-analysis was conducted that included the results from the RECOVERY trial and all previous randomised controlled trials of baricitinib or other JAK inhibitor in patients hospitalised with COVID-19. The RECOVERY trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

FindingsBetween 2 February 2021 and 29 December 2021, 8156 patients were randomly allocated to receive usual care plus baricitinib versus usual care alone. At randomisation, 95% of patients were receiving corticosteroids and 23% receiving tocilizumab (with planned use within the next 24 hours recorded for a further 9%). Overall, 513 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0{middle dot}87; 95% CI 0{middle dot}77-0{middle dot}98; p=0{middle dot}026). This 13% proportional reduction in mortality was somewhat smaller than that seen in a meta-analysis of 8 previous trials of a JAK inhibitor (involving 3732 patients and 425 deaths) in which allocation to a JAK inhibitor was associated with a 43% proportional reduction in mortality (rate ratio 0.57; 95% CI 0.45-0.72). Including the results from RECOVERY into an updated meta-analysis of all 9 completed trials (involving 11,888 randomised patients and 1484 deaths) allocation to baricitinib or other JAK inhibitor was associated with a 20% proportional reduction in mortality (rate ratio 0.80; 95% CI 0.71-0.89; p<0.001). In RECOVERY, there was no significant excess in death or infection due to non-COVID-19 causes and no excess of thrombosis, or other safety outcomes.

InterpretationIn patients hospitalised for COVID-19, baricitinib significantly reduced the risk of death but the size of benefit was somewhat smaller than that suggested by previous trials. The total randomised evidence to date suggests that JAK inhibitors (chiefly baricitinib) reduce mortality in patients hospitalised for COVID-19 by about one-fifth.

FundingUK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056).",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.02.24.22271466,2022-02-25,https://medrxiv.org/cgi/content/short/2022.02.24.22271466,Risk of COVID-19 related deaths for SARS-CoV-2 Omicron (B.1.1.529) compared with Delta (B.1.617.2),Isobel L. Ward; Charlotte Bermingham; Daniel Ayoubkhani; Owen J. Gethings; Koen Pouwels; Thomas Yates; Kamlesh Khunti; Julia Hippisley-Cox; Amitava Banerjee; Ann Sarah Walker; Vahe Nafilyan,"Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford; Diabetes Research Centre, University of Leicester; Diabetes Research Centre, University of Leicester; University of Oxford; University College London; University of Oxford; Office for National Statistics","ObjectiveTo assess the risk of death involving COVID-19 following infection from Omicron (B.1.1.539/BA.1) relative to Delta (B.1.617.2).

DesignRetrospective cohort study.

SettingEngland, UK, 1 December 2021 to 25 January 2022.

Participants1,035,163 people aged 18-100 years who tested positive for SARS-CoV-2 in the national surveillance programme, and had an infection identified as either Omicron- or Delta compatible.

Main outcome measuresDeath involving COVID-19 as identified from death certification records. The exposure of interest was the SARS-CoV-2 variant identified from NHS Test and Trace PCR positive tests taken in the community (pillar 2) and analysed by Lighthouse laboratories. Cause-specific Cox proportional hazard regression models were adjusted for sex, age, vaccination status, previous infection, calendar time, ethnicity, Index of Multiple Deprivation rank, household deprivation, university degree, keyworker status, country of birth, main language, region, disability, and comorbidities. Additionally, we tested for interactions between variant and sex, age, vaccination status and comorbidities.

ResultsThe risk of death involving COVID-19 was 67% lower for Omicron compared to Delta and the reduction in the risk of death involving COVID-19 for Omicron compared to Delta was more pronounced in males than in females and in people under 70 years old than in people aged 70 years or over. Regardless of age, reduction of the risk of death from Omicron relative to Delta more was more pronounced in people who had received a booster than in those having received only two doses.

ConclusionsOur results support early work showing the relative reduction in severity of Omicron compared to Delta in terms of hospitalisation and extends this research to assess COVID-19 mortality. Our work also highlights the importance of the vaccination booster campaign, where the reduction in risk of death involving COVID-19 is most pronounced in individuals who had received a booster.

What is already known on this topicThe Omicron variant, which refers to the whole lineage (BA.1, BA.2, BA.3) had already been shown to be more transmissible than the Delta variant, but there is emerging evidence suggests that the risk of hospitalisation and risk of death within 28 days after a SARS-COV-2 test is lower. However, with a highly transmissible infection and high levels of population testing, definition of death within 28 days is more likely to be susceptible to misclassification bias due to asymptomatic or co-incidental infection. There is no study so far comparing the risk of COVID-19 death as identified from death certification records, with the cause of death assessed by the physician who attended the patient in the last illness.

What this study addsUsing data from a large cohort of COVID-19 infections that occurred in December 2021, we examined the difference in the risk COVID-19 death, as identified from death certification records, between the Delta and Omicron BA.1 variant. Our study shows that risk of death involving COVID-19 was reduced by 67% following infection with the Omicron BA.1 variant relative to the Delta variant after adjusting for a wide range of potential confounders, including vaccination status and comorbidities. Importantly, we found that the relative risk of COVID-19 mortality following Omicron versus Delta infection varied by age and sex, with lower relative risk in younger individuals and for males than females. The reduction in risk of death involving COVID-19 was also most pronounced in individuals who had received a booster.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.02.23.22271388,2022-02-24,https://medrxiv.org/cgi/content/short/2022.02.23.22271388,"Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: community-based, matched cohort study",Daniel Ayoubkhani; Matthew L Bosworth; Sasha King; Koen B Pouwels; Myer Glickman; Vahe Nafilyan; Francesco Zaccardi; Kamlesh Khunti; Nisreen A Alwan; Ann Sarah Walker,Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Office for National Statistics; Office for National Statistics; University of Leicester; University of Leicester; University of Southampton; University of Oxford,"BackgroundIt is unclear whether receiving two COVID-19 vaccinations before SARS-CoV-2 infection reduces the risk of developing Long Covid symptoms. We examined whether the likelihood of symptoms 12 weeks after infection differed by vaccination status.

MethodsWe included COVID-19 Infection Survey participants aged 18-69 years who tested positive for SARS-CoV-2 between 26 April 2020 and 30 November 2021; we excluded participants who, before their first test-confirmed infection, had suspected COVID-19 or Long Covid symptoms, or were single-vaccinated. Participants who were double-vaccinated [&ge;]14 days before infection were 1:1 propensity-score matched, based on socio-demographic characteristics and time from infection to follow-up for Long Covid, to those unvaccinated at time of infection. We estimated adjusted odds ratios (aOR) of Long Covid symptoms [&ge;]12 weeks post-infection, comparing double-vaccinated with unvaccinated (reference group) participants.

ResultsThe study sample comprised 3,090 double-vaccinated participants (mean age 49 years, 54% female, 92% white, median follow-up from infection 96 days) and matched control participants. Long Covid symptoms were reported by 294 double-vaccinated participants (prevalence 9.5%) compared with 452 unvaccinated participants (14.6%), corresponding to an aOR for Long Covid symptoms of 0.59 (95% CI: 0.50 to 0.69). There was no evidence of heterogeneity by adenovirus vector versus messenger ribonucleic acid vaccines (p=0.25).

ConclusionsCOVID-19 vaccination is associated with reduced risk of Long Covid, emphasising the need for public health initiatives to increase population-level vaccine uptake. Longer follow-up is needed, as is the assessment of further vaccine doses and the Omicron variant.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.02.16.22271075,2022-02-21,https://medrxiv.org/cgi/content/short/2022.02.16.22271075,SARS-CoV-2 antibody persistence after five and twelve months: A cohort study from South-Eastern Norway,Marjut Sarjomaa; Lien  My Diep; Chi Zhang; Yngvar Tveten; Harald Reiso; Carina Thilesen; Svein Arne Nordb√∏; Kristine  Karlsrud Berg; Ingeborg Aaberge; Neil Pearce; Hege Kersten; Jan Paul Vandenbroucke; Randi Eikeland; Anne Kristin  M√∏ller Fell,Telemark Hospital: Sykehuset Telemark HF; Oslo Universitetssykehus; Norwegian Institute of Public Health: Folkehelseinstituttet; Telemark Hospital: Sykehuset Telemark HF; National Center for Vector-Borne Diseases; Unilabs Laboratory Medicine; St Olavs Hospital University Hospital in Trondheim: St Olavs Hospital Universitetssykehuset i Trondheim; S√∏rlandet Sykehus HF; Norwegian Institute of Public Health: Folkehelseinstituttet; London School of Hygiene & Tropical Medicine; Telemark Hospital: Sykehuset Telemark HF; University of Leiden: Universiteit Leiden; National Center for Vector-Borne Diseases; Telemark Hospital: Sykehuset Telemark HF,"ObjectivesTo assess total antibody levels against Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS CoV-2) spike protein up to 12 months after Coronavirus Disease (COVID-19) infection in non-vaccinated individuals and the possible predictors of antibody persistence.

MethodsThis is a prospective multi-centre longitudinal cohort study.

ParticipantsThe study included SARS-CoV-2 real-time polymerase chain reaction (RT-PCR) positive and negative participants in South-Eastern Norway from February to December 2020. Possible predictors of SARS-CoV-2 total antibody persistence was assessed. The SARS-CoV-2 total antibody levels against spike protein were measured three to five months after PCR in 391 PCR-positive and 703 PCR-negative participants; 212 PCR-positive participants were included in follow-up measurements at 10 to 12 months. The participants completed a questionnaire including information about symptoms, comorbidities, allergies, body mass index (BMI), and hospitalisation.

Primary outcomeThe SARS-CoV-2 total antibody levels against spike protein three to five and 10 to 12 months after PCR positive tests.

ResultsSARS-CoV-2 total antibodies against spike protein were present in 366 (94%) non-vaccinated PCR-positive participants after three to five months, compared with nine (1%) PCR-negative participants. After 10 to 12 months, antibodies were present in 204 (96%) non-vaccinated PCR-positive participants. Of the PCR-positive participants, 369 (94%) were not hospitalised. The mean age of the PCR-positive participants was 48 years (SD 15, range 20-85) and 50% of them were male. BMI [&ge;] 25 kg/m2 was positively associated with decreased antibody levels (OR 2.34, 95% CI 1.06 to 5.42). Participants with higher age and self-reported initial fever with chills or sweating were less likely to have decreased antibody levels (age: OR 0.97, 95% CI 0.94 to 0.99; fever: OR 0.33, 95% CI 0.13 to 0.75).

ConclusionOur results indicate that the level of SARS-CoV-2 total antibodies against spike protein persists for the vast majority of non-vaccinated PCR-positive persons at least 10 to 12 months after mild COVID-19.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.02.17.22271126,2022-02-18,https://medrxiv.org/cgi/content/short/2022.02.17.22271126,"Serological responses and six-month trajectories to COVID-19 Comirnaty and Spikevax booster vaccine, September 2021 to January 2022, London, United Kingdom",Georgina Ireland; Heather Whitaker; Shamez Ladhani; Frances Baawuah; Sathyvani Subbarao; Suzanne Elgohari; Alexandra Smith; Michelle O'Brien; Corinne Whillock; Oliver Martin; Paul Moss; Mary E Ramsay; Gayatri Amirthalingam; Kevin E Brown,UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; Brondesbury Medical Centre; UK Health Security Agency; UK Health Security Agency; University of Birmingham; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency,"In contrast to the increasing levels of high avidity S antibody measured by the Roche assay in the first 6 months following natural infection, marked waning is seen post 2 or 3 doses of vaccine. Although the kinetics differ between those with vaccine-induced immunity compared to those infected prior to vaccination (hybrid immunity), waning rates appear to be similar following 2 or 3 doses of vaccine. These data should allow countries to optimise the timing of future doses of vaccine.",public and global health,fuzzy,100,100
medRxiv,10.1101/2022.02.14.22270930,2022-02-15,https://medrxiv.org/cgi/content/short/2022.02.14.22270930,Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK),David A Jolliffe; Sian E Faustini; Hayley Holt; Natalia Perdek; Sheena Maltby; Mohammad Talaei; Matthew Greenig; Giulia Vivaldi; Florence Tydeman; Jane Symons; Gwyneth A Davies; Ronan Lyons; Frank Kee; Aziz Sheikh; Seif O Shaheen; Alex Richter; Adrian R Martineau,Queen Mary University of London; University of Birmingham; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Jane Symons Media; Swansea University; Swansea University; Queen's University Belfast; Edinburgh University; Queen Mary University of London; University of Birminghan; Queen Mary University of London,"BackgroundAntibody responses to SARS-CoV-2 vaccination vary for reasons that remain poorly understood.

MethodsWe tested for presence of combined IgG, IgA and IgM (IgGAM) anti-spike antibodies before and after administration of two doses of ChAdOx1 nCoV-19 (ChAdOx1, Oxford-AstraZeneca) or BNT162b2 (Pfizer-BioNTech) in UK adults participating in a population-based longitudinal study who received their first dose of vaccine from December 15, 2020 to July 10, 2021. Information on sixty-six potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of serological response to vaccination was captured using serial online questionnaires. We used logistic regression to estimate multivariable-adjusted odds ratios (aORs) for associations between independent variables and risk of seronegativity following two vaccine doses. Participants who were seronegative after receiving two vaccine doses were offered an additional antibody test following subsequent administration of a  booster dose of BNT162b2 or mRNA-1273 (Moderna) from September 23 to December 12, 2021.

FindingsSerology results following two vaccine doses were available for 9,101 participants, of whom 5,770 (63.4%) received ChAdOx1 and 3,331 (36.6%) received BNT162b2. Anti-spike IgGAM was undetectable in 378 (4.2%) participants at a median of 8.6 weeks (IQR 6.4-10.7 weeks) after their second dose of vaccine. Seronegativity following two doses of SARS-CoV-2 vaccination was associated with administration of ChAdOx1 vs BNT162b2 (aOR 7.03, 95% CI 4.39-11.24), shorter interval between first and second vaccine doses (aOR 2.37, 1.06-5.26, for <6 weeks vs >10 weeks; aOR 1.59, 1.18-2.13, for 6-10 weeks vs >10 weeks), poorer self-assessed general health (aOR 3.33, 1.49-7.46, for poor vs excellent), immunodeficiencies (aOR 6.75, 2.63-17.35) and prescription of systemic immunosuppressants (aOR 3.76, 2.44-5.78). By contrast, pre-vaccination SARS-CoV-2 seropositivity (aOR 0.16, 0.04-0.70, for symptomatic seropositives vs seronegatives) and supplemental vitamin D intake (aOR 0.73, 0.53-0.99) were associated with reduced risk of post-vaccination seronegativity. 247/378 (65.3%) of participants who were seronegative after two doses of ChAdOx1 vs BNT162b2 provided a third sample at a median of 7.8 weeks (IQR 5.8-10.4) after receiving a booster dose of BNT162b2 or mRNA-1273: eight (3.2%) of them remained seronegative after three vaccine doses, all of whom either had a primary immunodeficiency or were taking systemic immunosuppressant drugs.

InterpretationWe identify multiple determinants of antibody responses to two doses of ChAdOx1 or BNT162b2, many of which are potentially modifiable. Booster doses of BNT162b2 or mRNA-1273 were highly effective in achieving seroconversion in those who failed to mount antibody responses following two doses of ChAdOx1 or BNT162b2.

Study registrationhttps://clinicaltrials.gov/ct2/show/NCT04330599

FundingBarts Charity, Fischer Family Trust, The Exilarchs Foundation, DSM Nutritional Products, Health Data Research UK

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed, medRxiv, and Google Scholar for papers published from January 1, 2020, to February 1, 2022, using the search terms (antibody OR humoral OR serologic* OR immunogenic*) AND (SARS-CoV-2 vaccine OR ChAdOx1 or BNT162b2 coronavirus), with no language restrictions. Population-based studies investigating multiple potential determinants of vaccine immunogenicity in people with known pre-vaccination SARS-CoV-2 serostatus are lacking.

Added value of this studyThis large population-based study, conducted in a population with known pre-vaccination SARS-CoV-2 serostatus, examines a comprehensive range of potential sociodemographic, behavioural, clinical, pharmacological and nutritional determinants of antibody responses to administration of two major SARS-CoV-2 vaccines (i.e., ChAdOx1 or BNT162b2), many of which have not previously been investigated. It is also the first population-based study to characterise antibody responses to booster doses of SARS-CoV-2 vaccines in adults who were seronegative after their primary course of vaccination.

Implications of all the available evidenceIncreased risk of seronegativity following two doses of SARS-CoV-2 vaccines was associated with administration of ChAdOx1 vs BNT162b2, shorter interval between first and second vaccine doses, poorer self-assessed general health, immunocompromise and SARS-CoV-2 seronegativity pre-vaccination. Regular intake of vitamin D supplements was associated with reduced risk of post-vaccination seronegativity. Randomised controlled trials are now needed to test for causality. Booster doses of BNT162b2 or mRNA-1273 were highly effective in achieving seroconversion in the majority of people who failed to mount antibody responses following a primary course of vaccination, the few exceptions being a subset of those with primary immunodeficiency or systemic immunosuppressant drugs.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.02.10.22270799,2022-02-13,https://medrxiv.org/cgi/content/short/2022.02.10.22270799,Evaluating the effectiveness of rapid SARS-CoV-2 genome sequencing in supporting infection control teams: the COG-UK hospital-onset COVID-19 infection study,Oliver Stirrup; James Blackstone; Fiona Mapp; Alyson MacNeil; Monica Panca; Alison Holmes; Nicholas Machin; Gee Yen Shin; Tabitha Mahungu; Kordo Saeed; Tranprit Saluja; Yusri Taha; Nikunj Mahida; Cassie Pope; Anu Chawla; Teresa Cutino-Moguel; Asif Tamuri; Rachel Williams; Alistair Darby; David L Robertson; Flavia Flaviani; Eleni Nastouli; Samuel Robson; Darren Smith; Matthew Loose; Kenneth Laing; Irene Monahan; Beatrix Kele; Sam Haldenby; Ryan George; Matthew Bashton; Adam Witney; Matthew Byott; Francesc Coll; Michael Chapman; Sharon Peacock; - COG-UK HOCI Investigators; - COG-UK Consortium; Joseph Hughes; Gaia Nebbia; David G Partridge; Matthew Parker; James Richard Price; Christine Peters; Sunando Roy; Luke B Snell; Thushan I de Silva; Emma Thomson; Paul Flowers; Andrew Copas; Judith Breuer,"Institute for Global Health, UCL, London, UK; Comprehensive Clinical Trials Unit, UCL, London, UK; Institute for Global Health, UCL, London, UK; Comprehensive Clinical Trials Unit, UCL, London, UK; Comprehensive Clinical Trials Unit, UCL, London, UK; Imperial College Healthcare NHS Trust, London, UK; Manchester University NHS Foundation Trust, Manchester, UK; University College London Hospitals NHS Foundation Trust, London, UK; Royal Free NHS Foundation Trust, London, UK; University Hospital Southampton NHS Foundation Trust, Southampton, UK; Sandwell and West Birmingham NHS Trust, UK; Departments of Virology and Infectious Diseases, Newcastle Hospitals NHS Foundation Trust, Newcastle, UK; Nottingham University Hospitals NHS Trust, Nottingham, UK; St George's University Hospitals NHS Foundation Trust, London, UK; Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK; Barts Health NHS Trust, London, UK; Research Computing, UCL, London, UK; Department of Genetics & Genomic Medicine, UCL Great Ormond Street Institute of Child Health, UCL, London, UK; Centre for Genomic Research, University of Liverpool, Liverpool, UK; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK; University College London Hospitals NHS Foundation Trust, London, UK; Centre for Enzyme Innovation, University of Portsmouth, Portsmouth, UK; Department of Applied Sciences, Northumbria University, Newcastle, UK; School of Life Sciences, University of Nottingham, Nottingham, UK; Institute for Infection and Immunity, St George's University of London, London, UK; Institute for Infection and Immunity, St George's University of London, London, UK; Barts Health NHS Trust, London, UK; Centre for Genomic Research, University of Liverpool, Liverpool, UK; Manchester University NHS Foundation Trust, Manchester, UK; The Hub for Biotechnology in the Built Environment, Department of Applied Sciences, Northumbria University, Newcastle, UK; Institute for Infection and Immunity, St George's University of London, London, UK; University College London Hospitals NHS Foundation Trust, London, UK; Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Health Data Research UK Cambridge Hub, Cambridge UK; Department of Medicine, University of Cambridge, Cambridge, UK; ; ; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Sheffield Bioinformatics Core, The University of Sheffield, Sheffield, UK; Imperial College Healthcare NHS Trust, London, UK; NHS Greater Glasgow and Clyde, Glasgow, UK; Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, UCL, London, UK; Guy's and St Thomas' Hospital NHS Foundation Trust, London, UK; Department of Infection, Immunity and Cardiovascular Disease, Medical School, The University of Sheffield, Sheffield, UK; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; School of Psychological Sciences and Health, University of Strathclyde, Glasgow, UK; Institute for Global Health, UCL, London, UK; Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, UCL, London, UK","IntroductionViral sequencing of SARS-CoV-2 has been used for outbreak investigation, but there is limited evidence supporting routine use for infection prevention and control (IPC) within hospital settings.

MethodsWe conducted a prospective non-randomised trial of sequencing at 14 acute UK hospital trusts. Sites each had a 4-week baseline data-collection period, followed by intervention periods comprising 8 weeks of  rapid (<48h) and 4 weeks of  longer-turnaround (5-10 day) sequencing using a sequence reporting tool (SRT). Data were collected on all hospital onset COVID-19 infections (HOCIs; detected [&ge;]48h from admission). The impact of the sequencing intervention on IPC knowledge and actions, and on incidence of probable/definite hospital-acquired infections (HAIs) was evaluated.

ResultsA total of 2170 HOCI cases were recorded from October 2020-April 2021, with sequence reports returned for 650/1320 (49.2%) during intervention phases. We did not detect a statistically significant change in weekly incidence of HAIs in longer-turnaround (IRR 1.60, 95%CI 0.85-3.01; P=0.14) or rapid (0.85, 0.48-1.50; P=0.54) intervention phases compared to baseline phase. However, IPC practice was changed in 7.8% and 7.4% of all HOCI cases in rapid and longer-turnaround phases, respectively, and 17.2% and 11.6% of cases where the report was returned. In a per-protocol sensitivity analysis there was an impact on IPC actions in 20.7% of HOCI cases when the SRT report was returned within 5 days.

ConclusionWhile we did not demonstrate a direct impact of sequencing on the incidence of nosocomial transmission, our results suggest that sequencing can inform IPC response to HOCIs, particularly when returned within 5 days.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.02.07.22270451,2022-02-08,https://medrxiv.org/cgi/content/short/2022.02.07.22270451,Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose,Alexei Yavlinsky; Sarah Beale; Vincent Nguyen; Madhumita Shrotri; Thomas Edward Byrne; Cyril Geismar; Ellen Fragaszy; Susan J Hoskins; Wing Lam Erica Fong; Annalan Mathew Dwight Navaratnam; Isobel Braithwaite; Parth Patel; Jana Kovar; Andrew C Hayward; Robert W Aldridge,"Institute of Health Informatics, University College London, London, UK; Institute of Epidemiology and Health Care, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, UK; Institute of Health Informatics, University College London, UK; Institute of Health Informatics, University College London, UK; Institute of Health Informatics, University College London, UK; Institute of Epidemiology and Health Care, University College London, London, UK; Institute of Health Informatics, University College London, UK; Institute of Health Informatics, University College London, UK; Institute of Health Informatics, University College London, UK; Institute of Health Informatics, University College London, UK; Institute of Epidemiology and Health Care, University College London, London, UK; Institute of Epidemiology and Health Care, University College London, London, UK; Institute of Health Informatics, University College London, UK","The two most commonly-used SARS-CoV-2 vaccines in the UK, BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca), employ different immunogenic mechanisms. Compared to BNT162b2, two-dose immunisation with ChAdOx1 induces substantially lower peak anti-spike antibody (anti-S) levels and is associated with a higher risk of breakthrough infections. To provide preliminary indication of how a third booster BNT162b2 dose impacts anti-S levels, we performed a cross-sectional analysis using capillary blood samples from vaccinated adults (aged [&ge;]18 years) participating in Virus Watch, a prospective community cohort study in England and Wales. Blood samples were analysed using Roche Elecsys Anti-SARS-CoV-2 S immunoassay. We analysed anti-S levels by week since the third dose for vaccines administered on or after September 1, 2021 and stratified the results by second dose vaccine type (ChAdOx1 or BNT162b2), age, sex and clinical vulnerability. Anti-S levels peaked at two weeks post-booster for BNT162b2 (22,185 U/mL; 95%CI: 21,406-22,990) and ChAdOx1 second dose recipients (19,203 U/mL; 95%CI: 18,094-20,377). These were higher than the corresponding peak antibody levels post-second dose for BNT162b2 (12,386 U/mL; 95%CI: 9,801-15,653, week 2) and ChAdOx1 (1,192 U/mL; 95%CI: 818-1735, week 3). No differences emerged by second dose vaccine type, age, sex or clinical vulnerability. Anti-S levels declined post-booster for BNT162b2 (half-life=44 days) and ChAdOx1 second dose recipients (half-life=40 days). These rates of decline were steeper than those post-second dose for BNT162b2 (half-life=54 days) and ChAdOx1 (half-life=80 days). Our findings suggest that peak anti-S levels are higher post-booster than post-second dose, but that levels are projected to be similar after six months for BNT162b2 recipients. Higher peak anti-S levels post-booster may partially explain the increased effectiveness of booster vaccination compared to two-dose vaccination against symptomatic infection with the Omicron variant. Faster waning trajectories post third-dose may have implications for the timing of future booster campaigns or four-dose vaccination regimens for the clinically vulnerable.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.02.03.22270365,2022-02-06,https://medrxiv.org/cgi/content/short/2022.02.03.22270365,Post-peak dynamics of a national Omicron SARS-CoV-2 epidemic during January 2022,Paul Elliott; Oliver Eales; Barbara Bodinier; David Tang; Haowei Wang; Jakob Jonnerby; David Haw; Joshua Elliott; Matthew Whitaker; Caroline E. Walters; Christina Atchinson; Peter J. Diggle; Andrew J. Page; Alexander Trotter; Deborah Ashby; Wendy Barclay; Graham Taylor; Helen Ward; Ara Darzi; Graham Cooke; Marc Chadeau-Hyam; Christl A Donnelly,"School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Imperial College Healthcare NHS Trust, UK Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; School of Public Health, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc","BackgroundRapid transmission of the SARS-CoV-2 Omicron variant has led to the highest ever recorded case incidence levels in many countries around the world.

MethodsThe REal-time Assessment of Community Transmission-1 (REACT-1) study has been characterising the transmission of the SARS-CoV-2 virus using RT-PCR test results from self-administered throat and nose swabs from randomly-selected participants in England at ages 5 years and over, approximately monthly since May 2020. Round 17 data were collected between 5 and 20 January 2022 and provide data on the temporal, socio-demographic and geographical spread of the virus, viral loads and viral genome sequence data for positive swabs.

ResultsFrom 102,174 valid tests in round 17, weighted prevalence of swab positivity was 4.41% (95% credible interval [CrI], 4.25% to 4.56%), which is over three-fold higher than in December 2021 in England. Of 3,028 sequenced positive swabs, 2,393 lineages were determined and 2,374 (99.2%) were Omicron including 19 (0.80% of all Omicron lineages) cases of BA.2 sub-lineage and one BA.3 (0.04% of all Omicron) detected on 17 January 2022, and only 19 (0.79%) were Delta. The growth of the BA.2 Omicron sub-lineage against BA.1 and its sub-lineage BA.1.1 indicated a daily growth rate advantage of 0.14 (95% CrI, 0.03, 0.28) for BA.2, which corresponds to an additive R advantage of 0.46 (95% CrI, 0.10, 0.92).

Within round 17, prevalence was decreasing overall (R=0.95, 95% CrI, 0.93, 0.97) but increasing in children aged 5 to 17 years (R=1.13, 95% CrI, 1.09, 1.18). Those 75 years and older had a swab-positivity prevalence of 2.46% (95% CI, 2.16%, 2.80%) reflecting a high level of infection among a highly vulnerable group. Among the 3,613 swab-positive individuals reporting whether or not they had had previous infection, 2,334 (64.6%) reported previous confirmed COVID-19. Of these, 64.4% reported a positive test from 1 to 30 days before their swab date. Risks of infection were increased among essential/key workers (other than healthcare or care home workers) with mutually adjusted Odds Ratio (OR) of 1.15 (95% CI, 1.05, 1.26), people living in large compared to single-person households (6+ household size OR 1.73; 95% CI, 1.44, 2.08), those living in urban vs rural areas (OR 1.24, 95% CI, 1.13, 1.35) and those living in the most vs least deprived areas (OR 1.34, 95% CI, 1.20, 1.49).

ConclusionsWe observed unprecedented levels of infection with SARS-CoV-2 in England in January 2022, an almost complete replacement of Delta by Omicron, and evidence for a growth advantage for BA.2 compared to BA.1. The increase in the prevalence of infection with Omicron among children (aged 5 to 17 years) during January 2022 could pose a risk to adults, despite the current trend for prevalence in adults to decline. (Funded by the Department of Health and Social Care in England.)",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.02.04.22270479,2022-02-06,https://medrxiv.org/cgi/content/short/2022.02.04.22270479,Comparative effectiveness of different primary vaccination courses on mRNA based booster vaccines against SARs-COV-2 infections: A time-varying cohort analysis using trial emulation in the Virus Watch community cohort,Vincent Nguyen; Alexei Yavlinsky; Sarah Beale; Susan J Hoskins; Vasileios J Lampos; Isobel Braithwaite; Thomas Edward Byrne; Wing Lam Erica Fong; Ellen Fragaszy; Cyril Geismar; Jana Kovar; Annalan Mathew Dwight Navaratnam; Parth Patel; Madhumita Shrotri; Sophie Weber; Andrew Hayward; Robert W Aldridge,"University College London; University College London; University College London; Univerity College London; University College London; University College London; University College London; University College London, London School of Hygiene &Tropical Medicine; UCL, London School of Hygiene & Tropical Medicine; University College London; University College London; University College London; University College London; Univeristy College London; University College London; University College London; University College London","ImportanceThe Omicron (B.1.1.529) variant has increased SARs-CoV-2 infections in double vaccinated individuals globally, particularly in ChAdOx1 recipients. To tackle rising infections, the UK accelerated booster vaccination programmes used mRNA vaccines irrespective of an individuals primary course vaccine type with booster doses rolled out according to clinical priority. There is limited understanding of the effectiveness of different primary vaccination courses on mRNA based booster vaccines against SARs-COV-2 infections and how time-varying confounders can impact the evaluations comparing different vaccines as primary courses for mRNA boosters.

ObjectiveTo evaluate the comparative effectiveness of ChAdOx1 versus BNT162b2 as primary doses against SARs-CoV-2 in booster vaccine recipients whilst accounting for time-varying confounders.

DesignTrial emulation was used to reduce time-varying confounding-by-indication driven by prioritising booster vaccines based upon age, vulnerability and exposure status e.g. healthcare worker. Trial emulation was conducted by meta-analysing eight cohort results whose booster vaccinations were staggered between 16/09/2021 to 05/01/2022 and followed until 23/01/2022. Time from booster vaccination until SARS-CoV-2 infection, loss of follow-up or end-of-study was modelled using Cox proportional hazards models for each cohort and adjusted for age, sex, minority ethnic status, clinically vulnerability, and deprivation.

SettingProspective observational study using the Virus Watch community cohort in England and Wales.

ParticipantsPeople over the age of 18 years who had their booster vaccination between 16/09/2021 to 05/01/2022 without prior natural immunity.

ExposuresChAdOx1 versus BNT162b2 as a primary dose, and an mRNA booster vaccine.

ResultsAcross eight cohorts, 19,692 mRNA vaccine boosted participants were analysed with 12,036 ChAdOx1 and 7,656 BNT162b2 primary courses with a median follow-up time of 73 days (IQR:54-90). Median age, clinical vulnerability status and infection rates fluctuate through time. 7.2% (n=864) of boosted adults with ChAdOx1 primary course experienced a SARS-CoV-2 infection compared to 7.6% (n=582) of those with BNT162b2 primary course during follow-up. The pooled adjusted hazard ratio was 0.99 [95%CI:0.88-1.11], demonstrating no difference between the incidence of SARs-CoV-2 infections based upon the primary vaccine course.

Conclusion and RelevanceIn mRNA boosted individuals, we found no difference in protection comparing those with a primary course of BNT162b2 to those with aChAdOx1 primary course. This contrasts with pre-booster findings where previous research shows greater effectiveness of BNT162b2 than ChAdOx1 in preventing infection.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.02.01.22270269,2022-02-02,https://medrxiv.org/cgi/content/short/2022.02.01.22270269,Nucleocapsid and spike antibody responses post virologically confirmed SARS-CoV-2 infection: An observational analysis in the Virus Watch community cohort,Annalan Mathew Dwight Navaratnam; Madhumita Shrotri; Vincent Nguyen; Isobel Braithwaite; Sarah Beale; Thomas E Byrne; Wing Lam Erica Fong; Ellen Fragaszy; Cyril Geismar; Susan Hoskins; Jana Kovar; Parth Patel; Alexei Yavlinsky; Anna Aryee; Alison Rodger; Andrew C Hayward; Robert W Aldridge,University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London,"IntroductionSeroprevalence studies can provide a measure of cumulative incidence of SARS-CoV-2 infection, but a better understanding of antibody dynamics following infection is needed to assess longevity of detectability. Infection is characterised by detection of spike (anti-S) and nucleocapsid (anti-N) antibodies, whereas vaccination only stimulates anti-S. Consequently, in the context of a highly vaccinated population, presence of anti-N can be used as a marker of previous infection but waning over time may limit its use.

MethodsAdults aged [&ge;]18 years old, from households enrolled in the Virus Watch prospective community cohort study in England and Wales, provided monthly capillary blood samples which were tested for anti-S and anti-N. Participants self-reported vaccination dates and past medical history. Prior polymerase chain reaction (PCR) swabs were obtained through Second Generation Surveillance System (SGSS) linkage data. Primary outcome variables were seropositivity (antibodies at or above the manufacturers cut-off for positivity) and total anti-N and anti-S levels after PCR confirmed infection. Outcomes were analysed by days since infection, self-reported demographic and clinical factors.

ResultsA total of 13,802 eligible individuals, median age 63, provided 58,770 capillary blood samples. 537 of these had a prior positive PCR confirmed SARS-CoV-2 infection 0-269 days before the antibody sample date. 432 out of the 537 (80.44%) were anti-N positive and detection remained stable through-out follow-up. Median anti-N levels peaked between days 90 and 119 post PCR results and then began to decline. Logistic regression models, both univariable and multivariable, only showed higher odds of positive anti-N result between 0-269 days for 35-49 year olds, compared to 18-34 year olds. There is evidence of anti-N waning from 120 days onwards, with earlier waning for females and younger age categories.

DiscussionApproximately 4 in 5 participants with prior PCR-confirmed infection were anti-N positive, and this remained stable through follow-up for at least 269 days. However, median antibody levels began to decline from about 120 days post-infection. This suggests that anti-N have around 80% sensitivity for identifying previous COVID-19 infection and that this sensitivity is maintained through 269 days of follow up.

FundingThe research costs for the study have been supported by the MRC Grant Ref: MC_PC 19070 awarded to UCL on 30 March 2020 and MRC Grant Ref: MR/V028375/1 awarded on 17 August 2020. The study also received $15,000 of Facebook advertising credit to support a pilot social media recruitment campaign on 18th August 2020. The study also received funding from the UK Government Department of Health and Social Cares Vaccine Evaluation Programme to provide monthly Thriva antibody tests to adult participants. This study was supported by the Wellcome Trust through a Wellcome Clinical Research Career Development Fellowship to RA [206602].",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.02.01.22270235,2022-02-02,https://medrxiv.org/cgi/content/short/2022.02.01.22270235,Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study,Kamen A Tsvetanov; Lennart R B Spindler; Emmanuel A Stamatakis; Virginia FJ Newcombe; Victoria C Lupson; Doris A Chatfield; Anne E Manktelow; Joanne G Outtrim; Anne Elmer; Nathalie Kingston; John R Bradley; Edward T Bullmore; James B Rowe; David K Menon; - the Cambridge NeuroCOVID Group; - the NIHR COVID-19 BioResource; - the Cambridge NIHR Clinical Research Facility; - the CITIID-NIHR BioResource COVID-19 collaboration,"Department of Clinilcal Neurosciences, University of Cambridge, Cambridge, UK; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.; Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.; Division of Anaesthesia, Department of Medicine, University Cambridge, Cambridge, UK.; Division of Anaesthesia, Department of Medicine, University Cambridge, Cambridge, UK.; Division of Anaesthesia, Department of Medicine, University Cambridge, Cambridge, UK.; Division of Anaesthesia, Department of Medicine, University Cambridge, Cambridge, UK.; Division of Anaesthesia, Department of Medicine, University Cambridge, Cambridge, UK.; Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK; NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge, UK.; Department of Haematology, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.; Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.; Medical Research Council Cognition and Brain Sciences Unit, Department of Psychiatry, Cambridge, UK.; Division of Anaesthesia, Department of Medicine, University Cambridge, Cambridge, UK.; -; -; -; -","Human coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has multiple neurological consequences, but its long-term effect on brain health is still uncertain. The cerebrovascular consequences of COVID-19 may also affect brain health. Here we assess cerebrovascular health in 45 hospitalised patients using the resting state fluctuation amplitudes (RSFA) from functional magnetic resonance imaging, in relation to disease severity and in contrast with 42 controls. Widespread changes in frontoparietal RSFA were related to the severity of the acute COVID-19 episode, as indexed by COVID-19 WHO Progression Scale, inflammatory and coagulatory biomarkers. This relationship was not explained by chronic cardiorespiratory dysfunction, age, or sex. Exploratory analysis suggests that the level of cerebrovascular dysfunction is associated with cognitive, mental, and physical health at follow-up. The principal findings were consistent across univariate and multivariate approaches. The results indicate chronic cerebrovascular impairment following severe acute COVID-19, with the potential for long-term consequences on cognitive function and mental wellbeing.",neurology,fuzzy,100,100
medRxiv,10.1101/2022.01.31.22269194,2022-02-01,https://medrxiv.org/cgi/content/short/2022.01.31.22269194,"An outbreak of SARS-CoV-2 in a public-facing office in England, 2021",Barry Atkinson; Karin van Veldhoven; Ian Nicholls; Matthew Coldwell; Adam Clarke; Gillian Frost; Christina J Atchison; Amber I Raja; Allan M Bennett; Derek Morgan; Neil Pearce; Tony Fletcher; Elizabeth B Brickley; Yiqun Chen,UK Health Security Agency; London School of Hygiene & Tropical Medicine; UK Health Security Agency; Health and Safety Executive; Health and Safety Executive; Health and Safety Executive; UK Health Security Agency; London School of Hygiene & Tropical Medicine; UK Health Security Agency; Health and Safety Executive; London School of Hygiene & Tropical Medicine; UK Health Security Agency; London School of Hygiene & Tropical Medicine; Health and Safety Executive,"Between August-September 2021, an outbreak of SARS-CoV-2, with an attack rate of 55% (22/40 workers), occurred in a public-facing office in England. To identify workplace and worker-related risk factors, a comprehensive investigation involving surface sampling, environmental assessment, molecular and serological testing, and worker questionnaires was performed in September - October 2021. The results affirm the utility of surface sampling to identify SARS-CoV-2 control deficiencies and the importance of evolving, site-specific risk assessments with layered COVID-19 mitigation strategies.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.01.28.22270013,2022-01-29,https://medrxiv.org/cgi/content/short/2022.01.28.22270013,Agility and sustainability: A qualitative evaluation of COVID-19 Non-pharmaceutical Interventions (NPIs) in the UK logistics sector,Hua Wei; Sarah A Daniels; Carl A Whitfield; Yang Han; David W Denning; Ian Hall; Martyn Regan; Arpana Verma; Martie J van Tongeren,The University of Manchester; The University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester,"BackgroundThe emergence of SARS-CoV-2 triggered a chain of public health responses that radically changed our way of living and working. Non-healthcare sectors, such as the logistics sector, play a key role in such responses. This research aims to qualitatively evaluate the non-pharmaceutical interventions (NPIs) implemented in the UK logistics sector during the COVID-19 pandemic.

MethodsWe conducted nine semi-structured interviews in July-August 2020 and May-June 2021. In total 11 interviewees represented six companies occupying a range of positions in the UKs logistics sector, including takeaway food delivery, large and small goods delivery and home appliance installation, and logistics technology providers. Inductive thematic analysis was completed using NVivo12 to generate emerging themes and subthemes. Themes/subthemes relevant to interventions were mapped deductively onto an adapted Hierarchy of Control (HoC) framework, focusing on delivery workers. Themes/subthemes relevant to the process of implementation were analyzed to understand the barriers and facilitators of rapid responses.

ResultsHoC analysis suggests the sector has implemented a wide range of risk mitigation measures, with each company developing their own portfolio of measures. Contact-free delivery was the most commonly implemented measure and perceived effective. In addition, a broad range of measures were implemented, including social distancing, internal contact tracing, communication and collaboration with other key stakeholders of the sector. Process evaluation identified facilitators of rapid responses including capacity to develop interventions internally, localized government support, overwhelming external mandates, effective communication, leadership support and financial support for self-isolation, while barriers included unclear government guidance, shortage of testing capacity and supply, high costs and diversified language and cultural backgrounds. Main sustainability issues included compliance fatigue, and the possible mental health impacts of a prolonged rapid response.

ConclusionsThis research identified drivers and obstacles of rapid implementation of NPIs in response to a respiratory infection pandemic. Existing implementation process models do not consider speed to respond and the absence or lack of guidance in emergency situations such as the COVID-19. We recommend the development of a rapid response model to inform the design of effective and sustainable infection prevention and control policies and to focus future research priorities.

Contributions to the fieldO_LIThe study offered important insights into the process of the UK logistics sectors response to the COVID-19 pandemic.
C_LIO_LIThe Hierarchy of Control (HoC) framework was adapted for the evaluation of a collection of non-pharmaceutical interventions (NPIs) implemented in a non-healthcare sector.
C_LIO_LIThematic analysis of qualitative data generated themes that were relevant to the process of rapid implementation of NPIs during a public health emergency.
C_LIO_LIBarriers, facilitators and sustainability issues of the sectors rapid response to the COVID-19 pandemic have been highlighted to inform future research on implementation strategies.
C_LI",occupational and environmental health,fuzzy,100,100
medRxiv,10.1101/2022.01.26.22269901,2022-01-28,https://medrxiv.org/cgi/content/short/2022.01.26.22269901,The impact of the COVID-19 pandemic on health service utilisation following self-harm: a systematic review,Sarah Steeg; Ann John; David Gunnell; Nav Kapur; Dana Dekel; Lena Schmidt; Duleeka Kniipe; Ella Arensman; Keith Hawton; Julian PT Higgins; Emily Eyles; Catherine Macleod-Hall; Luke A McGuinness; Roger T Webb,University of Manchester; Swansea University; University of Bristol; University of Manchester; University of Swansea; University of Bristol; University of Bristol; University College Cork; University of Oxford; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Manchester,"BackgroundEvidence on the impacts of the pandemic on healthcare presentations for self-harm has accumulated rapidly. However, existing reviews do not include studies published beyond 2020.

AimsTo systematically review evidence on health services utilisation for self-harm during the COVID-19 pandemic.

MethodsA comprehensive search of multiple databases (WHO COVID-19 database; Medline; medRxiv; Scopus; PsyRxiv; SocArXiv; bioRxiv; COVID-19 Open Research Dataset, PubMed) was conducted. Studies reporting presentation frequencies for self-harm published from 1st Jan. 2020 to 7th Sept. 2021 were included. Study quality was assessed using a critical appraisal tool.

ResultsFifty-one studies were included. 59% (30/51) were rated as  low quality, 29% (15/51) as  moderate and 12% (6/51) as  high-moderate. Most evidence (84%, 43/51 studies) was from high-income countries. 47% (24/51) of studies reported reductions in presentation frequency, including all 6 rated as high-moderate quality, which reported reductions of 17- 56%. Settings treating higher lethality self-harm were overrepresented among studies reporting increased demand. Two of the 3 higher quality studies including study observation months from 2021 reported reductions in service utilisation. Evidence from 2021 suggested increased use of health services following self-harm among adolescents, particularly girls.

ConclusionsSustained reductions in service utilisation were seen into the first half of 2021. However, evidence from low- and middle-income countries is lacking. The increased use of health services among adolescents, particularly girls, into 2021 is of concern. Our findings may reflect changes in thresholds for help seeking, use of alternative sources of support and variable effects of the pandemic across different groups.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.01.26.22269540,2022-01-28,https://medrxiv.org/cgi/content/short/2022.01.26.22269540,Impact of voluntary risk-mitigation behaviour on transmission of the Omicron SARS-CoV-2 variant in England,Ellen Brooks-Pollock; Kate Northstone; Lorenzo Pellis; Francesca Scarabel; Amy C Thomas; Emily J Nixon; David A Matthews; Vicky Bower; Maria-Paz Garcia; Claire J Steves; Nicholas J Timpson; Leon Danon,"University of Bristol; University of Bristol; The University of Manchester; University of Manchester; University of Bristol; University of Bristol; University of Bristol; King's College London; King's College London; King's College London; University of Bristol; Department of Engineering Mathematics, University of Bristol, UK.","BackgroundThe Omicron variant of SARS-CoV-2 infection poses substantial challenges to public health. In England, ""plan B"" mitigation measures were introduced in December 2021 including increased home working and face coverings in shops, but stopped short of restrictions on social contacts. The impact of voluntary risk mitigation behaviours on future SARS-CoV-2 burden is unknown.

MethodsWe developed a rapid online survey of risk mitigation behaviours during the winter 2021 festive period and deployed in two longitudinal cohort studies in the UK (Avon Longitudinal Study of Parents and Children (ALSPAC) and TwinsUK/Covid Symptom Study (CSS) Biobank) in December 2021. Using an individual-based, probabilistic model of COVID-19 transmission between social contacts with SARS-CoV-2 Omicron variant parameters and realistic vaccine coverage in England, we describe the potential impact of the SARS-CoV-2 Omicron wave in England in terms of the effective reproduction number and cumulative infections, hospital admissions and deaths. Using survey results, we estimated in real-time the impact of voluntary risk mitigation behaviours on the Omicron wave in England, if implemented for the entire epidemic wave.

ResultsOver 95% of survey respondents (NALSPAC=2,686 and NTwins=6,155) reported some risk mitigation behaviours, with vaccination and using home testing kits reported most frequently. Less than half of those respondents reported that their behaviour was due to ""plan B"". We estimate that without risk mitigation behaviours, the Omicron variant is consistent with an effective reproduction number between 2.5 and 3.5. Due to the reduced vaccine effectiveness against infection with the Omicron variant, our modelled estimates suggest that between 55% and 60% of the English population could be infected during the current wave, translating into between 15,000 and 46,000 cumulative deaths, depending on assumptions about vaccine effectiveness. We estimate that voluntary risk reduction measures could reduce the effective reproduction number to between 1.8 and 2.2 and reduce the cumulative number of deaths by up to 24%.

ConclusionsWe conclude that voluntary measures substantially reduce the projected impact of the SARS-CoV-2 Omicron variant, but that voluntary measures alone would be unlikely to completely control transmission.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.01.26.22269877,2022-01-27,https://medrxiv.org/cgi/content/short/2022.01.26.22269877,The impacts of increased global vaccine sharing on the COVID-19 pandemic; a retrospective modelling study,Sam Moore; Edward M Hill; Louise J Dyson; Michael J Tildesley; Matt J Keeling,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"BackgroundThe SARS-CoV-2 pandemic has generated considerable morbidity and mortality world-wide. While the protection offered by vaccines (and booster doses) offers a method of mitigating the worst effects, by the end of 2021 the distribution of vaccine was highly heterogeneous with some countries achieving over 90% coverage in adults by the end of 2021, while others have less than 2%. In part, this is due to the availability of sufficient vaccine, although vaccine hesitancy also plays a role.

MethodsWe use an age-structured model of SARS-CoV-2 dynamics, matched to national data from 152 countries, to investigate the global impact of different vaccine sharing protocols during 2021. We assume a direct relationship between the emergence of variants with increased transmissibility and the cumulative amount of global infection, such that lower global prevalence leads to a lower reproductive number within each country. We compare five vaccine sharing scenarios, from the current situation, through sharing once a particular within-country threshold is reached (e.g. all over 40s have received 2 doses), to full sharing where all countries achieve equal age-dependent vaccine deployment.

FindingsCompared to the observed distribution of vaccine uptake, we estimate full vaccine sharing would have generated a 1.5% (PI -0.1 - 4.5%) reduction in infections and a 11.3% (PI 0.6 - 23.2%) reduction in mortality globally by January 2022. The greatest benefit of vaccine sharing would have been experienced by low and middle income countries, who see an average 5.2% (PI 2.5% - 10.4%) infection reduction and 26.8% (PI 24.1% - 31.3%) mortality reduction. Many high income countries, that have had high vaccine uptake (most notably Canada, Chile, UK and USA), suffer increased infections and mortality under most of the sharing protocols investigated, assuming no other counter measures had been taken. However, if reductions in vaccine supply in these countries had been offset by prolonged use of non-pharmaceutical intervention measures, we predict far greater reductions in global infection and mortality of 64.5% (PI 62.6% - 65.4%) and 62.8% (PI 44.0% - 76.3%), respectively.

InterpretationBy itself, our results suggest that although more equitable vaccine distribution would have had limited impact on overall infection numbers, vaccine sharing would have substantially reduced global mortality by providing earlier protection of the most vulnerable. If increased vaccine sharing from high income nations had been combined with slower easing of non pharmaceutical interventions to compensate for this, a large reduction in both infection and mortality globally would be expected, confounded by a lower risk of new variants arising.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.01.26.22269885,2022-01-27,https://medrxiv.org/cgi/content/short/2022.01.26.22269885,SARS-CoV-2 anti-spike antibody levels following second dose of ChAdOx1 nCov-19 or BNT162b2 in residents of long-term care facilities in England (VIVALDI),Oliver Stirrup; Maria Krutikov; Gokhan Tut; Tom Palmer; David Bone; Rachel Bruton; Christopher Fuller; Borscha Azmi; Tara Lancaster; Panagiota Sylla; Nayandeep Kaur; Eliska Spalkova; Christopher Bentley; Umayr Amin; Azar Jadir; Samuel Hulme; Rebecca Giddings; Hadjer Nacer-Laidi; Verity Baynton; Aidan Irwin-Singer; Andrew Hayward; Paul Moss; Andrew Copas; Laura Shallcross,"University College London; University College London; University of Birmingham, Medical School; UCL Institute for Global Health; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; UCL Institute of Health Informatics; UCL Institute of Health Informatics; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; UCL Institute of Health Informatics; UCL Institute of Health Informatics; UK Department of Health and Social Care; UK Department of Health and Social Care; UCL; University of Birmingham; UCL Institute for Global Health; UCL","BackgroundGeneral population studies have shown strong humoral response following SARS-CoV-2 vaccination with subsequent waning of anti-spike antibody levels. Vaccine-induced immune responses are often attenuated in frail and older populations such as Long-Term Care Facility (LTCF) residents but published data are scarce.

MethodsVIVALDI is a prospective cohort study in England which links serial blood sampling in LTCF staff and residents to routine healthcare records. We measured quantitative titres of SARS-CoV-2 anti-spike antibodies in residents and staff following second vaccination dose with ChAdOx1 nCov-19 (Oxford-AstraZeneca) or BNT162b2 (Pfizer-BioNTech). We investigated differences in peak antibody levels and rates of decline using linear mixed effects models.

ResultsWe report on 1317 samples from 402 residents (median age 86 years, IQR 78-91) and 632 staff (50 years, 37-58), [&le;]280 days from second vaccination dose. Peak antibody titres were 7.9-fold higher after Pfizer-BioNTech vaccine compared to Oxford-AstraZeneca (95%CI 3.6-17.0; P<0.01) but rate of decline was increased, and titres were similar at 6 months. Prior infection was associated with higher peak antibody levels in both Pfizer-BioNTech (2.8-fold, 1.9-4.1; P<0.01) and Oxford-AstraZeneca (4.8-fold, 3.2-7.1; P<0.01) recipients and slower rates of antibody decline. Increasing age was associated with a modest reduction in peak antibody levels for Oxford-AstraZeneca recipients.

ConclusionsDouble-dose vaccination elicits robust and stable antibody responses in older LTCF residents, suggesting comparable levels of vaccine-induced immunity to that in the general population. Antibody levels are higher after Pfizer-BioNTech vaccination but fall more rapidly compared to Oxford-AstraZeneca recipients and are enhanced by prior infection in both groups.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.01.21.22269605,2022-01-23,https://medrxiv.org/cgi/content/short/2022.01.21.22269605,Severe outcomes in residents of Long Term Care Facilities following infection with SARS-CoV-2 Omicron variant (VIVALDI study),Maria Krutikov; Oliver Stirrup; Hadjer Nacer-Laidi; Borscha Azmi; Chris Fuller; Gokhan Tut; Tom Palmer; Madhumita Shrotri; Aidan Irwin-Singer; Verity Baynton; - The COVID-19 Genomics UK (COG-UK) consortium; Andrew Hayward; Paul Moss; Andrew Copas; Laura Shallcross,"University College London; University College London; University College London; University College London; University College London; University of Birmingham, Medical School; University College London; University College London; UK Department of Health & Social Care; UK Department of Health & Social Care; ; UCL; University of Birmingham; University College London; UCL","BackgroundRecently there has been a rapid, global increase in SARS-CoV-2 infections associated with the Omicron variant (B.1.1.529). Although severity of Omicron cases may be reduced, the scale of infection suggests hospital admissions and deaths may be substantial. Definitive conclusions about disease severity require evidence from populations with the greatest risk of severe outcomes, such as residents of Long-Term Care Facilities (LTCFs).

MethodsWe used a cohort study to compare the risk of hospital admission or death in LTCF residents in England who had tested positive for SARS-CoV-2 in the period shortly before Omicron emerged (Delta dominant) and the Omicron-dominant period, adjusting for age, sex, vaccine type, and booster vaccination. Variants were confirmed by sequencing or spike-gene status in a subset.

ResultsRisk of hospital admission was markedly lower in 1241 residents infected in the Omicron-period (4.01% hospitalised, 95% CI: 2.87-5.59) compared to 398 residents infected in the pre-Omicron period (10.8% hospitalised, 95% CI: 8.13-14.29, adjusted Hazard Ratio 0.50, 95% CI: 0.29-0.87, p=0.014); findings were similar in residents with confirmed variant. No residents with previous infection were hospitalised in either period. Mortality was lower in the Omicron versus the pre-Omicron period, (p<0.0001).

ConclusionsRisk of severe outcomes in LTCF residents with the SARS-CoV-2 Omicron variant was substantially lower than that seen for previous variants. This suggests the current wave of Omicron infections is unlikely to lead to a major surge in severe disease in LTCF populations with high levels of vaccine coverage and/or natural immunity.

Trial Registration NumberISRCTN 14447421",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2022.01.21.22269651,2022-01-22,https://medrxiv.org/cgi/content/short/2022.01.21.22269651,"Prior health-related behaviours in children (2014-2020) and association with a positive SARS-CoV-2 test during adolescence (2020-2021): a retrospective cohort study using survey data linked with routine health data in Wales, UK",Emily Marchant; Emily Lowthian; Tom Crick; Lucy Griffiths; Richard Fry; Kevin Dadaczynski; Orkan Okan; Michaela James; Laura Cowley; Fatemeh Torabi; Jonathan Kennedy; Ashley Akbari; Ronan Lyons; Sinead Brophy,Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Fulda University of Applied Sciences; Technical University Munich; Swansea University; Public Health Wales; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University,"ObjectivesExamine if pre-COVID-19 pandemic (prior March 2020) health-related behaviours during primary school are associated with i) being tested for SARS-CoV-2 and ii) testing positive between 1 March 2020 to 31 August 2021.

DesignRetrospective cohort study using an online cohort survey (January 2018 to February 2020) linked to routine PCR SARS-CoV-2 test results.

SettingChildren attending primary schools in Wales (2018-2020), UK who were part of the HAPPEN school network.

ParticipantsComplete linked records of eligible participants were obtained for n=7,062 individuals. 39.1% (n=2,764) were tested (age 10.6{+/-}0.9, 48.9% girls) and 8.1% (n=569) tested positive for SARS-CoV-2 (age 10.6{+/-}1.0, 54.5% girls).

Main outcome measuresLogistic regression of health-related behaviours and demographics were used to determine Odds Ratios (OR) of factors associated with i) being tested for SARS-CoV-2 and ii) testing positive for SARS-CoV-2.

ResultsConsuming sugary snacks (1-2 days/week OR=1.24, 95% CI 1.04 - 1.49; 5-6 days/week 1.31, 1.07 - 1.61; reference 0 days) can swim 25m (1.21, 1.06 - 1.39) and age (1.25, 1.16 - 1.35) were associated with an increased likelihood of being tested for SARS-CoV-2. Eating breakfast (1.52, 1.01 - 2.27), weekly physical activity [&ge;] 60 mins (1-2 days 1.69, 1.04 - 2.74; 3-4 days 1.76, 1.10 - 2.82, reference 0 days), out of school club participation (1.06, 1.02 - 1.10), can ride a bike (1.39, 1.00 - 1.93), age (1.16, 1.05 - 1.28) and girls (1.21, 1.00 - 1.46) were associated with an increased likelihood of testing positive for SARS-CoV-2. Living in least deprived quintiles 4 (0.64, 0.46 - 0.90) and 5 (0.64, 0.46 - 0.89) compared to the most deprived quintile was associated with a decreased likelihood.

ConclusionsAssociations may be related to parental health literacy and monitoring behaviours. Physically active behaviours may include co-participation with others, and exposure to SARS-CoV-2. A risk versus benefit approach must be considered given the importance of health-related behaviours for development.

STRENGTHS AND LIMITATIONSO_LIInvestigation of the association of pre-pandemic child health-related behaviour measures with subsequent SARS-CoV-2 testing and infection.
C_LIO_LIReporting of multiple child health behaviours linked at an individual-level to routine records of SARS-CoV-2 testing data through the SAIL Databank.
C_LIO_LIChild-reported health behaviours were measured before the COVID-19 pandemic (1 January 2018 to 28 February 2020) which may not reflect behaviours during COVID-19.
C_LIO_LIHealth behaviours captured through the national-scale HAPPEN survey represent children attending schools that engaged with the HAPPEN Wales primary school network and may not be representative of the whole population of Wales.
C_LIO_LIThe period of study for PCR-testing for and testing positive for SARS-CoV-2 includes a time frame with varying prevalence rates, approaches to testing children (targeted and mass testing) and restrictions which were not measured in this study.
C_LI",public and global health,fuzzy,100,100
bioRxiv,10.1101/2022.01.14.475727,2022-01-18,https://biorxiv.org/cgi/content/short/2022.01.14.475727,Obesity associated with attenuated tissue immune cell responses in COVID-19,Shuang Andrew Guo; Georgina S Bowyer; John Robert Ferdinand; Mailis Maes; Zewen K Tuong; Eleanor Gilman; Rik G. H. Lindeboom; Masahiro Yoshida; Kaylee Worlock; Hudaa Gopee; Emily Stephenson; Paul A Lyons; Kenneth G. C. Smith; Muzlifah Haniffa; Kerstin B Meyer; Marko Z Nikolic; Richard G Wunderink; Alexander V Misharin; Gordon Dougan; Vilas Navapurkar; Sarah A Teichmann; Andrew Conway Morris; Menna R Clatworthy,University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Wellcome Sanger Institute; University College London; University College London; Newcastle University; Newcastle University; University of Cambridge; University of Cambridge; Newcastle University; Wellcome Sanger Institute; University College London; Northwestern University; Northwestern University; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Wellcome Sanger Institute; University of Cambridge; University of Cambridge,"Obesity is common and associated with more severe COVID-19, proposed to be in part related to an adipokine-driven pro-inflammatory state. Here we analysed single cell transcriptomes from bronchiolar lavage in three adult cohorts, comparing obese (Ob, body mass index (BMI) >30m2) and non-obese (N-Ob, BMI <30m2). Surprisingly, we found that Ob subjects had attenuated lung immune/inflammatory responses in SARS-CoV-2 infection, with decreased expression of interferon (IFN), IFN{gamma} and tumour necrosis factor (TNF) alpha response gene signatures in almost all lung epithelial and immune cell subsets, and lower expression of IFNG and TNF in specific lung immune cells. Analysis of peripheral blood immune cells in an independent adult cohort showed a similar, but less marked, reduction in type I IFN and IFN{gamma} response genes, as well as decreased serum IFN, in Ob patients with SARS-CoV-2. Nasal immune cells from Ob children with COVID-19 also showed reduced enrichment of IFN and IFN{gamma} response genes. Altogether, these findings show blunted tissue immune responses in Ob COVID-19 patients, with clinical implications.",immunology,fuzzy,100,100
medRxiv,10.1101/2022.01.18.22269082,2022-01-18,https://medrxiv.org/cgi/content/short/2022.01.18.22269082,OMICRON-ASSOCIATED CHANGES IN SARS-COV-2 SYMPTOMS IN THE UNITED KINGDOM,Karina-Doris Vihta; Koen B. Pouwels; Tim EA Peto; Emma Pritchard; Thomas House; Ruth Studley; Emma Rourke; Duncan Cook; Ian Diamond; Derrick Crook; David A Clifton; Philippa C. Matthews; Nicole Stoesser; David W. Eyre; Ann Sarah Walker; - COVID-19 Infection Survey team,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Manchester; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistcs; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ,"BackgroundThe SARS-CoV-2 Delta variant has been replaced by the highly transmissible Omicron BA.1 variant, and subsequently by Omicron BA.2. It is important to understand how these changes in dominant variants affect reported symptoms, while also accounting for symptoms arising from other co-circulating respiratory viruses.

MethodsIn a nationally representative UK community study, the COVID-19 Infection Survey, we investigated symptoms in PCR-positive infection episodes vs. PCR-negative study visits over calendar time, by age and vaccination status, comparing periods when the Delta, Omicron BA.1 and BA.2 variants were dominant.

ResultsBetween October-2020 and April-2022, 120,995 SARS-CoV-2 PCR-positive episodes occurred in 115,886 participants, with 70,683 (58%) reporting symptoms. The comparator comprised 4,766,366 PCR-negative study visits (483,894 participants); 203,422 (4%) reporting symptoms. Symptom reporting in PCR-positives varied over time, with a marked reduction in loss of taste/smell as Omicron BA.1 dominated, maintained with BA.2 (44%/45% 17 October 2021, 16%/13% 2 January 2022, 15%/12% 27 March 2022). Cough, fever, shortness of breath, myalgia, fatigue/weakness and headache also decreased after Omicron BA.1 dominated, but sore throat increased, the latter to a greater degree than concurrent increases in PCR-negatives. Fatigue/weakness increased again after BA.2 dominated, although to a similar degree to concurrent increases in PCR-negatives. Symptoms were consistently more common in adults aged 18-65 years than in children or older adults.

ConclusionsIncreases in sore throat (also common in the general community), and a marked reduction in loss of taste/smell, make Omicron harder to detect with symptom-based testing algorithms, with implications for institutional and national testing policies.

SummaryIn a UK community study, loss of taste/smell was markedly less commonly reported with Omicron BA.1/BA.2 than Delta SARS-CoV-2 infections, with smaller declines in reported shortness of breath, myalgia and fatigue/weakness, but increases in sore throat, challenging symptom-based testing algorithms.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.01.16.22269146,2022-01-17,https://medrxiv.org/cgi/content/short/2022.01.16.22269146,Development and validation of the Symptom Burden Questionnaire‚Ñ¢ for Long COVID: a Rasch analysis,Sarah E Hughes; Shamil Haroon; Anuradhaa Subramanian; Christel McMullan; Olalekan L Aiyegbusi; Grace M Turner; Louise Jackson; Elin Haf Davies; Chris Frost; Gary McNamara; Gary Price; Karen Matthews; Jennifer Camaradou; Jane Ormerod; Anita Walker; Melanie J Calvert,"University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; Aparito Limited; Aparito Limited; Aparito Limited; University of Birmingham; Patient and Public Involvement, Therapies for Long COVID (TLC) study, University of Birmingham; Patient and Public Involvement, Therapies for Long COVID (TLC) study, University of Birmingham; Patient and Public Involvement, Therapies for Long COVID (TLC) study, University of Birmingham; University of Birmingham; University of BIrmingham","ObjectiveTo describe the development and initial validation of a novel patient-reported outcome measure of Long COVID symptom burden, the Symptom-Burden Questionnaire for Long COVID (SBQ-LC).

Method and FindingsThis multi-phase, prospective mixed-methods study took place between April and August 2021 in the United Kingdom (UK). A conceptual framework and initial item pool were developed from published systematic reviews. Further concept elicitation and content validation was undertaken with adults with lived experience (n = 13) and clinicians (n = 10), and face validity was confirmed by the Therapies for Long COVID Study Patient and Public Involvement group (n = 25). The draft SBQ-LC was field tested by adults with self-reported Long COVID recruited via social media and international Long COVID support groups (n = 274). Thematic analysis of interview and survey transcripts established content validity and informed construction of the draft questionnaire. Rasch analysis of field test data guided item and scale refinement and provided evidence of the final SBQ-LCs measurement properties. The Rasch-derived SBQ-LC is composed of 17 independent scales with promising psychometric properties. Respondents rate symptom burden during the past 7-days using a dichotomous response or 4-point rating scale. Each scale provides coverage of a different symptom domain and returns a summed raw score that may be converted to a linear (0 - 100) score. Higher scores represent higher symptom burden.

ConclusionsThe SBQ-LC is a comprehensive patient-reported assessment of Long COVID symptom burden developed using modern psychometric methods. It measures symptoms of Long COVID important to individuals with lived experience and may be used to evaluate the impact of interventions and inform best practice in clinical management.",health informatics,fuzzy,100,100
medRxiv,10.1101/2022.01.13.22268948,2022-01-14,https://medrxiv.org/cgi/content/short/2022.01.13.22268948,Algorithmic Fairness and Bias Mitigation for Clinical Machine Learning: Insights from Rapid COVID-19 Diagnosis by Adversarial Learning,Jenny Yang; Andrew AS Soltan; Yang Yang; David A Clifton,The University of Oxford; University of Oxford; The University of Oxford; The University of Oxford,"Machine learning is becoming increasingly prominent in healthcare. Although its benefits are clear, growing attention is being given to how machine learning may exacerbate existing biases and disparities. In this study, we introduce an adversarial training framework that is capable of mitigating biases that may have been acquired through data collection or magnified during model development. For example, if one class is over-presented or errors/inconsistencies in practice are reflected in the training data, then a model can be biased by these. To evaluate our adversarial training framework, we used the statistical definition of equalized odds. We evaluated our model for the task of rapidly predicting COVID-19 for patients presenting to hospital emergency departments, and aimed to mitigate regional (hospital) and ethnic biases present. We trained our framework on a large, real-world COVID-19 dataset and demonstrated that adversarial training demonstrably improves outcome fairness (with respect to equalized odds), while still achieving clinically-effective screening performances (NPV>0.98). We compared our method to the benchmark set by related previous work, and performed prospective and external validation on four independent hospital cohorts. Our method can be generalized to any outcomes, models, and definitions of fairness.",health informatics,fuzzy,100,100
medRxiv,10.1101/2022.01.05.21268323,2022-01-06,https://medrxiv.org/cgi/content/short/2022.01.05.21268323,Lineage replacement and evolution captured by the United Kingdom Covid Infection Survey,Katrina A Lythgoe; Tanya Golubchik; Matthew Hall; Thomas House; George MacIntyre-Cockett; Helen Fryer; Laura Thomson; Anel Nurtay; David Buck; Angie Green; Amy Trebes; Paolo Piazza; Lorne J Lonie; Ruth Studley; Emma Rourke; Duncan Cook; Darren Smith; Matthew Bashton; Andrew Nelson; Matthew Crown; Clare McCann; Gregory R Young; Rui Andre Nunes de Santos; Zack Richards; Adnan Tariq; - Wellcome Sanger Institute COVID-19 Surveillance Team; - COVID-19 Infection Survey Group; - The COVID-19 Genomics UK (COG-UK) consortium; Christophe Fraser; Ian Diamond; Jeff Barrett; Sarah Walker; David Bonsall,University of Oxford; University of Oxford; University of Oxford; University of Manchester; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Office for National Statistics; Office for National Statistics; Office for National Statistics; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Northumbria University; Wellcome Sanger Institute; Office for National Statistics; ; University of Oxford; Office for National Statistics; Wellcome Sanger Institute; University of Oxford; University of Oxford,"The Office for National Statistics COVID-19 Infection Survey is a large household-based surveillance study based in the United Kingdom. Here, we report on the epidemiological and evolutionary dynamics of SARS-CoV-2 determined by analysing sequenced samples collected up until 13th November 2021. We observed four distinct sweeps or partial-sweeps, by lineages B.1.177, B.1.1.7/Alpha, B.1.617.2/Delta, and finally AY.4.2, a sublineage of B.1.617.2, with each sweeping lineage having a distinct growth advantage compared to their predecessors. Evolution was characterised by steady rates of evolution and increasing diversity within lineages, but with step increases in divergence associated with each sweeping major lineage, leading to a faster overall rate of evolution and fluctuating levels of diversity. These observations highlight the value of viral sequencing integrated into community surveillance studies to monitor the viral epidemiology and evolution of SARS-CoV-2, and potentially other pathogens, particularly as routine PCR testing is phased out or in settings where large-scale sequencing is not feasible.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2022.01.01.21268131,2022-01-05,https://medrxiv.org/cgi/content/short/2022.01.01.21268131,Bayesian Estimation of real-time Epidemic Growth Rates using Gaussian Processes: local dynamics of SARS-CoV-2 in England,Laura Marcela Guzman Rincon; Edward M Hill; Louise Dyson; Michael J Tildesley; Matt J Keeling,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"Quantitative assessments of the recent state of an epidemic and short-term projections into the near future are key public health tools that have substantial policy impacts, helping to determine if existing control measures are sufficient or need to be strengthened. Key to these quantitative assessments is the ability to rapidly and robustly measure the speed with which the epidemic is growing or decaying. Frequently, epidemiological trends are addressed in terms of the (time-varying) reproductive number R. Here, we take a more parsimonious approach and calculate the exponential growth rate, r, using a Bayesian hierarchical model to fit a Gaussian process to the epidemiological data. We show how the method can be employed when only case data from positive tests are available, and the improvement gained by including the total number of tests as a measure of heterogeneous testing effort. Although the methods are generic, we apply them to SARS-CoV-2 cases and testing in England, making use of the available high-resolution spatio-temporal data to determine long-term patterns of national growth, highlight regional growth and spatial heterogeneity.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.12.31.21268587,2022-01-02,https://medrxiv.org/cgi/content/short/2021.12.31.21268587,"The adverse impact of COVID-19 pandemic on cardiovascular disease prevention and management in England, Scotland and Wales: A population-scale descriptive analysis of trends in medication data",Caroline E Dale; Rohan Takhar; Ray Carragher; Fatemeh Torabi; Michalis Katsoulis; Stephen Duffield; Seamus Kent; Tanja Mueller; Amanj Kurdi; Stuart McTaggart; Hoda Abbasizanjani; Sam Hollings; Andrew Scourfield; Ronan Lyons; Rowena Griffiths; Jane Lyons; Gareth Davies; Dan Harris; Alex Handy; Mehrdad Alizadeh Mizani; Chris Tomlinson; Mark Ashworth; Spiros Denaxas; Amitava Banerjee; Jonathan Sterne; Kate Lovibond; Paul Brown; Ian Bullard; Rouven Priedon; Mamas A Mamas; Ann Slee; Paula Lorgelly; Munir Pirmohamed; Kamlesh Khunti; Naveed Sattar; Andrew Morris; Cathie Sudlow; Ashley Akbari; Marion Bennie; Reecha Sofat; - CVD-COVID-UK Consortium,"Institute of Health Informatics Research, University College London; Institute of Health Informatics Research, University College London; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde; Swansea University; Institute of Health Informatics Research, University College London; NICE; NICE; University of Strathclyde; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde; Public Health Scotland; Swansea University; NHS Digital, Leeds; UCLH NHS Foundation Trust; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Institute of Health Informatics Research, University College London; Institute of Health Informatics Research, University College London; Institute of Health Informatics Research, University College London; King's College London; Institute of Health Informatics Research, University College London; University College London; University of Bristol; Royal College of Physicians; NHS Digital, Leeds; NHS Digital; British Heart Foundation Data Science Centre, Health Data Research UK, London; Keele University; NHSX; Department of Applied Health Research, University College London; University of Liverpool; University of Leicester; University of Glasgow; Health Data Research UK; British Heart Foundation Data Science Centre, Health Data Research UK, London; Swansea University; University of Strathclyde; Institute of Health Informatics Research, University College London; ","ObjectivesTo estimate the impact of the COVID-19 pandemic on cardiovascular disease (CVD) and CVD management using routinely collected medication data as a proxy.

DesignDescriptive and interrupted time series analysis using anonymised individual-level population-scale data for 1.32 billion records of dispensed CVD medications across 15.8 million individuals in England, Scotland and Wales.

SettingCommunity dispensed CVD medications with 100% coverage from England, Scotland and Wales, plus primary care prescribed CVD medications from England (including 98% English general practices).

Participants15.8 million individuals aged 18+ years alive on 1st April 2018 dispensed at least one CVD medicine in a year from England, Scotland and Wales.

Main outcome measuresMonthly counts, percent annual change (1st April 2018 to 31st July 2021) and annual rates (1st March 2018 to 28th February 2021) of medicines dispensed by CVD/ CVD risk factor; prevalent and incident use.

ResultsYear-on-year change in dispensed CVD medicines by month were observed, with notable uplifts ahead of the first (11.8% higher in March 2020) but not subsequent national lockdowns. Using hypertension as one example of the indirect impact of the pandemic, we observed 491,203 fewer individuals initiated antihypertensive treatment across England, Scotland and Wales during the period March 2020 to end May 2021 than would have been expected compared to 2019. We estimated that this missed antihypertension treatment could result in 13,659 additional CVD events should individuals remain untreated, including 2,281 additional myocardial infarctions (MIs) and 3,474 additional strokes. Incident use of lipid-lowering medicines decreased by an average 14,793 per month in early 2021 compared with the equivalent months prior to the pandemic in 2019. In contrast, the use of incident medicines to treat type-2 diabetes (T2DM) increased by approximately 1,642 patients per month.

ConclusionsManagement of key CVD risk factors as proxied by incident use of CVD medicines has not returned to pre-pandemic levels in the UK. Novel methods to identify and treat individuals who have missed treatment are urgently required to avoid large numbers of additional future CVD events, further adding indirect cost of the COVID-19 pandemic.",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2021.12.30.21268307,2021-12-30,https://medrxiv.org/cgi/content/short/2021.12.30.21268307,Short-term Projections based on Early Omicron Variant Dynamics in England.,Matt J Keeling; Ellen Brooks-Pollock; Robert J Challen; Leon Danon; Louise Dyson; Julia Rose Gog; Laura Guzman-Rincon; Edward M Hill; Lorenzo M Pellis; Jonathan M Read; Michael Tildesley,"University of Warwick; University of Bristol; University of Exeter / Taunton NHS Trust; Department of Engineering Mathematics, University of Bristol, UK.; University of Warwick; University of Cambridge; University of Warwick; University of Warwick; The University of Manchester; Lancaster University; University of Warwick","Throughout the ongoing COVID-19 pandemic, the worldwide transmission and replication of SARS-COV-2, the causative agent of COVID-19 disease, has resulted in the opportunity for multiple mutations to occur that may alter the virus transmission characteristics, the effectiveness of vaccines and the severity of disease upon infection. The Omicron variant (B.1.1.529) was first reported to the WHO by South Africa on 24 November 2021 and was declared a variant of concern by the WHO on 26 November 2021. The variant was first detected in the UK on 27 November 2021 and has since been reported in a number of countries globally where it is frequently associated with rapid increase in cases. Here we present analyses of UK data showing the earliest signatures of the Omicron variant and mathematical modelling that uses the UK data to simulate the potential impact of this variant in the UK. In order to account for the uncertainty in transmission advantage, vaccine escape and severity at the time of writing, we carry out a sensitivity analysis to assess the impact of these variant characteristics on future risk.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.12.21.21268058,2021-12-27,https://medrxiv.org/cgi/content/short/2021.12.21.21268058,"Effectiveness of CoronaVac, ChAdOx1, BNT162b2 and Ad26.COV2.S among individuals with prior SARS-CoV-2 infection in Brazil",Thiago Cerqueira-Silva; Jason R Andrews; Viviane S Boaventura; Otavio T Ranzani; Vinicius de Araujo Oliveira; Enny S Paixao; Juracy Bertoldo Jr.; Tales Mota Machado; Matt D T Hitchings; Murilo Dorion; Margaret L Lind; Gerson O. Penna; Derek A.T. Cummings; Natalie E Dean; Guilherme Loureiro Werneck; Neil Pearce; Mauricio L Barreto; Albert I Ko; Julio Croda; Manoel Barral-Netto,"Instituto Goncalo Moniz, Fiocruz, Salvador, BA, Brazil; Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA,USA; Instituto Goncalo Moniz, Fiocruz, Salvador, BA, Brazil; Universidade Federal da Bahia, Salvador, BA, Brazil; Barcelona Institute for Global Health, ISGlobal, Spain / Pulmonary Division, University of Sao Paulo; Instituto Goncalo Moniz, Fiocruz, Salvador, BA, Brazil; Universidade Federal da Bahia, Salvador, BA, Brazil; Center for Data and Knowledge Integration for Healt; London School of Hygiene and Tropical Medicine, London, United Kingdom; Universidade Federal da Bahia, Salvador, BA, Brazil; Center for Data and Knowledge Integration for Health - Fiocruz, Salvador, BA, Brazil; Universidade Federal de Ouro Preto, Ouro Preto, MG, Brazil; Department of Biostatistics, College of Public Health & Health Professions, University of Florida, Gainesville, FL, USA; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Heaven, CT, USA; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Heaven, CT, USA; Nucleo de Medicina Tropical, Universidade de Brasilia, Brasilia, DF, Brazil; Escola Fiocruz de Governo, Fiocruz Brasilia. Brasilia, DF, Brazil; Department of Biology, University of Florida, Gainesville, FL, USA; Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA; Department of Biostatistics & Bioinformatics, Rollins School of Public Health, Emory University; Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil; London School of Hygiene and Tropical Medicine; Universidade Federal da Bahia, Salvador, BA, Brazil; Center for Data and Knowledge Integration for Health - Fiocruz, Salvador, BA, Brazil; Instituto Goncalo Moniz, Fiocruz, Salvador, BA, Brazil; Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Heaven, CT, USA; Universidade Federal de Mato Grosso do Sul, Campo Grande, MS, Brazil; Fiocruz Mato Grosso do Sul, Fundacao Oswaldo Cruz, Campo Grande, MS, Brazil; Instituto Goncalo Moniz, Fiocruz, Salvador, BA, Brazil; Universidade Federal da Bahia, Salvador, BA, Brazil; Center for Data and Knowledge Integration for Healt","BackgroundCOVID-19 vaccines have proven highly effective among SARS-CoV-2 naive individuals, but their effectiveness in preventing symptomatic infection and severe outcomes among individuals with prior infection is less clear.

MethodsUtilizing national COVID-19 notification, hospitalization, and vaccination datasets from Brazil, we performed a case-control study using a test-negative design to assess the effectiveness of four vaccines (CoronaVac, ChAdOx1, Ad26.COV2.S and BNT162b2) among individuals with laboratory-confirmed prior SARS-CoV-2 infection. We matched RT-PCR positive, symptomatic COVID-19 cases with RT-PCR-negative controls presenting with symptomatic illnesses, restricting both groups to tests performed at least 90 days after an initial infection. We used multivariable conditional logistic regression to compare the odds of test positivity, and the odds of hospitalization or death due to COVID-19, according to vaccination status and time since first or second dose of vaccines.

FindingsAmong individuals with prior SARS-CoV-2 infection, vaccine effectiveness against symptomatic infection [&ge;] 14 days from vaccine series completion was 39.4% (95% CI 36.1-42.6) for CoronaVac, 56.0% (95% CI 51.4-60.2) for ChAdOx1, 44.0% (95% CI 31.5-54.2) for Ad26.COV2.S, and 64.8% (95% CI 54.9-72.4) for BNT162b2. For the two-dose vaccine series (CoronaVac, ChAdOx1, and BNT162b2), effectiveness against symptomatic infection was significantly greater after the second dose compared with the first dose. Effectiveness against hospitalization or death [&ge;] 14 days from vaccine series completion was 81.3% (95% CI 75.3-85.8) for CoronaVac, 89.9% (95% CI 83.5-93.8) for ChAdOx1, 57.7% (95% CI -2.6-82.5) for Ad26.COV2.S, and 89.7% (95% CI 54.3-97.7) for BNT162b2.

InterpretationAll four vaccines conferred additional protection against symptomatic infections and severe outcomes among individuals with previous SARS-CoV-2 infection. Provision of a full vaccine series to individuals following recovery from COVID-19 may reduce morbidity and mortality.

FundingBrazilian National Research Council, Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, Oswaldo Cruz Foundation, JBS S.A., Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Generalitat de Catalunya.

RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed, medRxiv, and SSRN for articles published from January 1, 2020 until December 15, 2021, with no language restrictions, using the search terms ""vaccine effectiveness"" AND ""previous*"" AND (""SARS-CoV-2"" OR ""COVID-19""). We found several studies evaluating ChAdOx1 and BNT162b2, and one additionally reporting on mRNA-1273 and Ad26.COV2.S, which found that previously infected individuals who were vaccinated had lower risk of symptomatic SARS-CoV-2 infection. One study found that risk of hospitalization was lower for previously infected individuals after a full series of BNT162b2 or mRNA-1273. Limited evidence is available comparing effectiveness of one versus two doses among individuals with prior infection. No studies reported effectiveness of inactivated vaccines among previously infected individuals.

Added value of this studyWe used national databases of COVID-19 case surveillance, laboratory testing, and vaccination from Brazil to investigate effectiveness of CoronaVac, ChAdOx1, Ad26.COV2.S and BNT162b2 among individuals with a prior, laboratory-confirmed SARS-CoV-2 infection. We matched >22,000 RT-PCR-confirmed re-infections with >145,000 RT-PCR-negative controls using a test-negative design. All four vaccines were effective against symptomatic SARS-CoV-2 infections, with effectiveness from 14 days after series completion ranging from 39-65%. For vaccines with two-dose regimens, the second dose provided significantly increased effectiveness compared with one dose. Effectiveness against COVID-19-associated hospitalization or death from 14 days after series completion was >80% for CoronaVac, ChAdOx1and BNT162b2.

Implications of all the available evidenceWe find evidence that four vaccines, using three different platforms, all provide protection to previously infected individuals against symptomatic SARS-CoV-2 infection and severe outcomes, with a second dose conferring significant additional benefits. These results support the provision of a full vaccine series among individuals with prior SARS-CoV-2 infection.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.12.23.21268276,2021-12-25,https://medrxiv.org/cgi/content/short/2021.12.23.21268276,Risk of myocarditis following sequential COVID-19 vaccinations by age and sex,Martina Patone; Winnie Xue Mei; Lahiru Handunnetthi; Sharon Dixon; Francesco Zaccardi; Manu Shankar-Hari; Peter Watkinson; Kamlesh Khunti; Anthony Harnden; Carol AC Coupland; Keith M. Channon; Nicholas L Mills; Aziz Sheikh; Julia Hippisley-Cox,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Leicester; University of Edinburgh; University of Oxford; University of Leicester; University of Oxford; University of Oxford; University of Oxford; University of Edinburgh; University of Edinburgh; University of Oxford,"In an updated self-controlled case series analysis of 42,200,614 people aged 13 years or more, we evaluate the association between COVID-19 vaccination and myocarditis, stratified by age and sex, including 10,978,507 people receiving a third vaccine dose. Myocarditis risk was increased during 1-28 days following a third dose of BNT162b2 (IRR 2.02, 95%CI 1.40, 2.91). Associations were strongest in males younger than 40 years for all vaccine types with an additional 3 (95%CI 1, 5) and 12 (95% CI 1,17) events per million estimated in the 1-28 days following a first dose of BNT162b2 and mRNA-1273, respectively; 14 (95%CI 8, 17), 12 (95%CI 1, 7) and 101 (95%CI 95, 104) additional events following a second dose of ChAdOx1, BNT162b2 and mRNA-1273, respectively; and 13 (95%CI 7, 15) additional events following a third dose of BNT162b2, compared with 7 (95%CI 2, 11) additional events following COVID-19 infection. An association between COVID-19 infection and myocarditis was observed in all ages for both sexes but was substantially higher in those older than 40 years. These findings have important implications for public health and vaccination policy.

FundingHealth Data Research UK.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.12.23.21268279,2021-12-25,https://medrxiv.org/cgi/content/short/2021.12.23.21268279,Remote Covid Assessment in Primary Care (RECAP) risk prediction tool: derivation and real-world validation studies.,Ana B Espinosa-Gonzalez; Denys Prociuk; Francesca Fiorentino; Christian Ramtale; Ella Mi; Emma Mi; Ben Glampson; Cecilia Okusi; Jack Macartney; Laiba Husain; Martina Brown; Ben Browne; Caroline Warren; Rachna Chowla; Jonty Heaversedge; Trisha Greenhalgh; Simon de Lusignan; Brendan C Delaney,"Institute of Global Health Innovation, Dept of Surgery and Cancer, Imperial College London, UK; Institute of Global Health Innovation, Dept of Surgery and Cancer, Imperial College London, UK; Nightingale-Saunders Clinical Trials & Epidemiology Unit, King's Clinical Trials Unit, King's College London; Institute of Global Health Innovation, Dept of Surgery and Cancer, Imperial College London, UK; Institute of Global Health Innovation, Dept of Surgery and Cancer, Imperial College London, UK; Institute of Global Health Innovation, Dept of Surgery and Cancer, Imperial College London, UK; Imperial College Healthcare NHS Trust, London, UK; Nuffield Dept of Primary Care, University of Oxford, UK; Nuffield Dept of Primary Care, University of Oxford, UK; Nuffield Dept of Primary Care, University of Oxford, UK; South Central Ambulance Service NHS Trust, UK; South Central Ambulance Service NHS Trust, UK; South Central Ambulance Service NHS Trust, UK; Kings Health Partners, London, UK; South East London NHS Clinical Commissioning Group, London UK; Nuffield Dept of Primary Care, University of Oxford, UK; Nuffield Dept of Primary Care, University of Oxford, UK; Institute of Global Health Innovation, Dept of Surgery and Cancer, Imperial College London, UK","BackgroundAccurate assessment of COVID-19 severity in the community is essential for best patient care and efficient use of services and requires a risk prediction score that is COVID-19 specific and adequately validated in a community setting. Following a qualitative phase to identify signs, symptoms and risk factors, we sought to develop and validate two COVID-19-specific risk prediction scores RECAP-GP (without peripheral oxygen saturation (SpO2)) and RECAP-O2 (with SpO2).

MethodsProspective cohort study using multivariable logistic regression for model development. Data on signs and symptoms (model predictors) were collected on community-based patients with suspected COVID-19 via primary care electronic health records systems and linked with secondary data on hospital admission (primary outcome) within 28 days of symptom onset. Data sources: RECAP-GP: Oxford-Royal College of General Practitioners Research and Surveillance Centre (RSC) primary care practices (development), Northwest London (NWL) primary care practices, NHS COVID-19 Clinical Assessment Service (CCAS) (validation). RECAP-O2: Doctaly Assist platform (development, and validation in subsequent sample). Estimated sample size was 2,880 per model.

FindingsData were available from 8,311 individuals. Observations, such SpO2, were mostly missing in NWL, RSC, and CCAS data; however, SpO2 was available for around 70% of Doctaly patients. In the final predictive models, RECAP-GP included sex, age, degree of breathlessness, temperature symptoms, and presence of hypertension (Area Under the Curve (AUC): 0.802, Validation Negative Predictive Value (NPV) of  low risk 98.8%. RECAP-O2 included age, degree of breathlessness, fatigue, and SpO2 at rest (AUC: 0.843), Validation NPV of  low risk 99.4%.

InterpretationBoth RECAP models are a valid tool in the assessment of COVID-19 patients in the community. RECAP-GP can be used initially, without need for observations, to identify patients who require monitoring. If the patient is monitored at home and SpO2 is available, RECAP-O2 is useful to assess the need for further treatment escalation.

Research in context panelO_ST_ABSEvidence before the studyC_ST_ABSThis study was conceived during the first COVID-19 wave in the UK (March - April 2020), as members of the research team contributed to the development of national clinical guidelines for COVID-19 management in the community and to the Oxford COVID-19 rapid review to track signs and symptoms of COVID-19 internationally. The review was carried out according to Cochrane Collaboration standards for rapid reviews and identified systematic reviews and large-scale observational studies describing the signs and symptoms of COVID-19. Evidence gathered showed worsening of COVID-19 symptoms around the 7th day of disease and challenges in identifying patients with higher likelihood of severity to increase their monitoring. To this end, tools such NEWS2 have been used in the UK to assess COVID-19 patients in primary care, but they do not capture the characteristics of COVID-19 infection and/or are not suitable for community remote assessment. Several COVID-19 risk scores have been developed. QCOVID provides a risk of mortality considering patients existing risk factors but does not include acute signs and symptoms. ISARIC 4C Deterioration model has been specifically developed for hospital settings. In England, the NHS has implemented the Oximetry @home strategy to monitor patients with acute COVID-19 deemed at risk (older than 64 years old or with comorbidities) by providing pulse oximeters; however, the criteria for monitoring or for escalation of care have not been validated. There is, therefore, the need to develop a risk prediction score to establish COVID-19 patients risk of deterioration to be used in the community for both face to face or remote consultation.

Added value of this studyWe developed and validated two COVID-19 specific risk prediction scores. One to be used in the initial remote assessment of patients with acute COVID-19 to assess need for monitoring (RECAP-GP). The second one to assess the need for further treatment escalation and includes peripheral saturation of oxygen among the model predictors (RECAP-O2). To our knowledge, this is the first COVID-19 specific risk prediction score to assess and monitor COVID-19 patients risk of deterioration remotely. This will be a valuable resource to complement the use of oximetry in the community clinical decision-making when assessing a patient with acute COVID-19.

Implications of all available evidenceTo manage pandemic waves and their demand on healthcare, acute COVID-19 patients require close monitoring in the community and prompt escalation of their treatment. Guidance available so far relies on unvalidated tools and clinician judgement to assess deterioration. COVID-19 specific community-based risk prediction scores such as RECAP may contribute to reducing the uncertainty in the assessment and monitoring of COVID-19 patients, increase safety in clinical practice and improve outcomes by facilitating appropriate treatment escalation.",primary care research,fuzzy,100,100
medRxiv,10.1101/2021.12.22.21268252,2021-12-24,https://medrxiv.org/cgi/content/short/2021.12.22.21268252,Rapid increase in Omicron infections in England during December 2021: REACT-1 study,Paul Elliott; Barbara Bodinier; Oliver Eales; Haowei Wang; David Haw; Joshua Elliott; Matthew Whitaker; Jakob Jonnerby; David Tang; Caroline E. Walters; Christina Atchinson; Peter J. Diggle; Andrew J. Page; Alex Trotter; Deborah Ashby; Wendy Barclay; Graham Taylor; Helen Ward; Ara Darzi; Graham Cooke; Marc Chadeau-Hyam; Christl A Donnelly,"School of Public Health, Imperial College London, UKImperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical Research; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; Imperial College London; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; Imperial College London; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; Quadram Institute, Norwich, UK; Quadram Institute Bioscience; School of Public Health, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UKImperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical Research; Imperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical Research Centre, UKInstitute of Global Health Innovation at ; Department of Infectious Disease, Imperial College London, UKImperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency","BackgroundThe highest-ever recorded numbers of daily severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in England has been observed during December 2021 and have coincided with a rapid rise in the highly transmissible Omicron variant despite high levels of vaccination in the population. Although additional COVID-19 measures have been introduced in England and internationally to contain the epidemic, there remains uncertainty about the spread and severity of Omicron infections among the general population.

MethodsThe REal-time Assessment of Community Transmission-1 (REACT-1) study has been monitoring the prevalence of SARS-CoV-2 infection in England since May 2020. REACT-1 obtains self-administered throat and nose swabs from a random sample of the population of England at ages 5 years and over. Swabs are tested for SARS-CoV-2 infection by reverse transcription polymerase chain reaction (RT-PCR) and samples testing positive are sent for viral genome sequencing. To date 16 rounds have been completed, each including [~]100,000 or more participants with data collected over a period of 2 to 3 weeks per month. Socio-demographic, lifestyle and clinical information (including previous history of COVID-19 and symptoms prior to swabbing) is collected by online or telephone questionnaire. Here we report results from round 14 (9-27 September 2021), round 15 (19 October - 05 November 2021) and round 16 (23 November - 14 December 2021) for a total of 297,728 participants with a valid RT-PCR test result, of whom 259,225 (87.1%) consented for linkage to their NHS records including detailed information on vaccination (vaccination status, date). We used these data to estimate community prevalence and trends by age and region, to evaluate vaccine effectiveness against infection in children ages 12 to 17 years, and effect of a third (booster) dose in adults, and to monitor the emergence of the Omicron variant in England.

ResultsWe observed a high overall prevalence of 1.41% (1.33%, 1.51%) in the community during round 16. We found strong evidence of an increase in prevalence during round 16 with an estimated reproduction number R of 1.13 (1.06, 1.09) for the whole of round 16 and 1.27 (1.14, 1.40) when restricting to observations from 1 December onwards. The reproduction number in those aged 18-54 years was estimated at 1.23 (1.14, 1.33) for the whole of round 16 and 1.41 (1.23, 1.61) from 1 December. Our data also provide strong evidence of a steep increase in prevalence in London with an estimated R of 1.62 (1.34, 1.93) from 1 December onwards and a daily prevalence reaching 6.07% (4.06%, 9.00%) on 14 December 2021. As of 1 to 11 December 2021, of the 275 lineages determined, 11 (4.0%) corresponded to the Omicron variant. The first Omicron infection was detected in London on 3 December, and subsequent infections mostly appeared in the South of England. The 11 Omicron cases were all aged 18 to 54 years, double-vaccinated (reflecting the large numbers of people who have received two doses of vaccine in this age group) but not boosted, 9 were men, 5 lived in London and 7 were symptomatic (5 with classic COVID-19 symptoms: loss or change of sense of smell or taste, fever, persistent cough), 2 were asymptomatic, and symptoms were unknown for 2 cases. The proportion of Omicron (vs Delta or Delta sub-lineages) was found to increase rapidly with a daily increase of 66.0% (32.7%, 127.3%) in the odds of Omicron (vs. Delta) infection, conditional on swab positivity. Highest prevalence of swab positivity by age was observed in (unvaccinated) children aged 5 to 11 years (4.74% [4.15%, 5.40%]) similar to the prevalence observed at these ages in round 15. In contrast, prevalence in children aged 12 to 17 years more than halved from 5.35% (4.78%, 5.99%) in round 15 to 2.31% (1.91%, 2.80%) in round 16. As of 14 December 2021, 76.6% children at ages 12 to 17 years had received at least one vaccine dose; we estimated that vaccine effectiveness against infection was 57.9% (44.1%, 68.3%) in this age group. In addition, the prevalence of swab positivity in adults aged 65 years and over fell by over 40% from 0.84% (0.72%, 0.99%) in round 15 to 0.48% (0.39%,0.59%) in round 16 and for those aged 75 years and over it fell by two-thirds from 0.63% (0.48%,0.82%) to 0.21% (0.13%,0.32%). At these ages a high proportion of participants (>90%) had received a third vaccine dose; we estimated that adults having received a third vaccine dose had a three- to four-fold lower risk of testing positive compared to those who had received two doses.

ConclusionA large fall in swab positivity from round 15 to round 16 among 12 to 17 year olds, most of whom have been vaccinated, contrasts with the continuing high prevalence among 5 to 11 year olds who have largely not been vaccinated. Likewise there were large falls in swab positivity among people aged 65 years and over, the vast majority of whom have had a third (booster) vaccine dose; these results reinforce the importance of the vaccine and booster campaign. However, the rapidly increasing prevalence of SARS-CoV-2 infections in England during December 2021, coincident with the rapid rise of Omicron infections, may lead to renewed pressure on health services. Additional measures beyond vaccination may be needed to control the current wave of infections and prevent health services (in England and other countries) from being overwhelmed.

SummaryThe unprecedented rise in SARS-CoV-2 infections is concurrent with rapid spread of the Omicron variant in England and globally. We analysed prevalence of SARS-CoV-2 and its dynamics in England from end of November to mid-December 2021 among almost 100,000 participants from the REACT-1 study. Prevalence was high during December 2021 with rapid growth nationally and in London, and of the proportion of infections due to Omicron. We observed a large fall in swab positivity among mostly vaccinated older children (12-17 years) compared with unvaccinated younger children (5-11 years), and in adults who received a third vs. two doses of vaccine. Our results reiterate the importance of vaccination and booster campaigns; however, additional measures may be needed to control the rapid growth of the Omicron variant.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.12.21.21268214,2021-12-23,https://medrxiv.org/cgi/content/short/2021.12.21.21268214,Comparative effectiveness of ChAdOx1 versus BNT162b2 vaccines against SARS-CoV-2 infections in England and Wales: A cohort analysis using trial emulation in the Virus Watch community data,Vincent Grigori Nguyen; Alexei Yavlinsky; Sarah Beale; Susan J Hoskins; Vasileios Lampos; Isobel Braithwaite; Thomas Edward Byrne; Wing Lam Erica Fong; Ellen Fragaszy; Cyril Geismar; Jana Kovar; Annalan M D Navaratnam; Parth Patel; Madhumita Shrotri; Sophie Weber; Andrew Hayward; Robert W Aldridge,University College London; University College London; University College London; Univerity College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London,"IntroductionInfections of SARS-CoV-2 in vaccinated individuals have been increasing globally. Understanding the associations between vaccine type and a post-vaccination infection could help prevent further COVID-19 waves. In this paper, we use trial emulation to understand the impact of a phased introduction of the vaccine in the UK driven by vulnerability and exposure status. We estimate the comparative effectiveness of COVID-19 vaccines (ChAdOx1 versus BNT162b2) against post-vaccination infections of SARS-CoV-2 in a community setting in England and Wales.

MethodTrial emulation was conducted by pooling results from six cohorts whose recruitment was staggered between 1st January 2021 and 31st March 2021 and followed until 12th November 2021. Eligibility for each trial was based upon age (18+ at the time of vaccination), without prior signs of infection or an infection within the first 14 days of the first dose. Time from vaccination of ChAdOx1 or BNT162b2 until SARS-CoV-2 infection (positive polymerase chain reaction or lateral flow test after 14 of the vaccination) was modelled using Cox proportional hazards model for each cohort and adjusted for age at vaccination, gender, minority ethnic status, clinically vulnerable status and index of multiple deprivation quintile. For those without SARS-CoV-2 infection during the study period, follow-up was until loss-of-follow-up or end of study (12th November 2021). Pooled hazard ratios were generated using random-effects meta-analysis.

ResultsAcross six cohorts, there were a total of 21,283 participants who were eligible and vaccinated with either ChAdOx1 (n = 13,813) or BNT162b2 (n = 7,470) with a median follow-up time of 266 days (IQR: 235 - 282). By November 12th 2021, 750 (5.4%) adults who had ChAdOx1 as their vaccine experienced a SARS-CoV-2 infection, compared to 296 (4.0%) who had BNT162b2. We found that people who received ChAdOx1 vaccinations had 10.54 per 1000 people higher cumulative incidence for SARS-CoV-2 infection compared to BNT162b2 for infections during a maximum of 315 days of follow-up. When adjusted for age at vaccination, sex, minority ethnic status, index of multiple deprivation, and clinical vulnerability status, we found a pooled adjusted hazard ratio of 1.35 [HR: 1.35, 95%CI: 1.15 - 1.58], demonstrating a 35% increase in SARS-CoV-2 infections in people who received ChAdOx1 compared to BNT162b2.

DiscussionWe found evidence of greater effectiveness of receiving BNT162b2 compared to ChAdOx1 vaccines against SARS-CoV-2 infection in England and Wales during a time period when Delta became the most prevalent variant of concern. Our findings demonstrate the importance of booster (third) doses to maintain protection and suggest that these should be prioritised to those who received ChAdOx1 as their primary course.",epidemiology,fuzzy,100,100
bioRxiv,10.1101/2021.12.17.473248,2021-12-21,https://biorxiv.org/cgi/content/short/2021.12.17.473248,"SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion",Bo Meng; Isabella Ferreira; Adam Abdullahi; Niluka Goonawardane; Akatsuki Saito; Izumi Kimura; Daichi Yamasoba; Steven A Kemp; Guido Papa; Saman Fatihi; Surabhi Rathore; Pehuen Perera Gerba; Terumasa Ikeda; Mako Toyoda; Toong Seng Tan; Jin Kuramochi; Shigeki Mitsunaga; Takamasa Ueno; Oscar Charles; Dami Collier; - CITIID-NIHR BioResource COVID-19 Collaboration; - The Genotype to Phenotype Japan (G2P-Japan) Consortium; - Ecuador-COVID19 Consortium; John Bradley; Jinwook Choi; Kenneth Smith; Elo Madissoon; Kerstin Meyer; Petra Mlcochova; Rainer Doffinger; Sarah A Teichmann; Leo James; Joo Hyeon Lee; Teresa Brevini; Matteo Pizzuto; Myra Hosmillo; Donna Mallery; Samantha Zepeda; Alexandra Walls; Anshu Joshi; John Bowen; John Briggs; Alex Sigal; Laurelle Jackson; Sandile Cele; Anna De Marco; Fotios Sampaziotis; Davide Corti; David Veesler; Nicholas Matheson; Ian Goodfellow; Lipi Thukral; Kei Sato; Ravindra K Gupta,"University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Miyazaki; The University of Tokyo; Kumamoto University; University of Cambridge; LMB Cambridge; CSIR Institute of Genomics and Integrative Biology, Delhi, India; CSIR Institute of Genomics and Integrative Biology, Delhi, India; University of Cambridge; Kumamoto Univ; Kumamoto University, Kumamoto; Kuramochi Clinic Interpark; Kuramochi Clinic Interpark; National Institute of Genetics, Mishima, Shizuoka; Kumamoto University, Kumamoto; University College London; University of Cambridge; -; -; -; University of Cambridge; University of Cambridge; University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute; University of Cambridge; Cambridge University Hospitals NHS Trust; Cambridge University; MRC LMB; University of Cambridge; University of Cambridge; Humabs Biomed SA; University of Cambridge; MRC LMB Cambridge; University of Washington; University of Washington; University of Washington; University of Washington; University of Heidelberg; Africa Health Research Institute, Durban, South Africa; Africa Health Research Institute, Durban, South Africa; Africa Health Research Institute, Durban, South Africa; Humabs Biomed SA; University of Cambridge; Humabs Biomed SA; University of Washington; University of Cambridge; University of Cambridge; CSIR Institute of Genomics and Integrative Biology, Delhi, India; The University of Tokyo; University of Cambridge","The SARS-CoV-2 Omicron BA.1 variant emerged in late 2021 and is characterised by multiple spike mutations across all spike domains. Here we show that Omicron BA.1 has higher affinity for ACE2 compared to Delta, and confers very significant evasion of therapeutic monoclonal and vaccine-elicited polyclonal neutralising antibodies after two doses. mRNA vaccination as a third vaccine dose rescues and broadens neutralisation. Importantly, antiviral drugs remdesevir and molnupiravir retain efficacy against Omicron BA.1. We found that in human nasal epithelial 3D cultures replication was similar for both Omicron and Delta. However, in lower airway organoids, Calu-3 lung cells and gut adenocarcinoma cell lines live Omicron virus demonstrated significantly lower replication in comparison to Delta. We noted that despite presence of mutations predicted to favour spike S1/S2 cleavage, the spike protein is less efficiently cleaved in live Omicron virions compared to Delta virions. We mapped the replication differences between the variants to entry efficiency using spike pseudotyped virus (PV) entry assays. The defect for Omicron PV in specific cell types correlated with higher cellular RNA expression of TMPRSS2, and accordingly knock down of TMPRSS2 impacted Delta entry to a greater extent as compared to Omicron. Furthermore, drug inhibitors targeting specific entry pathways demonstrated that the Omicron spike inefficiently utilises the cellular protease TMPRSS2 that mediates cell entry via plasma membrane fusion. Instead, we demonstrate that Omicron spike has greater dependency on cell entry via the endocytic pathway requiring the activity of endosomal cathepsins to cleave spike. Consistent with suboptimal S1/S2 cleavage and inability to utilise TMPRSS2, syncytium formation by the Omicron spike was dramatically impaired compared to the Delta spike. Overall, Omicron appears to have gained significant evasion from neutralising antibodies whilst maintaining sensitivity to antiviral drugs targeting the polymerase. Omicron has shifted cellular tropism away from TMPRSS2 expressing cells that are enriched in cells found in the lower respiratory and GI tracts, with implications for altered pathogenesis.",microbiology,fuzzy,100,100
medRxiv,10.1101/2021.12.20.21268098,2021-12-21,https://medrxiv.org/cgi/content/short/2021.12.20.21268098,"Therapies for Long COVID in non-hospitalised individuals - from symptoms, patient-reported outcomes, and immunology to targeted therapies (The TLC Study): Study protocol",Shamil Haroon; Krishnarajah Nirantharakumar; Sarah Hughes; Anuradhaa Subramanian; Olalekan Lee Aiyegbusi; Elin Haf Davies; Puja Myles; Tim Williams; Grace Turner; Joht Singh Chandan; Christel McMullan; Janet Lord; David Wraith; Kirsty McGee; Alastair Denniston; Tom Taverner; Louise Jackson; Elizabeth Sapey; Georgios Gkoutos; Krishna Gokhale; Edward Leggett; Clare Iles; Christopher Frost; Gary McNamara; Amy Bamford; Tom Marshall; Dawit Zemedikun; Gary Price; Steven Marwaha; Nikita Simms-Williams; Kirsty Brown; Anita Walker; Karen Jones; Karen Matthews; Jennifer Camaradou; Michael Saint-Cricq; Sumita Kumar; Yvonne Alder; David Stanton; Lisa Agyen; Megan Baber; Hannah Blaize; Melanie Calvert,University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; Aparito; Medicines and Healthcare Products Regulatory Agency; Medicines and Healthcare Products Regulatory Agency; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; University of Birmingham; University of Birmingham; University of Birmingham; University ofBirmingham; University of Birmingham; Medicines and Healthcare Products Regulatory Agency; Medicines and Healthcare Products Regulatory Agency; Aparito; Aparito; University Hospitals Birmingham NHS Foundation Trust; University of Birmingham; University of Birmingham; N/A; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; Not applicable; University ofBirmingham,"IntroductionIndividuals with COVID-19 frequently experience symptoms and impaired quality of life beyond 4-12 weeks, commonly referred to as Long COVID. Whether Long COVID is one or several distinct syndromes is unknown. Establishing the evidence base for appropriate therapies is needed. We aim to evaluate the symptom burden and underlying pathophysiology of Long COVID syndromes in non-hospitalised individuals and evaluate potential therapies.

Methods and analysisA cohort of 4000 non-hospitalised individuals with a past COVID-19 diagnosis and 1000 matched controls will be selected from anonymised primary care records from the Clinical Practice Research Datalink (CPRD) and invited by their general practitioners to participate on a digital platform (Atom5). Individuals will report symptoms, quality of life, work capability, and patient reported outcome measures. Data will be collected monthly for one year.

Statistical clustering methods will be used to identify distinct Long COVID symptom clusters. Individuals from the four most prevalent clusters and two control groups will be invited to participate in the BioWear sub-study which will further phenotype Long COVID symptom clusters by measurement of immunological parameters and actigraphy.

We will review existing evidence on interventions for post-viral syndromes and Long COVID to map and prioritise interventions for each newly characterised Long COVID syndrome. Recommendations will be made using the cumulated evidence in an expert consensus workshop. A virtual supportive intervention will be coproduced with patients and health service providers for future evaluation.

Individuals with lived experience of Long COVID will be involved throughout this programme through a patient and public involvement group.

Ethics and disseminationEthical approval was obtained from the Solihull Research Ethics Committee, West Midlands (21/WM/0203). The study is registered on the ISRCTN Registry (1567490). Research findings will be presented at international conferences, in peer-reviewed journals, to Long COVID patient support groups and to policymakers.

Article SummaryO_ST_ABSStrengths and limitations of the studyC_ST_ABSO_LIThe study will generate a nationally representative cohort of individuals with Long COVID recruited from primary care.
C_LIO_LIWe will recruit controls matched on a wide range of demographic and clinical factors to assess differences in symptoms between people with Long COVID and similar individuals without a history of COVID-19.
C_LIO_LIWe will use a newly developed electronic patient reported outcome measure (Symptom Burden Questionnaire) for Long COVID to comprehensively assess a wide range of symptoms highlighted by existing literature, patients, and clinicians.
C_LIO_LIImmunological, proteomic, genetic, and wearable data captured in the study will allow deep phenotyping of Long COVID syndromes to help better target therapies.
C_LIO_LIA limitation is that a significant proportion of non-hospitalised individuals affected by COVID-19 in the first wave of the pandemic will lack confirmatory testing and will be excluded from recruitment to the study.
C_LI",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.12.20.21268113,2021-12-21,https://medrxiv.org/cgi/content/short/2021.12.20.21268113,A nationwide deep learning pipeline to predict stroke and COVID-19 death in atrial fibrillation,Alex Handy; Angela Wood; Cathie Sudlow; Christopher Tomlinson; Frank Kee; Johan H Thygesen; Mohammad Mamouei; Reecha Sofat; Richard Dobson; Hiu Yan (Samantha) Ip; Spiros Denaxas; - CVD-COVID-UK Consortium,"Institute of Health Informatics, University College London, London, UK; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; British Heart Foundation Data Science Centre, Health Data Research UK, London, UK; Institute of Health Informatics, University College London, London, UK; School of Medicine, Dentistry and Biomedical Sciences, Centre for Public Health, Queens University Belfast, UK; Institute of Health Informatics, University College London, London, UK; Deep Medicine, Oxford Martin School, University of Oxford, Oxford, UK; Institute of Health Informatics, University College London, London, UK; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Institute of Health Informatics, University College London, London, UK; CVD-COVID-UK Consortium","Deep learning (DL) and machine learning (ML) models trained on long-term patient trajectories held as medical codes in electronic health records (EHR) have the potential to improve disease prediction. Anticoagulant prescribing decisions in atrial fibrillation (AF) offer a use case where the benchmark stroke risk prediction tool (CHA2DS2-VASc) could be meaningfully improved by including more information from a patients medical history. In this study, we design and build the first DL and ML pipeline that uses the routinely updated, linked EHR data for 56 million people in England accessed via NHS Digital to predict first ischaemic stroke in people with AF, and as a secondary outcome, COVID-19 death. Our pipeline improves first stroke prediction in AF by 17% compared to CHA2DS2-VASc (0.61 (0.57-0.65) vs 0.52 (0.52-0.52) area under the receiver operating characteristics curves, 95% confidence interval) and provides a generalisable, opensource framework that other researchers and developers can build on.",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2021.12.16.21267934,2021-12-17,https://medrxiv.org/cgi/content/short/2021.12.16.21267934,Predictors of SARS-CoV-2 infection in a multi-ethnic cohort of United Kingdom healthcare workers: a prospective nationwide cohort study (UK-REACH),Christopher A Martin; Daniel Pan; Carl Melbourne; Lucy Teece; Avinash Aujayeb; Rebecca F Baggaley; Luke Bryant; Sue Carr; Bindu Gregary; Amit Gupta; Anna Louise Guyatt; Catherine John; Chris McManus; Joshua Nazareth; Laura B Nellums; Rubina Reza; Sandra Simpson; Martin D Tobin; Katherine Woolf; Stephen Zingwe; Kamlesh Khunti; Keith R Abrams; Laura J Gray; Manish Pareek; - UK-REACH Study Collaborative Group,University of Leicester; University of Leicester; University of Leicester; University of Leicester; Northumbria Specialist Emergency Care Hospital; University of Leicester; University of Leicester; General Medical Council; Royal Preston Hospital; Oxford University Hospitals NHS Foundation Trust; University of Leicester; University of Leicester; University College London; University of Leicester; University of Nottingham; Derbyshire Healthcare NHS Foundation Trust; Nottinghamshire Healthcare NHS Foundation Trust; University of Leicester; University College London; Berkshire Healthcare NHS Foundation Trust; University of Leicester; University of Warwick; University of Leicester; University of Leicester; ,"IntroductionHealthcare workers (HCWs), particularly those from ethnic minority groups, have been shown to be at disproportionately higher risk of infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) compared to the general population. However, there is insufficient evidence on how demographic and occupational factors influence infection risk among ethnic minority HCWs.

MethodsWe conducted a cross-sectional analysis using data from the United Kingdom Research study into Ethnicity And COVID-19 Outcomes in Healthcare workers (UK-REACH) cohort study. We used logistic regression to examine associations of demographic, household and occupational predictor variables with SARS-CoV-2 infection (defined by PCR, serology or suspected COVID-19) in a diverse group of HCWs.

Results2,496 of the 10,772 HCWs (23.2%) who worked during the first UK national lockdown in March 2020 reported previous SARS-CoV-2 infection. In an adjusted model, demographic and household factors associated with increased odds of infection included younger age, living with other key workers and higher religiosity. Important occupational risk factors associated with increased odds of infection included attending to a higher number of COVID-19 positive patients (aOR 2.49, 95%CI 2.03-3.05 for [&ge;]21 patients per week vs none), working in a nursing or midwifery role (1.35, 1.15- 1.58, compared to doctors), reporting a lack of access to personal protective equipment (1.27, 1.15 - 1.41) and working in an ambulance (1.95, 1.52-2.50) or hospital inpatient setting (1.54, 1.37 - 1.74). Those who worked in Intensive Care Units were less likely to have been infected (0.76, 0.63-0.90) than those who did not. Black HCWs were more likely to have been infected than their White colleagues, an effect which attenuated after adjustment for other known predictors.

ConclusionsWe identified key sociodemographic and occupational risk factors associated with SARS-CoV-2 infection amongst UK HCWs, and have determined factors that might contribute to a disproportionate odds of infection in HCWs from Black ethnic groups. These findings demonstrate the importance of social and occupational factors in driving ethnic disparities in COVID-19 outcomes, and should inform policies, including targeted vaccination strategies and risk assessments aimed at protecting HCWs in future waves of the COVID-19 pandemic.

Trial registrationISRCTN 11811602",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.12.16.21267904,2021-12-17,https://medrxiv.org/cgi/content/short/2021.12.16.21267904,Deficits in hospital care among clinically vulnerable children aged 0 to 4 years during the COVID-19 pandemic,David Etoori; Katie Harron; Louise Mc Grath-Lone; Maximiliane Verfeurden; Ruth Gilbert; Ruth Blackburn,University College London; University College London; University College London; University College London; University College London; University College London,"ObjectiveTo quantify deficits in hospital care for clinically vulnerable children during the COVID-19 pandemic.

DesignBirth cohort in Hospital Episode Statistics (HES).

SettingNHS hospitals in England.

Study populationAll children aged <5 years with a birth recorded in hospital administrative data (January 2010 to March 2021).

Main exposureClinical vulnerability defined by a chronic health condition, preterm birth (<37 weeks gestation) or low birthweight (<2500g).

Main outcomesDeficits in care defined by predicted rates for 2020, estimated from 2015- 2019, minus observed rates per 1000 child years during the pandemic (March 2020-2021).

ResultsOf 3,813,465 children, 17.7% (1 in 6) were clinically vulnerable (9.5% born preterm or low birthweight, 10.3% had a chronic condition). Deficits in hospital care during the pandemic were much higher for clinically vulnerable children than peers: respectively, outpatient attendances (314 versus 73 per 1000 child years), planned admissions (55 versus 10), and unplanned admissions (105 versus 79). Clinically vulnerable children accounted for 50.1% of the deficit in outpatient attendances, 55.0% in planned admissions, and 32.8% in unplanned hospital admissions. During the pandemic, weekly rates of planned care returned to pre-pandemic levels for infants with chronic conditions but not older children. Deficits in care differed by ethnic group and level of deprivation. Virtual outpatient attendances increased from 3.2% to 24.8% during the pandemic.

Conclusion1 in 6 clinically vulnerable children accounted for one-third to one half of the deficit in hospital care during the pandemic.",pediatrics,fuzzy,100,100
medRxiv,10.1101/2021.12.17.21267925,2021-12-17,https://medrxiv.org/cgi/content/short/2021.12.17.21267925,SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2,Oliver Eales; Andrew Page; Leonardo de Oliveira Martins; Haowei Wang; Barbara Bodinier; David Haw; Jakob Jonnerby; Christina Atchison; - The COVID-19 Genomics UK (COG-UK) Consortium; Deborah Ashby; Wendy Barclay; Graham Taylor; Graham Cooke; Helen Ward; Ara Darzi; Steven Riley; Marc Chadeau-Hyam; Christl A Donnelly; Paul Elliott,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Environment and Health, School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; ; School of Public Health, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Environment and Health, School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear","Since the emergence of SARS-CoV-2, evolutionary pressure has driven large increases in the transmissibility of the virus. However, with increasing levels of immunity through vaccination and natural infection the evolutionary pressure will switch towards immune escape. Here we present phylogenetic relationships and lineage dynamics within England (a country with high levels of immunity), as inferred from a random community sample of individuals who provided a self-administered throat and nose swab for rt-PCR testing as part of the REal-time Assessment of Community Transmission-1 (REACT-1) study. From 9 to 27 September 2021 (round 14) and 19 October to 5 November 2021 (round 15), all lineages sequenced within REACT-1 were Delta or a Delta sub-lineage with 44 unique lineages identified. The proportion of the original Delta variant (B.1.617.2) was found to be increasing between September and November 2021, which may reflect an increasing number of sub-lineages which have yet to be identified. The proportion of B.1.617.2 was greatest in London, which was further identified as a region with an increased level of genetic diversity. The Delta sub-lineage AY.4.2 was found to be robustly increasing in proportion, with a reproduction number 15% (8%, 23%) greater than its parent and most prevalent lineage, AY.4. Both AY.4.2 and AY.4 were found to be geographically clustered in September but this was no longer the case by late October/early November, with only the lineage AY.6 exhibiting clustering towards the South of England. Though no difference in the viral load based on cycle threshold (Ct) values was identified, a lower proportion of those infected with AY.4.2 had symptoms for which testing is usually recommend (loss or change of sense of taste, loss or change of sense of smell, new persistent cough, fever), compared to AY.4 (p = 0.026). The evolutionary rate of SARS-CoV-2, as measured by the mutation rate, was found to be slowing down during the study period, with AY.4.2 further found to have a reduced mutation rate relative to AY.4. As SARS-CoV-2 moves towards endemicity and new variants emerge, genomic data obtained from random community samples can augment routine surveillance data without the potential biases introduced due to higher sampling rates of symptomatic individuals.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.12.17.21267350,2021-12-17,https://medrxiv.org/cgi/content/short/2021.12.17.21267350,"Risk of SARS-CoV-2 testing, PCR-confirmed infections and COVID-19-related hospital admissions in children and young people: birth cohort study",Pia Hardelid; Graziella Favarato; Linda Wijlaars; Lynda Fenton; Jim McMenamin; Tom Clemens; Chris DIBBEN; Ai Milojevic; Alison Macfarlane; Jonathon Taylor; Steve Cunningham; Rachael Wood,"UCL Great Ormond Street Institute of Child Health; UCL Great Ormond Street Institute of Child Health; UCL Great Ormond Street Institute of Child Health; Public Health Scotland; Public Health Scotland; University of Edinburgh; University of Edinburgh; London School of Hygiene and Tropical Medicine; City, University of London; Tampere University; University of Edinburgh; Public Health Scotland","BackgroundThere have been no population-based studies of SARS-CoV-2 testing, PCR-confirmed infections and COVID-19-related hospital admissions across the full paediatric age range. We examine the epidemiology of SARS-CoV-2 in children and young people (CYP) aged <23 years.

MethodsWe used a birth cohort of all children born in Scotland since 1997, constructed via linkage between vital statistics, hospital records and SARS-CoV-2 surveillance data. We calculated risks of tests and PCR-confirmed infections per 1000 CYP-years between August and December 2020, and COVID-19-related hospital admissions per 100,000 CYP-years between February and December 2020. We used Poisson and Cox proportional hazards regression models to determine risk factors.

ResultsAmong the 1226855 CYP in the cohort, there were 378402 tests, 19005 PCR confirmed infections and 346 admissions, corresponding to rates of 770.8/1000 (95% confidence interval 768.4-773.3), 179.4 (176.9-182.0) and 29.4/100,000 (26.3-32.8) CYP-years respectively. Infants had the highest COVID-19-related admission rates. Chronic conditions, particularly multiple types of conditions, was strongly associated with COVID-19-related admissions across all ages. The hazard ratio for >1 chronic condition type was 12.2 (7.9-18.82) compared to children with no chronic conditions. 89% of admitted children had no chronic conditions recorded.

ConclusionsInfants, and CYP with chronic conditions are at highest risk of admission with COVID-19, however the majority of admitted CYP have no chronic conditions. These results provide evidence to support risk/benefit analyses for paediatric COVID-19 vaccination programmes. Studies examining whether maternal vaccine during pregnancy prevents COVID-19 admissions in infants are urgently needed.

FundingUK Research and Innovation-Medical Research Council",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.12.14.21267806,2021-12-16,https://medrxiv.org/cgi/content/short/2021.12.14.21267806,"REACT-1 round 15 final report: Increased breakthrough SARS-CoV-2 infections among adults who had received two doses of vaccine, but booster doses and first doses in children are providing important protection",Marc Chadeau-Hyam; Oliver Eales; Barbara Bodinier; Haowei Wang; David Haw; Matthew Whitaker; Caroline E. Walters; Jakob Jonnerby; Christina Atchinson; Peter J. Diggle; Andrew J. Page; Deborah Ashby; Wendy Barclay; Graham Taylor; Graham Cooke; Helen Ward; Ara Darzi; Christl A Donnelly; Paul Elliott,"School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; Quadram Institute, Norwich, UK; School of Public Health, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UKImperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical; School of Public Health, Imperial College London, UKImperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical Research; Imperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical Research Centre, UKInstitute of Global Health Innovation at ; School of Public Health, Imperial College London, UKMRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergency; School of Public Health, Imperial College London, UKImperial College Healthcare NHS Trust, UKNational Institute for Health Research Imperial Biomedical Research","BackgroundIt has been nearly a year since the first vaccinations against SARS-CoV-2 were delivered in England. The third wave of COVID-19 in England began in May 2021 as the Delta variant began to outcompete and largely replace other strains. The REal-time Assessment of Community Transmission-1 (REACT-1) series of community surveys for SARS-CoV-2 infection has provided insights into transmission dynamics since May 2020. Round 15 of the REACT-1 study was carried out from 19 October to 5 November 2021.

MethodsWe estimated prevalence of SARS-CoV2 infection and used multiple logistic regression to analyse associations between SARS-CoV-2 infection in England and demographic and other risk factors, based on RT-PCR results from self-administered throat and nose swabs in over 100,000 participants. We estimated (single-dose) vaccine effectiveness among children aged 12 to 17 years, and among adults compared swab-positivity in people who had received a third (booster) dose with those who had received two vaccine doses. We used splines to analyse time trends in swab-positivity.

ResultsDuring mid-October to early-November 2021, weighted prevalence was 1.57% (1.48%, 1.66%) compared to 0.83% (0.76%, 0.89%) in September 2021 (round 14). Weighted prevalence increased between rounds 14 and 15 across most age groups (including older ages, 65 years and over) and regions, with average reproduction number across rounds of R=1.09 (1.08, 1.11). During round 15, there was a fall in prevalence from a maximum around 20-21 October, with an R of 0.76 (0.70, 0.83), reflecting falls in prevalence at ages 17 years and below and 18 to 54 years. School-aged children had the highest weighted prevalence of infection: 4.95% (4.39%, 5.58%) in those aged 5 to 12 years and 5.21% (4.61%, 5.87%) in those aged 13 to 17 years. In multiple logistic regression, age, sex, key worker status and presence of one or more children in the home were associated with swab positivity. There was evidence of heterogeneity between rounds in swab positivity rates among vaccinated individuals at ages 18 to 64 years, and differences in key demographic and other variables between vaccinated and unvaccinated adults at these ages. Vaccine effectiveness against infection in children was estimated to be 56.2% (41.3%, 67.4%) in rounds 13, 14 and 15 combined, adjusted for demographic factors, with a similar estimate obtained for round 15 only. Among adults we found that those who received a third dose of vaccine were less likely to test positive compared to those who received only two vaccine doses, with adjusted odds ratio (OR) =0.38 (0.26, 0.55).

DiscussionSwab-positivity was very high at the start of round 15, reaching a maximum around 20 to 21 October 2021, and then falling through late October with an uncertain trend in the last few days of data collection. The observational nature of survey data and the relatively small proportion of unvaccinated adults call into question the comparability of vaccinated and unvaccinated groups at this relatively late stage in the vaccination programme. However, third vaccine doses for eligible adults and the vaccination of children aged 12 years and over are associated with lower infection risk and, thus, remain a high priority (with possible extension to children aged 5-12 years). These should help reduce SARS-CoV-2 transmission during the winter period when healthcare demands typically rise.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.12.16.21267906,2021-12-16,https://medrxiv.org/cgi/content/short/2021.12.16.21267906,Workplace Contact Patterns in England during the COVID-19 Pandemic: Analysis of the Virus Watch prospective cohort study,Sarah Beale; Susan J Hoskins; Thomas Edward Byrne; Erica Wing Lam Fong; Ellen Fragaszy; Cyril Geismar; Jana Kovar; Annalan MD Navaratnam; Vincent Nguyen; Parth Patel; Alexei Yavlinsky; Anne M Johnson; Robert W Aldridge; Andrew Hayward,University College London; Univerity College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London,"BackgroundWorkplaces are an important potential source of SARS-CoV-2 exposure; however, investigation into workplace contact patterns is lacking. This study aimed to investigate how workplace attendance and features of contact varied between occupations and over time during the COVID-19 pandemic in England.

MethodsData were obtained from electronic contact diaries submitted between November 2020 and November 2021 by employed/self-employed prospective cohort study participants (n=4,616). We used mixed models to investigate the main effects and potential interactions between occupation and time for: workplace attendance, number of people in shared workspace, time spent sharing workspace, number of close contacts, and usage of face coverings.

FindingsWorkplace attendance and contact patterns varied across occupations and time. The predicted probability of intense space sharing during the day was highest for healthcare (78% [95% CI: 75-81%]) and education workers (64% [59%-69%]), who also had the highest probabilities for larger numbers of close contacts (36% [32%-40%] and 38% [33%-43%] respectively). Education workers also demonstrated relatively low predicted probability (51% [44%-57%]) of wearing a face covering during close contact. Across all occupational groups, levels of workspace sharing and close contact were higher and usage of face coverings at work lower in later phases of the pandemic compared to earlier phases.

InterpretationMajor variations in patterns of workplace contact and mask use are likely to contribute to differential COVID-19 risk. Across occupations, increasing workplace contact and reduced usage of face coverings presents an area of concern given ongoing high levels of community transmission and emergence of variants.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.12.13.21267471,2021-12-15,https://medrxiv.org/cgi/content/short/2021.12.13.21267471,Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study,Rachael Andrea Evans; Olivia C Leavy; Matthew Richardson; Omer Elneima; Hamish J C McAuley; Aarti Shikotra; Amisha Singapuri; Marco Sereno; Ruth M Saunders; Victoria C Harris; Raminder Aul; Paul Beirne; Charlotte E Bolton; Jeremy S Brown; Gourab Choudhury; Nawar Diar Bakerly; Nicholas Easom; Carlos Echevarria; Jonathan Fuld; Nick Hart; John R Hurst; Mark Jones; Dhruv Parekh; Paul Pfeffer; Najib M Rahman; Sarah Rowland-Jones; Ajay M Shah; Dan G Wootton; Trudie Chalder; Melanie J Davies; Anthony De Soyza; John R Geddes; William Greenhalf; Neil J Greening; Liam G Heaney; Simon Heller; Luke Howard; Joseph Jacob; R Gisli Jenkins; Janet M Lord; Will D-C Man; Gerry P McCann; Stefan Neubauer; Peter JM Openshaw; Joanna Porter; Jennifer Quint; Matthew J Rowland; Janet Scott; Malcolm G Semple; Sally J Singh; David Thomas; Mark Toshner; Keir Lewis; Andrew Briggs; Annemarie B Docherty; Steven Kerr; Nazir I Lone; Aziz Sheikh; Mathew Thorpe; Bang Zheng; Ryan S Thwaites; James D Chalmers; Ling-Pei Ho; Alex Horsley; Michael Marks; Krisnah Poinasamy; Betty Raman; Ewen M Harrison; Louise V Wain; Christopher E Brightling; - PHOSP-COVID Collaborative Group,"University of Leicester; Department of Health Sciences, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; University Hospitals of Leicester,; St George's Univeristy Hospitals NHS Foundation Trust, London, United Kingdom; The Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; University of Nottingham, Nottingham, United Kingdom; Nottingham Univeristy Hospitals NHS Trust, Nottingham, United Kingdom; NIHR Nottingham Biomedical Research; UCL Respiratory, Department of Medicine, University College London, Rayne Institute, London, United Kingdom; University of Edinburgh, Edinburgh, Scotland, United Kingdom; NHS Lothian, Scotland, United Kingdom; Manchester Metropolitan University, Manchester, United Kingdom;  Salford Royal NHS Foundation Trust, Manchester, United Kingdom; Infection Research Group, Hull University Teaching Hospitals, Hull, United Kingdom; University of Hull, Hull, United Kingdom; The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom; Translational and Clinical Research Institute, Newcastle University, Newcastl; Department of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; University of Cambridge, Cambridge, United K; Lane Fox Respiratory Service, Guys and St Thomas NHS Foundation Trust, London, United Kingdom; University College London, London, United Kingdom; Royal Free London NHS Foundation Trust, London, United Kingdom; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; University of Southampton, Southampton, United Kingdom; University of Birmingham, Birmingham, United Kingdom; University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Queen Mary University of London, London, United Kingdom; Oxford University Hospitals NHS Trust, Oxford, United Kingdom; University of Oxford, Oxford, United Kingdom; Oxford NIHR Biomedical Research Centre, Oxford, Uni; University of Sheffield, Sheffield, United Kingdom; Sheffield Teaching NHS Foundation Trust, Sheffield, United Kingdom; King's College London, London, United Kingdom; King's College London NHS Foundation Trust, London, United Kingdom; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom; Liverpool University Hospitals NHS Foundation Tr; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom; South London and Maud; Diabetes Research Centre, University of Leicester, Leicester, United Kingdom; NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, Uni; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom; Newcastle upon Tyne Teaching Hospitals Trust, Newcastle upon Ty; University of Oxford; University of Liverpool, Liverpool, United Kingdom; The CRUK Liverpool Experimental Cancer Medicine Centre, Liverpool, United Kingdom; Liverpool University Hosp; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; Wellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, United Kingdom; Belfast Health & Social Care Trust, Belfast, United Kingdom; Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom; Imperial College Healthcare NHS Trust, London, United Kingdom; Imperial College London, London, United Kingdom; Centre for Medical Image Computing, University College London, London, United Kingdom; Lungs for Living Research Centre, University College London, London, Unit; National Heart and Lung Institute, Imperial College London, London, United Kingdom; MRC-Versus Arthritis Centre for Musculoskeletal Ageing Research, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom; NIH; Royal Brompton and Harefield Clinical Group, Guys and St Thomas NHS Foundation Trust, London, United Kingdom; National Heart and Lung Institute, Imperial Colleg; Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom; NIHR Leicester Biomedical Research Centre, University of Leicester, L; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; NIHR Biomedical Research Centre, John Radcl; National Heart and Lung Institute, Imperial College London, London, United Kingdom; UCL Respiratory, Department of Medicine, University College London, Rayne Institute, London, United Kingdom; ILD Service, University College London Hospital, Lo; National Heart and Lung Institute, Imperial College London, London, United Kingdom; Kadoorie Centre for Critical Care Research, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; MRC-University of Glasgow Centre for Virus Research, Glasgow, Scotland, United Kingdom; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, U; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; Imperial College London, London, UK; NIHR Cambridge Biomedical Research Centre, Cambridge, United Kingdom; NIHR Cambridge Clinical Research Facility, Cambridge, United Kingdom; Hywel Dda University Health Board, Wales, United Kingdom; University of Swansea, Wales, United Kingdom; Respiratory Innovation Wales, Wales, United Kingdom; London School of Hygiene & Tropical Medicine, London, United Kingdom; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, U; Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom; Usher Institute, University of Edinburgh, Edinburgh, Scotland, United Kingdom; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; University of Edinburgh, Edinburgh, Scotland, United Kingdom; National Heart and Lung Institute, Imperial College London, London, UK; University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom; MRC Human Immunology Unit, University of Oxford, Oxford, United Kingdom; Division of Infection, Immunity & Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom; anchester; Department of Clinical Research, London School of Hygiene & Tropical Medicine Keppel Street, London, United Kingdom; Hospital for Tropical Diseases, University ; Asthma UK and British Lung Foundation, London, United Kingdom; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; Department of Health Sciences, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, Uni; The Institute for Lung Health, NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; University Hospitals of Leicester,; -","BackgroundThere are currently no effective pharmacological or non-pharmacological interventions for Long-COVID. To identify potential therapeutic targets, we focussed on previously described four recovery clusters five months after hospital discharge, their underlying inflammatory profiles and relationship with clinical outcomes at one year.

MethodsPHOSP-COVID is a prospective longitudinal cohort study, recruiting adults hospitalised with COVID-19 across the UK. Recovery was assessed using patient reported outcomes measures (PROMs), physical performance, and organ function at five-months and one-year after hospital discharge. Hierarchical logistic regression modelling was performed for patient-perceived recovery at one-year. Cluster analysis was performed using clustering large applications (CLARA) k-medoids approach using clinical outcomes at five-months. Inflammatory protein profiling from plasma at the five-month visit was performed.

Findings2320 participants have been assessed at five months after discharge and 807 participants have completed both five-month and one-year visits. Of these, 35{middle dot}6% were female, mean age 58{middle dot}7 (SD 12{middle dot}5) years, and 27{middle dot}8% received invasive mechanical ventilation (IMV). The proportion of patients reporting full recovery was unchanged between five months 501/1965 (25{middle dot}5%) and one year 232/804 (28{middle dot}9%). Factors associated with being less likely to report full recovery at one year were: female sex OR 0{middle dot}68 (95% CI 0{middle dot}46-0{middle dot}99), obesity OR 0{middle dot}50 (95%CI 0{middle dot}34-0{middle dot}74) and IMV OR 0{middle dot}42 (95%CI 0{middle dot}23-0{middle dot}76).

Cluster analysis (n=1636) corroborated the previously reported four clusters:  very severe,  severe,  moderate/cognitive,  mild relating to the severity of physical, mental health and cognitive impairments at five months in a larger sample. There was elevation of inflammatory mediators of tissue damage and repair in both the very severe and the moderate/cognitive clusters compared to the mild cluster including interleukin-6 which was elevated in both comparisons. Overall, there was a substantial deficit in median (IQR) EQ5D-5L utility index from pre-COVID (retrospective assessment) 0{middle dot}88 (0{middle dot}74-1{middle dot}00), five months 0{middle dot}74 (0{middle dot}60-0{middle dot}88) to one year: 0{middle dot}74 (0{middle dot}59-0{middle dot}88), with minimal improvements across all outcome measures at one-year after discharge in the whole cohort and within each of the four clusters.

InterpretationThe sequelae of a hospital admission with COVID-19 remain substantial one year after discharge across a range of health domains with the minority in our cohort feeling fully recovered. Patient perceived health-related quality of life remains reduced at one year compared to pre-hospital admission. Systematic inflammation and obesity are potential treatable traits that warrant further investigation in clinical trials.

FundingUKRI & NIHR

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSWe systematically searched PubMed and Embase databases for large studies reporting one-year follow-up data for hospitalised COVID-19 patients published between January 1, 2021 and November 7, 2021, without language restrictions. Search terms related to COVID-19, hospitalisation and long-term follow-up were used. A large prospective cohort study from Wuhan, China (n = 1276) showed that 49% of patients reported at least one persistent symptom during a follow-up clinic visit at 12 months post COVID-19; no significant improvement in exercise capacity was observed between six- and 12-month visits. Another two large cohort studies in China (n = 2433) and Spain (n = 1950) with one-year follow-up data from telephone interviews showed that 45% and 81% of patients reported at least one residual COVID-19 symptom, respectively. However, no previous studies have compared the trajectories of COVID-19 recovery in patients classified by different clinical phenotypes, and there are no large studies investigating the relationship between systemic inflammation and ongoing health impairments post COVID-19.

Added value of this studyIn a diverse population of adults post-hospital admission with COVID-19, our large UK prospective multi-centre study reports several novel findings: the minority felt fully recovered at one year with minimal recovery from five months across any health domain; female sex and obesity are associated with being less likely to feel fully recovered at one year; several inflammatory mediators were increased in individuals with the most severe physical, mental health, and cognitive impairments compared to individuals with milder ongoing impairments.

Implications of all the available evidenceBoth pharmacological and non-pharmacological interventions are urgently needed to improve the ongoing burden following hospitalisation for COVID-19 both for individuals and healthcare systems; our findings support the use of a precision medicine approach with potential treatable traits of systemic inflammation and obesity.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.12.13.21267368,2021-12-15,https://medrxiv.org/cgi/content/short/2021.12.13.21267368,Acute COVID-19 severity and 16-month mental morbidity trajectories in patient populations of six nations,Ingibjorg Magnusdottir; Aniko Lovik; Anna Bara Unnarsdottir; Daniel L. McCartney; Helga Ask; Kadri Koiv; Lea Arregui Nordahl Christoffersen; Sverre Urnes Johnson; Andrew M McIntosh; Anna K. Kahler; Archie Campbell; Arna Hauksdottir; Chloe Fawns-Ritchie; Christian Erikstrup; Dorte Helenius; Drew Altschul; Edda Bjork Thordardottir; Elias Eythorsson; Emma M. Frans; Gunnar Tomasson; Harpa Lind Jonsdottir; Harpa Runarsdottir; Henrik Hjalgrim; Hronn Hardardottir; Juan Gonzalez-Hijon; Karina Banasik; Khoa Manh Dinh; Li Lu; Lili Milani; Lill Trogstad; Maria Didriksen; Omid V. Ebrahimi; Patrick F. Sullivan; Per Minor Magnus; Qing Shen; Ragnar Nesvag; Reedik Magi; Runolfur Palsson; Sisse Rye Ostrowski; Thomas Werge; Asle Hoffart; David J. Porteous; Fang Fang; Johanna Jakobsdottir; Kelli Lehto; Ole A. Andreassen; Ole B.V. Pedersen; Thor Aspelund; Unnur Anna Valdimarsdottir,"Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK; Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway; Estonian Genome Centre, Institute of Genomics, University of Tartu, Estonia; Institute of Biological Psychiatry, Mental Health Services Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark; Department of Psychology, University of Oslo, Oslo, Norway; Division of Psychiatry, University of Edinburgh, Edinburgh, UK; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK; Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark; Institute of Biological Psychiatry, Mental Health Services Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark; Department of Psychology, University of Edinburgh, Edinburgh, UK; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Faculty of Psychology, University of Iceland School of Health Sciences, Reykjavik, Iceland; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Danish Cancer Society Research Center, Copenhagen, Denmark; Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland; Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Translational Disease Systems Biology, Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark; Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway; Estonian Genome Centre, Institute of Genomics, University of Tartu, Estonia; Division of Infection Control and Environmental Health, Norwegian Institute of Public Health, Oslo, Norway; Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Department of Psychology, University of Oslo, Oslo, Norway; Departments of Genetics and Psychiatry, University of North Carolina, Chapel Hill, North Carolina, USA; Centre of Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway.; Estonian Genome Centre, Institute of Genomics, University of Tartu, Estonia; Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland; Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; Institute of Biological Psychiatry, Mental Health Services Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark; Department of Psychology, University of Oslo, Oslo, Norway; Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, UK; Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Estonian Genome Centre, Institute of Genomics, University of Tartu, Estonia; NORMENT Centre, Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Clinical Immunology, Zealand University Hospital, Denmark; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland; Centre of Public Health Sciences, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland","BACKGROUNDThe aim of this multinational study was to assess the development of adverse mental health symptoms among individuals diagnosed with COVID-19 in the general population by acute infection severity up to 16 months after diagnosis.

METHODSParticipants consisted of 247 249 individuals from seven cohorts across six countries (Denmark, Estonia, Iceland, Norway, Scotland, and Sweden) recruited from April 2020 through August 2021. We used multivariable Poisson regression to contrast symptom-prevalence of depression, anxiety, COVID-19 related distress, and poor sleep quality among individuals with and without a diagnosis of COVID-19 at entry to respective cohorts by time (0-16 months) from diagnosis. We also applied generalised estimating equations (GEE) analysis to test differences in repeated measures of mental health symptoms before and after COVID-19 diagnosis among individuals ever diagnosed with COVID-19 over time.

FINDINGSA total of 9979 individuals (4%) were diagnosed with COVID-19 during the study period and presented overall with a higher symptom burden of depression (prevalence ratio [PR] 1{middle dot}18, 95% confidence interval [95% CI] 1{middle dot}03-1{middle dot}36) and poorer sleep quality (1{middle dot}13, 1{middle dot}03-1{middle dot}24) but not with higher levels of symptoms of anxiety or COVID-19 related distress compared with individuals without a COVID-19 diagnosis. While the prevalence of depression and COVID-19 related distress attenuated with time, the trajectories varied significantly by COVID-19 acute infection severity. Individuals diagnosed with COVID-19 but never bedridden due to their illness were consistently at lower risks of depression and anxiety (PR 0{middle dot}83, 95% CI 0{middle dot}75-0{middle dot}91 and 0{middle dot}77, 0{middle dot}63-0{middle dot}94, respectively), while patients bedridden for more than 7 days were persistently at higher risks of symptoms of depression and anxiety (PR 1{middle dot}61, 95% CI 1{middle dot}27-2{middle dot}05 and 1{middle dot}43, 1{middle dot}26-1{middle dot}63, respectively) throughout the 16-month study period.

CONCLUSIONAcute infection severity is a key determinant of long-term mental morbidity among COVID-19 patients.",public and global health,fuzzy,100,92
medRxiv,10.1101/2021.12.14.21267460,2021-12-15,https://medrxiv.org/cgi/content/short/2021.12.14.21267460,Differential Risk of SARS-CoV-2 Infection by Occupation: Evidence from the Virus Watch prospective cohort study in England and Wales,Sarah Beale; Susan J Hoskins; Thomas Edward Byrne; Erica Wing Lam Fong; Ellen Fragaszy; Cyril Geismar; Jana Kovar; Annalan MD Navaratnam; Vincent Nguyen; Parth Patel; Alexei Yavlinsky; Anne Johnson; Martie Van Tongeren; Robert W Aldridge; Andrew Hayward,University College London; Univerity College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University of Manchester; University College London; University College London,"BackgroundWorkers differ in their risk of SARS-CoV-2 infection according to their occupation, but the direct contribution of occupation to this relationship is unclear. This study aimed to investigate how infection risk differed across occupational groups in England and Wales up to April 2022, after adjustment for potential confounding and stratification by pandemic phase.

MethodsData from 15,190 employed/self-employed participants in the Virus Watch prospective cohort study were used to generate risk ratios for virologically- or serologically-confirmed SARS-CoV-2 infection using robust Poisson regression, adjusting for socio-demographic and health-related factors and non-work public activities. We calculated attributable fractions (AF) amongst the exposed for belonging to each occupational group based on adjusted risk ratios (aRR).

FindingsIncreased risk was seen in nurses (aRR=1.44, 1.25-1.65; AF=30%, 20-39%), doctors (aRR=1.33, 1.08-1.65; AF=25%, 7-39%), carers (1.45, 1.19-1.76; AF=31%, 16-43%), primary school teachers (aRR=1.67, 1.42-1.96; AF=40%, 30-49%), secondary school teachers (aRR=1.48, 1.26-1.72; AF=32%, 21-42%), and teaching support occupations (aRR=1.42, 1.23-1.64; AF=29%, 18-39%) compared to office-based professional occupations. Differential risk was apparent in the earlier phases (Feb 2020 - May 2021) and attenuated later (June - October 2021) for most groups, although teachers and teaching support workers demonstrated persistently elevated risk across waves.

InterpretationOccupational differentials in SARS-CoV-2 infection risk vary over time and are robust to adjustment for socio-demographic, health-related, and non-workplace activity-related potential confounders. Direct investigation into workplace factors underlying elevated risk and how these change over time is needed to inform occupational health interventions.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.12.13.21267723,2021-12-14,https://medrxiv.org/cgi/content/short/2021.12.13.21267723,"Differential impact of Covid-19 on incidence of diabetes mellitus and cardiovascular diseases in acute, post-acute and long Covid-19: population-based cohort study in the United Kingdom",Emma Rezel-Potts; Abdel Douiri; Xiaohui Sun; Phillip J Chowienczyk; Ajay M Shah; Martin C Gulliford,King's College London; King's College London; King's College London; King's College London; King's College London; King's College London,"ObjectiveThis study aimed to estimate the incidence of new diabetes mellitus (DM) and cardiovascular diseases (CVD) up to one year after Covid-19 compared with matched controls.

MethodsA cohort study was conducted using electronic records for 1,473 family practices with a population of 14.9 million. Covid-19 patients without DM or CVD were individually matched with controls and followed up to October 2021. A difference-in-difference analysis estimated the net effect of Covid-19 allowing for baseline differences and covariates.

ResultsThere were 372,816 Covid-19 patients, with 2,935 CVD and 3,139 DM events, and 372,816 matched controls with 1,193 CVD and 1,861 DM events following the index date. Net incidence of DM increased in acute Covid-19 up to four weeks from index date (adjusted rate ratio, RR 1.71, 1.40 to 2.10) and remained elevated in post-acute (five to 12 weeks from index date; RR 1.17, 1.01 to 1.36) and long-Covid-19 (13 to 52 weeks, 1.20, 1.09 to 1.31). Acute Covid-19 was associated with net increased CVD incidence (RR 6.02, 95% confidence interval 4.84 to 7.47) including pulmonary embolism (RR 14.5, 7.72 to 27.4), atrial arrythmias (6.58, 3.78 to 11.4) and venous thromboses (5.44, 3.22 to 9.17). CVD incidence declined in post-acute Covid-19 (1.68, 1.41 to 2.01) and showed no net increase in long Covid-19 (0.95, 0.85 to 1.06).

ConclusionsDM incidence remains elevated up to one year following Covid-19. CVD is increased early after Covid-19 mainly from pulmonary embolism, atrial arrhythmias and venous thromboses.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.12.09.21267516,2021-12-09,https://medrxiv.org/cgi/content/short/2021.12.09.21267516,Changes in the trajectory of Long Covid symptoms following COVID-19 vaccination: community-based cohort study,Daniel Ayoubkhani; Charlotte Bermingham; Koen B Pouwels; Myer Glickman; Vahe Nafilyan; Francesco Zaccardi; Kamlesh Khunti; Nisreen A Alwan; Ann Sarah Walker,Office for National Statistics; Office for National Statistics; University of Oxford; Office for National Statistics; Office for National Statistics; University of Leicester; University of Leicester; University of Southampton; University of Oxford,"ObjectiveTo estimate associations between COVID-19 vaccination and Long Covid symptoms in adults who were infected with SARS-CoV-2 prior to vaccination.

DesignObservational cohort study using individual-level interrupted time series analysis.

SettingRandom sample from the community population of the UK.

Participants28,356 COVID-19 Infection Survey participants (mean age 46 years, 56% female, 89% white) aged 18 to 69 years who received at least their first vaccination after test-confirmed infection.

Main outcome measuresPresence of long Covid symptoms at least 12 weeks after infection over the follow-up period 3 February to 5 September 2021.

ResultsMedian follow-up was 141 days from first vaccination (among all participants) and 67 days from second vaccination (84% of participants). First vaccination was associated with an initial 12.8% decrease (95% confidence interval: -18.6% to -6.6%) in the odds of Long Covid, but increasing by 0.3% (-0.6% to +1.2%) per week after the first dose. Second vaccination was associated with an 8.8% decrease (-14.1% to -3.1%) in the odds of Long Covid, with the odds subsequently decreasing by 0.8% (-1.2% to -0.4%) per week. There was no statistical evidence of heterogeneity in associations between vaccination and Long Covid by socio-demographic characteristics, health status, whether hospitalised with acute COVID-19, vaccine type (adenovirus vector or mRNA), or duration from infection to vaccination.

ConclusionsThe likelihood of Long Covid symptoms reduced after COVID-19 vaccination, and the improvement was sustained over the follow-up period after the second dose. Vaccination may contribute to a reduction in the population health burden of Long Covid, though longer follow-up time is needed.

Summary boxWhat is already known on this topic

O_LICOVID-19 vaccines are effective at reducing rates of SARS-CoV-2 infection, transmission, hospitalisation, and death
C_LIO_LIThe incidence of Long Covid may be reduced if infected after vaccination, but the relationship between vaccination and pre-existing long COVID symptoms is unclear, as published studies are generally small and with self-selected participants
C_LI

What this study adds

O_LIThe likelihood of Long Covid symptoms reduced after COVID-19 vaccination, and the improvement was sustained over the follow-up period after the second dose
C_LIO_LIThere was no evidence of differences in this relationship by socio-demographic characteristics, health-related factors, vaccine type, or duration from infection to vaccination
C_LIO_LIAlthough causality cannot be inferred from this observational evidence, vaccination may contribute to a reduction in the population health burden of Long Covid; further research is needed to understand the biological mechanisms that may ultimately contribute to the development of therapeutics for Long Covid
C_LI",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.12.08.21267458,2021-12-08,https://medrxiv.org/cgi/content/short/2021.12.08.21267458,"Relative contribution of leaving home for work or education, transport, shopping and other activities on risk of acquiring COVID-19 infection outside the household in the second wave of the pandemic in England and Wales",Susan J Hoskins; Sarah Beale; Robert W Aldridge; Colette Smith; Clare French; Alex Yavlinksky; Vincent Nguyen; Thomas Edward Byrne; Jana Kovar; Ellen Fragaszy; W Fong; Cyril Geismar; Parth Patel; Ann Johnson; Andrew Edward Hayward,Univerity College London; University College London; UCL; University College London; University of Bristol; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; UCL,"BackgroundWith the potential for and emergence of new COVID-19 variants, such as the reportedly more infectious Omicron, and their potential to escape the existing vaccines, understanding the relative importance of which non-household activities increase risk of acquisition of COVID-19 infection is vital to inform mitigation strategies.

MethodsWithin an adult subset of the Virus Watch community cohort study, we sought to identify which non-household activities increased risk of acquisition of COVID-19 infection and which accounted for the greatest proportion of non-household acquired COVID-19 infections during the second wave of the pandemic. Among participants who were undertaking antibody tests and self-reporting PCR and lateral flow tests taken through the national testing programme, we identified those who were thought to be infected outside the household during the second wave of the pandemic. We used exposure data on attending work, using public or shared transport, using shops and other non-household activities taken from monthly surveys during the second wave of the pandemic. We used multivariable logistic regression models to assess the relative independent contribution of these exposures on risk of acquiring infection outside the household. We calculated Adjusted Population Attributable Fractions (APAF - the proportion of non-household transmission in the cohort thought to be attributable to each exposure) based on odds ratios and frequency of exposure in cases.

ResultsBased on analysis of 10475 adult participants including 874 infections acquired outside the household, infection was independently associated with: leaving home for work (AOR 1.20 (1.02 - 1.42) p=0.0307, APAF 6.9%); public transport use (AOR for use more than once per week 1.82 (1.49 - 2.23) p<0.0001, APAF for public transport 12.42%); and shopping (AOR for shopping more than once per week 1.69 (1.29 - 2.21) P=0.0003, APAF for shopping 34.56%). Other non-household activities such as use of hospitality and leisure venues were rare due to restrictions and there were no significant associations with infection risk.

ConclusionsA high proportion of the second wave of the pandemic was spent under conditions where people were being advised to work from home where possible, and to minimize exposure to shops, and a wide range of other businesses were subject to severe restrictions. Vaccines were being rolled out to high-risk groups. During this time, going to work was an important risk factor for infection but public transport use likely accounted for a lot of this risk. Only a minority of the cohort left home for work or used public or shared transport. By contrast, the majority of participants visited shops and this activity accounted for about one-third of non-household transmission.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.12.08.21267353,2021-12-08,https://medrxiv.org/cgi/content/short/2021.12.08.21267353,The challenge of limited vaccine supplies: impact of prior infection on anti-spike IgG antibody trajectories after a single COVID-19 vaccination,Jia Wei; Philippa Matthews; Nicole Stoesser; Ian Diamond; Ruth Studley; Emma Rourke; Duncan Cook; John Bell; John Newton; Jeremy Farrar; Alison Howarth; Brian Marsden; Sarah Hoosdally; Yvonne Jones; David Stuart; Derrick W Crook; tim E peto; Ann Sarah Walker; David W Eyre; Koen B Pouwels; - COVID-19 Infection Survey team,University of Oxford; University of Oxford; University of Oxford; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; NIHR Oxford Biomedical Research Centre; oxford university; University of Oxford; University of Oxford; University of Oxford; ,"Given high SARS-CoV-2 incidence, coupled with slow and inequitable vaccine roll-out, there is an urgent need for evidence to underpin optimum vaccine deployment, aiming to maximise global population immunity at speed. We evaluate whether a single vaccination in previously infected individuals generates similar initial and subsequent antibody responses to two vaccinations in those without prior infection. We compared anti-spike IgG antibody responses after a single dose of ChAdOx1, BNT162b2, or mRNA-1273 SARS-CoV-2 vaccines in the COVID-19 Infection Survey in the UK general population. In 100,849 adults who received at least one vaccination, 13,404 (13.3%) had serological and/or PCR evidence of prior infection. Prior infection significantly boosted antibody responses for all three vaccines, producing a higher peak level and longer half-life, and a response comparable to those without prior infection receiving two vaccinations. In those with prior infection, median time above the positivity threshold was estimated to last for >1 year after the first dose. Single-dose vaccination targeted to those previously infected may provide protection in populations with high rates of previous infection faced with limited vaccine supply, as an interim measure while vaccine campaigns are scaled up.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.12.03.21266112,2021-12-05,https://medrxiv.org/cgi/content/short/2021.12.03.21266112,Brain Injury in COVID-19 is Associated with Autoinflammation and Autoimmunity,Edward J Needham; Alex L Ren; Richard J Digby; Joanne G Outtrim; Dorothy A Chatfield; Virginia FJ Newcombe; Rainer Doffinger; Gabriela Barcenas-Morales; Claudia Fonseca; Michael J Taussig; Rowan M Burnstein; Cordelia Dunai; Nyarie Sithole; Nicholas J Ashton; Henrik Zetterberg; Magnus Gisslen; Eden Arvid; Emelie Marklund; Michael J Griffiths; Jonathan Cavanagh; Gerome Breen; Sarosh R Irani; Anne Elmer; Nathalie Kingston; John R Bradley; Leonie S Taams; Benedict D michael; Edward T Bullmore; Kenneth GC Smith; Paul A Lyons; Alasdair JC Coles; David K Menon; - Cambridge NeuroCOVID Group; - NIHR Cambridge Covid BioResource; - NIHR Cambridge Clinical Research Facility,"Department of Clinical Neurosciences, University of Cambridge, UK; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge, UK.; Cambridge Protein Arrays Ltd, Babraham Research Campus, Cambridge, UK; Cambridge Protein Arrays Ltd, Babraham Research Campus, Cambridge, UK; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.; Clinical Infection Microbiology and Neuroimmunology, Institute of Infection, Veterinary and Ecological Science, Liverpool, UK.; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden.; Department of Psychiatry and Neurochemistry, Institute of Neuroscience & Physiology, the Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden; C; Department of Infectious Diseases, Institute of Biomedicine, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; Region Vastra Gotaland; Department of Infectious Diseases, Institute of Biomedicine, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; Region Vastra Gotaland; Department of Infectious Diseases, Institute of Biomnedicine, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden; Region Vastra Gotalan; Institute of Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, UK.; Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, U; Department of Social Genetic and Developmental Psychiatry, King's College London, London, UK.; Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of Neurology, Oxford University H; Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK ; NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge, UK.; NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge, UK; Department of Medicine, University of Cambridge, Ad; Centre for Inflammation Biology and Cancer Immunology and Dept Inflammation Biology, School of Immunology and Microbial Sciences, Kings College London, Guys Cam; Clinical Infection Microbiology and Neuroimmunology, Institute of Infection, Veterinary and Ecological Science, Liverpool, UK.; Department of Psychiatry, University of Cambridge, Herchel Smith Building for Brain and Mind Sciences, Cambridge Biomedical Campus, Cambridge, UK.; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Je; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Je; Department of Clinical Neurosciences, University of Cambridge, UK; Division of Anaesthesia, Department of Medicine, University of Cambridge, UK.; ; ; ","COVID-19 has been associated with many neurological complications including stroke, delirium and encephalitis. Furthermore, many individuals experience a protracted post-viral syndrome which is dominated by neuropsychiatric symptoms, and is seemingly unrelated to COVID-19 severity. The true frequency and underlying mechanisms of neurological injury are unknown, but exaggerated host inflammatory responses appear to be a key driver of severe COVID-19 more broadly.

We sought to investigate the dynamics of, and relationship between, serum markers of brain injury (neurofilament light [NfL], Glial Fibrillary Acidic Protein [GFAP] and total Tau) and markers of dysregulated host response including measures of autoinflammation (proinflammatory cytokines) and autoimmunity. Brain injury biomarkers were measured using the Quanterix Simoa HDx platform, cytokine profiling by Luminex (R&D) and autoantibodies by a custom protein microarray.

During hospitalisation, patients with COVID-19 demonstrated elevations of NfL and GFAP in a severity-dependant manner, and there was evidence of ongoing active brain injury at follow-up 4 months later. Raised NfL and GFAP were associated with both elevations of pro-inflammatory cytokines and the presence of autoantibodies; autoantibodies were commonly seen against lung surfactant proteins as well as brain proteins such as myelin associated glycoprotein, but reactivity was seen to a large number of different antigens.

Furthermore, a distinct process characterised by elevation of serum total Tau was seen in patients at follow-up, which appeared to be independent of initial disease severity and was not associated with dysregulated immune responses in the same manner as NfL and GFAP.",neurology,fuzzy,100,100
medRxiv,10.1101/2021.11.24.21266818,2021-12-01,https://medrxiv.org/cgi/content/short/2021.11.24.21266818,Trends and associated factors for Covid-19 hospitalisation and fatality risk in 2.3 million adults in England,Thomas Beaney; Ana Luisa Neves; Ahmed Alboksmaty; Kelsey Flott; Aidan Fowler; Jonathan R Benger; Paul Aylin; Sarah Elkin; Ara Darzi; Jonathan Clarke,Imperial College London; Imperial College London; Imperial College London; Imperial College London; NHS England and Improvement; NHS Digital; Imperial College London; Imperial College London; Imperial College London; Imperial College London,"BackgroundThe Covid-19 case fatality ratio varies between countries and over time but it is unclear whether variation is explained by the underlying risk in those infected. This study aims to describe the trends and risk factors for admission and mortality rates over time in England.

MethodsIn this retrospective cohort study, we included all adults ([&ge;]18 years) in England with a positive Covid-19 test result between 1st October 2020 and 30th April 2021. Data were linked to primary and secondary care electronic health records and death registrations. Our outcomes were i) one or more emergency hospital admissions and ii) death from any cause, within 28 days of a positive test. Multivariable multilevel logistic regression was used to model each outcome with patient risk factors and time.

Results2,311,282 people were included in the study, of whom 164,046 (7.1%) were admitted and 53,156 (2.3%) died within 28 days. There was significant variation in the case hospitalisation and mortality risk over time, peaking in December 2020-February 2021, which remained after adjustment for individual risk factors. Older age groups, males, those resident in more deprived areas, and those with obesity had higher odds of admission and mortality. Of risk factors examined, severe mental illness and learning disability had the highest odds of admission and mortality.

ConclusionsIn one of the largest studies of nationally representative Covid-19 risk factors, case hospitalisation and mortality risk varied significantly over time in England during the second pandemic wave, independent of the underlying risk in those infected.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.11.29.21266847,2021-11-30,https://medrxiv.org/cgi/content/short/2021.11.29.21266847,Population level impact of a pulse oximetry remote monitoring programme on mortality and healthcare utilisation in the people with covid-19 in England: a national analysis using a stepped wedge design,Thomas Beaney; Jonathan Clarke; Ahmed Alboksmaty; Kelsey Flott; Aidan Fowler; Jonathan R Benger; Paul Aylin; Sarah Elkin; Ana Luisa Neves; Ara Darzi,Imperial College London; Imperial College London; Imperial College London; Imperial College London; NHS England and Improvement; NHS Digital; Imperial College London; Imperial College London; Imperial College London; Imperial College London,"ObjectivesTo identify the population level impact of a national pulse oximetry remote monitoring programme for covid-19 (COVID Oximetry @home; CO@h) in England on mortality and health service use.

DesignRetrospective cohort study using a stepped wedge pre- and post-implementation design.

SettingAll Clinical Commissioning Groups (CCGs) in England implementing a local CO@h programme.

Participants217,650 people with a positive covid-19 polymerase chain reaction test result and symptomatic, from 1st October 2020 to 3rd May 2021, aged [&ge;]65 years or identified as clinically extremely vulnerable. Care home residents were excluded.

InterventionsA pre-intervention period before implementation of the CO@h programme in each CCG was compared to a post-intervention period after implementation.

Main outcome measuresFive outcome measures within 28 days of a positive covid-19 test: i) death from any cause; ii) any A&E attendance; iii) any emergency hospital admission; iv) critical care admission; and v) total length of hospital stay.

ResultsImplementation of the programme was not associated with mortality or length of hospital stay. Implementation was associated with increased health service utilisation with a 12% increase in the odds of A&E attendance (95% CI: 6%-18%) and emergency hospital admission (95% CI: 5%-20%) and a 24% increase in the odds of critical care admission in those admitted (95% CI: 5%-47%). In a secondary analysis of CO@h sites with at least 10% or 20% of eligible people enrolled, there was no significant association with any outcome measure. However, uptake of the programme was low, with enrolment data received for only 5,527 (2.5%) of the eligible population.

ConclusionsAt a population level, there was no association with mortality following implementation of the CO@h programme, and small increases in health service utilisation were observed. Low enrolment of eligible people may have diluted the effects of the programme at a population level.",health systems and quality improvement,fuzzy,100,100
medRxiv,10.1101/2021.11.29.21266996,2021-11-29,https://medrxiv.org/cgi/content/short/2021.11.29.21266996,Deficits in planned hospital care for vulnerable adolescents in England during the COVID-19 pandemic: analysis of linked administrative data,Louise Mc Grath-Lone; David Etoori; Ruth Gilbert; Katie Harron; Jenny Woodman; Ruth Blackburn,University College London; University College London; University College London; University College London; University College London; University College London,"Planned hospital care (outpatient attendances and planned hospital admissions) was disrupted during the pandemic, but we lack evidence on which groups of young people were most impacted. We aimed to describe differences in planned care for vulnerable adolescents receiving childrens social care (CSC) services or special educational needs (SEN) support during the pandemic, relative to their peers. Using the ECHILD Database (linked de-identified administrative health, education and social care records for all children in England), we examined changes in planned hospital care from 23 March to 31 December 2020 for secondary school pupils in Years 7 to 11 (N=3,030,235). There were large deficits in planned care for adolescents overall, which disproportionately affected the 21% receiving SEN support or CSC services who bore 25% of the outpatient attendance deficit and 37% of the planned admissions deficit. These findings indicate a need for targeted  catch-up funding and resources, particularly for vulnerable groups.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.11.25.21266848,2021-11-29,https://medrxiv.org/cgi/content/short/2021.11.25.21266848,Evaluating the impact of a pulse oximetry remote monitoring programme on mortality and healthcare utilisation in patients with covid-19 assessed in Accident and Emergency departments in England: a retrospective matched cohort study,Thomas Beaney; Jonathan Clarke; Ahmed Alboksmaty; Kelsey Flott; Aidan Fowler; Jonathan R Benger; Paul Aylin; Sarah Elkin; Ara Darzi; Ana Luisa Neves,Imperial College London; Imperial College London; Imperial College London; Imperial College London; NHS England and Improvement; NHS Digital; Imperial College London; Imperial College London; Imperial College London; Imperial College London,"ObjectivesTo identify the impact of a national pulse oximetry remote monitoring programme for covid-19 (COVID Oximetry @home; CO@h) on health service use and mortality in patients attending Accident and Emergency (A&E) departments.

DesignRetrospective matched cohort study of patients enrolled onto the CO@h pathway from A&E.

SettingNational Health Service (NHS) A&E departments in England.

ParticipantsAll patients with a positive covid-19 test from 1st October 2020 to 3rd May 2021 who attended A&E from three days before to ten days after the date of the test. All patients who were admitted or died on the same or following day to the first A&E attendance within the time window were excluded.

InterventionsParticipants enrolled onto CO@h were matched using demographic and clinical criteria to participants who were not enrolled.

Main outcome measuresFive outcome measures were examined within 28 days of first A&E attendance: i) death from any cause; ii) any subsequent A&E attendance; iii) any emergency hospital admission; iv) critical care admission; and v) length of stay.

Results15,621 participants were included in the primary analysis, of whom 639 were enrolled onto CO@h and 14,982 were controls. Odds of death were 52% lower in those enrolled (95% CI: 7%-75% lower) compared to those not enrolled on CO@h. Odds of any A&E attendance or admission were 37% (95% CI: 16-63%) and 59% (95% CI: 16-63%) higher, respectively, in those enrolled. Of those admitted, those enrolled had 53% (95% CI: 7%-76%) lower odds of critical care admission. There was no significant impact on length of stay.

ConclusionsThese findings indicate that for patients assessed in A&E, pulse oximetry remote monitoring may be a clinically effective and safe model for early detection of hypoxia and escalation, leading to increased subsequent A&E attendance and admissions, and reduced critical care requirement and mortality.",health systems and quality improvement,fuzzy,100,100
bioRxiv,10.1101/2021.11.24.469860,2021-11-26,https://biorxiv.org/cgi/content/short/2021.11.24.469860,Nanopore ReCappable Sequencing maps SARS-CoV-2 5' capping sites and provides new insights into the structure of sgRNAs,Camilla Ugolini; Logan Mulroney; Adrien Leger; Matteo Castelli; Elena Criscuolo; Maia Kavanagh Williamson; Andrew D Davidson; Abdulaziz Almuqrin; Roberto Giambruno; Miten Jain; Gianmaria Frig√®; Hugh Olsen; George Tzertzinis; Ira Schildkraut; Madalee F Wulf; Ivan R. Corr√™a Jr.; Laurence Ettwiller; Nicola Clementi; Massimo Clementi; Nicasio Mancini; Ewan Birney; Mark Akeson; Francesco Nicassio; David A Matthews; Tommaso Leonardi,Italian Institute of Technology; Italian Institute of Technology; Oxford Nanopore Technologies; Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; University of Bristol; University of Bristol; University of Bristol; Istituto Italiano di Tecnologia; University of California Santa Cruz; Istituto Europeo di Oncologia; University of California Santa Cruz; New England Biolabs; New England Biolabs; New England Biolabs; New England Biolabs; New England Biolabs Inc; Vita-Salute San Raffaele University; Vita-Salute San Raffaele University; Universit√† Vita-Salute San Raffaele; European Bioinformatics Institute; University of California Santa Cruz; Istituto Italiano di Tecnologia; University of Bristol; Italian Institute of Technology,"The SARS-CoV-2 virus has a complex transcriptome characterised by multiple, nested sub genomic RNAs used to express structural and accessory proteins. Long-read sequencing technologies such as nanopore direct RNA sequencing can recover full-length transcripts, greatly simplifying the assembly of structurally complex RNAs. However, these techniques do not detect the 5' cap, thus preventing reliable identification and quantification of full-length, coding transcript models. Here we used Nanopore ReCappable Sequencing (NRCeq), a new technique that can identify capped full-length RNAs, to assemble a complete annotation of SARS-CoV-2 sgRNAs and annotate the location of capping sites across the viral genome. We obtained robust estimates of sgRNA expression across cell lines and viral isolates and identified novel canonical and non-canonical sgRNAs, including one that uses a previously un-annotated leader-to-body junction site. The data generated in this work constitute a useful resource for the scientific community and provide important insights into the mechanisms that regulate the transcription of SARS-CoV-2 sgRNAs.",genomics,fuzzy,100,100
medRxiv,10.1101/2021.11.24.21266748,2021-11-26,https://medrxiv.org/cgi/content/short/2021.11.24.21266748,COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: two prospective observational cohort studies,Kerstin Klaser; Erika Molteni; Mark S Graham; Liane S Canas; Marc F Osterdahl; Michela Antonelli; Liyuan Chen; Jie Deng; Benjamin Murray; Eric Kerfoot; Jonathan Wolf; Anna May; Ben Fox; Joan Capdevila Pujol; - The COVID-19 Genomics UK (COG-UK) consortium; Marc Modat; Alexander Hammers; Timothy Spector; Claire Steves; Carole Sudre; Sebastien Ourselin; Emma Duncan,King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; ZOE Limited; ZOE Limited; ZOE Limited; ZOE Limited; ; King's College London; King's College London; King's College London; King's College London; University College London; King's College London; King's College London,"BackgroundThe Delta (B.1.617.2) variant became the predominant UK circulating SARS-CoV-2 strain in May 2021. How Delta infection compares with previous variants is unknown.

MethodsThis prospective observational cohort study assessed symptomatic adults participating in the app-based COVID Symptom Study who tested positive for SARS-CoV-2 from May 26 to July 1, 2021 (Delta overwhelmingly predominant circulating UK variant), compared (1:1, age- and sex-matched) with individuals presenting from December 28, 2020 to May 6, 2021 (Alpha (B.1.1.7) predominant variant). We assessed illness (symptoms, duration, presentation to hospital) during Alpha- and Delta-predominant timeframes; and transmission, reinfection, and vaccine effectiveness during the Delta-predominant period.

Findings3,581 individuals (aged 18 to 100 years) from each timeframe were assessed. The seven most frequent symptoms were common to both variants. Within the first 28 days of illness, some symptoms were more common with Delta vs. Alpha infection (including fever, sore throat and headache) and vice versa (dyspnoea). Symptom burden in the first week was higher with Delta vs. Alpha infection; however, the odds of any given symptom lasting [&ge;]7 days was either lower or unchanged. Illness duration [&ge;]28 days was lower with Delta vs. Alpha infection, though unchanged in unvaccinated individuals. Hospitalisation for COVID-19 was unchanged. The Delta variant appeared more (1{middle dot}47) transmissible than Alpha. Re-infections were low in all UK regions. Vaccination markedly (69-84%) reduced risk of Delta infection.

InterpretationCOVID-19 from Delta or Alpha infections is clinically similar. The Delta variant is more transmissible than Alpha; however, current vaccines show good efficacy against disease.

FundingUK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation, Alzheimers Society, and ZOE Limited.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSTo identify existing evidence for differences (including illness, transmissibility, and vaccine effectiveness) from SARS-CoV-2 infection due to Alpha (B.1.1.7) and Delta (B.1.617.2) variants, we searched PubMed for peer-reviewed articles and medRxiv for preprint publications between March 1 and November 18, 2021 using keywords (""SARS-CoV-2"" OR ""COVID-19"") AND (""delta variant"" OR ""B.1.617.2"") AND (symptom* OR transmiss* OR ""disease duration"" OR ""illness duration"" OR ""symptom* duration""). Searches were not restricted by language. Among 169 identified PubMed articles, we found evidence that Delta variant has increased replication capacity (from 4-fold, up to 21-fold, compared with wild-type) and greater transmissibility (estimated between +20% and +97%), compared with previous strains. Currently available vaccines may have 2- to 5-fold lower neutralizing response to Delta vs. previous variants, depending on vaccine formulation, although their protective effect against severe disease and death appears to remain strong. REACT-1 study found that in UK infections were increasing exponentially in the 5-17-year old children in September 2021, coinciding with the start of the autumn school term in England. This was interpreted as an effect of the relatively low rate of vaccinated individuals in this age group. Other studies found that in unvaccinated individuals, Delta variant may be associated with higher odds of pneumonia, oxygen requirement, emergency care requests, ICU admission, and death. In a study of 27 (mainly young) cases, 22 persons were symptomatic, with fever (41%), cough (33%), headache (26%), and sore throat (26%) the commonest symptoms. We found no studies, beyond case series, investigating symptom and/or illness duration due to Delta variant infection otherwise.

Added value of this studyUsing data from one of the largest UK citizen science epidemiological initiatives, we describe and compare illness (symptom duration, burden, profile, risk of long illness, and hospital attendance) in symptomatic community-based adults presenting when either the Alpha or Delta variant was the predominant circulating strain of SARS-CoV-2 in the UK. We assess evidence of transmission, reinfection, and vaccine effectiveness. Our data show that the seven most common symptoms with Delta infection were the same as with Alpha infection. Risks of illness duration [&ge;]7 days and [&ge;]28 days, and of requiring hospital care, were not increased. In line with previous research, we found increased transmissibility of Delta vs. previous variants; and no evidence of increased re-infection rates. Our data support high vaccine efficacy of BNT162b2 and ChAdOx1 nCoV-19 formulations against Delta variant infection. Overall, our study adds quantitative information regarding meaningful clinical differences in COVID-19 due to Delta vs. other variants.

Implications of all the available evidenceOur observational data confirm that COVID-19 disease in UK in adults is generally comparable to infection with the Alpha variant, including in elderly individuals. Our data contribute to epidemiological surveillance from the wider UK population and may capture information from COVID-19 presentation within the community that might be missed in healthcare-based surveillance. Our data may be useful in informing healthcare service planning, vaccination policies, and measures for social protection.",epidemiology,fuzzy,94,100
medRxiv,10.1101/2021.11.22.21266692,2021-11-24,https://medrxiv.org/cgi/content/short/2021.11.22.21266692,Serological responses to COVID-19 booster vaccine in England,Georgina Ireland; Heather Whitaker; Shamez N Ladhani; Frances Baawuah; Vani Subbarao; Ezra Linley; Lenesha Warrener; Michelle O'Brien; Corrine Whillock; Paul Moss; Mary E Ramsay; Gayatri Amirthalingam; Kevin E Brown,"UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency; Brondesbury Medical Centre, Kilburn, London, United Kingdom; UK Health Security Agency; University of Birmingham; UK Health Security Agency; UK Health Security Agency; UK Health Security Agency","IntroductionThere are limited data on immune responses after COVID-19 vaccine boosters in individuals receiving primary immunisation with BNT162b2 (Pfizer-BioNTech) or AZD1222 (AstraZeneca).

MethodsA prospective, cohort study to assess SARS-CoV-2 antibody responses before and after booster vaccination with BNT162b2 in adults receiving either (i) two BNT162b2 doses <30 days apart (BNT162b2-control), (ii) two BNT162b2 doses [&ge;]30 days apart (BNT162b2-extended) or (iii) two AZD1222 doses [&ge;]30 days apart (AZD1222-extended) in London, England. SARS-CoV-2 spike protein antibody geometric mean titres (GMTs) before and 2-4 weeks after booster were compared.

ResultsOf 750 participants, 626 provided serum samples for up to 38 weeks after their second vaccine dose. Antibody GMTs peaked at 2-4 weeks after the second dose, before declining by 68% at 36-38 weeks after dose 2 for BNT162b2-control participants, 85% at 24-29 weeks for BNT162b2-extended participants and 78% at 24-29 weeks for AZD1222-extended participants. Antibody GMTs was highest in BNT162b2-extended participants (942 [95%CI, 797-1113]) than AZD1222-extended (183 [124-268]) participants at 24-29 weeks or BNT162b2-control participants at 36-38 weeks (208; 95%CI, 150-289). At 2-4 weeks after booster, GMTs were significantly higher than after primary vaccination in all three groups: 18,104 (95%CI, 13,911-23,560; n=47) in BNT162b2-control (76.3-fold), 13,980 (11,902-16,421; n=118) in BNT162b2-extended (15.9-fold) and 10,799 (8,510-13,704; n=43) in AZD1222-extended (57.2-fold) participants. BNT162b2-control participants (median:262 days) had a longer interval between primary and booster doses than BNT162b2-extended or AZD1222-extended (both median:186 days) participants.

ConclusionsWe observed rapid serological responses to boosting with BNT162b2, irrespective of vaccine type or schedule used for primary immunisation, with higher post-booster responses with longer interval between primary immunisation and boosting. Boosters will not only provide additional protection for those at highest risk of severe COVID-19 but also prevent infection and, therefore, interrupt transmission, thereby reducing infections rates in the population. Ongoing surveillance will be important for monitoring the duration of protection after the booster.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.11.22.21266512,2021-11-24,https://medrxiv.org/cgi/content/short/2021.11.22.21266512,Association of COVID-19 with arterial and venous vascular diseases: a population-wide cohort study of 48 million adults in England and Wales,Rochelle Knight; Venexia Walker; Samantha Ip; Jennifer A Cooper; Thomas Bolton; Spencer Keene; Rachel Denholm; Ashley Akbari; Hoda Abbasizanjani; Fatemeh Torabi; Efosa Omigie; Sam Hollings; Teri-Louise North; Renin Toms; Emanuele Di Angelantonio; Spiros Denaxas; Johan H Thygesen; Christopher Tomlinson; Ben Bray; Craig J Smith; Mark Barber; George Davey Smith; Nishi Chaturvedi; Cathie Sudlow; William N Whiteley; Angela Wood; Jonathan A C Sterne; - CVD-COVID-UK/COVID-IMPACT consortium; - Longitudinal Health and Wellbeing COVID-19 National Core Study,University of Bristol; University of Bristol; University of Cambridge; University of Bristol; University of Cambridge; University of Cambridge; University of Bristol; Swansea University; Swansea University; Swansea University; NHS Digital; NHS Digital; University of Bristol; University of Bristol; University of Cambridge; University College London; University College London; University College London; Kings College London; University of Manchester; Glasgow Caledonian University; University of Bristol; University College London; Health Data Research UK; University of Edinburgh; University of Cambridge; University of Bristol; ; ,"ImportanceThe long-term effects of COVID-19 on the incidence of vascular diseases are unclear.

ObjectiveTo quantify the association between time since diagnosis of COVID-19 and vascular disease, overall and by age, sex, ethnicity, and pre-existing disease.

DesignCohort study based on population-wide linked electronic health records, with follow up from January 1st to December 7th 2020.

Setting and participantsAdults registered with an NHS general practice in England or Wales and alive on January 1st 2020.

ExposuresTime since diagnosis of COVID-19 (categorised as 0-6 days, 1-2 weeks, 3-4, 5-8, 9-12, 13-26 and 27-49 weeks since diagnosis), with and without hospitalisation within 28 days of diagnosis.

Main outcomes and measuresPrimary outcomes were arterial thromboses (mainly acute myocardial infarction and ischaemic stroke) and venous thromboembolic events (VTE, mainly pulmonary embolism and lower limb deep vein thrombosis). We also studied other vascular events (transient ischaemic attack, haemorrhagic stroke, heart failure and angina). Hazard ratios were adjusted for demographic characteristics, previous disease diagnoses, comorbidities and medications.

ResultsAmong 48 million adults, 130,930 were and 1,315,471 were not hospitalised within 28 days of COVID-19. In England, there were 259,742 first arterial thromboses and 60,066 first VTE during 41.6 million person-years follow-up. Adjusted hazard ratios (aHRs) for first arterial thrombosis compared with no COVID-19 declined rapidly from 21.7 (95% CI 21.0-22.4) to 3.87 (3.58-4.19) in weeks 1 and 2 after COVID-19, 2.80 (2.61-3.01) during weeks 3-4 then to 1.34 (1.21-1.48) during weeks 27-49. aHRs for first VTE declined from 33.2 (31.3-35.2) and 8.52 (7.59-9.58) in weeks 1 and 2 to 7.95 (7.28-8.68) and 4.26 (3.86-4.69) during weeks 3-4 and 5-8, then 2.20 (1.99-2.44) and 1.80 (1.50-2.17) during weeks 13-26 and 27-49 respectively. aHRs were higher, for longer after diagnosis, after hospitalised than non-hospitalised COVID-19. aHRs were also higher among people of Black and Asian than White ethnicity and among people without than with a previous event. Across the whole population estimated increases in risk of arterial thromboses and VTEs were 2.5% and 0.6% respectively 49 weeks after COVID-19, corresponding to 7,197 and 3,517 additional events respectively after 1.4 million COVID-19 diagnoses.

Conclusions and RelevanceHigh rates of vascular disease early after COVID-19 diagnosis decline more rapidly for arterial thromboses than VTEs but rates remain elevated up to 49 weeks after COVID_19. These results support continued policies to avoid COVID-19 infection with effective COVID-19 vaccines and use of secondary preventive agents in high-risk patients.

Key pointsO_ST_ABSQuestionC_ST_ABSIs COVID-19 associated with higher long-term incidence of vascular diseases?

FindingsIn this cohort study of 48 million adults in England and Wales, COVID-19 was associated with higher incidence, that declined with time since diagnosis, of both arterial thromboses [week 1: adjusted HR [aHR] 21.7 (95% CI 21.0-22.4) weeks 27-49: aHR 1.34 (1.21-1.48)] and venous thromboembolism [week 1: aHR 33.2 (31.3-35.2), weeks 27-49 1.80 (1.50-2.17)]. aHRs were higher, for longer, after hospitalised than non-hospitalised COVID-19. The estimated excess number of arterial thromboses and venous thromboembolisms was 10,500.

MeaningAvoidance of COVID-19 infection through vaccination, and use of secondary preventive agents after infection in high-risk patients, may reduce post-COVID-19 acute vascular diseases.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.11.23.21266574,2021-11-24,https://medrxiv.org/cgi/content/short/2021.11.23.21266574,"Reinfection with SARS-CoV-2: outcome, risk factors and vaccine efficacy in a Scottish cohort",Paul M McKeigue; David McAllister; Chris Robertson; Diane Stockton; Helen Colhoun,University of Edinburgh; University of Glasgow; University of Strathclyde; Public Health Scotland; University of Edinburgh,"BackgroundThe objective of this study was to investigate how protection against COVID-19 conferred by previous infection is modified by vaccination.

MethodsIn a cohort of all 152655 individuals in Scotland alive at 90 days after a positive test for SARS-CoV-2 (confirmed by cycle threshold < 30, or two tests) followed till 22 September 2021, rate ratios for reinfection were estimated with calendar time or tests as timescale.

FindingsRates of detected and hospitalised reinfection with COVID-19 while unvaccinated were respectively 6.8 (95% CI 6.4 to 7.2) and 0.18 (95% CI 0.12 to 0.25) per 1000 person-months. These rates were respectively 68% and 74% lower than in a matched cohort of individuals who had not previously tested positive. Efficacy of two doses of vaccine in those with previous infection was estimated as as 84% (95 percent CI 81% to 86%) against detected reinfection and 71% (95 percent CI 29% to 88%) against hospitalised or fatal reinfection. The rate of detected reinfection after two doses of vaccine was 1.35 (95% CI 1.02 to 1.78) times higher in those vaccinated before first infection than in those unvaccinated at first infection.

InterpretationThe combination of natural infection and vaccination provides maximal protection against new infection with SARS-CoV-2: prior vaccination does not impair this protection.

FundingNo specific funding was received for this work.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSIn a recent systematic review of cohort studies reported up to July 2021, the average reduction in COVID-19 infection rates in those with previous infection compared with those without evidence of previous infection was 90%. There is little information about the protective effect of previous infection against severe COVID-19, or about how the protective effects of previous infection against reinfection and severe disease are modified by vaccination.

What this paper addsIn unvaccinated individuals the protection against hospitalised COVID-19 conferred by previous infection is similar to that induced by vaccination. In those with previous infection, vaccination reduces the rates of reinfection and hospitalised COVID-19 by about 70%.

Implications of all the available evidenceThe combination of natural infection and vaccination provides maximal protection against COVID-19: prior vaccination does not seriously impair this protection.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.11.19.21266529,2021-11-19,https://medrxiv.org/cgi/content/short/2021.11.19.21266529,Impact of the COVID-19 pandemic on community antibiotic prescribing and stewardship: a qualitative interview study with general practitioners in England,Aleksandra J Borek; Katherine Maitland; Monsey Mcleod; Anne Campbell; Benedict Hayhoe; Christopher C Butler; Liz Morrell; Laurence Roope; Alison Holmes; Ann Sarah Walker; Sarah Tonkin-Crine; - the STEP-UP study team,University of Oxford; University of Oxford; Imperial College London; Imperia College London; Imperial College London; University of Oxford; University of Oxford; University of Oxford; Imperial College London; University of Oxford; University of Oxford; ,"The COVID-19 pandemic has had a profound impact on the delivery of primary care services. We aimed to identify general practitioners (GPs) perceptions and experiences of how the COVID-19 pandemic influenced antibiotic prescribing and antimicrobial stewardship (AMS) in general practice in England. Twenty-four semi-structured interviews were conducted with 18 GPs at two time-points: autumn 2020 (14 interviews) and spring 2021 (10 interviews). Interviews were audio-recorded, transcribed and analysed thematically, taking a longitudinal approach. Participants reported a lower threshold for antibiotic prescribing (and fewer consultations) for respiratory infections and COVID-19 symptoms early in the pandemic, then returning to more usual (pre-pandemic) prescribing. They perceived less impact on antibiotic prescribing for urinary and skin infections. Participants perceived the changing ways of working and consulting (e.g., proportions of remote and in-person consultations), and the changing patient presentations and GP workload as influencing the fluctuations in antibiotic prescribing. This was compounded by decreased engagement with, and priority of, AMS due to COVID-19-related urgent priorities. Re-engagement with AMS is needed, e.g., through reviving antibiotic prescribing feedback and targets/incentives. While the pandemic disrupted the usual ways of working, it also produced opportunities, e.g., for re-organising ways of managing infections and AMS in the future.",primary care research,fuzzy,100,100
medRxiv,10.1101/2021.11.15.21266264,2021-11-16,https://medrxiv.org/cgi/content/short/2021.11.15.21266264,Association of COVID-19 employment disruption with mental and social wellbeing: evidence from nine UK longitudinal studies,Jacques Wels; Charlotte Booth; Bozena Wielgoszewska; Michael J Green; Giorgio Di Gessa; Charlotte F Huggins; Gareth J Griffith; Alex Siu Fung Kwong; Ruth C E Bowyer; Jane Maddock; Praveetha Patalay; Richard J Silverwood; Emla Fitzsimons; Richard John Shaw; Ellen J Thompson; Andrew Steptoe; Alun Hughes; Nishi Chaturvedi; Claire J Steves; Srinivasa Vittal Katikireddi; George B Ploubidis,University College London; University College London; University College London; University of Glasgow; University College London; University of Edinburgh; University of Bristol; University of Bristol; King's College London; University College London; University College London; University College London; University College London; University of Glasgow; Kings College London; University College London; University College London; University College London; King's College London; University of Glasgow; University College London,"BackgroundThe COVID-19 pandemic has led to major economic disruptions. In March 2020, the UK implemented the Coronavirus Job Retention Scheme - known as furlough - to minimize the impact of job losses. We investigate associations between change in employment status and mental and social wellbeing during the early stages of the pandemic.

MethodsData were from 25,670 respondents, aged 17 to 66, across nine UK longitudinal studies. Furlough and other employment changes were defined using employment status pre-pandemic and during the first lockdown (April-June 2020). Mental and social wellbeing outcomes included psychological distress, life satisfaction, self-rated health, social contact, and loneliness. Study-specific modified Poisson regression estimates, adjusting for socio-demographic characteristics and pre-pandemic mental and social wellbeing measures, were pooled using meta-analysis.

ResultsCompared to those who remained working, furloughed workers were at greater risk of psychological distress (adjusted risk ratio, ARR=1.12; 95% CI: 0.97, 1.29), low life satisfaction (ARR=1.14; 95% CI: 1.07, 1.22), loneliness (ARR=1.12; 95% CI: 1.01, 1.23), and poor self-rated health (ARR=1.26; 95% CI: 1.05, 1.50), but excess risk was less pronounced than that of those no longer employed (e.g., ARR for psychological distress=1.39; 95% CI: 1.21, 1.59) or in stable unemployment (ARR=1.33; 95% CI: 1.09, 1.62).

ConclusionsDuring the early stages of the pandemic, those furloughed had increased risk for poor mental and social wellbeing. However, their excess risk was lower in magnitude than that of those who became or remained unemployed, suggesting that furlough may have partly mitigated poorer outcomes.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2021.11.15.21266255,2021-11-16,https://medrxiv.org/cgi/content/short/2021.11.15.21266255,"COVID-19 vaccination, risk-compensatory behaviours, and social contacts in four countries in the UK",John Buckell; Joel Jones; Philippa C Matthews; Ian Diamond; Emma Rourke; Ruth Studley; Duncan Cook; Ann Sarah Walker; Koen B Pouwels; - The COVID-19 Infection Survey Team,University of Oxford; Office for National Statistics; University of Oxford; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; University of Oxford; ,"The physiological effects of vaccination against SARS-CoV-2 (COVID-19) are well documented, yet the behavioural effects are largely unknown. Risk compensation suggests that gains in personal safety, as a result of vaccination, are offset by increases in risky behaviour, such as socialising, commuting and working outside the home. This is potentially problematic because transmission of SARS-CoV-2 is driven by contacts, which could be amplified by vaccine-related risk compensation behaviours. Here, we show that behaviours were overall unrelated to personal vaccination, but - adjusting for variation in mitigation policies - were responsive to the level of vaccination in the wider population: individuals in the UK were risk compensating when rates of vaccination were rising. This effect was observed across four nations of the UK, each of which varied policies autonomously.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.11.10.21266124,2021-11-11,https://medrxiv.org/cgi/content/short/2021.11.10.21266124,Differences in COVID-19 vaccination coverage by occupation in England: a national linked data study,Vahe Nafilyan; Ted Dolby; Katie Finning; Jasper Morgan; Rhiannon Edge; Myer Glickman; Neil Pearce; Martie Van Tongeren,Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Lancaster University; Office for National Statistics; London School of Hygiene and Tropical Medicine; University of Manchester,"BackgroundMonitoring differences in COVID-19 vaccination uptake in different groups is crucial to help inform the policy response to the pandemic. A key gap is the absence of data on uptake by occupation.

MethodsUsing nationwide population-level data, we calculated the proportion of people who had received two doses of a COVID-19 vaccine (assessed on 31 August 2021) by detailed occupational categories in adults aged 40-64 and estimated adjusted odds ratios to examine whether these differences were driven by occupation or other factors, such as education. We also examined whether vaccination rates differed by ability to work from home.

ResultsOur study population included 14,298,147 adults 40-64. Vaccination rates differed markedly by occupation, being higher in administrative and secretarial occupations (90.8%); professional occupations (90.7%); and managers, directors and senior officials (90.6%); and lowest (83.1%) in people working in elementary occupations. We found substantial differences in vaccination rates looking at finer occupational groups even after adjusting for confounding factors, such as education. Vaccination rates were higher in occupations which can be done from home and lower in those which cannot. Many occupations with low vaccination rates also involved contact with the public or with vulnerable people

ConclusionsIncreasing vaccination coverage in occupations with low vaccination rates is crucial to help protecting the public and control infection, especially in occupations that cannot be done from home and involve contacts with the public. Policies such as  work from home if you can may only have limited future impact on hospitalisations and deaths

What is already known on this subject?Whilst several studies highlight differences in vaccination coverage by ethnicity, religion, socio-demographic factors and certain underlying health conditions, there is very little evidence on how vaccination coverage varies by occupation, in the UK and elsewhere. The few study looking at occupational differences in vaccine hesitancy focus on healthcare workers or only examined broad occupational groups. There is currently no large-scale study on occupational differences in COVID-19 vaccination coverage in the UK.

What this study adds?Using population-level linked data combining the 2011 Census, primary care records, mortality and vaccination data, we found that the vaccination rates of adults aged 40 to 64 years in England differed markedly by occupation. Vaccination rates were high in administrative and secretarial occupations, professional occupations and managers, directors and senior officials and low in people working in elementary occupations. Adjusting for other factors likely to be linked to occupation and vaccination, such as education, did not substantially alter the results. Vaccination rates were also associated with the ability to work from home, with the vaccination rate being higher in occupations which can be done performed from home. Policies aiming to increase vaccination rates in occupations that cannot be done from home and involve contacts with the public should be priorities",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.11.05.21265968,2021-11-09,https://medrxiv.org/cgi/content/short/2021.11.05.21265968,Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort.,Robert William Aldridge; Alexei Yavlinsky; Vincent Grigori Nguyen; Max T Eyre; Madhumita Shrotri; Annalan Mathew Dwight Navaratnam; Sarah Beale; Isobel Braithwaite; Thomas Edward Byrne; Jana Kovar; Ellen Fragaszy; Erica Wing Lam Fong; Cyril Roman Geismar; Parth Patel; Alison Rodger; Anne M Johnson; Andrew C Hayward,"University College London; University College London; University College London; Lancaster University, Liverpool School of Tropical Medicine; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London","BackgroundSARS-CoV-2 vaccines stimulate production of antibodies targeting the spike protein (anti-S). The level of antibodies following vaccination and trajectories of waning may differ between vaccines influencing the level of protection, how soon protection is reduced and, consequently the optimum timing of booster doses.

MethodsWe measured SARS-CoV-2 anti-S titre in the context of seronegativity for SARS-CoV-2 anti-Nucleocapsid (anti-N), in samples collected between 1st July and 24th October 2021 in a subset of adults in the Virus Watch community cohort. We compared anti-S levels after BNT162b2 (BioNTech/Pfizer) or ChAdOx1 (AstraZeneca/Oxford) vaccination using time since second dose of vaccination, age, sex and clinical vulnerability to investigate antibody waning. To investigate the use of anti-S levels as a correlate of protection against SARS-CoV-2 infection, we undertook a survival analysis (Kaplan-Meier and Cox) with individuals entering 21 days after their second dose of vaccine, or first antibody test after 1st July (whichever was latest) and exiting with the outcome of SARS-Cov-2 infection or at the end of follow up 24th October 2021. We also undertook a negative test design case-control analysis of infections occurring after the second vaccine dose (breakthrough infections) to determine whether the type of vaccine affected the risk of becoming infected.

Results24049 samples from 8858 individuals (5549 who received a second dose of ChAdOx1 and 3205 BNT162b2) who remained anti-N negative were included in the analysis of anti-S waning over time. Three weeks after the second dose of vaccine BNT162b2 mean anti-S levels were 9039 (95%CI: 7946-10905) U/ml and ChadOx1 were 1025 (95%CI: 917-1146) U/ml. For both vaccines, waning anti-S levels followed a log linear decline from three weeks after the second dose of vaccination. At 20 weeks after the second dose of vaccine, the mean anti-S levels were 1521 (95%CI: 1432-1616) U/ml for BNT162b2 and 342 (95%CI: 322-365) U/ml for ChadOx1. We identified 197 breakthrough infections and found a reduced risk of infection post second dose of vaccine for individuals with anti-S levels greater than or equal to 500 U/ml compared to those with levels under 500 U/ml (HR 0.62; 95%CIs:0.44-0.87; p=0.007). Time to reach an anti-S threshold of 500 U/ml was estimated at 96 days for ChAdOx1 and 257 days for BNT162b2. We found an increased risk of a breakthrough infection for those who received the ChAdOx1 compared to those who received BNT162b2 (OR: 1.43, 95% CIs:1.18-1.73, p<0.001).

DiscussionAnti-S levels are substantially higher following the second dose of BNT162b2 compared to ChAdOx1. There is a log linear waning in levels for both vaccines following the second dose. Anti-S levels are an important correlate of protection as demonstrated by those with anti-S levels < 500U/ml following vaccination being at significantly greater risk of subsequent infection. Since anti-S levels are substantially lower in ChAdOx1 than in BNT162b2 and both decline at similar rates we would expect waning immunity to occur earlier in ChAdOx1 compared to BNT162b2. Our results showing an increased risk of breakthrough infections for those who were vaccinated with ChAdOx1 compared to BNT162b2 are in line with this hypothesis. Consistent with our data, national analyses of vaccine effectiveness also suggest that waning of immunity for infection and, to a lesser extent for severe disease, is seen earlier in ChAdOx1 than in BNT162b2. Our data demonstrate the importance of booster doses to maintain protection in the elderly and clinically vulnerable and suggest that these should be prioritised to those who received ChAdOx1 as their primary course.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.11.08.21266079,2021-11-09,https://medrxiv.org/cgi/content/short/2021.11.08.21266079,The effect of notification window length on the epidemiological impact of COVID-19 contact tracing mobile applications,Trystan Leng; Edward M Hill; Matt J Keeling; Michael J Tildesley; Robin N Thompson,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"1The reduction in SARS-CoV-2 transmission from contact tracing applications (apps) depends both on the number of contacts notified and on the probability that those contacts quarantine after notification. Referring to the number of days preceding a positive test that contacts are notified as an apps notification window, we use an epidemiological model of SARS-CoV-2 transmission that captures the profile of infection to consider the trade-off between notification window length and active app-usage. We focus on 5-day and 2-day windows, the lengths used by the NHS COVID-19 app in England and Wales before and after 2nd August 2021, respectively. Short windows can be more effective at reducing transmission if they are associated with higher levels of active app usage and adherence to isolation upon notification, demonstrating the importance of understanding adherence to control measures when setting notification windows for COVID-19 apps.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.11.09.21266054,2021-11-09,https://medrxiv.org/cgi/content/short/2021.11.09.21266054,"Time varying association between deprivation, ethnicity and SARS-CoV-2 infections in England: a space-time study",Tullia Padellini; Radka Jersakova; Peter J Diggle; Chris Holmes; Ruairidh King; Brieuc Lehmann; Ann-Marie Mallon; George Nicholson; Sylvia Richardson; Marta Blangiardo,Imperial College London; The Alan Turing Institute; Lancaster University; The Alan Turing Institute; MRC Harwell; University of Oxford; MRC Harwell; University of Oxford; University of Cambridge; Imperial College London,"BackgroundEthnically diverse and socio-economically deprived communities have been differentially affected by the COVID-19 pandemic in the UK.

MethodUsing a multilevel regression model we assess the time-varying association between SARS-CoV-2 infections and areal level deprivation and ethnicity. We separately consider weekly test positivity rate (number of positive tests over the total number of tests) and estimated unbiased prevalence (proportion of individuals in the population who would test positive) at the Lower Tier Local Authority (LTLA) level. The model also adjusts for age, urbanicity, vaccine uptake and spatio-temporal correlation structure.

FindingsComparing the least deprived and predominantly White areas with most deprived and predominantly non-White areas over the whole study period, the weekly positivity rate increases by 13% from 2{middle dot}97% to 3{middle dot}35%. Similarly, prevalence increases by 10% from 0{middle dot}37% to 0{middle dot}41%. Deprivation has a stronger effect until October 2020, while the effect of ethnicity becomes slightly more pronounced at the peak of the second wave and then again in May-June 2021. Not all BAME groups were equally affected: in the second wave of the pandemic, LTLAs with large South Asian populations were the most affected, whereas areas with large Black populations did not show increased values for either outcome during the entire period under analysis.

InterpretationAt the area level, IMD and BAME% are both associated with an increased COVID-19 burden in terms of prevalence (disease spread) and test positivity (disease monitoring), and the strength of association varies over the course of the pandemic. The consistency of results across the two outcome measures suggests that community level characteristics such as deprivation and ethnicity have a differential impact on disease exposure or susceptibility rather than testing access and habits.

FundingsEPSRC, MRC, The Alan Turing Institute, NIH, UKHSA, DHSC, NIHR",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.11.08.21265312,2021-11-09,https://medrxiv.org/cgi/content/short/2021.11.08.21265312,"Understanding COVID-19 trajectories from a nationwide linked electronic health record cohort of 56 million people: phenotypes, severity, waves & vaccination",Johan H Thygesen; Christopher R Tomlinson; Sam Hollings; Mehrdad A Mizani; Alex Handy; Ashley Akbari; Amitava Banerjee; Jennifer A Cooper; Alvina G Lai; Kezhi Li; Bilal A Mateen; Naveed Sattar; Reecha Sofat; Ana Torralbo; Honghan Wu; Angela Wood; Jonathan AC Sterne; Christina Pagel; William Whiteley; Cathie Sudlow; Harry Hemingway; Spiros Denaxas; - CVD-COVID-UK Consortium,"Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; NHS Digital, Leeds, UK; Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; Population Data Science and Health Data Research UK, Swansea University, Swansea, UK; Institute of Health Informatics, University College London, London, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; The Wellcome Trust, London, UK; Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK; Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Clinical Operational Research Unit, University College London, London, UK; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK; Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; ","BackgroundUpdatable understanding of the onset and progression of individuals COVID-19 trajectories underpins pandemic mitigation efforts. In order to identify and characterize individual trajectories, we defined and validated ten COVID-19 phenotypes from linked electronic health records (EHR) on a nationwide scale using an extensible framework.

MethodsCohort study of 56.6 million people in England alive on 23/01/2020, followed until 31/05/2021, using eight linked national datasets spanning COVID-19 testing, vaccination, primary & secondary care and death registrations data. We defined ten COVID-19 phenotypes reflecting clinically relevant stages of disease severity using a combination of international clinical terminologies (e.g. SNOMED-CT, ICD-10) and bespoke data fields; positive test, primary care diagnosis, hospitalisation, critical care (four phenotypes), and death (three phenotypes). Using these phenotypes, we constructed patient trajectories illustrating the transition frequency and duration between phenotypes. Analyses were stratified by pandemic waves and vaccination status.

FindingsWe identified 3,469,528 infected individuals (6.1%) with 8,825,738 recorded COVID-19 phenotypes. Of these, 364,260 (11%) were hospitalised and 140,908 (4%) died. Of those hospitalised, 38,072 (10%) were admitted to intensive care (ICU), 54,026 (15%) received non-invasive ventilation and 21,404 (6%) invasive ventilation. Amongst hospitalised patients, first wave mortality (30%) was higher than the second (23%) in non-ICU settings, but remained unchanged for ICU patients. The highest mortality was for patients receiving critical care outside of ICU in wave 1 (51%). 13,083 (9%) COVID-19 related deaths occurred without diagnoses on the death certificate, but within 30 days of a positive test while 10,403 (7%) of cases were identified from mortality data alone with no prior phenotypes recorded. We observed longer patient trajectories in the second pandemic wave compared to the first.

InterpretationOur analyses illustrate the wide spectrum of severity that COVID-19 displays and significant differences in incidence, survival and pathways across pandemic waves. We provide an adaptable framework to answer questions of clinical and policy relevance; new variant impact, booster dose efficacy and a way of maximising existing data to understand individuals progression through disease states.

Research in ContextO_ST_ABSEvidence before the studyC_ST_ABSWe searched PubMed on October 14, 2021, for publications with the terms ""COVID-19"" or ""SARS-CoV-2"", ""severity"", and ""electronic health records"" or ""EHR"" without date or language restrictions. Multiple studies explore factors associated with severity of COVID-19 infection, and model predictions of outcome for hospitalised patients. However, most work to date focused on isolated facets of the healthcare system, such as primary or secondary care only, was conducted in subpopulations (e.g. hospitalised patients) of limited sample size, and often utilized dichotomised outcomes (e.g. mortality or hospitalisation) ignoring the full spectrum of disease. We identified no studies which comprehensively detailed severity of infections while describing disease severity across pandemic waves, vaccination status, and patient trajectories.

Added value of this studyTo our knowledge, this is the first study providing a comprehensive view of COVID-19 across pandemic waves using national data and focusing on severity, vaccination, and patient trajectories. Drawing on linked electronic health record (EHR) data on a national scale (56.6 million people alive and registered with GP in England), we describe key demographic factors, frequency of comorbidities, impact of the two main waves in England, and effect of full vaccination on COVID-19 severities. Additionally, we identify and describe patient trajectory networks which illustrate the main transition pathways of COVID-19 patients in the healthcare system. Finally, we provide reproducible COVID-19 phenotyping algorithms reflecting clinically relevant stages of disease severity i.e. positive tests, primary care diagnoses, hospitalisation, critical care treatments (e.g. ventilatory support) and mortality.

Implications of all the available evidenceThe COVID-19 phenotypes and trajectory analysis framework outlined produce a reproducible, extensible and repurposable means to generate national-scale data to support critical policy decision making. By modelling patient trajectories as a series of interactions with healthcare systems, and linking these to demographic and outcome data, we provide a means to identify and prioritise care pathways associated with adverse outcomes and highlight healthcare system  touch points which may act as tangible targets for intervention.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.11.05.21265977,2021-11-09,https://medrxiv.org/cgi/content/short/2021.11.05.21265977,"Waning, Boosting and a Path to Endemicity for SARS-CoV-2.",Matt J Keeling; Amy C Thomas; Edward M Hill; Robin N Thompson; Louise Dyson; Michael Tildesley; Sam Moore,University of Warwick; University of Bristol; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"In many countries, an extensive vaccination programme has substantially reduced the public-health impact of SARS-CoV-2, limiting the number of hospital admissions and deaths compared to an unmitigated epidemic. Ensuring a low-risk transition from the current situation to one in which SARS-CoV-2 is endemic requires maintenance of high levels of population immunity. The observed waning of vaccine efficacy over time suggests that booster doses may be required to maintain population immunity especially in the most vulnerable groups. Here, using data and models for England, we consider the dynamics of COVID-19 over a two-year time-frame, and the role that booster vaccinations can play in mitigating the worst effects. We find that boosters are necessary to suppress the imminent wave of infections that would be generated by waning vaccine efficacy. Projecting further into the future, the optimal deployment of boosters is highly sensitive to their long-term action. If protection from boosters wanes slowly (akin to protection following infection) then a single booster dose to the over 50s may be all that is needed over the next two-years. However, if protection wanes more rapidly (akin to protection following second dose vaccination) then annual or even biannual boosters are required to limit subsequent epidemic peaks an reduce the pressure on public health services.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.11.08.21265380,2021-11-08,https://medrxiv.org/cgi/content/short/2021.11.08.21265380,Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: A cohort study from OpenSAFELY,Amelia CA Green; Helen J Curtis; William J Hulme; Elizabeth J Williamson; Helen I McDonald; Krishnan Bhaskaran; Christopher T Rentsch; Anna Schultze; Brian MacKenna; Viyaasan Mahalingasivam; Laurie Tomlinson; Alex J Walker; Louis Fisher; Jon Massey; Colm D Andrews; Lisa E M Hopcroft; Caroline E Morton; Richard Croker; Jessica Morley; Amir Mehrkar; Sebastian CJ Bacon; David Evans; Peter Inglesby; George Hickman; Tom Ward; Simon Davy; Rohini Mathur; John Tazare; Rosalind M Eggo; Kevin Wing; Angel YS Wong; Harriet Forbes; Christopher Bates; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen JW Evans; Liam Smeeth; Ben Goldacre,University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Bristol; TPP; TPP; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundWhile the vaccines against COVID-19 are considered to be highly effective, COVID-19 vaccine breakthrough is likely and a small number of people will still fall ill, be hospitalised, or die from COVID-19, despite being fully vaccinated. With the continued increase in numbers of positive SARS-CoV-2 tests, describing the characters of individuals who have experienced a COVID-19 vaccine breakthrough could be hugely important in helping to determine who may be at greatest risk.

MethodWith the approval of NHS England we conducted a retrospective cohort study using routine clinical data from the OpenSAFELY TPP database of fully vaccinated individuals, linked to secondary care and death registry data, and described the characteristics of those experiencing a COVID-19 vaccine breakthrough.

ResultsAs of 01st November 2021, a total of 15,436,455 individuals were identified as being fully vaccinated against COVID-19, with a median follow-up time of 149 days (IQR: 107-179). From within this population, a total of 577245 (<4%) individuals reported a positive SARS-CoV-2 test. For every 1000 years of patient follow-up time, the corresponding incidence rate was 98.02 (95% CI 97.9-98.15). There were 16,120 COVID-19-related hospital admissions, 1,100 COVID-19 critical care admission patients and 3,925 COVID-19-related deaths; corresponding incidence rates of 2.72 (95% C 2.7-2.74), 0.19 (95% C 0.18-0.19) and 0.66 (95% C 0.65-0.67), respectively. When broken down by the initial priority group, higher rates of hospitalisation and death were seen in those in care homes and those over 80 years of age. Comorbidities with the highest rates of breakthrough COVID-19 included chronic kidney disease, dialysis, transplant, haematological malignancy, and immunocompromised.

ConclusionThe majority of COVID-19 vaccine breakthrough cases in England were mild with relatively few fully vaccinated individuals being hospitalised or dying as a result. However, some concerning differences in rates of breakthrough cases were identified in several clinical and demographic groups. While it is important to note that these findings are simply descriptive and cannot be used to answer why certain groups have higher rates of COVID-19 breakthrough than others, the emergence of the Omicron variant of COVID-19 coupled with the continued increase in numbers of positive SARS-CoV-2 tests are concerning. As numbers of fully vaccinated individuals increases and follow-up time lengthens, so too will the number of COVID-19 breakthrough cases. Additional analyses, aimed at identifying individuals at higher risk, are therefore required.",epidemiology,fuzzy,100,100
bioRxiv,10.1101/2021.11.05.467529,2021-11-08,https://biorxiv.org/cgi/content/short/2021.11.05.467529,Structural basis of main proteases of coronavirus bound to drug candidate PF-07321332,Jian Li; Cheng Lin; Xuelan Zhou; Fanglin Zhong; Pei Zeng; Haihai Jiang; Yang Yang; Peter McCormick; Yang Fu; Jin Zhang,"College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, China.; School of Basic Medical Sciences, Nanchang University, Nanchang 330031, China.; Shenzhen Crystalo Biopharmaceutical Co., Ltd, Shenzhen 518118, China.; Jiangxi Jmerry Biopharmaceutical Co., Ltd, Ganzhou 341000, China.; Jiangxi Jmerry Biopharmaceutical Co., Ltd, Ganzhou 341000, China.; School of Basic Medical Sciences, Nanchang University, Nanchang 330031, China.; Shenzhen Crystalo Biopharmaceutical Co., Ltd, Shenzhen 518118, China.; William Harvey Research Institute, Queen Mary University of London; School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong, China 518055; School of Basic Medical Sciences, Nanchang University, Nanchang 330031, China.","The high mutation rate of COVID-19 and the prevalence of multiple variants strongly support the need for pharmacological options to complement vaccine strategies. One region that appears highly conserved among different genus of coronaviruses is the substrate binding site of the main protease (Mpro or 3CLpro), making it an attractive target for the development of broad-spectrum drugs for multiple coronaviruses. PF-07321332 developed by Pfizer is the first orally administered inhibitor targeting the main protease of SARS-CoV-2, which also has shown potency against other coronaviruses. Here we report three crystal structures of main protease of SARS-CoV-2, SARS-CoV and MERS-CoV bound to the inhibitor PF-07321332. The structures reveal a ligand-binding site that is conserved among SARS-CoV-2, SARS-CoV and MERS-CoV, providing insights into the mechanism of inhibition of viral replication. The long and narrow cavity in the cleft between domains I and II of main protease harbors multiple inhibitor binding sites, where PF-07321332 occupies subsites S1, S2 and S4 and appears more restricted compared with other inhibitors. A detailed analysis of these structures illuminated key structural determinants essential for inhibition and elucidated the binding mode of action of main proteases from different coronaviruses. Given the importance of main protease for the treatment of SARS-CoV-2 infection, insights derived from this study should accelerate the design of safer and more effective antivirals.",biophysics,fuzzy,100,100
medRxiv,10.1101/2021.11.04.21265918,2021-11-05,https://medrxiv.org/cgi/content/short/2021.11.04.21265918,Longitudinal Changes of Cardiac and Aortic Imaging Phenotypes Following COVID-19 in the UK Biobank Cohort,Wenjia Bai; Betty Raman; Steffen E Peterson; Stefan Neubauer; Zahra Raisi-Estabragh; Nay Aung; Nicholas C Harvey; Naomi Allen; Rory Collins; Paul M Matthews,"Department of Brain Sciences, Imperial College London and British Heart Foundation Centre for Research Excellence, Imperial College London, London, UK; University of Oxford; William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, NIHR Oxford Biomedical Research Centre, University of Oxford and British Heart Foundation; William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London; William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London; MRC Lifecourse Epidemiology Centre, University of Southampton and NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital; Nuffield Department of Population Health, University of Oxford, Oxford, UK and UK Biobank, Stockport, UK; Nuffield Department of Population Health, University of Oxford, Oxford, UK and UK Biobank, Stockport, UK; Imperial College, London","Case studies conducted after recovery from acute infection with SARS-CoV-2 have frequently identified abnormalities on CMR imaging, suggesting the possibility that SARS-CoV-2 infection commonly leads to cardiac pathology. However, these observations have not been able to distinguish between associations that reflect pre-existing cardiac abnormalities (that might confer a greater likelihood of more severe infection) from those that arise as consequences of infection. To address this question, UK Biobank volunteers (n=1285; 54.5% women; mean age at baseline, 59.8 years old; 96.3% white) who attended an imaging assessment including cardiac magnetic resonance (CMR) before the start of the COVID-19 pandemic were invited to attend a second imaging assessment in 2021. Cases with evidence of previous SARS-CoV-2 infection were identified through linkage to PCR-testing or other medical records, or a positive antibody lateral flow test; n=640 in data available on 22 Sep 2021) and were matched to controls with no evidence of previous infection (n=645). The majority of these infections were milder and did not involve hospitalisation. Measures of cardiac and aortic structure and function were derived from the CMR images obtained on the cases before and after SARS-CoV-2 infection from images for the controls obtained over the same time interval using a previously validated, automated algorithm. Cases and controls had similar cardiac and aortic imaging phenotypes at their first imaging assessment. Changes between CMR imaging measures in cases before and after infection were not significantly different from those in the matched control group. Additional adjustment for comorbidities made no material difference to the results. While these results are preliminary and limited to imaging metrics derived from automated analyses, they do not suggest clinically significant persistent cardiac pathology in the UK Biobank population after generally milder (non-hospitalised) SARS-CoV-2 infection.",neurology,fuzzy,100,100
medRxiv,10.1101/2021.11.02.21265767,2021-11-03,https://medrxiv.org/cgi/content/short/2021.11.02.21265767,Determinants of pre-vaccination antibody responses to SARS-CoV-2: a population-based longitudinal study (COVIDENCE UK),Mohammad Talaei; Sian Faustini; Hayley Holt; David A. Jolliffe; Giulia Vivaldi; Matthew Greenig; Natalia Perdek; Sheena Maltby; Carola M Bigogno; Jane Symons; Gwyneth A. Davies; Ronan A. Lyons; Christopher J Griffiths; Frank Kee; Aziz Sheikh; Alex G. Richter; Seif O. Shaheen; Adrian R Martineau,Queen Mary University of London; University of Birmingham; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Jane Symons Media; Swansea University Medical School; Swansea University Medical School; Queen Mary University of London; Queens University Belfast; University of Edinburgh; University of Birminghan; Queen Mary University of London; Queen Mary University of London,"BackgroundProspective population-based studies investigating multiple determinants of pre-vaccination antibody responses to SARS-CoV-2 are lacking.

MethodsWe did a prospective population-based study in SARS-CoV-2 vaccine-naive UK adults recruited between May 1 and November 2, 2020, without a positive swab test result for SARS-CoV-2 prior to enrolment. Information on 88 potential sociodemographic, behavioural, nutritional, clinical and pharmacological risk factors was obtained through online questionnaires, and combined IgG/IgA/IgM responses to SARS-CoV-2 spike glycoprotein were determined in dried blood spots obtained between November 6, 2020 and April 18, 2021. We used logistic and linear regression to estimate adjusted odds ratios (aORs) and adjusted geometric mean ratios (aGMRs) for potential determinants of SARS-CoV-2 seropositivity (all participants) and antibody titres (seropositive participants only), respectively.

Results1696 (15.2%) of 11,130 participants were seropositive. Factors independently associated with increased risk of SARS-CoV-2 seropositivity included frontline health/care occupation (aOR 1.86, 95% CI 1.48-2.33), international travel (1.20, 1.07-1.35), number of visits to shops and other indoor public places ([&ge;]5 vs. 0/week: 1.29, 1.06-1.57, P-trend=0.01), body mass index (BMI) [&ge;]25 vs <25 kg/m2 (1.24, 1.11-1.39), Asian/Asian British vs White ethnicity (1.65, 1.10-2.49), and alcohol consumption [&ge;]15 vs 0 units/week (1.23, 1.04-1.46). Light physical exercise associated with decreased risk (0.80, 0.70-0.93, for [&ge;]10 vs 0-4 h/week). Among seropositive participants, higher titres of anti-Spike antibodies associated with factors including BMI [&ge;]30 vs <25 kg/m2 (aGMR 1.10, 1.02-1.19), Asian/Asian British vs White ethnicity (1.22, 1.04-1.44), frontline health/care occupation (1.24, 95% CI 1.11-1.39), international travel (1.11, 1.05-1.16), and number of visits to shops and other indoor public places ([&ge;]5 vs. 0/week: 1.12, 1.02-1.23, P-trend=0.01); these associations were not substantially attenuated by adjustment for COVID-19 disease severity.

ConclusionsHigher alcohol consumption and reduced light physical exercise represent new modifiable risk factors for SARS-CoV-2 infection. Recognised associations between Asian/Asian British ethnic origin and obesity and increased risk of SARS-CoV-2 seropositivity were independent of other sociodemographic, behavioural, nutritional, clinical and pharmacological factors investigated. Among seropositive participants, higher titres of anti-Spike antibodies in people of Asian ancestry and in obese people were not explained by greater COVID-19 disease severity in these groups.

FundingBarts Charity, Health Data Research UK.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.11.03.21265877,2021-11-03,https://medrxiv.org/cgi/content/short/2021.11.03.21265877,REACT-1 round 15 interim report: High and rising prevalence of SARS-CoV-2 infection in England from end of September 2021 followed by a fall in late October 2021,Marc Chadeau-Hyam; Oliver Eales; Barbara Bodinier; Haowei Wang; David J Haw; Matthew Whitaker; Caroline E Walters; Christina J Atchison; Peter J Diggle; Andrew J Page; Deborah Ashby; Wendy Barclay; Graham P Taylor; Graham Cooke; Helen Ward; Ara Darzi; Christl A. Donnelly; Paul Elliott,Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Quadram Institute; Imperial College London; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health,"BackgroundThe third wave of COVID-19 in England coincided with the rapid spread of the Delta variant of SARS-CoV-2 from the end of May 2021. Case incidence data from the national testing programme (Pillar 2) in England may be affected by changes in testing behaviour and other biases. Community surveys may provide important contextual information to inform policy and the public health response.

MethodsWe estimated patterns of community prevalence of SARS-CoV-2 infection in England using RT-PCR swab-positivity, demographic and other risk factor data from round 15 (interim) of the REal-time Assessment of Community Transmission-1 (REACT-1) study (round 15a, carried out from 19 to 29 October 2021). We compared these findings with those from round 14 (9 to 27 September 2021).

ResultsDuring mid- to late-October 2021 (round 15a) weighted prevalence was 1.72% (1.61%, 1.84%) compared to 0.83% (0.76%, 0.89%) in September 2021 (round 14). The overall reproduction number (R) from round 14 to round 15a was 1.12 (1.11, 1.14) with increases in prevalence over this period (September to October) across age groups and regions except Yorkshire and The Humber. However, within round 15a (mid- to late-October) there was evidence of a fall in prevalence with R of 0.76 (0.65, 0.88). The highest weighted prevalence was observed among children aged 5 to 12 years at 5.85% (5.10%, 6.70%) and 13 to 17 years at 5.75% (5.02%, 6.57%). At regional level, there was an almost four-fold increase in weighted prevalence in South West from round 14 at 0.59% (0.43%,0.80%) to round 15a at 2.18% (1.84%, 2.58%), with highest smoothed prevalence at subregional level also found in South West in round 15a. Age, sex, key worker status, and presence of children in the home jointly contributed to the risk of swab-positivity. Among the 126 sequenced positive swabs obtained up until 23 October, all were Delta variant; 13 (10.3%) were identified as the AY.4.2 sub-lineage.

DiscussionWe observed the highest overall prevalence of swab-positivity seen in the REACT-1 study in England to date in round 15a (October 2021), with a two-fold rise in swab-positivity from round 14 (September 2021). Despite evidence of a fall in prevalence from mid- to late-October 2021, prevalence remains high, particularly in school-aged children, with evidence also of higher prevalence in households with one or more children. Thus, vaccination of children aged 12 and over remains a high priority (with possible extension to children aged 5-12) to help reduce within-household transmission and disruptions to education, as well as among adults, to lessen the risk of serious disease among those infected.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.10.28.21265593,2021-11-02,https://medrxiv.org/cgi/content/short/2021.10.28.21265593,"The UK COVID-19 furlough scheme and associations with smoking, alcohol consumption and vaping: evidence from 8 UK longitudinal population surveys.",Michael J Green PhD; Jane Maddock PhD; Giorgio Di Gessa PhD; Bo≈ºena Wielgoszewska PhD; Sam Parsons PhD; Gareth J Griffith PhD; Jazz Croft PhD; Anna J Stevenson PhD; Charlotte F Huggins PhD; Charlotte Booth PhD; Jacques Wels; Richard J Silverwood PhD; Praveetha Patalay PhD; Alun D Hughes PhD; Nishi Chaturvedi MD; Laura D Howe PhD; Emla Fitzsimons PhD; Srinivasa Vittal Katikireddi PhD; George B Ploubidis PhD,"MRC/CSO Social & Public Health Sciences Unit, University of Glasgow; MRC Unit for Lifelong Health and Ageing, University College London; Institute of Epidemiology and Health Care, University College London; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; MRC Integrative Epidemiology Unit, University of Bristol; MRC Integrative Epidemiology Unit, University of Bristol; Centre for Genomic and Experimental Medicine, University of Edinburgh; Centre for Genomic and Experimental Medicine, University of Edinburgh; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; MRC Unit for Lifelong Health and Ageing, University College London; Centre for Longitudinal Studies, UCL Social Research Institute, University College; MRC Unit for Lifelong Health and Ageing, University College London; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; MRC Unit for Lifelong Health and Ageing, University College London; MRC Unit for Lifelong Health and Ageing, University College London; MRC Integrative Epidemiology Unit, University of Bristol; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; MRC/CSO Social & Public Health Sciences Unit, University of Glasgow; Centre for Longitudinal Studies, UCL Social Research Institute, University College London","BackgroundDisruptions to employment status can impact smoking and alcohol consumption. During the COVID-19 pandemic, the UK implemented a furlough scheme to prevent job loss. We examine how furlough was associated with participants smoking, vaping and alcohol consumption behaviours in the early stages of the pandemic.

MethodsData were from 27,841 participants in eight UK adult longitudinal surveys. Participants self-reported employment status and current smoking, current vaping and drinking alcohol (>4 days/week or 5+ drinks per typical occasion) both before and during the pandemic (April-July 2020). Risk ratios were estimated within each study using modified Poisson regression, adjusting for a range of potential confounders, including pre-pandemic behaviour. Findings were synthesised using random effects meta-analysis. Sub-group analyses were used to identify whether associations differed by gender, age or education.

ResultsCompared to stable employment, neither furlough, no longer being employed, nor stable unemployment were associated with smoking, vaping or drinking, following adjustment for pre-pandemic characteristics. However, some sex differences in these associations were observed, with stable unemployment associated with smoking for women (ARR=1.35; 95% CI: 1.00-1.82; I2: 47%) but not men (0.84; 95% CI: 0.67-1.05; I2: 0%). No longer being employed was associated with vaping among women (ARR=2.74; 95% CI: 1.59-4.72; I2: 0%) but not men (ARR=1.25; 95% CI: 0.83-1.87; I2: 0%). There was little indication of associations with drinking differing by age, gender or education.

ConclusionsWe found no clear evidence of furlough or unemployment having adverse impacts on smoking, vaping or drinking behaviours during the early stages of the COVID-19 pandemic in the UK, with differences in risk compared to those who remained employed largely explained by pre-pandemic characteristics.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.11.01.21265660,2021-11-02,https://medrxiv.org/cgi/content/short/2021.11.01.21265660,"Estimating the relationship between mobility, non-pharmaceutical interventions, and COVID-19 transmission in Ghana",Hamish Gibbs; Yang Liu; Sam Abbott; Isaac Baffoe-Nyarko; Dennis O. Laryea; Ernest Akyereko; Patrick Kuma-Aboagye; Ivy Asante; Oriol Mitja; - LSHTM CMMID COVID-19 Working Group; William Ampofo; Franklin Asiedu-Bekoe; Michael Marks; Rosalind M Eggo,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Ghana Health Service; Ghana Health Service; Ghana Health Service; Ghana Health Service; University of Ghana Noguchi Memorial Institute for Medical Research; Fight Against AIDS Foundation; ; University of Ghana Noguchi Memorial Institute for Medical Research; Ghana Health Service; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine,"BackgroundGovernments around the world have implemented non-pharmaceutical interventions to limit the transmission of COVID-19. While lockdowns and physical distancing have proven effective for reducing COVID-19 transmission, there is still limited understanding of how NPI measures are reflected in indicators of human mobility. Further, there is a lack of understanding about how findings from high-income settings correspond to low and middle-income contexts.

MethodsIn this study, we assess the relationship between indicators of human mobility, NPIs, and estimates of Rt, a real-time measure of the intensity of COVID-19 transmission. We construct a multilevel generalised linear mixed model, combining local disease surveillance data from subnational districts of Ghana with the timing of NPIs and indicators of human mobility from Google and Vodafone Ghana.

FindingsWe observe a relationship between reductions in human mobility and decreases in Rt during the early stages of the COVID-19 epidemic in Ghana. We find that the strength of this relationship varies through time, decreasing after the most stringent period of interventions in the early epidemic.

InterpretationOur findings demonstrate how the association of NPI and mobility indicators with COVID-19 transmission may vary through time. Further, we demonstrate the utility of combining local disease surveillance data with large scale human mobility data to augment existing surveillance capacity and monitor the impact of NPI policies.

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed and preprint archives for articles published in English that contained information about the COVID-19 pandemic published up to Nov 1, 2021, using the search terms ""coronavirus"", ""CoV"", ""COVID-19"", ""mobility"", ""movement"", and ""flow"". The data thus far suggests that NPI measures including physical distancing, reduction of travel, and use of personal protective equipment have been demonstrated to reduce COVID-19 transmission. Much of the existing research focuses on comparisons of NPI stringency with COVID-19 transmission among different high-income countries, or on high-income countries, leaving critical questions about the applicability of these findings to low- and middle-income settings.

Added value of this studyWe used a detailed COVID-19 surveillance dataset from Ghana, and unique high resolution spatial data on human mobility from Vodafone Ghana as well as Google smartphone GPS location data. We show how human mobility and NPI stringency were associated with changes in the effective reproduction number (Rt). We further demonstrate how this association was strongest in the early COVID-19 outbreak in Ghana, decreasing after the relaxation of national restrictions.

Implications of all the available evidenceThe change in association between human mobility, NPI stringency, and Rt may reflect a ""decoupling"" of NPI stringency and human mobility from disease transmission in Ghana as the COVID-19 epidemic progressed. This finding provides public health decision makers with important insights for the understanding of the utility of mobility data for predicting the spread of COVID-19.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.10.28.21265615,2021-10-29,https://medrxiv.org/cgi/content/short/2021.10.28.21265615,Transmission dynamics of SARS-CoV-2 in a strictly-Orthodox Jewish community in the UK,William Waites; Carl AB Pearson; Katherine M Gaskell; Thomas House; Lorenzo Pellis; Marina Johnson; Victoria Gould; Adam Hunt; Neil RH Stone; Ben Kasstan; Tracey Chantler; Sham Lal; Chrissy h Roberts; David Goldblatt; - CMMID COVID-19 Working Group; Michael Marks; Rosalind M Eggo,University of Edinburgh; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Manchester; The University of Manchester; University College London; London School of Hygiene and Tropical Medicine; University College London; London School of Hygiene and Tropical Medicine; University of Bristol; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; ; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine,"Some social settings such as households and workplaces, have been identified as high risk for SARS-CoV-2 transmission. Identifying and quantifying the importance of these settings is critical for designing interventions. A tightly-knit religious community in the UK experienced a very large COVID-19 epidemic in 2020, reaching 64.3% seroprevalence within 10 months, and we surveyed this community both for serological status and individual-level attendance at particular settings. Using these data, and a network model of people and places represented as a stochastic graph rewriting system, we estimated the relative contribution of transmission in households, schools and religious institutions to the epidemic, and the relative risk of infection in each of these settings. All congregate settings were important for transmission, with some such as primary schools and places of worship having a higher share of transmission than others. We found that the model needed a higher general-community transmission rate for women (3.3-fold), and lower susceptibility to infection in children to recreate the observed serological data. The precise share of transmission in each place was related to assumptions about the internal structure of those places. Identification of key settings of transmission can allow public health interventions to be targeted at these locations.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.10.22.21264701,2021-10-25,https://medrxiv.org/cgi/content/short/2021.10.22.21264701,Long-term health-related quality of life in non-hospitalised COVID-19 cases with confirmed SARS-CoV-2 infection in England: Longitudinal analysis and cross-sectional comparison with controls,Frank Sandmann; Elise Tessier; Joanne Lacy; Meaghan Kall; Edwin Van Leeuwen; Andre Charlett; Rosalind M Eggo; Gavin Dabrera; W. John Edmunds; Mary Ramsay; Helen Campbell; Gayatri Amirthalingam; Mark Jit,"Statistics, Modelling and Economics Department, UK Health Security Agency, 61 Colindale Ave, London NW9 5EQ, UK; COVID-19 National Epidemiology Cell, UK Health Security Agency, Wellington House, 133-155 Waterloo Rd, London SE1 8UG, UK; Immunisation Division, UK Health Security Agency, 61 Colindale Ave, London NW9 5EQ, UK; COVID-19 National Epidemiology Cell, UK Health Security Agency, Wellington House, 133-155 Waterloo Rd, London SE1 8UG, UK; Statistics, Modelling and Economics Department, UK Health Security Agency, 61 Colindale Ave, London NW9 5EQ, UK; Statistics, Modelling and Economics Department, UK Health Security Agency, 61 Colindale Ave, London NW9 5EQ, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, UK; COVID-19 National Epidemiology Cell, UK Health Security Agency, Wellington House, 133-155 Waterloo Rd, London SE1 8UG, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, UK; Immunisation Division, UK Health Security Agency, 61 Colindale Ave, London NW9 5EQ, UK; Immunisation Division, UK Health Security Agency, 61 Colindale Ave, London NW9 5EQ, UK; Immunisation Division, UK Health Security Agency, 61 Colindale Ave, London NW9 5EQ, UK; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E 7HT, UK","BackgroundThis study measured the long-term health-related quality of life of non-hospitalised COVID-19 cases with PCR-confirmed SARS-CoV-2(+) infection using the recommended instrument in England (the EQ-5D).

MethodsProspective cohort study of SARS-CoV-2(+) cases aged 12-85 years and followed up for six months from 01 December 2020, with cross-sectional comparison to SARS-CoV-2(-) controls. Main outcomes were loss of quality-adjusted life days (QALDs); physical symptoms; and COVID-19-related private expenditures. We analysed results using multivariable regressions with post-hoc weighting by age and sex, and conditional logistic regressions for the association of each symptom and EQ-5D limitation on cases and controls.

ResultsOf 548 cases (mean age 41.1 years; 61.5% female), 16.8% reported physical symptoms at month 6 (most frequently extreme tiredness, headache, loss of taste and/or smell, and shortness of breath). Cases reported more limitations with doing usual activities than controls. Almost half of cases spent a mean of {pound}18.1 on non-prescription drugs (median: {pound}10.0), and 52.7% missed work or school for a mean of 12 days (median: 10). On average, all cases lost 15.9 (95%-CI: 12.1, 19.7) QALDs, while those reporting symptoms at month 6 lost 34.1 (29.0, 39.2) QALDs. Losses also increased with older age. Cumulatively, the health loss from morbidity contributes at least 21% of the total COVID-19-related disease burden in England.

ConclusionsOne in 6 cases report ongoing symptoms at 6 months, and 10% report prolonged loss of function compared to pre-COVID-19 baselines. A marked health burden was observed among older COVID-19 cases and those with persistent physical symptoms.

summaryLosses of health-related quality of life in non-hospitalised COVID-19 cases increase by age and for cases with symptoms after 6 months. At a population level, at least 21% of the total COVID-19-related disease burden in England is attributable to morbidity.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.10.18.21264686,2021-10-23,https://medrxiv.org/cgi/content/short/2021.10.18.21264686,Regional excess mortality during the 2020 COVID-19 pandemic: a study of five European countries,Garyfallos Konstantinoudis; Michela Cameletti; Virgilio Gomez-Rubio; Inmaculada Leon Gomez; Monica Pirani; Gianluca Baio; Amparo Larrauri; Julien Riou; Matthias Egger; Paolo Vineis; Marta Blangiardo,Imperial College London; University of Bergamo; Universidad de Castilla-La Mancha; Institute of Health Carlos III; Imperial College London; University College London; Institute of Health Carlos III; University of Bern; University of Bern; Imperial College London; Imperial College,"The impact of the COVID-19 pandemic on excess mortality from all causes in 2020 varied across and within European countries. Using data for 2015-2019, we applied Bayesian spatio-temporal models to quantify the expected weekly deaths at the regional level had the pandemic not occurred in England, Greece, Italy, Spain, and Switzerland. With around 30%, Madrid, Castile-La Mancha, Castile-Leon (Spain) and Lombardia (Italy) were the regions with the highest excess mortality. In England, Greece and Switzerland, the regions most affected were Outer London and the West Midlands (England), Eastern, Western and Central Macedonia (Greece), and Ticino (Switzerland), with 15-20% excess mortality in 2020. Our study highlights the importance of the large transportation hubs for establishing community transmission in the first stages of the pandemic. Acting promptly to limit transmission around these hubs is essential to prevent spread to other regions and countries.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.10.13.21264937,2021-10-18,https://medrxiv.org/cgi/content/short/2021.10.13.21264937,Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study using OpenSAFELY,William J Hulme; Elizabeth J Williamson; Amelia CA Green; Krishnan Bhaskaran; Helen I McDonald; Christopher T Rentsch; Anna Schultze; John Tazare; Helen J Curtis; Alex J Walker; Laurie Tomlinson; Tom M Palmer; Elsie Horne; Brian MacKenna; Caroline E Morton; Amir Mehrkar; Louis Fisher; Sebastian CJ Bacon; David Evans; Peter Inglesby; George Hickman; Simon Davy; Tom Ward; Richard Croker; Rosalind M Eggo; Angel YS Wong; Rohini Mathur; Kevin Wing; Harriet Forbes; Daniel J Grint; Ian J Douglas; Stephen JW Evans; Liam Smeeth; Christopher Bates; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Jonathan AC Sterne; Miguel A Hernan; Ben Goldacre,"The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; London School of Hygiene and Tropical Medicine, London, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; London School of Hygiene and Tropical Medicine, London, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; London School of Hygiene and Tropical Medicine, London, UK; TPP, Horsforth, Leeds, UK; TPP, Horsforth, Leeds, UK; TPP, Horsforth, Leeds, UK; TPP, Horsforth, Leeds, UK; TPP, Horsforth, Leeds, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Bristol, Biomedical Research Centre, Bristol, UK; CAUSALab, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, ; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK","ObjectivesTo compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and the ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines against infection and COVID-19 disease in health and social care workers.

DesignCohort study, emulating a comparative effectiveness trial.

SettingLinked primary care, hospital, and COVID-19 surveillance records available within the OpenSAFELY-TPP research platform.

Participants317,341 health and social care workers vaccinated between 4 January and 28 February 2021, registered with a GP practice using the TPP SystmOne clinical information system in England, and not clinically extremely vulnerable.

InterventionsVaccination with either BNT162b2 or ChAdOx1 administered as part of the national COVID-19 vaccine roll-out.

Main outcome measuresRecorded SARS-CoV-2 positive test, or COVID-19 related Accident and Emergency attendance or hospital admission occurring within 20 weeks of vaccination.

ResultsThe cumulative incidence of each outcome was similar for both vaccines during the first 20 weeks post-vaccination. The cumulative incidence of recorded SARS-CoV-2 infection 6 weeks after vaccination with BNT162b2 was 19.2 per 1000 people (95%CI 18.6 to 19.7) and with ChAdOx1 was 18.9 (95%CI 17.6 to 20.3), representing a difference of -0.24 per 1000 people (95%CI -1.71 to 1.22). The difference in the cumulative incidence per 1000 people of COVID-19 accident and emergency attendance at 6 weeks was 0.01 per 1000 people (95%CI -0.27 to 0.28). For COVID-19 hospital admission, this difference was 0.03 per 1000 people (95%CI -0.22 to 0.27).

ConclusionsIn this cohort of healthcare workers where we would not anticipate vaccine type to be related to health status, we found no substantial differences in the incidence of SARS-CoV-2 infection or COVID-19 disease up to 20 weeks after vaccination. Incidence dropped sharply after 3-4 weeks and there were very few COVID-19 hospital attendance and admission events after this period. This is in line with expected onset of vaccine-induced immunity, and suggests strong protection against COVID-19 disease for both vaccines.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.10.13.21264956,2021-10-16,https://medrxiv.org/cgi/content/short/2021.10.13.21264956,Changes in paediatric respiratory infections at a UK teaching hospital 2016-2021; impact of the SARS-CoV-2 pandemic.,Sheila F Lumley; Nicholas Richens; Emily Lees; Jack Cregan; Elizabeth Kalimeris; Sarah Oakley; Marcus Morgan; Shelley Segal; Moya Dawson; Ann Sarah F Walker; David W Eyre; Derrick W Crook; Sally Beer; Alex Novak; Nicole Stoesser; Philippa C Matthews,University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; Oxford University Hospitals NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; Oxford University Hosptials NHS Foundation Trust; University of Oxford; University of Oxford; NIHR Oxford Biomedical Research Centre; Oxford University Hospitals NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford,"ObjectiveTo describe the impact of the SARS-CoV-2 pandemic on the incidence of paediatric viral respiratory tract infection in Oxfordshire, UK.

MethodsData on paediatric Emergency Department (ED) attendances (0-15 years inclusive), respiratory virus testing, vital signs and mortality at Oxford University Hospitals were summarised using descriptive statistics.

ResultsBetween 1-March-2016 and 30-July-2021, 155,056 ED attendances occurred and 7,195 respiratory virus PCRs were performed. Detection of all pathogens was suppressed during the first national lockdown. Rhinovirus and adenovirus rates increased when schools reopened September-December 2020, then fell, before rising in March-May 2021. The usual winter RSV peak did not occur in 2020/21, with an inter-seasonal rise (32/1,000 attendances in 0-3yr olds) in July 2021. Influenza remained suppressed throughout. A higher Paediatric Early Warning Score (PEWS) was seen for attendees with adenovirus during the pandemic compared to pre-pandemic (p=0.04, Mann-Witney U test), no other differences in PEWS were seen.

ConclusionsSARS-CoV-2 caused major changes in the incidence of paediatric respiratory viral infection in Oxfordshire, with implications for clinical service demand, testing strategies, timing of palivizumab RSV prophylaxis, and highlighting the need to understand which public health interventions are most effective for preventing respiratory virus infections.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.10.06.21264467,2021-10-07,https://medrxiv.org/cgi/content/short/2021.10.06.21264467,Illness characteristics of COVID-19 in children infected with the SARS-CoV-2 Delta variant,Erika Molteni; Carole Helene Sudre; Liane S Canas; Sunil S Bhopal; Robert C Hughes; Liyuan Chen; Jie Deng; Benjamin Murray; Eric Kerfoot; Michela S Antonelli; Mark S Graham; Kerstin Klaser; Anna May; Christina Hu; Joan Capdevila Pujol; Jonathan Wolf; Alexander Hammers; Timothy D Spector; Sebastien Ourselin; Marc Modat; Claire Steves; Michael Absoud; Emma L Duncan,"King's College London; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK.; King's College London; Newcastle University; Department of Population Health, Faculty of Epidemiology & Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK.; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK.; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK.; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK.; King's College London; King's College London; King's College London; ZOE Limited London, UK; ZOE Limited London, UK.; ZOE Limited London, UK.; ZOE Limited London, UK.; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK.; King's College London; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK.; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, UK.; King's College London; Childrens Neurosciences, Evelina London Childrens Hospital, St Thomas Hospital, Kings Health Partners, Academic Health Science Centre, London, UK.; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK.","BackgroundThe Delta (B.1.617.2) SARS-CoV-2 variant became the predominant UK circulating strain in May 2021. Whether COVID-19 from Delta infection differs to infection with other variants in children is unknown.

MethodsThrough the prospective COVID Symptom Study, 109,626 UK school-aged children were proxy-reported between December 28, 2020 and July 8, 2021. We selected all symptomatic children who tested positive for SARS-CoV-2 and were proxy-reported at least weekly, within two timeframes: December 28, 2020 to May 6, 2021 (Alpha (B.1.1.7) the main UK circulating variant); and May 26 to July 8, 2021 (Delta the main UK circulating variant). We assessed illness profiles (symptom prevalence, duration, and burden), hospital presentation, and presence of long ([&ge;]28 day) illness; and calculated odds ratios for symptoms presenting within the first 28 days of illness.

Findings694 (276 younger [5-11 years], 418 older [12-17 years]) symptomatic children tested positive for SARS-CoV-2 with Alpha infection and 706 (227 younger and 479 older) children with Delta infection. Median illness duration was short with either variant (overall cohort: 5 days (IQR 2-9.75) with Alpha, 5 days (IQR 2-9) with Delta). The seven most prevalent symptoms were common to both variants. Symptom burden over the first 28 days was slightly greater with Delta compared with Alpha infection (in younger children, 3 (IQR 2-5) with Alpha, 4 (IQR 2-7) with Delta; in older children 5 (IQR 3-8) with Alpha and 6 (IQR 3-9) with Delta infection in older children). The odds of several symptoms were higher with Delta than Alpha infection, including headache and fever. Few children presented to hospital, and long illness duration was uncommon, with either variant.

InterpretationCOVID-19 in UK school-aged children due to SARS-CoV-2 Delta strain B.1.617.2 resembles illness due to the Alpha variant B.1.1.7., with short duration and similar symptom burden.

FundingZOE Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, UK National Institute for Health Research, UK Medical Research Council, British Heart Foundation and Alzheimers Society.

EthicsEthics approval was granted by KCL Ethics Committee (reference LRS-19/20-18210).

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSTo identify existing evidence for differences in COVID-19 due to infection with Alpha (B.1.1.7) or Delta (B.1.617.2) SARS-CoV-2 variants, we searched PubMed for peer-reviewed articles and medRxiv for preprint publications between March 1, and September 17, 2021 using keywords (""SARS-CoV-2"" OR ""COVID-19"") AND (children OR p?ediatric*) AND (""delta variant"" OR ""B.1.617.2""). We did not restrict our search by language. Of twenty published articles identified in PubMed, we found one case study describing disease presentation associated with Delta variant infection in a child. Another study examining the increase in hospitalization rates of paediatric cases in USA from August 1, 2020 to August 27, 2021 stated that ""It is not known whether the B.1.617.2 (Delta) variant [...] causes different clinical outcomes in children and adolescents compared with variants that circulated earlier."" Four studies reported cases of transmission of the Delta variant in school and community contexts; and two discussed screening testing in school-aged children (thus not directly relevant to the research question here). Remaining papers did not target paediatric age specifically. We found no studies investigating differences in COVID-19 presentation (e.g., duration, burden, individual symptoms) in school-aged children either in the UK or world-wide.

Added value of this studyWe describe and compare illness profiles in symptomatic UK school-aged children (aged 5-17 years) with COVID-19 when either Alpha or Delta strains were the predominant circulating SARS-CoV-2 variant. Our data, collected through one of the largest UK citizen science epidemiological initiatives, show that symptom profile and illness duration of COVID-19 are broadly similar between the strains. Although there were slightly more symptoms with Delta than with Alpha, particularly in older children, this was offset by similar symptom duration (whether considered for symptoms individually or for illness overall). Our study adds quantitative information to the debate on whether there are meaningful clinical differences in COVID-19 due to Alpha vs. Delta variants; and contributes to the discussion regarding rationale for vaccinating children (particularly younger children) against SARS-CoV-2.

Implications of all the available evidenceOur data confirm that COVID-19 in UK school-aged children is usually of short duration and similar symptom burden, whether due to Delta or Alpha. Our data contribute to epidemiological surveillance from the wider UK population, and we capture common and generally mild paediatric presentations of COVID-19 that might be missed using clinician-based surveillance alone. Our data will also be useful for the vaccination debate.",pediatrics,fuzzy,94,100
medRxiv,10.1101/2021.10.07.21264655,2021-10-07,https://medrxiv.org/cgi/content/short/2021.10.07.21264655,The consequences of a year of the COVID-19 pandemic for the mental health of young adult twins in England and Wales,Kaili Rimfeld; Margherita Malanchini; Ryan Arathimos; Agnieszka Gidziela; Oliver Pain; Andrew McMillan; Rachel Ogden; Louise Webster; Amy E Packer; Nicholas G Shakeshaft; Kerry L Schofield; Jean-Baptiste Pingault; Andrea G Allegrini; Argyris Stringaris; Sophie von Stumm; Cathryn M Lewis; Robert Plomin,"King's College London; Department of Psychology, Queen Mary University of London; King's College London; Department of Psychology, Queen Mary University of London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Clinical, Educational & Health Psychology, Division of Psychology & Language Sciences, Faculty of Brain Sciences, University College London; Clinical, Educational & Health Psychology, Division of Psychology & Language Sciences, Faculty of Brain Sciences, University College London; Mood, Brain & Development Unit, Emotion and Development Branch, National Institute of Mental Health; Psychology in Education Research Centre, Department of Education, University of York; King's College London; King's College London","The COVID-19 pandemic has impacted all our lives, not only through the infection itself, but also through the measures taken to control the viruss spread (e.g., lockdown). Here we investigated how the COVID-19 pandemic and unprecedented lockdown affected the mental health of young adults in England and Wales. We compared the mental health symptoms of up to 4,000 twins in their mid-twenties in 2018 prior to the COVID-19 pandemic (T1) to those in a four-wave longitudinal data collection during the pandemic in April, July, and October 2020, and in March 2021 (T2-T5). The average changes in mental health were small-to-medium and mainly occurred from 2018 (T1) to March 2020 (T2, one month following the start of lockdown; average Cohen d=0.14). Despite the expectation of catastrophic effects on the pandemic on mental health of our young adults, we did not observe trends in worsening mental health during the pandemic (T3-T5). Young people with pre-existing mental health problems were adversely affected at the beginning of the pandemic, but their increased problems largely subsided as the pandemic persisted. Twin analyses indicated that the aetiology of individual differences did not change during the lockdown. The average heritability of mental health symptoms was 33% across 5 waves of assessment, and the average genetic correlation between T1 and T2-T5 was .95, indicating that genetic effects before the pandemic (T1) are substantially correlated with genetic effects up to a year later (T2-T5). We conclude that on average the mental health of young adults in England and Wales has been remarkably resilient to the effects of the pandemic and associated lockdown.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2021.10.05.21264543,2021-10-07,https://medrxiv.org/cgi/content/short/2021.10.05.21264543,Higher Hospitalization and Mortality Rates Among SARS-CoV-2 infected Persons in Rural America,Alfred Jerrod Anzalone; Ronald Horswell; Brian Hendricks; San Chu; William Hillegass; William Beasley; Jeremy Harper; Clifford Rosen; Lucio Miele; James McClay; Susan Santangelo; Sally Hodder; - N3C Consortium,University of Nebraska Medical Center; Pennington Biomedical Research Centre; West Virginia University; Pennington Biomedical Research Centre; University of Mississippi Medical Center; University of Oklahoma; Owl Health Works LLC; Maine Medical Center Research Institute; Louisiana State University Health Sciences Center; University of Nebraska Medical Center; Tufts University School of Medicine; West Virginia University; ,"IMPORTANCERural communities are among the most underserved and resource-scarce populations in the United States (US), yet there are limited data on COVID-19 mortality in rural America. Furthermore, rural data are rarely centralized, precluding comparability across urban and rural regions.

OBJECTIVEThe purpose of this study is to assess hospitalization rates and all-cause inpatient mortality among persons with definitive COVID-19 diagnoses residing in rural and urban areas.

DESIGN, SETTINGS, AND PARTICIPANTSThis retrospective cohort study from the National COVID Cohort Collaborative (N3C) examines a cohort of 573,018 patients from 27 US hospital systems presenting with SARS-CoV-2 infection between January 2020 and March 2021, of whom 117,897 were hospitalized. A sample of 450,725 hospitalized persons without COVID-19 diagnoses was identified for comparison.

EXPOSURESZIP Codes provided by source hospital systems were classified by urban-rural gradient through a crosswalk to the US Department of Agriculture Rural-Urban Commuting Area Codes.

MAIN OUTCOMES AND MEASURESPrimary outcomes were hospitalization and all-cause mortality among hospitalized patients. Kaplan-Meier analysis and mixed effects logistic regression were used to estimate 30-day survival in hospitalized patients and associations between rurality, hospitalization, and inpatient mortality while controlling for major risk factors.

RESULTSRural patients were more likely to be older, white, have higher body mass index, and diagnosed with SARS-CoV-2 later in the pandemic compared with their urban counterparts. Rural compared with urban inhabitants had higher rates of hospitalization (23% vs. 19%) and all-cause mortality among hospitalized patients (16% vs. 11%). After adjustment for demographic and baseline differences, rural residents (both urban adjacent and non-adjacent) with COVID-19 were more likely to be hospitalized (Adjusted Odds Ratio (AOR) 1.41, 95% Confidence Interval (CI), 1.37-1.45 and AOR 1.42, CI 1.35-1.50) and to die or be transferred to hospice (AOR 1.62, CI 1.30-1.49 and 1.38, CI 1.30-1.49), respectively. Similar differences in mortality were noted for hospitalized patients without SARS-CoV-2 infection.

CONCLUSIONSHospitalization and inpatient mortality are higher among rural compared with urban persons with COVID-19, even after adjusting for several factors, including age and comorbidities. Further research is needed to understand the factors that drive health disparities in rural populations.

KEY POINTSO_ST_ABSQUESTIONC_ST_ABSDo mortality and hospitalization rates among rural SARS-CoV-2 infected patients in the United States differ from that of their urban counterparts?

FINDINGSHospitalization and mortality rates were significantly greater among rural compared with urban patients, even after adjusting for rural-urban differences including age and comorbidities. Similarly, in persons without SARS-CoV-2 infection, mortality rates were also higher among rural patients.

MEANINGThese findings demonstrate a pervasive rural-urban discrepancy in all-cause inpatient mortality among rural individuals in the U.S. infected with SARS-COV-2 as well as among those who were uninfected. Further research is needed to understand factors driving health disparities among rural populations.",infectious diseases,fuzzy,96,100
medRxiv,10.1101/2021.09.30.21264338,2021-10-03,https://medrxiv.org/cgi/content/short/2021.09.30.21264338,"COVID-19 risk factors amongst 14,786 care home residents: An observational longitudinal analysis including daily community positive test rates of COVID-19, hospital stays, and vaccination status in Wales (UK) between 1st September 2020 and 1st May 2021.",Joe Hollinghurst; Robyn Hollinghurst; Laura North; Amy Mizen; Ashley Akbari; Sara Long; Ronan A Lyons; Richard Fry,Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University,"ObjectivesDetermine individual level risk factors for care home residents testing positive for SARS-CoV-2.

Study DesignLongitudinal observational cohort study using individual-level linked data.

SettingCare home residents in Wales (United Kingdom) between 1st September 2020 and 1st May 2021.

Participants14,786 older care home residents (aged 65+). Our dataset consisted of 2,613,341 individual-level daily observations within 697 care homes.

MethodsWe estimated odds ratios (ORs [95% confidence interval]) using multilevel logistic regression models. Our outcome of interest was a positive SARS-CoV-2 polymerase chain reaction (PCR) test. We included time dependent covariates for the estimated community positive test rate of COVID-19, hospital admissions, and vaccination status. Additional covariates were included for age, positive PCR tests prior to the study, sex, frailty (using the hospital frailty risk score), and specialist care home services.

ResultsThe multivariable logistic regression model indicated an increase in age (OR 1.01 [1.00,1.01] per year of age), community positive test rate (OR 1.13 [1.12,1.13] per percent increase in positive test rate), hospital inpatients (OR 7.40 [6.54,8.36]), and residents in care homes with non-specialist dementia care (OR 1.42 [1.01,1.99]) had an increased odds of a positive test. Having a positive test prior to the observation period (OR 0.58 [0.49,0.68]) and either one or two doses of a vaccine (0.21 [0.17,0.25] and 0.05 [0.02,0.09] respectively) were associated with a decreased odds of a positive test.

ConclusionsOur findings suggest care providers need to stay vigilant despite the vaccination rollout, and extra precautions should be taken when caring for the most vulnerable. Furthermore, minimising potential COVID-19 infection for care home residents admitted to hospital should be prioritised.

SUMMARY BOXESO_ST_ABSSection 1: What is already known on this topicC_ST_ABSO_LICare home residents are at a high risk of COVID-19 infection, but existing literature has mainly focussed on excess mortality rather than infection risk.
C_LIO_LIIn our study we were able to investigate associations between COVID-19 infections and the community positive test rate of COVID-19, the vaccination status of care home residents, hospital admissions, and frailty.
C_LI

Section 2: What this study addsO_LIOur study suggests an increased community positive test rate and hospital inpatients had an increased likelihood of a positive SARS-CoV-2 polymerase chain reaction test, whilst one or two doses of vaccination indicated a decreased chance of a positive test.
C_LIO_LIOur findings suggest care providers need to stay vigilant despite the vaccination rollout, and extra precautions should be taken when caring for the most vulnerable, especially in a hospital setting.
C_LI",geriatric medicine,fuzzy,100,100
medRxiv,10.1101/2021.09.28.21264260,2021-09-29,https://medrxiv.org/cgi/content/short/2021.09.28.21264260,The impact of SARS-CoV-2 vaccination on Alpha and Delta variant transmission,David W Eyre; Donald Taylor; Mark Purver; David Chapman; Tom Fowler; Koen Pouwels; Ann Sarah Walker; Tim EA Peto,University of Oxford; Department of Health and Social Care; Department of Health and Social Care; Deloitte MCS Ltd; Department of Health and Social Care; University of Oxford; University of Oxford; University of Oxford,"BackgroundPre-Delta, vaccination reduced SARS-CoV-2 transmission from individuals infected despite vaccination, potentially via reducing viral loads. While vaccination still lowers the risk of infection, similar viral loads in vaccinated and unvaccinated individuals infected with Delta question how much vaccination prevents transmission.

MethodsWe performed a retrospective observational cohort study of adult contacts of SARS-CoV-2-infected adult index cases using English contact testing data. We used multivariable Poisson regression to investigate associations between transmission and index case and contact vaccination, and how these vary with Alpha and Delta variants (classified using S-gene detection/calendar trends) and time since second vaccination.

Results54,667/146,243(37.4%) PCR-tested contacts of 108,498 index cases were PCR-positive. Two doses of BNT162b2 or ChAdOx1 vaccines in Alpha index cases were independently associated with reduced PCR-positivity in contacts (aRR, adjusted rate ratio vs. unvaccinated=0.32[95%CI 0.21-0.48] and 0.48[0.30-0.78] respectively). The Delta variant attenuated vaccine-associated reductions in transmission: two BNT162b2 doses reduced Delta transmission (aRR=0.50[0.39-0.65]), more than ChAdOx1 (aRR=0.76[0.70-0.82]). Variation in Ct values (indicative of viral load) explained 7-23% of vaccine-associated transmission reductions. Transmission reductions declined over time post-second vaccination, for Delta reaching similar levels to unvaccinated individuals by 12 weeks for ChAdOx1 and attenuating substantially for BNT162b2. Protection in contacts also declined in the 3 months post-second vaccination.

ConclusionsVaccination reduces transmission of Delta, but by less than the Alpha variant. The impact of vaccination decreased over time. Factors other than PCR Ct values at diagnosis are important in understanding vaccine-associated transmission reductions. Booster vaccinations may help control transmission together with preventing infections.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.09.28.21264240,2021-09-29,https://medrxiv.org/cgi/content/short/2021.09.28.21264240,Predicting hospital-onset COVID-19 infections using dynamic networks of patient contacts: an observational study,Ashlegh C Myall; James Richard Price; Robert L Peach; Mohamed Abbas; Siddharth Mookerjee; Nina Zhu; Isa Ahmad; Damien Keng Yen Ming; Farzan Ramzan; Daniel Teixeira; Christophe Graf; Andrea Y Wiesse; Stephan Harbarth; Alison Holmes; Mauricio Barahona,Imperial College London; Imperial College London; Imperial College London; University Hospital of Geneva; Imperial College London NHS Trust; Imperial College London; Imperial College London; Imperial College London; Imperial College London; University Hospital of Geneva; University Hospital of Geneva; The University of Edinburgh; University Hospital of Geneva; Imperial College London; Imperial College London,"BackgroundReal-time prediction is key to prevention and control of healthcare-associated infections. Contacts between individuals drive infections, yet most prediction frameworks fail to capture the dynamics of contact. We develop a real-time machine learning framework that incorporates dynamic patient contact networks to predict patient-level hospital-onset COVID-19 infections (HOCIs), which we test and validate on international multi-site datasets spanning epidemic and endemic periods.

MethodsOur framework extracts dynamic contact networks from routinely collected hospital data and combines them with patient clinical attributes and background contextual hospital data to forecast the infection status of individual patients. We train and test the HOCI prediction framework using 51,157 hospital patients admitted to a UK (London) National Health Service (NHS) Trust from 01 April 2020 to 01 April 2021, spanning UK COVID-19 surges 1 and 2. We then validate the framework by applying it to data from a non-UK (Geneva) hospital site during an epidemic surge (40,057 total inpatients) and to data from the same London Trust from a subsequent period post surge 2, when COVID-19 had become endemic (43,375 total inpatients).

FindingsBased on the training data (London data spanning surges 1 and 2), the framework achieved high predictive performance using all variables (AUC-ROC 0{middle dot}89 [0{middle dot}88-0{middle dot}90]) but was almost as predictive using only contact network variables (AUC-ROC 0{middle dot}88 [0{middle dot}86-0{middle dot}90]), and more so than using only hospital contextual (AUC-ROC 0{middle dot}82 [0{middle dot}80-0{middle dot}84]) or patient clinical (AUC-ROC 0{middle dot}64 [0{middle dot}62-0{middle dot}66]) variables. The top three risk factors we identified consisted of one hospital contextual variable (background hospital COVID-19 prevalence) and two contact network variables (network closeness, and number of direct contacts to infectious patients), and together achieved AUC-ROC 0{middle dot}85 [0{middle dot}82-0{middle dot}88]. Furthermore, the addition of contact network variables improved performance relative to hospital contextual variables on both the non-UK (AUC-ROC increased from 0{middle dot}84 [0{middle dot}82-0{middle dot}86] to 0{middle dot}88 [0{middle dot}86-0{middle dot}90]) and the UK validation datasets (AUC-ROC increased from 0{middle dot}52 [0{middle dot}49-0{middle dot}53] to 0{middle dot}68 [0{middle dot}64-0{middle dot}70]).

InterpretationOur results suggest that dynamic patient contact networks can be a robust predictor of respiratory viral infections spreading in hospitals. Their integration in clinical care has the potential to enhance individualised infection prevention and early diagnosis.

FundingMedical Research Foundation, World Health Organisation, Engineering and Physical Sciences Research Council, National Institute for Health Research, Swiss National Science Foundation, German Research Foundation.",health informatics,fuzzy,100,100
medRxiv,10.1101/2021.09.27.21264166,2021-09-29,https://medrxiv.org/cgi/content/short/2021.09.27.21264166,Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibody in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study,Maria Krutikov; Tom Palmer; Gokhan Tut; Christopher Fuller; Borscha Azmi; Rebecca Giddings; Madhumita Shrotri; Nayandeep Kaur; Panagiota Sylla; Tara Lancaster; Aidan Irwin-Singer; Andrew Hayward; Paul Moss; Andrew Copas; Laura Shallcross,"University College London; University College London; University of Birmingham, Medical School; University College London; University College London; University College London; University College London; University of Birmingham; University of Birmingham; University of Birmingham; Department of Health & Social Care; UCL; University of Birmingham; University College London; UCL","BackgroundLong Term Care Facilities (LTCF) have reported high SARS-CoV-2 infection rates and related mortality, but the proportion infected amongst survivors and duration of the antibody response to natural infection is unknown. We determined the prevalence and stability of nucleocapsid antibodies - the standard assay for detection of prior infection - in staff and residents from 201 LTCFs.

MethodsProspective cohort study of residents aged >65 years and staff of LTCFs in England (11 June 2020-7 May 2021). Serial blood samples were tested for IgG antibodies against SARS-CoV-2 nucleocapsid protein. Prevalence and cumulative incidence of antibody-positivity were weighted to the LTCF population. Cumulative incidence of sero-reversion was estimated from Kaplan-Meier curves.

Results9488 samples were included, 8636 (91%) of which could be individually-linked to 1434 residents or 3288 staff members. The cumulative incidence of nucleocapsid seropositivity was 35% (95% CI: 30-40%) in residents and 26% (95% CI: 23-30%) in staff over 11 months. The incidence rate of loss of antibodies (sero-reversion) was 2{middle dot}1 per 1000 person-days at risk, and median time to reversion was around 8 months.

InterpretationAt least one-quarter of staff and one-third of surviving residents were infected during the first two pandemic waves. Nucleocapsid-specific antibodies often become undetectable within the first year following infection which is likely to lead to marked underestimation of the true proportion of those with prior infection. Since natural infection may act to boost vaccine responses, better assays to identify natural infection should be developed.

FundingUK Government Department of Health and Social Care.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSA search was conducted of Ovid MEDLINE and MedRxiv on 21 July 2021 to identify studies conducted in long term care facilities (LTCF) that described seroprevalence using the terms ""COVID-19"" or ""SARS-CoV-2"" and ""nursing home"" or ""care home"" or ""residential"" or ""long term care facility"" and ""antibody"" or ""serology"" without date or language restrictions. One meta-analysis was identified, published before the introduction of vaccination, that included 2 studies with a sample size of 291 which estimated seroprevalence as 59% in LTCF residents. There were 28 seroprevalence surveys of naturally-acquired SARS-CoV-2 antibodies in LTCFs; 16 were conducted in response to outbreaks and 12 conducted in care homes without known outbreaks. 16 studies included more than 1 LTCF and all were conducted in Autumn 2020 after the first wave of infection but prior to subsequent peaks. Seroprevalence studies conducted following a LTCF outbreak were biased towards positivity as the included population was known to have been previously infected. In the 12 studies that were conducted outside of known outbreaks, seroprevalence varied significantly according to local prevalence of infection. The largest of these was a cross-sectional study conducted in 9,000 residents and 10,000 staff from 362 LTCFs in Madrid, which estimated seroprevalence in staff as 31{middle dot}5% and 55{middle dot}4% in residents. However, as this study was performed in one city, it may not be generalisable to the whole of Spain and sequential sampling was not performed. Of the 28 studies, 9 undertook longitudinal sampling for a maximum of four months although three of these reported from the same cohort of LTCFs in London. None of the studies reported on antibody waning amongst the whole resident population.

Added value of this studyWe estimated the proportion of care home staff and residents with evidence of SARS-CoV-2 natural infection using data from over 3,000 staff and 1,500 residents in 201 geographically dispersed LTCFs in England. Population selection was independent of outbreak history and the sample is therefore more reflective of the population who reside and work in LTCFs. Our estimates of the proportion of residents with prior natural infection are substantially higher than estimates based on population-wide PCR testing, due to limited testing coverage at the start of the pandemic. 1361 individuals had at least one positive antibody test and participants were followed for up to 11 months, which allowed modelling of the time to loss of antibody in over 600 individuals in whom the date of primary infection could be reliably estimated. This is the longest reported serological follow up in a population of LTCF residents, a group who are known to be most at risk of severe outcomes following infection with SARS-CoV-2 and provides important evidence on the duration that nucleocapsid antibodies remained detectable over the first and second waves of the pandemic.

Implications of all available researchA substantial proportion of the LTCF population will have some level of natural immunity to infection as a result of past infection. Immunological studies have highlighted greater antibody responses to vaccination in seropositive individuals, so vaccine efficacy in this population may be affected by this large pool of individuals who have survived past infection. In addition, although the presence of nucleocapsid-specific antibodies is generally considered as the standard marker for prior infection, we find that antibody waning is such that up to 50% of people will lose detectable antibody responses within eight months. Individual prior natural infection history is critical to assess the impact of factors such as vaccine response or protection against re-infection. These findings may have implications for duration of immunity following natural infection and indicate that alternative assays for prior infection should be developed.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.09.20.21263828,2021-09-23,https://medrxiv.org/cgi/content/short/2021.09.20.21263828,"Colchicine for COVID-19 in adults in the community (PRINCIPLE): a randomised, controlled, adaptive platform trial",- The PRINCIPLE Trial Collaborative Group; Jienchi Dorward; Ly-Mee Yu; Gail Hayward; Benjamin R Saville; Oghenekome Gbinigie; Oliver van Hecke; Emma Ogburn; Philip H Evans; Nicholas PB Thomas; Mahendra G Patel; Duncan Richards; Nicholas Berry; Michelle A Detry; Christina Saunders; Mark Fitzgerald; Victoria Harris; Milensu Shanyinde; Simon de Lusignan; Monique I Andersson; Christopher C Butler; FD Richard Hobbs,"; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom and Centre for the AIDS Programme of Research in South Africa ; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Berry Consultants, Texas, USA and Department of Biostatistics, Vanderbilt University School of Medicine, Tennessee, USA; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; College of Medicine and Health, University of Exeter and National Institute for Health Research, Clinical Research Network; Royal College of General Practitioners, London, UK, and National Institute for Health Research, Clinical Research Network; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom and School of Pharmacy and Medical Sciences, University of Bra; Oxford Clinical Trials Research Unit, Botnar Research Centre, University of Oxford, Oxford, UK; Berry Consultants, Texas, USA; Berry Consultants, Texas, USA; Berry Consultants, Texas, USA; Berry Consultants, Texas, USA; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Clinical Medicine, University of Oxford, United Kingdom,; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom","ObjectivesColchicine has been proposed as a COVID-19 treatment, but its effect on time to recovery is unknown. We aimed to determine whether colchicine is effective at reducing time to recovery and COVID-19 related hospitalisations/deaths among people in the community.

DesignProspective, multicentre, open-label, multi-arm, adaptive Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses (PRINCIPLE).

SettingNational trial run remotely from a central trial site and at multiple primary care centres across the United Kingdom.

ParticipantsAdults aged [&ge;]65, or [&ge;]18 years with comorbidities or shortness of breath, and unwell [&le;]14 days with suspected COVID-19 in the community.

InterventionsParticipants were randomised to usual care, usual care plus colchicine (500{micro}g daily for 14 days), or usual care plus other interventions.

Main outcome measuresThe co-primary endpoints were time to first self-reported recovery, and hospitalisation/death related to COVID-19, within 28 days, analysed using Bayesian models. The hypothesis for the time to recovery endpoint is evaluated first, and if superiority is declared on time to recovery, the hypothesis for the second co-primary endpoint of hospitalisation/death is then evaluated. To determine futility, we pre-specified a clinically meaningful benefit in time to first reported recovery as a hazard ratio of 1.2 or larger (equating to approximately 1.5 days benefit in the colchicine arm, assuming 9 days recovery in the usual care arm).

ResultsThe trial opened on April 2, 2020, with randomisation to colchicine starting on March 04, 2021 and stopping on May 26, 2021, because the pre-specified time to recovery futility criterion was met. The primary analysis model included 2755 SARS-CoV-2 positive participants, randomised to colchicine (n=156), usual care (n=1145), and other treatments (n=1454). Time to first self-reported recovery was similar in the colchicine group compared with usual care with an estimated hazard ratio of 0.919 [95% credible interval 0.72 to 1.16] and an estimated increase of 1.14 days [-1.86 to 5.21] in median time to self-reported recovery for colchicine versus usual care. The probability of meaningful benefit in time to recovery was very low at 1.8%. Results were similar in comparisons with concurrent controls. COVID-19 related hospitalisations/deaths were similar in the colchicine group versus usual care, with an estimated odds ratio of 0.76 [0.28 to 1.89] and an estimated difference of -0.4% [-2.7% to 2.4]. One serious adverse event occurred in the colchicine group and one in usual care.

ConclusionsColchicine did not improve time to recovery in people at higher risk of complications with COVID-19 in the community.

Trial registrationISRCTN86534580.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.09.16.21263684,2021-09-22,https://medrxiv.org/cgi/content/short/2021.09.16.21263684,The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units,Andrew Conway Morris; Katherine Sharrocks; Rachel Bousfield; Leanne Kermack; Mailis Maes; Ellen Higginson; Sally Forrest; Joannna Pereira-Dias; Claire Cormie; Timothy Old; Sophie Brooks; Islam Hamed; Alicia Koenig; Andrew Turner; Paul White; R. Andres Floto; Gordon Dougan; Effrossyni Gkrania-Klotsas; Theodore Gouliouris; Stephen Baker; Vilas Navapurkar,University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation trust; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; Cambridge University Hospitals,"BackgroundThe COVID-19 pandemic has overwhelmed the respiratory isolation capacity in hospitals; many wards lacking high-frequency air changes have been repurposed for managing patients infected with SARS-CoV-2 requiring either standard or intensive care. Hospital-acquired COVID-19 is a recognised problem amongst both patients and staff, with growing evidence for the relevance of airborne transmission. This study examined the effect of air filtration and ultra-violet (UV) light sterilisation on detectable airborne SARS-CoV-2 and other microbial bioaerosols.

MethodsWe conducted a crossover study of portable air filtration and sterilisation devices in a repurposed  surge COVID ward and  surge ICU. National Institute for Occupational Safety and Health (NIOSH) cyclonic aerosol samplers and PCR assays were used to detect the presence of airborne SARS-CoV-2 and other microbial bioaerosol with and without air/UV filtration.

ResultsAirborne SARS-CoV-2 was detected in the ward on all five days before activation of air/UV filtration, but on none of the five days when the air/UV filter was operational; SARS-CoV-2 was again detected on four out of five days when the filter was off. Airborne SARS-CoV-2 was infrequently detected in the ICU. Filtration significantly reduced the burden of other microbial bioaerosols in both the ward (48 pathogens detected before filtration, two after, p=0.05) and the ICU (45 pathogens detected before filtration, five after p=0.05).

ConclusionsThese data demonstrate the feasibility of removing SARS-CoV-2 from the air of repurposed  surge wards and suggest that air filtration devices may help reduce the risk of hospital-acquired SARS-CoV-2.

FundingWellcome Trust, MRC, NIHR",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.09.17.21262724,2021-09-21,https://medrxiv.org/cgi/content/short/2021.09.17.21262724,Deleterious drugs in COVID-19: a rapid systematic review and meta-analysis,Michael W Holder; Catherine Heeney; Stephen Malden; Uditha Perera; Aziz Sheikh,"The Usher Institute, University of Edinburgh; The Usher Institute, University of Edinburgh; The Usher Institute, University of Edinburgh; The Usher Institute, University of Edinburgh; The Usher Institute, University of Edinburgh","BackgroundConcerns have been expressed about a number of drugs that potentially worsen outcomes in patients with COVID-19. We sought to identify all potentially deleterious drug groups in COVID-19 and critically assess the underpinning strength of evidence pertaining to the harmful effects of these drugs.

Methods and findingsWe performed a rapid systematic review, searching Medline, Embase and two COVID-19 portfolios (WHO COVID-19 database and NIH iSearch COVID-19 portfolio) for papers and preprints related to primary studies investigating drugs identified as potentially deleterious. Primary outcomes were direct measures of susceptibility to infection, disease severity and mortality. Study quality was assessed using the National Heart, Lung, and Blood Institute quality assessment tools. Random-effects meta-analyses were used for data synthesis with further subgroup analyses where possible for specific outcome, study design, statistical adjustment and drug groups when two were combined. Sensitivity analyses were performed by removing any studies at high risk of bias and by publication status.

49 observational studies (15 peer-reviewed papers and 34 preprints) reported primary outcomes for eight drug groups hypothesised to be deleterious. Meta-analysis showed that acute inpatient corticosteroid use was associated with increased mortality (OR 2.22, 95% CI 1.26-3.90), however this result appeared to have been biased by confounding via indication. One subgroup analysis indicated an association between immunosuppressant use and susceptibility to COVID-19 among case control and cross-sectional studies (OR 1.29, 95% CI 1.19-1.40) but this was not found with cohort studies (OR 1.11, 95% CI 0.86-1.43). Studies which adjusted for multiple confounders showed that people taking angiotensin-converting-enzyme inhibitors (ACEIs) or angiotensin-II-receptor blockers (ARBs) required a lower level of care (OR 0.85, 95% CI 0.74-0.98). Furthermore, studies which combined these two drug groups in their analysis demonstrated an association with a lower mortality (OR 0.68, 95% CI 0.55-0.85).

ConclusionsWe found minimal high quality or consistent evidence that any drug groups increase susceptibility, severity or mortality in COVID-19. Converse to initial hypotheses, we found some evidence that regular use of ACEIs and ARBs prior to infection may be effective in reducing the level of care required, such as requiring intensive care, in patients with COVID-19.",pharmacology and therapeutics,fuzzy,100,100
medRxiv,10.1101/2021.09.13.21263487,2021-09-16,https://medrxiv.org/cgi/content/short/2021.09.13.21263487,SARS-CoV-2 anti-spike IgG antibody responses after second dose of ChAdOx1 or BNT162b2 in the UK general population,Jia Wei; Koen B. Pouwels; Nicole Stoesser; Philippa C. Matthews; Ian Diamond; Ruth Studley; Emma Rourke; Duncan Cook; John I Bell; John N Newton; Jeremy Farrar; Alison Howarth; Brian D. Marsden; Sarah Hoosdally; E Yvonne Jones; David I Stuart; Derrick W. Crook; Tim E.A. Peto; A.Sarah Walker; David W. Eyre,University of Oxford; University of Oxford; University of Oxford; University of Oxford; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford,"We investigated anti-spike IgG antibody responses and correlates of protection following second doses of ChAdOx1 or BNT162b2 SARS-CoV-2 vaccines in the UK general population. In 222,493 individuals, we found significant boosting of anti-spike IgG by second doses of both vaccines in all ages and using different dosing intervals, including the 3-week interval for BNT162b2. After second vaccination, BNT162b2 generated higher peak levels than ChAdOX1. Older individuals and males had lower peak levels with BNT162b2 but not ChAdOx1, while declines were similar across ages and sexes with ChAdOX1 or BNT162b2. Prior infection significantly increased antibody peak level and half-life with both vaccines. Anti-spike IgG levels were associated with protection from infection after vaccination and, to an even greater degree, after prior infection. At least 67% protection against infection was estimated to last for 2-3 months after two ChAdOx1 doses and 5-8 months after two BNT162b2 doses in those without prior infection, and 1-2 years for those unvaccinated after natural infection. A third booster dose may be needed, prioritised to ChAdOx1 recipients and those more clinically vulnerable.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.09.13.21262360,2021-09-16,https://medrxiv.org/cgi/content/short/2021.09.13.21262360,Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study,Paul M McKeigue; David McAllister; Chris Robertson; Sharon J Hutchinson; Stuart McGurnaghan; Diane Stockton; Helen M Colhoun,University of Edinburgh; University of Glasgow; University of Strathclyde; Glasgow Caledonian University; University of Edinburgh; Public Health Scotland; University of Edinburgh,"ObjectivesTo determine whether COVID-19 efficacy varies with clinical risk category and to investigate risk factors for severe COVID-19 in those who have received two doses of vaccine.

DesignMatched case-control study (REACT-SCOT).

SettingPopulation of Scotland from 1 December 2020 to 8 September 2021.

Main outcome measureSevere COVID-19, defined as cases with entry to critical care or fatal outcome.

ResultsEfficacy against severe COVID-19 of two doses of vaccine was 94% (95 percent CI 93% to 96%) in those without designated risk conditions, 89% (95 percent CI 86% to 91%) in those with moderate risk conditions, but only 73% (95 percent CI 64% to 79%) in those designated as clinically extremely vulnerable (CEV) and eligible for shielding. Of the 641 cases of severe COVID-19 in double-vaccinated individuals, 47% had moderate risk conditions and 38% were CEV. In the double-vaccinated CEV group, the rate ratio for severe disease (with no risk condition as reference category) was highest in solid organ transplants at 101 (95% CI 47 to 214) but even in this subgroup the absolute risk of severe COVID-19 was low (35 cases in 23678 person-months of follow-up).

ConclusionsTwo doses of vaccine protect against severe COVID-19 in CEV individuals but the residual risk in double-vaccinated individuals remains far higher in those who are CEV than in those who are not. These results lay a basis for determining eligibility for additional measures including passive immunization to protect those at highest risk.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.09.10.21263372,2021-09-15,https://medrxiv.org/cgi/content/short/2021.09.10.21263372,Localising Vaccination Services: Qualitative Insights on an Orthodox Jewish Collaboration with Public health during the UK coronavirus Vaccine Programme,Ben Kasstan; Sandra Mounier-Jack; Louise Letley; Katherine M Gaskell; Chrissy h Roberts; Neil Stone; Sham Lal; Rosalind M Eggo; Michael Marks; Tracey Chantler,University of Bristol; LSHTM; Public Health England; LSHTM; London School of Hygiene & Tropical Medicine (LSHTM); LSHTM; LSHTM; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine,"Ethnic and religious minorities have been disproportionately affected by the SARS-CoV-2 pandemic and are less likely to accept coronavirus vaccinations. Orthodox (Haredi) Jewish neighbourhoods in England experienced high incidences of SARS-CoV-2 in 2020-21 and measles outbreaks (2018-19) due to suboptimal childhood vaccination coverage. The objective of our study was to explore how the coronavirus vaccination programme (CVP) was co-delivered between public health services and an Orthodox Jewish health organisation.

Methods included 28 semi-structured interviews conducted virtually with public health professionals, community welfare and religious representatives, and household members. We examined CVP delivery from the perspectives of those involved in organising services and vaccine beneficiaries. Interview data was contextualised within debates of the CVP in Orthodox (Haredi) Jewish print and social media. Thematic analysis generated five considerations: i) Prior immunisation-related collaboration with public health services carved a role for Jewish health organisations to host and promote coronavirus vaccination sessions, distribute appointments, and administer vaccines ii) Public health services maintained responsibility for training, logistics, and maintaining vaccination records; iii) The localised approach to service delivery promoted vaccination in a minority with historically suboptimal levels of coverage; iv) Co-delivery promoted trust in the CVP, though a minority of participants maintained concerns around safety; v) Provision of CVP information and stakeholders response to situated (context-specific) challenges and concerns.

Drawing on this example of CVP co-delivery, we propose that a localised approach to delivering immunisation programmes could address service provision gaps in ways that involve trusted community organisations. Localisation of vaccination services can include communication or implementation strategies, but both approaches involve consideration of investment, engagement and coordination, which are not cost-neutral. Localising vaccination services in collaboration with welfare groups raises opportunities for the on-going CVP and other immunisation programmes, and constitutes an opportunity for ethnic and religious minorities to collaborate in safeguarding community health.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.09.12.21263448,2021-09-15,https://medrxiv.org/cgi/content/short/2021.09.12.21263448,Efficacy of vaccination against severe COVID-19 in relation to Delta variant and time since second dose: the REACT-SCOT case-control study,Paul M McKeigue; David McAllister; Sharon J Hutchinson; Chris Robertson; Diane Stockton; Helen M Colhoun,University of Edinburgh; University of Glasgow; Glasgow Caledonian University; University of Strathclyde; Public Health Scotland; University of Edinburgh,"BackgroundThe objectives of this study were to investigate whether vaccine efficacy against severe COVID-19 has decreased since Delta became the predominant variant; (2) whether efficacy wanes with time since second dose.

MethodsEfficacy was estimated in a matched case-control study that includes all diagnosed cases of COVID-19 in Scotland up to 19 August 2021. The main outcome measure was severe COVID-19, defined as cases with entry to critical care or fatal outcome.

FindingsEfficacy of vaccination against severe COVID-19 decreased in May 2021 coinciding with the replacement of the B.1.1.7 (Alpha) by the B.1.617.2 (Delta) variant in Scotland, but this decrease was reversed over the next month. In the most recent time window, the efficacy of two doses was 91% (95 percent CI 87% to 94%) for the AstraZeneca product and 92% (95 percent CI 88% to 95%) for mRNA (Pfizer or Moderna) products. Efficacy of the AstraZeneca product against severe COVID-19 declined with time since second dose to 69% (95 percent CI 52% to 80%) at 20 weeks from second dose. Efficacy of mRNA vaccines declined in the first ten weeks from second dose but more slowly thereafter to 93% (95 percent CI 88% to 96%) at 20 weeks from second dose.

InterpretationThese results are reassuring with respect to concerns that efficacy against severe COVID-19 might have fallen since the Delta variant became predominant, or that efficacy of mRNA vaccines wanes with increasing time since second dose. However it is now clear that efficacy of the AstraZeneca vaccine against severe COVID-19 wanes substantially by 20 weeks from second dose, suggesting that delivery of booster doses should initially focus on those who received this type of vaccine.

FundingNo specific funding was received for this work. HC is supported by an endowed chair from the AXA Research Foundation.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSSeveral reports have suggested that efficacy of COVID-19 vaccines has fallen since the Delta variant became predominant, or that efficacy wanes with time since second dose. The starting point for this study was the evidence of waning efficacy cited by the CDC, the FDA and more recently the UK Joint Committee on Vaccination and Immunisation in support of their recent recommendations for delivery of booster doses for the general population.

Added value of this studyThis study shows that efficacy of both AstraZeneca and mRNA vaccines against severe COVID-19 (fatal or requiring critical care) remains high (around 90%) in the most recent time window, but that efficacy of the AstraZeneca vaccine wanes to about 70% by 20 weeks from second dose. In contrast efficacy of the mRNA vaccines wanes rapidly at first but stabilises at about 90% by 20 weeks from second dose.

Implications of all the available evidenceThese results suggest that booster doses of vaccine are not needed for those who have received two doses of mRNA vaccine, except for vulnerable individuals who may require a third primary dose.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.09.09.21263026,2021-09-13,https://medrxiv.org/cgi/content/short/2021.09.09.21263026,The clinically extremely vulnerable to COVID: Identification and changes in health care while self-isolating (shielding) during the coronavirus pandemic,Jessica Erin Butler; Mintu Nath; Dimitra Blana; William P Ball; Nicola Beech; Corri Black; Graham Osler; Sebastien Peytrignet; Katie Wilde; Artur Wozniak; Simon Sawhney,University of Aberdeen; University of Aberdeen; University of Aberdeen; University of Aberdeen; NHS Grampian; NHS Grampian and University of Aberdeen; NHS Grampian; Health Foundation; University of Aberdeen; University of Aberdeen; NHS Grampian and University of Aberdeen,"BackgroundIn March 2020, the government of Scotland identified people deemed clinically extremely vulnerable to COVID due to their pre-existing health conditions. These people were advised to strictly self-isolate (shield) at the start of the pandemic, except for necessary healthcare. We examined who was identified as clinically extremely vulnerable, how their healthcare changed during isolation, and whether this process exacerbated healthcare inequalities.

MethodsWe linked those on the shielding register in NHS Grampian, a health authority in Scotland, to healthcare records from 2015-2020. We described the source of identification, demographics, and clinical history of the cohort. We measured changes in out-patient, in-patient, and emergency healthcare during isolation in the shielding population and compared to the general non-shielding population.

ResultsThe register included 16,092 people (3% of the population), clinically vulnerable primarily due to a respiratory disease, immunosuppression, or cancer. Among them, 42% were not identified by national healthcare record screening but added ad hoc, with these additions including more children and fewer economically-deprived.

During isolation, all forms of healthcare use decreased (25%-46%), with larger decreases in scheduled care than in emergency care. However, people shielding had better maintained scheduled care compared to the non-shielding general population: out-patient visits decreased 35% vs 49%; in-patient visits decreased 46% vs 81%. Notably, there was substantial variation in whose scheduled care was maintained during isolation: younger people and those with cancer had significantly higher visit rates, but there was no difference between sexes or socioeconomic levels.

ConclusionsHealthcare changed dramatically for the clinically extremely vulnerable population during the pandemic. The increased reliance on emergency care while isolating indicates that continuity of care for existing conditions was not optimal. However, compared to the general population, there was success in maintaining scheduled care, particularly in young people and those with cancer. We suggest that integrating demographic and primary care data would improve identification of the clinically vulnerable and could aid prioritising their care.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.09.03.21262888,2021-09-10,https://medrxiv.org/cgi/content/short/2021.09.03.21262888,Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform,Brian MacKenna; Nicholas A. Kennedy; Amir Mehkar; Anna Rowan; James Galloway; Kathryn E Mansfield; Katie Bechman; Julian Matthewman; Mark Yates; Jeremy Brown; Anna Schultze; Sam Norton; Alex J Walker; Caroline E Morton; David Harrison; Krishnan Bhaskaran; Christopher T Rentsch; Elizabeth Williamson; Richard Croker; Seb Bacon; George Hickman; Tom Ward; Simon Davy; Amelia Green; Louis Fisher; William Hulme; Chris Bates; Helen J Curtis; John Tazare; Rosalind M Eggo; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Laurie A Tomlinson; Rohini Mathur; Angel YS Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Liam Smeeth; Charlie W Lees; Stephen JW Evans; Ben Goldacre; Catherine Smith; Sinead M Langan,"The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Department of Gastroenterology, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK. IBD Research Group, University of Exeter, Exeter, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Centre of Rheumatic Diseases, Kings College London, Denmark Hill, London, SE5 9RS; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; Centre of Rheumatic Diseases, Kings College London, Denmark Hill, London SE5 9RS; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; Centre of Rheumatic Diseases, Kings College London, Denmark Hill, London SE5 9RS; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; Centre of Rheumatic Diseases, Kings College London, Denmark Hill, London SE5 9RS; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; Intensive Care National Audit & Research Centre (ICNARC), High Holborn, London WC1V 6AZ; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; he DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; Centre for Genomics and Experimental Medicine, University of Edinburgh Western General Hospital, Edinburgh, UK; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; St John's Institute of Dermatology, Guys and St Thomas' NHS Foundation Trust and Kings College London SE1 9RT; London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT. St John's Institute of Dermatology, Guys and St Thomas NHS Foundation Trust and Ki","BackgroundIt is unclear if people with immune-mediated inflammatory diseases (IMIDs) (joint, bowel and skin) and on immune modifying therapy have increased risk of serious COVID-19 outcomes.

MethodsWith the approval of NHS England we conducted a cohort study, using OpenSAFELY, analysingroutinely-collected primary care data linked to hospital admission, death and previously unavailable hospital prescription data. We used Cox regression (adjusting for confounders) to estimate hazard ratios (HR) comparing risk of COVID-19-death, death/critical care admission, and hospitalisation (March to September 2020) in: 1) people with IMIDs compared to the general population; and 2) people with IMIDs on targeted immune modifying drugs (e.g., biologics) compared to standard systemic treatment (e.g., methotrexate).

FindingsWe identified 17,672,065 adults; of 1,163,438 (7%) with IMIDs, 19,119 people received targeted immune modifying drugs, and 200,813 received standard systemics. We saw evidence of increased COVID-19-death (HR 1.23, 95%CI 1.20, 1.27), and COVID-19 hospitalisation (HR 1.32, 95%CI 1.29, 1.35) in individuals with IMIDs overall compared to individuals without IMIDs of the same age, sex, deprivation and smoking status. We saw no evidence of increased COVID-19 deaths with targeted compared to standard systemic treatments (HR 1.03, 95%CI 0.80, 1.33). There was no evidence of increased COVID-19-related death in those prescribed TNF inhibitors, IL-12/23, IL7, IL-6 or JAK inhibitors compared to standard systemics. Rituximab was associated with increased COVID-19 death (HR 1.68, 95%CI 1.11, 2.56); however, this finding may relate to confounding.

InterpretationCOVID-19 death and hospitalisation was higher in people with IMIDs. We saw no increased risk of adverse COVID-19 outcomes in those on most targeted immune modifying drugs for IMIDs compared to standard systemics.

RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed on May 19th, 2021, using the terms ""COVID-19"", ""SARS-CoV-2"" and ""rheumatoid arthritis"", ""psoriatic arthritis"" ""ankylosing spondylitis"", ""Crohns disease"" ""ulcerative colitis"" ""hidradenitis suppurativa"" and ""psoriasis"", to identify primary research articles examining severe COVID-19 outcome risk in individuals with immune-mediated inflammatory diseases (IMIDs) and those on immune modifying therapy. The studies identified (including matched cohort studies and studies in disease-specific registries) were limited by small sample sizes and number of outcomes. Most studies did not show a signal of increased adverse COVID-19 outcomes in those on targeted therapies, with the exception of rituximab. Additionally, disease-specific registries are subject to selection bias and lack denominator populations.

Added value of the studyIn our large population-based study of 17 million individuals, including 1 million people with IMIDs and just under 200,000 receiving immune modifying medications, we saw evidence that people with IMIDs had an increased risk of COVID-19-related death compared to the general population after adjusting for potential confounders (age, sex, deprivation, smoking status) (HR 1.23, 95%CI 1.20, 1.27). We saw differences by IMID type, with COVID-19-related death being increased by the most in people with inflammatory joint disease (HR 1.47, 95%CI 1.40, 1.54). We also saw some evidence that those with IMIDs were more likely, compared to the general population, to have COVID-19-related critical care admission/death (HR 1.24, 95%CI 1.21, 1.28) and hospitalisation (HR 1.32, 95%CI 1.29, 1.35).

Compared to people with IMIDs taking standard systemics, we saw no evidence of differences in severe COVID-19-related outcomes with TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-6 inhibitors and JAK inhibitors. However, there was some evidence that rituximab was associated with an increased risk of COVID-19-related death (HR 1.68, 95%CI 1.11, 2.56) and death/critical care admission (HR 1.92, 95%CI 1.31, 2.81). We also saw evidence of an increase in COVID-19-related hospital admissions in people prescribed rituximab (HR 1.59, 95%CI 1.16, 2.18) or JAK inhibition (HR 1.81, 95%CI 1.09, 3.01) compared to those on standard systemics, although this could be related to worse underlying health rather than the drugs themselves, and numbers of events were small.

This is the first study to our knowledge to use high-cost drug data on medicines supplied by hospitals at a national scale in England (to identify targeted therapies). The availability of these data fills an important gap in the medication record of those with more specialist conditions treated by hospitals creating an important opportunity to generate insights to these conditions and these medications

Implications of all of the available evidenceOur study offers insights into future risk mitigation strategies and SARS-CoV-2 vaccination priorities for individuals with IMIDs, as it highlights that those with IMIDs and those taking rituximab may be at risk of severe COVID-19 outcomes. Critically, our study does not show a link between most targeted immune modifying medications compared to standard systemics and severe COVID-19 outcomes. However, the increased risk of adverse COVID-19 outcomes that we saw in people with IMIDs and those treated with rituximab merits further study.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.09.03.21263023,2021-09-10,https://medrxiv.org/cgi/content/short/2021.09.03.21263023,Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort,Alex Handy; Amitava Banerjee; Angela Wood; Caroline Dale; Cathie Sudlow; Christopher Tomlinson; Daniel Bean; Johan H Thygesen; Mehrdad A Mizani; Michail Katsoulis; Reecha Sofat; Richard Dobson; Rohan Takhar; Sam Hollings; Spiros Denaxas; Venexia Walker; - CVD-COVID-UK Consortium,"Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK; Institute of Health Informatics, University College London, London, UK; British Heart Foundation Data Science Centre, Health Data Research UK, London, UK; Institute of Health Informatics, University College London, London, UK; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; Institute of Health Informatics, University College London, London, UK; Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Institute of Health Informatics, University College London, London, UK; NHS Digital, Leeds, UK; Institute of Health Informatics, University College London, London, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; CVD-COVID-UK Consortium","ObjectiveEvaluate antithrombotic (AT) use in individuals with atrial fibrillation (AF) and high stroke risk (CHA2DS2-VASc score>=2) and investigate whether pre-existing AT use may improve COVID-19 outcomes.

MethodsIndividuals with AF and a CHA2DS2-VASc score>=2 on January 1st 2020 were identified using pseudonymised, linked electronic health records for 56 million people in England and followed-up until May 1st 2021. Factors associated with pre-existing AT use were analysed using logistic regression. Differences in COVID-19 related hospitalisation and death were analysed using logistic and Cox regression for individuals exposed to pre-existing AT use vs no AT use, anticoagulants (AC) vs antiplatelets (AP) and direct oral anticoagulants (DOACs) vs warfarin.

ResultsFrom 972,971 individuals with AF and a CHA2DS2-VASc score>=2, 88.0% (n=856,336) had pre-existing AT use, 3.8% (n=37,418) had a COVID-19 related hospitalisation and 2.2% (n=21,116) died. Factors associated with no AT use included comorbidities that may contraindicate AT use (liver disease and history of falls) and demographics (socioeconomic status and ethnicity). Pre-existing AT use was associated with lower odds of death (OR=0.92 [0.87-0.96 at 95% CI]), but higher odds of hospitalisation OR=1.20 [1.15-1.26 at 95% CI]). The same pattern was observed for AC vs AP (death (OR=0.93 [0.87-0.98]), hospitalisation (OR=1.17 [1.11-1.24])) but not for DOACs vs warfarin (death (OR=1.00 [0.95-1.05]), hospitalisation (OR=0.86 [0.82-0.89]).

ConclusionsPre-existing AT use may offer marginal protection against COVID-19 death, with AC offering more protection than AP. Although this association may not be causal, it provides further incentive to improve AT coverage for eligible individuals with AF.

KEY QUESTIONSO_ST_ABSWhat is already known about this subject?C_ST_ABSO_LIAnticoagulants (AC), a sub-class of antithrombotics (AT), reduce the risk of stroke and are recommended for individuals with atrial fibrillation (AF) and at high risk of stroke (CHA2DS2-VASc score>=2, National Institute for Health and Care Excellence threshold). However, previous evaluations suggest that up to one third of these individuals may not be taking AC. Over estimation of bleeding and fall risk in elderly patients have been identified as potential factors in this under medicating.
C_LIO_LIIn response to the COVID-19 pandemic, several observational studies have observed correlations between pre-existing AT use, particularly anticoagulants (AC), and lower risk of severe COVID-19 outcomes such as hospitalisation and death. However, these correlations are inconsistent across studies and have not compared all major sub-types of AT in one study.
C_LI

What does this study add?O_LIThis study uses datasets covering primary care, secondary care, pharmacy dispensing, death registrations, multiple COVID-19 diagnoses routes and vaccination records for 56 million people in England and is the largest scale evaluation of AT use to date. This provides the statistical power to robustly analyse targeted sub-types of AT and control for a wide range of potential confounders. All code developed for the study is opensource and an updated nationwide evaluation can be rapidly created for future time points.
C_LIO_LIIn 972,971 individuals with AF and a CHA2DS2-VASc score>=2, we observed 88.0% (n=856,336) with pre-existing AT use which was associated with marginal protection against COVID-19 death (OR=0.92 [0.87-0.96 at 95% CI]).
C_LI

How might this impact on clinical practice?O_LIThese findings can help shape global AT medication policy and provide population-scale, observational analysis results alongside gold-standard randomised control trials to help assess whether a potential beneficial effect of pre-existing AT use on COVID-19 death alters risk to benefit assessments in AT prescribing decisions.
C_LI",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2021.09.02.21262979,2021-09-10,https://medrxiv.org/cgi/content/short/2021.09.02.21262979,"Exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021",Paul Elliott; David J Haw; Haowei Wang; Oliver Eales; Caroline E Walters; Kylie E. C. Ainslie; Christina J Atchison; Claudio Fronterre; Peter Diggle; Andrew J Page; Alex Trotter; Sophie J Prosolek; - The COVID-19 Genomics UK (COG-UK) consortium; Deborah Ashby; Christl Donnelly; Wendy Barclay; Graham P Taylor; Graham Cooke; Helen Ward; Ara Darzi; Steven Riley,"Imperial College London School of Public Health; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Quadram Institute; Quadram Institute Bioscience; Quadram Institute; The COVID-19 Genomics UK (COG-UK) consortium; Imperial College London; University of Oxford; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Dept Inf Dis Epi, Imperial College","BackgroundThe prevalence of SARS-CoV-2 infection continues to drive rates of illness and hospitalisations despite high levels of vaccination, with the proportion of cases caused by the Delta lineage increasing in many populations. As vaccination programs roll out globally and social distancing is relaxed, future SARS-CoV-2 trends are uncertain.

MethodsWe analysed prevalence trends and their drivers using reverse transcription-polymerase chain reaction (RT-PCR) swab-positivity data from round 12 (between 20 May and 7 June 2021) and round 13 (between 24 June and 12 July 2021) of the REal-time Assessment of Community Transmission-1 (REACT-1) study, with swabs sent to non-overlapping random samples of the population ages 5 years and over in England.

ResultsWe observed sustained exponential growth with an average doubling time in round 13 of 25 days (lower Credible Interval of 15 days) and an increase in average prevalence from 0.15% (0.12%, 0.18%) in round 12 to 0.63% (0.57%, 0.18%) in round 13. The rapid growth across and within rounds appears to have been driven by complete replacement of Alpha variant by Delta, and by the high prevalence in younger less-vaccinated age groups, with a nine-fold increase between rounds 12 and 13 among those aged 13 to 17 years. Prevalence among those who reported being unvaccinated was three-fold higher than those who reported being fully vaccinated. However, in round 13, 44% of infections occurred in fully vaccinated individuals, reflecting imperfect vaccine effectiveness against infection despite high overall levels of vaccination. Using self-reported vaccination status, we estimated adjusted vaccine effectiveness against infection in round 13 of 49% (22%, 67%) among participants aged 18 to 64 years, which rose to 58% (33%, 73%) when considering only strong positives (Cycle threshold [Ct] values < 27); also, we estimated adjusted vaccine effectiveness against symptomatic infection of 59% (23%, 78%), with any one of three common COVID-19 symptoms reported in the month prior to swabbing. Sex (round 13 only), ethnicity, household size and local levels of deprivation jointly contributed to the risk of higher prevalence of swab-positivity.

DiscussionFrom end May to beginning July 2021 in England, where there has been a highly successful vaccination campaign with high vaccine uptake, infections were increasing exponentially driven by the Delta variant and high infection prevalence among younger, unvaccinated individuals despite double vaccination continuing to effectively reduce transmission. Although slower growth or declining prevalence may be observed during the summer in the northern hemisphere, increased mixing during the autumn in the presence of the Delta variant may lead to renewed growth, even at high levels of vaccination.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.09.03.21263083,2021-09-07,https://medrxiv.org/cgi/content/short/2021.09.03.21263083,Suicide and self-harm in low- and middle- income countries during the COVID-19 pandemic: A systematic review,Duleeka Kniipe; Ann John; Prianka Padmanathan; Emily Eyles; Dana Dekel; Julian Higgins; Jason Bantjes; Rakhi Dandona; Catherine Macleod-Hall; Luke A McGuinness; Lena Schmidt; Roger Webb; David Gunnell,"Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; South Asian Clinical Toxicology Research Collaboration, Faculty of Medic; Population Data Science, Swansea University Medical School, Swansea, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.; Population Data Science, Swansea University Medical School, Swansea, UK; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.; National Institute of Health Research Biomedical Research Centre, Unive; Institute for Life Course Health Research, Department of Global Health, Faculty of medicine and Health Sciences, Stellenbosch University, South Africa.; Public Health Foundation of India, Gurugram, India; Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.; Sciome LLC, Research Triangle Park, NC, United States.; Division of Psychology & Mental Health, University of Manchester, Manchester, UK; National Institute of Health Research Greater Manchester Patient Safety Transl; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.; National Institute of Health Research Biomedical Research Centre, Unive","There is widespread concern over the potential impact of the COVID-19 pandemic on suicide and self-harm globally, particularly in low- and middle-income countries (LMIC) where the burden of these behaviours is greatest. We synthesised the evidence from the published literature on the impact of the pandemic on suicide and self-harm in LMIC.

This review is nested within a living systematic review that continuously identifies published evidence (all languages) through a comprehensive automated search of multiple databases (PubMed; Scopus; medRxiv, PsyArXiv; SocArXiv; bioRxiv; the WHO COVID-19 database; and the COVID-19 Open Research Dataset by Semantic Scholar (up to 11/2020), including data from Microsoft Academic, Elsevier, arXiv and PubMed Central.) All articles identified by the 4th August 2021 were screened. Papers reporting on data from a LMIC and presenting evidence on the impact of the pandemic on suicide or self-harm were included.

A total of 22 studies from LMIC were identified representing data from 12 countries. There was an absence of data from Africa. The reviewed studies mostly report on the early months of COVID-19 and were generally methodologically poor. Few studies directly assessed the impact of the pandemic. The most robust evidence, from time-series studies, indicate either a reduction or no change in suicide and self-harm behaviour.

As LMIC continue to experience repeated waves of the virus and increased associated mortality, against a backdrop of vaccine inaccessibility and limited welfare support, continued efforts are needed to track the indirect impact of the pandemic on suicide and self-harm in these countries.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.09.02.21263017,2021-09-05,https://medrxiv.org/cgi/content/short/2021.09.02.21263017,Monitoring populations at increased risk for SARS-CoV-2 infection in the community,Emma Pritchard; Joel Jones; Karina Vihta; Nicole Stoesser; Philippa C Matthews; David W Eyre; Thomas House; John I Bell; John N Newton; Jeremy Farrar; Derrick Crook; Susan Hopkins; Duncan Cook; Emma Rourke; Ruth Studley; Ian Diamond; Tim Peto; Koen B Pouwels; A Sarah Walker,University of Oxford; Office for National Statistics; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Manchester; University of Oxford; Public Health England; Wellcome Trust; University of Oxford; Public Health England; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; University of Oxford; University of Oxford,"BackgroundThe COVID-19 pandemic is rapidly evolving, with emerging variants and fluctuating control policies. Real-time population screening and identification of groups in whom positivity is highest could help monitor spread and inform public health messaging and strategy.

MethodsTo develop a real-time screening process, we included results from nose and throat swabs and questionnaires taken 19 July 2020-17 July 2021 in the UKs national COVID-19 Infection Survey. Fortnightly, associations between SARS-CoV-2 positivity and 60 demographic and behavioural characteristics were estimated using logistic regression models adjusted for potential confounders, considering multiple testing, collinearity, and reverse causality.

FindingsOf 4,091,537 RT-PCR results from 482,677 individuals, 29,903 (0{middle dot}73%) were positive. As positivity rose September-November 2020, rates were independently higher in younger ages, and those living in Northern England, major urban conurbations, more deprived areas, and larger households. Rates were also higher in those returning from abroad, and working in healthcare or outside of home. When positivity peaked December 2020-January 2021 (Alpha), high positivity shifted to southern geographical regions. With national vaccine roll-out from December 2020, positivity reduced in vaccinated individuals. Associations attenuated as rates decreased between February-May 2021. Rising positivity rates in June-July 2021 (Delta) were independently higher in younger, male, and unvaccinated groups. Few factors were consistently associated with positivity. 25/45 (56%) confirmed associations would have been detected later using 28-day rather than 14-day periods.

InterpretationPopulation-level demographic and behavioural surveillance can be a valuable tool in identifying the varying characteristics driving current SARS-CoV-2 positivity, allowing monitoring to inform public health policy.

FundingDepartment of Health and Social Care (UK), Welsh Government, Department of Health (on behalf of the Northern Ireland Government), Scottish Government, National Institute for Health Research.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.09.02.21262965,2021-09-02,https://medrxiv.org/cgi/content/short/2021.09.02.21262965,Whole genome sequencing identifies multiple loci for critical illness caused by COVID-19,Athanasios Kousathanas; Erola Pairo-Castineira; Konrad Rawlik; Alex Stuckey; Christopher A Odhams; Susan Walker; Clark D Russell; Tomas Malinauskas; Jonathan Millar; Katherine S Elliott; Fiona Griffiths; Wilna Oosthuyzen; Kirstie Morrice; Sean Keating; Bo Wang; Daniel Rhodes; Lucija Klaric; Marie Zechner; Nick Parkinson; Andrew D. Bretherick; Afshan Siddiq; Peter Goddard; Sally Donovan; David Maslove; Alistair Nichol; Malcolm G Semple; Tala Zainy; Fiona Maleady-Crowe; Linda Todd; Shahla Salehi; Julian Knight; Greg Elgar; Georgia Chan; Prabhu Arumugam; Tom A Fowler; Augusto Rendon; Manu Shankar-Hari; Charlotte Summers; Charles Hinds; Peter Horby; Danny McAuley; Hugh Montgomery; Peter J.M. Openshaw; Yang Wu; Jian Yang; Paul Elliott; Timothy Walsh; - GenoMICC Investigators; - 23andMe Investigators; - Covid-19 Human Genetics Initiative; Angie Fawkes; Lee Murphy; Kathy Rowan; Chris P Ponting; Veronique Vitart; James F Wilson; Richard H Scott; Sara Clohisey; Loukas Moutsianas; Andy Law; Mark J Caulfield; J. Kenneth Baillie,"Genomics England, London UK; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England, London UK; Genomics England, London UK; Genomics England, London UK; Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh, UK; Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England, London UK; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Genomics England, London UK; Genomics England, London UK; Genomics England, London UK; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland.; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; Genomics England, London UK; Genomics England, London UK; Genomics England, London UK; Genomics England, London UK; Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK; Genomics England, London UK; Genomics England, London UK; Genomics England, London UK; Genomics England, London UK; Genomics England, London UK; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; National Heart and Lung Institute, Imperial College London, London, UK; Institute for Molecular Bioscience, The University of Queensland, Brisbane, Australia; Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang 310024, China; Imperial College, London; Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; ; ; ; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Intensive Care National Audit & Research Centre, London, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, Teviot Place, Edinburgh EH8 9AG, UK.; Genomics England, London UK; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England, London UK; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England, London UK; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK","Critical illness in COVID-19 is caused by inflammatory lung injury, mediated by the host immune system. We and others have shown that host genetic variation influences the development of illness requiring critical care1 or hospitalisation2;3;4 following SARS-Co-V2 infection. The GenOMICC (Genetics of Mortality in Critical Care) study recruits critically-ill cases and compares their genomes with population controls in order to find underlying disease mechanisms.

Here, we use whole genome sequencing and statistical fine mapping in 7,491 critically-ill cases compared with 48,400 population controls to discover and replicate 22 independent variants that significantly predispose to life-threatening COVID-19. We identify 15 new independent associations with critical COVID-19, including variants within genes involved in interferon signalling (IL10RB, PLSCR1), leucocyte differentiation (BCL11A), and blood type antigen secretor status (FUT2). Using transcriptome-wide association and colocalisation to infer the effect of gene expression on disease severity, we find evidence implicating expression of multiple genes, including reduced expression of a membrane flippase (ATP11A), and increased mucin expression (MUC1), in critical disease.

We show that comparison between critically-ill cases and population controls is highly efficient for genetic association analysis and enables detection of therapeutically-relevant mechanisms of disease. Therapeutic predictions arising from these findings require testing in clinical trials.",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2021.08.26.21262523,2021-08-28,https://medrxiv.org/cgi/content/short/2021.08.26.21262523,"Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalized patients with COVID-19: A network meta-analysis",Peter J Godolphin; David J Fisher; Lindsay R Berry; Lennie PG Derde; Janet V Diaz; Anthony C Gordon; Elizabeth Lorenzi; John C Marshall; Srinivas Murthy; Manu Shankar-Hari; Jonathan AC Sterne; Jayne F Tierney; Claire L Vale,University College London; University College London; Berry Consultants; University Medical Center Utrecht; World Health Organization; Imperial College London; Berry Consultants; University of Toronto; University of British Columbia; King's College London; University of Bristol; University College London; University College London,"ObjectiveTo estimate pairwise associations between administration of tocilizumab, sarilumab and usual care or placebo with 28-day mortality, in COVID-19 patients receiving concomitant corticosteroids and non-invasive or mechanical ventilation, based on all available direct and indirect evidence.

MethodsEligible trials randomized hospitalized patients with COVID-19 that compared either interleukin-6 receptor antagonist with usual care or placebo in a recent prospective meta-analysis (27 trials, 10930 patients) or that directly compared tocilizumab with sarilumab. Data were restricted to patients receiving corticosteroids and either non-invasive or invasive ventilation at randomization.

Pairwise associations between tocilizumab, sarilumab and usual care or placebo for all-cause mortality 28 days after randomization were estimated using a frequentist contrast-based network meta-analysis of odds ratios (ORs), implementing multivariate fixed-effects models that assume consistency between the direct and indirect evidence.

ResultsOne trial (REMAP-CAP) was identified that directly compared tocilizumab with sarilumab and supplied results on all-cause mortality at 28-days. This network meta-analysis was based on 898 eligible patients (278 deaths) from REMAP-CAP and 3710 eligible patients from 18 trials (1278 deaths) from the prospective meta-analysis. Summary ORs were similar for tocilizumab [0.82 [0.71-0.95, P=0.008]] and sarilumab [0.80 [0.61-1.04, P=0.09]] compared with usual care or placebo. The summary OR for 28-day mortality comparing tocilizumab with sarilumab was 1.03 [95%CI 0.81-1.32, P=0.80]. The P value for the global test for inconsistency was 0.28.

ConclusionAdministration of either tocilizumab or sarilumab was associated with lower 28-day all-cause mortality compared with usual care or placebo. The association is not dependent on the choice of interleukin-6 receptor antagonist.",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2021.08.23.21261638,2021-08-26,https://medrxiv.org/cgi/content/short/2021.08.23.21261638,Unexplained longitudinal variability in COVID-19 antibody status by Lateral Flow Immuno-Antibody testing,Katrina A S Davis; Carolin Oetzmann; Ewan Carr; Michael Malim; Vanessa J Boshell; Grace Lavelle; Daniel J Leightley; Catherine Polling; Sharon Stevelink; Valentina Vitiello; Alice Wickersham; Reza Razavi; Matthew H Hotopf; - KCL-CHECK team,"KCL Institute of Psychiatry, Psychology and Neuroscience; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; ","BackgroundCOVID-19 antibody testing allows population studies to classify participants by previous SARS-CoV-2 infection status. Home lateral flow immune-antibody testing devices offer a very convenient way of doing this, but relatively little is known about how measurement and antibody variability will affect consistency in results over time. We examined consistency by looking at the outcome of two tests three months apart while COVID-19 infection rates were low (summer 2020 in the UK).

MethodsThe KCL-Coronavirus Health and Experiences in Colleagues at Kings is an occupational cohort of staff and postgraduate research students. Lateral flow immune-antibody testing kits were sent to participants homes in late June 2020 and late September 2020. Participants also completed regular surveys that included asking about COVID-19 symptoms and whether they thought they had been infected.

ResultsWe studied 1489 participants returned valid results in both June and September (59% of those sent kits). Lateral flow immune-antibody test was positive for 7.2% in June and 5.9% in September, with 3.9% positive in both. Being more symptomatic or suspecting infection increased the probability of ever being positive. Of those positive in June, 46% (49/107) were negative in September (seroreversion), and this was similar regardless of symptom characteristics, suspicion, and timing of possible infection. A possible outlier was those aged over 55 years, where only 3 of 13 (23%) had seroreversion.

DiscussionThese results do not follow the pattern reported from studies specifically designed to monitor seropositivity, which have found greater consistency over time and the influence of presence, timing and severity of symptoms on seroreversion. We suggest several factors that may have contributed to this difference: our low bar in defining initial seropositivity (single test); a non-quantitative test known to have relatively low sensitivity; participants carrying out testing. We would encourage other studies to use these real-world performance characteristics alongside those from laboratory studies to plan and analyse any antibody testing.",occupational and environmental health,fuzzy,100,100
medRxiv,10.1101/2021.08.18.21262237,2021-08-24,https://medrxiv.org/cgi/content/short/2021.08.18.21262237,Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK,Koen B Pouwels; Emma Pritchard; Philippa Matthews; Nicole B Stoesser; David W Eyre; Karina-Doris Vihta; Thomas House; Jodie Hay; John Bell; John Newton; Jeremy Farrar; Derrick W Crook; Duncan Cook; Emma Rourke; Ruth Studley; Tim E Peto; Ian Diamond; Sarah Walker; - COVID-19 Infection Survey Team,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Manchester; Glasgow Lighthouse Laboratory; University of Oxford; Public Health England; Wellcome Trust; NIHR Oxford Biomedical Research Centre; Office for National Statistics; Office for National Statistics; Office for National Statistics; Oxford University; Office for National Statistics; University of Oxford; -,"The effectiveness of BNT162b2, ChAdOx1, and mRNA-1273 vaccines against new SARS-CoV-2 infections requires continuous re-evaluation, given the increasingly dominant Delta variant. We investigated the effectiveness of the vaccines in a large community-based survey of randomly selected households across the UK. We found that the effectiveness of BNT162b2 and ChAd0x1 against any infections (new PCR positives) and infections with symptoms or high viral burden is reduced with the Delta variant. A single dose of the mRNA-1273 vaccine had similar or greater effectiveness compared to a single dose of BNT162b2 or ChAdOx1. Effectiveness of two doses remains at least as great as protection afforded by prior natural infection. The dynamics of immunity following second doses differed significantly between BNT162b2 and ChAdOx1, with greater initial effectiveness against new PCR-positives but faster declines in protection against high viral burden and symptomatic infection with BNT162b2. There was no evidence that effectiveness varied by dosing interval, but protection was higher among those vaccinated following a prior infection and younger adults. With Delta, infections occurring following two vaccinations had similar peak viral burden to those in unvaccinated individuals. SARS-CoV-2 vaccination still reduces new infections, but effectiveness and attenuation of peak viral burden are reduced with Delta.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.08.23.21261779,2021-08-24,https://medrxiv.org/cgi/content/short/2021.08.23.21261779,Association of cerebral venous thrombosis with recent COVID-19 vaccination: case-crossover study using ascertainment through neuroimaging in Scotland.,Paul M McKeigue; Raj Burgul; Jennifer Bishop; Chris Robertson; Jim McMenamin; Maureen O'Leary; David A. McAllister; Helen M Colhoun,"University of Edinburgh; Forth Valley Royal Hospital; Public Health Scotland; Department of Mathematics and Statistics, University of Strathclyde; Public Health Scotland; Public Health Scotland; University of Glasgow; University of Edinburgh","ObjectivesTo investigate the association of primary acute cerebral venous thrombosis (CVT) with COVID-19 vaccination through complete ascertainment of all diagnosed CVT in the population of Scotland.

DesignCase-crossover study comparing recent (1-14 days after vaccination) with less recent exposure to vaccination among cases of CVT.

SettingNational data for Scotland from 1 December 2020, with diagnosed CVT case ascertainment through neuroimaging studies up to 17 May 2021 and diagnostic coding of hospital discharges up to 28 April 2021 and with linkage to vaccination records.

Main outcome measurePrimary acute cerebral venous thrombosis

ResultsOf 50 primary acute CVT cases, 29 were ascertained only from neuroimaging studies, 2 were ascertained only from hospital discharges, and 19 were ascertained from both sources. Of these 50 cases, 14 had received the Astra-Zeneca ChAdOx1 vaccine and 3 the Pfizer BNT162b2 vaccine. The incidence of CVT per million doses in the first 14 days after vaccination was 2.2 (95% credible interval 0.9 to 4.1) for ChAdOx1 and 1 (95% credible interval 0.1 to 2.9) for BNT162b2. The rate ratio for CVT associated with exposure to ChAdOx1 in the first 14 days compared with exposure 15-84 days after vaccination was 3.2 (95% credible interval 1.1 to 9.5). The 95% credible interval for the rate ratio associated with recent versus less recent exposure to BNT162b2 (0.6 to 95.8) was too wide for useful inference.

ConclusionsThese findings support a causal association between CVT and the AstraZeneca vaccine. The absolute risk of post-vaccination CVT in this population-wide study in Scotland was lower than has been reported for populations in Scandinavia and Germany; the explanation for this is not clear.

What is already known on this topicThe risk of cerebral venous thrombosis (CVT) within 28 days of receiving the AstraZeneca ChAdOx1 vaccine has been estimated as 18 to 25 per million doses in Germany and Scandinavia, but only 5 per million doses in the UK based on the Yellow Card reporting scheme. Risk estimates based on adverse event reporting systems are subject to under-ascertainment and other biases.

What this study addsAll diagnosed cases of CVT in Scotland were ascertained by searching neuroimaging studies from December 2020 to May 2021 and linked to national vaccination records. The risk of CVT within 28 days of vaccination with ChAdOx1 was estimated as 3.5 per million doses with an upper bound of 6 per million doses, against a background incidence of about 12 per million adults per year. This indicates that the Yellow Card system has not seriously underestimated the risk in the UK; the explanation for higher risk in other European countries is not clear.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.08.19.21262231,2021-08-24,https://medrxiv.org/cgi/content/short/2021.08.19.21262231,Symptoms and SARS-CoV-2 positivity in the general population in the UK,Karina-Doris Vihta; Koen B. Pouwels; Tim Peto; Emma Pritchard; David W. Eyre; Thomas House; Owen Gethings; Ruth Studley; Emma Rourke; Duncan Cook; Ian Diamond; Derrick Crook; Philippa C. Matthews; Nicole Stoesser; Ann Sarah Walker; - COVID-19 Infection Survey team,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Manchester; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ,"BackgroundSeveral community-based studies have assessed the ability of different symptoms to identify COVID-19 infections, but few have compared symptoms over time (reflecting SARS-CoV-2 variants) and by vaccination status.

MethodsUsing data and samples collected by the COVID-19 Infection Survey at regular visits to representative households across the UK, we compared symptoms in new PCR-positives and comparator test-negative controls.

ResultsFrom 26/4/2020-7/8/2021, 27,869 SARS-CoV-2 PCR-positive episodes occurred in 27,692 participants (median 42 years (IQR 22-58)); 13,427 (48%) self-reported symptoms (""symptomatic positive episodes""). The comparator group comprised 3,806,692 test-negative visits (457,215 participants); 130,612 (3%) self-reported symptoms (""symptomatic negative visit""). Reporting of any symptoms in positive episodes varied over calendar time, reflecting changes in prevalence of variants, incidental changes (e.g. seasonal pathogens, schools re-opening) and vaccination roll-out. There was a small increase in sore throat reporting in symptomatic positive episodes and negative visits from April-2021. After May-2021 when Delta emerged there were substantial increases in headache and fever in positives, but not in negatives. Although specific symptom reporting in symptomatic positive episodes vs. negative visits varied by age, sex, and ethnicity, only small improvements in symptom-based infection detection were obtained; e.g. adding fatigue/weakness or all eight symptoms to the classic four symptoms (cough, fever, loss of taste/smell) increased sensitivity from 74% to 81% to 90% but tests per positive from 4.6 to 5.3 to 8.7.

ConclusionsWhilst SARS-CoV-2-associated symptoms vary by variant, vaccination status and demographics, differences are modest and do not warrant large-scale changes to targeted testing approaches given resource implications.

SummaryWithin the COVID-19 Infection Survey, recruiting representative households across the UK general population, SARS-CoV-2-associated symptoms varied by viral variant, vaccination status and demographics. However, differences are modest and do not currently warrant large-scale changes to targeted testing approaches.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.08.23.21262209,2021-08-23,https://medrxiv.org/cgi/content/short/2021.08.23.21262209,Population birth outcomes in 2020 and experiences of expectant mothers during the COVID-19 pandemic: a Born in Wales mixed methods study using routine data,Hope Jones; Mike Seaborne; Laura Cowley; David E Odd; Shantini Paranjothy; Ashley Akbari; Sinead Brophy,Swansea University; Swansea University; Public Health Wales; Cardiff University; University of Aberdeen; Swansea University; Swansea University,"BackgroundPregnancy can be a stressful time and the COVID-19 pandemic has affected all aspects of life. This study aims to investigate the impact of the pandemic on population birth outcomes in Wales, rates of primary immunisations and examine expectant mothers experiences of pregnancy including self-reported levels of stress and anxiety.

MethodsPopulation-level birth outcomes in Wales: Stillbirths, prematurity, birth weight and Caesarean section births before (2016-2019) and during (2020) the pandemic were compared using national-level routine anonymised data held in the Secure Anonymised Information Linkage (SAIL) Databank. The first three scheduled primary immunisations were compared between 2019 and 2020. Self-reported pregnancy experience: 215 expectant mothers (aged 16+) in Wales completed an online survey about their experiences of pregnancy during the pandemic. The qualitative survey data was analysed using codebook thematic analysis.

FindingsThere was no significant difference between annual outcomes including gestation and birth weight, stillbirths, and Caesarean sections for infants born in 2020 compared to 2016-2019. There was an increase in late term births ([&ge;]42 weeks gestation) during the first lockdown (OR: 1.28, p=0.019) and a decrease in moderate to late preterm births (32-36 weeks gestation) during the second lockdown (OR: 0.74, p=0.001). Fewer babies were born in 2020 (N=29,031) compared to 2016-2019 (average N=32,582). All babies received their immunisations in 2020, but there were minor delays in the timings of vaccines. Those due at 8-weeks were 8% less likely to be on time (within 28-days) and at 16-weeks, they were 19% less likely to be on time. The pandemic had a negative impact on the mental health of 71% of survey respondents, who reported anxiety, stress and loneliness; this was associated with attending scans without their partner, giving birth alone, and minimal contact with midwives.

InterpretationThe pandemic had a negative impact on mothers experiences of pregnancy; however, population-level data suggests that this did not translate to adverse birth outcomes for babies born during the pandemic.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.08.17.21262196,2021-08-22,https://medrxiv.org/cgi/content/short/2021.08.17.21262196,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial,James McGree; Carinna Hockham; Sradha Kotwal; Arlen Wilcox; Abhinav Bassi; Carol Pollock; Louise M Burrell; Tom Snelling; Vivek Jha; Meg Jardine; Mark Jones,Queensland University of Technology; Imperial College London; University of New South Wales; University of New South Wales; The George Institute for Global Health; Royal North Shore Hospital; University of Melbourne; The University of Sydney; University of New South Wales; University of New South Wales; The University of Sydney,"The CLARITY trial (Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease) investigates the effectiveness of angiotensin receptor blockers in addition to standard care compared to placebo (in Indian sites) with standard care in reducing the duration and severity of lung failure in patients with COVID-19. The CLARITY trial is a multi-centre, randomised controlled Bayesian adaptive trial with regular planned analyses where pre-specified decision rules will be assessed to determine whether the trial should be stopped due to sufficient evidence of treatment effectiveness or futility. Here we describe the statistical analysis plan for the trial, and define the pre-specified decision rules, including those that could lead to the trial being halted. The primary outcome is clinical status on a 7-point ordinal scale adapted from the WHO Clinical Progression scale assessed at Day 14. The primary analysis will follow the intention-to-treat principle. A Bayesian adaptive trial design was selected because there is considerable uncertainty about the extent of potential benefit of this treatment.

Trial registrationClinicalTrials.gov, NCT04394117. Registered on 19 May 2020.

https://clinicaltrials.gov/ct2/show/NCT04394117

Clinical Trial Registry of India: CTRI/2020/07/026831

Version and revisionsVersion 1.0. No revisions.",respiratory medicine,fuzzy,100,100
medRxiv,10.1101/2021.08.13.21261889,2021-08-18,https://medrxiv.org/cgi/content/short/2021.08.13.21261889,Robust SARS-CoV-2-specific and heterologous immune responses after natural infection in elderly residents of Long-Term Care Facilities,Gokhan Tut; Tara Lancaster; Megan S Butler; Panagiota Sylla; Eliska Spalkova; David Bone; Nayandeep Kaur; Christopher Bentley; Umayr Amin; Azar T Jadir; Samuel Hulme; Morenike Ayodele; Alexander C Dowell; Hayden Pearce; Sandra Margielewska-Davies; Kriti Verma; Samantha Nicol; Jusnara Begum; Elizabeth Jinks; Elif Tut; Rachel Bruton; Maria Krutikov; Madhumita Shrotri; Rebecca Giddings; Borscha Azmi; Chris Fuller; Aidan Irwin-Singer; Andrew Hayward; Andrew Copas; Laura Shallcross; Paul Moss,"Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK; UCL Institute of Health Informatics, London, UK; UCL Institute of Health Informatics, London, UK; UCL Institute of Health Informatics, London, UK; UCL Institute of Health Informatics, London, UK; UCL Institute of Health Informatics, London, UK; Department of Health and Social Care, London, UK; Health Data Research UK; UCL Institute for Global Health, London, UK; UCL Institute of Health Informatics, London, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK","Long term care facilities (LTCF) provide residential and/or nursing care support for frail and elderly people and many have suffered from a high prevalence of SARS-CoV-2 infection. Although mortality rates have been high in LTCF residents there is little information regarding the features of SARS-CoV-2-specific immunity after infection in this setting or how this may influence immunity to other infections. We studied humoral and cellular immunity against SARS-CoV-2 in 152 LTCF staff and 124 residents over a prospective 4-month period shortly after the first wave of infection and related viral serostatus to heterologous immunity to other respiratory viruses and systemic inflammatory markers. LTCF residents developed high levels of antibodies against spike protein and RBD domain which were stable over 4 months of follow up. Nucleocapsid-specific responses were also elevated in elderly donors but showed waning across all populations. Antibodies showed stable and equivalent levels of functional inhibition against spike-ACE2 binding in all age groups with comparable activity against viral variants of concern. SARS-CoV-2 seropositive donors showed high levels of antibodies to other beta-coronaviruses but serostatus did not impact humoral immunity to influenza or RSV. SARS-CoV-2-specific cellular responses were equivalent across the life course but virus-specific populations showed elevated levels of activation in older donors. LTCF residents who are survivors of SARS-CoV-2 infection thus show robust and stable immunity which does not impact responses to other seasonal viruses. These findings augur well for relative protection of LTCF residents to re-infection. Furthermore, they underlie the potent influence of previous infection on the immune response to Covid-19 vaccine which may prove to be an important determinant of future vaccine strategy.

One sentence summeryCare home residents show waning of nucleocapsid specific antibodies and enhanced expression of activation markers on SARS-CoV-2 specific cells",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.08.13.21261959,2021-08-13,https://medrxiv.org/cgi/content/short/2021.08.13.21261959,Factors influencing wellbeing in young people during COVID-19.,Michaela James; Hope Jones; Amana Baig; Emily Marchant; Tegan Waites; Charlotte Todd; Karen Hughes; Sinead Brophy,Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Public Health Wales; Bangor University; Swansea University,"COVID-19 infection and the resultant restrictions has impacted all aspects of life across the world. This study explores factors that promote or support wellbeing for young people during the pandemic, how they differ by age, using a self-reported online survey with those aged 8 - 25 in Wales between September 2020 and February 2021. Open-ended responses were analysed via thematic analysis to provide further context. A total of 6,291 responses were obtained from 81 education settings across Wales (including primary and secondary schools as well as sixth form, colleges and universities). Wellbeing was highest in primary school children and boys and lowest in those who were at secondary school children, who were girls and, those who preferred not to give a gender. Among primary school children, higher wellbeing was seen for those who played with others (rather than alone), were of Asian ethnicity (OR 2.3, 95% CI: 1.26 to 4.3), lived in a safe area (OR: 2.0, 95% CI: 1.67 to 2.5) and had more sleep. To support their wellbeing young people reported they would like to be able to play with their friends more. Among secondary school children those who were of mixed ethnicity reported lower wellbeing (OR: 5.10, 95% CI: 1.70 to 15.80). To support their wellbeing they reported they would like more support with mental health (due to anxiety and pressure to achieve when learning online). This study found self-reported wellbeing differed by gender, ethnicity and deprivation and found younger children report the need for play and to see friends to support wellbeing but older children/young people wanted more support with anxiety and educational pressures.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.08.12.21261987,2021-08-13,https://medrxiv.org/cgi/content/short/2021.08.12.21261987,Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2,Oliver Eales; Caroline E. Walters; Haowei Wang; David Haw; Kylie E. C. Ainslie; Christina Atchinson; Andrew Page; Sophie Prosolek; Alexander J. Trotter; Thanh Le Viet; Nabil-Fareed Alikhan; Leigh M Jackson; Catherine Ludden; - The COVID-19 Genomics UK (COG-UK) Consortium; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott; Steven Riley,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Medical School, University of Exeter, UK; Department of Medicine, University of Cambridge, UK; ; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc","BackgroundCommunity surveys of SARS-CoV-2 RT-PCR swab-positivity provide prevalence estimates largely unaffected by biases from who presents for routine case testing. The REal-time Assessment of Community Transmission-1 (REACT-1) has estimated swab-positivity approximately monthly since May 2020 in England from RT-PCR testing of self-administered throat and nose swabs in random non-overlapping cross-sectional community samples. Estimating infection incidence from swab-positivity requires an understanding of the persistence of RT-PCR swab positivity in the community.

MethodsDuring round 8 of REACT-1 from 6 January to 22 January 2021, of the 2,282 participants who tested RT-PCR positive, we recruited 896 (39%) from whom we collected up to two additional swabs for RT-PCR approximately 6 and 9 days after the initial swab. We estimated sensitivity and duration of positivity using an exponential model of positivity decay, for all participants and for subsets by initial N-gene cycle threshold (Ct) value, symptom status, lineage and age. Estimates of infection incidence were obtained for the entire duration of the REACT-1 study using P-splines.

ResultsWe estimated the overall sensitivity of REACT-1 to detect virus on a single swab as 0.79 (0.77, 0.81) and median duration of positivity following a positive test as 9.7 (8.9, 10.6) days. We found greater median duration of positivity where there was a low N-gene Ct value, in those exhibiting symptoms, or for infection with the Alpha variant. The estimated proportion of positive individuals detected on first swab, P0, was found to be higher for those with an initially low N-gene Ct value and those who were pre-symptomatic. When compared to swab-positivity, estimates of infection incidence over the duration of REACT-1 included sharper features with evident transient increases around the time of key changes in social distancing measures.

DiscussionHome self-swabbing for RT-PCR based on a single swab, as implemented in REACT-1, has high overall sensitivity. However, participants time-since-infection, symptom status and viral lineage affect the probability of detection and the duration of positivity. These results validate previous efforts to estimate incidence of SARS-CoV-2 from swab-positivity data, and provide a reliable means to obtain community infection estimates to inform policy response.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.08.13.21261861,2021-08-13,https://medrxiv.org/cgi/content/short/2021.08.13.21261861,"Healthcare presentations with self-harm and the association with COVID-19: an e-cohort whole-population-based study using individual-level linked routine electronic health records in Wales, UK, 2016 - March 2021",Marcos del Pozo Banos; Sze Chim Lee; Yasmin Friedmann; Ashley Akbari; Fatemeh Tobari; Keith R Lloyd; Ronan A Lyons; Ann John,"Swansea University Medical School; Swansea University Medical School; Swansea University Medical School; Swansea University, Health Data Research UK; Swansea University Medical School; Swansea University Medical School; Swansea University, Health Data Research UK; Swansea University Medical School","BackgroundMulti-setting population-based studies on healthcare service presentations with self-harm covering the first 12 months of the COVID-19 pandemic are yet to be published.

AimsAscertain changes across settings in healthcare service presentations with self-harm during Waves 1 and 2 of the COVID-19 pandemic.

MethodE-cohort study using individual-level linked routine healthcare data from Wales, UK, 2016-March 2021. We measured weekly proportion of self-harm contacts and people who self-harmed in contact with general practice (GP), emergency department (ED) and hospital admissions. We modelled weekly trends using linear regression and generalised estimated equations, quantifying time differences using difference-in-difference (DiD).

ResultsWe included 3,552,210 Welsh residents aged [&ge;]10 years. Counts of self-harm presentations across settings was at a minimum at the start of stay-at-home restrictions during both waves and recovered compared to previous years in 3-5 months. Those who self-harmed in April 2020 were more likely to be seen in GP compared to other settings and previous years - mean rate of OR=1.2, although actual numbers fell. The proportion of self-harm ED contacts admitted to hospital dropped from June 2020 (1.9 [1.5-2.3] pp/month). Self-harm and COVID-19 infection had a bidirectional effect - self-harm history had OR=1.4 [1.2-1.6] and incidence had DiD=1.1 [0.8-1.4].

ConclusionsThose that self-harmed and sought help during the COVID-19 pandemic potentially encountered stringent criteria for hospitalisation, particularly in Wave 2, while in Wave 1 they preferentially presented to GP. Reductions in contacts likely resulted in unmet healthcare needs which may later emerge placing further burden on individuals and healthcare services.

Relevance statementThis study provides novel findings on how the COVID-19 pandemic and the measures taken to curb its spread affected self-harm healthcare service presentations. To our knowledge no other population-based studies in the UK have linked routinely collected general practice (GP), emergency department (ED) and hospital admission data covering Waves 1 and 2 of the pandemic.

Reductions in presentations with self-harm during the pandemic may be the result of those not requiring ED care or hospitalisation avoiding seeking help during the pandemic as often as before. Those that did seek help potentially encountered more stringent criteria for hospitalisation, particularly during Wave 2. This likely resulted in unmet healthcare needs which may later emerge placing further burden on individuals and healthcare services. Measures should be put in place to ensure that those who self-harm receive appropriate assessment and intervention.",health informatics,fuzzy,100,100
medRxiv,10.1101/2021.08.05.21259863,2021-08-07,https://medrxiv.org/cgi/content/short/2021.08.05.21259863,Recording of 'COVID-19 vaccine declined' among vaccination priority groups: a cohort study on 57.9 million NHS patients' primary care records in situ using OpenSAFELY,Helen J Curtis; Peter Inglesby; Brian MacKenna; Richard Croker; William J Hulme; Christopher T Rentsch; Krishnan Bhaskaran; Alex J Walker; Caroline E Morton; David Evans; Amir Mehrkar; Sebastian CJ Bacon; Christopher Bates; George Hickman; Tom Ward; Jessica Morley; Jonathan Cockburn; Simon Davy; Anna Schultze; Elizabeth J Williamson; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Rosalind M Eggo; Kevin Wing; Angel YS Wong; Harriet Forbes; John Tazare; John Parry; Frank Hester; Sam Harper; Shaun O'Hanlon; Alex Eavis; Richard Jarvis; Dima Avramov; Paul Griffiths; Aaron Fowles; Nasreen Parkes; Stephen JW Evans; Ian J Douglas; Liam Smeeth; Ben Goldacre,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; EMIS; EMIS; EMIS; EMIS; EMIS; EMIS; EMIS; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundAll patients in England within vaccine priority groups were offered a COVID-19 vaccine by mid-April 2021. Clinical record systems contain codes to denote when such an offer has been declined by a patient (although these can in some cases be entered for a variety of other reasons including vaccination delay, or other administrative issues). We set out to describe the patterns of usage of codes for COVID-19 vaccines being declined.

MethodsWith the approval of NHS England and using the full pseudonymised primary care records for 57.9 million NHS patients, we identified all patients in key vaccine priority groups: aged over 50, or over 16 and at increased risk from COVID-19 (Clinically Extremely Vulnerable [CEV] or otherwise ""at risk""). We describe the proportion of patients recorded as declining a COVID-19 vaccination for each priority group, and by other clinical and demographic factors; whether patients recorded as ""declined"" subsequently went on to receive a vaccination; and the distribution of code usage across GP practices.

ResultsOf 24.5 million patients in priority groups as of May 25th 2021, 89.2% had received a vaccine, 8.8% had neither a vaccination nor a decline recorded, and 663,033 (2.7%) had a decline code recorded. Of patients with a recorded decline, 125,587 (18.9%) were subsequently vaccinated. Subsequent vaccination was slightly more common in the South Asian population than other ethnicities (e.g. 32.3% vs 22.8%, over 65s). The proportion of declining-unvaccinated patients varied strongly with ethnicity (Black 15.3%, South Asian 5.6%, White 1.5% in over 80s); and was higher in patients from more deprived areas. COVID-19 vaccine decline codes were present in almost all practices (98.8%), but with wide variation between practices in rates of usage. Among all priority groups, declining-unvaccinated status was most common in CEV (3.3%).

ConclusionsClinical codes indicative of COVID-19 vaccinations being declined are widely used in English general practice. They are substantially more common among Black and South Asian patients, and patients from more deprived areas. There is a need for more detailed survey and/or qualitative research with patients and clinicians to determine the most common reasons for these recorded declines.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.07.29.21261190,2021-07-31,https://medrxiv.org/cgi/content/short/2021.07.29.21261190,Right Ventricular Dysfunction in Ventilated Patients with COVID-19 (COVID-RV),Philip McCall; Jennifer Willder; Bethany Stanley; Claudia-Martina Messow; John Allan; Lisa Gemmell; Alex Puxty; Dominic Strachan; Colin Berry; Ben Shelley; - The COVID-RV investigators.,"Anaesthesia, Critical Care & Peri-operative Medicine Research Group, University of Glasgow, Glasgow, UK.; West of Scotland School of Anaesthesia, NHS Education for Scotland, Glasgow, UK.; Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.; Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.; Intensive Care Unit, University Hospital Crosshouse, Kilmarnock, UK.; Intensive Care Unit, Royal Alexandra Hospital, Paisley, UK.; Intensive Care Unit, Glasgow Royal Infirmary, Glasgow, UK.; Intensive Care Unit, University Hospital Wishaw, Wishaw, UK.; Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK.; Anaesthesia, Critical Care & Peri-operative Medicine Research Group, University of Glasgow, UK.; ","PurposeCOVID-19 is associated with cardiovascular complications, with right ventricular dysfunction (RVD) commonly reported. The combination of acute respiratory distress syndrome (ARDS), injurious invasive ventilation, micro/macro thrombi and the potential for direct myocardial injury create conditions where RVD is likely to occur. No study has prospectively explored the prevalence of RVD, and its association with mortality, in a cohort requiring mechanical ventilation.

MethodsProspective, multi-centre, trans-thoracic echocardiographic, cohort study of ventilated patients with COVID-19 in Scottish intensive care units. RVD was defined as the presence of severe RV dilatation and interventricular septal flattening. To explore role of myocardial injury, high sensitivity troponin and N-terminal pro B-type natriuretic peptide (NT-proBNP) were measured in all patients.

ResultsOne hundred and twenty-one patients were recruited to COVID-RV, 118 underwent imaging and it was possible to determine the primary outcome in 112. RVD was present in seven (6.2% [95%CI; 2.5%, 12.5%]) patients. Thirty-day mortality was 85.7% in those with RVD, compared to 44.8% in those without (p=0.051). Patients with RVD were more likely to have; pulmonary thromboembolism (p<0.001), higher plateau pressure (p=0.048), lower dynamic compliance (p=0.031), higher NT-proBNP (p<0.006) and more frequent abnormal troponin (p=0.048). Abnormal NT-proBNP (OR 4.77 [1.22, 21.32], p=0.03) and abnormal Troponin (16.54 [4.98, 67.12], p<0.001) independently predicted 30-day mortality.

ConclusionCOVID-RV demonstrates a prevalence of RVD in ventilated patients with COVID-19 of 6.2% and is associated with a mortality of 85.7%. Association is observed between RVD and each of the aetiological domains of; ARDS, ventilation, micro/macro thrombi and myocardial injury.",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2021.07.27.21261031,2021-07-29,https://medrxiv.org/cgi/content/short/2021.07.27.21261031,Prognostic accuracy of triage tools for adults with suspected COVID-19 in a pre-hospital setting: an observational cohort study,Carl Marincowitz; Laura Sutton; Tony Stone; Richard Pilbery; Richard Campbell; Ben Thomas; Janette Turner; Peter Bath; Fiona Bell; Katie Biggs; Madina Hasan; Frank Hopfgartner; Suvodeep Mazumdar; Jennifer Petrie; Steve Goodacre,"(CURE), Health Services Research School of Health and Related Research, University of Sheffield; Clinical Trials Research Unit (CTRU), Health Services Research School of Health and Related Research, University of Sheffield; CURE, Health Services Research School of Health and Related Research, University of Sheffield; Yorkshire Ambulance Service NHS Trust; CURE, Health Services Research School of Health and Related Research, University of Sheffield; Clinical Trials Research Unit (CTRU), Health Services Research School of Health and Related Research, University of Sheffield; CURE, Health Services Research School of Health and Related Research, University of Sheffield; Information School, University of Sheffield; Yorkshire Ambulance Service NHS Trust; Clinical Trials Research Unit (CTRU), Health Services Research School of Health and Related Research, University of Sheffield; Information School, University of Sheffield; Information School, University of Sheffield; Information School, University of Sheffield; Clinical Trials Research Unit (CTRU), Health Services Research School of Health and Related Research, University of Sheffield; CURE, Health Services Research School of Health and Related Research, University of Sheffield","Study ObjectiveTools proposed to triage patient acuity in COVID-19 infection have only been validated in hospital populations. We estimated the accuracy of five risk-stratification tools recommended to predict severe illness and compare accuracy to existing clinical decision-making in a pre-hospital setting.

MethodsAn observational cohort study using linked ambulance service data for patients attended by EMS crews in the Yorkshire and Humber region of England between 18th March 2020 and 29th June 2020 was conducted to assess performance of the PRIEST tool, NEWS2, the WHO algorithm, CRB-65 and PMEWS in patients with suspected COVID-19 infection. The primary outcome was death or need for organ support.

ResultsOf 7549 patients in our cohort, 17.6% (95% CI:16.8% to 18.5%) experienced the primary outcome. The NEWS2, PMEWS, PRIEST tool and WHO algorithm identified patients at risk of adverse outcomes with a high sensitivity (>0.95) and specificity ranging from 0.3 (NEWS2) to 0.41 (PRIEST tool). The high sensitivity of NEWS2 and PMEWS was achieved by using lower thresholds than previously recommended. On index assessment, 65% of patients were transported to hospital and EMS decision to transfer patients achieved a sensitivity of 0.84 (95% CI 0.83 to 0.85) and specificity of 0.39 (95% CI 0.39 to 0.40).

ConclusionUse of NEWS2, PMEWS, PRIEST tool and WHO algorithm could improve sensitivity of EMS triage of patients with suspected COVID-19 infection. Use of the PRIEST tool would improve sensitivity of triage without increasing the number of patients conveyed to hospital.",emergency medicine,fuzzy,100,100
medRxiv,10.1101/2021.07.26.21261140,2021-07-28,https://medrxiv.org/cgi/content/short/2021.07.26.21261140,Higher serological responses and increased vaccine effectiveness demonstrate the value of extended vaccine schedules in combatting COVID-19 in England,Gayatri Amirthalingam; Jamie Lopez Bernal; Nick J Andrews; Heather Whitaker; Charlotte Gower; Julia Stowe; Elise Tessier; Sathyavani Subbarao; Georgina Ireland; Frances Baawuah; Ezra Linley; Lenesha Warrener; Michelle O'Brien; Corinne Whillock; Paul Moss; Shamez N Ladhani; Kevin E Brown; Mary E Ramsay,Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Brondesbury Medical Centre; Public Health England; University of Birmingham; Public Health England; Public Health England; Public Health England,"IntroductionIn January 2021, the UK decided to prioritise the delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval until the second dose up to 12 weeks.

MethodsSerological responses were compared after BNT162b2 and AZD1222 vaccination with varying intervals in uninfected and previously-infected adults aged 50-89 years. These findings are evaluated against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England.

ResultsWe recruited 750 participants aged 50-89 years, including 126 (16.8%) with evidence of previous infection; 421 received BNT162b2 and 329 and AZD1222. For both vaccines, over 95% had seroconverted 35-55 days after dose one, and 100% seroconverted 7+ days after dose 2. Following a 65-84 day interval between two doses, geometric mean titres (GMTs) at 14-34 days were 6-fold higher for BNT162b2 (6703; 95%CI, 5887-7633) than AZD1222 (1093; 806-1483), which in turn were higher than those receiving BNT162b2 19-29 days apart (694; 540 - 893). For both vaccines, VE was higher across all age-groups from 14 days after dose two compared to one dose, but the magnitude varied with interval between doses. Higher two-dose VE was observed with >6 week intervals between BNT162b2 doses compared to the authorised 3-week schedule, including [&ge;]80 year-olds.

ConclusionOur findings support the UK approach of prioritising the first dose of COVID-19 vaccines, with evidence of higher protection following extended schedules. Given global vaccine constraints, these results are relevant to policymakers, especially with highly transmissible variants and rising incidence in many countries.

FundingPublic Health England",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.07.23.21260992,2021-07-25,https://medrxiv.org/cgi/content/short/2021.07.23.21260992,A cluster randomised trial of the impact of a policy of daily testing for contacts of COVID-19 cases on attendance and COVID-19 transmission in English secondary schools and colleges,Bernadette C Young; David W Eyre; Saroj Kendrick; Chris White; Sylvester Smith; George Beveridge; Toby Nonnenmacher; Fegor Ichofu; Joseph Hillier; Ian Diamond; Emma Rourke; Fiona Dawe; Ieuan Day; Lisa Davies; Paul Staite; Andrea Lacey; James McCrae; Ffion Jones; Joseph Kelly; Urszula Bankiewicz; Sarah Tunkel; Richard Ovens; David Chapman; Peter Marks; Nick Hicks; Tom Fowler; Susan Hopkins; Lucy Yardley; Tim EA Peto,"University of Oxford; University of Oxford; Department of Health and Social Care, UK Government; Department of Health and Social Care, UK Government; Department of Health and Social Care, UK Government; Department of Health and Social Care, UK Government; Department of Health and Social Care, UK Government; Department of Health and Social Care, UK Government; Department of Health and Social Care, UK Government; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Department of Health and Social Care, UK Government; Deloitte MCS limited; Deloitte MCS limited; Department of Health and Social Care, UK Government; Department of Health and Social Care, UK Government; Department of Health and Social Care, UK Government; Public Health England; University of Bristol; University of Oxford","BackgroundSchool-based COVID-19 contacts in England are asked to self-isolate at home. However, this has led to large numbers of missed school days. Therefore, we trialled daily testing of contacts as an alternative, to investigate if it would affect transmission in schools.

MethodsWe performed an open-label cluster randomised controlled trial in students and staff from secondary schools and further education colleges in England (ISRCTN18100261). Schools were randomised to self-isolation of COVID-19 contacts for 10 days (control) or to voluntary daily lateral flow device (LFD) testing for school contacts with LFD-negative contacts remaining at school (intervention). Household contacts were excluded from participation.

Co-primary outcomes in all students and staff were symptomatic COVID-19, adjusted for community case rates, to estimate within-school transmission (non-inferiority margin: <50% relative increase), and COVID-19-related school absence. Analyses were performed on an intention to treat (ITT) basis using quasi-Poisson regression, also estimating complier average causal effects (CACE). Secondary outcomes included participation rates, PCR results in contacts and performance characteristics of LFDs vs. PCR.

FindingsOf 99 control and 102 intervention schools, 76 and 86 actively participated (19-April-2021 to 27-June-2021); additional national data allowed most non-participating schools to be included in the co-primary outcomes. 2432/5763(42.4%) intervention arm contacts participated. There were 657 symptomatic PCR-confirmed infections during 7,782,537 days-at-risk (59.1/100k/week) and 740 during 8,379,749 days-at-risk (61.8/100k/week) in the control and intervention arms respectively (ITT adjusted incidence rate ratio, aIRR=0.96 [95%CI 0.75-1.22;p=0.72]) (CACE-aIRR=0.86 [0.55-1.34]). There were 55,718 COVID-related absences during 3,092,515 person-school-days (1.8%) and 48,609 during 3,305,403 person-school-days(1.5%) in the control and intervention arms (ITT-aIRR=0.80 [95%CI 0.53-1.21;p=0.29]) (CACE-aIRR 0.61 [0.30-1.23]). 14/886(1.6%) control contacts providing an asymptomatic PCR sample tested positive compared to 44/2981(1.5%) intervention contacts (adjusted odds ratio, aOR=0.73 [95%CI 0.33-1.61;p=0.44]). Rates of symptomatic infection in contacts were 44/4665(0.9%) and 79/5955(1.3%), respectively (aOR=1.21 [0.82-1.79;p=0.34]).

InterpretationDaily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission. COVID-19 rates in school-based contacts in both intervention and control groups were <2%. Daily contact testing is a safe alternative to home isolation following school-based exposures.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.07.22.21260416,2021-07-23,https://medrxiv.org/cgi/content/short/2021.07.22.21260416,"Obesity, Ethnicity, and Covid-19 Mortality: A population-based cohort study of 12.6 Million Adults in England",Thomas Yates; Annabel Summerfield; Cameron Razieh; Amitava Banerjee; Yogini Chudasama; Melanie J Davies; Clare Gillies; Nazrul Islam; Claire Lawson; Evgeny Mirkes; Francesco Zaccardi; Kamlesh Khunti; Vahe Nafilyan,University of Leicester; Office for National Statistics; University of Leicester; University College London; University of Leicester; University of Leicester; University of Leicester; University of Oxford; University of Leicester; University of Leicester; University of Leicester; University of Leicester; Office for National Statistics,"ImportanceObesity and ethnicity are well characterised risk factors for severe COVID-19 outcomes, but the differential effects of obesity on COVID-19 outcomes by race/ethnicity has not been examined robustly in the general population.

ObjectiveTo investigate the association between body mass index (BMI) and COVID-19 mortality across different ethnic groups.

Design, Setting, and ParticipantsThis is a retrospective cohort study using linked national Census, electronic health records and mortality data for English adults aged 40 years or older who were alive at the start of pandemic (24th January 2020).

ExposuresBMI obtained from electronic health records. Self-reported ethnicity (white, black, South Asian, other) was the effect-modifying variable.

Main Outcomes and MeasuresCOVID-19 related death identified by ICD-10 codes U07.1 or U07.2 mentioned on the death certificate from 24th January 2020 until December 28th 2020.

ResultsThe analysis included white (n = 11,074,708; mean age 61.9 [{+/-}13.4] years; 54% women), black (n = 416,542; 56.4 [{+/-}11.7] years; 57% women), South Asian (621,691; 55.7 [{+/-}12.4] years; 51% women) and other (n = 478,196; 55.3 [{+/-}11.6] years; 55% women) ethnicities with linked BMI data. The association between BMI and COVID-19 mortality was stronger in ethnic minority groups. Compared to a BMI of 22.5 kg/m2 in white ethnicities, the adjusted HR for COVID-19 mortality at a BMI of 30 kg/m2 in white, black, South Asian and other ethnicities was 0.95 (95% CI: 0.87-1.03), 1.72 (1.52-1.94), 2.00 (1.78-2.25) and 1.39 (1.21-1.61), respectively. The estimated risk of COVID-19 mortality at a BMI of 40 kg/m2 in white ethnicities (HR = 1.73) was equivalent to the risk observed at a BMI of 30.1 kg/m2, 27.0 kg/m2, and 32.2 kg/m2 in black, South Asian and other ethnic groups, respectively.

ConclusionsThis population-based study using linked Census and electronic health care records demonstrates that the risk of COVID-19 mortality associated with obesity is greater in ethnic minority groups compared to white populations.

QuestionDoes the association between BMI and COVID-19 mortality vary by ethnicity?

FindingsIn this study of 12.6 million adults, BMI was associated with COVID-19 in all ethnicities, but with stronger associations in ethnic minority populations such that the risk of COVID-19 mortality for a BMI of 40 kg/m2 in white ethnicities was observed at a BMI of 30.1 kg/m2, 27.0 kg/m2, and 32.2 kg/m2 in black, South Asian and other ethnicities, respectively.

MeaningBMI is a stronger risk factor for COVID-19 mortality in ethnic minorities. Obesity management is therefore a priority in these populations.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.07.20.21260558,2021-07-22,https://medrxiv.org/cgi/content/short/2021.07.20.21260558,Intentions to participate in cervical and colorectal cancer screening during the COVID-19 pandemic: a mixed-methods study,Rebecca Wilson; Harriet Quinn-Scoggins; Yvonne Moriarty; Jacqueline Hughes; Mark Goddard; Rebecca Cannings-John; Victoria Whitelock; Katriina L Whitaker; Detelina Grozeva; Julia Townson; Kirstie Osborne; Stephanie Smits; Michael Robling; Julie Hepburn; Graham Moore; Ardiana Gjini; Kate Brain; Jo Waller,"Cardiff University; Cardiff University; Cardiff University; Cardiff University; Cardiff University; Cardiff University; Cancer Research UK; University of Surrey; Cardiff University; Cardiff University; Cancer Research UK; Cardiff University; Cardiff University; Public Involvement Community, Health and Care Research Wales; Cardiff University; Public Health Wales; Cardiff University; Kings College London","Worldwide, cancer screening faced significant disruption in 2020 due to the COVID-19 pandemic. If this has led to changes in public attitudes towards screening and reduced intention to participate, there is a risk of long-term adverse impact on cancer outcomes. In this study, we examined previous participation and future intentions to take part in cervical and colorectal cancer (CRC) screening following the first national lockdown in the UK.

Overall, 7543 adults were recruited to a cross-sectional online survey in August-September 2020. Logistic regression analyses were used to identify correlates of strong screening intentions among 2,319 participants eligible for cervical screening and 2,502 eligible for home-based CRC screening. Qualitative interviews were conducted with a sub-sample of 30 participants. Verbatim transcripts were analysed thematically.

Of those eligible, 74% of survey participants intended to attend cervical screening and 84% intended to complete home-based CRC screening when next invited. Thirty percent and 19% of the cervical and CRC samples respectively said they were less likely to attend a cancer screening appointment now than before the pandemic. Previous non-participation was the strongest predictor of low intentions for cervical (aOR 26.31, 95% CI: 17.61-39.30) and CRC (aOR 67.68, 95% CI: 33.91-135.06) screening. Interview participants expressed concerns about visiting healthcare settings but were keen to participate when screening programmes resumed.

Intentions to participate in future screening were high and strongly associated with previous engagement in both programmes. As screening services recover, it will be important to monitor participation and to ensure people feel safe to attend.",oncology,fuzzy,100,98
medRxiv,10.1101/2021.07.19.21260782,2021-07-22,https://medrxiv.org/cgi/content/short/2021.07.19.21260782,Does COVID-19 vaccination improve mental health? A difference-in-difference analysis of the UnderstandingCoronavirus in America study,Jonathan Koltai; Julia Raifman; Jacob Bor; Martin McKee; David Stuckler,University of New Hampshire; Boston University; Boston University; London School of Hygiene and Tropical Medicine; Bocconi University,"BackgroundMental health problems increased during the COVID-19 pandemic. Knowledge that one is less at risk after being vaccinated may alleviate distress, but this hypothesis remains unexplored. Here we test whether psychological distress declined in those vaccinated against COVID-19 in the US and whether changes in perceived risk mediated any association.

MethodsA nationally-representative cohort of U.S. adults (N=5,792) in the Understanding America Study were interviewed every two weeks from March 2020 to June 2021 (28 waves). Difference-in-difference regression tested whether getting vaccinated reduced distress (PHQ-4 scores), with mediation analysis used to identify potential mechanisms, including perceived risks of infection, hospitalization, and death.

ResultsVaccination was associated with a 0.09 decline in distress scores (95% CI:-0.15 to -0.04) (0-12 scale), a 5.7% relative decrease compared to mean scores in the wave prior to vaccination. Vaccination was also associated with an 8.44 percentage point reduction in perceived risk of infection (95% CI:-9.15% to -7.73%), a 7.44-point reduction in perceived risk of hospitalization (95% CI:-8.07% to -6.82%), and a 5.03-point reduction in perceived risk of death (95% CI:-5.57% to -4.49%). Adjusting for risk perceptions decreased the vaccination-distress association by two-thirds. Event study models suggest vaccinated and never vaccinated respondents followed similar PHQ-4 trends pre-vaccination, diverging significantly post-vaccination. Analyses were robust to individual and wave fixed effects, time-varying controls, and several alternative modelling strategies. Results were similar across sociodemographic groups.

ConclusionReceiving a COVID-19 vaccination was associated with declines in distress and perceived risks of infection, hospitalization, and death. Vaccination campaigns could promote these additional benefits of being vaccinated.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.07.21.21260906,2021-07-22,https://medrxiv.org/cgi/content/short/2021.07.21.21260906,Disentangling post-vaccination symptoms from early COVID-19,Liane S Canas; Marc F. Osterdahl; Jie Deng; Christina Hu; Somesh Selvachandran; Lorenzo Polidori; Anna May; Erika Molteni; Benjamin Murray; Liyuan Chen; Eric Kerfoot; Kerstin Klaser; Michela Antonelli; Alexander Hammers; Tim Spector; Sebastien Ourselin; Claire J. Steves; Carole H. Sudre; Marc Modat; Emma L. Duncan,"School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; ZOE Limited, London, UK; ZOE Limited, London, UK; ZOE Limited, London, UK; ZOE Limited, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK;  King's College London & Guy's and St Thomas' PET Centre, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK.; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK.; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; Medical Research Council Unit for Lifelong Health and Ageing, Departme; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK.","BackgroundIdentifying and testing individuals likely to have SARS-CoV-2 is critical for infection control, including post-vaccination. Vaccination is a major public health strategy to reduce SARS-CoV-2 infection globally. Some individuals experience systemic symptoms post-vaccination, which overlap with COVID-19 symptoms. This study compared early post-vaccination symptoms in individuals who subsequently tested positive or negative for SARS-CoV-2, using data from the COVID Symptom Study (CSS) app.

DesignWe conducted a prospective observational study in UK CSS participants who were asymptomatic when vaccinated with Pfizer-BioNTech mRNA vaccine (BNT162b2) or Oxford-AstraZeneca adenovirus-vectored vaccine (ChAdOx1 nCoV-19) between 8 December 2020 and 17 May 2021, who subsequently reported symptoms within seven days (other than local symptoms at injection site) and were tested for SARS-CoV-2, aiming to differentiate vaccination side-effects per se from superimposed SARS-CoV-2 infection. The post-vaccination symptoms and SARS-CoV-2 test results were contemporaneously logged by participants. Demographic and clinical information (including comorbidities) were also recorded. Symptom profiles in individuals testing positive were compared with a 1:1 matched population testing negative, including using machine learning and multiple models including UK testing criteria.

FindingsDifferentiating post-vaccination side-effects alone from early COVID-19 was challenging, with a sensitivity in identification of individuals testing positive of 0.6 at best. A majority of these individuals did not have fever, persistent cough, or anosmia/dysosmia, requisite symptoms for accessing UK testing; and many only had systemic symptoms commonly seen post-vaccination in individuals negative for SARS-CoV-2 (headache, myalgia, and fatigue).

InterpretationPost-vaccination side-effects per se cannot be differentiated from COVID-19 with clinical robustness, either using symptom profiles or machine-derived models. Individuals presenting with systemic symptoms post-vaccination should be tested for SARS-CoV-2, to prevent community spread.

FundingZoe Limited, UK Government Department of Health and Social Care, Wellcome Trust, UK Engineering and Physical Sciences Research Council, UK National Institute for Health Research, UK Medical Research Council and British Heart Foundation, Alzheimers Society, Chronic Disease Research Foundation, Massachusetts Consortium on Pathogen Readiness (MassCPR).

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSThere are now multiple surveillance platforms internationally interrogating COVID-19 and/or post-vaccination side-effects. We designed a study to examine for differences between vaccination side-effects and early symptoms of COVID-19. We searched PubMed for peer-reviewed articles published between 1 January 2020 and 21 June 2021, using keywords: ""COVID-19"" AND ""Vaccination"" AND (""mobile application"" OR ""web tool"" OR ""digital survey"" OR ""early detection"" OR ""Self-reported symptoms"" OR ""side-effects""). Of 185 results, 25 studies attempted to differentiate symptoms of COVID-19 vs. post-vaccination side-effects; however, none used artificial intelligence (AI) technologies (""machine learning"") coupled with real-time data collection that also included comprehensive and systematic symptom assessment. Additionally, none of these studies attempt to discriminate the early signs of infection from side-effects of vaccination (specifically here: Pfizer-BioNTech mRNA vaccine (BNT162b2) and Oxford-AstraZeneca adenovirus-vectored vaccine (ChAdOx1 nCoV-19)). Further, none of these studies sought to provide comparisons with current testing criteria used by healthcare services.

Added value of this studyThis study, in a uniquely large community-based cohort, uses prospective data capture in a novel effort to identify individuals with COVID-19 in the immediate post-vaccination period. Our results show that early symptoms of SARS-CoV-2 cannot be differentiated from vaccination side-effects robustly. Thus, post-vaccination systemic symptoms should not be ignored, and testing should be considered to prevent COVID-19 dissemination by vaccinated individuals.

Implications of all the available evidenceOur study demonstrates the critical importance of testing symptomatic individuals - even if vaccinated - to ensure early detection of SARS-CoV-2 infection, helping to prevent future pandemic waves in the UK and elsewhere.",respiratory medicine,fuzzy,100,100
medRxiv,10.1101/2021.07.19.21260770,2021-07-22,https://medrxiv.org/cgi/content/short/2021.07.19.21260770,Uptake of infant and pre-school immunisations in Scotland and England during the COVID-19 pandemic: an observational study of routinely collected data,Fiona McQuaid; Rachel Mulholland; Yuma Sangpang Rai; Utkarsh Agrawal; Helen Bedford; Claire Cameron; Cheryl Gibbon; Partho Roy; Aziz Sheikh; Ting Shi; Colin Simpson; Judith Tait; Elise Tessier; Steve Turner; Jaime Villacampa Ortega; Joanne White; Rachael Wood,University of Edinburgh; University of Edinburgh; Public Health England; University of St Andrews; UCL Great Ormond Street Institute of Child Health; Public Health Scotland; Public Health Scotland; Public Health England; University of Edinburgh; University of Edinburgh; Victoria University of Wellington; Public Health Scotland; Public Health England; University of Aberdeen; Public Health Scotland; Public Health England; University of Edinburgh,"BackgroundIn 2020, the COVID-19 pandemic and control measures such as national lockdowns threatened to disrupt routine childhood immunisation programmes. Initial reports from the early weeks of lockdown in the UK and worldwide suggested that uptake could fall putting children at risk from multiple other infectious diseases. In Scotland and England, enhanced surveillance of national data for childhood immunisations was established to inform and rapidly assess the impact of the pandemic on infant and preschool immunisation uptake rates.

Methods and findingsWe undertook an observational study using routinely collected data for the year prior to the pandemic (2019), and immediately before, during and after the first period of the UK  lockdown in 2020. Data were obtained for Scotland from the Public Health Scotland ""COVID19 wider impacts on the health care system"" dashboard (https://scotland.shinyapps.io/phs-covid-wider-impact/) and for England from ImmForm.

Five vaccinations delivered at different ages were evaluated; three doses of the  6-in-1 DTaP/IPV/Hib/HepB vaccine and two doses of MMR. Uptake in the periods in 2020 compared to that in the baseline year of 2019 using binary logistic regression analysis. For Scotland, we analysed timely uptake of immunisations, defined as uptake within four weeks of the child becoming eligible by age for each immunisation and data were also analysed by geographical region and indices of deprivation. For both Scotland and England, we assessed whether immunisations were up to date at approximately 6 months (all doses 6-in-1) and 16-18 months (first MMR) of age.

We found that uptake rates within four weeks of eligibility in Scotland for all the five vaccine visits were higher during the 2020 lockdown period than in 2019. The difference ranged from 1.3% for the first dose of the 6-in-1 vaccine (95.3 vs 94%, OR 1.28, CI 1.18-1.39) to 14.3% for the second MMR dose (66.1 vs 51.8 %, OR 1.8, CI 1.74-1.87). Significant increases in uptake were seen across all deprivation levels, though, for MMR, there was evidence of greater improvement for children living in the least deprived areas.

In England, fewer children who had been due to receive their immunisations during the lockdown period were up to date at 6 months (6-in-1) or 18 months (first dose MMR). The fall in percentage uptake ranged from 0.5% for first 6-in1 (95.8 vs 96.3%, OR 0.89, CI 0.86-0.91) to 2.1% for third 6-in-1 (86.6 vs 88.7%, OR 0.82, CI 0.81-0.83).

ConclusionsThis study suggests that the national lockdown in Scotland was associated with a positive effect on timely childhood immunisation uptake, however in England a lower percentage of children were up to date at 6 and 18 months. Reason for the improve uptake in Scotland may include active measures taken to promote immunisation at local and national level during this period. Promoting immunisation uptake and addressing potential vaccine hesitancy is particularly important given the ongoing pandemic and COVID-19 vaccination campaigns.",pediatrics,fuzzy,100,100
medRxiv,10.1101/2021.07.21.21260926,2021-07-22,https://medrxiv.org/cgi/content/short/2021.07.21.21260926,"Increasing SARS-CoV-2 antibody prevalence in England at the start of the second wave: REACT-2 Round 4 cross-sectional study in 160,000 adults",Helen Ward; Christina J Atchison; Matt Whitaker; Christl A. Donnelly; Steven Riley; Deborah Ashby; Ara Darzi; Wendy Barclay; Graham Cooke; Paul Elliott,"School of Public Health, Imperial College London; School of Public Health, Imperial College London; School of Public Health, Imperial College London; School of Public Health, Imperial College London; School of Public Health, Imperial College London; School of Public Health, Imperial College London; Institute of Global Health Innovation, Imperial College London; Department of Infectious Disease, Imperial College London; Department of Infectious Disease, Imperial College London; School of Public Health, Imperial College London","BackgroundREACT-2 Study 5 is a population survey of the prevalence of SARS-CoV-2 antibodies in the community in England.

MethodsWe contacted a random sample of the population by sending a letter to named individuals aged 18 or over from the NHS GP registrations list. We then sent respondents a lateral flow immunoassay (LFIA) kit for SARS-CoV-2 antibody self-testing and asked them to perform the test at home and complete a questionnaire, including reporting of their test result. Overall, 161,537 adults completed questionnaires and self-administered LFIA tests for IgG against SARS-CoV-2 between 27 October and 10 November 2020.

ResultsThe overall adjusted and weighted prevalence was 5.6% (95% CI 5.4-5.7). This was an increase from 4.4% (4.3-4.5) in round 3 (September), a relative increase of 26.9% (24.0-29.9).The largest increase by age was in the 18 to 24 year old age group, which increased (adjusted and weighted) from 6.7% (6.3-7.2) to 9.9% (9.3-10.4), and in students, (adjusted, unweighted) from 5.9% (4.8-7.1) to 12.1% (10.8-13.5). Prevalence increased most in Yorkshire and The Humber, from 3.4% (3.0-3.8) to 6.3% (5.9-6.8) and the North West from 4.5% (4.2-4.9) to 7.7% (7.2-8.1). In contrast, the prevalence in London was stable, at 9.5% (9.0-9.9) and 9.5% (9.1-10.0) in rounds 3 and 4 respectively. We found the highest prevalence in people of Bangladeshi 15.1% (10.9-20.5), Pakistani 13.9% (11.2-17.2) and African 13.5% (10.7-16.8) ethnicity, and lowest in those of white British ethnicity at 4.2% (4.0-4.3).

InterpretationThe second wave of infection in England is apparent in increasing antibody prevalence, particularly in younger people, students, and in the Northern Regions. By late October a large proportion of the population remained susceptible to SARS-CoV-2 infection in England based on naturally acquired immunity from the first and early second wave.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.07.16.21260651,2021-07-20,https://medrxiv.org/cgi/content/short/2021.07.16.21260651,Evaluating discharges and readmissions using a COVID Virtual Ward model: a retrospective data study assessing patient outcomes and the likely staffing commitment,Suzy Gallier; Catherine Atkin; Vinay Reddy-Kolanu; Dhruv Parekh; Xiaoxu Zou; felicity Evison; Simon Ball; Elizabeth Sapey,University Hospitals Birmingham NHS Foundation Trust; University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University of Birmingham,"BackgroundCOVID-19 has placed a catastrophic burden on acute hospitals. In an attempt to reduce admissions and enable safe early discharge, a COVID virtual ward (CVW) care pathway has been supported by NHS England. This includes discharging people who meet objective criteria based on acuity scores and oxygen saturations, with pulse oximeters and daily phone calls for up to 14 days. Observational studies have reported the safety of this system, but without describing the outcomes from usual care.

MethodsA retrospective study using routinely collected health data from all adults with a confirmed positive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) swab result between 1st June 2020 and 31st Jan 2021 who attended the Emergency Department or Acute Medical Unit at QEHB, which does not have a CVW service. Criteria for CVW were applied using data from the first 24 hours of presentation to hospital and subsequent health outcomes were included for 28 days, including re-presentation, re-admission, ITU escalation and death. Results were compared to reported studies based in secondary care.

ResultsDuring the study period, 26,127 patients presented to QEHB hospital. 2301 had a positive SARS-CoV-2 swab. Of these, 1730 (75.2%) did not meet the criteria for the CVW and 571 (24.8%) did. Of the 571, 325 (56.9%) were discharged home within 24 hours and 246 (43.1%) were admitted for 24 hours or longer. Those admitted were older, with increased co-morbidities, 80.9% required hospital-supported acute therapies after the first 24 hours and 10.6% died. Of the 325 discharged, 44 were readmitted (13.5%), 30 (9.2%) with COVID-related symptoms, 5 (1.5%) required ITU and 1 patient (0.3%) died. These results were comparable to published studies with a CVW service.

DiscussionIn the current study, discharging patients without a CVW did not confer a greater risk of re-presentation, re-admission, ITU escalation or death. The majority of patients who remained in hospital despite meeting the CVW criteria did so for the provision of treatments or acute assessments. It remains uncertain whether a CVW delivers improvements in hard outcomes, and further research is needed.",respiratory medicine,fuzzy,100,100
medRxiv,10.1101/2021.07.16.21260628,2021-07-19,https://medrxiv.org/cgi/content/short/2021.07.16.21260628,"Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: cohort study in OpenSAFELY using linked primary care, secondary care and death registration data",Krishnan Bhaskaran; Christopher T Rentsch; George Hickman; William J Hulme; Anna Schultze; Helen J Curtis; Kevin Wing; Charlotte Warren-Gash; Laurie Tomlinson; Christopher Bates; Rohini Mathur; Brian MacKenna; Viyaasan Mahalingasivam; Angel YS Wong; Alex J Walker; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Sebastian CJ Bacon; Liam Smeeth; Ben Goldacre,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundThere is concern about medium to long-term adverse outcomes following acute COVID-19, but little relevant evidence exists. We aimed to investigate whether risks of hospital admission and death, overall and by specific cause, are raised following discharge from a COVID-19 hospitalisation.

Methods and FindingsWorking on behalf of NHS-England, we used linked primary care and hospital data in OpenSAFELY to compare risks of hospital admission and death, overall and by specific cause, between people discharged from COVID-19 hospitalisation (February-December 2020), and (i) demographically-matched controls from the 2019 general population; (ii) people discharged from influenza hospitalisation in 2017-19. We used Cox regression adjusted for personal and clinical characteristics.

24,673 post-discharge COVID-19 patients, 123,362 general population controls, and 16,058 influenza controls were followed for [&le;]315 days. Overall risk of hospitalisation or death (30968 events) was higher in the COVID-19 group than general population controls (adjusted-HR 2.23, 2.14-2.31) but similar to the influenza group (adjusted-HR 0.94, 0.91-0.98). All-cause mortality (7439 events) was highest in the COVID-19 group (adjusted-HR 4.97, 4.58-5.40 vs general population controls and 1.73, 1.60-1.87 vs influenza controls). Risks for cause-specific outcomes were higher in COVID-19 survivors than general population controls, and largely comparable between COVID-19 and influenza patients. However, COVID-19 patients were more likely than influenza patients to be readmitted/die due to their initial infection/other lower respiratory tract infection (adjusted-HR 1.37, 1.22-1.54), and to experience mental health or cognitive-related admission/death (adjusted-HR 1.36, 1.01-2.83); in particular, COVID-19 survivors with pre-existing dementia had higher risk of dementia death. One limitation of our study is that reasons for hospitalisation/death may have been misclassified in some cases due to inconsistent use of codes.

ConclusionsPeople discharged from a COVID-19 hospital admission had markedly higher risks for rehospitalisation and death than the general population, suggesting a substantial extra burden on healthcare. Most risks were similar to those observed after influenza hospitalisations; but COVID-19 patients had higher risks of all-cause mortality, readmissions/death due to the initial infection, and dementia death, highlighting the importance of post-discharge monitoring.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.07.13.21260425,2021-07-18,https://medrxiv.org/cgi/content/short/2021.07.13.21260425,Vaccine Confidence and Hesitancy at the start of COVID-19 vaccine deployment in the UK: An embedded mixed-methods study,Chrissy h Roberts; Hannah Brindle; Nina Trivedy Rogers; Rosalind M Eggo; Luisa Enria; Shelley Lees,"London School of Hygiene & Tropical Medicine (LSHTM); London School of Hygiene & Tropical Medicine; MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, United Kingdom; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London Schoolof Hygiene & Tropical Medicine","IntroductionApproval for the use of COVID-19 vaccines has been granted in a number of countries but there are concerns that vaccine uptake may be low amongst certain groups.

MethodsThis study used a mixed methods approach based on online survey and an embedded quantitative/qualitative design to explore perceptions and attitudes that were associated with intention to either accept or refuse offers of vaccination in different demographic groups during the early stages of the UKs mass COVID-19 vaccination programme (December 2020). Analysis used multivariate logistic regression, structural text modelling and anthropological assessments.

ResultsOf 4,535 respondents, 85% (n=3,859) were willing to have a COVID-19 vaccine. The rapidity of vaccine development and uncertainties about safety were common reasons for COVID-19 vaccine hesitancy. There was no evidence for the widespread influence of mis-information, although broader vaccine hesitancy was associated with intentions to refuse COVID-19 vaccines (OR 20.60, 95% CI 14.20-30.30, p<0.001). Low levels of trust in the decision-making (OR 1.63, 95% CI 1.08, 2.48, p=0.021) and truthfulness (OR 8.76, 95% CI 4.15-19.90, p<0.001) of the UK government were independently associated with higher odds of refusing COVID-19 vaccines. Compared to political centrists, conservatives and liberals were respectively more (OR 2.05, 95%CI 1.51-2.80, p<0.001) and less (OR 0.30, 95% CI 0.22-0.41, p<0.001) likely to refuse offered vaccines. Those who were willing to be vaccinated cited both personal and public protection as reasons, with some alluding to having a sense of collective responsibility.

ConclusionDominant narratives of COVID-19 vaccine hesitancy are misconceived as primarily being driven by misinformation. Key indicators of UK vaccine acceptance include prior behaviours, transparency of the scientific process of vaccine development, mistrust in science and leadership and individual political views. Vaccine programmes should leverage the sense of altruism, citizenship and collective responsibility that motivated many participants to get vaccinated.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.07.14.21260497,2021-07-18,https://medrxiv.org/cgi/content/short/2021.07.14.21260497,"Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study",Helen Ward; Matthew Whitaker; Sonja N Tang; Christina J Atchison; Ara Darzi; Christl A. Donnelly; Peter Diggle; Deborah Ashby; Steven Riley; Wendy S Barclay; Paul Elliott; Graham S Cooke,"Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Imperial College London; Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London School of Public Health; Imperial College","BackgroundThe programme to vaccinate adults in England has been rapidly implemented since it began in December 2020. The community prevalence of SARS-CoV-2 anti-spike protein antibodies provides an estimate of total cumulative response to natural infection and vaccination. We describe the distribution of SARS-CoV-2 IgG antibodies in adults in England in May 2021 at a time when approximately 7 in 10 adults had received at least one dose of vaccine.

MethodsSixth round of REACT-2 (REal-time Assessment of Community Transmission-2), a cross-sectional random community survey of adults in England, from 12 to 25 May 2021; 207,337 participants completed questionnaires and self-administered a lateral flow immunoassay test producing a positive or negative result.

ResultsVaccine coverage with one or more doses, weighted to the adult population in England, was 72.9% (95% confidence interval 72.7-73.0), varying by age from 25.1% (24.5-25.6) of those aged 18 to 24 years, to 99.2% (99.1-99.3) of those 75 years and older. In adjusted models, odds of vaccination were lower in men (odds ratio [OR] 0.89 [0.85-0.94]) than women, and in people of Black (0.41 [0.34-0.49]) compared to white ethnicity. There was higher vaccine coverage in the least deprived and highest income households. People who reported a history of COVID-19 were less likely to be vaccinated (OR 0.61 [0.55-0.67]). There was high coverage among health workers (OR 9.84 [8.79-11.02] and care workers (OR 4.17 [3.20-5.43]) compared to non-key workers, but lower in hospitality and retail workers (OR 0.73 [0.64-0.82] and 0.77 [0.70-0.85] respectively) after adjusting for age and key covariates.

The prevalence of antibodies (weighted to the adult population of England and adjusted for test characteristics) was 61.1% (95% CI 60.9-61.4), up from 6.6% (5.4-5.7) in round 4 (27 October to 10 November 2020) and 13.9% (13.7-14.1) in round 5 (26 January to 8 February 2021). Prevalence (adjusted and weighted) increased with age, from 35.8% (35.1-36.5) in those aged 18 to 24 years, to 95.3% (94.6-95.9) in people 75 and over. Antibodies were 30% less likely to be detected in men than women (adjusted OR 0.69, 0.68-0.70), and were higher in people of Asian (OR 1.67 [1.58-1.77]), Black (1.55 [1.41-1.69]), mixed 1.17 [1.06-1.29] and other (1.37 [1.23-1.51]) ethnicities compared with white ethnicity. Workers in hospitality (OR 0.69 [0.63-0.74]) and retail (0.71 [0.67-0.75]) were less likely to have antibodies.

Following two doses of Pfizer-BioNTech vaccine, antibody positivity (adjusted for test performance) was 100% (100-100) at all ages except 80 years and older when it was 97.8% (95.9-99.6). For AstraZeneca positivity was over 90% up to age 69, and then 89.2% (88.5-89.9) in 70-79 year olds and 83.6% (78.5-88.3) in those aged 80 and over. Following a single dose of Pfizer-BioNTech positivity ranged from 100.0% (91.1-100.0) in those aged 18-29 to 32.2% (18.2-51.1) in those aged 70-79 years. For AstraZeneca this was 72.2% (68.5-75.9) in the youngest and 46.2% (40.0-52.7) in the oldest age group.

DiscussionThe successful roll out of the vaccination programme in England has led to a high proportion of individuals having detectable antibodies, particularly in older age groups and those who have had two doses of vaccine. This is likely to be associated with high levels of protection from severe disease, and possibly from infection. Nonetheless, there remain some key groups with a lower prevalence of antibody, notably unvaccinated younger people, certain minority ethnic groups, those living in deprived areas and workers in some public facing employment. Obtaining improved rates of vaccination in these groups is essential to achieving high levels of protection against the virus through population immunity.

FundingDepartment of Health and Social Care in England.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.07.12.21260385,2021-07-16,https://medrxiv.org/cgi/content/short/2021.07.12.21260385,Estimating the effectiveness of first dose of COVID-19 vaccine against mortality in England: a quasi-experimental study,Charlotte Bermingham; Jasper Morgan; Daniel Ayoubkhani; Myer Glickman; Nazrul Islam; Aziz Sheikh; Jonathan Sterne; A. Sarah Walker; Vah√© Nafilyan,"Office for National Statistics, Newport, UK; Office for National Statistics, Newport, UK; Office for National Statistics, Newport, UK; Office for National Statistics, Newport, UK; Nuffield Department of Population Health, Big Data Institute, University of Oxford, Oxford, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; Health Data Research UK BREATHE Hub; Bristol Medical School, University of Bristol, UK; Nuffield department of Medicine, University of Oxford, Oxford, UK; Office for National Statistics, Newport, UK","BackgroundEstimating real-world vaccine effectiveness is vital to assess the impact of the vaccination programme on the pandemic and inform the ongoing policy response. However, estimating vaccine effectiveness using observational data is inherently challenging because of the non-randomised design and the potential for unmeasured confounding.

MethodsWe used a Regression Discontinuity Design (RDD) to estimate vaccine effectiveness against COVID-19 mortality in England, exploiting the discontinuity in vaccination rates resulting from the UKs age-based vaccination priority groups. We used the fact that people aged 80 or over were prioritised for the vaccine roll-out in the UK to compare the risk of COVID-19 and non-COVID-19 death in people aged 75-79 and 80-84.

FindingsThe prioritisation of vaccination of people aged 80 or above led to a large discrepancy in vaccination rates in people 80-84 compared to those 75-79 at the beginning of the vaccination campaign. We found a corresponding difference in COVID-19 mortality, but not in non-COVID-19 mortality, suggesting that our approach appropriately addresses the issue of unmeasured confounding factors. Our results suggest that the first vaccine dose reduced the risk of COVID-19 death by 52.6% (95% Cl 26.6-84.2) in those aged 80.

InterpretationsOur results support existing evidence that a first dose of a COVID-19 vaccine has a strong protective effect against COVID-19 mortality in older adults. The RDD estimate of vaccine effectiveness is comparable to previously published studies using different methods, suggesting that unmeasured confounding factors are unlikely to substantially bias these studies.

FundingOffice for National Statistics.

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed for studies reporting on the  real-world effectiveness of the COVID-19 vaccination on risk of death using terms such as ""COVID-19"", ""vaccine effectiveness"", ""mortality"" and ""death"". The relevant published studies on this topic report vaccine effectiveness estimates against risk of death ranging from 64.2% to 98.7%, for varying times post-vaccination. All of these are observational studies and therefore potentially subject to bias from unmeasured confounding. We found no studies that used a quasi-experimental method such as regression discontinuity design, which is not subject to bias from unmeasured confounding, to calculate the effectiveness of the COVID-19 vaccination on risk of COVID-19 death, or on other outcomes such as hospitalisation or infection.

Added value of this studyThe estimates of vaccine effectiveness based on observational data may be biased by unmeasured confounding. This study uses a regression discontinuity design to estimate vaccine effectiveness, exploiting the fact that the vaccination campaign in the UK was rolled out following age-based priority groups. This enables the calculation of an unbiased estimate of the effectiveness of the COVID-19 vaccine against risk of death.

The vaccine effectiveness estimate of 52.6% (95% Cl 26.6-84.2) is slightly lower but similar to previously published estimates, therefore suggesting that these estimates are not substantially affected by unmeasured confounding factors and confirming the effectiveness of the COVID-19 vaccine against risk of COVID-19 death.

Implications of all the available evidenceObtaining an unbiased estimate of COVID-19 vaccine effectiveness is of vital importance in informing policy for lifting COVID-19 related measures. The regression discontinuity design provides confidence that the existing estimates from observational studies are unlikely to be substantially biased by unmeasured confounding.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.07.12.21260387,2021-07-16,https://medrxiv.org/cgi/content/short/2021.07.12.21260387,Lessons learned and lessons missed: Impact of the Covid-19 pandemic on all-cause mortality in 40 industrialised countries prior to mass vaccination,Vasilis Kontis; James E Bennett; Robbie M Parks; Theo Rashid; Jonathan Pearson-Stuttard; Perviz Asaria; Bin Zhou; Michel Guillot; Colin D Mathers; Young-Ho Khang; Martin McKee; Majid Ezzati,"MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK; MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK; The Earth Institute, Columbia University, New York, NY, USA, and Department of Environmental Health Sciences, Mailman School of Public Health, Columbia Universi; MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK; MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK; MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK; MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK; Population Studies Center, Department of Sociology, University of Pennsylvania, Philadelphia, PA, USA and French Institute for Demographic Studies (INED), Paris; Independent Researcher, Geneva, Switzerland; Institute of Health Policy and Management, Seoul National University, Seoul, Republic of Korea; Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK; MRC Centre for Environment and Health, School of Public Health, Imperial College London, London, UK and Regional Institute for Population Studies, University of","Industrialised countries have varied in their early response to the Covid-19 pandemic, and how they have adapted to new situations and knowledge since the pandemic began. These variations in preparedness and policy may lead to different death tolls from Covid-19 as well as from other diseases. We applied an ensemble of 16 Bayesian probabilistic models to vital statistics data to estimate the impacts of the pandemic on weekly all-cause mortality for 40 industrialised countries from mid-February 2020 through mid-February 2021, before a large segment of the population was vaccinated in any of these countries. Taken over the entire year, an estimated 1,401,900 (95% credible interval 1,259,700-1,572,500) more people died in these 40 countries than would have been expected had the pandemic not taken place. This is equivalent to 140 (126-157) additional deaths per 100,000 people and a 15% (13-17) increase in deaths over this period in all of these countries combined. In Iceland, Australia and New Zealand, mortality was lower over this period than what would be expected if the pandemic had not occurred, while South Korea and Norway experienced no detectable change in mortality. In contrast, the populations of the USA, Czechia, Slovakia and Poland experienced at least 20% higher mortality. There was substantial heterogeneity across countries in the dynamics of excess mortality. The first wave of the pandemic, from mid-February to the end of May 2020, accounted for over half of excess deaths in Scotland, Spain, England and Wales, Canada, Sweden, Belgium and Netherlands. At the other extreme, the period between mid-September 2020 and mid-February 2021 accounted for over 90% of excess deaths in Bulgaria, Croatia, Czechia, Hungary, Latvia, Montenegro, Poland, Slovakia and Slovenia. Until the great majority of national and global populations have vaccine-acquired immunity, minimising the death toll of the pandemic from Covid-19 and other diseases will remain dependent on actions to delay and contain infections and continue routine health and social care.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.07.13.21260444,2021-07-16,https://medrxiv.org/cgi/content/short/2021.07.13.21260444,Adoption and continued use of mobile contact tracing technology: Multilevel explanations from a three-wave panel survey and linked data,Laszlo Horvath; Susan Banducci; Joshua Blamire; Cathrine Degnen; Oliver James; Andrew Jones; Daniel Stevens; Katharine Tyler,"University of Exeter; University of Exeter; University of Exeter; Newcastle University, UK; University of Exeter; University of Exeter; University of Exeter; University of Exeter","ObjectiveTo identify the key individual-level (demographics, attitudes, mobility) and contextual (Covid-19 case numbers, tiers of mobility restrictions, urban districts) determinants of adopting the NHS Covid-19 contact tracing app and continued use over-time.

Design and settingA three-wave panel survey conducted in England in July 2020 (background survey), November 2020 (first measure of mobile app adoption), and March 2021 (continued use of app and new adopters) linked with official data.

Primary outcomeRepeated measures of self-reported app usage.

ParticipantsN = 2,500 adults living in England, representative of Englands population in terms of regional distribution, age, and gender (2011 census).

ResultsWe observe initial app uptake at 41%, 95% CI [0.39,0.43], in November 2020 with a 12% dropout rate by March 2021, 95% CI [0.10,0.14]. We also found that 7% of nonusers as of wave 2 became new adopters by wave 3, 95% CI [0.05,0.08]. Initial uptake (or failure to use) of the app associated with social norms, privacy concerns, and misinformation about third-party data access, with those living in postal districts with restrictions on mobility less likely to use the app. Perceived lack of transparent evidence of effectiveness was associated with drop out of use. In addition, those who trusted the government were more likely to adopt in wave 3 as new adopters.

ConclusionsSuccessful uptake of the contact tracing app should be evaluated within the wider context of the UK Governments response to the crisis. Trust in government is key to adoption of the app in wave 3 while continued use is linked to perceptions of transparent evidence. Providing clear information to address privacy concerns could increase uptake, however, the disparities in continued use among ethnic minority participants needs further investigation as differences are not fully explained via attitudinal measures.

Article summaryO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LIOur data captures reported behaviour at two points to assess within-subject changes over time;
C_LIO_LIResults based on a large, nationally representative sample rather than the convenience, non-probability and/or limited-N samples of previous contact tracing studies;
C_LIO_LIIntegrating demographic/structural and attitudinal explanations relating to technology acceptance with questions adopted from the results of a deliberative poll;
C_LIO_LILimitation: studied population is England (see Section 2.3) where overall mobility is restricted in wave 3 during national lockdown, allowing for limited opportunities for app usage e.g. venue check-ins;
C_LIO_LIDrawing on our findings, an ethnic minority booster sample will in the future allow us to better understand inequalities across and within diverse ethnic populations.
C_LI",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.07.14.21260488,2021-07-16,https://medrxiv.org/cgi/content/short/2021.07.14.21260488,SARS-CoV-2 Antibody Lateral Flow Assay for antibody prevalence studies following vaccine roll out: a Diagnostic Accuracy Study,Alexandra H C Cann; Candice L Clarke; Jonathan C Brown; Tina Thomson; Maria Prendecki; Maya Moshe; Anjna Badhan; Paul Elliott; Ara Darzi; Steven Riley; Deborah Ashby; Michelle Willicombe; Peter Kelleher; Paul Randell; Helen Ward; Wendy Barclay; Graham Cooke,"Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health; Imperial College London; Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College Healthcare NHS Trust, UK; Imperial College London; Department of Infectious Disease, Imperial College London, UK; Imperial College London","BackgroundLateral flow immunoassays (LFIAs) have the potential to deliver affordable, large scale antibody testing and provide rapid results without the support of central laboratories. As part of the development of the REACT programme extensive evaluation of LFIA performance was undertaken with individuals following natural infection. Here we assess the performance of the selected LFIA to detect antibody responses in individuals who have received at least one dose of SARS-CoV-2 vaccine.

MethodsThis is a prospective diagnostic accuracy study.

SettingSampling was carried out at renal outpatient clinic and healthcare worker testing sites at Imperial College London NHS Trust. Laboratory analyses were performed across Imperial College London sites and university facilities.

ParticipantsTwo cohorts of patients were recruited; the first was a cohort of 108 renal transplant patients attending clinic following SARS-CoV-2 vaccine booster, the second cohort comprised 40 healthcare workers attending for first SARS-CoV-2 vaccination, and 21 day follow up. A total of 186 paired samples were collected.

InterventionsDuring the participants visit, capillary blood samples were analysed on LFIA device, while paired venous sampling was sent for serological assessment of antibodies to the spike protein (anti-S) antibodies. Anti-S IgG were detected using the Abbott Architect SARS-CoV-2 IgG Quant II CMIA.

Main outcome measuresThe accuracy of Fortress LFIA in detecting IgG antibodies to SARS-CoV-2 compared to anti-spike protein detection on Abbott Assay.

ResultsUsing the threshold value for positivity on serological testing of [&ge;]7.10 BAU/ml, the overall performance of the test produces an estimate of sensitivity of 91.94% (95% CI 85.67% to 96.06%) and specificity of 93.55% (95% CI 84.30% to 98.21%) using the Abbott assay as reference standard.

ConclusionsFortress LFIA performs well in the detection of antibody responses for intended purpose of population level surveys, but does not meet criteria for individual testing.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.07.09.21260271,2021-07-16,https://medrxiv.org/cgi/content/short/2021.07.09.21260271,Quantifying within-school SARS-CoV-2 transmission and the impact of lateral flow testing in secondary schools in England,Trystan Leng; Edward M Hill; Alex Holmes; Emma Southall; Robin N Thompson; Michael J Tildesley; Matt J Keeling; Louise Dyson,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"BackgroundTo control within-school SARS-CoV-2 transmission in England, secondary school pupils have been encouraged to participate in twice weekly mass testing via lateral flow device tests (LFTs) from 8th March 2021, to complement an isolation of close contacts policy in place since 31st August 2020. Strategies involving the isolation of close contacts can lead to high levels of absences, negatively impacting pupils.

MethodsWe fit a stochastic individual-based model of secondary schools to both community swab testing data and secondary school absences data. By simulating epidemics in secondary schools from 31st August 2020 until 21st May 2021, we quantify within-school transmission of SARS-CoV-2 in secondary schools in England, the impact of twice weekly mass testing on within-school transmission, and the potential impact of alternative strategies to the isolation of close contacts in reducing pupil absences.

FindingsThe within-school reproduction number, Rschool, has remained below 1 from 31st August 2020 until 21st May 2021. Twice weekly mass testing using LFTs have helped to control within-school transmission in secondary schools in England. A strategy of serial contact testing alongside mass testing substantially reduces absences compared to strategies involving isolating close contacts, with only a marginal increase in within-school transmission.

InterpretationSecondary school control strategies involving mass testing have the potential to control within-school transmission while substantially reducing absences compared to an isolation of close contacts policy.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.07.12.21260360,2021-07-15,https://medrxiv.org/cgi/content/short/2021.07.12.21260360,The impact of hypoxia on B cells in COVID-19,Prasanti Kotagiri; Federica Mescia; Aimee Hanson; Lorinda Turner; Laura Bergamaschi; Ana Penalver; Nathan Richoz; Stephen Moore; Brian Ortmann; Benjamin Dunmore; Helene Ruffieux; Michael Morgan; Zewen Kelvin Tuong; Rachael Bashford Rogers; Myra Hosmillo; Stephen Baker; Anne Elmer; Ian Goodfellow; Ravindra Gupta; Nathalie Kingston; Paul Lehner; Nicholas Matheson; Sylvia Richardson; Caroline Saunders; Michael Weekes; Berthold Gottgens; Mark Toshner; Christoph Hess; Patrick Maxwell; Menna Clatworthy; James A Nathan; John Bradley; Paul Lyons; Natalie Burrows; Kenneth G C Smith,Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Oxford University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University; Cambridge University,"Prominent early features of COVID-19 include severe, often clinically silent, hypoxia and a pronounced reduction in B cells, the latter important in defence against SARS-CoV-2. This brought to mind the phenotype of mice with VHL-deficient B cells, in which Hypoxia-Inducible Factors are constitutively active, suggesting hypoxia might drive B cell abnormalities in COVID-19. We demonstrated the breadth of early and persistent defects in B cell subsets in moderate/severe COVID-19, including reduced marginal zone-like, memory and transitional B cells, changes we also observed in B cell VHL-deficient mice. This was corroborated by hypoxia-related transcriptional changes in COVID-19 patients, and by similar B cell abnormalities in mice kept in hypoxic conditions, including reduced marginal zone and germinal center B cells. Thus hypoxia might contribute to B cell pathology in COVID-19, and in other hypoxic states. Through this mechanism it may impact on COVID-19 outcome, and be remediable through early oxygen therapy.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.07.07.21253295,2021-07-08,https://medrxiv.org/cgi/content/short/2021.07.07.21253295,Mortality among Care Home Residents in England during the first and second waves of the COVID-19 pandemic: an analysis of 4.3 million adults over the age of 65,Anna Schultze; Emily Nightingale; David Evans; William J Hulme; Alicia Rosello; Chris Bates; Jonathan Cockburn; Brian MacKenna; Helen J Curtis; Caroline E Morton; Richard Croker; Seb Bacon; Helen I McDonald; Christopher T. Rentsch; Krishnan Bhaskaran; Rohini Mathur; Laurie A Tomlinson; Elizabeth J Williamson; Harriet Forbes; John Tazare; Daniel J Grint; Alex J Walker; Peter Inglesby; Nicholas J DeVito; Amir Mehrkar; George Hickman; Simon Davy; Tom Ward; Louis Fisher; Amelia CA Green; Kevin Wing; Angel YS Wong; Robert McManus; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Ian J Douglas; Liam Smeeth; Rosalind M Eggo; Ben Goldacre; David A Leon,"London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT","BackgroundResidents in care homes have been severely impacted by the COVID-19 pandemic. We describe trends in risk of mortality among care home residents compared to residents in private homes in England.

MethodsOn behalf of NHS England, we used OpenSAFELY-TPP, an analytics platform running across the linked electronic health records of approximately a third of the English population, to calculate monthly age-standardised risks of death due to all causes and COVID-19 among adults aged >=65 years between 1/2/2019 and 31/03/2021. Care home residents were identified using linkage to the Care and Quality Commission.

FindingsWe included 4,329,078 people aged 65 years or older on the 1st of February 2019, 2.2% of whom were classified as residing in a care or nursing home. Age-standardised mortality risks were approximately 10 times higher among care home residents compared to non-residents in February 2019 residents (CMF = 10.59, 95%CI = 9.51, 11.81 among women, CMF = 10.82, 95%CI = 9.89, 11.84 among men). This increased to more than 17 times in April 2020 (CMF = 17.52, 95%CI = 16.38, 18.74 among women, CMF = 18.12, 95%CI = 17.17 - 19.12 among men) before returning to pre-pandemic levels in June 2020. CMFs did not increase during the second wave, despite a rise in the absolute age-standardised COVID-19 mortality risks.

InterpretationThe first COVID-19 wave had a disproportionate impact on care home residents in England compared to older private home residents. A degree of immunity, improved protective measures or changes in the underlying frailty of the populations may explain the lack of an increase in the relative mortality risks during the second wave. The care home population should be prioritised for measures aimed at controlling the spread of COVID-19.

FundingMedical Research Council MR/V015737/1",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.07.07.21260137,2021-07-08,https://medrxiv.org/cgi/content/short/2021.07.07.21260137,Anxiety and depression symptoms after COVID-19 infection: results from the COVID Symptom Study app,Kerstin Klaser; Ellen J Thompson; Long H Nguyen; Carole H Sudre; Michela Antonelli; Benjamin Murray; Liane S Canas; Erika Molteni; Mark S Graham; Eric Kerfoot; Liyuan Chen; Jie Deng; Anna May; Christina Hu; Andy Guest; Somesh Selvachandran; David A Drew; Marc Modat; Andrew T Chan; Jonathan Wolf; Timothy D Spector; Alexander Hammers; Emma L Duncan; Sebastien Ourselin; Claire J Steves,"King's College London; King's College London; Massachusetts General Hospital and Harvard Medical School; King's College London, University College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Limited; Zoe Limited; Zoe Limited; Zoe Limited; Massachusetts General Hospital; King's College London; Massachusetts General Hospital and Harvard Medical School; Zoe Limited; King's College London; King's College London; King's College London; King's College London; King's College London","BackgroundMental health issues have been reported after SARS-CoV-2 infection. However, comparison to prevalence in uninfected individuals and contribution from common risk factors (e.g., obesity, comorbidities) have not been examined. We identified how COVID-19 relates to mental health in the large community-based COVID Symptom Study.

MethodsWe assessed anxiety and depression symptoms using two validated questionnaires in 413,148 individuals between February and April 2021; 26,998 had tested positive for SARS-CoV-2. We adjusted for physical and mental pre-pandemic comorbidities, BMI, age, and sex.

FindingsOverall, 26.4% of participants met screening criteria for general anxiety and depression. Anxiety and depression were slightly more prevalent in previously SARS-CoV-2 positive (30.4%) vs. negative (26.1%) individuals. This association was small compared to the effect of an unhealthy BMI and the presence of other comorbidities, and not evident in younger participants ([&le;]40 years). Findings were robust to multiple sensitivity analyses. Association between SARS-CoV-2 infection and anxiety and depression was stronger in individuals with recent (<30 days) vs. more distant (>120 days) infection, suggesting a short-term effect.

InterpretationA small association was identified between SARS-CoV-2 infection and anxiety and depression symptoms. The proportion meeting criteria for self-reported anxiety and depression disorders is only slightly higher than pre-pandemic.

FundingZoe Limited, National Institute for Health Research, Chronic Disease Research Foundation, National Institutes of Health, Medical Research Council UK",epidemiology,fuzzy,94,100
medRxiv,10.1101/2021.07.02.21259897,2021-07-05,https://medrxiv.org/cgi/content/short/2021.07.02.21259897,Anti-spike antibody response to natural SARS-CoV-2 infection in the general population,Jia Wei; Philippa C Matthews; Nicole Stoesser; Thomas Maddox; Luke Lorenzi; Ruth Studley; John I Bell; John N Newton; Jeremy Farrar; Ian Diamond; Emma Rourke; Alison Howarth; Brian D Marsden; Sarah Hoosdally; E Yvonne Jones; David I Stuart; Derrick W Crook; Tim E.A. Peto; Koen B. Pouwels; A. Sarah Walker; David W Eyre,University of Oxford; University of Oxford; University of Oxford; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; NIHR Oxford Biomedical Research Centre; University of Oxford; University of Oxford; University of Oxford; University of Oxford,"We estimated the duration and determinants of antibody response after SARS-CoV-2 infection in the general population using representative data from 7,256 United Kingdom COVID-19 infection survey participants who had positive swab SARS-CoV-2 PCR tests from 26-April-2020 to 14-June-2021. A latent class model classified 24% of participants as  non-responders not developing anti-spike antibodies. These seronegative non-responders were older, had higher SARS-CoV-2 cycle threshold values during infection (i.e. lower viral burden), and less frequently reported any symptoms. Among those who seroconverted, using Bayesian linear mixed models, the estimated anti-spike IgG peak level was 7.3-fold higher than the level previously associated with 50% protection against reinfection, with higher peak levels in older participants and those of non-white ethnicity. The estimated anti-spike IgG half-life was 184 days, being longer in females and those of white ethnicity. We estimated antibody levels associated with protection against reinfection likely last 1.5-2 years on average, with levels associated with protection from severe infection present for several years. These estimates could inform planning for vaccination booster strategies.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.06.28.21259452,2021-07-03,https://medrxiv.org/cgi/content/short/2021.06.28.21259452,"Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people",Matthew Whitaker; Joshua Elliott; Marc Chadeau-Hyam; Steven Riley; Ara Darzi; Graham Cooke; Helen Ward; Paul Elliott,"Imperial College London; Imperial College London; Imperial College London; Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health","BackgroundLong COVID, describing the long-term sequelae after SARS-CoV-2 infection, remains a poorly defined syndrome. There is uncertainty about its predisposing factors and the extent of the resultant public health burden, with estimates of prevalence and duration varying widely.

MethodsWithin rounds 3-5 of the REACT-2 study, 508,707 people in the community in England were asked about a prior history of COVID-19 and the presence and duration of 29 different symptoms. We used uni-and multivariable models to identify predictors of persistence of symptoms (12 weeks or more). We estimated the prevalence of symptom persistence at 12 weeks, and used unsupervised learning to cluster individuals by symptoms experienced.

FindingsAmong the 508,707 participants, the weighted prevalence of self-reported COVID-19 was 19.2% (95% CI: 19.1,19.3). 37.7% of 76,155 symptomatic people post COVID-19 experienced at least one symptom, while 14.8% experienced three or more symptoms, lasting 12 weeks or more. This gives a weighted population prevalence of persistent symptoms of 5.75% (5.68, 5.81) for one and 2.22% (2.1, 2.26) for three or more symptoms. Almost a third of people (8,771/28,713 [30.5%]) with at least one symptom lasting 12 weeks or more reported having had severe COVID-19 symptoms (""significant effect on my daily life"") at the time of their illness, giving a weighted prevalence overall for this group of 1.72% (1.69,1.76). The prevalence of persistent symptoms was higher in women than men (OR: 1.51 [1.46,1.55]) and, conditional on reporting symptoms, risk of persistent symptoms increased linearly with age by 3.5 percentage points per decade of life. Obesity, smoking or vaping, hospitalisation, and deprivation were also associated with a higher probability of persistent symptoms, while Asian ethnicity was associated with a lower probability. Two stable clusters were identified based on symptoms that persisted for 12 weeks or more: in the largest cluster, tiredness predominated, while in the second there was a high prevalence of respiratory and related symptoms.

InterpretationA substantial proportion of people with symptomatic COVID-19 go on to have persistent symptoms for 12 weeks or more, which is age-dependent. Clinicians need to be aware of the differing manifestations of Long COVID which may require tailored therapeutic approaches. Managing the long-term sequelae of SARS-CoV-2 infection in the population will remain a major challenge for health services in the next stage of the pandemic.

FundingThe study was funded by the Department of Health and Social Care in England.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSRecent systematic reviews have documented the wide range of symptoms and reported prevalence of persistent symptoms following COVID-19. A dynamic review of Long COVID studies (NIHR Evidence) in March 2021 summarised the literature on the prevalence of persistent symptoms after acute COVID19, and reported that most studies (14) were of hospitalised patients, with higher prevalence of persistent symptoms compared with two community-based studies. There was limited evidence from community studies beyond 12 weeks. Another systematic review reported a median of over 70% of people with symptoms lasting at least 60 days. A review of risk factors for Long COVID found consistent evidence for an increased risk amongst women and those with high body mass index (BMI) but inconsistent findings on the role of age and little evidence concerning risks among different socioeconomic or ethnic groups which are often not well captured in routine healthcare records. Long COVID is increasingly recognised as heterogenous, likely underpinned by differing biological mechanisms, but there is not yet consensus on defining subtypes of the condition.

Added value of this studyThis community-based study of over half a million people was designed to be representative of the adult population of England. A random sample of adults ages 18 years and above registered with a GP were invited irrespective of previous access to services for COVID-19, providing an estimate of population prevalence that was representative of the whole population. The findings show substantial declines in symptom prevalence over the first 12 weeks following Covid-19, reported by nearly one fifth of respondents, of whom over a third remained symptomatic at 12 weeks and beyond, with little evidence for decline thereafter.

Risk factors identified for persistent symptoms (12 weeks or more) suggestive of Long COVID confirm some previous findings - an increased risk in women, obese and overweight individuals and those hospitalised for COVID-19, with strong evidence for an increasing risk with age. Additional evidence was found for an increased risk in those with lower income, smoking or vaping and healthcare or care home workers. A lower risk was found in those of Asian ethnicity.

Clustering identified two distinct groups of individuals with different symptom profiles at 12 weeks, highlighting the heterogeneity of clinical presentation. The smaller cluster had higher prevalence of respiratory and related symptoms, while for those in the larger cluster tiredness was the dominant symptom, with lower prevalence of organ-specific symptoms.

Implications of available evidenceThere is a high prevalence of persistent symptoms beyond 12 weeks after acute COVID-19, with little evidence of decline thereafter. This highlights the needs for greater support for patients, both through specialised services and, for those from low-income settings, financial support. The understanding that there are distinct clusters of persistent symptoms, the most common of which is dominated by fatigue, is important for the recognition and clinical management of the condition outside of specialised services.",infectious diseases,fuzzy,96,100
medRxiv,10.1101/2021.06.28.21259529,2021-07-01,https://medrxiv.org/cgi/content/short/2021.06.28.21259529,Global patterns of genetic variation and association with clinical phenotypes at genes involved in SARS-CoV-2 infection,Chao Zhang; Anurag Verma; Yuanqing Feng; Marcelo C. R. Melo; Michael McQuillan; Matthew Hansen; Anastasia Lucas; Joseph Park; Alessia Ranciaro; Simon Thompson; Meghan A. Rubel; Michael C. Campbell; William Beggs; JIBRIL HIRBO; Sununguko Wata Mpoloka; Gaonyadiwe George Mokone; - Regeneron Genetic Center; Thomas Nyambo; Dawit Wolde Meskel; Gurja Belay; Charles Fokunang; Alfred K. Njamnshi; Sabah A. Omar; Scott Williams; Daniel Rader; Marylyn D Ritchie; Cesar de la Fuente Nunez; Giorgio Sirugo; Sarah Tishkoff,"University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Perelman School of Medicine at the University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Howard; University of Pennsylvania; Vanderbilt University Medical Center; University of Botswana, Biological Sciences, Gaborone, Botswana; University of Botswana, Faculty of Medicine, Gaborone, Botswana; ; Department of Biochemistry, Kampala International University in Tanzania, Dar es Salaam, Tanzania; Addis Ababa University Department of Microbial Cellular and Molecular Biology, Addis Ababa, Ethiopia; Addis Ababa University Department of Microbial Cellular and Molecular Biology, Addis Ababa, Ethiopia; Department of Pharmacotoxicology and Pharmacokinetics, Faculty of Medicine and Biomedical Sciences, The University of Yaounde I, Yaounde, Cameroon; Department of Neurology, Central Hospital Yaounde; Brain Research Africa Initiative (BRAIN), Neuroscience Lab, Faculty of Medicine and Biomedical Sciences, The ; Center for Biotechnology Research and Development, Kenya Medical Research Institute, Nairobi, Kenya; Case Western Reserve University; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania","We investigated global patterns of genetic variation and signatures of natural selection at host genes relevant to SARS-CoV-2 infection (ACE2, TMPRSS2, DPP4, and LY6E). We analyzed novel data from 2,012 ethnically diverse Africans and 15,997 individuals of European and African ancestry with electronic health records, and integrated with global data from the 1000GP. At ACE2, we identified 41 non-synonymous variants that were rare in most populations, several of which impact protein function. However, three non-synonymous variants were common among Central African hunter-gatherers from Cameroon and are on haplotypes that exhibit signatures of positive selection. We identify strong signatures of selection impacting variation at regulatory regions influencing ACE2 expression in multiple African populations. At TMPRSS2, we identified 13 amino acid changes that are adaptive and specific to the human lineage. Genetic variants that are targets of natural selection are associated with clinical phenotypes common in patients with COVID-19.",genetic and genomic medicine,fuzzy,100,100
medRxiv,10.1101/2021.06.23.21259400,2021-06-30,https://medrxiv.org/cgi/content/short/2021.06.23.21259400,Temporal trends in primary care-recorded self-harm during and beyond the first year of the COVID-19 pandemic: time series analysis of electronic healthcare records for 2.8 million patients in the Greater Manchester Care Record,Sarah Steeg; Lana Bojaniƒá; George Tilston; Richard Williams; David A Jenkins; Matthew J Carr; Niels Peek; Darren M Ashcroft; Nav Kapur; Jennifer Voorhees; Roger T Webb,University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester; University of Manchester,"BackgroundSurveillance of clinically treated self-harm episode frequency is an important component of suicide prevention in the dynamic context of COVID-19. Studies published to date have investigated the initial months following the onset of the pandemic, despite national and regional restrictions persisting to Summer 2021.

MethodsWe conducted a descriptive time series analysis utilising data from the Greater Manchester Care Record, which contains de-identified, primary care health records of 2.8 million patients. Counts of incident and all episodes of self-harm recorded between 1st January 2019 and 31st May 2021 were made for all patients, with stratification by sex, age group, ethnicity, and index of multiple deprivation (IMD) quintile and examination of overall differences by national and regional restriction phases.

FindingsBetween 1st January 2019 and 31st May 2021, 33,444 episodes of self-harm by 13,148 individuals were recorded. Frequency ratios of incident and all episodes of self-harm were 0.59 (95% CI 0.51 to 0.69) and 0.69 (CI 0.63 to 0.75) respectively in April 2020 compared to February 2020. Between August 2020 and May 2021 frequency ratios were 0.92 (CI 0.88 to 0.96) for incident episodes and 0.86 (CI 0.84 to 0.88) for all episodes compared to the same months in 2019. Reductions were largest among men and people living in the most deprived neighbourhoods. An increase in all-episode self-harm (frequency ratio 1.09, CI 1.03 to 1.16) was observed for adolescents aged 10-17 between August 2020 and May 2021.

InterpretationThe COVID-19 pandemic has had a sustained impact on help seeking for self-harm. Reductions in primary care recorded self-harm have implications for clinicians ability to assess the needs and risks of individuals. Some patients may be experiencing prolonged untreated deterioration in their mental health while other groups are presenting in higher numbers. Our findings have important implications for primary care and mental health services in manging ongoing demand.

FundingUKRI COVID-19 Rapid Response Initiative (grant reference COV0499), University of Manchester Presidential Fellowship (SS), and NIHR Greater Manchester Patient Safety Translational Research Centre.",primary care research,fuzzy,100,100
medRxiv,10.1101/2021.06.21.21259145,2021-06-28,https://medrxiv.org/cgi/content/short/2021.06.21.21259145,Development and validation of blood-based prognostic biomarkers for severity of COVID disease outcome using EpiSwitch 3D genomic regulatory immuno-genetic profiling.,Ewan Hunter; Christina Koutsothanasi; Adam Wilson; Francisco Coroado Santos; Matthew Salter; Jurjen Westra; Ryan Powell; Ann Dring; Paulina Brajer; Benedict Egan; Parnall Matthew; Williams Catriona; Katzinski Aemilia; Lavin Thomas; Aroul Ramadass; William Messner; Amanda Brunton; Zoe Lyski; Peter Robbins; Jane Mellor; Rama Vancheeswaran; Andrew Barlow; Dmitri Pchejetski; Alexandre Akoulitchev,"Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oregon Health & Science University, Portland, OR; Oregon Health & Science University, Portland, OR; Oregon Health & Science University, Portland, OR; Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK and The Queen's College, University of Oxford, Oxford, UK; Department of Biochemistry, University of Oxford, Oxford, UK and The Queen's College, University of Oxford, Oxford, UK; West Hertfordshire NHS Trust, Watford, UK; West Hertfordshire NHS Trust, Watford, UK; Norwich Medical School, University of East Anglia; Oxford BioDynamics Plc, Oxford UK","The COVID-19 pandemic has raised several global public health challenges to which the international medical community have responded. Diagnostic testing and the development of vaccines against the SARS-CoV-2 virus have made remarkable progress to date. As the population is now faced with the complex lifestyle and medical decisions that come with living in a pandemic, a forward-looking understanding of how a COVID-19 diagnosis may affect the health of an individual represents a pressing need. Previously we used whole genome microarray to identify 200 3D genomic marker leads that could predict mild or severe COVID-19 disease outcomes from blood samples in a multinational cohort of COVID-19 patients. Here, we focus on the development and validation of a qPCR assay to accurately predict severe COVID-19 disease requiring intensive care unit (ICU) support and/or mechanical ventilation. From 200 original biomarker leads we established a classification model containing six markers. The markers were qualified and validated on 38 COVID-19 patients from an independent cohort. Overall, the six-marker model obtained a positive predictive value of 93% and balanced accuracy of 88% across 116 patients for the prognosis of COVID-19 severity requiring ICU care/ventilation support. The six-marker signature identifies individuals at the highest risk of developing severe complications in COVID-19 with high predictive accuracy and can assist in patient prognosis and clinical management decisions.",infectious diseases,fuzzy,92,100
medRxiv,10.1101/2021.06.21.21259237,2021-06-28,https://medrxiv.org/cgi/content/short/2021.06.21.21259237,Changes in mobility pre and post first SARS-CoV-2 vaccination: findings from a prospective community cohort study including GPS movement tracking in England and Wales (Virus Watch),Vincent Nguyen; Yunzhe Liu; Richard Mumford; Ben Flanagan; Parth Patel; Isobel Braithwaite; Madhumita Shrotri; Thomas Edward Byrne; Sarah Beale; Anna Aryee; Wing Lam Erica Fong; Ellen Fragaszy; Cyril Geismar; Annalan M D Navaratnam; Pia Hardelid; Jana Kovar; Addy Pope; Tao Cheng; Andrew Hayward; Robert W Aldridge; - The Virus watch Collaborative,"Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; SpaceTimeLab, Department of Civil, Environmental and Geomatic Engineering, University College London, London, UK; Esri UK; Esri UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Institute of Epidemiology and Health Care, University College London, London, UK; Esri UK; SpaceTimeLab, Department of Civil, Environmental and Geomatic Engineering, University College London, London, UK; Institute of Epidemiology and Health Care, University College London, London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; ","BackgroundSome evidence suggests that individuals may change adherence to public health policies aimed at reducing contact, transmission and spread of the SARS-CoV-2 virus after they receive their first SARS-CoV-2 vaccination. In this study, we aim to estimate the rate of change in average daily travel distance from a participants registered address before and after SARS-CoV-2 vaccination.

MethodParticipants were recruited into Virus Watch starting in June 2020. Weekly surveys were sent out to participants and vaccination status was collected from January 2021 onwards. Between September 2020 and February 2021, we invited 13,120 adult Virus Watch participants to contribute towards our tracker sub-cohort which uses the Global Positioning System (GPS) to collect data on movement. We used segmented linear regression to estimate the median daily travel distance before and after the first self-reported SARS-CoV-2 vaccine dose.

ResultsWe analysed the daily travel distance of 228 vaccinated adults. Between 157 days prior to vaccination until the day before vaccination, the median daily travel distance travelled was 8.9km (IQR: 3.50km, 24.17km). Between the day of vaccination and 100 days after vaccination, the median daily travel distance travelled was 10.30km (IQR: 4.11, 27.53km). Between 157 days prior to vaccination and the vaccination date, there was a daily median decrease in mobility of 40m (95%CI: -51m, -31m, p-value <0.001) per day. After the removal of outlier data, and between the vaccination date and 99 days after vaccination, there was a median daily increase in movement of 45.0m (95%CI: 25m, 65m, p-value = <0.001). Restricting the analysis to the 3rd national lockdown (4th of January 2021 to the 5th of April 2021), we found a median daily movement increase of 9m (95%CI: -25m, 45m, p = 0.57) in the 30 days prior to vaccination and the vaccination date, and a median daily movement increase of 10m (95%CI: -60m, 94m, p-value = 0.69) in the 30 days after vaccination.

ConclusionsOur study demonstrates the feasibility of collecting high volume geolocation data as part of research projects, and the utility of these for understanding public health issues. Our results are consistent with both an increase and decrease in movement after vaccination and suggest that, amongst Virus Watch participants, any changes in movement distances post-vaccination are small.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.06.21.21259104,2021-06-28,https://medrxiv.org/cgi/content/short/2021.06.21.21259104,Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review,Nuru Saadi; Y-Ling Chi; Srobana Ghosh; Rosalind M Eggo; Ciara McCarthy; Matthew Quaife; Jeanette Dawa; Mark Jit; Anna Vassall,"London School of Hygiene and Tropical Medicine; International Decision Support Inititative, Center for Global Health and Development; International Decision Support Inititative, Center for Global Health and Development; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine; Washington State University - Global Health Program, Nairobi, Kenya. Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine","BackgroundHow best to prioritise COVID-19 vaccination within and between countries has been a public health and an ethical challenge for decision-makers globally. We systematically reviewed epidemiological and economic modelling evidence on population priority groups to minimise COVID-19 mortality, transmission and morbidity outcomes.

MethodsWe searched the National Institute of Health iSearch COVID-19 Portfolio (a database of peer-reviewed and pre-print articles), Econlit, the Centre for Economic Policy Research and the National Bureau of Economic Research for mathematical modelling studies evaluating the impact of prioritising COVID-19 vaccination to population target groups. We narratively synthesised the main study conclusions on prioritisation and the conditions under which the conclusions changed.

FindingsThe search identified 1820 studies. 36 studies met the inclusion criteria and were narratively synthesised. 83% of studies described outcomes in high-income countries. We found that for countries seeking to minimise deaths, prioritising vaccination of senior adults was the optimal strategy and for countries seeking to minimise cases the young were prioritised. There were several exceptions to the main conclusion, notably reductions in deaths could be increased, if groups at high risk of both transmission and death could be further identified. Findings were also sensitive to the level of vaccine coverage.

InterpretationThe evidence supports WHO SAGE recommendations on COVID-19 vaccine prioritisation. There is however an evidence gap on optimal prioritisation for low- and middle-income countries, studies that included an economic evaluation, and studies that explore prioritisation strategies if the aim is to reduce overall health burden including morbidity.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.06.24.21259107,2021-06-28,https://medrxiv.org/cgi/content/short/2021.06.24.21259107,SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men,Oliver Stirrup; Florencia A.T. Boshier; Cristina Venturini; Jose Guerra-Assuncao; Adela Alcolea-Medina; Angela H. Becket; Themoula Charalampous; Ana da Silva Filipe; Sharon Glaysher; Tabassum Khan; Raghavendran Kulasegara-Shylini; Beatrix Kele; Irene M. Monahan; Guy Mollett; Matthew Parker; Emanuela Pelosi; Paul Randell; Sunando Roy; Joshua F. Taylor; Sophie J. Weller; Eleri Wilson-Davies; Phillip Wade; Rachel Williams; - COG-UK HOCI Variant Substudy consortium; - The COVID-19 Genomics UK (COG-UK) consortium; Andrew J. Copas; Teresa Cutino-Moguel; Nick Freemantle; Andrew C. Hayward; Alison Holmes; Joseph Hughes; Tabitha W. Mahungu; Gaia Nebbia; David G. Partridge; Cassie F. Pope; James R. Price; Samuel C. Robson; Kordo Saeed; Thushan I. de Silva; Luke B. Snell; Emma C. Thomson; Adam A. Witney; Judith Breuer,"Institute for Global Health, University College London, London, UK; Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom; Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom; Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom; Centre for Clinical Infection and Diagnostics Research, Kings College London; Centre for Enzyme Innovation, University of Portsmouth, Portsmouth, UK, PO1 2DT; Centre for Clinical Infection and Diagnostics Research, Kings College London; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; Portsmouth Hospitals University NHS Trust, Queen Alexandra Hospital, Portsmouth, UK, PO6 3LY; Division of Infection, The Royal London Hospital, Barts Health; Division of Infection, The Royal London Hospital, Barts Health; Division of Infection, The Royal London Hospital, Barts Health; Institute for Infection and Immunity, St Georges University of London, Cranmer Terrace, London, SW17 0RE; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; Sheffield Bioinformatics Core, The University of Sheffield, Sheffield, UK; Southampton Specialist Virology Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Department of Infection and Immunity, North West London Pathology, London, UK; Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom; Department of Microbiology, South West London Pathology, Jenner Wing, St. Georges Hospital, Blackshaw Road, London, SW17 0QT; Department of Virology, Royal Free London NHS Foundation Trust, London, United Kingdom; Southampton Specialist Virology Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield; Department of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom; -; -; Institute for Global Health, University College London, London, UK; Division of Infection, The Royal London Hospital, Barts Health; Institute for Clinical Trials and Methodology, University College London; Institute of Epidemiology and Health Care, UCL; Department of Infectious Disease, Faculty of Medicine, Imperial College London; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; Department of Virology, Royal Free London NHS Foundation Trust, London, United Kingdom; Department of Infectious Diseases, Guys and St Thomas Hospital NHS Foundation Trust, London; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield; Institute for Infection and Immunity, St Georges University of London; Imperial College Healthcare NHS Trust, London, UK; Centre for Enzyme Innovation, University of Portsmouth; Microbiology Innovation and Research Unit (MIRU), Department of Microbiology, University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, U; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield; Department of Infectious Diseases, Guys and St Thomas Hospital NHS Foundation Trust, London; MRC-University of Glasgow Centre for Virus Research, Glasgow, UK; Institute for Infection and Immunity, St Georges University of London, Cranmer Terrace, London, SW17 0RE; Department of Infection, Immunity and Inflammation, UCL Great Ormond Street Institute of Child Health, University College London, London, United Kingdom","BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage B.1.1.7 has been associated with an increased rate of transmission and disease severity among subjects testing positive in the community. Its impact on hospitalised patients is less well documented.

MethodsWe collected viral sequences and clinical data of patients admitted with SARS-CoV-2 and hospital-onset COVID-19 infections (HOCIs), sampled 16/11/2020 - 10/01/2021, from eight hospitals participating in the COG-UK-HOCI study. Associations between the variant and the outcomes of all-cause mortality and intensive therapy unit (ITU) admission were evaluated using mixed effects Cox models adjusted by age, sex, comorbidities, care home residence, pregnancy and ethnicity.

ResultsSequences were obtained from 2341 inpatients (HOCI cases = 786) and analysis of clinical outcomes was carried out in 2147 inpatients with all data available. The hazard ratio (HR) for mortality of B.1.1.7 compared to other lineages was 1.01 (95% CI 0.79-1.28, P=0.94) and for ITU admission was 1.01 (95% CI 0.75-1.37, P=0.96). Analysis of sex-specific effects of B.1.1.7 identified increased risk of mortality (HR 1.30, 95% CI 0.95-1.78) and ITU admission (HR 1.82, 95% CI 1.15-2.90) in females infected with the variant but not males (mortality HR 0.82, 95% CI 0.61-1.10; ITU HR 0.74, 95% CI 0.52-1.04).

ConclusionsIn common with smaller studies of patients hospitalised with SARS-CoV-2 we did not find an overall increase in mortality or ITU admission associated with B.1.1.7 compared to other lineages. However, women with B.1.1.7 may be at an increased risk of admission to intensive care and at modestly increased risk of mortality.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.06.24.21259374,2021-06-26,https://medrxiv.org/cgi/content/short/2021.06.24.21259374,A proteomic survival predictor for COVID-19 patients in intensive care,Vadim Demichev; Pinkus Tober-Lau; Tatiana Nazarenko; Simran Kaur Aulakh; Harry Whitwell; Oliver Lemke; Annika Roehl; Anja Freiwald; Mirja Mittermaier; Lukasz Szyrwiel; Daniela Ludwig; Clara Correia-Melo; Lena Lippert; Elisa T. Helbig; Paula Stubbemann; Nadine Olk; Charlotte Thibeault; Nana-Maria Gruening; Oleg Blyuss; Spyros Vernardis; Matthew White; Christoph B. Messner; Michael Joannidis; Thomas Sonnweber; Sebastian J. Klein; Alex Pizzini; Yvonne Wohlfarter; Sabina Sahanic; Richard Hilbe; Benedikt Schaefer; Sonja Wagner; Felix Machleidt; Carmen Garcia; Christoph Ruwwe-Gloesenkamp; Tilman Lingscheid; Laure Bosquillon de Jarcy; Miriam Stegemann; Moritz Pfeiffer; Linda Juergens; Sophy Denker; Daniel Zickler; Claudia Spies; Andreas Edel; Nils B. Mueller; Philipp Enghard; Aleksej Zelezniak; Rosa Bellmann-Weiler; Guenter Weiss; Archie Campbell; Caroline Hayward; David J. Porteous; Riccardo E. Marioni; Alexander Uhrig; Heinz Zoller; Judith Loeffler-Ragg; Markus A. Keller; Ivan Tancevski; John F. Timms; Alexey Zaikin; Stefan Hippenstiel; Michael Ramharter; Holger Mueller-Redetzky; Martin Witzenrath; Norbert Suttorp; Kathryn Lilley; Michael Muelleder; Leif Erik Sander; - PA-COVID- Study group; Florian Kurth; Markus Ralser,"The Francis Crick Institute; Charit√© - Universit√§tsmedizin Berlin; University College London; The Francis Crick Institute; Imperial College London; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; The Francis Crick Institute; Charit√© - Universit√§tsmedizin Berlin; The Francis Crick Institute; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Lobachevsky University,; The Francis Crick Institute; The Francis Crick Institute; Charit√© - Universit√§tsmedizin Berlin; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; The Francis Crick Institute; Medical University of Innsbruck; Medical University of Innsbruck; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; Charit√© - Universit√§tsmedizin Berlin; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; University College London; University College London; Charit√© - Universit√§tsmedizin Berlin; Bernhard Nocht Institute for Tropical Medicine; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; The University of Cambridge; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin","Global healthcare systems are challenged by the COVID-19 pandemic. There is a need to optimize allocation of treatment and resources in intensive care, as clinically established risk assessments such as SOFA and APACHE II scores show only limited performance for predicting the survival of severely ill COVID-19 patients. Comprehensively capturing the host physiology, we speculated that proteomics in combination with new data-driven analysis strategies could produce a new generation of prognostic discriminators. We studied two independent cohorts of patients with severe COVID-19 who required intensive care and invasive mechanical ventilation. SOFA score, Charlson comorbidity index and APACHE II score were poor predictors of survival. Plasma proteomics instead identified 14 proteins that showed concentration trajectories different between survivors and non-survivors. A proteomic predictor trained on single samples obtained at the first time point at maximum treatment level (i.e. WHO grade 7) and weeks before the outcome, achieved accurate classification of survivors in an exploratory (AUROC 0.81) as well as in the independent validation cohort (AUROC of 1.0). The majority of proteins with high relevance in the prediction model belong to the coagulation system and complement cascade. Our study demonstrates that predictors derived from plasma protein levels have the potential to substantially outperform current prognostic markers in intensive care.

Trial registrationGerman Clinical Trials Register DRKS00021688",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.06.21.21259254,2021-06-25,https://medrxiv.org/cgi/content/short/2021.06.21.21259254,"Acceptability, usability and performance of lateral flow immunoassay tests for SARS-CoV-2 antibodies: REACT-2 study of self-testing in non-healthcare key workers",Bethan Davies; Marzieh Araghi; Maya Moshe; He Gao; Kimberly Bennet; Jordan Jenkins; Christina Atchison; Ara Darzi; Deborah Ashby; Steven Riley; Wendy Barclay; Paul Elliott; Helen Ward; Graham Cooke,Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London,"BackgroundSeroprevalence studies in key worker populations are essential to understand the epidemiology of SARS-CoV-2. Various technologies, including laboratory assays and point-of-care self-tests, are available for antibody testing. The interpretation of seroprevalence studies requires comparative data on the performance of antibody tests.

MethodsIn June 2020, current and former members of the UK Police forces and Fire service performed a self-test lateral flow immunoassay (LFIA) and provided a saliva sample, nasopharyngeal swab, venous blood samples for Abbott ELISA and had a nurse performed LFIA. We present the prevalence of PCR positivity and antibodies to SARS-CoV-2 in this cohort following the first wave of infection in England; the acceptability and usability of self-test LFIAs (defined as use of the LFIA kit and provision of a valid result, respectively); and determine the sensitivity and specificity of LFIAs compared to laboratory ELISAs.

ResultsIn this cohort of non-healthcare key workers, 7.4% (396/5,348; 95% CI, 6.7-8.1) were antibody positive. Seroprevalence was 8.9% (6.9-11.4) in those under 40 years, 11.5% (8.8-15.0) in those of non-white British ethnicity and 7.8% (7.1-8.7) in those currently working. The self-test LFIA had an acceptability of 97.7% and a usability of 90.0%. There was substantial agreement between within-participant LFIA results (kappa 0.80; 0.77-0.83). The LFIAs (self-test and nurse-performed) had a similar performance: compared to ELISA, sensitivity was 82.1% (77.7-86.0) self-test and 76.4% (71.9-80.5) nurse-performed with specificity of 97.8% (97.3-98.2) and 98.5% (98.1-98.8) respectively.

ConclusionA greater proportion of the non-healthcare key worker cohort showed evidence of previous infection with SARS-CoV-2 than the general population at 6.0% (5.8-6.1) following the first wave in England. The high acceptability and usability reported by participants and the similar performance of self-test and nurse-performed LFIAs indicate that the self-test LFIA is fit for purpose for home-testing in occupational and community prevalence studies.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.06.24.21259277,2021-06-25,https://medrxiv.org/cgi/content/short/2021.06.24.21259277,Risk factors for long COVID: analyses of 10 longitudinal studies and electronic health records in the UK,Ellen J. Thompson; Dylan M. Williams; Alex J. Walker; Ruth E. Mitchell; Claire L. Niedzwiedz; Tiffany C. Yang; Charlotte Huggins; Alex S. F. Kwong; Richard Silverwood; Giorgio Di Gessa; Ruth C. E. Bowyer; Kate Northstone; Bo Hou; Michael J. Green; Brian Dodgeon; Katie J. Doores; Emma Duncan; Frances M. K. Williams; - OpenSAFELY Collaborative; Andrew Steptoe; David J. Porteous; Rosemary R. C. McEachan; Laurie Tomlinson; Ben Goldacre; Praveetha Patalay; George B. Ploubidis; Srinivasa Vittal Katikireddi; Kate Tilling; Christopher T. Rentsch; Nicholas J. Timpson; Nishi Chaturvedi; Claire J. Steves,King's College London; University College London; University of Oxford; University of Bristol; University of Glasgow; Bradford Teaching Hospitals NHS Foundation Trust; University of Edinburgh; University of Bristol; University College London; University College London; King's College London; University of Bristol; Bradford Teaching Hospitals NHS Foundation Trust; University of Glasgow; University College London; King's College London; King's College London; King's College London; ; University College London; University of Edinburgh; Bradford Teaching Hospitals NHS Foundation Trust; London School of Hygiene and Tropical Medicine; University of Oxford; University College London; University College London; University of Glasgow; University of Bristol; London School of Hygiene and Tropical Medicine; University of Bristol; University College London; King's College London,"BackgroundThe impact of long COVID is considerable, but risk factors are poorly characterised. We analysed symptom duration and risk factor from 10 longitudinal study (LS) samples and electronic healthcare records (EHR).

MethodsSamples: 6907 adults self-reporting COVID-19 infection from 48,901 participants in the UK LS, and 3,327 adults with COVID-19, were assigned a long COVID code from 1,199,812 individuals in primary care EHR. Outcomes for LS included symptom duration lasting 4+ weeks (long COVID) and 12+ weeks. Association with of age, sex, ethnicity, socioeconomic factors, smoking, general and mental health, overweight/obesity, diabetes, hypertension, hypercholesterolaemia, and asthma was assessed.

ResultsIn LS, symptoms impacted normal functioning for 12+ weeks in 1.2% (mean age 20 years) to 4.8% (mean age 63 y) of COVID-19 cases. Between 7.8% (mean age 28 y) and 17% (mean age 58 y) reported any symptoms for 12+ weeks, and greater proportions for 4+ weeks. Age was associated with a linear increased risk in long COVID between 20 and 70 years. Being female (LS: OR=1.49; 95%CI:1.24-1.79; EHR: OR=1.51 [1.41-1.61]), having poor pre-pandemic mental health (LS: OR=1.46 [1.17-1.83]; EHR: OR=1.57 [1.47-1.68]) and poor general health (LS: OR=1.62 [1.25-2.09]; EHR: OR=1.26; [1.18-1.35]) were associated with higher risk of long COVID. Individuals with asthma (LS: OR=1.32 [1.07-1.62]; EHR: OR=1.56 [1.46-1.67]), and overweight or obesity (LS: OR=1.25 [1.01-1.55]; EHR: OR=1.31 [1.21-1.42]) also had higher risk. Non-white ethnic minority groups had lower risk (LS: OR=0.32 [0.22-0.47]), a finding consistent in EHR. . Few participants had been hospitalised (0.8-5.2%).

ConclusionLong COVID is associated with sociodemographic and pre-existing health factors. Further investigations into causality should inform strategies to address long COVID in the population.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.06.22.21259336,2021-06-24,https://medrxiv.org/cgi/content/short/2021.06.22.21259336,Population disruption: estimating changes in population distribution in the UK during the COVID-19 pandemic,Hamish Gibbs; Naomi R Waterlow; James Cheshire; Leon Danon; Yang Liu; Chris Grundy; Adam J Kucharski; - LSHTM CMMID COVID-19 Working Group; Rosalind M Eggo,"London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; Department of Engineering Mathematics, University of Bristol, UK.; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; -; London School of Hygiene & Tropical Medicine","Mobility data have demonstrated major changes in human movement patterns in response to COVID-19 and associated interventions in many countries. This can involve sub-national redistribution, short-term relocations as well as international migration. In this paper, we combine detailed location data from Facebook measuring the location of approximately 6 million daily active Facebook users in 5km2 tiles in the UK with census-derived population estimates to measure population mobility and redistribution. We provide time-varying population estimates and assess spatial population changes with respect to population density and four key reference dates in 2020 (First lockdown, End of term, Beginning of term, Christmas). We also show how population estimates derived from the distribution of Facebook users vary compared to mid-2020 small area population estimates by the UK national statistics agencies. We estimate that between March 2020 and March 2021, the total population of the UK declined and we identify important spatial variations in this population change, showing that low-density areas have experienced lower population decreases than urban areas. We estimate that, for the top 10% highest population tiles, the population has decreased by 6.6%. Further, we provide evidence that geographic redistributions of population within the UK coincide with dates of non-pharmaceutical interventions including lockdowns and movement restrictions, as well as seasonal patterns of migration around holiday dates. The methods used in this study reveal significant changes in population distribution at high spatial and temporal resolutions that have not previously been quantified by available demographic surveys in the UK. We found early indicators of potential longer-term changes in the population distribution of the UK although it is not clear if these changes may persist after the COVID-19 pandemic.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.06.16.21258691,2021-06-21,https://medrxiv.org/cgi/content/short/2021.06.16.21258691,App-based COVID-19 surveillance and prediction: The COVID Symptom Study Sweden,Beatrice Kennedy; Hugo Fitipaldi; Ulf Hammar; Marlena Maziarz; Neli Tsereteli; Nikolay Oskolkov; Georgios Varotsis; Camilla A Franks; Diem T Nguyen; Lampros Spiliopoulos; Hans-Olov Adami; Jonas Bj√∂rk; Stefan Engblom; Katja Fall; Anna Grimby-Ekman; Jan-Eric Litton; Mats Martinell; Anna Oudin; Torbj√∂rn Sj√∂str√∂m; Toomas Timpka; Carole H Sudre; Mark S Graham; Julien Lavigne du Cadet; Andrew T. Chan; Richard Davies; Sajaysurya Ganesh; Anna May; S√©bastien Ourselin; Joan Capdevila Pujol; Somesh Selvachandran; Jonathan Wolf; Tim D Spector; Claire J Steves; Maria F Gomez; Paul W Franks; Tove Fall,"Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden; Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Sweden; Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden; Diabetic Complications Unit, Department of Clinical Sciences in Malm√∂, Lund University Diabetes Centre, Sweden; Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Sweden; Department of Biology, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Lund University, Sweden; Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden; Diabetic Complications Unit, Department of Clinical Sciences in Malm√∂, Lund University Diabetes Centre, Sweden; Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden; Diabetic Complications Unit, Department of Clinical Sciences in Malm√∂, Lund University Diabetes Centre, Sweden; Sk√•ne University Hospital, Malm√∂, Sweden; Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, Norway; Dept of Medical Epidemiology and Biostatistics, Karolinska Inst; Division of Occupational and Environmental Medicine, Lund University, Sweden; Clinical Studies Sweden, Forum South, Sk√•ne University Hospital, Lund, Sweden; Division of Scientific Computing, Department of Information Technology, Uppsala University, Sweden; Clinical Epidemiology and Biostatistics, School of Medical Sciences, √ñrebro University, √ñrebro, Sweden; Integrative Epidemiology, Institute of Environmental Med; Biostatistics, School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Sweden; Department of Public Health and Caring Sciences, Uppsala University, Sweden; Primary Care and Health, Region Uppsala, Sweden; Division for Occupational and environmental medicine, Lund University, Sweden; Department of Public Health and Clinical Medicine, Section of Sustainable Health,; Novus International Group AB, Sweden; Department of Medical and Health Sciences, Linkoping University, Sweden; MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK; Centre for Medical Image Computing, University College London, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; ZOE Limited; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; ZOE Limited; ZOE Limited; ZOE Limited; School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK; ZOE Limited; ZOE Limited; ZOE Limited; Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; Department of Twin Research and Genetic Epidemiology, King's College London, London, UK; Diabetic Complications Unit, Department of Clinical Sciences in Malm√∂, Lund University Diabetes Centre, Sweden; Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Sweden; Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Sweden","The app-based COVID Symptom Study was launched in Sweden in April 2020 to contribute to real-time COVID-19 surveillance. We enrolled 143,531 study participants ([&ge;]18 years) who contributed 10.6 million daily symptom reports between April 29, 2020 and February 10, 2021. Data from 19,161 self-reported PCR tests were used to create a symptom-based model to estimate the individual probability of symptomatic COVID-19, with an AUC of 0.78 (95% CI 0.74-0.83) in an external dataset. These individual probabilities were used to estimate daily regional COVID-19 prevalence, which were in turn used together with current hospital data to predict next week COVID-19 hospital admissions. We found that this hospital prediction model demonstrated a lower median absolute percentage error (MdAPE: 25.9%) across the five most populated regions in Sweden during the first pandemic wave than a model based on case notifications (MdAPE: 30.3%). During the second wave, the error rates were similar. When applying the same model to an English dataset, not including local COVID-19 test data, we observed MdAPEs of 22.3% and 19.0%, respectively, highlighting the transferability of the prediction model.",health informatics,fuzzy,100,100
medRxiv,10.1101/2021.06.17.21259103,2021-06-21,https://medrxiv.org/cgi/content/short/2021.06.17.21259103,REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant,Steven Riley; Caroline E. Walters; Haowei Wang; Oliver Eales; David Haw; Kylie E. C. Ainslie; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Andrew J. Page; Sophie J. Prosolek; Alexander J. Trotter; Le Viet Thanh; Nabil-Fareed Alikhan; Leigh M Jackson; Catherine Ludden; - The COVID-19 Genomics UK (COG-UK) Consortium; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Medical School, University of Exeter, UK; Department of Medicine, University of Cambridge, UK; -; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear","BackgroundEngland entered a third national lockdown from 6 January 2021 due to the COVID-19 pandemic. Despite a successful vaccine rollout during the first half of 2021, cases and hospitalisations have started to increase since the end of May as the SARS-CoV-2 Delta (B.1.617.2) variant increases in frequency. The final step of relaxation of COVID-19 restrictions in England has been delayed from 21 June to 19 July 2021.

MethodsThe REal-time Assessment of Community Transmision-1 (REACT-1) study measures the prevalence of swab-positivity among random samples of the population of England. Round 12 of REACT-1 obtained self-administered swab collections from participants from 20 May 2021 to 7 June 2021; results are compared with those for round 11, in which swabs were collected from 15 April to 3 May 2021.

ResultsBetween rounds 11 and 12, national prevalence increased from 0.10% (0.08%, 0.13%) to 0.15% (0.12%, 0.18%). During round 12, we detected exponential growth with a doubling time of 11 (7.1, 23) days and an R number of 1.44 (1.20, 1.73). The highest prevalence was found in the North West at 0.26% (0.16%, 0.41%) compared to 0.05% (0.02%, 0.12%) in the South West. In the North West, the locations of positive samples suggested a cluster in Greater Manchester and the east Lancashire area. Prevalence in those aged 5-49 was 2.5 times higher at 0.20% (0.16%, 0.26%) compared with those aged 50 years and above at 0.08% (0.06%, 0.11%). At the beginning of February 2021, the link between infection rates and hospitalisations and deaths started to weaken, although in late April 2021, infection rates and hospital admissions started to reconverge. When split by age, the weakened link between infection rates and hospitalisations at ages 65 years and above was maintained, while the trends converged below the age of 65 years. The majority of the infections in the younger group occurred in the unvaccinated population or those without a stated vaccine history. We observed the rapid replacement of the Alpha (B.1.1.7) variant of SARS-CoV-2 with the Delta variant during the period covered by rounds 11 and 12 of the study.

DiscussionThe extent to which exponential growth continues, or slows down as a consequence of the continued rapid roll-out of the vaccination programme, including to young adults, requires close monitoring. Data on community prevalence are vital to track the course of the epidemic and inform ongoing decisions about the timing of further lifting of restrictions in England.",infectious diseases,fuzzy,100,100
bioRxiv,10.1101/2021.06.21.449178,2021-06-21,https://biorxiv.org/cgi/content/short/2021.06.21.449178,Spatial transcriptomic characterization of COVID-19 pneumonitis identifies immune pathways related to tissue injury,Amy R Cross; Carlos de Andrea; Maria Villalba-Esparza; Manuel Landecho Acha; Lucia Cerundolo; Praveen Weeratunga; Rachel Etherington; Laura Denney; Graham Ogg; Ling-Pei Ho; Ian Roberts; Joanna Hester; Paul Klenerman; Ignacio Melero; Stephen Sansom; Fadi Issa,"University of Oxford; Universidad de Navarra; Department of Pathology, Clinica de la Universidad de Navarra, Pamplona, Spain; Clinica Universidad de Navarra; University of Oxford; Medical Research Council Human Immunology Unit, Radcliffe Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine, Universit; University of Oxford; University of Oxford; Medical Research Council Human Immunology Unit, Radcliffe Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine, Universit; University of Oxford; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; Universidad de Navarra; University of Oxford; University of Oxford","Severe lung damage in COVID-19 involves complex interactions between diverse populations of immune and stromal cells. In this study, we used a spatial transcriptomics approach to delineate the cells, pathways and genes present across the spectrum of histopathological damage in COVID-19 lung tissue. We applied correlation network-based approaches to deconvolve gene expression data from areas of interest within well preserved post-mortem lung samples from three patients. Despite substantial inter-patient heterogeneity we discovered evidence for a common immune cell signaling circuit in areas of severe tissue that involves crosstalk between cytotoxic lymphocytes and pro-inflammatory macrophages. Expression of IFNG by cytotoxic lymphocytes was associated with induction of chemokines including CXCL9, CXCL10 and CXCL11 which are known to promote the recruitment of CXCR3+ immune cells. The tumour necrosis factor (TNF) superfamily members BAFF (TNFSF13B) and TRAIL (TNFSF10) were found to be consistently upregulated in the areas with severe tissue damage. We used published spatial and single cell SARS-CoV-2 datasets to confirm our findings in the lung tissue from additional cohorts of COVID-19 patients. The resulting model of severe COVID-19 immune-mediated tissue pathology may inform future therapeutic strategies.

One Sentence SummarySpatial analysis identifies IFN{gamma} response signatures as focal to severe alveolar damage in COVID-19 pneumonitis.",immunology,fuzzy,100,100
medRxiv,10.1101/2021.06.17.21259100,2021-06-20,https://medrxiv.org/cgi/content/short/2021.06.17.21259100,COVID-19 Transmission Dynamics Underlying Epidemic Waves in Kenya,Samuel P C Brand; John Ojal; Rabia Aziza; Vincent Were; Emelda Okiro; Ivy Kombe; Caroline Mburu; Morris Ogero; Ambrose Agweyu; George M Warimwe; James Nyagwange; Henry Karanja; John Gitonga; Daisy Mugo; Sophie Uyoga; Ifedayo M O Adetifa; J Anthony G Scott; Edward Otieno; Nickson Murunga; Mark Otiende; Lynette I Ochola-Oyier; Charles N Agoti; George Githinji; Kadondi Kasera; Patrick Amoth; Mercy Mwangangi; Rashid Aman; Wangari Ng'ang'a; Benjamin Tsofa; Philip Bejon; Matt J Keeling; D James Nokes; Edwine Barasa,"University of Warwick; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; University of Warwick; Health Economics Research Unit, KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom; Department of Infectious Diseases Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Ministry of Health, Government of Kenya, Nairobi, Kenya; Ministry of Health, Government of Kenya, Nairobi, Kenya; Ministry of Health, Government of Kenya, Nairobi, Kenya; Ministry of Health, Government of Kenya, Nairobi, Kenya; Presidential Policy & Strategy Unit, The Presidency, Government of Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; University of Warwick; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya; Kenya Medical Research Institute (KEMRI) -Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya","Policy decisions on COVID-19 interventions should be informed by a local, regional and national understanding of SARS-CoV-2 transmission. Epidemic waves may result when restrictions are lifted or poorly adhered to, variants with new phenotypic properties successfully invade, or when infection spreads to susceptible sub-populations. Three COVID-19 epidemic waves have been observed in Kenya. Using a mechanistic mathematical model we explain the first two distinct waves by differences in contact rates in high and low social-economic groups, and the third wave by the introduction of a new higher-transmissibility variant. Reopening schools led to a minor increase in transmission between the second and third waves. Our predictions of current population exposure in Kenya ([~]75% June 1st) have implications for a fourth wave and future control strategies.

One Sentence SummaryCOVID-19 spread in Kenya is explained by mixing heterogeneity and a variant less constrained by high population exposure",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.06.15.21258542,2021-06-16,https://medrxiv.org/cgi/content/short/2021.06.15.21258542,"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial",Peter W Horby; Marion Mafham; Leon Peto; Mark Campbell; Guilherme Pessoa-Amorim; Enti Spata; Natalie Staplin; Jonathan R Emberson; Benjamin Prudon; Paul Hine; Thomas Brown; Christopher A Green; Rahuldeb Sarkar; Purav Desai; Bryan Yates; Tom Bewick; Simon Tiberi; Tim Felton; J Kenneth Baillie; Maya H Buch; Lucy C Chappell; Jeremy N Day; Saul N Faust; Thomas Jaki; Katie Jeffery; Edmund Juszczak; Wei Shen Lim; Alan Montgomery; Andrew Mumford; Kathryn Rowan; Guy Thwaites; David M Weinreich; Richard Haynes; Martin J Landray,"Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; North Tees and Hartlepool NHS Foundation Trust, Hartlepool, United Kingdom; Liverpool University Hospitals NHS Foundation Trust; Portsmouth Hospitals University NHS Foundation Trust, Portsmouth, United Kingdom; University Hospitals Birmingham NHS Foundation Trust; Medway NHS Foundation Trust; Calderdale and Huddersfield NHS Foundation Trust; Northumbria Healthcare NHS Foundation Trust; University Hospitals Of Derby and Burton NHS Foundation Trust; Barts Health NHS Trust; Manchester University NHS Foundation Trust; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; School of Life Sciences, Kings College London, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Respiratory Medicine Department, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Intensive Care National Audit and Research Centre, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","BackgroundREGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of REGEN-COV in patients admitted to hospital with COVID-19.

MethodsIn this randomised, controlled, open-label platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Eligible and consenting patients were randomly allocated (1:1) to either usual standard of care alone (usual care group) or usual care plus a single dose of REGEN-COV 8g (casirivimab 4g and imdevimab 4g) by intravenous infusion (REGEN-COV group). The primary outcome was 28-day mortality assessed first among patients without detectable antibodies to SARS-CoV-2 at randomisation (seronegative) and then in the overall population. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

FindingsBetween 18 September 2020 and 22 May 2021, 9785 patients were randomly allocated to receive usual care plus REGEN-COV or usual care alone, including 3153 (32%) seronegative patients, 5272 (54%) seropositive patients and 1360 (14%) patients with unknown baseline antibody status. In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to REGEN-COV and 451 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio 0{middle dot}80; 95% CI 0{middle dot}70-0{middle dot}91; p=0{middle dot}0010). In an analysis involving all randomised patients (regardless of baseline antibody status), 944 (20%) of 4839 patients allocated to REGEN-COV and 1026 (21%) of 4946 patients allocated to usual care died within 28 days (rate ratio 0{middle dot}94; 95% CI 0{middle dot}86-1{middle dot}03; p=0{middle dot}17). The proportional effect of REGEN-COV on mortality differed significantly between seropositive and seronegative patients (p value for heterogeneity = 0{middle dot}001).

InterpretationIn patients hospitalised with COVID-19, the monoclonal antibody combination of casirivimab and imdevimab (REGEN-COV) reduced 28-day mortality among patients who were seronegative at baseline.

FundingUK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056).",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.06.11.21258730,2021-06-16,https://medrxiv.org/cgi/content/short/2021.06.11.21258730,Relative perceived importance of different settings for SARS-CoV2 acquisition in England and Wales: Analysis of the Virus Watch Community Cohort,Sarah Beale; Thomas Edward Byrne; Ellen Benard Fragaszy; Jana Kovar; Vincent Grigori Nguyen; Anna Aryee; Wing Lam Erica Fong; Cyril Roman Geismar; Parth Patel; Madhumita Shrotri; Nicholas Patni; Isobel Braithwaite; Annalan Mathew Dwight Navaratnam; Robert William Aldridge; Andrew C Hayward,University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University of Oxford; University College London; University College London; University College London; University College London,"We aimed to assess the relative importance of different settings for SARS-CoV2 transmission in a large community cohort. We demonstrate the importance of home, work and education as venues for transmission. In children, education was most important and in older adults essential shopping was of high importance. Our findings support public health messaging about infection control at home, advice on working from home and restrictions in different venues.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.06.08.21258551,2021-06-15,https://medrxiv.org/cgi/content/short/2021.06.08.21258551,NHS CHECK: protocol for a cohort study investigating the psychosocial impact of the COVID-19 pandemic on healthcare workers,Danielle Lamb; Neil Greenberg; Matthew Hotopf; Rosalind Raine; Reza Razavi; Rupa Bhundia; Hannah Scott; Ewan Carr; Rafael Gafoor; Ioannis Bakolis; Siobhan Hegarty; Emilia Souliou; Anne Marie Rafferty; Rebecca Rhead; Danny Weston; Sam Gnanapragasam; Sally Marlow; Simon Wessely; Sharon Stevelink,UCL; King's College London; King's College London; UCL; King's College London; King's College London; King's College London; King's College London; ICL; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London,"IntroductionThe COVID-19 pandemic has had profound effects on the working lives of healthcare workers (HCWs), but the extent to which their well-being and mental health have been affected remains unclear. This longitudinal cohort study aims to recruit a cohort of NHS healthcare workers, conducting surveys at regular intervals to provide evidence about the prevalence of symptoms of mental disorders, investigate associated factors such as occupational contexts and support interventions available.

Methods and AnalysisAll staff, students, and volunteers working in each of the 18 participating NHS Trusts in England will be sent emails inviting them to complete a survey at baseline, with email invitations for the follow up surveys being sent 6 and 12 months later. Opening in late April 2020, the baseline survey collects data on demographics, occupational and organisational factors, experiences of COVID-19, a number of validated measures of symptoms of poor mental health (e.g. depression, anxiety, post-traumatic stress disorder; PTSD), and measures of constructs such as resilience and moral injury. These regular surveys will be complemented by in-depth psychiatric interviews with a select sample of healthcare workers. Qualitative interviews will also be conducted, to gain deeper understanding of the support programmes used or desired by staff, and facilitators and barriers to accessing such programmes.

Ethics and DisseminationEthical approval for the study was granted by the Health Research Authority (reference: 20/HRA/210, IRAS: 282686) and local Trust Research and Development approval. Cohort data are being collected via Qualtrics online survey software, are pseudonymised and held on secure University servers. Participants are aware that they can withdraw from the study at any time, and there is signposting to support services for any participant who feels they need it. Only those consenting to be contacted about further research will be invited to participate in the psychiatric and qualitative interview components of the study. Findings will be rapidly shared with NHS Trusts to enable better support of staff during the pandemic, and via academic publications in due course.

Strengths and limitations of this studyO_LIThe longitudinal cohort design addresses the lack of long-term data on this population, and the current predominance of cross-sectional evidence available.
C_LIO_LIThe availability of Trust HR data means we will be able to calculate response rates, and weight the data appropriately.
C_LIO_LIThe diagnostic interview component of the study will allow us to establish the true prevalence of mental disorders, which can be inflated by the measures used in most mental health and wellbeing cohort studies.
C_LIO_LIThe qualitative interviews will give deeper insight into the support programmes that HCWs find most helpful, and provide ideas for Trusts to improve their offer to staff.
C_LIO_LIThe three components of the study give breadth and depth lacking in much of the mental health and wellbeing research currently available, but there is a risk of over-burdening already stretched HCWs.
C_LI",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2021.06.11.21258690,2021-06-15,https://medrxiv.org/cgi/content/short/2021.06.11.21258690,Brain imaging before and after COVID-19 in UK Biobank,Gwena√´lle Douaud; Soojin Lee; Fidel Alfaro-Almagro; Christoph Arthofer; Chaoyue Wang; Paul McCarthy; Frederik Lange; Jesper L.R. Andersson; Ludovica Griffanti; Eugene Duff; Saad Jbabdi; Bernd Taschler; Peter Keating; Anderson M. Winkler; Rory Collins; Paul M. Matthews; Naomi Allen; Karla L. Miller; Thomas E. Nichols; Stephen M. Smith,"FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford; OHBA, Wellcome Centre for; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Department of; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Ear Institute, University College London, London, UK; National Institutes of Mental Health, National Institutes of Health, Bethesda, MD, USA; Nuffield Department of Population Health, University of Oxford, Oxford, UK; UK Dementia Research Institute and Department of Brain Sciences, Imperial College, London, UK; Nuffield Department of Population Health, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK; FMRIB Centre, Wellcome Centre for Integrative Neuroimaging (WIN), Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK","There is strong evidence for brain-related abnormalities in COVID-191-13. It remains unknown however whether the impact of SARS-CoV-2 infection can be detected in milder cases, and whether this can reveal possible mechanisms contributing to brain pathology. Here, we investigated brain changes in 785 UK Biobank participants (aged 51-81) imaged twice, including 401 cases who tested positive for infection with SARS-CoV-2 between their two scans, with 141 days on average separating their diagnosis and second scan, and 384 controls. The availability of pre-infection imaging data reduces the likelihood of pre-existing risk factors being misinterpreted as disease effects. We identified significant longitudinal effects when comparing the two groups, including: (i) greater reduction in grey matter thickness and tissue-contrast in the orbitofrontal cortex and parahippocampal gyrus, (ii) greater changes in markers of tissue damage in regions functionally-connected to the primary olfactory cortex, and (iii) greater reduction in global brain size. The infected participants also showed on average larger cognitive decline between the two timepoints. Importantly, these imaging and cognitive longitudinal effects were still seen after excluding the 15 cases who had been hospitalised. These mainly limbic brain imaging results may be the in vivo hallmarks of a degenerative spread of the disease via olfactory pathways, of neuroinflammatory events, or of the loss of sensory input due to anosmia. Whether this deleterious impact can be partially reversed, or whether these effects will persist in the long term, remains to be investigated with additional follow up.",neurology,fuzzy,100,100
medRxiv,10.1101/2021.06.09.21258629,2021-06-14,https://medrxiv.org/cgi/content/short/2021.06.09.21258629,IMPACT OF COVID-19 PANDEMIC ON SICKNESS ABSENCE FOR MENTAL ILL HEALTH IN NATIONAL HEALTH SERVICE STAFF,Diana van der Plaat; Rhiannon Edge; David Coggon; Martie van Tongersen; Rupert Muiry; Vaughan Parsons; Paul Cullinan; Ira Madan,Imperial College London; University of Lancaster; University of Southampton; University of Manchester; Guy's and St Thomas NHS Foundation Trust; Guy's and St Thomas NHS Foundation Trust; Imperial College London; Guy's and St Thomas' NHS Foundation Trust,"ObjectiveTo explore the patterns of sickness absence in National Health Service (NHS) staff attributable to mental ill health during the first wave of the Covid-19 epidemic in March - July 2020

DesignCase-referent analysis of a secondary data set

SettingNHS Trusts in England

ParticipantsPseudonymised data on 959,356 employees who were continuously employed by NHS trusts during 1 January 2019 to 31 July 2020

Main Outcome MeasuresTrends in the burden of sickness absence due to mental ill health from 2019 to 2020 according to demographic, regional and occupational characteristics.

ResultsOver the study period, 164,202 new sickness absence episodes for mental ill health were recorded in 12.5% (119,525) of the study sample. There was a spike of sickness absence for mental ill health in March-April 2020 (899,730 days lost) compared with 519,807 days in March-April 2019; the surge was driven by an increase in new episodes of long-term absence and had diminished by May/June 2020. The increase was greatest in those aged >60 years (227%) and among employees of Asian and Black ethnic origin (109%-136%). Among doctors and dentists the number of days absent declined by 12.7%. The biggest increase was in London (122%) and the smallest in the East Midlands (43.7%); the variation between regions reflected the rates of Covid-19 sickness absence during the same period.

ConclusionAlthough the Covid-19 epidemic led to an increase in sickness absence attributed to mental ill health in NHS staff, this had substantially declined by May/June 2020, corresponding with the decrease in pressures at work as the first wave of the epidemic subsided.

Article SummaryStrengths and limitations of this study

O_LILarge study population
C_LIO_LIStudy population were not self-selected
C_LIO_LIJob exposure matrix allowed adjustment for occupational exposure
C_LIO_LIData did not extend to the start of the second wave in September 2020
C_LI",occupational and environmental health,fuzzy,97,100
medRxiv,10.1101/2021.06.09.21258556,2021-06-13,https://medrxiv.org/cgi/content/short/2021.06.09.21258556,"Safety, Immunogenicity, and Efficacy of a COVID-19 Vaccine (NVX-CoV2373) Co-administered With Seasonal Influenza Vaccines",Paul Heath; Seth Toback; Eva Galiza; Catherine Cosgrove; James Galloway; Anna L. Goodman; Pauline A. Swift; Sankarasubramanian Rajaram; Alison Graves-Jones; Jonathan Edelman; Fiona Burns; Angela M. Minassian; Iksung Cho; Lakshmi Kumar; Joyce S. Plested; E. Joy Rivers; Andreana Robertson; Filip Dubovsky; Greg Glenn,"St Georges, University of London; Novavax; St. George's, University of London; St Georges University of London; Kings College London; Guy's and St Thomas' NHS Foundation Trust; Epsom and St. Helier University Hospitals NHS Trust; Seqirus; Seqirus; Seqirus; University College London, and Royal Free London NHS Foundation Trust; University of Oxford, and Oxford Health NHS Foundation Trust; Novavax; Novavax; Novavax; Novavax; Novavax; Novavax; Novavax","BackgroundThe safety and immunogenicity profile of COVID-19 vaccines when administered concomitantly with seasonal influenza vaccines has not yet been reported.

MethodsA sub-study on influenza vaccine co-administration was conducted as part of the phase 3 randomized trial of the safety and efficacy of NVX-CoV2373. The first [~]400 participants meeting main study entry criteria and with no contraindications to influenza vaccination were invited to join the sub-study. After randomization in a 1:1 ratio to receive NVX-CoV2373 (n=217) or placebo (n=214), sub-study participants received an age-appropriate, licensed, open-label influenza vaccine with dose 1 of NVX-CoV2373. Reactogenicity was evaluated via electronic diary for 7 days post-vaccination in addition to monitoring for unsolicited adverse events (AEs), medically-attended AEs (MAAEs), and serious AEs (SAEs). Influenza haemagglutination inhibition and SARS-CoV-2 anti-spike IgG assays were performed. Vaccine efficacy against PCR-confirmed, symptomatic COVID-19 was assessed. Comparisons were made between sub-study and main study participants.

FindingsSub-study participants were younger, more racially diverse, and had fewer comorbid conditions than main study participants. Reactogenicity events more common in the co-administration group included tenderness (70.1% vs 57.6%) or pain (39.7% vs 29.3%) at injection site, fatigue (27.7% vs 19.4%), and muscle pain (28.3% vs 21.4%). Rates of unsolicited AEs, MAAEs, and SAEs were low and balanced between the two groups. Co-administration resulted in no change to influenza vaccine immune response, while a reduction in antibody responses to the NVX-CoV2373 vaccine was noted. Vaccine efficacy in the sub-study was 87.5% (95% CI: -0.2, 98.4) while efficacy in the main study was 89.8% (95% CI: 79.7, 95.5).

InterpretationThis is the first study to demonstrate the safety, immunogenicity, and efficacy profile of a COVID-19 vaccine when co-administered with seasonal influenza vaccines. The results suggest concomitant vaccination may be a viable immunisation strategy.

FundingThis study was funded by Novavax, Inc.

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed for research articles published from December 2019 until 1 April 2021 with no language restrictions for the terms ""SARS-CoV-2"", ""COVID-19"", ""vaccine"", ""co-administration"", and ""immunogenicity"". There were no peer-reviewed publications describing the simultaneous use of any SARS-CoV-2 vaccine and another vaccine. Several vaccine manufacturers had recent publications on phase 3 trials results (Pfizer/BioNTech, Moderna, AstraZeneca, Janssen, and the Gamaleya Research Institute of Epidemiology and Microbiology). Neither these publications nor their clinical trials protocols (when publicly available) described co-administration and they often had trial criteria specifically excluding those with recent or planned vaccination with any licenced vaccine near or at the time of any study injection.

Added value of this studyImmune interference and safety are always a concern when two vaccines are administered at the same time. This is the first study to demonstrate the safety and immunogenicity profile and clinical vaccine efficacy of a COVID-19 vaccine when co-administered with a seasonal influenza vaccine.

Implications of all the available evidenceThis study provides much needed information to help guide national immunisation policy decision making on the critical issue of concomitant use of COVID-19 vaccines with influenza vaccines.",allergy and immunology,fuzzy,95,100
medRxiv,10.1101/2021.06.08.21258533,2021-06-12,https://medrxiv.org/cgi/content/short/2021.06.08.21258533,The impact of co-circulating pathogens on SARS-CoV-2/COVID-19 surveillance. How concurrent epidemics may decrease true SARS-CoV-2 percent positivity.,Aleksandra Kovacevic; Rosalind M Eggo; Marc Baguelin; Matthieu Domenech de Cell√®s; Lulla Opatowski,Institut Pasteur; London School of Hygiene & Tropical Medicine; Imperial College London; Max Planck Institute for Infection Biology; Univ Versailles Saint Quentin / Institut Pasteur / Inserm,"BackgroundCirculation of non-SARS-CoV-2 respiratory viruses during the COVID-19 pandemic may alter quality of COVID-19 surveillance, with possible consequences for real-time analysis and delay in implementation of control measures. Here, we assess the impact of an increased circulation of other respiratory viruses on the monitoring of positivity rates of SARS-CoV-2 and interpretation of surveillance data.

MethodsUsing a multi-pathogen Susceptible-Exposed-Infectious-Recovered (SEIR) transmission model formalizing co-circulation of SARS-CoV-2 and another respiratory we assess how an outbreak of secondary virus may inflate the number of SARS-CoV-2 tests and affect the interpretation of COVID-19 surveillance data. Using simulation, we assess to what extent the use of multiplex PCR tests on a subsample of symptomatic individuals can support correction of the observed SARS-CoV-2 percent positive during other virus outbreaks and improve surveillance quality.

ResultsModel simulations demonstrated that a non-SARS-CoV-2 epidemic creates an artificial decrease in the observed percent positivity of SARS-CoV-2, with stronger effect during the growth phase, until the peak is reached. We estimate that performing one multiplex test for every 1,000 COVID-19 tests on symptomatic individuals could be sufficient to maintain surveillance of other respiratory viruses in the population and correct the observed SARS-CoV-2 percent positive.

ConclusionsThis study highlights that co-circulating respiratory viruses can disrupt SARS-CoV-2 surveillance. Correction of the positivity rate can be achieved by using multiplex PCR, and a low number of samples is sufficient to avoid bias in SARS-CoV-2 surveillance.

SummaryCOVID-19 surveillance indicators may be impacted by increased co-circulation of other respiratory viruses delaying control measure implementation. Continued surveillance through multiplex PCR testing in a subsample of the symptomatic population may play a role in fixing this problem.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.06.08.21258546,2021-06-12,https://medrxiv.org/cgi/content/short/2021.06.08.21258546,Inequalities in healthcare disruptions during the Covid-19 pandemic: Evidence from 12 UK population-based longitudinal studies,Jane Maddock; Sam Parsons; Giorgio Di Gessa; Michael J Green; Ellen J Thompson; Anna J Stevenson; Alex S.F. Kwong; Eoin McElroy; Gillian Santorelli; Richard J Silverwood; Gabriella Captur; Nish Chaturvedi; Claire J Steves; Andrew Steptoe; Praveetha Patalay; George B Ploubidis; Srinivasa Vittal Katikireddi,University College London; University College London; University College London; University of Glasgow; King's College London; University of Edinburgh; University of Bristol; University of Leicester; Bradford Institute for Health Research; University College London; University College London; University College London; King's College London; University College London; University College London; University College London; University of Glasgow,"BackgroundHealth systems worldwide have faced major disruptions due to COVID-19 which could exacerbate health inequalities. The UK National Health Service (NHS) provides free healthcare and prioritises equity of delivery, but the pandemic may be hindering the achievement of these goals. We investigated associations between multiple social characteristics (sex, age, occupational social class, education and ethnicity) and self-reported healthcare disruptions in over 65,000 participants across twelve UK longitudinal studies.

MethodsParticipants reported disruptions from March 2020 up to late January 2021. Associations between social characteristics and three types of self-reported healthcare disruption (medication access, procedures, appointments) and a composite of any of these were assessed in logistic regression models, adjusting for age, sex and ethnicity where relevant. Random-effects meta-analysis was conducted to obtain pooled estimates.

ResultsPrevalence of disruption varied across studies; between 6.4% (TwinsUK) and 31.8 % (Understanding Society) of study participants reported any disruption. Females (Odd Ratio (OR): 1.27 [95%CI: 1.15,1.40]; I2=53%), older persons (e.g. OR: 1.39 [1.13,1.72]; I2=77% for 65-75y vs 45-54y), and Ethnic minorities (excluding White minorities) (OR: 1.19 [1.05,1.35]; I2=0% vs White) were more likely to report healthcare disruptions. Those in a more disadvantaged social class (e.g. OR: 1.17 [1.08, 1.27]; I2=0% for manual/routine vs managerial/professional) were also more likely to report healthcare disruptions, but no clear differences were observed by education levels.

ConclusionThe COVID-19 pandemic has led to unequal healthcare disruptions, which, if unaddressed, could contribute to the maintenance or widening of existing health inequalities.",health systems and quality improvement,fuzzy,97,100
medRxiv,10.1101/2021.06.07.21258476,2021-06-10,https://medrxiv.org/cgi/content/short/2021.06.07.21258476,Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics,Louise Dyson; Edward M Hill; Sam Moore; Jacob Curran-Sebastian; Michael J Tildesley; Katrina A Lythgoe; Thomas House; Lorenzo Pellis; Matt J Keeling,"The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, C; The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, C; The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, C; Department of Mathematics, University of Manchester, Manchester, United Kingdom; The Zeeman Institute for Systems Biology & Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, C; Big Data Institute, Old Road Campus, University of Oxford, United Kingdom.; Department of Mathematics, University of Manchester, Manchester, United Kingdom.; Department of Mathematics, University of Manchester, Manchester, United Kingdom.; The Zeeman Institute for Systems Biology \& Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, ","Viral reproduction of SARS-CoV-2 provides opportunities for the acquisition of advantageous mutations, altering viral transmissibility, disease severity, and/or allowing escape from natural or vaccine-derived immunity. We use three mathematical models: a parsimonious deterministic model with homogeneous mixing; an age-structured model; and a stochastic importation model to investigate the effect of potential variants of concern (VOCs). Calibrating to the situation in England in May 2021, we find epidemiological trajectories for putative VOCs are wide-ranging and dependent on their transmissibility, immune escape capability, and the introduction timing of a postulated VOC-targeted vaccine. We demonstrate that a VOC with a substantial transmission advantage over resident variants, or with immune escape properties, can generate a wave of infections and hospitalisations comparable to the winter 2020-2021 wave. Moreover, a variant that is less transmissible, but shows partial immune-escape could provoke a wave of infection that would not be revealed until control measures are further relaxed.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.06.08.21258535,2021-06-08,https://medrxiv.org/cgi/content/short/2021.06.08.21258535,Altered neutrophil phenotype and function in non-ICU COVID-19 patients correlated with disease severity,Kylie BR Belchamber; Onn S Thein; Jon Hazeldine; Frances S Grudzinska; Michael J Hughes; Alice E Jasper; Kay Por Yip; Elizabeth Sapey; Dhruv Parekh; David R Thickett; Aaron Scott,"Institute of Inflammation and Ageing, University of Birmingham; Institute of Inflammation and Ageing, University of Birmingham; 2National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham; Institute of Inflammation and Ageing, University of Birmingham; Institute of Inflammation and Ageing, University of Birmingham; Institute of Inflammation and Ageing, University of Birmingham; Institute of Inflammation and Ageing, University of Birmingham; Institute of Inflammation and Ageing, University of Birmingham; Institute of Inflammation and Ageing, University of Birmingham; Institute of Inflammation and Ageing, University of Birmingham; Institute of Inflammation and Ageing, University of Birmingham","RationalInfection with the SARS-CoV2 virus is associated with elevated neutrophil counts. Evidence of neutrophil dysfunction in COVID-19 is based predominantly on transcriptomics or single functional assays. Cell functions are interwoven pathways, and so understanding the effect of COVID-19 across the spectrum of neutrophil function may identify tractable therapeutic targets.

ObjectivesExamine neutrophil phenotype and functional capacity in COVID-19 patients versus age-matched controls (AMC)

MethodsIsolated neutrophils from 41 hospitalised, non-ICU COVID-19 patients and 23 AMC underwent ex vivo analyses for migration, bacterial phagocytosis, ROS generation, NET formation (NETosis) and cell surface receptor expression. DNAse 1 activity was measured, alongside circulating levels of cfDNA, MPO, VEGF, IL-6 and sTNFRI. All measurements were correlated to clinical outcome. Serial sampling on day 3-5 post hospitalisation were also measured.

ResultsCompared to AMC, COVID-19 neutrophils demonstrated elevated transmigration (p=0.0397) and NETosis (p=0.0366), but impaired phagocytosis (p=0.0236) associated with impaired ROS generation (p<0.0001). Surface expression of CD54 (p<0.0001) and CD11c (p=0.0008) was significantly increased and CD11b significantly decreased (p=0.0229) on COVID-19 patient neutrophils. COVID-19 patients showed increased systemic markers of NETosis including increased cfDNA (p=0.0153) and impaired DNAse activity (p<0.0.001). MPO (p<0.0001), VEGF (p<0.0001), TNFRI (p<0.0001) and IL-6 (p=0.009) were elevated in COVID-19, which positively correlated with disease severity by 4C score.

ConclusionCOVID-19 is associated with neutrophil dysfunction across all main effector functions, with altered phenotype, elevated migration, impaired antimicrobial responses and elevated NETosis. These changes represent a clear mechanism for tissue damage and highlight that targeting neutrophil function may help modulate COVID-19 severity.",intensive care and critical care medicine,fuzzy,100,92
medRxiv,10.1101/2021.06.08.21258531,2021-06-08,https://medrxiv.org/cgi/content/short/2021.06.08.21258531,"The UK Coronavirus Job Retention Scheme and changes in diet, physical activity and sleep during the COVID-19 pandemic: Evidence from eight longitudinal studies",Bozena Wielgoszewska; Jane Maddock; Michael J Green; Giorgio Di Gessa; Sam Parsons; Gareth J Griffith; Jazz Croft; Anna J Stevenson; Charlotte Booth; Richard J Silverwood; David Bann; Praveetha Patalay; Alun D Hughes; Nishi Chaturvedi; Laura D Howe; Emla Fitzsimons; Srinivasa Vittal Katikireddi; George B Ploubidis,"Centre for Longitudinal Studies, UCL Social Research Institute, University College London; MRC Unit for Lifelong Health and Ageing, University College London; MRC/CSO Social & Public Health Sciences Unit, University of Glasgow; Institute of Epidemiology and Health Care, University College London; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; MRC Integrative Epidemiology Unit, University of Bristol; MRC Integrative Epidemiology Unit, University of Bristol; Centre for Genomic and Experimental Medicine, University of Edinburgh; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; UCL; MRC Unit for Lifelong Health and Ageing, University College London; MRC Unit for Lifelong Health and Ageing, University College London; MRC Integrative Epidemiology Unit, University of Bristol; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; MRC/CSO Social & Public Health Sciences Unit, University of Glasgow; Centre for Longitudinal Studies, UCL Social Research Institute, University College London","BackgroundIn March 2020 the UK implemented the Coronavirus Job Retention Scheme (furlough) to minimize job losses. Our aim was to investigate associations between furlough and diet, physical activity, and sleep during the early stages of the COVID-19 pandemic.

MethodsWe analysed data from 25,092 participants aged 16 to 66 years from eight UK longitudinal studies. Changes in employment (including being furloughed) were defined by comparing employment status pre- and during the first lockdown. Health behaviours included fruit and vegetable consumption, physical activity, and sleeping patterns. Study-specific estimates obtained using modified Poisson regression, adjusting for socio-demographic characteristics and pre-pandemic health and health behaviours, were statistically pooled using random effects meta-analysis. Associations were also stratified by sex, age, and education.

ResultsAcross studies, between 8 and 25% of participants were furloughed. Compared to those who remained working, furloughed workers were slightly less likely to be physically inactive (RR:0.85, [0.75-0.97], I2=59%) and did not differ in diet and sleep behaviours, although findings for sleep were heterogenous (I2=85%). In stratified analyses, furlough was associated with low fruit and vegetable consumption among males (RR=1.11; 95%CI: 1.01-1.22; I2: 0%) but not females (RR=0.84; 95%CI: 0.68-1.04; I2: 65%). Considering change in these health behaviours, furloughed workers were more likely than those who remained working to report increased fruit and vegetable consumption, exercise, and hours of sleep.

ConclusionsThose furloughed exhibited broadly similar levels of health behaviours to those who remained in employment during the initial stages of the pandemic. There was little evidence to suggest that such social protection policies if used in the post-pandemic recovery period and during future economic crises would have adverse impacts on population health behaviours.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.06.08.21258132,2021-06-08,https://medrxiv.org/cgi/content/short/2021.06.08.21258132,"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial",Peter W Horby; Guilherme Pessoa-Amorim; Natalie Staplin; Jonathan R Emberson; Enti Spata; Mark Campbell; Leon Peto; Nigel Brunskill; Simon Tiberi; Victor Chew; Thomas Brown; Hasan Tahir; Beate Ebert; David R Chadwick; Tony Whitehouse; Rahuldeb Sarkar; Jonathan Clive Graham; J Kenneth Baillie; Buddha Basnyat; Maya H Buch; Lucy C Chappell; Jeremy N Day; Saul N Faust; Raph Hamers; Thomas Jaki; Katie Jeffery; Edmund Juszczak; Wei Shen Lim; Alan Montgomery; Andrew Mumford; Kathryn Rowan; Guy Thwaites; Marion Mafham; Richard Haynes; Martin J Landray,"Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; University of Leicester, Leicester, United Kingdom; Barts Health NHS Foundation Trust, London, United Kingdom; North Tees and Hartlepool NHS Foundation Trust, Hartlepool, United Kingdom; Portsmouth Hospitals University NHS Foundation Trust, Portsmouth, United Kingdom; Royal Free London NHS Foundation Trust, London, United Kingdom; North West Anglia NHS Foundation Trust, Peterborough, United Kingdom; James Cook University Hospital, Middlesbrough, United Kingdom; University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Medway NHS Foundation Trust, Gillingham, UK; North Cumbria Integrated Care NHS Foundation Trust, Carlisle, UK; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Oxford University Clinical Research Unit, Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal; Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; School of Life Sciences, Kings College London, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia and Faculty of Medicine, University of Indonesia, Jakarta, Indonesia, and Centre for Tropical Medicine; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Respiratory Medicine Department, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Intensive Care National Audit and Research Centre, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","BackgroundAspirin has been proposed as a treatment for COVID-19 on the basis of its antithrombotic properties.

MethodsIn this randomised, controlled, open-label platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care plus 150mg aspirin once daily until discharge or usual standard of care alone using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28-day mortality. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

FindingsBetween 01 November 2020 and 21 March 2021, 7351 patients were randomly allocated to receive aspirin and 7541 patients to receive usual care alone. Overall, 1222 (17%) patients allocated to aspirin and 1299 (17%) patients allocated to usual care died within 28 days (rate ratio 0{middle dot}96; 95% confidence interval [CI] 0{middle dot}89-1{middle dot}04; p=0{middle dot}35). Consistent results were seen in all pre-specified subgroups of patients. Patients allocated to aspirin had a slightly shorter duration of hospitalisation (median 8 vs. 9 days) and a higher proportion were discharged from hospital alive within 28 days (75% vs. 74%; rate ratio 1{middle dot}06; 95% CI 1{middle dot}02-1{middle dot}10; p=0{middle dot}0062). Among those not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (21% vs. 22%; risk ratio 0{middle dot}96; 95% CI 0{middle dot}90-1{middle dot}03; p=0{middle dot}23). Aspirin use was associated with an absolute reduction in thrombotic events of 0.6% (SE 0.4%) and an absolute increase in major bleeding events of 0.6% (SE 0.2%).

InterpretationIn patients hospitalised with COVID-19, aspirin was not associated with reductions in 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death but was associated with a small increase in the rate of being discharged alive within 28 days.

FundingUK Research and Innovation (Medical Research Council), National Institute of Health Research (Grant ref: MC_PC_19056), and the Wellcome Trust (Grant Ref: 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.06.03.21258289,2021-06-06,https://medrxiv.org/cgi/content/short/2021.06.03.21258289,Implementation of COVID-19 Preventive Measures in Primary and Secondary Schools Following Reopening of Schools in Autumn 2020; A Cross-Sectional Study of Parents' and Teachers' Experiences in England,Zahin Amin-Chowdhury; Marta Bertran; Meaghan Kall; Georgina Ireland; Felicity Aiano; Annabel Powell; Samuel E Jones; Andrew Brent; Bernadette Brent; Frances Baawuah; Ifeanychukwu Okike; Joanne Beckmann; Joanna Garstang; Shazaad Ahmed; Neisha Sundaram; Chris Bonell; Sinead Langan; James Hargreaves; Shamez N Ladhani,"Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Oxford University Hospitals NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; Public Health England; University Hospitals of Derby and Burton NHS foundation Trust; Specialist Children & Young People's Services, East London NHS Foundation Trust; Birmingham Community Healthcare Trust; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health England","ObjectiveThe main objective was to assess implementation of and ease of implementation of control measures in schools as reported by staff and parents.

DesignCross-sectional study.

SettingStaff and parents/guardian participants in the 132 primary schools and 20 secondary schools participating in sKIDs and sKIDsPLUS surveillances.

Main outcome measurePrevalence of control measures implemented in Autumn 2020, parental and staff perception of ease of implementation and acceptability of conducting school surveillance studies.

ResultsIn total, 56/152 (37%) schools participating in Public Health Englands sKIDs study of COVID in schools accepted the invitation to participate in the survey. By 28 December 2020, 1,953 parent and 986 staff respondents had completed the online questionnaire. While more than half the parents were positive about their children returning to school, roughly a third reported being a little anxious. 90% and 82% of primary and secondary school parents were either completely or partly reassured by the preventive measures implemented in their schools. Among staff, 80% of primary staff and 87% of secondary school staff felt that they were at higher risk of COVID-19 because of their profession; only 52% of primary school staff and 38% of secondary school staff reportedly felt safe. According to the teaching staff, most preventive measures were well-implemented apart from requiring 2-metre distancing between staff. For students, maintaining the 2-metre distance was reported to be particularly difficult. By extension, secondary schools also struggled to maintain small groups at all times or ensuring that the same staff were assigned to each student group (a problem also commonly reported by parents).

ConclusionsVariable implementation of infection control measures was reported by staff and parents. Whilst the majority were not worried about returning to school, some parents and staff, were concerned about returning to school and the risks posed to children, staff and household members.

Strengths and limitations of this studyO_ST_ABSStrengthsC_ST_ABSO_LIThis study is one of the few to investigate school staff and parents perceptions of the implementation of control measures implemented following the reopening of schools in England.
C_LIO_LIThe early establishment of COVID-19 surveillance in primary and secondary schools in the summer term 2020 provided a cohort to rapidly evaluate the experiences of parents and school staff during the autumn term before schools were required to close for the subsequent national lockdown.
C_LI

LimitationsO_LIAs the questionnaire and information provided was available in English only, there is likely to be an under-representation of families for whom English was not their main language.
C_LIO_LISome school responses were only provided by one participant so may not necessarily be representative of the whole school.
C_LIO_LIAlthough the surveillance included schools recruited nationally, a convenience sample was used and as such may not be representative of all primary and secondary schools in England.
C_LI",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.05.28.21257602,2021-06-02,https://medrxiv.org/cgi/content/short/2021.05.28.21257602,Prevalence of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales,Faith Miller; Vincent Nguyen; Annalan MD Navaratnam; Madhumita Shrotri; Jana Kovar; Andrew C Hayward; Ellen Fragaszy; Robert W Aldridge; - Virus Watch Collaborative; Pia Hardelid,UCL; UCL; UCL; UCL; UCL; UCL; UCL; UCL; ; University College London,"Using data from 4678 children participating in VirusWatch, a household cohort study, we estimated the prevalence of persistent symptoms lasting [&ge;]4 weeks as 1.7%, and 4.6% in children with a history of SARS-CoV-2 infection. Persistent symptom prevalence was higher in girls, teenagers and children with long-term conditions.",pediatrics,fuzzy,100,100
medRxiv,10.1101/2021.05.25.21257730,2021-06-01,https://medrxiv.org/cgi/content/short/2021.05.25.21257730,"Post-COVID assessment in a specialist clinical service: a 12-month, single-centre analysis of symptoms and healthcare needs in 1325 individuals.",Melissa Heightman; Jai Prashar; Toby Hillman; Michael Marks; Rebecca Livingston; Heidi Ridsdale; Kay Roy; Robert Bell; Michael Zandi; Patricia McNamara; Alisha Chauhan; Emma Denneny; Ronan Astin; Helen Purcell; Emily Attree; Lyth Hishmeh; Gordon Prescott; Rebecca Evans; Puja Mehta; Ewen Brennan; Jeremy Brown; Joanna Porter; Sarah Logan; Emma Wall; Hakim-Moulay Dehbi; Stephen Cone; Amitava Banerjee,University College London Hospitals NHS Trust; University College London; University College London NHS Trust; London School of Hygiene & Tropical Medicine; University College London NHS Trust; Central and North West London NHS Foundation Trust; University College London NHS Trust; University College London NHS Trust; University College London; University College London NHS Trust; University College London NHS Trust; University College London NHS Trust; University College London; University College London NHS Trust; UKDoctors#Longcovid; Long COVID SOS; University of Central Lancashire; University College London NHS Trust; University College London; University College London NHS Trust; University College London; University College London; University College London NHS Trust; University College London; University College London; University College London NHS Trust; University College London,"BackgroundComplications following SARS-CoV-2 infection require simultaneous characterisation and management to plan policy and health system responses. We describe the 12-month experience of the first UK dedicated Post-COVID clinical service to include both hospitalised and non-hospitalised patients.

MethodsIn a single-centre, observational analysis, we report outcomes for 1325 individuals assessed in the University College London Hospitals NHS Foundation Trust Post-COVID service between April 2020 and April 2021. Demography, symptoms, comorbidities, investigations, treatments, functional recovery, specialist referral and rehabilitation were compared by referral route (""post hospitalisation"", PH; ""non-hospitalised"", NH; and ""post emergency department"", PED). Symptoms associated with poor recovery or inability to return to work full-time were assessed using multivariable logistic regression.

Findings1325 individuals were assessed (PH 547 [41.3%], PED 212 [16%], NH 566 [42.7%]. Compared with PH and PED groups, NH were younger (median 44.6 [35.6-52.8] vs 58.3 [47.0-67.7] and 48.5 [39.4-55.7] years), more likely to be female (68.2%, 43.0% and 59.9%), less likely to be from an ethnic minority (30.9%, 52.7% and 41.0%) and seen later after symptom onset (median [IQR]:194 [118-298], 69 [51-111] and 76 [55-128] days) (all p<0.0001). NH patients had similar rates of onward specialist referral as PH and PED groups (18.7%, 16.1% and 18.9%, p=0.452), and were more likely to require support for breathlessness (23.7%, 5.5% and 15.1%, p<0.001) and fatigue (17.8%, 4.8%, 8.0%, p<0.001). Hospitalised patients had higher rates of pulmonary emboli, persistent lung interstitial abnormalities, and other organ impairment. 716 (54.0%) individuals reported <75% of optimal health (median [IQR] 70% [55%-85%]). Overall, less than half of employed individuals felt able to return to work full-time at first assessment.

InterpretationSymptoms following SARS-CoV-2 infection were significant in both post- and non-hospitalised patients, with significant ongoing healthcare needs and utilisation. Trials of interventions and patient-centred pathways for diagnostic and treatment approaches are urgently required.

FundingUCLH/UCL BRC

Research in contextO_ST_ABSPrevious evidenceC_ST_ABSLong COVID and post-COVID syndrome were first identified in April 2020. We searched PubMed and medrxiv for articles published up to April 30th, 2021, using the keywords ""long COVID"", ""post-COVID syndrome"", ""persistent symptoms"", ""hospitalised"", ""community"" and ""non-hospitalised"". We identified 17 articles and 7 systematic reviews. Fifteen studies have considered symptoms, multi-organ or functional impairment but only one study to-date has considered all these variables in non-hospitalised COVID patients. No studies have compared symptom burden and management between non-hospitalised and hospitalised individuals as systematically assessed and managed in a dedicated post-COVID service.

Added value of this studyFor the first time, we report the baseline characteristics, investigation and outcomes of initial assessment of all eligible patients in a dedicated multi-professional post-COVID service, including 547 post-hospitalisation, 566 non-hospitalised and 212 patients discharged from emergency department. Despite relatively low comorbidity and risk factor burden in non-hospitalised patients, we show that both non-hospitalised and hospitalised patients presenting with persistent symptoms after SARS-CoV2 infection have high rates of functional impairment, specialist referral and rehabilitation, even 6-12 months after the acute infection. These real-world data will inform models of care during and beyond the pandemic.

Implications of all the available evidenceThe significant, long-lasting health and social consequences of SARS-CoV-2 infection are not confined to those who required hospitalisation. As with other long-term conditions, care of patients experiencing Long COVID or specific end-organ effects require consistent, integrated, patient-centred approaches to investigation and management. At public health and policy level, burden of post-COVID morbidity demands renewed focus on effective infection suppression for all age groups.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.05.27.21257032,2021-05-31,https://medrxiv.org/cgi/content/short/2021.05.27.21257032,How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology,Naomi R Waterlow; Edwin Van Leeuwen; Nicholas G Davies; - CMMID COVID-19 working group; Stefan Flasche; Rosalind M Eggo,London School of Hygiene and Tropical Medicine; Public Health England; London School of Hygiene and Tropical Medicine; ; LSHTM; London School of Hygiene & Tropical Medicine,"We hypothesised that cross-protection from seasonal epidemics of human coronaviruses (HCoVs) could have affected SARS-CoV-2 transmission, including generating reduced susceptibility in children. To determine what the pre-pandemic distribution of immunity to HCoVs was, we fitted a mathematical model to 6 years of seasonal coronavirus surveillance data from England and Wales. We estimated a duration of immunity to seasonal HCoVs of 7.3 years (95%CI 6.8 - 7.9) and show that, while cross-protection between HCoV and SARS-CoV-2 may contribute to the age distribution, it is insufficient to explain the age pattern of SARS-CoV-2 infections in the first wave of the pandemic in England and Wales. Projections from our model illustrate how different strengths of cross-protection between circulating coronaviruses could determine the frequency and magnitude of SARS-CoV-2 epidemics over the coming decade, as well as the potential impact of cross-protection on future seasonal coronavirus transmission.

Significance statementCross-protection from seasonal epidemics of human coronaviruses (HCoVs) has been hypothesised to contribute to the relative sparing of children during the early phase of the pandemic. Testing this relies on understanding the pre-pandemic age-distribution of recent HCoV infections, but little is known about their dynamics. Using England and Wales as a case study, we use a transmission model to estimate the duration of immunity to seasonal coronaviruses, and show how cross-protection could have affected the age distribution of susceptibility during the first wave, and alter SARS-CoV-2 transmission patterns over the coming decade.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.05.22.21257633,2021-05-26,https://medrxiv.org/cgi/content/short/2021.05.22.21257633,Genomic reconstruction of the SARS-CoV-2 epidemic across England from September 2020 to May 2021,Harald S. Vohringer; Theo Sanderson; Matthew Sinnott; Nicola De Maio; Thuy Nguyen; Richard Goater; Frank Schwach; Ian Harrison; Joel Hellewell; Cristina Ariani; Sonia Goncalves; David Jackson; Ian Johnston; Alexander W. Jung; Callum Saint; John Sillitoe; Maria Suciu; Nick Goldman; Jasmina Panovska-Griffiths; - The Wellcome Sanger Institute Covid-19 Surveillance Team; - The COVID-19 Genomics UK (COG-UK) Consortium; Ewan Birney; Erik Volz; Sebastian Funk; Dominic Kwiatkowski; Meera Chand; Inigo Martincorena; Jeffrey C. Barrett; Moritz Gerstung,"European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK; Current address: Joint Biosecurity Center JBC; Wellcome Sanger Institute, Hinxton, UK; The Francis Crick Institute, London, UK; Wellcome Sanger Institute, Hinxton, UK; European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK; Wellcome Sanger Institute, Hinxton, UK; Wellcome Sanger Institute, Hinxton, UK; Wellcome Sanger Institute, Hinxton, UK; Public Health England PHE; Public Health England PHE; London School of Hygiene & Tropical Medicine, London, UK; Wellcome Sanger Institute, Hinxton, UK; Wellcome Sanger Institute, Hinxton, UK; Wellcome Sanger Institute, Hinxton, UK; Wellcome Sanger Institute, Hinxton, UK; European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK; Wellcome Sanger Institute, Hinxton, UK; Wellcome Sanger Institute, Hinxton, UK; Wellcome Sanger Institute, Hinxton, UK; European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK; Joint Biosecurity Center JBC, Big Data Institute, University of Oxford, UK; ; ; European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK; Imperial College, London, UK; London School of Hygiene & Tropical Medicine, London, UK; Wellcome Sanger Institute, Hinxton, UK; Public Health England PHE; Wellcome Sanger Institute, Hinxton, UK; Wellcome Sanger Institute, Hinxton, UK; European Molecular Biology Laboratory, European Bioinformatics Institute EMBL-EBI, Hinxton, UK; German Cancer Research Centre dkfz, Heidelberg, Germany","The evolution of the SARS-CoV-2 pandemic continuously produces new variants, which warrant timely epidemiological characterisation. Here we use the dense genomic surveillance generated by the COVID-19 Genomics UK Consortium to reconstruct the dynamics of 71 different lineages in each of 315 English local authorities between September 2020 and June 2021. This analysis reveals a series of sub-epidemics that peaked in the early autumn of 2020, followed by a jump in transmissibility of the B.1.1.7/Alpha lineage. Alpha grew when other lineages declined during the second national lockdown and regionally tiered restrictions between November and December 2020. A third more stringent national lockdown suppressed Alpha and eliminated nearly all other lineages in early 2021. However, a series of variants (mostly containing the spike E484K mutation) defied these trends and persisted at moderately increasing proportions. Accounting for sustained introductions, however, indicates that their transmissibility is unlikely to have exceeded that of Alpha. Finally, B.1.617.2/Delta was repeatedly introduced to England and grew rapidly in the early summer of 2021, constituting approximately 98% of sampled SARS-CoV-2 genomes on June 26.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.05.24.21257738,2021-05-26,https://medrxiv.org/cgi/content/short/2021.05.24.21257738,"Post-vaccination SARS-CoV-2 infection: risk factors and illness profile in a prospective, observational community-based case-control study",Michela Antonelli; Rose S Penfold; Jordi Merino; Carole H Sudre; Erika Molteni; Sarah Berry; Liane S Canas; Mark S Graham; Kerstin Klaser; Marc Modat; Benjamin Murray; Eric Kerfoot; Liyuan Chen; Jie Deng; Marc F √ñsterdahl; Nathan J Cheetham; David Alden Drew; Long Alden Nguyen; Joan Capdeila; Christina Hu; Somesh Selvachandran; Lorenzo Polidori; Anna May; Jonathan Wolf; Andrew T Chan; Alexander Hammers; Emma Duncan; Timothy Spector; Sebastien Ourselin; Claire J Steves,"King's College London; King's College London; Department of Medicine, Harvard Medical School, Boston, MA, USA; Centre for Medical Image Computing, University College London, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; Department of Twin Research and Genetic Epidemiology, King's College London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; King's College London; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; Department of Twin Research and Genetic Epidemiology, King's College London, UK; Department of Twin Research and Genetic Epidemiology, King's College London, UK; Massachusetts General Hospital; Massachusetts General Hospital and Harvard Medical School; Zoe Global, London, UK; Zoe Global, London, UK; Zoe Global, London, UK; Lorenzo Polidori; Zoe Global, London, UK; Zoe Global, London, UK; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; Department of Twin Research and Genetic Epidemiology, King's College London, UK; King's College London; School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK; Department of Twin Research and Genetic Epidemiology, King's College London, UK","BackgroundCOVID-19 vaccines show excellent efficacy in clinical trials and real-world data, but some people still contract SARS-CoV-2 despite vaccination. This study sought to identify risk factors associated with SARS-CoV-2 infection post-vaccination and describe characteristics of post-vaccination illness.

MethodsAmongst 1,102,192 vaccinated UK adults from the COVID Symptom Study, 2394 (0.2%) cases of post-vaccination SARS-CoV-2 infection were identified between 8th December 2020 and 1st May 2021. Using a control group of vaccinated individuals testing negative, we assessed the associations of age, frailty, comorbidity, area-level deprivation and lifestyle factors with infection. Illness profile post-vaccination was assessed using a second control group of unvaccinated cases.

FindingsOlder adults with frailty (OR=2.78, 95% CI=[1.98-3.89], p-value<0.0001) and individuals living in most deprived areas (OR=1.22 vs. intermediate group, CI[1.04-1.43], p-value=0.01) had increased odds of post-vaccination infection. Risk was lower in individuals without obesity (OR=0.6, CI[0.44-0.82], p-value=0.001) and those reporting healthier diet (OR=0.73, CI[0.62-0.86], p-value<0.0001). Vaccination was associated with reduced odds of hospitalisation (OR=0.36, CI[0.28-0.46], p-value<0.0001), and high acute-symptom burden (OR=0.51, CI[0.42-0.61], p-value<0.0001). In older adults, risk of [&ge;]28 days illness was lower following vaccination (OR=0.72, CI[0.51-1.00], p-value=0.05). Symptoms were reported less in positive-vaccinated vs. positive-unvaccinated individuals, except sneezing, which was more common post-vaccination (OR=1.24, CI[1.05-1.46], p-value=0.01).

InterpretationOur findings suggest that older individuals with frailty and those living in most deprived areas are at increased risk of infection post-vaccination. We also showed reduced symptom burden and duration in those infected post-vaccination. Efforts to boost vaccine effectiveness in at-risk populations, and to targeted infection control measures, may still be appropriate to minimise SARS-CoV-2 infection.

FundingThis work is supported by UK Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre (BRC) award to Guys & St Thomas NHS Foundation Trust in partnership with Kings College London and Kings College Hospital NHS Foundation Trust and via a grant to ZOE Global; the Wellcome Engineering and Physical Sciences Research Council (EPSRC) Centre for Medical Engineering at Kings College London (WT 203148/Z/16/Z). Investigators also received support from the Chronic Disease Research Foundation, the Medical Research Council (MRC), British Heart Foundation, the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, the Wellcome Flagship Programme (WT213038/Z/18/Z and Alzheimers Society (AS-JF-17-011), and the Massachusetts Consortium on Pathogen Readiness (MassCPR).

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSTo identify existing evidence for risk factors and characteristics of SARS-CoV-2 infection post-vaccination, we searched PubMed for peer-reviewed articles published between December 1, 2020 and May 18, 2021 using keywords (""COVID-19"" OR ""SARS-CoV-2"") AND (""Vaccine"" OR ""vaccination"") AND (""infection"") AND (""risk factor*"" OR ""characteristic*""). We did not restrict our search by language or type of publication. Of 202 articles identified, we found no original studies on individual risk and protective factors for COVID-19 infection following vaccination nor on nature and duration of symptoms in vaccinated, community-based individuals. Previous studies in unvaccinated populations have shown that social and occupational factors influence risk of SARS-CoV-2infection, and that personal factors (age, male sex, multiple morbidities and frailty) increased risk for adverse outcomes in COVID-19. Phase III clinical trials have demonstrated good efficacy of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infection, confirmed in published real-world data, which additionally showed reduced risk of adverse outcomes including hospitalisation and death.

Added value of this studyThis is the first observational study investigating characteristics of and factors associated with SARS-CoV-2 infection after COVID-19 vaccination. We found that vaccinated individuals with frailty had higher rates of infection after vaccination than those without. Adverse determinants of health such as increased social deprivation, obesity, or a less healthy diet were associated with higher likelihood of infection after vaccination. In comparison with unvaccinated individuals, those with post-vaccination infection had fewer symptoms of COVID-19, and more were entirely asymptomatic. Fewer vaccinated individuals experienced five or more symptoms, required hospitalisation, and, in the older adult group, fewer had prolonged illness duration (symptoms lasting longer than 28 days).

Implications of all the available evidenceSome individuals still contract COVID-19 after vaccination and our data suggest that frail older adults and those living in more deprived areas are at higher risk. However, in most individuals illness appears less severe, with reduced need for hospitalisation and lower risk of prolonged illness duration. Our results are relevant for health policy post-vaccination and highlight the need to prioritise those most at risk, whilst also emphasising the balance between the importance of personal protective measures versus adverse effects from ongoing social restrictions. Strategies such as timely prioritisation of booster vaccination and optimised infection control could be considered for at-risk groups. Research is also needed on how to enhance the immune response to vaccination in those at higher risk.",epidemiology,fuzzy,94,100
medRxiv,10.1101/2021.05.25.21257505,2021-05-25,https://medrxiv.org/cgi/content/short/2021.05.25.21257505,Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.,Jose F. Varona; Pedro Landete; Jose A Lopez-Martin; Vicente Estrada; Roger Paredes; Pablo Guisado-Vasco; Lucia Fernandez de Orueta; Miguel Torralba; Jesus Fortun; Roberto Vates; Jose Barberan; Bonaventura Clotet; Julio Ancochea; Daniel Carnevali; Noemi Cabello; Lourdes Porras; Paloma Gijon; Alfonso Monereo; Daniel Abad; Sonia Zu√±iga; Isabel Sola; Jordi Rodon; Nuria Izquierdo-Useros; Salvador Fudio; Maria Jose Pontes; Beatriz de Rivas; Patricia Giron de Velasco; Belen Sopesen; Antonio Nieto; Javier Gomez; Pablo Aviles; Rubin Lubomirov; Kris M White; Romel Rosales; Soner Yildiz; Ann-Kathrin Reuschl; Lucy G. Thorne; Clare Jolly; Greg J. Towers; Lorena Zuliani-Alvarez; Mehdi Bouhaddou; Kirsten Obernier; Luis Enjuanes; Jose M Fernandez-Sousa; - Plitidepsin COVID Study Group; Nevan J Krogan; Jose M. Jimeno; Adolfo Garcia-Sastre,"Departamento de Medicina Interna, Hospital Universitario HM Monteprincipe, HM Hospitales, Madrid, Spain. Facultad de Medicina, Universidad San Pablo-CEU, Madrid; Hospital Universitario de La Princesa. Madrid, Spain. Universidad Autonoma de Madrid, Madrid, Spain.; PharmaMar. Virology & Inflammation Dept. Colmenar Viejo, Madrid, Spain.; Hospital Clinico San Carlos, Madrid, Spain. Universidad Complutense de Madrid, Madrid, Spain.; IrsiCaixa AIDS Research Institute; Internal Medicine Department, Hospital Universitario Quironsalud, Madrid, Spain. Universidad Europea, Madrid, Spain.; Internal Medicine Department, Hospital Universitario de Getafe, Madrid, Spain. European University of Madrid, Madrid, Spain.; Internal Medicine, Guadalajara University Hospital, Guadalajara, Spain. University of Alcala, Madrid, Spain.; Hospital Universitario Ramon y Cajal, Madrid, Spain.; Internal Medicine Department, Hospital Universitario de Getafe, Madrid, Spain.; Hospital Universitario HM Monteprincipe, Madrid, Spain. Facultad de Medicina San Pablo CEU, Madrid, Spain.; Head of Infectious Diseases Department, Director of the Research Lab, IrsiCaixa, Barcelone, Spain. Professor of the UAB and the UVIC-UCC, Barcelone, Spain.; Hospital Universitario La Princesa, Madrid, Spain. Centro de Investigacion en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII; Hospital Universitario Quironsalud, Madrid, Spain Universidad Europea, Madrid, Spain.; Infectious Diseases Department, San Carlos University Hospital. Madrid Spain.; Internal Medicine, Hospital General de Ciudad Real, Ciudad Real, Spain.; Clinical Microbiology and Infectious Diseases Department, Hospital General Universitario Gregorio Mara√±on, Instituto de Investigacion Sanitaria Gregorio Mara√±on; Internal Medicine Department, Hospital Universitario de Getafe, Madrid, Spain; Internal Medicine Department, Hospital Universitario de Getafe, Madrid, Spain. European University of Madrid, Madrid, Spain.; Department of Molecular and Cell Biology, Centro Nacional de Biotecnologia (CNBCSIC), Madrid, Spain.; Department of Molecular and Cell Biology, Centro Nacional de Biotecnologia (CNBCSIC), Madrid, Spain.; IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la UAB, Bellaterra, Spain; IrsiCaixa AIDS Research Institute, 08916, Badalona, Spain. Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, 08916, Badalona, Spain.; PharmaMar - Clinical Pharmacology Unit. Colmenar Viejo, Madrid, Spain; PharmaMar - Medical Affairs Unit. Colmenar Viejo. Madrid, Spain.; PharmaMar - Medical Affairs Unit. Colmenar Viejo, Madrid, Spain.; PharmaMar. Virology & Inflammation Dept. Colmenar Viejo, Madrid, Spain.; PharmaMar. Virology & Inflammation Dept. Colmenar Viejo, Madrid, Spain. Sylentis, S.A.U., Tres Cantos, Madrid, Spain. Biocross, S.L., Valladolid, Spain.; PharmaMar - Statistics Unit. Colmenar Viejo, Madrid, Spain.; PharmaMar - Statistics Unit. Colmenar Viejo, Madrid, Spain.; PharmaMar - Preclinical Unit. Colmenar Viejo, Madrid, Spain; PharmaMar - Clinical Pharmacology Unit. Colmenar Viejo, Madrid, Spain; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Global Health Emerging Pathogens Institute, Icahn School of Medicine at ; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Global Health Emerging Pathogens Institute, Icahn School of Medicine at ; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Global Health Emerging Pathogens Institute, Icahn School of Medicine at ; Division of Infection and Immunity, University College Londo, London, WC1E 6BT, United Kigdom.; Division of Infection and Immunity, University College Londo, London, WC1E 6BT, United Kigdom.; Division of Infection and Immunity, University College Londo, London, WC1E 6BT, United Kigdom.; Division of Infection and Immunity, University College Londo, London, WC1E 6BT, United Kigdom; Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA. J. David Gladstone Institutes, San Francisco, CA 94158, USA. QBI, Coronavirus Research G; Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA. J. David Gladstone Institutes, San Francisco, CA 94158, USA. QBI, Coronavirus Research G; Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA. J. David Gladstone Institutes, San Francisco, CA 94158, USA. QBI, Coronavirus Research G; Department of Molecular and Cell Biology, Centro Nacional de Biotecnologia (CNB-CSIC), Madrid, Spain.; PharmaMar, S.A., Colmenar Viejo, Madrid, Spain.; ; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Quantitative Biosciences Institute (QBI), San Francisco, CA 94158, USA. ; PharmaMar. Virology & Inflammation Dept. Colmenar Viejo, Madrid, Spain.; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Global Health Emerging Pathogens Institute, Icahn School of Medicine at ","Plitidepsin is a marine-derived cyclic-peptide that inhibits SARS-CoV-2 replication at low nanomolar concentrations by the targeting of host protein eEF1A (eukaryotic translation-elongation-factor-1A). We evaluated a model of intervention with plitidepsin in hospitalized COVID-19 adult patients where three doses were assessed (1.5, 2 and 2.5 mg/day for 3 days, as a 90-minute intravenous infusion) in 45 patients (15 per dose-cohort). Treatment was well tolerated, with only two Grade 3 treatment-related adverse events observed (hypersensitivity and diarrhea). The discharge rates by Days 8 and 15 were 56.8% and 81.8%, respectively, with data sustaining dose-effect. A mean 4.2 log10 viral load reduction was attained by Day 15. Improvement in inflammation markers was also noted in a seemingly dose-dependent manner. These results suggest that plitidepsin impacts the outcome of patients with COVID-19.

One-Sentence SummaryPlitidepsin, an inhibitor of SARS-Cov-2 in vitro, is safe and positively influences the outcome of patients hospitalized with COVID-19.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.05.18.21257396,2021-05-23,https://medrxiv.org/cgi/content/short/2021.05.18.21257396,A Phenome-Wide Association Study of genes associated with COVID-19 severity reveals shared genetics with complex diseases in the Million Veteran Program,Anurag Verma; Noah L. Tsao; Lauren O. Thomann; Yuk-Lam Ho; Sudha K. Iyengar; Shiuh-Wen Luoh; Rotonya Carr; Dana C. Crawford; Jimmy T. Efird; Giulio Genovese; Adriana Hung; Kerry L. Ivey; Michael G. Levin; Julie Lynch; Pradeep Natarajan; Saiju Pyarajan; Alexander Bick; Lauren Costa; Giulio Genovese; Richard Hauger; Ravi Madduri; Gita A. Pathak; Renato Polimanti; Benjamin F. Voight; Marijana Vujkovic; Maryam Zekavat; Hongyu Zhao; Marylyn Ritchie; Kyong-Mi Chang; Kelly Cho; Juan P Casas; Philip S Tsao; J. Michael Gaziano; Christopher O?Donnell; Scott M. Damrauer; Katherine P. Liao,"Corporal Michael Crescenz VA Medical Center, Philadelphia, Philadelphia, USA;Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Ph; Corporal Michael Crescenz VA Medical Center, Philadelphia, Philadelphia, USA;Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Phi; VA Boston Healthcare System, Boston, Massachusetts, USA; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts, USA; Departments of Population and Quantitative Health Sciences, Ophthalmology and Visual Sciences and Genetics and Genome Sciences, Case Western Reserve University,; VA Portland Health Care System, Portland OR, USA; Corporal Michael Crescenz VA Medical Center, Philadelphia, Philadelphia, USA;Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Ph; Cleveland Institute for Computational Biology, Case Western Reserve University, Cleveland, Ohio, USA; Cooperative Studies Program Epidemiology Center, Health Services Research and Development, DVAHCS (Duke University Affiliate), Durham, North Carolina, USA.; Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.; Tennessee Valley Healthcare System (Nashville VA) , Nashville, Tennessee, USA; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts, USA; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, Utah, USA.; Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA.; VA Boston Healthcare System, Boston, Massachusetts, USA;Harvard Medical School, Boston, Massachusetts, USA; VA Boston Healthcare System, Boston, Massachusetts, USA;Vanderbilt University, Nashville, Tennessee, USA; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts, USA; Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA.; Department of Psychiatry, University of California, San Diego, La Jolla, CA; Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, ; University of Chicago Consortium for Advanced Science and Engineering, The University of Chicago, Chicago, Illinois, USA;Data Science and Learning Division, Arg; Department of Psychiatry, Yale School of Medicine, Connecticut, USA; Department of Psychiatry, Yale School of Medicine, Connecticut, USA; Corporal Michael Crescenz VA Medical Center, Philadelphia, Philadelphia, USA;Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Ph; Corporal Michael Crescenz VA Medical Center, Philadelphia, Philadelphia, USA;Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Ph; VA Boston Healthcare System, Boston, Massachusetts, USA; VA Connecticut Healthcare System, West Haven, CT, USA; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Corporal Michael Crescenz VA Medical Center, Philadelphia, Philadelphia, USA; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts, USA; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts, USA; VA Palo Alto Health Care System, Palo Alto, California, USA; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, Massachusetts, USA; VA Boston Healthcare System, Boston, Massachusetts, USA; Corporal Michael Crescenz VA Medical Center, Philadelphia, Philadelphia, USA;Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Phi; VA Boston Healthcare System, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA; Brigham and Women's Hospital, Boston, Massachusetts","The study aims to determine the shared genetic architecture between COVID-19 severity with existing medical conditions using electronic health record (EHR) data. We conducted a Phenome-Wide Association Study (PheWAS) of genetic variants associated with critical illness (n=35) or hospitalization (n=42) due to severe COVID-19 using genome-wide association summary from the Host Genetics Initiative. PheWAS analysis was performed using genotype-phenotype data from the Veterans Affairs Million Veteran Program (MVP). Phenotypes were defined by International Classification of Diseases (ICD) codes mapped to clinically relevant groups using published PheWAS methods. Among 658,582 Veterans, variants associated with severe COVID-19 were tested for association across 1,559 phenotypes. Variants at the ABO locus (rs495828, rs505922) associated with the largest number of phenotypes (nrs495828= 53 and nrs505922=59); strongest association with venous embolism, odds ratio (ORrs495828 1.33 (p=1.32 x 10-199), and thrombosis ORrs505922 1.33, p=2.2 x10-265. Among 67 respiratory conditions tested, 11 had significant associations including MUC5B locus (rs35705950) with increased risk of idiopathic fibrosing alveolitis OR 2.83, p=4.12 x 10-191; CRHR1 (rs61667602) associated with reduced risk of pulmonary fibrosis, OR 0.84, p=2.26x 10-12. The TYK2 locus (rs11085727) associated with reduced risk for autoimmune conditions, e.g., psoriasis OR 0.88, p=6.48 x10-23, lupus OR 0.84, p=3.97 x 10-06. PheWAS stratified by genetic ancestry demonstrated differences in genotype-phenotype associations across ancestry. LMNA (rs581342) associated with neutropenia OR 1.29 p=4.1 x 10-13 among Veterans of African ancestry but not European. Overall, we observed a shared genetic architecture between COVID-19 severity and conditions related to underlying risk factors for severe and poor COVID-19 outcomes. Differing associations between genotype-phenotype across ancestries may inform heterogenous outcomes observed with COVID-19. Divergent associations between risk for severe COVID-19 with autoimmune inflammatory conditions both respiratory and non-respiratory highlights the shared pathways and fine balance of immune host response and autoimmunity and caution required when considering treatment targets.",genetic and genomic medicine,fuzzy,91,92
medRxiv,10.1101/2021.05.13.21257161,2021-05-18,https://medrxiv.org/cgi/content/short/2021.05.13.21257161,"Occupation, Work-Related Contact, and SARS-CoV-2 Anti-Nucleocapsid Serological Status: Findings from the Virus Watch prospective cohort study",Sarah Beale; Parth Patel; Alison Rodger; Isobel Braithwaite; Thomas Edward Byrne; Wing Lam Erica Fong; Ellen Fragaszy; Cyril Geismar; Jana Kovar; Annalan MD Navaratnam; Vincent Nguyen; Madhumita Shrotri; Robert W Aldridge; Andrew C Hayward; - Virus Watch Collaborative,University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; ,"BackgroundWorkers differ in their risk of acquiring SARS-CoV-2 infection according to their occupation; however, few studies have been able to control for multiple confounders or investigate the work-related factors that drive differences in occupational risk. Using data from the Virus Watch community cohort study in England and Wales, we set out to estimate the total effect of occupation on SARS-CoV-2 serological status, whether this is mediated by frequency of close contact within the workplace, and how exposure to poorly ventilated workplaces varied across occupations.

MethodsWe used data from a sub-cohort (n =3761) of adults ([&ge;]18) tested for SARS-CoV-2 anti-nucleocapsid antibodies between 01 February-28 April 2021 and responded to a questionnaire about work during the pandemic. Anti-nucleocapsid antibodies were used as a proxy of prior natural infection with COVID-19. We used logistic decomposition to estimate the total and direct effect of occupation and indirect effect of workplace contact frequency on odds of seropositivity, adjusting for age, sex, household income and region. We investigated the relationship between occupation and exposure to poorly-ventilated workplace environments using ordinal logistic regression.

ResultsSeropositivity was 16.0% (113/707) amongst workers with daily close contact, compared to 12.9% (120/933) for those with intermediate-frequency contact and 9.6% (203/2121) for those with no work-related close contact. Healthcare (OR= 2.14, 95% CI 1.47,3.12), indoor trade, process and plant (2.09, 1.31,3.33), leisure and personal service (1.96, 1.004,3.84), and transport and mobile machine (2.17, 1.12,4.18) workers had elevated total odds of SARS-CoV-2 seropositivity compared to other professional and associate occupations. Frequency of workplace contact accounted for a variable part of the increased odds in different occupational groups (OR range 1.04 [1.0004,1.07] - 1.22 [1.07, 1.38]). Healthcare workers and indoor trades and process plant workers continued to have raised odds of infection after accounting for work-related contact, and also had had greater odds of frequent exposure to poorly-ventilated workplaces (respectively 2.15 [1.66, 2.79] and (1.51, [1.12, 2.04]).

DiscussionMarked variations in occupational odds of seropositivity remain after accounting for age, sex, region, and household income. Close contact in the workplace appears to contribute substantially to this variation. Reducing frequency of workplace contact is a critical part of COVID-19 control measures.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.05.14.21257229,2021-05-18,https://medrxiv.org/cgi/content/short/2021.05.14.21257229,Symptom profiles and accuracy of clinical definitions for COVID-19 in the community. Results of the Virus Watch community cohort.,Ellen Fragaszy; Madhumita Shrotri; Cyril Geismar; Anna Aryee; Sarah Beale; Isobel Braithwaite; Thomas Byrne; Wing Lam Erica Fong; Jo Gibbs; Pia Hardelid; Jana Kovar; Vasileios Edward Lampos; Eleni Nastouli; Annalan Mathew Dwight Navaratnam; Vincent Grigori Nguyen; Parth Patel; Robert W Aldridge; Andrew Hayward; - Virus Watch Collaborative,"Centre for Public Health Data Science, Institute of Health Informatics, University College London; Department of Infectious Disease Epidemiology, London School ; Centre for Public Health Data Science, Institute of Health Informatics, University College London; Centre for Public Health Data Science, Institute of Health Informatics, University College London; Institute of Epidemiology and Health Care, University College; Institute of Health Informatics, University College London; Centre for Public Health Data Science, Institute of Health Informatics, University College London; Institute of Epidemiology and Health Care, University College; Centre for Public Health Data Science, Institute of Health Informatics, University College London; Centre for Public Health Data Science, Institute of Health Informatics, University College London; Centre for Public Health Data Science, Institute of Health Informatics, University College London; Institute for Global Health, University College London; Department of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health; Institute of Epidemiology and Health Care, University College London; Department of Computer Science, University College London; Department of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health; Francis Crick Institute, London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London; . Institute of Epidemiology and Health Care, University Colle; Centre for Public Health Data Science, Institute of Health Informatics, University College London; Institute of Epidemiology and Health Care, University College; Centre for Public Health Data Science, Institute of Health Informatics, University College London; Centre for Public Health Data Science, Institute of Health Informatics, University College London; Institute of Epidemiology and Health Care, University College London; ","BackgroundUnderstanding the symptomatology and accuracy of clinical case definitions for COVID-19 in the community is important for the initiation of Test, Trace and Isolate (TTI) and may, in future, be important for early prescription of antivirals.

MethodsVirus Watch is a large community cohort with prospective daily recording of a wide range of symptoms and self-reporting of swab results (mainly undertaken through the UK TTI system). We compared frequency, severity, timing, and duration of symptoms in test positive and test negative cases. We compared the test performance of the current UK case definition used by TTI (any one of: new continuous cough, high temperature, or loss of or altered sense of smell or taste) with a wider definition that also included muscle aches, chills, headache, or loss of appetite.

FindingsWe included results from 8213 swabbed illnesses, 944 of which tested positive for SARS-CoV-2. All symptoms were more common in test positive than test negative illnesses and symptoms were also more severe and of longer duration. Common symptoms such as cough, headache, fatigue, muscle aches, and loss of appetite occurred early in the course of illness but were also very common in test-negative illnesses. In contrast, high temperature and loss of or altered sense of smell or taste were less frequently identified in swab positive illnesses but were markedly more common than in swab negative illnesses. The current UK definition had a sensitivity and specificity of 81% and 47% respectively for symptomatic COVID-19 compared to 93% and 26% for the broader definition. On average, cases met the broader case definition 0.3 days earlier than the current definition. 1.7-fold more illnesses met the broader definition than the current case definition.

InterpretationCOVID-19 is difficult to distinguish from other respiratory infections and common ailments on the basis of symptoms. Broadening the list of symptoms used to encourage engagement with TTI could moderately increase the number of infections identified and shorten delays to isolation, but with a large increase in the number of tests needed and the number of unwell individuals and contacts who are advised to self-isolate whilst awaiting results, and subsequently test negative for SARS-CoV-2.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.05.18.21257267,2021-05-18,https://medrxiv.org/cgi/content/short/2021.05.18.21257267,"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial",Peter W Horby; Mark Campbell; Enti Spata; Jonathan R Emberson; Natalie Staplin; Guilherme Pessoa-Amorim; Leon Peto; Martin Wiselka; Laura Wiffen; Simon Tiberi; Ben Caplin; Caroline Wroe; Christopher Green; Paul Hine; Benjamin Prudon; Tina George; Andrew Wight; J Kenneth Baillie; Buddha Basnyat; Maya H Buch; Lucy C Chappell; Jeremy N Day; Saul N Faust; Raph L Hamers; Thomas Jaki; Edmund Juszczak; Katie Jeffery; Wei Shen Lim; Alan Montgomery; Andrew Mumford; Kathryn Rowan; Guy Thwaites; Marion Mafham; Richard Haynes; Martin J Landray,"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom and International Severe Acute Res; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom and Oxford University Hospitals NHS Foundation Trust, Oxford, United King; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom and MRC Population Health Research Unit, University of Oxford, Oxford, Un; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom and MRC Population Health Research Unit, University of Oxford, Oxford, Un; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom and MRC Population Health Research Unit, University of Oxford, Oxford, Un; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom and Nuffield Department of Populat; Department of Infectious Diseases, University Hospital Leicester, Leicester, United Kingdom; Portsmouth Hospitals University NHS Foundation Trust, Portsmouth, United Kingdom; Department of Infection, Barts Health NHS Trust, London, United Kingdom; Department of Renal Medicine, University College London, London, United Kingdom and Royal Free London NHS Trust, London, United Kingdom; James Cook University Hospital, Middlesbrough, United Kingdom; University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom; North Tees and Hartlepool NHS Foundation Trust, Hartlepool, United Kingdom; Basildon and Thurrock Hospitals NHS Foundation Trust, Basildon, United Kingdom; Wirral University Teaching Hospital NHS Foundation Trust, Birkenhead, United Kingdom; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Oxford University Clinical Research Unit -Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal; Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; School of Life Course Sciences, King?s College London, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam and Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Univer; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia and Faculty of Medicine, University of Indonesia, Jakarta, Indonesia and Centre for Tropical Medicine ; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom and MRC Biostatistics Unit, University of Cambridge, Cambridge, United; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom and Respiratory Medicine Department, Nottingham University Hospitals NHS Trust, Notting; School of Medicine, University of Nottingham, Nottingham, United Kingdom; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Intensive Care National Audit & Research Centre, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam and Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, Univer; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom and Oxford University Hospitals NHS Foundation Trust, Oxford, United King; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom and MRC Population Health Research Unit, University of Oxford, Oxford, Un","BackgroundColchicine has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory actions.

MethodsIn this randomised, controlled, open-label trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19. Eligible and consenting adults were randomly allocated in a 1:1 ratio to either usual standard of care alone or usual standard of care plus colchicine twice daily for 10 days or until discharge (or one of the other treatment arms) using web-based simple (unstratified) randomisation with allocation concealment. The primary outcome was 28-day mortality. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

FindingsBetween 27 November 2020 and 4 March 2021, 5610 patients were randomly allocated to receive colchicine and 5730 patients to receive usual care alone. Overall, 1173 (21%) patients allocated to colchicine and 1190 (21%) patients allocated to usual care died within 28 days (rate ratio 1.01; 95% confidence interval [CI] 0.93-1.10; p=0.77). Consistent results were seen in all pre-specified subgroups of patients. There was no significant difference in duration of hospitalisation (median 10 days vs. 10 days) or the proportion of patients discharged from hospital alive within 28 days (70% vs. 70%; rate ratio 0.98; 95% CI 0.94-1.03; p=0.44). Among those not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (25% vs. 25%; risk ratio 1.02; 95% CI 0.96-1.09; p=0.47).

InterpretationIn adults hospitalised with COVID-19, colchicine was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

FundingUK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056). Wellcome Trust (Grant Ref: 222406/Z/20/Z) through the COVID-19 Therapeutics Accelerator.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.05.17.21256818,2021-05-18,https://medrxiv.org/cgi/content/short/2021.05.17.21256818,Local prevalence of transmissible SARS-CoV-2 infection : an integrative causal model for debiasing fine-scale targeted testing data,George Nicholson; Brieuc CL Lehmann; Tullia Padellini; Koen B Pouwels; Radka Jersakova; James Lomax; Ruairidh E King; Ann-Marie Mallon; Peter J Diggle; Sylvia Richardson; Marta Blangiardo; Chris Holmes,University of Oxford; University of Oxford; Imperial College London; University of Oxford; The Alan Turing Institute; The Alan Turing Institute; MRC Harwell Institute; MRC Harwell Institute; Lancaster University; MRC Biostatistics Unit; Imperial College London; University of Oxford,"Targeted surveillance testing schemes for SARS-CoV-2 focus on certain subsets of the population, such as individuals experiencing one or more of a prescribed list of symptoms. These schemes have routinely been used to monitor the spread of SARS-CoV-2 in countries across the world. The number of positive tests in a given region can provide local insights into important epidemiological parameters, such as prevalence and effective reproduction number. Moreover, targeted testing data has been used inform the deployment of localised non-pharmaceutical interventions. However, surveillance schemes typically suffer from ascertainment bias; the individuals who are tested are not necessarily representative of the wider population of interest. Here, we show that data from randomised testing schemes, such as the REACT study in the UK, can be used to debias fine-scale targeted testing data in order to provide accurate localised estimates of the number of infectious individuals. We develop a novel, integrative causal framework that explicitly models the process underlying the selection of individuals for targeted testing. The output from our model can readily be incorporated into longitudinal analyses to provide local estimates of the reproduction number. We apply our model to characterise the size of the infectious population in England between June 2020 and January 2021. Our local estimates of the effective reproduction number are predictive of future changes in positive case numbers. We also capture local increases in both prevalence and effective reproductive number in the South East from November 2020 to December 2020, reflecting the spread of the Kent variant. Our results illustrate the complementary roles of randomised and targeted testing schemes. Preparations for future epidemics should ensure the rapid deployment of both types of schemes to accurately monitor the spread of emerging and ongoing infectious diseases.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.05.15.21257017,2021-05-17,https://medrxiv.org/cgi/content/short/2021.05.15.21257017,Extended interval BNT162b2 vaccination enhances peak antibody generation in older people,Helen M Parry; Rachel Bruton; Christine Stephens; Kevin Brown; Gayatri Amirthalingam; Bassam Hallis; Ashley Otter; Jianmin Zuo; Paul Moss,"University of Birmingham, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham. B15 2TT, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham. B15 2TT, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham. B15 2TT, UK; National infection Service, Public Health England, Colindale, London NW9 5EQ, UK; National infection Service, Public Health England, Colindale, London NW9 5EQ, UK; National infection Service, Public Health England,  Porton Down, Salisbury, SP4 OJG, UK; National infection Service, Public Health England,  Porton Down, Salisbury, SP4 OJG, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham. B15 2TT, UK; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham. B15 2TT, UK","ObjectivesTo assess the relative immunogenicity of standard or extended interval BNT162b2 vaccination.

DesignPopulation based cohort study comparing immune responses 2 weeks after the second vaccine, with appropriate time-matched samples in participants who received standard or extended interval double vaccination.

SettingPrimary care networks, Birmingham, UK. December 2020 to April 2021.

Participants172 people aged over 80 years of age. All donors received the BNT162b2 Pfizer/BioNTech vaccination and were vaccinated with either a standard 3 week interval between doses or an extended interval schedule.

Main outcome measuresPeak quantitative spike-specific antibody and cellular immune responses.

ResultsIn donors without evidence of previous infection the peak antibody response was 3.5-fold higher in donors who had undergone delayed interval vaccination. Cellular immune responses were 3.6-fold lower.

ConclusionPeak antibody responses after the second BNT162b2 vaccine are markedly enhanced in older people when this is delayed to 12 weeks although cellular responses are lower. Extended interval vaccination may therefore offer the potential to enhance and extend humoral immunity. Further follow up is now required to assess long term immunity and clinical protection.

What is already known on this topicThe BNT162b2 vaccine is highly effective against Covid-19 infection and was delivered with a 3-week time interval in registration studies. However, this interval has been extended in many countries in order to extend population coverage with a single vaccine. It is not known how immune responses after the second dose are influenced by delaying the second vaccine.

What this study addsWe provide the first assessment of immune responses in the first 14 weeks after standard or extended interval BNT162b2 vaccination and show that delaying the second dose acts to strongly boost the peak antibody response in older people. The extended interval vaccination may offer a longer period of clinical protection. This information will be of value in optimizing vaccine regimens and help guide guide vaccination policies.",infectious diseases,fuzzy,100,92
medRxiv,10.1101/2021.05.12.21257123,2021-05-17,https://medrxiv.org/cgi/content/short/2021.05.12.21257123,Occupation and COVID-19 mortality in England: a national linked data study of 14.3 million adults,Vahe Nafilyan; Piotr Pawelek; Daniel Ayoubkhani; Sarah Rhodes; Lucy Pembrey; Melissa Matz; Michel P Coleman; Claudia Allemani; Ben Windsor-Shellard; Martie van Tongeren; Neil Pearce,"Office for National Statistics; Office for National Statistics; Office for National Statistics; School of Health Sciences, University of Manchester; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine; Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine; Office for National Statistics; School of Health Sciences, University of Manchester; London School of Hygiene and Tropical Medicine","ObjectiveTo estimate occupational differences in COVID-19 mortality, and test whether these are confounded by factors, such as regional differences, ethnicity and education or due to non-workplace factors, such as deprivation or pre-pandemic health.

DesignRetrospective cohort study

SettingPeople living in private households England

Participants14,295,900 people aged 40-64 years (mean age 52 years, 51% female) who were alive on 24 January 2020, living in private households in England in 2019, were employed in 2011, and completed the 2011 census.

Main outcome measuresCOVID-19 related death, assessed between 24 January 2020 and 28 December 2020. We estimated age-standardised mortality rates per 100,000 person-years at risk (ASMR) stratified by sex and occupations. To estimate the effect of occupation due to work-related exposures, we used Cox proportional hazard models to adjust for confounding (region, ethnicity, education), as well as non-workplace factors that are related to occupation.

ResultsThere is wide variation between occupations in COVID-19 mortality. Several occupations, particularly those involving contact with patients or the public, show three-fold or four-fold risks. These elevated risks were greatly attenuated after adjustment for confounding and mediating non-workplace factors. For example, the hazard ratio (HR) for men working as taxi and cab drivers or chauffeurs changed from 4.60 [95%CI 3.62-5.84] to 1.47 [1.14-1.89] after adjustment. More generally, the overall HR for men working in essential occupations compared with men in non-essential occupations changed from 1.45 [1.34 - 1.56] to 1.22 [1.13 - 1.32] after adjustment. For most occupations, confounding and other mediating factors explained about 70% to 80% of the age-adjusted hazard ratios.

ConclusionsWorking conditions are likely to play a role in COVID-19 mortality, particularly in occupations involving contact with COVID-19 patients or the public. However, there is also a substantial contribution from non-workplace factors, including regional factors, socio-demographic factors, and pre-pandemic health.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.05.13.21257144,2021-05-17,https://medrxiv.org/cgi/content/short/2021.05.13.21257144,REACT-1 round 11 report: low prevalence of SARS-CoV-2 infection in the community prior to the third step of the English roadmap out of lockdown,Steven Riley; David J Haw; Caroline E Walters; Howei Wang; Oliver Eales; Kylie E C Ainslie; Christina Atchison; Claudio Fronterre; Peter J Diggle; Andrew J Page; Alexander J Trotter; Thanh Le Viet; Nabil-Fareed Alikhan; Justin O'Grady; - The COVID-19 Genomics UK (COG-UK) Consortium; Deborah Ashby; Christl Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands; Imperial College London; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; ; Imperial College London; University of Oxford; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London","BackgroundNational epidemic dynamics of SARS-CoV-2 infections are being driven by: the degree of recent indoor mixing (both social and workplace), vaccine coverage, intrinsic properties of the circulating lineages, and prior history of infection (via natural immunity). In England, infections, hospitalisations and deaths fell during the first two steps of the ""roadmap"" for exiting the third national lockdown. The third step of the roadmap in England takes place on 17 May 2021.

MethodsWe report the most recent findings on community infections from the REal-time Assessment of Community Transmission-1 (REACT-1) study in which a swab is obtained from a representative cross-sectional sample of the population in England and tested using PCR. Round 11 of REACT-1 commenced self-administered swab-collection on 15 April 2021 and completed collections on 3 May 2021. We compare the results of REACT-1 round 11 to round 10, in which swabs were collected from 11 to 30 March 2021.

ResultsBetween rounds 10 and 11, prevalence of swab-positivity dropped by 50% in England from 0.20% (0.17%, 0.23%) to 0.10% (0.08%, 0.13%), with a corresponding R estimate of 0.90 (0.87, 0.94). Rates of swab-positivity fell in the 55 to 64 year old group from 0.17% (0.12%, 0.25%) in round 10 to 0.06% (0.04%, 0.11%) in round 11. Prevalence in round 11 was higher in the 25 to 34 year old group at 0.21% (0.12%, 0.38%) than in the 55 to 64 year olds and also higher in participants of Asian ethnicity at 0.31% (0.16%, 0.60%) compared with white participants at 0.09% (0.07%, 0.11%). Based on sequence data for positive samples for which a lineage could be identified, we estimate that 92.3% (75.9%, 97.9%, n=24) of infections were from the B.1.1.7 lineage compared to 7.7% (2.1%, 24.1%, n=2) from the B.1.617.2 lineage. Both samples from the B.1.617.2 lineage were detected in London from participants not reporting travel in the previous two weeks. Also, allowing for suitable lag periods, the prior close alignment between prevalence of infections and hospitalisations and deaths nationally has diverged.

DiscussionWe observed marked reductions in prevalence from March to April and early May 2021 in England reflecting the success of the vaccination programme and despite easing of restrictions during lockdown. However, there is potential upwards pressure on prevalence from the further easing of lockdown regulations and presence of the B.1.617.2 lineage. If prevalence rises in the coming weeks, policy-makers will need to assess the possible impact on hospitalisations and deaths. In addition, consideration should be given to other health and economic impacts if increased levels of community transmission occur.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.05.17.21257223,2021-05-17,https://medrxiv.org/cgi/content/short/2021.05.17.21257223,Serial interval of COVID-19 and the effect of Variant B.1.1.7: analyses from a prospective community cohort study (Virus Watch).,Cyril Roman Geismar; Ellen Fragaszy; Vincent Grigori Nguyen; Wing Lam Erica Fong; Madhumita Shrotri; Sarah Beale; Alison Rodger; Vasileios Lampos; Thomas Edward Byrne; Jana Kovar; Annalan Navaratnam; Parth Patel; Robert W Aldridge; Andrew Hayward; - Virus Watch Collaborative,University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; ,"IntroductionIncreased transmissibility of B.1.17 variant of concern (VOC) in the UK may explain its rapid emergence and global spread. We analysed data from putative household infector - infectee pairs in the Virus Watch Community cohort study to assess the serial interval of COVID-19 and whether this was affected by emergence of the B.1.17 variant.

MethodsThe Virus Watch study is an online, prospective, community cohort study following up entire households in England and Wales during the COVID-19 pandemic. Putative household infector-infectee pairs were identified where more than one person in the household had a positive swab matched to an illness episode. Data on whether individual infections were caused by the B.1.1.7 variant were not available. We therefore developed a classification system based on the percentage of cases estimated to be due to B.1.17 in national surveillance data for different English regions and study weeks.

ResultsOut of 24,887 illnesses reported, 915 tested positive for SARS-CoV-2 and 186 likely infector-infectee pairs in 186 households amongst 372 individuals were identified. The mean COVID-19 serial interval was 3.18 (95%CI: 2.55 - 3.81) days. There was no significant difference (p=0.267) between the mean serial interval for Variants of Concern (VOC) hotspots (mean = 3.64 days, (95%CI: 2.55 - 4.73)) days and non-VOC hotspots, (mean = 2.72 days, (95%CI: 1.48 - 3.96)).

ConclusionsOur estimates of the average serial interval of COVID-19 are broadly similar to estimates from previous studies and we find no evidence that B.1.1.7 is associated with a change in serial intervals. Alternative explanations such as increased viral load, longer period of viral shedding or improved receptor binding may instead explain the increased transmissibility and rapid spread and should undergo further investigation.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.05.13.21257146,2021-05-17,https://medrxiv.org/cgi/content/short/2021.05.13.21257146,Sociodemographic inequality in COVID-19 vaccination coverage amongst elderly adults in England: a national linked data study,Vahe Nafilyan; Ted Dolby; Cameron Razieh; Charlotte Gaughan; Jasper Morgan; Daniel Ayoubkhani; Ann Sarah Walker; Kamlesh Khunti; Myer Glickman; Thomas Yates,"Office for National Statistics; Office for National Statistics; Diabetes Research Centre, University of Leicester; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Diabetes Research Centre, University of Leicester; Office for National Statistics; Diabetes Research Centre, University of Leicester","ObjectiveTo examine inequalities in COVID-19 vaccination rates amongst elderly adults in England

DesignCohort study

SettingPeople living in private households and communal establishments in England

Participants6,829,643 adults aged [&ge;] 70 years (mean 78.7 years, 55.2% female) who were alive on 15 March 2021.

Main outcome measuresHaving received the first dose of a vaccine against COVID-19 by 15 March 2021. We calculated vaccination rates and estimated unadjusted and adjusted odds ratios using logistic regression models.

ResultsBy 15 March 2021, 93.2% of people living in England aged 70 years and over had received at least one dose of a COVID-19 vaccine. While vaccination rates differed across all factors considered apart from sex, the greatest disparities were seen between ethnic and religious groups. The lowest rates were in people of Black African and Black Caribbean ethnic backgrounds, where only 67.2% and 73.9% had received a vaccine, with adjusted odds of not being vaccinated at 5.01 (95% CI 4.86 - 5.16) and 4.85 (4.75 - 4.96) times greater than the White British group. The proportion of individuals self-identifying as Muslim and Buddhist who had received a vaccine was 79.1% and 84.1%, respectively. Older age, greater area deprivation, less advantaged socio-economic position (proxied by living in a rented home), being disabled and living either alone or in a multi-generational household were also associated with higher odds of not having received the vaccine.

ConclusionPeople disproportionately affected seem most hesitant to COVID-19 vaccinations. Policy Interventions to improve these disparities are urgently needed.

Summary BoxO_ST_ABSWhat is already known on this subject?C_ST_ABSThe UK began an ambitious vaccination programme to combat the COVID-19 pandemic on 8th December 2020. Existing evidence suggests that COVID-19 vaccination rates differ by level of area deprivation, ethnicity and certain underlying health conditions, such as learning disability and mental health problems.

What does this study add?Our study shows that first dose vaccination rates in adults aged 70 or over differed markedly by ethnic group and self-reported religious affiliation, even after adjusting for geography, socio-demographic factors and underlying health conditions. Our study also highlights differences in vaccination rates by deprivation, household composition, and disability status, factors disproportionately associated with SARS-CoV-2 infection. Public health policy and community engagement aimed at promoting vaccination uptake is these groups are urgently needed.

Strengths and limitations of this studyO_LIUsing nationwide linked population-level data from clinical records and the 2011 Census, we examined a wide range of socio-demographic characteristics not available n electronic health records
C_LIO_LIMost demographic and socio-economic characteristics are derived from the 2011 Census and therefore are 10 years old. However, we focus primarily on characteristics that are unlikely to change over time, such as ethnicity or religion, or likely to be stable for our population
C_LIO_LIBecause the data are based on the 2011 Census, it excluded people living in England in 2011 but not taking part in the 2011 Census; respondents who could not be linked to the 2011-2013 NHS patients register; recent migrants. Consequently, we excluded 5.4% of vaccinated people who could not be linked
C_LI",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.05.12.21257102,2021-05-15,https://medrxiv.org/cgi/content/short/2021.05.12.21257102,"Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors - a prospective community cohort study (Virus Watch)",Madhumita Shrotri; Ellen Fragaszy; Cyril Geismar; Vincent Nguyen; Sarah Beale; Isobel Braithwaite; Thomas Edward Byrne; Wing Lam Erica Fong; Jana Kovar; Annalan M D Navaratnam; Parth Patel; Anna Aryee; Jamie Lopez Bernal; Anne M Johnson; Alison Rodger; Andrew C Hayward; Robert W Aldridge,University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; Public Health England; University College London; University College London; University College London; University College London,"BackgroundVaccination constitutes the best long-term solution against Coronavirus Disease 2019 (COVID-19). Real-world immunogenicity data are sparse, particularly for ChAdOx1 and in populations with chronic conditions; and given the UKs extended dosing interval, it is also important to understand antibody responses in SARS-CoV-2-naive individuals following a single dose.

MethodsAdults aged [&ge;]18 years from households enrolled in Virus Watch, a prospective community cohort study in England and Wales, provided capillary blood samples and self-reported vaccination status. Primary outcome variables were quantitative Spike total antibody levels (U/ml) and seropositivity to Spike ([&ge;]0.8 U/ml), as per Roches Elecsys Anti-SARS-CoV-2 S assay. Samples seropositive for Nucleocapsid, and samples taken prior to vaccination, were excluded. Outcomes were analysed by days since vaccination, vaccine type (BNT162b2 and ChAdOx1), and a range of self-reported demographic and clinical factors.

Results8,517 vaccinated participants (median age 65 years [IQR: 58, 71]), contributed 13,232 samples (8,115 following ChAdOx1, 5,008 following BNT162b2). Seropositivity to Spike was 96.42% (95%CI 96, 96.79) at 28-34 days following a single dose, reaching 99.08% (97.8, 99.62) at 7-14 days after a second dose. Seropositivity rates, and Spike-antibody levels rose more quickly following the first dose of BNT162b2, however, were equivalent for both vaccines by 4 and 8 weeks, respectively. There was evidence of lower S-antibody levels with increasing age (p=0.0001). In partially vaccinated 65-79 year-olds, lower S-antibody levels were observed in men (25.9 vs 42.3 U/ml, p<0.0001), those with a chronic condition (33.0 vs 41.2 U/ml, p<0.0001), diabetes (22.32 vs 36.01 U/ml, p<0.0001), cardiovascular disease (32.1 vs 36.7 U/ml, p=0.0002), or history of cancer (30.1 vs 35.7 U/ml, p=0.0001), particularly those with haematological rather than solid organ cancer (7.48 vs 31.68 U/ml, p<0.0001), and those currently on immunosuppressive therapy (21.7 vs 35.6 U/ml, p<0.0001). Following a second dose, high S-antibody titres ([&ge;]250U/ml) were observed for nearly all individuals.

InterpretationA single dose of either BNT162b2 or ChAdOx1 leads to high Spike seropositivity rates in SARS-CoV-2-naive individuals. However, observed disparities in antibody levels after the first dose by vaccine type, age, and comorbidities highlight the importance of ongoing non-pharmaceutical preventative measures such as social distancing, for partially vaccinated adults, particularly those who are older and more clinically vulnerable.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.05.06.21256757,2021-05-14,https://medrxiv.org/cgi/content/short/2021.05.06.21256757,COVID-19 outbreak rates and infection attack rates associated with the workplace: a descriptive epidemiological study,Yiqun Chen; Timothy Aldridge; - UK COVID-19 National Core Studies Consortium; Claire F Ferraro; Fu-Meng Khaw,"Health and Safety Executive, UK; Health and Safety Executive, UK; ; National Infection Service, Public Health England, UK; Public Health England, UK","BackgroundA large number of COVID-19 outbreaks/clusters have been reported in a variety of workplace settings since the start of the pandemic. However, information on the rate of outbreak occurrences which helps to identify the type of workplaces that are more likely to experience an outbreak, or infection attack rates which estimates the potential extent of the virus transmission in an outbreak, has not yet been available to inform intervention strategies to limit transmission.

ObjectivesTo link datasets on workplace settings and COVID-19 workplace outbreaks in England in order to: identify the geographical areas and workplace sectors with a high rate of outbreaks; and compare infection attack rates by workplace size and sector.

MethodsWe analysed Public Health England (PHE) HPZone data on COVID-19 outbreaks in workplaces, covering the time period of 18 May - 12 October 2020. The workplaces analysed excluded care homes, hospitals and educational settings. We calculated the workplace outbreak rates by nine English regions, 151 Upper Tier Local Authorities (UTLAs) and twelve industrial sectors, using National Population Database (NPD) data extracted in May 2019 on the total number of the relevant workplaces as the denominator. We also calculated the infection attack rates by enterprise size (small, medium, large) and industrial sector, using PHE Situations of Interest (SOI) data on the number of test-confirmed COVID-19 cases in a workplace outbreak as the numerator, and using NPD data on the number employed in that workplace as the denominator.

ResultsIn total, 1,317 confirmed workplace outbreaks were identified from HPZone data, of which 1,305 were available for estimation of outbreak rates. The average outbreak rate was 66 per 100,000 workplaces. Of the nine geographical regions in England, the North West had the highest workplace outbreak rate (155/100,000 workplaces), based on 351 outbreaks. Of the UTLAs, the highest workplace outbreak rate was Blackburn with Darwen (387/100,000 workplaces). The industrial sector with the highest workplace outbreak rate was manufacturers and packers of food (1,672/100,000), based on 117 outbreaks: this was consistent across seven of the regions. In addition, high outbreak rates in warehouses were observed in the East Midlands and the North West.

In total, 390 outbreaks were identified from SOI data and 264 of them allowed for estimation of attack rates. The overall median attack rate was 3.4% of the employed persons with confirmed COVID-19 at a workplace with an outbreak. Most of these outbreaks (162) had an attack rate less than 6%. However, in a small number of outbreaks (57) the attack rate was over 15%. The attack rates increased as the size of the enterprise decreased. The highest attack rate was for outbreaks in close contact services (median 16.5%), which was followed by outbreaks in restaurants and catering (median 10.2%), and in manufacturers and packers of non-food products (median 6.7%).

ConclusionsOur linked dataset analysis approach allows early identification of geographical regions and industrial sectors with higher rates of COVID-19 workplace outbreaks as well as estimation of attack rates by enterprise size and sector. This can be used to inform interventions to limit transmission of the virus. Our approach to analysing the workplace outbreak data can also be applied to calculation of outbreak rates and attack rates in other types of settings such as care homes, hospitals and educational settings.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.05.08.21256867,2021-05-14,https://medrxiv.org/cgi/content/short/2021.05.08.21256867,SARS-CoV-2 lineage dynamics in England from January to March 2021 inferred from representative community samples,Oliver Eales; Andrew Page; Sonja N. Tang; Caroline E. Walters; Haowei Wang; David Haw; Alexander J. Trotter; Thanh Le Viet; Ebenezer Foster-Nyarko; Sophie Prosolek; Christina Atchinson; Deborah Ashby; Graham Cooke; Wendy Barclay; Christl A Donnelly; Justin O'Grady; Erik Volz; - The COVID-19 Genomics UK (COG-UK) Consortium; Ara Darzi; Helen Ward; Paul Elliott; Steven Riley,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Quadram Institute, Norwich, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; Quadram Institute, Norwich, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Quadram Institute, Norwich, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; ; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc","Genomic surveillance for SARS-CoV-2 lineages informs our understanding of possible future changes in transmissibility and vaccine efficacy. However, small changes in the frequency of one lineage over another are often difficult to interpret because surveillance samples are obtained from a variety of sources. Here, we describe lineage dynamics and phylogenetic relationships using sequences obtained from a random community sample who provided a throat and nose swab for rt-PCR during the first three months of 2021 as part of the REal-time Assessment of Community Transmission-1 (REACT-1) study. Overall, diversity decreased during the first quarter of 2021, with the B.1.1.7 lineage (first identified in Kent) predominant, driven by a 0.3 unit higher reproduction number over the prior wild type. During January, positive samples were more likely B.1.1.7 in younger and middle-aged adults (aged 18 to 54) than in other age groups. Although individuals infected with the B.1.1.7 lineage were no more likely to report one or more classic COVID-19 symptoms compared to those infected with wild type, they were more likely to be antibody positive 6 weeks after infection. Viral load was higher in B.1.1.7 infection as measured by cycle threshold (Ct) values, but did not account for the increased rate of testing positive for antibodies. The presence of infections with non-imported B.1.351 lineage (first identified in South Africa) during January, but not during February or March, suggests initial establishment in the community followed by fade-out. However, this occurred during a period of stringent social distancing and targeted public health interventions and does not immediately imply similar lineages could not become established in the future. Sequence data from representative community surveys such as REACT-1 can augment routine genomic surveillance.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.05.11.21257040,2021-05-13,https://medrxiv.org/cgi/content/short/2021.05.11.21257040,Trajectories of child emotional and behavioural difficulties before and during the COVID-19 pandemic in a longitudinal UK cohort,Elise Paul; Daphne Kounali; Alex Siu Fung Kwong; Daniel Smith; Ilaria Costantini; Deborah A Lawlor; Kapil Sayal; Helen Bould; Nicholas J Timpson; Kate Northstone; Melanie Lewcock; Kate J Tilling; Rebecca Pearson,University College London; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Nottingham; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol,"ImportanceCOVID-19 public health mitigation measures are likely to have detrimental effects on emotional and behavioural problems in children. However, longitudinal studies with pre-pandemic data are scarce.

ObjectiveTo explore trajectories of childrens emotional and behavioural difficulties during the COVID-19 pandemic.

Design and settingData were from children from the third generation of a birth cohort study; the Avon Longitudinal Study of Parents and Children - Generation 2 (ALSPAC-G2) in the southwest of England.

ParticipantsThe study population comprised of 708 children (median age at COVID-19 data collection was 4.4 years, SD=2.9, IQR= [2.2 to 6.9]), whose parents provided previous pre-pandemic surveys and a survey between 26 May and 5 July 2020 that focused on information about the COVID-19 pandemic as restrictions from the first lockdown in the UK were eased.

ExposuresWe employed multi-level mixed effects modelling with random intercepts and slopes to examine whether childrens trajectories of emotional and behavioural difficulties (a combined total difficulties score) during the pandemic differ from expected pre-pandemic trajectories.

Main outcomesChildren had up to seven measurements of emotional and behavioural difficulties from infancy to late childhood, using developmentally appropriate scales such as the Emotionality Activity Sociability Temperament Survey in infancy and Strengths and Difficulties Questionnaire in childhood.

ResultsThe observed normative pattern of childrens emotional and behavioural difficulties pre-pandemic, was characterised by an increase in scores during infancy peaking around the age of 2, and then declining throughout the rest of childhood. Pre-pandemic, the decline in difficulties scores after age 2 was 0.6 points per month; but was approximately one third of that in post-pandemic trajectories (there was a difference in mean rate of decline after age 2 of 0.2 points per month in pre vs during pandemic trajectories [95 % CI: 0.10 to 0.30, p <0.001]). This lower decline in scores over the years translated to older children having pandemic difficulty scores higher than would be expected from pre-pandemic trajectories (for example, an estimated 10.0 point (equivalent of 0.8 standard deviations) higher score (95% CI: 5.0 to 15.0) by age 8.5 years). Results remained similar although somewhat attenuated after adjusting for maternal anxiety and age.

Conclusion and relevanceThe COVID-19 pandemic may be associated with greater persistence of emotional and behavioural difficulties after the age 2. Emotional difficulties in childhood predict later mental health problems. Further evidence and monitoring of emotional and behavioural difficulties are required to fully understand the potential role of the pandemic on young children.

Key FindingsO_ST_ABSQuestionC_ST_ABSHow has the COVID-19 pandemic influenced emotional difficulties in young children?

FindingsUsing repeated longitudinal data from before and during the pandemic we provide evidence that emotional difficulty scores of primary school aged children are higher by an estimated 10.0 points (0.8 standard deviations) (95% CI: 5.0 to 15.0) by age 8.5 years than would be expected based on pre pandemic data.

MeaningThe level of difference in emotional difficulties found in the current study has been linked to increased likelihood of mental health problems in adolescence and adulthood. Therefore, this increase in difficulties needs careful monitoring and support.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2021.05.06.21256755,2021-05-13,https://medrxiv.org/cgi/content/short/2021.05.06.21256755,Clinical coding of long COVID in English primary care: a federated analysis of 58 million patient records in situ using OpenSAFELY,- The OpenSAFELY Collaborative; Alex J Walker; Brian MacKenna; Peter Inglesby; Christopher T Rentsch; Helen J Curtis; Caroline E Morton; Jessica Morley; Amir Mehrkar; Sebastian CJ Bacon; George Hickman; Christopher Bates; Richard Croker; David Evans; Tom Ward; Jonathan Cockburn; Simon Davy; Krishnan Bhaskaran; Anna Schultze; Elizabeth J Williamson; William J Hulme; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Rosalind M Eggo; Kevin Wing; Angel YS Wong; Harriet Forbes; John Tazare; John Parry; Frank Hester; Sam Harper; Shaun O'Hanlon; Alex Eavis; Richard Jarvis; Dima Avramov; Paul Griffiths; Aaron Fowles; Nasreen Parkes; Ian J Douglas; Stephen JW Evans; Liam Smeeth; Ben Goldacre,; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; EMIS; EMIS; EMIS; EMIS; EMIS; EMIS; EMIS; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundLong COVID is a term to describe new or persistent symptoms at least four weeks after onset of acute COVID-19. Clinical codes to describe this phenomenon were released in November 2020 in the UK, but it is not known how these codes have been used in practice.

MethodsWorking on behalf of NHS England, we used OpenSAFELY data encompassing 96% of the English population. We measured the proportion of people with a recorded code for long COVID, overall and by demographic factors, electronic health record software system, and week. We also measured variation in recording amongst practices.

ResultsLong COVID was recorded for 23,273 people. Coding was unevenly distributed amongst practices, with 26.7% of practices having not used the codes at all. Regional variation was high, ranging between 20.3 per 100,000 people for East of England (95% confidence interval 19.3-21.4) and 55.6 in London (95% CI 54.1-57.1). The rate was higher amongst women (52.1, 95% CI 51.3-52.9) compared to men (28.1, 95% CI 27.5-28.7), and higher amongst practices using EMIS software (53.7, 95% CI 52.9-54.4) compared to TPP software (20.9, 95% CI 20.3-21.4).

ConclusionsLong COVID coding in primary care is low compared with early reports of long COVID prevalence. This may reflect under-coding, sub-optimal communication of clinical terms, under-diagnosis, a true low prevalence of long COVID diagnosed by clinicians, or a combination of factors. We recommend increased awareness of diagnostic codes, to facilitate research and planning of services; and surveys of clinicians experiences, to complement ongoing patient surveys.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.05.10.21256912,2021-05-11,https://medrxiv.org/cgi/content/short/2021.05.10.21256912,Household overcrowding and risk of SARS-CoV-2: analysis of the Virus Watch prospective community cohort study in England and Wales,Robert W Aldridge; Helen Pineo; Ellen Fragaszy; Max Eyre; Jana Kovar; Vincent Nguyen; Sarah Beale; Thomas Byrne; Anna Aryee; Colette Smith; Delanjathan Devakumar; Jonathon Taylor; Vittal Katikireddi; Wing Lam Erica Fong; Cyril Geismar; Parth Patel; Madhumita Shrotri; Isobel Braithwaite; Annalan M D Navaratnam; Anne M Johnson; Andrew Hayward,"Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Institute for Environmental Design and Engineering, Bartlett School of Environment, Energy and Resources, University College London, London, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Institute of Epidemiology and Health Care, University Col; Centre of Health Informatics, Computing and Statistics, Lancaster Medical School, Lancaster University, Lancaster, LA1 4YW, UK; Institute of Epidemiology and Health Care, University College London, London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Institute of Epidemiology and Health Care, University Col; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Institute for Global Health, University College London, London, UK.; Institute for Global Health, University College London, London, UK.; Department of Civil Engineering, Tampere University, Finland.; MRC/CSO Social and Public Health Sciences Unit, University of Glasgow Institute of Health and Wellbeing, Glasgow, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Institute of Epidemiology and Health Care, University Col; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Institute of Epidemiology and Health Care, University Col; Institute for Global Health, University College London, London, UK.; Institute of Epidemiology and Health Care, University College London, London, UK","BackgroundHousehold overcrowding is associated with increased risk of infectious diseases across contexts and countries. Limited data exist linking household overcrowding and risk of COVID-19. We used data collected from the Virus Watch cohort to examine the association between overcrowded households and SARS-CoV-2.

MethodsThe Virus Watch study is a household community cohort of acute respiratory infections in England & Wales that began recruitment in June 2020. We calculated the persons per room for each household and classified accommodation as overcrowded when the number of rooms{square}was fewer than the number of people. We considered two primary outcomes - PCR-confirmed positive SARS-CoV-2 antigen tests and laboratory confirmed SARS-CoV-2 antibodies (Roche Elecsys anti-N total immunoglobulin assay). We used mixed effects logistic regression models that accounted for household structure to estimate the association between household overcrowding and SARS-CoV-2 infection.

ResultsThe proportion of participants with a positive SARS-CoV-2 PCR result was highest in the overcrowded group (6.6%; 73/1,102) and lowest in the under-occupied group (2.9%; 682/23,219). In a mixed effects logistic regression model that included age, sex, ethnicity, household income and geographical region, we found strong evidence of an increased odds of having a positive PCR SARS-CoV-2 antigen result (Odds Ratio 3.72; 95% CI: 1.92, 7.13; p-value < 0.001) and increased odds of having a positive SARS-CoV-2 antibody result in individuals living in overcrowded houses (2.96; 95% CI: 1.13, 7.74; p-value =0.027) compared to people living in under-occupied houses. The proportion of variation at the household level was 9.91% and 9.97% in the PCR and antibody models respectively.

DiscussionPublic health interventions to prevent and stop the spread of SARS-CoV-2 should consider the much greater risk of infection for people living in overcrowded households and pay greater attention to reducing household transmission. There is an urgent need to better recognise housing as a leading determinant of health in the context of a pandemic and beyond.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.05.05.21256668,2021-05-09,https://medrxiv.org/cgi/content/short/2021.05.05.21256668,COVID-19: Affect recognition through voice analysis during the winter lockdown in Scotland,Sofia de la Fuente Garcia; Fasih Haider; Saturnino Luz,The University of Edinburgh; The University of Edinburgh; The University of Edinburgh,"The COVID-19 pandemic has led to unprecedented restrictions in peoples lifestyle which have affected their psychological wellbeing. In this context, this paper investigates the use of social signal processing techniques for remote assessment of emotions. It presents a machine learning method for affect recognition applied to recordings taken during the COVID-19 winter lockdown in Scotland (UK). This method is exclusively based on acoustic features extracted from voice recordings collected through home and mobile devices (i.e. phones, tablets), thus providing insight into the feasibility of monitoring peoples psychological wellbeing remotely, automatically and at scale. The proposed model is able to predict affect with a concordance correlation coefficient of 0.4230 (using Random Forest) and 0.3354 (using Decision Trees) for arousal and valence respectively.

Clinical relevanceIn 2018/2019, 12% and 14% of Scottish adults reported depression and anxiety symptoms. Remote emotion recognition through home devices would support the detection of these difficulties, which are often underdiagnosed and, if untreated, may lead to temporal or chronic disability.",health informatics,fuzzy,100,100
medRxiv,10.1101/2021.05.05.21256649,2021-05-08,https://medrxiv.org/cgi/content/short/2021.05.05.21256649,Illness duration and symptom profile in a large cohort of symptomatic UK school-aged children tested for SARS-CoV-2,Erika Molteni; Carole Helene Sudre; Liane Santos Canas; Sunil S Bhopal; Robert C Hughes; Michela S Antonelli; Benjamin Murray; Kerstin Klaser; Eric Kerfoot; Liyuan Chen; Jie Deng; Christina Hu; Somesh Selvachandran; Kenneth Read; Joan Capdevila Pujol; Alexander Hammers; Timothy Spector; Sebastien Ourselin; Claire J Steves; Marc Modat; Michael Absoud; Emma L Duncan,King's College London; University College London; King's College London; King's College London; Newcastle University; London School of Hygiene & Tropical Medicine; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; ZOE Global Ltd; Zoe Global Ltd; ZOE Global Ltd; Zoe Global Ltd; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Evelina Hospital London; King's College London,"BackgroundIn children, SARS-CoV-2 is usually asymptomatic or causes a mild illness of short duration. Persistent illness has been reported; however, its prevalence and characteristics are unclear. We aimed to determine illness duration and characteristics in symptomatic UK school-aged children tested for SARS-CoV-2 using data from the COVID Symptom Study, the largest UK citizen participatory epidemiological study to date.

MethodsData from 258,790 children aged 5-17 years were reported by an adult proxy between 24 March 2020 and 22 February 2021. Illness duration and symptom profiles were analysed for all children testing positive for SARS-CoV-2 for whom illness duration could be determined, considered overall and within younger (5-11 years) and older (12-17 years) groups. Data from symptomatic children testing negative for SARS-CoV-2, matched 1:1 for age, gender, and week of testing, were also assessed.

Findings1,734 children (588 younger, 1,146 older children) had a positive SARS-CoV-2 test result and calculable illness duration within the study time frame. The commonest symptoms were headache (62.2%) and fatigue (55.0%). Median illness duration was six days (vs. three days in children testing negative), and was positively associated with age (rs 0.19, p<1.e-4) with median duration of seven days in older vs. five days in younger children.

Seventy-seven (4.4%) children had illness duration [&ge;]28 days (LC28), more commonly experienced by older vs. younger children (59 (5.1%) vs. 18 (3.1%), p=0.046). The commonest symptoms experienced by these children were fatigue (84%), headache (80%) and anosmia (80%); however, by day 28 the symptom burden was low (median, two). Only 25 (1.8%) of 1,379 children experienced symptoms for [&ge;]56 days. Few children (15 children, 0.9%) in the negatively-tested cohort experienced prolonged symptom duration; however, these children experienced greater symptom burden (both throughout their illness and at day 28) than children positive for SARS-CoV-2.

InterpretationSome children with COVID-19 experience prolonged illness duration. Reassuringly, symptom burden in these children did not increase with time, and most recovered by day 56. Some children who tested negative for SARS-CoV-2 also had persistent and burdensome illness. A holistic approach for all children with persistent illness during the pandemic is appropriate.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSSARS-CoV-2 in children is usually asymptomatic or manifests as a mild illness of short duration. Concerns have been raised regarding prolonged illness in children, with no clear resolution of symptoms several weeks after onset, as is observed in some adults. How common this might be in children, the clinical features of such prolonged illness in children, and how it might compare with illnesses from other respiratory viruses (and with general population prevalence of these symptoms) is unclear.

Added value of this studyWe provide systematic description of COVID-19 in UK school-aged children. Our data, collected in a digital surveillance platform through one of the largest UK citizen science initiatives, show that long illness duration after SARS-CoV-2 infection in school-aged children does occur, but is uncommon, with only a small proportion of children experiencing illness duration beyond four weeks; and the symptom burden in these children usually decreases over time. Almost all children have symptom resolution by eight weeks, providing reassurance about long-term outcomes. Additionally, symptom burden in children with long COVID was not greater than symptom burden in children with long illnesses due to causes other than SARS-CoV-2 infection.

Implications of all the available evidenceOur data confirm that COVID-19 in UK school-aged children is usually of short duration and of low symptom burden. Some children do experience longer illness duration, validating their experience; however, most of these children usually recover with time. Our findings highlight that appropriate resources will be necessary for any child with prolonged illness, whether due to COVID-19 or other illness. Our study provides timely and critical data to inform discussions around the impact and implications of the pandemic on paediatric healthcare resource allocation.",epidemiology,fuzzy,94,100
medRxiv,10.1101/2021.05.04.21256507,2021-05-06,https://medrxiv.org/cgi/content/short/2021.05.04.21256507,Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study,Satveer K Mahil; Mark Yates; Zenas Z Yiu; Sinead M Langan; Teresa Tsakok; Nick Dand; Kayleigh J Mason; Helen McAteer; Freya Meynall; Bolaji Coker; Alexandra Vincent; Dominic Urmston; Amber Vesty; Jade Kelly; Camille Lancelot; Lucy Moorhead; Herve Bachelez; Francesca Capon; Claudia R Contreras; Claudia De La Cruz; Paola Di Meglio; Paolo Gisondi; Denis Jullien; Jo Lambert; Luigi Naldi; Sam Norton; Luis Puig; Phyllis Spuls; Tiago Torres; Richard B Warren; Hoseah Waweru; John Weinman; Matt A Brown; James B Galloway; Christopher M Griffiths; Jonathan N Barker; Catherine H Smith,"St Johns Institute of Dermatology, Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK; Centre for Rheumatic Diseases, King's College London; Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Rese; Faculty of Epidemiology, and Population Health, London School of Hygiene and Tropical Medicine, London, UK; St Johns Institute of Dermatology, Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK; Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, London, UK; Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Rese; The Psoriasis Association, Northampton, UK; St Johns Institute of Dermatology, Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK; NIHR Biomedical Research Centre at Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK; NIHR Biomedical Research Centre at Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK; The Psoriasis Association, Northampton, UK; The Psoriasis Association, Northampton, UK; Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Rese; International Federation of Psoriasis Associations; St Johns Institute of Dermatology, Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK; Department of Dermatology, AP-HP Hopital Saint-Louis, Paris, France; King's College London; Catedra de Dermatologia, Hospital de Clinicas, Facultad de Ciencias Medicas, Universidad Nacional de Asuncion, Paraguay; Clinica Dermacross, Santiago, Chile; King's College London; Section of Dermatology and Venereology, University of Verona, Verona, Italy; Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France; Department of Dermatology, Ghent University, Ghent, Belgium; Centro Studi GISED, Bergamo, Italy; Psychology Department, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK; Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain; Department of Dermatology, Amsterdam Public Health/Infection and Immunology, Amsterdam University Medical Centers, Location AMC, Amsterdam, The Netherlands; Department of Dermatology, Centro Hospitalar do Porto, Portugal; Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Rese; International Federation of Psoriasis Associations; School of Cancer and Pharmaceutical Sciences, Kings College London, London, UK; Centre for Rheumatic Diseases, King's College London, London, UK; Centre for Rheumatic Diseases, King's College London, London, UK; 3Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Res; NIHR Biomedical Research Centre at Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK; St Johns Institute of Dermatology, Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK","BackgroundIndirect excess morbidity has emerged as a major concern in the COVID-19 pandemic. People with psoriasis may be particularly vulnerable to this because of prevalent anxiety and depression, multimorbidity and therapeutic use of immunosuppression.

ObjectiveCharacterise the factors associated with worsening psoriasis in the COVID-19 pandemic, using mental health status (anxiety and depression) as the main exposure of interest.

MethodsGlobal cross-sectional study using a primary outcome of self-reported worsening of psoriasis. Individuals with psoriasis completed an online self-report questionnaire (PsoProtectMe; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection Me) between May 2020 and January 2021. Each individual completed a validated screen for anxiety (Generalized Anxiety Disorder-2) and depression (Patient Health Questionnaire-2). Odds ratios (OR) and 95% confidence intervals (CI) were estimated using multivariable logistic regression.

Results4,043 people with psoriasis (without COVID-19) from 86 countries self-reported to PsoProtectMe (mean age 47.2 years [SD 15.1]; mean BMI 27.6kg/m2 [SD 6.0], 2,684 [66.4%] female and 3,016 [74.6%] of white European ethnicity). 1,728 (42.7%) participants (1322 [77%] female) reported worsening of their psoriasis in the pandemic. A positive screen for anxiety or depression associated with worsening psoriasis in age and gender adjusted (OR 2.04, 95% CI 1.77-2.36), and fully adjusted (OR 2.01, 95% CI 1.72-2.34) logistic regression models. Female sex, obesity, shielding behaviour and systemic immunosuppressant non-adherence also associated with worsening psoriasis. The commonest reason for non-adherence was concern regarding complications related to COVID-19.

ConclusionsThese data indicate an association between poor mental health and worsening psoriasis in the pandemic. Access to holistic care including psychological support may mitigate potentially long-lasting effects of the pandemic on health outcomes in psoriasis. The study also highlights an urgent need to address patient concerns about immunosuppressant-related risks, which may be contributing to non-adherence.",dermatology,fuzzy,100,100
medRxiv,10.1101/2021.04.28.21256261,2021-05-02,https://medrxiv.org/cgi/content/short/2021.04.28.21256261,Aspirin and NSAID use and the risk of COVID-19,David Alden Drew; Chuan-Guo Guo; Karla Lee; Long Nguyen; Amit D Joshi; Chun-Han Lo; Wenjie Ma; Raaj S Mehta; Sohee Kwon; Christina M Astley; Mingyang Song; Richard Davies; Joan Capdevila; Mary M Ni Lochlainn; Carole Sudre; Mark S Graham; Thomas Varsavsky; Maria F. Gomez; Beatrice Kennedy; Hugo Fitipaldi; Jonathan Wolf; Timothy Spector; Sebastien Ourselin; Claire Steves; Andrew T. Chan,Massachusetts General Hospital; Massachusetts General Hospital; Department of Twin Research and Genetic Epidemiology; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Boston Children's Hospital; Massachusetts General Hospital; Zoe Global Ltd.; Zoe Global Ltd; King's College London; Kings College London; King's College London; Kings College London; Lund University; Uppsala University; Lund University; Zoe Global Ltd.; King's College London; King's College London; King's College London; Massachusetts General Hospital,"Early reports raised concern that use of non-steroidal anti-inflammatory drugs (NSAIDs) may increase risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19). Users of the COVID Symptom Study smartphone application reported use of aspirin and other NSAIDs between March 24 and May 8, 2020. Users were queried daily about symptoms, COVID-19 testing, and healthcare seeking behavior. Cox proportional hazards regression was used to determine the risk of COVID-19 among according to aspirin or non-aspirin NSAID users. Among 2,736,091 individuals in the U.S., U.K., and Sweden, we documented 8,966 incident reports of a positive COVID-19 test over 60,817,043 person-days of follow-up. Compared to non-users and after stratifying by age, sex, country, day of study entry, and race/ethnicity, non-aspirin NSAID use was associated with a modest risk for testing COVID-19 positive (HR 1.23 [1.09, 1.32]), but no significant association was observed among aspirin users (HR 1.13 [0.92, 1.38]). After adjustment for lifestyle factors, comorbidities and baseline symptoms, any NSAID use was not associated with risk (HR 1.02 [0.94, 1.10]). Results were similar for those seeking healthcare for COVID-19 and were not substantially different according to lifestyle and sociodemographic factors or after accounting for propensity to receive testing. Our results do not support an association of NSAID use, including aspirin, with COVID-19 infection. Previous reports of a potential association may be due to higher rates of comorbidities or use of NSAIDs to treat symptoms associated with COVID-19.

One Sentence SummaryNSAID use is not associated with COVID-19 risk.",epidemiology,fuzzy,94,100
medRxiv,10.1101/2021.04.30.21256119,2021-04-30,https://medrxiv.org/cgi/content/short/2021.04.30.21256119,Association between oral anticoagulants and COVID-19 related outcomes: two cohort studies,Angel YS Wong; Laurie Tomlinson; Jeremy P Brown; William Elson; Alex J Walker; Anna J Schultze; Caroline E Morton; David Evans; Peter Inglesby; Brian MacKenna; Krishnan Bhaskaran; Christopher T. Rentsch; Emma Powell; Elizabeth T. Williamson; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; Jonathan Cockburn; Helen I McDonald; Rohini I Mathur; Kevin Wing; Harriet Forbes; Rosalind M Eggo; Stephen Evans; Liam Smeeth; Ben Goldacre; Ian J Douglas,"London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Trop. Med.; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; TPP; London School of Medicine and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Bristol; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine","ObjectivesWe investigated the role of routinely prescribed oral anticoagulants (OACs) in COVID-19 outcomes, comparing current OAC use versus non-use in Study 1; and warfarin versus direct oral anticoagulants (DOACs) in Study 2.

DesignTwo cohort studies, on behalf of NHS England.

SettingPrimary care data and pseudonymously-linked SARS-CoV-2 antigen testing data, hospital admissions, and death records from England.

ParticipantsStudy 1: 70,464 people with atrial fibrillation (AF) and CHA{square}DS{square}-VASc score of 2. Study 2: 372,746 people with non-valvular AF.

Main outcome measuresTime to test for SARS-CoV-2, testing positive for SARS-CoV-2, COVID-19 related hospital admission, COVID-19 deaths or non-COVID-19 deaths in Cox regression.

ResultsIn Study 1, we included 52,416 current OAC users and 18,048 non-users. We observed no difference in risk of being tested for SARS-CoV-2 associated with current use (adjusted HR, 1.01, 95%CI, 0.96 to 1.05) versus non-use. We observed a lower risk of testing positive for SARS-CoV-2 (adjusted HR, 0.73, 95%CI, 0.60 to 0.90), and COVID-19 deaths (adjusted HR, 0.69, 95%CI, 0.49 to 0.97) associated with current use versus non-use. In Study 2, we included 92,339 warfarin users and 280,407 DOAC users. We observed a lower risk of COVID-19 deaths (adjusted HR, 0.79, 95%CI, 0.76 to 0.83) associated with warfarin versus DOACs. Similar associations were found for all other outcomes.

ConclusionsAmong people with AF and a CHA{square}DS{square}-VASc score of 2, those receiving OACs had a lower risk of receiving a positive COVID-19 test and severe COVID-19 outcomes than non-users; this might be explained by a causal effect of OACs in preventing severe COVID-19 outcomes or more cautious behaviours leading to reduced infection risk. There was no evidence of a higher risk of severe COVID-19 outcomes associated with warfarin versus DOACs in people with non-valvular AF regardless of CHA{square}DS{square}-VASc score.

Key pointsO_ST_ABSWhat is already known on this topicC_ST_ABSO_LICurrent studies suggest that prophylactic or therapeutic anticoagulant use, particularly low molecular weight heparin, lower the risk of pulmonary embolism and mortality during hospitalisation among patients with COVID-19.
C_LIO_LIReduced vitamin K status has been reported to be correlated with severity of COVID-19. This could mean that warfarin, as a vitamin K antagonist, is associated with more severe COVID-19 disease than non-vitamin K anticoagulants.
C_LI

What this study addsO_LIIn 70,464 people with atrial fibrillation, at the threshold of being treated with an OAC based on risk of stroke, we observed a lower risk of testing positive for SARS-CoV-2 and COVID-19 related deaths associated with routinely prescribed OACs, relative to non-use.
C_LIO_LIThis might be explained by OACs preventing severe COVID-19 outcomes, or more cautious behaviours and environmental factors reducing the risk of SARS-CoV-2 infection in those taking OACs.
C_LIO_LIIn 372,746 people with non-valvular atrial fibrillation, there was no evidence of a higher risk of severe COVID-19 outcomes associated with warfarin compared with DOACs.
C_LI",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.04.26.21255732,2021-04-28,https://medrxiv.org/cgi/content/short/2021.04.26.21255732,Deprivation and Exposure to Public Activities during the COVID-19 Pandemic in England and Wales,Sarah Beale; Isobel Braithwaite; Annalan MD Navaratnam; Pia Hardelid; Alison Rodger; Anna Aryee; Thomas Edward Byrne; Wing Lam Erica Fong; Ellen Fragaszy; Cyril Geismar; Jana Kovar; Vincent Nguyen; Parth Patel; Madhumita Shrotri; Robert W Aldridge; Andrew C Hayward; - Virus Watch Collaborative,"University College London; University College London; University College London; University College London; University College London; Royal Free London NHS Foundation Trust,; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; ","BackgroundDifferential exposure to public activities and non-household contacts may contribute to stark deprivation-related inequalities in SARS-CoV-2 infection and outcomes, but has not been directly investigated. We set out to investigate whether participants in Virus Watch - a large community cohort study based in England and Wales - reported different levels of exposure to public activities and non-household contacts during the Autumn-Winter phase of the COVID-19 pandemic according to postcode-level socioeconomic deprivation.

MethodsParticipants (n=20120-25228 across surveys) reported their daily activities during three weekly periods in late November 2020, late December 2020, and mid-February 2021. Deprivation was quantified based on participants postcode of residence using English or Welsh Indices of Multiple Deprivation quintiles. We used Poisson mixed effect models with robust standard errors to estimate the relationship between deprivation and risk of exposure to public activities during each survey period.

ResultsRelative to participants in the least deprived areas, participants in the most deprived areas persistently exhibited elevated risk of exposure to vehicle sharing (aRR range across time points 1.73-8.52), public transport (aRR 3.13-5.73), work or education outside of the household (aRR 1.09-1.21), essential shops (aRR 1.09-1.13) and non-household contacts (aRR 1.15-1.19) across multiple survey periods.

ConclusionDifferential exposure to essential public activities in deprived communities is likely to contribute to inequalities in infection risk and outcomes during the COVID-19 pandemic. Public health interventions to reduce exposure during essential activities and financial and practical support to enable low-paid workers to stay at home during periods of intense transmission may reduce COVID-related inequalities.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.04.24.21255968,2021-04-27,https://medrxiv.org/cgi/content/short/2021.04.24.21255968,MORTALITY OF CARE HOME RESIDENTS AND COMMUNITY-DWELLING CONTROLS DURING THE COVID-19 PANDEMIC IN 2020: MATCHED COHORT STUDY,Martin C Gulliford; A Toby Prevost; Andrew Clegg; Emma C Rezel-Potts,King's College London; King's College London; University of Leeds; King's College London,"ObjectiveTo estimate mortality of care home (CH) residents, and matched community-dwelling controls, during the Covid-19 pandemic from primary care electronic health records.

DesignMatched cohort study

SettingGeneral practices contributing to the Clinical Practice Research Datalink Aurum Database in England.

ParticipantsThere were 83,627 CH residents contributing data in 2020, with 26,923 deaths; 80,730 (97%) were matched on age, gender and general practice with 300,445 community-dwelling adults.

Main outcome measuresAll-cause mortality. Adjusted rate ratios (RR) by negative binomial regression were adjusted for age, gender, number of long-term conditions (LTCs), frailty category, region, calendar month or week, and clustering by general practice.

ResultsDuring April 2020, the mortality rate of CH residents was 27.2 deaths per 1,000 patients per week, compared with 2.31 per 1,000 for controls, RR 11.1 (95% confidence interval 10.1 to 12.2). Compared with CH residents, LTCs and frailty were differentially associated with greater mortality in community-dwelling controls. During April 2020, mortality rates per 1,000 patients per week for persons with 9+ LTCs were: CH, 37.9; controls 17.7; RR 2.14 (1.18 to 3.89). In severe frailty, mortality rates were: CH, 29.6; controls 5.1; RR 6.17 (5.74 to 6.62).

ConclusionsIndividual-patient data from primary care electronic health records may be used to estimate mortality in care home residents. Mortality is substantially higher than for community-dwelling comparators and showed a disproportionate increase in the first wave of the Covid-19 pandemic. Multiple morbidity and frailty were associated with greater absolute risks but lower relative risks because community-dwelling frail or multi-morbid patients also experienced high mortality.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.04.21.21255807,2021-04-27,https://medrxiv.org/cgi/content/short/2021.04.21.21255807,A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 - the ATOMIC2 trial,Timothy SC Hinks; Lucy Cureton; Ruth Knight; Ariel Wang; Jennifer L Cane; Vicki S Barber; Joanna Black; Susan J Dutton; James Melhorn; Maisha Jabeen; Phil Moss; Rajendar Garlapati; Tanya Baron; Graham Johnson; Fleur Cantle; David Clarke; Samer Elkhodair; Jonathan Underwood; Daniel Lasserson; Ian D Pavord; Sophie B Morgan; Duncan Richards,"University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; St George's Hospital, London; East Lancashire NHS Hospitals; Oxford University Hospitals NHS Trust; Royal Derby Hospital; Kings College Hospital, London; Royal Berkshire Hospital; University College London Hospital; Cardiff University; Oxford University Hospitals NHS Trust; University of Oxford; University of Oxford; University of Oxford","BackgroundThe antibacterial, anti-inflammatory and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-moderate disease are lacking. We assessed whether azithromycin is effective in reducing hospitalisation in patients with mild-moderate COVID-19.

MethodsThis open-label, randomised superiority clinical trial at 19 centres in the United Kingdom enrolled adults, [&ge;]18 years, presenting to hospitals with clinically-diagnosed highly-probable or confirmed COVID-19 infection, with <14 days symptoms, considered suitable for initial ambulatory management. Patients were randomised (1:1) to azithromycin (500 mg daily orally for 14 days) or to standard care without macrolides. The primary outcome was the difference in proportion of participants with death or hospital admission from any cause over the 28 days from randomisation, assessed according to intention-to-treat (ITT). Trial registration: ClinicalTrials.gov, NCT04381962, Study closed.

Findings298 participants were enrolled from 3rd June 2020 to 29th January 2021. The primary outcome was assessed in 292 participants. The primary endpoint was not significantly different between the azithromycin and control groups (Adjusted OR 0{middle dot}91 [95% CI 0{middle dot}43-1{middle dot}92], p=0{middle dot}80). Rates of respiratory failure, progression to pneumonia, all-cause mortality, and adverse events, including serious cardiovascular events, were not significantly different between groups.

InterpretationIn patients with mild-moderate COVID-19 managed without hospital admission, adding azithromycin to standard care treatment did not reduce the risk of subsequent hospitalisation or death. Our findings do not support the use of azithromycin in patients with mild-moderate COVID-19.

FundingNIHR Oxford BRC, University of Oxford and Pfizer Inc.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched MEDLINE and the Cochrane Central register of Controlled Trials (CENTRAL) with the terms (""azithromycin"") AND (""COVID"" OR ""COVID-19"") AND (""clinical trials""), until March 25, 2021, with no language restrictions. We identified 42 studies, among which there were four completed randomised trials of azithromycin (with or without hydroxychloroquine) in hospitalised patients with severe disease, and three completed randomised trials of azithromycin in mild COVID-19 in primary care. The four trials in hospitalised patients randomised 8,988 participants to azithromycin or standard care or hydroxychloroquine and found no evidence of a difference in mortality, duration of hospital stay or peak disease severity. Of the three trials in primary care, these randomised participants with early disease to 3 or 5 days of therapy, of which only one assessed azithromycin as standalone therapy. This large, adaptive platform trial in the UK randomised 540 participants in primary care to 3 days treatment with azithromycin versus 875 to standard care alone and found no meaningful difference in time to first reported recovery, or of rates of hospitalisation (3% versus 3%) and there were no deaths. We did not identify any randomised trials in patients with COVID-19 managed in ambulatory care.

Added value of this studyThe ATOMIC2 trial was uniquely-designed to assess azithromycin as a standalone therapy in those with mild-moderately COVID-19 presenting to emergency care, but assessed as appropriate for initial ambulatory management without hospital admission. ATOMIC2 also uniquely assessed high-dose, long-duration treatment to investigate the efficacy of putative anti-inflammatory effects. We found that azithromycin 500 mg daily for 14 days did not reduce the proportion of participants who died or required hospital admission from any cause over the 28 days from randomisation.

Implications of all the available evidenceOur findings, taken together with existing data, suggest there is no evidence that azithromycin reduces hospitalisation, respiratory failure or death compared with standard care, either in early disease in the community, or those hospitalised with severe disease, or in those with moderate disease managed on an ambulatory pathway.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.04.22.21255949,2021-04-25,https://medrxiv.org/cgi/content/short/2021.04.22.21255949,Optimal health and economic impact of non-pharmaceutical intervention measures prior and post vaccination in England: a mathematical modelling study,Michael Tildesley; Anna Vassall; Steven Riley; Mark Jit; Frank Sandmann; Edward M Hill; Robin Thompson; Benjamin Atkins; John Edmunds; Louise M Dyson; Matt J Keeling,"University of Warwick; London School of Hygiene and Tropical Medicine; Dept Inf Dis Epi, Imperial College; London School of Hygiene & Tropical Medicine; Public Health England; University of Warwick; University of Warwick; University of Warwick; London School of Hygiene and Tropical Medicine; University of Warwick; University of Warwick","BackgroundEven with good progress on vaccination, SARS-CoV-2 infections in the UK may continue to impose a high burden of disease and therefore pose substantial challenges for health policy decision makers. Stringent government-mandated physical distancing measures (lockdown) have been demonstrated to be epidemiologically effective, but can have both positive and negative economic consequences. The duration and frequency of any intervention policy could, in theory, could be optimised to maximise economic benefits while achieving substantial reductions in disease.

MethodsHere we use a pre-existing SARS-CoV-2 transmission model to assess the health and economic implications of different strengths of control through time in order to identify optimal approaches to non-pharmaceutical intervention stringency in the UK, considering the role of vaccination in reducing the need for future physical distancing measures. The model is calibrated to the COVID-19 epidemic in England and we carry out retrospective analysis of the optimal timing of precautionary breaks in 2020 and the optimal relaxation policy from the January 2021 lockdown, considering the willingness to pay for health improvement.

ResultsWe find that the precise timing and intensity of interventions is highly dependent upon the objective of control. As intervention measures are relaxed, we predict a resurgence in cases, but the optimal intervention policy can be established dependent upon the willingness to pay (WTP) per QALY loss avoided. Our results show that establishing an optimal level of control can result in a reduction in net monetary loss of billions of pounds, dependent upon the precise WTP value.

ConclusionsIt is vital, as the UK emerges from lockdown, but continues to face an on-going pandemic, to accurately establish the overall health and economic costs when making policy decisions. We demonstrate how some of these can be quantified, employing mechanistic infectious disease transmission models to establish optimal levels of control for the ongoing COVID-19 pandemic.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.04.22.21255948,2021-04-25,https://medrxiv.org/cgi/content/short/2021.04.22.21255948,"Point of Care Testing using rapid automated Antigen Testing for SARS-COV-2 in Care Homes; an exploratory safety, usability and diagnostic agreement evaluation",Massimo Micocci; Peter Buckle; Gail Hayward; A. Joy Allen; Kerrie Davies; Patrick Kierkegaard; Karen Spilsbury; Carl Thompson; Anita Astle; Ros Heath; Claire Sharpe; Cyd Akrill; Dan Lasserson; Rafael Perera; Richard Body; Adam L Gordon,"NIHR London In Vitro Diagnostics Co-operative, Department of Surgery and Cancer, Imperial College London, London, UK; NIHR London In Vitro Diagnostics Co-operative, Department of Surgery and Cancer, Imperial College London, London, UK; NIHR Community Healthcare Medtech and IVD cooperative, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; NIHR Newcastle In Vitro Diagnostics Co-operative, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK; Healthcare Associated Infections Research Group, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK. NIHR Leeds In Vitro Diagnostics Co-opera; NIHR London In Vitro Diagnostics Co-operative, Department of Surgery and Cancer, Imperial College London, London, UK.; School of Healthcare, University of Leeds, Leeds, UK. NIHR Applied Research Collaboration Yorkshire and Humber, UK; School of Healthcare, University of Leeds, Leeds, UK. NIHR Applied Research Collaboration Yorkshire and Humber, UK; Wren Hall Nursing Home, Selston, UK; Landermeads Nursing Home, Nottingham, UK; Ashmere Nottinghamshire Ltd, Notts, UK; Springfield Healthcare, Leeds, UK; Warwick Medical School, University of Warwick, Coventry, UK; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; NIHR Applied Research Collaboration - Yorkshire and Humber (YHARC), UK; Division of Medical Sciences and Graduate Entry Medicine, School of Medicine, University of Nottingham, UK. NIHR Applied Research Collaboration-East Midlands (A","IntroductionSuccessful adoption of POCTs (Point-of-Care tests) for COVID-19 in care homes requires the identification of ideal use cases and a full understanding of contextual and usability factors that affect test results and minimise biosafety risks. This paper presents findings from a scoping-usability and test performance study of a microfluidic immunofluorescence assay for COVID-19 in care homes.

MethodsA mixed-methods evaluation was conducted in four UK care homes to scope usability and to assess the agreement with qRT-PCR. A dry run with luminescent dye was carried out to explore biosafety issues.

ResultsThe agreement analysis was carried out on 227 asymptomatic participants (159 staff and 68 residents) and 14 symptomatic participants (5 staff and 9 residents). Asymptomatic specimens showed 50% (95% CI: 1.3%-98.7%) positive agreement and 96% (95% CI: 92.5%-98.1%) negative agreement with overall prevalence and bias-adjusted Kappa (PABAK) of 0.911 (95% CI: 0.857-0.965). Symptomatic specimens showed 83.3% (95% CI: 35.9%-99.6%) positive agreement and 100% (95% CI: 63.1%-100%) negative agreement with overall prevalence and bias-adjusted Kappa (PABAK) of 0.857 (95% CI: 0.549-1).

The dry run showed four main sources of contamination that led to the modification of the standard operating procedures. Simulation after modification showed no further evidence of contamination.

ConclusionCareful consideration of biosafety issues and contextual factors associated with care home are mandatory for safe use the POCT. Whilst POCT may have some utility for ruling out COVID-19, further diagnostic accuracy evaluations are needed to promote effective adoption.",health systems and quality improvement,fuzzy,90,100
medRxiv,10.1101/2021.04.22.21255911,2021-04-23,https://medrxiv.org/cgi/content/short/2021.04.22.21255911,The impact of SARS-CoV-2 vaccines on antibody responses in the general population in the United Kingdom,Jia Wei; Nicole Stoesser; Philippa C Matthews; Ruth Studley; Iain Bell; John I Bell; John N Newton; Jeremy Farrar; Ian Diamond; Emma Rourke; Alison Howarth; Brian D Marsden; Sarah Hoosdally; E Yvonne Jones; David I Stuart; Derrick W Crook; Tim EA Peto; Koen B Pouwels; David W Eyre; A Sarah Walker; - COVID-19 Infection Survey team,"University of Oxford; University of Oxford; University of Oxford; Office for National Statistics, UK; Office for National Statistics, UK; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics, UK; Office for National Statistics, UK; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ","Real-world data on antibody response post-vaccination in the general population are limited. 45,965 adults in the UKs national COVID-19 Infection Survey receiving Pfizer-BioNTech or Oxford-AstraZeneca vaccines had 111,360 anti-spike IgG measurements. Without prior infection, seroconversion rates and quantitative antibody levels post single dose were lower in older individuals, especially >60y. Two doses achieved high responses across all ages, particularly increasing seroconversion in older people, to similar levels to those achieved after prior infection followed by a single dose. Antibody levels rose more slowly and to lower levels with Oxford-AstraZeneca vs Pfizer-BioNTech, but waned following a single Pfizer-BioNTech dose. Latent class models identified four responder phenotypes: older people, males, and those having long-term health conditions were more commonly  low responders. Where supplies are limited, vaccines should be prioritised for those not previously infected, and second doses to individuals >60y. Further data on the relationship between vaccine-mediated protection and antibody responses are needed.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.04.22.21255913,2021-04-23,https://medrxiv.org/cgi/content/short/2021.04.22.21255913,Impact of vaccination on SARS-CoV-2 cases in the community: a population-based study using the UK COVID-19 Infection Survey,Emma Pritchard; Philippa Matthews; Nicole Stoesser; David Eyre; Owen Gethings; Karina-Doris Vitha; Joel Jones; Thomas House; Harper VanSteenhouse; Iain Bell; John Bell; John Newton; Jeremy Farrar; Ian Diamond; Emma Rourke; Ruth Studley; Derrick W Crook; tim E peto; Ann Sarah Walker; Koen B Pouwels,"University of Oxford; University of Oxford; University of Oxford; University of Oxford; Office for National Statistics; University of Oxford; Office for National Statistics; University of Manchester; Glasgow Lighthouse Laboratory; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics,; Office for National Statistics; Office for National Statistics; NIHR Oxford Biomedical Research Centre; oxford university; University of Oxford; University of Oxford","ObjectivesTo assess the effectiveness of COVID-19 vaccination in preventing SARS-CoV-2 infection in the community.

DesignProspective cohort study.

SettingThe UK population-representative longitudinal COVID-19 Infection Survey.

Participants373,402 participants aged [&ge;]16 years contributing 1,610,562 RT-PCR results from nose and throat swabs between 1 December 2020 and 3 April 2021.

Main outcome measuresNew RT-PCR-positive episodes for SARS-CoV-2 overall, by self-reported symptoms, by cycle threshold (Ct) value (<30 versus [&ge;]30), and by gene positivity (compatible with the B.1.1.7 variant versus not).

ResultsOdds of new SARS-CoV-2 infection were reduced 65% (95% CI 60 to 70%; P<0.001) in those [&ge;]21 days since first vaccination with no second dose versus unvaccinated individuals without evidence of prior infection (RT-PCR or antibody). In those vaccinated, the largest reduction in odds was seen post second dose (70%, 95% CI 62 to 77%; P<0.001).There was no evidence that these benefits varied between Oxford-AstraZeneca and Pfizer-BioNTech vaccines (P>0.9).There was no evidence of a difference in odds of new SARS-CoV-2 infection for individuals having received two vaccine doses and with evidence of prior infection but not vaccinated (P=0.89). Vaccination had a greater impact on reducing SARS-CoV-2 infections with evidence of high viral shedding Ct<30 (88% reduction after two doses; 95% CI 80 to 93%; P<0.001) and with self-reported symptoms (90% reduction after two doses; 95% CI 82 to 94%; P<0.001); effects were similar for different gene positivity patterns.

ConclusionVaccination with a single dose of Oxford-AstraZeneca or Pfizer-BioNTech vaccines, or two doses of Pfizer-BioNTech, significantly reduced new SARS-CoV-2 infections in this large community surveillance study. Greater reductions in symptomatic infections and/or infections with a higher viral burden are reflected in reduced rates of hospitalisations/deaths, but highlight the potential for limited ongoing transmission from asymptomatic infections in vaccinated individuals.

RegistrationThe study is registered with the ISRCTN Registry, ISRCTN21086382.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.04.12.21255275,2021-04-19,https://medrxiv.org/cgi/content/short/2021.04.12.21255275,Children develop strong and sustained cross-reactive immune responses against spike protein following SARS-CoV-2 infection,Alexander C Dowell; Megan S. Butler; Elizabeth Jinks; Gokhan Tut; Tara Lancaster; Panagiota Sylla; Jusnara Begum; Rachel Bruton; Hayden Pearce; Kriti Verma; Nicola Logan; Grace Tyson; Eliska Spalkova; Sandra Margielewska-Davies; Graham S. Taylor; Eleni Syrimi; Frances Baawuah; Joanne Beckmann; Ifeanyichukwu Okike; Shazaad Ahmad; Joanna Garstang; Andrew Brent; Bernadette Brent; Georgina Ireland; Felicity Aiano; Zahin Amin-Chowdhury; Samuel Jones; Ray Borrow; Ezra Linley; Rafaq Azad; John Wright; Dagmar Waiblinger; Chris Davis; Emma C Thomson; Massimo Palmarini; Brian James Willett; Wendy S Barclay; John Poh; Vanessa Saliba; Gayatri Amirthalingam; Kevin Brown; Mary Ramsay; Jianmin Zuo; Paul Moss; Shamez Ladhani,"Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; University of Birmingham; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; University of Birmingham; MRC-University of Glasgow Centre for Virus Research, 464 Bearsden Road, Glasgow G61-1QH, UK; MRC-University of Glasgow Centre for Virus Research, 464 Bearsden Road, Glasgow G61-1QH, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; East London NHS Foundation Trust, 9 Allie Street, London E1 8DE, UK; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK 4.	University Hospitals of Derby and Burton NHS Foundation Trust, Uttoxeter New Road, Derby; Manchester University NHS Foundation Trust, Oxford Road, Manchester M13 9WL, UK; Birmingham Community Healthcare NHS Trust, Holt Street, Aston B7 4BN, UK; Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford OX3 7HE University of Oxford, Wellington Square, Oxford OX1 2JD, UK; Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford OX3 7HE; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom; Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom; Bradford Teaching Hospitals NHS Foundation Trust; Bradford Teaching Hospitals NHS Foundation Trust; Bradford Teaching Hospitals NHS Foundation Trust; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; Imperial College, London; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Institute of Immunology & Immunotherapy, Collage of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Public Health England, 61 Colindale Avenue, London NW9 5EQ, UK","SARS-CoV-2 infection is generally mild or asymptomatic in children but the biological basis for this is unclear. We studied the profile of antibody and cellular immunity in children aged 3-11 years in comparison with adults. Antibody responses against spike and receptor binding domain (RBD) were high in children and seroconversion boosted antibody responses against seasonal Beta-coronaviruses through cross-recognition of the S2 domain. Seroneutralisation assays against alpha, beta and delta SARS-CoV-2 variants demonstrated comparable neutralising activity between children and adults. T cell responses against spike were >2-fold higher in children compared to adults and displayed a TH1 cytokine profile. SARS-CoV-2 spike-specific T cells were also detected in many seronegative children, revealing pre-existing responses that were cross-reactive with seasonal Alpha and Beta-coronaviruses. Importantly, all children retained high antibody titres and cellular responses at 6 months after infection whilst relative antibody waning was seen in adults. Spike-specific responses in children also remained broadly stable beyond 12 months. Children thus distinctly generate robust, cross-reactive and sustained immune responses after SARS-CoV-2 infection with focussed specificity against spike protein. These observations demonstrate novel features of SARS-CoV-2-specific immune responses in children and may provide insight into their relative clinical protection. Furthermore, this information will help to guide the introduction of vaccination regimens in the paediatric population.",allergy and immunology,fuzzy,100,100
medRxiv,10.1101/2021.04.08.21255100,2021-04-15,https://medrxiv.org/cgi/content/short/2021.04.08.21255100,REACT-1 round 10 report: Level prevalence of SARS-CoV-2 swab-positivity in England during third national lockdown in March 2021,Steven Riley; Oliver Eales; David Haw; Caroline E. Walters; Haowei Wang; Kylie E. C. Ainslie; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear","BackgroundIn England, hospitalisations and deaths due to SARS-CoV-2 have been falling consistently since January 2021 during the third national lockdown of the COVID-19 pandemic. The first significant relaxation of that lockdown occurred on 8 March when schools reopened.

MethodsThe REal-time Assessment of Community Transmission-1 (REACT-1) study augments routine surveillance data for England by measuring swab-positivity for SARS-CoV-2 in the community. The current round, round 10, collected swabs from 11 to 30 March 2021 and is compared here to round 9, in which swabs were collected from 4 to 23 February 2021.

ResultsDuring round 10, we estimated an R number of 1.00 (95% confidence interval 0.81, 1.21). Between rounds 9 and 10 we estimated national prevalence has dropped by [~]60% from 0.49% (0.44%, 0.55%) in February to 0.20% (0.17%, 0.23%) in March. There were substantial falls in weighted regional prevalence: in South East from 0.36% (0.29%, 0.44%) in round 9 to 0.07% (0.04%, 0.12%) in round 10; London from 0.60% (0.48%, 0.76%) to 0.16% (0.10%, 0.26%); East of England from 0.47% (0.36%, 0.60%) to 0.15% (0.10%, 0.24%); East Midlands from 0.59% (0.45%, 0.77%) to 0.19% (0.13%, 0.28%); and North West from 0.69% (0.54%, 0.88%) to 0.31% (0.21%, 0.45%). Areas of apparent higher prevalence remain in parts of the North West, and Yorkshire and The Humber. The highest prevalence in March was found among school-aged children 5 to 12 years at 0.41% (0.27%, 0.62%), compared with the lowest in those aged 65 to 74 and 75 and over at 0.09% (0.05%, 0.16%). The close approximation between prevalence of infections and deaths (suitably lagged) is diverging, suggesting that infections may have resulted in fewer hospitalisations and deaths since the start of widespread vaccination.

ConclusionWe report a sharp decline in prevalence of infections between February and March 2021. We did not observe an increase in the prevalence of SARS-CoV-2 following the reopening of schools in England, although the decline of prevalence appears to have stopped. Future rounds of REACT-1 will be able to measure the rate of growth or decline from this current plateau and hence help assess the effectiveness of the vaccination roll-out on transmission of the virus as well as the potential size of any third wave during the ensuing months.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.04.08.21255099,2021-04-14,https://medrxiv.org/cgi/content/short/2021.04.08.21255099,Occupational risks of COVID-19 in NHS workers in England,Diana van der Plaat; Ira Madan; David Coggon; Martie van Tongeren; Rhiannon Edge; Rupert Muiry; Vaughan Parsons; Paul Cullinan,Imperial College London; Guy's and St Thomas' NHS Foundation Trust; Southampton General Hospital; University of Manchester; Lancaster University; Guy's and St Thomas NHS Foundation Trust; Guy's and St Thomas NHS Foundation Trust; Imperial College London,"ObjectiveTo quantify occupational risks of Covid-19 among healthcare staff during the first wave of the pandemic in England

MethodsUsing pseudonymised data on 902,813 individuals continuously employed by 191 National Health Service trusts during 1.1.19 to 31.7.20, we explored demographic and occupational risk factors for sickness absence ascribed to Covid-19 during 9.3.20 to 31.7.20 (n = 92,880). We estimated odds ratios (ORs) by multivariable logistic regression.

ResultsWith adjustment for employing trust, demographic characteristics, and previous frequency of sickness absence, risk relative to administrative/clerical occupations was highest in additional clinical services (including care assistants) (OR 2.31 [2.25-2.37]), registered nursing and midwifery professionals (OR 2.28 [2.23-2.34]) and allied health professionals (OR 1.94 [1.88-2.01]), and intermediate in doctors and dentists (OR 1.55 [1.50-1.61]). Differences in risk were higher after the employing trust had started to care for documented Covid-19 patients, and were reduced, but not eliminated, following additional adjustment for exposure to infected patients or materials, assessed by a job-exposure matrix. For prolonged Covid-19 sickness absence (episodes lasting >14 days), the variation in risk by staff group was somewhat greater.

ConclusionsAfter allowance for possible bias and confounding by non-occupational exposures, we estimated that relative risks for Covid-19 among most patient-facing occupations were between 1.5 and 2.5. The highest risks were in those working in additional clinical services, nursing and midwifery and in allied health professions. Better protective measures for these staff groups should be a priority. Covid-19 may meet criteria for compensation as an occupational disease in some healthcare occupations.

Key messagesO_LIWhat is already known about this subject?
Healthcare workers and other keyworkers (workers whose job was considered essential to societal functioning) had a higher likelihood of testing positive for COVID-19 than other workers during the first lockdown in England. Amongst healthcare workers, those working in inpatient settings had the highest rate of infection.
C_LIO_LIWhat are the new findings?
Between March and July 2000, the overall risk of COVID-19 sickness absence in National Health Service staff in England was lower at older ages, higher in non-white staff, and (in comparison with administrative and clerical staff) more than doubled in registered nurses and among workers such as healthcare assistants providing support to health professionals. Risk in health care scientists was little different from that in administrative and clerical occupations
C_LIO_LIHow might this impact on policy or clinical practice in the foreseeable future?
Our results suggest that the risk reduction strategies that were in place for healthcare scientists were effective. However, the protection for nursing and supporting health professionals was insufficient. In the event of a further  wave of infections resulting in high hospital admissions, attention should be paid to ensuring that risk reduction strategies for nurses and supporting health professionals are improved.
C_LI",occupational and environmental health,fuzzy,100,100
bioRxiv,10.1101/2021.04.13.439482,2021-04-13,https://biorxiv.org/cgi/content/short/2021.04.13.439482,Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice,Kai Wu; Angela Choi; Matthew Koch; Sayda Elbashir; LingZhi Ma; Diana Lee; Angela Woods; Carole Henry; Charis Palandjian; Anna Hill; Hardik Jani; Julian Quinones; Naveen Nunna; Adrian B McDermott; Samantha Falcone; Elisabeth Narayanan; Tonya Colpitts; Hamilton Bennett; Kizzmekia Corbett; Robert Seder; Barney S Graham; Guillaume BE Stewart-Jones; Andrea Carfi; Darin K Edwards,"Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Moderna, Inc; Moderna, Inc; Moderna, Inc; Moderna, Inc; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Moderna, Inc; Moderna, Inc; Moderna, Inc","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of a global pandemic. Safe and effective COVID-19 vaccines are now available, including mRNA-1273, which has shown 94% efficacy in prevention of symptomatic COVID-19 disease. However, the emergence of SARS-CoV-2 variants has led to concerns of viral escape from vaccine-induced immunity. Several variants have shown decreased susceptibility to neutralization by vaccine-induced immunity, most notably B.1.351 (Beta), although the overall impact on vaccine efficacy remains to be determined. Here, we present the initial evaluation in mice of 2 updated mRNA vaccines designed to target SARS-CoV-2 variants: (1) monovalent mRNA-1273.351 encodes for the spike protein found in B.1.351 and (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. Both vaccines were evaluated as a 2-dose primary series in mice; mRNA-1273.351 was also evaluated as a booster dose in animals previously vaccinated with mRNA-1273. The results demonstrated that a primary vaccination series of mRNA-1273.351 was effective at increasing neutralizing antibody titers against B.1.351, while mRNA-1273.211 was effective at providing broad cross-variant neutralization. A third (booster) dose of mRNA-1273.351 significantly increased both wild-type and B.1.351-specific neutralization titers. Both mRNA-1273.351 and mRNA-1273.211 are being evaluated in pre-clinical challenge and clinical studies.",microbiology,fuzzy,96,94
medRxiv,10.1101/2021.04.10.21254672,2021-04-12,https://medrxiv.org/cgi/content/short/2021.04.10.21254672,Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial,- The PRINCIPLE Trial Collaborative Group; Ly-Mee Yu; Mona Bafadhel; Jienchi Dorward; Gail Hayward; Benjamin R Saville; Oghenekome Gbinigie; Oliver van Hecke; Emma Ogburn; Philip H Evans; Nicholas PB Thomas; Mahendra G Patel; Nicholas Berry; Michelle A Detry; Christina T Saunders; Mark Fitzgerald; Victoria Harris; Simon de Lusignan; Monique I Andersson; Peter J Barnes; Richard EK Russell; Dan V Nicolau Jr.; Sanjay Ramakrishnan; FD Richard Hobbs; Christopher C Butler,"; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Clinical Medicine, University of Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom and Centre for the AIDS Programme of Research in South Africa ; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Berry Consultants, Texas, USA and Department of Biostatistics, Vanderbilt University School of Medicine, Tennessee, USA; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; College of Medicine and Health, University of Exeter and National Institute for Health Research, Clinical Research Network; Royal College of General Practitioners, London, UK, and National Institute for Health Research, Clinical Research Network; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Berry Consultants, Texas, USA; Berry Consultants, Texas, USA; Berry Consultants, Texas, USA; Berry Consultants, Texas, USA; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Clinical Medicine, University of Oxford, United Kingdom,; National Heart and Lung Institute, Imperial College, London, United Kingdom; Nuffield Department of Clinical Medicine, University of Oxford, United Kingdom; UQ Centre for Clinical Research, University of Queensland, Brisbane, Australia and Nuffield Department of Clinical Medicine, University of Oxford, United Kingdo; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom","BACKGROUNDInhaled budesonide has shown efficacy for treating COVID-19 in the community but has not yet been tested in effectiveness trials.

METHODSWe performed a multicenter, open-label, multi-arm, adaptive platform randomized controlled trial involving people aged [&ge;]65 years, or [&ge;]50 years with comorbidities, and unwell [&le;]14 days with suspected COVID-19 in the community (PRINCIPLE). Participants were randomized to usual care, usual care plus inhaled budesonide (800{micro}g twice daily for 14 days), or usual care plus other interventions. The co-primary endpoints are time to first self-reported recovery, and hospitalization/death related to COVID-19, both measured over 28 days from randomisation and analysed using Bayesian models.

RESULTSThe trial opened on April 2, 2020. Randomization to inhaled budesonide began on November 27, 2020 and was stopped on March 31, 2021 based on an interim analysis using data from March 4, 2021. Here, we report updated interim analysis data from March 25, 2021, at which point the trial had randomized 4663 participants with suspected COVID-19. Of these, 2617 (56.1%) tested SARS-CoV-2 positive and contributed data to this interim budesonide primary analysis; 751 budesonide, 1028 usual care and 643 to other interventions. Time to first self-reported recovery was shorter in the budesonide group compared to usual care (hazard ratio 1.208 [95% BCI 1.076 - 1.356], probability of superiority 0.999, estimated benefit [95% BCI] of 3.011 [1.134 - 5.41] days). Among those in the interim budesonide primary analysis who had the opportunity to contribute data for 28 days follow up, there were 59/692 (8.5%) COVID-19 related hospitalizations/deaths in the budesonide group vs 100/968 (10.3%) in the usual care group (estimated percentage benefit, 2.1% [95% BCI -0.7% - 4.8%], probability of superiority 0.928).

CONCLUSIONSIn this updated interim analysis, inhaled budesonide reduced time to recovery by a median of 3 days in people with COVID-19 with risk factors for adverse outcomes. Once 28 day follow up is complete for all participants randomized to budesonide, final analyses of time to recovery and hospitalization/death will be published. (Funded by the National Institute of Health Research/ United Kingdom Research Innovation [MC_PC_19079]; PRINCIPLE ISRCTN number, ISRCTN86534580.)",primary care research,fuzzy,100,100
medRxiv,10.1101/2021.04.08.21254580,2021-04-10,https://medrxiv.org/cgi/content/short/2021.04.08.21254580,North West London Covid-19 Vaccination Programme: Real-world evidence for Vaccine uptake and effectiveness.,Ben Glampson; James Brittain; Amit Kaura; Abdul Mulla; Luca Mercuri; Stephen Brett; Paul Aylin; Tessa Sandall; Ian Goodman; Julian Redhead; Kavitha Saravanakumar; Erik Mayer,"ICT, Imperial College Healthcare NHS Trust, Praed Street, W2 1NY, London, UK; Department of Surgery & Cancer, Imperial College London, 10th Floor QEQM building, St Marys Hospital Campus, Praed Street, W2 1NY, London, UK; Imperial College London and Imperial College Healthcare NHS Trust, Hammersmith Hospital, W12 0HS, London, UK; ICT, Imperial College Healthcare NHS Trust, Praed Street, W2 1NY, London, UK; ICT, Imperial College Healthcare NHS Trust, Praed Street, W2 1NY, London, UK; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, W12 0HS, London, UK; School of Public Health, Imperial College London, Medical School Building, St Mary's Hospital, W2 1PG, London, UK; North West London Collaboration of Clinical Commissioning Groups, 15 Marylebone Road, NW1 5JD, London, UK; Hillingdon Clinical Commissioning Group, Boundary House, Cricket Field Rd, Uxbridge, UB8 1QG, UK; Medical Director's Office, Imperial College Healthcare NHS Trust, Praed Street, W2 1NY, London, UK; Collaboration of Clinical Commissioning Groups, 15 Marylebone Road,  NW1 5JD, London, UK; Department of Surgery & Cancer, Imperial College London, 10th Floor QEQM building, St Marys Hospital Campus Praed Street, W2 1NY, London, UK","ObjectiveTo assess the early vaccine administration coverage and vaccine effectiveness and outcome data across an integrated care system of eight CCGs leveraging a unique population-level care dataset

DesignRetrospective cohort study.

SettingIndividuals eligible for COVID 19 vaccination in North West London based on linked primary and secondary care data.

Participants2,183,939 individuals eligible for COVID 19 vaccination

ResultsDuring the NWL vaccine programme study time period 5.88% of individuals declined and did not receive a vaccination. Black or black British individuals had the highest rate of declining a vaccine at 16.14% (4,337). There was a strong negative association between deprivation and rate of declining vaccination (r=-0.94, p<0.01) with 13.5% of individuals declining vaccination in the most deprived postcodes compared to 0.98% in the least deprived postcodes.

In the first six days after vaccination 344 of 389587 individuals tested positive for COVID-19 (0.09%). The rate increased to 0.13% (525/389,243) between days 7 and 13, before then gradually falling week on week.

At 28 days post vaccination there was a 74% (HR 0.26 (0.19-0.35)) and 78% (HR 0.22 (0.18-0.27)) reduction in risk of testing positive for COVID-19 for individuals that received the Oxford/Astrazeneca and Pfizer/BioNTech vaccines respectively, when compared with unvaccinated individuals.

After vaccination very low rates of hospital admission were seen in individuals testing positive for COVID-19 (0.01% of all patients vaccinated).

ConclusionsThis study provides further evidence that a single dose of either the Pfizer/BioNTech vaccine or the Oxford/Astrazeneca vaccine is effective at reducing the risk of testing positive for COVID-19 up to 60 days across all adult age groups, ethnic groups, and risk categories in an urban UK population. There was no difference in effectiveness up to 28 days between the Oxford/Astrazeneca and Pfizer/BioNtech vaccines.

In those declining vaccination higher rates were seen in those living in the most deprived areas and in Black and Black British groups.

There was no definitive evidence to suggest COVID-19 was transmitted as a result of vaccination hubs during vaccine the administration roll-out in NWL, and the risk of contracting COVID-19 and/or becoming hospitalised after vaccination has been demonstrated to be very low in the vaccinated population.",health informatics,fuzzy,100,100
medRxiv,10.1101/2021.04.08.21255128,2021-04-10,https://medrxiv.org/cgi/content/short/2021.04.08.21255128,Changing patterns of sickness absence among healthcare workers in England during the COVID-19 pandemic.,Rhiannon Edge; Diana A van der Plaat; Vaughan Parsons; David Coggon; Martie J van Tongeren; Rupert Muiry; Ira Madan; Paul Cullinan,"Lancaster University; National Heart and Lung Institute (NHLI), Imperial College London; Guys and St Thomas NHS Foundation Trust; MRC Lifecourse Epidemiology Unit, University of Southampton; Centre for Occupational and Environmental Health, University of Manchester; Guys and St Thomas NHS Foundation Trust; Guy's and St Thomas' NHS Foundation Trust; National Heart and Lung Institute (NHLI), Imperial College London","ObjectiveTo explore impacts of the COVID-19 pandemic on patterns of sickness absence among staff employed by the National Health Service (NHS) in England.

MethodsWe analysed prospectively collected, pseudonymised data on 959,356 employees who were continuously employed by NHS trusts during 1 January 2019 to 31 July 2020, comparing the frequency of new sickness absence in 2020 with that at corresponding times in 2019.

ResultsAfter exclusion of episodes directly related to COVID-19, the overall incidence of sickness absence during the initial 10 weeks of the pandemic (March-May 2020) was more than 20% lower than in corresponding weeks of 2019, but trends for specific categories of illness varied. Marked increases were observed for asthma (122%), infectious diseases (283%) and mental illness (42.3%), while reductions were apparent for gastrointestinal problems (48.4%), genitourinary/gynaecological disorders (33.8%), eye problems (42.7%), injury and fracture (27.7%), back problems (19.6%), other musculoskeletal disorders (29.3%), disorders of ear, nose and throat (32.7%), cough/flu (24.5%) and cancer (24.1%). A doubling of new absences for pregnancy-related disorders during 18 May to 19 July of 2020 was limited to women with earlier COVID-19 sickness absence.

ConclusionsVarious factors will have contributed to the large and divergent changes that were observed. The findings add to concerns regarding delays in diagnosis and treatment of cancers, and support a need to plan for a large backlog of treatment for many other diseases. Further research should explore the rise in absence for pregnancy-related disorders among women with earlier COVID-19 sickness absence.

O_TEXTBOX1. What is already known about this subject?

Historically, rates of sickness absence among the NHS workforce in England have been relatively high but stable. Reports of a marked increase during the first wave of the COVID-19 pandemic have not distinguished between different categories of underlying illness.

2. What are the new findings?

During the first wave of COVID-19, incidence of sickness-absence changed markedly when compared to the previous year, with major increases for some categories of illness, and large declines for many others, including cancer.

3. How might this impact on policy or clinical practice in the foreseeable future?

The findings support a need to plan for effects from delayed diagnosis and treatment of cancer, and to manage a large backlog of treatment for many other diseases.

C_TEXTBOX",occupational and environmental health,fuzzy,100,100
medRxiv,10.1101/2021.04.07.21255072,2021-04-09,https://medrxiv.org/cgi/content/short/2021.04.07.21255072,Behavioural responses to Covid-19 health certification: A rapid review,John Drury; Guanlan Mao; Ann John; Atiya Kamal; James Rubin; Clifford Stott; Tushna Vandrevala; Theresa Marteau,University of Sussex; University of Sussex; Swansea University; Birmingham City University; King's College London; Keele University; Kingston University; University of Cambridge,"BackgroundCovid-status certification - certificates for those who test negative for the SARS-CoV-2 virus, test positive for antibodies, or who have been vaccinated against SARS-CoV-2 - has been proposed to enable safer access to a range of activities. Realising these benefits will depend in part upon the behavioural and social impacts of certification. The aim of this rapid review was to describe public attitudes towards certification, and its possible impact on uptake of testing and vaccination, protective behaviours, and crime.

MethodA search was undertaken in peer-reviewed databases, pre-print databases, and the grey literature, from 2000 to December 2020. Studies were included if they measured attitudes towards or behavioural consequences of health certificates based on one of three indices of Covid-19 status: test-negative result for current infectiousness, test-positive for antibodies conferring natural immunity, or vaccination(s) conferring immunity.

ResultsThirty-three papers met the inclusion criteria, only three of which were rated as low risk of bias. Public attitudes were generally favourable towards the use of immunity certificates for international travel, but unfavourable towards their use for access to work and other activities. A significant minority was strongly opposed to the use of certificates of immunity for any purpose. The limited evidence suggested that intention to get vaccinated varied with the activity enabled by certification or vaccination (e.g., international travel). Where vaccination is seen as compulsory this could lead to unwillingness to accept a subsequent vaccination. There was some evidence that restricting access to settings and activities to those with antibody test certificates may lead to deliberate exposure to infection in a minority. Behaviours that reduce transmission may decrease upon health certificates based on any of the three indices of Covid-19 status, including physical distancing and handwashing.

ConclusionsThe limited evidence suggests that health certification in relation to COVID-19 - outside of the context of international travel - has the potential for harm as well as benefit. Realising the benefits while minimising the harms will require real-time evaluations allowing modifications to maximise the potential contribution of certification to enable safer access to a range of activities.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.04.07.21254497,2021-04-09,https://medrxiv.org/cgi/content/short/2021.04.07.21254497,Characterising contact in disease outbreaks via a network model of spatial-temporal proximity,Ashleigh C Myall; Robert L Peach; Yu Wan; Siddharth Mookerjee; Elita Jauneikaite; Frankie Bolt; James Richard Price; Frances Davies; Andrea Yeong Wiesse; Alison Holmes; Mauricio Barahona,Imperial College London; Imperial College London; Imperial College London; Imperial College NHS Trust; Imperial College London; Imperial College London; Imperial College London; Imperial College NHS Trust; University of Edinburgh; Imperial College London; Imperial College London,"Contact tracing is a key tool in epidemiology to identify and control outbreaks of infectious diseases. Existing contact tracing methodologies produce contact maps of individuals based on a binary definition of contact which can be hampered by missing data and indirect contacts. Here, we present a Spatial-temporal Epidemiological Proximity (StEP) model to recover contact maps in disease outbreaks based on movement data. The StEP model accounts for imperfect data by considering probabilistic contacts between individuals based on spatial-temporal proximity of their movement trajectories, creating a robust movement network despite possible missing data and unseen transmission routes. Using real-world data we showcase the potential of StEP for contact tracing with outbreaks of multidrug-resistant bacteria and COVID-19 in a large hospital group in London, UK. In addition to the core structure of contacts that can be recovered using traditional methods of contact tracing, the StEP model reveals missing contacts that connect seemingly separate outbreaks. Comparison with genomic data further confirmed that these recovered contacts indeed improve characterisation of disease transmission and so highlights how the StEP framework can inform effective strategies of infection control and prevention.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.04.01.21254765,2021-04-07,https://medrxiv.org/cgi/content/short/2021.04.01.21254765,"Mental health inequalities in healthcare, economic, and housing disruption during COVID -19: an investigation in 12 longitudinal studies",Giorgio Di Gessa; Jane Maddock; Michael J Green; Ellen J Thompson; Eoin McElroy; Helena L Davies; Jessica Mundy; Anna J Stevenson; Alex S.F Kwong; Gareth J Griffith; Srinivasa Vittal Katikireddi; Claire L Niedzwiedz; George B Ploubidis; Emla Fitzsimons; Morag Henderson; Richard J. Silverwood; Nishi Chaturvedi; Gerome Breen; Claire J Steves; Andrew Steptoe; David J Porteous; Praveetha Patalay,"Institute of Epidemiology and Health Care, University College London; MRC Unit for Lifelong Health and Ageing, University College London; MRC/CSO Social & Public Health Sciences Unit, University of Glasgow; Department of Twin Research and Genetic Epidemiology, School of Life Course Sciences, Kings College London; Department of Neuroscience, Psychology and Behaviour, University of Leicester; Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, Kings College London; Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, Kings College London; Centre for Genomic and Experimental Medicine, University of Edinburgh; Division of Psychiatry, University of Edinburgh and MRC Integrative Epidemiology Unit, University of Bristol; MRC Integrative Epidemiology Unit, University of Bristol; MRC/CSO Social & Public Health Sciences Unit, University of Glasgow; Institute of Health & Wellbeing, University of Glasgow; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; Centre for Longitudinal Studies, UCL Social Research Institute, University College London; MRC Unit for Lifelong Health and Ageing, University College London; Social, Genetic & Developmental Psychiatry Centre, Institute of Psychiatry, Psychology & Neuroscience, Kings College London and Maudsley Biomedical Research Cen; Department of Twin Research and Genetic Epidemiology, School of Life Course Sciences, Kings College London; Institute of Epidemiology and Health Care, University College London; Centre for Genomic and Experimental Medicine, University of Edinburgh; Centre for Longitudinal Studies and MRC Unit for Lifelong Health and Ageing, University College London","BackgroundThe COVID-19 pandemic and associated virus suppression measures have disrupted lives and livelihoods and people already experiencing mental ill-health may have been especially vulnerable.

AimTo quantify mental health inequalities in disruptions to healthcare, economic activity and housing.

Method59,482 participants in 12 UK longitudinal adult population studies with data collected prior to and during the COVID-19 pandemic. Within each study we estimated the association between psychological distress assessed pre-pandemic and disruptions since the start of the pandemic to three domains: healthcare (medication access, procedures, or appointments); economic activity (employment, income, or working hours); and housing (change of address or household composition). Meta-analyses were used to pool estimates across studies.

ResultsAcross the analysed datasets, one to two-thirds of participants experienced at least one disruption, with 2.3-33.2% experiencing disruptions in two or more domains. One standard deviation higher pre-pandemic psychological distress was associated with: (i) increased odds of any healthcare disruptions (OR=1.30; [95% CI:1.20-1.40]) with fully adjusted ORs ranging from 1.24 [1.09-1.41] for disruption to procedures and 1.33 [1.20- 1.49] for disruptions to prescriptions or medication access; (ii) loss of employment (OR=1.13 [1.06-1.21]) and income (OR=1.12 [1.06 -1.19]) and reductions in working hours/furlough (OR=1.05 [1.00-1.09]); (iii) no associations with housing disruptions (OR=1.00 [0.97-1.03]); and (iv) increased likelihood of experiencing a disruption in at least two domains (OR=1.25 [1.18-1.32]) or in one domain (OR=1.11 [1.07-1.16]) relative to no disruption.

ConclusionPeople experiencing psychological distress pre-pandemic have been more likely to experience healthcare and economic disruptions, and clusters of disruptions across multiple domains during the pandemic. Failing to address these disruptions risks further widening the existing inequalities in mental health.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2021.03.31.21254687,2021-04-05,https://medrxiv.org/cgi/content/short/2021.03.31.21254687,"SARS-CoV-2 infectivity by viral load, S gene variants and demographic factors and the utility of lateral flow devices to prevent transmission",Lennard YW Lee; Stefan Rozmanowski; Matthew Pang; Andre Charlett; Charlotte Anderson; Gareth J Hughes; Matthew Barnard; Leon Peto; Richard Vipond; Alex Sienkiewicz; Susan Hopkins; John Bell; Derrick W Crook; Nick Gent; A Sarah Walker; Tim EA Peto; David W Eyre,University of Oxford; UK Government Department of Health and Social Care; UK Government Department of Health and Social Care; Public Health England; Public Health England; Public Health England; UK Government Department of Health and Social Care; University of Oxford; Public Health England; Public Health England; Public Health England; University of Oxford; University of Oxford; Public Health England; University of Oxford; University of Oxford; University of Oxford,"BackgroundHow SARS-CoV-2 infectivity varies with viral load is incompletely understood. Whether rapid point-of-care antigen lateral flow devices (LFDs) detect most potential transmission sources despite imperfect sensitivity is unknown.

MethodsWe combined SARS-CoV-2 testing and contact tracing data from England between 01-September-2020 and 28-February-2021. We used multivariable logistic regression to investigate relationships between PCR-confirmed infection in contacts of community-diagnosed cases and index case viral load, S gene target failure (proxy for B.1.1.7 infection), demographics, SARS-CoV-2 incidence, social deprivation, and contact event type. We used LFD performance to simulate the proportion of cases with a PCR-positive contact expected to be detected using one of four LFDs.

Results231,498/2,474,066 (9%) contacts of 1,064,004 index cases tested PCR-positive. PCR-positive results in contacts independently increased with higher case viral loads (lower Ct values) e.g., 11.7%(95%CI 11.5-12.0%) at Ct=15 and 4.5%(4.4-4.6%) at Ct=30. B.1.1.7 infection increased PCR-positive results by [~]50%, (e.g. 1.55-fold, 95%CI 1.49-1.61, at Ct=20). PCR-positive results were most common in household contacts (at Ct=20.1, 8.7%[95%CI 8.6-8.9%]), followed by household visitors (7.1%[6.8-7.3%]), contacts at events/activities (5.2%[4.9-5.4%]), work/education (4.6%[4.4-4.8%]), and least common after outdoor contact (2.9%[2.3-3.8%]). Contacts of children were the least likely to test positive, particularly following contact outdoors or at work/education. The most and least sensitive LFDs would detect 89.5%(89.4-89.6%) and 83.0%(82.8-83.1%) of cases with PCR-positive contacts respectively.

ConclusionsSARS-CoV-2 infectivity varies by case viral load, contact event type, and age. Those with high viral loads are the most infectious. B.1.1.7 increased transmission by [~]50%. The best performing LFDs detect most infectious cases.

Key pointsIn 2,474,066 contacts of 1,064,004 SARS-CoV-2 cases, PCR-positive tests in contacts increased with higher index case viral loads, the B.1.1.7 variant and household contact. Children were less infectious. Lateral flow devices can detect 83.0-89.5% of infections leading to onward transmission.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.27.21254452,2021-03-29,https://medrxiv.org/cgi/content/short/2021.03.27.21254452,Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK),Hayley Holt; Mohammad Talaei; Matthew Greenig; Dominik Zenner; Jane Symons; Clare Relton; Katherine S Young; Molly R Davies; Katherine N Thompson; Jed Ashman; Sultan Saeed Rajpoot; Ahmed Ali Kayyale; Sarah El Rifai; Philippa J Lloyd; David A Jolliffe; Sarah Finer; Stamatina Iliodromiti; Alec Miners; Nicholas S Hopkinson; Bodrul Alam; Paul E Pfeffer; David McCoy; Gwyneth A Davies; Ronan A Lyons; Chris J Griffiths; Frank Kee; Aziz Sheikh; Gerome Breen; Seif O Shaheen; Adrian R Martineau,"Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Jane Symons Media; Queen Mary University of London; King's College London; King's College London; King's College London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; Queen Mary University of London; London School of Hygiene and Tropical Medicine; Imperial College London; Edenfield Road Surgery, Rochdale, UK; Queen Mary University of London; Quen Mary University London; Swansea University Medical School; Swansea University Medical School; Queen Mary University of London; Queen's University Belfast; Edinburgh University; King's College London; Queen Mary University of London; Queen Mary University of London","BackgroundRisk factors for severe COVID-19 include older age, male sex, obesity, Black or Asian ethnicity and underlying medical conditions. Whether these factors also influence susceptibility to developing COVID-19 is uncertain.

MethodsWe undertook a prospective, population-based cohort study (COVIDENCE UK) from 1st May 2020 to 5th February 2021. Baseline information on potential risk factors was captured by online questionnaire. Monthly follow-up questionnaires captured incident COVID-19. We used logistic regression models to estimate multivariable-adjusted odds ratios (aORs) for associations between potential risk factors and risk of COVID-19.

FindingsWe recorded 446 incident cases of COVID-19 in 15,227 participants (2.9%). Increased risk of developing COVID-19 was independently associated with Asian/Asian British vs. White ethnicity (aOR 2.31, 95% CI 1.35-3.95), household overcrowding (aOR per additional 0.5 people/bedroom 1.26, 1.11-1.43), any vs. no visits to/from other households in previous week (aOR 1.33, 1.07-1.64), number of visits to indoor public places (aOR per extra visit per week 1.05, 1.01-1.09), frontline occupation excluding health/social care vs. no frontline occupation (aOR 1.49, 1.12-1.98), and raised body mass index (BMI) (aOR 1.51 [1.20-1.90] for BMI 25.0-30.0 kg/m2 and 1.38 [1.05-1.82] for BMI >30.0 kg/m2 vs. BMI <25.0 kg/m2). Atopic disease was independently associated with decreased risk (aOR 0.76, 0.59-0.98). No independent associations were seen for age, sex, other medical conditions, diet, or micronutrient supplement use.

InterpretationAfter rigorous adjustment for factors influencing exposure to SARS-CoV-2, Asian/Asian British ethnicity and raised BMI were associated with increased risk of developing COVID-19, while atopic disease was associated with decreased risk.

FundingBarts Charity, Health Data Research UK",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.21.21254061,2021-03-26,https://medrxiv.org/cgi/content/short/2021.03.21.21254061,Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status,David W Eyre; Sheila F Lumley; Jia Wei; Stuart Cox; Tim James; Anita Justice; Gerald Jesuthasan; Alison Howarth; Stephanie B Hatch; Brian D Marsden; E Yvonne Jones; David I Stuart; Daniel Ebner; Sarah Hoosdally; Derrick Crook; Tim EA Peto; Timothy M Walker; Nicole EA Stoesser; Philippa C Matthews; Koen B Pouwels; A Sarah Walker; Katie Jeffery,University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; Oxford University Hospitals; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals,"ObjectivesWe investigate determinants of SARS-CoV-2 anti-spike IgG responses in healthcare workers (HCWs) following one or two doses of Pfizer-BioNTech or Oxford-AstraZeneca vaccines.

MethodsHCWs participating in regular SARS-CoV-2 PCR and antibody testing were invited for serological testing prior to first and second vaccination, and 4 weeks post-vaccination if receiving a 12-week dosing interval. Quantitative post-vaccination anti-spike antibody responses were measured using the Abbott SARS-CoV-2 IgG II Quant assay (detection threshold: [&ge;]50 AU/ml). We used multivariable logistic regression to identify predictors of seropositivity and generalised additive models to track antibody responses over time.

ResultsVaccine uptake was 80%, but less in lower-paid roles and Black, south Asian and minority ethnic groups. 3570/3610(98.9%) HCWs were seropositive >14 days post-first vaccination and prior to second vaccination, 2706/2720(99.5%) after Pfizer-BioNTech and 864/890(97.1%) following Oxford-AstraZeneca vaccines. Previously infected and younger HCWs were more likely to test seropositive post-first vaccination, with no evidence of differences by sex or ethnicity. All 470 HCWs tested >14 days after second vaccine were seropositive. Quantitative antibody responses were higher after previous infection: median(IQR) >21 days post-first Pfizer-BioNTech 14,604(7644-22,291) AU/ml vs. 1028(564-1985) AU/ml without prior infection (p<0.001). Oxford-AstraZeneca vaccine recipients had lower readings post-first dose compared to Pfizer-BioNTech, with and without previous infection, 10,095(5354-17,096) and 435(203-962) AU/ml respectively (both p<0.001 vs. Pfizer-BioNTech). Antibody responses post-second vaccination were similar to those after prior infection and one vaccine dose.

ConclusionsVaccination leads to detectable anti-spike antibodies in nearly all adult HCWs. Whether differences in response impact vaccine efficacy needs further study.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.21.21253968,2021-03-26,https://medrxiv.org/cgi/content/short/2021.03.21.21253968,Characteristics of Long Covid: findings from a social media surve,Nida Ziauddeen; Deepti Gurdasani; Margaret E O'Hara; Claire Hastie; Paul Roderick; Guiqing Yao; Nisreen A Alwan,"University of Southampton; Queen Mary University of London; Patient contributor, Long Covid Support: www.longcovid.org; Patient contributor, Long Covid Support: www.longcovid.org; University of Southampton; University of Leicester; University of Southampton","Many people are not recovering for months after being infected with SARS-CoV-2. Long Covid has emerged as a major public health concern that needs defining, quantifying, and describing. We aimed to explore the initial and ongoing symptoms of Long Covid following SARS-CoV-2 infection and describe its impact on daily life in people who were not admitted to hospital during the first two weeks of the illness. We co-produced a survey with people living with Long Covid. We collected the data through an online survey using convenience non-probability sampling, with the survey posted both specifically on Long Covid support groups and generally on social media. The criteria for inclusion were adults with lab-confirmed (PCR or antibody) or suspected COVID-19 managed in the community (non-hospitalised) in the first two weeks of illness. We used agglomerative hierarchical clustering to identify specific symptom clusters, and their demographic and functional correlates.

We analysed data from 2550 participants with a median duration of illness of 7.7 months (interquartile range (IQR) 7.4-8.0). The mean age was 46.5 years (standard deviation 11 years) with 82.8% females and 79.9% of participants based in the UK. 89.5% described their health as good, very good or excellent before COVID-19. The most common initial symptoms that persisted were exhaustion, chest pressure/tightness, shortness of breath and headache. Cough, fever, and chills were common initial symptoms that became less prevalent later in the illness, whereas cognitive dysfunction and palpitations became more prevalent later in the illness. 26.5% reported lab-confirmation of infection. The biggest difference in ongoing symptoms between those who reported testing positive and those who did not was loss of smell/taste. Ongoing symptoms affected at least 3 organ systems in 83.5% of participants.

Most participants described fluctuating (57.7%) or relapsing symptoms (17.6%). Physical activity, stress and sleep disturbance commonly triggered symptoms. A third (32%) reported they were unable to live alone without any assistance at six weeks from start of illness. 16.9% reported being unable to work solely due to COVID-19 illness. 66.4% reported taking time off sick (median of 60 days, IQR 20, 129). 37.0% reported loss of income due to illness, and 64.4% said they were unable to perform usual activities/duties.

Acute systems clustered broadly into two groups: a majority cluster (n=2235, 88%) with cardiopulmonary predominant symptoms, and a minority cluster (n=305, 12%) with multisystem symptoms. Similarly, ongoing symptoms broadly clustered in two groups; a majority cluster (n=2243, 88.8%) exhibiting mainly cardiopulmonary, cognitive symptoms and exhaustion, and a minority cluster (n=283, 11.2%) exhibited more multisystem symptoms. Belonging to the more severe multisystem cluster was associated with more severe functional impact, lower income, younger age, being female, worse baseline health, and inadequate rest in the first two weeks of the illness, with no major differences in the cluster patterns when restricting analysis to the lab-confirmed subgroup.

This is an exploratory survey of Long Covid characteristics. Whilst it is important to acknowledge that it is a non-representative population sample, it highlights the heterogeneity of persistent symptoms, and the significant functional impact of prolonged illness following confirmed or suspected SARS-CoV-2 infection. To study prevalence, predictors and prognosis, research is needed in a representative population sample using standardised case definitions (to include those not lab-confirmed in the first pandemic wave).",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.03.22.21254130,2021-03-26,https://medrxiv.org/cgi/content/short/2021.03.22.21254130,"Trends, patterns and psychological influences on COVID-19 vaccination intention: findings from a large prospective community cohort study in England and Wales (Virus Watch)",Thomas E Byrne; Parth Patel; Madhumita Shrotri; Sarah Beale; Susan Michie; Jabeer Butt; Nicky Hawkins; Pia Hardelid; Alison Rodger; Anna Aryee; Isobel Braithwaite; Wing Lam Erica Fong; Ellen Fragaszy; Cyril Geismar; Jana Kovar; Annalan M D Navaratnam; Vincent Nguyen; Andrew Hayward; Robert W Aldridge; - Virus Watch Collaborative,"Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK & Institute of Epidemiology and Health Care, University Co; Centre for Behaviour Change, University College London, London, UK.; Race Equality Foundation, UK.; Independent Consultant; Department of Population, Policy and Practice, UCL Great Ormond Street Institute of Child Health, London, UK.; Institute for Global Health, University College London, London, UK. & Royal Free London NHS Foundation Trust,  London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK. & Department of Infectious Disease Epidemiology, London S; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK. & Institute of Epidemiology and Health Care, University C; Institute of Epidemiology and Health Care, University College London, London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK. & Institute of Epidemiology and Health Care, University C; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK. & Institute of Epidemiology and Health Care, University C; Institute of Epidemiology and Health Care, University College London, London, UK; Centre for Public Health Data Science, Institute of Health Informatics, University College London, UK.; ","ObjectivesTo assess trends in intention to accept a COVID-19 vaccine between 1 December 2020 and 25 February 2021, explore associations between socio-demographic factors and vaccination intention and investigate how COVID-19 vaccine- and illness-related attitudes, beliefs and emotions influence vaccination intention.

DesignProspective household community cohort study of COVID-19 infection (Virus Watch).

SettinOnline survey of Virus Watch study participants in the community across England and Wales.

ParticipantsIndividuals could enrol in Virus Watch if all household members agreed to participate and at least one household member had access to the internet, an email address, and could read English. All Virus Watch participants aged 16 years and over who responded to questions relating to COVID-19 vaccine intention in questionnaires between December 2020 and February 2021 were included in this analysis.

Main outcome measuresVaccination intention was measured by individual participant responses to  Would you accept a COVID-19 vaccine if offered?, collected between 1-14 December 2020 and 17-25 February 2021. Possible responses were  Yes,  No and  Unsure (December 2020 &February 2021) and  Already had a COVID-19 vaccine (February 2021 only). Responses to a 13-item questionnaire collected between 4-11 January 2021 were analysed using factor analysis to investigate psychological influences (attitudes, beliefs and emotions) on vaccination intention.

ResultsSurvey response rate was 56% (20,792/36,998) in December 2020 and 52% (20,284/38,727) in February 2021, with 14,713 adults reporting across both time points. Of participants reporting across both timepoints, 13,281 (90%) answered  Yes and 1,432 (10%) responded  No or  Unsure in December 2020. Of those answering  No or  Unsure in December 2020, 1,233 (86%) went on to answer  Yes or  Already had a COVID-19 vaccine in February 2021. The magnitude of this shift was consistent across all ethnic groups measured and all levels of social deprivation. Age was most strongly associated with vaccination intention, with 16-24-year-olds more likely to respond ""No"" or ""Unsure"" than those aged 75+ in December 2020 (RR: 4.32, 95% CI: 2.40-7.78 &2.93 95% CI: 2.19-3.92, respectively) and February 2021 (RR: 5.30 95% CI: 1.39-20.20 &20.21 95%CI: 7.19-56.78). The association between ethnicity and vaccination intention has weakened, but not disappeared, over time. Both vaccine- and illness-related psychological factors were shown to influence vaccination intention.

ConclusionsOver four in five adults (86%) who were reluctant or intending to refuse a COVID-19 vaccine in December 2020 had changed their mind in February 2021 and planned on accepting, or had already accepted, a vaccine.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.03.24.21254227,2021-03-26,https://medrxiv.org/cgi/content/short/2021.03.24.21254227,COVID-19 Vaccination Prioritization Based on Cardiovascular Risk Factors and Number-Needed-to-Vaccinate to Prevent Death,Darryl P Leong; Amitava Banerjee; Salim Yusuf,McMaster University; University College London; McMaster University,"The supply limitations of COVID-19 vaccines have led to the need to prioritize vaccine distribution. Obesity, diabetes and hypertension have been associated with an increased risk of severe COVID-19 infection. Approximately half as many individuals with a cardiovascular risk factor need to be vaccinated against COVID-19 to prevent related death as compared with individuals without a risk factor. Our analysis suggests that prioritizing adults with these cardiovascular risk factors for vaccination is likely to be an efficient way to reduce population COVID-19 mortality.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.03.26.21254390,2021-03-26,https://medrxiv.org/cgi/content/short/2021.03.26.21254390,Regional performance variation in external validation of four prediction models for severity of COVID-19 at hospital admission: An observational multi-centre cohort study,Kristin Wickstrom; Valeria Vitelli; Ewan Carr; Aleksander Rygh Holten; Rebecca Bendayan; Andrew Henry Reiner; Daniel Bean; Tom Searle; Anthony Shek; Zeljko Kraljevic; James T Teo; Richard Dobson; Kristian Tonby; Alvaro Kohn-Luque; Erik Koldberg Amundsen,Oslo University Hospital; University of Oslo; King's College London; Oslo University Hospital; King's College London; Oslo University Hospital; King's College London; King's College London; King's College London; King's College London; Kings College Hospital NHS Foundation Trust; Kings College London; Oslo University Hospital; University of Oslo; Oslo University Hospital,"BackgroundSeveral prediction models for coronavirus disease-19 (COVID-19) have been published. Prediction models should be externally validated to assess their performance before implementation. This observational cohort study aimed to validate published models of severity for hospitalized patients with COVID-19 using clinical and laboratory predictors.

MethodsPrediction models fitting relevant inclusion criteria were chosen for validation. The outcome was either mortality or a composite outcome of mortality and ICU admission (severe disease). 1295 patients admitted with symptoms of COVID-19 at Kings Cross Hospital (KCH) in London, United Kingdom, and 307 patients at Oslo University Hospital (OUH) in Oslo, Norway were included. The performance of the models was assessed in terms of discrimination and calibration.

ResultsWe identified two models for prediction of mortality (referred to as Xie and Zhang1) and two models for prediction of severe disease (Allenbach and Zhang2).

The performance of the models was variable. For prediction of mortality Xie had good discrimination at OUH with an area under the receiver-operating characteristic (AUROC) 0.87 [95 % confidence interval (CI) 0.79-0.95] and acceptable discrimination at KCH, AUROC 0.79 [0.76-0.82]. In prediction of severe disease, Allenbach had acceptable discrimination (OUH AUROC 0.81 [0.74-0.88] and KCH AUROC 0.72 [0.68-0.75]). The Zhang models had moderate to poor discrimination. Initial calibration was poor for all models but improved with recalibration.

ConclusionsThe performance of the four prediction models was variable. The Xie model had the best discrimination for mortality, while the Allenbach model had acceptable results for prediction of severe disease.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.26.21254391,2021-03-26,https://medrxiv.org/cgi/content/short/2021.03.26.21254391,Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of Long-Term Care Facilities (VIVALDI study),Madhumita Shrotri; Maria Krutikov; Tom Palmer; Rebecca Giddings; Borscha Azmi; Sathyavani Subbarao; Christopher Fuller; Aidan Irwin-Singer; Daniel Davies; Gokhan Tut; Jamie Lopez Bernal; Paul Moss; Andrew Hayward; Andrew Copas; Laura Shallcross,"University College London; University College London; University College London; University College London; University College London; Public Health England; University College London; Department of Health and Social Care, UK; Palantir Technologies UK Ltd; University of Birmingham; Public Health England; University of Birmingham; University College London; University College London; University College London","BackgroundThe effectiveness of SARS-CoV-2 vaccines in frail older adults living in Long-Term Care Facilities (LTCFs) is uncertain. We estimated protective effects of the first dose of ChAdOx1 and BNT162b2 vaccines against infection in this population.

MethodsCohort study comparing vaccinated and unvaccinated LTCF residents in England, undergoing routine asymptomatic testing (8 December 2020 - 15 March 2021). We estimated the relative hazard of PCR-positive infection using Cox proportional hazards regression, adjusting for age, sex, prior infection, local SARS-CoV-2 incidence, LTCF bed capacity, and clustering by LTCF.

ResultsOf 10,412 residents (median age 86 years) from 310 LTCFs, 9,160 were vaccinated with either ChAdOx1 (6,138; 67%) or BNT162b2 (3,022; 33%) vaccines. A total of 670,628 person days and 1,335 PCR-positive infections were included. Adjusted hazard ratios (aHRs) for PCR-positive infection relative to unvaccinated residents declined from 28 days following the first vaccine dose to 0{middle dot}44 (0{middle dot}24, 0{middle dot}81) at 28-34 days and 0{middle dot}38 (0{middle dot}19, 0{middle dot}77) at 35-48 days. Similar effect sizes were seen for ChAdOx1 (aHR 0{middle dot}32 [0{middle dot}15-0{middle dot}66] and BNT162b2 (aHR 0{middle dot}35 [0{middle dot}17, 0{middle dot}71]) vaccines at 35-48 days. Mean PCR cycle threshold values were higher, implying lower infectivity, for infections [&ge;]28 days post-vaccination compared with those prior to vaccination (31{middle dot}3 vs 26{middle dot}6, p<0{middle dot}001).

InterpretationThe first dose of BNT162b2 and ChAdOx1 vaccines was associated with substantially reduced SARS-CoV-2 infection risk in LTCF residents from 4 weeks to at least 7 weeks.

FundingUK Government Department of Health and Social Care.

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSWe conducted a systematic search for studies which evaluated SARS-CoV-2 vaccine effectiveness in residents of long-term care facilities (LTCFs) published between 01/01/2020 and 11/03/2021. We used variations of search terms for ""COVID-19"" AND ""vaccine effectiveness"" OR ""vaccine efficacy"" AND ""care homes"" OR ""long term care facilities"" OR ""older people"" on Ovid MEDLINE and MedRxiv. We identified one pre-print article regarding LTCFs in Denmark, which reported that a single dose of BNT162b was ineffective against SARS-CoV-2 infection in residents, however, participants received the second vaccine dose 24 days following the first dose on average, which is likely to be too soon to capture the protective effects of a single vaccine dose. Additionally, we identified two pre-print reports of studies evaluating vaccine effectiveness against symptomatic infection and hospitalisation amongst older adults in the community. The first of these found 81% vaccine effectiveness against COVID-19-related hospitalisation at 28-34 days following a single dose of BNT162b or ChAdOx1 in [&ge;]80-year-olds. The second of these found vaccine effectiveness against symptomatic infection of 60% at 28-34 days and 73% at 35+ days following a single dose of ChAdOx1 in [&ge;]70-year-olds. No studies were identified that focused on the effectiveness of a single vaccine dose against infection amongst LTCF residents at more than 4 weeks post-vaccination, a particularly important question in the context of the UK policy decision to extend the dose interval beyond 3 weeks.

Added value of this studyWe conducted a prospective cohort study of 10,412 residents aged [&ge;]65 years, from 310 LTCFs across England, to investigate the protective effect of the first dose of the ChAdOx1 and BNT162b vaccines against SARS-CoV-2 infection in frail older adults. We retrieved results from routine monthly PCR testing, as well as outbreak and clinical testing for SARS-CoV-2, thereby capturing data on asymptomatic as well as symptomatic infections, which we linked to vaccination records. We estimated vaccine effectiveness to be 56% (19-76%) at 28-34 days, and 62% (23-81%) at 35-48 days following a single dose of ChAdOx1 or BNT162. Our findings suggest that the risk of SARS-CoV-2 infection is substantially reduced from 28 days following the first dose of either vaccine and that this effect is maintained for at least 7 weeks, with similar protection offered by both vaccine types. We also found that PCR cycle threshold (Ct) values, which are negatively associated with the ability to isolate virus, were significantly higher in infections occurring at [&ge;] 28days post vaccination compared to those occurring in the unvaccinated period, suggesting that vaccination may reduce onward transmission of SARS-CoV-2 in breakthrough infections. To the best of our knowledge, our findings constitute the first real-world evidence on vaccine effectiveness against infection for ChAdOx1, in any age group. We can also infer that both vaccines are effective against the B.1.1.7 variant, because our analysis period coincided with the rapid emergence of B.1.1.7 in England during the second wave of the pandemic.

Implications of all the available evidenceOur findings add to the growing body of evidence on the protective effect of the BNT162b vaccines in residents of LTCFs and demonstrate the effectiveness of ChAdOx1 in this vulnerable population. Evaluating single-dose vaccine efficacy has become increasingly important in light of extended dosing intervals that have been implemented in order to maximise vaccine coverage across high-risk groups. Further work is required to evaluate the effectiveness of the first vaccine dose after 8-12 weeks, as well as following the second dose, and to evaluate the long-term impact of vaccination on SARS-CoV-2 infection, transmission and mortality in LTCFs. This will inform policy decisions regarding the ongoing need for disease control measures in LTCF such as visitor restrictions, which continue to have a detrimental impact on the wellbeing of residents, their relatives, and staff.

Supplementary material attached.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.22.21254057,2021-03-24,https://medrxiv.org/cgi/content/short/2021.03.22.21254057,"Physical, cognitive and mental health impacts of COVID-19 following hospitalisation: a multi-centre prospective cohort study",Rachael Andrea Evans; Hamish McAuley; Ewen M Harrison; Aarti Shikotra; Amisha Singapuri; Marco Sereno; Omer Elneima; Annemarie B Docherty; Nazir I Lone; Olivia C Leavy; Luke Daines; J Kenneth Baillie; Jeremy S Brown; Trudie Chalder; Anthony De Soyza; Nawar Diar Bakerly; Nicholas Easom; John R Geddes; Neil J Greening; Nick Hart; Liam G Heaney; Simon Heller; Luke Howard; Joseph Jacob; R Gisli Jenkins; Caroline Jolley; Steven Kerr; Onn M Kon; Keir Lewis; Janet M Lord; Gerry P McCann; Stefan Neubauer; Peter JM Openshaw; Paul Pfeffer; Matthew Rowland; Malcolm G Semple; Sally J Singh; Aziz Sheikh; David Thomas; Mark Toshner; James D Chalmers; Ling-Pei Ho; Alex Horsley; Michael Marks; Krisnah Poinasamy; Louise V Wain; Christopher E Brightling,"University of Leicester; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom; Department of Health Sciences, University of Leicester, Leicester, United Kingdom; Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Intensive Care Unit, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom; UCL Respiratory, Department of Medicine, University College London, Rayne Institute, London, United Kingdom; Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, United Kingdom; Newcastle upon Tyne Teaching Hospitals Trust, Newcastle upon Ty; Manchester Metropolitan University, Manchester, United Kingdom; Salford Royal NHS Foundation Trust, Manchester, United Kingdom; Infection Research Group, Hull University Teaching Hospitals, Hull, United Kingdom; NIHR Oxford Health BRC, Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom; Oxford Health NHS Foundation Trust, Oxford, ; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; Lane Fox Respiratory Service, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Wellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, United Kingdom; Belfast Health & Social Care Trust, Belfast, United Kingdom; Department of Oncology and Metabolism, University of Sheffield, Sheffield, United Kingdom; Imperial College Healthcare NHS Trust, London, United Kingdom; Centre for Medical Image Computing, University College London, London, United Kingdom; Lungs for Living Research Centre, University College London, London, Unit; National Heart and Lung Institute, Imperial College London, London, United Kingdom; Centre for Human and Applied Physiological Sciences, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, King's College London, Lond; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Respiratory Medicine, Imperial College Healthcare NHS Trust, London, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United ; Hywel Dda University Health Board, Wales, United Kingdom; University of Swansea, Wales, United Kingdom;(3) Respiratory Innovation Wales, Wales, United Kingdom; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom; Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom; Leicester NIHR Biomedical Research Centre, University of Leicester, L; Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; NIHR Biomedical Research Centre, John Radcl; National Heart and Lung Institute, Imperial College London, London, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Queen Mary University of London, London, United Kingdom; Kadoorie Centre for Critical Care Research, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, U; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; Immunology and Inflammation, Imperial College, London, United Kingdom; Cambridge NIHR BRC, Cambridge, United Kingdom; NIHR Cambridge Clinical Research Facility, Cambridge, United Kingdom; University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom; MRC Human Immunology Unit, University of Oxford, Oxford, United Kingdom; Division of Infection, Immunity & Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom; Department of Clinical Research, London School of Hygiene & Tropical Medicine Keppel Street, London, United Kingdom; Hospital for Tropical Diseases, University ; Asthma UK and British Lung Foundation, London, United Kingdom; Department of Health Sciences, University of Leicester, Leicester, United Kingdom; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, Uni; The Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom","BackgroundThe impact of COVID-19 on physical and mental health, and employment following hospitalisation is poorly understood.

MethodsPHOSP-COVID is a multi-centre, UK, observational study of adults discharged from hospital with a clinical diagnosis of COVID-19 involving an assessment between two- and seven-months later including detailed symptom, physiological and biochemical testing. Multivariable logistic regression was performed for patient-perceived recovery with age, sex, ethnicity, body mass index (BMI), co-morbidities, and severity of acute illness as co-variates. Cluster analysis was performed using outcomes for breathlessness, fatigue, mental health, cognition and physical function.

FindingsWe report findings of 1077 patients discharged in 2020, from the assessment undertaken a median 5 [IQR4 to 6] months later: 36% female, mean age 58 [SD 13] years, 69% white ethnicity, 27% mechanical ventilation, and 50% had at least two co-morbidities. At follow-up only 29% felt fully recovered, 20% had a new disability, and 19% experienced a health-related change in occupation. Factors associated with failure to recover were female, middle-age, white ethnicity, two or more co-morbidities, and more severe acute illness. The magnitude of the persistent health burden was substantial and weakly related to acute severity. Four clusters were identified with different severities of mental and physical health impairment: 1) Very severe (17%), 2) Severe (21%), 3) Moderate with cognitive impairment (17%), 4) Mild (46%), with 3%, 7%, 36% and 43% feeling fully recovered, respectively. Persistent systemic inflammation determined by C-reactive protein was related to cluster severity, but not acute illness severity.

InterpretationWe identified factors related to recovery from a hospital admission with COVID-19 and four different phenotypes relating to the severity of physical, mental, and cognitive health five months later. The implications for clinical care include the potential to stratify care and the need for a pro-active approach with wide-access to COVID-19 holistic clinical services.

Funding: UKRI and NIHR",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.19.21253940,2021-03-24,https://medrxiv.org/cgi/content/short/2021.03.19.21253940,"COVID-19 Infection Risk amongst 14,104 Vaccinated Care Home Residents: A national observational longitudinal cohort study in Wales, United Kingdom, December 2020 to March 2021",Joe Hollinghurst; Laura North; Malorie Perry; Ashley Akbari; Mike B Gravenor; Ronan A Lyons; Richard Fry,Swansea University; Swansea University; Public Health Wales; Swansea University; Swansea University; Swansea University; Swansea University,"BackgroundVaccinations for COVID-19 have been prioritised for older people living in care homes. However, vaccination trials included limited numbers of older people.

AimWe aimed to study infection rates of SARS-CoV-2 for older care home residents following vaccination and identify factors associated with increased risk of infection.

Study Design and SettingWe conducted an observational data-linkage study including 14,104 vaccinated older care home residents in Wales (UK) using anonymised electronic health records and administrative data.

MethodsWe used Cox proportional hazards models to estimate hazard ratios (HRs) for the risk of testing positive for SARS-CoV-2 infection following vaccination, after landmark times of either 7 or 21-days post-vaccination. We adjusted hazard ratios for age, sex, frailty, prior SARS-CoV-2 infections and vaccination type.

ResultsWe observed a small proportion of care home residents with positive PCR tests following vaccination 1.05% (N=148), with 90% of infections occurring within 28-days. For the 7-day landmark analysis we found a reduced risk of SARS-CoV-2 infection for vaccinated individuals who had a previous infection; HR (95% confidence interval) 0.54 (0.30,0.95), and an increased HR for those receiving the Pfizer-BioNTECH vaccine compared to the Oxford-AstraZeneca; 3.83 (2.45,5.98). For the 21-day landmark analysis we observed high HRs for individuals with low and intermediate frailty compared to those without; 4.59 (1.23,17.12) and 4.85 (1.68,14.04) respectively.

ConclusionsIncreased risk of infection after 21-days was associated with frailty. We found most infections occurred within 28-days of vaccination, suggesting extra precautions to reduce transmission risk should be taken in this time frame.",geriatric medicine,fuzzy,100,100
medRxiv,10.1101/2021.03.16.21253371,2021-03-24,https://medrxiv.org/cgi/content/short/2021.03.16.21253371,Axes of Prognosis: Identifying Subtypes of COVID-19 Outcomes,Emma Whitfield; Claire Coffey; Huayu Zhang; Ting Shi; Xiaodong Wu; Qiang Li; Honghan Wu,"Institute of Health Informatics, UCL, London, United Kingdom; University of Cambridge, Cambridge, United Kingdom; Usher Institute, University of Edinburgh, United Kingdom; Usher Institute, University of Edinburgh, United Kingdom; Shanghai East Hospital, Tongji University, Shanghai, China; Shanghai East Hospital, Tongji University, Shanghai, China; Institute of Health Informatics, UCL, London, United Kingdom","COVID-19 is a disease with vast impact, yet much remains unclear about patient outcomes. Most approaches to risk prediction of COVID-19 focus on binary or tertiary severity outcomes, despite the heterogeneity of the disease. In this work, we identify heterogeneous subtypes of COVID-19 outcomes by considering  axes of prognosis. We propose two innovative clustering approaches -  Layered Axes and  Prognosis Space - to apply on patients outcome data. We then show how these clusters can help predict a patients deterioration pathway on their hospital admission, using random forest classification. We illustrate this methodology on a cohort from Wuhan in early 2020. We discover interesting subgroups of poor prognosis, particularly within respiratory patients, and predict respiratory subgroup membership with high accuracy. This work could assist clinicians in identifying appropriate treatments at patients hospital admission. Moreover, our method could be used to explore subtypes of  long COVID and other diseases with heterogeneous outcomes.",health informatics,fuzzy,100,92
medRxiv,10.1101/2021.03.16.21253377,2021-03-24,https://medrxiv.org/cgi/content/short/2021.03.16.21253377,First and second SARS-CoV-2 waves in inner London: A comparison of admission characteristics and the effects of the B.1.1.7 variant,Luke B Snell; Wenjuan Wang; Adela Alcolea-Medina; Themoula Charalampous; Gaia Nebbia; Rahul Batra; Leonardo de Jongh; Finola Higgins; Yanzhong Wang; Jonathan D Edgeworth; Vasa Curcin,"King's College London; School of Population Health and Environmental Sciences, King's College London, London, UK; Viapath, London, UK; Centre for Clinical Infection and Diagnostics Research, School of Immunology and Microbial Sciences,  King's College London, London, UK; Centre for Clinical Infection and Diagnostics Research, School of Immunology and Microbial Sciences,  King's College London, London, UK; Centre for Clinical Infection and Diagnostics Research, School of Immunology and Microbial Sciences,  King's College London, London, UK; NIHR Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust; NIHR Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust; School of Population Health and Environmental Sciences, King's College London, London, UK; Centre for Clinical Infection and Diagnostics Research, School of Immunology and Microbial Sciences,  King's College London, London, UK; School of Population Health and Environmental Sciences, King's College London, London, UK","IntroductionA second wave of SARS-CoV-2 infection spread across the UK in 2020 linked with emergence of the more transmissible B.1.1.7 variant. The emergence of new variants, particularly during relaxation of social distancing policies and implementation of mass vaccination, highlights the need for real-time integration of detailed patient clinical data alongside pathogen genomic data. We linked clinical data with viral genome sequence data to compare cases admitted during the first and second waves of SARS-CoV-2 infection.

MethodsClinical, laboratory and demographic data from five electronic health record (EHR) systems was collected for all cases with a positive SARS-CoV-2 RNA test between March 13th 2020 and February 17th 2021. SARS-CoV-2 viral sequencing was performed using Oxford Nanopore Technology. Descriptive data are presented comparing cases between waves, and between cases of B.1.1.7 and non-B.1.1.7 variants.

ResultsThere were 5810 SARS-CoV-2 RNA positive cases comprising inpatients (n=2341), healthcare workers (n=1549), outpatients (n=874), emergency department (ED) attenders not subsequently admitted (n=532), inter-hospital transfers (n=281) and nosocomial cases (n=233). There were two dominant waves of hospital admissions, with wave one starting from March 13th (n=838) and wave two from October 20th (n=1503), both with a temporally aligned rise in nosocomial cases (n=96 in wave one, n=137 in wave two). 1470 SARS-CoV-2 isolates were successfully sequenced, including 216/838 (26%) admitted cases from wave one, 472/1503 (31%) admitted cases in wave two and 121/233 (52%) nosocomial cases. The first B.1.1.7 variant was identified on 15th November 2020 and increased rapidly such that it comprised 400/472 (85%) of sequenced isolates from admitted cases in wave two. Females made up a larger proportion of admitted cases in wave two (47.3% vs 41.8%, p=0.011), and in those infected with the B.1.1.7 variant compared to non-B.1.1.7 variants (48.0% vs 41.8%, p=0.042). A diagnosis of frailty was less common in wave two (11.5% v 22.8%, p<0.001) and in the group infected with B.1.1.7 (14.5% v 22.4%, p=0.001). There was no difference in severity on admission between waves, as measured by hypoxia at admission (wave one: 64.3% vs wave two: 65.5%, p=0.67). However, a higher proportion of cases infected with the B.1.1.7 variant were hypoxic on admission compared to other variants (70.0% vs 62.5%, p=0.029).

ConclusionsAutomated EHR data extraction linked with SARS-CoV-2 genome sequence data provides valuable insight into the evolving characteristics of cases admitted to hospital with COVID-19. The proportion of cases with hypoxia on admission was greater in those infected with the B.1.1.7 variant, which supports evidence the B.1.1.7 variant is associated with more severe disease. The number of nosocomial cases was similar in both waves despite introduction of many infection control interventions before wave two, an observation requiring further investigation.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.15.21253542,2021-03-24,https://medrxiv.org/cgi/content/short/2021.03.15.21253542,Comparison between one and two dose SARS-CoV-2 vaccine prioritisation for a fixed number of vaccine doses,Edward M Hill; Matt J Keeling,University of Warwick; University of Warwick,"The swift development of SARS-CoV-2 vaccines has been met with worldwide commendation. How-ever, in the context of an ongoing pandemic there is an interplay between infection and vaccination. Whilst infection can grow exponentially, vaccination rates are generally limited by supply and logistics. With the first SARS-CoV-2 vaccines receiving medical approval requiring two doses, there has been scrutiny on the spacing between doses; an elongated period between doses allows more of the population to receive a first vaccine dose in the short-term generating wide-spread partial immunity. Focusing on data from England, we investigated prioritisation of a one dose or two dose vaccination schedule given a fixed number of vaccine doses and with respect to a measure of maximising averted deaths. We optimised outcomes for two different estimates of population size and relative risk of mortality for at-risk groups within the Phase 1 vaccine priority order. Vaccines offering relatively high protection from the first dose favour strategies that prioritise giving more people one dose, although with increasing vaccine supply eventually those eligible and accepting vaccination will receive two doses. Whilst optimal dose timing can substantially reduce the overall mortality risk, there needs to be careful consideration of the logistics of vaccine delivery.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.18.21253888,2021-03-23,https://medrxiv.org/cgi/content/short/2021.03.18.21253888,"Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol.",Louise Sigfrid; Tom M Drake; Ellen Pauley; Edwin C Jesudason; Piero Olliaro; Wei Shen Lim; Annelise Gillesen; Colin Berry; David Lowe; Joanne McPeake; Nazir Lone; Muge Cevik; Daniel Munblit; Anna Casey; Peter Bannister; Clark D Russell; Lynsey Goodwin; Antonia Ho; Lance Turtle; Margret E O'Hara; Claire Hastie; Chloe Donohue; Rebecca Spencer; Cara Donegan; Alison Gummery; Janet Harrison; Hayley Hardwick; Claire E Hastie; Gail Carson; Laura Merson; John Kenneth Baillie; Peter Openshaw; Ewen M Harrison; Annemarie Docherty; Malcolm G Semple; Janet T Scott,"ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK; Centre for Medical Informatics, University of Edinburgh, Edinburgh, UK; University of Edinburgh Medical School, Edinburgh, UK.; NHS Lothian, Edinburgh, UK,; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.; Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK.; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.; Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK; NHS Greater Glasgow and Clyde, Emergency Department, Glasgow, UK; School of Medicine, Dentistry and Nursing, University of Glasgow, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; University of St Andrews; Sechenov First Moscow State Medical University, Imperial College London, Imperial College London, RSMU; Medical Student, Brighton and Sussex Medical School, UK; Brighton & Sussex Medical School, Brighton, UK; Centre for Inflammation Research, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Studies, Univeristy of Liverpool. Tropical and Infectious Diseases Unit, North Manchester General Hospital, De; University of Glasgow, Glasgow, UK; NIHR Health Protection Research Unit in emerging and zoonotic infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, L; Long COVID Support, Birmingham, UK; Long COVID Support, Birmingham, UK; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; Institute of Infection, Veterinary and Ecological Sciences (IVES), University of Liverpool, Liverpool, UK.; Institute of Infection, Veterinary and Ecological Sciences (IVES), University of Liverpool, Liverpool, UK.; Institute of Infection, Veterinary and Ecological Sciences (IVES), University of Liverpool, Liverpool, UK.; National Institute of Health Research (NIHR) Health Protection research Unit in Emerging and Zoonotic Infections, Liverpool, UK. 2. Institute of Infection and G; National Institute of Health Research (NIHR) Health Protection research Unit in Emerging and Zoonotic Infections, Liverpool, UK. 2. Institute of Infection and G; Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK.; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK; Roslin Institute, University of Edinburgh, Edinburgh, UK; National Heart and Lung Institute, Imperial College, London UK.; Director Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK.; Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, UK. 2. Intensive Care Unit, Royal Infirmary Edinburgh, Edinburgh, UK; Health Protection Research Unit In Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, UK 2. ; MRC-University of Glasgow Center for Virus research","Structured AbstractO_ST_ABSObjectivesC_ST_ABSThe long-term consequences of severe Covid-19 requiring hospital admission are not well characterised. The objective of this study was to establish the long-term effects of Covid-19 following hospitalisation and the impact these may have on patient reported outcome measures.

DesignA multicentre, prospective cohort study with at least 3 months follow-up of participants admitted to hospital between 5th February 2020 and 5th October 2020.

Setting31 hospitals in the United Kingdom.

Participants327 hospitalised participants discharged alive from hospital with confirmed/high likelihood SARS-CoV-2 infection.

Main outcome measures and comparisonsThe primary outcome was self-reported recovery at least ninety days after initial Covid-19 symptom onset. Secondary outcomes included new symptoms, new or increased disability (Washington group short scale), breathlessness (MRC Dyspnoea scale) and quality of life (EQ5D-5L). We compared these outcome measures across age, comorbidity status and in-hospital Covid-19 severity to identify groups at highest risk of developing long-term difficulties. Multilevel logistic and linear regression models were built to adjust for the effects of patient and centre level risk factors on these outcomes.

ResultsIn total 53.7% (443/824) contacted participants responded, yielding 73.8% (327/443) responses with follow-up of 90 days or more from symptom onset. The median time between symptom onset of initial illness and completing the participant questionnaire was 222 days (Interquartile range (IQR) 189 to 269 days). In total, 54.7% (179/327) of participants reported they did not feel fully recovered. Persistent symptoms were reported by 93.3% (305/325) of participants, with fatigue the most common (82.8%, 255/308), followed by breathlessness (53.5%, 175/327). 46.8% (153/327) reported an increase in MRC dyspnoea scale of at least one grade. New or worse disability was reported by 24.2% (79/327) of participants. Overall (EQ5D-5L) summary index was significantly worse at the time of follow-up (median difference 0.1 points on a scale of 0 to 1, IQR: -0.2 to 0.0). Females under the age of 50 years were five times less likely to report feeling recovered (adjusted OR 5.09, 95% CI 1.64 to 15.74), were more likely to have greater disability (adjusted OR 4.22, 95% CI 1.12 to 15.94), twice as likely to report worse fatigue (adjusted OR 2.06, 95% CI 0.81 to 3.31) and seven times more likely to become more breathless (adjusted OR 7.15, 95% CI 2.24 to 22.83) than men of the same age.

ConclusionsSurvivors of Covid-19 experienced long-term symptoms, new disability, increased breathlessness, and reduced quality of life. These findings were present even in young, previously healthy working age adults, and were most common in younger females. Policymakers should fund further research to identify effective treatments for long-Covid and ensure healthcare, social care and welfare support is available for individuals with long-Covid.

Section 1: What is already known on this topicO_LILong-term symptoms after hospitalisation for Covid-19 have been reported, but it is not clear what impact this has on quality of life.
C_LIO_LIIt is not known which patient groups are most likely to have long-term persistent symptoms following hospitalisation for Covid-19, or if this differs by disease severity.
C_LI

Section 2: What this study addsO_LIMore than half of patients reported not being fully recovered 7 months after onset of Covid-19 symptoms.
C_LIO_LIPreviously healthy participants and those under the age of 50 had higher odds of worse long-term outcomes compared to older participants and those with comorbidities.
C_LIO_LIYounger women and those with more severe acute disease in-hospital had the worst long-term outcomes.
C_LIO_LIPolicy makers need to ensure there is long-term support for people experiencing long-Covid and should plan for lasting long-term population morbidity. Funding for research to understand mechanisms underlying long-Covid and identify potential interventions for testing in randomised trials is urgently required.
C_LI",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.20.21254010,2021-03-22,https://medrxiv.org/cgi/content/short/2021.03.20.21254010,Older biological age is associated with adverse COVID-19 outcomes: A cohort study in UK Biobank,Qingning Wang; Veryan Codd; Zahra Raisi-Estabragh; Crispin Musicha; Bountziouka Vasiliki; Stephen Kaptoge; Elias Allara; Emanuele Di Angelantonio; Adam S Butterworth; Angela M Wood; John R Thompson; Steffen E Petersen; Nicholas C Harvey; John N Danesh; Nilesh J Samani; Christopher P Nelson,Univeristy of Leicester; Univeristy of Leicester; Queen Mary University of London; Univeristy of Leicester; Univeristy of Leicester; Univeristy of Cambridge; Univeristy of Cambridge; Univeristy of Cambridge; Univeristy of Cambridge; Univeristy of Cambridge; Univeristy of Leicester; Queen Mary University of London; University of Southampton; Univeristy of Cambridge; Univeristy of Leicester; University of Leicester,"BackgroundOlder chronological age is the most powerful risk factor for adverse coronavirus disease-19 (COVID-19) outcomes. It is uncertain, however, whether older biological age, as assessed by leucocyte telomere length (LTL), is also associated with COVID-19 outcomes.

MethodsWe associated LTL values obtained from participants recruited into UK Biobank (UKB) during 2006-2010 with adverse COVID-19 outcomes recorded by 30 November 2020, defined as a composite of any of the following: hospital admission, need for critical care, respiratory support, or mortality. Using information on 131 LTL-associated genetic variants, we conducted exploratory Mendelian randomisation (MR) analyses in UKB to evaluate whether observational associations might reflect cause-and-effect relationships.

FindingsOf 6,775 participants in UKB who had tested positive for infection with SARS-CoV-2 in the community, there were 914 (13.5%) with adverse COVID-19 outcomes. The odds ratio (OR) for adverse COVID-19 outcomes was 1{middle dot}17 (95% CI 1{middle dot}05-1{middle dot}31; P=0{middle dot}004) per 1-SD shorter usual LTL, after adjustment for chronological age, sex and ethnicity. Similar ORs were observed in analyses that: adjusted for additional risk factors; disaggregated the composite outcome and reduced the scope for selection or collider bias. In MR analyses, the OR for adverse COVID-19 outcomes was directionally concordant but non-significant.

InterpretationShorter LTL, indicative of older biological age, is associated with higher risk of adverse COVID-19 outcomes, independent of several major risk factors for COVID-19 including chronological age. Further data are needed to determine whether this association reflects causality.

FundingUK Medical Research Council, Biotechnology and Biological Sciences Research Council and British Heart Foundation.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.11.21253275,2021-03-21,https://medrxiv.org/cgi/content/short/2021.03.11.21253275,Effect of vaccination on transmission of COVID-19: an observational study in healthcare workers and their households,Anoop Shah; Ciara Gribben; Jennifer Bishop; Peter Hanlon; David Caldwell; Rachael Wood; Martin Reid; Jim McMenamin; David Goldberg; Diane Stockton; Sharon Hutchinson; Chris Robertson; Paul M McKeigue; Helen M Colhoun; David McAllister,London School of Hygiene and Tropical Medicine; Public Health Scotland; Public Health Scotland; University of Glasgow; Public Health Scotland; PublicHealth Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; University of Glasgow,"BackgroundThe effect of vaccination for COVID-19 on onward transmission is unknown.

MethodsA national record linkage study determined documented COVID-19 cases and hospitalisations in unvaccinated household members of vaccinated and unvaccinated healthcare workers from 8th December 2020 to 3rd March 2021. The primary endpoint was COVID-19 14 days following the first dose.

ResultsThe cohort comprised of 194,362 household members (mean age 31{middle dot}1 {+/-} 20{middle dot}9 years) and 144,525 healthcare workers (mean age 44{middle dot}4 {+/-} 11{middle dot}4 years). 113,253 (78{middle dot}3%) of healthcare workers received at least one dose of the BNT162b2 mRNA or ChAdOx1 nCoV-19 vaccine and 36,227 (25{middle dot}1%) received a second dose. There were 3,123 and 4,343 documented COVID-19 cases and 175 and 177 COVID-19 hospitalisations in household members of healthcare workers and healthcare workers respectively. Household members of vaccinated healthcare workers had a lower risk of COVID-19 case compared to household members of unvaccinated healthcare worker (rate per 100 person-years 9{middle dot}40 versus 5{middle dot}93; HR 0{middle dot}70, 95% confidence interval [CI] 0{middle dot}63 to 0{middle dot}78). The effect size for COVID-19 hospitalisation was similar, with the confidence interval crossing the null (HR 0{middle dot}77 [95% CI 0{middle dot}53 to 1{middle dot}10]). The rate per 100 person years was lower in vaccinated compared to unvaccinated healthcare workers for documented (20{middle dot}13 versus 8{middle dot}51; HR 0{middle dot}45 [95% CI 0{middle dot}42 to 0{middle dot}49]) and hospitalized COVID-19 (0{middle dot}97 versus 0{middle dot}14; HR 0{middle dot}16 [95% CI 0{middle dot}09 to 0{middle dot}27]). Compared to the period before the first dose, the risk of documented COVID-19 case was lower at [&ge;] 14 days after the second dose for household members (HR 0{middle dot}46 [95% CI 0{middle dot}30to 0{middle dot}70]) and healthcare workers (HR 0{middle dot}08 [95% CI 0{middle dot}04 to 0{middle dot}17]).

InterpretationVaccination of health care workers was associated with a substantial reduction in COVID-19 cases in household contacts consistent with an effect of vaccination on transmission.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.03.17.21253853,2021-03-20,https://medrxiv.org/cgi/content/short/2021.03.17.21253853,"Modelling the impact of rapid tests, tracing and distancing in lower-income countries suggest optimal policies varies with rural-urban settings",Xilin Jiang; Wenfeng Gong; Zlatina Dobreva; Ya Gao; Matthew Quaife; Christophe Fraser; Chris Holmes,"University of Oxford; Bill & Melinda Gates Foundation; Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK; Department of International Health, Johns Hopkins University; Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK; University of Oxford; University of Oxford","Low- and middle-income countries (LMICs) remain of high potential for hotspots for COVID-19 deaths and emerging variants given the inequality of vaccine distribution and their vulnerable healthcare systems. We aim to evaluate containment strategies that are sustainable and effective for LMICs. We constructed synthetic populations with varying contact and household structures to capture LMIC demographic characteristics that vary across communities. Using an agent- based model, we explored the optimal containment strategies for rural and urban communities by designing and simulating setting-specific strategies that deploy rapid diagnostic tests, symptom screening, contact tracing and physical distancing. In low-density rural communities, we found implementing either high quality (sensitivity > 50%) antigen rapid diagnostic tests or moderate physical distancing could contain the transmission. In urban communities, we demonstrated that both physical distancing and case finding are essential for containing COVID-19 (average infection rate < 10%). In high density communities that resemble slums and squatter settlements, physical distancing is less effective compared to rural and urban communities. Lastly, we demonstrated contact tracing is essential for effective containment. Our findings suggested that rapid diagnostic tests could be prioritised for control and monitor COVID-19 transmission and highlighted that contact survey data could guide strategy design to save resources for LMICs. An accompanying open source R package is available for simulating COVID-19 transmission based on contact network models.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.03.18.21253443,2021-03-20,https://medrxiv.org/cgi/content/short/2021.03.18.21253443,Intensity of COVID-19 in care homes following Hospital Discharge in the early stages of the UK epidemic,Joe Hollinghurst; Laura North; Chris Emmerson; Ashley Akbari; Fatemeh Torabi; Ronan A Lyons; Alan G Hawkes; Ed Bennett; Mike B Gravenor; Richard Fry,Swansea University; Swansea University; Public Health Wales; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University,"BackgroundA defining feature of the COVID-19 pandemic in many countries was the tragic extent to which care home residents were affected, and the difficulty preventing introduction and subsequent spread of infection. Management of risk in care homes requires good evidence on the most important transmission pathways. One hypothesised route at the start of the pandemic, prior to widespread testing, was transfer of patients from hospitals, which were experiencing high levels of nosocomial events.

MethodsWe tested the hypothesis that hospital discharge events increased the intensity of care home cases using a national individually linked health record cohort in Wales, UK. We monitored 186,772 hospital discharge events over the period March to July 2020, tracking individuals to 923 care homes and recording the daily case rate in the homes populated by 15,772 residents. We estimated the risk of an increase in cases rates following exposure to a hospital discharge using multi-level hierarchical logistic regression, and a novel stochastic Hawkes process outbreak model.

FindingsIn regression analysis, after adjusting for care home size, we found no significant association between hospital discharge and subsequent increases in care home case numbers (odds ratio: 0.99, 95% CI 0.82, 1.90). Risk factors for increased cases included care home size, care home resident density, and provision of nursing care. Using our outbreak model, we found a significant effect of hospital discharge on the subsequent intensity of cases. However, the effect was small, and considerably less than the effect of care home size, suggesting the highest risk of introduction came from interaction with the community. We estimated approximately 1.8% of hospital discharged patients may have been infected.

InterpretationThere is growing evidence in the UK that the risk of transfer of COVID-19 from the high-risk hospital setting to the high-risk care home setting during the early stages of the pandemic was relatively small. Although access to testing was limited to initial symptomatic cases in each care home at this time, our results suggest that reduced numbers of discharges, selection of patients, and action taken within care homes following transfer all may have contributed to mitigation. The precise key transmission routes from the community remain to be quantified.",health informatics,fuzzy,100,100
medRxiv,10.1101/2021.03.16.21253719,2021-03-17,https://medrxiv.org/cgi/content/short/2021.03.16.21253719,Knowledge barriers in the symptomatic-COVID-19 testing programme in the UK: an observational study,Mark S Graham; Anna May; Thomas Varsavsky; Carole Sudre; Benjamin Murray; Kerstin Klaser; Michela Antonelli; Liane Canas; Erika Molteni; Marc Modat; David Alden Drew; Long Nguyen; Benjamin Rader; Christina Hu; Joan Capdevila; Alexander Hammers; Andrew Chan; Jonathan Wolf; John Brownstein; Timothy Spector; Sebastien Ourselin; Claire Steves; Christina Astley,King's College London; Zoe; King's College London; University College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Massachusetts General Hospital; Massachusetts General Hospital and Harvard Medical School; Boston University; Zoe; Zoe; King's College London; Massachusetts General Hospital and Harvard Medical School; Zoe; Boston Children's Hospital; King's College London; King's College London; King's College London; Boston Children's Hospital,"BackgroundSymptomatic testing programmes are crucial to the COVID-19 pandemic response. We sought to examine United Kingdom (UK) testing rates amongst individuals with test-qualifying symptoms, and factors associated with not testing.

MethodsWe analysed a cohort of untested symptomatic app users (N=1,237), nested in the Zoe COVID Symptom Study (Zoe, N= 4,394,948); and symptomatic survey respondents who wanted, but did not have a test (N=1,956), drawn from the University of Maryland-Facebook Covid-19 Symptom Survey (UMD-Facebook, N=775,746).

FindingsThe proportion tested among individuals with incident test-qualifying symptoms rose from [~]20% to [~]75% from April to December 2020 in Zoe. Testing was lower with one vs more symptoms (73.0% vs 85.0%), or short vs long symptom duration (72.6% vs 87.8%). 40.4% of survey respondents did not identify all three test-qualifying symptoms. Symptom identification decreased for every decade older (OR=0.908 [95% CI 0.883-0.933]). Amongst symptomatic UMD-Facebook respondents who wanted but did not have a test, not knowing where to go was the most cited factor (32.4%); this increased for each decade older (OR=1.207 [1.129-1.292]) and for every 4-years fewer in education (OR=0.685 [0.599-0.783]).

InterpretationDespite current UK messaging on COVID-19 testing, there is a knowledge gap about when and where to test, and this may be contributing to the [~]25% testing gap. Risk factors, including older age and less education, highlight potential opportunities to tailor public health messages.

FundingZoe Global Limited, Department of Health, Wellcome Trust, EPSRC, NIHR, MRC, Alzheimers Society, Facebook Sponsored Research Agreement.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSTo assess current evidence on test uptake in symptomatic testing programmes, and the reasons for not testing, we searched PubMed from database inception for research using the keywords (COVID-19) AND (testing) AND ((access) OR (uptake)). We did not find any work reporting on levels of test uptake amongst symptomatic individuals. We found three papers investigating geographic barriers to testing. We found one US based survey reporting on knowledge barriers to testing, and one UK based survey reporting on barriers in the period March - August 2020. Neither of these studies were able to combine testing behaviour with prospectively collected symptom reports from the users surveyed.

Added value of this studyThrough prospective collection of symptom and test reports, we were able to estimate testing uptake amongst individuals with test-qualifying symptoms in the UK. Our results indicate that whilst testing has improved since the start of the pandemic, there remains a considerable testing gap. Investigating this gap we find that individuals with just one test-qualifying symptom or short symptom duration are less likely to get tested. We also find knowledge barriers to testing: a substantial proportion of individuals do not know which symptoms qualify them for a COVID-19 test, and do not know where to seek testing. We find a larger knowledge gap in individuals with older age and fewer years of education.

Implications of all the available evidenceDespite the UK having a simple set of symptom-based testing criteria, with tests made freely available through nationalised healthcare, a quarter of individuals with qualifying symptoms do not get tested. Our findings suggest testing uptake may be limited by individuals not acting on mild or transient symptoms, not recognising the testing criteria, and not knowing where to get tested. Improved messaging may help address this testing gap, with opportunities to target individuals of older age or fewer years of education. Messaging may prove even more valuable in countries with more fragmented testing infrastructure or more nuanced testing criteria, where knowledge barriers are likely to be greater.",public and global health,fuzzy,94,100
bioRxiv,10.1101/2021.03.14.435295,2021-03-16,https://biorxiv.org/cgi/content/short/2021.03.14.435295,3D genomic capture of regulatory immuno-genetic profiles in COVID-19 patients for prognosis of severe COVID disease outcome,Ewan Hunter; Christina Koutsothanasi; Adam Wilson; Francisco Coroado Santos; Matthew Salter; Ryan Powell; Ann Dring; Paulina Brajer; Benedict Egan; Jurjen Westra; Aroul Ramadass; William Messner; Amanda Brunton; Zoe Lyski; Rama Vancheeswaran; Andrew Barlow; Dmitri Pchejetski; Alexandre Akoulitchev,"Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oxford BioDynamics Plc, Oxford UK; Oregon Health & Science University, Portland, OR; Oregon Health & Science University, Portland, OR; Oregon Health & Science University, Portland, OR; West Hertfordshire NHS Trust, Watford, UK; West Hertfordshire NHS Trust, Watford, UK; Norwich Medical School, University of East Anglia; Oxford BioDynamics Plc, Oxford UK","Human infection with the SARS-CoV-2 virus leads to coronavirus disease (COVID-19). A striking characteristic of COVID-19 infection in humans is the highly variable host response and the diverse clinical outcomes, ranging from clinically asymptomatic to severe immune reactions leading to hospitalization and death. Here we used a 3D genomic approach to analyse blood samples at the time of COVID diagnosis, from a global cohort of 80 COVID-19 patients, with different degrees of clinical disease outcomes. Using 3D whole genome EpiSwitch(R) arrays to generate over 1 million data points per patient, we identified a distinct and measurable set of differences in genomic organization at immune-related loci that demonstrated prognostic power at baseline to stratify patients with mild forms of illness and those with severe forms that required hospitalization and intensive care unit (ICU) support. Further analysis revealed both well established and new COVID-related dysregulated pathways and loci, including innate and adaptive immunity; ACE2; olfactory, G{beta}{psi}, Ca2+ and nitric oxide (NO) signalling; prostaglandin E2 (PGE2), the acute inflammatory cytokine CCL3, and the T-cell derived chemotactic cytokine CCL5. We identified potential therapeutic agents for mitigation of severe disease outcome, with several already being tested independently, including mTOR inhibitors (rapamycin and tacrolimus) and general immunosuppressants (dexamethasone and hydrocortisone). Machine learning algorithms based on established EpiSwitch(R) methodology further identified a subset of 3D genomic changes that could be used as prognostic molecular biomarker leads for the development of a COVID-19 disease severity test.",biochemistry,fuzzy,92,100
medRxiv,10.1101/2021.03.09.21253012,2021-03-15,https://medrxiv.org/cgi/content/short/2021.03.09.21253012,The local and systemic response to SARS-CoV-2 infection in children and adults,Masahiro Yoshida; Kaylee B Worlock; Ni Huang; Rik GH Lindeboom; Colin R Butler; Natsuhiko Kumasaka; Cecilia Dominguez Conde; Lira Mamanova; Liam Bolt; Laura Richardson; Krzysztof Polanski; Elo Madissoon; Josephine L Barnes; Jessica Allen-Hyttinen; Eliz Kilich; Brendan C Jones; Angus de Wilton; Anna Wilbrey-Clark; Waradon Sungnak; Jan Patrick Prett; Elena Prigmore; Henry Yung; Puja Mehta; Aarash Saleh; Anita Saigal; Vivian Chu; Jonathan M Cohen; Clare Cane; Aikaterini Iordanidou; Soichi Shibuya; Ann-Kathrin Reuschl; A. Christine Argento; Richard G Wunderink; Sean B Smith; Taylor A Poor; Catherine A Gao; Jane E Dematte; - NU SCRIPT Study Investigators; Gary Reynolds; Muzlifah Haniffa; Georgina S Bowyer; Matthew Coates; Menna R Clatworthy; Fernando J Calero-Nieto; Berthold Gottgens; Neil J Sebire; Clare Jolly; Paolo de Coppi; Claire M Smith; Alexander V Misharin; Sam M Janes; Sarah A Teichmann; Marko Z Nikolic; Kerstin B Meyer,"UCL Respiratory, Division of Medicine, University College London, London, UK; UCL Respiratory, Division of Medicine, University College London, London, UK; Wellcome Sanger Institute, Cambridge, UK; Wellcome Sanger Institute, Cambridge, UK; UCL Great Ormond Street Institute of Child Health, London, UK; Wellcome Trust Sanger Institute; Wellcome Sanger Institute, Cambridge, UK; Wellcome Sanger Institute, Cambridge, UK; Wellcome Sanger Institute, Cambridge, UK; Wellcome Sanger Institute, Cambridge, UK; Wellcome Sanger Institute, Cambridge, UK; Wellcome Sanger Institute, Cambridge, UK; UCL Respiratory, Division of Medicine, University College London, London, UK; UCL Respiratory, Division of Medicine, University College London, London, UK; University College London Hospitals NHS Foundation Trust, London, UK; UCL Great Ormond Street Institute of Child Health, London, UK; University College London Hospital Trust; Wellcome Sanger Institute, Cambridge, UK; Wellcome Sanger Institute; Wellcome Sanger Institute, Cambridge, UK; Wellcome Sanger Institute, Cambridge, UK; UCL Respiratory, Division of Medicine, University College London, London, UK; UCL Respiratory, Division of Medicine, University College London, London, UK; Royal Free Hospital, London, UK; Royal Free Hospital, London, UK; Royal Free Hospital, London, UK; University College London Hospitals NHS Foundation Trust, London, UK; Royal Free Hospital, London, UK; Royal Free Hospital, London, UK; UCL Great Ormond Street Institute of Child Health, London, UK; Division of Infection and Immunity, University College London, London, UK; Division of Pulmonary and Critical Care Medicine, Northwestern University, Feinberg School of Medicine, Chicago, USA; Northwestern University Feinberg School of Medicine; Division of Pulmonary and Critical Care Medicine, Northwestern University, Feinberg School of Medicine, Chicago, USA; Division of Pulmonary and Critical Care Medicine, Northwestern University, Feinberg School of Medicine, Chicago, USA; Division of Pulmonary and Critical Care Medicine, Northwestern University, Feinberg School of Medicine, Chicago, USA; Division of Pulmonary and Critical Care Medicine, Northwestern University, Feinberg School of Medicine, Chicago, USA; ; Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK; Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK; Department of Medicine, University of Cambridge, Cambridge CB2 0QQ, UK; University of Cambridge, Department of Medicine; University of Cambride, Department of Medicine; Wellcome Trust & MRC Cambridge Stem Cell Institute and Department of Haematology, University of Cambridge, Cambridge UK; Wellcome Trust & MRC Cambridge Stem Cell Institute and Department of Haematology, University of Cambridge, Cambridge UK; NIHR Great Ormond Street BRC and Institute of Child Health, London, UK; Division of Infection and Immunity, University College London, UK; UCL Great Ormond Street Institute of Child Health, London, UK; UCL Great Ormond Street Institute of Child Health, London, UK; Northwestern University; UCL Respiratory, Division of Medicine, University College London, London, UK; Wellcome Sanger Institute, Cambridge, UK; UCL Respiratory, Division of Medicine, University College London, London, UK; Wellcome Sanger Institute, Cambridge, UK","While a substantial proportion of adults infected with SARS-CoV-2 progress to develop severe disease, children rarely manifest respiratory complications. Therefore, understanding differences in the local and systemic response to SARS-CoV-2 infection between children and adults may provide important clues about the pathogenesis of SARS-CoV-2 infection. To address this, we first generated a healthy reference multi-omics single cell data set from children (n=30) in whom we have profiled triple matched samples: nasal and tracheal brushings and PBMCs, where we track the developmental changes for 42 airway and 31 blood cell populations from infancy, through childhood to adolescence. This has revealed the presence of naive B and T lymphocytes in neonates and infants with a unique gene expression signature bearing hallmarks of innate immunity. We then contrast the healthy reference with equivalent data from severe paediatric and adult COVID-19 patients (total n=27), from the same three types of samples: upper and lower airways and blood. We found striking differences: children with COVID-19 as opposed to adults had a higher proportion of innate lymphoid and non-clonally expanded naive T cells in peripheral blood, and a limited interferon-response signature. In the airway epithelium, we found the highest viral load in goblet and ciliated cells and describe a novel inflammatory epithelial cell population. These cells represent a transitional regenerative state between secretory and ciliated cells; they were found in healthy children and were enriched in paediatric and adult COVID-19 patients. Epithelial cells display an antiviral and neutrophil-recruiting gene signature that is weaker in severe paediatric versus adult COVID-19. Our matched blood and airway samples allowed us to study the spatial dynamics of infection. Lastly, we provide a user-friendly interface for this data1 as a highly granular reference for the study of immune responses in airways and blood in children.",pediatrics,fuzzy,100,100
medRxiv,10.1101/2021.03.12.21253484,2021-03-13,https://medrxiv.org/cgi/content/short/2021.03.12.21253484,Limits of lockdown: characterising essential contacts during strict physical distancing,Amy C Thomas; Leon Danon; Hannah Christensen; Kate Northstone; Daniel Smith; Emily J Nixon; Adam Trickey; Gibran Hemani; Sarah Sauchelli; Adam Finn; Nicholas J Timpson; Ellen Brooks-Pollock,"University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; University of Bristol; NIHR Bristol Biomedical Research Centre, University of Bristol; University of Bristol; University of Bristol; University of Bristol","COVID-19 has exposed health inequalities within countries and globally. The fundamental determining factor behind an individuals risk of infection is the number of social contacts they make. In many countries, physical distancing measures have been implemented to control transmission of SARS-CoV-2, reducing social contacts to a minimum. Characterising unavoidable social contacts is key for understanding the inequalities behind differential risks and planning vaccination programmes. We utilised an existing English longitudinal birth cohort, which is broadly representative of the wider population (n=6807), to explore social contact patterns and behaviours when strict physical distancing measures were in place during the UKs first lockdown in March-May 2020. Essential workers, specifically those in healthcare, had 4.5 times as many contacts as non-essential workers [incident rate ratio = 4.42 (CI95%: 3.88-5.04)], whilst essential workers in other sectors, mainly teaching and the police force had three times as many contacts [IRR = 2.84 (2.58-3.13)]. The number of individuals in a household, which is conflated by number of children, increases essential social contacts by 40%. Self-isolation effectively reduces numbers of contacts outside of the home, but not entirely. Together, these findings will aid the interpretation of epidemiological data and impact the design of effective SARS-CoV-2 control strategies, such as vaccination, testing and contact tracing.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.03.10.21253173,2021-03-12,https://medrxiv.org/cgi/content/short/2021.03.10.21253173,"High household transmission of SARS-CoV-2 in the United States: living density, viral load, and disproportionate impact on communities of color",Carla Cerami; Tyler Rapp; Feng-Chang Lin; Kathleen Tompkins; Christopher Basham; Meredith Smith Muller; Maureen Whittelsey; Haoming Zhang; Srijana Bhattarai Chhetri; Judy Smith; Christy Litel; Kelly Lin; Mehal Churiwal; Salman Khan; Faith Claman; Rebecca Rubinstein; Katie Mollan; David Wohl; Lakshmanane Premkumar; Jonathan J. Juliano; Jessica T Lin,"MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; University of North Carolina School of Medicine; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA; Institute of Global Health and Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC USA","BackgroundFew prospective studies of SARS-CoV-2 transmission within households have been reported from the United States, where COVID-19 cases are the highest in the world and the pandemic has had disproportionate impact on communities of color.

Methods and FindingsThis is a prospective observational study. Between April-October 2020, the UNC CO-HOST study enrolled 102 COVID-positive persons and 213 of their household members across the Piedmont region of North Carolina, including 45% who identified as Hispanic/Latinx or non-white. Households were enrolled a median of 6 days from onset of symptoms in the index case. Secondary cases within the household were detected either by PCR of a nasopharyngeal (NP) swab on study day 1 and weekly nasal swabs (days 7, 14, 21) thereafter, or based on seroconversion by day 28. After excluding household contacts exposed at the same time as the index case, the secondary attack rate (SAR) among susceptible household contacts was 60% (106/176, 95% CI 53%-67%). The majority of secondary cases were already infected at study enrollment (73/106), while 33 were observed during study follow-up. Despite the potential for continuous exposure and sequential transmission over time, 93% (84/90, 95% CI 86%-97%) of PCR-positive secondary cases were detected within 14 days of symptom onset in the index case, while 83% were detected within 10 days. Index cases with high NP viral load (>10^6 viral copies/ul) at enrollment were more likely to transmit virus to household contacts during the study (OR 4.9, 95% CI 1.3-18 p=0.02). Furthermore, NP viral load was correlated within families (ICC=0.44, 95% CI 0.26-0.60), meaning persons in the same household were more likely to have similar viral loads, suggesting an inoculum effect. High household living density was associated with a higher risk of secondary household transmission (OR 5.8, 95% CI 1.3-55) for households with >3 persons occupying <6 rooms (SAR=91%, 95% CI 71-98%). Index cases who self-identified as Hispanic/Latinx or non-white were more likely to experience a high living density and transmit virus to a household member, translating into an SAR in minority households of 70%, versus 52% in white households (p=0.05).

ConclusionsSARS-CoV-2 transmits early and often among household members. Risk for spread and subsequent disease is elevated in high-inoculum households with limited living space. Very high infection rates due to household crowding likely contribute to the increased incidence of SARS-CoV-2 infection and morbidity observed among racial and ethnic minorities in the US. Quarantine for 14 days from symptom onset of the first case in the household is appropriate to prevent onward transmission from the household. Ultimately, primary prevention through equitable distribution of effective vaccines is of paramount importance.

AUTHORS SUMMARYO_ST_ABSWhy was this study done?C_ST_ABSO_LIUnderstanding the secondary attack rate and the timing of transmission of SARS-CoV-2 within households is important to determine the role of household transmission in the larger pandemic and to guide public health policies about quarantine.
C_LIO_LIProspective studies looking at the determinants of household transmission are sparse, particularly studies including substantial racial and ethnic minorities in the United States and studies with adequate follow-up to detect sequential transmission events.
C_LIO_LIIdentifying individuals at high risk of transmitting and acquiring SARS-CoV-2 will inform strategies for reducing transmission in the household, or reducing disease in those exposed.
C_LI

What did the researchers do and find?O_LIBetween April-November 2020, the UNC CO-HOST study enrolled 102 households across the Piedmont region of North Carolina, including 45% with an index case who identified as racial or ethnic minorities.
C_LIO_LIOverall secondary attack rate was 60% with two-thirds of cases already infected at study enrollment.
C_LIO_LIDespite the potential for sequential transmission in the household, the majority of secondary cases were detected within 10 days of symptom onset of the index case.
C_LIO_LIViral loads were correlated within families, suggesting an inoculum effect.
C_LIO_LIHigh viral load in the index case was associated with a greater likelihood of household transmission.
C_LIO_LISpouses/partners of the COVID-positive index case and household members with obesity were at higher risk of becoming infected.
C_LIO_LIHigh household living density contributed to an increased risk of household transmission.
C_LIO_LIRacial/ethnic minorities had an increased risk of acquiring SARS-CoV-2 in their households in comparison to members of the majority (white) racial group.
C_LI

What do these findings mean?O_LIHousehold transmission often occurs quickly after a household member is infected.
C_LIO_LIHigh viral load increases the risk of transmission.
C_LIO_LIHigh viral load cases cluster within households - suggesting high viral inoculum in the index case may put the whole household at risk for more severe disease.
C_LIO_LIIncreased household density may promote transmission within racial and ethnic minority households.
C_LIO_LIEarly at-home point-of-care testing, and ultimately vaccination, is necessary to effectively decrease household transmission.
C_LI",infectious diseases,fuzzy,92,100
medRxiv,10.1101/2021.03.11.21253189,2021-03-12,https://medrxiv.org/cgi/content/short/2021.03.11.21253189,"Risk, clinical course and outcome of ischemic stroke in patients hospitalized with COVID-19: a multicenter cohort study",Wouter M Sluis; Marijke Linschoten; J Matthijs Biesbroek; Heleen M den Hertog; Tessa Ribbers; Dennis Nieuwkamp; Reinier C van Houwelingen; Andreas Dias; Ingeborg WM van Uden; Joost P Kerklaan; H. Paul Bienfait; Sarah E Vermeer; Sonja W de Jong; Mariam Ali; Marieke JH Wermer; Marieke T de Graaf; Paul JAM Brouwers; Folkert W Asselbergs; L Jaap Kappelle; H Bart van der Worp; Annemijn M Algra; - CAPACITY-COVID collaborative consortium,"University Medical Center Utrecht; University Medical Center Utrecht; Diakonessenhuis Utrecht; Isala Hospital Zwolle; Jeroen Bosch Hospital 's Hertogenbosch; Jeroen Bosch Hospital 's Hertogenbosch; Treant Hospital Emmen; Ikazia Hospital Rotterdam; Catharina Hospital Eindhoven; St. Antonius Hospital Nieuwegein; Gelre Hospital Apeldoorn; Rijnstate Hospital Arnhem; St. Jansdal Hospital Harderwijk; Amsterdam UMC, Amsterdam; Leiden University Medical Center, Leiden; Zaans Medical Center, Zaandam; Medisch Spectrum Twente, Enschede; University Medical Center Utrecht; University Medical Center Utrecht; University Medical Center Utrecht; University Medical Center Utrecht; ","Background and purposeThe frequency of ischemic stroke in patients with COVID-19 varies in the current literature, and risk factors are unknown. We assessed the incidence, risk factors, and outcomes of acute ischemic stroke in hospitalized patients with COVID-19.

MethodsWe included patients with a laboratory confirmed SARS-CoV-2 infection admitted in 16 hospitals participating in the international CAPACITY-COVID registry between March 1st and August 1st, 2020. Patients were screened for the occurrence of acute ischemic stroke. We calculated the cumulative incidence of ischemic stroke and compared risk factors, cardiovascular complications, and in-hospital mortality in patients with and without ischemic stroke.

ResultsWe included 2147 patients with COVID-19, of whom 586 (27.3%) needed treatment at an intensive care unit (ICU). Thirty-eight patients (1.8%) had an ischemic stroke. Patients with stroke were older, but did not differ in sex or cardiovascular risk factors. Median time between onset of COVID-19 symptoms and diagnosis of stroke was two weeks. The incidence of ischemic stroke was higher among patients who were treated at an ICU (16/586; 2.7% versus 22/1561; 1.4%; p=0.039). Pulmonary embolism was more common in patients with (8/38; 21.1%) than in those without stroke (160/2109; 7.6%; adjusted RR: 2.08; 95%CI:1.52-2.84). Twenty-seven patients with ischemic stroke (71.1%) died during admission or were functional dependent at discharge and in-hospital mortality. Patients with ischemic stroke were at a higher risk of in-hospital mortality (adjusted RR 1.56; 95%CI:1.13-2.15) than patients without stroke.

ConclusionsIn this multicenter cohort study, the cumulative incidence of acute ischemic stroke in hospitalized patients with COVID-19 was approximately 2%, with a higher risk in patients treated at an ICU. The majority of stroke patients had a poor outcome. The association between ischemic stroke and pulmonary embolism warrants further investigation.",neurology,fuzzy,100,100
medRxiv,10.1101/2021.03.09.21253218,2021-03-12,https://medrxiv.org/cgi/content/short/2021.03.09.21253218,An observational cohort study on the incidence of SARS-CoV-2 infection and B.1.1.7 variant infection in healthcare workers by antibody and vaccination status,Sheila F Lumley; Gillian Rodger; Bede Constantinides; Nicholas Sanderson; Kevin K Chau; Teresa L Street; Alison Howarth; Stephanie B Hatch; Brian D Marsden; Stuart Cox; Tim James; Fiona Warren; Liam J Peck; Thomas G Ritter; Zoe de Toledo; Laura Warren; David Axten; Richard J Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Meera Chand; - Oxford University Hospitals Staff Testing Group; Derrick Crook; Christopher P Conlon; Koen B Pouwels; A Sarah Walker; Tim EA Peto; Susan Hopkins; Timothy M Walker; Nicole EA Stoesser; Philippa C Matthews; Katie Jeffery; David W Eyre,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Public Health England; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Public Health England; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; University of Oxford,"BackgroundNatural and vaccine-induced immunity will play a key role in controlling the SARS-CoV-2 pandemic. SARS-CoV-2 variants have the potential to evade natural and vaccine-induced immunity.

MethodsIn a longitudinal cohort study of healthcare workers (HCWs) in Oxfordshire, UK, we investigated the protection from symptomatic and asymptomatic PCR-confirmed SARS-CoV-2 infection conferred by vaccination (Pfizer-BioNTech BNT162b2, Oxford-AstraZeneca ChAdOx1 nCOV-19) and prior infection (determined using anti-spike antibody status), using Poisson regression adjusted for age, sex, temporal changes in incidence and role. We estimated protection conferred after one versus two vaccinations and from infections with the B.1.1.7 variant identified using whole genome sequencing.

Results13,109 HCWs participated; 8285 received the Pfizer-BioNTech vaccine (1407 two doses) and 2738 the Oxford-AstraZeneca vaccine (49 two doses). Compared to unvaccinated seronegative HCWs, natural immunity and two vaccination doses provided similar protection against symptomatic infection: no HCW vaccinated twice had symptomatic infection, and incidence was 98% lower in seropositive HCWs (adjusted incidence rate ratio 0.02 [95%CI <0.01-0.18]). Two vaccine doses or seropositivity reduced the incidence of any PCR-positive result with or without symptoms by 90% (0.10 [0.02-0.38]) and 85% (0.15 [0.08-0.26]) respectively. Single-dose vaccination reduced the incidence of symptomatic infection by 67% (0.33 [0.21-0.52]) and any PCR-positive result by 64% (0.36 [0.26-0.50]). There was no evidence of differences in immunity induced by natural infection and vaccination for infections with S-gene target failure and B.1.1.7.

ConclusionNatural infection resulting in detectable anti-spike antibodies and two vaccine doses both provide robust protection against SARS-CoV-2 infection, including against the B.1.1.7 variant.

SummaryNatural infection resulting in detectable anti-spike antibodies and two vaccine doses both provided [&ge;] 85% protection against symptomatic and asymptomatic SARS-CoV-2 infection in healthcare workers, including against the B.1.1.7 variant. Single dose vaccination reduced symptomatic infection by 67%.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.08.21253110,2021-03-10,https://medrxiv.org/cgi/content/short/2021.03.08.21253110,Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 Long Term Care Facilities (VIVALDI study),Maria Krutikov; Tom Palmer; Gokhan Tut; Chris Fuller; Madhumita Shrotri; Haydn Williams; Daniel Davies; Aidan Irwin-Singer; James Robson; Andrew Hayward; Paul Moss; Andrew Copas; Laura J Shallcross,UCL; UCL; University of Birmingham; UCL; UCL; Four Seasons Healthcare Group; Palantir Ltd; UK Department of Health and Social Care; Four Seasons Healthcare Group; UCL; University of Birmingham; UCL; UCL,"BackgroundSARS-CoV-2 infection represents a major challenge for Long Term Care Facilities (LTCFs) and many residents and staff are now sero-positive following persistent outbreaks. We investigated the relationship between the presence of SARS-CoV-2 specific antibodies and subsequent infection in this population.

MethodsProspective cohort study of infection in staff and residents in 100 LTCFs in England between October 2020 and February 2021. Blood samples were collected at baseline (June 2020), 2 and 4 months and tested for IgG antibodies to nucleocapsid and spike protein. PCR testing for SARS-CoV-2 was undertaken weekly in staff and monthly in residents. The primary analysis estimated the relative hazard of a PCR-positive test by baseline antibody status, from Cox regression adjusted for age and gender, and stratified by LTCF.

FindingsStudy inclusion criteria were met by 682 residents and 1429 staff. Baseline IgG antibodies to nucleocapsid were detected in 226 residents (33%) and 408 staff (29%). A total of 93 antibody-negative residents had a PCR-positive test (0.054 per month at risk) compared to 4 antibody-positive residents (0.007 per month at risk). There were 111 PCR-positive tests in antibody-negative staff (0.042 per month at risk) compared to 10 in antibody-positive staff (0.009 per month at risk). The adjusted hazard ratios for reinfection in staff and residents with a baseline positive versus negative antibody test were 0.13 (95% CI 0.05-0.40) and 0.39 ((95% CI: 0.19-0.77) respectively. Of 12 reinfected participants with data on symptoms, 11 were symptomatic. Antibody titres to spike and nucleocapsid were comparable in PCR-positive and PCR-negative cases.

InterpretationThe presence of IgG antibodies to nucleocapsid was associated with substantially reduced risk of reinfection in staff and residents for up to 10 months after primary infection.

FundingUK Government Department of Health and Social Care

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe performed a systematic search of MEDLINE (Ovid) and MedRxiv on 18 January 2021 for studies in LTCFs that described the risk of infection in individuals who were seropositive for SARS-CoV-2 compared to individuals who were seronegative. Search terms were deliberately broad to improve capture of relevant literature and included ""SARS-CoV-2""OR ""COVID-19"" OR ""coronavirus"" AND ""care home"" OR ""nursing home"" OR ""long term care facility"" with no date or language restrictions. We did not identify any publications that focussed on risk of reinfection in seropositive individuals, but subsequent to our search one study has been published using data from two LTCFs in London, UK. This study reported a 96% reduction in the odds of reinfection in individuals who were seropositive compared to those who were seronegative based on 4-month follow-up in 161 participants. We found 10 studies that performed seroprevalence surveys in either staff or staff and residents in LTCFs in 8 cohorts. Five of these were carried out in response to SARS-CoV-2 outbreaks within the care homes, either as part of the subsequent investigation or as post-infection surveillance. The largest of these, which enrolled both staff and residents, was performed in 6 LTCFs and performed longitudinal antibody testing.

Added value of this studyWe undertook a cohort study in staff and residents from 100 LTCFs in England to investigate whether individuals with evidence of prior SARS-CoV-2 infection could be infected twice. Staff and residents were offered up to three rounds of antibody testing and antibody results were linked to PCR test results which were obtained weekly from staff and monthly from residents through the national SARS-CoV-2 testing programme. This study, which was conducted in >2000 staff and residents, suggests that antibodies provide high levels of protection against reinfection for up to 10 months. Almost all cases of reinfection were symptomatic, but no cases required hospital treatment. Amongst those with detectable baseline antibodies, quantitative antibody titres against spike protein and nucleocapsid were comparable between cases of reinfection and those who did not become reinfected.

Implications of all available evidenceDespite high background rates of infection in LTCFs, the overall risk of reinfection was low in this population. This is broadly consistent with findings from large cohort studies of hospital staff, but, importantly, extends the evidence of substantial protection to frail elderly, who are vulnerable to severe outcomes of SARS-CoV-2 due to age-related changes in immunity (immune-senescence) and high levels of comorbidity. The low risk of reinfection in our study suggests identification of immune correlates of protection in this population will require pooling of data across multiple cohorts.

As vaccination coverage in residents approaches 100% in England, it will be important to understand whether vaccination and natural infection provide comparable levels of protection against infection. Such insights will inform future policy decisions regarding re-vaccination schedules in LTCF, and the longer-term need for non-pharmaceutical interventions to prevent SARS-CoV-2 transmission, such as asymptomatic testing and visitor restrictions.",geriatric medicine,fuzzy,100,100
medRxiv,10.1101/2021.03.09.21252736,2021-03-10,https://medrxiv.org/cgi/content/short/2021.03.09.21252736,"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial",Peter W Horby; Lise Estcourt; Leon Peto; Jonathan R Emberson; Natalie Staplin; Enti Spata; Guilherme Pessoa-Amorim; Mark Campbell; Alistair Roddick; Nigel E Brunskill; Tina George; Daniel Zehnder; Simon Tiberi; Ni Ni Aung; Alison Uriel; John Widdrington; George Koshy; Thomas Brown; Steven Scott; J Kenneth Baillie; Maya H Buch; Lucy C Chappell; Jeremy N Day; Saul N Faust; Thomas Jaki; Katie Jeffery; Edmund Juszczak; Wei Shen Lim; Alan Montgomery; Andrew Mumford; Kathryn Rowan; Guy Thwaites; Marion Mafham; David Roberts; Richard Haynes; Martin J Landray,"Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; University of Leicester, Leicester, United Kingdom; Basildon and Thurrock Hospitals NHS Foundation Trust, Basildon, United Kingdom; North Cumbria Integrated Care NHS Foundation Trust, Carlisle, United Kingdom; Barts Health NHS Foundation Trust, London, United Kingdom; North Tees and Hartlepool NHS Foundation Trust, Hartlepool, United Kingdom; North Manchester General Hospital, Pennine Acute Hospitals NHS Trust, Bury, United Kingdom; Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United Kingdom; North West Anglia NHS Foundation Trust, Peterborough, United Kingdom; Portsmouth Hospitals NHS Foundation Trust, Portsmouth, United Kingdom; Countess of Chester Hospital, Chester, United Kingdom; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; School of Life Sciences, Kings College London, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Respiratory Medicine Department, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Intensive Care National Audit and Research Centre, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","BackgroundTreatment of COVID-19 patients with plasma containing anti-SARS-CoV-2 antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the safety and efficacy of convalescent plasma in patients admitted to hospital with COVID-19.

MethodsIn this randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) several possible treatments are being compared with usual care in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated to receive either usual care plus high titre convalescent plasma or usual care alone. The primary outcome was 28-day mortality.

FindingsBetween 28 May 2020 and 15 January 2021, 5795 patients were randomly allocated to receive convalescent plasma and 5763 to usual care alone. There was no significant difference in 28-day mortality between the two groups: 1398 (24%) of 5795 patients allocated convalescent plasma and 1408 (24%) of 5763 patients allocated usual care died within 28 days (rate ratio [RR] 1{middle dot}00; 95% confidence interval [CI] 0{middle dot}93 to 1{middle dot}07; p=0{middle dot}93). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (66% vs. 67%; rate ratio 0{middle dot}98; 95% CI 0{middle dot}94-1{middle dot}03, p=0{middle dot}50). Among those not on invasive mechanical ventilation at baseline, there was no significant difference in the proportion meeting the composite endpoint of progression to invasive mechanical ventilation or death (28% vs. 29%; rate ratio 0{middle dot}99; 95% CI 0{middle dot}93-1{middle dot}05, p=0{middle dot}79).

InterpretationAmong patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes.

FundingUK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant refs: MC_PC_19056; COV19-RECPLA).",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.04.21252921,2021-03-08,https://medrxiv.org/cgi/content/short/2021.03.04.21252921,A systematic review and meta-analysis of longitudinal cohort studies comparing mental health before versus during the COVID-19 pandemic,Eric Robinson; Angelina R Sutin; Michael Daly; Andrew Jones,University of Liverpool; Florida State University; Maynooth University; University of Liverpool,"BackgroundIncreases in mental health problems have been observed in some studies during the COVID-19 pandemic. It is unclear whether changes have been large and experienced by most population sub-groups, persisted over time or been symptom specific.

MethodsWe systematically reviewed and meta-analysed longitudinal cohort studies that examined changes in mental health among the same group of participants before and during the pandemic (PROSPERO: CRD42021231256). Searches for published and unpublished studies were conducted in January 2021. Changes in mental health (standardised mean change; SMC) were examined using meta-analyses.

FindingsSixty-five studies were included. There was an overall increase in mental health symptoms that was most pronounced during March-April 2020 (SMC = .102 [95% CI: .026 to .192], p = 0.03) before significantly declining over time (May-July SMC = .067 [95% CI: -.022 to .157], p = .141). Compared to measures of anxiety (SMC = 0.13, p = 0.02) and general mental health (SMC = -.03, p = 0.65), increases in depression and mood disorder symptoms tended to be larger (SMC = 0.22, p < .001) and reductions over time appeared less pronounced. Increased mental health symptoms were observed across most population subgroups examined but there was no evidence of any change in symptoms among samples with a pre-existing mental health condition.

InterpretationThere was a small increase in mental health symptoms soon after the outbreak of the COVID-19 pandemic that decreased and was comparable to pre-pandemic levels by mid-2020 among most population sub-groups and symptom types.

FundingN/A

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSThere have been reported increases in mental health problems during the outbreak of the COVID-19 pandemic. However, it is unclear whether changes in mental health problems have been symptom specific, how changes have differed across populations and whether increased mental health problems have persisted over time. We systematically reviewed and meta-analysed longitudinal cohort studies that examined mental health among the same participants prior to and during the pandemic in 2020. This approach allowed us to quantify the mental health burden associated with the outbreak of the pandemic and how it has changed over time. We searched Pubmed, SCOPUS, Web of Science and PsychInfo from January 2020 to January 11, 2021 and identified eligible unpublished articles available on pre-print servers.

Added value of this studyWe identified 65 eligible articles that reported 201 comparisons of mental health pre vs. post pandemic outbreak. Meta-analysis indicated that longitudinal cohort studies that examined mental health prior to and during the COVID-19 pandemic in 2020 showed a significant but statistically small increase in mental health symptoms. The overall increase in mental health symptoms was most pronounced during the early stages of the pandemic (March-April), before decreasing and being generally comparable to pre-pandemic levels by mid-2020.

Compared to anxiety and general measures of mental health functioning, increases tended to be larger in depressive symptoms and although statistically small, remained elevated past the early stages of the pandemic. Increases in mental health symptoms were observed across most population sub-groups, but there was no evidence of a change in mental health symptoms among samples of participants with a pre-existing mental health condition.

Implications of all the available evidenceFindings confirm that the initial outbreak of the pandemic was associated with a significant but statistically small increase in mental health symptoms. Given that small effects may have meaningful cumulative consequences at the population level, there is a need for continued mental health provision and monitoring particularly during periods of the pandemic when infection rates and deaths are high. Further into the pandemic, mental health problems decreased significantly, which indicated recovery and resilience in overall mental health. Contrary to predictions made early in the pandemic, there was also no evidence of a worsening of mental health symptoms among samples of participants with a pre-existing mental health condition. Overall the results of the present analyses suggest that the pandemic may not have caused an unprecedented and long lasting mental health crisis, instead there appears to have been resilience in mental health.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2021.03.04.21252918,2021-03-08,https://medrxiv.org/cgi/content/short/2021.03.04.21252918,An increase in willingness to vaccinate against COVID-19 in the US between October 2020 and February 2021: longitudinal evidence from the Understanding America Study,Michael Daly; Andrew Jones; Eric Robinson,Maynooth University; University of Liverpool; University of Liverpool,"BackgroundRecent evidence suggests that willingness to vaccinate against COVID-19 has been declining throughout the pandemic and is low among ethnic minority groups.

MethodsObservational study using a nationally representative longitudinal sample (N =7,840) from the Understanding America Study (UAS). Changes in the percentage of respondents willing to vaccinate, undecided, or intending to refuse a COVID-19 vaccine were examined over 20 survey waves from April 1 2020 to February 15 2021.

ResultsAfter a sharp decline in willingness to vaccinate against COVID-19 between April and October 2020 (from 74.0% to 52.7%), willingness to vaccinate increased by 8.1% (p <.001) to 60.8% between October 2020 and February 2021. A significant increase in willingness to vaccinate was observed across all demographic groups examined and Black (15.6% increase) and Hispanic participants (12.1% increase) showed particularly large changes.

ConclusionsWillingness to vaccinate against COVID-19 increased in the US from October 2020 to February 2021.

Funding statementN/A",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.03.04.21252931,2021-03-08,https://medrxiv.org/cgi/content/short/2021.03.04.21252931,A common TMPRSS2 variant protects against severe COVID-19,"Alessia David; Nicholas Parkinson; Thomas P Peacock; Erola Pairo-Castineira; Tarun Khanna; Aurelie Cobat; Albert Tenesa; Vanessa Sancho-Shimizu; - GenOMICC Investigators, ISARIC4C Investigators; Jean-Laurent Casanova; Laurent Abel; Wendy S Barclay; J Kenneth Baillie; Michael J.E. Sternberg","Centre for Integrative System Biology and Bioinformatics, Imperial College London, London; Roslin Institute, University of Edinburgh; Department of Infectious Diseases, Imperial College London; Roslin Institute, University of Edinburgh; Centre for Integrative System Biology and Bioinformatics, Imperial College London; Laboratory of Human Genetics of Infectious Diseases, INSERM; Roslin Institute, University of Edinburgh; Department of Paediatric Infectious Diseases & Virology, Imperial College London; ; St. Giles Laboratory of Human Genetics of Infectious Diseases, The Rockefeller University; Laboratory of Human Genetics of Infectious Diseases, INSERM; Department of Infectious Diseases, Imperial College London; Roslin Institute, University of Edinburgh; Centre for Integrative System Biology and Bioinformatics, Imperial College London","Infection with SARS-CoV-2 has a wide range of clinical presentations, from asymptomatic to life-threatening. Old age is the strongest factor associated with increased COVID19-related mortality, followed by sex and pre-existing conditions. The importance of genetic and immunological factors on COVID19 outcome is also starting to emerge, as demonstrated by population studies and the discovery of damaging variants in genes controlling type I IFN immunity and of autoantibodies that neutralize type I IFNs. The human protein transmembrane protease serine type 2 (TMPRSS2) plays a key role in SARS-CoV-2 infection, as it is required to activate the virus spike protein, facilitating entry into target cells. We focused on the only common TMPRSS2 non-synonymous variant predicted to be damaging (rs12329760), which has a minor allele frequency of [~]25% in the population. In a large population of SARS-CoV-2 positive patients, we show that this variant is associated with a reduced likelihood of developing severe COVID19 (OR 0.87, 95%CI:0.79-0.97, p=0.01). This association was stronger in homozygous individuals when compared to the general population (OR 0.65, 95%CI:0.50-0.84, p=1.3x10-3). We demonstrate in vitro that this variant, which causes the amino acid substitution valine to methionine, impacts the catalytic activity of TMPRSS2 and is less able to support SARS-CoV-2 spike-mediated entry into cells.

TMPRSS2 rs12329760 is a common variant associated with a significantly decreased risk of severe COVID19. Further studies are needed to assess the expression of the TMPRSS2 across different age groups. Moreover, our results identify TMPRSS2 as a promising drug target, with a potential role for camostat mesilate, a drug approved for the treatment of chronic pancreatitis and postoperative reflux esophagitis, in the treatment of COVID19. Clinical trials are needed to confirm this.",genetic and genomic medicine,fuzzy,100,100
medRxiv,10.1101/2021.03.04.21252528,2021-03-08,https://medrxiv.org/cgi/content/short/2021.03.04.21252528,Case fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England,Daniel J Grint; Kevin Wing; Elizabeth Williamson; Helen I McDonald; Krishnan Bhaskaran; David Evans; Stephen JW Evans; Alex J Walker; George Hickman; Emily Nightingale; Anna Schultze; Christopher T Rentsch; Chris Bates; Jonathan Cockburn; Helen J Curtis; Caroline E Morton; Sebastian Bacon; Simon Davy; Angel YS Wong; Amir Mehrkar; Laurie Tomlinson; Ian J Douglas; Rohini Mathur; Paula Blomquist; Brian MacKenna; Peter Ingelsby; Richard Croker; John Parry; Frank Hester; Sam Harper; Nicolas J DeVito; Will Hulme; John Tazare; Ben Goldacre; Liam Smeeth; Rosalind M Eggo,"Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; COVID-19 Outbreak Surveillance Team, Public Health England, London, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, UK; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK; Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, UK",The B.1.1.7 variant of concern (VOC) is increasing in prevalence across Europe. Accurate estimation of disease severity associated with this VOC is critical for pandemic planning. We found increased risk of death for VOC compared with non-VOC cases in England (HR: 1.67 (95% CI: 1.34 - 2.09; P<.0001). Absolute risk of death by 28-days increased with age and comorbidities. VOC has potential to spread faster with higher mortality than the pandemic to date.,infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.08.21253112,2021-03-08,https://medrxiv.org/cgi/content/short/2021.03.08.21253112,OpenSAFELY: Risks of COVID-19 hospital admission and death for people with learning disabilities - a cohort study.,Elizabeth Williamson; Helen I McDonald; Krishnan Bhaskaran; Alex J Walker; Sebastian Bacon; Simon Davy; Anna Schultze; Laurie Tomlinson; Chris Bates; Mary Ramsay; Helen J Curtis; Harriet Forbes; Kevin Wing; Caroline Minassian; John Tazare; Caroline E Morton; Emily Nightingale; Amir Mehrkar; Dave Evans; Peter Inglesby; Brian MacKenna; Jonathan Cockburn; Christopher T Rentsch; Rohini Mathur; Angel Wong; Rosalind M Eggo; William J Hulme; Richard Croker; John Parry; Frank Hester; Sam Harper; Ian Douglas; Stephen JW Evans; Liam Smeeth; Ben Goldacre; Hannah Kuper,"London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; NIHR Health Protection Research Unit (HPRU) in Immunisation; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; Public Health England, London; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT","ObjectivesTo assess the association between learning disability and risk of hospitalisation and mortality from COVID-19 in England among adults and children.

DesignWorking on behalf of NHS England, two cohort studies using patient-level data for >17 million people from primary care electronic health records were linked with death data from the Office for National Statistics and hospitalization data from NHS Secondary Uses Service using the OpenSAFELY platform.

SettingGeneral practices in England which use TPP software.

ParticipantsParticipants were males and females, aged up to 105 years, from two cohorts: (1) wave 1, registered with a TPP practice as of 1st March 2020 and followed until 31st August, 2020; (2) wave 2 registered 1st September 2020 and followed until 31st December 2020 (for admissions) or 8th February 2021 (for deaths). The main exposure group was people included on a general practice learning disability register (LDR), with a subgroup of people classified as having profound or severe learning disability. We also identified patients with Down syndrome and cerebral palsy (whether or not on the learning disability register).

Main outcome measures(i) COVID-19 related death, (ii) COVID-19 related hospitalisation. Non-COVID-19 related death was also explored.

ResultsIn wave 1, of 14,301,415 included individuals aged 16 and over, 90,095 (0.63%) were identified as being on the LDR. 30,173 COVID-related hospital admissions, 13,919 COVID-19 related deaths and 69,803 non-COVID deaths occurred; of which 538 (1.8%), 221 (1.6%) and 596 (0.85%) were among individuals on the LDR, respectively. In wave 2, 27,611 COVID-related hospital admissions, 17,933 COVID-19 related deaths and 54,171 non-COVID deaths occurred; of which 383 (1.4%), 260 (1.4%) and 470 (0.87%) were among individuals on the LDR. Wave 1 hazard ratios for individuals on the LDR, adjusted for age, sex, ethnicity and geographical location, were 5.3 (95% confidence interval (CI) 4.9, 5.8) for COVID-19 related hospital admissions and 8.2 (95% CI: 7.1, 9.4) for COVID-19 related death. Wave 2 produced similar estimates. Associations were stronger among those classed as severe-profound and among those in residential care. Down syndrome and cerebral palsy were associated with increased hazard of both events in both waves; Down syndrome to a much greater extent. Hazards of non-COVID-19 related death followed similar patterns with weaker associations.

ConclusionsPeople with learning disabilities have markedly increased risks of hospitalisation and mortality from COVID-19. This raised risk is over and above that seen for non-COVID causes of death. Ensuring prompt access to Covid-19 testing and health care and consideration of prioritisation for COVID-19 vaccination and other targeted preventive measures are warranted.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.03.21252856,2021-03-06,https://medrxiv.org/cgi/content/short/2021.03.03.21252856,REACT-1 round 9 final report: Continued but slowing decline of prevalence of SARS-CoV-2 during national lockdown in England in February 2021,Steven Riley; Caroline E. Walters; Haowei Wang; Oliver Eales; David Haw; Kylie E. C. Ainslie; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear","BackgroundEngland will start to exit its third national lockdown in response to the COVID-19 pandemic on 8th March 2021, with safe effective vaccines being rolled out rapidly against a background of emerging transmissible and immunologically novel variants of SARS-CoV-2. A subsequent increase in community prevalence of infection could delay further relaxation of lockdown if vaccine uptake and efficacy are not sufficiently high to prevent increased pressure on healthcare services.

MethodsThe PCR self-swab arm of the REal-time Assessment of Community Transmission Study (REACT-1) estimates community prevalence of SARS-CoV-2 infection in England based on random cross-sections of the population ages five and over. Here, we present results from the complete round 9 of REACT-1 comprising round 9a in which swabs were collected from 4th to 12th February 2021 and round 9b from 13th to 23rd February 2021. We also compare the results of REACT-1 round 9 to round 8, in which swabs were collected mainly from 6th January to 22nd January 2021.

ResultsOut of 165,456 results for round 9 overall, 689 were positive. Overall weighted prevalence of infection in the community in England was 0.49% (0.44%, 0.55%), representing a fall of over two thirds from round 8. However the rate of decline of the epidemic has slowed from 15 (13, 17) days, estimated for the period from the end of round 8 to the start of round 9, to 31 days estimated using data from round 9 alone (lower confidence limit 17 days). When comparing round 9a to 9b there were apparent falls in four regions, no apparent change in one region and apparent rises in four regions, including London where there was a suggestion of sub-regional heterogeneity in growth and decline. Smoothed prevalence maps suggest large contiguous areas of growth and decline that do not align with administrative regions.

Prevalence fell by 50% or more across all age groups in round 9 compared to round 8, with prevalence (round 9) ranging from 0.21% in those aged 65 and over to 0.71% in those aged 13 to 17 years. Round 9 prevalence was highest among Pakistani participants at 2.1% compared to white participants at 0.45% and Black participants at 0.83%. There were higher adjusted odds of infection for healthcare and care home workers, for those working in public transport and those working in education, school, nursery or childcare and lower adjusted odds for those not required to work outside the home.

ConclusionsCommunity prevalence of swab-positivity has declined markedly between January and February 2021 during lockdown in England, but remains high; the rate of decline has slowed in the most recent period, with a suggestion of pockets of growth. Continued adherence to social distancing and public health measures is required so that infection rates fall to much lower levels. This will help to ensure that the benefits of the vaccination roll-out programme in England are fully realised.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.03.02.21252444,2021-03-03,https://medrxiv.org/cgi/content/short/2021.03.02.21252444,An overview of the National COVID-19 Chest Imaging Database: data quality and cohort analysis,Dominic Cushnan; Oscar Bennett; Rosalind Berka; Ottavia Bertolli; Ashwin Chopra; Samie Dorgham; Alberto Favaro; Tara Ganepola; Mark Halling-Brown; Gergely Imreh; Joseph Jacob; Emily Jefferson; Fran√ßois Lemarchand; Daniel Schofield; Jeremy C Wyatt; - NCCID Collaborative,"AI Lab, NHSX, London, UK; Faculty, London, UK; Faculty, London, UK; Faculty, London, UK; Faculty, London, UK; Faculty, London, UK; Faculty, London, UK; Faculty, London, UK; Scientific Computing, Royal Surrey NHS Foundation Trust, Guildford, UK; Faculty, London, UK; Centre for Medical Image Computing, University College London, London, UK; Health Informatics Centre (HIC), School of Medicine, University of Dundee, UK; AI Lab, NHSX, London, UK; AI Lab, NHSX, London, UK; University of Southampton, Southampton, UK; ","The National COVID-19 Chest Imaging Database (NCCID) is a centralised database containing chest X-rays, chest Computed Tomography (CT) scans and cardiac Magnetic Resonance Images (MRI) from patients across the UK, jointly established by NHSX, the British Society of Thoracic Imaging (BSTI), Royal Surrey NHS Foundation Trust (RSNFT) and Faculty. The objective of the initiative is to support a better understanding of the coronavirus SARS-CoV-2 disease (COVID-19) and development of machine learning (ML) technologies that will improve care for patients hospitalised with a severe COVID-19 infection. The NCCID is now accumulating data from 20 NHS Trusts and Health Boards across England and Wales, with a total contribution of approximately 25,000 imaging studies in the training set (at time of writing) and is actively being used as a research tool by several organisations. This paper introduces the training dataset, including a snapshot analysis performed by NHSX covering: the completeness of clinical data, the availability of image data for the various use-cases (diagnosis, prognosis and longitudinal risk) and potential model confounders within the imaging data. The aim is to inform both existing and potential data users of the NCCIDs suitability for developing diagnostic/prognostic models. In addition, a cohort analysis was performed to measure the representativeness of the NCCID to the wider COVID-19 affected population. Three major aspects were included: geographic, demographic and temporal coverage, revealing good alignment in some categories, e.g., sex and identifying areas for improvements to data collection methods, particularly with respect to geographic coverage. All analyses and discussions are focused on the implications for building ML tools that will generalise well to the clinical use cases.",radiology and imaging,fuzzy,100,100
medRxiv,10.1101/2021.03.02.21252734,2021-03-03,https://medrxiv.org/cgi/content/short/2021.03.02.21252734,Relation of severe COVID-19 in Scotland to transmission-related factors and risk conditions eligible for shielding support: REACT-SCOT case-control study,Paul M McKeigue; David McAllister; David Caldwell; Ciara Gribben; Jen Bishop; Stuart J McGurnaghan; Matthew Armstrong; Joke Delvaux; Sam Colville; Sharon Hutchinson; Chris Robertson; Nazir Lone; Jim McMenamin; David Goldberg; Helen M Colhoun,University of Edinburgh; University of Glasgow; Public Health Scotland; Public Health Scotland; Public Health Scotland; University of Edinburgh; Public Health Scotland; Public Health Scotland; Public Health Scotland; Glasgow Caledonian University; Public Health Scotland; Strathclyde University; Public Health Scotland; University of Edinburgh; Public Health Scotland; Public Health Scotland; University of Edinburgh,"BackgroundClinically vulnerable individuals have been advised to shield themselves during the COVID-19 epidemic. The objectives of this study were to investigate: (1) the risk of severe COVID-19 in those eligible for shielding, and (2) the relation of severe COVID-19 to transmission-related factors in those in shielding and the general population.

MethodsAll 178578 diagnosed cases of COVID-19 in Scotland from 1 March 2020 to 18 February 2021 were matched for age, sex and primary care practice to 1744283 controls from the general population. This dataset (REACT-SCOT) was linked to the list of 212702 individuals identified as eligible for shielding. Severe COVID-19 was defined as cases that entered critical care or were fatal.

ResultsWith those without risk conditions as reference category, the univariate rate ratio for severe COVID-19 was 3.21 (95% CI 3.01 to 3.41) in those with moderate risk conditions and 6.3 (95% CI 5.8 to 6.8) in those eligible for shielding. The highest rate was in solid organ transplant recipients: rate ratio 13.4 (95% CI 9.6 to 18.8). Risk of severe COVID-19 increased with the number of adults but decreased with the number of school-age children in the household. Severe COVID-19 was strongly associated with recent exposure to hospital (defined as 5 to 14 days before presentation date): rate ratio 12.3 (95% CI 11.5 to 13.2) overall. To test for causality, a case-crossover analysis was undertaken; with less recent exposure only (15 to 24 days before first testing positive) as reference category, the rate ratio associated with recent exposure only was 5.9 (95% CI 3.6 to 9.7). The population attributable risk fraction for recent exposure to hospital peaked at 50% in May 2020 and again at 65% in December 2020.

ConclusionsThe effectiveness of shielding vulnerable individuals was limited by the inability to control transmission in hospital and from other adults in the household. For solid organ transplant recipients, in whom the efficacy of vaccines is uncertain, these results support a policy of offering vaccination to household contacts. Mitigating the impact of the epidemic requires control of nosocomial transmission.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.02.27.21252593,2021-03-01,https://medrxiv.org/cgi/content/short/2021.02.27.21252593,Surgical activity in England and Wales during the COVID-19 pandemic: a nationwide observational cohort study,Thomas D Dobbs; John A G Gibson; Alexander J Fowler; Tom E Abbott; Tasnin Shahid; Fatemeh Torabi; Rowena Griffiths; Ronan A Lyons; Rupert M Pearse; Iain S Whitaker,"Swansea University Medical School; Swansea University Medical School; Queen Mary, University of London; Queen Mary University of London; Queen Mary University of London; Swansea University; Swansea University; Swansea University; Queen Mary University of London; Swansea University Medical School","ObjectivesTo report the volume of surgical activity and the number of cancelled surgical procedures during the COVID-19 pandemic.

Design and settingAnalysis of electronic health record data from the National Health Service (NHS) in England and Wales.

MethodsWe used hospital episode statistics for all adult patients undergoing surgery between 1st January 2020 and 31st December 2020. We identified surgical procedures using a previously published list of procedure codes. Procedures were stratified by urgency of surgery as defined by NHS England. We calculated the deficit of surgical activity by comparing the expected number of procedures from the years 2016-2019 with the actual number of procedures in 2020. We estimated the cumulative number of cancelled procedures by 31st December 2021 according patterns of activity in 2020.

ResultsThe total number of surgical procedures carried out in England and Wales in 2020 was 3,102,674 compared to the predicted number of 4,671,338. This represents a 33.6% reduction in the national volume of surgical activity. There were 763,730 emergency surgical procedures (13.4% reduction), compared to 2,338,944 elective surgical procedures (38.6% reduction). The cumulative number of cancelled or postponed procedures was 1,568,664. We estimate that this will increase to 2,358,420 by 31st December 2021.

ConclusionsThe volume of surgical activity in England and Wales was reduced by 33.6% in 2020, resulting in over 1,568,664 cancelled operations. This deficit will continue to grow in 2021.

Summary boxesO_ST_ABSWhat is already known on this topicC_ST_ABSO_LIThe COVID-19 pandemic necessitated a rapid change in the provision of care, including the suspension of a large proportion of surgical activity
C_LIO_LISurgical activity has yet to return to normal and has been further impacted by subsequent waves of the pandemic
C_LIO_LIThis will lead to a large backlog of cases
C_LI

What this study addsO_LI3,102,674 surgical procedures were performed in England and Wales during 2020, a 33.6% reduction on the expected yearly surgical activity
C_LIO_LIOver 1.5 million procedures were not performed, with this deficit likely to continue to grow to 2.3 million by the end of 2021
C_LIO_LIThis deficit is the equivalent of more than 6 months of pre-pandemic surgical activity, requiring a monumental financial and logistic challenge to manage
C_LI",surgery,fuzzy,100,100
medRxiv,10.1101/2021.02.26.21252512,2021-03-01,https://medrxiv.org/cgi/content/short/2021.02.26.21252512,REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England,Helen Ward Professor; Graham Cooke Professor; Matthew Whitaker Mr; Rozlyn Redd Dr; Oliver Eales Mr; Jonathan Brown Mr; Katharine Collet Ms; Emily Cooper Ms; Daunt Anna Dr; Jones Kathryn Dr; Moshe Maya Ms; Michelle Willicombe Dr; Sophie Day Professor; Christina Atchison Dr; Ara Darzi Professor; Christl A Donnelly Professor; Steven Riley Professor; Deborah Ashby Professor; Wendy S Barclay Professor; Paul Elliott Professor,Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London,"BackgroundEngland has experienced high rates of SARS-CoV-2 infection during the COVID-19 pandemic, affecting in particular minority ethnic groups and more deprived communities. A vaccination programme began in England in December 2020, with priority given to administering the first dose to the largest number of older individuals, healthcare and care home workers.

MethodsA cross-sectional community survey in England undertaken between 26 January and 8 February 2021 as the fifth round of the REal-time Assessment of Community Transmission-2 (REACT-2) programme. Participants completed questionnaires, including demographic details and clinical and COVID-19 vaccination histories, and self-administered a lateral flow immunoassay (LFIA) test to detect IgG against SARS-CoV-2 spike protein. There were sufficient numbers of participants to analyse antibody positivity after 21 days from vaccination with the PfizerBioNTech but not the AstraZeneca/Oxford vaccine which was introduced slightly later.

ResultsThe survey comprised 172,099 people, with valid IgG antibody results from 155,172. The overall prevalence of antibodies (weighted to be representative of the population of England and adjusted for test sensitivity and specificity) in England was 13.9% (95% CI 13.7, 14.1) overall, 37.9% (37.2, 38.7) in vaccinated and 9.8% (9.6, 10.0) in unvaccinated people. The prevalence of antibodies (weighted) in unvaccinated people was highest in London at 16.9% (16.3, 17.5), and higher in people of Black (22.4%, 20.8, 24.1) and Asian (20.0%, 19.0, 21.0) ethnicity compared to white (8.5%, 8.3, 8.7) people. The uptake of vaccination by age was highest in those aged 80 years or older (93.5%). Vaccine confidence was high with 92.0% (91.9, 92.1) of people saying that they had accepted or intended to accept the offer. Vaccine confidence varied by age and ethnicity, with lower confidence in young people and those of Black ethnicity. Particular concerns were identified around pregnancy, fertility and allergies. In 971 individuals who received two doses of the Pfizer-BioNTech vaccine, the proportion testing positive was high across all age groups. Following a single dose of Pfizer-BioNTech vaccine after 21 days or more, 84.1% (82.2, 85.9) of people under 60 years tested positive (unadjusted) with a decreasing trend with increasing age, but high responses to a single dose in those with confirmed or suspected prior COVID at 90.1% (87.2, 92.4) across all age groups.

ConclusionsThere is uneven distribution of SARS-CoV-2 antibodies in the population with a higher burden in key workers and some minority ethnic groups, similar to the pattern in the first wave. Confidence in the vaccine programme is high overall although it was lower in some of the higher prevalence groups which suggests the need for improved communication about specific perceived risks. Two doses of Pfizer-BioNTech vaccine, or a single dose following previous infection, confers high levels of antibody positivity across all ages. Further work is needed to understand the relationship between antibody positivity, clinical outcomes such as hospitalisation, and transmission.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.02.25.21252433,2021-03-01,https://medrxiv.org/cgi/content/short/2021.02.25.21252433,Predicting COVID-19 related death using the OpenSAFELY platform,Elizabeth J Williamson; John Tazare; Krishnan Bhaskaran; Helen I McDonald; Alex J Walker; Laurie Tomlinson; Kevin Wing; Sebastian Bacon; Chris Bates; Helen J Curtis; Harriet Forbes; Caroline Minassian; Caroline E Morton; Emily Nightingale; Amir Mehrkar; Dave Evans; Brian D Nicholson; Dave Leon; Peter Inglesby; Brian MacKenna; Nicholas G Davies; Nicholas J DeVito; Henry Drysdale; Jonathan Cockburn; William J Hulme; Jessica Morley; Ian Douglas; Christopher T Rentsch; Rohini Mathur; Angel Wong; Anna Schultze; Richard Croker; John Parry; Frank Hester; Sam Harper; Richard Grieve; David A Harrison; Ewout W Steyerberg; Rosalind M Eggo; Karla Diaz-Ordaz; Ruth Keogh; Stephen JW Evans; Liam Smeeth; Ben Goldacre,"London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; NIHR Health Protection Research Unit (HPRU) in Immunisation; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; TPP, TPP House, 129 Low Lane, Horsforth, Leeds, LS18 5PX; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; Intensive Care National Audit & Research Centre (ICNARC), 24 High Holborn, Holborn, London WC1V 6AZ; Leiden University Medical Center, Leiden, the Netherlands; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; London School of Hygiene & Tropical Medicine, Keppel Street, WC1E 7HT; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, OX26GG","ObjectivesTo compare approaches for obtaining relative and absolute estimates of risk of 28-day COVID-19 mortality for adults in the general population of England in the context of changing levels of circulating infection.

DesignThree designs were compared. (A) case-cohort which does not explicitly account for the time-changing prevalence of COVID-19 infection, (B) 28-day landmarking, a series of sequential overlapping sub-studies incorporating time-updating proxy measures of the prevalence of infection, and (C) daily landmarking. Regression models were fitted to predict 28-day COVID-19 mortality.

SettingWorking on behalf of NHS England, we used clinical data from adult patients from all regions of England held in the TPP SystmOne electronic health record system, linked to Office for National Statistics (ONS) mortality data, using the OpenSAFELY platform.

ParticipantsEligible participants were adults aged 18 or over, registered at a general practice using TPP software on 1st March 2020 with recorded sex, postcode and ethnicity. 11,972,947 individuals were included, and 7,999 participants experienced a COVID-19 related death. The study period lasted 100 days, ending 8th June 2020.

PredictorsA range of demographic characteristics and comorbidities were used as potential predictors. Local infection prevalence was estimated with three proxies: modelled based on local prevalence and other key factors; rate of A&E COVID-19 related attendances; and rate of suspected COVID-19 cases in primary care.

Main outcome measuresCOVID-19 related death.

ResultsAll models discriminated well between patients who did and did not experience COVID-19 related death, with C-statistics ranging from 0.92-0.94. Accurate estimates of absolute risk required data on local infection prevalence, with modelled estimates providing the best performance.

ConclusionsReliable estimates of absolute risk need to incorporate changing local prevalence of infection. Simple models can provide very good discrimination and may simplify implementation of risk prediction tools in practice.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.02.25.21252402,2021-02-28,https://medrxiv.org/cgi/content/short/2021.02.25.21252402,Racial and ethnic differences in COVID-19 vaccine hesitancy and uptake,Long H. Nguyen; Amit D. Joshi; David A. Drew; Jordi Merino; Wenjie Ma; Sohee Kwon; Kai Wang; Mark S. Graham; Lorenzo Polidori; Cristina Menni; Carole H. Sudre; Adjoa Anyane-Yeboa; Christina M. Astley; Erica T. Warner; Christina Hu; Somesh Selvachandran; Richard Davies; Denis Nash; Paul W. Franks; Jonathhan Wolf; Sebastien Ourselin; Claire J Steves; Tim D. Spector; Andrew T. Chan; - COPE Consortium,Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; King's College London; Zoe Global Ltd.; King's College London; King's College London; Massachusetts General Hospital and Harvard Medical School; Broad Institute of MIT and Harvard; Massachusetts General Hospital and Harvard Medical School; Zoe Global Ltd.; Zoe Global Ltd.; Zoe Global Ltd.; City University of New York; Lund University; Zoe Global Ltd.; King's College London; King's College London; King's College London; Massachusetts General Hospital and Harvard Medical School; ,"BackgroundRacial and ethnic minorities have been disproportionately impacted by COVID-19. In the initial phase of population-based vaccination in the United States (U.S.) and United Kingdom (U.K.), vaccine hesitancy and limited access may result in disparities in uptake.

MethodsWe performed a cohort study among U.S. and U.K. participants in the smartphone-based COVID Symptom Study (March 24, 2020-February 16, 2021). We used logistic regression to estimate odds ratios (ORs) of COVID-19 vaccine hesitancy (unsure/not willing) and receipt.

ResultsIn the U.S. (n=87,388), compared to White non-Hispanic participants, the multivariable ORs of vaccine hesitancy were 3.15 (95% CI: 2.86 to 3.47) for Black participants, 1.42 (1.28 to 1.58) for Hispanic participants, 1.34 (1.18 to 1.52) for Asian participants, and 2.02 (1.70 to 2.39) for participants reporting more than one race/other. In the U.K. (n=1,254,294), racial and ethnic minorities had similarly elevated hesitancy: compared to White participants, their corresponding ORs were 2.84 (95% CI: 2.69 to 2.99) for Black participants, 1.66 (1.57 to 1.76) for South Asian participants, 1.84 (1.70 to 1.98) for Middle East/East Asian participants, and 1.48 (1.39 to 1.57) for participants reporting more than one race/other. Among U.S. participants, the OR of vaccine receipt was 0.71 (0.64 to 0.79) for Black participants, a disparity that persisted among individuals who specifically endorsed a willingness to obtain a vaccine. In contrast, disparities in uptake were not observed in the U.K.

ConclusionsCOVID-19 vaccine hesitancy was greater among racial and ethnic minorities, and Black participants living in the U.S. were less likely to receive a vaccine than White participants. Lower uptake among Black participants in the U.S. during the initial vaccine rollout is attributable to both hesitancy and disparities in access.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.02.23.21251975,2021-02-25,https://medrxiv.org/cgi/content/short/2021.02.23.21251975,The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers (UK-REACH): Protocol for a prospective longitudinal cohort study of healthcare and ancillary workers in UK healthcare settings,Katherine Woolf; Carl Melbourne; Luke Bryant; Anna Louise Guyatt; Ian Christopher McManus; Amit Gupta; Robert C Free; Laura Nellums; Sue Carr; Catherine John; Christopher A Martin; Louise V Wain; Laura J Gray; Claire Garwood; Vishant Modhwadia; Keith Abrams; Martin D Tobin; Kamlesh Khunti; Manish Pareek; - UK-REACH Study Collaborative Group,"University College London; University of Leicester; University of Leicester; University of Leicester; University College London; University Hospitals Oxford NHS Foundation Trust; University of Leicester; University of Nottingham; General Medical Council, University Hospitals Leicester NHS Trust; University of Leicester; University of Leicester; University of Leicester; University of Leicester; University of Leicester; University of Leicester; University of York; University of Leicester; University of Leicester; University of Leicester; ","IntroductionThe COVID-19 pandemic has resulted in significant morbidity and mortality, and has devastated economies in many countries. Amongst the groups identified as being at increased risk from COVID-19 are healthcare workers (HCWs) and ethnic minority groups. Emerging evidence suggests HCWs from ethnic minority groups are at increased risk of adverse COVID-19-related physical and mental health outcomes. To date there has been no large-scale analysis of these risks in UK healthcare workers or ancillary workers in healthcare settings, stratified by ethnicity or occupation type, and adjusted for potential confounders. This paper reports the protocol for a prospective longitudinal questionnaire study of UK HCWs, as part of the UK-REACH programme (The United Kingdom Research study into Ethnicity And COVID-19 outcomes in Healthcare workers).

Methods and analysisA baseline questionnaire with follow-up questionnaires at 4 and 8 months will be administered to a national cohort of UK healthcare workers and ancillary workers in healthcare settings, and those registered with UK healthcare regulators. With consent, data will be linked to health records, and participants followed up for 25 years.

Univariate associations between ethnicity and primary outcome measures (clinical COVID-19 outcomes, and physical and mental health) and key confounders/explanatory variables will be tested, followed by multivariable analyses to test for associations between ethnicity and key outcomes adjusted for the confounder/explanatory variables, with interactions included as appropriate. Using follow-up data, multilevel models will be used to model changes over time by ethnic group, facilitating understanding of absolute and relative risks in different ethnic groups, and generalisability of findings.

Ethics and disseminationThe study is approved by Health Research Authority (reference 20/HRA/4718), and carries minimal risk to participants. We aim to manage the small risk of participant distress due to being asked questions on sensitive topics by clearly indicating on the participant information sheet that the questionnaire covers sensitive topics and that participants are under no obligation to answer these, or indeed any other, questions, and by providing links to support organisations. Results will be disseminated with reports to Government and papers uploaded to pre-print servers and submitted to peer reviewed journals.

Registration detailsTrial ID: ISRCTN11811602

STRENGTHS AND LIMITATIONS OF THIS STUDYO_LINational, UK-wide, study, aiming to capture variety of healthcare worker job roles including ancillary workers in healthcare settings.
C_LIO_LILongitudinal study including three waves of questionnaire data collection, and linkage to administrative data over 25 years, with consent.
C_LIO_LIUnique support from all major UK healthcare worker regulators, relevant healthcare worker organisations, and a Professional Expert Panel to increase participant uptake and the validity of findings.
C_LIO_LIPotential for self-selection bias and low response rates, and the use of electronic invitations and online data collection makes it harder to reach ancillary workers without regular access to work email addresses.
C_LI",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.02.24.21252338,2021-02-25,https://medrxiv.org/cgi/content/short/2021.02.24.21252338,"Health impact and cost-effectiveness of COVID-19 vaccination in Sindh Province, Pakistan",Carl Andrew Pearson; Fiammetta Bozzani; Simon R Procter; Nicholas G Davies; Maryam Huda; Henning Tarp Jensen; Marcus Keogh-Brown; Muhammad Khalid; Sedona Sweeney; Sergio Torres-Rueda; - CHiL COVID-19 Working Group; - CMMID COVID-19 Working Group; Rosalind M Eggo; Anna Vassall; Mark Jit,"London School of Hygiene & Tropical Medicine; Centre for Health Economics in London, London School of Hygiene & Tropical Medicine; Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene & Tropical Medicine;  Centre for Health Economics in London, London School of ; Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene & Tropical Medicine; Aga Khan University Hospital; Centre for Health Economics in London, London School of Hygiene & Tropical Medicine; Centre for Health Economics in London, London School of Hygiene & Tropical Medicine; Ministry of National Health Services Regulations & Coordination, Pakistan; Centre for Health Economics in London, London School of Hygiene & Tropical Medicine; Centre for Health Economics in London, London School of Hygiene & Tropical Medicine; Centre for Health Economics in London, London School of Hygiene & Tropical Medicine; Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene & Tropical Medicine; Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene & Tropical Medicine; Centre for Health Economics in London, London School of Hygiene & Tropical Medicine; Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene & Tropical Medicine;  Centre for Health Economics in London, London School of ","BackgroundMultiple COVID-19 vaccines appear to be safe and efficacious, but only high-income countries have the resources to procure sufficient vaccine doses for most of their eligible populations. The World Health Organization has published guidelines for vaccine prioritisation, but most vaccine impact projections have focused on high-income countries, and few incorporate economic considerations. To address this evidence gap, we projected the health and economic impact of different vaccination scenarios in Sindh province, Pakistan (population: 48 million).

Methods and FindingsWe fitted a compartmental transmission model to COVID-19 cases and deaths in Sindh from 30 April to 15 September 2020. We then projected cases, deaths, and hospitalization outcomes over 10 years under different vaccine scenarios. Finally, we combined these projections with a detailed economic model to estimate incremental costs (from healthcare and partial societal perspectives), disability adjusted life years (DALYs), and incremental cost-effectiveness ratio (ICER) for each scenario.

We project that one-year of vaccine distribution, at delivery rates consistent with COVAX projections, using an infection-blocking vaccine at $3/dose with 70% efficacy and 2.5 year duration of protection is likely to avert around 0.9 (95% Credible Interval: 0.9, 1.0) million cases, 10.1 (95% CrI: 10.1, 10.3) thousand deaths and 70.1 (95% CrI: 69.9, 70.6) thousand DALYs, with an ICER of $27.9 per DALY averted from the health system perspective. Varying these assumptions, we generally find that prioritizing the older (65+) population prevents more deaths, but broad distribution from the outset is economically comparable in many scenarios, and either scheme can be cost-effective for low per-dose costs. However, high vaccine prices ($10/dose) may not be cost-effective.

The principal drivers of the health outcomes are the fitted values for the overall transmission scaling parameter and disease natural history parameters from other studies, particularly age specific probabilities of infection and symptomatic disease, as well as social contact rates. Other parameters are investigated in sensitivity analyses.

These projections are limited by the mechanisms present in the model. Because the model is a single-population compartmental model, detailed impacts of non-pharmaceutical interventions (NPIs) such as household isolation cannot be practically represented or evaluated in combination with vaccine programmes. Similarly, the model cannot consider prioritizing groups like healthcare or other essential workers. Additionally, because the future impact and implementation cost of NPIs is uncertain, how these would interact with vaccination remains an open question.

ConclusionsCOVID-19 vaccination can have a considerable health impact, and is likely to be cost-effective if more optimistic vaccine scenarios apply. Preventing severe disease is an important contributor to this impact, but the advantage of focusing initially on older, high-risk populations may be smaller in generally younger populations where many people have already been infected, typical of many low- and -middle income countries, as long as vaccination gives good protection against infection as well as disease.

Author SummaryO_ST_ABSWhy Was This Study Done?C_ST_ABS- The evidence base for health and economic impact of COVID-19 vaccination in low- and middle-income settings is limited.
- Searching PubMed, medRxiv, and econLit using the search term (""coronavirus"" OR ""covid"" OR ""ncov"") AND (""vaccination"" OR ""immunisation"") AND (""model"" OR ""cost"" OR ""economic"") for full text articles published in any language between 1 January 2020 and 20 January 2021, returned 29 (PubMed), 1,167 (medRxiv) and 0 (econLit) studies: 20 overall were relevant, with only 4 exclusively focused on low- or middle-income countries (India, China, Mexico), while 3 multi-country analyses also included low- or middle-income settings,
- However only three of these studies are considered economic outcomes, all of them comparing the costs of vaccination to the costs of non-pharmaceutical interventions and concluding that both are necessary to reduce infections and maximise economic benefit.
- The majority of studies are set in high-income settings and conclude that targeting COVID-19 vaccination to older age groups is the preferred strategy to minimise mortality, particularly when vaccine supplies are constrained, while other age- or occupational risk groups should be priorities when vaccine availability increases or when other policy objectives are pursued.


What Did the Researchers Do and Find?- We combined epidemiological and economic analysis of COVID-19 vaccination based on real-world disease and programmatic information in the Sindh province of Pakistan.
- We found vaccination in this setting is likely to be highly cost-effective, and even cost saving, as long as the vaccine is reasonably priced and efficacy is high.
- Unlike studies in high-income settings, we also found that vaccination programmes targeting all adults may have almost as much benefit as those initially targeted at older populations, likely reflecting the higher previous infection rates and different demography in these settings.


What Do These Findings Mean?- Lower- and middle-income countries (LMICs) and international bodies providing guidance for LMICs need to consider evidence specific to these settings when making recommendations about COVID-19 vaccination.
- Further data and model-based analyses in such settings are urgently needed in order to ensure that vaccination decisions are appropriate to these contexts.",health economics,fuzzy,100,100
medRxiv,10.1101/2021.02.23.21252276,2021-02-24,https://medrxiv.org/cgi/content/short/2021.02.23.21252276,Inequalities in the decline and recovery of pathological cancer diagnoses during the first six months of the COVID-19 pandemic: a population-based study,Ashleigh C. Hamilton; David W. Donnelly; Maurice B. Loughrey; Richard C. Turkington; Colin Fox; Deirdre Fitzpatrick; Ciaran E. O'Neill; Anna T. Gavin; Helen G. Coleman,"Centre for Public Health, Queen's University Belfast; Northern  Ireland Cancer Registry; Department of Pathology, Belfast Health and Social Care Trust, Northern Ireland; Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast; Northern Ireland Cancer Registry; Northern Ireland Cancer Registry; Northern Ireland Cancer Registry; Northern Ireland Cancer Registry; Centre for Public Health, Queen's University Belfast","BackgroundThe restructuring of healthcare systems to cope with the demands of the COVID-19 pandemic has led to a reduction in clinical services such as cancer screening and diagnostics.

MethodsData from the four Northern Ireland pathology labs was used to assess trends in pathological cancer diagnoses from 1st March to 12th September 2020 overall and by cancer site, gender and age. These trends were compared to the same timeframe from 2017-2019.

ResultsBetween 1st March and 12th September 2020 there was a 23% reduction in cancer diagnoses compared to the same time period in the preceding three years. Although some recovery occurred in August and September 2020, this revealed inequalities across certain patient groups. Pathological diagnoses of lung, prostate and gynaecological malignancies remained well below pre-pandemic levels. Males and younger/middle-aged adults, particularly the 50-59 year old patient group, also lagged behind other population demographic groups in terms of returning to expected numbers of pathological cancer diagnoses.

ConclusionsThere is a critical need to protect cancer diagnostic services in the ongoing pandemic to facilitate timely investigation of potential cancer cases. Targeted public health campaigns may be needed to reduce emerging inequalities in cancer diagnoses as the COVID-19 pandemic continues.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.02.18.21251973,2021-02-23,https://medrxiv.org/cgi/content/short/2021.02.18.21251973,REACT-1 round 9 interim report: downward trend of SARS-CoV-2 in England inFebruary 2021 but still at high prevalence,Steven Riley; Caroline E. Walters; Haowei Wang; Oliver Eales; David Haw; Kylie E. C. Ainslie; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear","Background and MethodsEngland entered its third national lockdown of the COVID-19 pandemic on 6th January 2021 with the aim of reducing the daily number of deaths and pressure on healthcare services. The real-time assessment of community transmission study (REACT-1) obtains throat and nose swabs from randomly selected people in England in order to describe patterns of SARS-CoV-2 prevalence. Here, we report data from round 9a of REACT-1 for swabs collected between 4th and 13th February 2021.

ResultsOut of 85,473 tested-swabs, 378 were positive. Overall weighted prevalence of infection in the community in England was 0.51%, a fall of more than two thirds since our last report (round 8) in January 2021 when 1.57% of people tested positive. We estimate a halving time of 14.6 days and a reproduction number R of 0.72, based on the difference in prevalence between the end of round 8 and the beginning of round 9. Although prevalence fell in all nine regions of England over the same period, there was greater uncertainty in the trend for North West, North East, and Yorkshire and The Humber. Prevalence fell substantially across all age groups with highest prevalence among 18- to 24-year olds at 0.89% (0.47%, 1.67%) and those aged 5 to12 years at 0.86% (0.60%, 1.24%). Large household size, living in a deprived neighbourhood, and Asian ethnicity were all associated with increased prevalence. Healthcare and care home workers were more likely to test positive compared to other workers.

ConclusionsThere is a strong decline in prevalence of SARS-CoV-2 in England among the general population five to six weeks into lockdown, but prevalence remains high: at levels similar to those observed in late September 2020. Also, the number of COVID-19 cases in hospitals is higher than at the peak of the first wave in April 2020. The effects of easing of social distancing when we transition out of lockdown need to be closely monitored to avoid a resurgence in infections and renewed pressure on health services.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.02.17.21251928,2021-02-20,https://medrxiv.org/cgi/content/short/2021.02.17.21251928,Mortality after surgery with SARS-CoV-2 infection in England: A population-wide epidemiological study,Tom EF Abbott; Alexander J Fowler; Tom D Dobbs; John A Gibson; Tasnin Shahid; Priyanthi Dias; Ashley Akbari; Iain Whitaker; Rupert M Pearse,"William Harvey Research Institute, Queen Mary University of London, UK, EC1M 6BQ; William Harvey Research Institute, Queen Mary University of London, UK, EC1M 6BQ; Reconstructive and Regenerative Medicine Group (ReconRegen), Institute of Life Sciences, Swansea University Medical School, Swansea, UK; Welsh Centre for Burns and Plastics, Morriston Hospital, Swansea, UK; William Harvey Research Institute, Queen Mary University of London, UK, EC1M 6BQ; William Harvey Research Institute, Queen Mary University of London, UK, EC1M 6BQ; Health Data Research UK, Swansea University Medical School, Swansea, UK.; Reconstructive and Regenerative Medicine Group (ReconRegen), Institute of Life Sciences, Swansea University Medical School, Swansea, UK; William Harvey Research Institute, Queen Mary University of London, UK, EC1M 6BQ","ObjectivesTo confirm the incidence of perioperative SARS-CoV-2 infection and associated mortality after surgery.

Design and settingAnalysis of routine electronic health record data from National Health Service (NHS) hospitals in England.

MethodsWe extracted data from Hospital Episode Statistics in England describing adult patients undergoing surgery between 1st January 2020 and 31st October 2020. The exposure was SARS-CoV-2 infection defined by ICD-10 codes. The primary outcome measure was 90-day in-hospital mortality. Data were analysed using multivariable logistic regression adjusted for age, sex, Charlson co-morbidity index, index of multiple deprivation, presence of cancer, surgical procedure type and admission acuity. Results are presented as n (%) and odds ratios (OR) with 95% confidence intervals.

ResultsWe identified 1,972,153 patients undergoing surgery of whom 11,940 (0.6%) had SARS-CoV-2. In total, 19,100 (1.0%) patients died in hospital. SARS-CoV-2 infection was associated with a much greater risk of death (SARS-CoV-2: 2,618/11,940 [21.9%] vs No SARS-CoV-2: 16,482/1,960,213 [0.8%]; OR: 5.8 [5.5 - 6.1]; p<0.001). Amongst patients undergoing elective surgery 1,030/1,374,985 (0.1%) had SARS-CoV-2 of whom 83/1,030 (8.1%) died, compared with 1,092/1,373,955 (0.1%) patients without SARS-CoV-2 (OR: 29.0 [22.5 -37.3]; p<0.001). Amongst patients undergoing emergency surgery 9,742/437,891 (2.2%) patients had SARS-CoV-2, of whom 2,466/9,742 (25.3%) died compared with 14,817/428,149 (3.5%) patients without SARS-CoV-2 (OR: 5.7 [5.4 - 6.0]; p<0.001).

ConclusionsThe low incidence of SARS-CoV-2 infection in NHS surgical pathways suggests current infection prevention and control policies are highly effective. However, the high mortality amongst patients with SARS-CoV-2 suggests these precautions cannot be safely relaxed.

Summary boxesO_ST_ABSWhat is already known on this topicC_ST_ABSO_LIHigh mortality rates have been reported amongst surgical patients who develop COVID-19 but we dont know how this compares to the concurrent surgical population unaffected by COVID-19.
C_LIO_LIStrict infection prevention and control procedures have substantially reduced the capacity of surgical treatment pathways in many hospitals.
C_LIO_LIThe very large backlog in delayed and cancelled surgical procedures is a growing public health concern.
C_LI

What this study addsO_LIFewer than 1 in 100 surgical patients are affected by COVID-19 in the English National Health Service.
C_LIO_LIElective surgical patients who do develop COVID-19 are 30 times more likely to die while in hospital.
C_LIO_LIInfection prevention and control procedures in NHS surgical pathways are highly effective but cannot be safely relaxed.
C_LI",surgery,fuzzy,100,100
medRxiv,10.1101/2021.02.16.21251853,2021-02-19,https://medrxiv.org/cgi/content/short/2021.02.16.21251853,Mortality in COVID-19 amongst women on Hormone Replacement Therapy or Combined Oral Contraception: A cohort study,Hajira Dambha-Miller; William Hinton; Mark Joy; Michael Feher; Simon de Lusignan,University of Southampton; University of Oxford; University of Surrey; University of Oxford; University of Oxford,"ObjectiveTo investigate the association between Hormone Replacement Therapy (HRT) or Combined Oral Contraception (COCP) use, and the likelihood of death in women with COVID-19.

DesignA cohort study

Setting465 general practices in England within the Oxford-Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) primary care database.

Population1,863,478 women aged over 18 years

MethodsWe identified a cohort of women with COVID-19 from the computerised medical records of the RCGP RSC database. Mixed-effects logistic regression models were used to quantify the association between HRT or COCP use, and all-cause mortality among women with COVID-19 in unadjusted and adjusted models.

ResultsThere were 5451 COVID-19 cases within the cohort. HRT was associated with a significantly lower likelihood of all-cause mortality in COVID-19 (adjusted OR 0.22, 95%{square}CI 0.05 to 0.94). There were no reported events for all-cause mortality in women prescribed COCPs. This prevented further examination of the impact of COCP.

ConclusionsWomen on HRT with COVID-19 had a lower likelihood of death. Further work is needed in larger cohorts to examine the association of COCP in COVID-19. Our findings support the current hypothesis that oestrogens may contribute a protective effect against COVID-19 severity.

FundingThis study was funded by a School for Primary Care National Institute for Health Research grant (SPCR2014-10043).",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.02.15.21251552,2021-02-19,https://medrxiv.org/cgi/content/short/2021.02.15.21251552,Evaluating the effect of COVID-19 on dispensing patterns: a national cohort analysis,Fatemeh Torabi; Ashley Akbari; Laura North; Daniel Harris; Gareth Davies; Mike Gravenor; Rowena Griffiths; Jane Lyons; Neil Jenkins; Andrew Morris; Julian Halcox; Ronan A. Lyons,"Population   Data   Science   and   Health   Data   Research   UK,Swansea University; Population   Data   Science   and   Health   Data   Research   UK,Swansea University; Population   Data   Science   and   Health   Data   Research   UK,Swansea University; Population   Data   Science   and   Health   Data   Research   UK,Swansea University; Population   Data   Science   and   Health   Data   Research   UK,Swansea University; Swansea University; Population   Data   Science   and   Health   Data   Research   UK,Swansea University; Population Data Science and Health Data Research UK, SwanseaUniversity; NHS Wales Shared Services Partnership; Swansea University; Population Data Science and Health Data Research UK, Swansea University; Population Data Science and Health Data Research UK, Swansea University","BackgroundMedication prescribing and dispensing often regarded as one of the most effective ways to manage and improve population health. Prescribed and dispensed medications can be monitored through data linkage for each patient. We hypothesised that changes in patient care resulting from COVID-19, changed the way patients access their prescribed medication.

ObjectiveTo develop an efficient approach for evaluation of the impact of COVID-19 on drug dispensing patterns.

MethodsRetrospective observational study using national patient-level dispensing records in Wales-UK. Total dispensed drug items between 01-Jan-2016 and 31-Dec-2019 (counterfactual pre-COVID-19) were compared to 2020 (COVID-19 year). We compared trends of dispensed items in three main British National Formulary (BNF) sections(Cardiovascular system, Central Nervous System, Immunological & Vaccine) using European Age-Standardized rates. We developed an online tool to enable monitoring of changes in dispensing as the pandemic evolves.

ResultAmongst all BNF chapters, 52,357,639 items were dispensed in 2020 compared to 49,747,141 items in 2019 demonstrating a relative increase of 5.25% in 2020(95%CI[5.21,5.29]). Comparison of monthly patterns of 2020 and 2019 dispensed items showed a notable difference between the total number of dispensed drug items each month, with an average difference (D) of +290,055 and average Relative Change (RC) of +5.52%. The greatest RC was observed in a substantial March-2020 increase (D=+1,501,242 and RC=+28%), followed by second peak in June (D=+565,004, RC=+10.97%). May was characterised by lower dispensing (D=-399,244, RC=-5.9%). Cardiovascular categories were characterised, across all age groups, by dramatic March-2020 increases, at the epidemic peak, followed by months of lower than expected dispensing, and gradual recovery by September. The Central Nervous System category was similar, but with only a short decline in May, and quicker recovery. A stand-out grouping was Immunological and Vaccine, which dropped to very low levels across all age groups, and all months (including the March dispensing peak).

ConclusionsAberration in clinical service delivery during COVID-19 led to substantial changes in community pharmacy drug dispensing. This change may contribute to a long-term burden of COVID-19, raising the importance of a comprehensive and timely monitoring of changes for evaluation of the potential impact on clinical care and outcomes",health systems and quality improvement,fuzzy,100,100
medRxiv,10.1101/2021.02.17.21251812,2021-02-19,https://medrxiv.org/cgi/content/short/2021.02.17.21251812,Changes in the rate of cardiometabolic and pulmonary events during the COVID-19 pandemic,Alex J Walker; John Tazare; George Hickman; Christopher T Rentsch; Elizabeth J Williamson; Krishnan Bhaskaran; David Evans; Kevin Wing; Rohini Mathur; Angel YS Wong; Anna Schultze; Sebastian CJ Bacon; Christopher Bates; Caroline E Morton; Helen J Curtis; Emily Nightingale; Helen I McDonald; Amir Mehrkar; Peter Inglesby; Brian MacKenna; Jonathan Cockburn; William J Hulme; Harriet Forbes; Caroline Minassian; Richard Croker; John Parry; Frank Hester; Sam Harper; Rosalind M Eggo; Stephen JW Evans; Liam Smeeth; Ian J Douglas; Laurie Tomlinson; Ben Goldacre,University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundThere has been extensive speculation about the relationship between COVID-19 and various cardiometabolic and pulmonary conditions. This a complex question: COVID-19 may cause a cardiometabolic or respiratory event; admission for a clinical event may result in hospital-acquired SARS-CoV-2 infection; both may contribute to a patient surpassing the threshold for presenting to services; and the presence of a pandemic may change whether patients present to services at all. To inform analysis of these questions, we set out to describe the overall rate of various key clinical events over time, and their relationship with COVID-19.

MethodsWorking on behalf of NHS England, we used data from the OpenSAFELY platform containing data from approximately 40% of the population of England. We selected the whole adult population of 17m patients and within this identified two further mutually exclusive groups: patients who tested positive for SARS-CoV-2 in the community; and patients hospitalised with COVID-19. We report counts of death, DVT, PE, ischaemic stroke, MI, heart failure, AKI and diabetic ketoacidosis in each month between February 2019 and October 2020 within each of: the general population, community SARS-CoV-2 cases, and hospitalised patients with COVID-19. Outcome events were defined using hospitalisations, GP records and cause of death data.

ResultsFor all outcomes except death there was a lower count of events in April 2020 compared to April 2019. For most outcomes the minimum count of events was in April 2020, where the decrease compared to April 2019 in events ranged from 5.9% (PE) to 40.0% (heart failure). Despite hospitalised COVID-19 patients making up just 0.14% of the population in April 2020, these patients accounted for an extremely high proportion of cardiometabolic and respiratory events in that month (range of proportions 10.3% (DVT) to 33.5% (AKI)).

InterpretationWe observed a substantial drop in the incidence of cardiometabolic and pulmonary events in the non-COVID-19 general population, but high occurrence of COVID-19 among patients with these events. Shortcomings in routine NHS secondary care data, especially around the timing and order of events, make causal interpretations challenging. We caution that the intermediate findings reported here should be used to inform the design and interpretation of any studies using a general population comparator to evaluate the relationship between COVID-19 and other clinical events.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.02.10.21251484,2021-02-16,https://medrxiv.org/cgi/content/short/2021.02.10.21251484,An analysis of school absences in England during the Covid-19 pandemic,Emma R Southall; Alex Holmes; Edward M Hill; Benjamin D Atkins; Trystan Leng; Robin N Thompson; Louise J Dyson; Matt J Keeling; Michael Tildesley,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"The introduction of SARS-CoV-2, the virus that causes COVID-19 infection, in the UK in early 2020, resulted in the UK government introducing several control policies in order to reduce the spread of disease. As part of these restrictions, schools were closed to all pupils in March (except for vulnerable and key worker children), before re-opening to certain year groups in June. Finally all school children returned to the classroom in September. In this paper, we analyse the data on school absences from September 2020 to December 2020 as a result of COVID-19 infection and how that varied through time as other measures in the community were introduced. We utilise data from the Educational Settings database compiled by the Department for Education and examine how pupil and teacher absences change in both primary and secondary schools.

Our results show that absences as a result of COVID-19 infection rose steadily following the re-opening of schools in September. Cases in teachers were seen to decline during the November lockdown, particularly in those regions that had previously been in tier 3, the highest level of control at the time. Cases in secondary school pupils increased for the first two weeks of the November lockdown, before decreasing. Since the introduction of the tier system, the number of absences owing to confirmed infection in primary schools was observed to be significantly lower than in secondary schools across all regions and tiers.

In December, we observed a large rise in the number of absences per school in secondary school settings in the South East and Greater London, but such rises were not observed in other regions or in primary school settings. We conjecture that the increased transmissibility of the new variant in these regions may have contributed to this rise in cases in secondary schools. Finally, we observe a positive correlation between cases in the community and cases in schools in most regions, with weak evidence suggesting that cases in schools lag behind cases in the surrounding community. We conclude that there is not significant evidence to suggest that schools are playing a significant role in driving spread in the community and that careful monitoring may be required as schools re-open to determine the effect associated with open schools upon community incidence.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.02.10.21251480,2021-02-12,https://medrxiv.org/cgi/content/short/2021.02.10.21251480,Symptom reporting in over 1 million people: community detection of COVID-19,Joshua Elliott; Matthew Whitaker; Barbara Bodinier; Steven Riley; Helen Ward; Graham Cooke; Ara Darzi; Marc Chadeau-Hyam; Paul Elliott,Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London,,infectious diseases,fuzzy,96,100
medRxiv,10.1101/2021.02.11.21251587,2021-02-12,https://medrxiv.org/cgi/content/short/2021.02.11.21251587,Assessing the impact of secondary school reopening strategies on within-school COVID-19 transmission and absences: a modelling study,Trystan Leng; Edward M Hill; Robin N Thompson; Michael J Tildesley; Matt J Keeling; Louise J Dyson,University of Warwick; University of Warwick; University of  Warwick; University of Warwick; University of Warwick; University of Warwick,,infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.02.11.21249258,2021-02-11,https://medrxiv.org/cgi/content/short/2021.02.11.21249258,"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial",Peter W Horby; Mark Campbell; Natalie Staplin; Enti Spata; Jonathan R Emberson; Guilherme Pessoa-Amorim; Leon Peto; Christopher E Brightling; Rahuldeb Sarkar; Koshy Thomas; Vandana Jeebun; Abdul Ashish; Redmond Tully; David Chadwick; Muhammad Sharafat; Richard Stewart; Banu Rudran; J Kenneth Baillie; Maya H Buch; Lucy C Chappell; Jeremy N Day; Saul N Furst; Thomas Jaki; Katie Jeffery; Edmund Juszczak; Wei Shen Lim; Alan Montgomery; Andrew Mumford; Kathryn Rowan; Guy Thwaites; Marion Mafham; Richard Haynes; Martin J Landray,"Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; Medway Foundation NHS Trust, Gillingham, United Kingdom; King?s College London, London, United Kingdom; Basildon and Thurrock Hospitals NHS Foundation Trust, Basildon, United Kingdom; Department of Respiratory Medicine, North Tees & Hartlepool NHS Foundation Trust, Stockton-on-Tees, United Kingdom; Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom; Royal Oldham Hospital, Northern Care Alliance, Oldham, United Kingdom; Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United Kingdom; North West Anglia NHS Foundation Trust, Peterborough, United Kingdom; Milton Keynes University Hospital, Milton Keynes, United Kingdom; Luton & Dunstable University Hospital, Luton, United Kingdom; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; School of Life Sciences, Kings College London, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Respiratory Medicine Department, Nottingham University Hospitals NHS Foundation Trust, Nottingham, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom; Intensive Care National Audit and Research Centre, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","Findings: Between 23 April 2020 and 25 January 2021, 4116 adults were included in the assessment of tocilizumab, including 562 (14%) patients receiving invasive mechanical ventilation, 1686 (41%) receiving non-invasive respiratory support, and. 1868 (45%) receiving no respiratory support other than oxygen. Median CRP was 143 [IQR 107-205] mg/L and 3385 (82%) patients were receiving systemic corticosteroids at randomisation. Overall, 596 (29%) of the 2022 patients allocated tocilizumab and 694 (33%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0.86; 95% confidence interval [CI] 0.77-0.96; p=0.007). Consistent results were seen in all pre-specified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital alive within 28 days (54% vs. 47%; rate ratio 1.23; 95% CI 1.12-1.34; p<0.0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (33% vs. 38%; risk ratio 0.85; 95% CI 0.78-0.93; p=0.0005). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes regardless of the level of respiratory support received and in addition to the use of systemic corticosteroids.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.02.08.21250525,2021-02-09,https://medrxiv.org/cgi/content/short/2021.02.08.21250525,"COVID-19 infection and outcomes in a population-based cohort of 17,173 adults with intellectual disabilities compared with the general population",Angela Henderson; Micheal Fleming; Sally-Ann Cooper; Jill Pell; Craig Melville; Daniel MacKay; Christopher Hatton; Deborah Kinnear,University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; Manchester Metropolitan University; University of Glasgow,"ObjectivesTo compare COVID-19 infection, severe infection, mortality, case-fatality, and excess deaths, among adults with intellectual disabilities and those without.

DesignRecord-linkage of all adults recorded with intellectual disabilities in Scotlands Census, 2011, and a 5% sample of other adults, to COVID-19 test results (Electronic Communication of Surveillance in Scotland), hospitalisations (Scottish Morbidity Record 01), and deaths (National Records of Scotland).

SettingGeneral population; 24th January 2020 - 15th August 2020

ParticipantsSuccessful linkage of 94.8% provided data on 17,173 adults with, and 195,859 without, intellectual disabilities.

OutcomesCrude rates of COVID-19 infection, severe infection (hospitalisation/death), mortality, and case fatality; age-, sex- and deprivation-standardised severe infection and mortality ratios; annual all-cause mortality for 2020 and 2015-2019.

ResultsAdults with intellectual disabilities had higher rates of COVID-19 infection (957/100,000 versus 513/100,000); severe infection (549/100,000 versus 237/100,000); mortality (259/100,000 versus 114/100,000); and case-fatality (30% versus 24%). Poorer COVID-19 outcomes remained after standardising for age, sex and deprivation: standardised severe infection ratio 2.59 (95% CI 1.80, 3.39) and mortality ratio 3.20 (95% CI 2.16, 4.25). These were higher among 55-64 year olds: 7.12 (95% CI 3.73, 10.50) and 16.16 (95% CI7.69, 24.63) respectively. Among adults with intellectual disabilities, all-cause mortality was only slightly higher in 2020 than the previous five years: standardised mortality ratios 2.49 (95% CI 2.17, 2.81) and 2.38 (95% CI 2.26, 2.49) respectively.

ConclusionsAdults with intellectual disabilities were more likely to be infected with COVID-19, and had worse outcomes once infected, particularly those under 65 years. Non-pharmaceutical interventions directed at formal and informal carers are essential to reduce transmission and all adults with intellectual disabilities should be immediately prioritised for vaccination regardless of age.

Summary boxO_ST_ABSWhat is already known on this topicC_ST_ABSO_LICOVID-19 mortality is higher within multi-occupancy residences.
C_LIO_LIAdults with intellectual disabilities may be at higher risk of COVID-19 mortality than other adults, but there are gaps in the evidence.
C_LIO_LICOVID-19 case-fatality may be no different, or as much as 2.75 times higher in adults with intellectual disabilities compared with other adults.
C_LI

What this study addsO_LICompared with general population adults, adults with intellectual disabilities were almost twice as likely to become infected with COVID-19, 2.3 times as likely to have severe infection, 2.3 times as likely to have COVID-19 mortality, and had 25% higher COVID-19 case-fatality.
C_LIO_LIAfter standardising for age, sex and deprivation, people with intellectual disabilities were 3.2 times more at risk of covid-19 mortality and 2.6 times more at risk of severe infection relative to those with no intellectual disabilities
C_LIO_LICompared with general population adults, adults with intellectual disabilities had poorer outcomes among non-elderly age-groups particularly those aged 55-65 years, men, and those living in less-deprived neighbourhoods.
C_LIO_LINon-pharmaceutical initiatives are important for carers and care-provider organisations, and adults with intellectual disabilities should be prioritised in the national rollouts of COVID-19 vaccination programmes, regardless of age, sex, or neighbourhood deprivation.
C_LI",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.02.04.21251155,2021-02-08,https://medrxiv.org/cgi/content/short/2021.02.04.21251155,Impact of school closures on the health and well-being of primary school children in Wales UK; a routine data linkage study using the HAPPEN survey (2018-2020).,Michaela James; Emily Marchant; Margaret A Defeyter; Jayne V Woodside; Sinead Brophy,Swansea University; Swansea University; Northumbria University; Queen's University Belfast; Swansea University,"IntroductionIn response to the COVID-19 pandemic, school closures were implemented across the United Kingdom. This study aimed to explore the impact of school closures on childrens health by comparing health and wellbeing outcomes collected during school closures (April - June 2020) with data from the same period in 2019 and 2018.

MethodsData were collected online via the  HAPPEN At Home survey, which captured the typical health behaviours of children aged 8 - 11 years between April - June 2020. These data were compared with data in 2018 and 2019 also collected between April-June, from HAPPEN. Free school meal (FSM) status was used as a proxy for socio-economic deprivation. Analyses were repeated stratifying by FSM.

ResultsComparing responses between April - June in 2020 (n=1068), 2019 (n=1150) and 2018 (n=475), there were improvements in physical activity levels, sleep time, happiness and general wellbeing for children during school closures compared to previous years. However, children on FSM ate less fruit and vegetables (21% (95%CI (5.7% to 37%)) and had lower self-assessed school competence compared to 2019. Compared to those not on FSM they also spent less time doing physical activity (13.03% (95%CI: 3.3% to 21.7%) and consumed more takeaways (16.3% (95%CI: 2%-30%)) during school closures.

ConclusionThis study suggests that schools play an important role in reducing inequalities in physical health. The physical health (e.g. physical activity and diet) of children eligible for FSM may be impacted by prolonged school closures.

What is already known on this subject?In response to the COVID-19 pandemic, by mid-March 2020, 138 countries had implemented national school closures to reduce the number of social contacts between pupils, therefore interrupting the transmission of COVID-19 as part of pandemic plans. UNESCO warned that the global scale and speed of the educational disruption would be unparalleled. There is an ongoing debate with regard to the effectiveness of schools closures on transmission rates, but the fact schools are closed for a long period of time could have detrimental impacts on pupils physical and mental health.

This study provides evidence of any differences in the health and wellbeing of children prior to and during the COVID-19 enforced lockdown and school closures between March and June 2020. These findings could have a significant impact for the future and support schools to better understand their pupils physical, psychological, emotional and social health. It also contributes to a significant literature gap regarding the impact of school closures on school-aged children.

What this study adds?Improvements in physical activity levels, sleep time, happiness and general wellbeing were observed in general for children during school closures compared to previous years. However, children on FSM reported eating less fruit and vegetables and had lower self-assessed school competence compared to 2019. Compared to those not on FSM they also spent less time doing physical activity and consumed more takeaways during school closures. These trends are not evident among children not on FSM. All children reported improvements in wellbeing during lockdown especially on the happiness with family measure.

Overall, findings suggest schools help to reduce inequalities in physical health for socio-economically deprived children. During school closures children from deprived backgrounds are likely to have poorer physical health (e.g. less time spent doing physical activities and poorer diet) and this is not observed in children who are not in receipt of FSM. This research suggests that school closures will result in widening health inequalities and when schools return measures will need to be in place to readdress the widened gap in physical health.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.02.04.21251087,2021-02-08,https://medrxiv.org/cgi/content/short/2021.02.04.21251087,Staff-Pupil SARS-CoV-2 Infection Pathways in Schools: A Population Level Linked Data Approach,Daniel A Thompson; Hoda Abbasizanjani; Richard Fry; Emily Marchant; Lucy J Griffiths; Ashley Akbari; Joseph Hollinghurst; Laura North; Jane Lyons; Fatemeh Torabi; Gareth Davies; Mike B Gravenor; Ronan A Lyons,Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University,"BackgroundBetter understanding of the role that children and school staff play in the transmission of SARS-CoV-2 is essential to guide policy development on controlling infection whilst minimising disruption to childrens education and wellbeing.

MethodsOur national e-cohort (n=500,779) study used anonymised linked data for pupils, staff and associated households linked via educational settings. We estimated the risk of testing positive for SARS-CoV-2 infection for staff and pupils over the period August - December 2020, dependent on measures of recent exposure to known cases linked to their educational settings.

ResultsThe total number of cases in a school was not associated with a subsequent increase in the risk of testing positive (Staff OR per case 0.92, 95%CI 0.85, 1.00; Pupils OR per case 0.98, 95%CI 0.93, 1.02). Amongst pupils, the number of recent cases within the same year group was significantly associated with subsequent increased risk of testing positive (OR per case 1.12, 95%CI 1.08 - 1.15). These effects were adjusted for a range of demographic covariates, and in particular any known cases within the same household, which had the strongest association with testing positive (Staff OR 39.86, 95%CI 35.01, 45.38, pupil OR 9.39, 95%CI 8.94 - 9.88).

ConclusionsIn a national school cohort, the odds of staff testing positive for SARS-CoV-2 infection were not significantly increased in the 14-day period after case detection in the school. However, pupils were found to be at increased risk, following cases appearing within their own year group, where most of their contacts occur. Strong mitigation measures over the whole of the study period may have reduced wider spread within the school environment.

O_TEXTBOXWhat is knownO_LIEvidence of the role schools play in the transmission of SARS-CoV-2 is limited
C_LIO_LIHigher positivity rates are observed in school staff compared to pupils
C_LIO_LILack of evidence on transmission pathways transmission into and within schools
C_LI

What this study addsO_LIFirst UK national level study of transmission between pupils and staff in a school environment during the SARS-CoV-2 pandemic.
C_LIO_LISchools opening September-December 2020 was not associated with an increased subsequent risk of testing positive in staff
C_LIO_LIPupils were found to be at increased risk of testing positive, following cases appearing within their own year group
C_LI

C_TEXTBOX",health informatics,fuzzy,100,100
medRxiv,10.1101/2021.02.07.21251297,2021-02-08,https://medrxiv.org/cgi/content/short/2021.02.07.21251297,The changing characteristics of COVID-19 presentations: A regional comparison of SARS-CoV-2 hospitalised patients during the first and second wave.,Catherine Atkin; Vicky Kamwa; Vinay Reddy-Kolanu; Dhruv Parekh; Felicity Evison; Peter Nightingale; Suzy Gallier; Simon Ball; Elizabeth Sapey,"Acute Medicine, Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham; Acute Medicine, Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, University of Birmingham; Acute Medicine, University Hospitals Birmingham NHS Foundation Trust; A. Intensive Care Medicine, University Hospitals Birmingham NHS Foundation Trust, Edgbaston, Birmingham, B15 2GW, UK.     B. Birmingham Acute Care Research Grou; Research Analytics Department of Health Informatics, University Hospitals Birmingham NHS Foundation Trust; NIHR Clinical Research Facility Statistician, University Hospitals Birmingham NHS Foundation Trust; PIONEER Technical Director, Lead for Research Analytics Department of Health Informatics, University Hospitals Birmingham NHS Foundation Trust; A. Chief Medical Officer, University Hospitals Birmingham NHS Foundation Trust  B. HDR-UK Midlands Site and Better Care Programme, University Hospitals Birmingh; A. Director of PIONEER: Health Data Research UK (HDRUK) Health Data Research Hub for Acute Care  B. Birmingham Acute Care Research Group, Institute of Inflammat","BackgroundThis study assesses COVID-19 hospitalised patient demography and outcomes during wave 1 and wave 2, prior to new variants of the virus.

MethodsAll patients with a positive SARS-CoV-2 swab between 10th March 2020 and 5th July 2020 (wave 1) and 1st September 2020 and 16th November 2020 (wave 2) admitted to University Hospitals Birmingham NHS Foundation Trust were included (n=4856), followed for 28 days.

ResultsWave 2 patients were younger, more ethnically diverse, had less co-morbidities and disease presentation was milder on presentation. After matching for these factors, mortality was reduced, but without differences in intensive care admissions.

ConclusionPrior to new SARS-CoV-2 variants, outcomes for hospitalised patients with COVID-19 were improving but with similar intensive care needs.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.02.03.21251054,2021-02-05,https://medrxiv.org/cgi/content/short/2021.02.03.21251054,Age-related heterogeneity in Neutralising antibody responses to SARS-CoV-2 following BNT162b2 vaccination,Dami Collier; Isabella Ferreira; Rawlings Datir; Prasanti Kotagiri; Eleanor Lim; Bo Meng; - The CITIID-NIHR Bioresource COVID-19 Collaboration; Anne Elmer; Nathalie Kingston; Barbara Graves; Barbara Graves; Kenneth GC Smith; John Bradley; Paul Lyons; Lourdes Ceron-Gutierrez; Gabriela Barcenas-Morales; Michelle Linterman; Laura McCoy; Rainer Doffinger; Mark Wills; Ravindra K Gupta,UCL; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; -; Cambridge; NIHR; NIHR; Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Babraham Institute; UCL; University of Cambridge; University of Cambridge; University of Cambridge,"Two dose mRNA vaccination provides excellent protection against SARS-CoV-2. However, there are few data on vaccine efficacy in elderly individuals above the age of 801. Additionally, new variants of concern (VOC) with reduced sensitivity to neutralising antibodies have raised fears for vulnerable groups. Here we assessed humoral and cellular immune responses following vaccination with mRNA vaccine BNT162b22 in elderly participants prospectively recruited from the community and younger health care workers. Median age was 72 years and 51% were females amongst 140 participants. Neutralising antibody responses after the first vaccine dose diminished with increasing age, with a marked drop in participants over 80 years old. Sera from participants below and above 80 showed significantly lower neutralisation potency against B.1.1.7, B.1.351 and P.1. variants of concern as compared to wild type. Those over 80 were more likely to lack any neutralisation against VOC compared to younger participants following first dose. The adjusted odds ratio for inadequate neutralisation activity against the B.1.1.7, P.1 and B.1.351 variant in the older versus younger age group was 4.3 (95% CI 2.0-9.3, p<0.001), 6.7 (95% CI 1.7-26.3, p=0.008) and 1.7 (95% CI 0.5-5.7, p=0.41). Binding IgG and IgA antibodies were lower in the elderly, as was the frequency of SARS-CoV-2 Spike specific B-memory cells. We observed a trend towards lower somatic hypermutation in participants with suboptimal neutralisation, and elderly participants demonstrated clear reduction in class switched somatic hypermutation, driven by the IgA1/2 isotype. SARS-CoV-2 Spike specific T-cell IFN{gamma} and IL-2 responses fell with increasing age, and both cytokines were secreted primarily by CD4 T cells. We conclude that the elderly are a high risk population that warrant specific measures in order to mitigate against vaccine failure, particularly where variants of concern are circulating.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.02.02.21251043,2021-02-05,https://medrxiv.org/cgi/content/short/2021.02.02.21251043,COVID-19 infection and subsequent thromboembolism: A self-controlled case series analysis of a population cohort,Frederick Ho; Kenneth Man; Mark Toshner; Colin Church; Carlos Celis-Morales; Ian Wong; Colin Berry; Naveed Sattar; Jill Pell,University of Glasgow; UCL; University of Cambridge; NHS Greater Glasgow and Clyde; University of Glasgow; UCL; University of Glasgow; University of Glasgow; University of Glasgow,"ObjectiveAn unexpectedly large number of people infected with Covid-19 had experienced a thrombotic event. This study aims to assess the associations between Covid-19 infection and thromboembolism including myocardial infarction (MI), ischaemic stroke, deep-vein thrombosis (DVT), and pulmonary embolism (PE).

Patients and MethodsA self-controlled case-series study was conducted covering the whole of Scotlands general population. The study population comprised individuals with confirmed (positive test) Covid-19 and at least one thromboembolic event between March 2018 and October 2020. Their incidence rates during the risk interval (5 days before to 56 days after the positive test) and the control interval (the remaining periods) were compared intra-personally.

ResultsAcross Scotland, 1,449 individuals tested positive for Covid-19 and experienced a thromboembolic event. The risk of thromboembolism was significantly elevated over the whole risk period but highest in the 7 days following the positive test (IRR 12.01, 95% CI 9.91-14.56) in all included individuals. The association was also present in individuals not originally hospitalised for Covid-19 (IRR 4.07, 95% CI 2.83-5.85). Risk of MI, stroke, PE and DVT were all significantly higher in the week following a positive test. The risk of PE and DVT was particularly high and remained significantly elevated even 56 days following the test.

ConclusionConfirmed Covid-19 infection was associated with early elevations in risk with MI, ischaemic stroke, and substantially stronger and prolonged elevations with DVT and PE both in hospital and community settings. Clinicians should consider thromboembolism, especially PE, among people with Covid-19 in the community.",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2021.02.03.21251004,2021-02-05,https://medrxiv.org/cgi/content/short/2021.02.03.21251004,Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England,Vahe Nafilyan; Nazrul Islam; Rohini Mathur; Daniel Ayoubkhani; Amitava Banerjee; Myer Glickman; Ben Humberstone; Ian DIamond; Kamlesh Khunti,"Office for National Statistics; Nuffield Department of Population Health, Big Data Institute, University of Oxford; London School of Hygiene and Tropical Medicine; Office for National Statistics; University College London; Office for National Statistics; Office for National Statistics; Office for National Statistics; Diabetes Research Centre, University of Leicester","BackgroundEthnic minorities have experienced disproportionate COVID-19 mortality rates in the UK and many other countries. We compared the differences in the risk of COVID-19 related death between ethnic groups in the first and second waves the of COVID-19 pandemic in England. We also investigated whether the factors explaining differences in COVID-19 death between ethnic groups changed between the two waves.

MethodsUsing data from the Office for National Statistics Public Health Data Asset on individuals aged 30-100 years living in private households, we conducted an observational cohort study to examine differences in the risk of death involving COVID-19 between ethnic groups in the first wave (from 24th January 2020 until 31st August 2020) and second wave (from 1st September to 28th December 2020). We estimated age-standardised mortality rates (ASMR) in the two waves stratified by ethnic groups and sex. We also estimated hazard ratios (HRs) for ethnic-minority groups compared with the White British population, adjusted for geographical factors, socio-demographic characteristics, and pre-pandemic health conditions.

ResultsThe study population included over 28.9 million individuals aged 30-100 years living in private households. In the first wave, all ethnic minority groups had a higher risk of COVID-19 related death compared to the White British population. In the second wave, the risk of COVID-19 death remained elevated for people from Pakistani (ASMR: 339.9 [95% CI: 303.7 - 376.2] and 166.8 [141.7 - 191.9] deaths per 100,000 population in men and women) and Bangladeshi (318.7 [247.4 - 390.1] and 127.1 [91.1 - 171.3] in men and women)background but not for people from Black ethnic groups. Adjustment for geographical factors explained a large proportion of the differences in COVID-19 mortality in the first wave but not in the second wave. Despite an attenuation of the elevated risk of COVID-19 mortality after adjusting for sociodemographic characteristics and health status, the risk was substantially higher in people from Bangladeshi and Pakistani background in both the first and the second waves.

ConclusionBetween the first and second waves of the pandemic, the reduction in the difference in COVID-19 mortality between people from Black ethnic background and people from the White British group shows that ethnic inequalities in COVID-19 mortality can be addressed. The continued higher rate of mortality in people from Bangladeshi and Pakistani background is alarming and requires focused public health campaign and policy changes.

*VN and NI contributed equally to this paper

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSA recent systematic review by Pan and colleagues demonstrated that people of ethnic minority background in the UK and the USA have been disproportionately affected by the Coronavirus (COVID-19) pandemic, compared to White populations. While several studies have investigated whether adjusting for socio-demographic and economic factors and medical history reduces the estimated difference in risk of mortality and hospitalisation, the reasons for the differences in the risk of experiencing harms from COVID-19 are still being explored during the course of the pandemic. Studies so far have analysed the ethnic differences in COVID-19 mortality in the first wave of the pandemic. The evidence on the temporal trend of ethnic inequalities in COVID-19 mortality, especially those from the second wave of the pandemic, is scarce.

Added value of this studyUsing data from the Office for National Statistics (ONS) Public Health Data Asset on 29 million adults aged 30-100 years living in private households in England, we conducted an observational cohort study to examine the differences in the risk of death involving COVID-19 between ethnic groups in the first wave (from 24th January 2020 until 31st August 2020) and second wave (from 1st September to 28th December 2020). We find that in the first wave all ethnic minority groups were at elevated risk of COVID-19 related death compared to the White British population. In the second wave, the differences in the risk of COVID-19 related death attenuated for Black African and Black Caribbean groups, remained substantially higher in people from Bangladeshi background, and worsened in people from Pakistani background. We also find that some of the factors explaining these differences in mortality have changed in the two waves.

Implications of all the available evidenceThe risk of COVID-19 mortality during the first wave of the pandemic was elevated in people from ethnic minority background. An appreciable reduction in the difference in COVID-19 mortality in the second wave of the pandemic between people from Black ethnic background and people from the White British group is reassuring, but the continued higher rate of mortality in people from Bangladeshi and Pakistani background is alarming and requires focused public health campaign and policy response. Focusing on treating underlying conditions, although important, may not be enough in reducing the inequalities in COVID-19 mortality. Focused public health policy as well as community mobilisation and participatory public health campaign involving community leaders may help reduce the existing and widening inequalities in COVID-19 mortality.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.02.03.21250974,2021-02-05,https://medrxiv.org/cgi/content/short/2021.02.03.21250974,Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the US,Estee Y Cramer; Evan L Ray; Velma K Lopez; Johannes Bracher; Andrea Brennen; Alvaro J Castro Rivadeneira; Aaron Gerding; Tilmann Gneiting; Katie H House; Yuxin Huang; Dasuni Jayawardena; Abdul H Kanji; Ayush Khandelwal; Khoa Le; Anja Muehlemann; Jarad Niemi; Apurv Shah; Ariane Stark; Yijin Wang; Nutcha Wattanachit; Martha W Zorn; Youyang Gu; Sansiddh Jain; Nayana Bannur; Ayush Deva; Mihir Kulkarni; Srujana Merugu; Alpan Raval; Siddhant Shingi; Avtansh Tiwari; Jerome White; Neil F Abernethy; Spencer Woody; Maytal Dahan; Spencer Fox; Kelly Gaither; Michael Lachmann; Lauren Ancel Meyers; James G Scott; Mauricio Tec; Ajitesh Srivastava; Glover E George; Jeffrey C Cegan; Ian D Dettwiller; William P England; Matthew W Farthing; Robert H Hunter; Brandon Lafferty; Igor Linkov; Michael L Mayo; Matthew D Parno; Michael A Rowland; Benjamin D Trump; Yanli Zhang-James; Samuel Chen; Stephen V Faraone; Jonathan Hess; Christopher P Morley; Asif Salekin; Dongliang Wang; Sabrina M Corsetti; Thomas M Baer; Marisa C Eisenberg; Karl Falb; Yitao Huang; Emily T Martin; Ella McCauley; Robert L Myers; Tom Schwarz; Daniel Sheldon; Graham Casey Gibson; Rose Yu; Liyao Gao; Yian Ma; Dongxia Wu; Xifeng Yan; Xiaoyong Jin; Yu-Xiang Wang; YangQuan Chen; Lihong Guo; Yanting Zhao; Quanquan Gu; Jinghui Chen; Lingxiao Wang; Pan Xu; Weitong Zhang; Difan Zou; Hannah Biegel; Joceline Lega; Steve McConnell; VP Nagraj; Stephanie L Guertin; Christopher Hulme-Lowe; Stephen D Turner; Yunfeng Shi; Xuegang Ban; Robert Walraven; Qi-Jun Hong; Stanley Kong; Axel van de Walle; James A Turtle; Michal Ben-Nun; Steven Riley; Pete Riley; Ugur Koyluoglu; David DesRoches; Pedro Forli; Bruce Hamory; Christina Kyriakides; Helen Leis; John Milliken; Michael Moloney; James Morgan; Ninad Nirgudkar; Gokce Ozcan; Noah Piwonka; Matt Ravi; Chris Schrader; Elizabeth Shakhnovich; Daniel Siegel; Ryan Spatz; Chris Stiefeling; Barrie Wilkinson; Alexander Wong; Sean Cavany; Guido Espana; Sean Moore; Rachel Oidtman; Alex Perkins; David Kraus; Andrea Kraus; Zhifeng Gao; Jiang Bian; Wei Cao; Juan Lavista Ferres; Chaozhuo Li; Tie-Yan Liu; Xing Xie; Shun Zhang; Shun Zheng; Alessandro Vespignani; Matteo Chinazzi; Jessica T Davis; Kunpeng Mu; Ana Pastore y Piontti; Xinyue Xiong; Andrew Zheng; Jackie Baek; Vivek Farias; Andreea Georgescu; Retsef Levi; Deeksha Sinha; Joshua Wilde; Georgia Perakis; Mohammed Amine Bennouna; David Nze-Ndong; Divya Singhvi; Ioannis Spantidakis; Leann Thayaparan; Asterios Tsiourvas; Arnab Sarker; Ali Jadbabaie; Devavrat Shah; Nicolas Della Penna; Leo A Celi; Saketh Sundar; Russ Wolfinger; Dave Osthus; Lauren Castro; Geoffrey Fairchild; Isaac Michaud; Dean Karlen; Matt Kinsey; Luke C. Mullany; Kaitlin Rainwater-Lovett; Lauren Shin; Katharine Tallaksen; Shelby Wilson; Elizabeth C Lee; Juan Dent; Kyra H Grantz; Alison L Hill; Joshua Kaminsky; Kathryn Kaminsky; Lindsay T Keegan; Stephen A Lauer; Joseph C Lemaitre; Justin Lessler; Hannah R Meredith; Javier Perez-Saez; Sam Shah; Claire P Smith; Shaun A Truelove; Josh Wills; Maximilian Marshall; Lauren Gardner; Kristen Nixon; John C. Burant; Lily Wang; Lei Gao; Zhiling Gu; Myungjin Kim; Xinyi Li; Guannan Wang; Yueying Wang; Shan Yu; Robert C Reiner; Ryan Barber; Emmanuela Gaikedu; Simon Hay; Steve Lim; Chris Murray; David Pigott; Heidi L Gurung; Prasith Baccam; Steven A Stage; Bradley T Suchoski; B. Aditya Prakash; Bijaya Adhikari; Jiaming Cui; Alexander Rodriguez; Anika Tabassum; Jiajia Xie; Pinar Keskinocak; John Asplund; Arden Baxter; Buse Eylul Oruc; Nicoleta Serban; Sercan O Arik; Mike Dusenberry; Arkady Epshteyn; Elli Kanal; Long T Le; Chun-Liang Li; Tomas Pfister; Dario Sava; Rajarishi Sinha; Thomas Tsai; Nate Yoder; Jinsung Yoon; Leyou Zhang; Sam Abbott; Nikos I Bosse; Sebastian Funk; Joel Hellewell; Sophie R Meakin; Katharine Sherratt; Mingyuan Zhou; Rahi Kalantari; Teresa K Yamana; Sen Pei; Jeffrey Shaman; Michael L Li; Dimitris Bertsimas; Omar Skali Lami; Saksham Soni; Hamza Tazi Bouardi; Turgay Ayer; Madeline Adee; Jagpreet Chhatwal; Ozden O Dalgic; Mary A Ladd; Benjamin P Linas; Peter Mueller; Jade Xiao; Yuanjia Wang; Qinxia Wang; Shanghong Xie; Donglin Zeng; Alden Green; Jacob Bien; Logan Brooks; Addison J Hu; Maria Jahja; Daniel McDonald; Balasubramanian Narasimhan; Collin Politsch; Samyak Rajanala; Aaron Rumack; Noah Simon; Ryan J Tibshirani; Rob Tibshirani; Valerie Ventura; Larry Wasserman; Eamon B O'Dea; John M Drake; Robert Pagano; Quoc T Tran; Lam Si Tung Ho; Huong Huynh; Jo W Walker; Rachel B Slayton; Michael A Johansson; Matthew Biggerstaff; Nicholas G Reich,"University of Massachusetts, Amherst; University of Massachusetts, Amherst; Centers for Disease Control and Prevention; Chair of Econometrics and Statistics, Karlsruhe Institute of Technology; Computational Statistics Group, Heidelberg Institute for Theoretical Studies; IQT; University of Massachusetts, Amherst; University of Massachusetts, Amherst; Institute of Stochastics, Karlsruhe Institute of Technology; University of Massachusetts, Amherst; University of Massachusetts, Amherst; University of Massachusetts, Amherst; University of Massachusetts, Amherst; University of Massachusetts, Amherst; University of Massachusetts, Amherst; Institute of Mathematical Statistics and Actuarial Science, University of Bern; Iowa State University; University of Massachusetts, Amherst; University of Massachusetts, Amherst; University of Massachusetts, Amherst; University of Massachusetts, Amherst; University of Massachusetts, Amherst; Unaffiliated; Wadhwani Institute of Artificial Intelligence; Wadhwani Institute of Artificial Intelligence; Wadhwani Institute of Artificial Intelligence; Wadhwani Institute of Artificial Intelligence; Wadhwani Institute of Artificial Intelligence; Wadhwani Institute of Artificial Intelligence; Wadhwani Institute of Artificial Intelligence; Wadhwani Institute of Artificial Intelligence; Wadhwani Institute of Artificial Intelligence; University of Washington; University of Texas at Austin; Texas Advanced Computing Center; University of Texas at Austin; Texas Advanced Computing Center; Santa Fe Institute; University of Texas at Austin; University of Texas at Austin; University of Texas at Austin; University of Southern California; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; US Army Engineer Research and Development Center; State University of New York Upstate Medical University; State University of New York Upstate Medical University; State University of New York Upstate Medical University; State University of New York Upstate Medical University; State University of New York Upstate Medical University; Syracuse University; State University of New York Upstate Medical University; University of Michigan - Ann Arbor; Trinity University, San Antonio; University of Michigan - Ann Arbor; University of Michigan - Ann Arbor; University of Michigan - Ann Arbor; University of Michigan - Ann Arbor; University of Michigan - Ann Arbor; University of Michigan - Ann Arbor; University of Michigan - Ann Arbor; University of Massachusetts, Amherst; University of Massachusetts, Amherst; Northeastern University; University of California, San Diego; University of Washington; University of California, San Diego; University of California, San Diego; University of California at Santa Barbara; University of California at Santa Barbara; University of California at Santa Barbara; University of California, Merced; Jilin University; University of Science and Technology of China; University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; University of California, Los Angeles; University of Arizona; University of Arizona; Construx; Signature Science, LLC; Signature Science, LLC; Signature Science, LLC; Signature Science, LLC; Rensselaer Polytechnic Institute; University of Washington; Unaffiliated; Arizona State University; Brown University; Manhasset Secondary School; Brown University; Predictive Science, Inc; Predictive Science, Inc; Imperial College, London; Predictive Science, Inc; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; Oliver Wyman; University of Notre Dame; University of Notre Dame; University of Notre Dame; University of Chicago; University of Notre Dame; University of Notre Dame; Masaryk University; Masaryk University; Microsoft; Microsoft; Microsoft; Microsoft; Microsoft; Microsoft; Microsoft; Microsoft; Microsoft; ISI Foundation; Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University; Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University; Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University; Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University; Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University; Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University; Operations Research Center, Massachusetts Institute of Technology; Operations Research Center, Massachusetts Institute of Technology; Sloan School of Management, Massachusetts Institute of Technology; Operations Research Center, Massachusetts Institute of Technology; Sloan School of Management, Massachusetts Institute of Technology; Operations Research Center, Massachusetts Institute of Technology; Operations Research Center, Massachusetts Institute of Technology; Massachusetts Institute of Technology; Massachusetts Institute of Technology; Massachusetts Institute of Technology; New York University; Massachusetts Institute of Technology; Massachusetts Institute of Technology; Massachusetts Institute of Technology; Institute for Data, Systems, and Society, Massachusetts Institute of Technology; Institute for Data, Systems, and Society, Massachusetts Institute of Technology; Institute for Data, Systems, and Society, Massachusetts Institute of Technology; Laboratory for Computational Physiology, Massachusetts Institute of Technology; Laboratory for Computational Physiology, Massachusetts Institute of Technology; River Hill High School; SAS Institute Inc; Los Alamos National Laboratory; Los Alamos National Laboratory; Los Alamos National Laboratory; Los Alamos National Laboratory; TRIUMF; University of Victoria; Johns Hopkins University Applied Physics Lab; Johns Hopkins University Applied Physics Lab; Johns Hopkins University Applied Physics Lab; Johns Hopkins University Applied Physics Lab; Johns Hopkins University Applied Physics Lab; Johns Hopkins University Applied Physics Lab; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Unaffiliated; University of Utah; Johns Hopkins Bloomberg School of Public Health; Ecole Polytechnique Federale de Lausanne; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Unaffiliated; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins Bloomberg School of Public Health; Unaffiliated; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Unaffiliated; Iowa State University; Iowa State University; Iowa State University; Iowa State University; Clemson University; College of William & Mary; Iowa State University; University of Virginia; University of Washington; University of Washington; University of Washington; University of Washington; University of Washington; University of Washington; University of Washington; IEM, Inc.; IEM, Inc.; IEM, Inc.; IEM, Inc.; Georgia Institute of Technology; University of Iowa; Georgia Institute of Technology; Georgia Institute of Technology; Georgia Institute of Technology; Virginia Tech; Georgia Institute of Technology; Georgia Insitute of Technology; Metron, Inc.; Georgia Insitute of Technology; Georgia Insitute of Technology; Georgia Insitute of Technology; Google Cloud; Google Cloud; Google Cloud; Google Cloud; Google Cloud; Google Cloud; Google Cloud; Google Cloud; Google Cloud; Harvard University; Google Cloud; Google Cloud; Google Cloud; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; The University of Texas at Austin; The University of Texas at Austin; Columbia University; Columbia University; Columbia University; Operations Research Center, Massachusetts Institute of Technology; Sloan School of Management, Massachusetts Institute of Technology; Operations Research Center, Massachusetts Institute of Technology; Operations Research Center, Massachusetts Institute of Technology; Operations Research Center, Massachusetts Institute of Technology; Emory University Medical School; Georgia Insitute of Technology; MGH; MGH; Value Analytics Labs; MGH; Boston University School of Medicine; MGH; Georgia Insitute of Technology; Columbia University; Columbia University; Columbia University; UNC Chapel Hill; Carnegie Mellon University; University of Southern California; Carnegie Mellon University; Carnegie Mellon University; Carnegie Mellon University; University of British Columbia; Stanford University; Carnegie Mellon University; Stanford University; Carnegie Mellon University; University of Washington; Carnegie Mellon University; Stanford University; Carnegie Mellon University; Carnegie Mellon University; University of Georgia; University of Georgia; Unaffiliated; Walmart Inc.; Dalhousie University; Virtual Power System Inc.; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; Centers for Disease Control and Prevention; University of Massachusetts, Amherst","Short-term probabilistic forecasts of the trajectory of the COVID-19 pandemic in the United States have served as a visible and important communication channel between the scientific modeling community and both the general public and decision-makers. Forecasting models provide specific, quantitative, and evaluable predictions that inform short-term decisions such as healthcare staffing needs, school closures, and allocation of medical supplies. Starting in April 2020, the US COVID-19 Forecast Hub (https://covid19forecasthub.org/) collected, disseminated, and synthesized tens of millions of specific predictions from more than 90 different academic, industry, and independent research groups. A multi-model ensemble forecast that combined predictions from dozens of different research groups every week provided the most consistently accurate probabilistic forecasts of incident deaths due to COVID-19 at the state and national level from April 2020 through October 2021. The performance of 27 individual models that submitted complete forecasts of COVID-19 deaths consistently throughout this year showed high variability in forecast skill across time, geospatial units, and forecast horizons. Two-thirds of the models evaluated showed better accuracy than a naive baseline model. Forecast accuracy degraded as models made predictions further into the future, with probabilistic error at a 20-week horizon 3-5 times larger than when predicting at a 1-week horizon. This project underscores the role that collaboration and active coordination between governmental public health agencies, academic modeling teams, and industry partners can play in developing modern modeling capabilities to support local, state, and federal response to outbreaks.

Significance StatementThis paper compares the probabilistic accuracy of short-term forecasts of reported deaths due to COVID-19 during the first year and a half of the pandemic in the US. Results show high variation in accuracy between and within stand-alone models, and more consistent accuracy from an ensemble model that combined forecasts from all eligible models. This demonstrates that an ensemble model provided a reliable and comparatively accurate means of forecasting deaths during the COVID-19 pandemic that exceeded the performance of all of the models that contributed to it. This work strengthens the evidence base for synthesizing multiple models to support public health action.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.02.01.21250839,2021-02-03,https://medrxiv.org/cgi/content/short/2021.02.01.21250839,Extremely high SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK,Katherine M Gaskell; Marina Johnson; Victoria Gould; Adam Hunt; Neil RH Stone; William Waites; Ben Kasstan; Tracey Chantler; Sham Lal; Chrissy h. Roberts; David Goldblatt; Rosalind M Eggo; Michael M Marks,"Department of Clinical Research, London School of Hygiene & Tropical Medicine, Keppel Street, London. WC1E 7HT UK; Great Ormond Street Institute of Child Health Biomedical Research Centre, University College London; Department of Clinical Research, London School of Hygiene & Tropical Medicine, Keppel Street, London. WC1E 7HT UK; Great Ormond Street Institute of Child Health Biomedical Research Centre, University College London; Department of Clinical Research, London School of Hygiene & Tropical Medicine, Keppel Street, London. WC1E 7HT UK & Hospital for Tropical Diseases, University C; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London. WC1E 7HT UK; Centre for Health, Law and Society, University of Bristol Law School, Bristol. BS1 1RJ; Department of Global Health and Development, London School of Hygiene & Tropical Medicine, Keppel Street, London. WC1E 7HT UK; Department of Clinical Research, London School of Hygiene & Tropical Medicine, Keppel Street, London. WC1E 7HT UK; Department of Clinical Research, London School of Hygiene & Tropical Medicine, Keppel Street, London. WC1E 7HT UK; Great Ormond Street Institute of Child Health Biomedical Research Centre, University College London; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, Keppel Street, London. WC1E 7HT UK; Department of Clinical Research, London School of Hygiene & Tropical Medicine, Keppel Street, London. WC1E 7HT UK & Hospital for Tropical Diseases, University C","BackgroundEthnic and religious minorities have been disproportionately affected by SARS-CoV-2 worldwide. The UK strictly-Orthodox Jewish community has been severely affected by the pandemic. This group shares characteristics with other ethnic minorities including larger family sizes, higher rates of household crowding and relative socioeconomic deprivation. We studied a UK strictly-Orthodox Jewish population to understand how COVID-19 had spread within this community.

MethodsWe performed a household-focused cross-sectional SARS-CoV-2 serosurvey specific to three antigen targets. Randomly-selected households completed a standardised questionnaire and underwent serological testing with a multiplex assay for SARS-CoV-2 IgG antibodies. We report clinical illness and testing before the serosurvey, seroprevalence stratified by age and gender. We used random-effects models to identify factors associated with infection and antibody titres.

FindingsA total of 343 households, consisting of 1,759 individuals, were recruited. Serum was available for 1,242 participants. The overall seroprevalence for SARS-CoV-2 was 64.3% (95% CI 61.6-67.0%). The lowest seroprevalence was 27.6% in children under 5 years and rose to 73.8% in secondary school children and 74% in adults. Antibody titres were higher in symptomatic individuals and declined over time since reported COVID-19 symptoms, with the decline more marked for nucleocapsid titres.

InterpretationIn this tight-knit religious minority population in the UK, we report one of the highest SARS-CoV-2 seroprevalence levels in the world to date. In the context of this high force of infection, all age groups experienced a high burden of infection. Actions to reduce the burden of disease in this and other minority populations are urgently required.

FundingThis work was jointly funded by UKRI and NIHR [COV0335; MR/V027956/1], a donation from the LSHTM Alumni COVID-19 response fund, HDR UK, the MRC and the Wellcome Trust. The funders had no role in the design, conduct or analysis of the study or the decision to publish. The authors have no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Research In ContextO_ST_ABSEvidence before the studyC_ST_ABSIn January 2020, we searched PubMed for articles on rates of SARS-CoV-2 infection amongst ethnic minority groups and amongst the Jewish population. Search teams included ""COVID-19"", ""SARS-CoV-2"", seroprevalence, ""ethnic minority"", and ""Jewish"" with no language restrictions. We also searched UK government documents on SARS-CoV-2 infection amongst minority groups. By January 2020, a large number of authors had reported that ethnic minority groups experienced higher numbers of cases and increased hospitalisations due to COVID-19. A small number of articles provided evidence that strictly-Orthodox Jewish populations had experienced a high rate of SARS-CoV-2 infection but extremely limited data was available on overall population level rates of infection amongst specific ethnic minority population groups. There was also extremely limited data on rates of infection amongst young children from ethnic minority groups.

Added value of the studyWe report findings from a population representative, household survey of SARS-CoV-2 infection amongst a UK strictly Orthodox Jewish population. We demonstrate an extremely high seroprevalence rate of SARS-CoV-2 in this population which is more than five times the estimated seroprevalence nationally and five times the estimated seroprevalence in London. In addition the large number of children in our survey, reflective of the underlying population structure, allows us to demonstrate that in this setting there is a significant burden of disease in all age groups with secondary school aged children having an equivalent seroprevalence to adults.

Implications of the available evidenceOur data provide clear evidence of the markedly disproportionate impact of SARS-CoV-2 in minority populations. In this setting infection occurs at high rates across all age groups including pre-school, primary school and secondary school-age children. Contextually appropriate measures to specifically reduce the impact of SARS-CoV-2 amongst minority populations are urgently required.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.02.02.21250989,2021-02-03,https://medrxiv.org/cgi/content/short/2021.02.02.21250989,Short report: Ethnicity and COVID-19 death in the early part of the COVID-19 second wave in England: an analysis of OpenSAFELY data from 1st September to 9th November 2020,Krishnan Bhaskaran; Rohini Mathur; Christopher T Rentsch; Caroline E Morton; William J Hulme; Anna Schultze; Brian McKenna; Rosalind M Eggo; Angel YS Wong; Elizabeth J Williamson; Harriet J Forbes; Kevin Wing; Helen I McDonald; Chris J Bates; Sebastian CJ Bacon; Alex J Walker; David Evans; Peter Inglesby; Amir Mehrkar; Helen J Curtis; Nichola J DeVito; Richard Croker; Henry Drysdale; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Laurie Tomlinson; Stephen JW Evans; Richard Grieve; Liam Smeeth; Ben Goldacre,"London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; London School of Hygiene and Tropical Medicine; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP, TPP House, Horsforth, Leeds; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford; TPP, TPP House, Horsforth, Leeds; TPP, TPP House, Horsforth, Leeds; TPP, TPP House, Horsforth, Leeds; TPP, TPP House, Horsforth, Leeds; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford","Black and minority ethnic groups were at raised risk of dying from COVID-19 during the first few months of the COVID-19 epidemic in England. We aimed to investigate whether ethnic inequalities in COVID-19 deaths were similar in the more recent ""second wave"" of the epidemic. Working on behalf of NHS England, we used primary care and linked ONS mortality data within the OpenSAFELY platform. All adults in the database at 1st September 2020 and with at least 1 year of prior follow-up and a record of ethnicity were included. The outcome was COVID-19-related death (death with COVID-19 listed as a cause of death on the death certificate). Follow-up was to 9th November 2020. Hazard ratios for ethnicity were calculated using Cox regression models adjusted for age and sex, and then further adjusted for deprivation. 13,223,154 people were included. During the study period, people of South Asian ethnicity were at higher risk of death due to COVID-19 than white people after adjusting for age and sex (HR = 3.47, 95% CI 2.99-4.03); the association attenuated somewhat on further adjustment for index of multiple deprivation (HR = 2.86, 2.46-3.33, Table 2). In contrast with the first wave of the epidemic, we found little evidence of a raised risk in black or other ethnic groups compared to white (HR for black vs white = 1.28, 0.87-1.88 adjusted for age and sex; and 1.01, 0.69-1.49 further adjusted for deprivation). Our findings suggest that ethnic inequalities in the risk of dying COVID-19-related death have changed between the first and early second wave of the epidemic in England.

O_TBL View this table:
org.highwire.dtl.DTLVardef@987a5org.highwire.dtl.DTLVardef@1a8a141org.highwire.dtl.DTLVardef@1f2de56org.highwire.dtl.DTLVardef@1e2f9b8org.highwire.dtl.DTLVardef@78bfcc_HPS_FORMAT_FIGEXP  M_TBL O_FLOATNOTable 2:C_FLOATNO O_TABLECAPTIONAssociation between ethnicity and COVID-19 death 1st Sept - 9th Nov 2020

C_TABLECAPTION C_TBL",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.01.30.21250777,2021-02-01,https://medrxiv.org/cgi/content/short/2021.01.30.21250777,Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study,Hayley E Jones; Ranya Mulchandani; Sian Taylor-Phillips; A E Ades; Justin Shute; Keith Perry; Nastassya Chandra; Tim Brooks; Andre Charlett; Matthew Hickman; Isabel Oliver; Stephen Kaptoge; John Danesh; Emanuele Di Angelantonio; - COMPARE Study investigators; - EDSAB-HOME investigators; David H WYLLIE,University of Bristol; Public Health England; University of Warwick; University of Bristol; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; University of Bristol; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; ; ; Public Health England,"BackgroundSARS-CoV-2 antibody tests are used for population surveillance and might have a future role in individual risk assessment. Lateral flow immunoassays (LFIAs) can deliver results rapidly and at scale, but have widely varying accuracy.

MethodsIn a laboratory setting, we performed head-to-head comparisons of four LFIAs: the Rapid Test Consortiums AbC-19 Rapid Test, OrientGene COVID IgG/IgM Rapid Test Cassette, SureScreen COVID-19 Rapid Test Cassette, and Biomerica COVID-19 IgG/IgM Rapid Test. We analysed blood samples from 2,847 key workers and 1,995 pre-pandemic blood donors with all four devices.

FindingsWe observed a clear trade-off between sensitivity and specificity: the IgG band of the SureScreen device and the AbC-19 device had higher specificities but OrientGene and Biomerica higher sensitivities. Based on analysis of pre-pandemic samples, SureScreen IgG band had the highest specificity (98.9%, 95% confidence interval 98.3 to 99.3%), which translated to the highest positive predictive value across any pre-test probability: for example, 95.1% (95%CI 92.6, 96.8%) at 20% pre-test probability. All four devices showed higher sensitivity at higher antibody concentrations (""spectrum effects""), but the extent of this varied by device.

InterpretationThe estimates of sensitivity and specificity can be used to adjust for test error rates when using these devices to estimate the prevalence of antibody. If tests were used to determine whether an individual has SARS-CoV-2 antibodies, in an example scenario in which 20% of individuals have antibodies we estimate around 5% of positive results on the most specific device would be false positives.

FundingPublic Health England.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched for evidence on the accuracy of the four devices compared in this study: OrientGene COVID IgG/IgM Rapid Test Cassette, SureScreen COVID-19 Rapid Test Cassette, Biomerica COVID-19 IgG/IgM Rapid Test and the UK Rapid Test Consortiums AbC-19 Rapid Test. We searched Ovid MEDLINE (In-Process & Other Non-Indexed Citations and Daily), PubMed, MedRxiv/BioRxiv and Google Scholar from January 2020 to 16th January 2021. Search terms included device names AND ((SARS-CoV-2) OR (covid)). Of 303 records assessed, data were extracted from 24 studies: 18 reporting on the accuracy of the OrientGene device, 7 SureScreen, 2 AbC-19 and 1 Biomerica. Only three studies compared the accuracy of two or more of the four devices. With the exception of our previous report on the accuracy of the AbC-19 device, which the current manuscript builds upon, sample size ranged from 7 to 684. For details, see Supplementary Materials.

The largest study compared OrientGene, SureScreen and Biomerica. SureScreen was estimated to have the highest specificity (99.8%, 95% CI 98.9 to 100%) and OrientGene the highest sensitivity (92.6%), but with uncertainty about the latter result due to small sample sizes. The other two comparative studies were small (n = 65, n = 67) and therefore provide very uncertain results.

We previously observed spectrum effects for the AbC-19 device, such that sensitivity is upwardly biased if estimated only from PCR-confirmed cases. The vast majority of previous studies estimated sensitivity in this way.

Added value of this studyWe performed a large scale (n = 4,842), head-to-head laboratory-based evaluation and comparison of four lateral flow devices, which were selected for evaluation by the UK Department of Health and Social Cares New Tests Advisory Group, on the basis of a survey of test and performance data available. We evaluated the performance of diagnosis based on both IgG and IgM bands, and the IgG band alone. We found a clear trade-off between sensitivity and specificity across devices, with the SureScreen and AbC-19 devices being more specific and OrientGene and Biomerica more sensitive. Based on analysis of 1,995 pre-pandemic blood samples, we are 99% confident that SureScreen (IgG band reading) has the highest specificity of the four devices (98.9%, 95% CI 98.3, 99.3%).

We found evidence that all four devices have reduced sensitivity at lower antibody indices, i.e. spectrum effects. However, the extent of this varies by device and appears to be less for other devices than for AbC-19.

Our estimates of sensitivity and specificity are likely to be higher than would be observed in real use of these devices, as they were based on majority readings of three trained laboratory personnel.

Implications of all the available evidenceWhen used in epidemiological studies of antibody prevalence, the estimates of sensitivity and specificity provided in this study can be used to adjust for test errors. Increased precision in error rates will translate to increased precision in seroprevalence estimates. If lateral flow devices were used for individual risk assessment, devices with maximum specificity would be preferable. However, if, for an example, 20% of the tested population had antibodies, we estimate that around 1 in 20 positive results on the most specific device would be incorrect.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.01.28.21250606,2021-01-31,https://medrxiv.org/cgi/content/short/2021.01.28.21250606,REACT-1 round 8 final report: high average prevalence with regional heterogeneity of trends in SARS-CoV-2 infection in the community in England during January 2021,Steven Riley; Oliver Eales; Caroline E. Walters; Haowei Wang; Kylie E. C. Ainslie; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear","In early January 2021, England entered its third national lockdown of the COVID-19 pandemic to reduce numbers of deaths and pressure on healthcare services, while rapidly rolling out vaccination to healthcare workers and those most at risk of severe disease and death. REACT-1 is a survey of SARS-CoV-2 prevalence in the community in England, based on repeated cross-sectional samples of the population. Between 6th and 22nd January 2021, out of 167,642 results, 2,282 were positive giving a weighted national prevalence of infection of 1.57% (95% CI, 1.49%, 1.66%). The R number nationally over this period was estimated at 0.98 (0.92, 1.04). Prevalence remained high throughout, but with suggestion of a decline at the end of the study period. The average national trend masked regional heterogeneity, with robustly decreasing prevalence in one region (South West) and increasing prevalence in another (East Midlands). Overall prevalence at regional level was highest in London at 2.83% (2.53%, 3.16%). Although prevalence nationally was highest in the low-risk 18 to 24 year old group at 2.44% (1.96%, 3.03%), it was also high in those over 65 years who are most at risk, at 0.93% (0.82%, 1.05%). Large household size, living in a deprived neighbourhood, and Black and Asian ethnicity were all associated with higher levels of infections compared to smaller households, less deprived neighbourhoods and other ethnicities. Healthcare and care home workers, and other key workers, were more likely to test positive compared to other workers. If sustained lower prevalence is not achieved rapidly in England, pressure on healthcare services and numbers of COVID-19 deaths will remain unacceptably high.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.01.25.21249942,2021-01-30,https://medrxiv.org/cgi/content/short/2021.01.25.21249942,Development and external validation of prognostic models for COVID-19 to support risk stratification in secondary care,Nicola J Adderley; Thomas Taverner; Malcolm Price; Christopher Sainsbury; David Greenwood; Joht Singh Chandan; Yemisi Takwoingi; Rashan Haniffa; Isaac Hosier; Carly Welch; Dhruv Parekh; Suzy Gallier; Krishna M Gokhale; Alastair K Denniston; Elizabeth Sapey; Krishnarajah Nirantharakumar,University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Oxford; University of Birmingham; University of Birmingham; University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham,"ObjectivesExisting UK prognostic models for patients admitted to hospital with COVID-19 are limited by reliance on comorbidities, which are under-recorded in secondary care, and lack of imaging data among the candidate predictors. Our aims were to develop and externally validate novel prognostic models for adverse outcomes (death, intensive therapy unit (ITU) admission) in UK secondary care; and externally validate the existing 4C score.

DesignCandidate predictors included demographic variables, symptoms, physiological measures, imaging, laboratory tests. Final models used logistic regression with stepwise selection.

SettingModel development was performed in data from University Hospitals Birmingham (UHB). External validation was performed in the CovidCollab dataset.

ParticipantsPatients with COVID-19 admitted to UHB January-August 2020 were included.

Main outcome measuresDeath and ITU admission within 28 days of admission.

Results1040 patients with COVID-19 were included in the derivation cohort; 288 (28%) died and 183 (18%) were admitted to ITU within 28 days of admission. Area under the receiver operating curve (AUROC) for mortality was 0.791 (95%CI 0.761-0.822) in UHB and 0.767 (95%CI 0.754-0.780) in CovidCollab; AUROC for ITU admission was 0.906 (95%CI 0.883-0.929) in UHB and 0.811 (95%CI 0.795-0.828) in CovidCollab. Models showed good calibration. Addition of comorbidities to candidate predictors did not improve model performance. AUROC for the 4C score in the UHB dataset was 0.754 (95%CI 0.721-0.786).

ConclusionsThe novel prognostic models showed good discrimination and calibration in derivation and external validation datasets, and outperformed the existing 4C score. The models can be integrated into electronic medical records systems to calculate each individual patients probability of death or ITU admission at the time of hospital admission. Implementation of the models and clinical utility should be evaluated.

Article SummaryO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LIWe developed novel prognostic models predicting mortality and ITU admission within 28 days of admission for patients hospitalised with COVID-19, using a large routinely collected dataset gathered at admission with a wide range of possible predictors (demographic variables, symptoms, physiological measures, imaging, laboratory test results).
C_LIO_LIThese novel models showed good discrimination and calibration in both derivation and external validation cohorts, and outperformed the existing ISARIC model and 4C score in the derivation dataset. We found that addition of comorbidities to the set of candidate predictors included in model derivation did not improve model performance.
C_LIO_LIIf integrated into hospital electronic medical records systems, the model algorithms will provide a predicted probability of mortality or ITU admission for each patient based on their individual data at, or close to, the time of admission, which will support clinicians decision making with regard to appropriate patient care pathways and triage. This information might also assist clinicians in explaining complex prognostic assessments and decisions to patients and their relatives.
C_LIO_LIA limitation of the study was that in the external validation cohort we were unable to examine all of the predictors included in the original full UHB model due to only a reduced set of candidate predictors being available in CovidCollab. Nevertheless, the reduced model performed well and the results suggest it may be applicable in a wide range of datasets where only a reduced set of predictor variables is available.
C_LIO_LIFurthermore, it was not possible to carry out stratified analysis by ethnicity as the UHB dataset contained too few patients in most of the strata, and no ethnicity data was available in the CovidCollab dataset.
C_LI",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.01.28.21250680,2021-01-29,https://medrxiv.org/cgi/content/short/2021.01.28.21250680,"The effect of SARS-CoV-2 variant B.1.1.7 on symptomatology, re-infection and transmissibility",Mark S Graham; Carole H Sudre; Anna May; Michela Antonelli; Benjamin Murray; Thomas Varsavsky; Kerstin Klaser; Liane Dos Santos Canas; Erika Molteni; Marc Modat; David Alden Drew; Long Alden Nguyen; Lorenzo Polidori; Somesh Selvachandran; Christina Hu; Joan Capdevila Pujol; - The COVID-19 Genomics UK (COG-UK) consortium; Alexander Hammers; Andrew T Chan; Jonathan Wolf; Timothy Spector; Claire Steves; Sebastien Ourselin,King's College London; MRC Unit for Lifelong Health and Ageing; Zoe Global Limited; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Massachusetts General Hospital; Massachusetts General Hospital and Harvard Medical School; Zoe Global Limited; Zoe Global Limited; Zoe Global Limited; Zoe Global Limited; ; King's College London; Massachusetts General Hospital; Zoe Global Limited; King's College London; King's College London; King's College London,"BackgroundSARS-CoV-2 variant B.1.1.7 was first identified in December 2020 in England. It is not known if the new variant presents with variation in symptoms or disease course, if previously infected individuals may become reinfected with the new variant, or how the variants increased transmissibility affects measures to reduce its spread.

MethodsUsing longitudinal symptom reports from 36,920 users of the COVID Symptom Study app testing positive for Covid-19 between 28 September and 27 December 2020, we performed an ecological study to examine the association between the regional proportion of B.1.1.7 and reported symptoms, disease course, rates of reinfection, and transmissibility.

FindingsWe found no evidence for changes in reported symptoms or disease duration associated with B.1.1.7. We found a likely reinfection rate of 0.7% (95% CI 0.6-0.8), but no evidence that this was higher compared to older strains. We found an increase in R(t) by a factor of 1.35 (95% CI 1.02-1.69). Despite this, we found that R(t) fell below 1 during regional and national lockdowns, even in regions with high proportions of B.1.1.7.

InterpretationThe lack of change in symptoms indicates existing testing and surveillance infrastructure do not need to change specifically for the new variant, and the reinfection findings suggest that vaccines are likely to remain effective against the new variant.

FundingZoe Global Limited, Department of Health, Wellcome Trust, EPSRC, NIHR, MRC, Alzheimers Society.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSTo identify existing evidence on SARS-CoV-2 variant B.1.1.7 we searched PubMed and Google Scholar for articles between 1 December 2020 and 1 February 2021 using the keywords Covid-19 AND B.1.1.7, finding 281 results. We did not find any studies that investigated B.1.1.7-associated changes in the symptoms experienced, their severity and duration, but found one study showing B.1.1.7 did not change the ratio of symptomatic to asymptomatic infections. We found six articles describing laboratory-based investigations of the responses of B.1.1.7 to vaccine-induced immunity to B.1.1.7, but no work investigating what this means for natural immunity and the likelihood of reinfection outside of the lab. We found five articles demonstrating the increased transmissibility of B.1.1.7.

Added value of this studyTo our knowledge, this is the first study to explore changes in symptom type and duration, as well as community reinfection rates, associated with B.1.1.7. The work uses self-reported symptom logs from 36,920 users of the COVID Symptom Study app reporting positive test results between 28 September and 27 December 2020. We find that B.1.1.7 is not associated with changes in the symptoms experienced in Covid-19, nor their duration. Building on existing lab studies, our work suggests that natural immunity developed from previous infection provides similar levels of protection to B.1.1.7. We add to the emerging consensus that B.1.1.7 exhibits increased transmissibility.

Implications of all the available evidenceOur findings suggest that existing criteria for obtaining a Covid-19 test in the community need not change for the rise of B.1.1.7. The fact that immunity developed from infection by wild type variants protects against B.1.1.7 provides an indication that vaccines will remain effective against B.1.1.7. R(t) fell below 1 during the UKs national lockdown, even in regions with high levels of B.1.1.7, but further investigation is required to establish the factors that enabled this, to facilitate countries seeking to control the spread of B.1.1.7.",epidemiology,fuzzy,94,100
medRxiv,10.1101/2021.01.26.21250480,2021-01-28,https://medrxiv.org/cgi/content/short/2021.01.26.21250480,"Individual factors underlie temperature variation in sickness and in health: influence of age, BMI and genetic factors in a multi-cohort study",Rose S. Penfold; Maria Beatrice Zazzara; Marc F. √ñsterdahl; - GSTT CovidCollaborative; Carly Welch; Mary Ni Lochlainn; Maxim Freidin; Ruth C.E. Bowyer; Ellen E.J. Thompson; Michela Antonelli; Yu Xian Rachel Tan; Carole Sudre; Marc Modat; Benjamin Murray; Jonathan Wolf; Sebastien Ourselin; Tonny Veenith; Janet M. Lord; Claire J. Steves,"King's College London, Department of Twin Research & Genetic Epidemiology; Guy's and St Thomas' NHS Foundation Trust; King's College London, Department of Twin Research & Genetic Epidemiology;  Catholic University of the Sacred Heart Faculty of Medicine and Surgery, Department ; Guy's and St Thomas' NHS Foundation Trust; ; University of Birmingham, Institute of Inflammation & Ageing; King's College London, Department of Twin Research & Genetic Epidemiology; King's College London, Department of Twin Research & Genetic Epidemiology; King's College London, Department of Twin Research & Genetic Epidemiology; King's College London, Department of Twin Research & Genetic Epidemiology; King's College London, School of Biomedical Engineering & Imaging Sciences London; Royal College of Surgeons in Ireland, Department of Medicine; King's College London, School of Biomedical Engineering & Imaging Sciences London; King's College London, School of Biomedical Engineering & Imaging Sciences; King's College London, School of Biomedical Engineering & Imaging Sciences; Zoe Global Limited London; King's College London, School of Biomedical Engineering & Imaging Sciences; University of Birmingham, Institute of Inflammation and Ageing; University of Birmingham, Institute of Inflammation and Ageing; Department of Twin Research and Genetic Epidemiology, King's College London","IntroductionAgeing affects immune function resulting in aberrant fever response to infection. We assess the effects of biological variables on basal temperature and temperature in COVID-19 infection, proposing an updated temperature threshold for older adults.

MethodsParticipants:

O_LIUnaffected twin volunteers: 1089 adult TwinsUK participants.
C_LIO_LILondon hospitalised COVID-19+: 520 adults with emergency admission.
C_LIO_LIBirmingham hospitalised COVID-19+: 757 adults with emergency admission.
C_LIO_LICommunity-based COVID-19+: 3972 adults self-reporting a positive test using the COVID Symptom Study mobile application.
C_LI

AnalysisHeritability assessed using saturated and univariate ACE models; Linear mixed-effect and multivariable linear regression analysing associations between temperature, age, sex and BMI; multivariable logistic regression analysing associations between fever ([&ge;]37.8{degrees}C) and age; receiver operating characteristic (ROC) analysis to identify temperature threshold for adults [&ge;] 65 years.

ResultsAmong unaffected volunteers, lower BMI (p=0.001), and older age (p<0.001) associated with lower basal temperature. Basal temperature showed a heritability of 47% (95% Confidence Interval 18-57%).

In COVID-19+ participants, increasing age associated with lower temperatures in cohorts (c) and (d) (p<0.001). For each additional year of age, participants were 1% less likely to demonstrate a fever (OR 0.99; p<0.001).

Combining healthy and COVID-19+ participants, a temperature of 37.4{degrees}C in adults [&ge;]65 years had similar sensitivity and specificity to 37.8{degrees}C in adults <65 years for discriminating fever in COVID-19.

ConclusionsAgeing affects temperature in health and acute infection. Significant heritability indicates biological factors contribute to temperature regulation.

Our observations indicate a lower threshold (37.4{degrees}C) should be considered for assessing fever in older adults.

Key PointsO_LIOlder adults, particularly those with lower BMI, have a lower basal temperature and a lower temperature in response to infection
C_LIO_LIBasal temperature is heritable, suggesting biological factors underlying temperature regulation
C_LIO_LIOur findings support a lower temperature threshold of 37.4{degrees}C for identifying possible COVID-19 infection in older adults
C_LIO_LIThis has implications for case detection, surveillance and isolation and could be incorporated into observation assessment
C_LI",geriatric medicine,fuzzy,94,100
medRxiv,10.1101/2021.01.26.21249744,2021-01-27,https://medrxiv.org/cgi/content/short/2021.01.26.21249744,The King's College London Coronavirus Health and Experiences of Colleagues at King's Study: SARS-CoV-2 antibody response in a higher education sample,Daniel Leightley Dr; Valentina Vitiello Dr; Alice Wickersham Ms; Katrina A.S. Davis Dr; Gabriella Bergin-Cartwright Ms; Grace Lavelle Dr; Sharon A.M. Stevelink Dr; Matthew Hotopf Prof; Reza Razavi Prof,"Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; The School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.","ObjectiveTo assess the feasibility of home antibody testing as part of large-scale study, the Kings College London Coronavirus Health and Experiences of Colleagues at Kings (KCL CHECK).

MethodsParticipants of the KCL CHECK study were sent a SureScreen Diagnostics COVID-19 IgG/IgM Rapid Test Cassette to complete at home in June 2020 (phase 1) and September 2020 (phase 2). Participants were asked to upload a test result image to a study website. Test result images and sociodemographic information were analysed by the research team.

ResultsA total of n=2716 participants enrolled in the KCL CHECK study, with n=2003 (73.7%) and n=1825 (69.3%) consenting and responding to phase 1 and 2. Of these, n=1882 (93.9%; phase 1) and n=1675 (91.8%; phase 2) returned a valid result. n=123 (6.5%; phase 1) and n=91 (5.4%; phase 2) tested positive for SARS-CoV-2 antibodies. A total of n=1488 participants provided a result in both phases, with n=57 (3.8%) testing positive for SARS- CoV-2 antibodies across both phases, suggesting a reduction in the number of positive antibody results over time. Initial comparisons showed variation by age group, gender and clinical role.

ConclusionsOur study highlights the feasibility of rapid, repeated and low-cost SARS-CoV-2 serological testing without the need for face-to-face contact.

What is already known about this subject?Higher education institutions have a duty of care to minimise the spread and transmission of COVID-19 in its campuses, and among staff and students. The reopening of higher education buildings and campuses has brought about a mass movement of students, academics and support staff from across the UK. Serological antibody studies can assist by highlighting groups of people and behaviours associated with high risk of COVID-19.

What are the new findings?We report a framework for SARS-CoV-2 serological antibody testing in an occupational group of postgraduate research students and current members of staff at Kings College London. Over two phases of data collection, 6.5% (phase 1) and 5.4% (phase 2) tested positive for SARS-CoV-2 antibodies, with only 3.8% testing positive for antibodies in both phases, suggesting a reduction in positive antibody results over time.

How might this impact on policy or clinical practice in the foreseeable future?Our study highlights the feasibility of rapidly deploying low-cost and repeatable SARS-CoV-2 serological testing, without the need for face-to-face contact, to support the higher education system of the UK.",health policy,fuzzy,100,100
medRxiv,10.1101/2021.01.25.21250356,2021-01-26,https://medrxiv.org/cgi/content/short/2021.01.25.21250356,"Trends, regional variation, and clinical characteristics of COVID-19 vaccine recipients: a retrospective cohort study in 23.4 million patients using OpenSAFELY.",Helen J Curtis; Peter Inglesby; Caroline E Morton; Brian MacKenna; Alex J Walker; Jessica Morley; Amir Mehrkar; Sebastian CJ Bacon; George Hickman; Christopher Bates; Richard Croker; David Evans; Tom Ward; Jonathan Cockburn; Simon Davy; Krishnan Bhaskaran; Anna Schultze; Christopher T Rentsch; Elizabeth J Williamson; William J Hulme; Amelia Green; Anna Rowan; Louis Fisher; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel YS Wong; Harriet Forbes; Ian J Douglas; John Parry; Frank Hester; Sam Harper; Shaun O'Hanlon; Alex Eavis; Richard Jarvis; Dima Avramov; Aaron Fowles; Nasreen Parkes; Paul Griffiths; Stephen JW Evans; Liam Smeeth; Ben Goldacre,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; EMIS Group; EMIS Group; EMIS Group; EMIS Group; University of Oxford; EMIS Group; EMIS Group; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundOn December 8th 2020, NHS England administered the first COVID-19 vaccination as part of an ambitious vaccination programme during a global health emergency.

AimsTo describe trends and variation in vaccine coverage by key clinical and demographic groups; to create a framework for near-real-time monitoring of vaccine coverage in key subgroups.

MethodsWorking on behalf of NHS England we analysed 57.9 million patient records in situ and in near-real-time within the infrastructure of the Electronic Health Record (EHR) software vendors EMIS and TPP using OpenSAFELY. We describe vaccine coverage and time trends across a range of demographic and fine-grained clinical subgroups in eight Joint Committee on Vaccination and Immunisation (JCVI) priority cohorts.

Results20,852,692 patients (36%) received a COVID-19 vaccine between December 8th 2020 and March 17th 2021. Of patients aged [&ge;]80 not in a care home (JCVI group 2) 94.7% received a vaccine, but with substantial variation by ethnicity (White 96.2% vaccinated, Black 68.3%) and deprivation (least deprived 96.6%, most deprived 90.7%). Overall, patients with pre-existing medical conditions were equally or more likely to be vaccinated with two exceptions: severe mental illness (89.5% vaccinated) and learning disability (91.4%). 275,205 vaccine recipients were identified as care home residents (priority group 1; 91.2% coverage). 1,257,914 (6.0%) recipients have had a second dose. Detailed characteristics of recipients in all cohorts are reported.

ConclusionsThe NHS in England has rapidly delivered mass vaccination. We were able to deploy a data monitoring framework using publicly auditable methods and a secure, in-situ processing model, using linked but pseudonymised patient-level NHS data on 57.9 million patients with very short delays from vaccine administration to completed analysis. Targeted activity may be needed to address lower vaccination coverage observed among certain key groups: ethnic minorities, those living in deprived areas, and people with severe mental illness or learning disabilities.",public and global health,fuzzy,100,100
medRxiv,10.1101/2021.01.22.21250304,2021-01-25,https://medrxiv.org/cgi/content/short/2021.01.22.21250304,Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19: a descriptive cohort study within the OpenSAFELY platform,John Tazare; Alex J Walker; Laurie Tomlinson; George Hickman; Christopher T Rentsch; Elizabeth J Williamson; Krishnan Bhaskaran; David Evans; Kevin Wing; Rohini Mathur; Angel YS Wong; Anna Schultze; Sebastian CJ Bacon; Christopher Bates; Caroline E Morton; Helen J Curtis; Emily Nightingale; Helen I McDonald; Amir Mehrkar; Peter Inglesby; Simon Davy; Brian MacKenna; Jonathan Cockburn; William J Hulme; Charlotte Warren-Gash; Ketaki Bhate; Emma Powell; Any Mulick; Harriet Forbes; Caroline Minassian; Richard Croker; John Parry; Frank Hester; Sam Harper; Rosalind M Eggo; Stephen JW Evans; Liam Smeeth; Ian J Douglas; Ben Goldacre,London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundPatients with COVID-19 are thought to be at higher risk of cardiometabolic and pulmonary complications, but quantification of that risk is limited. We aimed to describe the overall burden of these complications in survivors of severe COVID-19.

MethodsWorking on behalf of NHS England, we used linked primary care records, death certificate and hospital data from the OpenSAFELY platform. We constructed three cohorts: patients discharged following hospitalisation with COVID-19, patients discharged following hospitalisation with pneumonia in 2019, and a frequency-matched cohort from the general population in 2019. We studied eight cardiometabolic and pulmonary outcomes. Absolute rates were measured in each cohort and Cox regression models were fitted to estimate age/sex adjusted hazard ratios comparing outcome rates between discharged COVID-19 patients and the two comparator cohorts.

ResultsAmongst the population of 31,716 patients discharged following hospitalisation with COVID-19, rates for majority of outcomes peaked in the first month post-discharge, then declined over the following four months. Patients in the COVID-19 population had markedly increased risk of all outcomes compared to matched controls from the 2019 general population, especially for pulmonary embolism (HR 12.86; 95% CI: 11.23 - 14.74). Outcome rates were more similar when comparing patients discharged with COVID-19 to those discharged with pneumonia in 2019, although COVID-19 patients had increased risk of type 2 diabetes (HR 1.23; 95% CI: 1.05 - 1.44).

InterpretationCardiometabolic and pulmonary adverse outcomes are markedly raised following hospitalisation for COVID-19 compared to the general population. However, the excess risks were more comparable to those seen following hospitalisation with pneumonia. Identifying patients at particularly high risk of outcomes would inform targeted preventive measures.

FundingWellcome, Royal Society, National Institute for Health Research, National Institute for Health Research Oxford Biomedical Research Centre, UK Medical Research Council, UK Research and Innovation, Health and Safety Executive.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.01.22.21249968,2021-01-25,https://medrxiv.org/cgi/content/short/2021.01.22.21249968,An external validation of the QCovid risk prediction algorithm for risk of mortality from COVID-19 in adults: national validation cohort study in England,Vahe Nafilyan; Ben Humberstone; Nisha Metha; Ian Diamond; Luke Lorenzi; Piotr Pawelek; Ryan Schofield; Jasper Morgan; Paul Brown; Ronan Lyons; Aziz Sheikh; Julia Hippisley-Cox,Office for National Statistics; Office for National Statistics; Office of the Chief Medical Officer; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Swansea University; University of Edinburgh; University of Oxford,"BackgroundTo externally validate a risk prediction algorithm (QCovid) to estimate mortality outcomes from COVID-19 in adults in England.

MethodsPopulation-based cohort study using the ONS Public Health Linked Data Asset, a cohort based on the 2011 Census linked to Hospital Episode Statistics, the General Practice Extraction Service Data for pandemic planning and research, radiotherapy and systemic chemotherapy records. The primary outcome was time to COVID-19 death, defined as confirmed or suspected COVID-19 death as per death certification. Two time periods were used: (a) 24th January to 30th April 2020; and (b) 1st May to 28th July 2020. We evaluated the performance of the QCovid algorithms using measures of discrimination and calibration for each validation time period.

FindingsThe study comprises 34,897,648 adults aged 19-100 years resident in England. There were 26,985 COVID-19 deaths during the first time-period and 13,177 during the second. The algorithms had good calibration in the validation cohort in both time periods with close correspondence of observed and predicted risks. They explained 77.1% (95% CI: 76.9% to 77.4%) of the variation in time to death in men in the first time-period (R2); the D statistic was 3.76 (95% CI: 3.73 to 3.79); Harrells C was 0.935 (0.933 to 0.937). Similar results were obtained for women, and in the second time-period. In the top 5% of patients with the highest predicted risks of death, the sensitivity for identifying deaths in the first time period was 65.9% for men and 71.7% for women. People in the top 20% of predicted risks of death accounted for 90.8% of all COVID-19 deaths for men and 93.0% for women.

InterpretationThe QCovid population-based risk algorithm performed well, showing very high levels of discrimination for COVID-19 deaths in men and women for both time periods. It has the potential to be dynamically updated as the pandemic evolves and therefore, has potential use in guiding national policy.

FundingNational Institute of Health Research

RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSPublic policy measures and clinical risk assessment relevant to COVID-19 need to be aided by rigorously developed and validated risk prediction models. A recent living systematic review of published risk prediction models for COVID-19 found most models are subject to a high risk of bias with optimistic reported performance, raising concern that these models may be unreliable when applied in practice. A population-based risk prediction model, QCovid risk prediction algorithm, has recently been developed to identify adults at high risk of serious COVID-19 outcomes, which overcome many of the limitations of previous tools.

Added value of this studyCommissioned by the Chief Medical Officer for England, we validated the novel clinical risk prediction model (QCovid) to identify risks of short-term severe outcomes due to COVID-19. We used national linked datasets from general practice, death registry and hospital episode data for a population-representative sample of over 34 million adults. The risk models have excellent discrimination in men and women (Harrells C statistic>0.9) and are well calibrated. QCovid represents a new, evidence-based opportunity for population risk-stratification.

Implications of all the available evidenceQCovid has the potential to support public health policy, from enabling shared decision making between clinicians and patients in relation to health and work risks, to targeted recruitment for clinical trials, and prioritisation of vaccination, for example.",public and global health,fuzzy,100,100
bioRxiv,10.1101/2021.01.25.428136,2021-01-25,https://biorxiv.org/cgi/content/short/2021.01.25.428136,mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge,Michelle Meyer; Yuan Wang; Darin Edwards; Gregory R Smith; Aliza B Rubenstein; Palaniappan Ramanathan; Chad E Mire; Colette Pietzsch; Xi Chen; Yongchao Ge; Wan Sze Cheng; Carole Henry; Angela Woods; LingZhi Ma; Guillaume B. E. Stewart-Jones; Kevin W Bock; Minai Mahnaz; Bianca M Nagata; Sivakumar Periasamy; Pei-Yong Shi; Barney S Graham; Ian N Moore; Irene Ramos; Olga G. Troyanskaya; Elena Zaslavsky; Andrea Carfi; Stuart C Sealfon; Alexander Bukreyev,"University of Texas Medical Branch; Princeton University; Moderna Inc; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Texas Medical Branch; University of Texas Medical Branch; University of Texas Medical Branch; Flatiron Institute, Simons Foundation; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Moderna Inc; Moderna Inc; Moderna Inc; Moderna Inc; National Institute of Health; National Institutes of Health; National Institutes of Health; University of Texas Medical Branch; University of Texas Medical Branch; National Institutes of Health; National Institutes of Health; Icahn School of Medicine at Mount Sinai; Princeton University; Icahn School of Medicine at Mount Sinai; Moderna Inc; Icahn School of Medicine at Mount Sinai; University of Texas Medical Branch at Galveston","The mRNA-1273 vaccine was recently determined to be effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from interim Phase 3 results. Human studies, however, cannot provide the controlled response to infection and complex immunological insight that are only possible with preclinical studies. Hamsters are the only model that reliably exhibit more severe SARS-CoV-2 disease similar to hospitalized patients, making them pertinent for vaccine evaluation. We demonstrate that prime or prime-boost administration of mRNA-1273 in hamsters elicited robust neutralizing antibodies, ameliorated weight loss, suppressed SARS-CoV-2 replication in the airways, and better protected against disease at the highest prime-boost dose. Unlike in mice and non-human primates, mRNA-1273- mediated immunity was non-sterilizing and coincided with an anamnestic response. Single-cell RNA sequencing of lung tissue permitted high resolution analysis which is not possible in vaccinated humans. mRNA-1273 prevented inflammatory cell infiltration and the reduction of lymphocyte proportions, but enabled antiviral responses conducive to lung homeostasis. Surprisingly, infection triggered transcriptome programs in some types of immune cells from vaccinated hamsters that were shared, albeit attenuated, with mock-vaccinated hamsters. Our results support the use of mRNA-1273 in a two-dose schedule and provides insight into the potential responses within the lungs of vaccinated humans who are exposed to SARS-CoV-2.",immunology,fuzzy,96,94
medRxiv,10.1101/2021.01.21.20240887,2021-01-22,https://medrxiv.org/cgi/content/short/2021.01.21.20240887,"The psychosocial impact of the COVID-19 pandemic on 4,378 UK healthcare workers and ancillary staff: initial baseline data from a cohort study collected during the first wave of the pandemic.",Danielle Lamb; Sam Gnanapragasam; Neil Greenberg; Rupa Bhundia; Ewan Carr; Matthew Hotopf; Reza Razavi; Rosalind Raine; Sean Cross; Amy Dewar; Mary Docherty; Sarah Dorrington; Stephani Hatch; Charlotte Wilson-Jones; Daniel Leightley; Ira Madan; Sally Marlow; Isabel McMullen; Anne Marie Rafferty; Martin Parsons; Catherine Polling; Danai Serfioti; Helen Gaunt; Peter Aitken; Joanna Morris-Bone; Chloe Simela; Veronica French; Rachel Harris; Sharon A.M. Stevelink; Simon Wessely,"Department of Applied Health Research, UCL, 1-19 Torrington Place, London, WC1E 7HB; South London and Maudsley NHS Foundation Trust, London, UK; Health Protection Research Unit, King's College London, Weston Education Centre, 10 Cutcombe Road, London, SE5 9RJ; Department of Psychological Medicine, King's College London, London, UK.; Department of Biostatistics and Health Informatics, King's College London, London, UK; National Institute of Health Research Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust.; 1 Lambeth Palace Rd, South Bank, London, SE1 7EU; Dept of Applied Health Research, UCL; Department of Psychological Medicine, King's College Hospital. Denmark Hill. SE5 9RS; Guy's and St Thomas' NHS Foundation Trust; Department of Psychological Medicine, King's College Hospital. Denmark Hill. SE5 9RS; Institute of Psychiatry, Psychology and Neuroscience, King's College London; Institute of Psychiatry, Psychology and Neuroscience, King's College London; Institute of Psychiatry, Psychology and Neuroscience, King's College London; King's Centre for Military Health Research, Department of Psychological Medicine, King's College London, London, UK. AND Department of Psychological Medicine, K; Guy's and St Thomas' NHS Foundation Trust, London; Institute of Psychiatry, Psychology and Neuroscience, King's College London; Department of Psychological Medicine, King's College Hospital, South London and Maudsley NHS Foundation Trust; Adult Nursing, King's College London; Mental Health Liaison Team, King's College Hospital; Institute of Psychiatry, Psychology and Neuroscience, King's College London; King's Centre for Military Health Research, King's College London, Room 307, Weston Education Centre, 10 Cutcombe Road, London SE5 9RJ; University Hospital of Leciester NHS Trust. Groby Road Leciester LE4 9QP; Devon Partnership NHS Trust, Trust HQ, R&D, Dryden Road, Exeter, Devon, EX2 5AF; Avon & Wiltshire Mental Health Partnership NHS Trust, R&D, Fromeside, Blackberry Hill Hospital, Bristol, BS16 1EG; Guy's and St Thomas' NHS Foundation Trust, London; Nottinghamshire Healthcare NHS Foundation Trust; Cornwall Partnership Foundation NHS Trust/ Research and Innovation Team; King's Centre for Military Health Research, Department of Psychological Medicine, King's College London, London, UK. AND Department of Psychological Medicine, K; Department of Psychological Medicine, King's College London, Weston Education, Denmark Hill, London, SE5 9JR","ObjectivesThis study reports preliminary findings on the prevalence of, and factors associated with, mental health and wellbeing outcomes of healthcare workers during the early months (April-June) of the COVID-19 pandemic in the UK.

MethodsPreliminary cross-sectional data were analysed from a cohort study (n=4,378). Clinical and non-clinical staff of three London-based NHS Trusts (UK), including acute and mental health Trusts, took part in an online baseline survey. The primary outcome measure used is the presence of probable common mental disorders (CMDs), measured by the General Health Questionnaire (GHQ-12). Secondary outcomes are probable anxiety (GAD-7), depression (PHQ-9), Post-Traumatic Stress Disorder (PTSD) (PCL-6), suicidal ideation (CIS-R), and alcohol use (AUDIT). Moral injury is measured using the Moray Injury Event Scale (MIES).

ResultsAnalyses showed substantial levels of CMDs (58.9%, 95%CI 58.1 to 60.8), and of PTSD (30.2%, 95%CI 28.1 to 32.5) with lower levels of depression (27.3%, 95%CI 25.3 to 29.4), anxiety (23.2%, 95%CI 21.3 to 25.3), and alcohol misuse (10.5%, 95%CI, 9.2 to 11.9). Women, younger staff, and nurses tended to have poorer outcomes than other staff, except for alcohol misuse. Higher reported exposure to moral injury (distress resulting from violation of ones moral code) was strongly associated with increased levels of CMDs, anxiety, depression, PTSD symptoms, and alcohol misuse.

ConclusionsOur findings suggest that mental health support for healthcare workers should consider those demographics and occupations at highest risk. Rigorous longitudinal data are needed in order to respond to the potential long-term mental health impacts of the pandemic.

HighlightsO_ST_ABSWhat is already known about this subject?C_ST_ABSO_LILarge-scale population studies report increased prevalence of depression, anxiety, and psychological distress during the COVID-19 pandemic.
C_LIO_LIEvidence from previous epidemics indicates a high and persistent burden of adverse mental health outcomes among healthcare workers.
C_LI

What are the new findings?O_LISubstantial levels of probable common mental disorders and post-traumatic stress disorder were found among healthcare workers.
C_LIO_LIGroups at increased risk of adverse mental health outcomes included women, nurses, and younger staff, as well as those who reported higher levels of moral injury.
C_LI

How might this impact on policy or clinical practice in the foreseeable future?O_LIThe mental health offering to healthcare workers must consider the interplay of demographic, social, and occupational factors.
C_LIO_LIAdditional longitudinal research that emphasises methodological rigor, namely with use of standardised diagnostic interviews to establish mental health diagnoses, is necessary to better understand the mental health burden, identify those most at risk, and provide appropriate support without pathologizing ordinary distress responses.
C_LI",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2021.01.20.21250158,2021-01-22,https://medrxiv.org/cgi/content/short/2021.01.20.21250158,REACT-1 round 8 interim report: SARS-CoV-2 prevalence during the initial stages of the third national lockdown in England,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E. Walters; Haowei Wang; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear","BackgroundHigh prevalence of SARS-CoV-2 virus in many northern hemisphere populations is causing extreme pressure on healthcare services and leading to high numbers of fatalities. Even though safe and effective vaccines are being deployed in many populations, the majority of those most at-risk of severe COVID-19 will not be protected until late spring, even in countries already at a more advanced stage of vaccine deployment.

MethodsThe REal-time Assessment of Community Transmission study-1 (REACT-1) obtains throat and nose swabs from between 120,000 and 180,000 people in the community in England at approximately monthly intervals. Round 8a of REACT-1 mainly covers a period from 6th January 2021 to 15th January 2021. Swabs are tested for SARS-CoV-2 virus and patterns of swab-positivity are described over time, space and with respect to individual characteristics. We compare swab-positivity prevalence from REACT-1 with mobility data based on the GPS locations of individuals using the Facebook mobile phone app. We also compare results from round 8a with those from round 7 in which swabs were collected from 13th November to 24th November (round 7a) and 25th November to 3rd December 2020 (round 7b).

ResultsIn round 8a, we found 1,962 positives from 142,909 swabs giving a weighted prevalence of 1.58% (95% CI, 1.49%, 1.68%). Using a constant growth model, we found no strong evidence for either growth or decay averaged across the period; rather, based on data from a limited number of days, prevalence may have started to rise at the end of round 8a. Facebook mobility data showed a marked decrease in activity at the end of December 2020, followed by a rise at the start of the working year in January 2021. Between round 7b and round 8a, prevalence increased in all adult age groups, more than doubling to 0.94% (0.83%, 1.07%) in those aged 65 and over. Large household size, living in a deprived neighbourhood, and Black and Asian ethnicity were all associated with increased prevalence. Both healthcare and care home workers, and other key workers, had increased odds of swab-positivity compared to other workers.

ConclusionDuring the initial 10 days of the third COVID-19 lockdown in England in January 2021, prevalence of SARS-CoV-2 was very high with no evidence of decline. Until prevalence in the community is reduced substantially, health services will remain under extreme pressure and the cumulative number of lives lost during this pandemic will continue to increase rapidly.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.01.15.21249756,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.15.21249756,Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,Krishnan Bhaskaran; Sebastian CJ Bacon; Stephen JW Evans; Chris J Bates; Christopher T Rentsch; MacKenna Brian; Laurie Tomlinson; Alex J Walker; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre,"London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; The Phoenix Partnership; The Phoenix Partnership; Winton Centre for Risk and Evidence Communication, Centre for Mathematical Sciences, University of Cambridge; London School of Hygiene and Tropical Medicine; University of Oxford","BackgroundMortality from COVID-19 shows a strong relationship with age and pre-existing medical conditions, as does mortality from other causes. However it is unclear how specific factors are differentially associated with COVID-19 mortality as compared to mortality from other causes.

MethodsWorking on behalf of NHS England, we carried out a cohort study within the OpenSAFELY platform. Primary care data from England were linked to national death registrations. We included all adults (aged [&ge;]18 years) in the database on 1st February 2020 and with >1 year of continuous prior registration, the cut-off date for deaths was 9th November 2020. Associations between individual-level characteristics and COVID-19 and non-COVID deaths were estimated by fitting age- and sex-adjusted logistic models for these two outcomes.

Results17,456,515 individuals were included. 17,063 died from COVID-19 and 134,316 from other causes. Most factors associated with COVID-19 death were similarly associated with non-COVID death, but the magnitudes of association differed. Older age was more strongly associated with COVID-19 death than non-COVID death (e.g. ORs 40.7 [95% CI 37.7-43.8] and 29.6 [28.9-30.3] respectively for [&ge;]80 vs 50-59 years), as was male sex, deprivation, obesity, and some comorbidities. Smoking, history of cancer and chronic liver disease had stronger associations with non-COVID than COVID-19 death. All non-white ethnic groups had higher odds than white of COVID-19 death (OR for Black: 2.20 [1.96-2.47], South Asian: 2.33 [2.16-2.52]), but lower odds than white of non-COVID death (Black: 0.88 [0.83-0.94], South Asian: 0.78 [0.75-0.81]).

InterpretationSimilar associations of most individual-level factors with COVID-19 and non-COVID death suggest that COVID-19 largely multiplies existing risks faced by patients, with some notable exceptions. Identifying the unique factors contributing to the excess COVID-19 mortality risk among non-white groups is a priority to inform efforts to reduce deaths from COVID-19.

FundingWellcome, Royal Society, National Institute for Health Research, National Institute for Health Research Oxford Biomedical Research Centre, UK Medical Research Council, Health Data Research UK.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.01.19.21249840,2021-01-20,https://medrxiv.org/cgi/content/short/2021.01.19.21249840,Impact of SARS-CoV-2 B.1.1.7 Spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2,Dami Collier; Anna De Marco; Isabella Ferreira; Bo Meng; Rawlings Datir; Alexandra C. Walls; Steven A. Kemp S; Jessica Bassi; Dora Pinto; Chiara Silacci Fregni; Siro Bianchi; M. Alejandra Tortorici; John Bowen; Katja Culap; Stefano Jaconi; Elisabetta Cameroni; Gyorgy Snell; Matteo S. Pizzuto; Alessandra Franzetti Pellanda; Christian Garzoni; Agostino Riva; - The CITIID-NIHR BioResource COVID-19 Collaboration; Anne Elmer; Nathalie Kingston; Barbara Graves; Laura McCoy; Ken Smith; John Bradley; Ceron Ceron-Gutierrez L; Gabriela Barcenas-Morales; Herbert W. Virgin; Antonio Lanzavecchia; Luca Piccoli; Rainer Doffinger; Mark Wills; David Veesler; Davide Corti; Ravindra Gupta,UCL; Vir Biotechnology; University of Cambridge; University of Cambridge; University of Cambridge; University of Washington; University of Cambridge; Vir Biotechnology; Vir Biotechnology; Vir Biotechnology; Vir Biotechnology; University of Washington; University of Washington; Vir Biotehcnology; Vir Biotechnology; Vir Biotechnology; Vir Biotechnology; Vir Biotechnology; Clinica Luganese Moncucco; Clinica Luganese Moncucco; Luigi Sacco Hospital; ; Addenbrookes Hospital; NIHR; Cambridge NIHR; UCL; University of Cambridge; University of Cambridge; Addenbrookes Hospital; Addenbrookes Hospital; Vir Biotechnology; Vir Biotechnology; Vir Biotechnology; Addenbrookes Hospital; University of Cambridge; University of Washington; Vir Biotechnology; University of Cambridge,"Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant now seen in 50 countries. It is unclear whether responses to SARS-CoV-2 vaccines based on the prototypic strain will be impacted by mutations found in B.1.1.7. Here we assessed immune responses following vaccination with mRNA-based vaccine BNT162b2. We measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 amino acid mutations found in the B.1.1.7 spike protein. The vaccine sera exhibited a broad range of neutralising titres against the wild-type pseudoviruses that were modestly reduced against B.1.1.7 variant. This reduction was also evident in sera from some convalescent patients. Decreased B.1.1.7 neutralisation was also observed with monoclonal antibodies targeting the N-terminal domain (9 out of 10), the Receptor Binding Motif (RBM) (5 out of 31), but not in neutralising mAbs binding outside the RBM. Introduction of the E484K mutation in a B.1.1.7 background to reflect newly emerging viruses in the UK led to a more substantial loss of neutralising activity by vaccine-elicited antibodies and mAbs (19 out of 31) over that conferred by the B.1.1.7 mutations alone. E484K emergence on a B.1.1.7 background represents a threat to the vaccine BNT162b.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.01.14.21249801,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.14.21249801,Factor V is an immune inhibitor that is expressed at increased levels in leukocytes of patients with severe Covid-19,Jun Wang; Prasanti Kotagiri; Paul Lyons; Federica Mescia; Laura Bergamaschi; Lorinda Turner; Rafia Al-Lamki; Michael D Morgan; Fernando J Calero-Nieto; Karsten Bach; Nicole Mende; Nicola K Wilson; Emily R Watts; - Cambridge Institute of Therapeutic Immunology and Infectious Disease - NIHR Covid BioResource; Patrick Chinnery; Nathalie Kingston; Sofia Papadia; Kathleen Stirrups; Neil Walker; Ravindra K Gupta; Mark Toshner; Michael Weekes; James A Nathan; Sarah Walmsley; Willem Hendrik Ouwehand; Mary Kasanicki; Berthold Gottgens; John C Marioni; Smith GC Smith; Jordan S Pober; John R Bradley,University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Edinburgh; ; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; University of Cambridge; University of Edinburgh; Prof; Cambridge University Hospitals; University of Cambridge; EMBL-EBI; University of Cambridge; Yale University; University of Cambridge,"Severe Covid-19 is associated with elevated plasma Factor V (FV) and increased risk of thromboembolism. We report that neutrophils, T regulatory cells (Tregs), and monocytes from patients with severe Covid-19 express FV, and expression correlates with T cell lymphopenia. In vitro full length FV, but not FV activated by thrombin cleavage, suppresses T cell proliferation. Increased and prolonged FV expression by cells of the innate and adaptive immune systems may contribute to lymphopenia in severe Covid-19. Activation by thrombin destroys the immunosuppressive properties of FV. Anticoagulation in Covid-19 patients may have the unintended consequence of suppressing the adaptive immune system.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.01.15.21249885,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.15.21249885,Epidemiology of post-COVID syndrome following hospitalisation with coronavirus: a retrospective cohort study,Daniel Ayoubkhani; Kamlesh Khunti; Vahe Nafilyan; Thomas Maddox; Ben Humberstone; Ian Diamond; Amitava Banerjee,Office for National Statistics; University of Leicester; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University College London,"ObjectivesThe epidemiology of post-COVID syndrome (PCS) is currently undefined. We quantified rates of organ-specific impairment following recovery from COVID-19 hospitalisation compared with those in a matched control group, and how the rate ratio (RR) varies by age, sex, and ethnicity.

DesignObservational, retrospective, matched cohort study.

SettingNHS hospitals in England.

Participants47,780 individuals (mean age 65 years, 55% male) in hospital with COVID-19 and discharged alive by 31 August 2020, matched to controls on demographic and clinical characteristics.

Outcome measuresRates of hospital readmission, all-cause mortality, and diagnoses of respiratory, cardiovascular, metabolic, kidney and liver diseases until 30 September 2020.

ResultsMean follow-up time was 140 days for COVID-19 cases and 153 days for controls. 766 (95% confidence interval: 753 to 779) readmissions and 320 (312 to 328) deaths per 1,000 person-years were observed in COVID-19 cases, 3.5 (3.4 to 3.6) and 7.7 (7.2 to 8.3) times greater, respectively, than in controls. Rates of respiratory, diabetes and cardiovascular events were also significantly elevated in COVID-19 cases, at 770 (758 to 783), 127 (122 to 132) and 126 (121 to 131) events per 1,000 person-years, respectively. RRs were greater for individuals aged <70 than [&ge;] 70 years, and in ethnic minority groups than the White population, with the biggest differences observed for respiratory disease: 10.5 [9.7 to 11.4] for <70 years versus 4.6 [4.3 to 4.8] for [&ge;] 70 years, and 11.4 (9.8 to 13.3) for Non-White versus 5.2 (5.0 to 5.5) for White.

ConclusionsIndividuals discharged from hospital following COVID-19 face elevated rates of multi-organ dysfunction compared with background levels, and the increase in risk is neither confined to the elderly nor uniform across ethnicities. The diagnosis, treatment and prevention of PCS require integrated rather than organ- or disease-specific approaches. Urgent research is required to establish risk factors for PCS.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.01.13.21249721,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.13.21249721,"Increased infections, but not viral burden, with a new SARS-CoV-2 variant",Ann Sarah Walker; Karina Doris Vihta; Owen Gethings; Emma Pritchard; Joel Jones; Thomas House; Iain Bell; John Bell; John Newton; Jeremy Farrar; Ian Diamond; Ruth Studley; Emma Rourke; Jodie Hay; Susan Hopkins; Derrick W Crook; Tim Peto; Philippa Matthews; David W Eyre; Nicole W Stoesser; Koen Pouwels; - the COVID-19 Infection Survey team,University of Oxford; University of Oxford; Office for National Statistics; University of Oxford; Office for National Statistics; University of Manchester; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Glasgow; Public Health England; NIHR Oxford Biomedical Research Centre; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ,"BackgroundA new variant of SARS-CoV-2, B.1.1.7/VOC202012/01, was identified in the UK in December-2020. Direct estimates of its potential to enhance transmission are limited.

MethodsNose and throat swabs from 28-September-2020 to 2-January-2021 in the UKs nationally representative surveillance study were tested by RT-PCR for three genes (N, S and ORF1ab). Those positive only on ORF1ab+N, S-gene target failures (SGTF), are compatible with B.1.1.7/VOC202012/01. We investigated cycle threshold (Ct) values (a proxy for viral load), percentage of positives, population positivity and growth rates in SGTF vs non-SGTF positives.

Results15,166(0.98%) of 1,553,687 swabs were PCR-positive, 8,545(56%) with three genes detected and 3,531(23%) SGTF. SGTF comprised an increasing, and triple-gene positives a decreasing, percentage of infections from late-November in most UK regions/countries, e.g. from 15% to 38% to 81% over 1.5 months in London. SGTF Ct values correspondingly declined substantially to similar levels to triple-gene positives. Population-level SGTF positivity remained low (<0.25%) in all regions/countries until late-November, when marked increases with and without self-reported symptoms occurred in southern England (to 1.5-3%), despite stable rates of non-SGTF cases. SGTF positivity rates increased on average 6% more rapidly than rates of non-SGTF positives (95% CI 4-9%) supporting addition rather than replacement with B.1.1.7/VOC202012/01. Excess growth rates for SGTF vs non-SGTF positives were similar in those up to high school age (5% (1-8%)) and older individuals (6% (4-9%)).

ConclusionsDirect population-representative estimates show that the B.1.1.7/VOC202012/01 SARS-CoV-2 variant leads to higher infection rates, but does not seem particularly adapted to any age group.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.01.11.20248765,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.11.20248765,Early immune pathology and persistent dysregulation characterise severe COVID-19,Laura Bergamaschi; Federica Mescia; Lorinda Turner; Aimee Hanson; Prasanti Kotagiri; Benjamin J. Dunmore; Helene Ruffieux; Aloka DeSa; Oisin Huhn; Michael D Morgan; Pehuen Pereyra Gerber; Mark R. Wills; Stephen Baker; Fernando J Calero Nieto; Rainer Doffinger; Gordon Dougan; Anne Elmer; Ian G Goodfellow; Ravindra K. Gupta; Myra Hosmillo; Kelvin Hunter; Nathalie Kingston; Paul J. Lehner; Nicholas J. Matheson; Jeremy K. Nicholson; Anna M. Petrunkina; Sylvia Richardson; Caroline Saunders; James E.D. Thaventhiran; Erik J.M. Toonen; Michael P. Weekes; - CambridgeInstituteofTherapeuticImmunologyandInfectiousDisease-NationalInstituteofHealthResearch(CITI; Berthold Gottgens; Mark Toshner; Christoph Hess; John R. Bradley; Paul A. Lyons; Kenneth G.C. Smith,"Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cancer Research UK, Cambridge Institute, Robinson Way, Cambridge, CB2 0RE, UK; Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Haematology, Wellcome & MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Clinical Biochemistry and Immunology, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge CB2 ; Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Haematology, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; The Centre for Computational and Systems Medicine, Health Futures Institute, Murdoch University, Murdoch, Western Australia WA 6150, Australia; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; MRC Biostatistics Unit, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK; Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge CB2 ; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; R&D Department, Hycult Biotech, 5405 PD Uden, The Netherlands; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; ; Department of Haematology, Wellcome & MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK","In a study of 207 SARS-CoV2-infected individuals with a range of severities followed over 12 weeks from symptom onset, we demonstrate that an early robust bystander CD8 T cell immune response, without systemic inflammation, is characteristic of asymptomatic or mild disease. Those presenting to hospital had delayed bystander responses and systemic inflammation already evident at around symptom onset. Such early evidence of inflammation suggests immunopathology may be inevitable in some individuals, or that preventative intervention might be needed before symptom onset. Viral load does not correlate with the development of this pathological response, but does with its subsequent severity. Immune recovery is complex, with profound persistent cellular abnormalities correlating with a change in the nature of the inflammatory response, where signatures characteristic of increased oxidative phosphorylation and reactive-oxygen species-associated inflammation replace those driven by TNF and IL-6. These late immunometabolic inflammatory changes and unresolved immune defects may have clinical implications.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2021.01.15.21249871,2021-01-15,https://medrxiv.org/cgi/content/short/2021.01.15.21249871,Impact of COVID-19 on Care-Home Mortality and Life Expectancy in Scotland,Jennifer Kirsty Burton; Martin Reid; Ciara Gribben; David Caldwell; David N Clark; Peter Hanlon; Terence J Quinn; Colin Fischbacher; Peter Knight; Bruce Guthrie; David McAllister,University of Glasgow; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; University of Glasgow; University of Glasgow; Public Health Scotland; Public Health Scotland; University of Edinburgh; University of Glasgow,"IntroductionCOVID-19 deaths are commoner among care-home residents, but the mortality burden has not been quantified.

MethodsCare-home residency was identified via a national primary care registration database linked to national mortality data. Life expectancy was estimated using Makeham-Gompertz models, to (i) describe yearly life expectancy from Nov 2015 to Oct 2020 (ii) compare life expectancy (during 2016-2018) between care-home residents and the wider Scottish population and (iii) apply care-home life expectancy estimates to COVID-19 death counts to estimate years of life lost (YLL).

ResultsAmong care-home residents, life expectancy in 2015/16 to 2019/20 ranged from 2.7 to 2.3 years for women and 2.3 to 1.8 years for men. Life expectancy was lowest in 2019/20. Age-sex specific life expectancy in 2016-2018 in care-home residents was lower than in the Scottish population (10 and 2.5 years in those aged 70 and 90 respectively). Rather than using national life tables, applying care-home specific life expectancies to COVID-19 deaths yields, mean YLLs for care-home residents were 2.6 and 2.2 for women and men respectively, with total care-home resident YLLs of 3,560 years in women and 2,046 years in men. In people aged over-70, approximately half of deaths and a quarter of YLL attributed to COVID-19 were accounted for by the 5% of over-70s who were care-home residents.

ConclusionPrioritising care-home residents for vaccination is justified not only in terms of total deaths, but also in terms of years of life lost.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed to 1st December 2020, with the terms (""nursing home"" OR ""care-home"" OR ""long-term care"" OR ""residential care"") AND (""mortality"" OR ""life expectancy"" OR ""length of stay""). We also searched for studies specific to the impact of the COVID-19 pandemic on those living in care-homes. We restricted our search to publications in English. Usual care-home life expectancy, in a UK context, has not previously been defined. One systematic review of length of stay was identified, which found significant heterogeneity in factors and associations. The impact of COVID-19 on excess mortality among care-home residents was noted, but the impact on life expectancy was not reported. Studies evaluating life expectancy among older people in the COVID-19 pandemic have not taken account of residency in their estimates.

Added value of this studyUsing Scottish national representative linked data we describe the usual life expectancy of older adults (aged [&ge;]70 years) living in care-homes, compared to older people living elsewhere. Deaths among care-home residents account for a considerable proportion of all mortality in older adults, around 19% for men and 30% for women. Life expectancy in care-home residents during the pandemic fell by almost 6 months, from 2.7 to 2.3 years in men and 2.1 to 1.8 years in women. In total, over 5,600 Years of Life were Lost (YLL) by care-home residents in Scotland who died with COVID-19. Around half of COVID-19 deaths and a quarter of YLL in those aged 70 years and over occurred among care-home residents. During the COVID-19 pandemic a smaller proportion of deaths among care-home residents occurred in hospitals.

Implications of all the available evidencePrioritising the 5% of older adults who are care-home residents for vaccination against COVID-19 is justified both in terms of total deaths and total years of life lost. Individual and societal planning for care needs in older age relies on understanding usual care-home life expectancy and patterns of mortality. Understanding life expectancy may help clinicians, residents and their families make decisions about their health care, facilitating more informed discussions around their priorities and wishes. Population-wide estimates of YLL and burden of disease should take account of residency status, given the significant differences between life expectancy of those living in care-homes from their peers in other settings.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2021.01.11.21249461,2021-01-13,https://medrxiv.org/cgi/content/short/2021.01.11.21249461,A national retrospective cohort study of mechanical ventilator availability and its association with mortality risk in intensive care patients with COVID-19,Harrison Wilde; Thomas A Mellan; Iwona Hawryluk; John Dennis; Spiros Denaxas; Christina Pagel; Andrew Duncan; Samir Bhatt; Seth Flaxman; Bilal A Mateen; Sebastian Vollmer,University of Warwick; Imperial College; Imperial College London; University of Exeter; University College London; University College London; Imperial College London; Imperial College London; Imperial College London; The Alan Turing Institute; University of Warwick,"ObjectivesTo determine if there is an association between survival rates in intensive care units (ICU) and occupancy of the unit on the day of admission.

DesignNational retrospective observational cohort study during the COVID-19 pandemic.

Setting90 English hospital trusts (i.e. groups of hospitals functioning as single operational units).

Participants6,686 adults admitted to an ICU in England between 2nd April and 1st December, 2020 (inclusive), with presumed or confirmed COVID-19, for whom data was submitted to the national surveillance programme and met study inclusion criteria.

InterventionsN/A

Main Outcomes and MeasuresA Bayesian hierarchical approach was used to model the association between hospital trust level (mechanical ventilation compatible) bed occupancy, and in-hospital all-cause mortality. Results were adjusted for unit characteristics (pre-pandemic size), individual patient-level demographic characteristics (age, sex, ethnicity, time-to-ICU admission), and recorded chronic comorbidities (obesity, diabetes, respiratory disease, liver disease, heart disease, hypertension, immunosuppression, neurological disease, renal disease).

Results121,151 patient-days were observed, with a mortality rate of 20.8 per 1,000 patient days. Adjusting for patient-level factors, mortality was higher for admissions during periods of high occupancy (>85% occupancy versus the baseline of 45 to 85%) [OR 1.18 (95% posterior credible interval (PCI): 1.00 to 1.38)]. In contrast, mortality was decreased for admissions during periods of low occupancy (<45% relative to the baseline) [OR 0.79 (95% PCI: 0.69 to 0.90)].

Conclusion and RelevanceIncreasing occupancy of beds compatible with mechanical ventilation, a proxy for operational strain, is associated with a higher mortality risk for individuals admitted to ICU. Public health interventions (such as expeditious vaccination programmes and non-pharmaceutical interventions) to control both incidence and prevalence of COVID-19, and therefore keep ICU occupancy low in the context of the pandemic, are necessary to mitigate the impact of this type of resource saturation.

O_TEXTBOXSummary Box

What is already known on this topicPre-pandemic, higher occupancy of intensive care units was shown to be associated with increased mortality risk. However, there is limited data on the extent to which occupancy levels impacted patient outcomes during the COVID-19 pandemic, especially in light of the mobilisation of significant additional resources. A recent study from Belgium reported a 42% higher mortality during periods of ICU surge capacity deployment, although in the analysis surge capacity was evaluated only as a binary variable, and notably this contradicts earlier results from smaller studies in Australia and Wales, where no association between ICU occupancy and mortality was identified.

What this study addsThe results of this study suggest that survival rates for patients with COVID-19 in intensive care settings appears to deteriorate as the occupancy of (surge capacity) beds compatible with mechanical ventilation (a proxy for operational pressure), increases. Moreover, this risk doesnt occur above a specific threshold, but rather appears linear; whereby going from 0% occupancy to 100% occupancy increases risk of mortality by 69% (after adjusting for relevant individual-level factors). Furthermore, risk of mortality based on occupancy on the date of recorded outcome is even higher; OR 2.98 (95% posterior credible interval: 2.33 - 3.83). As such, this national-level cohort study of England provides compelling evidence for a relationship between occupancy and critical care mortality, and highlights the needs for decisive action to control the incidence and prevalence of COVID-19.

C_TEXTBOX",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2021.01.06.21249352,2021-01-08,https://medrxiv.org/cgi/content/short/2021.01.06.21249352,OpenSAFELY NHS Service Restoration Observatory 1: describing trends and variation in primary care clinical activity for 23.3 million patients in England during the first wave of COVID-19,Helen J Curtis; Brian MacKenna; Richard Croker; Alex J Walker; Peter Inglesby; Jessica Morley; Amir Mehrkar; Caroline E Morton; Seb Bacon; George Hickman; Chris Bates; David Evans; Tom Ward; Jonathan Cockburn; Simon Davy; Krishnan T. Bhaskaran; Anna Schultze; Christopher T. Rentsch; Elizabeth J Williamson; Will Hulme; Helen I McDonald; Laurie Tomlinson; Kevin Wing; Rohini I Mathur; Harriet Forbes; Angel Wong; Rosalind M Eggo; Henry Drysdale; John Parry; Frank Hester; Sam Harper; Ian J Douglas; Stephen Evans; Liam Smeeth; Ben Goldacre,"University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; LSHTM; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; London School of Medicine and Tropical Medicine; LSHTM; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; LSHTM; University of Oxford; TPP; TPP; TPP; LSHTM; LSHTM; LSHTM; University of Oxford","BackgroundThe COVID-19 pandemic has disrupted healthcare activity globally. The NHS in England stopped most non-urgent work by March 2020, but later recommended that services should be restored to near-normal levels before winter where possible. The authors are developing the OpenSAFELY NHS Service Restoration Observatory, using data to describe changes in service activity during COVID-19, and reviewing signals for action with commissioners, researchers and clinicians. Here we report phase one: generating, managing, and describing the data.

ObjectiveTo describe the volume and variation of coded clinical activity in English primary care across 23.8 million patients records, taking respiratory disease and laboratory procedures as key examples.

MethodsWorking on behalf of NHS England we developed an open source software framework for data management and analysis to describe trends and variation in clinical activity across primary care EHR data on 23.8 million patients; and conducted a population cohort-based study to describe activity using CTV3 coding hierarchy and keyword searches from January 2019-September 2020.

ResultsMuch activity recorded in general practice declined to some extent during the pandemic, but largely recovered by September 2020, with some exceptions. There was a large drop in coded activity for commonly used laboratory tests, with broad recovery to pre-pandemic levels by September. One exception was blood coagulation tests such as International Normalised Ratio (INR), with a smaller reduction (median tests per 1000 patients in 2020: February 8.0; April 6.2; September 7.0). The overall pattern of recording for respiratory symptoms was less affected, following an expected seasonal pattern and classified as ""no change"" from the previous year. Respiratory tract infections exhibited a sustained drop compared with pre-pandemic levels, not returning to pre-pandemic levels by September 2020. Various COVID-19 codes increased through the period. We observed a small decline associated with high level codes for long-term respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Asthma annual reviews experienced a small drop but since recovered, while COPD annual reviews remain below baseline.

ConclusionsWe successfully delivered an open source software framework to describe trends and variation in clinical activity across an unprecedented scale of primary care data. The COVD-19 pandemic led to a substantial change in healthcare activity. Most laboratory tests showed substantial reduction, largely recovering to near-normal levels by September 2020, with some important tests less affected. Records of respiratory infections decreased with the exception of codes related to COVID-19, whilst activity of other respiratory disease codes was mixed. We are expanding the NHS Service Restoration Observatory in collaboration with clinicians, commissioners and researchers and welcome feedback.",health systems and quality improvement,fuzzy,100,100
medRxiv,10.1101/2020.12.27.20248896,2021-01-02,https://medrxiv.org/cgi/content/short/2020.12.27.20248896,Vaccination and Non-Pharmaceutical Interventions: when can the UK relax about COVID-19?,Sam Moore; Edward M Hill; Michael Tildesley; Louise M Dyson; Matt J Keeling,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"BackgroundThe announcement of efficacious vaccine candidates against SARS-CoV-2 has been met with worldwide acclaim and relief. Many countries already have detailed plans for vaccine targeting based on minimising severe illness, death and healthcare burdens. Normally, relatively simple relationships between epidemiological parameters, vaccine efficacy and vaccine uptake predict the success of any immunisation programme. However, the dynamics of vaccination against SARS-CoV-2 is made more complex by age-dependent factors, changing levels of infection and the potential relaxation of non-pharmaceutical interventions (NPIs) as the perceived risk declines.

MethodsIn this study we use an age-structured mathematical model, matched to a range of epidemiological data in the UK, that also captures the roll-out of a two-dose vaccination programme targeted at specific age groups.

FindingsWe consider the interaction between the UK vaccination programme and future relaxation (or removal) of NPIs. Our predictions highlight the population-level risks of early relaxation leading to a pronounced wave of infection, hospital admissions and deaths. Only vaccines that offer high infection-blocking efficacy with high uptake in the general population allow relaxation of NPIs without a huge surge in deaths.

InterpretationWhile the novel vaccines against SARS-CoV-2 offer a potential exit strategy for this outbreak, this is highly contingent on the infection-blocking (or transmission-blocking) action of the vaccine and the population uptake, both of which need to be carefully monitored as vaccine programmes are rolled out in the UK and other countries.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSVaccination has been seen as a key tool in the fight against SARS-CoV-2. The vaccines already developed represent a major technological achievement and have been shown to generate significant immune responses, as well as offering considerable protection against disease. However, to date there is limited information on the degree of infection-blocking these vaccines are likely to induce. Mathematical models have already successfully been used to consider age- and risk-structured targeting of vaccination, highlighting the importance of prioritising older and high-risk individuals.

Added value of this studyTranslating current knowledge and uncertainty of vaccine behaviour into meaningful public health messages requires models that fully capture the within-country epidemiology as well as the complex roll-out of a two-dose vaccination programme. We show that under reasonable assumptions for vaccine efficacy and uptake the UK is unlikely to reach herd immunity, which means that non-pharmaceutical interventions cannot be released without generating substantial waves of infection.

Implications of all the available evidenceVaccination is likely to provide substantial individual protection to those receiving two doses, but the degree of protection to the wider population is still uncertain. While substantial immunisation of the most vulnerable groups will allow for some relaxation of controls, this must be done gradually to prevent large scale public health consequences.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.12.30.20248603,2021-01-01,https://medrxiv.org/cgi/content/short/2020.12.30.20248603,SARS-CoV-2 positivity in asymptomatic-screened dental patients,David I Conway; Shauna Culshaw; Maura Edwards; Claire Clark; Chris Watling; Chris Robertson; Raymond Braid; Emma O'Keefe; Niall McGoldrick; Jacky Burns; Stacey Provan; Harper VanSteenhouse; Jodie Hay; Rory Gunson; - Dental COVID-19 Surveillance Survey Group,University of Glasgow and Public Health Scotland; University of Glasgow; NHS Ayrshire and Arran; Public Health Scotland; Public Health Scotland; Strathclyde University and Public Health Scotland; Public Health Scotland; NHS Fife; NHS Fife; NHS Fife; NHS Greater Glasgow & Clyde; BioClavis Ltd; University of Glasgow; NHS Greater Glasgow & Clyde; ,"Enhanced community surveillance is a key pillar of the public health response to COVID-19. Asymptomatic carriage of SARS-CoV-2 is a potentially significant source of transmission, yet remains relatively poorly understood. Disruption of dental services continues with significantly reduced capacity. Ongoing precautions include pre- and/or at appointment COVID-19 symptom screening and use of enhanced personal protective equipment (PPE). This study aimed to investigate SARS-CoV-2 infection in dental patients to inform community surveillance and improve understanding of risks in the dental setting. Thirty-one dental care centres across Scotland invited asymptomatic screened patients over 5-years-old to participate. Following verbal consent and completion of sociodemographic and symptom history questionnaire, trained dental teams took a combined oropharyngeal and nasal swab sample using standardised VTM-containing testkits. Samples were processed by the Lighthouse Lab and patients informed of their results by SMS/e-mail with appropriate self-isolation guidance in the event of a positive test. Over a 13-week period (from 3August to 31October2020) n=4,032 patients, largely representative of the population, were tested. Of these n=22 (0.5%; 95%CI 0.5%, 0.8%) tested positive for SARS-CoV-2. The positivity rate increased over the period, commensurate with uptick in community prevalence identified across all national testing monitoring data streams. All positive cases were successfully followed up by the national contact tracing program. To the best of our knowledge this is the first report of a COVID-19 testing survey in asymptomatic-screened patients presenting in a dental setting. The positivity rate in this patient group reflects the underlying prevalence in community at the time. These data are a salient reminder, particularly when community infection levels are rising, of the importance of appropriate ongoing Infection Prevention Control and PPE vigilance, which is relevant as healthcare team fatigue increases as the pandemic continues. Dental settings are a valuable location for public health surveillance.",dentistry and oral medicine,fuzzy,100,100
medRxiv,10.1101/2020.12.24.20248822,2020-12-26,https://medrxiv.org/cgi/content/short/2020.12.24.20248822,Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England,Nicholas G Davies; Sam Abbott; Rosanna C. Barnard; Christopher I. Jarvis; Adam J. Kucharski; James D Munday; Carl A. B. Pearson; Timothy Russell; Damien Tully; Alex D. Washburne; Tom Wenseleers; Amy Gimma; William Waites; Kerry L. M. Wong; Kevin van Zandvoort; Justin D. Silverman; - CMMID COVID-19 Working Group; - The COVID-19 Genomics UK (COG-UK) Consortium; Karla Diaz-Ordaz; Ruth H Keogh; Rosalind M Eggo; Sebastian Funk; Mark Jit; Katherine E. Atkins; W. John Edmunds,"London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Selva Analytics LLC; KU Leuven; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; College of Information Science and Technology, Pennsylvania State University; ; ; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine","A novel SARS-CoV-2 variant, VOC 202012/01 (lineage B.1.1.7), emerged in southeast England in November 2020 and is rapidly spreading towards fixation. Using a variety of statistical and dynamic modelling approaches, we estimate that this variant has a 43-90% (range of 95% credible intervals 38-130%) higher reproduction number than preexisting variants. A fitted two-strain dynamic transmission model shows that VOC 202012/01 will lead to large resurgences of COVID-19 cases. Without stringent control measures, including limited closure of educational institutions and a greatly accelerated vaccine roll-out, COVID-19 hospitalisations and deaths across England in 2021 will exceed those in 2020. Concerningly, VOC 202012/01 has spread globally and exhibits a similar transmission increase (59-74%) in Denmark, Switzerland, and the United States.",epidemiology,fuzzy,100,100
bioRxiv,10.1101/2020.12.23.424229,2020-12-25,https://biorxiv.org/cgi/content/short/2020.12.23.424229,Patterns of within-host genetic diversity in SARS-CoV-2,Gerry Tonkin-Hill; Inigo Martincorena; Roberto Amato; Andrew R J Lawson; Moritz Gerstung; Ian Johnston; David K Jackson; Naomi R Park; Stefanie V Lensing; Michael A Quail; S√≥nia Gon√ßalves; Cristina Ariani; Michael Spencer Chapman; William L Hamilton; Luke W Meredith; Grant Hall; Aminu S Jahun; Yasmin Chaudhry; Myra Hosmillo; Malte L Pinckert; Iliana Georgana; Anna Yakovleva; Laura G Caller; Sarah L Caddy; Theresa Feltwell; Fahad A Khokhar; Charlotte J Houldcroft; Martin D Curran; Surendra Parmar; - The COVID-19 Genomics UK (COG-UK) Consortium; Alex Alderton; Rachel Nelson; Ewan Harrison; John Sillitoe; Stephen D Bentley; Jeffrey C Barrett; M. Estee Torok; Ian G Goodfellow; Cordelia Langford; Dominic Kwiatkowski; - Wellcome Sanger Institute COVID-19 Surveillance Team,"Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge and The Francis Crick Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge and Cambridge Institute of Therapeutic Immunology and Infectious Disease; Department of Medicine, University of Cambridge; Public Health England; Public Health England; COG-UK; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute and European Bioinformatics Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Wellcome Sanger Institute; Wellcome Sanger Institute and Oxford University; ","Monitoring the spread of SARS-CoV-2 and reconstructing transmission chains has become a major public health focus for many governments around the world. The modest mutation rate and rapid transmission of SARS-CoV-2 prevents the reconstruction of transmission chains from consensus genome sequences, but within-host genetic diversity could theoretically help identify close contacts. Here we describe the patterns of within-host diversity in 1,181 SARS-CoV-2 samples sequenced to high depth in duplicate. 95% of samples show within-host mutations at detectable allele frequencies. Analyses of the mutational spectra revealed strong strand asymmetries suggestive of damage or RNA editing of the plus strand, rather than replication errors, dominating the accumulation of mutations during the SARS-CoV-2 pandemic. Within and between host diversity show strong purifying selection, particularly against nonsense mutations. Recurrent within-host mutations, many of which coincide with known phylogenetic homoplasies, display a spectrum and patterns of purifying selection more suggestive of mutational hotspots than recombination or convergent evolution. While allele frequencies suggest that most samples result from infection by a single lineage, we identify multiple putative examples of co-infection. Integrating these results into an epidemiological inference framework, we find that while sharing of within-host variants between samples could help the reconstruction of transmission chains, mutational hotspots and rare cases of superinfection can confound these analyses.",genomics,fuzzy,100,100
medRxiv,10.1101/2020.12.21.20248607,2020-12-22,https://medrxiv.org/cgi/content/short/2020.12.21.20248607,Time use and social mixing during and around festive periods: Potential changes in the age distribution of COVID-19 cases from increased intergenerational interactions,Edwin van Leeuwen; Frank G. Sandmann; Rosalind M. Eggo; - PHE Joint modelling group; Peter J. White,Public Health England; Public Health England; London School of Hygiene &Tropical Medicine; London School of Hygiene & Tropical Medicine; ; Public Health England; Imperial College London,"RationaleAmid the ongoing coronavirus disease 2019 (COVID-19) pandemic in which many countries have adopted physical distancing measures, tiered restrictions, and episodic ""lockdowns,"" the impact of potentially increased social mixing during festive holidays on the age distribution of new COVID-19 cases remains unclear.

ObjectiveWe aimed to gain insights into possible changes in the age distribution of COVID-19 cases in the UK after temporarily increased intergenerational interactions in late December 2020.

MethodWe modelled changes in time use and social mixing based on age-stratified contact rates using historical nationally-representative surveys and up-to-date Google mobility data from four weeks before and after the festive period. We explored changes in the effective reproduction number and the age distribution of cases, in four scenarios: (1) ""normal"": time use and contact patterns as observed historically, (2) ""pre-lockdown"": patterns as seen before the lockdown in November 2020, (3) ""lockdown"": patterns restricted as in November 2020, and (4) ""festive break"": similar to 3 but with social visits over the holiday period as in 1.

ResultsAcross ages, the estimated Reff decreases during the festive break in scenarios 1-3 and returns to pre-holiday levels in scenarios 2-3, while remaining relatively stable in scenario 4. Relative incidence is likely to decrease in children aged 0-15 but increase in other ages. Changes in age distribution were large during the holidays, and are likely to start before the holidays for individuals aged 16-24 years in scenarios 1-3.

ConclusionsOur modelling findings suggest that increased contacts during the festive period may shift the age distribution of COVID-19 cases from children towards adults. Given that COVID-19-related hospitalisations and deaths rise by age, more intergenerational mixing risks an increased burden in the period following the holidays.

HighlightsO_LIHome visits are associated with increased intergenerational mixing.
C_LIO_LIThe effective reproduction number is likely to remain stable or even reduce slightly due to a reduction in contacts at work and school.
C_LIO_LIRelative incidence is likely to become lower in children, but higher in the
C_LIO_LIolder (more vulnerable) age groups around the holiday period, which could lead to increased health care burden.
C_LI",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.12.21.20248475,2020-12-22,https://medrxiv.org/cgi/content/short/2020.12.21.20248475,Clinical outcomes and risk factors for COVID-19 among migrant populations in high-income countries: a systematic review,Sally E Hayward; Anna Deal; Cherie Cheng; Alison F Crawshaw; Miriam Orcutt; Tushna F Vandrevala; Marrie Norredam; Manuel Carballo; Yusuf Ciftci; Ana Requena-Mendez; Chris Greenaway; Jessica Carter; Felicity Knights; Anushka Mehrotra; Farah Seedat; Kayvan Bozorgmehr; Apostolos Veizis; Ines Campos-Matos; Fatima Wurie; Teymur Noori; Martin McKee; Bernadette Kumar; Sally Hargreaves,"Institute for Infection and Immunity, St George's University of London; Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine; Institute for Infection and Immunity, St George's University of London; Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine; Institute for Infection and Immunity, St George's University of London; Institute for Infection and Immunity, St George's University of London; Institute for Global Health, University College London; Faculty of Business and Social Sciences, Kingston University; Danish Research Centre for Migration, Ethnicity and Health, University of Copenhagen; International Centre for Migration, Health, and Development; Doctors of the World UK; Department of Medicine-Solna, Karolinska Institutet; and Barcelona Institute for Global Health (ISGlobal-University of Barcelona); Department of Medicine, McGill University; Institute for Infection and Immunity, St George's University of London; Institute for Infection and Immunity, St George's University of London; Institute for Infection and Immunity, St George's University of London; Public Health England; Public Health, Bielefeld University; Section for Health Equity Studies & Migration, Heidelberg University Hospital; Medecins Sans Frontieres Greece; Public Health England; and UCL Collaborative Centre for Inclusion Health; Public Health England; and UCL Research Department of Epidemiology and Public Health; European Centre for Disease Prevention and Control (ECDC); Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine; Norwegian Institute of Public Health; Institute for Infection and Immunity, St George's University of London","BackgroundMigrants, including refugees, asylum seekers, labour migrants, and undocumented migrants, now constitute a considerable proportion of most high-income countries populations, including their skilled and unskilled workforces. Migrants may be at increased risk of COVID-19 due to their health and social circumstances, yet the extent to which they are being affected and their predisposing risk factors are not clearly understood. We did a systematic review to assess clinical outcomes of COVID-19 in migrant populations (cases, hospitalisations, deaths), indirect health and social impacts, and to determine key risk factors.

MethodsWe did a systematic review following PRISMA guidelines, registered with PROSPERO (CRD42020222135). We searched databases including PubMed, Global Health, Scopus, CINAHL, and pre-print databases (medRxiv) via the WHO Global Research on COVID-19 database to Nov 18, 2020 for peer-reviewed and grey literature pertaining to migrants (defined as foreign born) and COVID-19 in 82 high-income countries. We used our international networks to source national datasets and grey literature. Data were extracted on our primary outcomes (cases, hospitalisations, deaths) and we evaluated secondary outcomes on indirect health and social impacts, and risk factors, using narrative synthesis.

Results3016 data sources were screened with 158 from 15 countries included in the analysis (35 data sources for primary outcomes: cases [21], hospitalisations [4]; deaths [15]; 123 for secondary outcomes). We found that migrants are at increased risk of infection and are disproportionately represented among COVID-19 cases. Available datasets suggest a similarly disproportionate representation of migrants in reported COVID-19 deaths, as well as increased all-cause mortality in migrants in some countries in 2020. Undocumented migrants, migrant health and care workers, and migrants housed in camps and labour compounds may have been especially affected. In general, migrants have higher levels of many risk factors and vulnerabilities relevant to COVID-19, including increased exposure to SARS-CoV-2 due to high-risk occupations and overcrowded accommodation, and barriers to health care including inadequate information, language barriers, and reduced entitlement to healthcare coverage related to their immigration status.

ConclusionsMigrants in high-income countries are at high risk of exposure to, and infection with, COVID-19. These data are of immediate relevance to national public health responses to the pandemic and should inform policymaking on strategies for reducing transmission of COVID-19 in this population. Robust data on testing uptake and clinical outcomes in migrants, and barriers and facilitators to COVID-19 vaccination, are urgently needed, alongside strengthening engagement with diverse migrant groups.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.12.18.20248477,2020-12-20,https://medrxiv.org/cgi/content/short/2020.12.18.20248477,Face covering adherence is positively associated with better mental health and wellbeing: a longitudinal analysis of the CovidLife surveys,Drew M Altschul; Chloe Fawns-Ritchie; Alex Kwong; Louise Hartley; Clifford Nangle; Rachel Edwards; Rebecca Dawson; Christie Levein; Archie Campbell; Robin Flaig; Andrew McIntosh; Ian Deary; Riccardo Marioni; Caroline Hayward; Cathie Sudlow; Elaine Douglas; David Bell; David Porteous,The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; University of Stirling; University of Stirling; The University of Edinburgh,"Face masks or coverings are effective at reducing airborne infection rates, yet pandemic mitigation measures, including wearing face coverings, have been suggested to contribute to reductions in quality of life and poorer mental health. Longitudinal analyses of more than 11,000 participants across the UK found no association between lower adherence to face covering guidelines and poorer mental health. The opposite appears to be true. Even after controlling for behavioral, social, and psychological confounds, including measures of pre-pandemic mental health, individuals who wore face coverings ""most of the time"" or ""always"" had better mental health and wellbeing than those who did not. These results suggest that wearing face coverings more often will not negatively impact mental health.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.12.16.20247684,2020-12-18,https://medrxiv.org/cgi/content/short/2020.12.16.20247684,International Comparisons of Harmonized Laboratory Value Trajectories to Predict Severe COVID-19: Leveraging the 4CE Collaborative Across 342 Hospitals and 6 Countries: A Retrospective Cohort Study,Griffin M Weber; Chuan Hong; Nathan P Palmer; Paul Avillach; Shawn N Murphy; Alba Guti√©rrez-Sacrist√°n; Zongqi Xia; Arnaud Serret-Larmande; Antoine Neuraz; Gilbert S. Omenn; Shyam Visweswaran; Jeffrey G Klann; Andrew M South; Ne Hooi Will Loh; Mario Cannataro; Brett K Beaulieu-Jones; Riccardo Bellazzi; Giuseppe Agapito; Mario Alessiani; Bruce J Aronow; Douglas S Bell; Antonio Bellasi; Vincent Benoit; Michele Beraghi; Martin Boeker; John Booth; Silvano Bosari; Florence T Bourgeois; Nicholas W Brown; Mauro Bucalo; Luca Chiovato; Lorenzo Chiudinelli; Arianna Dagliati; Batsal Devkota; Scott L DuVall; Robert W Follett; Thomas Ganslandt; Noelia Garc√≠a Barrio; Tobias Gradinger; Romain Griffier; David A Hanauer; John H Holmes; Petar Horki; Kenneth M Huling; Richard W Issitt; Vianney Jouhet; Mark S Keller; Detlef Kraska; Molei Liu; Yuan Luo; Kristine E Lynch; Alberto Malovini; Kenneth D Mandl; Chengsheng Mao; Anupama Maram; Michael E Matheny; Thomas Maulhardt; Maria Mazzitelli; Marianna Milano; Jason H Moore; Jeffrey S Morris; Michele Morris; Danielle L Mowery; Thomas P Naughton; Kee Yuan Ngiam; James B Norman; Lav P Patel; Miguel Pedrera Jimenez; Rachel B Ramoni; Emily R Schriver; Luigia Scudeller; Neil J Sebire; Pablo Serrano Balazote; Anastasia Spiridou; Amelia LM Tan; Byorn W.L. Tan; Valentina Tibollo; Carlo Torti; Enrico M Trecarichi; Michele Vitacca; Alberto Zambelli; Chiara Zucco; - The Consortium for Clinical Characterization of COVID-19 by EHR (4CE); Isaac S Kohane; Tianxi Cai; Gabriel A Brat,"Harvard Medical School; Harvard Medical School; Harvard Medical School; Harvard Medical School; Massachusetts General Hospital; Harvard Medical School; University of Pittsburgh; H√¥pital Europ√©en Georges Pompidou, Assistance Publique - H√¥pitaux de Paris; H√¥pital Necker-Enfants Malade, Assistance Publique Hopitaux de Paris (APHP), University of Paris; University of Michigan; University of Pittsburgh; Massachusetts General Hospital; Brenner Children's Hospital, Wake Forest School of Medicine; National University Health System, Singapore; University Magna Graecia of Catanzaro, Italy; Harvard Medical School; University of Pavia, Italy; University Magna Graecia of Catanzaro, Italy; ASST Pavia, Lombardia Region Health System; Cincinnati Children's Hospital Medical Center, University of Cincinnati; David Geffen School of Medicine at UCLA; ASST Papa Giovanni XXIII, Bergamo; APHP Greater Paris University Hospital; ASST Pavia; Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany; Great Ormond Street Hospital for Children, UK; IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Harvard Medical School; Harvard Medical School; BIOMERIS (BIOMedical Research Informatics Solutions); Istituti Clinici Scientifici Maugeri SpA SB IRCCS; ASST Papa Giovanni XXIII, Bergamo; University of Pavia, Italy; The Children's Hospital of Philadelphia; VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System; David Geffen School of Medicine at UCLA; University Medicine Mannheim, Heidelberg University; Hospital Universitario 12 de Octubre, Madrid, Spain; University Medicine Mannheim, Heidelberg University; Bordeaux University Hospital; University of Michigan; University of Pennsylvania Perelman School of Medicine; Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany; Harvard Medical School; Great Ormond Street Hospital for Children, UK; Bordeaux University Hospital; Harvard Medical School; University Hospital Erlangen; Harvard School of Public Health; Northwestern University; VA Informatics and Computing Infrastructure; Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, Italy.; Boston Children's Hospital; Northwestern University; Harvard Medical School; Tennessee Valley Healthcare System Veterans Affairs Medical Center; Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany; University Magna Graecia of Catanzaro, Italy; University Magna Graecia of Catanzaro, Italy; University of Pennsylvania Perelman School of Medicine; University of Pennysylvania Perelman School of Medicine; University of Pittsburgh; University of Pennsylvania Perelman School of Medicine; Harvard Medical School; National Univerisity Health Systems Singapore; Harvard Medical School; University Of Kansas Medical Center; Hospital Universitario 12 de Octubre, Madrid, Spain; Department of Veterans Affairs; University of Pennsylvania Health System; IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano; Great Ormond Street Hospital for Children NIHR BRC, UK; Hospital Universitario 12 de Octubre, Madrid, Spain; Great Ormond Street Hospital for Children, UK; Harvard Medical School; National University Hospital, Singapore; Istituti Clinici Scientifici Maugeri SpA SB IRCCS, Pavia, Italy.; University Magna Graecia of Catanzaro, Italy; University Magna Graecia of Catanzaro, Italy; ICS S. Maugeri IRCCS Pavia Italy; ASST Papa Giovanni XXIII, Bergamo; University Magna Graecia of Catanzaro, Italy; ; Harvard Medical School; Harvard Medical School; Harvard Medical School","ObjectivesTo perform an international comparison of the trajectory of laboratory values among hospitalized patients with COVID-19 who develop severe disease and identify optimal timing of laboratory value collection to predict severity across hospitals and regions.

DesignRetrospective cohort study.

SettingThe Consortium for Clinical Characterization of COVID-19 by EHR (4CE), an international multi-site data-sharing collaborative of 342 hospitals in the US and in Europe.

ParticipantsPatients hospitalized with COVID-19, admitted before or after PCR-confirmed result for SARS-CoV-2.

Primary and secondary outcome measuresPatients were categorized as ""ever-severe"" or ""never-severe"" using the validated 4CE severity criteria. Eighteen laboratory tests associated with poor COVID-19-related outcomes were evaluated for predictive accuracy by area under the curve (AUC), compared between the severity categories. Subgroup analysis was performed to validate a subset of laboratory values as predictive of severity against a published algorithm. A subset of laboratory values (CRP, albumin, LDH, neutrophil count, D-dimer, and procalcitonin) was compared between North American and European sites for severity prediction.

ResultsOf 36,447 patients with COVID-19, 19,953 (43.7%) were categorized as ever-severe. Most patients (78.7%) were 50 years of age or older and male (60.5%). Longitudinal trajectories of CRP, albumin, LDH, neutrophil count, D-dimer, and procalcitonin showed association with disease severity. Significant differences of laboratory values at admission were found between the two groups. With the exception of D-dimer, predictive discrimination of laboratory values did not improve after admission. Sub-group analysis using age, D-dimer, CRP, and lymphocyte count as predictive of severity at admission showed similar discrimination to a published algorithm (AUC=0.88 and 0.91, respectively). Both models deteriorated in predictive accuracy as the disease progressed. On average, no difference in severity prediction was found between North American and European sites.

ConclusionsLaboratory test values at admission can be used to predict severity in patients with COVID-19. Prediction models show consistency across international sites highlighting the potential generalizability of these models.",health informatics,fuzzy,100,100
bioRxiv,10.1101/2020.12.18.423439,2020-12-18,https://biorxiv.org/cgi/content/short/2020.12.18.423439,SNPnexus COVID: Facilitating the analysis of COVID-19 host genetics,Jorge Oscanoa; Lavanya Sivapalan; Maryam Abdollahyan; Emanuela Gadaleta; Claude Chelala,"Barts Cancer Institute, Queen Mary University of London; Barts Cancer Institute, Queen Mary University of London; Barts Cancer Institute, Queen Mary University of London; Barts Cancer Institute, Queen Mary University of London; Barts Cancer Insitute, Queen Mary University of London","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demanded an unprecedented scientific response, with researchers collaborating on a global scale to better understand how host genetics can influence susceptibility to coronavirus infection and the severity of COVID-19 symptoms. The number of projects directed towards sequencing patients genomes has increased rapidly during this time with the rate of data generation outpacing the resources available for analysis and biological interpretation of these datasets. SNPnexus COVID is a cutting-edge web-based analytical platform that allows researchers to analyse and interpret the functional implications of genetic variants in COVID-19 patient genomes and to prioritise those that demonstrate clinical utility for the prevention, management and/or treatment of COVID-19. Our resource links to diverse multifactorial datasets and information resources that would require substantial time and computational power to otherwise mine independently. This streamlines biological data interpretation and allows researchers to better understand the multidimensional characteristics of their data. Importantly, SNPnexus COVID is powered by the SNPnexus software and follows its intuitive infrastructure, which precludes the need for programmatic experience in its users.

SNPnexus COVID is freely available at https://www.snp-nexus.org/v4/covid/",genomics,fuzzy,100,100
medRxiv,10.1101/2020.12.14.20248155,2020-12-16,https://medrxiv.org/cgi/content/short/2020.12.14.20248155,Investigating mental and physical disorders associated with COVID-19 in online health forums,Rashmi Patel; Fabrizio Smeraldi; Maryam Abdollahyan; Jessica Irving; Conrad Bessant,"King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; South London and Maudsley NHS Foundation Trust, London, UK; Queen Mary University of London, UK; Memobine Ltd, Cambridge, UK; The Alan Turing Institute, London, UK; Barts Cancer Institute, London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; Queen Mary University of London, UK; Memobine Ltd, Cambridge, UK; The Alan Turing Institute, London, UK","ObjectivesOnline health forums provide rich and untapped real-time data on population health. Through novel data extraction and natural language processing (NLP) techniques, we characterise the evolution of mental and physical health concerns relating to the COVID-19 pandemic among online health forum users.

Setting and designWe obtained data from 739,434 posts by 53,134 unique users of three leading online health forums: HealthBoards, Inspire and HealthUnlocked, from the period 1st January 2020 to 31st May 2020. Using NLP, we analysed the content of posts related to COVID-19.

Primary outcome measuresO_LIProportion of forum posts containing COVID-19 keywords
C_LIO_LIProportion of forum users making their very first post about COVID-19
C_LIO_LINumber of COVID-19 related posts containing content related to physical and mental health comorbidities
C_LI

ResultsPosts discussing COVID-19 and related comorbid disorders spiked in early- to mid-March around the time of global implementation of lockdowns prompting a large number of users to post on online health forums for the first time. The pandemic and corresponding public response has had a significant impact on posters queries regarding mental health.

ConclusionsWe demonstrate it is feasible to characterise the content of online health forum user posts regarding COVID-19 and measure changes over time. Social media data sources such as online health forums can be harnessed to strengthen population-level mental health surveillance.

Article SummaryO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LIAnalysing online health forum data using NLP revealed a substantial rise in activity which correlated with the onset of the COVID-19 pandemic.
C_LIO_LIReal-time data sources such as online health forums are essential for monitoring fluctuating population health and tailoring responses to daily pressures.
C_LIO_LIIt is not yet possible to establish COVID-19 status or whether concerned posters have pre-existing mental or physical health issues, are recovered, or have become unwell for the first time.
C_LIO_LIOnline health forums are help-seeking forums, which introduces self-selection bias.
C_LI",health informatics,fuzzy,100,100
medRxiv,10.1101/2020.12.15.20248096,2020-12-16,https://medrxiv.org/cgi/content/short/2020.12.15.20248096,"Anosmia and other SARS-CoV-2 positive test-associated symptoms, across three national, digital surveillance platforms as the COVID-19 pandemic and response unfolded: an observation study",Carole Helene Sudre; Ayya Keshet; Mark S Graham; Amit D Joshi; Smadar Shilo; Hagai Rossman; Benjamin Murray; Erika Molteni; Kerstin Klaser; Liane S Canas; Michela Antonelli; Marc Modat; Joan Capdevila Pujol; Sajaysurya Ganesh; Jonathan Wolf; Tomer Meir; Andrew T Chan; Claire Steves; Timothy Spector; John S Brownstein; Eran Segal; Sebastien Ourselin; Christina Astley,University College London; Weizmann Institute of Science; King's College London; Massachusetts General Hospital; Weizmann Institute of Science; Weizmann Institute of Science; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Global Limited; Zoe Global Limited; Zoe Global Limited; Weizmann Institute of Science; Massachusetts General Hospital; King's College London; King's College London; Boston Children's Hospital; Weizmann Institute of Science; King's College London; Boston Children's Hospital,"BackgroundMultiple participatory surveillance platforms were developed across the world in response to the COVID-19 pandemic, providing a real-time understanding of community-wide COVID-19 epidemiology. During this time, testing criteria broadened and healthcare policies matured. We sought to test whether there were consistent associations of symptoms with SARS-CoV-2 test status across three national surveillance platforms, during periods of testing and policy changes, and whether inconsistencies could better inform our understanding and future studies as the COVID-19 pandemic progresses.

MethodsFour months (1st April 2020 to 31st July 2020) of observation through three volunteer COVID-19 digital surveillance platforms targeting communities in three countries (Israel, United Kingdom, and United States). Logistic regression of self-reported symptom on self-reported SARS-CoV-2 test status (or test access), adjusted for age and sex, in each of the study cohorts. Odds ratios over time were compared to known changes in testing policies and fluctuations in COVID-19 incidence.

FindingsAnosmia/ageusia was the strongest, most consistent symptom associated with a positive COVID-19 test, based on 658,325 tests (5% positive) from over 10 million respondents in three digital surveillance platforms using longitudinal and cross-sectional survey methodologies. During higher-incidence periods with broader testing criteria, core COVID-19 symptoms were more strongly associated with test status. Lower incidence periods had, overall, larger confidence intervals.

InterpretationThe strong association of anosmia/ageusia with self-reported SARS-CoV-2 test positivity is omnipresent, supporting its validity as a reliable COVID-19 signal, regardless of the participatory surveillance platform or testing policy. This analysis highlights that precise effect estimates, as well as an understanding of test access patterns to interpret differences, are best done only when incidence is high. These findings strongly support the need for testing access to be as open as possible both for real-time epidemiologic investigation and public health utility.

FundingNIH, NIHR, Alzheimers Society, Wellcome Trust

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSAs the COVID-19 pandemic has evolved, testing capacity expanded and governmental guidelines adapted, generally encouraging testing with a broader set of symptoms, not just fever with respiratory symptoms. In parallel, multiple large-scale citizen science digital surveillance platforms launched to complement knowledge from laboratory and somewhat smaller clinical studies. Symptoms such as loss of sense of smell have been identified as strongly predictive of COVID-19 infection in both clinical and syndromic surveillance analyses, and have therefore been used to inform these testing policy changes and access expansion.

Added value of this studyThis study identifies symptoms that are or are not consistently associated with SARS-CoV-2 test positivity over time and across three country-based COVID-19 surveillance platforms in the United States, United Kingdom and Israel. These platforms are website and smartphone based, as well as cross-sectional and longitudinal. The study period of 4 months covers fluctuating COVID-19 prevalence during the fall of the first wave and, in some areas, rise of the second wave. In addition, the study period overlaps expansion of test access and test seeking. Importantly, these analyses track and highlight the value of individual symptoms to predict SARS-CoV-2 test positivity under a range of conditions.

Implications of all the available evidenceDespite differences in surveillance methodology, access to SARS-CoV-2 testing and disease prevalence, loss of sense of smell or taste was consistently the strongest predictor of COVID-19 infection across all platforms over time. As access to testing broadened, the relevance of COVID-like symptoms and consistency of their predictive ability became apparent. However, confidence bounds generally widened with a fall in COVID-19 incidence. Therefore, for the most robust symptom-based COVID-19 prediction models should consider surveillance data during periods of higher incidence and improved test access, and effect estimates that replicate across different epidemiologic conditions and platforms.",infectious diseases,fuzzy,94,100
medRxiv,10.1101/2020.12.15.20248244,2020-12-16,https://medrxiv.org/cgi/content/short/2020.12.15.20248244,REACT-1 round 7 updated report: regional heterogeneity in changes in prevalence of SARS-CoV-2 infection during the second national COVID-19 lockdown in England,Steven Riley; Caroline E. Walters; Haowei Wang; Oliver Eales; Kylie E. C. Ainslie; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear","BackgroundEngland exited a four-week second national lockdown on 2nd December 2020 initiated in response to the COVID-19 pandemic. Prior results showed that prevalence dropped during the first half of lockdown, with greater reductions in higher-prevalence northern regions.

MethodsREACT-1 is a series of community surveys of SARS-CoV-2 RT-PCR swab-positivity in England, designed to monitor the spread of the epidemic and thus increase situational awareness. Round 7 of REACT-1 commenced swab-collection on 13th November 2020. A prior interim report included data from 13th to 24th November 2020 for 105,122 participants. Here, we report data for the entire round with swab results obtained up to 3rd December 2020.

ResultsBetween 13th November and 3rd December (round 7) there were 1,299 positive swabs out of 168,181 giving a weighted prevalence of 0.94% (95% CI 0.87%, 1.01%) or 94 per 10,000 people infected in the community in England. This compares with a prevalence of 1.30% (1.21%, 1.39%) from 16th October to 2nd November 2020 (round 6), a decline of 28%. Prevalence during the latter half of round 7 was 0.91% (95% CI, 0.81%, 1.03%) compared with 0.96% (0.87%, 1.05%) in the first half. The national R number in round 7 was estimated at 0.96 (0.88, 1.03) with a decline in prevalence observed during the first half of this period no longer apparent during the second half at the end of lockdown. During round 7 there was a marked fall in prevalence in West Midlands, a levelling off in some regions and a rise in London. R numbers at regional level ranged from 0.60 (0.41, 0.80) in West Midlands up to 1.27 (1.04, 1.54) in London, where prevalence was highest in the east and south-east of the city. Nationally, between 13th November and 3rd December, the highest prevalence was in school-aged children especially at ages 13-17 years at 2.04% (1.69%, 2.46%), or approximately 1 in 50.

ConclusionBetween the previous round and round 7 (during lockdown), there was a fall in prevalence of SARS-CoV-2 swab-positivity nationally, but it did not fall uniformly over time or by geography. Continued vigilance is required to reduce rates of infection until effective immunity at the population level can be achieved through the vaccination programme.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.12.10.20245944,2020-12-14,https://medrxiv.org/cgi/content/short/2020.12.10.20245944,"Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial",Peter W Horby; Alistair Roddick; Enti Spata; Natalie Staplin; Jonathan R Emberson; Guilherme Pessoa-Amorim; Leon Peto; Mark Campbell; Christopher Brightling; Ben Prudon; David Chadwick; Andrew Ustianowski; Abdul Ashish; Stacy Todd; Bryan Yates; Robert Buttery; Stephen Scott; Diego Maseda; J Kenneth Baillie; Maya H Buch; Lucy C Chappell; Jeremy N Day; Saul N Faust; Thomas Jaki; Katie Jeffery; Edmund Juszczak; Wei Shen Lim; Alan Montgomery; Andrew Mumford; Kathryn Rowan; Guy Thwaites; Marion Mafham; Richard Haynes; Martin J Landray,"Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; Department of Respiratory Medicine, North Tees & Hartlepool NHS Foundation Trust, Stockton-on-Tees, United Kingdom; Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United Kingdom; North Manchester General Hospital & University of Manchester, Manchester, United Kingdom; Wrightington Wigan and Leigh NHS Foundation Trust, Wigan, United Kingdom; Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom; Northumbria Healthcare NHS Foundation Trust, North Tyneside, United Kingdom; North West Anglia NHS Foundation Trust, Peterborough, United Kingdom; The Countess of Chester Hospital NHS Foundation Trust, Chester, United Kingdom; Mid Cheshire Hospitals NHS Foundation Trust, Crewe, United Kingdom; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom; School of Life Sciences, King's College London, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom; MRC Biostatistics Unit, University of Cambridge, Cambridge, United Ki; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Respiratory Medicine Department, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; School of Cellular and Molecular Medicine, University of Bristol, Bristol, United kingdom; Intensive Care National Audit & Research Centre, London, United Kingdom; Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam, and Nuffield Department of Medicine, University of Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","BackgroundAzithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We evaluated the efficacy and safety of azithromycin in hospitalised patients with COVID-19.

MethodsIn this randomised, controlled, open-label, adaptive platform trial, several possible treatments were compared with usual care in patients hospitalised with COVID-19 in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once daily by mouth or intravenously for 10 days or until discharge (or one of the other treatment arms). Patients were twice as likely to be randomised to usual care as to any of the active treatment groups. The primary outcome was 28-day mortality. The trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

FindingsBetween 7 April and 27 November 2020, 2582 patients were randomly allocated to receive azithromycin and 5182 patients to receive usual care alone. Overall, 496 (19%) patients allocated to azithromycin and 997 (19%) patients allocated to usual care died within 28 days (rate ratio 1{middle dot}00; 95% confidence interval [CI] 0{middle dot}90-1{middle dot}12; p=0{middle dot}99). Consistent results were seen in all pre-specified subgroups of patients. There was no difference in duration of hospitalisation (median 12 days vs. 13 days) or the proportion of patients discharged from hospital alive within 28 days (60% vs. 59%; rate ratio 1{middle dot}03; 95% CI 0{middle dot}97-1{middle dot}10; p=0{middle dot}29). Among those not on invasive mechanical ventilation at baseline, there was no difference in the proportion meeting the composite endpoint of invasive mechanical ventilation or death (21% vs. 22%; risk ratio 0{middle dot}97; 95% CI 0{middle dot}89-1{middle dot}07; p=0{middle dot}54).

InterpretationIn patients hospitalised with COVID-19, azithromycin did not provide any clinical benefit. Azithromycin use in patients hospitalised with COVID-19 should be restricted to patients where there is a clear antimicrobial indication.

FundingUK Research and Innovation (Medical Research Council) and National Institute of Health Research (Grant ref: MC_PC_19056).",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.12.11.20247742,2020-12-14,https://medrxiv.org/cgi/content/short/2020.12.11.20247742,Changes in cardiovascular disease monitoring in English primary care during the COVID-19 pandemic: an observational cohort study,Clare R Bankhead; Sarah Lay-Flurrie; Brian D Nicholson; James P Sheppard; Chris P Gale; Harshana Liyanage; Dylan McGagh; Mark Minchin; Rafael Perera; Julian Sherlock; Margaret Smith; Nicholas PB Thomas; Cynthia Wright Drakesmith; Simon D de Lusignan; Richard Hobbs,University of Oxford; University of Oxford; Nuffield Department of Primary Care Health Sciences; University of Oxford; University of Leeds; University of Oxford; University of Oxford; National Institute for Health and Care Excellence; University of Oxford; University of Oxford; University of Oxford; Royal College of General Practitioners; University of Oxford; University of Oxford; University of Oxford,"ObjectiveTo quantify the impact and recovery in cardiovascular disease monitoring in primary care associated with the first COVID-19 lockdown.

DesignRetrospective nationwide primary care cohort study, utilising data from 1st January 2018 to 27th September 2020.

SettingWe extracted primary care electronic health records data from 514 primary care practices in England contributing to the Oxford Royal College of General Practitioners Clinical Informatics Digital Hub (ORCHID). These practices were representative of English primary care across urban and non-urban practices.

ParticipantsThe ORCHID database included 6,157,327 active patients during the study period, and 13,938,390 patient years of observation (final date of follow-up 27th September 2020). The mean (SD) age was 38{+/-}24 years, 49.4% were male and the majority were of white ethnicity (65% [21.9% had unknown ethnicity])

ExposureThe primary exposure was the first national lockdown in the UK, starting on 23rd March 2020.

Main outcome measuresRecords of cholesterol, blood pressure, HbA1c and International Normalised Ratio (INR) measurement derived from coded entries in the primary care electronic health record.

ResultsRates of cholesterol, blood pressure, HbA1c and INR recording dropped by 23-87% in the week following the first UK national lockdown, compared with the previous week. The largest decline was seen in cholesterol (IRR 0.13, 95% CI 0.11 to 0.15) and smallest for INR (IRR 0.77, 95% CI 0.72 to 0.81).

Following the immediate drop, rates of recorded tests increased on average by 5-9% per week until 27th September 2020. However, the number of recorded measures remained below that expected for the time of year, reaching 51.8% (95% CI 51.8 to 51.9%) for blood pressure, 63.7%, (95% CI 63.7% to 63.8%) for cholesterol measurement and 70.3% (95% CI 70.2% to 70.4%) for HbA1c. Rates of INR recording declined throughout the previous two years, a trend that continued after lockdown. There were no differences in the times series trends based on sex, age, ethnicity or deprivation.

ConclusionsCardiovascular disease monitoring in English primary care declined substantially from the time of the first UK lockdown. Despite a consistent recovery in activity, there is still a substantial shortfall in the numbers of recorded measurements to those expected. Strategies are required to ensure cardiovascular disease monitoring is maintained during the COVID-19 pandemic.",primary care research,fuzzy,100,100
medRxiv,10.1101/2020.12.10.20247155,2020-12-14,https://medrxiv.org/cgi/content/short/2020.12.10.20247155,Self-harm presentations to Emergency Departments and Place of Safety during the first wave of the UK COVID-19 pandemic: South London and Maudsley data on service use from February to June 2020.,Eleanor Nuzum; Evangelia Martin; Gemma Morgan; Rina Dutta; Christoph Mueller; Catherine Polling; Megan Pritchard; Sumithra Velupillai; Robert Stewart,South London and Maudsley NHS Foundation Trust; South London and Maudsley NHS Foundation Trust; South London and Maudsley NHS Foundation Trust; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London,"The lockdown and social distancing policy imposed due to the COVID-19 pandemic has had a substantial impact on both mental health service delivery, and the ways in which people are accessing these services. Previous reports from the South London and Maudsley NHS Trust (SLaM; a large mental health service provider for around 1.2m residents in South London) have highlighted increased use of virtual contacts by mental health teams, with dropping numbers of face-to-face contacts over the first wave of the pandemic. There has been concern that the impact of the COVID-19 pandemic would lead to higher mental health emergencies, particularly instances of self-harm. However, with people advised to stay at home during the  first wave lockdown, it is as yet unclear whether this impacted mental health service presentations. Taking advantage of SLaMs Clinical Records Interactive Search (CRIS) data resource with daily updates of information from its electronic mental health records, this paper describes overall presentations to Emergency Department (ED) mental health liaison teams, and those with self-harm. The paper focussed on three periods: i) a pre-lockdown period 1st February to 15th March, ii) a lockdown period 16th March to 10th May and iii) a post-lockdown period 11th May to 28th June. In summary, all attendances to EDs for mental health support decreased during the lockdown period, including those with self-harm. All types of self-harm decreased during lockdown, with self-poisoning remaining the most common. Attendances to EDs for mental health support increased post-lockdown, although were only just approaching pre-lockdown levels by the end of June 2020.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.12.05.20241927,2020-12-11,https://medrxiv.org/cgi/content/short/2020.12.05.20241927,Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion,Steven A Kemp; Dami A Collier; Rawlings Datir; Isabella ATM Ferreira; Salma Gayed; Aminu Jahun; Myra Hosmillo; Chloe Rees-Spear; Petra Mlcochova; Ines Ushiro Lumb; David Roberts; Anita Chandra; Nigel Temperton; - The COVID-19 Genomics UK (COG-UK) Consortium; Katherine Sharrocks; Elizabeth Blane; - The CITIID-NIHR BioResource COVID-19 Collaboration; John A Briggs; Marit van Gils; Ken G Smith; John R Bradley; Chris Smith; Rainer Doffinger; Lourdes Ceron-Gutierrez; Gabriela Barcenas-Morales; David Pollock; Richard Goldstein; Anna Smielewska; Jordan P Skittrall; Theo Gouliouris; Ian G Goodfellow; Effrossyni Gkrania-Klotsas; Chris JR Illingworth; Laura E McCoy; Ravindra K Gupta,"Division of Infection and Immunity, University College London, London, UK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.; Department of Pathology, University of Cambridge, Cambridge; Department of Pathology, University of Cambridge, Cambridge; Division of Infection and Immunity, University College London, London, UK.; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Public Health England, Colindale, London, UK; Public Health England, Colindale, London, UK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK; -; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; -; Medical Research Council Laboratory of Molecular Biology, Cambridge, UK.; University of Amsterdam; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.; NIHR Cambridge Clinical Research Facility, Cambridge, UK.; Department of Applied Mathematics and Theoretical Physics, University of Cambridge, UK; Addenbrookes Hospital; Addenbrookes Hospital; Addenbrookes Hospital; University of Colorado School of Medicine; Division of Infection & Immunity, University College London, UK; Department of Virology, Cambridge University NHS Hospitals Foundation Trust; Clinical Microbiology and Public Health Laboratory, Addenbrookes Hospital, Cambridge, UK; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.; Department of Pathology, University of Cambridge, Cambridge; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK.; MRC Biostatistics Unit, University of Cambridge, Cambridge,  UK; Division of Infection and Immunity, University College London, London, UK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK.","SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are designed around Wuhan-1 Spike, this raises the theoretical possibility of virus escape, particularly in immunocompromised individuals where prolonged viral replication occurs. Here we report chronic SARS-CoV-2 with reduced sensitivity to neutralising antibodies in an immune suppressed individual treated with convalescent plasma, generating whole genome ultradeep sequences by both short and long read technologies over 23 time points spanning 101 days. Although little change was observed in the overall viral population structure following two courses of remdesivir over the first 57 days, N501Y in Spike was transiently detected at day 55 and V157L in RdRp emerged. However, following convalescent plasma we observed large, dynamic virus population shifts, with the emergence of a dominant viral strain bearing D796H in S2 and{Delta} H69/{Delta}V70 in the S1 N-terminal domain NTD of the Spike protein. As passively transferred serum antibodies diminished, viruses with the escape genotype diminished in frequency, before returning during a final, unsuccessful course of convalescent plasma. In vitro, the Spike escape double mutant bearing{Delta} H69/{Delta}V70 and D796H conferred decreased sensitivity to convalescent plasma, whilst maintaining infectivity similar to wild type. D796H appeared to be the main contributor to decreased susceptibility, but incurred an infectivity defect. The{Delta} H69/{Delta}V70 single mutant had two-fold higher infectivity compared to wild type and appeared to compensate for the reduced infectivity of D796H. Consistent with the observed mutations being outside the RBD, monoclonal antibodies targeting the RBD were not impacted by either or both mutations, but a non RBD binding monoclonal antibody was less potent against{Delta} H69/{Delta}V70 and the double mutant. These data reveal strong selection on SARS-CoV-2 during convalescent plasma therapy associated with emergence of viral variants with reduced susceptibility to neutralising antibodies.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.12.08.20246231,2020-12-11,https://medrxiv.org/cgi/content/short/2020.12.08.20246231,Artificial intelligence-enabled analysis of UK and US public attitudes on Facebook and Twitter towards COVID-19 vaccinations,Amir Hussain; Ahsen Tahir; Zain Hussain; Zakariya Sheikh; Mandar Gogate; Kia Dashtipour; Azhar Ali; Aziz Sheikh,"Edinburgh Napier University, UK; Edinburgh Napier University, UK; Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh, UK; Edinburgh Medical School, College of Medicine and Veterinary Medicine, University of Edinburgh, UK; Edinburgh Napier University, UK; Edinburgh Napier University, UK; NHS Forth Medical Group, UK & Harvard T.H. Chan School of Public Health, USA; Usher Institute, Edinburgh Medical School, University of Edinburgh, UK","BackgroundGlobal efforts towards the development and deployment of a vaccine for SARS-CoV-2 are rapidly advancing. We developed and applied an artificial-intelligence (AI)-based approach to analyse social-media public sentiment in the UK and the US towards COVID-19 vaccinations, to understand public attitude and identify topics of concern.

MethodsOver 300,000 social-media posts related to COVID-19 vaccinations were extracted, including 23,571 Facebook-posts from the UK and 144,864 from the US, along with 40,268 tweets from the UK and 98,385 from the US respectively, from 1st March - 22nd November 2020. We used natural language processing and deep learning based techniques to predict average sentiments, sentiment trends and topics of discussion. These were analysed longitudinally and geo-spatially, and a manual reading of randomly selected posts around points of interest helped identify underlying themes and validated insights from the analysis.

ResultsWe found overall averaged positive, negative and neutral sentiment in the UK to be 58%, 22% and 17%, compared to 56%, 24% and 18% in the US, respectively. Public optimism over vaccine development, effectiveness and trials as well as concerns over safety, economic viability and corporation control were identified. We compared our findings to national surveys in both countries and found them to correlate broadly.

ConclusionsAI-enabled social-media analysis should be considered for adoption by institutions and governments, alongside surveys and other conventional methods of assessing public attitude. This could enable real-time assessment, at scale, of public confidence and trust in COVID-19 vaccinations, help address concerns of vaccine-sceptics and develop more effective policies and communication strategies to maximise uptake.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.12.03.20242941,2020-12-07,https://medrxiv.org/cgi/content/short/2020.12.03.20242941,Contrasting factors associated with COVID-19-related ICU and death outcomes: interpretable multivariable analyses of the UK CHESS dataset.,Massimo Cavallaro; Haseeb Moiz; Matt J Keeling; Noel D McCarthy,University of Warwick; University of Warwick; University of Warwick; University of Warwick,"Identification of those at greatest risk of death due to the substantial threat of COVID-19 can benefit from novel approaches to epidemiology that leverage large datasets and complex machine-learning models, provide data-driven intelligence, and guide decisions such as intensive-care unit admission (ICUA). The objective of this study is two-fold, one substantive and one methodological: substantively to evaluate the association of demographic and health records with two related, yet different, outcomes of severe COVID-19 (viz., death and ICUA); methodologically to compare interpretations based on logistic regression and on gradient-boosted decision tree (GBDT) predictions interpreted by means of the Shapley impacts of covariates. Very different association of some factors, e.g., obesity and chronic respiratory diseases, with death and ICUA may guide review of practice. Shapley explanation of GBDTs identified varying effects of some factors among patients, thus emphasising the importance of individual patient assessment. The results of this study are also relevant for the evaluation of complex automated clinical decision systems, which should optimise prediction scores whilst remaining interpretable to clinicians and mitigating potential biases.

Author summaryThe design is a retrospective cohort study of 13954 in-patients of ages ranging from 1 to 105 year (IQR: 56, 70, 81) with a confirmed diagnosis of COVID-19 by 28th June 2020. This study used multivariable logistic regression to generate odd ratios (ORs) multiply adjusted for 37 covariates (comorbidities, demographic, and others) selected on the basis of clinical interest and prior findings. Results were supplemented by gradient-boosted decision tree (GBDT) classification to generate Shapley values in order to evaluate the impact of the covariates on model output for all patients. Factors are differentially associated with death and ICUA and among patients.

Deaths due to COVID-19 were associated with immunosuppression due to disease (OR 1.39, 95% CI 1.10-1.76), type-2 diabetes (OR 1.31, 95% CI 1.17-1.46), chronic respiratory disease (OR 1.19, 95% CI 1.05-1.35), age (OR 1.56/10-year increment, 95% CI 1.52-1.61), and male sex (OR 1.54, 95% CI1.42-1.68). Associations of ICUA with some factors differed in direction (e.g., age, chronic respiratory disease). Self-reported ethnicities were strongly but variably associated with both outcomes.

GBDTs had similar performance (ROC-AUC, ICUA 0.83, death 0.68 for GBDT; 0.80 and 0.68 for logistic regression). We derived importance scores based on Shapley values which were consistent with the ORs, despite the underlying machine-learning model being intrinsically different to the logistic regression. Chronic heart disease, hypertension, other comorbidities, and some ethnicities had Shapley impacts on death ranging from positive to negative among different patients, although consistently associated with ICUA for all. Immunosuppressive disease, type-2 diabetes, and chronic liver and respiratory diseases had positive impacts on death with either positive or negative on ICUA.

We highlight the complexity of informing clinical practice and public-health interventions. We recommend that clinical support systems should not only predict patients at risk, but also yield interpretable outputs for validation by domain experts.",health informatics,fuzzy,100,100
medRxiv,10.1101/2020.12.02.20242933,2020-12-04,https://medrxiv.org/cgi/content/short/2020.12.02.20242933,Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19,Anthony Shek; Daniel M Bean; Rebecca Bendayan; James TH Teo; Richard JB Dobson; Ajay M Shah; Rosita Zakeri,King's College London; King's College London; King's College London; Kings College Hospital NHS Foundation Trust; Kings College London; King's College London; King's College London,"BackgroundThe association between cardiovascular (CV) risk factors, such as hypertension and diabetes, established CV disease (CVD), and susceptibility to CV complications or mortality in COVID-19 remains unclear.

MethodsWe conducted a cohort study of consecutive adults hospitalised for severe COVID-19 between 1st March and 30th June 2020. Pre-existing CVD, CV risk factors and associations with mortality and CV complications were ascertained.

FindingsAmong 1,721 patients (median age 71 years, 57% male), 349 (20.3%) had pre-existing CVD (CVD), 888 (51.6%) had CV risk factors without CVD (RF-CVD), 484 (28.1%) had neither. Patients with CVD were older with a higher burden of non-CV comorbidities. During follow-up, 438 (25.5%) patients died: 37% with CVD, 25.7% with RF-CVD and 16.5% with neither. CVD was independently associated with in-hospital mortality among patients <70 years of age (adjusted HR 2.43 [95%CI 1.16-5.07]), but not in those [&ge;]70 years (aHR 1.14 [95%CI 0.77-1.69]). RF-CVD were not independently associated with mortality in either age group (<70y aHR 1.21 [95%CI 0.72-2.01], [&ge;]70y aHR 1.07 [95%CI 0.76-1.52]). Most CV complications occurred in patients with CVD (66%) versus RF-CVD (17%) or neither (11%; p<0.001). 213 [12.4%] patients developed venous thromboembolism (VTE). CVD was not an independent predictor of VTE.

InterpretationIn patients hospitalised with COVID-19, pre-existing established CVD appears to be a more important contributor to mortality than CV risk factors in the absence of CVD. CVD-related hazard may be mediated, in part, by new CV complications. Optimal care and vigilance for destabilised CVD are essential in this patient group.",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2020.12.03.20243535,2020-12-04,https://medrxiv.org/cgi/content/short/2020.12.03.20243535,OpenSAFELY: impact of national guidance on switching from warfarin to direct oral anticoagulants (DOACs) in early phase of COVID-19 pandemic in England,Helen J Curtis; Brian MacKenna; Alex J Walker; Richard Croker; Amir Mehrkar; Caroline E Morton; Seb Bacon; George Hickman; Peter Inglesby; Chris Bates; David Evans; Tom Ward; Jonathan Cockburn; Simon Davy; Krishnan Bhaskaran; Anna Schultze; Christopher T Rentsch; Elizabeth Williamson; William Hulme; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Henry Drysdale; Rosalind M Eggo; Kevin Wing; Angel Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Ian J Douglas; Liam Smeeth; Ben Goldacre,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundEarly in the COVID-19 pandemic the NHS recommended that appropriate patients anticoagulated with warfarin should be switched to direct acting oral anticoagulants (DOACs), requiring less frequent blood testing. Subsequently, a national safety alert was issued regarding patients being inappropriately co-prescribed two anticoagulants following a medication change, and associated monitoring.

ObjectiveTo describe which people were switched from warfarin to DOACs; identify potentially unsafe co-prescribing of anticoagulants; and assess whether abnormal clotting results have become more frequent during the pandemic.

MethodsWorking on behalf of NHS England we conducted a population cohort based study using routine clinical data from >17 million adults in England.

Results20,000 of 164,000 warfarin patients (12.2%) switched to DOACs between March and May 2020, most commonly to edoxaban and apixaban. Factors associated with switching included: older age, recent renal function test, higher number of recent INR tests recorded, atrial fibrillation diagnosis and care home residency. There was a sharp rise in co-prescribing of warfarin and DOACs from typically 50-100 per month to 246 in April 2020, 0.06% of all people receiving a DOAC or warfarin. INR testing fell by 14% to 506.8 patients tested per 1000 warfarin patients each month. We observed a very small increase in elevated INRs (n=470) during April compared with January (n=420).

ConclusionsIncreased switching of anticoagulants from warfarin to DOACs was observed at the outset of the COVID-19 pandemic in England following national guidance. There was a small but substantial number of people co-prescribed warfarin and DOACs during this period. Despite a national safety alert on the issue, a widespread rise in elevated INR test results was not found. Primary care has responded rapidly to changes in patient care during the COVID-19 pandemic.",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2020.11.30.20240010,2020-12-03,https://medrxiv.org/cgi/content/short/2020.11.30.20240010,Is Point-of-Care testing feasible and safe in care homes in England? An exploratory usability and accuracy evaluation of Point-of-Care Polymerase Chain Reaction test for SARS-COV-2,Massimo Micocci; Adam Gordon; Mikyung Kelly Seo; Joy A Allen; Kerrie Davies; Dan Lasserson; Carl Thompson; Karen Spilsbury; Cyd Akrill; Ros Heath; Anita Astle; Claire Sharpe; Rafael Perera; Gail Hayward; Peter Buckle,"NIHR London In Vitro Diagnostics Co-operative, Dept of Surgery and Cancer, Faculty of Medicine, Imperial College London St. Mary's Hospital London; Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Nottingham, UK;NIHR Applied Research Collaboration-East Midlands (ARC-EM), N; NIHR London In Vitro Diagnostics Co-operative, Dept of Surgery and Cancer, Faculty of Medicine, Imperial College London St. Mary's Hospital London; NIHR Newcastle In Vitro Diagnostics Co-operative, Translational and Clinical Research Institute, Newcastle University, Newcastle Upon Tyne, UK; Healthcare Associated Infections Research Group, University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK; Warwick Medical School, University of Warwick, UK; School of Healthcare, University of Leeds, Leeds, UK; School of Healthcare, University of Leeds, Leeds, UK; NIHR Applied Research Collaboration Yorkshire and Humber, UK; Springfield Healthcare, Leeds, UK; Landermeads Nursing Home, Nottingham, UK; Wren Hall Nursing Home, Selston, UK; Ashmere Nottinghamshire Ltd, Notts, UK; Nuffield Department of Primary Care Health Sciences, University of Oxford, UK; NIHR Community Healthcare MedTech and IVD Co-operative,Oxford,UK; NIHR London In Vitro Diagnostics Co-operative, Dept of Surgery and Cancer, Faculty of Medicine, Imperial College London St. Mary's Hospital London","IntroductionReliable rapid testing on COVID-19 is needed in care homes to reduce the risk of outbreaks and enable timely care. Point-of-care testing (POCT) in care homes could provide rapid actionable results. This study aimed to examine the usability and test performance of point of care polymerase chain reaction (PCR) for COVID-19 in care homes.

MethodsPoint-of-care PCR for detection of SARS-COV2 was evaluated in a purposeful sample of four UK care homes. Test agreement with laboratory real-time PCR and usability and use errors were assessed.

ResultsPoint of care and laboratory polymerase chain reaction (PCR) tests were performed on 278 participants. The point of care and laboratory tests returned uncertain results or errors for 17 and 5 specimens respectively. Agreement analysis was conducted on 256 specimens. 175 were from staff: 162 asymptomatic; 13 symptomatic. 69 were from residents: 59 asymptomatic; 10 symptomatic. Asymptomatic specimens showed 83.3% (95% CI: 35.9%-99.6%) positive agreement and 98.7% negative agreement (95% CI: 96.2%-99.7%), with overall prevalence and bias-adjusted kappa (PABAK) of 0.965 (95% CI: 0.932 - 0.999). Symptomatic specimens showed 100% (95% CI: 2.5%-100%) positive agreement and 100% negative agreement (95% CI: 85.8%-100%), with overall PABAK of 1. No usability-related hazards emerged from this exploratory study.

ConclusionApplications of point-of-care PCR testing in care homes can be considered with appropriate preparatory steps and safeguards. Agreement between POCT and laboratory PCR was good. Further diagnostic accuracy evaluations and in-service evaluation studies should be conducted, if the test is to be implemented more widely, to build greater certainty on this initial exploratory analysis.

Key pointsO_LIPoint of care tests (POCT) in care homes are feasible and could increase testing capacity for the control of COVID-19 infection.
C_LIO_LIThe test of agreement between POCT and laboratory PCR for care home residents and the staff was good.
C_LIO_LIAdoption of POCT in care homes can be considered with appropriate preparatory steps and safeguards in place.
C_LIO_LIRepetitive errors and test malfunctioning can be mitigated with bespoke training for care home staff.
C_LIO_LIIntegrated care pathways should be investigated to test the high variability of the context of use.
C_LI",health systems and quality improvement,fuzzy,90,100
medRxiv,10.1101/2020.12.01.20241729,2020-12-03,https://medrxiv.org/cgi/content/short/2020.12.01.20241729,International estimates of intended uptake and refusal of COVID-19 vaccines: A rapid systematic review and meta-analysis of large nationally representative samples,Eric Robinson; Andrew Jones; India Lesser; Michael Daly,University of Liverpool; University of Liverpool; University of Liverpool; Maynooth University,"BackgroundWidespread uptake of COVID-19 vaccines will be essential to extinguishing the COVID-19 pandemic. Vaccines have been developed in unprecedented time and hesitancy towards vaccination among the general population is unclear.

MethodsSystematic review and meta-analysis of studies using large nationally representative samples (n[&ge;]1000) to examine the percentage of the population intending to vaccinate, unsure, or intending to refuse a COVID-19 vaccine when available. Generic inverse meta-analysis and meta-regression were used to pool estimates and examine time trends. PubMed, Scopus and pre-printer servers were searched from January-November, 2020. Registered on PROSPERO (CRD42020223132).

FindingsTwenty-eight nationally representative samples (n = 58,656) from 13 countries indicate that as the pandemic has progressed, the percentage of people intending to vaccinate and refuse vaccination have been decreasing and increasing respectively. Pooled data from surveys conducted during June-October suggest that 60% (95% CI: 49% to 69%) intend to vaccinate and 20% (95% CI: 13% to 29%) intend to refuse vaccination, although intentions vary substantially between samples and countries (I2 > 90%). Being female, younger, of lower income or education level and belonging to an ethnic minority group were consistently associated with being less likely to intend to vaccinate. Findings were consistent across higher vs. lower quality studies.

InterpretationIntentions to be vaccinated when a COVID-19 vaccine becomes available have been declining globally and there is an urgent need to address social inequalities in vaccine hesitancy and promote widespread uptake of vaccines as they become available.

FundingN/A

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed, Scopus and pre-print servers for manuscripts from January to November, 2020, reporting on studies examining intentions to be vaccinated against COVID-19 in large nationally representative samples (N[&ge;]1000). No language restrictions were applied. Search terms were [(COVID OR coronavirus OR SARS-COV-2) AND (Vaccine OR Vaccination) AND (Inten* OR willing* OR attitud* OR hypothetical)]. From 792 articles, we identified 20 eligible articles reporting on 28 nationally representative samples.

Added value of this studyThis is the first systematic study and meta-analysis to estimate the proportion of the global population willing to be vaccinated against vs. intending to refuse a vaccine when COVID-19 vaccines become available and how this trend has changed over time, using large and nationally representative samples. Results indicate that COVID-19 vaccination intentions vary substantially across countries, the percentage of the population intending to be vaccinated has declined across countries as the pandemic has progressed (March-May estimate: 79%, June-October estimate: 60%) and a growing number report intending to refuse a vaccine, when available (March-May estimate: 12%, June-October estimate: 20%). There is consistent socio-demographic patterning of vaccination intentions; being female, younger, of lower income or education level and belonging to an ethnic minority group are associated with a reduced likelihood of intending to be vaccinated when a vaccine become available.

Implications of all the available evidenceIntentions to vaccinate against COVID-19 among the general public when a vaccine becomes available have been declining and this will limit the effectiveness of COVID-19 vaccination programmes. Findings highlight the need to improve public acceptability, trust and concern over the safety and benefit of COVID-19 vaccines and target vaccine uptake in disadvantaged groups who have already been disproportionately affected by the pandemic.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.11.27.20238147,2020-12-02,https://medrxiv.org/cgi/content/short/2020.11.27.20238147,"Ethnicity, Household Composition and COVID-19 Mortality: A National Linked Data Study",Vahe Nafilyan; Nazrul Islam; Daniel Ayoubkhani; Clare Gilles; Srinivasa Vittal Katikireddi; Rohini Mathur; Annabel Summerfield; Karen Tingay; Miqdad Asaria; Ann John; Peter Goldblatt; Amitava Banerjee; Myer Glickman; Kamlesh Khunti,"Office for National Statistics; Nuffield Department of Population Health, Big Data Institute, University of Oxford; Office for National Statistics; Diabetes Research Centre, University of Leicester; University of Glasgow; London School of Hygiene and Tropical Medicine; Office for National Statistics; Office for National Statistics; London School of Economics and Political Sciences; Swansea University; UCL Institute of Health Equity, University College London; University College London; Office for National Statistics; Diabetes Research Centre, University of Leicester","BackgroundEthnic minorities have experienced disproportionate COVID-19 mortality rates. We estimated associations between household composition and COVID-19 mortality in older adults ([&ge;] 65 years) using a newly linked census-based dataset, and investigated whether living in a multi-generational household explained some of the elevated COVID-19 mortality amongst ethnic minority groups.

MethodsUsing retrospective data from the 2011 Census linked to Hospital Episode Statistics (2017-2019) and death registration data (up to 27th July 2020), we followed adults aged 65 years or over living in private households in England from 2 March 2020 until 27 July 2020 (n=10,078,568). We estimated hazard ratios (HRs) for COVID-19 death for people living in a multi-generational household compared with people living with another older adult, adjusting for geographical factors, socio-economic characteristics and pre-pandemic health. We conducted a causal mediation analysis to estimate the proportion of ethnic inequalities explained by living in a multi-generational household.

ResultsLiving in a multi-generational household was associated with an increased risk of COVID-19 death. After adjusting for confounding factors, the HRs for living in a multi-generational household with dependent children were 1.13 [95% confidence interval 1.01-1.27] and 1.17 [1.01-1.35] for older males and females. The HRs for living in a multi-generational household without dependent children were 1.03 [0.97 - 1.09] for older males and 1.22 [1.12 - 1.32] for older females. Living in a multi-generational household explained between 10% and 15% of the elevated risk of COVID-19 death among older females from South Asian background, but very little for South Asian males or people in other ethnic minority groups.

ConclusionOlder adults living with younger people are at increased risk of COVID-19 mortality, and this is a notable contributing factor to the excess risk experienced by older South Asian females compared to White females. Relevant public health interventions should be directed at communities where such multi-generational households are highly prevalent.

FundingThis research was funded by the Office for National Statistics.",epidemiology,fuzzy,100,100
bioRxiv,10.1101/2020.12.02.408047,2020-12-02,https://biorxiv.org/cgi/content/short/2020.12.02.408047,Effective in-vitro inactivation of SARS-CoV-2 by commercially available mouthwashes,Katherine Davies; Hubert Buczkowski; Stephen R Welch; Nicole Green; Damian Mawer; Neil Woodford; Allen D.G Roberts; Peter Nixon; David Seymour; Marian J Killip,Public Health England; Public Health England; Public Health England; Public Health England; York Hospitals NHS Foundation Trust; Public Health England; Public Health England; York Hospitals NHS Foundation Trust; York Hospitals NHS Foundation Trust; Public Health England,"Infectious SARS-CoV-2 can be recovered from the oral cavities and saliva of COVID-19 patients with potential implications for disease transmission. Reducing viral load in patient saliva using antiviral mouthwashes may therefore have a role as a control measure in limiting virus spread, particularly in dental settings. Here, the efficacy of SARS-CoV-2 inactivation by seven commercially available mouthwashes with a range of active ingredients were evaluated in vitro. We demonstrate [&ge;]4.1 to [&ge;]5.5 log10 reduction in SARS-CoV-2 titre following a one minute treatment with commercially available mouthwashes containing 0.01-0.02% stabilised hypochlorous acid or 0.58% povidone iodine, and non-specialist mouthwashes with both alcohol-based and alcohol-free formulations designed for home use. In contrast, products containing 1.5% hydrogen peroxide or 0.2% chlorhexidine gluconate were ineffective against SARS-CoV-2 in these tests. This study contributes to the growing body of evidence surrounding virucidal efficacy of mouthwashes/oral rinses against SARS-CoV-2, and has important applications in reducing risk associated with aerosol generating procedures in dentistry and potentially for infection control more widely.",microbiology,fuzzy,100,100
medRxiv,10.1101/2020.11.27.20239087,2020-11-30,https://medrxiv.org/cgi/content/short/2020.11.27.20239087,Dietary supplements during the COVID-19 pandemic: insights from 1.4M users of the COVID Symptom Study app - a longitudinal app-based community survey,Panayiotis Louca; Benjamin Murray; Kerstin Klaser; Mark S Graham; Mohsen Mazidi; Emily R Leeming; Ellen J Thompson; Ruth Bowyer; David Alden Drew; Long Alden Nguyen; Jordi Merino; Maria F Gomez; Olatz Mompeo; Ricardo Costeira; Carole H Sudre; Rachel Gibson; Claire Steves; Jonathan Wolf; Paul W Franks; Sebastien Ourselin; Andrew T Chan; Sarah E Berry; Ana Valdes; Philip Calder; Tim D Spector; Cristina Menni,King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Lund University; King's College London; King's College London; University College London; King's College London; King's College London; Zoe Global Limited; Lund University; King's College London; Massachusetts General Hospital and Harvard Medical School; King's College London; King's College London; University of Southampton; King's College London; King's College London,"ObjectivesDietary supplements may provide nutrients of relevance to ameliorate SARS-CoV-2 infection, although scientific evidence to support a role is lacking. We investigate whether the regular use of dietary supplements can reduce the risk of testing positive for SARS-CoV-2 infection in around 1.4M users of the COVID Symptom Study App who completed a supplement use questionnaire.

DesignLongitudinal app-based community survey and nested case control study.

SettingSubscribers to an app that was launched to enable self-reported information related to SARS-CoV-2 infection for use in the general population in three countries.

Main ExposureSelf-reported regular dietary supplement usage since the beginning of the pandemic.

Main Outcome MeasuresSARS-CoV-2 infection confirmed by viral RNA polymerase chain reaction test (RT-PCR) or serology test. A secondary outcome was new-onset anosmia.

ResultsIn an analysis including 327,720 UK participants, the use of probiotics, omega-3 fatty acids, multivitamins or vitamin D was associated with a lower risk of SARS-CoV-2 infection by 14%(95%CI: [8%,19%]), 12%(95%CI: [8%,16%]), 13%(95%CI: [10%,16%]) and 9%(95%CI: [6%,12%]), respectively, after adjusting for potential confounders. No effect was observed for vitamin C, zinc or garlic supplements. When analyses were stratified by sex, age and body mass index (BMI), the protective associations for probiotics, omega-3 fatty acids, multivitamins and vitamin D were observed in females across all ages and BMI groups, but were not seen in men. The same overall pattern of association was observed in both the US and Swedish cohorts. Results were further confirmed in a sub-analysis of 993,365 regular app users who were not tested for SARS-CoV-2 with cases (n= 126,556) defined as those with new onset anosmia (the strongest COVID-19 predictor).

ConclusionWe observed a modest but significant association between use of probiotics, omega-3 fatty acid, multivitamin or vitamin D supplements and lower risk of testing positive for SARS-CoV-2 in women. No clear benefits for men were observed nor any effect of vitamin C, garlic or zinc for men or women. Randomised controlled trials of selected supplements would be required to confirm these observational findings before any therapeutic recommendations can be made.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.11.25.20238600,2020-11-29,https://medrxiv.org/cgi/content/short/2020.11.25.20238600,Spatially resolved simulations of the spread of COVID-19 in European countries,Andrea Parisi; Samuel P C Brand; Joe Hilton; Rabia Aziza; Matt J Keeling; D. James Nokes,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; Kemri-Wellcome Trust,"We explore the spatial and temporal spread of the novel SARS-CoV-2 virus under containment measures in three European countries based on fits to data of the early outbreak. Using data from Spain and Italy, we estimate an age dependent infection fatality ratio for SARS-CoV-2, as well as risks of hospitalization and intensive care admission. We use them in a model that simulates the dynamics of the virus using an age structured, spatially detailed agent based approach, that explicitly incorporates governamental interventions, changes in mobility and contact patterns occurred during the COVID-19 outbreak in each country. Our simulations reproduce several of the features of its spatio-temporal spread in the three countries studied. They show that containment measures combined with high density are responsible for the containment of cases within densely populated areas, and that spread to less densely populated areas occurred during the late stages of the first wave. The capability to reproduce observed features of the spatio-temporal dynamics of SARS-CoV-2 makes this model a potential candidate for forecasting the dynamics of SARS-CoV-2 in other settings, and we recommend its application in low and lower-middle countries which remain understudied.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.11.23.20237313,2020-11-24,https://medrxiv.org/cgi/content/short/2020.11.23.20237313,"Identifying optimal combinations of symptoms to trigger diagnostic work-up of suspected COVID-19 cases in vaccine trials: analysis from a community-based, prospective, observational cohort",Michela Antonelli; Joan Capdevila; Amol Chaudhari; Julia Granerod; Liane S Canas; Mark S Graham; Kerstin Klaser; Marc Modat; Erika Molteni; Ben Murray; Carole H Sudre; Richard Davies; Anna May; Long H Nguyen; David A Drew; Amit Joshi; Andrew T Chan; Jakob Cramer; Tim Spector; Jonathan Wolf; Sebastien Ourselin; Claire J Steves; Alfred E Loeliger,King's College London; Zoe Global; Coalition for Epidemic Preparedness Innovations; Coalition for Epidemic Preparedness Innovations; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; University College London; Zoe Global; Zoe Global; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Coalition for Epidemic Preparedness Innovations; King's College London; Zoe Global; King's College London; King's College London; Coalition for Epidemic Preparedness Innovations,"ObjectivesDiagnostic work-up following any COVID-19 associated symptom will lead to extensive testing, potentially overwhelming laboratory capacity whilst primarily yielding negative results. We aimed to identify optimal symptom combinations to capture most cases using fewer tests with implications for COVID-19 vaccine developers across different resource settings and public health.

MethodsUK and US users of the COVID-19 Symptom Study app who reported new-onset symptoms and an RT-PCR test within seven days of symptom onset were included. Sensitivity, specificity, and number of RT-PCR tests needed to identify one case (test per case [TPC]) were calculated for different symptom combinations. A multi-objective evolutionary algorithm was applied to generate combinations with optimal trade-offs between sensitivity and specificity.

FindingsUK and US cohorts included 122,305 (1,202 positives) and 3,162 (79 positive) individuals. Within three days of symptom onset, the COVID-19 specific symptom combination (cough, dyspnoea, fever, anosmia/ageusia) identified 69% of cases requiring 47 TPC. The combination with highest sensitivity (fatigue, anosmia/ageusia, cough, diarrhoea, headache, sore throat) identified 96% cases requiring 96 TPC.

InterpretationWe confirmed the significance of COVID-19 specific symptoms for triggering RT-PCR and identified additional symptom combinations with optimal trade-offs between sensitivity and specificity that maximize case capture given different resource settings.

HighlightsO_LIWidely recommended symptoms identified only [~]70% COVID-19 cases
C_LIO_LIAdditional symptoms increased case finding to > 90% but tests needed doubled
C_LIO_LIOptimal symptom combinations maximise case capture considering available resources
C_LIO_LIImplications for COVID-19 vaccine efficacy trials and wider public health
C_LI",health informatics,fuzzy,100,100
medRxiv,10.1101/2020.11.19.20234120,2020-11-23,https://medrxiv.org/cgi/content/short/2020.11.19.20234120,Actionable druggable genome-wide Mendelian randomization identifies repurposingopportunities for COVID-19,Liam Gaziano; Claudia Giambartolomei; Alexandre C Pereira; Anna Gaulton; Daniel C Posner; Sonja A Swanson; Yuk Lam Ho; Sudha K Iyengar; Nicole M Kosik; Marijana Vujkovic; David R Gagnon; A Patricia Bento; Pedro Beltrao; Inigo Barrio Hernandez; Lars Ronnblom; Niklas Hagberg; Christian Lundtoft; Claudia Langenberg; Maik Pietzner; Dennis Valentine; Elias Allara; Praveen Surendran; Stephen Burgess; Jing Hua Zhao; James E Peters; Bram P Prins; John Danesh; Poornima Devineni; Yunling Shi; Kristine E Lynch; Scott L DuVall; Helene Garcon; Lauren Thomann; Jin J Zhou; Bryan R Gorman; Jennifer E Huffman; Christopher J O'Donnell; Philip S Tsao; Jean C Beckham; Saiju Pyarajan; Sumitra Muralidhar; Grant D Huang; Rachel Ramoni; Adriana M Hung; Kyong-Mi Chang; Yan V Sun; Jacob Joseph; Andrew R Leach; Todd L Edwards; Kelly Cho; J Michael Gaziano; Adam S Butterworth; Juan P Casas,"VA Boston Healthcare System, University of Cambridge; Instituto Italiano di Tecnologia, University of California Los Angeles; University of Sao Paulo, Harvard University; European Molecular Biology Laboratory, European Bioinformatics Institute; VA Boston Healthcare System; Erasmus Medical Center; VA Boston Healthcare System; Case Western Reserve University and Louis Stoke Cleveland VAMC; VA Boston Healthcare System; The Corporal Michael J. Crescenz VA Medical Center, the University of Pennsylvania Perelman School of Medicine; Boston University, VA Boston Healthcare System; European Molecular Biology Laboratory, European Bioinformatics Institute; European Molecular Biology Laboratory, European Bioinformatics Institute; European Molecular Biology Laboratory, European Bioinformatics Institute; Uppsala University; Uppsala University; Uppsala University; Charite University Medicine Berlin,  Universityof Cambridge; Universityof Cambridge; University College London; University of Cambridge; Wellcome Genome Campus and University of Cambridge; University of Cambridge; University of Cambridge; Imperial College London; Wellcome Genome Campus and University of Cambridge; University of Cambridge; VA Boston Healthcare System; VA Boston Healthcare System; VA Salt Lake City Health Care System, University of Utah; VA Salt Lake City Health Care System, University of Utah; VA Boston Healthcare System; VA Boston Healthcare System; University of Arizona, Phoenix VA Health Care System; VA Boston Healthcare System; VA Boston Healthcare System; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Palo Alto Health Care System, Stanford University School of Medicine; Durham VA Medical Center, Duke University School of Medicine; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs; Department of Veterans Affairs, Vanderbilt University; The Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania; Atlanta VA Health Care System, Emory University Rollins School of Public Health; VA Boston Healthcare System and Brigham & Women's Hospital; European Molecular Biology Laboratory, European Bioinformatics Institute; Department of Veterans Affairs Tennessee Valley Healthcare System, Vanderbilt Genetics Institute Vanderbilt University Medical Center; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School; University of Cambridge, Wellcome Genome Campus and University of Cambridge; VA Boston Healthcare System, Brigham and Women's Hospital, Harvard Medical School","Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization (MR) analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and >1 million controls. We found significant Mendelian randomization results for three proteins (ACE2: P=1.6x10-6, IFNAR2: P=9.8x10-11, and IL-10RB: P=1.9x10-14) using cis-eQTL genetic instruments that also had strong evidence for colocalization with COVID-19 hospitalization. To disentangle the shared eQTL signal for IL10RB and IFNAR2, we conducted phenome-wide association scans and pathway enrichment analysis, which suggested that IFNAR2 is more likely to play a role in COVID-19 hospitalization. Our findings prioritize trials of drugs targeting IFNAR2 and ACE2 for early management of COVID-19.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.11.19.20234849,2020-11-22,https://medrxiv.org/cgi/content/short/2020.11.19.20234849,Community factors and excess mortality in first wave of the COVID-19 pandemic.,Bethan Davies; Brandon L Parkes; James Bennett; Daniela Fecht; Marta Blangiardo; Majid Ezzati; Paul Elliott,Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London,"Risk factors for increased risk of death from Coronavirus Disease 19 (COVID-19) have been identified1,2 but less is known on characteristics that make communities resilient or vulnerable to the mortality impacts of the pandemic. We applied a two-stage Bayesian spatial model to quantify inequalities in excess mortality at the community level during the first wave of the pandemic in England. We used geocoded data on all deaths in people aged 40 years and older during March-May 2020 compared with 2015-2019 in 6,791 local communities. Here we show that communities with an increased risk of excess mortality had a high density of care homes, and/or high proportion of residents on income support, living in overcrowded homes and/or high percent of people with a non-White ethnicity (including Black, Asian and other minority ethnic groups). Conversely, after accounting for other community characteristics, we found no association between population density or air pollution and excess mortality. Overall, the social and environmental variables accounted for around 15% of the variation in mortality at community level. Effective and timely public health and healthcare measures that target the communities at greatest risk are urgently needed if England and other industrialised countries are to avoid further widening of inequalities in mortality patterns during the second wave.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.11.18.20233932,2020-11-20,https://medrxiv.org/cgi/content/short/2020.11.18.20233932,REACT-1 round 6 updated report: high prevalence of SARS-CoV-2 swab positivity with reduced rate of growth in England at the start of November 2020,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E. Walters; Haowei Wang; Christina Atchinson; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; School of Public Health, Imperial College London, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; CHICAS, Lancaster Medical School, Lancaster University, UK and Health Data Research, UK; School of Public Health, Imperial College London, UK; School of Public Health, Imperial College London, UK MRC Centre for Global infectious Disease Analysis and Abdul Latif Jameel Institute for Disease and Emergenc; Department of Infectious Disease, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedic; Department of Infectious Disease, Imperial College London, UK; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear; Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Research Centre, UK Institute of Global Health Innovation a; School of Public Health, Imperial College London, UK Imperial College Healthcare NHS Trust, UK National Institute for Health Research Imperial Biomedical Resear","BackgroundEngland is now in the midst of its second wave of the COVID-19 pandemic. Multiple regions of the country are at high infection prevalence and all areas experienced rapid recent growth of the epidemic during October 2020.

MethodsREACT-1 is a series of community surveys of SARS-CoV-2 RT-PCR swab-positivity in England designed to monitor the spread of the epidemic and thus increase situational awareness. Round 6 of REACT-1 commenced swab-collection on 16th October. A prior interim report included data from 16th to 25th October for 85,971 participants. Here, we report data for the entire round on 160,175 participants with swab results obtained up to 2nd November 2020.

ResultsOverall weighted prevalence of infection in the community in England was 1.3% or 130 people per 10,000 infected, up from 60 people per 10,000 in the round 5 report (18th September to 5th October 2020), doubling every 24 days on average since the prior round. The corresponding R number was estimated to be 1.2. Prevalence of infection was highest in North West (2.4%, up from 1.2%), followed by Yorkshire and The Humber (2.3% up from 0.84%), West Midlands (1.6% up from 0.60%), North East (1.5% up from 1.1%), East Midlands (1.3% up from 0.56%), London (0.97%, up from 0.54%), South West (0.80% up from 0.33%), South East (0.69% up from 0.29%), and East of England (0.69% up from 0.30%). Rapid growth in the South observed in the first half of round 6 was no longer apparent in the second half of round 6. We also observed a decline in prevalence in Yorkshire and The Humber during this period. Comparing the first and second halves of round 6, there was a suggestion of decline in weighted prevalence in participants aged 5 to 12 years and in those aged 25 to 44 years. While prevalence remained high, in the second half of round 6 there was suggestion of a slight fall then rise that was seen nationally and also separately in both the North and the South.

ConclusionThe impact of the second national lockdown in England is not yet known. We provide here a detailed description of swab-positivity patterns at national, regional and local scales for the period immediately preceding lockdown, against which future trends in prevalence can be evaluated.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.11.18.20230649,2020-11-20,https://medrxiv.org/cgi/content/short/2020.11.18.20230649,A network modelling approach to assess non-pharmaceutical disease controls in a worker population: An application to SARS-CoV-2,Edward M Hill; Benjamin D Atkins; Matt J Keeling; Louise Dyson; Michael J Tildesley,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"BackgroundAs part of a concerted pandemic response to protect public health, businesses can enact non-pharmaceutical controls to minimise exposure to pathogens in workplaces and premises open to the public. Amendments to working practices can lead to the amount, duration and/or proximity of interactions being changed, ultimately altering the dynamics of disease spread. These modifications could be specific to the type of business being operated.

MethodsWe use a data-driven approach to parameterise an individual-based network model for transmission of SARS-CoV-2 amongst the working population, stratified into work sectors. The network is comprised of layered contacts to consider the risk of spread in multiple encounter settings (workplaces, households, social and other). We analyse several interventions targeted towards working practices: mandating a fraction of the population to work from home; using temporally asynchronous work patterns; and introducing measures to create  COVID-secure workplaces. We also assess the general role of adherence to (or effectiveness of) isolation and test and trace measures and demonstrate the impact of all these interventions across a variety of relevant metrics.

ResultsThe progress of the epidemic can be significantly hindered by instructing a significant proportion of the workforce to work from home. Furthermore, if required to be present at the workplace, asynchronous work patterns can help to reduce infections when compared with scenarios where all workers work on the same days, particularly for longer working weeks. When assessing COVID-secure workplace measures, we found that smaller work teams and a greater reduction in transmission risk reduced the probability of large, prolonged outbreaks. Finally, following isolation guidance and engaging with contact tracing without other measures is an effective tool to curb transmission, but is highly sensitive to adherence levels.

ConclusionsIn the absence of sufficient adherence to non-pharmaceutical interventions, our results indicate a high likelihood of SARS-CoV-2 spreading widely throughout a worker population. Given the heterogeneity of demographic attributes across worker roles, in addition to the individual nature of controls such as contact tracing, we demonstrate the utility of a network model approach to investigate workplace-targeted intervention strategies and the role of test, trace and isolation in tackling disease spread.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.11.18.20225029,2020-11-20,https://medrxiv.org/cgi/content/short/2020.11.18.20225029,The Invasive Respiratory Infection Surveillance (IRIS) Initiative reveals significant reductions in invasive bacterial infections during the COVID-19 pandemic,Angela B Brueggemann; Melissa J Jansen van Rensburg; David Shaw; Noel D McCarthy; Keith A Jolley; Martin CJ Maiden; Mark PG van der Linden,University of Oxford; University of Oxford; University of Oxford; University of Warwick; University of Oxford; University of Oxford; University Hospital RWTH Aachen,"BackgroundStreptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis are leading causes of invasive diseases including bacteraemic pneumonia and meningitis, and of secondary infections post-viral respiratory disease. They are typically transmitted via respiratory droplets. We investigated rates of invasive disease due to these pathogens during the early phase of the COVID-19 pandemic.

MethodsLaboratories in 26 countries across six continents submitted data on cases of invasive disease due to S pneumoniae, H influenzae and N meningitidis from 1 January 2018 to 31 May 2020. Weekly cases in 2020 vs 2018-2019 were compared. Streptococcus agalactiae data were collected from nine laboratories for comparison to a non-respiratory pathogen. The stringency of COVID-19 containment measures was quantified by the Oxford COVID-19 Government Response Tracker. Changes in population movements were assessed by Google COVID-19 Community Mobility Reports. Interrupted time series modelling quantified changes in rates of invasive disease in 2020 relative to when containment measures were imposed.

FindingsAll countries experienced a significant, sustained reduction in invasive diseases due to S pneumoniae, H influenzae and N meningitidis, but not S agalactiae, in early 2020, which coincided with the introduction of COVID-19 containment measures in each country. Similar impacts were observed across most countries despite differing stringency in COVID-19 control policies. There was no evidence of a specific effect due to enforced school closures.

InterpretationThe introduction of COVID-19 containment policies and public information campaigns likely reduced transmission of these bacterial respiratory pathogens, leading to a significant reduction in life-threatening invasive diseases in many countries worldwide.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.11.18.20234369,2020-11-19,https://medrxiv.org/cgi/content/short/2020.11.18.20234369,Antibodies to SARS-CoV-2 are associated with protection against reinfection,Sheila F Lumley; Nicole E Stoesser; Philippa C Matthews; Alison Howarth; Stephanie B Hatch; Brian D Marsden; Stuart Cox; Tim James; Fiona Warren; Liam J Peck; Thomas G Ritter; Zoe de Toledo; Laura Warren; David Axten; Richard J Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Meera Chand; - Oxford University Hospitals Staff Testing Group; Derrick W Crook; Christopher P Conlon; Koen B Pouwels; A Sarah Walker; Tim EA Peto; Susan Hopkins; Tim M Walker; Katie Jeffery; David W Eyre,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Public Health England; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Public Health England; University of Oxford; University of Oxford; University of Oxford,"BackgroundIt is critical to understand whether infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) protects from subsequent reinfection.

MethodsWe investigated the incidence of SARS-CoV-2 PCR-positive results in seropositive and seronegative healthcare workers (HCWs) attending asymptomatic and symptomatic staff testing at Oxford University Hospitals, UK. Baseline antibody status was determined using anti-spike and/or anti-nucleocapsid IgG assays and staff followed for up to 30 weeks. We used Poisson regression to estimate the relative incidence of PCR-positive results and new symptomatic infection by antibody status, accounting for age, gender and changes in incidence over time.

ResultsA total of 12219 HCWs participated and had anti-spike IgG measured, 11052 were followed up after negative and 1246 after positive antibody results including 79 who seroconverted during follow up. 89 PCR-confirmed symptomatic infections occurred in seronegative individuals (0.46 cases per 10,000 days at risk) and no symptomatic infections in those with anti-spike antibodies. Additionally, 76 (0.40/10,000 days at risk) anti-spike IgG seronegative individuals had PCR-positive tests in asymptomatic screening, compared to 3 (0.21/10,000 days at risk) seropositive individuals. Overall, positive baseline anti-spike antibodies were associated with lower rates of PCR-positivity (with or without symptoms) (adjusted rate ratio 0.24 [95%CI 0.08-0.76, p=0.015]). Rate ratios were similar using anti-nucleocapsid IgG alone or combined with anti-spike IgG to determine baseline status.

ConclusionsPrior SARS-CoV-2 infection that generated antibody responses offered protection from reinfection for most people in the six months following infection. Further work is required to determine the long-term duration and correlates of post-infection immunity.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.11.12.20229955,2020-11-15,https://medrxiv.org/cgi/content/short/2020.11.12.20229955,Mobile consulting (mConsulting) as an option for accessing healthcare services for communities in remote rural areas and urban slums in low- and middle- income countries: A mixed methods study,Bronwyn Harris; Motunrayo Ajisola; Raisa Alam; Jocelyn Antsley Watkins; Theodoros N Arvanitis; Pauline Bakibinga; Beatrice Chipwaza; Nazratun Nayeem Choudhury; Olufunke Fayhun; Peter Kibe; Akinyinka Omigbodun; Eme Owoaje; Senga Pemba; Rachel Potter; Narjis Rizvi; Jackie Sturt; Jonathan A.K Cave; Romaina Iqbal; Caroline Kabaria; Albino Kalolo; Catherine Kyobutungi; Richard J Lilford; Titus Mashanya; Sylvester Ndegese; Omar Rahman; Saleem Sayani; Rita Yusuf; Frances Griffiths,"Warwick Medical School, University of Warwick, UK; Department of Sociology, Faculty of Social Sciences, University of Ibadan, Ibadan, Oyo State, Nigeria; Centre for Health, Population and Development, Independent University Bangladesh, Dhaka, Bangladesh; Warwick Medical School, University of Warwick, UK; Institute of Digital Healthcare, WMG, University of Warwick, UK; African Population and Health Research Center, Nairobi, Kenya; St Francis University College of Health and Allied Sciences, Tanzania; Centre for Health, Population and Development, Independent University Bangladesh, Dhaka, Bangladesh; Department of Sociology, Faculty of Social Sciences, University of Ibadan, Ibadan, Oyo State, Nigeria; African Population and Health Research Center, Nairobi, Kenya; Department of Obstetrics and Gynaecology, Faculty of Clinical Sciences, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria; Department of Community Medicine, Faculty of Public Health, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria; St Francis University College of Health and Allied Sciences, Tanzania; Clinical Trials Unit Warwick Medical School, University of Warwick, University of Warwick, UK; Community Health Sciences Department, Aga Khan University, Karachi, Pakistan; King's College London, Florence Nightingale Faculty of Nursing and Midwifery, London, UK; Department of Economics, University of Warwick, UK; Community Health Sciences Department, Aga Khan University, Karachi, Pakistan; African Population and Health Research Center, Nairobi, Kenya; St Francis University College of Health and Allied Sciences, Tanzania; African Population and Health Research Center, Nairobi, Kenya; Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK; St Francis University College of Health and Allied Sciences, Tanzania; St Francis University College of Health and Allied Sciences, Tanzania; University of Liberal Arts Bangladesh, Dhaka, Bangladesh; Aga Khan Development Network Digital Health Resource Centre (Asia and Africa), Aga Khan University, Karachi, Pakistan; Centre for Health, Population and Development, Independent University Bangladesh, Dhaka, Bangladesh; Warwick Medical School, University of Warwick, UK","ObjectiveRemote or mobile consulting (mConsulting) is being promoted to strengthen health systems, deliver universal health coverage and facilitate safe clinical communication during COVID-19 and beyond. We explored whether mConsulting is a viable option for communities with minimal resources in low- and middle-income countries (LMICs).

MethodsWe reviewed evidence published since 2018 about mConsulting in LMICs and undertook a scoping study (pre-COVID) in two rural settings (Pakistan, Tanzania) and five urban slums (Kenya, Nigeria, Bangladesh), using policy/document review, secondary analysis of survey data (from the urban sites), and thematic analysis of interviews/workshops with community members, healthcare workers, digital/telecommunications experts, mConsulting providers, local and national decision-makers. Project advisory groups guided the study in each country.

ResultsWe reviewed five empirical studies and seven reviews, analysed data from 5,219 urban slum households and engaged with 419 stakeholders in rural and urban sites. Regulatory frameworks are available in each country. mConsulting services are operating through provider platforms (n=5-17) and, at community-level, some direct experience of mConsulting with healthcare workers using their own phones was reported - for emergencies, advice and care follow-up. Stakeholder willingness was high, provided challenges are addressed in technology, infrastructure, data security, confidentiality, acceptability and health system integration. mConsulting can reduce affordability barriers and facilitate care-seeking practices.

ConclusionsThere are indications of readiness for mConsulting in communities with minimal resources. However, wider system strengthening is needed to bolster referrals, specialist services, laboratories and supply-chains to fully realise the continuity of care and responsiveness that mConsulting services offer, particularly during/beyond COVID-19.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.11.10.20229146,2020-11-13,https://medrxiv.org/cgi/content/short/2020.11.10.20229146,"Awareness, knowledge and trust in the Greek authorities towards COVID-19 pandemic: results from the Epirus Health Study cohort",Afroditi Kanellopoulou; Fotios Koskeridis; Georgios Markozannes; Emmanouil Bouras; Chrysa Soutziou; Konstantinos Chaliasos; Michail T Doumas; Dimitrios E Sigounas; Vasilios T Tzovaras; Agapios Panos; Yiolanda Stergiou; Kassiani Mellou; Dimitrios Papamichail; Eleni Aretouli; Dimitrios Chatzidimitriou; Fani Chatzopoulou; Eleni Bairaktari; Ioanna Tzoulaki; Evangelos Evangelou; Evangelos C Rizos; Evangelia Ntzani; Konstantinos Vakalis; Konstantinos K Tsilidis,"University of Ioannina; University of Ioannina; University of Ioannina; University of Ioannina, Aristotle University of Thessaloniki; Ioannina Medical Care; University of Ioannina; Ioannina Medical Care; Ioannina Medical Care; Ioannina Medical Care; University of Ioannina; University of Ioannina; Hellenic National Public Health Organization; University of West Attica; University of Ioannina, Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; University of Ioannina; University of Ioannina, Imperial College London; University of Ioannina, Imperial College London; University Hospital of Ioannina, European University of Cyprus; University of Ioannina, Brown University; Ioannina Medical Care; University of Ioannina, Imperial College London","BackgroundTo assess the level of knowledge and trust in the policy decisions taken regarding the coronavirus disease (COVID-19) pandemic among Epirus Health Study (EHS) participants.

MethodsThe EHS is an ongoing and deeply-phenotyped prospective cohort study that has recruited 667 participants in northwest Greece until August 31st, 2020. Level of knowledge on coronavirus (SARS-CoV-2) transmission and COVID-19 severity was labeled as poor, moderate or good. Variables assessing knowledge and beliefs towards the pandemic were summarized overall and by gender, age group (25-39, 40-49, 50-59, [&ge;]60 years) and period of report (before the lifting of lockdown measures in Greece: March 30th to May 3rd, and two post-lockdown time periods: May 4th to June 31st, July 1st to August 31st). An exposure-wide association analysis was conducted to evaluate the associations between 153 explanatory variables and participants knowledge. Correction for multiple comparisons was applied using a false discovery rate (FDR) threshold of 5%.

ResultsA total of 563 participants (49 years mean age; 60% women) had available information on the standard EHS questionnaire, the clinical and biochemical measurements, and the COVID-19-related questionnaire. Percentages of poor, moderate and good knowledge status regarding COVID-19 were 4.5%, 10.0% and 85.6%, respectively. The majority of participants showed absolute or moderate trust in the Greek health authorities for the management of the epidemic (90.1%), as well as in the Greek Government (84.7%) and the official national sources of information (87.4%). Trust in the authorities was weaker in younger participants and those who joined the study after the lifting of lockdown measures (p-value[&le;]0.001). None of the factors examined was associated with participants level of knowledge after correction for multiple testing.

ConclusionsHigh level of knowledge about the COVID-19 pandemic and trust in the Greek authorities was observed, possibly due to the plethora of good quality publicly available information and the timely management of the pandemic at its early stages in Greece. Information campaigns for the COVID-19 pandemic should be encouraged even after the lifting of lockdown measures to increase public awareness.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.11.11.20229500,2020-11-13,https://medrxiv.org/cgi/content/short/2020.11.11.20229500,Association of social distancing and masking with risk of COVID-19,Sohee Kwon; Amit D. Joshi; Chun-Han Lo; David Alden Drew; Long Nguyen; Chuan-Guo Guo; Wenjie Ma; Raaj S. Mehta; Erica T. Warner; Christina M. Astley; Jordi Merino; Benjamin Murray; Jonathan Wolf; Sebastien Ourselin; Claire Steves; Timothy Spector; Jaime E. Hart; Mingyang Song; Trang VoPham; Andrew T. Chan,Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Boston Children's Hospital; Massachusetts General Hospital; King's College London; Zoe Global Limited; King's College London; King's College London; King's College London; Harvard T.H. Chan School of Public Health; Massachusetts General Hospital; Fred Hutchinson Cancer Research Center; Massachusetts General Hospital,"Given the continued burden of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) disease (COVID-19) across the U.S., there is a high unmet need for data to inform decision-making regarding social distancing and universal masking. We examined the association of community-level social distancing measures and individual masking with risk of predicted COVID-19 in a large prospective U.S. cohort study of 198,077 participants. Individuals living in communities with the greatest social distancing had a 31% lower risk of predicted COVID-19 compared with those living in communities with poor social distancing. Self-reported masking was associated with a 63% reduced risk of predicted COVID-19 even among individuals living in a community with poor social distancing. These findings provide support for the efficacy of mask-wearing even in settings of poor social distancing in reducing COVID-19 transmission. In the current environment of relaxed social distancing mandates and practices, universal masking may be particularly important in mitigating risk of infection.",infectious diseases,fuzzy,94,100
medRxiv,10.1101/2020.11.10.20229278,2020-11-13,https://medrxiv.org/cgi/content/short/2020.11.10.20229278,Changing probability of experiencing food insecurity by socioeconomic and demographic groups during the COVID-19 pandemic in the UK,Jonathan Koltai; Veronica Toffolutti; Martin McKee; David Stuckler,Bocconi University; Bocconi University; The London School of Hygiene & Tropical Medicine; Bocconi University,"BackgroundFood supply concerns have featured prominently in the UK response to the COVID-19 pandemic. We assess changes in food insecurity in the UK population from April to July 2020.

MethodWe analyze 11,095 respondents from the April through July waves of the Understanding Society COVID-19 longitudinal study survey linked with Wave 9 of the UK Understanding Society study. Food insecurity was defined as having used a food bank in the last 4 weeks; being hungry but not eating in the last week; or not able to eat healthy and nutritious food in the last week. Unadjusted estimates to examine changes in population prevalence and logistic regression were used to assess the association between employment transitions and food insecurity.

FindingsThe prevalence of reporting at least one form of food insecurity rose from 7{middle dot}1% in April to 20{middle dot}2% by July 2020. Some of the largest increases were among Asian respondents (22{middle dot}91 percentage points), the self-employed (15{middle dot}90 percentage points), and 35-44-year-olds (17{middle dot}08 percentage points). In logistic regression models, those moving from employment to unemployment had higher odds of reporting food insecurity relative to furloughed individuals (OR = 2{middle dot}23; 95% CI: 1{middle dot}20-4{middle dot}131) and to the persistently employed (OR=2{middle dot}38; 95% CI: 1{middle dot}33-4{middle dot}27), adjusting for sociodemographic characteristics. Furloughed individuals did not differ significantly in their probability of experiencing food insecurity compared to the persistently employed (OR=1{middle dot}07; 95% CI: 0{middle dot}83 to 1{middle dot}37).

InterpretationFood insecurity has increased substantially in the UK. Steps are needed to provide subsidies or food support to vulnerable groups.

O_TEXTBOXEvidence before this studyWe searched Google Scholar with the terms ""COVID-19"" and ""food insecurity"" and ""UK""; and ""food insecurity"" and ""UK"" and ""coronavirus"", published between January 1st and October 31st, 2020. One cross-sectional report was identified, which found higher levels of food insecurity in early April 2020 relative to 2018. Importantly, the report relied on items used to measure food insecurity that referred to a 12-month time span in 2018 and then a 30-day time span in April 2020, a potential source of bias for examining changes in population prevalence over time.

Added value of this studyHere we provide the first longitudinal national probability study that tracks temporal changes in population prevalence of food insecurity several months following the initial COVID-19-related lockdown measures in the UK. The prevalence of food insecurity rose for all socioeconomic and demographic and groups from April to July 2020, but did so for some more than others. Some of the largest increases in food insecurity were among Asian respondents, the self-employed, respondents aged 35-44, and those living in Scotland, London, and the North West of England. At the individual level, losing employment was associated with a higher odds of food insecurity compared to those furloughed under the Coronavirus Job Retention Scheme and the persistently employed. Importantly, furloughed individuals did not differ in their probability of food insecurity relative to the persistently employed.

Implications of all the available evidenceThis study documents an alarming increase in food insecurity in the United Kingdom during the pandemic, with important implications for policy. While Coronavirus the Job Retention Scheme appeared to have conferred some protection, it is clear that not enough has been done to mitigate overall increases food insecurity in the UK. Steps are needed to provide subsidies or food support, especially since during the pandemic emergency food assistance may not be readily accessible. Taken together our results show that, while COVID is first of all a health crisis, it also has potential to become an escalating social and economic crisis if steps are not taken to protect the weak.

C_TEXTBOX",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.11.11.20220962,2020-11-13,https://medrxiv.org/cgi/content/short/2020.11.11.20220962,Short-term forecasts to inform the response to the COVID-19 epidemic in the UK,Sebastian Funk; Sam Abbott; Benjamin D Atkins; Marc Baguelin; J Kenneth Baillie; Paul J Birrell; Joshua Blake; Nikos I Bosse; Joshua Burton; Jonathan Carruthers; Nicholas G Davies; Daniela de Angelis; Louise Dyson; W. John Edmunds; Rosalind M Eggo; Neil M Ferguson; Katy A M Gaythorpe; Erin Gorsich; Glen Guyver-Fletcher; Joel Hellewell; Edward M Hill; Alexander Holmes; Thomas A House; Chris Jewell; Mark Jit; Thibaut Jombart; Indra Joshi; Matt J Keeling; Edward Kendall; Edward S Knock; Adam J Kucharski; Katrina A Lythgoe; Sophie R Meakin; James D Munday; Peter JM Openshaw; Christopher Overton; Filippo Pagani; Jonathan Pearson; Pablo N Perez-Guzman; Lorenzo Pellis; Francesca Scarabel; Malcolm Gracie Semple; Ming Tang; Michael Tildesley; Edwin van Leeuwen; Lilith Whittles; - CMMID COVID-19 Working Group; - Imperial College COVID-19 Response Team; - ISARIC4C Investigators,"London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Warwick; Imperial College; Roslin Institute, University of Edinburgh; Public Health England; University of Cambridge; London School of Hygiene & Tropical Medicine; University of Manchester; Public Health England; London School of Hygiene and Tropical Medicine; University of Cambridge; University of Warwick; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; Imperial College; Imperial College London; University of Warwick; University of Warwick; London School of Hygiene & Tropical Medicine; University of Warwick; University of Warwick; University of Manchester; Lancaster University; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; NHSX; University of Warwick; NHS England & NHS Improvement; Imperial College; London School of Hygiene & Tropical Medicine; University of Oxford; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; Imperial College London; Manchester University; Manchester University; NHSX; Imperial College; The University of Manchester; York University; University of Liverpool; NHS England & NHSE Improvement; University of Warwick; Public Health England; Imperial College; ; ; ","BackgroundShort-term forecasts of infectious disease can aid situational awareness and planning for outbreak response. Here, we report on multi-model forecasts of Covid-19 in the UK that were generated at regular intervals starting at the end of March 2020, in order to monitor expected healthcare utilisation and population impacts in real time.

MethodsWe evaluated the performance of individual model forecasts generated between 24 March and 14 July 2020, using a variety of metrics including the weighted interval score as well as metrics that assess the calibration, sharpness, bias and absolute error of forecasts separately. We further combined the predictions from individual models into ensemble forecasts using a simple mean as well as a quantile regression average that aimed to maximise performance. We compared model performance to a null model of no change.

ResultsIn most cases, individual models performed better than the null model, and ensembles models were well calibrated and performed comparatively to the best individual models. The quantile regression average did not noticeably outperform the mean ensemble.

ConclusionsEnsembles of multi-model forecasts can inform the policy response to the Covid-19 pandemic by assessing future resource needs and expected population impact of morbidity and mortality.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.11.09.20228015,2020-11-12,https://medrxiv.org/cgi/content/short/2020.11.09.20228015,A time-resolved proteomic and diagnostic map characterizes COVID-19 disease progression and predicts outcome,Vadim Demichev; Pinkus Tober-Lau; Tatiana Nazarenko; Charlotte Thibeault; Harry Whitwell; Oliver Lemke; Annika R√∂hl; Anja Freiwald; Lukasz Szyrwiel; Daniela Ludwig; Clara Correia-Melo; Elisa Theresa Helbig; Paula Stubbemann; Nana-Maria Gr√ºning; Oleg Blyuss; Spyros Vernardis; Matthew White; Christoph B. Messner; Michael Joannidis; Thomas Sonnweber; Sebastian J. Klein; Alex Pizzini; Yvonne Wohlfarter; Sabina Sahanic; Richard Hilbe; Benedikt Schaefer; Sonja Wagner; Mirja Mittermaier; Felix Machleidt; Carmen Garcia; Christoph Ruwwe-Gl√∂senkamp; Tilman Lingscheid; Laure Bosquillon de Jarcy; Miriam S. Stegemann; Moritz Pfeiffer; Linda J√ºrgens; Sophy Denker; Daniel Zickler; Philipp Enghard; Aleksej Zelezniak; Archie Campbell; Caroline Hayward; David J. Porteous; Riccardo Marioni; Alexander Uhrig; Holger M√ºller-Redetzky; Heinz Zoller; Judith L√∂ffler-Ragg; Markus A. Keller; Ivan Tancevski; John F. Timms; Alexey Zaikin; Stefan Hippenstiel; Michael Ramharter; Martin Witzenrath; Norbert Suttorp; Kathryn Lilley; Michael M√ºlleder; Leif Erik Sander; - PA-COVID-19 Study group; Markus Ralser; Florian Kurth,The Francis Crick Institute; Charit√© - Universit√§tsmedizin Berlin; University College London; Charite Universitaetsmedizin Berlin; Imperial College London; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; The Francis Crick Institute; Charit√© - Universit√§tsmedizin Berlin; The Francis Crick Institute; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Lobachevsky University; The Francis Crick Institute; The Francis Crick Institute; Charit√© - Universit√§tsmedizin Berlin; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; The Francis Crick Institute; The University of Edinburgh; The University of Edinburgh; The University of Edinburgh; University of Edinburgh; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; University College London; University College London; Charit√© - Universit√§tsmedizin Berlin; Bernhard Nocht Institute for Tropical Medicine; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; The University of Cambridge; Charit√© - Universit√§tsmedizin Berlin; Charit√© - Universit√§tsmedizin Berlin; ; Charite University Medicine; Charit√© - Universit√§tsmedizin Berlin,"COVID-19 is highly variable in its clinical presentation, ranging from asymptomatic infection to severe organ damage and death. There is an urgent need for predictive markers that can guide clinical decision-making, inform about the effect of experimental therapies, and point to novel therapeutic targets. Here, we characterize the time-dependent progression of COVID-19 through different stages of the disease, by measuring 86 accredited diagnostic parameters and plasma proteomes at 687 sampling points, in a cohort of 139 patients during hospitalization. We report that the time-resolved patient molecular phenotypes reflect an initial spike in the systemic inflammatory response, which is gradually alleviated and followed by a protein signature indicative of tissue repair, metabolic reconstitution and immunomodulation. Further, we show that the early host response is predictive for the disease trajectory and gives rise to proteomic and diagnostic marker signatures that classify the need for supplemental oxygen therapy and mechanical ventilation, and that predict the time to recovery of mildly ill patients. In severely ill patients, the molecular phenotype of the early host response predicts survival, in two independent cohorts and weeks before outcome. We also identify age-specific molecular response to COVID-19, which involves increased inflammation and lipoprotein dysregulation in older patients. Our study provides a deep and time resolved molecular characterization of COVID-19 disease progression, and reports biomarkers for risk-adapted treatment strategies and molecular disease monitoring. Our study demonstrates accurate prognosis of COVID-19 outcome from proteomic signatures recorded weeks earlier.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.11.05.20226662,2020-11-07,https://medrxiv.org/cgi/content/short/2020.11.05.20226662,Risk mitigating behaviours in people with inflammatory joint and skin disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey,Satveer K Mahil; Mark Yates; Sinead M Langan; Zenas ZN Yiu; Teresa Tsakok; Nick Dand; Kayleigh J Mason; Helen McAteer; Freya Meynall; Bolaji Coker; Alexandra Vincent; Dominic Urmston; Amber Vesty; Jade Kelly; Camille Lancelot; Lucy Moorhead; Herve Bachelez; Ian N Bruce; Francesca Capon; Claudia Romina Contreras; Andrew P Cope; Claudia De La Cruz; Paola Di Meglio; Paolo Gisondi; Kimme Hyrich; Denis Jullien; Jo Lambert; Hoseah Waweru; Helena Marzo-Ortega; Iain McInnes; Luigi Naldi; Sam Norton; Lluis Puig; Phyllis Spuls; Raj Sengupta; Tiago Torres; RIchard B Warren; John Weinman; Christopher EM Griffiths; Jonathan N Barker; Matthew A Brown; James B Galloway; Catherine H Smith,"St Johns Institute of Dermatology; Centre for Rheumatic Diseases, King's College London; St Johns Institute of Dermatology; Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Rese; St Johns Institute of Dermatology; Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, Kings College London, London, UK. ; Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Rese; The Psoriasis Association, Northampton, UK; St Johns Institute of Dermatology; NIHR Biomedical Research Centre at Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK; NIHR Biomedical Research Centre at Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK; The Psoriasis Association, Northampton, UK; The Psoriasis Association, Northampton, UK; Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Rese; International Federation of Psoriasis Associations; St Johns Institute of Dermatology; Department of Dermatology, AP-HP Hopital Saint-Louis, Paris, France 12INSERM U1163, Imagine Institute for Human Genetic Diseases, Universite de Paris, Paris, Fr; Kellegren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Ce; Department of Medical and Molecular Genetics, School of Basic and Medical Biosciences, Faculty of Life Sciences and Medicine, Kings College London, London, UK; Catedra de Dermatologia, Hospital de Clinicas, Facultad de Ciencias Medicas, Universidad Nacional de Asuncion, Paraguay; Centre for Rheumatic Diseases, Kings College London; Clinica Dermacross, Santiago, Chile; NIHR Biomedical Research Centre at Guys and St Thomas NHS Foundation Trust and Kings College London, London, UK; Section of Dermatology and Venereology, University of Verona, Verona, Italy; Kellegren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Ce; Department of Dermatology, Edouard Herriot Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France Groupe de recherche sur le psoriasis (GrPso) de l; Department of Dermatology, Ghent University, Ghent, Belgium; International Federation of Psoriasis Associations Bromma, Sweden; University of Leeds Leeds Institute of Rheumatic and Musculoskeletal Medicine, Section of Musculoskeletal Disease Leeds, West Yorkshire, UK; University of Glasgow, Institute of Infection, Immunity and Inflammation; Centro Studi GISED Bergamo, Italy; Centre for Rheumatic Diseases, Kings College London; Hospital de la Santa Creu i Sant Pau, Dermatology Barcelona, Spain; Amsterdam University Medical Centres, Department of Dermatology, Amsterdam Public Health/Infection and Immunology; Royal National Hospital for Rheumatic Diseases, Bath; Centro Hospitalar do Porto, Portugal; The University of Manchester, Dermatology Centre, Salford Royal NHS Foundation Trust Manchester, Manchester, UK; Kings College London, Institute of Pharmaceutical Sciences London, London, UK; The University of Manchester, Dermatology Centre, Salford Royal NHS Foundation Trust Manchester, Manchester, UK; St Johns Institute of Dermatology; NIHR Biomedical Research Centre at Guys and Saint Thomas NHS Foundation Trust and Kings College London, UK; Centre for Rheumatic Diseases, Kings College London; St Johns Institute of Dermatology","ObjectivesRegistry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse COVID-19 outcomes compared to patients receiving no systemic treatments. We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation.

MethodsOnline surveys were completed by individuals with Rheumatic and Musculoskeletal Diseases (RMD) (UK only) or psoriasis (globally) between 4th May and 7th September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterised international variation in a mixed effects model.

ResultsOf 3,720 participants (2,869 psoriasis, 851 RMD) from 74 countries, 2,262 (60.8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term  shielding). A greater proportion of those receiving targeted therapies (biologics and JAK inhibitors) reported shielding compared to those receiving no systemic therapy (adjusted odds ratio [OR] 1.63, 95% CI 1.35-1.97) and standard systemic agents (OR 1.39, 95% CI 1.22-1.56). Shielding was associated with established risk factors for severe COVID-19 (male sex [OR 1.14, 95% CI 1.05-1.24], obesity [OR 1.38, 95% CI 1.23-1.54], comorbidity burden [OR 1.43, 95% CI 1.15-1.78]), a primary indication of RMD (OR 1.37, 95% CI 1.27-1.48) and a positive anxiety or depression screen (OR 1.57, 95% CI 1.36-1.80). Modest differences in the proportion shielding were observed across nations.

ConclusionsGreater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk mitigation strategies and may help inform updated public health guidelines as the pandemic continues.

Key messagesO_ST_ABSWhat is already known about this subject?C_ST_ABSO_LIAt the beginning of the COVID-19 pandemic, patients with immune mediated inflammatory diseases (IMIDs) on targeted systemic immunosuppressive therapy were considered to be at higher risk of severe COVID-19. Subsequent registry data suggest that this may not the case.
C_LI

What does this study add?O_LIHere we characterise shielding behaviour in patients with IMIDs from a global survey. We identified that targeted systemic therapy associates with increased shielding behaviour, as do demographic risk factors for severe COVID-19 including male gender and obesity.
C_LIO_LIShielding behaviour varies across nations, albeit modestly when case-mix is taken into account.
C_LI

How might this impact on clinical practice or future developments?O_LIVariable shielding behaviour amongst patients with IMIDs may be an important confounder when considering differential COVID-19 risk between therapy types, so should be accounted for in analyses where possible.
C_LI",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.11.06.20227108,2020-11-07,https://medrxiv.org/cgi/content/short/2020.11.06.20227108,Primary school staff reflections on school closures due to COVID-19 and recommendations for the future: a national qualitative survey,Emily Marchant; Charlotte Todd; Michaela James; Tom Crick; Russell Dwyer; Sinead Brophy,Swansea University; Swansea University; Swansea University; Swansea University; St Thomas Community Primary School; Swansea University,"School closures due to the COVID-19 global pandemic are likely to have a range of negative consequences spanning the domains of child development, education and health, in addition to the widening of inequalities and inequities. Research is required to improve understanding of the impact of school closures on the education, health and wellbeing of pupils and school staff, the challenges posed during reopening and importantly to identify how countries can return to in-school education and to inform policy. This qualitative study aimed to reflect on the perspectives and experiences of primary school staff (pupils aged 3-11) in Wales regarding school closures and the initial reopening of schools and to identify recommendations for the future. A total of 208 school staff completed a national online survey through the HAPPEN primary school network, consisting of questions about school closures (March to June 2020), the phased reopening of schools (June to July 2020) and a return to full-time education. Thematic analysis of survey responses highlighted that primary school staff perceive that gaps in learning, health and wellbeing have increased and inequalities have widened during school closures. Findings from this study identified five recommendations; (i) prioritise the health and wellbeing of pupils and staff; (ii) focus on enabling parental engagement and support; (iii) improve digital competence amongst pupils, teachers and parents; (iv) consider opportunities for smaller class sizes and additional staffing; and (v) improve the mechanism of communication between schools and families, and between government and schools.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.11.05.20223289,2020-11-06,https://medrxiv.org/cgi/content/short/2020.11.05.20223289,Longitudinal proteomic profiling of high-risk patients with COVID-19 reveals markers of severity and predictors of fatal disease,Jack Gisby; Candice L Clarke; Nicholas Medjeral-Thomas; Talat H Malik; Artemis Papadaki; Paige M Mortimer; Norzawani B Buang; Shanice Lewis; Marie Pereira; Frederic Toulza; Ester Fagnano; Marie-Anne Mawhin; Emma E Dutton; Lunnathaya Tapeng; Arianne C Richard; Paul Kirk; Jacques Behmoaras; Eleanor Sandhu; Stephen P McAdoo; Maria F Prendecki; Matthew C Pickering; Marina Botto; Michelle Willicombe; David C Thomas; James E. Peters,Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of Cambridge; MRC Biostatistics Unit University of Cambridge; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London,"End-stage kidney disease (ESKD) patients are at high risk of severe COVID-19. We measured 436 circulating proteins in serial blood samples from hospitalised and non-hospitalised ESKD patients with COVID-19 (n=256 samples from 55 patients). Comparison to 51 non-infected patients revealed 221 differentially expressed proteins, with consistent results in a separate subcohort of 46 COVID-19 patients. 203 proteins were associated with clinical severity, including IL6, markers of monocyte recruitment (e.g. CCL2, CCL7), neutrophil activation (e.g. proteinase-3) and epithelial injury (e.g. KRT19). Machine learning identified predictors of severity including IL18BP, CTSD, GDF15, and KRT19. Survival analysis with joint models revealed 69 predictors of death. Longitudinal modelling with linear mixed models uncovered 32 proteins displaying different temporal profiles in severe versus non-severe disease, including integrins and adhesion molecules. These data implicate epithelial damage, innate immune activation, and leucocyte-endothelial interactions in the pathology of severe COVID-19 and provide a resource for identifying drug targets.",infectious diseases,fuzzy,100,100
bioRxiv,10.1101/2020.11.06.369439,2020-11-06,https://biorxiv.org/cgi/content/short/2020.11.06.369439,Allosteric hotspots in the main protease of SARS-CoV-2,L√©onie Str√∂mich; Nan Wu; Mauricio Barahona; Sophia N Yaliraki,Imperial College London; Imperial College London; Imperial College London; Imperial College London,"AO_SCPLOWBSTRACTC_SCPLOWInhibiting the main protease of SARS-CoV-2 is of great interest in tackling the COVID-19 pandemic caused by the virus. Most efforts have been centred on inhibiting the binding site of the enzyme. However, considering allosteric sites, distant from the active or orthosteric site, broadens the search space for drug candidates and confers the advantages of allosteric drug targeting. Here, we report the allosteric communication pathways in the main protease dimer by using two novel fully atomistic graph theoretical methods: Bond-to-bond propensity analysis, which has been previously successful in identifying allosteric sites without a priori knowledge in benchmark data sets, and, Markov transient analysis, which has previously aided in finding novel drug targets in catalytic protein families. We further score the highest ranking sites against random sites in similar distances through statistical bootstrapping and identify four statistically significant putative allosteric sites as good candidates for alternative drug targeting.",bioinformatics,fuzzy,100,100
medRxiv,10.1101/2020.11.01.20224014,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.01.20224014,MODELLING PRESYMPTOMATIC INFECTIOUSNESS IN COVID-19,Russell Cheng; Christopher Dye; John Dagpunar; Brian Williams,University of Southampton; Oxford University; University of Southampton; Stellenbosch University,"This paper considers SEPIR, the extension of an existing parametric SEIR continuous simulation compartment model. Both models can be fitted to real data as they include parameters that can simply be estimated from the data. However SEPIR deploys an additional presymptomatic (also called asymptomatic) infectious stage that is not included in SEIR but which is known to exist in COVID-19. This stage is also parametrised and so can be fitted to data. Both SEPIR and the existing SEIR model assume a homogeneous mixing population, an idealisation that is unrealistic in practice when dynamically varying control strategies are deployed against virus. This means that if either model is to represent more than just a single period in the behaviour of the epidemic, then the parameters of the model will have to be time dependent. This issue is also discussed in this paper.",epidemiology,fuzzy,93,100
medRxiv,10.1101/2020.11.02.20223891,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.02.20223891,Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco,Genay Pilarowski; Paul Lebel; Sara Sunshine; Jamin Liu; Emily Crawford; Carina Marquez; Luis Rubio; Gabriel Chamie; Jackie Martinez; James Peng; Douglas Black; Wesley Wu; John Pak; Matthew T Laurie; Diane Jones; Steve Miller; Jon Jacobo; Susana Rojas; Susy Rojas; Robert Nakamura; Valerie Tulier-Laiwa; Maya Petersen; Diane V Havlir; - The CLIAHUB Consortium; Joseph DeRisi,"Department of Pathology, Stanford University, Stanford, CA 94305, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California San Francisco, CA 94143, USA; Department of Biochemistry and Biophysics, University of California San Francisco, CA 94143, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA and Department of Microbiology and Immunology, University of California San Francisco, CA 94143; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA; Department of Biochemistry and Biophysics, University of California San Francisco, CA 94143, USA; Unidos en Salud, San Francisco, CA 94143, USA; Department of Laboratory Medicine, University of California San Francisco CA 94131, USA; Latino Task Force-COVID-19, San Francisco, CA 94110, USA; Latino Task Force-COVID-19, San Francisco, CA 94110, USA; Latino Task Force-COVID-19, San Francisco, CA 94110, USA; California Department of Public Health, Microbial Diseases Laboratory, Richmond, CA, 94804, USA; Latino Task Force-COVID-19, San Francisco, CA 94110, USA; Division of Epidemiology and Biostatistics, University of California, Berkeley, Berkeley, CA 94720, USA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA 94143, USA; ; Chan Zuckerberg Biohub, San Francisco, CA 94158, USA and Department of Biochemistry and Biophysics, University of California San Francisco, CA 94143, USA","We evaluated the performance of the Abbott BinaxNOW Covid-19 rapid antigen test to detect virus among persons, regardless of symptoms, at a public plaza site of ongoing community transmission. Titration with cultured clinical SARS-CoV-2 yielded a human observable threshold between 1.6x104-4.3x104 viral RNA copies (cycle threshold (Ct) of 30.3-28.8 in this assay). Among 878 subjects tested, 3% (26/878) were positive by RT-PCR, of which 15/26 had a Ct<30, indicating high viral load. 40% (6/15) of Ct<30 were asymptomatic. Using this Ct<30 threshold for Binax-CoV2 evaluation, the sensitivity of the Binax-CoV2 was 93.3% (14/15), 95% CI: 68.1-99.8%, and the specificity was 99.9% (855/856), 95% CI: 99.4-99.9%.",infectious diseases,fuzzy,92,100
medRxiv,10.1101/2020.11.03.20220699,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.03.20220699,A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital,Daniel J Cooper; Sara Lear; Laura Watson; Ashley Shaw; Mark Ferris; Rainer Doffinger; Rachel Bousfield; Katherine Sharrocks; Michael Weekes; Ben Warne; Dominic Sparkes; Nick K Jones; Lucy Rivett; Matthew Routledge; Afzal Chaudhry; Katherine Dempsey; Montgomery Matson; Adil Lakha; George Gathercole; Olivia O'Connor; Emily Wilson; Orthi Shahzad; Kieran Toms; Rachel Thompson; Ian Halsall; David Halsall; Sally Houghton; Sofia Papadia; Nathalie Kingston; Kathleen Stirrups; Barbara Graves; Neil Walker; Hannah Stark; - The CITIID-NIHR BioResource COVID-19 Collaboration; Daniela De Angelis; Shaun Seaman; John Bradley; M Est√©e T√∂r√∂k; Ian G. Goodfellow; Stephen Baker,"Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; NIHR Cambridge Clinical Research Facility; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; NIHR Cambridge Clinical Research Facility.; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; University of Cambridge School of Clinical Medicine; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, NIHR Cambridge Biomedical Research Centre; NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust; ; MRC Biostatistics Unit, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of pathology, Division of virology, University of Cambridge; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK","BackgroundThe COVID-19 pandemic continues to grow at an unprecedented rate. Healthcare workers (HCWs) are at higher risk of SARS-CoV-2 infection than the general population but risk factors for HCW infection are not well described.

MethodsWe conducted a prospective sero-epidemiological study of HCWs at a UK teaching hospital using a SARS-CoV-2 immunoassay. Risk factors for seropositivity were analysed using multivariate logistic regression.

Findings410/5,698 (7{middle dot}2%) staff tested positive for SARS-CoV-2 antibodies. Seroprevalence was higher in those working in designated COVID-19 areas compared with other areas (9{middle dot}47% versus 6{middle dot}16%) Healthcare assistants (aOR 2{middle dot}06 [95%CI 1{middle dot}14-3{middle dot}71]; p=0{middle dot}016) and domestic and portering staff (aOR 3{middle dot}45 [95% CI 1{middle dot}07-11{middle dot}42]; p=0{middle dot}039) had significantly higher seroprevalence than other staff groups after adjusting for age, sex, ethnicity and COVID-19 working location. Staff working in acute medicine and medical sub-specialities were also at higher risk (aOR 2{middle dot}07 [95% CI 1{middle dot}31-3{middle dot}25]; p<0{middle dot}002). Staff from Black, Asian and minority ethnic (BAME) backgrounds had an aOR of 1{middle dot}65 (95% CI 1{middle dot}32 - 2{middle dot}07; p<0{middle dot}001) compared to white staff; this increased risk was independent of COVID-19 area working. The only symptoms significantly associated with seropositivity in a multivariable model were loss of sense of taste or smell, fever and myalgia; 31% of staff testing positive reported no prior symptoms.

InterpretationRisk of SARS-CoV-2 infection amongst HCWs is heterogeneous and influenced by COVID-19 working location, role, age and ethnicity. Increased risk amongst BAME staff cannot be accounted for solely by occupational factors.

FundingWellcome Trust, Addenbrookes Charitable Trust, National Institute for Health Research, Academy of Medical Sciences, the Health Foundation and the NIHR Cambridge Biomedical Research Centre.

Research in context

Evidence before this studySpecific risk factors for SARS-CoV-2 infection in healthcare workers (HCWs) are not well defined. Additionally, it is not clear how population level risk factors influence occupational risk in defined demographic groups. Only by identifying these factors can we mitigate and reduce the risk of occupational SARS-CoV-2 infection. We performed a review of the evidence for HCW-specific risk factors for SARS-CoV-2 infection. We searched PubMed with the terms ""SARS-CoV-2"" OR ""COVID-19"" AND ""Healthcare worker"" OR ""Healthcare Personnel"" AND ""Risk factor"" to identify any studies published in any language between December 2019 and September 2020. The search identified 266 studies and included a meta-analysis and two observational studies assessing HCW cohort seroprevalence data. Seroprevalence and risk factors for HCW infections varied between studies, with contradictory findings. In the two serological studies, one identified a significant increased risk of seroprevalence in those working with COVID-19 patients (Eyre et al 2020), as well as associations with job role and department. The other study (Dimcheff et al 2020) found no significant association between seropositivity and any identified demographic or occupational factor. A meta-analysis of HCW (Gomez-Ochoa et al 2020) assessed >230,000 participants as a pooled analysis, including diagnoses by both RT-PCR and seropositivity for SARS-CoV-2 antibodies and found great heterogeneity in study design and reported contradictory findings. Of note, they report a seropositivity rate of 7% across all studies reporting SARS-CoV-2 antibodies in HCWs. Nurses were the most frequently affected healthcare personnel and staff working in non-emergency inpatient settings were the most frequently affected group. Our search found no prospective studies systematically evaluating HCW specific risk factors based entirely on seroprevalence data.

Added value of this studyOur prospective cohort study of almost 6,000 HCWs at a large UK teaching hospital strengthens previous findings from UK-based cohorts in identifying an increased risk of SARS-CoV-2 exposure amongst HCWs. Specifically, factors associated with SARS-CoV-2 exposure include caring for confirmed COVID-19 cases and identifying as being within specific ethnic groups (BAME staff). We further delineated the risk amongst BAME staff and demonstrate that occupational factors alone do not account for all of the increased risk amongst this group. We demonstrate for the first time that healthcare assistants represent a key at-risk occupational group, and challenge previous findings of significantly higher risk amongst nursing staff. Seroprevalence in staff not working in areas with confirmed COVID-19 patients was only marginally higher than that of the general population within the same geographical region. This observation could suggest the increased risk amongst HCWs arises through occupational exposure to confirmed cases and could account for the overall higher seroprevalence in HCWs, rather than purely the presence of staff in healthcare facilities. Over 30% of seropositive staff had not reported symptoms consistent with COVID-19, and in those who did report symptoms, differentiating COVID-19 from other causes based on symptom data alone was unreliable.

Implications of all the available evidenceInternational efforts to reduce the risk of SARS-CoV-2 infection amongst HCWs need to be prioritised. The risk of SARS-CoV-2 infection amongst HCWs is heterogenous but also follows demonstrable patterns. Potential mechanisms to reduce the risk for staff working in areas with confirmed COVID-19 patients include improved training in hand hygiene and personal protective equipment (PPE), better access to high quality PPE, and frequent asymptomatic testing. Wider asymptomatic testing in healthcare facilities has the potential to reduce spread of SARS-CoV-2 within hospitals, thereby reducing patient and staff risk and limiting spread between hospitals and into the wider community. The increased risk of COVID-19 amongst BAME staff cannot be explained by purely occupational factors; however, the increased risk amongst minority ethnic groups identified here was stark and necessitates further evaluation.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.11.02.20224824,2020-11-04,https://medrxiv.org/cgi/content/short/2020.11.02.20224824,"The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers",Sheila F Lumley; Jia Wei; Nicole Stoesser; Philippa Matthews; Alison Howarth; Stephanie Hatch; Brian Marsden; Stuart Cox; Tim James; Liam Peck; Thomas Ritter; Zoe de Toledo; Richard Cornall; E Yvonne Jones; David I Stuart; Gavin Screaton; Daniel Ebner; Sarah Hoosdally; Derrick Crook; - Oxford University Hospitals Staff Testing Group; Christopher P Conlon; Koen Pouwels; Ann Sarah Walker; Tim EA Peto; Timothy M Walker; Katie Jeffery; David W Eyre,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; Oxford University Hospitals; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals; University of Oxford,"BackgroundSARS-CoV-2 IgG antibody measurements can be used to estimate the proportion of a population exposed or infected and may be informative about the risk of future infection. Previous estimates of the duration of antibody responses vary.

MethodsWe present 6 months of data from a longitudinal seroprevalence study of 3217 UK healthcare workers (HCWs). Serial measurements of IgG antibodies to SARS-CoV-2 nucleocapsid were obtained. Bayesian mixed linear models were used to investigate antibody waning and associations with age, gender, ethnicity, previous symptoms and PCR results.

ResultsIn this cohort of working age HCWs, antibody levels rose to a peak at 24 (95% credibility interval, CrI 19-31) days post-first positive PCR test, before beginning to fall. Considering 452 IgG seropositive HCWs over a median of 121 days (maximum 171 days) from their maximum positive IgG titre, the mean estimated antibody half-life was 85 (95%CrI, 81-90) days. The estimated mean time to loss of a positive antibody result was 137 (95%CrI 127-148) days. We observed variation between individuals; higher maximum observed IgG titres were associated with longer estimated antibody half-lives. Increasing age, Asian ethnicity and prior self-reported symptoms were independently associated with higher maximum antibody levels, and increasing age and a positive PCR test undertaken for symptoms with longer antibody half-lives.

ConclusionIgG antibody levels to SARS-CoV-2 nucleocapsid wane within months, and faster in younger adults and those without symptoms. Ongoing longitudinal studies are required to track the long-term duration of antibody levels and their association with immunity to SARS-CoV-2 reinfection.

SummarySerially measured SARS-CoV-2 anti-nucleocapsid IgG titres from 452 seropositive healthcare workers demonstrate levels fall by half in 85 days. From a peak result, detectable antibodies last a mean 137 days. Levels fall faster in younger adults and following asymptomatic infection.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.28.20221804,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.28.20221804,"Genetic association analysis of SARS-CoV-2 infection in 455,838 UK Biobank participants",Jack A Kosmicki; Julie E Horowitz; Nilanjana Banerjee; Rouel Lanche; Anthony Marcketta; Evan Maxwell; Xiaodong Bai; Dylan Sun; Joshua D Backman; Deepika Sharma; Hyun M Kang; Colm O'Dushlaine; Ashish Yadav; Adam J Mansfield; Alexander H Li; Kyoko Watanabe; Lauren Gurski; Shane E McCarthy; Adam E Locke; Shareef Khalid; Sean O'Keeffe; Joelle Mbatchou; Olympe Chazara; Yunfeng Huang; Erika Kvikstad; Amanda O'Neill; Paul Nioi; Margaret M Parker; Slave Petrovski; Heiko Runz; Joseph Szustakowski; Quanli Wang; Emily Wong; Aldo Cordova-Palomera; Erin Smith; Sandor Szalma; Xiuwen Zheng; Sahar Esmaeli; Justin W Davis; Yi-Pin Lai; Xing Chen; Anne E Justice; Joseph B Leader; Tooraj Mirshahi; David J Carey; Anurag Verma; Marylyn D Ritchie; Giorgio Sirugo; Daniel J. Rader; Gundula Povysil; David B Goldstein; Krzysztof Kiryluk; Erola Pairo-Castineira; Konrad Rawlik; Dorota Pasko; Susan Walker; Alison Meynert; Athanasios Kousathanas; Loukas Moutsianas; Albert Tenesa; Mark Caulfield; Richard Scott; James F Wilson; J Kenneth Baillie; Guillaume Butler-Laporte; Tomoko Nakanishi; Mark Lathrop; J Brent Richards; Marcus Jones; Suganthi Balasubramanian; William Salerno; Alan Shuldiner; Jonathan Marchini; John Overton; Lukas Habegger; Michael Cantor; Jeffrey Reid; Aris Baras; Goncalo R Abecasis; Manuel A Ferreira,"Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; AstraZeneca; Biogen; Bristol Myers Squibb; AstraZeneca; Alnylam Pharmaceuticals; Alnylam Pharmaceuticals; AstraZeneca; Biogen; Bristol Myers Squibb; AstraZeneca; Takeda; Takeda; Takeda; Takeda; Abbvie; Abbvie; Abbvie; Pfizer; Pfizer; Geisinger Health; Geisinger Health System; Geisinger Health System; Geisinger Health System; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Columbia University; Columbia University; Columbia University; University of Edinburgh; University of Edinburgh; Genomics England; Genomics England; University of Edinburgh; Genomics England; Genomics England; University of Edinburgh; Genomics England; Genomics England; University of Edinburgh; Roslin Institute, University of Edinburgh; McGill University; McGill University; McGill University; McGill University; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Regeneron Pharmaceuticals","Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease-19 (COVID-19), a respiratory illness that can result in hospitalization or death. We investigated associations between rare genetic variants and seven COVID-19 outcomes in 543,213 individuals, including 8,248 with COVID-19. After accounting for multiple testing, we did not identify any clear associations with rare variants either exome-wide or when specifically focusing on (i) 14 interferon pathway genes in which rare deleterious variants have been reported in severe COVID-19 patients; (ii) 167 genes located in COVID-19 GWAS risk loci; or (iii) 32 additional genes of immunologic relevance and/or therapeutic potential. Our analyses indicate there are no significant associations with rare protein-coding variants with detectable effect sizes at our current sample sizes. Analyses will be updated as additional data become available, with results publicly browsable at https://rgc-covid19.regeneron.com.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.29.20222414,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.29.20222414,How well does societal mobility restriction help control the COVID-19 pandemic? Evidence from real-time evaluation,Juhwan Oh; Hwa-Young Lee; Khuong Quynh Long; Jeffery F Marcuns; Chris Bullen; Osvaldo Enrique Artaza Barrios; Seung-sik Hwang; Young Sahng Suh; Judith McCool; S. Patrick Kaucher; Chang-Chung Chan; Soonman Kwon; Naoki Kondo; Hoang Van Minh; J. Robin Moon; Mikael Rostila; Ole F. Norheim; Myoungsoon You; Mellissa Withers; Mu Li; Eun-Jeung Lee; Caroline Benski; Soo Kyung Park; Eun-Woo Nam; Katie Gottschalk; Matthew M. Kavanagh; Tran Thi Giang Huong; Jong-Koo Lee; S.V. Subramanian; Lawrence O. Gostin; Martin McKee,"1. Harvard University T.H.Chan School of Public Health 2. Seoul National University College of Medicine; 1. Harvard University T H Chan School of Public Health  2. Institute of Convergence Science, Convergence Science Academy, Yonsei University,; Hanoi University of Public Health; Boston University School of Medicine; The University of Auckland School of Population Health; The University of the Americas; Seoul National University Graduate School of Public Health; Harvard University T.H.Chan School of Public Health; The University of Auckland School of Population Health; Mailman School of Public Health, Columbia University; National Taiwan University College of Public Health; Seoul National University Graduate School of Public Health; Kyoto University School of Public Health; Hanoi University of Public Health; City University of New York Graduate School of Public Health & Health Policy; Stockholm University; 1.University of Bergen 2. Harvard University T.H.Chan School of Public Health; Seoul National University Graduate School of Public Health; University of Southern California; The University of Sydney; Berlin Free University; University Hospital of Geneva; National Health Insurance Research Institute; Yonsei University, Wonju-campus; Georgetown University; Georgetown University; Hanoi Medical University; Seoul National University College of Medicine; Harvard University T.H.Chan School of Public Health; Georgetown University; London School of Hygiene and Tropical Medicine","ObjectivesTo determine the impact of restrictions on mobility on reducing transmission of COVID-19.

DesignDaily incidence rates lagged by 14 days were regressed on mobility changes using LOESS regression and logit regression between the day of the 100th case in each country to August 31, 2020.

Setting34 OECD countries plus Singapore and Taiwan.

ParticipantsGoogle mobility data were obtained from people who turned on mobile device-based global positioning system (GPS) and agreed to share their anonymized position information with Google.

InterventionsWe examined the association of COVID-19 incidence rates with mobility changes, defined as changes in categories of domestic location, against a pre-pandemic baseline, using country-specific daily incidence data on newly confirmed COVID-19 cases and mobility data.

ResultsIn two thirds of examined countries, reductions of up to 40% in commuting mobility (to workplaces, transit stations, retailers, and recreation) were associated with decreased COVID-19 incidence, more so early in the pandemic. However, these decreases plateaued as mobility remained low or decreased further. We found smaller or negligible associations between mobility restriction and incidence rates in the late phase in most countries.

ConclusionMild to moderate degrees of mobility restriction in most countries were associated with reduced incidence rates of COVID-19 that appear to attenuate over time, while some countries exhibited no effect of such restrictions. More detailed research is needed to precisely understand the benefits and limitations of mobility restrictions as part of the public health response to the COVID-19 pandemic.

WHAT IS ALREADY KNOWN ON THIS TOPICSince SARS-CoV-2 became a pandemic, restrictions on mobility such as limitations on travel and closure of offices, restaurants, and shops have been imposed in an unprecedented way in both scale and scope to prevent the spread of COVID-19 in the absence of effective treatment options or a vaccine. Although mobility restriction has also brought about tremendous costs such as negative economic growth and other collateral impacts on health such as increased morbidity and mortality from lack of access to other essential health services, little evidence exists on the effectiveness of mobility restriction for the prevention of disease transmission. A search of PUBMED and Google Scholar for publications on this topic through Sep 20, 2020 revealed that most of the evidence on the effectiveness of physical distancing comes from mathematical modeling studies using a variety of assumptions. One study investigated only the combined effect of several interventions, including physical distancing, among SARS-CoV-2 infected patients.

WHAT THIS STUDY ADDSThis is the first study to investigate the association between change in mobility and incidence of COVID-19 globally using real-time measures of mobility at the population level. For this, we used Google Global Mobility data and the daily incidence of COVID-19 for 36 countries from the day of 100th case detection through August 31, 2020. Our findings from LOESS regression show that in two-thirds of countries, reductions of up to 40% in commuting mobility were associated with decreased COVID-19 incidence, more so early in the pandemic. This decrease, however, plateaued as mobility decreased further. We found that associations between mobility restriction and incidence became smaller or negligible in the late phase of the pandemic in most countries. The reduced incidence rate of COVID-19 cases with a mild to moderate degree of mobility restriction in most countries suggests some value to limited mobility restriction in early phases of epidemic mitigation. The lack of impact in some others, however, suggests further research is needed to confirm these findings and determine the distinguishing factors for when mobility restrictions are helpful in decreasing viral transmission. Governments should carefully consider the level and period of mobility restriction necessary to achieve the desired benefits and minimize harm.",health policy,fuzzy,100,100
medRxiv,10.1101/2020.10.30.20223123,2020-11-03,https://medrxiv.org/cgi/content/short/2020.10.30.20223123,High prevalence of SARS-CoV-2 swab positivity and increasing R number in England during October 2020: REACT-1 round 6 interim report,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E Walters; Haowei Wang; Christina J Atchison; Claudio Fronterre; Peter J Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health","BackgroundREACT-1 measures prevalence of SARS-CoV-2 infection in representative samples of the population in England using PCR testing from self-administered nose and throat swabs. Here we report interim results for round 6 of observations for swabs collected from the 16th to 25th October 2020 inclusive.

MethodsREACT-1 round 6 aims to collect data and swab results from 160,000 people aged 5 and above. Here we report results from the first 86,000 individuals. We estimate prevalence of PCR-confirmed SARS-CoV-2 infection, reproduction numbers (R) and temporal trends using exponential growth or decay models. Prevalence estimates are presented both unweighted and weighted to be representative of the population of England, accounting for response rate, region, deprivation and ethnicity. We compare these interim results with data from round 5, based on swabs collected from 18th September to 5th October 2020 inclusive.

ResultsOverall prevalence of infection in the community in England was 1.28% or 128 people per 10,000, up from 60 per 10,000 in the previous round. Infections were doubling every 9.0 (6.1, 18) days with a national reproduction number (R) estimated at 1.56 (1.27, 1.88) compared to 1.16 (1.05, 1.27) in the previous round. Prevalence of infection was highest in Yorkshire and The Humber at 2.72% (2.12%, 3.50%), up from 0.84% (0.60%, 1.17%), and the North West at 2.27% (1.90%, 2.72%), up from 1.21% (1.01%, 1.46%), and lowest in South East at 0.55% (0.45%, 0.68%), up from 0.29% (0.23%, 0.37%). Clustering of cases was more prevalent in Lancashire, Manchester, Liverpool and West Yorkshire, West Midlands and East Midlands. Interim estimates of R were above 2 in the South East, East of England, London and South West, but with wide confidence intervals. Nationally, prevalence increased across all age groups with the greatest increase in those aged 55-64 at 1.20% (0.99%, 1.46%), up 3-fold from 0.37% (0.30%, 0.46%). In those aged over 65, prevalence was 0.81% (0.58%, 0.96%) up 2-fold from 0.35% (0.28%, 0.43%). Prevalence remained highest in 18 to 24-year olds at 2.25% (1.47%, 3.42%).

ConclusionThe co-occurrence of high prevalence and rapid growth means that the second wave of the epidemic in England has now reached a critical stage. Whether via regional or national measures, it is now time-critical to control the virus and turn R below one if further hospital admissions and deaths from COVID-19 are to be avoided.",infectious diseases,fuzzy,100,100
bioRxiv,10.1101/2020.11.01.362319,2020-11-02,https://biorxiv.org/cgi/content/short/2020.11.01.362319,Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 months following primary infection,Jianmin Zuo; Alex Dowell; Hayden Pearce; Kriti Verma; Heather Long; Jusnara Begum; Felicity Aiano; Zahin Amin-Chowdhury; Bassam Hallis; Lorrain Stapley; Ray Borrow; Ezra Linley; Shazaad Ahmad; Ben Parker; Alex Horsley; Gayatri Amirthalingam; Kevin Brown; Mary E Ramsay; Shamez Ladhani; Paul Moss,"Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Institute of Immunology and Immunotherapy, University of Birmingham; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunoassay Lab, National Infection Service, Porton Down SP4 0JG; Immunoassay Lab, National Infection Service, Porton Down SP4 0JG; Sero-epidemiology Unit, PHE,  Manchester Royal Infirmary, Manchester, M13 9WL; Sero-epidemiology Unit, PHE,  Manchester Royal Infirmary, Manchester, M13 9WL; Manchester University NHS Foundation Trust; NIHR Manchester Clinical Research Facility, Manchester Royal Infirmary, Oxford Rd, Manchester, M13 9WL; University of Manchester and NIHR Manchester Clinical Research Facility, Manchester University NHS Foundation Trust, Manchester M23 9LT; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Immunisation and Countermeasures Division, National Infection Service, PHE Colindale. 61 Colindale Avenue, London NW9 5EQ.; Institute of Immunology and Immunotherapy, University of Birmingham","The immune response to SARS-CoV-2 is critical in both controlling primary infection and preventing re-infection. However, there is concern that immune responses following natural infection may not be sustained and that this may predispose to recurrent infection. We analysed the magnitude and phenotype of the SARS-CoV-2 cellular immune response in 100 donors at six months following primary infection and related this to the profile of antibody level against spike, nucleoprotein and RBD over the previous six months. T-cell immune responses to SARS-CoV-2 were present by ELISPOT and/or ICS analysis in all donors and are characterised by predominant CD4+ T cell responses with strong IL-2 cytokine expression. Median T-cell responses were 50% higher in donors who had experienced an initial symptomatic infection indicating that the severity of primary infection establishes a  setpoint for cellular immunity that lasts for at least 6 months. The T-cell responses to both spike and nucleoprotein/membrane proteins were strongly correlated with the peak antibody level against each protein. The rate of decline in antibody level varied between individuals and higher levels of nucleoprotein-specific T cells were associated with preservation of NP-specific antibody level although no such correlation was observed in relation to spike-specific responses. In conclusion, our data are reassuring that functional SARS-CoV-2-specific T-cell responses are retained at six months following infection although the magnitude of this response is related to the clinical features of primary infection.",immunology,fuzzy,100,100
medRxiv,10.1101/2020.10.29.20222174,2020-10-30,https://medrxiv.org/cgi/content/short/2020.10.29.20222174,COVID-19 collateral: Indirect acute effects of the pandemic on physical and mental health in the UK,Kathryn E Mansfield; Rohini Mathur; John Tazare; Alasdair D Henderson; Amy Mulick; Helena Carreira; Anthony A Matthews; Patrick Bidulka; Alicia Gayle; Harriet Forbes; Sarah Cook; Angel Wong; Helen Strongman; Kevin Wing; Charlotte Warren-Gash; Sharon L Cadogan; Liam Smeeth; Joseph Hayes; Jennifer Quint; Martin McKee; Sin√©ad Langan,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; Karolinska Institutet; London School of Hygiene and Tropical Medicine; Imperial College; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; Imperial College; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine,"BackgroundConcerns have been raised that the response to the UK COVID-19 pandemic may have worsened physical and mental health, and reduced use of health services. However, the scale of the problem is unquantified, impeding development of effective mitigations. We asked what has happened to general practice contacts for acute physical and mental health outcomes during the pandemic?

MethodsUsing electronic health records from the Clinical Research Practice Datalink (CPRD) Aurum (2017-2020), we calculated weekly primary care contacts for selected acute physical and mental health conditions (including: anxiety, depression, acute alcohol-related events, asthma and chronic obstructive pulmonary disease [COPD] exacerbations, cardiovascular and diabetic emergencies). We used interrupted time series (ITS) analysis to formally quantify changes in conditions after the introduction of population-wide restrictions ( lockdown) compared to the period prior to their introduction in March 2020.

FindingsThe overall population included 9,863,903 individuals on 1st January 2017. Primary care contacts for all conditions dropped dramatically after introduction of population-wide restrictions. By July 2020, except for unstable angina and acute alcohol-related events, contacts for all conditions had not recovered to pre-lockdown levels. The largest reductions were for contacts for: diabetic emergencies (OR: 0.35, 95% CI: 0.25-0.50), depression (OR: 0.53, 95% CI: 0.52-0.53), and self-harm (OR: 0.56, 95% CI: 0.54-0.58).

InterpretationThere were substantial reductions in primary care contacts for acute physical and mental conditions with restrictions, with limited recovery by July 2020. It is likely that much of the deficit in care represents unmet need, with implications for subsequent morbidity and premature mortality. The conditions we studied are sufficiently severe that any unmet need will have substantial ramifications for the people experiencing the conditions and healthcare provision. Maintaining access must be a key priority in future public health planning (including further restrictions).

FundingWellcome Trust Senior Fellowship (SML), Health Data Research UK.

RESULTS IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSA small study in 47 GP practices in a largely deprived, urban area of the UK (Salford) reported that primary care consultations for four broad diagnostic groups (circulatory disease, common mental health problems, type 2 diabetes mellitus and malignant cancer) declined by 16-50% between March and May 2020, compared to what was expected based on data from January 2010 to March 2020. We searched Medline for other relevant evidence of the indirect effect of the COVID-19 pandemic on physical and mental health from inception to September 25th 2020, for articles published in English, with titles including the search terms (""covid*"" or ""coronavirus"" or ""sars-cov-2""), and title or abstracts including the search terms (""indirect impact"" or ""missed diagnos*"" or ""missing diagnos*"" or ""delayed diagnos*"" or ((""present*"" or ""consult*"" or ""engag*"" or ""access*"") AND (""reduction"" or ""decrease"" or ""decline"")). We found no further studies investigating the change in primary care contacts for specific physical- and mental-health conditions indirectly resulting from the COVID-19 pandemic or its control measures. There has been a reduction in hospital admissions and presentations to accident and emergency departments in the UK, particularly for myocardial infarctions and cerebrovascular accidents. However, there is no published evidence specifically investigating the changes in primary care contacts for severe acute physical and mental health conditions.

Added value of this studyTo our knowledge this is the first study to explore changes in healthcare contacts for acute physical and mental health conditions in a large population representative of the UK. We used electronic primary care health records of nearly 10 million individuals across the UK to investigate the indirect impact of COVID-19 on primary care contacts for mental health, acute alcohol-related events, asthma/chronic obstructive pulmonary disease (COPD) exacerbations, and cardiovascular and diabetic emergencies up to July 2020. For all conditions studied, we found primary care contacts dropped dramatically following the introduction of population-wide restriction measures in March 2020. By July 2020, with the exception of unstable angina and acute alcohol-related events, primary care contacts for all conditions studied had not recovered to pre-lockdown levels. In the general population, estimates of the absolute reduction in the number of primary care contacts up to July 2020, compared to what we would expect from previous years varied from fewer than 10 contacts per million for some cardiovascular outcomes, to 12,800 per million for depression and 6,600 for anxiety. In people with COPD, we estimated there were 43,900 per million fewer contacts for COPD exacerbations up to July 2020 than what we would expect from previous years.

Implicatins of all the available evidenceWhile our results may represent some genuine reduction in disease frequency (e.g. the restriction measures may have improved diabetic glycaemic control due to more regular daily routines at home), it is more likely the reduced primary care conatcts we saw represent a substantial burden of unmet need (particularly for mental health conditions) that may be reflected in subsequent increased mortality and morbidity. Health service providers should take steps to prepare for increased demand in the coming months and years due to the short and longterm ramifications of reduced access to care for severe acute physical and mental health conditions. Maintaining access to primary care is key to future public health planning in relation to the pandemic.",primary care research,fuzzy,100,100
bioRxiv,10.1101/2020.10.29.339317,2020-10-30,https://biorxiv.org/cgi/content/short/2020.10.29.339317,"COVID Moonshot: Open Science Discovery of SARS-CoV-2 Main Protease Inhibitors by Combining Crowdsourcing, High-Throughput Experiments, Computational Simulations, and Machine Learning",- The COVID Moonshot Consortium; Hagit Achdout; Anthony Aimon; Dominic S Alonzi; Robert Arbon; Elad Bar-David; Haim Barr; Amir Ben-Shmuel; James Bennett; Vitaliy A. Bilenko; Vitaliy A. Bilenko; Melissa L. Boby; Bruce Borden; Pascale Boulet; Gregory R. Bowman; Juliane Brun; Lennart Brwewitz; Sarma BVNBS; Mark Calmiano; Anna Carbery; Daniel Carney; Emma Cattermole; Edcon Chang; Eugene Chernyshenko; John D. Chodera; Austin Clyde; Joseph E. Coffland; Galit Cohen; Jason Cole; Alessandro Contini; Lisa Cox; Tristan Ian Croll; Milan Cvitkovic; Alex Dias; Kim Donckers; David L. Dotson; Alice Douangamath; Shirly Duberstein; Tim Dudgeon; Louise Dunnett; Peter K. Eastman; Noam Erez; Charles J. Eyermann; Mike Fairhead; Gwen Fate; Daren Fearon; Oleg Fedorov; Matteo Ferla; Rafaela S. Fernandes; Lori Ferrins; Mihajlo Filep; Richard Foster; Holly Foster; Laurent Fraisse; Ronen Gabizon; Adolfo Garcia-Sastre; Victor O. Gawriljuk; Paul Gehrtz; Carina Gileadi; Charline Giroud; William G. Glass; Robert Glen; Itai Glinert; Andre S. Godoy; Marian Gorichko; Tyler Gorrie-Stone; Ed J. Griffen; Sophie Hahn; Amna Haneef; Storm Hassell Hart; Jag Heer; Michael Henry; Michelle Hill; Sam Horrell; Qiu Yu Huang; Victor D. Huliak; Victor D. Huliak; Matthew F.D. Hurley; Tomer Israely; Andrew Jajack; Jitske Jansen; Eric Jnoff; Dirk Jochmans; Tobias John; Steven De Jonghe; Benjamin Kaminow; Lulu Kang; Anastassia L. Kantsadi; Peter W. Kenny; J. L. Kiappes; Serhii O. Kinakh; Serhii O. Kinakh; Lizbe Koekemoer; Boris Kovar; Tobias Krojer; Van La; Alpha A. Lee; Bruce A. Lefker; Haim Levy; Ivan G. Logvinenko; Ivan G. Logvinenko; Nir London; Petra Lukacik; Hannah Bruce Macdonald; Elizabeth M. MacLean; Laetitia L Makower; Tika R. Malla; Tatiana Matviiuk; Willam McCorkindale; Briana L. McGovern; Sharon Melamed; Kostiantyn P. Melnykov; Kostiantyn P. Melnykov; Oleg Michurin; Pascal Miesen; Halina Mikolajek; Bruce F. Milne; David Minh; Aaron Morris; Garrett M. Morris; Melody Jane Morwitzer; Demetri Moustakas; Charles Mowbray; Aline M. Nakamura; Jose Brandao Neto; Johan Neyts; Luong Nguyen; Gabriela D. Noske; Vladas Oleinikovas; Glaucius Oliva; Gijs J. Overheul; David Owen; Ruby Pai; Jin Pan; Nir Paran; Alexander Payne; Benjamin Perry; Maneesh Pingle; Jakir Pinjari; Boaz Politi; Ailsa Powell; Vladimir Psenak; Ivan Pulido; Reut Puni; Victor L. Rangel; Rambabu N. Reddi; Paul Rees; St Patrick Reid; Lauren Reid; Efrat Resnick; Emily Grace Ripka; Matthew C. Robinson; Ralph P. Robinson; Jaime Rodriguez-Guerra; Romel Rosales; Dominic A. Rufa; Kadi Saar; Kumar Singh Saikatendu; Eidarus Salah; David Schaller; Jenke Scheen; Celia A. Schiffer; Chris Schofield; Mikhail Shafeev; Aarif Shaikh; Ala M. Shaqra; Jiye Shi; Khriesto Shurrush; Sukrit Singh; Assa Sittner; Peter Sjo; Rachael Skyner; Adam Smalley; Bart Smeets; Mihaela D. Smilova; Leonardo J. Solmesky; John Spencer; Claire Strain-Damerell; Vishwanath Swamy; Hadas Tamir; Jenny C. Taylor; Rachael E. Tennant; Warren Thompson; Andrew Thompson; Susana Tomasio; Charlie Tomlinson; Igor S. Tsurupa; Igor S. Tsurupa; Anthony Tumber; Ioannis Vakonakis; Ronald P. van Rij; Laura Vangeel; Finny S. Varghese; Mariana Vaschetto; Einat B. Vitner; Vincent Voelz; Andrea Volkamer; Frank von Delft; Annette von Delft; Martin Walsh; Walter Ward; Charlie Weatherall; Shay Weiss; Kris M. White; Conor Francis Wild; Karolina D Witt; Matthew Wittmann; Nathan Wright; Yfat Yahalom-Ronen; Nese Kurt Yilmaz; Daniel Zaidmann; Ivy Zhang; Hadeer Zidane; Nicole Zitzmann; Sarah N Zvornicanin,"; Israel Institution of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; University of Oxford; Memorial Sloan Kettering Cancer Center; Israel Institution of Biological Research; The Weizmann Institute of Science; Israel Institution of Biological Research; University of Oxford; Enamine Ltd; Enamine Ltd; Memorial Sloan Kettering Cancer Center; Folding@home Consortium; DNDi; Washington University School of Medicine; University of Oxford; University of Oxford; Sai Life Sciences; UCB; University of Oxford;Diamond Light Source; Takeda Development Center Americas, Inc.; University of Oxford; Takeda Development Center Americas, Inc.; Enamine Ltd; Memorial Sloan Kettering Cancer Center; Argonne National Laboratory; N/A; The Weizmann Institute of Science; Cambridge Crystallographic Datacentre; University of Milan; Life Compass Consulting Ltd; Cambridge Institute for Medical Research, The University of Cambridge; PostEra Inc.; Diamond Light Source Ltd; Research Complex at Harwell; Katholieke Universiteit Leuven; N/A; Diamond Light Source Ltd; Research Complex at Harwell; The Weizmann Institute of Science; Informatics Matters; Diamond Light Source Ltd; Research Complex at Harwell; Department of Bioengineering until Sept. 1, then Department of Chemistry; Israel Institution of Biological Research; Northeastern University; University of Oxford; Thames Pharma Partners; Diamond Light Source Ltd; Research Complex at Harwell; University of Oxford; University of Oxford; University of Sao Paulo; Northeastern University; Weizmann Institute of Science; University of Leeds; University of Leeds; DNDi; The Weizmann Institute of Science; Icahn School of Medicine at Mount Sinai; University of Sao Paulo; The Weizmann Institute of Science; University of Oxford; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Cambridge; Israel Institution of Biological Research; University of Sao Paulo; Taras Shevchenko National University of Kyiv; Diamond Light Source Ltd; Research Complex at Harwell; MedChemica Ltd; DNDi; Illinois Institute of Technology; University of Sussex; UCB; Memorial Sloan Kettering Cancer Center; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; University of Massachusetts Chan Medical School; Enamine Ltd; Enamine Ltd; Temple University; Israel Institution of Biological Research; PostEra Inc.; Radboud University Medical Center; UCB; Katholieke Universiteit Leuven; University of Oxford; Katholieke Universiteit Leuven; Memorial Sloan Kettering Cancer Center; Illinois Institute of Technology; University of Oxford; Independent Scientist; University of Oxford; Enamine Ltd; Enamine Ltd; University of Oxford; M2M solutions, s.r.o; University of Oxford; Illinois Institute of Technology; PostEra Inc.; University of Cambridge; Thames Pharma Partners LLC; Israel Institution of Biological Research; Enamine Ltd; Enamine Ltd; The Weizmann Institute of Science; Diamond Light Source Ltd; Research Complex at Harwell; Memorial Sloan Kettering Cancer Center; University of Oxford; University of Oxford; University of Oxford; Enamine Ltd; University of Cambridge; Icahn School of Medicine at Mount Sinai; Israel Institution of Biological Research; Enamine Ltd; Enamine Ltd; Enamine Ltd; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; University of Coimbra and University of Aberdeen; Illinois Institute of Technology; PostEra Inc; University of Oxford; Department of Pathology and Microbiology; Relay Therapeutics; DNDi; University of Sao Paulo; Diamond Light Source Ltd; Research Complex at Harwell; Katholieke Universiteit Leuven; PostEra Inc.; University of Sao Paulo; UCB; University of Sao Paulo; Radboud University Medical Center; Diamond Light Source Ltd; Research Complex at Harwell; PostEra Inc.; PostEra Inc.; Israel Institution of Biological Research; Memorial Sloan Kettering Cancer Center; DNDi; Sai Life Sciences; Sai Life Sciences; Israel Institution of Biological Research; Diamond Light Source Ltd; Research Complex at Harwell; M2M solutions, s.r.o; Memorial Sloan Kettering Cancer Center; Israel Institution of Biological Research; School of Pharmaceutical Sciences of Ribeirao Preto; The Weizmann Institute of Science; Compass Bussiness Partners Ltd; Department of Pathology and Microbiology; MedChemica Ltd; The Weizmann Institute of Science; PostEra Inc.; PostEra Inc.; Thames Pharma Partners LLC; Charite Universitatsmedizin Berlin; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; University of Cambridge; Takeda Development Center Americas, Inc.; University of Oxford; Charite Universitatsmedizin Berlin; Memorial Sloan Kettering Cancer Center; University of Massachusetts Chan Medical School; University of Oxford; Enamine Ltd; Sai Life Sciences; University of Massachusetts Chan Medical School; UCB; The Weizmann Institute of Science; Memorial Sloan Kettering Cancer Center; Israel Institution of Biological Research; DNDi; Diamond Light Source Ltd; Research Complex at Harwell; UCB; Radboud University Medical Center; University of Oxford; The Weizmann Institute of Science; University of Sussex; Diamond Light Source Ltd; Research Complex at Harwell; Sai Life Sciences; Israel Institution of Biological Research; University of Oxford; Lhasa Limited; Diamond Light Source Ltd; Research Complex at Harwell; University of Oxford; Collaborative Drug Discovery; Diamond Light Source Ltd; Research Complex at Harwell; Enamine Ltd; Enamine Ltd; University of Oxford; University of Oxford; Radboud University Medical Center; Katholieke Universiteit Leuven; Radboud University Medical Center; Collaborative Drug Discovery; Israel Institution of Biological Research; Temple University; Charite Universitatsmedizin Berlin; Diamond Light Source Ltd; University of Oxford; Research Complex at Harwell; University of Johannesburg; University of Oxford; Diamond Light Source Ltd; Research Complex at Harwell; Walter Ward Consultancy & Training; Collaborative Drug Discovery; Israel Institution of Biological Research; Icahn School of Medicine at Mount Sinai; University of Oxford; University of Oxford; Memorial Sloan Kettering Cancer Center; University of Oxford; Israel Institution of Biological Research; University of Massachusetts Chan Medical School; The Weizmann Institute of Science; Memorial Sloan Kettering Cancer Center; The Weizmann Institute of Science; University of Oxford; University of Massachusetts Chan Medical School","The COVID-19 pandemic was a stark reminder that a barren global antiviral pipeline has grave humanitarian consequences. Pandemics could be prevented in principle by accessible, easily deployable broad-spectrum oral antivirals. Here we report the results of the COVID Moonshot, a fully open-science, crowd sourced, structure-enabled drug discovery campaign targeting the SARS-CoV-2 main protease. We discovered a novel chemical series that is differentiated from current Mpro inhibitors in that it maintains a new non-covalent, non-peptidic scaffold with nanomolar potency. Our approach leveraged crowdsourcing, high-throughput structural biology, machine learning, and exascale molecular simulations and high-throughput chemistry. In the process, we generated a detailed map of the structural plasticity of the SARS-CoV-2 main protease, extensive structure-activity relationships for multiple chemotypes, and a wealth of biochemical activity data. In a first for a structure-based drug discovery campaign, all compound designs (>18,000 designs), crystallographic data (>840 ligand-bound X-ray structures), assay data (>10,000 measurements), and synthesized molecules (>2,400 compounds) for this campaign were shared rapidly and openly, creating a rich open and IP-free knowledgebase for future anti-coronavirus drug discovery.",biochemistry,fuzzy,100,100
bioRxiv,10.1101/2020.10.26.356014,2020-10-28,https://biorxiv.org/cgi/content/short/2020.10.26.356014,"COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms",Marek Ostaszewski; Anna Niarakis; Alexander Mazein; Inna Kuperstein; Robert Phair; Aurelio Orta-Resendiz; Vidisha Singh; Sara Sadat Aghamiri; Marcio Luis Acencio; Enrico Glaab; Andreas Ruepp; Gisela Fobo; Corinna Montrone; Barbara Brauner; Goar Frishman; Julia Somers; Matti Hoch; Shailendra Kumar Gupta; Julia Scheel; Hanna Borlinghaus; Tobias Czauderna; Falk Schreiber; Arnau Montagud; Miguel Ponce de Leon; Akira Funahashi; Yusuke Hiki; Noriko Hiroi; Takahiro G Yamada; Andreas Drager; Alina Renz; Muhammad Naveez; Zsolt Bocskei; Daniela Bornigen; Liam Fergusson; Marta Conti; Marius Rameil; Vanessa Nakonecnij; Jakob Vanhoefer; Leonard Schmiester; Muying Wang; Emily E Ackerman; Jason E Shoemaker; Jeremy Zucker; Kristie L Oxford; Jeremy Teuton; Ebru Kocakaya; Gokce Yagmur Summak; Kristina Hanspers; Martina Kutmon; Susan Coort; Lars Eijssen; Friederike Ehrhart; Rex D. A. B.; Denise Slenter; Marvin Martens; Nhung Pham; Robin Haw; Bijay Jassal; Lisa Matthews; Marija Orlic-Milacic; Andrea Senff-Ribeiro; Karen Rothfels; Veronica Shamovsky; Ralf Stephan; Cristoffer Sevilla; Thawfeek Mohamed Varusai; Jean-Marie Ravel; Vera Ortseifen; Silvia Marchesi; Piotr Gawron; Ewa Smula; Laurent Heirendt; Venkata Satagopam; Guanming Wu; Anders Riutta; Martin Golebiewski; Stuart Owen; Carole Goble; Xiaoming Hu; Rupert Overall; Dieter Maier; Angela Bauch; Benjamin M Gyori; John A Bachman; Carlos Vega; Valentin Groues; Miguel Vazquez; Pablo Porras; Luana Licata; Marta Iannuccelli; Francesca Sacco; Denes Turei; Augustin Luna; Ozgun Babur; Sylvain Soliman; Alberto Valdeolivas; Marina Esteban-Medina; Maria Pena-Chilet; Kinza Rian; Tomas Helikar; Bhanwar Lal Puniya; Anastasia Nesterova; Anton Yuryev; Anita de Waard; Dezso Modos; Agatha Treveil; Marton Laszlo Olbei; Bertrand De Meulder; Aurelien Naldi; Aurelien Dugourd; Laurence Calzone; Chris Sander; Emek Demir; Tamas Korcsmaros; Tom C Freeman; Franck Auge; Jacques S Beckmann; Jan Hasenauer; Olaf Wolkenhauer; Egon Willighagen; Alexander R Pico; Chris Evelo; Lincoln D Stein; Henning Hermjakob; Julio Saez-Rodriguez; Joaquin Dopazo; Alfonso Valencia; Hiroaki Kitano; Emmanuel Barillot; Charles Auffray; Rudi Balling; Reinhard Schneider; - the COVID-19 Disease Map Community,"Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Biology, Univ. Evry, University of Paris-Saclay, GenHotel, Genopole, 91025, Evry, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Institut Curie, PSL Research University, Paris, France.; Integrative Bioinformatics, Inc., 346 Paul Ave, Mountain View, CA, USA; Institut Pasteur, HIV, Inflammation and Persistence Unit, Paris, France; Laboratoire Europeen de Recherche pour la Polyarthrite Rhumatoide - Genhotel, Univ Evry, Universite Paris-Saclay, 2, rue Gaston Cremieux, 91057 EVRY-GENOPOLE ce; Inserm- Institut national de la sante et de la recherche medicale. Saint-Louis Hospital 1 avenue Claude Vellefaux Pavillon Bazin 75475 Paris; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Institute of Experimental Genetics (IEG), Helmholtz Zentrum Munchen-German Research Center for Environmental Health (GmbH), Ingolstadter Landstrasse 1, D-85764 ; Institute of Experimental Genetics (IEG), Helmholtz Zentrum Munchen-German Research Center for Environmental Health (GmbH), Ingolstadter Landstrasse 1, D-85764 ; Institute of Experimental Genetics (IEG), Helmholtz Zentrum Munchen-German Research Center for Environmental Health (GmbH), Ingolstadter Landstrasse 1, D-85764 ; Institute of Experimental Genetics (IEG), Helmholtz Zentrum Munchen-German Research Center for Environmental Health (GmbH), Ingolstadter Landstrasse 1, D-85764 ; Institute of Experimental Genetics (IEG), Helmholtz Zentrum Munchen-German Research Center for Environmental Health (GmbH), Ingolstadter Landstrasse 1, D-85764 ; Oregong Health & Sciences Univerity; Department of Molecular and Medical Genetics; 3222 SW Research Drive, Portland, Oregon, U.S.A 97239; Department of Systems Biology and Bioinformatics, University of Rostock, 18051 Rostock, Germany; Department of Systems Biology and Bioinformatics, University of Rostock, 18051 Rostock, Germany; Department of Systems Biology and Bioinformatics, University of Rostock, 18051 Rostock, Germany; Department of Computer and Information Science, University of Konstanz, Konstanz, Germany; Monash University, Faculty of Information Technology, Department of Human-Centred Computing, Wellington Rd, Clayton VIC 3800, Australia; Department of Computer and Information Science, University of Konstanz, Konstanz, Germany; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Keio University, Department of Biosciences and Informatics, 3-14-1 Hiyoshi Kouhoku-ku Yokohama Japan 223-8522; Keio University, Department of Biosciences and Informatics, 3-14-1 Hiyoshi Kouhoku-ku Yokohama Japan 223-8522; Sanyo-Onoda City University, Faculty of Pharmaceutical Sciences, University St.1-1-1, Yamaguchi, Japan 756-0884; Keio University, Department of Biosciences and Informatics, 3-14-1 Hiyoshi Kouhoku-ku Yokohama Japan 223-8522; Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tu; Computational Systems Biology of Infections and Antimicrobial-Resistant Pathogens, Institute for Bioinformatics and Medical Informatics (IBMI), University of Tu; Riga Technical University, Institute of Applied Computer Systems,1 Kalku Street, LV-1658 Riga, Latvia; Sanofi R&D Translational Sciences; Bioinformatics Core Facility, Universitaetsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; The University of Edinburgh, Royal (Dick) School of Veterinary Medicine, Easter Bush Campus, Midlothian, EH25 9RG; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; University of Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Helmholtz Zentrum Munchen - German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; Department of Chemical Engineering, University of Pittsburgh; University of Pittsburgh, Department of Chemical and Petroleum Engineering; Dept. of Chemical & Petroleum Engineering, University of Pittsburgh; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Pacific Northwest National Laboratory; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Ankara University, Stem Cell Institute, Ceyhun Atif Kansu St. No: 169 06520 Cevizlidere/ANKARA/TURKEY; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Department of Bioninformatics-BiGCaT, NUTRIM, Maastricht University, Universiteitssingel 60, 6229 ER Maastricht, The Netherlands; Maastricht University, Department of Bioinformatics, NUTRIM, Universiteitssingel 60; 6229 ER Maastricht; The Netherlands; Center for Systems Biology and Molecular Medicine, Yenepoya (Deemed to be University), Mangalore 575018, India; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Department of Bioinformatics - BiGCaT, NUTRIM, Maastricht University, 6229 ER Maastricht, The Netherlands; Maastricht University, NUTRIM, Bioinformatics-BiGCaT, PO Box 616, 6200 MD, Maastricht, the Netherlands; Adaptive Oncology, Ontario Institute for Cancer Research, MaRS Centre, 661 University Avenue, Suite 510, Toronto, Ontario, Canada M5G 0A3; Ontario Institute for Cancer Research (OICR), 661 University Ave Suite 510, Toronto, ON M5G 0A3, Canada; NYU Grossman School of Medicine, New York NY 10016 USA; Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; Ontario Institute for Cancer Research (OICR) (Canada); Ontario Institute for Cancer Research, Department of Computational Biology, MaRS Centre, South Tower, 661 University Avenue, Suite 500, Toronto, Ontario, Canada; NYU Langone Medical Center, New York, USA; Ontario Institute for Cancer Research, MaRS Centre, 661 University Ave, Suite 510, Toronto, Ontario, Canada; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD; Reactome, EMBL-EBI, Cambridge, UK; University of Lorraine, INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, F-54000 Nancy, France.; Senior Research Group in Genome Research of Industrial Microorganisms, Center for Biotechnology, Bielefeld University, Universitaetsstrasse 27, 33615 Bielefeld,; Uppsala University - Sweden; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239-3098, USA; Gladstone Institutes, Institute for Data Science and Biotechnology, 1650 Owens St., San Francisco, CA 94131, USA; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; The University of Manchester, Department of Computer Science, Oxford Road, Manchester, M13 9PL, UK; Heidelberg Institute for Theoretical Studies (HITS), Schloss-Wolfsbrunnenweg 35, D-69118 Heidelberg (Germany); German Center for Neurodegenerative Diseases (DZNE) Dresden, Tatzberg 41, 01307 Dresden, Germany.; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Biomax Informatics AG, Robert-Koch-Str. 2, 82152 Planegg, Germany; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Harvard Medical School, Laboratory of Systems Pharmacology, 200 Longwood Avenue, Boston, MA; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Barcelona Supercomputing Center (BSC), Barcelona, Spain; EMBL-EBI, Molecular Systems, Wellcome Genome Campus, CB10 1SD, Hinxton, UK; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; University of Rome Tor Vergata, Department of Biology, Via della Ricerca Scientifica 1, 00133 Rome, Italy; Heidelberg Univarsity, Institute for Computational Biomedicine, BQ 0053, Im Neuenheimer Feld 267, 69120 Heidelberg, Germany; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; University of Massachusetts Boston, Computer Science Department, 100 William T, Morrissey Blvd, Boston, MA 02125; Inria Saclay Ile-de-France; Heidelberg University, Faculty of Medicine and Heidelberg University Hospital, Institute of Computational Biomedicine, Bioquant, 69120 Heidelberg, Germany; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio, 41013, Sevilla, Spain.; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; University of Nebraska-Lincoln, Department of Biochemistry, 1901 Vine St., Lincoln, NE, 68588, USA; Elsevier, Life Science Department; Elsevier, Professional Services, 1600 John F Kennedy Blvd #1800, Philadelphia, PA 19103; Elsevier, Research Collaborations Unit, 71 Hanley Lane, Jericho, VT 05465; Quadram Institute Bioscience, Rosalind Franklin Road, Norwich Research Park, Norwich, NR4 7UQ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Earlham Institute, Norwich Research Park, Norwich, NR4 7UZ, United Kingdom; Association EISBM; Inria Saclay - Ile de France, Lifeware group, 91120 Palaiseau, France; Heidelberg University, Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Bioquant, Heidelberg, Germany; Institut Curie, PSL Research University, Mines Paris Tech, Inserm, U900, F-75005, Paris, France.; cBio Center, Divisions of Biostatistics and Computational Biology, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.; Oregon Health and Science University, Department of Molecular and Medical Genetics, 3222 SW Research Drive, Mail Code: L103, Portland, Oregon, U.S.A. 97239; Earlham Institute, Norwich Research Park, NR4 7UZ, Norwich, UK; The Roslin Institute, University of Edinburgh EH25 9RG; Sanofi R&D, Translational Sciences, 1 av Pierre Brossolette 91395 Chilly-Mazarin France; University of Lausanne, Lausanne, Switzerland; Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, Germany; University of Rostock, Dept of Systems Biology & Bioinformatics; Department of Bioinformatics-BiGCaT, NUTRIM, Maastricht University, Maastricht, The Netherlands; Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA, USA; Dept. Bioinformatics - BiGCaT, Maastricht University, The Netherlands; Ontario Institute for Cancer Research, Adaptive Oncology Theme, 661 University Ave, Toronto, ON M5G 1M1 Canada; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, UK; Institute for Computational Biomedicine Heidelberg University, Faculty of Medicine, Im Neuenheimer Feld 267, 69120 Heidelberg; Clinical Bioinformatics Area. Fundacion Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain.; Barcelona Supercomputing Center (BSC), Barcelona, Spain; Systems Biology Institute, Tokyo Japan; Institut Curie, PSL Research University, Paris, France.; European Institute for Systems Biology and Medicine (EISBM), Vourles, France; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg; -","We describe a large-scale community effort to build an open-access, interoperable, and computable repository of COVID-19 molecular mechanisms - the COVID-19 Disease Map. We discuss the tools, platforms, and guidelines necessary for the distributed development of its contents by a multi-faceted community of biocurators, domain experts, bioinformaticians, and computational biologists. We highlight the role of relevant databases and text mining approaches in enrichment and validation of the curated mechanisms. We describe the contents of the Map and their relevance to the molecular pathophysiology of COVID-19 and the analytical and computational modelling approaches that can be applied for mechanistic data interpretation and predictions. We conclude by demonstrating concrete applications of our work through several use cases and highlight new testable hypotheses.",systems biology,fuzzy,100,100
medRxiv,10.1101/2020.10.25.20219048,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.25.20219048,Viral load in community SARS-CoV-2 cases varies widely and temporally,Ann Sarah Walker; Emma Pritchard; Thomas House; Julie V Robotham; Paul J Birrell; Iain Bell; John I Bell; John N Newton; Jeremy Farrar; Ian Diamond; Ruth Studley; Jodie Hay; Karina-Doris Vihta; Timothy EA Peto; Nicole Stoesser; Philippa C Matthews; David W Eyre; Koen Pouwels; - the COVID-19 Infection Survey team,University of Oxford; University of Oxford; University of Manchester; Public Health England; Public Health England; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Glasgow; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; ,"Information on SARS-CoV-2 in representative community surveillance is limited, particularly cycle threshold (Ct) values (a proxy for viral load). Of 3,312,159 nose and throat swabs taken 26-April-2020 to 13-March-2021 in the UKs national COVID-19 Infection Survey, 27,902(0.83%) were RT-PCR-positive, 10,317(37%), 11,012(40%) and 6,550(23%) for 3, 2 or 1 of the N, S and ORF1ab genes respectively, with median Ct=29.2 ([~]215 copies/ml; IQR Ct=21.9-32.8, 14-56,400 copies/ml). Independent predictors of lower Cts (i.e. higher viral load) included self-reported symptoms and more genes detected, with at most small effects of sex, ethnicity and age. Single-gene positives almost invariably had Ct>30, but Cts varied widely in triple-gene positives, including without symptoms. Population-level Cts changed over time, with declining Ct preceding increasing SARS-CoV-2 positivity. Of 6,189 participants with IgG S-antibody tests post-first RT-PCR-positive, 4,808(78%) were ever antibody-positive; Cts were significantly higher in those remaining antibody-negative. Community SARS-CoV-2 Ct values could be a useful epidemiological early-warning indicator.

IMPACT STATEMENTCt values from SARS-CoV-2 RT-PCR tests vary widely and over calendar time. They have the potential to be used more broadly in public testing programmes as an ""early-warning"" system for shifts in infectious load and hence transmission.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.25.20219071,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.25.20219071,"Causes of death in mental health service users during the first wave of the COVID-19 pandemic: South London and Maudsley data from March to June 2020, compared with 2015-2019.",Robert Stewart; Amelia Jewell; Matthew Broadbent; Ioannis Bakolis; Jayati Das-Munshi,"King's College London; South London and Maudsley NHS Foundation Trust, London, UK; South London and Maudsley NHS Foundation Trust, London, UK; King's College London, London, UK; King's College London, London, UK","The COVID-19 pandemic is likely to have had a particularly high impact on the health and wellbeing of people with pre-existing mental disorders. This may include higher than expected mortality rates due to severe infections themselves, due to other comorbidities, or through increased suicide rates during lockdown. However, there has been very little published information to date on causes of death in mental health service users. Taking advantage of a large mental healthcare database linked to death registrations, we describe numbers of deaths within specific underlying-cause-of-death groups for the period from 1st March to 30th June in 2020 and compare these with the same four-month periods in 2015-2019. In past and current service users, there were 2561 deaths in March-June 2020, compared to an average of 1452 for the same months in 2015-19: an excess of 1109. The 708 deaths with COVID-19 as the underlying cause in 2020 accounted for 63.8% of that excess. The remaining excess was accounted for by unnatural/unexplained deaths and by deaths recorded as due to neurodegenerative conditions, with no excess in those attributed to cancer, circulatory disorders, digestive disorders, respiratory disorders, or other disease codes. Of 295 unexplained deaths in 2020 with missing data on cause, 162 (54.9%) were awaiting a formal death notice (i.e. the group that included deaths awaiting a coroners inquest) - an excess of 129 compared to the average of previous years, accounting for 11.6% of the excess in total deaths.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.10.26.20219428,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219428,Community prevalence of SARS-CoV-2 in England during April to September 2020: Results from the ONS Coronavirus Infection Survey,Koen B Pouwels; Thomas House; Emma Pritchard; Julie V Robotham; Paul Birrell; Andrew Gelman; Karina-Doris Vihta; Nikola Bowers; Ian Boreham; Heledd Thomas; James Lewis; Iain Bell; John I Bell; John N Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Ann Sarah Walker,University of Oxford; University of Manchester; University of Oxford; Public Health England; Public Health England; Columbia University; University of Oxford; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford,"BackgroundDecisions regarding the continued need for control measures to contain the spread of SARS-CoV-2 rely on accurate and up-to-date information about the number of people and risk factors for testing positive. Existing surveillance systems are not based on population samples and are generally not longitudinal in design.

MethodsFrom 26 April to 19 September2020, 514,794 samples from 123,497 individuals were collected from individuals aged 2 years and over from a representative sample of private households from England. Participants completed a questionnaire and nose and throat swab were taken. The percentage of individuals testing positive for SARS-CoV-2 RNA was estimated over time using dynamic multilevel regression and post-stratification, to account for potential residual non-representativeness. Potential changes in risk factors for testing positive over time were also evaluated using multilevel regression models.

FindingsBetween 26 April and 19 September 2020, in total, results were available from 514,794 samples from 123,497 individuals, of which 489 were positive overall from 398 individuals. The percentage of people testing positive for SARS-CoV-2 changed substantially over time, with an initial decrease between end of April and June, followed by low levels during the summer, before marked increases end of August and September 2020. Having a patient-facing role and working outside your home were important risk factors for testing positive in the first period but not (yet) in the second period of increased positivity rates, and age (young adults) being an important driver of the second period of increased positivity rates. A substantial proportion of infections were in individuals not reporting symptoms (53%-70%, dependent on calendar time).

InterpretationImportant risk factors for testing positive varied substantially between the initial and second periods of higher positivity rates, and a substantial proportion of infections were in individuals not reporting symptoms, indicating that continued monitoring for SARS-CoV-2 in the community will be important for managing the epidemic moving forwards.

FundingThis study is funded by the Department of Health and Social Care. KBP, ASW, EP and JVR are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (PHE) (NIHR200915). AG is supported by U.S. National Institute of Health and Office of Naval Research. ASW is also supported by the NIHR Oxford Biomedical Research Centre and by core support from the Medical Research Council UK to the MRC Clinical Trials Unit [MC_UU_12023/22] and is an NIHR Senior Investigator. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, Department of Health, or PHE.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSUnprecedented control measures, such as national lockdowns, have been widely implemented to contain the spread of SARS-CoV-2. Decisions regarding the continued need for social distancing measures in the overall population, specific subgroups and geographic areas heavily rely on accurate and up-to-date information about the number of people and risk factors for testing positive. We searched PubMed and medRxiv and bioRxiv preprint servers up to 6 June 2020 for epidemiological studies using the terms ""SARS-CoV-2"" and ""prevalence"" or ""incidence"" without data or language restrictions. Most studies were small or had only information about current presence of the virus for a small subset of patients, or used data not representative of the community, such as hospital admissions, deaths or self-reported symptoms. Large population-based studies, such as the current study, are required to understand risk factors and the dynamics of the epidemic.

Added value of this studyThis is the first longitudinal community survey of SARS-CoV-2 infection at national and regional levels in the UK. With more than 500,000 swabs from more than 120,000 individuals this study provides robust evidence that the percentage of individuals from the general community in England testing positive for SARS-CoV-2 clearly declined between end of April and June 2020,, followed by consistently low levels during the summer, before marked increases end of August and September 2020. Risk factors for testing positive varied substantially between the initial and second periods of higher positivity rates, with having a patient-facing role and working outside your home being important risk factors in the first period but not (yet) in the second period, and age (young adults) being an important driver of the second period of increased positivity rates. Positive tests commonly occurred without symptoms being reported.

Implications of all the available evidenceThe observed decline in the percentage of individuals testing positive adds to the increasing body of empirical evidence and theoretical models that suggest that the lockdown imposed on 23 March 2020 in England was associated, at least temporarily, with a decrease in infections. Important risk factors for testing positive varied substantially between the initial and second periods of higher positivity rates, and a substantial proportion of infections were in individuals not reporting symptoms, indicating that continued monitoring for SARS-CoV-2 in the community will be important for managing the epidemic moving forwards.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.26.20219659,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219659,Detecting COVID-19 infection hotspots in England using large-scale self-reported data from a mobile application,Thomas Varsavsky; Mark S Graham; Liane S Canas; Sajaysurya Ganesh; Joan Capdevila Puyol; Carole H Sudre; Benjamin Murray; Marc Modat; M. Jorge Cardoso; Christina M Astley; David A Drew; Long H Nguyen; Tove Fall; Maria F Gomez; Paul W Franks; Andrew T Chan; Richard Davies; Jonathan Wolf; Claire J Steves; Tim D Spector; Sebastien Ourselin,King's College London; King's College London; King's College London; Zoe Global Limited; Zoe Global Limited; King's College London; King's College London; King's College London; King's College London; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Uppsala University; Lund University; Lund University; Massachusetts General Hospital; Zoe Global Limited; Zoe Global Limited; King's College London; King's College London; King's College London,"BackgroundAs many countries seek to slow the spread of COVID-19 without reimposing national restrictions, it has become important to track the disease at a local level to identify areas in need of targeted intervention.

MethodsWe performed modelling on longitudinal, self-reported data from users of the COVID Symptom Study app in England between 24 March and 29 September, 2020. Combining a symptom-based predictive model for COVID-19 positivity and RT-PCR tests provided by the Department of Health we were able to estimate disease incidence, prevalence and effective reproduction number. Geographically granular estimates were used to highlight regions with rapidly increasing case numbers, or hotspots.

FindingsMore than 2.8 million app users in England provided 120 million daily reports of their symptoms, and recorded the results of 170,000 PCR tests. On a national level our estimates of incidence and prevalence showed similar sensitivity to changes as two national community surveys: the ONS and REACT-1 studies. On 28 September 2020 we estimated 15,841 (95% CI 14,023-17,885) daily cases, a prevalence of 0.53% (95% CI 0.45-0.60), and R(t) of 1.17 (95% credible interval 1.15-1.19) in England. On a geographically granular level, on 28 September 2020 we detected 15 of the 20 regions with highest incidence according to Government test data, with indications that our method may be able to detect rapid case increases in regions where Government testing provision is more limited.

InterpretationSelf-reported data from mobile applications can provide an agile resource to inform policymakers during a fast-moving pandemic, serving as an independent and complementary resource to more traditional instruments for disease surveillance.

FundingZoe Global Limited, Department of Health, Wellcome Trust, EPSRC, NIHR, MRC, Alzheimers Society.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSTo identify instances of the use of digital tools to perform COVID-19 surveillance, we searched PubMed for peer-reviewed articles between 1 January and 14 October 2020, using the keywords COVID-19 AND ((mobile application) OR (web tool) OR (digital survey)). Of the 382 results, we found eight that utilised user-reported data to ascertain a users COVID-19 status. Of these, none sought to provide disease surveillance on a national level, or to compare these predictions to other tools to ascertain their accuracy. Furthermore, none of these papers sought to use their data to highlight geographical areas of concern.

Added value of this studyTo our knowledge, we provide the first demonstration of mobile technology to provide national-level disease surveillance. Using over 120 million reports from more than 2.8 million users across England, we estimate incidence, prevalence, and the effective reproduction number. We compare these estimates to those from national community surveys to understand the effectiveness of these digital tools. Furthermore, we demonstrate the large number of users can be used to provide disease surveillance with high geographical granularity, potentially providing a valuable source of information for policymakers seeking to understand the spread of the disease.

Implications of all the available evidenceOur findings suggest that mobile technology can be used to provide real-time data on the national and local state of the pandemic, enabling policymakers to make informed decisions in a fast-moving pandemic.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.10.26.20219576,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219576,Impact of the COVID-19 pandemic on remote mental healthcare and prescribing in psychiatry,Rashmi Patel; Jessica Irving; Aimee Brinn; Matthew Broadbent; Hitesh Shetty; Megan Pritchard; Johnny Downs; Robert Stewart; Robert Harland; Philip McGuire,"King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; South London and Maudsley NHS Foundation Trust, London, UK; South London and Maudsley NHS Foundation Trust, London, UK; South London and Maudsley NHS Foundation Trust, London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK; South London and Maudsley NHS Foundation Trust, London, UK; King's College London (Institute of Psychiatry, Psychology and Neuroscience), London, UK","ObjectivesThe recent COVID-19 pandemic has disrupted mental healthcare delivery, with many services shifting from in- person to remote patient contact. We investigated the impact of the pandemic on the use of remote consultation and on the prescribing of psychiatric medications.

Design and settingThe Clinical Record Interactive Search tool (CRIS) was used to examine de-identified electronic health records (EHRs) of people receiving mental healthcare from the South London and Maudsley (SLaM) NHS Foundation Trust. Data from the period before and after the onset of the pandemic were analysed using linear regression, and visualised using locally estimated scatterplot smoothing (LOESS).

ParticipantsAll patients receiving care from SLaM between 7th January 2019 and 20th September 2020 (around 37,500 patients per week).

Outcome measuresO_LIThe number of clinical contacts (in-person, remote or non-attended) with mental healthcare professionals per week
C_LIO_LIPrescribing of antipsychotic and mood stabiliser medications per week
C_LI

ResultsFollowing the onset of the pandemic, the frequency of in-person contacts was significantly reduced compared to that in the previous year ({beta} coefficient: -5829.6 contacts, 95% CI -6919.5 to -4739.6, p<0.001), while the frequency of remote contacts significantly increased ({beta} coefficient: 3338.5 contacts, 95% CI 3074.4 to 3602.7, p<0.001). Rates of remote consultation were lower in older adults than in working age adults, children and adolescents. Despite this change in the type of patient contact, antipsychotic and mood stabiliser prescribing remained at similar levels.

ConclusionsThe COVID-19 pandemic has been associated with a marked increase in remote consultation, particularly among younger patients. However, there was no evidence that this has led to changes in psychiatric prescribing. Nevertheless, further work is needed to ensure that older patients are able to access mental healthcare remotely.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.10.26.20219550,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219550,Human movement can inform the spatial scale of interventions against COVID-19 transmission,Hamish Gibbs; Emily Nightingale; Yang Liu; James Cheshire; Leon Danon; Liam Smeeth; Carl AB Pearson; Chris Grundy; - LSHTM CMMID COVID-19 Working Group; Adam J Kucharski; Rosalind M Eggo,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; University of Exeter; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; ; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,"BackgroundIn 2020, the UK enacted an intensive, nationwide lockdown on March 23 to mitigate transmission of COVID-19. As restrictions began to ease, resurgences in transmission were targeted by geographically-limited interventions of various stringencies. Understanding the spatial scale of networks of human interaction, and how these networks change over time, is critical to inform interventions targeted at the most at-risk areas without unnecessarily restricting areas at low risk of resurgence.

MethodsWe use detailed human mobility data aggregated from Facebook users to determine how the spatially-explicit network of movements changed before and during the lockdown period, in response to the easing of restrictions, and to the introduction of locally-targeted interventions. We also apply community detection techniques to the weighted, directed network of movements to identify geographically-explicit movement communities and measure the evolution of these community structures through time.

FindingsWe found that the mobility network became more sparse and the number of mobility communities decreased under the national lockdown, a change that disproportionately affected long distance journeys central to the mobility network. We also found that the community structure of areas in which locally-targeted interventions were implemented following epidemic resurgence did not show reorganization of community structure but did show small decreases in indicators of travel outside of local areas.

InterpretationWe propose that communities detected using Facebook or other mobility data be used to assess the impact of spatially-targeted restrictions and may inform policymakers about the spatial extent of human movement patterns in the UK. These data are available in near real-time, allowing quantification of changes in the distribution of the population across the UK, as well as changes in travel patterns to inform our understanding of the impact of geographically-targeted interventions.

Putting Research Into ContextO_ST_ABSEvidence before this studyC_ST_ABSLarge-scale intensive interventions in response to the COVID-19 pandemic have been implemented globally, significantly affecting human movement patterns. Mobility data show spatially-explicit network structure, but it is not clear how that structure changed in response to national or locally-targeted interventions.

Added value of this studyWe used daily mobility data aggregated from Facebook users to quantify changes in the travel network in the UK during the national lockdown, and in response to local interventions. We identified changes in human behaviour in response to interventions and identified the community structure inherent in these networks. This approach to understanding changes in the travel network can help quantify the extent of strongly connected communities of interaction and their relationship to the extent of spatially-explicit interventions.

Implications of all the available evidenceWe show that spatial mobility data available in near real-time can give information on connectivity that can be used to understand the impact of geographically-targeted interventions and in the future, to inform spatially-targeted intervention strategies.

Data SharingData used in this study are available from the Facebook Data for Good Partner Program by application. Code and supplementary information for this paper are available online (https://github.com/hamishgibbs/facebook_mobility_uk), alongside publication.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.10.26.20219642,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219642,A2B-COVID: A method for evaluating potential SARS-CoV-2 transmission events,Christopher J R Illingworth; William L Hamilton; Christopher H Jackson; Ashley Popay; Luke Meredith; Charlotte J Houldcroft; Myra Hosmillo; Aminu Jahun; Matthew Routledge; Ben Warne; Laura Caller; Sarah Caddy; Anna Yakovleva; Grant Hall; Fahad A Khokhar; Theresa Feltwell; Malte Pinckert; Iliana Georgana; Yasmin Chaudhry; Martin Curran; Surendra Parmar; Dominic Sparkes; Lucy Rivett; Nick K Jones; Sushmita Sridhar; Sally Forest; Tom Dymond; Kayleigh Grainger; Chris Workman; Effrossyni Gkrania-Klotsas; Nicholas M Brown; Michael Weekes; Stephen Baker; Sharon J Peacock; Theodore Gouliouris; Ian G. Goodfellow; Daniela de Angelis; M. Estee Torok,"MRC Biostatistics Unit, University of Cambridge; Department of Medicine, University of Cambridge; MRC Biostatistics Unit, University of Cambridge; Public Health England Field Epidemiology Unit, Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust, Cambridge; Department of Medicine, University of Cambridge; Francis Crick Institute; Cambridge Institute for Therapeutic Immunology and Infectious Disease; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Medicine, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Department of Pathology, University of Cambridge; Public Health England Clinical Microbiology and Public Health Laboratory, Cambridge; Public Health England Clinical Microbiology and Public Health Laboratory, Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Department of Medicine, University of Cambridge; Cambridge Institute for Therapeutic Immunology and Infectious Disease, Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University; Cambridge University; Department of Medicine, University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; MRC Biostatistics Unit, University of Cambridge; University of Cambridge","Identifying linked cases of infection is a key part of the public health response to viral infectious disease. Viral genome sequence data is of great value in this task, but requires careful analysis, and may need to be complemented by additional types of data. The Covid-19 pandemic has highlighted the urgent need for analytical methods which bring together sources of data to inform epidemiological investigations. We here describe A2B-COVID, an approach for the rapid identification of linked cases of coronavirus infection. Our method combines knowledge about infection dynamics, data describing the movements of individuals, and novel approaches to genome sequence data to assess whether or not cases of infection are consistent or inconsistent with linkage via transmission. We apply our method to analyse and compare data collected from two wards at Cambridge University Hospitals, showing qualitatively different patterns of linkage between cases on designated Covid-19 and non-Covid-19 wards. Our method is suitable for the rapid analysis of data from clinical or other potential outbreak settings.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.10.26.20219725,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219725,"Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults",Helen Ward; Graham Cooke; Christina J Atchison; Matthew Whitaker; Joshua Elliott; Maya Moshe; Jonathan C Brown; Barney Flower; Anna Daunt; Kylie E. C. Ainslie; Deborah Ashby; Christl A. Donnelly; Steven Riley; Ara Darzi; Wendy Barclay; Paul Elliott,"Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London","BackgroundThe prevalence and persistence of antibodies following a peak SARS-CoV-2 infection provides insights into its spread in the community, the likelihood of reinfection and potential for some level of population immunity.

MethodsPrevalence of antibody positivity in England, UK (REACT2) with three cross-sectional surveys between late June and September 2020. 365104 adults used a self-administered lateral flow immunoassay (LFIA) test for IgG. A laboratory comparison of LFIA results to neutralization activity in panel of sera was performed.

ResultsThere were 17,576 positive tests over the three rounds. Antibody prevalence, adjusted for test characteristics and weighted to the adult population of England, declined from 6.0% [5.8, 6.1], to 4.8% [4.7, 5.0] and 4.4% [4.3, 4.5], a fall of 26.5% [-29.0, -23.8] over the three months of the study. There was a decline between rounds 1 and 3 in all age groups, with the highest prevalence of a positive result and smallest overall decline in positivity in the youngest age group (18-24 years: -14.9% [-21.6, -8.1]), and lowest prevalence and largest decline in the oldest group (75+ years: -39.0% [-50.8, -27.2]); there was no change in antibody positivity between rounds 1 and 3 in healthcare workers (+3.45% [-5.7, +12.7]).

The decline from rounds 1 to 3 was largest in those who did not report a history of COVID-19, (-64.0% [-75.6, -52.3]), compared to -22.3% ([-27.0, -17.7]) in those with SARS-CoV-2 infection confirmed on PCR.

DiscussionThese findings provide evidence of variable waning in antibody positivity over time such that, at the start of the second wave of infection in England, only 4.4% of adults had detectable IgG antibodies using an LFIA. Antibody positivity was greater in those who reported a positive PCR and lower in older people and those with asymptomatic infection. These data suggest the possibility of decreasing population immunity and increasing risk of reinfection as detectable antibodies decline in the population.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.26.20219485,2020-10-27,https://medrxiv.org/cgi/content/short/2020.10.26.20219485,Predicting the impact of COVID-19 interruptions on transmission of gambiense human African trypanosomiasis in two health zones of the Democratic Republic of Congo,Maryam Aliee; Soledad Castano; Christopher Davis; Swati Patel; Erick Mwamba Miaka; Simon EF Spencer; Matt J Keeling; Nakul Chitnis; Kat S Rock,"University of Warwick; Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute; University of Warwick; University of Warwick; Programme National de Lutte contre la Trypanosomiase Humaine Africaine, Kinshasa, the Democratic Republic of the Congo; University of Warwick; University of Warwick; Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; University of Warwick","Many control programmes against neglected tropical diseases have been interrupted due to COVID-19 pandemic, including those that rely on active case finding. In this study we focus on gambiense human African trypanosomiasis (gHAT), where active screening was suspended in the Democratic Republic of Congo (DRC) due to the pandemic. We use two independent mathematical models to predict the impact of COVID-19 interruptions on transmission and reporting, and the achievement of 2030 elimination of transmission (EOT) goal for gHAT in two moderate-risk regions of DRC. We consider different interruption scenarios, including reduced passive surveillance in fixed health facilities, and whether this suspension lasts until the end of 2020 or 2021. Our models predict an increase in the number of new infections in the interruption period only if both active screening and passive surveillance were suspended, and with slowed reduction - but no increase - if passive surveillance remains fully functional. In all scenarios, the EOT may be slightly pushed back if no mitigation such as increased screening coverage is put in place. However, we emphasise that the biggest challenge will remain in the higher prevalence regions where EOT is already predicted to be behind schedule without interruptions unless interventions are bolstered.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.10.19.20214494,2020-10-21,https://medrxiv.org/cgi/content/short/2020.10.19.20214494,Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App,Carole H Sudre; Benjamin Murray; Thomas Varsavsky; Mark S Graham; Rose S Penfold; Ruth C.E Bowyer; Joan Capdevila Pujol; Kerstin Klaser; Michela Antonelli; Liane S Canas; Erika Molteni; Marc Modat; M. Jorge Cardoso; Anna May; Sajaysurya Ganesh; Richard Davies; Long H Nguyen; David Alden Drew; Christina M Astley; Amit D. Joshi; Jordi Merino; Neli Tsereteli; Tove Fall; Maria F Gomez; Emma Duncan; Christina Menni; Frances MK Williams; Paul W Franks; Andrew T Chan; Jonathan Wolf; Sebastien Ourselin; Timothy Spector; Claire J Steves,KCL; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Global Limited; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Global Limited; Zoe Global Limited; Zoe Global Limited; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital; Boston Children's Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Lund University; Uppsala University; Lund University; King's College London; King's College London; King's College London; Lund University; Massachusetts General Hospital; Zoe Global Limited; King's College London; King's College London; King's College London,"Reports of ""Long-COVID"", are rising but little is known about prevalence, risk factors, or whether it is possible to predict a protracted course early in the disease. We analysed data from 4182 incident cases of COVID-19 who logged their symptoms prospectively in the COVID Symptom Study app. 558 (13.3%) had symptoms lasting >=28 days, 189 (4.5%) for >=8 weeks and 95 (2.3%) for >=12 weeks. Long-COVID was characterised by symptoms of fatigue, headache, dyspnoea and anosmia and was more likely with increasing age, BMI and female sex. Experiencing more than five symptoms during the first week of illness was associated with Long-COVID, OR=3.53 [2.76;4.50]. A simple model to distinguish between short and long-COVID at 7 days, which gained a ROC-AUC of 76%, was replicated in an independent sample of 2472 antibody positive individuals. This model could be used to identify individuals for clinical trials to reduce long-term symptoms and target education and rehabilitation services.",infectious diseases,fuzzy,94,100
medRxiv,10.1101/2020.10.15.20213108,2020-10-20,https://medrxiv.org/cgi/content/short/2020.10.15.20213108,FebriDx point-of-care test in patients with suspected COVID-19: a pooled diagnostic accuracy study,Samuel G Urwin; B Clare Lendrem; Jana Suklan; Kile Green; Sara Graziadio; Peter Buckle; Paul M Dark; Adam L Gordon; Daniel S Lasserson; Brian Nicholson; D Ashley Price; Charles Reynard; Mark H Wilcox; Gail Hayward; Graham Prestwich; Valerie Tate; Tristan W Clark; Raja V Reddy; Hamish Houston; Ankur Gupta-Wright; Laurence John; Richard Body; A Joy Allen,"NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle-upon-Tyne Hospitals Foundation Trust, Newcastle-upon-Tyne, UK; NIHR Newcastle In Vitro Diagnostics Co-operative, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK; NIHR Newcastle In Vitro Diagnostics Co-operative, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK; NIHR Newcastle In Vitro Diagnostics Co-operative, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK; NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle-upon-Tyne Hospitals Foundation Trust, Newcastle-upon-Tyne, UK; Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, UK; Division of Infection, Immunity & Respiratory Medicine, University of Manchester, UK; School of Medicine, University of Nottingham, UK; NIHR Applied Research Collaboration East Midlands (ARC-EM), Nottingham, UK; NIHR Community Healthcare MedTech and In Vitro Diagnostics Cooperative, Oxford Health NHS Foundation Trust, Oxford, UK; Division of Health Sciences, University ; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle-upon-Tyne Hospitals Foundation Trust, Newcastle-upon-Tyne, UK; NIHR Doctoral Research Fellowship Programme, UK; Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK; Healthcare Associated Infections Research Group, NIHR Leeds In Vitro Diagnostics Co-operative, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds; NIHR Community Healthcare MedTech and In Vitro Diagnostics Co-operative, Oxford Health NHS Foundation Trust, Oxford, UK; Nuffield Department of Primary Care Hea; Yorkshire and Humber Academic Health Science Network, Wakefield, UK; Patient Public Involvement (PPI) Member, Precision Antimicrobial Prescribing PPI Group, NIHR Community Healthcare MedTech and In Vitro Diagnostics Cooperative, ; School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Infection, University Hospital Sout; Department of Respiratory Medicine, Kettering General Hospital NHS Foundation Trust, Kettering, UK; Northwick Park Hospital, London North West University Healthcare NHS Trust, Harrow, UK; Institute for Global Health, University College London, London, UK; Ealing Hospital, London North West University Healthcare NHS Trust, London, UK; Clinical Res; Northwick Park Hospital, London North West University Healthcare NHS Trust, Harrow, UK; Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK; Emergency Department, Manchester Royal Infirmary, Ma; NIHR Newcastle In Vitro Diagnostics Co-operative, Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, UK","BackgroundWe conducted a systematic review and individual patient data (IPD) meta-analysis to evaluate the diagnostic accuracy of a commercial point-of-care test, the FebriDx lateral flow device (LFD), in adult patients with suspected COVID-19. The FebriDx LFD is designed to distinguish between viral and bacterial respiratory infection.

MethodsWe searched MEDLINE, EMBASE, PubMed, Google Scholar, LitCovid, ClinicalTrials.gov and preprint servers on the 13th of January 2021 to identify studies reporting diagnostic accuracy of FebriDx (myxovirus resistance protein A component) versus real time reverse transcriptase polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 in adult patients suspected of COVID-19. IPD were sought from studies meeting the eligibility criteria. Studies were screened for risk of bias using the QUADAS-2 tool. A bivariate linear mixed model was fitted to the data to obtain a pooled estimate of sensitivity and specificity with 95% confidence intervals (95% CIs). A summary receiver operating characteristic (SROC) curve of the model was constructed. A sub-group analysis was performed by meta-regression using the same modelling approach to compare pooled estimates of sensitivity and specificity between patients with a symptom duration of 0 to 7 days and >7 days, and patients aged between 16 to 73 years and >73 years.

ResultsTen studies were screened, and three studies with a total of 1481 patients receiving hospital care were included. FebriDx produced an estimated pooled sensitivity of 0.911 (95% CI: 0.855-0.946) and specificity of 0.868 (95% CI: 0.802-0.915) compared to RT-PCR. There were no significant differences between the sub-groups of 0 to 7 days and >7 days in estimated pooled sensitivity (p = 0.473) or specificity (p = 0.853). There were also no significant differences between the sub-groups of 16 to 73 years of age and >73 years of age in estimated pooled sensitivity (p = 0.946) or specificity (p = 0.486).

ConclusionsBased on the results of three studies, the FebriDx LFD had high diagnostic accuracy for COVID-19 in a hospital setting, however, the pooled estimates of sensitivity and specificity should be interpreted with caution due to the small number of studies included, risk of bias, and inconsistent reference standards. Further research is required to confirm these findings, and determine how FebriDx would perform in different healthcare settings and patient populations.

Trial registrationThis study was conducted at pace as part of the COVID-19 National Diagnostic Research and Evaluation Platform (CONDOR) national test evaluation programme (https://www.condor-platform.org), and as a result, no protocol was developed, and the study was not registered.

Lay summaryTests to diagnose COVID-19 are crucial to help control the spread of the disease and to guide treatment. Over the last few months, tests have been developed to diagnose COVID-19 either by detecting the presence of the virus or by detecting specific markers linked to the virus being active in the body. These tests use complex machines in laboratories accepting samples from large geographical areas. Sometimes it takes days for test results to come back. So, to reduce the wait for results, new portable tests are being developed. These  point-of-care (POC) tests are designed to work close to where patients require assessment and care such as hospital emergency departments, GP surgeries or care homes. For these new POC tests to be useful, they should ideally be as good as standard laboratory tests.

In this study we looked at published research into a new test called FebriDx. FebriDx is a POC test that detects the bodys response to infection, and is claimed to be able to detect the presence of any viral infection, including infections due to the SARS-CoV-2 virus which causes COVID-19, as well as bacterial infections which can have similar symptoms. The FebriDx result was compared with standard laboratory tests for COVID-19 performed on the same patients throat and nose swab sample. We were able to analyse data from three studies with a total of 1481 adult patients who were receiving hospital care with symptoms of COVID-19 during the UK pandemic. Approximately one fifth of the patients were diagnosed as positive for SARS-CoV-2 virus using standard laboratory tests for COVID-19.

Our analysis demonstrated that FebriDx correctly identified 91 out of 100 patients who had COVID-19 according to the standard laboratory test. FebriDx also correctly identified 87 out of 100 patients who did not have COVID-19 according to the standard laboratory test. These results have important implications for how these tests could be used. As there were slightly fewer FebriDx false results when the results of the standard laboratory test were positive (9 out of 100) than when the results of the standard laboratory test were negative (13 out of 100), we can have slightly more confidence in a positive test result using FebriDx than a negative FebriDx result.

Overall, we have shown that the FebriDx POC test performed well during the UK COVID-19 pandemic when compared with laboratory tests, especially when COVID-19 was indicated. For the future, this means that the FebriDx POC test might be helpful in making a quick clinical decision on whether to isolate a patient with COVID-19-like symptoms arriving in a busy emergency department. However, our results indicate it would not completely replace the need to conduct a laboratory test in certain cases to confirm COVID-19.

There are limitations to our findings. For example, we do not know if FebriDx will work in a similar way with patients in different settings such as in the community or care homes. Similarly, we do not know whether other viral and bacterial infections which cause similar COVID-19 symptoms, and are more common in the autumn and winter months, could influence the FebriDx test accuracy. Our findings are also only based on three studies.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.15.20208454,2020-10-18,https://medrxiv.org/cgi/content/short/2020.10.15.20208454,Modelling SARS-CoV-2 transmission in a UK university setting,Edward M Hill; Benjamin D Atkins; Matt J Keeling; Michael Tildesley; Louise Dyson,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"Around 40% of school leavers in the UK attend university and individual universities generally host thousands of students each academic year. Bringing together these student communities during the COVID-19 pandemic may require strong interventions to control transmission. Prior modelling analyses of SARS-CoV-2 transmission within universities using compartmental modelling approaches suggest that outbreaks are almost inevitable.

We constructed a network-based model to capture the interactions of a student population in different settings (housing, social and study). For a single academic term of a representative campus-based university, we ran a susceptible-latent-infectious-recovered type epidemic process, parameterised according to available estimates for SARS-CoV-2. We investigated the impact of: adherence to (or effectiveness of) isolation and test and trace measures; room isolation of symptomatic students; and supplementary mass testing.

With all adhering to test, trace and isolation measures, we found that 22% (7% - 41%) of the student population could be infected during the autumn term, compared to 69% (56% - 76%) when assuming zero adherence to such measures. Irrespective of the adherence to isolation measures, on average a higher proportion of students resident on-campus became infected compared to students resident off-campus. Room isolation generated minimal benefits. Regular mass testing, together with high adherence to isolation and test and trace measures, could substantially reduce the proportion infected during the term compared to having no testing.

Our findings suggest SARS-CoV-2 may readily transmit in a university setting if there is limited adherence to nonpharmaceutical interventions and/or there are delays in receiving test results. Following isolation guidance and effective contact tracing curbed transmission and reduced the expected time an adhering student would spend in isolation.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.14.20212555,2020-10-16,https://medrxiv.org/cgi/content/short/2020.10.14.20212555,Multi-organ impairment in low-risk individuals with long COVID,Andrea Dennis; Malgorzata Wamil; Sandeep Kapur; Johann Alberts; Andrew Badley; Gustav Anton Decker; Stacey A Rizza; Rajarshi Banerjee; Amitava Banerjee,Perspectum; Great Western Hospitals NHS Foundation Trust; Mayo Clinic Healthcare; Alliance Medical; Mayo Clinic; Mayo Clinic International; Mayo Clinic; Perspectum; University College London,"BackgroundSevere acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) infection has disproportionately affected older individuals and those with underlying medical conditions. Research has focused on short-term outcomes in hospital, and single organ involvement. Consequently, impact of long COVID (persistent symptoms three months post-infection) across multiple organs in low-risk individuals is yet to be assessed.

MethodsAn ongoing prospective, longitudinal, two-centre, observational study was performed in individuals symptomatic after recovery from acute SARS-CoV-2 infection. Symptoms and organ function (heart, lungs, kidneys, liver, pancreas, spleen) were assessed by standardised questionnaires (EQ-5D-5L, Dyspnoea-12), blood investigations and quantitative magnetic resonance imaging, defining single and multi-organ impairment by consensus definitions.

FindingsBetween April and September 2020, 201 individuals (mean age 44 (SD 11.0) years, 70% female, 87% white, 31% healthcare workers) completed assessments following SARS-CoV-2 infection (median 140, IQR 105-160 days after initial symptoms). The prevalence of pre-existing conditions (obesity: 20%, hypertension: 6%; diabetes: 2%; heart disease: 4%) was low, and only 18% of individuals had been hospitalised with COVID-19. Fatigue (98%), muscle aches (88%), breathlessness (87%), and headaches (83%) were the most frequently reported symptoms. Ongoing cardiorespiratory (92%) and gastrointestinal (73%) symptoms were common, and 42% of individuals had ten or more symptoms.

There was evidence of mild organ impairment in heart (32%), lungs (33%), kidneys (12%), liver (10%), pancreas (17%), and spleen (6%). Single (66%) and multi-organ (25%) impairment was observed, and was significantly associated with risk of prior COVID-19 hospitalisation (p<0.05).

InterpretationIn a young, low-risk population with ongoing symptoms, almost 70% of individuals have impairment in one or more organs four months after initial symptoms of SARS-CoV-2 infection. There are implications not only for burden of long COVID but also public health approaches which have assumed low risk in young people with no comorbidities.

FundingThis work was supported by the UKs National Consortium of Intelligent Medical Imaging through the Industry Strategy Challenge Fund, Innovate UK Grant 104688, and also through the European Unions Horizon 2020 research and innovation programme under grant agreement No 719445.",health policy,fuzzy,100,100
medRxiv,10.1101/2020.10.12.20211342,2020-10-14,https://medrxiv.org/cgi/content/short/2020.10.12.20211342,Network Graph Representation of COVID-19 Scientific Publications to Aid Knowledge Discovery,George Cernile; Trevor Heritage; Neil Sebire; Ben Gordon; Taralyn Schwering; Shana Kazemlou; Yulia Borecki,Inspirata Ltd; Inspirata Ltd; HDRUK London UK; HDRUK London UK; Inspirata Ltd; Inspirata Ltd; Inspirata Ltd,"IntroductionNumerous scientific journal articles have been rapidly published related to COVID-19 making navigation and understanding of relationships difficult.

MethodsA graph network was constructed from the publicly available CORD-19 database of COVID-19-related publications using an engine leveraging medical knowledgebases to identify discrete medical concepts and an open source tool (Gephi) used to visualise the network.

ResultsThe network shows connections between disease, medication and procedures identified from title and abstracts of 195,958 COVID-19 related publications (CORD-19 Dataset). Connections between terms with few publications, those unconnected to the main network and those irrelevant were not displayed. Nodes were coloured by knowledgebase and node size related to the number of publications containing the term. The dataset and visualisations made publicly accessible via a webtool.

ConclusionKnowledge management approaches (text mining and graph networks) can effectively allow rapid navigation and exploration of entity interrelationships to improve understanding of diseases such as COVID-19.",health informatics,fuzzy,100,100
medRxiv,10.1101/2020.10.12.20211227,2020-10-14,https://medrxiv.org/cgi/content/short/2020.10.12.20211227,High and increasing prevalence of SARS-CoV-2 swab positivity in England during end September beginning October 2020: REACT-1 round 5 updated report,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E Walters; Haowei Wang; Christina J Atchison; Claudio Fronterre; Peter J Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health","BackgroundREACT-1 is quantifying prevalence of SARS-CoV-2 infection among random samples of the population in England based on PCR testing of self-administered nose and throat swabs. Here we report results from the fifth round of observations for swabs collected from the 18th September to 5th October 2020. This report updates and should be read alongside our round 5 interim report.

MethodsRepresentative samples of the population aged 5 years and over in England with sample size ranging from 120,000 to 175,000 people at each round. Prevalence of PCR-confirmed SARS-CoV-2 infection, estimation of reproduction number (R) and time trends between and within rounds using exponential growth or decay models.

Results175,000 volunteers tested across England between 18th September and 5th October. Findings show a national prevalence of 0.60% (95% confidence interval 0.55%, 0.71%) and doubling of the virus every 29 (17, 84) days in England corresponding to an estimated national R of 1.16 (1.05, 1.27). These results correspond to 1 in 170 people currently swab-positive for the virus and approximately 45,000 new infections each day. At regional level, the highest prevalence is in the North West, Yorkshire and The Humber and the North East with strongest regional growth in North West, Yorkshire and The Humber and West Midlands.

ConclusionRapid growth has led to high prevalence of SARS-CoV-2 virus in England, with highest rates in the North of England. Prevalence has increased in all age groups, including those at highest risk. Improved compliance with existing policy and, as necessary, additional interventions are required to control the spread of SARS-CoV-2 in the community and limit the numbers of hospital admissions and deaths from COVID-19.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.11.20210658,2020-10-14,https://medrxiv.org/cgi/content/short/2020.10.11.20210658,What is the evidence for transmission of COVID-19 by children in schools? A living systematic review,Wei Xu; Xue Li; Marshall Dozier; Yazhou He; Amir Kirolos; Zhongyu Lang; Catherine Mathews; Nandi Siegfried; Evropi Theodoratou,University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; South African Medical Research Council; South African Medical Research Council; University of Edinburgh,"BackgroundIt is of paramount importance to understand the transmission of SARS-CoV-2 in schools, which could support the decision-making about educational facilities closure or re-opening with effective prevention and control measures in place.

MethodsWe conducted a systematic review and meta-analysis to investigate the extent of SARS-CoV-2 transmission in schools. We performed risk of bias evaluation of all included studies using the Newcastle-Ottawa Scale (NOS).

Results2,178 articles were retrieved and 11 studies were included. Five cohort studies reported a combined 22 student and 21 staff index cases that exposed 3,345 contacts with 18 transmissions [overall infection attack rate (IAR): 0.08% (95% CI: 0.00%-0.86%)]. IARs for students and school staff were 0.15% (95% CI: 0.00%-0.93%) and 0.70% (95% CI: 0.00%-3.56%) respectively. Six cross-sectional studies reported 639 SARS-CoV-2 positive cases in 6,682 study participants tested [overall SARS-CoV-2 positivity rate: 8.00% (95% CI: 2.17%-16.95%)]. SARS-CoV-2 positivity rate was estimated to be 8.74% (95% CI: 2.34%-18.53%) among students, compared to 13.68% (95% CI: 1.68%-33.89%) among school staff. Gender differences were not found for secondary infection (OR: 1.44, 95% CI: 0.50-4.14, P= 0.49) and SARS-CoV-2 positivity (OR: 0.90, 95% CI: 0.72-1.13, P= 0.36) in schools. Fever, cough, dyspnea, ageusia, anosmia, rhinitis, sore throat, headache, myalgia, asthenia, and diarrhoea were all associated with the detection of SARS-CoV-2 antibodies (based on two studies). Overall, study quality was judged to be poor with risk of performance and attrition bias, limiting the confidence in the results.

ConclusionsThere is limited high-quality evidence available to quantify the extent of SARS-CoV-2 transmission in schools or to compare it to community transmission. Emerging evidence suggests lower IAR and SARS-CoV-2 positivity rate in students compared to school staff. Future prospective and adequately controlled cohort studies are necessary to confirm this finding.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.10.13.20211813,2020-10-14,https://medrxiv.org/cgi/content/short/2020.10.13.20211813,"Precautionary breaks: planned, limited duration circuit breaks to control the prevalence of COVID-19",Matt J Keeling; Glen Guyver-Fletcher; Alexander Holmes; Louise J Dyson; Michael Tildesley; Edward M Hill; Graham F Medley,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; London School of Hygiene and Tropical Medicine,"The COVID-19 pandemic in the UK has been characterised by periods of exponential growth and decline, as different non-pharmaceutical interventions (NPIs) are brought into play. During the early uncontrolled phase of the outbreak (early March 2020) there was a period of prolonged exponential growth with epidemiological observations such as hospitalisation doubling every 3-4 days (growth rate r {approx} 0.2). The enforcement of strict lockdown measures led to a noticeable decline in all epidemic quantities (r {approx} -0.06) that slowed during the summer as control measures were relaxed (r {approx} -0.02). Since August, infections, hospitalisations and deaths have been rising (precise estimation of the current growth rate is difficult due to extreme regional heterogeneity and temporal lags between the different epidemiological observations) and various NPIs have been applied locally throughout the UK in response.

Controlling any rise in infection is a compromise between public health and societal costs, with more stringent NPIs reducing cases but damaging the economy and restricting freedoms. Currently, NPI imposition is made in response to the epidemiological state, are of indefinite length and are often imposed at short notice, greatly increasing the negative impact. An alternative approach is to consider planned, limited duration periods of strict NPIs aiming to purposefully reduce prevalence before such emergency NPIs are required. These ""precautionary breaks"" may offer a means of keeping control of the epidemic, while their fixed duration and the forewarning may limit their society impact. Here, using simple analysis and age-structured models matched to the unfolding UK epidemic, we investigate the action of precautionary breaks. In particular we consider their impact on the prevalence of infection, as well as the total number of predicted hospitalisations and deaths. We find that precautionary breaks provide the biggest gains when the growth rate is low, but offer a much needed brake on increasing infection when the growth rate is higher, potentially allowing other measures (such as contact tracing) to regain control.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.10.11.20210625,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.11.20210625,Mental health service activity during COVID-19 lockdown among individuals with learning disabilities: South London and Maudsley data on services and mortality from January to July 2020,Evangelia Martin; Eleanor Nuzum; Matthew Broadbent; Robert Stewart,King's College London; King's College London; South London and Maudsley NHS Foundation Trust; King's College London,"The lockdown and social distancing policy imposed due to the COVID-19 pandemic is likely to have had a widespread impact on mental healthcare service provision and use. Previous reports from the South London and Maudsley NHS Trust (SLaM; a large mental health service provider for 1.2m residents in South London) highlighted a shift to virtual contacts among those accessing community mental health and home treatment teams and an increase in deaths over the pandemics first wave. However, there is a need to quantify this for individuals with particular vulnerabilities, including those with learning disabilities and other neurodevelopmental disorders. Taking advantage of the Clinical Record Interactive Search (CRIS) data resource with 24-hourly updates of electronic mental health records data, this paper describes daily caseloads and contact numbers (face-to-face and virtual) for individuals with potential neurodevelopmental disorders across community, specialist, crisis and inpatient services. The report focussed on the period 1st January to 31st July 2020. We also report on daily accepted and discharged trust referrals, total trust caseloads and daily inpatient admissions and discharges for individuals with potential neurodevelopmental disorders. In addition, daily deaths are described for all current and previous SLaM service users with potential neurodevelopmental disorders over this period. In summary, comparing periods before and after 16th March 2020 there was a shift from face-to-face contacts to virtual contacts across all teams. The largest declines in caseloads and total contacts were seen in Home Treatment Team, Liaison/A&E and Older Adult teams. Reduced accepted referrals and inpatient admissions were observed and there was an 103% increase in average daily deaths in the period after 16th March, compared to the period 1st January to 15th March (or a 282% increase if the 2-month period from 16th March to 15th May was considered alone).",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.10.08.20209411,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.08.20209411,"Elevated antiviral, myeloid and endothelial inflammatory markers in severe COVID-19",Ryan Thwaites; Ashley Sanchez Sevilla Uruchurtu; Matthew Siggins; Felicity Liew; Clark D Russell; Shona Moore; Edwin Carter; Simon Abrams; Charlotte-Eve Short; Thilipan Thaventhiran; Emma Bergstrom; Zoe Gardener; Stephanie Ascough; Christopher Chiu; Annemarie B Docherty; David Hunt; Yanick Crow; Tom Solomon; Graham Taylor; Lance Turtle; Ewen M Harrison; Malcolm Gracie Semple; J Kenneth Baillie; Peter JM Openshaw,"Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of Edinburgh; University of Liverpool; University of Edinburgh; University of Liverpool; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Liverpool; Imperial College London; University ofLiverpool; University of Edinburgh; University of Liverpool; Roslin Institute, University of Edinburgh; Imperial College London","Introductory paragraphThe mechanisms that underpin COVID-19 disease severity, and determine the outcome of infection, are only beginning to be unraveled. The host inflammatory response contributes to lung injury, but circulating mediators levels fall below those in classical  cytokine storms. We analyzed serial plasma samples from 619 patients hospitalized with COVID-19 recruited through the prospective multicenter ISARIC clinical characterization protocol U.K. study and 39 milder community cases not requiring hospitalization. Elevated levels of numerous mediators including angiopoietin-2, CXCL10, and GM-CSF were seen at recruitment in patients who later died. Markers of endothelial injury (angiopoietin-2 and von-Willebrand factor A2) were detected early in some patients, while inflammatory cytokines and markers of lung injury persisted for several weeks in fatal COVID-19 despite decreasing antiviral cytokine levels. Overall, markers of myeloid or endothelial cell activation were associated with severe, progressive, and fatal disease indicating a central role for innate immune activation and vascular inflammation in COVID-19.",infectious diseases,fuzzy,91,100
medRxiv,10.1101/2020.10.09.20209957,2020-10-13,https://medrxiv.org/cgi/content/short/2020.10.09.20209957,Development and validation of the 4C Deterioration model for adults hospitalised with COVID-19,Rishi K Gupta; Ewen M Harrison; Antonia Ho; Annemarie B Docherty; Stephen R Knight; Maarten van Smeden; Ibrahim Abubakar; Marc Lipman; Matteo Quartagno; Riinu B Pius; Iain Buchan; Gail Carson; Thomas M Drake; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter Horby; Clare Jackson; Kenneth McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Piero L Olliaro; Mark G Pritchard; Clark D Russell; James Scott-Brown; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie LM Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Mahdad Noursadeghi,"University College London; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; Medical Research Council University of Glasgow Centre for Virus Research, Glasgow, UK; University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Institute for Global Health, University College London, Gower Street, London, WC1E 6BT; UCL Respiratory, Division of Medicine, University College London, London, UK; MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK; University of Edinburgh; Institute of Population Health Sciences, University of Liverpool; University of Oxford; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; University of Liverpool; Institute of Microbiology & Infection, University of Birmingham; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; University of Liverpool; University of Liverpool; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; University of Liverpool; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; University of Oxford; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; University of Edinburgh; University of Oxford; University of Oxford; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; School of Informatics, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; University of Edinburgh; Department of Child Life and Health, University of Edinburgh, UK; Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT","Prognostic models to predict the risk of clinical deterioration in acute COVID-19 are required to inform clinical management decisions. Among 75,016 consecutive adults across England, Scotland and Wales prospectively recruited to the ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) study, we developed and validated a multivariable logistic regression model for in-hospital clinical deterioration (defined as any requirement of ventilatory support or critical care, or death) using 11 routinely measured variables. We used internal-external cross-validation to show consistent measures of discrimination, calibration and clinical utility across eight geographical regions. We further validated the final model in held-out data from 8,252 individuals in London, with similarly consistent performance (C-statistic 0.77 (95% CI 0.75 to 0.78); calibration-in-the-large 0.01 (-0.04 to 0.06); calibration slope 0.96 (0.90 to 1.02)). Importantly, this model demonstrated higher net benefit than using other candidate scores to inform decision-making. Our 4C Deterioration model thus demonstrates unprecedented clinical utility and generalisability to predict clinical deterioration among adults hospitalised with COVID-19.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.08.20209304,2020-10-12,https://medrxiv.org/cgi/content/short/2020.10.08.20209304,Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: a matched cohort study using linked English electronic health records data,Helena Carreira; Helen Strongman; Maria Peppa; Helen I McDonald; Isabel dos-Santos-Silva; Susannah Stanway; Liam Smeeth; Krishnan Bhaskaran,"London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; NIHR Health Protection Research Unit in Immunisation; London School of Medicine and Tropical Medicine, NIHR Health Protection Research Unit in Immunisation; London School of Hygiene and Tropical Medicine; The Royal Marsden NHS Foundation Trust; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine","BackgroundPeople with active cancer are recognised as at risk of COVID-19 complications, but it is unclear whether the much larger population of cancer survivors is at elevated risk. We aimed to address this by comparing cancer survivors and cancer-free controls for (i) prevalence of comorbidities considered risk factors for COVID-19; and (ii) risk of severe influenza, as a marker of susceptibility to severe outcomes from epidemic respiratory viruses.

MethodsWe included survivors ([&ge;]1 year) of the 20 most common cancers, and age, sex and general practice-matched cancer-free controls, derived from UK primary care data linked to cancer registrations, hospital admissions and death registrations. Comorbidity prevalences were calculated 1 and 5 years from cancer diagnosis. Risk of hospitalisation or death due to influenza was compared using Cox models adjusted for baseline demographics and comorbidities.

Findings108,215 cancer survivors and 523,541 cancer-free controls were included. Cancer survivors had more asthma, other respiratory, cardiac, diabetes, neurological, renal, and liver disease, and less obesity, compared with controls, but there was variation by cancer site. There were 205 influenza hospitalisations/deaths, with cancer survivors at higher risk than controls (adjusted HR 2.78, 95% CI 2.04-3.80). Haematological cancer survivors had large elevated risks persisting for >10 years (HR overall 15.17, 7.84-29.35; HR >10 years from cancer diagnosis 10.06, 2.47-40.93). Survivors of other cancers had evidence of raised risk up to 5 years from cancer diagnosis only (HR 2.22, 1.31-3.74).

InterpretationRisks of severe COVID-19 outcomes are likely to be elevated in cancer survivors. This should be taken into account in policies targeted at clinical risk groups, and vaccination for both influenza, and, when available, COVID-19, should be encouraged in cancer survivors.

FundingWellcome Trust, Royal Society, NIHR.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSFew data are available to date on how COVID-19 affects cancer survivors. We searched PubMed with the keywords ""influenza cancer survivors"" to identify studies that compared severe influenza outcomes in cancer survivors and in a control group. No study was identified.

Added value of this studyIn this matched cohort study of routinely collected electronic health records, we demonstrated raised risks of influenza hospitalisation or mortality in survivors from haematological malignancies for >10 years after diagnosis, and in survivors from solid cancers up to 5 years after diagnosis.

Implications of all the available evidenceCancer survivorship appears to be an important risk factor for severe influenza outcomes, suggesting that cancer survivors may also be at raised risk of poor COVID-19 outcomes. This should be taken into account in public health policies targeted at protecting clinical risk groups. Influenza vaccination should be encouraged in this group, and may need to be extended to a wider population of medium- to long-term cancer survivors than currently recommended.",oncology,fuzzy,100,100
bioRxiv,10.1101/2020.10.10.331348,2020-10-11,https://biorxiv.org/cgi/content/short/2020.10.10.331348,Single-dose intranasal administration of AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 in mice,Rodney G. King; Aaron Silva-Sanchez; Jessica N. Peel; Davide Botta; Selene Meza-Perez; Rameeza Allie; Michael D. Schultz; Mingyong Liu; John E. Bradley; Shihong Qiu; Guang Yang; Fen Zhou; Esther Zumaquero; Thomas S. Simpler; Betty Mousseau; John T. Killian Jr.; Brittany Dean; Qiao Shang; Jennifer L. Tipper; Christopher Risley; Kevin S. Harrod; Ray Feng; Young Lee; Bethlehem Shiberu; Vyjayanthi Krishnan; Isabelle Peguillet; Jianfeng Zhang; Todd Green; Troy D. Randall; Bertrand Georges; Frances E Lund; Scot Roberts,"University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; University of Alabama at Birmingham; Altimmune Inc.; Altimmune Inc.; Altimmune Inc.; Altimmune Inc.; Altimmune Inc.; Altimmune Inc.; University of Alabama at Birmingham; University of Alabama at Birmingham; Altimmune, Inc.; University of Alabama at Birmingham; Altimmune Inc.","The coronavirus disease 2019 (COVID-19) pandemic has highlighted the urgent need for effective preventive vaccination to reduce burden and spread of severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) in humans. Intranasal vaccination is an attractive strategy to prevent COVID-19 as the nasal mucosa represents the first-line barrier to SARS-CoV-2 entry before viral spread to the lung. Although SARS-CoV-2 vaccine development is rapidly progressing, the current intramuscular vaccines are designed to elicit systemic immunity without conferring mucosal immunity. Here, we show that AdCOVID, an intranasal adenovirus type 5 (Ad5)-vectored vaccine encoding the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, elicits a strong and focused immune response against RBD through the induction of mucosal IgA, serum neutralizing antibodies and CD4+ and CD8+ T cells with a Th1-like cytokine expression profile. Therefore, AdCOVID, which promotes concomitant systemic and local mucosal immunity, represents a promising COVID-19 vaccine candidate.",immunology,fuzzy,100,92
medRxiv,10.1101/2020.10.07.20208918,2020-10-09,https://medrxiv.org/cgi/content/short/2020.10.07.20208918,Cardiovascular drugs and COVID-19 clinical outcomes: a living systematic review and meta-analysis,Innocent Gerald Asiimwe; Sudeep Pushpakom; Richard Turner; Ruwanthi Kolamunnage-Dona; Andrea Jorgensen; Munir Pirmohamed,University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool,"OBJECTIVETo continually evaluate the rapidly evolving evidence base on the role of cardiovascular drugs in COVID-19 clinical outcomes (susceptibility to infection, hospitalization, hospitalization length, disease severity, and all-cause mortality).

DESIGNLiving systematic review and meta-analysis.

DATA SOURCESEligible publications identified from >500 databases indexed through 31st July 2020 and additional studies from reference lists, with planned continual surveillance for at least two years.

STUDY SELECTIONObservational and interventional studies that report on the association between cardiovascular drugs and COVID-19 clinical outcomes.

DATA EXTRACTIONSingle-reviewer extraction and quality evaluation (using ROBINS-I), with half the records independently extracted and evaluated by a second reviewer.

RESULTSOf 23,427 titles screened, 175 studies were included in the quantitative synthesis. The most reported drug classes were angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) with ACEI/ARB exposure being associated with higher odds of testing positive for COVID-19 (pooled unadjusted OR 1.15, 95% CI 1.02 to 1.30). Among patients with COVID-19, unadjusted estimates showed that ACEI/ARB exposure was associated with being hospitalized (OR 2.25, 1.70 to 2.98) and having severe disease (OR 1.50, 1.27 to 1.77) but not with the length of hospitalization (mean difference -0.45, -1.33 to 0.43 days) or all-cause mortality (OR 1.25, CI 0.98 to 1.58). However, after adjustment, ACEI/ARB exposure was not associated with testing positive for COVID-19 (pooled adjusted OR 1.01, 0.93 to 1.10), being hospitalized (OR 1.16, 0.80 to 1.68), having severe disease (1.04, 0.76 to 1.42), or all-cause mortality (0.86, 0.64 to 1.15). Similarly, subgroup analyses involving only hypertensive patients revealed that ACEI/ARB exposure was not associated with being hospitalized (OR 0.84, 0.58 to 1.22), disease severity (OR 0.88, 0.68 to 1.14) or all-cause mortality (OR 0.77, 0.54 to 1.12) while it decreased the length of hospitalization (mean difference -0.71, -1.11 to -0.30 days). After adjusting for relevant covariates, other cardiovascular drug classes were mostly not found to be associated with poor COVID-19 clinical outcomes. However, the validity of these findings is limited by a high level of heterogeneity in terms of effect sizes and a serious risk of bias, mainly due to confounding in the included studies.

CONCLUSIONOur comprehensive review shows that ACEI/ARB exposure is associated with COVID-19 outcomes such as susceptibility to infection, severity, and hospitalization in unadjusted analyses. However, after adjusting for potential confounding factors, this association is not evident. Patients on cardiovascular drugs should continue taking their medications as currently recommended. Higher quality evidence in the form of randomized controlled trials will be needed to determine any adverse or beneficial effects of cardiovascular drugs.

PRIMARY FUNDING SOURCENone

SYSTEMATIC REVIEW REGISTRATIONPROSPERO (CRD42020191283)",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.03.20206375,2020-10-06,https://medrxiv.org/cgi/content/short/2020.10.03.20206375,"Renin Angiotensin System Inhibition and Susceptibility and Outcomes from COVID-19: A Systematic Review and Meta-analysis of 69,200 COVID-19 Patients",Yi Zhang; Shikai Yu; Yawei Xu; Bryan Williams,"Shanghai Tenth Peoples Hospital; Shanghai Tenth People's Hospital, Tongji University School of Medicine; Shanghai Tenth People Hospital; University College London","BackgroundEarly observational studies suggested that the use of the renin angiotensin system (RAS) inhibitors, specifically angiotensin converting enzyme inhibitors or angiotensin receptor blockers, may increase the risk of infection with SARS-CoV-2 and adversely affect the prognosis or survival of infected patients. To explore the impact of RAS inhibitor use on the risk of SARS-CoV-2 infection and the prognosis of SARS-CoV-2 infected patients, from all published studies.

Methods and FindingsA systematic review and meta-analysis of the use of RAS inhibitors in relation to infection with SARS-CoV-2 and/or the severity and mortality associated with COVID-19 was conducted. English language bibliographic databases PubMed, Web of Science, OVID Embase, Scopus, MedRxiv, BioRxiv, searched from Jan 1st, 2020 to July 20th, 2020. 58 observational studies (69,200 COVID-19 patients and 3,103,335 controls) were included. There was no difference in the susceptibility to SARS-CoV-2 infection between RAS inhibitor users and non-users (unadjusted OR 1.05, 95% CI 0.90 to 1.21), (adjusted OR 0.93, 95% CI 0.85 to 1.02), (adjusted HR 1.07, 95% CI 0.87 to 1.31). There was no significant difference in the severe Covid-19 case rate between RAS inhibitor users and non-users (unadjusted OR 1.05, 95% CI 0.81 to 1.36), (adjusted OR 0.76, 95% CI 0.52 to 1.12), or in mortality due to COVID-19 between RAS inhibitor users and non-users (unadjusted OR 1.12, 95% CI 0.88 to 1.44), (adjusted OR 0.97, 95% CI 0.77 to 1.23), (adjusted HR 0.62, 95% CI 0.34 to 1.14).

ConclusionsIn the most comprehensive analysis of all available data to date, treatment with RAS inhibitors was not associated with increased risk of infection, severity of disease, or mortality due to COVID-19. The best available evidence suggests that these treatments should not be discontinued on the basis of concern about risk associated with COVID-19.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.10.03.20206284,2020-10-06,https://medrxiv.org/cgi/content/short/2020.10.03.20206284,The excess insulin requirement in severe COVID-19 compared to non-COVID-19 viral pneumonitis is related to the severity of respiratory failure and pre-existing diabetes.,Sam Lockhart; Harry Griffiths; Bogdan Petrisor; Ammara Usman; Julia Calvo-Latorre; Laura Heales; Vishakha Bansiya; Razeen Mahroof; Andrew Conway Morris,"1.	MRC Metabolic Diseases Unit, Wellcome Trust-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, UK.; John V Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge; John V Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge; John V Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge; Wolfson Diabetes and Endocrinology Clinic, Cambridge University Hospital NHS Foundation Trust, Cambridge; John V Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge; Wolfson Diabetes and Endocrinology Clinic, Cambridge University Hospital NHS Foundation Trust, Cambridge; John V Farman Intensive Care Unit, Addenbrookes Hospital, Cambridge; University of Cambridge","ObjectiveSevere COVID-19 has been anecdotally associated with high insulin requirements. It has been proposed that this may be driven by a direct diabetogenic effect of the virus that is unique to SARS-CoV-2, but evidence to support this is limited. To explore this, we compared insulin requirements in patients with severe COVID-19 and non-COVID-19 viral pneumonitis.

Research DesignRetrospective cohort study of patients with severe COVID-19 admitted to our intensive care unit between March and June 2020. A historical control cohort of non-COVID-19 viral pneumonitis patients was identified from routinely collected audit data.

ResultsInsulin requirements were similar in patients with COVID-19 and non-COVID-19 viral pneumonitis after adjustment for pre-existing diabetes and severity of respiratory failure.

ConclusionsIn this single center study, we could not find evidence of a unique diabetogenic effect of COVID-19. We suggest that high insulin requirements in this disease relate to its propensity to cause severe respiratory failure in patients with pre-existing metabolic disease.",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2020.10.02.20205591,2020-10-04,https://medrxiv.org/cgi/content/short/2020.10.02.20205591,Risk factors associated with SARS-CoV-2 infection and outbreaks in Long Term Care Facilities in England: a national survey,Laura Shallcross; Danielle Burke; Owen Abbott; Alasdair Donaldson; Gemma Hallatt; Andrew Hayward; Susan Hopkins; Maria Krutikov; Katie Sharp; Leone Wardman; Sapphira Thorne,UCL; Office for National Statistics; Office for National Statistics; UK Department of Health and Social Care; Palantir; UCL; Public Health England; UCL; Office for National Statistics; Office for National Statistics; Office for National Statistics,"BackgroundOutbreaks of SARS-CoV-2 have occurred worldwide in Long Term Care Facilities (LTCFs), but the reasons why some facilities are particularly vulnerable to infection are poorly understood. We aimed to identify risk factors for SARS-CoV-2 infection and outbreaks in LTCFs.

MethodsCross-sectional survey of all LTCFs providing dementia care or care to adults >65 years in England with linkage to SARS-CoV-2 test results. Exposures included: LTCF characteristics, staffing factors, and use of disease control measures. Main outcomes included risk factors for infection and outbreaks, estimated using multivariable logistic regression, and survey and test-based weighted estimates of SARS-CoV-2 prevalence.

Findings5126/9081 (56%) LTCFs participated in the survey, with 160,033 residents and 248,594 staff. The weighted period prevalence of infection in residents and staff respectively was 10.5% (95% CI: 9.9-11.1%) and 3.8% (95%: 3.4-4.2%) and 2724 LTCFs (53.1%) had [&ge;]1 infection. Odds of infection and/or outbreaks were reduced in LTCFs that paid sickness pay, cohorted staff, did not employ agency staff and had higher staff to resident ratios. Higher odds of infection and outbreaks were identified in facilities with more admissions, lower cleaning frequency, poor compliance with isolation and ""for profit"" status.

InterpretationHalf of LTCFs had no cases suggesting they remain vulnerable to outbreaks. Reducing transmission from staff requires adequate sick pay, minimal use of temporary staff, improved staffing ratios and staff cohorting. Transmission from residents is associated with the number of admissions to the facility and poor compliance with isolation.

FundingUK Government Department of Health & Social Care

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSCOVID-19 outbreaks have occurred worldwide in long-term care facilities (LTCFs), which provide care to elderly and vulnerable residents, and are associated with high mortality. The reasons why LTCFs are particularly vulnerable to COVID-19 are poorly understood. Most studies of risk factors for COVID-19 to date have been limited by scale, and poor quality administrative, demographic and infection control data. We conducted a systematic search on 27 July 2020 in MEDLINE Ovid, WHO COVID-19 database and in MedRxiv to identify studies reporting risk factors for COVID-19 infection or outbreaks in LTCFs, with no date or language restrictions. We used the search terms ""COVID-19"", ""SARS-CoV-2"", ""coronavirus"" and ""care home"", ""nursing home"", ""long term care facilit"" and excluded studies that did not investigate LTCF-level risk factors. 14 studies met our inclusion criteria comprising 11 cross-sectional studies and 3 surveys. The largest cross-sectional study was conducted in 9395 specialised nursing facilities across 30 states in USA; the largest survey was conducted in 124 LTCFs in Haute-Garrone region of France. Risk of bias was high across all studies, and results could not be pooled due to heterogeneity between studies. Main risk factors for infection and/or outbreaks related to the size of the facility, lower ratios of staff to residents, urban location, higher occupancy, and the community prevalence of infection. Only one study collected data on the use of disease control measures during the pandemic, and no studies provided data on risk factors such as the use of temporary staff, or the impact of staff working across multiple locations.

Added value of this studyWe conducted a national telephone survey with managers of all LTCFs in England which provided dementia care or care to residents aged > 65 years to collect data on the number of staff and residents in each facility, confirmed SARS-CoV-2 infections, characteristics of the facility e.g.size, staffing (use of temporary staff, staffing ratios, sickness pay) and disease control measures such as cohorting and isolation. We identified risk factors for infection in residents and staff, outbreaks (defined as [&ge;]1 case per LTCF) and large outbreaks using logistic regression. We also estimated the proportion of staff and residents who had been infected with SARS-CoV-2. Responses were obtained from 5126 of out 9081 (56%) of eligible LTCFs. To our knowledge, this is the largest and most detailed survey of risk factors for SARS-CoV-2 infection and outbreaks that has been conducted in LTCFs.

Implications of all the available evidenceAlmost half of LTCFs surveyed in this study did not report any cases of infection, and remain vulnerable to infection and outbreaks, highlighting the need for effective control measures. Reducing transmission from staff requires adequate sick pay, minimal use of temporary staff, improved staffing ratios and staff cohorting. Transmission from residents is associated with the number of admissions to the facility and poor compliance with control measures such as isolation.",geriatric medicine,fuzzy,100,100
medRxiv,10.1101/2020.09.30.20204727,2020-10-02,https://medrxiv.org/cgi/content/short/2020.09.30.20204727,High prevalence of SARS-CoV-2 swab positivity in England during September 2020: interim report of round 5 of REACT-1 study,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E. Walters; Haowei Wang; Christina J Atchison; Claudio Fronterre; Peter J. Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health","BackgroundREACT-1 is a community survey of PCR confirmed swab-positivity for SARS-CoV-2 among random samples of the population in England. This interim report includes data from the fifth round of data collection currently underway for swabs sampled from the 18th to 26th September 2020.

MethodsRepeated cross-sectional surveys of random samples of the population aged 5 years and over in England with sample size ranging from 120,000 to 160,000 people in each round of data collection. Collection of self-administered nose and throat swab for PCR and questionnaire data. Prevalence of swab-positivity by round and by demographic variables including age, sex, region, ethnicity. Estimation of reproduction number (R) between and within rounds, and time trends using exponential growth or decay model. Assessment of geographical clustering based on boundary-free spatial model.

ResultsOver the 9 days for which data are available, we find 363 positives from 84,610 samples giving a weighted prevalence to date of 0.55% (0.47%, 0.64%) in round 5. This implies that 411,000 (351,000, 478,000) people in England are virus-positive under the assumption that the swab assay is 75% sensitive. Using data from the most recent two rounds, we estimate a doubling time of 10.6 (9.4, 12.0) days covering the period 20th August to 26th September, corresponding to a reproduction number R of 1.47 (1.40, 1.53). Using data only from round 5 we estimate a reproduction number of 1.06 (0.74, 1.46) with probability of 63% that R is greater than 1. Between rounds 4 and 5 there was a marked increase in unweighted prevalence at all ages. In the most recent data, prevalence was highest in the 18 to 24 yrs age group at 0.96% (0.68%, 1.36%). At 65+ yrs prevalence increased [~]7-fold between rounds 4 and 5 from 0.04% (0.03%, 0.07%) to 0.29% (0.23%, 0.37%). Prevalence increased in all regions between rounds 4 and 5, giving the highest unweighted prevalence in round 5 in the North West at 0.86% (0.69%, 1.06%). In London, prevalence increased [~]5-fold from 0.10% (0.06%, 0.17%) to 0.49% (0.36%, 0.68%). Regional R values ranged from 1.32 (1.16,1.50) in Yorkshire and the Humber to 1.63 (1.42, 1.88) in the East Midlands over the same period. In the most recent data, there was extensive clustering in the North West, Midlands and in and around London with pockets of clustering in other regions including the South West, North East and East of England. Odds of swab-positivity were [~]2-fold higher in people of Asian and Black ethnicity compared with white participants.

ConclusionRapid growth has led to high prevalence of SARS-CoV-2 virus in England among all regions and age groups, including those age groups at highest risk. Although there is evidence of a recent deceleration in the epidemic, current levels of prevalence will inevitably result in additional hospitalisations and mortality in coming weeks. A re-doubling of public health efforts is needed to return to a declining phase of the epidemic.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.09.28.20202929,2020-09-29,https://medrxiv.org/cgi/content/short/2020.09.28.20202929,T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses,Ane Ogbe; Barbara Kronsteiner; Donal T Skelly; Matthew Pace; Anthony Brown; Emily Adland; Kareena Adair; Hossain Delowar Akhter; Mohammad Ali; Serat-E Ali; Adrienn Angyal; M. Azim Ansari; Carolina V Arancibia-Carcamo; Helen Brown; Senthil Chinnakannan; Christopher P Conlon; Catherine de Lara; Thushan de Silva; Christina Dold; Tao Dong Dong; Timothy Donnison; David W Eyre; Amy Flaxman; Helen A Fletcher; Joshua Gardner; James T Grist; Carl-Philipp Hackstein; Kanoot Jaruthamsophon; Katie Jeffrey; Teresa Lambe; Lian Lee; Wenqin Li; Nicholas Lim; Philippa C Matthews; Alexander J Mentzer; Shona C Moore; Dean J Naisbitt; Monday Ogese; Graham Ogg; Peter Openshaw; Munir Pirmohamed; Andrew J Pollard; Narayan Ramamurthy; Patpong Rongkard; Sarah Rowland-Jones; Oliver L Sampson; Gavin Screaton; Alessandro Sette; Lizzie Stafford; Craig Thompson; Paul J Thomson; Ryan Thwaites; Vinicius Vieira; Daniela Weiskopf; Panagiota Zacharopoulou; - Oxford Immunology Network Covid-19 Response T cell Consortium; - Oxford Protective T cell Immunology for COVID-19 (OPTIC) Clinical team; Lance Turtle; Paul Klenerman; Philip Goulder; John Frater; Eleanor Barnes; Susanna Dunachie,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Liverpool; University of Oxford; University of Oxford; University of Liverpool; University of Sheffield; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Sheffield; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Liverpool; University of Oxford; University of Oxford; University of Liverpool; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Liverpool; University of Liverpool; University of Liverpool; University of Oxford; Imperial College; University of Liverpool; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; La Jolla Institute for Immunology; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Liverpool; Imperial College; University of Oxford; La Jolla Institute for Immunology; University of Oxford; ; ; University of Liverpool; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford,"A major issue in identification of protective T cell responses against SARS-CoV-2 lies in distinguishing people infected with SARS-CoV-2 from those with cross-reactive immunity generated by exposure to other coronaviruses. We characterised SARS-CoV-2 T cell immune responses in 168 PCR-confirmed SARS-CoV-2 infected subjects and 118 seronegative subjects without known SARS-CoV-2 exposure using a range of T cell assays that differentially capture immune cell function. Strong ex vivo ELISpot and proliferation responses to multiple antigens (including M, NP and ORF3) were found in those who had been infected by SARS-CoV-2 but were rare in pre-pandemic and unexposed seronegative subjects. However, seronegative doctors with high occupational exposure and recent COVID-19 compatible illness showed patterns of T cell responses characteristic of infection, indicating that these readouts are highly sensitive. By contrast, over 90% of convalescent or unexposed people showed proliferation and cellular lactate responses to spike subunits S1/S2, indicating pre-existing cross-reactive T cell populations. The detection of T cell responses to SARS-CoV-2 is therefore critically dependent on the choice of assay and antigen. Memory responses to specific non-spike proteins provides a method to distinguish recent infection from pre-existing immunity in exposed populations.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.09.26.20202150,2020-09-28,https://medrxiv.org/cgi/content/short/2020.09.26.20202150,Comparison of mental health service activity before and shortly after UK social distancing responses to the COVID-19 pandemic: February-March 2020,Robert Stewart; Evangelia Martin; Ioannis Bakolis; Matthew Broadbent; Nicola Byrne; Sabine Landau,King's College London; South London and Maudsley NHS Foundation Trust; King's College London; King's College London; South London and Maudsley NHS Foundation Trust; King's College London,"This study sought to provide an early description of mental health service activity before and after national implementation of social distancing for COVID-19. A time series analysis was carried out of daily service-level activity on data from a large mental healthcare provider in southeast London, from 01.02.2020 to 31.03.2020, comparing activity before and after 16.03.2020: i) inpatient admissions, discharges and numbers, ii) contact numbers and daily caseloads (Liaison, Home Treatment Teams, Community Mental Health Teams); iii) numbers of deaths for past and present patients. Daily face-to-face contact numbers fell for liaison, home treatment and community services with incomplete compensatory rises in non-face-to-face contacts. Daily caseloads fell for all services, apart from working age and child/adolescent community teams. Inpatient numbers fell 13.6% after 16th March, and daily numbers of deaths increased by 61.8%.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.09.25.20201731,2020-09-27,https://medrxiv.org/cgi/content/short/2020.09.25.20201731,Antihypertensive Medications and COVID-19 Diagnosis and Mortality: Population-based Case-Control Analysis in the United Kingdom,Emma Rezel-Potts; Abdel Douiri; Phil J Chowienczyk; Martin C Gulliford,King's College London; King's College London; King's College London; King's College London,"ObjectivesTo evaluate antihypertensive medications and COVID-19 diagnosis and mortality, accounting for healthcare seeking behaviour.

DesignA population-based case control study with additional cohort analysis.

SettingPrimary care patients from the UK Clinical Practice Research Datalink (CPRD).

Participants16 866 patients with COVID-19 events in the CPRD from 29th January to June 25th 2020 and 70 137 matched controls.

Main outcome measuresWe explored associations between COVID-19 diagnosis and prescriptions for angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta-blockers (B), calcium-channel blockers (C), thiazide diuretics (D) and other antihypertensive drugs (O). We evaluated all-cause mortality among COVID-19 cases. Analyses were adjusted for covariates and consultation frequency.

ResultsIn covariate adjusted analyses, ACEIs were associated with lower odds of COVID-19 diagnosis (0.82, 95% confidence interval 0.77 to 0.88) as were ARBs, 0.87 (0.80 to 0.95) with little attenuation from adjustment for consultation frequency. In fully adjusted analyses, C and D were also associated with lower odds of COVID-19. Increased odds of COVID-19 for B (1.19, 1.12 to 1.26), were attenuated after adjustment for consultation frequency (1.01, 0.95 to 1.08). In adjusted analyses, patients treated with ACEIs or ARBs had similar mortality to patients treated with classes B, C, D or O (1.00, 0.83 to 1.20) or patients receiving no antihypertensive therapy (0.99, 0.83 to 1.18).

ConclusionsAssociations were sensitive to adjustment for confounding and healthcare seeking, but there was no evidence that antihypertensive therapy is associated with increased risk of COVID-19 diagnosis or mortality; most classes of antihypertensive therapy showed negative associations with COVID-19 diagnosis.",primary care research,fuzzy,100,100
medRxiv,10.1101/2020.09.24.20200048,2020-09-25,https://medrxiv.org/cgi/content/short/2020.09.24.20200048,Genetic mechanisms of critical illness in Covid-19,Erola Pairo-Castineira; Sara Clohisey; Lucija Klaric; Andrew Bretherick; Konrad Rawlik; Nicholas Parkinson; Dorota Pasko; Susan Walker; Anne Richmond; Max Head Fourman; Andy Law; James Furniss; Elvina Gountouna; Nicola Wrobel; Clark D Russell; Loukas Moutsianas; Bo Wang; Alison Meynert; Zhijian Yang; Ranran Zhai; Chenqing Zheng; Fiona Griffith; Wilna Oosthuyzen; Barbara Shih; Se√°n Keating; Marie Zechner; Chris Haley; David J Porteous; Caroline Hayward; Julian Knight; Charlotte Summers; Manu Shankar-Hari; Lance Turtle; Antonia Ho; Charles Hinds; Peter Horby; Alistair Nichol; David Maslove; Lowell Ling; Paul Klenerman; Danny McAuley; Hugh Montgomery; Timothy Walsh; - The GenOMICC Investigators; - The ISARIC4C Investigators; - The Covid-19 Human Genetics Initiative; Xia Shen; Kathy Rowan; Angie Fawkes; Lee Murphy; Chris P Ponting; Albert Tenesa; Mark Caulfield; Richard Scott; Peter JM Openshaw; Malcolm G Semple; Veronique Vitart; James F Wilson; J Kenneth Baillie,"Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; The Roslin Institute; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; Genomics England; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; University of Edinburgh Centre for Inflammation Research, The Queen's Medical Research Institute, Edinburgh, UK; Genomics England; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Biostatistics Group, School of Life Sciences, Sun Yat-sen University, Guangzhou, China.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinb; Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK.; Department of Medicine, University of Cambridge, Cambridge, UK.; Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London, UK; School of Immunology and Microbial Sciences, King's College London; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, L; MRC-University of Glasgow Centre for Virus Research, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, Univer; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK.; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ, UK.; Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin, Ireland; Australian and New Zealand Intensive Care Research Cen; Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre, Kingston, ON, Canada.; Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China.; University of Oxford; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, Northern Ireland, UK; Department of Intensive Care Medicine, Royal Vi; UCL Centre for Human Health and Performance, London, W1T 7HA, UK.; Intenstive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA, UK.; -; -; -; Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.; Intensive Care National Audit & Research Centre, London, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK.; Genomics England; William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK; Genomics England; National Heart & Lung Institute, Imperial College London (St Mary's Campus), Norfolk Place, Paddington, London W2 1PG, UK.; University of Liverpool, Liverpool, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK.; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK; Ce; Roslin Institute, University of Edinburgh","The subset of patients who develop critical illness in Covid-19 have extensive inflammation affecting the lungs1 and are strikingly different from other patients: immunosuppressive therapy benefits critically-ill patients, but may harm some non-critical cases.2 Since susceptibility to life-threatening infections and immune-mediated diseases are both strongly heritable traits, we reasoned that host genetic variation may identify mechanistic targets for therapeutic development in Covid-19.3

GenOMICC (Genetics Of Mortality In Critical Care, genomicc.org) is a global collaborative study to understand the genetic basis of critical illness. Here we report the results of a genome-wide association study (GWAS) in 2244 critically-ill Covid-19 patients from 208 UK intensive care units (ICUs), representing >95% of all ICU beds. Ancestry-matched controls were drawn from the UK Biobank population study and results were confirmed in GWAS comparisons with two other population control groups: the 100,000 genomes project and Generation Scotland.

We identify and replicate three novel genome-wide significant associations, at chr19p13.3 (rs2109069, p = 3.98 x 10-12), within the gene encoding dipeptidyl peptidase 9 (DPP9), at chr12q24.13 (rs10735079, p =1.65 x 10-8) in a gene cluster encoding antiviral restriction enzyme activators (OAS1, OAS2, OAS3), and at chr21q22.1 (rs2236757, p = 4.99 x 10-8) in the interferon receptor gene IFNAR2. Consistent with our focus on extreme disease in younger patients with less comorbidity, we detect a stronger signal at the known 3p21.31 locus than previous studies (rs73064425, p = 4.77 x 10-30).

We identify potential targets for repurposing of licensed medications. Using Mendelian randomisation we found evidence in support of a causal link from low expression of IFNAR2, and high expression of TYK2, to life-threatening disease. Transcriptome-wide association in lung tissue revealed that high expression of the monocyte/macrophage chemotactic receptor CCR2 is associated with severe Covid-19.

Our results identify robust genetic signals relating to key host antiviral defence mechanisms, and mediators of inflammatory organ damage in Covid-19. Both mechanisms may be amenable to targeted treatment with existing drugs. Large-scale randomised clinical trials will be essential before any change to clinical practice.",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2020.09.22.20194183,2020-09-24,https://medrxiv.org/cgi/content/short/2020.09.22.20194183,Modelling optimal vaccination strategy for SARS-CoV-2.,Sam Moore; Edward M Hill; Louise Dyson; Michael Tildesley; Matt J Keeling,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"The COVID-19 outbreak has highlighted our vulnerability to novel infections. Faced with this threat and no effective treatment, in line with many other countries, the UK adopted enforced social distancing (lockdown) to reduce transmission- successfully reducing the reproductive number, R, below one. However, given the large pool of susceptible individuals that remain, complete relaxation of controls is likely to generate a substantial second wave. Vaccination remains the only foreseeable means of both containing the infection and returning to normal interactions and behaviour. Here, we consider the optimal targeting of vaccination within the UK, with the aim of minimising future deaths or quality adjusted life year (QALY) losses. We show that, for a range of assumptions on the action and efficacy of the vaccine, targeting older age groups first is optimal and can avoid a second wave if the vaccine prevents transmission as well as disease.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.09.22.20199661,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.22.20199661,Risk of adverse COVID-19 outcomes for people living with HIV: a rapid review and meta-analysis,Maya Mellor; Anne Bast; Nicholas Jones; Nia Roberts; Jose Ordonez-Mena; Alastair Reith; Christopher C Butler; Philippa C Matthews; Jienchi Dorward,"Medical Sciences Division, University of Oxford, Oxford, UK; Medical Sciences Division, University of Oxford, Oxford, UK; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; Outreach Librarian Knowledge Centre, Bodleian Health Care Libraries, Oxford, UK; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK and NIHR Biomedical Research Centre, Oxford University Hospitals NHS Found; Medical Sciences Division, University of Oxford, Oxford, UK; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.; Nuffield Department of Medicine, University of Oxford, Oxford, UK and Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Founda; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK and Centre for the AIDS Programme of Research in South Africa, University ","ObjectiveTo assess whether people living with HIV (PLWH) are at increased risk of COVID-19 mortality or adverse outcomes, and whether antiretroviral therapy (ART) influences this risk.

DesignRapid review with meta-analysis and narrative synthesis.

MethodsWe searched databases including Embase, Medline, medRxiv, and Google Scholar up to 26th August 2020 for studies describing COVID-19 outcomes in PLWH and conducted a meta-analysis of higher quality studies.

ResultsWe identified 1,908 studies and included 19 in the review. In a meta-analysis of five studies, PLWH had a higher risk of COVID-19 mortality (hazard ratio (HR) 1.93, 95% Confidence Interval (CI): 1.59-2.34) compared to people without HIV. Risk of death remained elevated for PLWH in a subgroup analysis of hospitalised cohorts (HR 1.54, 95% CI: 1.05-2.24) and studies of PLWH across all settings (HR 2.08, 95%CI: 1.69-2.56). Eight other studies assessed the association between HIV and COVID-19 outcomes, but provided inconclusive, lower-quality evidence due to potential confounding and selection bias.

There were insufficient data on the effect of CD4+ T cell count and HIV viral load on COVID-19 outcomes. Eleven studies reported COVID-19 outcomes by ART-regimen. In the two largest studies, tenofovir-disoproxil-fumarate (TDF)-based regimens were associated with a lower risk of adverse COVID-19 outcomes, although these analyses are susceptible to confounding by comorbidities.

ConclusionEvidence is emerging that suggests a moderately increased risk of COVID-19 mortality amongst PLWH. Further investigation into the relationship between COVID-19 outcomes and CD4+ T cell count, HIV viral load, ART and the use of TDF is warranted.",hiv aids,fuzzy,91,100
medRxiv,10.1101/2020.09.21.20194019,2020-09-23,https://medrxiv.org/cgi/content/short/2020.09.21.20194019,Putting (Big) Data in Action: Saving Lives with Countrywide Population Movement Monitoring Using Mobile Devices during the COVID-19 Crisis,Miklos Karoly Szocska; Peter Pollner; Istvan Schiszler; Tamas Joo; Tamas Palicz; Martin McKee; - Magyar Telekom Nyrt.; - Telenor Magyarorszag Zrt.; Adam Sohonyai; Jozsef Szoke; Adam Toth; Peter Gaal,"Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team; University of London,  London School of Hygiene and Tropical Medicine, Department of Health Services Research and Policy; ; ; Vodafone Hungary; Vodafone Hungary; Vodafone Hungary; Semmelweis University, Faculty of Health and Public Administration, Health Services Management Training Centre, Digital Health and Data Utilisation Team","Many countries have implemented strict social distancing measures in the hope of reducing transmission of SARS-CoV-2 but the effectiveness of these measures is determined by the willingness of populations to comply with restrictions. Consequently, a system of monitoring population movement using existing data sources can inform those making decisions about policy responses to the COVID-19 pandemic. We describe a collaboration with all 3 major domestic telecommunication companies in Hungary to use aggregated anonymous mobile phone usage data to calculate two indices for assessing the effect of movement restrictions: a ""mobility-index"" and a ""stay-at-home (or resting) index"". The strengths and weaknesses of this approach are compared with the smartphone-based, COVID-19 Community Mobility Reports from Google. Data generated by mobile phones have long been identified as a potential means to analyse mass population movement, but its operationalisation raises several technical questions, such as making sense of Call Detail Records, collation of data from different mobile network providers, and personal data protection concerns. The method described here addresses these issues and offers an effective and inexpensive tool to monitor the impact of social distancing measures, achieving high levels of accuracy and resolution. Especially in populations where uptake of smartphones is modest, this method has certain advantages over app-based solutions, with greater population coverage, but it is not an alternative to smartphone-based solutions used for contact tracing and quarantine monitoring. We believe that this method can easily be adapted by other countries.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.09.21.20196428,2020-09-22,https://medrxiv.org/cgi/content/short/2020.09.21.20196428,"Sharing a household with children and risk of COVID-19: a study of over 300,000 adults living in healthcare worker households in Scotland",Rachael Wood; Emma C Thomson; Robert Galbraith; Ciara Gribben; David Caldwell; Jennifer Bishop; Martin Reid; Anoop Shah; Kate Templeton; David Goldberg; Chris Robertson; Sharon Hutchinson; Helen M Colhoun; Paul M McKeigue; David McAllister,"University of Edinburgh, Public Heath Scotland; University of Glasgow; Retired; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; London School of Hygiene and Tropical Medicine; University of Edinburgh; Public Health Scotland; Public Health Scotland; Public Health Scotland; University of Edinburgh; University of Edinburgh; University of Glasgow","ObjectiveChildren are relatively protected from COVID-19, possibly due to cross-protective immunity. We investigated if contact with children also affords adults a degree of protection from COVID-19.

DesignCohort study based on linked administrative data.

SettingScotland

Study populationAll NHS Scotland healthcare workers and their household contacts as of March 2020.

Main exposureNumber of young children (0-11 years) living in the participants household.

Main outcomesCOVID-19 requiring hospitalisation, and any COVID-19 (any positive test for SARS-CoV-2) in adults aged [&ge;]18 years between 1 March and 12 October 2020.

Results241,266, 41,198, 23,783 and 3,850 adults shared a household with 0, 1, 2, and 3 or more young children respectively. Over the study period, the risk of COVID-19 requiring hospitalisation was reduced progressively with increasing numbers of household children - fully adjusted hazard ratio (aHR) 0.93 per child (95% CI 0.79-1.10). The risk of any COVID-19 was similarly reduced, with the association being statistically significant (aHR per child 0.93; 95% CI 0.88-0.98). After schools reopened to all children in August 2020, no association was seen between exposure to young children and risk of any COVID-19 (aHR per child 1.03; 95% CI 0.92-1.14).

ConclusionBetween March and October 2020, living with young children was associated with an attenuated risk of any COVID-19 and COVID-19 requiring hospitalisation among adults living in healthcare worker households. There was no evidence that living with young children increased adults risk of COVID-19, including during the period after schools re-opened.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.09.17.20196436,2020-09-21,https://medrxiv.org/cgi/content/short/2020.09.17.20196436,Comparison of COVID-19 outcomes among shielded and non-shielded populations: A general population cohort study of 1.3 million,Bhautesh D Jani; Frederick K Ho; David J Lowe; Jamie P Traynor; Sean MacBride-Stewart; Patrick B Mark; Frances S Mair; Jill P Pell,University of Glasgow; University of Glasgow; NHS Greater Glasgow and Clyde; NHS Greater Glasgow and Clyde; NHS Greater Glasgow and Clyde; University of Glasgow; University of Glasgow; University of Glasgow,"Many western countries used shielding (extended self-isolation) of people presumed to be at high-risk from COVID-19 to protect them and reduce healthcare demand. To investigate the effectiveness of this strategy, we linked family practitioner, prescribing, laboratory, hospital and death records and compared COVID-19 outcomes among shielded and non-shielded individuals in the West of Scotland. Of the 1.3 million population, 27,747 (2.03%) were advised to shield, and 353,085 (26.85%) were classified a priori as moderate risk. COVID-19 testing was more common in the shielded (7.01%) and moderate risk (2.03%) groups, than low risk (0.73%). Referent to low-risk, the shielded group had higher confirmed infections (RR 8.45, 95% 7.44-9.59), case-fatality (RR 5.62, 95% CI 4.47-7.07) and population mortality (RR 57.56, 95% 44.06-75.19). The moderate-risk had intermediate confirmed infections (RR 4.11, 95% CI 3.82-4.42) and population mortality (RR 25.41, 95% CI 20.36-31.71) but, due to their higher prevalence, made the largest contribution to deaths (PAF 75.30%). Age [&ge;]70 years accounted for 49.55% of deaths. In conclusion, shielding has not been effective at preventing deaths in individuals at high risk. Also, to be effective as a population strategy, shielding criteria would need to be widely expanded to include other criteria, such as the elderly.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.09.15.20194795,2020-09-18,https://medrxiv.org/cgi/content/short/2020.09.15.20194795,"Acute, non-COVID related medical admissions during the first wave of COVID-19: A retrospective comparison of changing patterns of disease",Bridget Riley; Mary Packer; Suzy Gallier; Elizabeth Sapey; Catherine Atkin,"University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; PIONEER Hub, University Hospitals Birmingham NHS Foundation Trust; PIONEER Hub, University of Birmingham; PIONEER Hub, University of Birmingham","BackgroundThe COVID-19 pandemic was associated with social restrictions in the UK from 16th March 2020. It was unclear if the lockdown period was associated with differences in the case-mix of non-COVID acute medical admissions compared with the previous year.

MethodsRetrospective data were collected for 1st-30th April 2019 and 1st-30th April 2020 from University Hospitals Birmingham NHS Foundation Trust, one of the largest hospitals in the UK with over 2 million patient contacts per year. The latter time period was chosen to coincide with the peak of COVID-19 cases in the West Midlands. All patients admitted under acute medicine during these time periods were included. COVID-19 was confirmed by SARS-Cov-2 swab or a probable case of COVID-19 based on World Health Organization diagnostic parameters. Non-COVID patients were those with a negative SARS-Cov-2 swab and no suspicion of COVID-19. Data was sourced from UHBs in-house electronic health system (EHS).

ResultsThe total number of acute medical admissions fell comparing April 2019 (n = 2409) to April 2020 (n = 1682). As a proportion of total admissions, those aged under 45 years decreased, while those aged 46 and over did not change.

The number of admissions due to psychiatric conditions and overdoses was higher in April 2020 (p < 0.001). When viewed as a proportion of admissions, alcohol-related admissions (p = 0.004), psychiatric conditions and overdoses (p< 0.001) increased in April 2020 than in April 2019. The proportion of patients who were in hospital due to falls also increased in April 2020 (p< 0.001). In the same period, the absolute number and the proportion of admissions that were due to non-specific chest pain, to musculoskeletal complaints and patients who self-discharged prior to assessment decreased (p = 0.02, p = 0.01 and p = 0.002 respectively).

There were no significant differences in non-COVID-related intensive care admissions or mortality between the same months in the two years.

ConclusionIn this large, single-centre study, there was a change in hospitalised case-mix when comparing April 2019 with April 2020: an increase in conditions which potentially reflect social isolation (falls, drug and alcohol misuse and psychiatric illness) and a decrease in conditions which rarely require in-patient hospital treatment (musculoskeletal pain and non-cardiac chest pain) especially among younger adults. These results highlight two areas for further research; the impact of social isolation on health and whether younger adults could be offered alternative health services to avoid potentially unnecessary hospital assessment.",emergency medicine,fuzzy,100,100
medRxiv,10.1101/2020.09.17.20196469,2020-09-18,https://medrxiv.org/cgi/content/short/2020.09.17.20196469,Renin-angiotensin system inhibitors and susceptibility to COVID-19 in patients with hypertension: a propensity score-matched cohort study in primary care,Shamil Haroon; Anuradhaa Subramanian; Jennifer Cooper; Astha Anand; Krishna Gokhale; Nathan Byne; Samir Dhalla; Dionisio Acosta-Mena; Thomas Taverner; Kelvin Okoth; Jingya Wang; Joht Singh Chandan; Christopher Sainsbury; Dawit Tefra Zemedikun; G Neil Thomas; Dhruv Parekh; Tom Marshall; Elizabeth Sapey; Nicola J Adderley; Krishnarajah Nirantharakumar,"University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; Cegedim Health Data, Cegedim Rx, London, UK; Cegedim Health Data, Cegedim Rx, London, UK; Cegedim Health Data, Cegedim Rx, London, UK; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham and Department of Diabetes, Gartnavel General Hospital, NHS Greater Glasgow and Clyde, UK; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham","Introduction A significant proportion of patients with Coronavirus Disease-19 (COVID-19) have hypertension and are treated with renin-angiotensin system (RAS) inhibitors, namely angiotensin-converting enzyme I inhibitors (ACE inhibitors) or angiotensin II type-1 receptor blockers (ARBs). These medications have been postulated to influence susceptibility to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). The objective of this study was to assess a possible association between prescription of RAS inhibitors and the incidence of COVID-19 and all-cause mortality. Methods We conducted a propensity-score matched cohort study to assess the incidence of COVID-19 among patients with hypertension who were prescribed ACE inhibitors or ARBs compared to patients treated with calcium channel blockers (CCBs) in a large UK-based primary care database (The Health Improvement Network). We estimated crude incidence rates for confirmed/suspected COVID-19 among those prescribed ACE inhibitors, ARBs and CCBs. We used a Cox proportional hazards model to produce adjusted hazard ratios for COVID-19 comparing patients prescribed ACE inhibitors or ARBs to those prescribed CCBs. We further assessed all-cause mortality as a secondary outcome and a composite of accidents, trauma or fractures as a negative control outcome to assess for residual confounding. Results In the propensity score matched analysis, 83 of 18,895 users (0.44%) of ACE inhibitors developed COVID-19 over 8,923 person-years, an incidence rate of 9.3 per 1000 person-years. 85 of 18,895 (0.45%) users of CCBs developed COVID-19 over 8,932 person-years, an incidence rate of 9.5 per 1000 person-years. The adjusted hazard ratio for suspected/confirmed COVID-19 for users of ACE inhibitors compared to CCBs was 0.92 (95% CI 0.68 to 1.26). 79 out of 10,623 users (0.74%) of ARBs developed COVID-19 over 5010 person-years, an incidence rate of 15.8 per 1000 person-years, compared to 11.6 per 1000 person-years among users of CCBs. The adjusted hazard ratio for suspected/confirmed COVID-19 for users of ARBs compared to CCBs was 1.38 (95% CI 0.98 to 1.95). There were no significant associations between use of ACE inhibitors or ARBs and all-cause mortality, compared to use of CCBs. We found no evidence of significant residual confounding with the negative control analysis. Conclusion Current use of ACE inhibitors was not associated with the risk of suspected or confirmed COVID-19 whereas use of ARBs was associated with a statistically non-significant 38% relative increase in risk compared to use of CCBs. However, no significant associations were observed between prescription of either ACE inhibitors or ARBs and all-cause mortality during the peak of the pandemic.",infectious diseases,fuzzy,100,100
bioRxiv,10.1101/2020.09.16.297945,2020-09-16,https://biorxiv.org/cgi/content/short/2020.09.16.297945,Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing,Bjoern Meyer; Jeanne Chiaravalli; Stacy Gellenoncourt; Philip Brownridge; Dominic P. Bryne; Leonard A. Daly; Arturas Grauslys; Marius Walter; Fabrice Agou; Lisa A. Chakrabarti; Charles S. Craik; Claire E. Eyers; Patrick A. Eyers; Yann Gambin; Andrew R Jones; Emma Sierecki; Eric Verdin; Marco Vignuzzi; Edward Emmott,Institut Pasteur; Institut Pasteur; Institut Pasteur; University of Liverpool; University of Liverpool; University of Liverpool; University of Liverpool; Buck Institute for Aging; Institut Pasteur; Institut Pasteur; UCSF; University of Liverpool; University of Liverpool; UNSW; University of Liverpool; UNSW; Buck Institute for Aging; Institut Pasteur; University of Liverpool,"SARS-CoV-2 is the causative agent behind the COVID-19 pandemic, and responsible for over 170 million infections, and over 3.7 million deaths worldwide. Efforts to test, treat and vaccinate against this pathogen all benefit from an improved understanding of the basic biology of SARS-CoV-2. Both viral and cellular proteases play a crucial role in SARS-CoV-2 replication, and inhibitors targeting proteases have already shown success at inhibiting SARS-CoV-2 in cell culture models. Here, we study proteolytic cleavage of viral and cellular proteins in two cell line models of SARS-CoV-2 replication using mass spectrometry to identify protein neo-N-termini generated through protease activity. We identify previously unknown cleavage sites in multiple viral proteins, including major antigenic proteins S and N, which are the main targets for vaccine and antibody testing efforts. We discovered significant increases in cellular cleavage events consistent with cleavage by SARS-CoV-2 main protease, and identify 14 potential high-confidence substrates of the main and papain-like proteases, validating a subset with in vitro assays. We showed that siRNA depletion of these cellular proteins inhibits SARS-CoV-2 replication, and that drugs targeting two of these proteins: the tyrosine kinase SRC and Ser/Thr kinase MYLK, showed a dose-dependent reduction in SARS-CoV-2 titres. Overall, our study provides a powerful resource to understand proteolysis in the context of viral infection, and to inform the development of targeted strategies to inhibit SARS-CoV-2 and treat COVID-19.",microbiology,fuzzy,100,100
medRxiv,10.1101/2020.09.12.20191973,2020-09-14,https://medrxiv.org/cgi/content/short/2020.09.12.20191973,Inequality in access to health and care services during lockdown - Findings from the COVID-19 survey in five UK national longitudinal studies,Constantin-Cristian Topriceanu; Andrew Wong; James C Moon; Alun Hughes; David Bann; Nishi Chaturvedi; Praveetha Patalay; Gabriella Conti; Gabriella Captur,University College London; UCL; UCL; UCL; University College London; UCL; University College London; UCL; University College London,"Background: Access to health services and adequate care is influenced by sex, ethnicity, socio-economic position (SEP) and burden of co-morbidities. However, it is unknown whether the COVID-19 pandemic further deepened these already existing health inequalities. Methods: Participants were from five longitudinal age-homogenous British cohorts (born in 2001, 1990, 1970, 1958 and 1946). A web and telephone-based survey provided data on cancelled surgical or medical appointments, and the number of care hours received during the UK COVID-19 national lockdown. Using binary or ordered logistic regression, we evaluated whether these outcomes differed by sex, ethnicity, SEP and having a chronic illness. Adjustment was made for study-design, non-response weights, psychological distress, presence of children or adolescents in the household, keyworker status, and whether participants had received a shielding letter. Meta-analyses were performed across the cohorts and meta-regression evaluated the effect of age as a moderator. Findings: 14891 participants were included. Females (OR 1.40, 95% confidence interval [1.27,1.55]) and those with a chronic illness (OR 1.84 [1.65-2.05]) experienced significantly more cancellations during lockdown (all p<0.0001). Ethnic minorities and those with a chronic illness required a higher number of care hours during the lockdown (both OR approx. 2.00, all p<0.002). Age was not independently associated with either outcome in meta-regression. SEP was not associated with cancellation or care hours. Interpretation: The UK government's lockdown approach during the COVID-19 pandemic appears to have deepened existing health inequalities, impacting predominantly females, ethnic-minorities and those with chronic illnesses. Public health authorities need to implement urgent policies to ensure equitable access to health and care for all in preparation for a second wave.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.09.13.20193730,2020-09-14,https://medrxiv.org/cgi/content/short/2020.09.13.20193730,Mental health service activity during COVID-19 lockdown among individuals with Personality Disorders: South London and Maudsley data on services and mortality from January to May 2020,Eleanor Nuzum; Evangelia Martin; Matthew Broadbent; Robert Stewart,South London and Maudsley NHS Foundation Trust; South London and Maudsley NHS Foundation Trust; South London and Maudsley NHS Foundation Trust; King's College London,"The lockdown and social distancing policy imposed due to the COVID-19 pandemic is likely to have a widespread impact on mental healthcare for both services themselves and the people accessing those services. Previous reports from the South London and Maudsley NHS Trust (SLaM; a large mental health service provider for 1.2m residents in South London) highlighted a shift to virtual contacts among those accessing community mental health and home treatment teams and an increase in deaths over the pandemics first wave. However, there is a need to understand this further for specific groups, including those diagnosed with a personality disorder who might have particular vulnerabilities. Taking advantage of the Clinical Record Interactive Search (CRIS) data resource with 24-hourly updates of electronic mental health records data, this paper describes daily caseloads and contact numbers (face-to-face and virtual) for individuals with personality disorders across community, specialist, crisis and inpatient services. The report focussed on the period 1st January to 31st May 2020. We also report on daily accepted and discharged trust referrals, total trust caseloads and daily inpatient admissions and discharges for individuals with personality disorders. In addition, daily deaths are described for all current and previous SLaM service users with personality disorder over this period. In summary, comparing periods before and after 16th March 2020 there was a shift from face-to-face contacts to virtual contacts across all teams. Liaison and Older Adult teams showed the largest drop in caseloads, whereas Early Intervention in Psychosis service caseloads remained the same. Reduced accepted referrals and inpatient admissions were observed and there was a 28% increase in average daily deaths in the period after 16th March, compared to the period 1st January to 15th March.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.09.10.20191841,2020-09-11,https://medrxiv.org/cgi/content/short/2020.09.10.20191841,The King's College London Coronavirus Health and Experiences of Colleagues at King's Study: SARS-CoV-2 antibody response in an occupational sample,Daniel Leightley; Valentina Vitiello; Gabriella Bergin-Cartwright; Alice Wickersham; Katrina A S Davis; Sharon Stevelink; Matthew Hotopf; Reza Razavi; - On behalf of the KCL CHECK research team,"Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; The School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and   Medicine, King's College London, London, UK.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London.; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London; Department of Psychological Medicine, Institute of Psychiatry Psychology and Neuroscience, King's College London; The School of Biomedical Engineering and Imaging Sciences, Faculty of Life Sciences and Medicine, King's College London; ","We report test results for SARS-CoV-2 antibodies in an occupational group of postgraduate research students and current members of staff at Kings College London. Between June and July 2020, antibody testing kits were sent to n=2296 participants; n=2004 (86.3%) responded, of whom n=1882 (93.9%) returned valid test results. Of those that returned valid results, n=124 (6.6%) tested positive for SARS-CoV-2 antibodies, with initial comparisons showing variation by age group and clinical exposure.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.09.11.20192492,2020-09-11,https://medrxiv.org/cgi/content/short/2020.09.11.20192492,Resurgence of SARS-CoV-2 in England: detection by community antigen surveillance,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E Walters; Haowei Wang; Christina J Atchison; Claudio Fronterre; Peter J Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Lancaster University; Imperial College London; Imperial College London; Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London","Background Based on cases and deaths, transmission of SARS-CoV-2 in England peaked in late March and early April 2020 and then declined until the end of June. Since the start of July, cases have increased, while deaths have continued to decrease. Methods We report results from 594,000 swabs tested for SARS-CoV-2 virus obtained from a representative sample of people in England over four rounds collected regardless of symptoms, starting in May 2020 and finishing at the beginning of September 2020. Swabs for the most recent two rounds were taken between 24th July and 11th August and for round 4 between 22nd August and 7th September. We estimate weighted overall prevalence, doubling times between and within rounds and associated reproduction numbers. We obtained unweighted prevalence estimates by sub-groups: age, sex, region, ethnicity, key worker status, household size, for which we also estimated odds of infection. We identified clusters of swab-positive participants who were closer, on average, to other swab-positive participants than would be expected. Findings Over all four rounds of the study, we found that 72% (67%, 76%) of swab-positive individuals were asymptomatic at the time of swab and in the week prior. The epidemic declined between rounds 1 and 2, and rounds 2 and 3. However, the epidemic was increasing between rounds 3 and 4, with a doubling time of 17 (13, 23) days corresponding to an R value of 1.3 (1.2, 1.4). When analysing round 3 alone, we found that the epidemic had started to grow again with 93% probability. Using only the most recent round 4 data, we estimated a doubling time of 7.7 (5.5, 12.7) days, corresponding to an R value of 1.7 (1.4, 2.0). Cycle threshold values were lower (viral loads were higher) for rounds 1 and 4 than they were for rounds 2 and 3. In round 4, we observed the highest prevalence in participants aged 18 to 24 years at 0.25% (0.16%, 0.41%), increasing from 0.08% (0.04%, 0.18%) in round 3. We observed the lowest prevalence in those aged 65 and older at 0.04% (0.02%, 0.06%) which was stable compared with round 3. Participants of Asian ethnicity had elevated odds of infection. We identified clusters in and around London, transient clusters in the Midlands, and an expanding area of clustering in the North West and more recently in Yorkshire and the Humber. Interpretation Although low levels of transmission persisted in England through to mid-summer 2020, the prevalence of SARS-CoV-2 is now increasing. We found evidence of accelerating transmission at the end of August and beginning of September. Representative community antigen sampling can increase situational awareness and help improve public health decision making even at low prevalence.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.09.04.20187781,2020-09-09,https://medrxiv.org/cgi/content/short/2020.09.04.20187781,Hydroxychloroquine for prevention of COVID-19 mortality: a population-based cohort study,Christopher T Rentsch; Nicholas J DeVito; Brian MacKenna; Caroline E Morton; Krishnan Bhaskaran; Jeremy P Brown; Anna Schultze; William J Hulme; Richard Croker; Alex J Walker; Elizabeth J Williamson; Chris Bates; Seb Bacon; Amir Mehrkar; Helen J Curtis; David Evans; Kevin Wing; Peter Inglesby; Rohini Mathur; Henry Drysdale; Angel YS Wong; Helen I McDonald; Jonathan Cockburn; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Liam Smeeth; Ian J Douglas; William G Dixon; Stephen JW Evans; Laurie Tomlinson; Ben Goldacre,London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; University of Oxford; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Medicine and Tropical Medicine; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; The Phoenix Partnership; The Phoenix Partnership; The Phoenix Partnership; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; The University of Manchester; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundHydroxychloroquine has been shown to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, but early clinical studies found no benefit treating patients with coronavirus disease 2019 (COVID-19). We set out to evaluate the effectiveness of hydroxychloroquine for prevention, as opposed to treatment, of COVID-19 mortality.

MethodsWe pre-specified and conducted an observational, population-based cohort study using national primary care data and linked death registrations in the OpenSAFELY platform, representing 40% of the general population in England. We used Cox regression to estimate the association between ongoing routine hydroxychloroquine use prior to the COVID-19 outbreak in England and risk of COVID-19 mortality among people with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). Model adjustment was informed by a directed acyclic graph.

ResultsOf 194,637 patients with RA or SLE, 30,569 (15.7%) received [&ge;] 2 prescriptions of hydroxychloroquine in the six months prior to 1 March 2020. Between 1 March 2020 and 13 July 2020, there were 547 COVID-19 deaths, 70 among hydroxychloroquine users. Estimated standardised cumulative COVID-19 mortality was 0.23% (95% CI 0.18-0.29) among users and 0.22% (95% CI 0.20-0.25) among non-users; an absolute difference of 0.008% (95% CI -0.051-0.066). After accounting for age, sex, ethnicity, use of other immunuosuppressives, and geographic region, no association with COVID-19 mortality was observed (HR 1.03, 95% CI 0.80-1.33). We found no evidence of interactions with age or other immunosuppressives. Quantitative bias analyses indicated observed associations were robust to missing information regarding additional biologic treatments for rheumatological disease. We observed similar associations with the negative control outcome of non-COVID-19 mortality.

ConclusionWe found no evidence of a difference in COVID-19 mortality among patients who received hydroxychloroquine for treatment of rheumatological disease prior to the COVID-19 outbreak in England.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSPublished trials and observational studies to date have shown no evidence of benefit of hydroxychloroquine as a treatment for hospitalised patients who already have COVID-19. A separate question remains: whether routine ongoing use of hydroxychloroquine in people without COVID-19 protects against new infections or severe outcomes. We searched MEDLINE/PubMed for pharmacoepidemiological studies evaluating hydroxychloroquine for prevention of severe COVID-19 outcomes. The keywords ""hydroxychloroquine AND (COVID OR coronavirus OR SARS-CoV-2) AND (prophyl* OR prevent*) AND (rate OR hazard OR odds OR risk)"" were used and results were filtered to articles from the last year with abstracts available. 109 papers were identified for screening; none investigated pre-exposure prophylactic use of hydroxychloroquine for prevention of severe COVID-19 outcomes. Clinical trials of prophylactic use of hydroxychloroquine are ongoing; however, the largest trial does not expect to meet recruitment targets due to ""...unjustified extrapolation and exaggerated safety concerns together with intense politicisation and negative publicity."" In the absence of reported clinical trials, evidence can be generated from real-world data to support the need for randomised clinical trials.

Added value of this studyIn this cohort study representing 40% of the population of England, we investigated whether routine use of hydroxychloroquine prior to the COVID-19 outbreak prevented COVID-19 mortality. Using robust pharmacoepidemiological methods, we found no evidence to support a substantial benefit of hydroxychloroquine in preventing COVID-19 mortality. At the same time, we have shown no significant harm, and this generates the equipoise to justify continuing randomised trials. We have demonstrated in this study that it is feasible to address specific hypotheses about medicines in a rapid and transparent manner to inform interim clinical decision making and support the need for large-scale, randomised trial data.

Implications of all the available evidenceThis is the first study to investigate the ongoing routine use of hydroxychloroquine and risk of COVID-19 mortality in a general population. While we found no evidence of any protective benefit, due to the observational nature of the study, residual confounding remains a possibility. Completion of trials for prevention of severe outcomes is warranted, but prior to the completion of these, we found no evidence to support the use of hydroxychloroquine for prevention of COVID-19 mortality.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.09.05.20188821,2020-09-08,https://medrxiv.org/cgi/content/short/2020.09.05.20188821,Ethnicity and clinical outcomes in COVID-19A Systematic Review and Meta-analysis,Shirley Sze; Daniel Pan; Laura J Gray; Clareece R Nevill; Christopher A Martin; Joshua Nazareth; Jatinder S Minhas; Pip Divall; Kamlesh Khunti; Keith Abrams; Laura B Nellums; Manish Pareek,University of Leicester; University of Leicester; University of Leicester; University of Leicester; University of Leicester; University of Leicester; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; University of Leicester; University of Nottingham; University of Leicester,"ImportanceThe association of ethnicity with outcomes in patients with COVID-19 is unclear.

ObjectiveTo determine whether the risk of SARS-CoV-2 infection, COVID-19 intensive care unit (ICU) admission and mortality are associated with ethnicity.

Data SourcesWe searched all English language articles published 1st December 2019 - 30th June 2020 within MEDLINE, EMBASE, PROSPERO and the Cochrane library using indexing terms for COVID-19 and ethnicity, as well as manuscripts awaiting peer review on MedRxiv during the same period.

Study SelectionIncluded studies reported original clinical data, disaggregated by ethnicity, on patients with confirmed or suspected COVID-19. We excluded correspondence, area level, modelling and basic science articles. Two independent reviewers screened articles for inclusion. Of 926 identified articles, 35 were included in the meta-analyses.

Data Extraction and SynthesisThe review was conducted according to PRISMA guidelines. Reviewers independently extracted data using a piloted form on: (1) rates of infection, ICU admission and mortality by ethnicity; and (2) unadjusted and adjusted data comparing ethnic minority and White groups. Data were pooled using random effects models.

Main Outcomes and MeasuresOutcomes were: (1) infection with SARS-CoV-2 confirmed on molecular testing; (2) ICU admission; and (3) mortality in COVID-19 confirmed and suspected cases.

Results13,535,562 patients from 35 studies were included in the meta-analyses. Black, Asian and Hispanic individuals had a greater risk of infection compared to White individuals (Black: pooled adjusted RR: 2.06, 95% CI: 1.59-2.67; Asian: 1.35, 95%CI: 1.15-1.59; Hispanic: 1.77, 95% CI: 1.39-2.25). Black individuals were significantly more likely to be admitted to ICU than White individuals (pooled adjusted RR: 1.61, 95% CI: 1.02-2.55). Risk of mortality was similar across ethnicities among hospitalised patients, but increased among Asian and Mixed ethnic groups in the general population.

ConclusionsBlack, Asian and Hispanic ethnic groups are at increased risk of SARS-CoV-2 infection. Black individuals may be more likely to require ICU admission for COVID-19. There may also be disparities in risk of death from COVID-19 at a population level. Our findings are of critical public health importance and should inform policy on minimising SARS-CoV-2 exposure in ethnic minority groups.

KEY POINTSO_ST_ABSQuestionC_ST_ABSIs ethnicity associated with vulnerability to, and outcomes from, coronavirus disease 2019 (COVID-19)?

FindingsIn this systematic review and meta-analysis, rates of infection and outcomes from COVID-19 were compared between ethnic groups. Individuals from Black, Asian and Hispanic ethnicity were significantly more vulnerable to SARS-CoV-2 infection than those of White ethnicity. Black individuals were more likely to need intensive care unit (ICU) admission for COVID-19 than White individuals. Risk of mortality was similar across ethnicities among hospitalised patients, but increased among Asian and Mixed ethnic groups in the general population.

MeaningThere is strong evidence for an increased risk of SARS-CoV-2 infection amongst ethnic minorities, and targeted public health policies are required to reduce this risk.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.09.02.20185892,2020-09-07,https://medrxiv.org/cgi/content/short/2020.09.02.20185892,Prognostic accuracy of emergency department triage tools for adults with suspected COVID-19: The PRIEST observational cohort study,Ben Thomas; Steve Goodacre; Ellen Lee; Laura Sutton; Amanda Loban; Simon Waterhouse; Richard Simmonds; Katie Biggs; Carl Marincowitz; Jose Schutter; Sarah Connelly; Elena Sheldon; Jamie Hall; Emma Young; Andrew Bentley; Kirsty Challen; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter,University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Manchester University NHS Foundation Trust; Lancashire Teaching Hospitals NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Barts Health NHS Trust; University of Sheffield; University of Sheffield; Imperial College Healthcare NHS Trust; Manchester University NHS Foundation Trust,"ObjectivesThe World Health Organisation (WHO) and National Institute for Health and Care Excellence (NICE) recommend various triage tools to assist decision-making for patients with suspected COVID-19. We aimed to estimate the accuracy of triage tools for predicting severe illness in adults presenting to the emergency department (ED) with suspected COVID-19 infection.

MethodsWe undertook a mixed prospective and retrospective observational cohort study in 70 EDs across the United Kingdom (UK). We collected data from people attending with suspected COVID-19 between 26 March 2020 and 28 May 2020, and used presenting data to determine the results of assessment with the following triage tools: the WHO algorithm, NEWS2, CURB-65, CRB-65, PMEWS and the swine flu adult hospital pathway (SFAHP). We used 30-day outcome data (death or receipt of respiratory, cardiovascular or renal support) to determine prognostic accuracy for adverse outcome.

ResultsWe analysed data from 20892 adults, of whom 4672 (22.4%) died or received organ support (primary outcome), with 2058 (9.9%) receiving organ support and 2614 (12.5%) dying without organ support (secondary outcomes). C-statistics for the primary outcome were: CURB-65 0.75; CRB-65 0.70; PMEWS 0.77; NEWS2 (score) 0.77; NEWS2 (rule) 0.69; SFAHP (6-point) 0.70; SFAHP (7-point) 0.68; WHO algorithm 0.61. All triage tools showed worse prediction for receipt of organ support and better prediction for death without organ support.

At the recommended threshold, PMEWS and the WHO criteria showed good sensitivity (0.96 and 0.95 respectively), at the expense of specificity (0.31 and 0.27 respectively). NEWS2 showed similar sensitivity (0.96) and specificity (0.28) when a lower threshold than recommended was used.

ConclusionCURB-65, PMEWS and NEWS2 provide good but not excellent prediction for adverse outcome in suspected COVID-19, and predicted death without organ support better than receipt of organ support. PMEWS, the WHO criteria and NEWS2 (using a lower threshold than usually recommended) provide good sensitivity at the expense of specificity.

RegistrationISRCTN registry, ISRCTN28342533, http://www.isrctn.com/ISRCTN28342533",emergency medicine,fuzzy,100,100
medRxiv,10.1101/2020.09.03.20187377,2020-09-05,https://medrxiv.org/cgi/content/short/2020.09.03.20187377,Impact of baseline cases of cough and fever on UK COVID-19 diagnostic testing rates: estimates from the Bug Watch community cohort study,Max T Eyre; Rachel Burns; Victoria Kirkby; Catherine Smith; Spiros Denaxas; Vincent Nguyen; Andrew Hayward; Laura Shallcross; Ellen Fragaszy; Robert W Aldridge,"Centre of Health Informatics, Computing and Statistics, Lancaster Medical School, Lancaster University, Lancaster, LA1 4YW, UK; Liverpool School of Tropical Med; Centre of Public Health Data Science, Institute of Health Informatics, University College London, London, NW1 2DA, UK; Centre of Public Health Data Science, Institute of Health Informatics, University College London, London, NW1 2DA, UK; Institute of Health Informatics, University College London, London, NW1 2DA, UK; Institute of Health Informatics, University College London, London, NW1 2DA, UK; Health Data Research UK, London, NW1 2DA, UK; The Alan Turing Institute, London; Centre of Public Health Data Science, Institute of Health Informatics, University College London, London, NW1 2DA, UK; Institute of Epidemiology and Health Care; Institute of Epidemiology and Health Care, University College London, London, WC1E 7HB, UK; Institute of Health Informatics, University College London, London, NW1 2DA, UK; Institute of Health Informatics, University College London, London, NW1 2DA, UK; Faculty of Epidemiology and Population Health, London School of Hygiene and Tro; Centre of Public Health Data Science, Institute of Health Informatics, University College London, London, NW1 2DA, UK","BackgroundDiagnostic testing forms a major part of the UKs response to the current COVID-19 pandemic with tests offered to people with a continuous cough, high temperature or anosmia. Testing capacity must be sufficient during the winter respiratory season when levels of cough and fever are high due to non-COVID-19 causes. This study aims to make predictions about the contribution of baseline cough or fever to future testing demand in the UK.

MethodsIn this analysis of the Bug Watch prospective community cohort study, we estimated the incidence of cough or fever in England in 2018-2019. We then estimated the COVID-19 diagnostic testing rates required in the UK for baseline cough or fever cases for the period July 2020-June 2021. This was explored for different rates of the population requesting tests and four second wave scenarios and then compared to current national capacity.

ResultsThe baseline incidence of cough or fever in the UK is expected to rise rapidly from 154,554 (95%CI 103,083 - 231,725) cases per day in August 2020 to 250,708 (95%CI 181,095 - 347,080) in September, peaking at 444,660 (95%CI 353,084 - 559,988) in December. If 80% of baseline cough or fever cases request tests, average daily UK testing demand would exceed current capacity for five consecutive months (October 2020 to February 2021), with a peak demand of 147,240 (95%CI 73,978 - 239,502) tests per day above capacity in December 2020.

ConclusionsOur results show that current national COVID-19 testing capacity is likely to be exceeded by demand due to baseline cough and fever alone. This study highlights that the UKs response to the COVID-19 pandemic must ensure that a high proportion of people with symptoms request tests, and that testing capacity is immediately scaled up to meet this high predicted demand.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.09.01.20185793,2020-09-03,https://medrxiv.org/cgi/content/short/2020.09.01.20185793,Prognostic accuracy of emergency department triage tools for children with suspected COVID-19: The PRIEST observational cohort study,Katie Biggs; Ben Thomas; Steve Goodacre; Ellen Lee; Laura Sutton; Matthew Bursnall; Amanda Loban; Simon Waterhouse; Richard Simmonds; Carl Marincowitz; Jose Schutter; Sarah Connelly; Elena Sheldon; Jamie Hall; Emma Young; Andrew Bentley; Kirsty Challen; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter,University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Manchester University NHS Foundation Trust; Lancashire Teaching Hospitals NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Barts Health NHS Trust; University of Sheffield; University of Sheffield; Imperial College Healthcare NHS Trust; Manchester University NHS Foundation Trust,"ObjectivesEmergency department clinicians can use triage tools to predict adverse outcome and support management decisions for children presenting with suspected COVID-19. We aimed to estimate the accuracy of triage tools for predicting severe illness in children presenting to the emergency department (ED) with suspected COVID-19 infection.

MethodsWe undertook a mixed prospective and retrospective observational cohort study in 44 EDs across the United Kingdom (UK). We collected data from children attending with suspected COVID-19 between 26 March 2020 and 28 May 2020, and used presenting data to determine the results of assessment using the WHO algorithm, swine flu hospital pathway for children (SFHPC), Paediatric Observation Priority Score (POPS) and Childrens Observation and Severity Tool (COAST). We recorded 30-day outcome data (death or receipt of respiratory, cardiovascular or renal support) to determine prognostic accuracy for adverse outcome.

ResultsWe collected data from 1530 children, including 26 (1.7%) with an adverse outcome. C-statistics were 0.80 (95% confidence interval 0.73-0.87) for the WHO algorithm, 0.80 (0.71-0.90) for POPS, 0.76 (0.67-0.85) for COAST, and 0.71 (0.59-0.82) for SFHPC. Using pre-specified thresholds, the WHO algorithm had the highest sensitivity (0.85) and lowest specificity (0.75), but POPS and COAST could optimise sensitivity (0.96 and 0.92 respectively) at the expense of specificity (0.25 and 0.38 respectively) by using a threshold of any score above zero instead of the pre-specified threshold.

ConclusionExisting triage tools have good but not excellent prediction for adverse outcome in children with suspected COVID-19. POPS and COAST could achieve an appropriate balance of sensitivity and specificity for supporting decisions to discharge home by considering any score above zero to be positive.

RegistrationISRCTN registry, ISRCTN28342533, http://www.isrctn.com/ISRCTN28342533",emergency medicine,fuzzy,100,100
medRxiv,10.1101/2020.09.02.20186502,2020-09-03,https://medrxiv.org/cgi/content/short/2020.09.02.20186502,Real-time monitoring of COVID-19 dynamics using automated trend fitting and anomaly detection,Thibaut Jombart; Stephane Ghozzi; Dirk Schumacher; Quentin Leclerc; Mark Jit; Stefan Flasche; Felix Greaves; Tom Ward; Rosalind M Eggo; Emily Nightingale; Sophie Meakin; Oliver J Brady; - Centre for Mathematical Modelling of Infectious Diseases COVID-19 Working Group; Graham Medley; Michael Hohle; John Edmunds,"London School of Hygiene and Tropical Medicine (LSHTM); Department of Epidemiology, Helmholtz Centre for Infection Research, Brunswick, Lower Saxony, Germany; R Epidemics Consortium; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; LSHTM; Joint Biosecurity Centre; Joint Biosecurity Centre; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; LSHTM; London School of Hygiene and Tropical Medicine; ; LSHTM; Department of Mathematics, Stockholm University, Sweden; LSHTM","As several countries gradually release social distancing measures, rapid detection of new localised COVID-19 hotspots and subsequent intervention will be key to avoiding large-scale resurgence of transmission. We introduce ASMODEE (Automatic Selection of Models and Outlier Detection for Epidemics), a new tool for detecting sudden changes in COVID-19 incidence. Our approach relies on automatically selecting the best (fitting or predicting) model from a range of user-defined time series models, excluding the most recent data points, to characterise the main trend in an incidence. We then derive prediction intervals and classify data points outside this interval as outliers, which provides an objective criterion for identifying departures from previous trends. We also provide a method for selecting the optimal breakpoints, used to define how many recent data points are to be excluded from the trend fitting procedure. The analysis of simulated COVID-19 outbreaks suggest ASMODEE compares favourably with a state-of-art outbreak-detection algorithm while being simpler and more flexible. We illustrate our method using publicly available data of NHS Pathways reporting potential COVID-19 cases in England at a fine spatial scale, for which we provide a template automated analysis pipeline. ASMODEE is implemented in the free R package trendbreaker.",health informatics,fuzzy,100,100
medRxiv,10.1101/2020.09.02.20186817,2020-09-03,https://medrxiv.org/cgi/content/short/2020.09.02.20186817,Revealing the extent of the COVID-19 pandemic in Kenya based on serological and PCR-test data,John Ojal; Samuel PC Brand; Vincent Were; Emelda A Okiro; Ivy Kadzo Kombe; Caroline Mburu; Rabia Aziza; Morris Ogero; Ambrose Agweyu; George M Warimwe; Sophie Uyoga; Ifedayo M. O Adetifa; John Anthony Scott; Edward Otieno; Lynette I Ochola-Oyier; Charles Nyaigoti Agoti; Kadondi Kasera; Patrick Amoth; Mercy Mwangangi; Rashid Aman; Wangari Ng'ang'a; Benjamin Tsofa; Philip Bejon; Edwine Barasa; Matt J Keeling; D James Nokes,"Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya and London School of Hygiene and Tropical Medicine; The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, UK.; Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya; Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya; KEMRI-Wellcome Trust Research Programme; Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya; The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, UK.; Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya; Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya; KEMRI-Wellcome Trust Research Programme; KEMRI Wellcome Trust Research Programme; KEMRI-Wellcome Trust Research Programme; London School of Hygiene & Tropical Medicine; Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya; Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya; Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya; Ministry of Health, Government of Kenya, Kenya; Ministry of Health, Government of Kenya, Kenya; Ministry of Health, Government of Kenya, Kenya; Ministry of Health, Government of Kenya, Kenya; Presidential Policy & Strategy Unit, The Presidency, Government of Kenya; Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya; Kenya Medical Research Institute -Wellcome Trust Research Programme, Kenya; KEMRI-Wellcome Trust Research Programme; The Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research (SBIDER), University of Warwick, UK; KEMRI-Wellcome Trust Research Programme, Kenya and School of Life Sciences, University of Warwick, UK","Policy makers in Africa need robust estimates of the current and future spread of SARS-CoV-2. Data suitable for this purpose are scant. We used national surveillance PCR test, serological survey and mobility data to develop and fit a county-specific transmission model for Kenya. We estimate that the SARS-CoV-2 pandemic peaked before the end of July 2020 in the major urban counties, with 34 - 41% of residents infected, and will peak elsewhere in the country within 2-3 months. Despite this penetration, reported severe cases and deaths are low. Our analysis suggests the COVID-19 disease burden in Kenya may be far less than initially feared. A similar scenario across sub-Saharan Africa would have implications for balancing the consequences of restrictions with those of COVID-19.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.09.01.20183822,2020-09-02,https://medrxiv.org/cgi/content/short/2020.09.01.20183822,Trust and Transparency in times of Crisis: Results from an Online Survey During the First Wave (April 2020) of the COVID-19 Epidemic in the UK,Luisa Enria; Naomi Waterlow; Nina Trivedy Rogers; Hannah Brindle; Sham Lal; Rosalind M Eggo; Shelley Lees; Chrissy h Roberts,London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; UCL; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine (LSHTM),"BackgroundThe success of a governments COVID-19 control strategy relies on public trust and broad acceptance of response measures. We investigated public perceptions of the UK governments COVID-19 response, focusing on the relationship between trust and transparency, during the first wave (April 2020) of the COVID-19 pandemic in the United Kingdom.

MethodsAnonymous survey data were collected (2020-04-06 to 2020-04-22) from 9,322 respondents, aged 20+ using an online questionnaire. We took a mixed methods approach to data analysis, combining statistical analyses, structural topic modelling (STM) and qualitative thematic coding of a sub-set of responses. Missing data were imputed via multiple imputation.

ResultsMost respondents (95.1%) supported government enforcement of behaviour change. While 52.1% of respondents thought the government was making good decisions, differences were apparent across demographic groups, for example respondents from Scotland had lower odds of responding positively than respondents in London. Higher educational levels saw decreasing odds of having a positive opinion of the government response and decreasing household income associated with decreasing positive opinion. Of respondents who thought the government was not making good decisions 60% believed the economy was being prioritised over people and their health. Positive views on government decision-making were associated with positive views on government transparency about the COVID-19 response. Qualitative analysis about government transparency highlighted five key themes: (1) the justification of opacity due to the condition of crisis, (2) generalised mistrust of politics, (3) concerns about the role of scientific evidence, (4) quality of government communication and (5) questions about political decision-making processes.

ConclusionWe recommend targeted community engagement tailored to different groups experiences and a focus on accountability and openness around how decisions are made in the response to the UK COVID-19 pandemic.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.08.26.20182279,2020-09-01,https://medrxiv.org/cgi/content/short/2020.08.26.20182279,COVID-19 infection dynamics in care homes in the East of England: a retrospective genomic epidemiology study,William L Hamilton; Gerry Tonkin-Hill; Emily Smith; Dinesh Aggarwal; Charlotte Houldcroft; Ben Warne; Colin Brown; Luke Meredith; Myra Hosmillo; Aminu Jahun; Martin Curran; Surendra Parmar; Laura Caller; Sarah Caddy; Fahad Khokhar; Anna Yakovleva; Grant Hall; Theresa Feltwell; Malte Pinckert; Iliana Georgana; Yasmin Chaudhry; Nicholas Brown; Sonia Goncalves; Roberto Amato; Ewan Harrison; Mathew Beale; Michael Spencer Chapman; David Jackson; Ian Johnston; Alex Alderton; John Sillitoe; Cordelia Langford; Gordon Dougan; Sharon Peacock; Dominic Kwiatowski; Ian Goodfellow; M. Estee Torok; - COVID-19 Genomics Consortium UK,"University of Cambridge; Wellcome Sanger Institute; Cambridgeshire County Council, UK; Public Health England; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; Wellcome Sanger Institute; University of Cambridge; University of Cambridge; ","COVID-19 poses a major challenge to care homes, as SARS-CoV-2 is readily transmitted and causes disproportionately severe disease in older people. Here, 1,167 residents from 337 care homes were identified from a dataset of 6,600 COVID-19 cases from the East of England. Older age and being a care home resident were associated with increased mortality. SARS-CoV-2 genomes were available for 700 residents from 292 care homes. By integrating genomic and temporal data, 409 viral clusters within the 292 homes were identified, indicating two different patterns - outbreaks among care home residents and independent introductions with limited onward transmission. Approximately 70% of residents in the genomic analysis were admitted to hospital during the study, providing extensive opportunities for transmission between care homes and hospitals. Limiting viral transmission within care homes should be a key target for infection control to reduce COVID-19 mortality in this population.

Impact statementSARS-CoV-2 can spread efficiently within care homes causing COVID-19 outbreaks among residents, who are at increased risk of severe disease, emphasising the importance of stringent infection control in this population.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.08.26.20180950,2020-09-01,https://medrxiv.org/cgi/content/short/2020.08.26.20180950,"What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study",Louise Sigfrid; Muge Cevik; Edwin Jesudason; Wei Shen Lim; Jordi Rello; John Humphrey Amuasi; Fernando Bozza; Carlo Palmieri; Daniel Munblit; Jan Cato Holter; Anders Benjamin Kildal; Clark D Russell; Antonia Ho; Lance Turtle; Thomas M Drake; Anna Beltrame; Katrina Hann; Ibrahim Richard Bangura; Rob Fowler; Sulaiman Lakoh; Colin Berry; David J Lowe; Joanne McPeake; Madiha Hashmi; Anne Margarita Dyrhol-Riise; Chloe Donohue; Daniel R Plotkin; Hayley Hardwick; Natalie Elkheir; Nazir Lone; Annemarie B Docherty; Ewen M Harrison; Kenneth J Baille; Gail Carson; Malcolm G Semple; Janet T Scott,"ISARIC Global Support Centre,  University of Oxford; University of St Andrews; NHS Lothian; Nottingham University Hospitals NHS Trust; Vall d Hebron Institute of Research; Kwame Nkrumah University of Science and Technology and Kumasi Center for Collaborative Research in Tropical Medicine; Fundacao Oswaldo Cruz; University of Liverpool; Institute of Childs Health, Sechenov First Moscow State Medical University (Sechenov University); Oslo University Hospital; University Hospital of North Norway; University of Edinburgh; University of Glasgow; University of Liverpool; University of Edinburgh; IRCCS Sacro Cuore Don Calabria Hospital; Sustainable Health Systems; Dorothy Springer Trust; Sunnybrook hospital, University of Toronto; Sustainable Health Systems; University of Glasgow; Queen Elizabeth University Hospital; NHS Greater Glasgow and Clyde, University of Glasgow Institute of Health and Wellbeing; Critical Care Medicine, Ziauddin University, Pakistan Registry of Intensive CarE (PRICE); Oslo University hospital; Liverpool Clinical Trials Centre, University of Liverpool; University of Oxford; National Institute of Health Research (NIHR) Health Protection research Unit in Emerging and Zoonotic Infections, Liverpool, University of Liverpool; London School of Hygiene and Tropical Medicine; Usher Institute; Usher Institute, University of Edinburgh; Usher Institute,  University of Edinburgh; Roslin Institute, University of Edinburgh; ISARIC, University of Oxford; Health Protection Research Unit In Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool; MRC-University of Glasgow Centre for Virus Research","IntroductionVery little is known about possible clinical sequelae that may persist after resolution of the acute Coronavirus Disease 2019 (COVID-19). A recent longitudinal cohort from Italy including 143 patients recovered after hospitalisation with COVID-19 reported that 87% had at least one ongoing symptom at 60 day follow-up. Early indications suggest that patients with COVID-19 may need even more psychological support than typical ICU patients. The assessment of risk factors for longer term consequences requires a longitudinal study linked to data on pre-existing conditions and care received during the acute phase of illness.

Methods and analysisThis is an international open-access prospective, observational multi-site study. It will enrol patients following a diagnosis of COVID-19. Tier 1 is developed for following up patients day 28 post-discharge, additionally at 3 to 6 months intervals. This module can be used to identify sub-sets of patients experiencing specific symptomatology or syndromes for further follow up. A Tier 2 module will be developed for in-clinic, in-depth follow up. The primary aim is to characterise physical consequences in patients post-COVID-19. Secondary aim includes estimating the frequency of and risk factors for post-COVID-19 medical sequalae, psychosocial consequences and post-COVID-19 mortality. A subset of patients will have sampling to characterize longer term antibody, innate and cell-mediated immune responses to SARS-CoV-2.

Ethics and disseminationThis collaborative, open-access study aims to characterize the frequency of and risk factors for long-term consequences and characterise the immune response over time in patients following a diagnosis of COVID-19 and facilitate standardized and longitudinal data collection globally. The outcomes of this study will inform strategies to prevent long term consequences; inform clinical management, direct rehabilitation, and inform public health management to reduce overall morbidity and improve outcomes of COVID-19.

Article summaryO_ST_ABSStrengths and limitations of this studyC_ST_ABSO_LIAs an international prospective, observational study we provide open-access standardised tools that can be adapted by any site interested in following up patients with COVID-19, for independent or combined analysis, to forward knowledge into short and long term consequences of COVID-19.
C_LIO_LIThis study aims to inform strategies to prevent longer term sequalae; inform clinical management, rehabilitation, and public health management strategies to reduce morbidity and improve outcomes.
C_LIO_LIThe protocol will be used for a sub-set of patients, already included in the existing cohort of more than 85,973 individuals hospitalized with confirmed COVID-19 infection across 42 countries (as of 20 July 2020), using the ISARIC/WHO standardized Core- or RAPID Case Report Forms (CRFs).
C_LIO_LIThe data will be linked with data on pre-existing comorbidities, presentation, clinical care and treatments documented in the existing cohort already documented using the ISARIC/WHO standardized Core- or RAPID CRFs.
C_LIO_LIThe data collection tool is developed to facilitate wide dissemination and uptake, by enabling patient self-assessment, however, follow up of patients requires consent and resources, which might limit the uptake and bias the data towards countries /sites with capacity to follow up patients over time.
C_LI",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.08.25.20182162,2020-08-31,https://medrxiv.org/cgi/content/short/2020.08.25.20182162,Optimising social mixing strategies to mitigate the impact of COVID-19 in six European countries: a mathematical modelling study,Romain Ragonnet; Guillaume Briffoteaux; Bridget M Williams; Julian Savulescu; Matthew Segal; Milinda Abayawardana; Rosalind M Eggo; Daniel Tuyttens; Nouredine Melab; Ben J Marais; Emma S McBryde; James M Trauer,"Monash University; University of Mons, Belgium; Monash University; University of Oxford; Monash University; Monash University; London School of Hygiene & Tropical Medicine; University of Mons, Belgium; Universite de Lille, CNRS CRIStAL, Inria Lille, France; University of Sydney; James Cook University; Monash University","BackgroundIf SARS-CoV-2 elimination is not feasible, strategies are needed to minimise the impact of COVID-19 in the medium-to-long term, until safe and effective vaccines can be used at the population-level.

MethodsUsing a mathematical model, we identified contact mitigation strategies that minimised COVID-19-related deaths or years of life lost (YLLs) over a time-horizon of 15 months, using an intervention lasting six or 12 months, in Belgium, France, Italy, Spain, Sweden and the UK. We used strategies that either altered age- or location-specific contact patterns. The optimisation was performed under the constraint that herd immunity should be achieved by the end of the intervention period if post-infection immunity was persistent. We then tested the effect of waning immunity on the strategies.

FindingsStrategies of contact mitigation by age were much more effective than those based on mitigation by location. Extremely stringent contact reductions for individuals aged over 50 were required in most countries to minimise deaths or YLLs. The median final proportion of the population ever-infected with SARS-CoV-2 after herd immunity was reached ranged between 30% and 43%, depending on the country and intervention duration. Compared to an unmitigated scenario, optimised age-specific mitigation was predicted to avert over 1 million deaths across the six countries. The optimised scenarios assuming persistent immunity resulted in comparable hospital occupancies to that experienced during the March-April European wave. However, if immunity was shortlived, high burdens were expected without permanent contact mitigation.

InterpretationOur analysis suggests that age-selective mitigation strategies can reduce the mortality impacts of COVID-19 dramatically even when significant transmission occurs. The stringency of the required restrictions in some groups raises concerns about the practicality of these strategies. If post-infection immunity was short-lived, solutions based on a mitigation period designed to increase population immunity should be accompanied with ongoing contact mitigation to prevent large epidemic resurgence.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.08.24.20180679,2020-08-29,https://medrxiv.org/cgi/content/short/2020.08.24.20180679,Cellular immune response to SARS-CoV-2 infection in humans: a systematic review,Madhumita Shrotri; May C I van Schalkwyk; Nathan Post; Danielle Eddy; Catherine Huntley; David Leeman; Samuel Rigby; Sarah V Williams; William H Bermingham; Paul Kellam; John Maher; Adrian M Shields; Gayatri Amirthalingam; Sharon J Peacock; Sharif A Ismail,London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; University Hospitals Birmingham; Imperial College London; King's College London; University of Birmingham; Public Health England; University of Cambridge; London School of Hygiene & Tropical Medicine,"IntroductionUnderstanding the cellular immune response to SARS-CoV-2 is critical to vaccine development, epidemiological surveillance and control strategies. This systematic review critically evaluates and synthesises the relevant peer-reviewed and pre-print literature published in recent months.

MethodsFor this systematic review, independent keyword-structured literature searches were carried out in MEDLINE, Embase and COVID-19 Primer for studies published from 01/01/2020-26/06/2020. Papers were independently screened by two researchers, with arbitration of disagreements by a third researcher. Data were independently extracted into a pre-designed Excel template and studies critically appraised using a modified version of the MetaQAT tool, with resolution of disagreements by consensus. Findings were narratively synthesised.

Results61 articles were included. Almost all studies used observational designs, were hospital-based, and the majority had important limitations. Symptomatic adult COVID-19 cases consistently show peripheral T cell lymphopenia, which positively correlates with increased disease severity, duration of RNA positivity, and non-survival; while asymptomatic and paediatric cases display preserved counts. People with severe or critical disease generally develop more robust, virus-specific T cell responses. T cell memory and effector function has been demonstrated against multiple viral epitopes, and, cross-reactive T cell responses have been demonstrated in unexposed and uninfected adults, but the significance for protection and susceptibility, respectively, remains unclear.

InterpretationA complex pattern of T cell response to SARS-CoV-2 infection has been demonstrated, but inferences regarding population level immunity are hampered by significant methodological limitations and heterogeneity between studies. In contrast to antibody responses, population-level surveillance of the cellular response is unlikely to be feasible in the near term. Focused evaluation in specific sub-groups, including vaccine recipients, should be prioritised.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.08.24.20179192,2020-08-26,https://medrxiv.org/cgi/content/short/2020.08.24.20179192,UK prevalence of underlying conditions which increase the risk of severe COVID-19 disease: a point prevalence study using electronic health records,Jemma L Walker; Daniel J Grint; Helen Strongman; Rosalind M Eggo; Maria Peppa; Caroline Minassian; Kathryn E Mansfield; Christopher T. Rentsch; Ian J Douglas; Rohini Mathur; Angel Wong; Jennifer K Quint; Nick Andrews; Jamie Lopez Bernal; J Anthony Scott; Mary Ramsay; Liam Smeeth; Helen I McDonald,"London School of Hygiene & Tropical Medicine, Public Health England; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; Imperial College London; Public Health England; Public Health England; London School of Hygiene & Tropical Medicine; Public Health England; London School of Hygiene & Tropical Medicine; London School of Medicine and Tropical Medicine","BackgroundThis study aimed to describe the population at risk of severe COVID-19 due to underlying health conditions across the United Kingdom in 2019.

MethodsWe used anonymised electronic health records from the Clinical Practice Research Datalink GOLD to describe the point prevalence on 5 March 2019 of the at-risk population following national guidance. Prevalence for any risk condition and for each individual condition is given overall and stratified by age and region. We repeated the analysis on 5 March 2014 for full regional representation and to describe prevalence of underlying health conditions in pregnancy. We additionally described the population of cancer survivors, and assessed the value of linked secondary care records for ascertaining COVID-19 at-risk status.

FindingsOn 5 March 2019, 24{middle dot}4% of the UK population were at risk due to a record of at least one underlying health condition, including 8{middle dot}3% of school-aged children, 19{middle dot}6% of working-aged adults, and 66{middle dot}2% of individuals aged 70 years or more. 7{middle dot}1% of the population had multimorbidity. The size of the at-risk population was stable over time comparing 2014 to 2019, despite increases in chronic liver disease and diabetes and decreases in chronic kidney disease and current asthma. Separately, 1{middle dot}6% of the population had a new diagnosis of cancer in the past five years.

InterpretationThe population at risk of severe COVID-19 (aged [&ge;]70 years, or with an underlying health condition) comprises 18.5 million individuals in the UK, including a considerable proportion of school-aged and working-aged individuals.

FundingNIHR HPRU in Immunisation

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched Pubmed for peer-reviewed articles, preprints, and research reports on the size and distribution of the population at risk of severe COVID. We used the terms (1) risk factor or co-morbidity or similar (2) COVID or SARS or similar and (3) prevalence to search for studies aiming to quantify the COVID-19 at-risk UK population published in the previous year to 19 July 2020, with no language restrictions. We found one study which modelled prevalence of risk factors based on the Global Burden of Disease (which included the UK) and one study which estimated that 8.4 million individuals aged [&ge;]30 years in the UK were at risk based on prevalence of a subset of relevant conditions in England. There were no studies which described the complete COVID-19 at-risk population across the UK.

Added value of this studyWe used a large, nationally-representative dataset based on electronic health records to estimate prevalence of increased risk of severe COVID-19 across the United Kingdom, including all conditions in national guidance. We stratified by age, sex and region to enable regionally-tailored prediction of COVID-19-related healthcare burden and interventions to reduce transmission of infection, and planning and modelling of vaccination of the at-risk population. We also quantified the value of linked secondary care records to supplement primary care records.

Implications of all the available evidenceIndividuals at moderate or high risk of severe COVID-19 according to current national guidance (aged [&ge;]70 years, or with a specified underlying health condition) comprise 18{middle dot}5 million individuals in the United Kingdom, rather than the 8.43 million previously estimated.

The 8{middle dot}3% of school-aged children and 19{middle dot}6% of working-aged adults considered at-risk according to national guidance emphasises the need to consider younger at-risk individuals in shielding policies and when re-opening schools and workplaces, but also supports prioritising vaccination based on age and condition-specific mortality risk, rather than targeting all individuals with underlying conditions, who form a large population even among younger age groups.

Among individuals aged [&ge;]70 years, 66{middle dot}2% had at least one underlying health condition, suggesting an age-targeted approach to vaccination may efficiently target individuals at risk of severe COVID-19.

These national estimates broadly support the use of Global Burden of Disease modelled estimates and age-targeted vaccination strategies in other countries.",epidemiology,fuzzy,100,100
bioRxiv,10.1101/2020.08.25.265074,2020-08-26,https://biorxiv.org/cgi/content/short/2020.08.25.265074,Identification of a polymorphism in the N gene of SARS-CoV-2 that adversely impacts detection by a widely-used RT-PCR assay,Manu Vanaerschot; Sabrina A Mann; James T Webber; Jack Kamm; Sidney M Bell; John Bell; Si Noon Hong; Minh Phuong Nguyen; Lienna Y Chan; Karan D Bhatt; Michelle Tan; Angela M Detweiler; Alex Espinosa; Wesley Wu; Joshua Batson; David Dynerman; - CLIAHUB Consortium; Debra A Wadford; Andreas Puschnik; Norma Neff; Vida Ahyong; Steve Miller; Patrick Ayscue; Cristina M Tato; Simon Paul; Amy Kistler; Joseph L DeRisi; Emily Dawn Crawford,Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; Chan Zuckerberg Initiative; California Department of Public Health; Madera County Department of Public Health; Madera County Department of Public Health; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; California Department of Public Health; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; -; California Department of Public Health; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; University of California San Francisco; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub; Madera County Department of Public Health; Chan Zuckerberg Initiative; Chan Zuckerberg Biohub; Chan Zuckerberg Biohub,"We identify a mutation in the N gene of SARS-CoV-2 that adversely affects annealing of a commonly used RT-PCR primer; epidemiologic evidence suggests the virus retains pathogenicity and competence for spread. This reinforces the importance of using multiple targets, preferably in at least 2 genes, for robust SARS-CoV-2 detection.

Article Summary LineA SARS-CoV-2 variant that occurs worldwide and has spread in California significantly affects diagnostic sensitivity of an N gene assay, highlighting the need to employ multiple viral targets for detection.",molecular biology,fuzzy,92,100
medRxiv,10.1101/2020.08.21.20177246,2020-08-24,https://medrxiv.org/cgi/content/short/2020.08.21.20177246,Using symptom-based case predictions to identify host genetic factors that contribute to COVID-19 susceptibility,Irene V van Blokland; Pauline Lanting; Anil PS Ori; Judith M Vonk; Robert CA Warmerdam; Johanna C Herkert; Floranne Boulogne; Annique Claringbould; Esteban A Lopera-Maya; Meike Bartels; Jouke-Jan Hottenga; Andrea Ganna; Juha Karjalainen; - Lifelines COVID-19 cohort study; - The COVID-19 Host Genetics Initiative; Caroline Hayward; Chloe Fawns-Ritchie; Archie Campbell; David Porteous; Elizabeth T Cirulli; Kelly M Schiabor Barrett; Stephen Riffle; Alexandre Bolze; Simon White; Francisco Tanudjaja; Xueqing Wang; Jimmy M Ramirez III; Yan Wei Lim; James T Lu; Nicole L Washington; Eco JC de Geus; Patrick Deelen; H Marike Boezen; Lude H Franke,"University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and University of Groningen, University Medica; University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and University of Groningen, University Medica; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Structural Computational Biology unit, EMB; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland; Broad Institute of MIT and Harvard, Cambridge, MA, USA and Analytic and Tra; ; ; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Department of Psychology, University of Edinburgh, 7 George Square, Edinburgh EH8 9JZ; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Medical Genetics Section, Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Helix, 101 S Ellsworth Ave Suite 350, San Mateo, California 94401, USA; Department of Biological Psychology, FGB, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands and Amsterdam Public Health research institute, Amsterdam UMC; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands and Department of Genetics, University Medical; University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen,  Department of Genetics, Groningen, The Netherlands","Epidemiological and genetic studies on COVID-19 are currently hindered by inconsistent and limited testing policies to confirm SARS-CoV-2 infection. Recently, it was shown that it is possible to predict potential COVID-19 cases using cross-sectional self-reported disease-related symptoms. Using a previously reported COVID-19 prediction model, we show that it is possible to conduct a GWAS on predicted COVID-19, and this GWAS benefits from the larger sample size to provide new insights into the genetic susceptibility of the disease. Furthermore, we find suggestive evidence that genetic variants for other viral infectious diseases do not overlap with COVID-19 susceptibility and that severity of COVID-19 may have a different genetic architecture compared to COVID-19 susceptibility. Our findings demonstrate the added value of using self-reported symptom assessments to quickly monitor novel endemic viral outbreaks in a scenario of limited testing. Should there be another outbreak of a novel infectious disease, we recommend repeatedly collecting data of disease-related symptoms.",genetic and genomic medicine,fuzzy,100,100
medRxiv,10.1101/2020.08.18.20177691,2020-08-22,https://medrxiv.org/cgi/content/short/2020.08.18.20177691,"Genetically-predicted vitamin D status, ambient UVB during the pandemic and COVID-19 risk in UK Biobank: Mendelian Randomisation study",Xue Li; Jos van Geffen; Michiel van Weele; Xiangrui Meng; XIAOMENG ZHANG; Yazhou He; Maria Timofeeva; Harry Campbell; Malcolm G Dunlop; Lina Zgaga; Evropi Theodoratou,"School of Public Health and the Second Affiliated Hospital, Zhejiang University; Royal Netherlands Meteorological Institute (KNMI), De Bilt, the Netherlands; Royal Netherlands Meteorological Institute (KNMI), De Bilt, the Netherlands; Vanke School of public Health,Tsinghua University; Usher Institute; Centre for Global Health, Usher Institute, University of Edinburgh; DIAS, Danish Institute for Advanced Study, Department of Public Health, University of Southern Denmark; Centre for Global Health, Usher Institute, University of Edinburgh; Institute of Genetics and Molecular Medicine; Department of Public Health and Primary Care, Institute of Population Health, Trinity College Dublin; University of Edinburgh","A growing body of evidence shows that poor vitamin D status has been associated with an increased susceptibility to viral and bacterial respiratory infections. In this study, we aimed to examine the association between vitamin D and COVID-19 risk and outcomes, and to explore potential causal effects. We used logistic regression to identify associations between different vitamin D variables (25-hydroxyvitamin D concentration (25-OHD), ambient UVB and genetically-predicted 25-OHD concentrations) and COVID-19 (risk of infection, hospitalisation and death) in 495,780 participants from UK Biobank. We subsequently performed a Mendelian Randomisation (MR) study to test if there was any causal effect. In total, 1,746 COVID-19 cases and 399 COVID-19 deaths occurred between March and June 2020. We found significant inverse associations between COVID-19 infection and 25-OHD in univariable models, but these associations were non-significant after adjustment for confounders. Ambient UVB was strongly and inversely associated with hospitalization and death. Although the main MR analysis showed that genetically-predicted vitamin D levels were not causally associated with COVID-19 risk, MR sensitivity analysis using weighted mode method indicated a potential causal effect (OR=0.72, 95% CI:0.53-0.98; P=0.041). In conclusion, our study found suggestive evidence of association between vitamin D and the risk or severity of COVID-19 but further studies are needed.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.08.19.20178137,2020-08-22,https://medrxiv.org/cgi/content/short/2020.08.19.20178137,Testing for coronavirus (SARS-CoV-2) infection in populations with low infection prevalence: the largely ignored problem of false positives and the value of repeat testing,Cathie Sudlow; Peter Diggle; Oliver Warlow; David Seymour; Ben Gordon; Rhos Walker; Charles Warlow,"BHF Data Science Centre, Health Data Research UK; Usher Institute, University of Edinburgh; University of Lancaster; Health Data Research UK; Ventient Energy; Health Data Research UK; Health Data Research UK; Health Data Research UK; University of Edinburgh","BackgroundCalls are increasing for widespread SARS-CoV-2 infection testing of people from populations with a very low prevalence of infection. We quantified the impact of less than perfect diagnostic test accuracy on populations, and on individuals, in low prevalence settings, focusing on false positives and the role of confirmatory testing.

MethodsWe developed a simple, interactive tool to assess the impact of different combinations of test sensitivity, specificity and infection prevalence in a notional population of 100,000. We derived numbers of true positives, true negatives, false positives and false negatives, positive predictive value (PPV - the percentage of test positives that are true positives) and overall test accuracy for three testing strategies: (1) single test for all; (2) add repeat testing in test positives; (3) add further repeat testing in those with discrepant results. We also assessed the impact on test results for individuals having one, two or three tests under these three strategies.

ResultsWith sensitivity of 80%, infection prevalence of 1 in 2,000, and specificity 99.9% on all tests, PPV in the tested population of 100,000 will be only 29% with one test, increasing to > 99.5% (100% when rounded to the nearest %) with repeat testing in strategies 2 or 3. More realistically, if specificity is 95% for the first and 99.9% for subsequent tests, single test PPV will be only 1%, increasing to 86% with repeat testing in strategy 2, or 79% with strategy 3 (albeit with 6 fewer false negatives than strategy 2). In the whole population, or in particular individuals, PPV increases as infection becomes more common in the population but falls to unacceptably low levels with lower test specificity.

ConclusionTo avoid multiple unnecessary restrictions on whole populations, and in particular individuals, from widespread population testing for SARS-CoV-2, the crucial roles of extremely high test specificity and of confirmatory testing must be fully appreciated and incorporated into policy decisions.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.08.17.20175117,2020-08-21,https://medrxiv.org/cgi/content/short/2020.08.17.20175117,Real-time spatial health surveillance: mapping the UK COVID-19 epidemic,Richard Fry; Joe Hollinghurst; Helen R Stagg; Daniel A Thompson; Claudio Fronterre; Chris Orton; Ronan A Lyons; David V Ford; Aziz Sheikh; Peter J Diggle,Swansea University; Swansea University; Edinburgh University; Swansea University; Lancaster University; Swansea University; Swansea University; Swansea University; Edinburgh University; Lancaster University,"The COVID-19 pandemic has highlighted the need for robust data linkage systems and methods for identifying outbreaks of disease in near real-time. Using self-reported app data and the Secure Anonymised Information Linkage (SAIL) Databank, we demonstrate the use of sophisticated spatial modelling for near-real-time prediction of COVID-19 prevalence at small-area resolution to inform strategic government policy areas. A pre-requisite to an effective control strategy is that predictions need to be accompanied by estimates of their precision, to guard against over-reaction to potentially spurious features of  best guess predictions. In the UK, important emerging risk-factors such as social deprivation or ethnicity vary over small distances, hence risk needs to be modelled at fine spatial resolution to avoid aggregation bias. We demonstrate that existing geospatial statistical methods originally developed for global health applications are well-suited to this task and can be used in an anonymised databank environment, thus preserving the privacy of the individuals who contribute their data.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.08.17.20161760,2020-08-19,https://medrxiv.org/cgi/content/short/2020.08.17.20161760,"SARS-CoV-2 (COVID-19) infection in pregnant women: characterization of symptoms and syndromes predictive of disease and severity through real-time, remote participatory epidemiology.",Erika Molteni; Christina M Astley; Wenjie Ma; Carole Helene Sudre; Laura A Magee; Benjamin Murray; Tove Fall; Maria F Gomez; Neli Tsereteli; Paul W Franks; John S Brownstein; Richard Davies; Jonathan Wolf; Timothy Spector; Sebastien Ourselin; Claire Steves; Andrew T Chan; Marc Modat,"King's College London; Boston Children's Hospital and Harvard Medical School; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA; King's College London; Department of Women and Childrens Health, School of Life Course Sciences and the Institute of Women and Childrens Health, Kings College London, London, United K; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, United Kingdom; Department of Medical Sciences and Science for Life Laboratory, Uppsala University, Sweden; Department of Clinical Sciences, Lund University Diabetes Centre, Jan Waldenstroems gata 35, SE-21428, Malmo, Sweden; Department of Clinical Sciences, Lund University Diabetes Centre, Jan Waldenstroems gata 35, SE-21428, Malmo, Sweden; Department of Clinical Sciences, Lund University Diabetes Centre, Jan Waldenstroems gata 35, SE-21428, Malmo, Sweden.; Boston Childrens Hospital and Harvard Medical School, Boston, MA, USA; Zoe Global Limited, London, United Kingdom; Zoe Global Limited, London, United Kingdom; King's College London; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, United Kingdom; King's College London; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA; School of Biomedical Engineering & Imaging Sciences, Kings College London, London, United Kingdom","BackgroundFrom the beginning of COVID-19 pandemic, pregnant women have been considered at greater risk of severe morbidity and mortality. However, data on hospitalized pregnant women show that the symptom profile and risk factors for severe disease are similar to those among women who are not pregnant, although preterm birth, Cesarean delivery, and stillbirth may be more frequent and vertical transmission is possible. Limited data are available for the cohort of pregnant women that gave rise to these hospitalized cases, hindering our ability to quantify risk of COVID-19 sequelae for pregnant women in the community.

ObjectiveTo test the hypothesis that pregnant women in community differ in their COVID-19 symptoms profile and disease severity compared to non-pregnant women. This was assessed in two community-based cohorts of women aged 18-44 years in the United Kingdom, Sweden and the United States of America.

Study designThis observational study used prospectively collected longitudinal (smartphone application interface) and cross-sectional (web-based survey) data. Participants in the discovery cohort were drawn from 400,750 UK, Sweden and US women (79 pregnant who tested positive) who self-reported symptoms and events longitudinally via their smartphone, and a replication cohort drawn from 1,344,966 USA women (162 pregnant who tested positive) cross-sectional self-reports samples from the social media active user base. The study compared frequencies of symptoms and events, including self-reported SARS-CoV-2 testing and differences between pregnant and non-pregnant women who were hospitalized and those who recovered in the community. Multivariable regression was used to investigate disease severity and comorbidity effects.

ResultsPregnant and non-pregnant women positive for SARS-CoV-2 infection drawn from these community cohorts were not different with respect to COVID-19-related severity. Pregnant women were more likely to have received SARS-CoV-2 testing than non-pregnant, despite reporting fewer clinical symptoms. Pre-existing lung disease was most closely associated with the severity of symptoms in pregnant hospitalized women. Heart and kidney diseases and diabetes were additional factors of increased risk. The most frequent symptoms among all non-hospitalized women were anosmia [63% in pregnant, 92% in non-pregnant] and headache [72%, 62%]. Cardiopulmonary symptoms, including persistent cough [80%] and chest pain [73%], were more frequent among pregnant women who were hospitalized. Gastrointestinal symptoms, including nausea and vomiting, were different among pregnant and non-pregnant women who developed severe outcomes.

ConclusionsAlthough pregnancy is widely considered a risk factor for SARS-CoV-2 infection and outcomes, and was associated with higher propensity for testing, the profile of symptom characteristics and severity in our community-based cohorts were comparable to those observed among non-pregnant women, except for the gastrointestinal symptoms. Consistent with observations in non-pregnant populations, comorbidities such as lung disease and diabetes were associated with an increased risk of more severe SARS-CoV-2 infection during pregnancy. Pregnant women with pre-existing conditions require careful monitoring for the evolution of their symptoms during SARS-CoV-2 infection.",epidemiology,fuzzy,94,100
medRxiv,10.1101/2020.08.14.20168088,2020-08-16,https://medrxiv.org/cgi/content/short/2020.08.14.20168088,"Robust, reproducible clinical patterns in hospitalised patients with COVID-19",Jonathan E Millar; Lucile Neyton; Sohan Seth; Jake Dunning; Laura Merson; Srinivas Murthy; Clark D Russell; Sean Keating; Maaike Swets; Carole H Sudre; Timothy D Spector; Sebastien Ourselin; Claire J Steves; Jonathan Wolf; - ISARIC4C Investigators; Annemarie B Docherty; Ewen M Harrison; Peter JM Openshaw; Malcolm G Semple; J Kenneth Baillie,"Division of Functional Genetics and Development, Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Division of Functional Genetics and Development, Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Institute for Adaptive and Neural Computation, School of Informatics, University of Edinburgh, Edinburgh, United Kingdom; National Infection Service, Public Health England, United Kingdom; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; BC Childrens Hospital, University of British Columbia, Vancouver, Canada; Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom; Intensive Care Unit, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom; Division of Functional Genetics and Development, Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; School of Biomedical and Imaging Sciences, Kings College London, London, United Kingdom; Department of Twin Research and Genetic Epidemiology, Kings College London, London, United Kingdom; School of Biomedical and Imaging Sciences, Kings College London, London, United Kingdom; Department of Twin Research and Genetic Epidemiology, Kings College London, London, United Kingdom; ZOE Global Ltd., London, United Kingdom; ; Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; Centre for Medical Informatics, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom; National Heart and Lung Institute, Imperial College London, London, United Kingdom; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life; Division of Functional Genetics and Development, Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom","BackgroundSevere COVID-19 is characterised by fever, cough, and dyspnoea. Symptoms affecting other organ systems have been reported. However, it is the clinical associations of different patterns of symptoms which influence diagnostic and therapeutic decision-making. In this study, we applied simple machine learning techniques to a large prospective cohort of hospitalised patients with COVID-19 identify clinically meaningful sub-groups.

MethodsWe obtained structured clinical data on 59 011 patients in the UK (the ISARIC Coronavirus Clinical Characterisation Consortium, 4C) and used a principled, unsupervised clustering approach to partition the first 25 477 cases according to symptoms reported at recruitment. We validated our findings in a second group of 33 534 cases recruited to ISARIC-4C, and in 4 445 cases recruited to a separate study of community cases.

FindingsUnsupervised clustering identified distinct sub-groups. First, a core symptom set of fever, cough, and dyspnoea, which co-occurred with additional symptoms in three further patterns: fatigue and confusion, diarrhoea and vomiting, or productive cough. Presentations with a single reported symptom of dyspnoea or confusion were common, and a subgroup of patients reported few or no symptoms. Patients presenting with gastrointestinal symptoms were more commonly female, had a longer duration of symptoms before presentation, and had lower 30-day mortality. Patients presenting with confusion, with or without core symptoms, were older and had a higher unadjusted mortality. Symptom clusters were highly consistent in replication analysis using a further 35446 individuals subsequently recruited to ISARIC-4C. Similar patterns were externally verified in 4445 patients from a study of self-reported symptoms of mild disease.

InterpretationThe large scale of the ISARIC-4C study enabled robust, granular discovery and replication of patient clusters. Clinical interpretation is necessary to determine which of these observations have practical utility. We propose that four patterns are usefully distinct from the core symptom groups: gastro-intestinal disease, productive cough, confusion, and pauci-symptomatic presentations. Importantly, each is associated with an in-hospital mortality which differs from that of patients with core symptoms. These observations deepen our understanding of COVID-19 and will influence clinical diagnosis, risk prediction, and future mechanistic and clinical studies.

FundingMedical Research Council; National Institute Health Research; Well-come Trust; Department for International Development; Bill and Melinda Gates Foundation; Liverpool Experimental Cancer Medicine Centre.",infectious diseases,fuzzy,94,100
medRxiv,10.1101/2020.08.13.20174193,2020-08-15,https://medrxiv.org/cgi/content/short/2020.08.13.20174193,CovidNudge: diagnostic accuracy of a novel lab-free point-of-care diagnostic for SARS-CoV-2,Malick M Gibani; Christofer Toumazou; Mohammadreza Sohbati; Rashmita Sahoo; Maria Karvela; Tsz-Kin Hon; Sara De Mateo; Alison Burdett; K Y Felice Leung; Jake Barnett; Arman Orbeladze; Song Luan; Stavros Pournias; Jiayang Sun; Barnaby Flower; Judith Bedzo-Nutakor; Maisarah Amran; Rachael Quinlan; Keira Skolimowska; Robert Klaber; Gary Davies; David Muir; Paul Randell; Derrick W M Crook; Graham P Taylor; Wendy Barclay; Nabeela Mughal; Luke S P Moore; Katie Jeffery; Graham S Cooke,"Imperial College London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; Department of Infectious Disease, Imperial College London, United Kingdom; DnaNudge Ltd, Translation and Innovation Hub, Imperial College White City Campus, London; Imperial College Healthcare NHS Trust, United Kingdom.; Department of Infectious Disease, Imperial College London, United Kingdom; Imperial College Healthcare NHS Trust, United Kingdom; Imperial College Healthcare NHS Trust, United Kingdom; Chelsea & Westminster NHS Foundation Trust, London; Imperial College Healthcare NHS Trust, United Kingdom; Imperial College Healthcare NHS Trust, United Kingdom; NIHR Oxford Biomedical Research Centre; Department of Infectious Disease, Imperial College London, United Kingdom; Department of Infectious Disease, Imperial College London, United Kingdom; Chelsea & Westminster NHS Foundation Trust, London; Chelsea & Westminster NHS Foundation Trust, London; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Department of Infectious Disease, Imperial College London, United Kingdom","3.BackgroundAccess to rapid diagnosis is key to the control and management of SARS-CoV-2. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) testing usually requires a centralised laboratory and significant infrastructure. We describe the development and diagnostic accuracy assessment of a novel, rapid point-of-care RT-PCR test, the DnaNudge(R) platform CovidNudge test, which requires no laboratory handling or sample pre-processing.

MethodsNasopharyngeal swabs are inserted directly into a cartridge which contains all reagents and components required for RT-PCR reactions, including multiple technical replicates of seven SARS-CoV-2 gene targets (rdrp1, rdrp2, e-gene, n-gene, n1, n2 and n3) and human ribonuclease P (RNaseP) as positive control. Between April and May 2020, swab samples were tested in parallel using the CovidNudge direct-to-cartridge platform and standard laboratory RT-PCR using swabs in viral transport medium. Samples were collected from three groups: self-referred healthcare workers with suspected COVID-19 (Group 1, n=280/386; 73%); patients attending the emergency department with suspected COVID-19 (Group 2, n=15/386; 4%) and hospital inpatient admissions with or without suspected COVID-19 (Group 3, n=91/386; 23%).

ResultsOf 386 paired samples tested across all groups, 67 tested positive on the CovidNudge platform and 71 with standard laboratory RT-PCR. The sensitivity of the test varied by group (Group 1 93% [84-98%], Group 2 100% [48-100%] and Group 3 100% [29-100%], giving an average sensitivity of 94.4% (95% confidence interval 86-98%) and an overall specificity of 100% (95%CI 99-100%; Group 1 100% [98-100%]; Group 2 100% [69-100%] and Group 3 100% [96-100%]). Point of care testing performance was comparable during a period of high (25%) and low (3%) background prevalence. Amplification of the viral nucleocapsid (n1, n2, n3) targets were most sensitive for detection of SARS-CoV2, with the assay able to detect 1x104 viral particles in a single swab.

ConclusionsThe CovidNudge platform offers a sensitive, specific and rapid point of care test for the presence of SARS-CoV-2 without laboratory handling or sample pre-processing. The implementation of such a device could be used to enable rapid decisions for clinical care and testing programs.

4. RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSThe WHO has highlighted the development of rapid, point-of-care diagnostics for detection of SARS-CoV-2 as a key priority to tackle COVID-19. The Foundation for Innovative Diagnostics (FIND) has identified over 90 point-of-care, near patient or mobile tests for viral detection of SARS-CoV-2. However, the most widely available rapid tests to date require some sample handling which limits their use at point-of-care. In addition, pressure on supply chains is restricting access to current diagnostics and alternatives are needed urgently.

Added value of this studyWe describe the development and clinical validation of COVID nudge, a novel point-of-care RT-PCR diagnostic, evaluated during the first wave of the SARS-CoV-2 epidemic. The platform is able to achieve high analytic sensitivity and specificity from dry swabs within a self-contained cartridge. The lack of downstream sample handling makes it suitable for use in a range of clinical settings, without need for a laboratory or specialized operator. Multiplexed assays within the cartridge allow inclusion of a positive human control, which reduces the false negative testing rate due to insufficient sampling.

Implication of the available evidencePoint-of-care testing can relieve pressure on centralized laboratories and increase overall testing capacity, complementing existing approaches. These findings support a role for COVID Nudge as part of strategies to improve access to rapid diagnostics to SARS-CoV-2. Since May 2020, the system has been implemented in UK hospitals and is being rolled out nationwide.",infectious diseases,fuzzy,92,100
medRxiv,10.1101/2020.08.12.20173690,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.12.20173690,"Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults",Helen Ward; Christina J Atchison; Matthew Whitaker; Kylie E. C. Ainslie; Joshua Elliott; Lucy C Okell; Rozlyn Redd; Deborah Ashby; Christl A. Donnelly; Wendy Barclay; Ara Darzi; Graham Cooke; Steven Riley; Paul Elliott,"Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Dept Inf Dis Epi, Imperial College; Imperial College London","BackgroundEngland, UK has experienced a large outbreak of SARS-CoV-2 infection. As in USA and elsewhere, disadvantaged communities have been disproportionately affected.

MethodsNational REal-time Assessment of Community Transmission-2 (REACT-2) prevalence study using a self-administered lateral flow immunoassay (LFIA) test for IgG among a random population sample of 100,000 adults over 18 years in England, 20 June to 13 July 2020.

ResultsData were available for 109,076 participants, yielding 5,544 IgG positive results; adjusted (for test performance) and re-weighted (for sampling) prevalence was 6.0% (95% Cl: 5.8, 6.1). Highest prevalence was in London (13.0% [12.3, 13.6]), among people of Black or Asian (mainly South Asian) ethnicity (17.3% [15.8, 19.1] and 11.9% [11.0, 12.8] respectively) and those aged 18-24 years (7.9% [7.3, 8.5]). Adjusted odds ratio for care home workers with client-facing roles was 3.1 (2.5, 3.8) compared with non-essential workers. One third (32.2%, [31.0-33.4]) of antibody positive individuals reported no symptoms. Among symptomatic cases, most (78.8%) reported symptoms during the peak of the epidemic in England in March (31.3%) and April (47.5%) 2020. We estimate that 3.36 million (3.21, 3.51) people have been infected with SARS-CoV-2 in England to end June 2020, with an overall infection fatality ratio (IFR) of 0.90% (0.86, 0.94); age-specific IFR was similar among people of different ethnicities.

ConclusionThe SARS-CoV-2 pandemic in England disproportionately affected ethnic minority groups and health and care home workers. The higher risk of infection in minority ethnic groups may explain their increased risk of hospitalisation and mortality from COVID-19.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.08.13.20174227,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.13.20174227,Long-Term Exposure to Outdoor Air Pollution and COVID-19 Mortality: an ecological analysis in England,Zhiqiang Feng; Mark Cherrie; Chris DIBBEN,University of Edinburgh; University of Edinburgh; University of Edinburgh,"There is an urgent need to examine what individual and environmental risk factors are associated with COVID-19 mortality. This objective of this study is to investigate the association between long term exposure to air pollution and COVID-19 mortality. We conducted a nationwide, ecological study using zero-inflated negative binomial models to estimate the association between long term (2014-2018) small area level exposure to NOx, PM2.5, PM10 and SO2 and COVID-19 mortality rates in England adjusting for socioeconomic factors and infection exposure. We found that all four pollutant concentrations were positively associated with COVID-19 mortality. The increase in mortality risk ratio per inter quarter range increase was for PM2.5:11%, 95%CIs 6%-17%), PM10 (5%; 95%CIs 1%-11%), NOx (11%, 95%CIs 6%-15%) and SO2 (7%, 95%CIs 3%-11%) were respectively in adjusted models. Public health intervention may need to protect people who are in highly polluted areas from COVID-19 infections.",occupational and environmental health,fuzzy,100,100
medRxiv,10.1101/2020.08.12.20171405,2020-08-14,https://medrxiv.org/cgi/content/short/2020.08.12.20171405,OpenSAFELY: Do adults prescribed Non-steroidal anti-inflammatory drugs have an increased risk of death from COVID-19?,Angel YS Wong; Brian MacKenna; Caroline Morton; Anna Schultze; Alex J Walker; Krishnan Bhaskaran; Jeremy Brown; Christopher T. Rentsch; Elizabeth Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen Evans; Liam Smeeth; Ian Douglas; Ben Goldacre,"London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","ImportanceThere has been speculation that non-steroidal anti-inflammatory drugs (NSAIDs) may negatively affect coronavirus disease 2019 (COVID-19) outcomes, yet clinical evidence is limited.

ObjectiveTo assess the association between NSAID use and deaths from COVID-19 using OpenSAFELY, a secure analytical platform.

DesignTwo cohort studies (1st March-14th June 2020).

SettingWorking on behalf of NHS England, we used routine clinical data from >17 million patients in England linked to death data from the Office for National Statistics.

ParticipantsStudy 1: General population (people with an NSAID prescription in the last three years). Study 2: people with rheumatoid arthritis/osteoarthritis.

ExposuresCurrent NSAID prescription within the 4 months before 1st March 2020.

Main Outcome and MeasureWe used Cox regression to estimate hazard ratios (HRs) for COVID-19 related death in people currently prescribed NSAIDs, compared with those not currently prescribed NSAIDs, adjusting for age, sex, comorbidities and other medications.

ResultsIn Study 1, we included 535,519 current NSAID users and 1,924,095 non-users in the general population. The crude HR for current use was 1.25 (95% CI, 1.07-1.46), versus non-use. We observed no evidence of difference in risk of COVID-19 related death associated with current use (HR, 0.95, 95% CI, 0.80-1.13) in the fully adjusted model.

In Study 2, we included 1,711,052 people with rheumatoid arthritis/osteoarthritis, of whom 175,631 (10%) were current NSAID users. The crude HR for current use was 0.43 (95% CI, 0.36-0.52), versus non-use. In the fully adjusted model, we observed a lower risk of COVID-19 related death (HR, 0.78, 95% CI, 0.65-0.94) associated with current use of NSAID versus non-use.

Conclusion and RelevanceWe found no evidence of a harmful effect of NSAIDs on COVID-19 related deaths. Risks of COVID-19 do not need to influence decisions about therapeutic use of NSAIDs.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.08.10.20171496,2020-08-11,https://medrxiv.org/cgi/content/short/2020.08.10.20171496,Characterisation of 22446 patients attending UK emergency departments with suspected COVID-19 infection: Observational cohort study,Steve Goodacre; Ben Thomas; Ellen Lee; Laura Sutton; Amanda Loban; Simon Waterhouse; Richard Simmonds; Katie Biggs; Carl Marincowitz; Jose Schutter; Sarah Connelly; Elena Sheldon; Jamie Hall; Emma Young; Andrew Bentley; Kirsty Challen; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter,"University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Manchester University NHS Foundation Trust, Wythenshawe Hospital; Lancashire Teaching Hospitals NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Barts Health NHS Trust; University of Sheffield; University of Sheffield; Imperial College Healthcare NHS Trust; Manchester University NHS Foundation Trust","BackgroundHospital emergency departments play a crucial role in the Initial management of suspected COVID-19 infection. We aimed to characterise patients attending emergency departments with suspected COVID-19, including subgroups based on sex, ethnicity and COVID-19 test results.

MethodsWe undertook a mixed prospective and retrospective observational cohort study in 70 emergency departments across the United Kingdom (UK). We collected presenting data from 22446 people attending with suspected COVID-19 between 26 March 2020 and 28 May 2020. Outcomes were admission to hospital, COVID-19 result, organ support (respiratory, cardiovascular or renal), and death, by record review at 30 days.

ResultsAdults were acutely unwell (median NEWS2 score 4) and had high rates of admission (67.1%), COVID-19 positivity (31.2%), organ support (9.8%) and death (15.9%). Children had much lower rates of admission (27.4%), COVID-19 positivity (1.2%), organ support (1.4%) and death (0.3%). Adult men and women presented in similar numbers (10210 versus 10506), but men were more likely to be admitted (72.9% v 61.4%), require organ support (12.2% v 7.7%) and die (18.7% v 13.3%). Black or Asian adults tended to be younger than White adults (median age 54, 50 and 67 years), were less likely to be admitted (60.8%, 57.3%, 69.6%) or die (11.9%, 11.2%, 16.8%), but were more likely to require organ support (15.9%, 14.3%, 8.9%) or have a positive COVID-19 test (40.8%, 42.1%, 30.0%). Adults admitted with confirmed COVID-19 had similar age and comorbidities (except chronic lung disease) to those who did not have COVID-19 confirmed, but were much more likely to need organ support (22.2% v 8.9%) or die (32.7% v 15.9%).

ConclusionsImportant differences exist between patient groups presenting to the emergency department with suspected COVID-19. People with confirmed COVID-19 have a poor prognosis, compared with similar emergency admissions without confirmed COVID-19.

RegistrationISRCTN registry, ISRCTN56149622, http://www.isrctn.com/ISRCTN28342533",emergency medicine,fuzzy,100,100
medRxiv,10.1101/2020.08.10.20171421,2020-08-11,https://medrxiv.org/cgi/content/short/2020.08.10.20171421,Long-term exposure to air-pollution and COVID-19 mortality in England: a hierarchical spatial analysis,Garyfallos Konstantinoudis; Tullia Padellini; James E Bennett; Bethan Davies; Majid Ezzati; Marta Blangiardo,Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London,"BackgroundRecent studies suggested a link between long-term exposure to air-pollution and COVID-19 mortality. However, due to their ecological design, based on large spatial units, they neglect the strong localised air-pollution patterns, and potentially lead to inadequate confounding adjustment. We investigated the effect of long-term exposure to NO2 and PM2{middle dot}5 on COVID-19 deaths up to June 30, 2020 in England using high geographical resolution. Methods We included 38 573 COVID-19 deaths up to June 30, 2020 at the Lower Layer Super Output Area level in England (n=32 844 small areas). We retrieved averaged NO2 and PM2{middle dot}5 concentration during 2014-2018 from the Pollution Climate Mapping. We used Bayesian hierarchical models to quantify the effect of air-pollution while adjusting for a series of confounding and spatial autocorrelation.

FindingsWe find a 0{middle dot}5% (95% credible interval: -0{middle dot}2%-1{middle dot}2%) and 1{middle dot}4% (-2{middle dot}1%-5{middle dot}1%) increase in COVID-19 mortality rate for every 1g/m3 increase in NO2 and PM2{middle dot}5 respectively, after adjusting for confounding and spatial autocorrelation. This corresponds to a posterior probability of a positive effect of 0{middle dot}93 and 0{middle dot}78 respectively. The spatial relative risk at LSOA level revealed strong patterns, similar for the different pollutants. This potentially captures the spread of the disease during the first wave of the epidemic.

InterpretationOur study provides some evidence of an effect of long-term NO2 exposure on COVID-19 mortality, while the effect of PM2{middle dot}5 remains more uncertain.

FundingMedical Research Council, Wellcome Trust, Environmental Protection Agency and National Institutes of Health.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.08.10.20171033,2020-08-11,https://medrxiv.org/cgi/content/short/2020.08.10.20171033,Post-exertion oxygen saturation as a prognostic factor for adverse outcome in patients attending the emergency department with suspected COVID-19: Observational cohort study,Steve Goodacre; Ben Thomas; Ellen Lee; Laura Sutton; Katie Biggs; Carl Marincowitz; Amanda Loban; Simon Waterhouse; Richard Simmonds; Jose Schutter; Sarah Connelly; Elena Sheldon; Jamie Hall; Emma Young; Andrew Bentley; Kirsty Challen; Chris Fitzsimmons; Tim Harris; Fiona Lecky; Andrew Lee; Ian Maconochie; Darren Walter,"University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Manchester University NHS Foundation Trust, Wythenshawe Hospital; Lancashire Teaching Hospitals NHS Foundation Trust; Sheffield Children's NHS Foundation Trust; Barts Health NHS Trust; University of Sheffield; University of Sheffield; Imperial College Healthcare NHS Trust; Manchester University NHS Foundation Trust","BackgroundMeasurement of post-exertion oxygen saturation has been proposed to assess illness severity in suspected COVID-19 infection. We aimed to determine the accuracy of post-exertional oxygen saturation for predicting adverse outcome in suspected COVID-19.

MethodsWe undertook an observational cohort study across 70 emergency departments during first wave of the COVID-19 pandemic in the United Kingdom. We collected data prospectively, using a standardised assessment form, and retrospectively, using hospital records, from patients with suspected COVID-19, and reviewed hospital records at 30 days for adverse outcome (death or receiving organ support). Patients with post-exertion oxygen saturation recorded were selected for this analysis.

ResultsWe analysed data from 817 patients with post-exertion oxygen saturation recorded after excluding 54 in whom measurement appeared unfeasible. The c-statistic for post-exertion change in oxygen saturation was 0.589 (95% confidence interval 0.465 to 0.713), and the positive and negative likelihood ratios of a 3% or more desaturation were respectively 1.78 (1.25 to 2.53) and 0.67 (0.46 to 0.98). Multivariable analysis showed that post-exertion oxygen saturation was not a significant predictor of adverse outcome when baseline clinical assessment was taken into account (p=0.368). Secondary analysis excluding patients in whom post-exertion measurement appeared inappropriate resulted in a c-statistic of 0.699 (0.581 to 0.817), likelihood ratios of 1.98 (1.26 to 3.10) and 0.61 (0.35 to 1.07), and some evidence of additional prognostic value on multivariable analysis (p=0.019).

ConclusionsPost-exertion oxygen saturation provides modest prognostic information in the assessment of patients attending the emergency department with suspected COVID-19.

RegistrationISRCTN registry, ISRCTN56149622, http://www.isrctn.com/ISRCTN28342533

Key messagesWhat is already known on this subject?

O_LIPost exertional decrease in oxygen saturation can be used to predict prognosis in chronic lung diseases
C_LIO_LIPost exertional desaturation has been proposed as a way of predicting adverse outcome in people with suspected COVID-19
C_LI

What this study adds:

O_LIPost-exertion oxygen saturation provides modest prognostic information in the assessment of patients attending the emergency department with suspected COVID-19
C_LI",emergency medicine,fuzzy,100,100
medRxiv,10.1101/2020.08.07.20169490,2020-08-07,https://medrxiv.org/cgi/content/short/2020.08.07.20169490,HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform,Krishnan Bhaskaran; Christopher T Rentsch; Brian MacKenna; Anna Schultz; Amir Mehrkar; Chris Bates; Rosalind M Eggo; Caroline E Morton; Seb Bacon; Peter Inglesby; Ian J Douglas; Alex J Walker; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Harriet J Forbes; Helen J Curtis; William Hulme; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Liam Smeeth; Ben Goldacre,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; TPP; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundIt is unclear whether HIV infection is associated with risk of COVID-19 death. We aimed to investigate this in a large-scale population-based study in England.

MethodsWorking on behalf of NHS England, we used the OpenSAFELY platform to analyse routinely collected electronic primary care data linked to national death registrations. People with a primary care record for HIV infection were compared to people without HIV. COVID-19 death was defined by ICD-10 codes U07.1 or U07.2 anywhere on the death certificate. Cox regression models were used to estimate the association between HIV infection and COVID-19 death, initially adjusted for age and sex, then adding adjustment for index of multiple deprivation and ethnicity, and finally for a broad range of comorbidities. Interaction terms were added to assess effect modification by age, sex, ethnicity, comorbidities and calendar time.

Results17.3 million adults were included, of whom 27,480 (0.16%) had HIV recorded. People living with HIV were more likely to be male, of black ethnicity, and from a more deprived geographical area than the general population. There were 14,882 COVID-19 deaths during the study period, with 25 among people with HIV. People living with HIV had nearly three-fold higher risk of COVID-19 death than those without HIV after adjusting for age and sex (HR=2.90, 95% CI 1.96-4.30). The association was attenuated but risk remained substantially raised, after adjustment for deprivation and ethnicity (adjusted HR=2.52, 1.70-3.73) and further adjustment for comorbidities (HR=2.30, 1.55-3.41). There was some evidence that the association was larger among people of black ethnicity (HR = 3.80, 2.15-6.74, compared to 1.64, 0.92-2.90 in non-black individuals, p-interaction=0.045)

InterpretationHIV infection was associated with a markedly raised risk of COVID-19 death in a country with high levels of antiretroviral therapy coverage and viral suppression; the association was larger in people of black ethnicity.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.08.05.20169078,2020-08-06,https://medrxiv.org/cgi/content/short/2020.08.05.20169078,Transient dynamics of SARS-CoV-2 as England exited national lockdown,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Caroline E Walters; Haowei Wang; Christina J Atchison; Peter Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Ara Darzi; Paul Elliott,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Imperial College London; Imperial College London; Imperial College Healthcare NHS Trust; Imperial College London; Imperial College London; Imperial College Healthcare NHS Trust; Imperial College London School of Public Health","Control of the COVID-19 pandemic requires a detailed understanding of prevalence of SARS-CoV-2 virus in the population. Case-based surveillance is necessarily biased towards symptomatic individuals and sensitive to varying patterns of reporting in space and time. The real-time assessment of community transmission antigen study (REACT-1) is designed to overcome these limitations by obtaining prevalence data based on a nose and throat swab RT-PCR test among a representative community-based sample in England, including asymptomatic individuals. Here, we describe results comparing rounds 1 and 2 carried out during May and mid June / early July 2020 respectively across 315 lower tier local authority areas. In round 1 we found 159 positive samples from 120,620 tested swabs while round 2 there were 123 positive samples from 159,199 tested swabs, indicating a downwards trend in prevalence from 0.13% (95% CI, 0.11%, 0.15%) to 0.077% (0.065%, 0.092%), a halving time of 38 (28, 58) days, and an R of 0.89 (0.86, 0.93). The proportion of swab-positive participants who were asymptomatic at the time of sampling increased from 69% (61%, 76%) in round 1 to 81% (73%, 87%) in round 2. Although health care and care home workers were infected far more frequently than other workers in round 1, the odds were markedly reduced in round 2. Age patterns of infection changed between rounds, with a reduction by a factor of five in prevalence in 18 to 24 year olds. Our data were suggestive of increased risk of infection in Black and Asian (mainly South Asian) ethnicities. Using regional and detailed case location data, we detected increased infection intensity in and near London. Under multiple sensitivity analyses, our results were robust to the possibility of false positives. At the end of the initial lockdown in England, we found continued decline in prevalence and a shift in the pattern of infection by age and occupation. Community-based sampling, including asymptomatic individuals, is necessary to fully understand the nature of ongoing transmission.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.08.01.20166405,2020-08-04,https://medrxiv.org/cgi/content/short/2020.08.01.20166405,"Physical activity, BMI and COVID-19: an observational and Mendelian randomisation study",Xiaomeng Zhang; Xue Li; Ziwen Sun; Yazhou He; Wei Xu; Harry Campbell; Malcolm G Dunlop; Maria Timofeeva; Evropi Theodoratou,University of Edinburgh; Zhejiang University; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh,"Physical activity (PA) is known to be a protective lifestyle factor against several non-communicable diseases while its impact on infectious diseases, including Coronavirus Disease 2019 (COVID-19) is not as clear. We performed univariate and multivariate logistic regression to identify associations between body mass index (BMI) and both objectively and subjectively measured PA collected prospectively and COVID-19 related outcomes (Overall COVID-19, inpatient COVID-19, outpatient COVID-19, and COVID-19 death) in the UK Biobank (UKBB) cohort. Subsequently, we tested causality by using two-sample Mendelian randomisation (MR) analysis. In the multivariable model, the increased acceleration vector magnitude PA (AMPA) was associated with a decreased probability of overall and outpatient COVID-19. No association was found between self-reported moderate-to-vigorous PA (MVPA) or BMI and COVID-19 related outcomes. Although no causal association was found by MR analyses, this may be due to limited power and we conclude policies to encourage and facilitate exercise at a population level during the pandemic should be considered.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.08.03.20164897,2020-08-04,https://medrxiv.org/cgi/content/short/2020.08.03.20164897,Risk of hospitalisation with coronavirus disease 2019 in healthcare workers and their households:a nationwide linkage cohort study,Anoop SV Shah; Rachael Wood; Ciara Gribben; David Caldwell; Jennifer Bishop; Amanda Weir; Sharon Kennedy; Martin Reid; Alison Smith-Palmer; David Goldberg; Jim McMenamin; Colin Fischbacher; Chris Robertson; Sharon Hutchinson; Paul M McKeigue; Helen M Colhoun; David McAllister,London School of Hygiene and Tropical Medicine; Public Health Scotland; Public health scotland; Public health scotland; Public health scotland; Public health scotland; Public health scotland; Public health scotland; Public health scotland; Health protection scotland; Public health scotland; Public health scotland; Public health scotland; Public health scotland; University of Edinburgh; University of Edinburgh; University of Glasgow,"ObjectiveMany healthcare staff work in high-risk settings for contracting and transmitting Severe Acute Respiratory Syndrome Coronavirus 2. Their risk of hospitalisation for coronavirus disease 2019 (COVID-19), and that of their households, is poorly understood.

Design and settings and participantsDuring the peak period for COVID-19 infection in Scotland (1st March 2020 to 6th June 2020) we conducted a national record linkage study to compare the risk of COVID-19 hospitalisation among healthcare workers (age: 18-65 years), their households and other members of the general population.

Main outcomeHospitalisation with COVID-19

ResultsThe cohort comprised 158,445 healthcare workers, the majority being patient facing (90,733 / 158,445; 57.3%), and 229,905 household members. Of all COVID-19 hospitalisations in the working age population (18-65-year-old), 17.2% (360 / 2,097) were in healthcare workers or their households. Adjusting for age, sex, ethnicity, socio-economic deprivation and comorbidity, the risk of COVID-19 hospitalisation in non-patient facing healthcare workers and their households was similar to the risk in the general population (hazards ratio [HR] 0.81; 95%CI 0.52-1.26 and 0.86; 95%CI 0.49-1.51 respectively). In models adjusting for the same covariates however, patient facing healthcare workers, compared to non-patient facing healthcare workers, were at higher risk (HR 3.30; 95%CI 2.13-5.13); so too were household members of patient facing healthcare workers (HR 1.79; 95%CI 1.10-2.91). On sub-dividing patient-facing healthcare workers into those who worked in front-door, intensive care and non-intensive care aerosol generating settings and other, those in  front door roles were at higher risk (HR 2.09; 95%CI 1.49-2.94). For most patient facing healthcare workers and their households, the estimated absolute risk of COVID-19 hospitalisation was less than 0.5% but was 1% and above in older men with comorbidity.

ConclusionsHealthcare workers and their households contribute a sixth of hospitalised COVID-19 cases. Whilst the absolute risk of hospitalisation was low overall, patient facing healthcare workers and their households had 3- and 2-fold increased risks of COVID-19 hospitalisation.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.08.03.20167122,2020-08-04,https://medrxiv.org/cgi/content/short/2020.08.03.20167122,Ethnic minority groups in England and Wales - factors affecting the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking Census and death records,Daniel Ayoubkhani; Vahe Nafilyan; Chris White; Peter Goldblatt; Charlotte Gaughan; Louisa Blackwell; Nicky Rogers; Amitava Banerjee; Kamlesh Khunti; Myer Glickman; Ben Humberstone; Ian Diamond,"Office for National Statistics; Office for National Statistics; Office for National Statistics; UCL Institute for Health Equity; Office for National Statistics; Office for National Statistics; Office for National Statistics; Institute of Health Informatics, University College London; Diabetes Research Centre, University of Leicester; Office for National Statistics; Office for National Statistics; Office for National Statistics","ObjectivesTo estimate population-level associations between ethnicity and coronavirus disease 2019 (COVID-19) mortality, and to investigate how ethnicity-specific mortality risk evolved over the course of the pandemic.

DesignRetrospective cohort study using linked administrative data.

SettingEngland and Wales, deaths occurring 2 March to 15 May 2020.

ParticipantsRespondents to the 2011 Census of England and Wales aged [&le;]100 years and enumerated in private households, linked to death registrations and adjusted to account for emigration before the outcome period, who were alive on 1 March 2020 (n=47,872,412).

Main outcome measureDeath related to COVID-19, registered by 29 May 2020.

Statistical methodsWe estimated hazard ratios (HRs) for ethnic minority groups compared with the White population using Cox regression models, controlling for geographical, demographic, socio-economic, occupational, and self-reported health factors. HRs were estimated on the full outcome period and separately for pre- and post-lockdown periods in the UK.

ResultsIn the age-adjusted models, people from all ethnic minority groups were at elevated risk of COVID-19 mortality; the HRs for Black males and females were 3.13 [95% confidence interval: 2.93 to 3.34] and 2.40 [2.20 to 2.61] respectively. However, in the fully adjusted model for females, the HRs were close to unity for all ethnic groups except Black (1.29 [1.18 to 1.42]). For males, COVID-19 mortality risk remained elevated for the Black (1.76 [1.63 to 1.90]), Bangladeshi/Pakistani (1.35 [1.21 to 1.49]) and Indian (1.30 [1.19 to 1.43]) groups. The HRs decreased after lockdown for all ethnic groups, particularly Black and Bangladeshi/Pakistani females.

ConclusionsDifferences in COVID-19 mortality between ethnic groups were largely attenuated by geographical and socio-economic factors, although some residual differences remained. Lockdown was associated with reductions in excess mortality risk in ethnic minority populations, which has major implications for a second wave of infection or local spikes. Further research is needed to understand the causal mechanisms underpinning observed differences in COVID-19 mortality between ethnic groups.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.08.04.20163782,2020-08-04,https://medrxiv.org/cgi/content/short/2020.08.04.20163782,Fitting models to the COVID-19 outbreak and estimating R,Matt J Keeling; Louise Dyson; Glen Guyver-Fletcher; Alex Holmes; Malcolm G Semple; - ISARIC4C Investigators; Michael J Tildesley; Edward M Hill,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Liverpool; ; University of Warwick; University of Warwick,"The COVID-19 pandemic has brought to the fore the need for policy makers to receive timely and ongoing scientific guidance in response to this recently emerged human infectious disease. Fitting mathematical models of infectious disease transmission to the available epidemiological data provides a key statistical tool for understanding the many quantities of interest that are not explicit in the underlying epidemiological data streams. Of these, the effective reproduction number, R, has taken on special significance in terms of the general understanding of whether the epidemic is under control (R < 1). Unfortunately, none of the epidemiological data streams are designed for modelling, hence assimilating information from multiple (often changing) sources of data is a major challenge that is particularly stark in novel disease outbreaks.

Here, focusing on the dynamics of the first-wave (March-June 2020), we present in some detail the inference scheme employed for calibrating the Warwick COVID-19 model to the available public health data streams, which span hospitalisations, critical care occupancy, mortality and serological testing. We then perform computational simulations, making use of the acquired parameter posterior distributions, to assess how the accuracy of short-term predictions varied over the timecourse of the outbreak. To conclude, we compare how refinements to data streams and model structure impact estimates of epidemiological measures, including the estimated growth rate and daily incidence.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.07.30.20165464,2020-08-02,https://medrxiv.org/cgi/content/short/2020.07.30.20165464,Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score,Stephen R Knight; Antonia Ho; Riinu Pius; Iain Buchan; Gail Carson; Thomas M Drake; Jake Dunning; Cameron J Fairfield; Carrol Gamble; Christopher A Green; Rishi K Gupta; Sophie Halpin; Hayley Hardwick; Karl Holden; Peter W Horby; Clare Jackson; Kenneth A McLean; Laura Merson; Jonathan S Nguyen-Van-Tam; Lisa Norman; Mahdad Noursadeghi; Piero L Olliaro; Mark G Pritchard; Clark D Russell; Catherine A Shaw; Aziz Sheikh; Tom Solomon; Cathie Sudlow; Olivia V Swann; Lance Turtle; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Annemarie B Docherty; Ewen M Harrison,"Centre for Medical Informatics, The Usher Institute, University of Edinburgh; Medical Research Council University of Glasgow Centre for Virus Research, Glasgow, UK; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; Institute of Population Health Sciences, University of Liverpool; University of Oxford; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; National Infection Service Public Health England; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; Institute of Microbiology & Infection, University of Birmingham; University College London; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and  Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and ; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and  Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and ; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; Division of Infection and Immunity, University College London, Gower Street, London, WC1E 6BT; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, United Kingdom; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, United Kingdom; Queens Medical Research Institute, University of Edinburgh, Edinburgh, UK; Department of Clinical Surgery, University of Edinburgh; Centre for Medical Informatics, The Usher Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and  Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and ; Health Data Research UK, Gibbs Building, 215 Euston Road, London, NW1 2BE; Department of Child Life and Health, University of Edinburgh, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and  Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and ; National Heart and Lung Institute, Imperial College London, London, UK; Roslin Institute, University of Edinburgh; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections and  Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and ; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK; Centre for Medical Informatics, Usher Institute, University of Edinburgh, UK","ObjectivesTo develop and validate a pragmatic risk score to predict mortality for patients admitted to hospital with covid-19.

DesignProspective observational cohort study: ISARIC WHO CCP-UK study (ISARIC Coronavirus Clinical Characterisation Consortium [4C]). Model training was performed on a cohort of patients recruited between 6 February and 20 May 2020, with validation conducted on a second cohort of patients recruited between 21 May and 29 June 2020.

Setting260 hospitals across England, Scotland, and Wales.

ParticipantsAdult patients ([&ge;]18 years) admitted to hospital with covid-19 admitted at least four weeks before final data extraction.

Main outcome measuresIn-hospital mortality.

ResultsThere were 34 692 patients included in the derivation dataset (mortality rate 31.7%) and 22 454 in the validation dataset (mortality 31.5%). The final 4C Mortality Score included eight variables readily available at initial hospital assessment: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness, urea, and C-reactive protein (score range 0-21 points). The 4C risk stratification score demonstrated high discrimination for mortality (derivation cohort: AUROC 0.79; 95% CI 0.78 - 0.79; validation cohort 0.78, 0.77-0.79) with excellent calibration (slope = 1.0). Patients with a score [&ge;]15 (n = 2310, 17.4%) had a 67% mortality (i.e., positive predictive value 67%) compared with 1.0% mortality for those with a score [&le;]3 (n = 918, 7%; negative predictive value 99%). Discriminatory performance was higher than 15 pre-existing risk stratification scores (AUROC range 0.60-0.76), with scores developed in other covid-19 cohorts often performing poorly (range 0.63-0.73).

ConclusionsWe have developed and validated an easy-to-use risk stratification score based on commonly available parameters at hospital presentation. This outperformed existing scores, demonstrated utility to directly inform clinical decision making, and can be used to stratify inpatients with covid-19 into different management groups. The 4C Mortality Score may help clinicians identify patients with covid-19 at high risk of dying during current and subsequent waves of the pandemic.

Study registrationISRCTN66726260",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.07.30.20164921,2020-08-01,https://medrxiv.org/cgi/content/short/2020.07.30.20164921,Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study,Ricardo Costeira; Karla A Lee; Benjamin Murray; Colette Christiansen; Juan Castillo-Fernandez; Mary Ni Lochlainn; Joan Capdevila Pujol; Iain Buchan; Louise C Kenny; Jonathan Wolf; Janice Rymer; Sebastien Ourselin; Claire Steves; Timothy Spector; Louise Newson; Jordana Bell,King's College London; Department of Twin Research and Genetic Epidemiology; King's College London; King's College London; King's College London; King's College London; Zoe Global Limited; University of Liverpool; University of Liverpool; Zoe Global Limited; King's College London; King's College London; King's College London; King's College London; Newson HealthMenopause & Wellbeing Centre; King's College London,"BackgroundMen and older women have been shown to be at higher risk of adverse COVID-19 outcomes. Animal model studies of SARS-CoV and MERS suggest that the age and sex difference in COVID-19 symptom severity may be due to a protective effect of the female sex hormone estrogen. Females have shown an ability to mount a stronger immune response to a variety of viral infections because of more robust humoral and cellular immune responses.

ObjectivesWe sought to determine whether COVID-19 positivity increases in women entering menopause. We also aimed to identify whether premenopausal women taking exogenous hormones in the form of the combined oral contraceptive pill (COCP) and post-menopausal women taking hormone replacement therapy (HRT) have lower predicted rates of COVID-19, using our published symptom-based model.

DesignThe COVID Symptom Study developed by Kings College London and Zoe Global Limited was launched in the UK on 24th March 2020. It captured self-reported information related to COVID-19 symptoms. Data used for this study included records collected between 7th May - 15th June 2020.

Main outcome measuresWe investigated links between COVID-19 rates and 1) menopausal status, 2) COCP use and 3) HRT use, using symptom-based predicted COVID-19, tested COVID-19, and disease severity based on requirement for hospital attendance or respiratory support.

ParticipantsFemale users of the COVID Symptom Tracker Application in the UK, including 152,637 women for menopause status, 295,689 for COCP use, and 151,193 for HRT use. Analyses were adjusted for age, smoking and BMI.

ResultsPost-menopausal women aged 40-60 years had a higher rate of predicted COVID (P=0.003) and a corresponding range of symptoms, with consistent, but not significant trends observed for tested COVID-19 and disease severity. Women aged 18-45 years taking COCP had a significantly lower predicted COVID-19 (P=8.03E-05), with a reduction in hospital attendance (P=0.023). Post-menopausal women using HRT or hormonal therapies did not exhibit consistent associations, including increased rates of predicted COVID-19 (P=2.22E-05) for HRT users alone.

ConclusionsOur findings support a protective effect of estrogen on COVID-19, based on positive association between predicted COVID-19 and menopausal status, and a negative association with COCP use. HRT use was positively associated with COVID-19 symptoms; however, the results should be considered with caution due to lack of data on HRT type, route of administration, duration of treatment, and potential comorbidities.

Trial registrationThe App Ethics has been approved by KCL ethics Committee REMAS ID 18210, review reference LRs-19/20-18210",obstetrics and gynecology,fuzzy,94,100
medRxiv,10.1101/2020.07.30.20165134,2020-08-01,https://medrxiv.org/cgi/content/short/2020.07.30.20165134,"Improving COVID-19 critical care mortality over time in England: A national cohort study, March to June 2020",John Dennis; Andrew McGovern; Sebastian Vollmer; Bilal A Mateen,University of Exeter; University of Exeter; University of Warwick; The Alan Turing Institute,"ObjectivesTo determine the trend in mortality risk over time in people with severe COVID-19 requiring critical care (high intensive unit [HDU] or intensive care unit [ICU]) management.

MethodsWe accessed national English data on all adult COVID-19 specific critical care admissions from the COVID-19 Hospitalisation in England Surveillance System (CHESS), up to the 29th June 2020 (n=14,958). The study period was 1st March until 30th May, meaning every patient had 30 days of potential follow-up available. The primary outcome was in-hospital 30-day all-cause mortality. Hazard ratios for mortality were estimated for those admitted each week using a Cox proportional hazards models, adjusting for age (non-linear restricted cubic spline), sex, ethnicity, comorbidities, and geographical region.

Results30-day mortality peaked for people admitted to critical care in early April (peak 29.1% for HDU, 41.5% for ICU). There was subsequently a sustained decrease in mortality risk until the end of the study period. As a linear trend from the first week of April, adjusted mortality risk decreased by 11.2% (adjusted HR 0.89 [95% CI 0.87 - 0.91]) per week in HDU, and 9.0% (adjusted HR 0.91 [95% CI 0.88 - 0.94]) in ICU.

ConclusionsThere has been a substantial mortality improvement in people admitted to critical care with COVID-19 in England, with markedly lower mortality in people admitted in mid-April and May compared to earlier in the pandemic. This trend remains after adjustment for patient demographics and comorbidities suggesting this improvement is not due to changing patient characteristics. Possible causes include the introduction of effective treatments as part of clinical trials and a falling critical care burden.",health systems and quality improvement,fuzzy,100,100
medRxiv,10.1101/2020.07.29.20164269,2020-07-30,https://medrxiv.org/cgi/content/short/2020.07.29.20164269,The potential health and economic impact of dexamethasone treatment for patients with COVID-19,RICARDO AGUAS; Adam Mahdi; RIMA SHRETTA; Peter Horby; Martin Landray; Lisa J White,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford,"Dexamethasone has been shown to reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment would be rolled out in the UK and globally, as well as its cost-effectiveness of implementing this intervention. We estimate that, for the UK, approximately 12,000 [4,250 - 27,000] lives could be saved by January 2021. Assuming that dexamethasone has a similar effect size in settings where access to oxygen therapies is limited, this would translate into approximately 650,000 [240,000 - 1,400,000] lives saved globally. If dexamethasone acts differently in these settings, the impact could be less than half of this value. To estimate the full potential of dexamethasone in the global fight against COVID-19, it is essential to perform clinical research in settings with limited access to oxygen and/or ventilators, e.g. in low and middle-income countries.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.07.29.20162701,2020-07-30,https://medrxiv.org/cgi/content/short/2020.07.29.20162701,Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England,Philippa M Wells; Katie M Doores; Simon Couvreur; Rocio Martin Martinez; Jeffrey Seow; Carl Graham; Sam Acors; Neophytos Kouphou; Stuart Neil; Richard Tedder; Pedro Matos; Kate Poulton; Maria Jose Lista; Ruth Dickenson; Helin Sertkaya; Thomas Maguire; Edward Scourfield; Ruth Bowyer; Deborah Hart; Aoife O'Byrne; Kathryn Steele; Oliver Hemmings; Carolina Rosadas; Myra McClure; Joan Capedevila-Pujol; Jonathan wolf; Sebastien Ourseilin; Matthew Brown; Michael Malim; Timothy Spector; Claire Steves,King's College London; King's College London; KCL; King's College London; KCL; KCL; KCL; KCL; KCL; Imperial; KCL; KCL; KCL; KCL; KCL; KCL; KCL; KCL; KCL; KCL; KCL; KCL; Imperial College London; Imperial College London; KCL; Zoe Global; Zoe Global; KCL; KCL; King's College London; King's College London,"BackgroundUnderstanding of the true asymptomatic rate of infection of SARS-CoV-2 is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms.

MethodsWe undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike glycoprotein and nucleocapsid protein of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 previously modelled on PCR positive individuals from a dataset of over 2 million.

FindingsWe demonstrated a seroprevalence of 12% (51participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 symptoms: fever, cough or anosmia. Specificity of anosmia for seropositivity was 95%, compared to 88% for fever cough and anosmia combined. 34 individuals in the cohort were predicted to be Covid-19 positive using the App algorithm, and of those, 18 (52%) were seropositive.

InterpretationSeroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response.

FundingNIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC",epidemiology,fuzzy,92,100
medRxiv,10.1101/2020.07.26.20161570,2020-07-28,https://medrxiv.org/cgi/content/short/2020.07.26.20161570,"Magnitude, demographics and dynamics of the impact of the first phase of the Covid-19 pandemic on all-cause mortality in 17 industrialised countries",Vasilis Kontis; James E Bennett; Theo Rashid; Robbie M Parks; Jonathan Pearson-Stuttard; Michel Guillot; Perviz Asaria; Bin Zhou; Marco Battaglini; Gianni Corsetti; Martin McKee; Mariachiara Di Cesare; Colin D Mathers; Majid Ezzati,Imperial College London; Imperial College London; Imperial College London; Columbia University; Imperial College London; University of Pennsylvania; Imperial College London; Imperial College London; Italian National Institute of Statistics; Italian National Institute of Statistics; London School of Hygiene & Tropical Medicine; Middlesex University London; Independent Researcher; Imperial College London,"The Covid-19 pandemic affects mortality directly through infection as well as through changes in the social, environmental and healthcare determinants of health1. The impacts on mortality are likely to vary across countries in magnitude, timing, and age and sex composition. Here, we applied an ensemble of 16 Bayesian probabilistic models to vital statistics data, by age group and sex, to consistently and comparably estimate the impacts of the first phase of the pandemic on all-cause mortality for 17 industrialised countries. The models accounted for factors that affect death rates including seasonality, temperature, and public holidays, as well as for medium-long-term secular trends and the dependency of death rates in each week on those in preceding week(s). From mid-February through the end of May 2020, an estimated 202,900 (95% credible interval 179,400-224,900) more people died in these 17 countries than would have had the pandemic not taken place. Nearly three quarters of these excess deaths occurred in England and Wales, Italy and Spain, where less than half of the total population of these countries live. When all-cause mortality is considered, the total number of deaths, deaths per 100,000 people, and relative increase in deaths were similar between men and women in most countries. Further, in many countries, the balance of excess deaths changed from male-dominated early in the pandemic to being equal or female-dominated later on.

Taken over the entire first phase of the pandemic, there was no detectable rise in all-cause mortality in New Zealand, Bulgaria, Hungary, Norway, Denmark and Finland and for women in Austria and Switzerland (posterior probability of an increase in deaths <90%). Women in Portugal and men in Austria experienced relatively small increases in all-cause mortality, with posterior probabilities of 90-99%. For men in Switzerland and Portugal, and both sexes in the Netherlands, France, Sweden, Belgium, Italy, Scotland, Spain and England and Wales, all-cause mortality increased as a result of the pandemic with a posterior probability >99%. After accounting for population size, England and Wales and Spain experienced the highest death toll, nearly 100 deaths per 100,000 people; they also had the largest relative (percent) increase in deaths (37% (95% credible interval 30-44) in England and Wales; 38% (31-44) in Spain). New Zealand, Bulgaria, Hungary, Norway, Denmark and Finland experienced changes in deaths that ranged from possible slight declines to increases of no more than 5%. The large impact in England and Wales stems partly from having experienced (together with Spain) the highest weekly increases in deaths, more than doubling in some weeks, and having had (together with Sweden) the longest duration when deaths exceeded levels that would be expected in the absence of the pandemic.

The heterogeneous magnitude and character of the excess deaths due to the Covid-19 pandemic reflect differences in how well countries have managed the pandemic (e.g., timing, extent and adherence to lockdowns and other social distancing measures; effectiveness of test, trace and isolate mechanisms), and the resilience and preparedness of the health and social care system (e.g., effective facility and community care pathways; minimising spread of infection within hospitals and care homes, and between them and the community).",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.07.23.20160747,2020-07-27,https://medrxiv.org/cgi/content/short/2020.07.23.20160747,Associations of severe COVID-19 with polypharmacy in the REACT-SCOT case-control study,Paul M McKeigue; Sharon Kennedy; Amanda Weir; Jen Bishop; Stuart J McGurnaghan; David McAllister; Chris Robertson; Rachael Wood; Nazir Lone; Janet Murray; Thomas M Caparrotta; Alison Smith-Palmer; David Goldberg; Jim McMenamin; Colin Ramsay; Bruce Guthrie; Sharon Hutchinson; Helen M Colhoun,University of Edinburgh; Public Health Scotland; Public Health Scotland; Public Health Scotland; University of Edinburgh; University of Glasgow; University of Strathclyde; NHS Information Services Division (Public Health Scotland); University of Edinburgh; Public Health Scotland; University of Edinburgh; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; University of Edinburgh; Glasgow Caledonian University; University of Edinburgh,"ObjectivesTo investigate the relation of severe COVID-19 to prior drug prescribing.

DesignMatched case-control study (REACT-SCOT) based on record linkage to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days.

SettingScottish population.

Main outcome measureSevere COVID-19, defined by entry to critical care or fatal outcome.

ParticipantsAll 4272 cases of severe COVID-19 in Scotland since the start of the epidemic, with 36948 controls matched for age, sex and primary care practice.

ResultsSevere COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in care homes, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.7, 13.2), and was not accounted for by treatment of conditions designated as conferring increased risk. Of 17 drug classes postulated at the start of the epidemic to be ""medications compromising COVID"", all were associated with increased risk of severe COVID-19. The largest effect was for antipsychotic agents: rate ratio 4.14 (3.39, 5.07). Other drug classes with large effects included proton pump inhibitors (rate rato 2.19 (1.70, 2.80) for >= 2 defined daily doses/day), opioids (3.62 (2.65, 4.94) for >= 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates, and were stronger with recent than with non-recent exposure.

ConclusionsSevere COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression or dyskinesia, have anticholinergic effects or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Although the evidence for causality is not conclusive, these results support existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy as a potential means of reducing COVID-19 risk.

RegistrationENCEPP number EUPAS35558

What is already known on this topicTwo previous studies have examined the relationship of severe COVID-19 to drugs for the cardiovascular system. This is the first systematic study of the relationship of severe COVID-19 to prior drug prescribing.

What this study addsSevere COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression or dyskinesia, have anticholinergic effects or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. These results support earlier warnings that these drug classes that these drugs might increase susceptibility to COVID-19, and reinforce existing guidance on reducing overprescribing of these drug classes.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.07.25.20156471,2020-07-27,https://medrxiv.org/cgi/content/short/2020.07.25.20156471,Using social contact data to predict and compare the impact of social distancing policies with implications for school re-opening,Ellen Brooks-Pollock; Jonathan M Read; Angela R McLean; Matt J Keeling; Leon Danon,University of Bristol; Lancaster University; University of Oxford; University of Warwick; University of Exeter,"BackgroundIn the absence of a vaccine, SARS-CoV-2 transmission has been controlled by preventing person-to-person interactions via social distancing measures. In order to re-open parts of society, policy-makers need to consider how combinations of measures will affect transmission and understand the trade-offs between them.

MethodsWe use age-specific social contact data, together with epidemiological data, to quantify the components of the COVID-19 reproduction number. We estimate the impact of social distancing policies on the reproduction number by turning contacts on and off based on context and age. We focus on the impact of re-opening schools against a background of wider social distancing measures.

ResultsWe demonstrate that pre-collected social contact data can be used to provide a time-varying estimate of the reproduction number (R). We find that following lockdown (when R=0.7 (95% CI 0.6, 0.8)), opening primary schools as a modest impact on transmission (R = 0.89 (95%CI: 0.82 - 0.97)) as long as other social interactions are not increased. Opening secondary and primary schools is predicted to have a larger impact (R = 1.22, 95%CI: 1.02 - 1.53)). Contact tracing and COVID security can be used to mitigate the impact of increased social mixing to some extent, however social distancing measures are still required to control transmission.

ConclusionsOur approach has been widely used by policy-makers to project the impact of social distancing measures and assess the trade-offs between them. Effective social distancing, contact tracing and COVID-security are required if all age groups are to return to school while controlling transmission.",infectious diseases,fuzzy,100,100
bioRxiv,10.1101/2020.07.26.221572,2020-07-26,https://biorxiv.org/cgi/content/short/2020.07.26.221572,COVID-19 and Rheumatoid Arthritis share myeloid pathogenic and resolving pathways,Lucy MacDonald; Thomas Dan Otto; Aziza Elmesmari; Barbara Tolusso; Domenico Somma; Charles McSharry; Elisa Gremese; Iain B McInnes; Stefano Alivernini; Mariola Kurowska-Stolarska,"Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, United Kingdom; Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, United Kingdom; Research into Inflammatory Arthritis Centre Versus Arthritis (RACE) ,University of Glasgow, Glasgow, United Kingdom; Division of Rheumatology, Universita Cattolica del Sacro Cuore, Rome, Italy; Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom.; Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom.; Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, United Kingdom.; Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore; Research into Inflammatory Arthritis Centre Versus Arthritis (RACE), University of Glasgow, Glasgow, United Kingdom.","BackgroundWe recently delineated the functional biology of pathogenic and inflammation resolving synovial tissue macrophage clusters in rheumatoid arthritis (RA). Whilst RA is not a viral respiratory syndrome, it represents a pro-inflammatory cytokine-driven chronic articular condition often accompanied by cardiovascular and lung pathologies. We hypothesised that functionally equivalent macrophage clusters in the lung might govern inflammation and resolution of COVID-19 pneumonitis.

MethodsTo provide insight into the targetable functions of COVID-19 bronchoalveolar lavage (BALF) macrophage clusters, a comparative analysis of BALF macrophage single cell transcriptomics (scRNA-seq) with synovial tissue (ST) macrophage scRNA-seq and functional biology was performed. The function of shared BALF and ST MerTK inflammation-resolving pathway was confirmed with inhibitor in primary macrophage-synovial fibroblast co-cultures. Results. Distinct BALF FCNpos and FCNposSPP1pos macrophage clusters emerging in severe COVID-19 patients were closely related to ST CD48highS100A12pos and CD48posSPP1pos clusters driving synovitis in active RA. They shared transcriptomic profile and pathogenic mechanisms. Healthy lung resident alveolar FABP4pos macrophages shared a regulatory transcriptomic profile, including TAM (Tyro, Axl, MerTK) receptors pathway with synovial tissue TREM2pos macrophages that govern RA remission. This pathway was substantially altered in BALF macrophages of severe COVID-19. In vitro dexamethasone inhibited tissue inflammation via macrophages MerTK function.

ConclusionPathogenesis and resolution of COVID-19 pneumonitis and RA synovitis might be driven by similar macrophage clusters and pathways. The MerTK-dependent anti-inflammatory mechanisms of dexamethasone, and the homeostatic function of TAM pathways that maintain RA in remission advocate the therapeutic MerTK agonism to ameliorate the cytokine storm and pneumonitis of severe COVID-19.",immunology,fuzzy,100,91
medRxiv,10.1101/2020.07.24.20149815,2020-07-26,https://medrxiv.org/cgi/content/short/2020.07.24.20149815,Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: An observational cohort study,Rishi K Gupta; Michael Marks; Thomas H. A. Samuels; Akish Luintel; Tommy Rampling; Humayra Chowdhury; Matteo Quartagno; Arjun Nair; Marc Lipman; Ibrahim Abubakar; Maarten van Smeden; Wai Keong Wong; Bryan Williams; Mahdad Noursadeghi,"Institute for Global Health, University College London, London, UK; London School of Hygiene and Tropical Medicine; University College London Hospitals NHS Trust; University College London Hospitals NHS Trust; University College London Hospitals NHS Trust; University College London Hospitals NHS Trust; MRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, UK; University College London Hospitals NHS Trust; UCL Respiratory, Division of Medicine, University College London, London, UK; Institute for Global Health, University College London, London, UK; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; University College London Hospitals NHS Trust; NIHR University College London Hospitals Biomedical Research Centre; Division of Infection & Immunity, University College London, UK","BackgroundThe number of proposed prognostic models for COVID-19, which aim to predict disease outcomes, is growing rapidly. It is not known whether any are suitable for widespread clinical implementation. We addressed this question by independent and systematic evaluation of their performance among hospitalised COVID-19 cases.

MethodsWe conducted an observational cohort study to assess candidate prognostic models, identified through a living systematic review. We included consecutive adults admitted to a secondary care hospital with PCR-confirmed or clinically diagnosed community-acquired COVID-19 (1st February to 30th April 2020). We reconstructed candidate models as per their original descriptions and evaluated performance for their original intended outcomes (clinical deterioration or mortality) and time horizons. We assessed discrimination using the area under the receiver operating characteristic curve (AUROC), and calibration using calibration plots, slopes and calibration-in-the-large. We calculated net benefit compared to the default strategies of treating all and no patients, and against the most discriminating predictor in univariable analyses, based on a limited subset of a priori candidates.

ResultsWe tested 22 candidate prognostic models among a cohort of 411 participants, of whom 180 (43.8%) and 115 (28.0%) met the endpoints of clinical deterioration and mortality, respectively. The highest AUROCs were achieved by the NEWS2 score for prediction of deterioration over 24 hours (0.78; 95% CI 0.73-0.83), and a novel model for prediction of deterioration <14 days from admission (0.78; 0.74-0.82). Calibration appeared generally poor for models that used probability outcomes. In univariable analyses, admission oxygen saturation on room air was the strongest predictor of in-hospital deterioration (AUROC 0.76; 0.71-0.81), while age was the strongest predictor of in-hospital mortality (AUROC 0.76; 0.71-0.81). No prognostic model demonstrated consistently higher net benefit than using the most discriminating univariable predictors to stratify treatment, across a range of threshold probabilities.

ConclusionsOxygen saturation on room air and patient age are strong predictors of deterioration and mortality among hospitalised adults with COVID-19, respectively. None of the prognostic models evaluated offer incremental value for patient stratification to these univariable predictors.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.07.22.20159772,2020-07-25,https://medrxiv.org/cgi/content/short/2020.07.22.20159772,Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the COVID-19 era,Kiesha Prem; Kevin van Zandvoort; Petra Klepac; Rosalind M Eggo; Nicholas G Davies; - Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group; Alex R Cook; Mark Jit,"London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; ; Saw Swee Hock School of Public Health, National University of Singapore; London School of Hygiene & Tropical Medicine","Mathematical models have played a key role in understanding the spread of directly-transmissible infectious diseases such as Coronavirus Disease 2019 (COVID-19), as well as the effectiveness of public health responses. As the risk of contracting directly-transmitted infections depends on who interacts with whom, mathematical models often use contact matrices to characterise the spread of infectious pathogens. These contact matrices are usually generated from diary-based contact surveys. However, the majority of places in the world do not have representative empirical contact studies, so synthetic contact matrices have been constructed using more widely available setting-specific survey data on household, school, classroom, and workplace composition combined with empirical data on contact patterns in Europe. In 2017, the largest set of synthetic contact matrices to date were published for 152 geographical locations. In this study, we update these matrices with the most recent data and extend our analysis to 177 geographical locations. Due to the observed geographic differences within countries, we also quantify contact patterns in rural and urban settings where data is available. Further, we compare both the 2017 and 2020 synthetic matrices to out-of-sample empirically-constructed contact matrices, and explore the effects of using both the empirical and synthetic contact matrices when modelling physical distancing interventions for the COVID-19 pandemic. We found that the synthetic contact matrices reproduce the main traits of the contact patterns in the empirically-constructed contact matrices. Models parameterised with the empirical and synthetic matrices generated similar findings with few differences observed in age groups where the empirical matrices have missing or aggregated age groups. This finding means that synthetic contact matrices may be used in modelling outbreaks in settings for which empirical studies have yet to be conducted.

Author summaryThe risk of contracting a directly transmitted infectious disease such as the Coronavirus Disease 2019 (COVID-19) depends on who interacts with whom. Such person-to-person interactions vary by age and locations--e.g., at home, at work, at school, or in the community--due to the different social structures. These social structures, and thus contact patterns, vary across and within countries. Although social contact patterns can be measured using contact surveys, the majority of countries around the world, particularly low- and middle-income countries, lack nationally representative contact surveys. A simple way to present contact data is to use matrices where the elements represent the rate of contact between subgroups such as age groups represented by the columns and rows. In 2017, we generated age- and location-specific synthetic contact matrices for 152 geographical regions by adapting contact pattern data from eight European countries using country-specific data on household size, school and workplace composition. We have now updated these matrices with the most recent data (Demographic Household Surveys, World Bank, UN Population Division) extending the coverage to 177 geographical locations, covering 97.2% of the worlds population. We also quantified contact patterns in rural and urban settings. When compared to out-of-sample empirically-measured contact patterns, we found that the synthetic matrices reproduce the main features of these contact patterns.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.07.19.20156869,2020-07-25,https://medrxiv.org/cgi/content/short/2020.07.19.20156869,Paired nasopharyngeal and deep lung testing for SARS-CoV2 reveals a viral gradient in critically ill patients: a multi-centre study,Islam Hamed; Nesreen Shaban; Marwan Nassar; Sam Love; Martin D Curran; Stephen Webb; Huina Yang; Anthony Rostron; Katherine Watson; Vilas Navapurkar; Razeenn Mahroof; Andrew Conway Morris,"John Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge, UK; John Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge, UK; John Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge, UK; John Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge, UK; Clinical Microbiology and Public Health Laboratory, Public Health England, Cambridge, United Kingdom; Royal Papworth Hospital, Cambridge, UK; Royal Papworth Hospital, Cambridge, UK; Sunderland Royal Hospital, South Tyneside and Sunderland NHS Foundation Trust, UK; Sunderland Royal Hospital, South Tyneside and Sunderland NHS Foundation Trust, UK; John Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge, UK; John Farman Intensive Care Unit, Addenbrooke's Hospital, Cambridge, UK; University of Cambridge","Samples for diagnostic tests for SARS-CoV-2 can be obtained from the upper (nasopharyngeal/oropharyngeal swabs) or lower respiratory tract (sputum or tracheal aspirate or broncho-alveolar lavage - BAL). Data from different testing sites indicates different rates of positivity. Reverse-transcriptase polymerase chain reaction (RT-PCR) allows for semi-quantitative estimates of viral load as time to crossing threshold (Ct) is inversely related to viral load.

ObjectivesThe objective of our study was to evaluate SARS-CoV2 RNA loads between paired nasopharyngeal (NP) and deep lung (endotracheal aspirate or BAL) samples from critically ill patients.

MethodsSARS-CoV-2 RT-PCR results were retrospectively reviewed for 51 critically ill patients from 5 intensive care units in 3 hospitals ; Addenbrookes Hospital Cambridge (3 units), Royal Papworth Cambridge (1 unit), and Royal Sunderland Hospital (1 unit). At the times when paired NP and deep lung samples were obtained, one patient had been on oxygen only, 6 patients on non-invasive ventilation, 18 patients on ECMO, and 26 patients mechanically ventilated.

ResultsResults collected showed significant gradient between NP and deep lung viral loads. Median Ct value was 29 for NP samples and 24 for deep lung samples. Of 51 paired samples, 16 were negative (below limit of detection) on NP swabs but positive (above limit of detection) on deep lung sample, whilst 2 were negative on deep sample but positive on NP (both patients were on ECMO).

ConclusionsIt has been suggested that whilst SARS-CoV1 tends to replicate in the lower respiratory tract, SARS-CoV2 replicates more vigorously in the upper respiratory tract. These data challenge that assumption. These data suggest that viral migration to, and proliferation in, the lower respiratory tract may be a key factor in the progression to critical illness and the development of severe acute respiratory syndrome (SARS). Factors which promote this migration should be examined for association with severe COVID-19. From a practical point of view, patients with suspected severe COVID-19 should have virological samples obtained from the lower respiratory tract where-ever possible, as upper respiratory samples have a significant negative rate.",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2020.07.22.20159632,2020-07-24,https://medrxiv.org/cgi/content/short/2020.07.22.20159632,Excess mortality during the COVID-19 outbreak in Italy: a two-stage interrupted time series analysis,Matteo Scortichini; Rochelle Schneider dos Santos; Francesca De' Donato; Manuela De Sario; Paola Michelozzi; Marina Davoli; Pierre Masselot; Francesco Sera; Antonio Gasparrini,London School of Hygiene and Tropical Medicine; LSHTM; Lazio Regional Health Service; Lazio Regional Health Service; Lazio Regional Health Service; Lazio Regional Health Service; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,"BackgroundItaly was the first country outside China to experience the impact of the COVID-19 pandemic, which resulted in a significant health burden. This study presents an analysis of the excess mortality across the 107 Italian provinces, stratified by sex, age group, and period of the outbreak.

MethodsThe analysis was performed using a two-stage interrupted time series design using daily mortality data for the period January 2015 - May 2020. In the first stage, we performed province-level quasi-Poisson regression models, with smooth functions to define a baseline risk while accounting for trends and weather conditions and to flexibly estimate the variation in excess risk during the outbreak. Estimates were pooled in the second stage using a mixed-effects multivariate meta-analysis.

ResultsIn the period 15 February - 15 May 2020, we estimated an excess of 47,490 (95% empirical confidence intervals: 43,984 to 50,362) deaths in Italy, corresponding to an increase of 29.5% (95%eCI: 26.8 to 31.9%) from the expected mortality. The analysis indicates a strong geographical pattern, with the majority of excess deaths occurring in northern regions, where few provinces experienced up to 800% increase during the peak in late March. There were differences by sex, age, and area both in the overall impact and in its temporal distribution.

ConclusionsThis study offers a detailed picture of excess mortality during the first months of the COVID-19 pandemic in Italy. The strong geographical and temporal patterns can be related to implementation of lockdown policies and multiple direct and indirect pathways in mortality risk.

Key MessagesO_LIThis study evaluated mortality trends in Italy during the COVID-19 pandemic, reporting an excess of 47,490 (95% empirical confidence intervals: 43,984 to 50,362) deaths in the period 15 February - 15 May 2020, corresponding to an increase of 29.5% (95%eCI: 26.8 to 31.9%) from the expected mortality.
C_LIO_LIThere is a strong geographical pattern, with 71.0% of the estimated excess deaths occurring in just three northern regions (Lombardy, Veneto, and Emilia-Romagna), and few provinces showing increases in mortality up to 800% during the peak of the pandemic.
C_LIO_LIThe impact was slightly higher is men compared to women, with 24,655 and 23,125 excess deaths respectively, and varied by age, with higher mortality in the group 70-79 years old and evidence of a lower but measurable risk even in people less than 60.
C_LIO_LIThe analysis by week suggests differential trends, with more delayed impacts in women and elderly, and the risk limited to the early period in Central and Southern Italy, likely related to the implementation of lockdown policies and contributions from direct and indirect risk pathways.
C_LI",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.07.24.20161281,2020-07-24,https://medrxiv.org/cgi/content/short/2020.07.24.20161281,Strategies to reduce the risk of SARS-CoV-2 re-introduction from international travellers,Samuel Clifford; Billy J Quilty; Timothy W Russell; Yang Liu; Yung-Wai Desmond Chan; Carl A B Pearson; Rosalind M Eggo; Akira Endo; - CMMID COVID-19 Working Group; Stefan Flasche; W John Edmunds,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; ; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine,"To mitigate SARS-CoV-2 transmission risks from international travellers, many countries currently use a combination of up to 14 days of self-quarantine on arrival and testing for active infection. We used a simulation model of air travellers arriving to the UK from the EU or the USA and the timing of their stages of infection to evaluate the ability of these strategies to reduce the risk of seeding community transmission. We find that a quarantine period of 8 days on arrival with a PCR test on day 7 (with a 1-day delay for test results) can reduce the number of infectious arrivals released into the community by a median 94% compared to a no quarantine, no test scenario. This reduction is similar to that achieved by a 14-day quarantine period (median 99% reduction). Shorter quarantine periods still can prevent a substantial amount of transmission; all strategies in which travellers spend at least 5 days (the mean incubation period) in quarantine and have at least one negative test before release are highly effective (e.g. a test on day 5 with release on day 6 results in a median 88% reduction in transmission potential). Without intervention, the current high prevalence in the US (40 per 10,000) results in a higher expected number of infectious arrivals per week (up to 23) compared to the EU (up to 12), despite an estimated 8 times lower volume of travel in July 2020.

Requiring a 14-day quarantine period likely results in less than 1 infectious traveller each entering the UK per week from the EU and the USA (97.5th percentile). We also find that on arrival the transmission risk is highest from pre-symptomatic travellers; quarantine policies will shift this risk increasingly towards asymptomatic infections if eventually-symptomatic individuals self-isolate after the onset of symptoms. As passenger numbers recover, strategies to reduce the risk of re-introduction should be evaluated in the context of domestic SARS-CoV-2 incidence, preparedness to manage new outbreaks, and the economic and psychological impacts of quarantine.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.07.15.20152967,2020-07-17,https://medrxiv.org/cgi/content/short/2020.07.15.20152967,Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study.,Gisli Jenkins; Tom Drake; Annemarie B Docherty; Ewan Harrison; Jennifer Quint; Huzaifa Adamali; Sarah Agnew; Suresh Babu; Christopher Barber; Shaney Barratt; Elisabeth Bendstrup; Stephen Bianchi; Diego Castillo; Nazia Chaudhuri; Felix Chua; Robina Coker; William Chang; Anjali Cranshaw; Louise Crowley; Davinder Dosanjh; Christine Fiddler; Ian A Forrest; Peter George; Michael Gibbons; Katherine Groom; Sarah Haney; Simon Hart; Emily Heiden; Michael Henry; Ling-Pei Ho; Rachel Hoyles; John Hutchinson; Killian Hurley; Mark Jones; Steve Jones; Maria Kokosi; Michael Kreuter; Laura Mackay; Siva Mahendran; Georgios Margaritopoulos; Maria Molina-Molina; Philip Molyneaux; Aidan D O'Brien; Katherine O'Reilly; Alice Packham; Helen Parfrey; Venerino Poletti; Joanna Porter; Elisabetta Renzoni; Pilar Rivera-Ortega; Anne-Marie Russell; Gauri Saini; Lisa G Spencer; Giulia Stella; Helen Stone; Sharon Sturney; David Thickett; Muhunthan Thillai; Timothy Wallis; Katie Ward; Athol U Wells; Alex West; Melissa Wickremasinghe; Felix Woodhead; Glenn Herson; Lucy Howard; Peter JM Openshaw; J Kenneth Baillie; Malcolm Gracie Semple; Iain Stewart,"University of Nottingham; Centre for Medical Informatics, The Usher Institute, University of Edinburgh, Edinburgh, EH16 4UX; University of Edinburgh; University of Edinburgh; Imperial College London; Academic Respiratory Unit, University of Bristol, Southmead Hospital, Bristol, BS10 5NB.; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Queen Alexandra Hospital, Portsmouth, UK.; Northern General Hospital, Sheffield, S5 7AU, UK; Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Southmead Hospital, Bristol, UK, BS10 5NB.; Centre for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99,8200 Aarhus N, Denmar; Northern General Hospital, Sheffield, S5 7AU, UK.; ILD Unit, Respiratory Medicine Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Royal Brompton Hospital; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Nottingham University Hospital; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Respiratory Medicine, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK.; Royal Brompton Hospital; South West Peninsula ILD Network, Royal Devon & Exeter Foundation NHS Trust Barrack Road, Exeter EX2 5DW, UK; Respiratory Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London W12 0HS, UK; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Respiratory Research Group, Hull York Medical School, Castle Hill Hospital, Cottingham, UK, HU16 5JQ; University Hospitals Southampton NHS Foundation Trust, Southampton, UK; Cork University Hospital, Cork, Ireland; University of Oxford; Oxford Interstitial Lung Disease Service, Oxford University Hospitals NHS Foundation Trust, Oxford, OX3 7LE, UK; University of Nottingham; Beaumont Hospital, Dublin, Ireland.; NIHR Southampton Biomedical Research Centre & Clinical and Experimental Sciences, University of Southampton, Southampton, UK; Action for Pulmonary Fibrosis; Guys and St Thomas' Hospital; Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg, Germany and German Center for Lung Research, 69126 Heidelber; Northumbria Specialist Emergency Care Hospital, Northumbria Way, Northumbria Healthcare NHS Foundation Trust, Cramlington, NE23 6NZ; Kingston Hospital NHS Foundation Trust. Galsworthy Road, Kingston upon Thames, Surrey KT2 7QB, UK.; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; ILD Unit, Respiratory Department, University Hospital of Bellvitge, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain.; Imperial College London; University Hospital Limerick, Dooradoyle, Limerick, Ireland.; Department of Respiratory Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.; Birmingham Interstitial Lung Disease Unit, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; Department of Diseases of the Thorax, Morgagni Hospital, Forli, Italy.; University College London; Royal Brompton Hospital; ILD Unit, Manchester University Hospital NHS FT, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK; Imperial College London; Nottingham University Hospitals; Liverpool Interstitial Lung Disease Service, Aintree site, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL, UK.; Laboratory of Biochemistry and Genetics, Pneumology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.; University Hospital North Midlands NHS Trust, Royal Stoke University Hospital, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.; Royal United Hospitals Bath NHS Foundation Trust, Combe Park, Bath BA1 3NG, UK; University of Birmingham, Birmingham, UK.; Cambridge Interstitial Lung Disease Service, Royal Papworth Hospital NHS Foundation Trust, Cambridge Biomedical Campus, Cambridge CB2 0AY, UK; University of Southampton; Imperial College London; Royal Brompton Hospital; Guys and St Thomas' Hospital; Imperial Healthcare NHS Trust, St Mary's Hospital, The Bays, S Wharf Rd, Paddington, London W2 1NY, UK.; Glenfield Hospital Leicester; Nottingham University Hospitals Trust; Nottingham University Hospitals Trust; Imperial College London; Roslin Institute, University of Edinburgh; University of Liverpool; University of Nottingham","RationaleThe impact of COVID-19 on patients with Interstitial Lung Disease (ILD) has not been established.

ObjectivesTo assess outcomes following COVID-19 in patients with ILD versus those without in a contemporaneous age, sex and comorbidity matched population.

MethodsAn international multicentre audit of patients with a prior diagnosis of ILD admitted to hospital with COVID-19 between 1 March and 1 May 2020 was undertaken and compared with patients, without ILD obtained from the ISARIC 4C cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished IPF from non-IPF ILD and used lung function to determine the greatest risks of death.

Measurements and Main ResultsData from 349 patients with ILD across Europe were included, of whom 161 were admitted to hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity-score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching ILD patients with COVID-19 had higher mortality (HR 1.60, Confidence Intervals 1.17-2.18 p=0.003) compared with age, sex and comorbidity matched controls without ILD. Patients with a Forced Vital Capacity (FVC) of <80% had an increased risk of death versus patients with FVC [&ge;]80% (HR 1.72, 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR 1.98, 1.13-3.46).

ConclusionsPatients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD.",respiratory medicine,fuzzy,100,100
medRxiv,10.1101/2020.07.14.20153734,2020-07-16,https://medrxiv.org/cgi/content/short/2020.07.14.20153734,"Place and causes of acute cardiovascular mortality during the COVID19 pandemic: retrospective cohort study of 580,972 deaths in England and Wales, 2014 to 2020",Jianhua Wu; Mamas Mamas; Mohamed Mohamed; Chun Shing Kwok; Chris Roebuck; Ben Humberstone; Tom Denwood; Tom Luescher; Mark De Belder; John Deanfield; Chris Gale,University of Leeds; Keele University; Keele University; Keele University; NHS Digital; ONS; NHS Digital; Imperial College; Barts Health NHS Trust; UCL; University of Leeds,"ImportanceThe COVID-19 pandemic has resulted in a decline in admissions with cardiovascular (CV) emergencies. The fatal consequences of this are unknown.

ObjectivesTo describe the place and causes of acute CV death during the COVID-19 pandemic.

DesignRetrospective nationwide cohort.

SettingEngland and Wales.

ParticipantsAll adult (age [&ge;]18 years) acute CV deaths (n=580,972) between 1st January 2014 and 2nd June 2020.

ExposureThe COVID-19 pandemic (defined as from the onset of the first COVID-19 death in England on 2nd March 2020).

Main outcomesPlace (hospital, care home, home) and acute CV events directly contributing to death as stated on the first part of the Medical Certificate of Cause of Death.

ResultsAfter 2nd March 2020, there were 22,820 acute CV deaths of which 5.7% related to COVID-19, and an excess acute CV mortality of 1752 (+8%) compared with the expected daily deaths in the same period. Deaths in the community accounted for nearly half of all deaths during this period. Care homes had the greatest increase in excess acute CV deaths (1065, +40%), followed by deaths at home (1728, +34%) and in hospital (57, +0%). The most frequent cause of acute CV death during this period was stroke (8,290, 36.3%), followed by acute coronary syndrome (ACS) (5,532, 24.2%), heart failure (5,280, 23.1%), pulmonary embolism (2,067, 9.1%) and cardiac arrest (1,037, 4.5%). Deep vein thrombosis had the greatest increase in cause of excess acute CV death (18, +25%), followed pulmonary embolism (340, +19%) and stroke (782, +10%). The greatest cause of excess CV death in care homes was stroke (700, +48%), compared with cardiac arrest (80, +56%) at home, and pulmonary embolism (126, +14%) and cardiogenic shock (41, +14%) in hospital.

Conclusions and relevanceThe COVID-19 pandemic has resulted in an inflation in acute CV deaths above that expected for the time of year, nearly half of which occurred in the community. The most common cause of acute CV death was stroke followed by acute coronary syndrome and heart failure. This is key information to optimise messaging to the public and enable health resource planning.",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2020.07.14.20152629,2020-07-15,https://medrxiv.org/cgi/content/short/2020.07.14.20152629,Covid-19 infection and attributable mortality in UK Long Term Care Facilities: Cohort study using active surveillance and electronic records (March-June 2020),Peter F Dutey-Magni; Haydn Williams; Arnoupe Jhass; Greta Rait; Harry Hemingway; Andrew C Hayward; Laura Shallcross,University College London; Four Seasons Healthcare Group; UCL; University College London; University College London; University College London; UCL,"BackgroundEpidemiological data on COVID-19 infection in care homes are scarce. We analysed data from a large provider of long-term care for older people to investigate infection and mortality during the first wave of the pandemic.

MethodsCohort study of 179 UK care homes with 9,339 residents and 11,604 staff.We used manager-reported daily tallies to estimate the incidence of suspected and confirmed infection and mortality in staff and residents. Individual-level electronic health records from 8,713 residents were used to model risk factors for confirmed infection, mortality, and estimate attributable mortality.

Results2,075/9,339 residents developed COVID-19 symptoms (22.2% [95% confidence interval: 21.4%; 23.1%]), while 951 residents (10.2% [9.6%; 10.8%]) and 585 staff (5.0% [4.7%; 5.5%]) had laboratory-confirmed infections. The incidence of confirmed infection was 152.6 [143.1; 162.6] and 62.3 [57.3; 67.5] per 100,000 person-days in residents and staff respectively. 121/179 (67.6%) care homes had at least one COVID-19 infection or COVID-19-related death. Lower staffing ratios and higher occupancy rates were independent risk factors for infection.

217/607 residents with confirmed infection died (case-fatality rate: 35.7% [31.9%; 39.7%]). Mortality in residents with no direct evidence of infection was two-fold higher in care homes with outbreaks versus those without (adjusted HR 2.2 [1.8; 2.6]).

ConclusionsFindings suggest many deaths occurred in people who were infected with COVID-19, but not tested. Higher occupancy and lower staffing levels were independently associated with risks of infection. Protecting staff and residents from infection requires regular testing for COVID-19 and fundamental changes to staffing and care home occupancy.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.07.15.20151852,2020-07-15,https://medrxiv.org/cgi/content/short/2020.07.15.20151852,"Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.",Peter Horby; Marion Mafham; Louise Linsell; Jennifer L Bell; Natalie Staplin; Jonathan R Emberson; Martin Wiselka; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Anthony Whitehouse; Timothy Felton; John Williams; Jakki Faccenda; Jonathan Underwood; J Kenneth Baillie; Lucy Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Wei Shen Lim; Alan Montgomery; Kathryn Rowan; Joel Tarning; James A Watson; Nicholas J White; Edmund Juszczak; Richard Haynes; Martin J Landray,"Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; University Hospitals fo Leicester NHS Trust and University of Leicester; Regional Infectious Diseases Unit, North Manchester General Hospital & University of Manchester, Manchester, UK; Research and Development Department, Northampton General Hospital, Northampton, United Kingdom; Department of Respiratory Medicine, North Tees & Hartlepool NHS Foundation Trust, Stockton-on-Tees, United Kingdom; University Hospitals Birmingham NHS Foundation Trust and Institute of Microbiology & Infection, University of Birmingham, United Kingdom; Univeristy of Manchester and Manchester University NHS Foundation Trust, Manchester, United Kingdom; James Cook University Hospital, Middlesbrough, United Kingdom; North West Anglia NHS Foundation Trust, Peterborough, United Kingdom; Department of Infectious Diseases, Cardiff and Vale University Health Board; Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; School of Life Sciences, King's College London, London, United Kingdom; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom; MRC Biostatistics Unit, University of Cambridge, Cambridge, United Ki; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; Respiratory Medicine Department, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Intensive Care National Audit & Research Centre, London, United Kingdom; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Hea; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Hea; Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Centre for Tropical Medicine and Global Hea; Nuffield Department of Population Health, University of Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom","BackgroundHydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (COVID-19) on the basis of in vitro activity, uncontrolled data, and small randomized studies.

MethodsThe Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. We report the preliminary results for the comparison of hydroxychloroquine vs. usual care alone. The primary outcome was 28-day mortality.

Results1561 patients randomly allocated to receive hydroxychloroquine were compared with 3155 patients concurrently allocated to usual care. Overall, 418 (26.8%) patients allocated hydroxychloroquine and 788 (25.0%) patients allocated usual care died within 28 days (rate ratio 1.09; 95% confidence interval [CI] 0.96 to 1.23; P=0.18). Consistent results were seen in all pre-specified subgroups of patients. Patients allocated to hydroxychloroquine were less likely to be discharged from hospital alive within 28 days (60.3% vs. 62.8%; rate ratio 0.92; 95% CI 0.85-0.99) and those not on invasive mechanical ventilation at baseline were more likely to reach the composite endpoint of invasive mechanical ventilation or death (29.8% vs. 26.5%; risk ratio 1.12; 95% CI 1.01-1.25). There was no excess of new major cardiac arrhythmia.

ConclusionsIn patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality but was associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death.

FundingMedical Research Council and NIHR (Grant ref: MC_PC_19056).

Trial registrationsThe trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.07.13.20152793,2020-07-14,https://medrxiv.org/cgi/content/short/2020.07.13.20152793,At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR based tests?: A systematic review of individual participant data,Sue Mallett; Joy Allen; Sara Graziadio; Stuart A Taylor; Naomi S Sakai; Kile Green; Jana Suklan; Chris Hyde; Bethany Shinkins; Zhivko Zhelev; Jaime Peters; Philip Turner; Nia W Roberts; Lavinia Ferrante di Ruffano; Robert Wolff; Penny Whiting; Amanda Winter; Gauraang Bhatnagar; Brian D Nicholson; Steve Halligan,"University College London, UK; Newcastle University, UK; Newcastle upon Tyne Hospitals NHS Foundation Trust, UK; University College London, UK; University College London, UK; Newcastle University, UK; Newcastle University, UK; University of Exeter, UK; University of Leeds, UK; University of Exeter, UK; University of Exeter, UK; University of Oxford, UK; University of Oxford, UK; University of Birmingham, UK; Kleijnen Systematic Reviews Ltd, UK; University of Bristol, UK; Newcastle University, UK; Frimley Health NHS Foundation Trust, UK; University of Oxford, UK; University College London, UK","STRUCTURED SUMMARYO_ST_ABSBackgroundC_ST_ABSTests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral ribonucleic acid (RNA), using reverse transcription polymerase chain reaction (RT-PCR) are pivotal to detecting current coronavirus disease (COVID-19) and duration of detectable virus indicating potential for infectivity.

MethodsWe conducted an individual participant data (IPD) systematic review of longitudinal studies of RT-PCR test results in symptomatic SARS-CoV-2. We searched PubMed, LitCOVID, medRxiv and COVID-19 Living Evidence databases. We assessed risk of bias using a QUADAS- 2 adaptation. Outcomes were the percentage of positive test results by time and the duration of detectable virus, by anatomical sampling sites.

FindingsOf 5078 studies screened, we included 32 studies with 1023 SARS-CoV-2 infected participants and 1619 test results, from -6 to 66 days post-symptom onset and hospitalisation. The highest percentage virus detection was from nasopharyngeal sampling between 0 to 4 days post-symptom onset at 89% (95% confidence interval (CI) 83 to 93) dropping to 54% (95% CI 47 to 61) after 10 to 14 days. On average, duration of detectable virus was longer with lower respiratory tract (LRT) sampling than upper respiratory tract (URT). Duration of faecal and respiratory tract virus detection varied greatly within individual participants. In some participants, virus was still detectable at 46 days post- symptom onset.

InterpretationRT-PCR misses detection of people with SARS-CoV-2 infection; early sampling minimises false negative diagnoses. Beyond ten days post-symptom onset, lower RT or faecal testing may be preferred sampling sites. The included studies are open to substantial risk of bias so the positivity rates are probably overestimated.

PANEL: RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSThere are numerous reports of negative severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription polymerase chain reaction (RT-PCR) test results in participants with known SARS-CoV-2 infection, and increasing awareness that the ability of RT-PCR tests to detect virus depends on the timing of sample retrieval and anatomical sampling site.

Individual studies suggest that positive test results from RT-PCR with nasopharyngeal sampling declines within a week of symptoms and that a positive test later in the disease course is more likely from sputum, bronchoalveolar lavage (BAL) or stool, but data are inconsistent.

Added value of this studyWe searched 5078 titles and abstracts for longitudinal studies reporting individual participant data (IPD) for RT-PCR for participants with COVID-19 linked to either time since symptom onset or time since hospitalisation. Search included SARS-CoV-2 and RT-PCR keywords and MeSH terms. Each included study was subject to careful assessment of risk of bias. This IPD systematic review (SR) addresses RT-PCR test detection rates at different times since symptom onset and hospitalisation for different sampling sites, and summarises the duration of detectable virus. To our knowledge, this is the first rapid SR addressing this topic. We identified 32 studies available as published articles or pre-prints between January 1st and April 24th 2020, including participants sampled at 11 different sampling sites and some participants sampled at more than one site. At earlier time points, nasopharyngeal sampling had the highest virus detection, but the duration of shedding was shorter compared to lower respiratory tract sampling. At 10 to 14 days post-symptom onset, the percentage of positive nasopharyngeal test results was 54% compared to 89% at day 0 to 4. Presence and duration of faecal detection varied by participant, and in nearly half duration was shorter than respiratory sample detection. Virus detection varies for participants and can continue to be detected up to 46 days post-symptom onset or hospitalisation. The included studies were open to substantial risk of bias, so the detection rates are probably overestimates. There was also poor reporting of sampling methods and sparse data on sampling methods that are becoming more widely implemented, such as self-sampling and short nasal swab sampling (anterior nares/mid turbinate).

Implications of all the available evidenceResults from this IPD SR of SARS-CoV-2 testing at different time points and using different anatomical sample sites are important to inform strategies of testing. For prevention of ongoing transmission of SARS-CoV-2, samples for RT-PCR testing need to be taken as soon as possible post-symptom onset, as we confirm that RT-PCR misses more people with infection if sampling is delayed. The percentage of positive RT-PCR tests is also highly dependent on the anatomical site sampled in infected people. Sampling at more than one anatomical site may be advisable as there is variation between individuals in the sites that are infected, as well as the timing of SARS-CoV-2 virus detection at an anatomical site. Testing ten days after symptom onset will lead to a higher frequency of negative tests, particularly if using only upper respiratory tract sampling. However, our estimates may considerably understate the frequency of negative RT-PCR results in people with SARS-CoV- 2 infection. Further investment in this IPD approach is recommended as the amount data available was small given the scale of the pandemic and the importance of the question. More studies, learning from our observations about risk of bias and strengths of example studies (Box 1, Box 2) are urgently needed to inform the optimal sampling strategy by including self-collected samples such as saliva and short nasal swabs. Better reporting of anatomical sampling sites with a detailed methodology on sample collection is also urgently needed.",infectious diseases,fuzzy,92,100
medRxiv,10.1101/2020.07.13.20152710,2020-07-14,https://medrxiv.org/cgi/content/short/2020.07.13.20152710,Excess mortality in mental health service users during the COVID-19 pandemic described by ethnic group: South London and Maudsley data,Robert Stewart; Matthew Broadbent; Jayati Das-Munshi,King's College London; South London and Maudsley NHS Foundation Trust; King's College London,"The COVID-19 pandemic in the UK was accompanied by excess all-cause mortality at a national level, only part of which was accounted for by known infections. Excess mortality has previously been described in people who had received care from the South London and Maudsley NHS Foundation Trust (SLaM), a large mental health service provider for 1.2m residents in south London. SLaMs Clinical Record Interactive Search (CRIS) data resource receives 24-hourly updates from its full electronic health record, including regularly sourced national mortality on all past and present SLaM service users. SLaMs urban catchment has high levels of deprivation and is ethnically diverse, so the objective of the descriptive analyses reported in this manuscript was to compare mortality in SLaM service users from 16th March to 15th May 2020 to that for the same period in 2019 within specific ethnic groups: i) White British, ii) Other White, iii) Black African/Caribbean, iv) South Asian, v) Other, and vi) missing/not stated. For Black African/Caribbean patients (the largest minority ethnic group) this ratio was 3.33, compared to 2.47 for White British patients. Considering premature mortality (restricting to deaths below age 70), these ratios were 2.74 and 1.96 respectively. Ratios were also high for those from Other ethnic groups (2.63 for all mortality, 3.07 for premature mortality).",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.07.11.20147157,2020-07-14,https://medrxiv.org/cgi/content/short/2020.07.11.20147157,Effects of environmental factors on severity and mortality of COVID-19,Domagoj Kifer; Dario Bugada; Judit Villar-Garcia; Ivan Gudelj; Cristina Menni; Carole Helene Sudre; Frano Vuckovic; Ivo Ugrina; Luca F Lorini; Silvia Bettinelli; Nicola Ughi; Alessandro Maloberti; Oscar Epis; Cristina Giannattasio; Claudio Rossetti; Livije Kalogjera; Jasminka Persec; Luke Ollivere; Benjamin Ollivere; Huadong Yan; Ting Cai; Guruprasad Aithal; Claire Steves; Anu Kantele; Mikael Kajova; Olli Vapalahti; Antti Sajantila; Rafal Wojtowicz; Waldemar Wierzba; Zbigniew Krol; Artur Zaczynski; Katarzyna Zycinska; Marek Postula; Ivica Luksic; Rok Civljak; Alemka Markotic; Christian Mahnkopf; Andreas Markl; Johannes Brachmann; Benjamin Murray; Sebastien Ourselin; Julio Pascual; Ana M Valdes; Margarita Posso; Juan Horcajada; Xavier Castells; Massimo Allegri; Dragan Primorac; Timothy Spector; Clara Barrios; Gordan Lauc,"University of Zagreb; Emergency and Intensive Care Department - ASST Papa Giovanni XXII Hospital - Bergamo - Italy; Hospital del Mar-IMIM, Barcelona, Spain; Genos; King's College London; KCL; Genos; Genos; Emergency and Intensive Care Department - ASST Papa Giovanni XXII Hospital - Bergamo - Italy; Emergency and Intensive Care Department - ASST Papa Giovanni XXII Hospital - Bergamo - Italy; ASST GOM Niguarda; ASST GOM Niguarda; ASST GOM Niguarda; ASST GOM Niguarda; ASST GOM Niguarda; School of Medicine, University Hospital ""Sestre milosrdnice"" Zagreb, Croatia; University Hospital Dubrava Zagreb, Croatia, University of Zagreb School of Dental Medicine; Nottingham University Trust; University of Nottingham, School of Medicine; Department of Infectious Diseases, Key Laboratory of Diagnosis and Treatment of Digestive System Tumors of Zhejiang Province, Hwamei Hospital, University of Chi; Hwa Mei Hospital, University of Chinese Academy of Sciences; School of Medicine, University of Nottingham; King's College London; Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; University of Helsinki; Department of Forensic Medicine, University of Helsinki, Finland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw, Poland; Medical University of Warsaw, Warsaw, Poland; Medical University of Warsaw, Warsaw, Poland; Clinical Hospital Dubrava, Zagreb; Hospital for Infectious Diseases, Zagreb, Croatia; Hospital for Infectious Diseases; REGIOMED-KLINIKEN GmbH, Gustav-Hirschfeld-Ring 3, 96450 Coburg, Germany; REGIOMED-KLINIKEN GmbH, Gustav-Hirschfeld-Ring 3, 96450 Coburg, Germany; REGIOMED Kliniken; School of Biomedical Engineering & Imaging Sciences, King's College London; School of Biomedical Engineering & Imaging Sciences, King's College London; Department of Nephrology, Hospital del Mar, Barcelona, Spain; University of Nottingham, School of Medicine, Nottingham NIHR BRC; Department of Epidemiology and Evaluation, Hospital del Mar-IMIM, Barcelona, Spain; Department of Infectious Diseases, Hospital del Mar. Barcelona, Spain; Department of Epidemiology and Evaluation, Hospital del Mar-IMIM, Barcelona, Spain; Pain Therapy Service Policlinico of Monza Hospital - Monza Italy & Italian Pain Group - Milan - Italy; St. Catherine Hospital; King's College London; Hospital del Mar. Barcelona, Spain; University of Zagreb","BackgroundMost respiratory viruses show pronounced seasonality, but for SARS-CoV-2 this still needs to be documented.

MethodsWe examined the disease progression of COVID-19 in 6,914 patients admitted to hospitals in Europe and China. In addition, we evaluated progress of disease symptoms in 37,187 individuals reporting symptoms into the COVID Symptom Study application.

FindingsMeta-analysis of the mortality risk in eight European hospitals estimated odds ratios per one day increase in the admission date to be 0.981 (0.973-0.988, p<0.001) and per increase in ambient temperature of one degree Celsius to be 0.854 (0.773-0.944, p=0.007). Statistically significant decreases of comparable magnitude in median hospital stay, probability of transfer to Intensive Care Unit and need for mechanical ventilation were also observed in most, but not all hospitals. The analysis of individually reported symptoms of 37,187 individuals in the UK also showed the decrease in symptom duration and disease severity with time.

InterpretationSeverity of COVID-19 in Europe decreased significantly between March and May and the seasonality of COVID-19 is the most likely explanation. Mucosal barrier and mucociliary clearance can significantly decrease viral load and disease progression, and their inactivation by low relative humidity of indoor air might significantly contribute to severity of the disease.",infectious diseases,fuzzy,94,100
medRxiv,10.1101/2020.07.12.20151753,2020-07-14,https://medrxiv.org/cgi/content/short/2020.07.12.20151753,"COVID-19 incidence and R decreased on the Isle of Wight after the launch of the Test, Trace, Isolate programme",Michelle Kendall; Luke Milsom; Lucie Abeler-Dorner; Chris Wymant; Luca Ferretti; Mark Briers; Chris Holmes; David Bonsall; Johannes Abeler; Christophe Fraser,University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; Alan Turing Institute; University of Oxford; Alan Turing Institute; University of Oxford; University of Oxford; University of Oxford,"In May 2020 the UK introduced a Test, Trace, Isolate programme in response to the COVID-19 pandemic. The programme was first rolled out on the Isle of Wight and included Version 1 of the NHS contact tracing app. We used COVID-19 daily case data to infer incidence of new infections and estimate the reproduction number R for each of 150 Upper Tier Local Authorities in England, and at the National level, before and after the launch of the programme on the Isle of Wight. We used Bayesian and Maximum-Likelihood methods to estimate R, and compared the Isle of Wight to other areas using a synthetic control method. We observed significant decreases in incidence and R on the Isle of Wight immediately after the launch. These results are robust across each of our approaches. Our results show that the sub-epidemic on the Isle of Wight was controlled significantly more effectively than the sub-epidemics of most other Upper Tier Local Authorities, changing from having the third highest reproduction number R (of 150) before the intervention to the tenth lowest afterwards. The data is not yet available to establish a causal link. However, the findings highlight the need for further research to determine the causes of this reduction, as these might translate into local and national non-pharmaceutical intervention strategies in the period before a treatment or vaccination becomes available.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.07.10.20150524,2020-07-11,https://medrxiv.org/cgi/content/short/2020.07.10.20150524,Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study,Steven Riley; Kylie E. C. Ainslie; Oliver Eales; Benjamin Jeffrey; Caroline E. Walters; Christina J Atchison; Peter J. Diggle; Deborah Ashby; Christl A. Donnelly; Graham Cooke; Wendy Barclay; Helen Ward; Graham Taylor; Ara Darzi; Paul Elliott,"Dept Inf Dis Epi, Imperial College; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Lancaster University; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London; Imperial College London School of Public Health","BackgroundEngland has experienced one of the highest rates of confirmed COVID-19 mortality in the world. SARS-CoV-2 virus has circulated in hospitals, care homes and the community since January 2020. Our current epidemiological knowledge is largely informed by clinical cases with far less understanding of community transmission.

MethodsThe REal-time Assessment of Community Transmission (REACT) study is a nationally representative prevalence survey of SARS-CoV-2 virus swab-positivity in the community in England. We recruited participants regardless of symptom status.

ResultsWe found 159 positives from 120,610 swabs giving an average prevalence of 0.13% (95% CI: 0.11%,0.15%) from 1st May to 1st June 2020. We showed decreasing prevalence with a halving time of 8.6 (6.2, 13.6) days, implying an overall reproduction number R of 0.57 (0.45, 0.72). Adults aged 18 to 24 yrs had the highest swab-positivity rates, while those >64 yrs had the lowest. Of the 126 participants who tested positive with known symptom status in the week prior to their swab, 39 reported symptoms while 87 did not, giving an estimate that 69% (61%,76%) of people were symptom-free for the 7 days prior testing positive in our community sample. Symptoms strongly associated with swab-positivity were: nausea and/or vomiting, diarrhoea, blocked nose, loss of smell, loss of taste, headache, chills and severe fatigue. Recent contact with a known COVID-19 case was associated with odds of 24 (16, 38) for swab-positivity. Compared with non-key workers, odds of swab-positivity were 7.7 (2.4, 25) among care home (long-term care facilities) workers and 5.2 (2.9, 9.3) among health care workers. However, some of the excess risk associated with key worker status was explained by recent contact with COVID-19 cases. We found no strong evidence for geographical variability in positive swab results.

ConclusionOur results provide a reliable baseline against which the impact of subsequent relaxation of lockdown can be assessed to inform future public health efforts to control transmission.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.07.10.20151118,2020-07-11,https://medrxiv.org/cgi/content/short/2020.07.10.20151118,The 4C Initiative (Clinical Care for Cardiovascular disease in the COVID-19 pandemic): monitoring the indirect impact of the coronavirus pandemic on services for cardiovascular diseases in the UK,- TC CVD-COVID-UK Consortium; Simon Ball; Amitava Banerjee; Colin Berry; Jonathan Boyle; Benjamin Bray; William Bradlow; Afzal Chaudhry; Rikki Crawley; John Danesh; Alastair Denniston; Florian Falter; Jonine Figueroa; Christopher Hall; Harry Hemingway; Emily Jefferson; Tom Johnson; Graham King; Ken Lee; Paul McKean; Suzanne Mason; Nicholas Mills; Ewen Pearson; Munir Pirmohamed; Michael TC Poon; Rouven Priedon; Anoop Shah; Reecha Sofat; Jonathan Sterne; Fiona Strachan; Cathie LM Sudlow; Zsolt Szarka; William Whiteley; Mike Wyatt,"; Health Data Research UK Midlands, University of Birmingham; University College London; Institute of Cardiovascular and Medical Sciences, University of Glasgow; Cambridge University Hospitals NHS Foundation Trust; IQVIA; University Hospitals Birmingham NHS Trust; Health Data Research UK Cambridge; Barnsley Hospital NHS Foundation Trust; Health Data Research UK Cambridge; University Hospitals Birmingham NHS Trust; Royal Papworth Hospital NHS Foundation Trust; University of Edinburgh; Health Informatics Centre, University of Dundee; Health Data Research UK London, Institute of Health Informatics, University College London; Population Health and Genomics, University of Dundee; University Hospitals Bristol and Weston NHS Foundation Trust; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Centre for Cardiovascular cience, University of Edinburgh; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Health Data Research UK North; Centre for Cardiovascular Science, University of Edinburgh; Health Data Research UK Scotland; Institute of Systems, Molecular and Integrative Biology and MRC Centre for Drug Safety Science, University of Liverpool; Usher Institute, University of Edinburgh; BHF Data Science Centre, Health Data Research UK; Centre for Cardiovascular Science, University of Edinburgh; Health Data Research UK London, Institute of Health Informatics, University College London; Health Data Research UK South West, Population Health Sciences, University of Bristol; Centre for Cardiovascular Science, University of Edinburgh; BHF Data Science Centre, Health Data Research UK; Health Informatics Centre, University of Dundee; Centre for Clinical Brain Sciences, University of Edinburgh; University Hospitals Bristol and Weston NHS Foundation Trust","BackgroundThe coronavirus (COVID-19) pandemic affects cardiovascular diseases (CVDs) directly through infection and indirectly through health service reorganisation and public health policy. Real-time data are needed to quantify direct and indirect effects. We aimed to monitor hospital activity for presentation, diagnosis and treatment of CVDs during the pandemic to inform on indirect effects.

MethodsWe analysed aggregate data on presentations, diagnoses and treatments or procedures for selected CVDs (acute coronary syndromes, heart failure, stroke and transient ischaemic attack, venous thromboembolism, peripheral arterial disease and aortic aneurysm) in UK hospitals before and during the COVID-19 epidemic. We produced an online visualisation tool to enable near real-time monitoring of trends.

FindingsNine hospitals across England and Scotland contributed hospital activity data from 28 Oct 2019 (pre-COVID-19) to 10 May 2020 (pre-easing of lockdown), and for the same weeks during 2018-2019. Across all hospitals, total admissions and emergency department (ED) attendances decreased after lockdown (23 March 2020) by 57.9% (57.1-58.6%) and 52.9% (52.2-53.5%) respectively compared with the previous year. Activity for cardiac, cerebrovascular and other vascular conditions started to decline 1-2 weeks before lockdown, and fell by 31-88% after lockdown, with the greatest reductions observed for coronary artery bypass grafts, carotid endarterectomy, aortic aneurysm repair and peripheral arterial disease procedures. Compared with before the first UK COVID-19 (31 January 2020), activity declined across diseases and specialties between the first case and lockdown (total ED attendances RR 0.94, 0.93-0.95; total hospital admissions RR 0.96, 0.95-0.97) and after lockdown (attendances RR 0.63, 0.62-0.64; admissions RR 0.59, 0.57-0.60). There was limited recovery towards usual levels of some activities from mid-April 2020.

InterpretationSubstantial reductions in total and cardiovascular activities are likely to contribute to a major burden of indirect effects of the pandemic, suggesting they should be monitored and mitigated urgently.

FundingBritish Heart Foundation, Health Data Research UK",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.07.10.20150656,2020-07-11,https://medrxiv.org/cgi/content/short/2020.07.10.20150656,Diagnostic value of skin manifestation of SARS-CoV-2 infection,Alessia Visconti; Veronique Bataille; Niccolo' Rossi; Justine Kluk; Ruth Murphy; Susana Puig; Rabi Nambi; Ruth C. E. Bowyer; Benjamin Murray; Abigail Bournot; Jonathan Wolf; Sebastien Ourselin; Claire Steves; Timothy Spector; Mario Falchi,King's College London; King's College London; King's College London; Zoe Global Limited; Sheffield Teaching Hospitals NHS Foundation Trust; Hospital Clinic of Barcelona; University Hospitals of Derby and Burton NHS Foundation Trust; King's College London; King's College London; Zoe Global Ltd; Zoe Global Ltd; King's College London; King's College London; King's College London; King's College London,"SARS-CoV-2 causes multiple immune-related reactions at various stages of the disease. The wide variety of skin presentations has delayed linking these to the virus. Previous studies had attempted to look at the prevalence and timing of SARS-COV-2 rashes but were based on mostly hospitalized severe cases and had little follow up. Using data collected on a subset of 336,847 eligible UK users of the COVID Symptom Study app, we observed that 8.8% of the swab positive cases (total: 2,021 subjects) reported either a body rash or an acral rash, compared to 5.4% of those with a negative swab test (total: 25,136). Together, these two skin presentations showed an odds ratio (OR) of 1.67 (95% confidence interval [CI]: 1.41-1.96) for being swab positive. Skin rashes were also predictive in the larger untested group of symptomatic app users (N=54,652), as 8.2% of those who had reported at least one classical COVID-19 symptom, i.e., fever, persistent cough, and/or anosmia, also reported a rash. Data from an independent online survey of 11,546 respondents with a rash showed that in 17% of swab positive cases, the rash was the initial presentation. Furthermore, in 21%, the rash was the only clinical sign. Skin rashes cluster with other COVID-19 symptoms, are predictive of a positive swab test and occur in a significant number of cases, either alone or before other classical symptoms. Recognising rashes is important in identifying new and earlier COVID-19 cases.",epidemiology,fuzzy,94,100
medRxiv,10.1101/2020.07.08.20148965,2020-07-10,https://medrxiv.org/cgi/content/short/2020.07.08.20148965,A case-control and cohort study to determine the relationship between ethnic background and severe COVID-19,Rosita Zakeri; Rebecca Bendayan; Mark Ashworth; Daniel M Bean; Hiten Dodhia; Stevo Durbaba; Kevin O Gallagher; Claire Palmer; Vasa Curcin; Elizabeth Aitken; William Bernal; Richard D Barker; Sam Norton; Martin C Gulliford; James T Teo; James Galloway; Richard J Dobson; Ajay M Shah,"King's College, London; King's College, London; King's College, London; King's College London; King's College, London; King's College, London; King's College, London; King's College Hospital; King's College, London; Lewisham & Greenwich NHS Trust; King's College Hospital; King's College Hospital; King's College, London; King's College London; Kings College Hospital NHS Foundation Trust; King's College, London; King's College London; King's College London","BackgroundPeople of minority ethnic background may be disproportionately affected by severe COVID-19 for reasons that are unclear. We sought to examine the relationship between ethnic background and (1) hospital admission for severe COVID-19; (2) in-hospital mortality.

MethodsWe conducted a case-control study of 872 inner city adult residents admitted to hospital with confirmed COVID-19 (cases) and 3,488 matched controls randomly sampled from a primary healthcare database comprising 344,083 people resident in the same region. To examine in-hospital mortality, we conducted a cohort study of 1827 adults consecutively admitted with COVID-19. Data collected included hospital admission for COVID-19, demographics, comorbidities, in-hospital mortality. The primary exposure variable was self-defined ethnicity.

ResultsThe 872 cases comprised 48.1% Black, 33.7% White, 12.6% Mixed/Other and 5.6% Asian patients. In conditional logistic regression analyses, Black and Mixed/Other ethnicity were associated with higher admission risk than white (OR 3.12 [95% CI 2.63-3.71] and 2.97 [2.30-3.85] respectively). Adjustment for comorbidities and deprivation modestly attenuated the association (OR 2.28 [1.87-2.79] for Black, 2.66 [2.01-3.52] for Mixed/Other). Asian ethnicity was not associated with higher admission risk (OR 1.20 [0.86-1.66]). In the cohort study of 1827 patients, 455 (28.9%) died over a median (IQR) of 8 (4-16) days. Age and male sex, but not Black (adjusted HR 0.84 [0.63-1.11]) or Mixed/Other ethnicity (adjusted HR 0.69 [0.43-1.10]), were associated with in-hospital mortality. Asian ethnicity was associated with higher in-hospital mortality (adjusted HR 1.54 [0.98-2.41]).

ConclusionsBlack and Mixed ethnicity are independently associated with greater admission risk with COVID-19 and may be risk factors for development of severe disease. Comorbidities and socioeconomic factors only partly account for this and additional ethnicity-related factors may play a large role. The impact of COVID-19 may be different in Asians.

Funding sourcesBritish Heart Foundation (CH/1999001/11735 and RE/18/2/34213 to AMS); the National Institute for Health Research Biomedical Research Centre (NIHR BRC) at Guys & St Thomas NHS Foundation Trust and Kings College London (IS-BRC-1215-20006); and the NIHR BRC at South London and Maudsley NHS Foundation Trust and Kings College London (IS-BRC-1215-20018).",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.07.07.20148460,2020-07-08,https://medrxiv.org/cgi/content/short/2020.07.07.20148460,Reconstructing the global dynamics of under-ascertained COVID-19 cases and infections,Timothy W Russell; Nick Golding; Joel Hellewell; Sam Abbott; Lawrence Wright; Carl A B Pearson; Kevin van Zandvoort; Christopher I Jarvis; Hamish Gibbs; Yang Liu; Rosalind M Eggo; John W Edmunds; Adam J Kucharski,"London School of Hygiene and Tropical Medicine; Telethon Kids Institute and Curtin University; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine; Defence Science and Technology Laboratory/Sopra Steria, Fareham, United Kingdom; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine; Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine","BackgroundAsymptomatic or subclinical SARS-CoV-2 infections are often unreported, which means that confirmed case counts may not accurately reflect underlying epidemic dynamics. Understanding the level of ascertainment (the ratio of confirmed symptomatic cases to the true number of symptomatic individuals) and undetected epidemic progression is crucial to informing COVID-19 response planning, including the introduction and relaxation of control measures. Estimating case ascertainment over time allows for accurate estimates of specific outcomes such as seroprevalence, which is essential for planning control measures.

MethodsUsing reported data on COVID-19 cases and fatalities globally, we estimated the proportion of symptomatic cases (i.e. any person with any of fever >= 37.5{degrees}C, cough, shortness of breath, sudden onset of anosmia, ageusia or dysgeusia illness) that were reported in 210 countries and territories, given those countries had experienced more than ten deaths. We used published estimates of the case fatality ratio (CFR) as an assumed baseline. We then calculated the ratio of this baseline CFR to an estimated local delay-adjusted CFR to estimate the level of under-ascertainment in a particular location. We then fit a Bayesian Gaussian process model to estimate the temporal pattern of under-ascertainment.

ResultsWe estimate that, during March 2020, the median percentage of symptomatic cases detected across the 84 countries which experienced more than ten deaths ranged from 2.38% (Bangladesh) to 99.6% (Chile). Across the ten countries with the highest number of total confirmed cases as of 6th July 2020, we estimated that the peak number of symptomatic cases ranged from 1.4 times (Chile) to 17.8 times (France) larger than reported. Comparing our model with national and regional seroprevalence data where available, we find that our estimates are consistent with observed values. Finally, we estimated seroprevalence for each country. Despite low case detection in some countries, our results that adjust for this still suggest that all countries have had only a small fraction of their populations infected as of July 2020.

ConclusionsWe found substantial under-ascertainment of symptomatic cases, particularly at the peak of the first wave of the SARS-CoV-2 pandemic, in many countries. Reported case counts will therefore likely underestimate the rate of outbreak growth initially and underestimate the decline in the later stages of an epidemic. Although there was considerable under-reporting in many locations, our estimates were consistent with emerging serological data, suggesting that the proportion of each countrys population infected with SARS-CoV-2 worldwide is generally low.

FundingWellcome Trust, Bill & Melinda Gates Foundation, DFID, NIHR, GCRF, ARC.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.07.06.20147348,2020-07-07,https://medrxiv.org/cgi/content/short/2020.07.06.20147348,Community prevalence of SARS-CoV-2 in England: Results from the ONS Coronavirus Infection Survey Pilot,Koen B Pouwels; Thomas House; Julie V Robotham; Paul Birrell; Andrew B Gelman; Nikola Bowers; Ian Boreham; Heledd Thomas; James Lewis; Iain Bell; John I Bell; John Newton; Jeremy Farrar; Ian Diamond; Pete Benton; Sarah Walker,University of Oxford; University of Manchester; Public Health England; Public Health England; Columbia University; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; Office for National Statistics; University of Oxford; Public Health England; Wellcome Trust; Office for National Statistics; Office for National Statistics; University of Oxford,"ObjectiveTo estimate the percentage of individuals infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) over time in the community in England and to quantify risk factors.

DesignRepeated cross-sectional surveys of population-representative households with longitudinal follow-up if consent given.

SettingEngland

Participants34,992 Individuals aged 2 years and over from 16,722 private residential households. Data were collected in a pilot phase of the survey between 26 April and 28 June 2020.

Main outcome measuresPercentage of individuals in the community testing positive for SARS-CoV-2 RNA using throat and nose swabs. Individuals were asked about any symptoms and potential risk factors.

ResultsThe percentage of people in private-residential households testing positive for SARS-CoV-2 reduced from 0.32% (95% credible interval (CrI) 0.19% to 0.52%) on 26 April to 0.08% (95% CrI 0.05% to 0.12%) on 28 June, although the prevalence stabilised near the end of the pilot. Factors associated with an increased risk of testing positive included having a job with direct patient contact (relative exposure (RE) 4.06, 95% CrI 2.42 to 6.77)), working outside the home (RE 2.49, 95% CrI 1.39 to 4.45), and having had contact with a hospital (RE 2.20, 95% CrI 1.09 to 4.16 for having been to a hospital individually and RE 1.95, 95% CrI 0.81 to 4.09 for a household member having been to a hospital). In 133 visits where individuals tested positive, 82 (61%, 95% CrI 53% to 69%) reported no symptoms, stably over time.

ConclusionThe percentage of SARS-CoV-2 positive individuals declined between 26 April and 28 June 2020. Positive tests commonly occurred without symptoms being reported. Working outside your home was an important risk factor, indicating that continued monitoring for SARS-CoV-2 in the community will be essential for early detection of increases in infections following return to work and other relaxations of control measures.

What is already known on this topic- Unprecedented control measures, such as national lockdowns, have been widely implemented to contain the spread of SARS-CoV-2.
- Previous mass surveillance has been based on data sources such as hospital admission, deaths or self-reported symptoms that do not measure community prevalence of virus directly.
- Decisions regarding the continued need for social distancing measures in the overall population, specific subgroups and geographic areas heavily rely on accurate and up-to-date information about the number of people and risk factors for testing positive.


What this study adds- The percentage of individuals from the general community in England testing positive for SARS-CoV-2 clearly declined between 26 April and 28 June 2020 from around one in three 300 to around one in a thousand.
- Risk factors for testing positive included having a job with direct patient contact, having had (indirect) contact with a hospital in the past 2 weeks, and working outside your home.
- Positive tests commonly occurred without symptoms being reported and the percentage of individuals with a positive test that reported no symptoms was stable over time.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.07.03.20145912,2020-07-06,https://medrxiv.org/cgi/content/short/2020.07.03.20145912,Ultraviolet A Radiation and COVID-19 Deaths: A Multi Country Study,Mark Cherrie; Tom Clemens; Claudio Colandrea; Zhiqiang Feng; David Webb; Chris Dibben; Richard B Weller,University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh,"ObjectivesTo determine whether UVA exposure might be associated with COVID-19 deaths

DesignEcological regression, with replication in two other countries and pooled estimation

Setting2,474 counties of the contiguous USA, 6,755 municipalities in Italy, 6,274 small areas in England. Only small areas in their  Vitamin D winter (monthly mean UVvitd of under 165 KJ/m2) from Jan to April 2020.

Participants

The  at-risk population is the total small area population, with measures to incorporate spatial infection into the model. The model is adjusted for potential confounders including long-term winter temperature and humidity.

Main outcome measuresWe derive UVA measures for each area from remote sensed data and estimate their relationship with COVID-19 mortality with a random effect for States, in a multilevel zero-inflated negative binomial model. In the USA and England death certificates had to record COVID-19. In Italy excess deaths in 2020 over expected from 2015-19.

Data sourcesSatellite derived mean daily UVA dataset from Japan Aerospace Exploration Agency. Data on deaths compiled by Center for Disease Control (USA), Office for National Statistics (England) and Italian Institute of Statistics.

ResultsDaily mean UVA (January-April 2020) varied between 450 to 1,000 KJ/m2 across the three countries. Our fully adjusted model showed an inverse correlation between UVA and COVID-19 mortality with a Mortality Risk Ratio (MRR) of 0.71 (0.60 to 0.85) per 100KJ/m2 increase UVA in the USA, 0.81 (0.71 to 0.93) in Italy and 0.49 (0.38 to 0.64) in England. Pooled MRR was 0.68 (0.52 to 0.88).

ConclusionsOur analysis, replicated in 3 independent national datasets, suggests ambient UVA exposure is associated with lower COVID-19 specific mortality. This effect is independent of vitamin D, as it occurred at irradiances below that likely to induce significant cutaneous vitamin D3 synthesis. Causal interpretations must be made cautiously in observational studies. Nonetheless this study suggests strategies for reduction of COVID-19 mortality.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.07.03.20145839,2020-07-04,https://medrxiv.org/cgi/content/short/2020.07.03.20145839,"The Impact of COVID-19 on Adjusted Mortality Risk in Care Homes for Older Adults in Wales, United Kingdom: A retrospective population-based cohort study for mortality in 2016-2020",Joe Hollinghurst; Jane Lyons; Richard Fry; Ashley Akbari; Mike Gravenor; Alan Watkins; Fiona Verity; Ronan A Lyons,Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University; Swansea University,"BackgroundMortality in care homes has had a prominent focus during the COVID-19 outbreak. Multiple and interconnected challenges face the care home sector in the prevention and management of outbreaks of COVID-19, including adequate supply of personal protective equipment, staff shortages, and insufficient or lack of timely COVID-19 testing. Care homes are particularly vulnerable to infectious diseases.

AimTo analyse the mortality of older care home residents in Wales during COVID-19 lockdown and compare this across the population of Wales and the previous 4-years.

Study Design and SettingWe used anonymised Electronic Health Records (EHRs) and administrative data from the Secure Anonymised Information Linkage (SAIL) Databank to create a cross-sectional cohort study. We anonymously linked data for Welsh residents to mortality data up to the 14th June 2020.

MethodsWe calculated survival curves and adjusted Cox proportional hazards models to estimate hazard ratios (HRs) for the risk of mortality. We adjusted hazard ratios for age, gender, social economic status and prior health conditions.

ResultsSurvival curves show an increased proportion of deaths between 23rd March and 14th June 2020 in care homes for older people, with an adjusted HR of 1{middle dot}72 (1{middle dot}55, 1{middle dot}90) compared to 2016. Compared to the general population in 2016-2019, adjusted care home mortality HRs for older adults rose from 2{middle dot}15 (2{middle dot}11,2{middle dot}20) in 2016-2019 to 2{middle dot}94 (2{middle dot}81,3{middle dot}08) in 2020.

ConclusionsThe survival curves and increased HRs show a significantly increased risk of death in the 2020 study periods.",public and global health,fuzzy,100,100
bioRxiv,10.1101/2020.07.01.182709,2020-07-01,https://biorxiv.org/cgi/content/short/2020.07.01.182709,Genetic architecture of host proteins interacting with SARS-CoV-2,Maik Pietzner; Eleanor Wheeler; Julia Carrasco-Zanini; Johannes Raffler; Nicola D. Kerrison; Erin Oerton; Victoria P.W. Auyeung; Chris Finan; Juan P. Casas; Rachel Ostroff; Steve A. Williams; Gabi Kastenm√ºller; Markus Ralser; Eric G. Gamazon; Nicholas J. Wareham; Aroon Dinesh Hingorani; Claudia Langenberg,University of Cambridge; University of Cambridge; University of Cambridge; Helmholtz Zentrum M√ºnchen - German Research Center for Environmental Health (GmbH); University of Cambridge; University of Cambridge; University of Cambridge; University College London; Harvard Medical School; SomaLogic Inc.; SomaLogic Inc.; Helmholtz Zentrum M√ºnchen - German Research Center for Environmental Health (GmbH); The Francis Crick Institute; Vanderbilt University Medical Center; University of Cambridge; University College London; University of Cambridge,"Strategies to develop therapeutics for SARS-CoV-2 infection may be informed by experimental identification of viral-host protein interactions in cellular assays and measurement of host response proteins in COVID-19 patients. Identification of genetic variants that influence the level or activity of these proteins in the host could enable rapid  in silico assessment in human genetic studies of their causal relevance as molecular targets for new or repurposed drugs to treat COVID-19. We integrated large-scale genomic and aptamer-based plasma proteomic data from 10,708 individuals to characterize the genetic architecture of 179 host proteins reported to interact with SARS-CoV-2 proteins or to participate in the host response to COVID-19. We identified 220 host DNA sequence variants acting in cis (MAF 0.01-49.9%) and explaining 0.3-70.9% of the variance of 97 of these proteins, including 45 with no previously known protein quantitative trait loci (pQTL) and 38 encoding current drug targets. Systematic characterization of pQTLs across the phenome identified protein-drug-disease links, evidence that putative viral interaction partners such as MARK3 affect immune response, and establish the first link between a recently reported variant for respiratory failure of COVID-19 patients at the ABO locus and hypercoagulation, i.e. maladaptive host response. Our results accelerate the evaluation and prioritization of new drug development programmes and repurposing of trials to prevent, treat or reduce adverse outcomes. Rapid sharing and dynamic and detailed interrogation of results is facilitated through an interactive webserver (https://omicscience.org/apps/covidpgwas/).",genomics,fuzzy,100,100
medRxiv,10.1101/2020.06.29.20142448,2020-06-30,https://medrxiv.org/cgi/content/short/2020.06.29.20142448,Using past and current data to estimate potential crisis service use in mental healthcare after the COVID-19 lockdown: South London and Maudsley data,Robert Stewart; Matthew Broadbent,King's College London; South London and Maudsley NHS Foundation Trust,"The lockdown policy response to the COVID-19 pandemic in the UK has a potentially important impact on provision of mental healthcare with uncertain consequences over the 12 months ahead. Past activity may provide a means to predict future demand. Taking advantage of the Clinical Record Interactive Search (CRIS) data resource at the South London and Maudsley NHS Trust (SLaM; a large mental health service provider for 1.2m residents in south London), we carried out a range of descriptive analyses to inform the Trust on patient groups who might be most likely to require inpatient and home treatment team (HTT) crisis care. We considered the 12 months following UK COVID-19 lockdown policy on 16th March, drawing on comparable findings from previous years, and quantified levels of change in service delivery to those most likely to receive crisis care. For 12-month crisis days from 16th March in 2015-19, we found that most (over 80%) were accounted for by inpatient care (rather than HTT), most (around 75%) were used by patients who were current or recent Trust patients at the commencement of follow-up, and highest numbers were used by patients with a previously recorded schizophreniform disorder diagnosis. For current/recent patients on 16th March there had been substantial reductions in use of inpatient care in the following 31 days in 2020, more than previous years; changes in total non-inpatient contact numbers did not differ in 2020 compared to previous years, although there had been a marked switch from face-to-face to virtual contacts.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.06.28.20141986,2020-06-29,https://medrxiv.org/cgi/content/short/2020.06.28.20141986,Protocol for the development and evaluation of a tool for predicting risk of short-term adverse outcomes due to COVID-19 in the general UK population,Julia Hippisley-Cox; Ashley Kieran Clift; Carol AC Coupland; Ruth Keogh; Karla Diaz-Ordaz; Elizabeth Williamson; Ewen Harrison; Andrew Hayward; Harry Hemingway; Peter Horby; Nisha Mehta; Jonathan Kieran Benger; Kamlesh Khunti; David Spiegelhalter; Aziz Sheikh; Jonathan Valabhji; Ronan A Lyons; John Robson; Malcolm Gracie Semple; Frank Kee; Peter Johnson; Susan Jebb; Tony Williams; David Coggon,"University of Oxford; University of Oxford; University of Nottingham; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Edinburgh; University College London; University College London; University of Oxford; Department of Health and Social Care; NHS Digital; University of Leicester; University of Cambridge; University of Edinburgh; Imperial College London; Swansea University; Queen Mary University London; University of Liverpool; Queen's University Belfast; University of Southampton; University of Oxford; Working Fit, Ltd.; University of Southampton","IntroductionNovel coronavirus 2019 (COVID-19) has propagated a global pandemic with significant health, economic and social costs. Emerging emergence has suggested that several factors may be associated with increased risk from severe outcomes or death from COVID-19. Clinical risk prediction tools have significant potential to generate individualised assessment of risk and may be useful for population stratification and other use cases.

Methods and analysisWe will use a prospective open cohort study of routinely collected data from 1205 general practices in England in the QResearch database. The primary outcome is COVID-19 mortality (in or out-of-hospital) defined as confirmed or suspected COVID-19 mentioned on the death certificate, or death occurring in a person with SARS-CoV-2 infection between 24th January and 30th April 2020. Our primary outcome in adults is COVID-19 mortality (including out of hospital and in hospital deaths). We will also examine COVID-19 hospitalisation in children. Time-to-event models will be developed in the training data to derive separate risk equations in adults (19-100 years) for males and females for evaluation of risk of each outcome within the 3-month follow-up period (24th January to 30th April 2020), accounting for competing risks. Predictors considered will include age, sex, ethnicity, deprivation, smoking status, alcohol intake, body mass index, pre-existing medical co-morbidities, and concurrent medication. Measures of performance (prediction errors, calibration and discrimination) will be determined in the test data for men and women separately and by ten-year age group. For children, descriptive statistics will be undertaken if there are currently too few serious events to allow development of a risk model. The final model will be externally evaluated in (a) geographically separate practices and (b) other relevant datasets as they become available.

Ethics and disseminationThe project has ethical approval and the results will be submitted for publication in a peer-reviewed journal.

Strengths and limitations of the studyO_LIThe individual-level linkage of general practice, Public Health England testing, Hospital Episode Statistics and Office of National Statistics death register datasets enable a robust and accurate ascertainment of outcomes
C_LIO_LIThe models will be trained and evaluated in population-representative datasets of millions of individuals
C_LIO_LIShielding for clinically extremely vulnerable was advised and in place during the study period, therefore risk predictions influenced by the presence of some  shielding conditions may require careful consideration
C_LI",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.06.26.20140921,2020-06-28,https://medrxiv.org/cgi/content/short/2020.06.26.20140921,Short Communication: Vitamin D and COVID-19 infection and mortality in UK Biobank,Claire E Hastie; Jill P Pell; Naveed Sattar,University of Glasgow; University of Glasgow; University of Glasgow,"PurposeVitamin D has been proposed as a potential causal factor in COVID-19 risk. We aimed to establish whether blood 25-hydroxyvitamin D (25(OH)D) concentration was associated with COVID-19 mortality, and inpatient confirmed COVID-19 infection, in UK Biobank participants.

MethodsUK Biobank recruited 502,624 participants aged 37-73 years between 2006 and 2010. Baseline exposure data, including 25(OH)D concentration, were linked to COVID-19 mortality. Univariable and multivariable Cox proportional hazards regression analyses were performed for the association between 25(OH)D and COVID-19 death, and poisson regression analyses for the association between 25(OH)D and severe COVID-19 infection.

ResultsComplete data were available for 341,484 UK Biobank participants, of which 656 had inpatient confirmed COVID-19 infection and 203 died of COVID-19 infection. Vitamin D was associated with severe COVID-19 infection and mortality univariably (mortality HR=0.99; 95% CI 0.98-0.998; p=0.016), but not after adjustment for confounders (mortality HR=0.998; 95% CI=0.99-1.01; p=0.696).

ConclusionsOur findings do not support a potential link between vitamin D concentrations and risk of severe COVID-19 infection and mortality. Recommendations for vitamin D supplementation to lessen COVID-19 risks may provide false reassurance.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.06.26.20139873,2020-06-28,https://medrxiv.org/cgi/content/short/2020.06.26.20139873,Secondary pneumonia in critically ill ventilated patients with COVID-19,Mailis Maes; Ellen Higginson; Joana Pereira Dias; Martin D Curran; Surendra Parmar; Fahad Khokhar; Delphine Cuchet-Louren√ßo; Janine Lux; Sapna Sharma-Hajela; Benjamin Ravenhill; Razeen Mahroof; Amelia Solderholm; Sally Forrest; Sushmita Sridhar; Nicholas M Brown; Stephen Baker; Vilas Navapurkar; Gordon Dougan; Josefin Bartholdson Scott; Andrew Conway Morris,"Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Public Health England, Clinical Microbiology and Public Health Laboratory, Addenbrookes Hospital, Cambridge, United Kingdom; Public Health England, Clinical Microbiology and Public Health Laboratory, Addenbrookes Hospital, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Department of Medicine, University of Cambridge, Cambridge, United Kingdom; John Farman ICU, Addenbrookes Hospital, Cambridge, United Kingdom; John Farman ICU, Addenbrookes Hospital, Cambridge, United Kingdom; John Farman ICU, Addenbrookes Hospital, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Wellcome  Sanger Insitute, Hinxton, United Kingdom; Public Health England, Clinical Microbiology and Public Health Laboratory, Addenbrookes Hospital, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom; John Farman ICU, Addenbrookes Hospital, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, United Kingdom; University of Cambridge","BackgroundPandemic COVID-19 caused by the coronavirus SARS-CoV-2 has a high incidence of patients with severe acute respiratory syndrome (SARS). Many of these patients require admission to an intensive care unit (ICU) for invasive artificial ventilation and are at significant risk of developing a secondary, ventilator-associated pneumonia (VAP).

ObjectivesTo study the incidence of VAP, as well as differences in secondary infections, and bacterial lung microbiome composition of ventilated COVID-19 and non-COVID-19 patients.

MethodsIn this prospective observational study, we compared the incidence of VAP and secondary infections using a combination of a TaqMan multi-pathogen array and microbial culture. In addition, we determined the lung microbime composition using 16S RNA analyisis. The study involved eighteen COVID-19 and seven non-COVID-19 patients receiving invasive ventilation in three ICUs located in a single University teaching hospital between April 13th 2020 and May 7th 2020.

ResultsWe observed a higher percentage of confirmed VAP in COVID-19 patients. However, there was no statistical difference in the detected organisms or pulmonary microbiome when compared to non-COVID-19 patients.

ConclusionCOVID-19 makes people more susceptible to developing VAP, partly but not entirely due to the increased duration of ventilation. The pulmonary dysbiosis caused by COVID-19, and the array of secondary infections observed are similar to that seen in critically ill patients ventilated for other reasons.",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2020.06.24.20139048,2020-06-25,https://medrxiv.org/cgi/content/short/2020.06.24.20139048,A geotemporal survey of hospital bed saturation across England during the first wave of the COVID-19 Pandemic,Bilal A Mateen; Harrison Wilde; John m Dennis; Andrew Duncan; Nicholas John Meyrick Thomas; Andrew P McGovern; Spiros Denaxas; Matt J Keeling; Sebastian J Vollmer,"The Alan Turing Institute; University of Warwick; Kings College Hospital NHS Foundation Trust; University of Warwick, Department of Statistics; University of Exeter Medical School; The Alan Turing Institute; Imperial College London, Faculty of Natural Sciences; University of Exeter Medical School; Royal Devon and Exeter NHS Foundation Trust, Diabetes and Endocrinology; University of Exeter Medical School; University College London; University of Warwick; The Alan Turing Institute; University of Warwick, Department of Statistics","BackgroundNon-pharmacological interventions were introduced based on modelling studies which suggested that the English National Health Service (NHS) would be overwhelmed by the COVID-19 pandemic. In this study, we describe the pattern of bed occupancy across England during the first wave of the pandemic, January 31st to June 5th 2020.

MethodsBed availability and occupancy data was extracted from daily reports submitted by all English secondary care providers, between 27-Mar and 5-June. Two thresholds for  safe occupancy were utilized (85% as per Royal College of Emergency Medicine and 92% as per NHS Improvement).

FindingsAt peak availability, there were 2711 additional beds compatible with mechanical ventilation across England, reflecting a 53% increase in capacity, and occupancy never exceeded 62%. A consequence of the repurposing of beds meant that at the trough, there were 8{middle dot}7% (8,508) fewer general and acute (G&A) beds across England, but occupancy never exceeded 72%. The closest to (surge) capacity that any trust in England reached was 99{middle dot}8% for general and acute beds. For beds compatible with mechanical ventilation there were 326 trust-days (3{middle dot}7%) spent above 85% of surge capacity, and 154 trust-days (1{middle dot}8%) spent above 92%. 23 trusts spent a cumulative 81 days at 100% saturation of their surge ventilator bed capacity (median number of days per trust = 1 [range: 1 to 17]). However, only 3 STPs (aggregates of geographically co-located trusts) reached 100% saturation of their mechanical ventilation beds.

InterpretationThroughout the first wave of the pandemic, an adequate supply of all bed-types existed at a national level. Due to an unequal distribution of bed utilization, many trusts spent a significant period operating above  safe-occupancy thresholds, despite substantial capacity in geographically co-located trusts; a key operational issue to address in preparing for a potential second wave.

FundingThis study received no funding.

Research In ContextO_ST_ABSEvidence Before This StudyC_ST_ABSWe identified information sources describing COVID-19 related bed and mechanical ventilator demand modelling, as well as bed occupancy during the first wave of the pandemic by performing regular searches of MedRxiv, PubMed and Google, using the terms  COVID-19,  mechanical ventilators,  bed occupancy,  England,  UK,  demand, and  non-pharmacological interventions (NPIs), until June 20th, 2020. Two UK-specific studies were found that modelled the demand for mechanical ventilators, one of which incorporated sensitivity analysis based on the introduction of NPIs and found that their effects might prevent the healthcare system being overwhelmed. Separately, several news reports were found pertaining to a single hospital that reached ventilator capacity in England during the first wave of the pandemic, however, no single authoritative source was identified detailing impact across all hospital sites in England.

Added Value of This StudyThis national study of hospital-level bed occupancy in England provides unique and timely insight into bed-specific resource utilization during the first wave of the COVID-19 pandemic, nationally, and by specific (geographically defined) health footprints. We found evidence of an unequal distribution of resource utilization across England. Although occupancy of beds compatible with mechanical ventilation never exceeded 62% at the national level, 52 (30%) hospitals across England reached 100% saturation at some point during the first wave of the pandemic. Close examination of the geospatial data revealed that in the vast majority of circumstances there was relief capacity in geographically co-located hospitals. Over the first wave it was theoretically possible to markedly reduce (by 95.1%) the number of hospitals at 100% saturation of their mechanical ventilator bed capacity by redistributing patients to nearby hospitals.

Implications Of All The Available EvidenceNow-casting using routinely collected administrative data presents a robust approach to rapidly evaluate the effectiveness of national policies introduced to prevent a healthcare system being overwhelmed in the context of a pandemic illness. Early investment in operational field hospital and an independent sector network may yield more overtly positive results in the winter, when G&A occupancy-levels regularly exceed 92% in England, however, during the first wave of the pandemic they were under-utilized. Moreover, in the context of the non-pharmacological interventions utilized during the first wave of COVID-19, demand for beds and mechanical ventilators was much lower than initially predicted, but despite this many trust spent a significant period of time operating above  safe-occupancy thresholds. This finding demonstrates that it is vital that future demand (prediction) models reflect the nuances of local variation within a healthcare system. Failure to incorporate such geographical variation can misrepresent the likelihood of surpassing availability thresholds by averaging out over regions with relatively lower demand, and presents a key operational issue for policymakers to address in preparing for a potential second wave.",health systems and quality improvement,fuzzy,100,100
medRxiv,10.1101/2020.06.21.20136853,2020-06-23,https://medrxiv.org/cgi/content/short/2020.06.21.20136853,Modelling the impact of lockdown easing measures on cumulative COVID-19 cases and deaths in England,Hisham Ziauddeen; Naresh Subramaniam; Deepti Gurdasani,"Dept. of Psychiatry, University of Cambridge, Cambridge, UK; Dept. of Psychiatry, University of Cambridge, Cambridge UK; Queen Mary University of London","BackgroundAs countries begin to ease the lockdown measures instituted to control the COVID-19 pandemic, there is a risk of a resurgence of the pandemic, and early reports of this are already emerging from some countries. Unlike many other countries, the UK started easing lockdown in England when levels of community transmission were still high, and this could have a major impact on case numbers and deaths. However thus far, the likely impacts of easing restrictions at this point in the pandemic have not been quantified. Using a Bayesian model, we assessed the potential impacts of successive lockdown easing measures in England, focussing on scenarios where the reproductive number (R) remains [&le;]1 in line with the UK governments stated aim.

MethodsWe developed a Bayesian model to infer incident cases and R in England, from incident death data from the Office of National Statistics. We then used this to forecast excess cases and deaths in multiple plausible scenarios in which R increases at one or more time points, compared to a baseline scenario where R remains unchanged by the easing of lockdown.

FindingsThe model inferred an R of 0.752 on the 13th May when England first started easing lockdown. In the most conservative scenario where R increases to 0.80 as lockdown was eased further on 1st June and then remained constant, the model predicts an excess 257 (95% 108-492) deaths and 26,447 (95% CI 11,105-50,549) cumulative cases over 90 days. In the scenario with maximal increases in R (but staying [&le;]1) with successive easing of lockdown, the model predicts 3,174 (95% 1,334-6,060) excess cumulative deaths and 421,310 (95% 177,012-804,811) excess cases.

ResultsWhen levels of transmission are high, even small changes in R with easing of lockdown can have significant impacts on expected cases and deaths, even if R remains [&le;]1. This will have a major impact on population health, tracing systems and health care services in England.. Following an elimination strategy rather than one of maintenance of R below 1 would substantially mitigate the impact of the COVID-19 epidemic within England. This study provides urgently needed information for developing public health policy for the next stages of the pandemic.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.06.22.20137182,2020-06-23,https://medrxiv.org/cgi/content/short/2020.06.22.20137182,Obesity during the COVID-19 pandemic: cause of high risk or an effect of lockdown? A population-based electronic health record analysis in 1 958 184 individuals.,Michail Katsoulis; Laura Pasea; Alvina Lai; Richard JB Dobson; Spiros Denaxas; Harry Hemingway; Amitava Banerjee,UCL; University College London; University College London; University College London; University College London; University College London; University College London,"BackgroundObesity is a modifiable risk factor for coronavirus(COVID-19)-related mortality. We estimated excess mortality in obesity, both ""direct"", through infection, and ""indirect"", through changes in healthcare, and also due to potential increasing obesity during lockdown.

MethodsIn population-based electronic health records for 1 958 638 individuals in England, we estimated 1-year mortality risk(""direct"" and ""indirect"" effects) for obese individuals, incorporating: (i)pre-COVID-19 risk by age, sex and comorbidities, (ii)population infection rate, and (iii)relative impact on mortality(relative risk, RR: 1.2, 1.5, 2.0 and 3.0). Using causal inference models, we estimated impact of change in body-mass index(BMI) and physical activity during 3-month lockdown on 1-year incidence for high-risk conditions(cardiovascular diseases, CVD; diabetes; chronic obstructive pulmonary disease, COPD and chronic kidney disease, CKD), accounting for confounders.

FindingsFor severely obese individuals (3.5% at baseline), at 10% population infection rate, we estimated direct impact of 240 and 479 excess deaths in England at RR 1.5 and 2.0 respectively, and indirect effect of 383 to 767 excess deaths, assuming 40% and 80% will be affected at RR=1.2. Due to BMI change during the lockdown, we estimated that 97 755 (5.4%: normal weight to overweight, 5.0%: overweight to obese and 1.3%: obese to severely obese) to 434 104 individuals (15%: normal weight to overweight, 15%: overweight to obese and 6%: obese to severely obese) individuals would be at higher risk for COVID-19 over one year.

InterpretationPrevention of obesity and physical activity are at least as important as physical isolation of severely obese individuals during the pandemic.

O_TEXTBOXResearch in contextO_ST_ABSEvidence before this studyC_ST_ABSWe searched PubMed, medRxiv, bioRxiv, arXiv, and Wellcome Open Research for peer-reviewed articles, preprints, and research reports on obesity, excess mortality and change in body-mass index in the coronavirus disease 2019 (COVID-19), using the search terms ""obesity"", ""coronavirus"", ""COVID-19"", and similar terms, and ""mortality"", up to June 15, 2020. We found no prior studies of excess deaths in obese individuals due to COVID-19 pandemic, and no studies of long-term estimates or the relative impact of COVID-19 on mortality. Moreover, there were no studies of change in body-mass index during lockdown periods. Without these data, it is difficult to make specific recommendations in obese people at individual or population level during the pandemic.

Added value of this studyWe estimated excess COVID-19-related mortality in severely obese individuals, targeted in physical distancing and isolation policies in UK government guidance. Assuming 10% infection rate, we estimated a direct impact of 240 to 479 excess deaths in England and indirect effect of 383 to 767 excess deaths. On the other hand, we estimated that between 97 755 and 434 104 individuals may develop high-risk conditions for COVID-19 mortality during a 3-month lockdown due to change in body-mass index and physical activity.

Implications of all the available evidenceThese analyses support COVID-19 and non-COVID-19 impact assessment in policy planning during the pandemic. The implications of distancing and isolation measures on incidence and mortality from chronic diseases, particularly relating to obesity, needs to be considered in clinical practice, public health and research.

C_TEXTBOX",health policy,fuzzy,100,100
medRxiv,10.1101/2020.06.22.20137216,2020-06-23,https://medrxiv.org/cgi/content/short/2020.06.22.20137216,"Proteomic blood profiling in mild, severe and critical COVID-19 patients",Hamel Patel; Nicholas J Ashton; Richard J Dobson; Lars-magnus Anderson; Aylin Yilmaz; Kaj Blennow; Magnus Gisslen; Henrik Zetterberg,King's College London; University of Gothenburg; Kings College London; Sahlgrenska university hospital; University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg,"The recent SARS-CoV-2 pandemic manifests itself as a mild respiratory tract infection in the majority of individuals leading to COVID-19 disease. However, in some infected individuals, this can progress to severe pneumonia and acute respiratory distress syndrome (ARDS), leading to multi-organ failure and death. The purpose of this study is to explore the proteomic differences between mild, severe and critical COVID-19 positive patients. Blood protein profiling was performed on 59 COVID-19 mild (n=26), severe (n=9) or critical (n=24) cases and 28 controls using the OLINK inflammation, autoimmune, cardiovascular and neurology panels. Differential expression analysis was performed within and between disease groups to generate nine different analyses. From the 368 proteins measured per individual, more than 75% were observed to be significantly perturbed in COVID-19 cases. Six proteins (IL6, CKAP4, Gal-9, IL-1ra, LILRB4 and PD-L1) were identified to be associated with disease severity. The results have been made readily available through an interactive web-based application for instant data exploration and visualization, and can be accessed at https://phidatalab-shiny.rosalind.kcl.ac.uk/COVID19/. Our results demonstrate that dynamic changes in blood proteins that associate with disease severity can potentially be used as early biomarkers to monitor disease severity in COVID-19 and serve as potential therapeutic targets.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.06.22.20137273,2020-06-22,https://medrxiv.org/cgi/content/short/2020.06.22.20137273,Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report,Peter Horby; Wei Shen Lim; Jonathan Emberson; Marion Mafham; Jennifer Bell; Louise Linsell; Natalie Staplin; Christopher Brightling; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Christopher Green; Timothy Felton; David Chadwick; Kanchan Rege; Christopher Fegan; Lucy C Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Alan Montgomery; Kathryn Rowan; Edmund Juszczak; J Kenneth Baillie; Richard Haynes; Martin J Landray; - RECOVERY Collaborative Group,"Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.; Respiratory Medicine Department, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; MRC Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Institute for Lung Health, Leicester NIHR Biomedical Research Centre, University of Leicester, Leicester, United Kingdom; Regional Infectious Diseases Unit, North Manchester General Hospital & University of Manchester, Manchester, United Kingdom; Research and Development Department, Northampton General Hospital, Northampton, United Kingdom; Department of Respiratory Medicine, North Tees & Hartlepool NHS Foundation Trust, Stockton-on-Tees, United Kingdom; University Hospitals Birmingham NHS Foundation Trust and Institute of Microbiology & Infection, University of Birmingham, Birmingham, United Kingdom; University of Manchester and Manchester University NHS Foundation Trust, Manchester, United Kingdom; Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United Kingdom; North West Anglia NHS Foundation Trust, Peterborough, United Kingdom; Department of Research and Development, Cardiff and Vale University Health Board, Cardiff, United Kingdom; School of Life Course Sciences, Kings College London, London, United Kingdom; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust and University of Southampton, ; Department of Mathematics and Statistics, Lancaster University, Lancaster, United Kingdom and MRC Biostatistics Unit, University of Cambridge, Cambridge, United; Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom; School of Medicine, University of Nottingham, Nottingham, United Kingdom; Intensive Care National Audit & Research Centre, London, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom; ","BackgroundCoronavirus disease 2019 (COVID-19) is associated with diffuse lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing progression to respiratory failure and death.

MethodsThe Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, adaptive, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. We report the preliminary results for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone. The primary outcome was 28-day mortality.

Results2104 patients randomly allocated to receive dexamethasone were compared with 4321 patients concurrently allocated to usual care. Overall, 454 (21.6%) patients allocated dexamethasone and 1065 (24.6%) patients allocated usual care died within 28 days (age-adjusted rate ratio [RR] 0.83; 95% confidence interval [CI] 0.74 to 0.92; P<0.001). The proportional and absolute mortality rate reductions varied significantly depending on level of respiratory support at randomization (test for trend p<0.001): Dexamethasone reduced deaths by one-third in patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; p<0.001), by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; p=0.002), but did not reduce mortality in patients not receiving respiratory support at randomization (17.0% vs. 13.2%, RR 1.22 [95% CI 0.93 to 1.61]; p=0.14).

ConclusionsIn patients hospitalized with COVID-19, dexamethasone reduced 28-day mortality among those receiving invasive mechanical ventilation or oxygen at randomization, but not among patients not receiving respiratory support.

Trial registrationsThe RECOVERY trial is registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

FundingMedical Research Council and National Institute for Health Research (Grant ref: MC_PC_19056).",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.06.19.20135491,2020-06-20,https://medrxiv.org/cgi/content/short/2020.06.19.20135491,"Inhaled corticosteroid use and risk COVID-19 related death among 966,461 patients with COPD or asthma: an OpenSAFELY analysis",- The OpenSAFELY Collaborative; Anna Schultze; Alex J Walker; Brian MacKenna; Caroline E Morton; Krishnan Bhaskaran; Jeremy P Brown; Christopher T. Rentsch; Elizabeth J Williamson; Henry Drysdale; Richard Croker; Seb Bacon; William J Hulme; Chris Bates; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Laurie Tomlinson; Rohini Mathur; Kevin Wing; Angel YS Wong; Harriet Forbes; John Parry; Frank Hester; Sam Harper; Stephen JW Evans; Jennifer Quint; Liam Smeeth; Ian J Douglas; Ben Goldacre,"; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; US Department of Veterans Affairs, London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine, NIHR Health Protection Research Unit (HPRU) in Immunisation; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; TPP; TPP; TPP; London School of Hygiene and Tropical Medicine; National Heart and Lung Institute, Imperial College; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford","BackgroundEarly descriptions of the coronavirus outbreak showed a lower prevalence of asthma and COPD than was expected for people diagnosed with COVID-19, leading to speculation that inhaled corticosteroids (ICS) may protect against infection with SARS-CoV-2, and development of serious sequelae. We evaluated the association between ICS and COVID-19 related death using linked electronic health records in the UK.

MethodsWe conducted cohort studies on two groups of people (COPD and asthma) using the OpenSAFELY platform to analyse data from primary care practices linked to national death registrations. People receiving an ICS were compared to those receiving alternative respiratory medications. Our primary outcome was COVID-19 related death.

FindingsWe identified 148,588 people with COPD and 817,973 people with asthma receiving relevant respiratory medications in the four months prior to 01 March 2020. People with COPD receiving ICS were at a greater risk of COVID-19 related death compared to those receiving a long-acting beta agonist (LABA) and a long-acting muscarinic antagonist (LAMA) (adjusted HR = 1.38, 95% CI = 1.08 - 1.75). People with asthma receiving high dose ICS were at an increased risk of death compared to those receiving a short-acting beta agonist (SABA) only (adjusted HR = 1.52, 95%CI = 1.08 - 2.14); the adjusted HR for those receiving low-medium dose ICS was 1.10 (95% CI = 0.82 - 1.49). Quantitative bias analyses indicated that an unmeasured confounder of only moderate strength of association with exposure and outcome could explain the observed associations in both populations.

InterpretationThese results do not support a major role of ICS in protecting against COVID-19 related deaths. Observed increased risks of COVID-19 related death among people with COPD and asthma receiving ICS can be plausibly explained by unmeasured confounding due to disease severity.

FundingThis work was supported by the Medical Research Council MR/V015737/1.",respiratory medicine,fuzzy,100,100
medRxiv,10.1101/2020.06.18.20134742,2020-06-20,https://medrxiv.org/cgi/content/short/2020.06.18.20134742,Racial and ethnic determinants of Covid-19 risk,Chun-Han Lo; Long H. Nguyen; David A. Drew; Mark S. Graham; Erica T. Warner; Amit D. Joshi; Christina M. Astley; Chuan-Guo Guo; Wenjie Ma; Raaj S. Mehta; Sohee Kwon; Mingyang Song; Richard Davies; Joan Capdevila; Karla A. Lee; Mary Ni Lochlainn; Thomas Varsavsky; Carole H. Sudre; Jonathan Wolf; Yvette C. Cozier; Lynn Rosenberg; Lynne R. Wilkens; Christopher A. Haiman; Loic Le Marchand; Julie R. Palmer; Tim D. Spector; Sebastien Ourselin; Claire J. Steves; Andrew T. Chan; - COPE Consortium,"Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; School of Biomedical Engineering & Imaging Sciences, King's College London, London, U.K.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; Computational Epidemiology Lab and Division of Endocrinology, Boston Children's Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; Zoe Global Limited, London, U.K.; Zoe Global Limited, London, U.K.; Department of Twin Research and Genetic Epidemiology, King's College London, London, U.K.; Department of Twin Research and Genetic Epidemiology, King's College London, London, U.K.; School of Biomedical Engineering & Imaging Sciences, King's College London, London, U.K.; School of Biomedical Engineering & Imaging Sciences, King's College London, London, U.K.; Zoe Global Limited, London, U.K.; Slone Epidemiology Center, Boston University, Boston, Massachusetts, U.S.A.; Slone Epidemiology Center, Boston University, Boston, Massachusetts, U.S.A.; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, U.S.A.; Department of Preventative Medicine, Keck School of Medicine, University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, U.; Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, U.S.A.; Slone Epidemiology Center, Boston University, Boston, Massachusetts, U.S.A.; Department of Twin Research and Genetic Epidemiology, King's College London, London, U.K.; School of Biomedical Engineering & Imaging Sciences, King's College London, London, U.K.; Department of Twin Research and Genetic Epidemiology, King's College London, London, U.K.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School. Boston, Massachusetts, U.S.A.; ","BackgroundRacial and ethnic minorities have disproportionately high hospitalization rates and mortality related to the novel coronavirus disease 2019 (Covid-19). There are comparatively scant data on race and ethnicity as determinants of infection risk.

MethodsWe used a smartphone application (beginning March 24, 2020 in the United Kingdom [U.K.] and March 29, 2020 in the United States [U.S.]) to recruit 2,414,601 participants who reported their race/ethnicity through May 25, 2020 and employed logistic regression to determine the adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for a positive Covid-19 test among racial and ethnic groups.

ResultsWe documented 8,858 self-reported cases of Covid-19 among 2,259,841 non-Hispanic white; 79 among 9,615 Hispanic; 186 among 18,176 Black; 598 among 63,316 Asian; and 347 among 63,653 other racial minority participants. Compared with non-Hispanic white participants, the risk for a positive Covid-19 test was increased across racial minorities (aORs ranging from 1.24 to 3.51). After adjustment for socioeconomic indices and Covid-19 exposure risk factors, the associations (aOR [95% CI]) were attenuated but remained significant for Hispanic (1.58 [1.24-2.02]) and Black participants (2.56 [1.93-3.39]) in the U.S. and South Asian (1.52 [1.38-1.67]) and Middle Eastern participants (1.56 [1.25-1.95]) in the U.K. A higher risk of Covid-19 and seeking or receiving treatment was also observed for several racial/ethnic minority subgroups.

ConclusionsOur results demonstrate an increase in Covid-19 risk among racial and ethnic minorities not completely explained by other risk factors for Covid-19, comorbidities, and sociodemographic characteristics. Further research investigating these disparities are needed to inform public health measures.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.06.17.20133959,2020-06-20,https://medrxiv.org/cgi/content/short/2020.06.17.20133959,A downscaling approach to compare COVID-19 count data from databases aggregated at different spatial scales,Andre Python; Andreas Bender; Marta Blangiardo; Janine B Illian; Ying Lin; Baoli Liu; Tim C D Lucas; Siwei Tan; Yingying Wen; Davit Svanidze; Jianwei Yin,University of Oxford; LMU Munich; Imperial College London; Glasgow University; Fuzhou University; Oxford University; University of Oxford; Zhejiang University; Zhejiang University; Goettingen University; Zhejiang University,"As the COVID-19 pandemic continues to threaten various regions around the world, obtaining accurate and reliable COVID-19 data is crucial for governments and local communities aiming at rigorously assessing the extent and magnitude of the virus spread and deploying efficient interventions. Using data reported between January and February 2020 in China, we compared counts of COVID-19 from near-real time spatially disaggregated data (city-level) with fine-spatial scale predictions from a Bayesian downscaling regression model applied to a reference province-level dataset. The results highlight discrepancies in the counts of coronavirus-infected cases at district level and identify districts that may require further investigation.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.06.16.20133116,2020-06-18,https://medrxiv.org/cgi/content/short/2020.06.16.20133116,Mental health during the COVID-19 pandemic in two longitudinal UK population cohorts,Alex Siu Fung Kwong; Rebecca M Pearson; Mark J Adams; Kate Northstone; Kate Tilling; Daniel Smith; Chloe Fawns-Ritchie; Helen Bould; Naomi Warne; Stan Zammit; David J Gunnell; Paul Moran; Nadia Micali; Abraham Reichenberg; Matthew Hickman; Dheeraj Rai; Simon Haworth; Archie Campbell; Drew Altschul; Robin Flaig; Andrew M McIntosh; Deborah A Lawlor; David Porteous; Nicholas J Timpson,University of Bristol; University of Bristol; University of Edinburgh; University of Bristol; University of Bristol; University of Bristol; University of Edinburgh; University of Bristol; University of Bristol; Cardiff University; University of Bristol; University of Bristol; UCL; Mount Sinai; University of Bristol; University of Bristol; University of Bristol; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Bristol; University of Edinburgh; University of Bristol,"BackgroundThe impact of COVID-19 on mental health is unclear. Evidence from longitudinal studies with pre pandemic data are needed to address (1) how mental health has changed from pre-pandemic levels to during the COVID-19 pandemic and (2), whether there are groups at greater risk of poorer mental health during the pandemic?

MethodsWe used data from COVID-19 surveys (completed through April/May 2020), nested within two large longitudinal population cohorts with harmonised measures of mental health: two generations of the Avon Longitudinal Study of Parents and Children (ALPSAC): the index generation ALSPAC-G1 (n= 2850, mean age 28) and the parents generation ALSPAC-G0 (n= 3720, mean age = 59) and Generation Scotland: Scottish Family Health Study (GS, (n= 4233, mean age = 59), both with validated pre-pandemic measures of mental health and baseline factors. To answer question 1, we used ALSPAC-G1, which has identical mental health measures before and during the pandemic. Question 2 was addressed using both studies, using pre-pandemic and COVID-19 specific factors to explore associations with depression and anxiety in COVID-19.

FindingsIn ALSPAC-G1 there was evidence that anxiety and lower wellbeing, but not depression, had increased in COVID-19 from pre-pandemic assessments. The percentage of individuals with probable anxiety disorder was almost double during COVID-19: 24% (95% CI 23%, 26%) compared to pre-pandemic levels (13%, 95% CI 12%, 14%), with clinically relevant effect sizes. In both ALSPAC and GS, depression and anxiety were greater in younger populations, women, those with pre-existing mental and physical health conditions, those living alone and in socio-economic adversity. We did not detect evidence for elevated risk in key workers or health care workers.

InterpretationThese results suggest increases in anxiety and lower wellbeing that may be related to the COVID-19 pandemic and/or its management, particularly in young people. This research highlights that specific groups may be disproportionally at risk of elevated levels of depression and anxiety during COVID-19 and supports recent calls for increasing funds for mental health services.

FundingThe UK Medical Research Council (MRC), the Wellcome Trust and University of Bristol.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.06.16.20133157,2020-06-18,https://medrxiv.org/cgi/content/short/2020.06.16.20133157,Combined point of care nucleic acid and antibody testing for SARS-CoV-2: a prospective cohort study in suspected moderate to severe COVID-19 disease.,Petra Mlcochova; Dami Collier; Allyson V Ritchie; Sonny M Assennato; Myra Hosmillo; Neha Goel; Bo Meng; Krishna Chatterji; Vivien Mendoza; Nigel Temperton; Leo Kiss; Katarzyna A Ciazyns; Xiaoli Xiong; John AG Briggs; James Nathan; Federica Mescia; Hongyi Zhang; Petros Barmpounakis; Nikos Demeris; Richard Skells; Paul Lyons; John Bradley; Stephen Baker; Jean Pierre Allain; Kenneth GC Smith; Ian Goodfellow; Ravindra K Gupta,"University of Cambridge; UCL; Diagnostics for the Real World Europe Ltd; DRW; University of Cambridge; University of Cambridge; University of Cambridge; NIHR Cambridge Clinical Research Facility; CUH NHS Trust; University of Kent; Medical Research Council Laboratory of Molecular Biology, Cambridge; Medical Research Council Laboratory of Molecular Biology, Cambridge; Medical Research Council Laboratory of Molecular Biology; Medical Research Council Laboratory of Molecular Biology; University of Cambridge; University of Cambridge; CUH NHS Trust; Athens University of Economics and Business; Cambridge Clinical Trials Unit-Cancer Theme; Cambridge Clinical Trials Unit-Cancer Theme; University of Cambridge; University of Cambridge; Cambridge University; Diagnostics for the Real World EU Ltd; University of Cambridge; ig299@cam.ac.uk; University of Cambridge","BackgroundRapid COVID-19 diagnosis in hospital is essential for patient management and identification of infectious patients to limit the potential for nosocomial transmission. The diagnosis of infection is complicated by 30-50% of COVID-19 hospital admissions with nose/throat swabs testing negative for SARS-CoV-2 nucleic acid, frequently after the first week of illness when SARS-CoV-2 antibody responses become detectable. We assessed the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease in the emergency department.

MethodsWe developed (i) an in vitro neutralization assay using a lentivirus expressing a genome encoding luciferase and pseudotyped with spike (S) protein and (ii) an ELISA test to detect IgG antibodies to nucleocapsid (N) and S proteins from SARS-CoV-2. We tested two lateral flow rapid fingerprick tests with bands for IgG and IgM. We then prospectively recruited participants with suspected moderate to severe COVID-19 and tested for SARS-CoV-2 nucleic acid in a combined nasal/throat swab using the standard laboratory RT-PCR and a validated rapid POC nucleic acid amplification (NAAT) test. Additionally, serum collected at admission was retrospectively tested by in vitro neutralisation, ELISA and the candidate POC antibody tests. We evaluated the performance of the individual and combined rapid POC diagnostic tests against a composite reference standard of neutralisation and standard laboratory based RT-PCR.

Results45 participants had specimens tested for nucleic acid in nose/throat swabs as well as stored sera for antibodies. Using the composite reference standard, prevalence of COVID-19 disease was 53.3% (24/45). Median age was 73.5 (IQR 54.0-86.5) years in those with COVID-19 disease by our reference standard and 63.0 (IQR 41.0-72.0) years in those without disease. The overall detection rate by rapid NAAT was 79.2% (95CI 57.8-92.9%), decreasing from 100% (95% CI 65.3-98.6%) in days 1-4 to 50.0% (95% CI 11.8-88.2) for days 9-28 post symptom onset. Correct identification of COVID-19 with combined rapid POC diagnostic tests was 100% (95CI 85.8-100%) with a false positive rate of 5.3-14.3%, driven by POC LFA antibody tests.

ConclusionsCombined POC tests have the potential to transform our management of COVID-19, including inflammatory manifestations later in disease where nucleic acid test results are negative. A rapid combined approach will also aid recruitment into clinical trials and in prescribing therapeutics, particularly where potentially harmful immune modulators (including steroids) are used.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.06.15.20131722,2020-06-17,https://medrxiv.org/cgi/content/short/2020.06.15.20131722,"Delirium is a presenting symptom of COVID-19 in frail, older adults: a cohort study of 322 hospitalised and 535 community-based older adults",Maria Beatrice Zazzara; Rose S. Penfold; Amy L. Roberts; Karla Lee; Hannah Dooley; Carole H. Sudre; Carly Welch; Ruth C. E. Bowyer; Alessia Visconti; Massimo Mangino; Maxim B. Freydin; Julia S. El-Sayed Moustafa; Kerrin Small; Benjamin Murray; Marc Modat; Jonathan Wolf; Sebastien Ourselin; Finbarr C. Martin; Claire J. Steves; Mary Ni Lochlainn,"Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; Department of Gerontology, Neuroscience and O; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; School of Biomedical Engineering and Imaging Sciences, King's College London, Westminster Bridge Road, SE17EH, London, UK; Institute of Inflammation and Ageing, University of Birmingham, B15 2TT; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; NIHR Biomedical Research Centre at Guy's and ; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; School of Biomedical Engineering and Imaging Sciences, King's College London, Westminster Bridge Road, SE17EH, London, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, Westminster Bridge Road, SE17EH, London, UK; Zoe Global Limited,164 Westminster Bridge Road, London SE1 7RW, UK; School of Biomedical Engineering and Imaging Sciences, King's College London, Westminster Bridge Road, SE17EH, London, UK; Population Health Sciences, King's College London, Westminster Bridge Road, SE17EH, London, UK; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH; Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Hospital, London, SE1 7EH","BackgroundFrailty, increased vulnerability to physiological stressors, is associated with adverse outcomes. COVID-19 exhibits a more severe disease course in older, co-morbid adults. Awareness of atypical presentations is critical to facilitate early identification.

ObjectiveTo assess how frailty affects presenting COVID-19 symptoms in older adults.

DesignObservational cohort study of hospitalised older patients and self-report data for community-based older adults.

SettingAdmissions to St Thomas Hospital, London with laboratory-confirmed COVID-19. Community-based data for 535 older adults using the COVID Symptom Study mobile application.

SubjectsHospital cohort: patients aged 65 and over (n=322); unscheduled hospital admission between March 1st, 2020-May 5th, 2020; COVID-19 confirmed by RT-PCR of nasopharyngeal swab. Community-based cohort: participants aged 65 and over enrolled in the COVID Symptom Study (n=535); reported test-positive for COVID-19 from March 24th (application launch)-May 8th, 2020.

MethodsMultivariate logistic regression analysis performed on age-matched samples from hospital and community-based cohorts to ascertain association of frailty with symptoms of confirmed COVID-19.

ResultsHospital cohort: significantly higher prevalence of delirium in the frail sample, with no difference in fever or cough. Community-based cohort :significantly higher prevalence of probable delirium in frailer, older adults, and fatigue and shortness of breath.

ConclusionsThis is the first study demonstrating higher prevalence of delirium as a COVID-19 symptom in older adults with frailty compared to other older adults. This emphasises need for systematic frailty assessment and screening for delirium in acutely ill older patients in hospital and community settings. Clinicians should suspect COVID-19 in frail adults with delirium.",geriatric medicine,fuzzy,94,100
medRxiv,10.1101/2020.06.13.20130419,2020-06-16,https://medrxiv.org/cgi/content/short/2020.06.13.20130419,Mental health service activity during COVID-19 lockdown: South London and Maudsley data on working age community and home treatment team services and mortality from February to mid-May 2020,Robert Stewart; Evangelia Martin; Matthew Broadbent,King's College London; King's College London; South London and Maudsley NHS Foundation Trust,"The lockdown and social distancing policy response to the COVID-19 pandemic in the UK has a potentially important impact on provision of mental healthcare; however, there has been relatively little quantification of this. Taking advantage of the Clinical Record Interactive Search (CRIS) data resource with 24-hourly updates of electronic mental health records data, this paper describes daily caseloads and contact numbers (face-to-face and virtual) for home treatment teams (HTTs) and working age adult community mental health teams (CMHTs) from 1st February to 15th May 2020 at the South London and Maudsley NHS Trust (SLaM), a large mental health service provider for 1.2m residents in south London. In addition daily deaths are described for all current and previous SLaM service users over this period and the same dates in 2019. In summary, comparing periods before and after 16th March 2020 the CMHT sector showed relatively stable caseloads and total contact numbers, but a substantial shift from face-to-face to virtual contacts, while HTTs showed the same changeover but reductions in caseloads and total contacts (although potentially an activity rise again during May). Number of deaths for the two months between 16th March and 15th May were 2.4-fold higher in 2020 than 2019, with 958 excess deaths.",psychiatry and clinical psychology,fuzzy,100,100
medRxiv,10.1101/2020.06.12.20129056,2020-06-16,https://medrxiv.org/cgi/content/short/2020.06.12.20129056,Symptom clusters in Covid19: A potential clinical prediction tool from the COVID Symptom study app,Carole H Sudre; Karla Lee; Mary Ni Lochlainn; Thomas Varsavsky; Benjamin Murray; Mark S. Graham; Cristina Menni; Marc Modat; Ruth C.E. Bowyer; Long H Nguyen; David Alden Drew; Amit D Joshi; Wenjie Ma; Chuan Guo Guo; Chun Han Lo; Sajaysurya Ganesh; Abubakar Buwe; Joan Capdevila Pujol; Julien Lavigne du Cadet; Alessia Visconti; Maxim Freydin; Julia S. El Sayed Moustafa; Mario Falchi; Richard Davies; Maria F. Gomez; Tove Fall; M. Jorge Cardoso; Jonathan Wolf; Paul W Franks; Andrew T Chan; Timothy D Spector; Claire J Steves; Sebastien Ourselin,King's College London; Department of Twin Research and Genetic Epidemiology; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Massachusetts General Hospital; Zoe Global Limited; Zoe Global Limited; Zoe Global Limited; Zoe Global Limited; King's College London; King's College London; King's College London; King's College London; Zoe Global Limited; Lund University; Lund University; King's College London; Zoe Global Limited; Lund University; Massachusetts General Hospital; King's College London; King's College London; King's College London,"As no one symptom can predict disease severity or the need for dedicated medical support in COVID-19, we asked if documenting symptom time series over the first few days informs outcome. Unsupervised time series clustering over symptom presentation was performed on data collected from a training dataset of completed cases enlisted early from the COVID Symptom Study Smartphone application, yielding six distinct symptom presentations. Clustering was validated on an independent replication dataset between May 1-May 28th, 2020. Using the first 5 days of symptom logging, the ROC-AUC of need for respiratory support was 78.8%, substantially outperforming personal characteristics alone (ROC-AUC 69.5%). Such an approach could be used to monitor at-risk patients and predict medical resource requirements days before they are required.

One sentence summaryLongitudinal clustering of symptoms can predict the need for respiratory support in severe COVID-19.",health informatics,fuzzy,94,100
bioRxiv,10.1101/2020.06.16.153817,2020-06-16,https://biorxiv.org/cgi/content/short/2020.06.16.153817,The IMEx Coronavirus interactome: an evolving map of Coronaviridae-Host molecular interactions,Livia Perfetto; Chiara Pastrello; Noemi Del-Toro; Margaret Duesbury; Marta Iannuccelli; Max Kotlyar; Luana Licata; Birgit Meldal; Kalpana Panneerselvam; Simona Panni; Negin Rahimzadeh; Sylvie Ricard-Blum; Lukasz Salwinski; Anjali Shrivastava; Gianni Cesareni; Matteo Pellegrini; Sandra Orchard; Igor Jurisica; Henning Hermjakob; Pablo Porras,"European Molecular Biology Laboratory European Bioinformatics Institute (EMBL-EBI); Krembil Research Institute, Data Science Discovery Centre for Chronic Diseases, University Health Network, 5KD-407, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Can; European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK.; European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK.   UCLA-DOE Institute, UCLA, ; Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, Rome, Italy; Krembil Research Institute, Data Science Discovery Centre for Chronic Diseases, University Health Network, 5KD-407, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Can; Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, Rome, Italy; European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK.; European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK.; Department of Biology, Ecology and Earth Sciences, Universita della Calabria, Rende, Italy; UCLA-DOE Institute, UCLA, Los Angeles, USA. Providence John Wayne Cancer Institute, Santa Monica, USA; Univ Lyon, University Claude Bernard Lyon 1, INSA Lyon, CPE, Institute of Molecular and Supramolecular Chemistry and Biochemistry (ICBMS), UMR 5246, F-69622 Vil; UCLA-DOE Institute, UCLA, Los Angeles, USA; European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK.; Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, Rome, Italy; Department of Molecular, Cell and Developmental Biology, UCLA, Los Angeles, USA; European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK.; Krembil Research Institute, Data Science Discovery Centre for Chronic Diseases, University Health Network, 5KD-407, 60 Leonard Avenue, Toronto, ON, M5T 0S8, Can; European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK.; European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Wellcome Genome Campus, Hinxton, CB10 1SD, UK.","The current Coronavirus Disease 2019 (COVID-19) pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has spurred a wave of research of nearly unprecedented scale. Among the different strategies that are being used to understand the disease and develop effective treatments, the study of physical molecular interactions enables studying fine-grained resolution of the mechanisms behind the virus biology and the human organism response. Here we present a curated dataset of physical molecular interactions, manually extracted by IMEx Consortium curators focused on proteins from SARS-CoV-2, SARS-CoV-1 and other members of the Coronaviridae family. Currently, the dataset comprises over 2,200 binarized interactions extracted from 86 publications. The dataset can be accessed in the standard formats recommended by the Proteomics Standards Initiative (HUPO-PSI) at the IntAct database website (www.ebi.ac.uk/intact), and will be continuously updated as research on COVID-19 progresses.",bioinformatics,fuzzy,100,100
medRxiv,10.1101/2020.06.05.20123448,2020-06-12,https://medrxiv.org/cgi/content/short/2020.06.05.20123448,"The effectiveness of social bubbles as part of a Covid-19 lockdown exit strategy, a modelling study",Trystan Leng; Connor White; Joe Hilton; Adam J Kucharski; Lorenzo Pellis; Helena Stage; Nicholas G Davies; Matt J Keeling; Stefan Flasche,University of Warwick; University of Warwick; University of Warwick; London School of Hygiene & Tropical Medicine; The University of Manchester; University of Manchester; London School of Hygiene and Tropical Medicine; University of Warwick; LSHTM,"BackgroundDuring the Covid-19 lockdown, contact clustering in social bubbles may allow extending contacts beyond the household at minimal additional risk and hence has been considered as part of modified lockdown policy or a gradual lockdown exit strategy. We estimated the impact of such strategies on epidemic and mortality risk using the UK as a case study.

MethodsWe used an individual based model for a synthetic population similar to the UK, that is stratified into transmission risks from the community, within the household and from other households in the same social bubble. The base case considers a situation where non-essential shops and schools are closed, the secondary household attack rate is 20% and the initial reproduction number is 0.8. We simulate a number of strategies including variations of social bubbles, i.e. the forming of exclusive pairs of households, for particular subsets of households (households including children and single occupancy households), as well as for all households. We test the sensitivity of the results to a range of alternative model assumptions and parameters.

ResultsClustering contacts outside the household into exclusive social bubbles is an effective strategy of increasing contacts while limiting some of the associated increase in epidemic risk. In the base case scenario social bubbles reduced cases and fatalities by 17% compared to an unclustered increase of contacts. We find that if all households were to form social bubbles the reproduction number would likely increase to 1.1 and therefore beyond the epidemic threshold of one. However, strategies that allow households with young children or single occupancy households to form social bubbles only increased the reproduction number by less than 10%. The corresponding increase in morbidity and mortality is proportional to the increase in the epidemic risk but is largely focussed in older adults independently of whether these are included in the social bubbles.

ConclusionsSocial bubbles can be an effective way of extending contacts beyond the household limiting the increase in epidemic risk, if managed appropriately.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.06.10.20127563,2020-06-12,https://medrxiv.org/cgi/content/short/2020.06.10.20127563,"Multimorbidity, Polypharmacy, and COVID-19 infection within the UK Biobank cohort.",Ross McQueenie; Hamish Foster; Bhautesh D Jani; Srinivasa Vittal Katikireddi; Naveed Sattar; Jill P Pell; Frederick K Ho; Claire L Niedzwiedz; Claire E Hastie; Jana Anderson; Patrick B Mark; Michael Sullivan; Frances S Mair; Barbara I Nicholl,"University of Glasgow, Instutute of Health and Wellbeing; University of Glasgow, Instutute of Health and Wellbeing; University of Glasgow, Institute of Health and Wellbeing; University of Glasgow, Institute of Health and Wellbeing; University of Glasgow, Institute of Cardiovascular and Medical Sciences; University of Glasgow, Institute of Health and Wellbeing; University of Glasgow, Institute of Health and Wellbeing; University of Glasgow, Institute of Health and Wellbeing; University of Glasgow, Institute of Health and Wellbeing; University of Glasgow, Institute of Health and Wellbeing; University of Glasgow, Institute of Cardiovascular and Medical Sciences; University of Glasgow, Institute of Cardiovascular and Medical Sciences; University of Glasgow, Institute of Health and Wellbeing; University of Glasgow, Institute of Health and Wellbeing","BACKGROUNDIt is now well recognised that the risk of severe COVID-19 increases with some long-term conditions (LTCs). However, prior research primarily focuses on individual LTCs and there is a lack of data on the influence of multimorbidity ([&ge;]2 LTCs) on the risk of COVID-19. Given the high prevalence of multimorbidity, more detailed understanding of the associations with multimorbidity and COVID-19 would improve risk stratification and help protect those most vulnerable to severe COVID-19. Here we examine the relationships between multimorbidity, polypharmacy (a proxy of multimorbidity), and COVID-19; and how these differ by sociodemographic, lifestyle, and physiological prognostic factors.

METHODS AND FINDINGSWe studied data from UK Biobank (428,199 participants; aged 37-73; recruited 2006-2010) on self-reported LTCs, medications, sociodemographic, lifestyle, and physiological measures which were linked to COVID-19 test data. Poisson regression models examined risk of COVID-19 by multimorbidity/polypharmacy and effect modification by COVID-19 prognostic factors (age/sex/ethnicity/socioeconomic status/smoking/physical activity/BMI/systolic blood pressure/renal function). 4,498 (1.05%) participants were tested; 1,324 (0.31%) tested positive for COVID-19. Compared with no LTCs, relative risk (RR) of COVID-19 in those with 1 LTC was no higher (RR 1.12 (CI 0.96-1.30)), whereas those with [&ge;]2 LTCs had 48% higher risk; RR 1.48 (1.28-1.71). Compared with no cardiometabolic LTCs, having 1 and [&ge;]2 cardiometabolic LTCs had a higher risk of COVID-19; RR 1.28 (1.12-1.46) and 1.77 (1.46-2.15), respectively. Polypharmacy was associated with a dose response increased risk of COVID-19. All prognostic factors were associated with a higher risk of COVID-19 infection in multimorbidity; being non-white, most socioeconomically deprived, BMI [&ge;]40 kg/m2, and reduced renal function were associated with the highest risk of COVID-19 infection: RR 2.81 (2.09-3.78); 2.79 (2.00-3.90); 2.66 (1.88-3.76); 2.13 (1.46-3.12), respectively. No multiplicative interaction between multimorbidity and prognostic factors was identified. Important limitations include the low proportion of UK Biobank participants with COVID-19 test data (1.05%) and UK Biobank participants being more affluent, healthier and less ethnically diverse than the general population.

CONCLUSIONSIncreasing multimorbidity, especially cardiometabolic multimorbidity, and polypharmacy are associated with a higher risk of developing COVID-19. Those with multimorbidity and additional factors, such as non-white ethnicity, are at heightened risk of COVID-19.

Author summaryO_ST_ABSWhy was this study done?C_ST_ABSO_LIMultimorbidity is a growing global challenge, but thus far LTC prognostic factors for severe COVID-19 primarily involve single conditions and there is a lack of data on the influence of multimorbidity on the risk of COVID-19.
C_LIO_LIAs countries move from the lockdown phase of COVID-19, clinicians need more information about risk stratification to appropriately advise patients with multimorbidity about risk prevention steps.
C_LI

What did the researchers do and find?O_LIParticipants with multimorbidity ([&ge;]2 LTCs) had a 48% higher risk of a positive COVID-19 test, those with cardiometabolic multimorbidity had a 77% higher risk, than those without that type of multimorbidity.
C_LIO_LIThose from non-white ethnicities with multimorbidity had nearly three times the risk of having COVID-19 infection compared to those of white ethnicity
C_LIO_LIPeople with multimorbidity with the highest risk of COVID-19 infection were the most socioeconomically deprived, those with BMI [&ge;]40 kg/m2, and those with reduced renal function.
C_LI

What do these findings mean?O_LIIndividuals with [&ge;]2 LTCs, especially if these are cardiometabolic in nature, should be particularly stringent in adhering to preventive measures, such as physical distancing and hand hygiene.
C_LIO_LIOur findings have implications for clinicians, occupational health and employers when considering work-place environments, appropriate advice for patients, and adaptations that might be required to protect such staff, identified here, as higher risk.
C_LI",epidemiology,fuzzy,100,91
medRxiv,10.1101/2020.06.10.20127175,2020-06-11,https://medrxiv.org/cgi/content/short/2020.06.10.20127175,Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic.,Amitava Banerjee; Suliang Chen; Laura Pasea; Alvina Lai; Michail Katsoulis; Spiros Denaxas; Vahe Nafilyan; Bryan Williams; Wai Keong Wong; Ameet Bakhai; Kamlesh Khunti; Deenan Pillay; Mahdad Noursadeghi; Honghan Wu; Nilesh Pareek; Daniel Bromage; Theresa Mcdonagh; Jonathan Byrne; James T Teo; Ajay Shah; Ben Humberstone; Liang V Tang; Anoop SV Shah; Andrea Rubboli; Yutao Guo; Yu Hu; Cathie LM Sudlow; Gregory YH Lip; Harry Hemingway,"University College London; University College London; University College London; University College London; UCL; University College London; Office for National Statistics; UCL; University College London Hospitals NHS Trust; Royal Free Hospitals NHS Trust; University of Leicester; UCL; UCL; UCL; King's College Hospital; Kings College London; Kings College London; Kings London NHS Trust; Kings College Hospital NHS Foundation Trust; King's College London; Office for National Statistics; Huazhong University of Science and Technology, Wuhan, China; University of Edinburgh; Ospedale S. Maria delle Croci, Ravenna, Italy; PLA General Hospital, Beijing, China.; Huazhong University of Science and Technology, Wuhan, China.; University of Edinburgh; University of Liverpool; UCL","BackgroundCardiovascular diseases(CVD) increase mortality risk from coronavirus infection(COVID-19), but there are concerns that the pandemic has affected supply and demand of acute cardiovascular care. We estimated excess mortality in specific CVDs, both ""direct"", through infection, and ""indirect"", through changes in healthcare.

MethodsWe used population-based electronic health records from 3,862,012 individuals in England to estimate pre- and post-COVID-19 mortality risk(""direct"" effect) for people with incident and prevalent CVD. We incorporated: (i)pre-COVID-19 risk by age, sex and comorbidities, (ii)estimated population COVID-19 prevalence, and (iii)estimated relative impact of COVID-19 on mortality(relative risk, RR: 1.5, 2.0 and 3.0). For ""indirect"" effects, we analysed weekly mortality and emergency department data for England/Wales and monthly hospital data from England(n=2), China(n=5) and Italy(n=1) for CVD referral, diagnosis and treatment until 1 May 2020.

FindingsCVD service activity decreased by 60-100% compared with pre-pandemic levels in eight hospitals across China, Italy and England during the pandemic. In China, activity remained below pre-COVID-19 levels for 2-3 months even after easing lockdown, and is still reduced in Italy and England. Mortality data suggest indirect effects on CVD will be delayed rather than contemporaneous(peak RR 1.4). For total CVD(incident and prevalent), at 10% population COVID-19 rate, we estimated direct impact of 31,205 and 62,410 excess deaths in England at RR 1.5 and 2.0 respectively, and indirect effect of 49932 to 99865 excess deaths.

InterpretationSupply and demand for CVD services have dramatically reduced across countries with potential for substantial, but avoidable, excess mortality during and after the COVID-19 pandemic.

FundingNIHR, HDR UK, Astra Zeneca",cardiovascular medicine,fuzzy,100,100
bioRxiv,10.1101/2020.06.11.145920,2020-06-11,https://biorxiv.org/cgi/content/short/2020.06.11.145920,SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness,Kizzmekia S. Corbett; Darin Edwards; Sarah R. Leist; Olubukola M. Abiona; Seyhan Boyoglu-Barnum; Rebecca A. Gillespie; Sunny Himansu; Alexandra Schafer; Cynthia T. Ziwawo; Anthony T. DiPiazza; Kenneth H. Dinnon; Sayda M. Elbashir; Christine A. Shaw; Angela Woods; Ethan J. Fritch; David R. Martinez; Kevin W. Bock; Mahnaz Minai; Bianca M. Nagata; Geoffrey B. Hutchinson; Kapil Bahl; Dario Garcia-Dominguez; LingZhi Ma; Isabella Renzi; Wing-Pui Kong; Stephen D. Schmidt; Lingshu Wang; Yi Zhang; Laura J. Stevens; Emily Phung; Lauren A. Chang; Rebecca J. Loomis; Nedim Emil Altaras; Elisabeth Narayanan; Mihir Metkar; Vlad Presnyak; Catherine Liu; Mark K. Louder; Wei Shi; Kwanyee Leung; Eun Sung Yang; Ande West; Kendra L. Gully; Nianshuang Wang; Daniel Wrapp; Nicole A. Doria-Rose; Guillaume Stewart-Jones; Hamilton Bennett; Martha C. Nason; Tracy J. Ruckwardt; Jason S. McLellan; Mark R. Denison; James D. Chappell; Ian N. Moore; Kaitlyn M. Morabito; John R. Mascola; Ralph S. Baric; Andrea Carfi; Barney S Graham,"Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Moderna, Inc.; Department of Epidemiology; University of North Carolina at Chapel Hill; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Moderna, Inc.; Department of Epidemiology; University of North Carolina at Chapel Hill; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Department of Epidemiology; University of North Carolina at Chapel Hill; Moderna, Inc.; Moderna, Inc.; Moderna, Inc.; Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill; Department of Epidemiology; University of North Carolina at Chapel Hill; National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Moderna, Inc.; Moderna, Inc.; Moderna, Inc.; Moderna, Inc.; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Department of Pediatrics, Vanderbilt University Medical Center; Institute for Biomedical Sciences, George Washington University; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Moderna, Inc.; Moderna, Inc.; Moderna, Inc.; Moderna, Inc.; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Department of Epidemiology; University of North Carolina at Chapel Hill; Department of Epidemiology; University of North Carolina at Chapel Hill; Department of Molecular Biosciences; University of Texas at Austin; Department of Molecular Biosciences; University of Texas at Austin; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Moderna, Inc.; Moderna, Inc.; Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Department of Molecular Biosciences; University of Texas at Austin; Department of Pediatrics, Vanderbilt University Medical Center; Department of Pediatrics, Vanderbilt University Medical Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Vaccine Research Center; National Institute of Allergy and Infectious Diseases; National Institutes of Health; Department of Epidemiology; University of North Carolina at Chapel Hill; Department of Microbiology and Immunology, School of Medicine, University of North Caro; Moderna, Inc.; Vaccine Research Center, NIAID, NIH","A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation.",immunology,fuzzy,96,94
medRxiv,10.1101/2020.06.08.20125211,2020-06-09,https://medrxiv.org/cgi/content/short/2020.06.08.20125211,Estimating weekly excess mortality at subnational level in Italy during the COVID-19 pandemic,Marta Blangiardo; Michela Cameletti; Monica Pirani; Gianni Corsetti; Marco Battaglini; Gianluca Baio,Imperial College London; University of Bergamo; Imperial College London; Italian Statistical Institute; Italian Statistical Institute; University College London,"ObjectivesTo provide a sub-national analysis of excess mortality during the COVID-19 pandemic in Italy.

DesignPopulation-based on all-cause mortality official data, available as counts by age and sex.

SettingThe 7,904 municipalities in Italy.

ParticipantsAll residents in Italy in the years 2016 to 2020.

Main outcome measuresAll-cause mortality weekly rates for each municipality, based on the first four months of 2016 - 2019. Predicted all-cause weekly deaths and mortality rates at municipality level for 2020, based on the modelled spatio-temporal trends.

ResultsThere was strong evidence of excess mortality for Northern Italy; Lombardia showed higher mortality rates than expected from the end of February, with 23,946 (23,013 to 24,786) total excess deaths. North-West and North-East regions showed higher mortality from the beginning of March, with 6,942 (6,142 to 7,667) and 8,033 (7,061 to 9,044) total excess deaths respectively. After discounting for the number of COVID-19-confirmed deaths, Lombardia still registered 10,197 (9,264 to 11,037) excess deaths, while regions in the North-West and North-East had 2,572 (1,772 to 3,297) and 2,047 (1,075 to 3,058) extra deaths, respectively. We observed marked geographical differences at municipality level. The city of Bergamo (Lombardia) showed the largest percent excess 88.9% (81.9% to 95.2%) at the peak of the pandemic. An excess of 84.2% (73.8% to 93.4%) was also estimated at the same time for the city of Pesaro (Central Italy), in stark contrast with the rest of the region, which does not show evidence of excess deaths.

ConclusionsOur study gives a comprehensive picture of the evolution of all-cause mortality in Italy from 2016 to 2020 and describes the spatio-temporal differences in excess mortality during the COVID-19 pandemic. Our model shows heterogeneous impact of COVID-19, and it can be used to help policy- makers target measures to limit the burden on the health-care system as well as reducing social and economic consequences. Our probabilistic methodology is useful for real-time mortality surveillance, continuously monitoring local temporal trends and flagging where and when mortality rates deviate from the expected range, which might suggest a second wave of the pandemic.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.06.05.20121962,2020-06-07,https://medrxiv.org/cgi/content/short/2020.06.05.20121962,TRACKing Excess Deaths (TRACKED): an interactive online tool to monitor excess deaths associated with COVID-19 pandemic in the United Kingdom,Michael TC Poon; Paul M Brennan; Kai Jin; Jonine Figueroa; Cathie LM Sudlow,"Usher Institute; Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh; Brain Tumour Centre of Excellence, Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh; University of Edinburgh; Health Data Research UK","BackgroundWe aimed to describe trends of excess mortality in the United Kingdom (UK) stratified by nation and cause of death, and to develop an online tool for reporting the most up to date data on excess mortality.

MethodsPopulation statistics agencies in the UK including the Office for National Statistics (ONS), National Records of Scotland (NRS), and Northern Ireland Statistics and Research Agency (NISRA) publish weekly data on deaths. We used mortality data up to 22nd May in the ONS and the NISRA and 24th May in the NRS. Crude mortality for non-COVID deaths (where there is no mention of COVID-19 on the death certificate) calculated. Excess mortality defined as difference between observed mortality and expected average of mortality from previous 5 years.

ResultsThere were 56,961 excess deaths and 8,986 were non-COVID excess deaths. England had the highest number of excess deaths per 100,000 population (85) and Northern Ireland the lowest (34). Non-COVID mortality increased from 23rd March and returned to the 5-year average on 10th May. In Scotland, where underlying cause mortality data besides COVID-related deaths was available, the percentage excess over the 8-week period when COVID-related mortality peaked was: dementia 49%, other causes 21%, circulatory diseases 10%, and cancer 5%. We developed an online tool (TRACKing Excess Deaths - TRACKED) to allow dynamic exploration and visualisation of the latest mortality trends (http://trackingexcessdeaths.com).

ConclusionsContinuous monitoring of excess mortality trends and further integration of age- and gender-stratified and underlying cause of death data beyond COVID-19 will allow dynamic assessment of the impacts of indirect and direct mortality of the COVID-19 pandemic.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.06.05.20122226,2020-06-07,https://medrxiv.org/cgi/content/short/2020.06.05.20122226,"Different adiposity measures across sex, age, ethnicity, and COVID-19",Naveed Sattar; Frederick K Ho; Jason MR Gill; Nazim Ghouri; Stuart R Gray; Carlos A Celis-Morales; Srinivasa Vittal Katikireddi; Colin Berry; Jill P Pell; John JV McMurray; Paul Welsh,University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University Of Glasgow,"We examined the link between BMI and risk of a positive test for SARS-CoV-2 and risk of COVID-19-related death among UK Biobank participants. Among 4855 participants tested for SARS-CoV-2 in hospital, 839 were positive and of these 189 died from COVID-19. Poisson models with penalised thin plate splines were run relating exposures of interest to test positivity and case-fatality, adjusting for confounding factors. BMI was associated strongly with positive test, and risk of death related to COVID-19. The gradient of risk in relation to BMI was steeper in those under 70, compared with those aged 70 years or older for COVID-19 related death (Pinteraction=0.03). BMI was more strongly related to test positivity (Pinteraction=0.010) and death (Pinteraction=0.002) in non-whites, compared with whites. These data add support for adiposity being more strongly linked to COVID-19-related deaths in younger people and non-white ethnicities. If future studies confirm causality, lifestyle interventions to improve adiposity status may be important to reduce the risk of COVID-19 in all, but perhaps particularly, non-white communities.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.06.02.20120642,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.02.20120642,Estimating excess visual loss in people with neovascular age-related macular degeneration during the COVID-19 pandemic,Darren S Thomas; Alasdair Warwick; Abraham Olvera-Barrios; Catherine Egan; Roy Schwartz; Sudeshna Patra; Haralabos Eleftheriadis; Anthony P Khawaja; Andrew Lotery; Philipp L Mueller; Robin Hamilton; Ella Preston; Paul Taylor; Adnan Tufail; - UK EMR Users Group,"Institute of Health Informatics, University College London, London, UK; Institute of Cardiovascular Science, University College London, London, UK & Moorfields Eye Hospital NHS Foundation Trust, London, UK.; Moorfields Eye Hospital NHS Turst & Institute of Ophthalmology UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Health Informatics, University College London, London, UK; Bart's Health NHS Trust, London, UK; King's College Hospital NHS Trust, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Faculty of Medicine, University of Southampton, Southampton, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Moorfields Eye Hospital NHS Foundation Trust, London, UK & Institute of Ophthalmology, UCL; Moorfields Eye Hospital NHS Foundation Trust, London, UK; Institute of Health Informatics, University College London, London, UK; Moorfields Eye Hospital NHS Trust & Institute of Ophthalmology UCL; ","ObjectivesTo report the reduction in new neovascular age-related macular degeneration (nAMD) referrals during the COVID-19 pandemic and estimate the impact of delayed treatment on visual outcomes at one year.

DesignRetrospective clinical audit and simulation model.

SettingMultiple UK NHS ophthalmology centres.

ParticipantsData on the reduction in new nAMD referrals was obtained from four NHS Trusts in England comparing April 2020 to April 2019. To estimate the potential impact on one-year visual outcomes, a stratified bootstrap simulation model was developed drawing on an electronic medical records dataset of 20,825 nAMD eyes from 27 NHS Trusts.

Main outcome measuresSimulated mean visual acuity and proportions of eyes with vision [&le;]6/60, [&le;]6/24 and [&ge;]6/12 at one year under four hypothetical scenarios: no treatment delay, 3, 6 and 9-month treatment delays. Estimated additional number of eyes with vision [&le;]6/60 at one year nationally.

ResultsThe number of nAMD referrals at four major eye treatment hospital groups based in England dropped on average by 72% (range 65 to 87%) in April 2020 compared to April 2019. Simulated one-year visual outcomes for 1000 nAMD eyes with a 3-month treatment delay suggested an increase in the proportion of eyes with vision [&le;]6/60 from 15.5% (13.2 to 17.9) to 23.3% (20.7 to25.9), and a decrease in the proportion of eyes with vision [&ge;]6/12 (driving vision) from 35.1% (32.1 to 38.1) to 26.4% (23.8 to29.2). Outcomes worsened incrementally with longer modelled delays. Assuming nAMD referrals are reduced to this level at the national level for only one month, these simulated results suggest an additional 186-365 eyes with vision [&le;]6/60 at one-year with even a short treatment delay.

ConclusionsWe report a large decrease in nAMD referrals during the first month of COVID-19 lockdown and provide an important public health message regarding the risk of delayed treatment. As a conservative estimate, a treatment delay of 3 months could lead to a >50% relative increase in the number of eyes with vision [&le;]6/60 and 25% relative decrease in the number of eyes with driving vision at one year.",ophthalmology,fuzzy,100,100
medRxiv,10.1101/2020.06.02.20118489,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.02.20118489,Development and implementation of a customised rapid syndromic diagnostic test for severe pneumonia,Vilas Navapurkar; Josefin Bartholdson-Scott; Mailis Maes; Thomas P Hellyer; Ellen Higginson; Sally Forrest; Joana Pereira Dias; Surendra Parmar; Emma Heasman-Hunt; Petra Polgarova; Joanne Brown; Lissamma Titti; William PW Smith; Jonathan Scott; Anthony Rostron; Matthew Routledge; David Sapsford; M. Estee Torok; Ronan McMullan; David Enoch; Vanessa Wong; - VAPrapid investigators; Martin D Curran; Nicholas Brown; A John Simpson; Jurgen Herre; Gordon Dougan; Andrew Conway Morris,"Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; University of Cambridge; Translational and Clinical Research Institute, Newcastle University, United Kingdom; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England Microbiology Laboratory, Addenbrooke's Hospital, Cambridge; Public Health England Microbiology Laboratory, Addenbrooke's Hospital, Cambridge; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; Translational and Clinical Research Institute, Newcastle University, United Kingdom; Translational and Clinical Research Institute, Newcastle University, United Kingdom; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS FoundationTrust; Wellcome-Wolfson Institute for Experimental Medicine, Queens University Belfast, United Kingdom; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; ; Public Health England Microbiology Laboratory, Addenbrookes Hospital, Cambridge; Public Health England Microbiology Laboratory, Addenbrooke's Hospital, Cambridge; Translational and Clinical Research Institute, Newcastle University, United Kingdom; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; University of Cambridge","BackgroundMicrobial cultures for the diagnosis of pneumonia take several days to return a result, and are frequently negative, compromising antimicrobial stewardship. The objective of this study was to establish the performance of a syndromic molecular diagnostic approach, using a custom TaqMan array card (TAC) covering 52 respiratory pathogens, and assess its impact on antimicrobial prescribing.

MethodsThe TAC was validated against a retrospective multi-centre cohort of broncho-alveolar lavage samples. The TAC was assessed prospectively in patients undergoing investigation for suspected pneumonia, with a comparator cohort formed of patients investigated when the TAC laboratory team were unavailable.

Co-primary outcomes were sensitivity compared to conventional microbiology and, for the prospective study, time to result. Metagenomic sequencing was performed to validate findings in prospective samples. Antibiotic free days (AFD) were compared between the study cohort and comparator group.

Results128 stored samples were tested, with sensitivity of 97% (95% CI 88-100%). Prospectively 95 patients were tested by TAC, with 71 forming the comparator group. TAC returned results 51 hours (IQR 41-69 hours) faster than culture and with sensitivity of 92% (95% CI 83-98%) compared to conventional microbiology. 94% of organisms identified by sequencing were detected by TAC. There was a significant difference in the distribution of AFDs with more AFDs in the TAC group (p=0.02). TAC group were more likely to experience antimicrobial de-escalation (OR 2.9 (95%1.5-5.5).

ConclusionsImplementation of a syndromic molecular diagnostic approach to pneumonia led to faster results, with high sensitivity and impact on antibiotic prescribing.

Trial registrationThe prospective study was registered with clinicaltrials.gov NCT03996330",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2020.06.04.20121434,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.04.20121434,The impact of school reopening on the spread of COVID-19 in England,Matt J Keeling; Michael J Tildesley; Benjamin D Atkins; Bridget Penman; Emma Southall; Glen Guyver-Fletcher; Alex Holmes; Hector McKimm; Erin E Gorsich; Edward M Hill; Louise Dyson,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"By mid-May, cases of COVID-19 in the UK had been declining for over a month; a multi-phase emergence from lockdown was planned, including a scheduled partial reopening of schools on 1st June. Although evidence suggests that children generally display mild symptoms, the size of the school-age population means the total impact of reopening schools is unclear. Here, we present work from mid-May that focused on the imminent opening of schools and consider what these results imply for future policy.

We compared eight strategies for reopening primary and secondary schools in England. Modifying a transmission model fitted to UK SARS-CoV-2 data, we assessed how reopening schools affects contact patterns, anticipated secondary infections and the relative change in the reproduction number, R. We determined the associated public health impact and its sensitivity to changes in social-distancing within the wider community.

We predicted reopening schools with half-sized classes or focused on younger children was unlikely to push R above one. Older children generally have more social contacts, so reopening secondary schools results in more cases than reopening primary schools, while reopening both could have pushed R above one in some regions. Reductions in community social-distancing were found to outweigh and exacerbate any impacts of reopening. In particular, opening schools when the reproduction number R is already above one generates the largest increase in cases.

Our work indicates that while any school reopening will result in increased mixing and infection amongst children and the wider population, reopening schools alone in June was unlikely to push R above one. Ultimately, reopening decisions are a difficult trade-off between epidemiological consequences and the emotional, educational and developmental needs of children. Into the future, there are difficult questions about what controls can be instigated such that schools can remain open if cases increase.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.06.04.20122069,2020-06-05,https://medrxiv.org/cgi/content/short/2020.06.04.20122069,Mechanical ventilation utilization in COVID-19: A systematic review and meta-analysis,Mohammed A Almeshari; Nowaf Y Alobaidi; Mansour Al Asmri; Eyas Alhuthail; Ziyad Alshehri; Farhan Alenezi; Elizabeth Sapey; Dhruv Parekh,University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; Taibah University; King Saud bin Abdulaziz University for Health Sciences; University of Birmingham; University of Birmingham,"BackgroundIn December 2019, SARS-CoV-2 caused a global pandemic with a viral infection called COVID-19. The disease usually causes respiratory symptoms but in a small proportion of patients can lead to a pneumonitis, Adult Respiratory Distress Syndrome and death. Invasive Mechanical Ventilation (IMV) is considered a life-saving treatment for COVID-19 patients and a huge demand for IMV devices was reported globally. This review aims to provide insight on the initial IMV practises for COVID-19 patients in the initial phase of the pandemic.

MethodsElectronic databases (Embase and MEDLINE) were searched for applicable articles using relevant keywords. The references of included articles were hand searched. Articles that reported the use of IMV in adult COVID-19 patients were included in the review. The NIH quality assessment tool for cohort and cross-sectional studies was used to appraise studies.

Results106 abstracts were identified from the databases search, of which 16 were included. 5 studies were included in the meta-analysis. In total, 9988 patients were included across all studies. The overall cases of COVID-19 requiring IMV ranged from 2-77%. Increased age and pre-existing comorbidities increased the likelihood of IMV requirement. The reported mortality rate in patients receiving IMV ranged between 50-100%. On average, IMV was required and initiated between 10-10.5 days from symptoms onset. When invasively ventilated, COVID-19 patients required IMV for a median of 10-17 days across studies. Little information was provided on ventilatory protocols or management strategies and were inconclusive.

ConclusionIn these initial reporting studies for the first month of the pandemic, patients receiving IMV were older and had more pre-existing co-morbidities than those who did not require IMV. The mortality rate was high in COVID-19 patients who received IMV. Studies are needed to evaluate protocols and modalities of IMV to improve outcomes and identify the populations most likely to benefit from IMV.",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2020.06.01.20116608,2020-06-03,https://medrxiv.org/cgi/content/short/2020.06.01.20116608,Is death from Covid-19 a multistep process?,Neil Pearce; Giovenale Moirano; Milena Maule; Manolis Kogevinas; Xavier Rodo; Deborah Lawlor; Jan Vandenbroucke; Christina Vandenbroucke-Grauls; Fernando P Polack; Adnan Custovic,"London School of Hygiene and Tropical Medicine; University of Turin, Italy; University of Turin, Italy; ISGlobal; ISGlobal; University of Bristol; Leiden University Medical Center; Amsterdam UMC; Vanderbilt Unversity; Imperial College London","Covid-19 death has a different relationship with age than is the case for other severe respiratory pathogens. The Covid-19 death rate increases exponentially with age, and the main risk factors are age itself, as well as having underlying conditions such as hypertension, diabetes, cardiovascular disease, severe chronic respiratory disease and cancer. Furthermore, the almost complete lack of deaths in children suggests that infection alone is not sufficient to cause death; rather, one must have gone through a number of changes, either as a result of undefined aspects of aging, or as a result of chronic disease. These characteristics of Covid-19 death are consistent with the multistep model of disease, a model which has primarily been used for cancer, and more recently for amyotrophic lateral sclerosis (ALS). We applied the multi-step model to data on Covid-19 case fatality rates (CFRs) from China, South Korea, Italy, Spain and Japan. In all countries we found that a plot of ln (CFR) against ln (age) was approximately linear with a slope of about 5. As a comparison, we also conducted similar analyses for selected other respiratory diseases. SARS showed a similar log-log age-pattern to that of Covid-19, albeit with a lower slope, whereas seasonal and pandemic influenza showed quite different age-patterns. Thus, death from Covid-19 and SARS appears to follow a distinct age-pattern, consistent with a multistep model of disease that in the case of Covid-19 is probably defined by comorbidities and age producing immune-related susceptibility. Identification of these steps would be potentially important for prevention and therapy for SARS-COV-2 infection.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.06.01.20118943,2020-06-02,https://medrxiv.org/cgi/content/short/2020.06.01.20118943,"Greater risk of severe COVID-19 in non-White ethnicities is not explained by cardiometabolic, socioeconomic, or behavioural factors, or by 25(OH)-vitamin D status: study of 1,326 cases from the UK Biobank",Zahra Raisi-Estabragh; Celeste McCracken; Mae S Bethell; Jackie Cooper; Cyrus Cooper; Mark J Caulfield; Patricia B Munroe; Nicholas C Harvey; Steffen E Petersen,"William Harvey Research Institute; William Harvey Research Institute; North West Anglia NHS Foundation Trust; William Harvey Research Institute; MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; William Harvey Research Institute; William Harvey Research Institute; MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; William Harvey Research Institute","BackgroundWe examined whether the greater severity of coronavirus disease 2019 (COVID-19) amongst men and non-White ethnicities is explained by cardiometabolic, socio-economic, or behavioural factors.

MethodsWe studied 4,510 UK Biobank participants tested for COVID-19 (positive, n = 1,326). Multivariate logistic regression models including age, sex, and ethnicity were used to test whether addition of: 1)cardiometabolic factors (diabetes, hypertension, high cholesterol, prior myocardial infarction, smoking, BMI); 2)25(OH)-vitamin D; 3)poor diet; 4)Townsend deprivation score; 5)housing (home type, overcrowding); or 6)behavioural factors (sociability, risk taking) attenuated sex/ethnicity associations with COVID-19 status.

ResultsThere was over-representation of men and non-White ethnicities in the COVID-19 positive group. Non-Whites had, on average, poorer cardiometabolic profile, lower 25(OH)-vitamin D, greater material deprivation, and were more likely to live in larger households and flats/apartments. Male sex, non-White ethnicity, higher BMI, Townsend deprivation score, and household overcrowding were independently associated with significantly greater odds of COVID-19. The pattern of association was consistent for men and women; cardiometabolic, socio-demographic and behavioural factors did not attenuate sex/ethnicity associations.

ConclusionsSex and ethnicity differential pattern of COVID-19 is not adequately explained by variations in cardiometabolic factors, 25(OH)-vitamin D levels, or socio-economic factors. Investigation of alternative biological pathways and different genetic susceptibilities is warranted.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.05.31.20118638,2020-06-02,https://medrxiv.org/cgi/content/short/2020.05.31.20118638,Respiratory Failure in Covid19 is associated with increased monocyte expression of complement receptor 3,Rajeev Gupta; Vanya A Gant; Bryan Williams; Tariq Enver,UCL Cancer Institute; UCL Hospitals NHS Trust; UCLH NHS Hospitals Foundation Trust; UCL Cancer Institute,"A key question in COVID-19 infection is why some previously healthy patients develop severe pulmonary failure and some ultimately die. Initial pulmonary failure does not exhibit classical features of ARDS; hypercoagulability is a common laboratory feature, and pulmonary thrombotic microangiopathy has been reported post mortem1,2,3. Biomarkers cannot robustly identify such patients pre-emptively and no specific interventions exist to mitigate clinical deterioration. Mononuclear phagocytic cells are key immune cells and bind fibrinogen through the CD11b/CD18 dimer CR3, whose activated form can initiate microthrombus formation. Accordingly, we profiled circulating monocyte CD11b/CD18 cell surface density from COVID-19 infected adults who were (i) symptomatic but breathless, (ii) requiring ventilatory support, and (iii) recovering following ICU care for hypoxia.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.05.31.20114520,2020-06-02,https://medrxiv.org/cgi/content/short/2020.05.31.20114520,Rapid point of care nucleic acid testing for SARS-CoV-2 in hospitalised patients: a clinical trial and implementation study,Dami A Collier; Sonny M Assennato; Nyarie Sithole; Katherine Sharrocks; Allyson Ritchie; Pooja Ravji; Matt Routledge; Dominic Sparkes; Jordan Skittrall; Ben Warne; Anna smielewska; ISOBEL RAMSEY; NEHA GOEL; MARTIN CURRAN; DAVID ENOCH; RHYS TASSELL; MICHELLE LINEHAM; DEVAN VAGHELA; CLARE LEONG; HOI PING MOK; JOHN BRADLEY; KENNETH GC SMITH; Vivien Mendoza; NIKOS DEMIRIS; MARTIN BESSER; GORDON DOUGAN; PAUL J LEHNER; Mark Siedner; HONGYI ZHANG; CLAIRE WADDINGTON; HELEN LEE; Ravindra K Gupta,UCL; DRW; CUH; CUH; DRW; CUH; cut; CUH; CUH; CUH; CUH; CUH; DRW; CUH; CUH; CUH; CUH; CUH; CUH; CUH; CAMBRIDGE UNIVERSITY; UNIVERSITY OF CAMBRIDGE; CUH; Athens University of Economics and Business; CUH; UNIVERSITY OF CAMBRIDGE; UNIVERSITY OF CAMBRIDGE; Harvard Medical School; CUH; CUH; DRW; University of Cambridge,"BackgroundThere is urgent need for safe and efficient triage protocols for hospitalized COVID-19 suspects to appropriate isolation wards. A major barrier to timely discharge of patients from the emergency room and hospital is the turnaround time for many SARS-CoV-2 nucleic acid tests. We validated a point of care nucleic acid amplification based platform SAMBA II for diagnosis of COVID-19 and performed an implementation study to assess its impact on patient disposition at a major academic hospital.

MethodsWe prospectively recruited COVID-19 suspects admitted to hospital (NCT04326387). In an initial pilot phase, individuals were tested using a nasal/throat swab with the SAMBA II SARS-CoV-2 rapid diagnostic platform in parallel with a combined nasal/throat swab for standard central laboratory RT-PCR testing. In the second implementation phase, we examined the utility of adding the SAMBA platform to routine care. In the pilot phase, we measured concordance and assay validity using the central laboratory as the reference standard and assessed assay turnaround time. In the implementation phase, we assessed 1) time to definitive bed placement from admission, 2) time spent on COVID-19 holding wards, 3) proportion of patients in isolation versus COVID negative areas following a test, comparing the implementation phase with the 10 days prior to implementation.

ResultsIn phase I, 149 participants were included in the pilot. By central laboratory RT-PCR testing, 32 (21.5%) tested positive and 117 (78.5%). Sensitivity and specificity of the SAMBA assay compared to RT-PCR lab test were 96.9% (95% CI 0.838-0.999) and 99.1% (0.953-0.999), respectively. Median time to result was 2.6 hours (IQR 2.3 to 4.8) for SAMBA II SARS-CoV-2 test and 26.4 hours (IQR 21.4 to 31.4) for the standard lab RT-PCR test (p<0.001). In the first 10 days of the SAMBA implementation phase, we conducted 992 tests, with the majority (59.8%) used for hospital admission, and the remainder for pre-operative screening (11.3%), discharge planning (10%), in-hospital screening of new symptoms (9.7%). Comparing the pre-implementation (n=599) with the implementation phase, median time to definitive bed placement from admission was reduced from 23.4 hours (8.6-41.9) to 17.1 hours (9.0-28.8), P=0.02 in Cox analysis, adjusted for age, sex, comorbidities and clinical severity at presentation. Mean length of stay on a COVID-19  holding ward decreased from 58.5 hours to 29.9 hours (P<0.001). Use of single occupancy rooms amongst those tested fell from 30.8% before to 21.2% (P=0.03) and 11 hospital bay closures (on average 6 beds each) were avoided after implementation of the POC assay.

ConclusionsThe SAMBA II SARS-CoV-2 rapid assay performed well compared to a centralized laboratory RT-PCR platform and demonstrated shorter time to result both in trial and real-world settings. It was also associated with faster time to definitive bed placement from the emergency room, greater availability of isolation rooms, avoidance of hospital bay closures, and greater movement of patients to COVID negative open ""green"" category wards. Rapid testing in hospitals has the potential to transform ability to deal with the COVID-19 epidemic.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.05.28.20115394,2020-06-02,https://medrxiv.org/cgi/content/short/2020.05.28.20115394,Rapid Epidemiological Analysis of Comorbidities andTreatments as risk factors for COVID-19 in Scotland(REACT-SCOT): a population-based case-control study,Paul M McKeigue; Amanda Weir; Jen Bishop; Stuart McGurnaghan; Sharon Kennedy; David McAllister; Chris Robertson; Rachael Wood; Nazir Lone; Janet Murray; Thomas Caparrotta; Alison Smith-Palmer; David Goldberg; Jim McMenamin; Colin Ramsay; Sharon Hutchinson; Helen M Colhoun,University of Edinburgh; Public Health Scotland; Public Health Scotland; University of Edinburgh; NHS Information Services Division (Public Health Scotland); University of Glasgow; University of Strathclyde; NHS Information Services Division (Public Health Scotland); University of Edinburgh; Public Health Scotland; University of Edinburgh; Public Health Scotland; Public Health Scotland; Public Health Scotland; Public Health Scotland; University of Glasgow; University of Edinburgh,"BackgroundThe objectives of this study were to identify risk factors for severe COVID-19 and to lay the basis for risk stratification based on demographic data and health records.

Methods and FindingsThe design was a matched case-control study. Severe COVID-19 was defined as either a positive nucleic acid test for SARS-CoV-2 in the national database followed by entry to a critical care unit or death within 28 days, or a death certificate with COVID-19 as underlying cause. Up to ten controls per case matched for sex, age and primary care practice were selected from the population register. All diagnostic codes from the past five years of hospitalisation records and all drug codes from prescriptions dispensed during the past nine months were extracted. Rate ratios for severe COVID-19 were estimated by conditional logistic regression.

There were 4272 severe cases. In a logistic regression using the age-sex distribution of the national population, the odds ratios for severe disease were 2.87 for a 10-year increase in age and 1.63 for male sex. In the case-control analysis, the strongest risk factor was residence in a care home, with rate ratio (95% CI) 21.4 (19.1, 23.9).

Univariate rate ratios (95% CIs) for conditions listed by public health agencies as conferring high risk were 2.75 (1.96, 3.88) for Type 1 diabetes, 1.60 (1.48, 1.74) for Type 2 diabetes, 1.49 (1.37, 1.61) for ischemic heart disease, 2.23 (2.08, 2.39) for other heart disease, 1.96 (1.83, 2.10) for chronic lower respiratory tract disease, 4.06 (3.15, 5.23) for chronic kidney disease, 5.4 (4.9, 5.8) for neurological disease, 3.61 (2.60, 5.00) for chronic liver disease and 2.66 (1.86, 3.79) for immune deficiency or suppression.

78% of cases and 52% of controls had at least one listed condition (NA of cases and NA of controls under age 40). Severe disease was associated with encashment of at least one prescription in the past nine months and with at least one hospital admission in the past five years [rate ratios 3.10 (2.59, 3.71)] and 2.75 (2.53, 2.99) respectively] even after adjusting for the listed conditions. In those without listed conditions significant associations with severe disease were seen across many hospital diagnoses and drug categories. Age and sex provided 2.58 bits of information for discrimination. A model based on demographic variables, listed conditions, hospital diagnoses and prescriptions provided an additional 1.25 bits (C-statistic 0.825). A limitation of this study is that records from primary care were not available.

ConclusionsAlong with older age and male sex, severe COVID-19 is strongly associated with past medical history across all age groups. Many comorbidities beyond the risk conditions designated by public health agencies contribute to this. A risk classifier that uses all the information available in health records, rather than only a limited set of conditions, will more accurately discriminate between low-risk and high-risk individuals who may require shielding until the epidemic is over.

Author summaryMost people infected with the SARS-CoV-2 coronavirus do not become seriously ill. It is The risk of severe or fatal illness is higher in older than in younger people, and is higher in people with conditions such as asthma and diabetes than in people without these conditions. Using Scotlands capability for linking electronic health records, we report the first systematic study of the relation of severe or fatal COVID-19 to pre-existing health conditions and other risk factors. We show that the strongest risk factor, apart from age, is residence in a care home. The conditions associated with increased risk include not only those already designated by public health agencies - asthma, diabetes, heart disease, disabling neurological disease, kidney disease - but many other diagnoses, associated with frailty and poor health. This lays a basis for constructing risk scores based on electronic health records that can be used to advise people at high risk of severe disease to shield themselves when there cases in their neighbourhood.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.05.27.20083287,2020-06-01,https://medrxiv.org/cgi/content/short/2020.05.27.20083287,Estimating excess mortality in people with cancer and multimorbidity in the COVID-19 emergency,Alvina G Lai; Laura Pasea; Amitava Banerjee; Spiros Denaxas; Michail Katsoulis; Wai Hoong Chang; Bryan Williams; Deenan Pillay; Mahdad Noursadeghi; David Linch; Derralynn Hughes; Martin D Forster; Clare Turnbull; Natalie K Fitzpatrick; Kathryn Boyd; Graham R Foster; Matt Cooper; Monica Jones; Kathy Pritchard-Jones; Richard Sullivan; Geoff Hall; Charlie Davie; Mark Lawler; Harry Hemingway,"University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; University College London; Royal Free NHS Foundation Trust; University College London; Institute of Cancer Research; University College London; Northern Ireland Cancer Network; Queen Mary University of London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; Kings College London; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; DATA-CAN, Health Data Research UK hub for cancer hosted by UCLPartners; University College London","BackgroundCancer and multiple non-cancer conditions are considered by the Centers for Disease Control and Prevention (CDC) as high risk conditions in the COVID-19 emergency. Professional societies have recommended changes in cancer service provision to minimize COVID-19 risks to cancer patients and health care workers. However, we do not know the extent to which cancer patients, in whom multi-morbidity is common, may be at higher overall risk of mortality as a net result of multiple factors including COVID-19 infection, changes in health services, and socioeconomic factors.

MethodsWe report multi-center, weekly cancer diagnostic referrals and chemotherapy treatments until April 2020 in England and Northern Ireland. We analyzed population-based health records from 3,862,012 adults in England to estimate 1-year mortality in 24 cancer sites and 15 non-cancer comorbidity clusters (40 conditions) recognized by CDC as high-risk. We estimated overall (direct and indirect) effects of COVID-19 emergency on mortality under different Relative Impact of the Emergency (RIE) and different Proportions of the population Affected by the Emergency (PAE). We applied the same model to the US, using Surveillance, Epidemiology, and End Results (SEER) program data.

ResultsWeekly data until April 2020 demonstrate significant falls in admissions for chemotherapy (45-66% reduction) and urgent referrals for early cancer diagnosis (70-89% reduction), compared to pre-emergency levels. Under conservative assumptions of the emergency affecting only people with newly diagnosed cancer (incident cases) at COVID-19 PAE of 40%, and an RIE of 1.5, the model estimated 6,270 excess deaths at 1 year in England and 33,890 excess deaths in the US. In England, the proportion of patients with incident cancer with [&ge;]1 comorbidity was 65.2%. The number of comorbidities was strongly associated with cancer mortality risk. Across a range of model assumptions, and across incident and prevalent cancer cases, 78% of excess deaths occur in cancer patients with Harry [&ge;]1 comorbidity.

ConclusionWe provide the first estimates of potential excess mortality among people with cancer and multimorbidity due to the COVID-19 emergency and demonstrate dramatic changes in cancer services. To better inform prioritization of cancer care and guide policy change, there is an urgent need for weekly data on cause-specific excess mortality, cancer diagnosis and treatment provision and better intelligence on the use of effective treatments for comorbidities.",oncology,fuzzy,100,100
medRxiv,10.1101/2020.05.27.20114447,2020-05-28,https://medrxiv.org/cgi/content/short/2020.05.27.20114447,Automated and partially-automated contact tracing: a rapid systematic review to inform the control of COVID-19,Isobel Braithwaite; Tom Callender; Miriam Bullock; Robert W Aldridge,"UCL Public Health Data Science Research Group, Institute of Health Informatics, University College London, London, UK; Department of Applied Health Research, University College London, London, UK; UCL Collaborative Centre for Inclusion Health, University College London, London UK; UCL Public Health Data Science Group, Institute of Health Informatics, University College London, London UK","BackgroundAutomated or partially-automated contact tracing tools are being deployed by many countries to contain SARS-CoV-2; however, the evidence base for their use is not well-established.

MethodsWe undertook a rapid systematic review of automated or partially-automated contact tracing, registered with PROSPERO (CRD42020179822). We searched PubMed, EMBASE, OVID Global Health, EBSCO COVID Portal, Cochrane Library, medRxiv, bioRxiv, arXiv and Google Advanced for articles relevant to COVID-19, SARS, MERS, influenza or Ebola from 1/1/200014/4/2020. Two authors reviewed all full-text manuscripts. One reviewer extracted data using a pre-piloted form; a second independently verified extracted data. Primary outcomes were the number or proportion of contacts (and/or subsequent cases) identified; secondary outcomes were indicators of outbreak control, app/tool uptake, resource use, cost-effectiveness and lessons learnt. The Effective Public Health Practice Project tool or CHEERS checklist were used in quality assessment.

Findings4,033 citations were identified and 15 were included. No empirical evidence of automated contact tracings effectiveness (regarding contacts identified or transmission reduction) was identified. Four of seven included modelling studies suggested that controlling COVID-19 requires high population uptake of automated contact-tracing apps (estimates from 56% to 95%), typically alongside other control measures. Studies of partially-automated contact tracing generally reported more complete contact identification and follow-up, and greater intervention timeliness (0.5-5 hours faster), than previous systems. No meta-analyses were possible.

InterpretationAutomated contact tracing has potential to reduce transmission with sufficient population uptake and usage. However, there is an urgent need for well-designed prospective evaluations as no studies provided empirical evidence of its effectiveness.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.05.19.20106641,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20106641,Study Data Element Mapping: Feasibility of Defining Common Data Elements Across COVID-19 Studies,Priscilla Mathewson; Ben Gordon; Kay Snowley; Clara Fennessy; Alastair Denniston; Neil Sebire,University of Birmingham; HDRUK; HDRUK; HDRUK; HDRUK; Great Ormond Street Hospital and ICH London,"BackgroundNumerous clinical studies are now underway investigating aspects of COVID-19. The aim of this study was to identify a selection of national and/or multicentre clinical COVID-19 studies in the United Kingdom to examine the feasibility and outcomes of documenting the most frequent data elements common across studies to rapidly inform future study design and demonstrate proof-of-concept for further subject-specific study data element mapping to improve research data management.

Methods25 COVID-19 studies were included. For each, information regarding the specific data elements being collected was recorded. Data elements collated were arbitrarily divided into categories for ease of visualisation. Elements which were most frequently and consistently recorded across studies are presented in relation to their relative commonality.

ResultsAcross the 25 studies, 261 data elements were recorded in total. The most frequently recorded 100 data elements were identified across all studies and are presented with relative frequencies. Categories with the largest numbers of common elements included demographics, admission criteria, medical history and investigations. Mortality and need for specific respiratory support were the most common outcome measures, but with specific studies including a range of other outcome measures.

ConclusionThe findings of this study have demonstrated that it is feasible to collate specific data elements recorded across a range of studies investigating a specific clinical condition in order to identify those elements which are most common among studies. These data may be of value for those establishing new studies and to allow researchers to rapidly identify studies collecting data of potential use hence minimising duplication and increasing data re-use and interoperability",health informatics,fuzzy,100,100
medRxiv,10.1101/2020.05.19.20106781,2020-05-26,https://medrxiv.org/cgi/content/short/2020.05.19.20106781,Hypertension and renin-angiotensin system blockers are not associated with expression of Angiotensin Converting Enzyme 2 (ACE2) in the kidney,Xiao Jiang; James M. Eales; David Scannali; Alicja Nazgiewicz; Priscilla Prestes; Michelle Maier; Matthew J. Denniff; Xiaoguang Xu; Sushant Saluja; Eddie Cano-Gamez; Wojciech Wystrychowski; Monika Szulinska; Andrzej Antczak; Sean Byars; Maciej Glyda; Robert Krol; Joanna Zywiec; Ewa Zukowska-Szczechowska; Louise M. Burrell; Adrian S. Woolf; Adam Greenstein; Pawel Bogdanski; Bernard Keavney; Andrew P. Morris; Anthony Heagerty; Bryan Williams; Stephen B. Harrap; Gosia Trynka; Nilesh J. Samani; Tomasz J. Guzik; Fadi J. Charchar; Maciej Tomaszewski,"University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Federation University Australia, Ballarat, Victoria, Australia; Federation University Australia, Ballarat, Victoria, Australia; University of Leicester, Leicester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Wellcome Sanger Institute, Cambridge, UK; Medical University of Silesia, Katowice, Poland; Poznan University of Medical Sciences, Poznan, Poland.; Karol Marcinkowski University of Medical Sciences, Poznan, Poland; The University of Melbourne, Parkville, Victoria, Australia; Nicolaus Copernicus University, Bydgoszcz, Poland; Medical University of Silesia, Katowice, Poland; Medical University of Silesia, Zabrze, Poland; Silesian Medical College, Katowice, Poland; University of Melbourne, Melbourne, Victoria, Australia; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; Poznan University of Medical Sciences, Poznan, Poland; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University of Manchester, Manchester, UK; University College London, London, UK; University of Melbourne, Melbourne, Victoria, Australia; Wellcome Sanger Institute, Cambridge, UK; University of Leicester, Leicester, UK; University of Glasgow, Glasgow, UK; Federation University Australia, Ballarat, Victoria, Australia; University of Manchester, Manchester, UK","Angiotensin converting enzyme 2 (ACE2) is the cellular entry point for severe acute respiratory syndrome coronavirus (SARS-CoV-2) - the cause of COVID-19 disease. It has been hypothesized that use of renin-angiotensin system (RAS) inhibiting medications in patients with hypertension, increases the expression of ACE2 and thereby increases the risk of COVID-19 infection and severe outcomes or death. However, the effect of RAS-inhibition on ACE2 expression in human tissues of key relevance to blood pressure regulation and COVID-19 infection has not previously been reported.

We examined how hypertension, its major metabolic co-phenotypes and antihypertensive medications relate to ACE2 renal expression using information from up to 436 patients whose kidney transcriptomes were characterised by RNA-sequencing. We further validated some of the key observations in other human tissues and/or a controlled experimental model. Our data reveal increasing expression of ACE2 with age in both human lungs and the kidney. We show no association between renal expression of ACE2 and either hypertension or common types of RAS inhibiting drugs. We demonstrate that renal abundance of ACE2 is positively associated with a biochemical index of kidney function and show a strong enrichment for genes responsible for kidney health and disease in ACE2 co-expression analysis.

Collectively, our data indicate that neither hypertension nor antihypertensive treatment are likely to alter individual risk of SARS-CoV-2 infection or influence clinical outcomes in COVID-19 through changes of ACE2 expression. Our data further suggest that in the absence of SARS-CoV-2 infection, kidney ACE2 is most likely nephro-protective but the age-related increase in its expression within lungs and kidneys may be relevant to the risk of SARS-CoV-2 infection.",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2020.05.20.20107680,2020-05-25,https://medrxiv.org/cgi/content/short/2020.05.20.20107680,Age- and sex-specific total mortality impacts of the early weeks of the Covid-19 pandemic in England and Wales: Application of a Bayesian model ensemble to mortality statistics,Vasilis Kontis; James E Bennett; Robbie M Parks; Theo Rashid; Jonathan Pearson-Stuttard; Perviz Asaria; Michel Guillot; Marta Blangiardo; Majid Ezzati,"MRC Centre for Environment and Health, School of Public Health, Imperial College London; MRC Centre for Environment and Health, School of Public Health, Imperial College London; The Earth Institute, Columbia University; MRC Centre for Environment and Health, School of Public Health, Imperial College London; MRC Centre for Environment and Health, School of Public Health, Imperial College London; MRC Centre for Environment and Health, School of Public Health, Imperial College London; Population Studies Center, Department of Sociology, University of Pennsylvania; French Institute for Demographic Studies (INED), Paris, France; MRC Centre for Environment and Health, School of Public Health, Imperial College London; MRC Centre for Environment and Health, School of Public Health, Imperial College London","BackgroundThe Covid-19 pandemic affects mortality directly through infection as well as through changes in the social, environmental and healthcare determinants of health. The impacts on mortality are likely to vary, in both magnitude and timing, by age and sex. Our aim was to estimate the total mortality impacts of the pandemic, by sex, age group and week.

MethodsWe developed an ensemble of 16 Bayesian models that probabilistically estimate the weekly number of deaths that would be expected had the Covid-19 pandemic not occurred. The models account for seasonality of death rates, medium-long-term trends in death rates, the impact of temperature on death rates, association of death rates in each week on those in preceding week(s), and the impact of bank holidays. We used data from January 2010 through mid-February 2020 (i.e., week starting 15th February 2020) to estimate the parameters of each model, which was then used to predict the number of deaths for subsequent weeks as estimates of death rates if the pandemic had not occurred. We subtracted these estimates from the actual reported number of deaths to measure the total mortality impact of the pandemic.

ResultsIn the week that began on 21st March, the same week that a national lockdown was put in place, there was a >92% probability that there were more deaths in men and women aged [&ge;]45 years than would occur in the absence of the pandemic; the probability was 100% from the subsequent week. Taken over the entire period from mid-February to 8th May 2020, there were an estimated ~ 49,200 (44,700-53,300) or 43% (37-48) more deaths than would be expected had the pandemic not taken place. 22,900 (19,300-26,100) of these deaths were in females (40% (32-48) higher than if there had not been a pandemic), and 26,300 (23,800-28,700) in males (46% (40-52) higher). The largest number of excess deaths occurred among women aged >85 years (12,400; 9,300-15,300), followed by men aged >85 years (9,600; 7,800-11,300) and 75-84 years (9,000; 7,500-10,300).

The cause of death assigned to the majority (37,295) of these excess deaths was Covid-19. There was nonetheless a >99.99% probability that there has been an increase in deaths assigned to other causes in those aged [&ge;]45 years. However, by the 8th of May, the all-cause excess mortality had become virtually equal to deaths assigned to Covid-19, and non-Covid excess deaths had diminished to close to zero, or possibly become negative, in all age-sex groups.

InterpretationThe death toll of Covid-19 pandemic, in middle and older ages, is substantially larger than the number of deaths reported as a result of confirmed infection, and was visible in vital statistics when the national lockdown was put in place. When all-cause mortality is considered, the mortality impact of the pandemic on men and women is more similar than when comparing deaths assigned to Covid-19 as underlying cause of death.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.05.21.20108936,2020-05-23,https://medrxiv.org/cgi/content/short/2020.05.21.20108936,Risk Factors for COVID-19 versus non-COVID-19 related in-hospital and community deaths by Local Authority District in Great Britain,Samuel Paul Leighton; Danielle Jane Leighton; James Herron; Rachel Upthegrove; Jonathan Cavanagh; Georgios Gkoutos; Breda Cullen; Pavan K Mallikarjun,University of Glasgow; University of Glasgow; University of Glasgow; University of Birmingham; University of Glasgow; University of Birmingham & Associate Director of Health Data Research UK; University of Glasgow; University of Birmingham,"ObjectivesTo undertake a preliminary hypothesis-generating analysis exploring putative risk factors for coronavirus diseae 2019 (COVID-19) population-adjusted deaths, compared with non-COVID-19 related deaths, at a local authority district (LAD) level in hospital, care homes and at home.

DesignEcological retrospective cohort study

SettingLocal authority districts (LADs) in England, Scotland and Wales (Great Britain (GB)).

ParticipantsAll LAD deaths registered by week 16 of 2020.

Main Outcome MeasuresDeath registration where COVID-19 is mentioned as a contributing factor per 100,000 people in all settings, and in i) cares homes, ii) hospitals or iii) home only, in comparison to non-COVID-19 related deaths.

ResultsAcross GB by week 16 of 2020, 20,684 deaths had been registered mentioning COVID-19, equivalent to 25.6 per 100,000 people. Significant risk factors for LAD COVID-19 death in comparison to non-COVID-19 related death were air pollution and proportion of the population who were female. Significant protective factors were higher air temperature and proportion of the population who were ex-smokers. Conversely, for all COVID-19 unrelated deaths in comparison to COVID-19 deaths, higher rates of communal living, higher population rates of chronic kidney disease, chronic obstructive pulmonary disease, cerebrovascular disease deaths under 75 and dementia were predictive of death, whereas, higher rates of flight passengers was protective. Looking at individual setttings, the most notable findings in care homes was Scotland being a significant risk factor for COVID-19 related deaths compared to England. For hospital setting, the proportion of the population who were from black and Asian minority ethnic (BAME) groups significantly predicted COVID-19 related death.

ConclusionsThis is the first study within GB to assess COVID-19 related deaths in comparison to COVID-19 unrelated deaths across hospital, care homes and home combined. As an ecological study, the results cannot be directly extrapolated to individuals. However, the analysis may be informative for public health policy and protective measures. From our hypothesis-generating analysis, we propose that air pollution is a significant risk factor and high temperature a significant protective factor for COVID-19 related deaths. These factors cannot readily be modelled at an individual level. Scottish local authorities and local authorities with a higher proportion of individuals of BAME origin are potential risk factors for COVID-19 related deaths in care homes and in hospitals, respectively. Altogether, this analysis shows the benefits of access to high quality open data for public information, public health policy and further research.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.05.22.20109892,2020-05-23,https://medrxiv.org/cgi/content/short/2020.05.22.20109892,"Occupation and risk of COVID-19: prospective cohort study of 120,621 UK Biobank participants",Miriam Mutambudzi; Claire L Niedzwiedz; Ewan B Macdonald; Alastair H Leyland; Frances S Mair; Jana J Anderson; Carlos A Celis-Morales; John Cleland; John Forbes; Jason MR Gill; Claire Hastie; Frederick K Ho; Bhautesh D Jani; Daniel F Mackay; Barbara I Nicholl; Naveed I Sattar; Paul I Welsh; Jill P Pell; Srinivasa Vittal Katikireddi; Evangelia Demou,"University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University Of Glasgow; University of Glasgow, Institute of Health and Wellbeing; University of Glasgow; University of Glasgow","ObjectivesTo investigate severe COVID-19 risk by occupational group.

MethodsBaseline UK Biobank data (2006-10) for England were linked to SARS-CoV-2 test results from Public Health England (16 March to 26 July 2020). Included participants were employed or self-employed at baseline, alive and aged less than 65 years in 2020. Poisson regression models adjusted sequentially for baseline demographic, socioeconomic, work-related, health, and lifestyle-related risk factors to assess risk ratios (RRs) for testing positive in hospital or death due to COVID-19 by three occupational classification schemes (including Standard Occupation Classification 2000).

ResultsOf 120,075 participants, 271 had severe COVID-19. Relative to non-essential workers, healthcare workers (RR 7.43, 95% CI:5.52,10.00), social and education workers (RR 1.84, 95% CI:1.21,2.82) and other essential workers (RR=1.60, 95% CI:1.05,2.45) had higher risk of severe COVID-19. Using more detailed groupings, medical support staff (RR 8.70, 95% CI:4.87,15.55), social care (RR 2.46, 95% CI:1.47,4.14) and transport workers (RR= 2.20, 95% CI:1.21,4.00) had highest risk within the broader groups. Compared to white non-essential workers, non-white non-essential workers had a higher risk (RR 3.27, 95% CI: 1.90,5.62) and non-white essential workers had the highest risk (RR 8.34, 95% CI:5.17,13.47). Using SOC2000 major groups, associate professional and technical occupations, personal service occupations and plant and machine operatives had higher risk, compared to managers and senior officials.

ConclusionsEssential workers have higher risk of severe COVID-19. These findings underscore the need for national and organizational policies and practices that protect and support workers with elevated risk of severe COVID-19.

Trial registration-N/AO_LSTWhat is already known on this topicC_LSTO_LIEssential workers have a higher exposure to the SARS-CoV-2 virus due to the nature of their work.
C_LIO_LIIn comparison to non-essential workers, healthcare workers appear to have a higher risk of SARS-CoV-2 infection.
C_LI

O_LSTWhat this study addsC_LSTO_LIHealthcare workers had a more than seven-fold higher risk of severe COVID-19; those working in social care and transport occupations had a two-fold higher risk.
C_LIO_LIAdjusting for potential confounding and mediating variables did not fully account for the differences in the observed risk amongst most occupational groups.
C_LIO_LINon-white essential workers had the highest risk of severe COVID-19 infection.
C_LI

O_LSTHow might this impact on policy or clinical practice in the foreseeable future?C_LSTO_LIOur findings reinforce the need for adequate health and safety arrangements and provision of PPE, particularly in the health and social care sectors, and highlight the need for national and organizational policies and practices that protect and support workers with elevated risk of SARS-CoV-2 infection.
C_LI",occupational and environmental health,fuzzy,100,100
medRxiv,10.1101/2020.05.20.20108183,2020-05-23,https://medrxiv.org/cgi/content/short/2020.05.20.20108183,A Rapid Review of the Asymptomatic Proportion of PCR-Confirmed SARS-CoV-2 Infections in Community Settings,Sarah Beale; Andrew Hayward; Laura Shallcross; Robert W Aldridge; Ellen Fragaszy,University College London; University College London; University College London; University College London; University College London,"BackgroundUp to 80% of active SARS-CoV-2 infections are proposed to be asymptomatic based on cross-sectional studies. However, accurate estimates of the asymptomatic proportion require systematic detection and follow-up to differentiate between truly asymptomatic and pre-symptomatic cases. We conducted a rapid review and meta-analysis of current evidence regarding the asymptomatic proportion of PCR-confirmed SARS-CoV-2 infections based on methodologically-appropriate studies in community settings.

MethodsWe searched Medline and EMBASE for peer-reviewed articles, and BioRxiv and MedRxiv for pre-prints published prior to 05/05/2020. We included studies based in community settings that involved systematic PCR testing on participants and follow-up symptom monitoring regardless of symptom status. We extracted data on study characteristics, frequencies of PCR-confirmed infections by symptom status, and (if available) cycle threshold values and/or duration of viral shedding by symptom status. We computed estimates of the asymptomatic proportion and 95% confidence intervals for each study and overall using random effect meta-analysis.

FindingsWe screened 270 studies and included 6. The pooled estimate for the asymptomatic proportion of SARS-CoV-2 infections was 11% (95% CI 4%-18%). Estimates of baseline viral load appeared to be similar for asymptomatic and symptomatic cases based on available data in three studies, though detailed reporting of cycle threshold values and natural history of viral shedding by symptom status was limited.

InterpretationThe asymptomatic proportion of SARS-CoV-2 infections is relatively low when estimated from methodologically-appropriate studies. Further investigation into the degree and duration of infectiousness for asymptomatic infections is warranted.

FundingMedical Research Council",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.05.18.20086157,2020-05-22,https://medrxiv.org/cgi/content/short/2020.05.18.20086157,COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis,Nicola L Boddington; Andre Charlett; Suzanne Elgohari; Jemma L Walker; Helen Mcdonald; Chloe Byers; Laura Coughlan; Tatiana Garcia Vilaplana; Rosie Whillock; Mary Sinnathamby; Nikolaos Panagiotopoulos; Louise Letley; Pauline MacDonald; Roberto Vivancos; Obaghe Edeghere; Joseph Shingleton; Emma Bennett; Daniel J Grint; Helen Strongman; Kathryn E Mansfield; Christopher Rentsch; Caroline Minassian; Ian J Douglas; Rohini Mathur; Maria Peppa; Simon Cottrell; Jim McMenamin; Maria Zambon; Mary Ramsay; Gavin Dabrera; Vanessa Saliba; Jamie Lopez Bernal,Public Health England; Public Health England; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; Public Health Wales; Public Health Scotland; Public Health England; Public Health England; Public Health England; Public Health England; Public Health England,"ObjectivesFollowing detection of the first virologically-confirmed cases of COVID-19 in Great Britain, an enhanced surveillance study was initiated by Public Health England to describe the clinical presentation, course of disease and underlying health conditions associated with infection of the first few hundred cases.

MethodsInformation was collected on the first COVID-19 cases according to the First Few X WHO protocol. Case-control analyses of the sensitivity, specificity and predictive value of symptoms and underlying health conditions associated with infection were conducted. Point prevalences of underlying health conditions among the UK general population were presented.

FindingsThe majority of FF100 cases were imported (51.4%), of which the majority had recent travel to Italy (71.4%). 24.7% were secondary cases acquired mainly through household contact (40.4%). Children had lower odds of COVID-19 infection compared with the general population.

The clinical presentation of cases was dominated by cough, fever and fatigue. Non-linear relationships with age were observed for fever, and sensitivity and specificity of symptoms varied by age.

Conditions associated with higher odds of COVID-19 infection (after adjusting for age and sex) were chronic heart disease, immunosuppression and multimorbidity.

ConclusionThis study presents the first epidemiological and clinical summary of COVID-19 cases in Great Britain. The FFX study design enabled systematic data collection. The study characterized underlying health conditions associated with infection and set relative risks in context with population prevalence estimates. It also provides important evidence for generating case definitions to support public health risk assessment, clinical triage and diagnostic algorithms.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.05.18.20105288,2020-05-21,https://medrxiv.org/cgi/content/short/2020.05.18.20105288,Current tobacco smoking and risk from COVID-19: results from a population symptom app in over 2.4 million people,Nicholas S Hopkinson; Niccolo Rossi; Julia El-Sayed Moustafa; Anthony A Laverty; Jennifer K Quint; Maxim B Freydin; Alessia Visconti; Benjamin Murray; Marc Modat; Sebastien Ourselin; Kerrin Small; Richard Davies; Jonathan Wolf; Timothy Spector; Claire J Steves; Mario Falchi,"Imperial College London; King's College London; King's College London; Imperial College London; Imperial College, London; King's College London; King's College, London; King's College, London; King's College, London; King's College, London; King's College, London; Zoe Global Ltd; Zoe Global Ltd; King's College London; King's College London; King's College, London","BackgroundThe association between current tobacco smoking, the risk of developing COVID-19 and the severity of illness is an important information gap.

MethodsUK users of the COVID Symptom Study app provided baseline data including demographics, anthropometrics, smoking status and medical conditions, were asked to log symptoms daily from 24th March 2020 to 23rd April 2020. Participants reporting that they did not feel physically normal were taken through a series of questions, including 14 potential COVID-19 symptoms and any hospital attendance. The main study outcome was the association between current smoking and the development of ""classic"" symptoms of COVID-19 during the pandemic defined as fever, new persistent cough and breathlessness. The number of concurrent COVID-19 symptoms was used as a proxy for severity. In addition, association of subcutaneous adipose tissue expression of ACE2, both the receptor for SARS-CoV-2 and a potential mediator of disease severity, with smoking status was assessed in a subset of 541 twins from the TwinsUK cohort.

ResultsData were available on 2,401,982 participants, mean(SD) age 43.6(15.1) years, 63.3% female, overall smoking prevalence 11.0%. 834,437 (35%) participants reported being unwell and entered one or more symptoms. Current smokers were more likely to develop symptoms suggesting a diagnosis of COVID-19; classic symptoms adjusted OR[95%CI] 1.14[1.10 to 1.18]; >5 symptoms 1.29[1.26 to 1.31]; >10 symptoms 1.50[1.42 to 1.58]. Smoking was associated with reduced ACE2 expression in adipose tissue (Beta(SE)=-0.395(0.149); p=7.01x10-3).

InterpretationThese data are consistent with smokers having an increased risk from COVID-19.

FundingZoe provided in kind support for all aspects of building, running and supporting the app and service to all users worldwide. The study was also supported by grants from the Wellcome Trust, UK Research and Innovation and British Heart Foundation.

RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSThe interaction between current smoking and COVID-19 is unclear. Smoking is known to increase susceptibility to viral infections and appears to be associated with worse outcomes in people admitted to hospital with COVID-19. However, case series have reported relatively low levels of current smoking among individuals admitted to hospital with the condition, raising the possibility that smoking has a protective effect against the disease.

Added value of this studyData from a large UK population who are users of a symptom reporting app during the pandemic supports the hypothesis that smokers are more likely to develop symptoms consistent with COVID-19 and that they have an increased symptom burden.

Implications of all the available evidenceThese population data, combined with evidence of a worse outcome in smokers hospitalised with the condition, support the contention that smoking increases individual risk from COVID-19. Support to help people to quit smoking should therefore form part of efforts to deal with the pandemic.",respiratory medicine,fuzzy,94,100
medRxiv,10.1101/2020.05.14.20101824,2020-05-19,https://medrxiv.org/cgi/content/short/2020.05.14.20101824,Changing travel patterns in China during the early stages of the COVID-19 pandemic,Hamish Gibbs; Yang Liu; Carl AB Pearson; Christopher I Jarvis; Chris Grundy; Billy J Quilty; Charlie Diamond; Rosalind M Eggo,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine,"Understanding changes in human mobility in the early stages of the COVID-19 pandemic is crucial for assessing the impacts of travel restrictions designed to reduce disease spread. Here, relying on data from mainland China, we investigated the spatio-temporal characteristics of human mobility between 1st January and 1st March 2020 and discussed their public health implications. An outbound travel surge from Wuhan before travel restrictions were implemented was also observed across China due to the Lunar New Year, indicating that holiday travel may have played a larger role in mobility changes compared to impending travel restrictions. Holiday travel also shifted healthcare pressure related to COVID-19 towards locations with lower access to care. Network analyses showed no sign of major changes in the transportation network after Lunar New Year. Changes observed were temporary and have not yet led to structural reorganisation of the transportation network at the time of this study.

One sentence summaryUnderstanding travel before, during, and after the introduction of travel restrictions in China in response to the COVID-19 Pandemic.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.05.11.20098269,2020-05-18,https://medrxiv.org/cgi/content/short/2020.05.11.20098269,Accessibility and allocation of public parks and gardens during COVID-19 social distancing in England and Wales,Niloofar Shoari; Majid Ezzati; Jill Baumgartner; Diego Malacarne; Daniela Fecht,Imperial College London; Imperial College London; McGill University; Imperial College London; Imperial College London,"Visiting parks and gardens may attenuate the adverse physical and mental health impacts of social distancing implemented to reduce the spread of COVID-19. We quantified access to public parks and gardens in urban areas of England and Wales, and the potential for park crowdedness during periods of high use. We combined data from the Office for National Statistics and Ordnance Survey to quantify (i) the number of parks within 500 and 1,000 metres of urban postcodes (i.e., availability), (ii) the distance of postcodes to the nearest park (i.e., accessibility), and (iii) per-capita space in each park for people living within 1,000m. We examined how these measures vary by city and share of homes that are flats. Around 25.4 million people can access public parks or gardens within a ten-minute walk, while 3.8 million residents live farther away; of these 21% are children and 13% are elderly. Areas with a higher share of flats on average are closer to a park but people living in these areas are potentially less able to meet social distancing requirements while in parks during periods of high use. Cities in England and Wales can provide residents with access to green space that enables outdoor exercise and play during social distancing. Cities aiming to facilitate social distancing while keeping public green spaces open might require implementing measures such as dedicated park times for different age groups or entry allocation systems that, combined with smartphone apps or drones, can monitor and manage the total number of people using the park.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.05.12.20098921,2020-05-18,https://medrxiv.org/cgi/content/short/2020.05.12.20098921,Behavioural change towards reduced intensity physical activity is disproportionately prevalent among adults with serious health issues or self-perception of high risk during the UK COVID-19 lockdown.,Nina Trivedy Rogers; Naomi Waterlow; Hannah E Brindle; Luisa Enria; Rosalind M Eggo; Shelley Lees; Chrissy h Roberts,University College London (UCL); London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; University of Bath; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,"ImportanceThere are growing concerns that the UK COVID-19 lockdown has reduced opportunities to maintain health through physical activity, placing individuals at higher risk of chronic disease and leaving them more vulnerable to severe sequelae of COVID-19.

ObjectiveTo examine whether the UKs lockdown measures have had disproportionate impacts on intensity of physical activity in groups who are, or who perceive themselves to be, at heightened risk from COVID-19.

Designs, Setting, ParticipantsUK-wide survey of adults aged over 20, data collected between 2020-04-06 and 2020-04-22.

ExposuresSelf-reported doctor-diagnosed obesity, hypertension, type I/II diabetes, lung disease, cancer, stroke, heart disease. Self-reported disabilities and depression. Sex, gender, educational qualifications, household income, caring for school-age children. Narrative data on coping strategies.

Main Outcomes and MeasuresChange in physical activity intensity after implementation of UK COVID-19 lockdown (self-reported).

ResultsMost (60%) participants achieved the same level of intensity of physical activity during the lockdown as before the epidemic. Doing less intensive physical activity during the lockdown was associated with obesity (OR 1.21, 95% CI 1.02-1.41), hypertension (OR 1.52, 1.33-1.71), lung disease (OR 1.31,1.13-1.49), depression (OR 2.02, 1.82-2.22) and disability (OR 2.34, 1.99-2.69). Participants who reduced their physical activity intensity also had higher odds of being female, living alone or having no garden, and more commonly expressed sentiments about personal or household risks in narratives on coping.

Conclusions and relevanceGroups who reduced physical activity intensity included disproportionate numbers of people with either heightened objective clinical risks or greater tendency to express subjective perceptions of risk. Policy on exercise for health during lockdowns should include strategies to facilitate health promoting levels of physical activity in vulnerable groups, including those with both objective and subjective risks.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.05.09.20082909,2020-05-15,https://medrxiv.org/cgi/content/short/2020.05.09.20082909,Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission,Lucy Rivett; Sushmita Sridhar; Dominic Sparkes; Matthew Routledge; Nicholas K. Jones; Sally Forrest; Jamie Young; Joana Pereira-Dias; William L Hamilton; Mark Ferris; Estee Torok; Luke Meredith; The CITIID-NIHR COVI Bioresource Collaboration; Martin Curran; Stewart Fuller; Afzal Chaudhry; Ashley Shaw; Richard J. Samsworth; John R. Bradley; Gordon Dougan; Kenneth G. C. Smith; Paul J. Lehner; Nicholas J. Matheson; Giles Wright; Ian Goodfellow; Stephen Baker; Michael P. Weekes,"Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK and Clinical Microbiology & Public Health Laboratory, Publ; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Cambridge, UK and Wellcome Sanger Institute, Hinxton, UK; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK and Clinical Microbiology & Public Health Laboratory, Publ; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK and Clinical Microbiology & Public Health Laboratory, Publ; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK; Clinical Microbiology & Public Health Cambridge Institute; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Cambridge, UK; Academic department of Medical Genetics, University of Cambridge, Cambridge, UK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Cambridge, UK; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK and Clinical Microbiology & Public Health Laboratory, Publ; Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, UK; Department of Medicine, University of Cambridge, Cambridge, UK; Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, University of Cambrid; Clinical Microbiology & Public Health Laboratory, Public Health England, Cambridge, UK; National Institutes for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; National Institutes for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Statistical Laboratory, Centre for Mathematical Sciences, Cambridge, UK; Department of Medicine, University of Cambridge, Cambridge, UK and National Institutes for Health Research Cambridge Biomedical Research Centre, Cambridge, UK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Cambridge, UK and Department of Medicine, University of Ca; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Cambridge, UK and Department of Medicine, University of Ca; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK, Cambridge Institute of Therapeutic Immunology & Infectiou; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK and Cambridge Institute of Therapeutic Immunology & Infect; Occupational Health and Wellbeing, Cambridge Biomedical Campus, Cambridge, UK; Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK; Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), University of Cambridge, Cambridge, UK and Department of Medicine, University of Ca; Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK and Cambridge Institute of Therapeutic Immunology & Infect","Significant differences exist in the availability of healthcare worker (HCW) SARS-CoV-2 testing between countries, and existing programmes focus on screening symptomatic rather than asymptomatic staff. Over a 3-week period (April 2020), 1,032 asymptomatic HCWs were screened for SARS-CoV-2 in a large UK teaching hospital. Symptomatic staff and symptomatic household contacts were additionally tested. Real-time RT-PCR was used to detect viral RNA from a throat+nose self-swab.

3% of HCWs in the asymptomatic screening group tested positive for SARS-CoV-2. 17/30 (57%) were truly asymptomatic/pauci-symptomatic. 12/30 (40%) had experienced symptoms compatible with coronavirus disease 2019 (COVID-19) >7 days prior to testing, most self-isolating, returning well. Clusters of HCW infection were discovered on two independent wards. Viral genome sequencing showed that the majority of HCWs had the dominant lineage B{middle dot}1. Our data demonstrates the utility of comprehensive screening of HCWs with minimal or no symptoms. This approach will be critical for protecting patients and hospital staff.

Appendix: The CITIID-NIHR COVID-19 BioResource CollaborationO_ST_ABSPrincipal InvestigatorsC_ST_ABSStephen Baker, John Bradley, Gordon Dougan, Ian Goodfellow, Ravi Gupta, Paul J. Lehner, Paul A. Lyons, Nicholas J. Matheson, Kenneth G.C. Smith, M. Estee Torok, Mark Toshner, Michael P. Weekes

Infectious Diseases DepartmentNicholas K. Jones, Lucy Rivett, Matthew Routledge, Dominic Sparkes, Ben Warne

SARS-CoV-2 testing teamJosefin Bartholdson Scott, Claire Cormie, Sally Forrest, Harmeet Gill, Iain Kean, Mailis Maes, Joana Pereira-Dias, Nicola Reynolds, Sushmita Sridhar, Michelle Wantoch, Jamie Young

COG-UK Cambridge Sequencing TeamSarah Caddy, Laura Caller, Theresa Feltwell, Grant Hall, William Hamilton, Myra Hosmillo, Charlotte Houldcroft, Aminu Jahun, Fahad Khokhar, Luke Meredith, Anna Yakovleva

NIHR BioResourceHelen Butcher, Daniela Caputo, Debra Clapham-Riley, Helen Dolling, Anita Furlong, Barbara Graves, Emma Le Gresley, Nathalie Kingston, Sofia Papadia, Hannah Stark, Kathleen E. Stirrups, Jennifer Webster

Research nursesJoanna Calder, Julie Harris, Sarah Hewitt, Jane Kennet, Anne Meadows, Rebecca Rastall, Criona O,Brien, Jo Price, Cherry Publico, Jane Rowlands, Valentina Ruffolo, Hugo Tordesillas

NIHR Cambridge Clinical Research FacilityKaren Brookes, Laura Canna, Isabel Cruz, Katie Dempsey, Anne Elmer, Naidine Escoffery, Stewart Fuller, Heather Jones, Carla Ribeiro, Caroline Saunders, Angela Wright

Cambridge Cancer Trial CentreRutendo Nyagumbo, Anne Roberts

Clinical Research Network EasternAshlea Bucke, Simone Hargreaves, Danielle Johnson, Aileen Narcorda, Debbie Read, Christian Sparke, Lucy Warboys

Administrative staff, CUHKirsty Lagadu, Lenette Mactavous

CUH NHS Foundation TrustTim Gould, Tim Raine, Ashley Shaw

Cambridge Cancer Trials CentreClaire Mather, Nicola Ramenatte, Anne-Laure Vallier

Legal/EthicsMary Kasanicki

CUH Improvement and Transformation TeamPenelope-Jane Eames, Chris McNicholas, Lisa Thake

Clinical Microbiology & Public Health Laboratory (PHE):

Neil Bartholomew, Nick Brown, Martin Curran, Surendra Parmar, Hongyi Zhang

Occupational HealthAilsa Bowring, Mark Ferris, Geraldine Martell, Natalie Quinnell, Giles Wright, Jo Wright

Health and SafetyHelen Murphy

Department of Medicine Sample LogisticsBenjamin J. Dunmore, Ekaterina Legchenko, Stefan Graf, Christopher Huang, Josh Hodgson, Kelvin Hunter, Jennifer Martin, Federica Mescia, Ciara ODonnell, Linda Pointon, Joy Shih, Rachel Sutcliffe, Tobias Tilly, Zhen Tong, Carmen Treacy, Jennifer Wood

Department of Medicine Sample Processing and Acquisition:

Laura Bergamaschi, Ariana Betancourt, Georgie Bowyer, Aloka De Sa, Maddie Epping, Andrew Hinch, Oisin Huhn, Isobel Jarvis, Daniel Lewis, Joe Marsden, Simon McCallum, Francescsa Nice, Ommar Omarjee, Marianne Perera, Nika Romashova, Mateusz Strezlecki, Natalia Savoinykh Yarkoni, Lori Turner

Epic team/other computing supportBarrie Bailey, Afzal Chaudhry, Rachel Doughton, Chris Workman

Statistics/modellingRichard J. Samworth, Caroline Trotter",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.05.10.20096925,2020-05-15,https://medrxiv.org/cgi/content/short/2020.05.10.20096925,"NON-WHITE ETHNICITY, MALE SEX, AND HIGHER BODY MASS INDEX, BUT NOT MEDICATIONS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ARE ASSOCIATED WITH CORONAVIRUS DISEASE 2019 (COVID-19) HOSPITALISATION: REVIEW OF THE FIRST 669 CASES FROM THE UK BIOBANK",Zahra Raisi-Estabragh; Celeste McCracken; Maddalena Ardissino; Mae S Bethell; Jackie Cooper; Cyrus Cooper; Nicholas C Harvey; Steffen E Petersen,"William Harvey Research Institute; William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, UK; Sir Alexander Fleming Building, Imperial College London, London, UK; North West Anglia NHS Foundation Trust, Hinchingbrooke Hospital, Huntingdon, UK; William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, UK; MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK; William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, UK","BackgroundCardiometabolic morbidity and medications, specifically Angiotensin Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs), have been linked with adverse outcomes from coronavirus disease 2019 (COVID-19). This study aims to investigate factors associated with COVID-19 positivity for the first 669 UK Biobank participants; compared with individuals who tested negative, and with the untested, presumed negative, rest of the population.

MethodsWe studied 1,474 participants from the UK Biobank who had been tested for COVID-19. Given UK testing policy, this implies a hospital setting, suggesting at least moderate to severe symptoms. We considered the following exposures: age, sex, ethnicity, body mass index (BMI), diabetes, hypertension, hypercholesterolaemia, ACEi/ARB use, prior myocardial infarction (MI), and smoking. We undertook comparisons between: 1) COVID-19 positive and COVID-19 tested negative participants; and 2) COVID-19 tested positive and the remaining participants (tested negative plus untested, n=501,837). Logistic regression models were used to investigate univariate and mutually adjusted associations.

ResultsAmong participants tested for COVID-19, non-white ethnicity, male sex, and greater BMI were independently associated with COVID-19 positive result. Non-white ethnicity, male sex, greater BMI, diabetes, hypertension, prior MI, and smoking were independently associated with COVID-19 positivity compared to the remining cohort (test negatives plus untested). However, similar associations were observed when comparing those who tested negative for COVID-19 with the untested cohort; suggesting that these factors associate with general hospitalisation rather than specifically with COVID-19.

ConclusionsAmong participants tested for COVID-19 with presumed moderate to severe symptoms in a hospital setting, non-white ethnicity, male sex, and higher BMI are associated with a positive result. Other cardiometabolic morbidities confer increased risk of hospitalisation, without specificity for COVID-19. Notably, ACE/ARB use did not associate with COVID-19 status.",cardiovascular medicine,fuzzy,100,100
medRxiv,10.1101/2020.05.11.20096347,2020-05-15,https://medrxiv.org/cgi/content/short/2020.05.11.20096347,"The effects of ARBs, ACEIs and statins on clinical outcomes of COVID-19 infection among nursing home residents",Anton De Spiegeleer; Antoon Bronselaer; James T Teo; Geert Byttebier; Guy De Tre; Luc Belmans; Richard Dobson; Evelien Wynendaele; Christophe Van De Wiele; Filip Vandaele; Diemer Van Dijck; Daniel Bean; David Fedson; Bart De Spiegeleer,"Ghent University, Belgium; Ghent University, Belgium; Kings College Hospital NHS Foundation Trust, UK; Bioconstat BV, Belgium; Ghent University, Belgium; Ghent University, Belgium; Kings College London, UK; Ghent University, Belgium; Ghent University, Belgium; VZW Zorg-Saam Zusters Kindsheid Jesu, Belgium; Corilus Health IT Center, Belgium; King's College London, UK; Former University of Virginia, USA; Ghent University, Belgium","Background.COVID-19 infection has limited preventive or therapeutic drug options at this stage. Some of common existing drugs like angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARB) and the HMG-CoA reductase inhibitors ( statins) have been hypothesised to impact on disease severity. However, up till now, no studies investigating this association were conducted in the most vulnerable and affected population groups, i.e. older people residing in nursing homes. The purpose of this study has been to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19 infected older people residing in nursing homes.

Methods and Findings.We undertook a retrospective multi-centre cohort study in two Belgian nursing homes that experienced similar COVID-19 outbreaks. COVID-19 diagnoses were based on clinical suspicion and/or viral presence using PCR of nasopharyngeal samples. A total of 154 COVID-19 positive subjects was identified. The outcomes were 1) serious COVID-19 defined as a long-stay hospital admission (length of stay [&ge;] 7 days) or death (at hospital or nursing home) within 14 days of disease onset, and 2) asymptomatic, i.e. no disease symptoms in the whole study-period while still being PCR diagnosed. Disease symptoms were defined as any COVID-19-related clinical symptom (e.g. coughing, dyspnoea, sore throat) or sign (low oxygen saturation and fever) for [&ge;] 2 days out of 3 consecutive days.

Logistic regression models with Firth corrections were applied on these 154 subjects to analyse the association between ACEi/ARB and/or statin use with the outcomes. Age, sex, functional status, diabetes and hypertension were used as covariates. Sensitivity analyses were conducted to evaluate the robustness of our statistical significant findings.

We found a statistically significant association between statin intake and the absence of symptoms during COVID-19 infection (unadjusted OR 2.91; CI 1.27-6.71; p=0.011), which remained statistically significant after adjusting for age, sex, functional status, diabetes mellitus and hypertension. The strength of this association was considerable and clinically important. Although the effects of statin intake on serious clinical outcome (long-stay hospitalisation or death) were in the same beneficial direction, these were not statistically significant (OR 0.75; CI 0.25-1.85; p=0.556). There was also no statistically significant association between ACEi/ARB and asymptomatic status (OR 1.52; CI 0.62-3.50; p=0.339) or serious clinical outcome (OR 0.79; CI 0.26-1.95; p=0.629).

Conclusions.Our data indicate that statin intake in old, frail people could be associated with a considerable beneficial effect on COVID-19 related clinical symptoms. The role of statins and any interaction with renin-angiotensin system drugs need to be further explored in larger observational studies as well as randomised clinical trials.",geriatric medicine,fuzzy,100,100
medRxiv,10.1101/2020.05.08.20095687,2020-05-14,https://medrxiv.org/cgi/content/short/2020.05.08.20095687,Rapid implementation of real-time SARS-CoV-2 sequencing to investigate healthcare-associated COVID-19 infections,Luke W Meredith; William L Hamilton; Ben Warne; Charlotte J Houldcroft; Myra Hosmillo; Aminu Jahun; Martin D Curran; Surendra Parmar; Laura Caller; Sarah L Caddy; Fahad A Khokhar; Anna Yakovleva; Grant R Hall; Theresa Feltwell; Sally N Forret; Sushmita Sridhar; Michael p Weekes; Stephen Baker; Nicholas Brown; Elinor Moore; Theodore Gouliouris; Ashley Popay; Iain Roddick; Mark Reacher; Sharon Peacock; Gordon Dougan; M. Estee Torok; Ian Goodfellow,University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; University of Cambridge; University of Cambridge; University of Cambridge; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University; Cambridge University; Public Health England; Cambridge University Hospitals NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Public Health England; Public Health England; Public Health England; University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge,"BackgroundThe burden and impact of healthcare-associated COVID-19 infections is unknown. We aimed to examine the utility of rapid sequencing of SARS-CoV-2 combined with detailed epidemiological analysis to investigate healthcare-associated COVID-19 infections and to inform infection control measures.

MethodsWe set up rapid viral sequencing of SARS-CoV-2 from PCR-positive diagnostic samples using nanopore sequencing, enabling sample-to-sequence in less than 24 hours. We established a rapid review and reporting system with integration of genomic and epidemiological data to investigate suspected cases of healthcare-associated COVID-19.

ResultsBetween 13 March and 24 April 2020 we collected clinical data and samples from 5191 COVID-19 patients in the East of England. We sequenced 1000 samples, producing 747 complete viral genomes. We conducted combined epidemiological and genomic analysis of 299 patients at our hospital and identified 26 genomic clusters involving 114 patients. 66 cases (57.9%) had a strong epidemiological link and 15 cases (13.2%) had a plausible epidemiological link. These results were fed back to clinical, infection control and hospital management teams, resulting in infection control interventions and informing patient safety reporting.

ConclusionsWe established real-time genomic surveillance of SARS-CoV-2 in a UK hospital and demonstrated the benefit of combined genomic and epidemiological analysis for the investigation of healthcare-associated COVID-19 infections. This approach enabled us to detect cryptic transmission events and identify opportunities to target infection control interventions to reduce further healthcare-associated infections.",infectious diseases,fuzzy,100,100
bioRxiv,10.1101/2020.05.11.089409,2020-05-13,https://biorxiv.org/cgi/content/short/2020.05.11.089409,An integrated in silico immuno-genetic analytical platform provides insights into COVID-19 serological and vaccine targets,Daniel Ward; Matthew Higgins; Jody Phelan; Martin L. Hibberd; Susana Campino; Taane G Clark,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine,"BackgroundThe COVID-19 pandemic, caused by the SARS-CoV-2 virus, has a major global health and socio-economic burden. It has instigated the mobilisation of resources into the development of control tools, such as diagnostics and vaccines. The poor performance of some diagnostic serological tools has emphasised the need for up to date immune-informatic analyses to inform the selection of viable targets for further study. This requires the integration and analysis of genetic and immunological data for SARS-CoV-2 and its homology with other human coronavirus species to understand cross-reactivity.

MethodsWe have developed an online ""immuno-analytics"" resource to facilitate SARS-CoV-2 research, combining an extensive B/T-cell epitope mapping and prediction meta-analysis, and human CoV sequence homology mapping and protein database annotation, with an updated variant database and geospatial tracking for >7,800 non-synonymous mutation positions derived from >150,000 whole genome sequences. To demonstrate its utility, we present an integrated analysis of SARS-CoV-2 spike and nucleocapsid proteins, both being vaccine and serological diagnostic targets, including an analysis of changes in relevant mutation frequencies over time.

ResultsOur analysis reveals that the nucleocapsid protein in its native form appears to be a sub-optimal target for use in serological diagnostic platforms. The most frequent mutations were the spike protein D614G and nsp12 L314P, which were common (>86%) across all the geographical regions. Some mutations in the spike protein (e.g. A222V and L18F) have increased in frequency in Europe during the latter half of 2020, detected using our automated algorithms. The tool also suggests that orf3a proteins may be a suitable alternative target for diagnostic serologic assays in a post-vaccine surveillance setting.

ConclusionsThe immuno-analytics tool can be accessed online (http://genomics.lshtm.ac.uk/immuno) and will serve as a useful resource for biological discovery and surveillance in the fight against SARS-CoV-2. Further, the tool may be adapted to inform on biological targets in future outbreaks, including potential emerging human coronaviruses that spill over from animal hosts.",bioinformatics,fuzzy,100,100
medRxiv,10.1101/2020.05.08.20094474,2020-05-12,https://medrxiv.org/cgi/content/short/2020.05.08.20094474,"The Association of Social Distancing, Population Density, and Temperature with the SARS-CoV-2 Instantaneous Reproduction Number in Counties Across the United States",David Rubin; Jing Huang; Brian T Fisher; Antonio Gasparrini; Vicky Tam; Lihai Song; Xi Wang; Jason Kaufman; Kate Fitzpatrick; Arushi Jain; Heather Griffis; Koby Crammer; Gregory Tasian,"Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania; Perelman School of Medicine at the University of Pennsylvania; London School of Hygiene and Tropical Medicine; Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; Children's Hospital of Philadelphia; Perelman School of Medicine at the University of Pennsylvania; Children's Hospital of Philadelphia; CHOP; Children's Hospital of Philadelphia; The Technion, Haifa, Israel; The Children's Hospital of Philadelphia","ImportanceThe Covid-19 pandemic has been marked by considerable heterogeneity in outbreaks across the United States. Local factors that may be associated with variation in SARS-CoV-2 transmission have not been well studied.

ObjectiveTo examine the association of county-level factors with variation in the SARS-CoV-2 reproduction number over time.

DesignObservational study

Setting211 counties in 46 states and the District of Columbia between February 25, 2020 and April 23, 2020.

ParticipantsResidents within the counties (55% of the US population)

ExposuresSocial distancing as measured by percent change in visits to non-essential businesses, population density, lagged daily wet bulb temperatures.

Main Outcomes and MeasuresThe instantaneous reproduction number (Rt) which is the estimated number of cases generated by one case at a given time during the pandemic.

ResultsMedian case incidence was 1185 cases and fatality rate was 43.7 deaths per 100,000 people for the top decile of 21 counties, nearly ten times the incidence and fatality rate in the lowest density quartile. Average Rt in the first two weeks was 5.7 (SD 2.5) in the top decile, compared to 3.1 (SD 1.2) in the lowest quartile. In multivariable analysis, a 50% decrease in visits to non-essential businesses was associated with a 57% decrease in Rt (95% confidence interval, 56% to 58%). Cumulative temperature effects over 4 to 10 days prior to case incidence were nonlinear; relative Rt decreased as temperatures warmed above 32{degrees}F to 53{degrees}F, which was the point of minimum Rt, then increased between 53{degrees}F and 66{degrees}F, at which point Rt began to decrease. At 55{degrees}F, and with a 70% reduction in visits to non-essential business, 96% of counties were estimated to fall below a threshold Rt of 1.0, including 86% of counties among the top density decile and 98% of counties in the lowest density quartile.

Conclusions and RelevanceSocial distancing, lower population density, and temperate weather change were associated with a decreased SARS-Co-V-2 Rt in counties across the United States. These relationships can inform selective public policy planning in communities during the SARS-CoV-2 pandemic.

Key PointsO_ST_ABSQuestionC_ST_ABSHow is the instantaneous reproduction number (Rt) of SARS-CoV-2 influenced by local area effects of social distancing, wet bulb temperature, and population density in counties across the United States?

FindingsSocial distancing, temperate weather, and lower population density were associated with a decrease in Rt. Of these county-specific factors, social distancing appeared to be the most significant in reducing SARS-CoV-2 transmission.

MeaningRt varies significantly across counties. The relationship between Rt and county-specific factors can inform policies to reduce SARS-CoV-2 transmission in selective and heterogeneous communities.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.05.07.20093849,2020-05-11,https://medrxiv.org/cgi/content/short/2020.05.07.20093849,The contribution of asymptomatic SARS-CoV-2 infections to transmission - a model-based analysis of the Diamond Princess outbreak,Jon C Emery; Timothy W Russel; Yang Liu; Joel Hellewell; Carl AB Pearson; - CMMID 2019-nCoV working group; Gwen M Knight; Rosalind M Eggo; Adam J Kucharski; Sebastian Funk; Stefan Flasche; Rein M G J Houben,London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; -; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,"BackgroundSome key gaps in the understanding of SARS-CoV-2 infection remain. One of them is the contribution to transmission from individuals experiencing asymptomatic infections. We aimed to characterise the proportion and infectiousness of asymptomatic infections using data from the outbreak on the Diamond Princess cruise ship.

MethodsWe used a transmission model of COVID-19 with asymptomatic and presymptomatic states calibrated to outbreak data from the Diamond Princess, to quantify the contribution of asymptomatic infections to transmission. Data available included the date of symptom onset for symptomatic disease for passengers and crew, the number of symptom agnostic tests done each day, and date of positive test for asymptomatic and presymptomatic individuals.

FindingsOn the Diamond Princess 74% (70-78%) of infections proceeded asymptomatically, i.e. a 1:3.8 case-to-infection ratio. Despite the intense testing 53%, (51-56%) of infections remained undetected, most of them asymptomatic. Asymptomatic individuals were the source for 69% (20-85%) of all infections. While the data did not allow identification of the infectiousness of asymptomatic infections, assuming no or low infectiousness resulted in posterior estimates for the net reproduction number of an individual progressing through presymptomatic and symptomatic stages in excess of 15.

InterpretationAsymptomatic SARS-CoV-2 infections may contribute substantially to transmission. This is essential to consider for countries when assessing the potential effectiveness of ongoing control measures to contain COVID-19.

FundingERC Starting Grant (#757699), Wellcome trust (208812/Z/17/Z), HDR UK (MR/S003975/1)",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.05.10.20083683,2020-05-11,https://medrxiv.org/cgi/content/short/2020.05.10.20083683,Predictions of COVID-19 dynamics in the UK: short-term forecasting and analysis of potential exit strategies,Matt J Keeling; Edward Hill; Erin Gorsich; Bridget Penman; Glen Guyver-Fletcher; Alex Holmes; Trystan Leng; Hector McKimm; Massimiliano Tamborrino; Louise Dyson; Michael Tildesley,University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick; University of Warwick,"BackgroundEfforts to suppress transmission of SARS-CoV-2 in the UK have seen non-pharmaceutical interventions being invoked. The most severe measures to date include all restaurants, pubs and cafes being ordered to close on 20th March, followed by a ""stay at home"" order on the 23rd March and the closure of all non-essential retail outlets for an indefinite period. Government agencies are presently analysing how best to develop an exit strategy from these measures and to determine how the epidemic may progress once measures are lifted. Mathematical models are currently providing short and long term forecasts regarding the future course of the COVID-19 outbreak in the UK to support evidence-based policymaking.

MethodsWe present a deterministic, age-structured transmission model that uses real-time data on confirmed cases requiring hospital care and mortality to provide up-to-date predictions on epidemic spread in ten regions of the UK. The model captures a range of age-dependent heterogeneities, reduced transmission from asymptomatic infections and produces a good fit to the key epidemic features over time. We simulated a suite of scenarios to assess the impact of differing approaches to relaxing social distancing measures from 7th May 2020, on the estimated number of patients requiring inpatient and critical care treatment, and deaths. With regard to future epidemic outcomes, we investigated the impact of reducing compliance, ongoing shielding of elder age groups, reapplying stringent social distancing measures using region based triggers and the role of asymptomatic transmission.

FindingsWe find that significant relaxation of social distancing measures from 7th May onwards can lead to a rapid resurgence of COVID-19 disease and the health system being quickly overwhelmed by a sizeable, second epidemic wave. In all considered age-shielding based strategies, we projected serious demand on critical care resources during the course of the pandemic. The reintroduction and release of strict measures on a regional basis, based on ICU bed occupancy, results in a long epidemic tail, until the second half of 2021, but ensures that the health service is protected by reintroducing social distancing measures for all individuals in a region when required.

DiscussionOur work confirms the effectiveness of stringent non-pharmaceutical measures in March 2020 to suppress the epidemic. It also provides strong evidence to support the need for a cautious, measured approach to relaxation of lockdown measures, to protect the most vulnerable members of society and support the health service through subduing demand on hospital beds, in particular bed occupancy in intensive care units.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.05.07.20094557,2020-05-11,https://medrxiv.org/cgi/content/short/2020.05.07.20094557,"Early impact of the COVID-19 pandemic and social distancing measures on routine childhood vaccinations in England, January to April 2020",Helen I McDonald; Elise Tessier; Joanne M White; Matthew Woodruff; Charlotte Knowles; Chris Bates; John Parry; Jemma L Walker; J Anthony Scott; Liam Smeeth; Joanne Yarwood; Mary Ramsay; Michael Edelstein,London School of Medicine and Tropical Medicine; NIHR Health Protection Research Unit (HPRU) in Immunisation; Public Health England; Public Health England; TPP (Leeds) Ltd; TPP (Leeds) Ltd; TPP (Leeds) Ltd; TPP (Leeds) Ltd; London School of Hygiene and Tropical Medicine; Public Health England; NIHR Health Protection Research Unit (HPRU) in Immunisation; London School of Hygiene and Tropical Medicine; NIHR Health Protection Research Unit (HPRU) in Immunisation; London School of Hygiene and Tropical Medicine; NIHR Health Protection Research Unit (HPRU) in Immunisation; Public Health England; Public Health England; NIHR Health Protection Research Unit (HPRU) in Immunisation; Public Health England,"Electronic health records were used to assess the early impact of COVID-19 on routine childhood vaccination in England to 26 April 2020.

MMR vaccination counts fell from February 2020, and in the three weeks after introduction of social distancing measures were 19.8% lower (95% CI -20.7 to -18.9%) than the same period in 2019, before improving in mid-April. A gradual decline in hexavalent vaccination counts throughout 2020 was not accentuated on introduction of social distancing.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.05.08.20078386,2020-05-11,https://medrxiv.org/cgi/content/short/2020.05.08.20078386,"Drive-through testing for SARS-CoV-2 in symptomatic health and social care workers and household members: an observational cohort study in Tayside, Scotland",Benjamin Parcell; Kathryn Brechin; Sarah Allstaff; Meg Park; Wendy Third; Susan Bean; Chris Hind; Rajiv Farmer; James D Chalmers,NHS Tayside; NHS Tayside; NHS Tayside; NHS Tayside; NHS Tayside; NHS Tayside; NHS Tayside; NHS Tayside; University of Dundee,"It has been recognised that health and social care workers (HSCW) experience higher rates of infection with SARS-CoV-2. Widespread testing of HSCWs and their symptomatic household contacts (SHCs) has not been fully implemented in the United Kingdom. We describe the results of a testing programme for HSCWs and SHCs in a single UK region (Tayside, Scotland). The testing service was established 17 th March 2020 as the first in the country, and samples were collected at a drive-through testing hub based at a local community hospital. HSCWs with mild symptoms who were self-isolating and the SHCs of HSCWs who would therefore be absent from work attended for testing. From 17 th March 2020 to 11 th April, 1887 HSCWs and SHCs underwent testing. Clinical information was available for 1727 HSCWs and SHCs. 4/155 (2.6%) child contacts, 73/374 (19.5%) adult contacts and 325/1173 (27.7%) HSCWs tested positive for SARS-CoV-2. 15 of 188 undetermined cases were positive (8.0%). We estimate that testing prevented up to 3634 lost work days from HSCW testing, 2795 from adult SHC testing and 1402 lost work days from child SHC testing. The establishment of this testing programme has assisted the infection prevention and control team in their investigation of transmission and supported adequate staffing in health and social care sectors.",infectious diseases,fuzzy,95,100
medRxiv,10.1101/2020.05.05.20092296,2020-05-09,https://medrxiv.org/cgi/content/short/2020.05.05.20092296,Ethnicity and risk of death in patients hospitalised for COVID-19 infection: an observational cohort study in an urban catchment area,Elizabeth Sapey; Suzy Gallier; Chris Mainey; Peter Nightingale; David McNulty; Hannah Crothers; Felicity Evison; Katharine Reeves; Domenico Pagano; Alastair K Denniston; Krishnarajah Nirantharakumar; Peter Diggle; Simon Ball,University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS FoundationTrust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trust; University of Birmingham; University of Lancaster; University Hospitals Birmingham NHS Foundation Trust,"BackgroundStudies suggest that certain Black and Asian Minority Ethnic groups experience poorer outcomes from COVID-19 but these studies have not provided insight into potential reasons for this. We hypothesised that outcomes would be poorer for those of South Asian ethnicity hospitalised from a confirmed SARS-CoV-2 infection, once confounding factors, health seeking behaviours and community demographics were considered and that this might reflect a more aggressive disease course in these patients.

MethodsPatients with confirmed SARS-CoV-2 infection requiring admission to University Hospitals Birmingham NHS Foundation Trust(UHB) in Birmingham UK between 10th March 2020-17th April 2020 were included. Standardised Admission Ratio(SAR) and Standardised Mortality Ratio(SMR) were calculated using observed COVID-19 admissions/deaths and 2011 census data. Hazard Ratio (aHR) for mortality was estimated using Cox proportional hazard model adjusting and propensity score matching.

ResultsAll patients admitted to UHB with COVID-19 during the study period were included (2217 in total). Fifty-eight percent were male, 69.5% White and the majority (80.2%) had co-morbidities. Eighteen and a half percent were of South Asian ethnicity, and these patients were more likely to be younger, have no co-morbidities but twice the prevalence of diabetes than White patients. SAR and SMR suggested more admissions and deaths in South Asian patients than would be predicted and they were more likely to present with severe disease despite no delay in presentation since symptom onset. South Asian ethnicity was associated with an increased risk of death; both by Cox regression (Hazard Ratio 1.4 (95%CI 1.2-1.8) after adjusting for age, sex, deprivation and comorbidities and by propensity score matching, matching for the same factors but categorising ethnicity into South Asian or not (Hazard ratio 1.3 (1.0-1.6)).

ConclusionsThose of South Asian ethnicity appear at risk of worse COVID-19 outcomes, further studies need to establish the underlying mechanistic pathways.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.05.06.20092734,2020-05-08,https://medrxiv.org/cgi/content/short/2020.05.06.20092734,The impact of Coronavirus disease 2019 (COVID-19) on health systems and household resources in Africa and South Asia,Nicholas G Davies; Sedona Sweeney; Sergio Torres-Rueda; Fiammetta Bozzani; Nichola Kitson; Edwine Barasa; Simon Procter; Matthew Quaife; - LSHTM Centre for Mathematical Modelling of Infectious Diseases COVID-19 Working Group; Rosalind M Eggo; Anna Vassall; Mark Jit,London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; KEMRI-Wellcome Trust Research Programme; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; -; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,"BackgroundCoronavirus disease 2019 (COVID-19) epidemics strain health systems and households. Health systems in Africa and South Asia may be particularly at risk due to potential high prevalence of risk factors for severe disease, large household sizes and limited healthcare capacity.

MethodsWe investigated the impact of an unmitigated COVID-19 epidemic on health system resources and costs, and household costs, in Karachi, Delhi, Nairobi, Addis Ababa and Johannesburg. We adapted a dynamic model of SARS-CoV-2 transmission and disease to capture country-specific demography and contact patterns. The epidemiological model was then integrated into an economic framework that captured city-specific health systems and household resource use.

FindingsThe cities severely lack intensive care beds, healthcare workers and financial resources to meet demand during an unmitigated COVID-19 epidemic. A highly mitigated COVID-19 epidemic, under optimistic assumptions, may avoid overwhelming hospital bed capacity in some cities, but not critical care capacity.

InterpretationViable mitigation strategies encompassing a mix of responses need to be established to expand healthcare capacity, reduce peak demand for healthcare resources, minimise progression to critical care and shield those at greatest risk of severe disease.

FundingBill & Melinda Gates Foundation, European Commission, National Institute for Health Research, Department for International Development, Wellcome Trust, Royal Society, Research Councils UK.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSWe conducted a PubMed search on May 5, 2020, with no language restrictions, for studies published since inception, combining the terms (""cost"" OR ""economic"") AND ""covid"". Our search yielded 331 articles, only two of which reported estimates of health system costs of COVID-19. The first study estimated resource use and medical costs for COVID-19 in the United States using a static model of COVID 19. The second study estimated the costs of polymerase chain reaction tests in the United States. We found no studies examining the economic implications of COVID-19 in low- or middle-income settings.

Added value of this studyThis is the first study to use locally collected data in five cities (Karachi, Delhi, Nairobi, Addis Ababa and Johannesburg) to project the healthcare resource and health economic implications of an unmitigated COVID-19 epidemic. Besides the use of local data, our study moves beyond existing work to (i) consider the capacity of health systems in key cities to cope with this demand, (ii) consider healthcare staff resources needed, since these fall short of demand by greater margins than hospital beds, and (iii) consider economic costs to health services and households.

Implications of all the evidenceDemand for ICU beds and healthcare workers will exceed current capacity by orders of magnitude, but the capacity gap for general hospital beds is narrower. With optimistic assumptions about disease severity, the gap between demand and capacity for general hospital beds can be closed in some, but not all the cities. Efforts to bridge the economic burden of disease to households are needed.",health economics,fuzzy,100,100
medRxiv,10.1101/2020.05.04.20079301,2020-05-08,https://medrxiv.org/cgi/content/short/2020.05.04.20079301,"COVID-19 and homelessness in England: a modelling study of theCOVID-19 pandemic among people experiencing homelessness, and theimpact of a residential intervention to isolate vulnerable people andcare for people with symptoms",Dan Lewer; Isobel Braithwaite; Miriam Bullock; Max T Eyre; Robert W Aldridge,University College London; University College London; University College London; Lancaster University Medical School; University College London,"BackgroundThere is an ongoing pandemic of the viral respiratory disease COVID-19. People experiencing homelessness are vulnerable to infection and severe disease. Health and housing authorities in England have developed a residential intervention that aims to isolate those vulnerable to severe disease (COVID-PROTECT) and care for people with symptoms (COVID-CARE).

MethodsWe used a discrete-time Markov chain model to forecast COVID-19 infections among people experiencing homelessness, given strong containment measures in the general population and some transmission among 35,817 people living in 1,065 hostels, and 11,748 people sleeping rough (the do nothing scenario). We then estimated demand for beds if those eligible are offered COVID-PROTECT and COVID-CARE. We estimated the reduction in the number of COVID-19 cases, deaths, and hospital admissions that could be achieved by these interventions. We also conducted sensitivity and scenario analyses to identify programme success factors.

ResultsIn a do nothing scenario, we estimate that 34% of the homeless population could get COVID-19 between March and August 2020, with 364 deaths, 4,074 hospital admissions and 572 critical care admissions. In our base intervention scenario, demand for COVID-PROTECT peaks at 9,934 beds, and demand for COVID-CARE peaks at 1,366 beds. The intervention could reduce transmission by removing symptomatic individuals from the community, and preventing vulnerable individuals from being infected. This could lead to a reduction of 164 deaths, 2,624 hospital admissions, and 248 critical care admissions over this period. Sensitivity analyses showed that the number of deaths is sensitive to transmission of COVID-19 in COVID-PROTECT. If COVID-PROTECT capacity is limited, scenario analyses show the benefit of prioritising people who are vulnerable to severe disease.

ConclusionSupportive accommodation can mitigate the impact of the COVID-19 pandemic on the homeless population of England, and reduce the burden on acute hospitals.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.05.04.20090597,2020-05-08,https://medrxiv.org/cgi/content/short/2020.05.04.20090597,Segmentation and shielding of the most vulnerable members of the population as elements of an exit strategy from COVID-19 lockdown,Bram A.D. van Bunnik; Alex L.K. Morgan; Paul Bessell; Giles Calder-Gerver; Feifei Zhang; Samuel Haynes; Jordan Ashworth; Shengyuan Zhao; Nicola Rose Cave; Meghan R. Perry; Hannah C. Lepper; Lu Lu; Paul Kellam; Aziz Sheikh; Graham F. Medley; Mark E.J. Woolhouse,"Usher Institute, University of Edinburgh,Edinburgh, UK; School of Biological Sciences, University of Edinburgh, Edinburgh, UK; School of Biological Sciences, University of Edinburgh, Edinburgh, UK; The Roslin Institute, University of Edinburgh, Edinburgh, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; School of Biological Sciences, University of Edinburgh, Edinburgh, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; School of Biological Sciences, University of Edinburgh, Edinburgh, UK; Clinical Infection Research Group, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; Department of Medicine, Division of Infectious Diseases, Imperial College London, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; Centre for Mathematical Modelling of Infectious Disease, London School of Hygiene and Tropical Medicine, London, UK; Usher Institute, University of Edinburgh, Edinburgh, UK; School of Biological Sciences, University of Edinburgh, Edinburgh, UK","In this study we demonstrate that the adoption of a segmenting and shielding (S&S) strategy could increase scope to partially exit COVID-19 lockdown while limiting the risk of an overwhelming second wave of infection.

The S&S strategy has an antecedent in the ""cocooning"" of infants by immunisation of close family members (Forsyth et al., 2015), and forms a pillar of infection, prevention and control (IPC) strategies (RCN, 2017). We are unaware of it being proposed as a major public health initiative previously.

We illustrate the S&S strategy using a mathematical model that segments the vulnerable population and their closest contacts, the ""shielders"". We explore the effects on the epidemic curve of a gradual ramping up of protection for the vulnerable population and a gradual ramping down of restrictions on the non-vulnerable population over a period of 12 weeks after lockdown.

The most important determinants of outcome are: i) post-lockdown transmission rates within the general population segment and between the general and vulnerable segments; ii) the fraction of the population in the vulnerable and shielder segments; iii) adherence with need to be protected; and iv) the extent to which population immunity builds up in all segments.

We explored the effects of extending the duration of lockdown and faster or slower transition to post-lockdown conditions and, most importantly, the trade-off between increased protection of the vulnerable segment and fewer restrictions on the general population.

We illustrate how the potential for the relaxation of restrictions interacts with specific policy objectives. We show that the range of options for relaxation in the general population can be increased by maintaining restrictions on the shielder segment and by intensive routine screening of shielders.

We find that the outcome of any future policy is strongly influenced by the contact matrix between segments and the relationships between physical distancing measures and transmission rates. These relationships are difficult to quantify so close monitoring of the epidemic would be essential during and after the exit from lockdown.

More generally, S&S has potential applications for any infectious disease for which there are defined proportions of the population who cannot be treated or who are at risk of severe outcomes.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.05.06.20092999,2020-05-07,https://medrxiv.org/cgi/content/short/2020.05.06.20092999,OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients.,- The OpenSAFELY Collaborative; Elizabeth Williamson; Alex J Walker; Krishnan J Bhaskaran; Seb Bacon; Chris Bates; Caroline E Morton; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I Mcdonald; Brian MacKenna; Laurie Tomlinson; Ian J Douglas; Christopher T Rentsch; Rohini Mathur; Angel Wong; Richard Grieve; David Harrison; Harriet Forbes; Anna Schultze; Richard T Croker; John Parry; Frank Hester; Sam Harper; Rafael Perera; Stephen Evans; Liam Smeeth; Ben Goldacre,; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford; TPP; London School of Hygiene and Tropical Medicine; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; ICNARC; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford; TPP; TPP; TPP; University of Oxford; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; University of Oxford,"BackgroundEstablishing who is at risk from a novel rapidly arising cause of death, and why, requires a new approach to epidemiological research with very large datasets and timely data. Working on behalf of NHS England we therefore set out to deliver a secure and pseudonymised analytics platform inside the data centre of a major primary care electronic health records vendor establishing coverage across detailed primary care records for a substantial proportion of all patients in England. The following results are preliminary.

Data sourcesPrimary care electronic health records managed by the electronic health record vendor TPP, pseudonymously linked to patient-level data from the COVID-19 Patient Notification System (CPNS) for death of hospital inpatients with confirmed COVID-19, using the new OpenSAFELY platform.

Population17,425,445 adults.

Time period1st Feb 2020 to 25th April 2020.

Primary outcomeDeath in hospital among people with confirmed COVID-19.

MethodsCohort study analysed by Cox-regression to generate hazard ratios: age and sex adjusted, and multiply adjusted for co-variates selected prospectively on the basis of clinical interest and prior findings.

ResultsThere were 5683 deaths attributed to COVID-19. In summary after full adjustment, death from COVID-19 was strongly associated with: being male (hazard ratio 1.99, 95%CI 1.88-2.10); older age and deprivation (both with a strong gradient); uncontrolled diabetes (HR 2.36 95% CI 2.18-2.56); severe asthma (HR 1.25 CI 1.08-1.44); and various other prior medical conditions. Compared to people with ethnicity recorded as white, black people were at higher risk of death, with only partial attenuation in hazard ratios from the fully adjusted model (age-sex adjusted HR 2.17 95% CI 1.84-2.57; fully adjusted HR 1.71 95% CI 1.44-2.02); with similar findings for Asian people (age-sex adjusted HR 1.95 95% CI 1.73-2.18; fully adjusted HR 1.62 95% CI 1.431.82).

ConclusionsWe have quantified a range of clinical risk factors for death from COVID-19, some of which were not previously well characterised, in the largest cohort study conducted by any country to date. People from Asian and black groups are at markedly increased risk of in-hospital death from COVID-19, and contrary to some prior speculation this is only partially attributable to pre-existing clinical risk factors or deprivation; further research into the drivers of this association is therefore urgently required. Deprivation is also a major risk factor with, again, little of the excess risk explained by co-morbidity or other risk factors. The findings for clinical risk factors are concordant with policies in the UK for protecting those at highest risk. Our OpenSAFELY platform is rapidly adding further NHS patients records; we will update and extend these results regularly.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.05.02.20078642,2020-05-06,https://medrxiv.org/cgi/content/short/2020.05.02.20078642,Impact of ethnicity on outcome of severe COVID-19 infection. Data from an ethnically diverse UK tertiary centre,James T Teo; Daniel Bean; Rebecca Bendayan; Richard Dobson; Ajay Shah,Kings College Hospital NHS Foundation Trust; King's College London; King's College London; Kings College London; King's College London,"During the current COVID-19 pandemic, it has been suggested that BAME background patients may be disproportionately affected compared to White but few detailed data are available. We took advantage of near real-time hospital data access and analysis pipelines to look at the impact of ethnicity in 1200 consecutive patients admitted between 1st March 2020 and 12th May 2020 to Kings College Hospital NHS Trust in London (UK).

Our key findings are firstly that BAME patients are significantly younger and have different co-morbidity profiles than White individuals. Secondly, there is no significant independent effect of ethnicity on severe outcomes (death or ITU admission) within 14-days of symptom onset, after adjustment for age, sex and comorbidities.",intensive care and critical care medicine,fuzzy,100,100
medRxiv,10.1101/2020.05.02.20086231,2020-05-06,https://medrxiv.org/cgi/content/short/2020.05.02.20086231,Trends in excess cancer and cardiovascular deaths in Scotland during the COVID-19 pandemic 30 December 2019 to 20 April 2020,Jonine Figueroa; Paul Brennan; Evropi Theodoratou; Michael Poon; Karin Purshouse; Farhat Din; Kai Jin; Ines Mesa-Eguiagaray; Malcolm G Dunlop; Peter S Hall; David Cameron; Sarah Wild; Cathie  LM Sudlow,University of Edinburgh; University of Edinburgh - Brain Tumour Centre of Excellence; University of Edinburgh - Centre for Clinical Brain Sciences; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; Institute of Genetics and Molecular Medicine; University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh,"Understanding the trends in causes of death for different diseases during the current COVID-19 pandemic is important to determine whether there are excess deaths beyond what is normally expected. Using the most recent report from National Records Scotland (NRS) on 29 April 2020, we examined the percentage difference in crude numbers of deaths in 2020 compared to the average for 2015-2019 by week of death within calendar year. To determine if trends were similar, suggesting underreporting/underdiagnosed COVID-19 related deaths, we also looked at the trends in % differences for cardiovascular disease deaths. From the first 17 weeks of data, we found a peak in excess deaths at week 14 of 2020, about four weeks after the first case in Scotland was detected on 1 March 2020-- but by week 17 these excesses had returned to normal levels, 4 weeks after lockdown in the UK began. Similar observations were seen for cardiovascular disease-related deaths. These observations suggest that the short-term increase in excess cancer and cardiovascular deaths might be associated with undetected/unconfirmed deaths related to COVID-19. Both of these conditions make patients more susceptible to infection and lack of widespread access to testing for COVID-19 are likely to have resulted in under-estimation of COVID-19 mortality. These data further suggest that the cumulative toll of COVID-19 on mortality is likely undercounted. More detailed analysis is needed to determine if these excesses were directly or indirectly related to COVID-19. Disease specific mortality will need constant monitoring for the foreseeable future as changes occur in increasing capacity and access to testing, reporting criteria, changes to health services and different measures are implemented to control the spread of the COVID-19. Multidisciplinary, multi-institutional, national and international collaborations for complementary and population specific data analysis is required to respond and mitigate adverse effects of the COVID-19 pandemic and to inform planning for future pandemics.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.04.28.20083170,2020-05-05,https://medrxiv.org/cgi/content/short/2020.04.28.20083170,Quantifying and mitigating the impact of the COVID-19 pandemic on outcomes in colorectal cancer,Amit Sud; Michael Jones; John Broggio; Stephen Scott; Chey Loveday; Bethany Torr; Alice Garrett; David L. Nicol; Shaman Jhanji; Stephen A. Boyce; Matthew Williams; Georgios Lyratzopoulos; Claire Barry; Elio Riboli; Emma Kipps; Ethna McFerran; Mark Lawler; David C. Muller; Muti Abulafi; Richard Houlston; Clare Ann Turnbull,"Institute of Cancer Research; Institute of Cancer Research; Public Health England; RM Partners, West London Cancer Alliance; Institute of Cancer Research; Institute of Cancer Research; Institute of Cancer Research; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; Imperial College; University College London; RM Partners, West London Cancer Alliance; Imperial College London; Royal Marsden NHS Foundation Trust; Queen's University Belfast; Queen's University Belfast; Imperial College London; Croydon Health Services NHS Trust, on behalf of RMP NICE FIT Steering Group; Institute of Cancer Research; Institute of Cancer Research","BackgroundThe COVID-19 pandemic has caused disruption across cancer pathways for diagnosis and treatment. In England, 32% of colorectal cancer (CRC) is diagnosed via urgent symptomatic referral from primary care, the ""2-week-wait"" (2WW) pathway. Access to routine endoscopy is likely to be a critical bottleneck causing delays in CRC management due to chronic limitation in capacity, acute competition for physician time, and safety concerns.

MethodsWe used age-specific, stage-specific 10 year CRC survival for England 2007-2017 and 2WW CRC cases volumes. We used per-day hazard ratios of CRC survival generated from observational studies of CRC diagnosis-to-treatment interval to model the effect of different durations of per-patient delay. We utilised data from a large London observational study of faecal immunochemical testing (FIT) in symptomatic patients to model FIT-triage to mitigate delay to colonoscopy.

FindingsModest delays result in significant reduction in survival from CRC with a 4-month delay resulting across age groups in [&ge;]20% reduction in survival in Stage 3 disease and in total over a year, 1,419 attributable deaths across the 11,266 CRC patients diagnosed via the 2WW pathway. FIT triage of >10 ug Hb/g would salvage 1,292/1,419 of the attributable deaths and reduce colonoscopy requirements by >80%. Diagnostic colonoscopy offers net survival in all age groups, providing nosocomial COVID-19 infection rates are kept low (<2{middle dot}5%).

InterpretationTo avoid significant numbers of avoidable deaths from CRC, normal diagnostic and surgical throughput must be maintained. An accrued backlog of cases will present to primary care following release of lockdown, supranormal endoscopy capacity will be required to manage this without undue delays. FIT-triage of symptomatic cases provides a rational approach by which to avoid patient delay and mitigate pressure on capacity in endoscopy. This would also reduce exposure to nosocomial COVID-19 infection, relevant in particular to older patient groups.

FundingBreast Cancer Now, Cancer Research UK, Bobby Moore Fund for Cancer Research, National Institute for Health Research (NIHR).",oncology,fuzzy,100,100
medRxiv,10.1101/2020.04.29.20084111,2020-05-05,https://medrxiv.org/cgi/content/short/2020.04.29.20084111,Risk of symptomatic Covid-19 among frontline healthcare workers,Long H. Nguyen; David Alden Drew; Amit D. Joshi; Chuan-Guo Guo; Wenjie Ma; Raaj S. Mehta; Daniel R. Sikavi; Chun-Han Lo; Sohee Kwon; Mingyang Song; Lorelei A. Mucci; Meir Stampfer; Walter C. Willett; A. Heather Eliassen; Jaime Hart; Jorge E. Chavarro; Janet Rich-Edwards; Richard Davies; Joan Capdevila; Karla A. Lee; Mary Ni Lochlainn; Thomas Varsavsky; Mark Graham; Carol H. Sudre; M. Jorge Cardoso; Jonathan Wolf; Sebastien Ourselin; Claire Steves; Timothy Spector; Andrew T. Chan,Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Massachusetts General Hospital and Harvard Medical School; Harvard T.H. Chan School of Public Health; Harvard T.H. Chan School of Public Health; Harvard T.H. Chan School of Public Health; Harvard T.H. Chan School of Public Health; Harvard T.H. Chan School of Public Health; Harvard T.H. Chan School of Public Health; Harvard T.H. Chan School of Public Health; Zoe Global Ltd.; Zoe Global Ltd.; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Global Ltd.; King's College London; King's College London; King's College London; Massachusetts General Hospital and Harvard Medical School,"BackgroundData for frontline healthcare workers (HCWs) and risk of SARS-CoV-2 infection are limited and whether personal protective equipment (PPE) mitigates this risk is unknown. We evaluated risk for COVID-19 among frontline HCWs compared to the general community and the influence of PPE.

MethodsWe performed a prospective cohort study of the general community, including frontline HCWs, who reported information through the COVID Symptom Study smartphone application beginning on March 24 (United Kingdom, U.K.) and March 29 (United States, U.S.) through April 23, 2020. We used Cox proportional hazards modeling to estimate multivariate-adjusted hazard ratios (aHRs) of a positive COVID-19 test.

FindingsAmong 2,035,395 community individuals and 99,795 frontline HCWs, we documented 5,545 incident reports of a positive COVID-19 test over 34,435,272 person-days. Compared with the general community, frontline HCWs had an aHR of 11{middle dot}6 (95% CI: 10{middle dot}9 to 12{middle dot}3) for reporting a positive test. The corresponding aHR was 3{middle dot}40 (95% CI: 3{middle dot}37 to 3{middle dot}43) using an inverse probability weighted Cox model adjusting for the likelihood of receiving a test. A symptom-based classifier of predicted COVID-19 yielded similar risk estimates. Compared with HCWs reporting adequate PPE, the aHRs for reporting a positive test were 1{middle dot}46 (95% CI: 1{middle dot}21 to 1{middle dot}76) for those reporting PPE reuse and 1{middle dot}31 (95% CI: 1{middle dot}10 to 1{middle dot}56) for reporting inadequate PPE. Compared with HCWs reporting adequate PPE who did not care for COVID-19 patients, HCWs caring for patients with documented COVID-19 had aHRs for a positive test of 4{middle dot}83 (95% CI: 3{middle dot}99 to 5{middle dot}85) if they had adequate PPE, 5{middle dot}06 (95% CI: 3{middle dot}90 to 6{middle dot}57) for reused PPE, and 5{middle dot}91 (95% CI: 4{middle dot}53 to 7{middle dot}71) for inadequate PPE.

InterpretationFrontline HCWs had a significantly increased risk of COVID-19 infection, highest among HCWs who reused PPE or had inadequate access to PPE. However, adequate supplies of PPE did not completely mitigate high-risk exposures.

FundingZoe Global Ltd., Wellcome Trust, EPSRC, NIHR, UK Research and Innovation, Alzheimers Society, NIH, NIOSH, Massachusetts Consortium on Pathogen Readiness

RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSThe prolonged course of the coronavirus disease 2019 (COVID-19) pandemic, coupled with sustained challenges supplying adequate personal protective equipment (PPE) for frontline healthcare workers (HCW), have strained global healthcare systems in an unprecedented fashion. Despite growing awareness of this problem, there are few data to inform policy makers on the risk of COVID-19 among HCWs and the impact of PPE on their disease burden. Prior reports of HCW infections are based on cross sectional data with limited individual-level information on risk factors for infection. A PubMed search for articles published between January 1, 2020 and May 5, 2020 using the terms ""covid-19"", ""healthcare workers"", and ""personal protective equipment,"" yielded no population-scale investigations exploring this topic.

Added value of this studyIn a prospective study of 2,135,190 individuals, frontline HCWs may have up to a 12-fold increased risk of reporting a positive COVID-19 test. Compared with those who reported adequate availability of PPE, frontline HCWs with inadequate PPE had a 31% increase in risk. However, adequate availability of PPE did not completely reduce risk among HCWs caring for COVID-19 patients.

Implications of all the available evidenceBeyond ensuring adequate availability of PPE, additional efforts to protect HCWs from COVID-19 are needed, particularly as lockdown is lifted in many regions of the world.",epidemiology,fuzzy,94,100
medRxiv,10.1101/2020.04.28.20082222,2020-05-03,https://medrxiv.org/cgi/content/short/2020.04.28.20082222,"Risk prediction for poor outcome and death in hospital in-patients with COVID-19: derivation in Wuhan, China and external validation in London, UK",Huayu Zhang; Ting Shi; Xiaodong Wu; Xin Zhang; Kun Wang; Daniel Bean; Richard Dobson; James T Teo; Jiaxing Sun; Pei Zhao; Chenghong Li; Kevin Dhaliwal; Honghan Wu; Qiang Li; Bruce Guthrie,"Centre for Medical Informatics, Usher Institute, University of Edinburgh, Scotland, United Kingdom; Centre for Global Health, Usher Institute, University of Edinburgh, Scotland, United Kingdom; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Peoples Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, England, United Kingdom; Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, England, United Kingdom; Department of Stroke and Neurology, Kings College Hospital NHS Foundation Trust, London, England, United Kingdom; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Wuhan Sixth Hospital, Jianghan University, Wuhan, China; Centre for Inflammation Research, Queens Medical Research Institute, University of Edinburgh, Scotland, United Kingdom; Centre for Medical Informatics, Usher Institute, University of Edinburgh, Scotland, United Kingdom; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Centre for Population Health Sciences, Usher Institute, University of Edinburgh, Scotland, United Kingdom","BackgroundAccurate risk prediction of clinical outcome would usefully inform clinical decisions and intervention targeting in COVID-19. The aim of this study was to derive and validate risk prediction models for poor outcome and death in adult inpatients with COVID-19.

MethodsModel derivation using data from Wuhan, China used logistic regression with death and poor outcome (death or severe disease) as outcomes. Predictors were demographic, comorbidity, symptom and laboratory test variables. The best performing models were externally validated in data from London, UK.

Findings4.3% of the derivation cohort (n=775) died and 9.7% had a poor outcome, compared to 34.1% and 42.9% of the validation cohort (n=226). In derivation, prediction models based on age, sex, neutrophil count, lymphocyte count, platelet count, C-reactive protein and creatinine had excellent discrimination (death c-index=0.91, poor outcome c-index=0.88), with good-to-excellent calibration. Using two cut-offs to define low, high and very-high risk groups, derivation patients were stratified in groups with observed death rates of 0.34%, 15.0% and 28.3% and poor outcome rates 0.63%, 8.9% and 58.5%. External validation discrimination was good (c-index death=0.74, poor outcome=0.72) as was calibration. However, observed rates of death were 16.5%, 42.9% and 58.4% and poor outcome 26.3%, 28.4% and 64.8% in predicted low, high and very-high risk groups.

InterpretationOur prediction model using demography and routinely-available laboratory tests performed very well in internal validation in the lower-risk derivation population, but less well in the much higher-risk external validation population. Further external validation is needed. Collaboration to create larger derivation datasets, and to rapidly externally validate all proposed prediction models in a range of populations is needed, before routine implementation of any risk prediction tool in clinical care.

FundingMRC, Wellcome Trust, HDR-UK, LifeArc, participating hospitals, NNSFC, National Key R&D Program, Pudong Health and Family Planning Commission

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSSeveral prognostic models for predicting mortality risk, progression to severe disease, or length of hospital stay in COVID-19 have been published.1 Commonly reported predictors of severe prognosis in patients with COVID-19 include age, sex, computed tomography scan features, C-reactive protein (CRP), lactic dehydrogenase, and lymphocyte count. Symptoms (notably dyspnoea) and comorbidities (e.g. chronic lung disease, cardiovascular disease and hypertension) are also reported to have associations with poor prognosis.2 However, most studies have not described the study population or intended use of prediction models, and external validation is rare and to date done using datasets originating from different Wuhan hospitals.3 Given different patterns of testing and organisation of healthcare pathways, external validation in datasets from other countries is required.

Added value of this studyThis study used data from Wuhan, China to derive and internally validate multivariable models to predict poor outcome and death in COVID-19 patients after hospital admission, with external validation using data from Kings College Hospital, London, UK. Mortality and poor outcome occurred in 4.3% and 9.7% of patients in Wuhan, compared to 34.1% and 42.9% of patients in London. Models based on age, sex and simple routinely available laboratory tests (lymphocyte count, neutrophil count, platelet count, CRP and creatinine) had good discrimination and calibration in internal validation, but performed only moderately well in external validation. Models based on age, sex, symptoms and comorbidity were adequate in internal validation for poor outcome (ICU admission or death) but had poor performance for death alone.

Implications of all the available evidenceThis study and others find that relatively simple risk prediction models using demographic, clinical and laboratory data perform well in internal validation but at best moderately in external validation, either because derivation and external validation populations are small (Xie et al3) and/or because they vary greatly in casemix and severity (our study). There are three decision points where risk prediction may be most useful: (1) deciding who to test; (2) deciding which patients in the community are at high-risk of poor outcomes; and (3) identifying patients at high-risk at the point of hospital admission. Larger studies focusing on particular decision points, with rapid external validation in multiple datasets are needed. A key gap is risk prediction tools for use in community triage (decisions to admit, or to keep at home with varying intensities of follow-up including telemonitoring) or in low income settings where laboratory tests may not be routinely available at the point of decision-making. This requires systematic data collection in community and low-income settings to derive and evaluate appropriate models.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.04.27.20081810,2020-05-03,https://medrxiv.org/cgi/content/short/2020.04.27.20081810,Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics,Christoph B. Messner; Vadim Demichev; Daniel Wendisch; Laura Michalick; Matthew White; Anja Freiwald; Kathrin Textoris-Taube; Spyros I. Vernardis; Anna-Sophia Egger; Marco Kreidl; Daniela Ludwig; Christiane Kilian; Federica Agostini; Aleksej Zelezniak; Charlotte Thibeault; Moritz Pfeiffer; Stefan Hippenstiel; Andreas Hocke; Christof von Kalle; Archie Campbell; Caroline Hayward; David J. Porteous; Riccardo E. Marioni; Claudia Langenberg; Kathryn S. Lilley; Wolfgang M. Kuebler; Michael Muelleder; Christian Drosten; Martin Witzenrath; Florian Kurth; Leif Erik Sander; Markus Ralser,"The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, United Kingdom; The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, United Kingdom; Charite Universitaetsmedizin, Berlin, Dept. of Infectious Diseases and Respiratory Medicine, 10117 Berlin, Germany; Charite Universitaetsmedizin, Institute of Physiology, 10117 Berlin, Germany; The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, United Kingdom; Charite Universitaetsmedizin, Core Facility - High Throughput Mass Spectrometry, 10117 Berlin, German; Charite Universitaetsmedizin, Core Facility - High Throughput Mass Spectrometry, 10117 Berlin, Germany; The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, United Kingdom; The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, United Kingdom; The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, London NW11AT, United Kingdom; Charite Universitaetsmedizin, Department of Biochemistry, 10117 Berlin, Germany; Charite Universitaetsmedizin, Department of Biochemistry, 10117 Berlin, Germany; Charite Universitaetsmedizin, Department of Biochemistry, 10117 Berlin, Germany; Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg SE-412 96, Sweden; Charite Universitaetsmedizin, Berlin, Dept. of Infectious Diseases and Respiratory Medicine, 10117 Berlin, Germany; Charite Universitaetsmedizin, Berlin, Dept. of Infectious Diseases and Respiratory Medicine, 10117 Berlin, Germany; Charite Universitaetsmedizin, Berlin, Dept. of Infectious Diseases and Respiratory Medicine, 10117 Berlin, Germany; Charite Universitaetsmedizin, Berlin, Dept. of Infectious Diseases and Respiratory Medicine, 10117 Berlin, Germany; Berlin Institute of Health (BIH), and  Charite Universitaetsmedizin, Clinical Study Center (CSC), 10117 Berlin, Germany; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh United Kingdom and Usher Institute, Universi; MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, United Kingdom; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh EH4 2XU, United Kingdom; Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh EH4 2XU, United Kingdom; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, United Kingdom; Department of Biochemistry, The University of Cambridge, Cambridge, CB21GA, United Kingdom; Charite Universitaetsmedizin, Berlin, Institute of Physiology, 10117 Berlin, Germany; Charite Universitaetsmedizin, Core Facility - High Throughput Mass Spectrometry, 10117 Berlin, Germany; Charite Universitaetsmedizin, Berlin, Department of Virology, 10117 Berlin, Germany; Charite Universitaetsmedizin, Berlin, Dept. of Infectious Diseases and Respiratory Medicine, 10117 Berlin, Germany; Charite Universitaetsmedizin, Berlin, Dept. of Infectious Diseases and Respiratory Medicine, 10117 Berlin, Germany and Department of Tropical Medicine, Bernhard; Charite Universitaetsmedizin, Berlin, Dept. of Infectious Diseases and Respiratory Medicine, 10117 Berlin, Germany; Charite Universitaetsmedizin, Berlin, Department of Biochemistry, 10117 Berlin, and The Francis Crick Institute, Molecular Biology of Metabolism Laboratory, Lon","The COVID-19 pandemic is an unprecedented global challenge. Highly variable in its presentation, spread and clinical outcome, novel point-of-care diagnostic classifiers are urgently required. Here, we describe a set of COVID-19 clinical classifiers discovered using a newly designed low-cost high-throughput mass spectrometry-based platform. Introducing a new sample preparation pipeline coupled with short-gradient high-flow liquid chromatography and mass spectrometry, our methodology facilitates clinical implementation and increases sample throughput and quantification precision. Providing a rapid assessment of serum or plasma samples at scale, we report 27 biomarkers that distinguish mild and severe forms of COVID-19, of which some may have potential as therapeutic targets. These proteins highlight the role of complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling upstream and downstream of Interleukin 6. Application of novel methodologies hence transforms proteomics from a research tool into a rapid-response, clinically actionable technology adaptable to infectious outbreaks.

Highlights- A completely redesigned clinical proteomics platform increases throughput and precision while reducing costs.
- 27 biomarkers are differentially expressed between WHO severity grades for COVID-19.
- The study highlights potential therapeutic targets that include complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling both upstream and downstream of interleukin 6.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.04.27.20081711,2020-05-03,https://medrxiv.org/cgi/content/short/2020.04.27.20081711,Response strategies for COVID-19 epidemics in African settings: a mathematical modelling study,Kevin van Zandvoort; Christopher I Jarvis; Carl Pearson; Nicholas G Davies; CMMID COVID-19 working group; Timothy W Russell; Adam J Kucharski; Mark J Jit; Stefan Flasche; Rosalind M Eggo; Francesco Checchi,London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; ; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; LSHTM; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,"BackgroundThe health impact of COVID-19 may differ in African settings as compared to countries in Europe or China due to demographic, epidemiological, environmental and socio-economic factors. We evaluated strategies to reduce SARS-CoV-2 burden in African countries, so as to support decisions that balance minimising mortality, protecting health services and safeguarding livelihoods.

MethodsWe used a Susceptible-Exposed-Infectious-Recovered mathematical model, stratified by age, to predict the evolution of COVID-19 epidemics in three countries representing a range of age distributions in Africa (from oldest to youngest average age: Mauritius, Nigeria and Niger), under various effectiveness assumptions for combinations of different non-pharmaceutical interventions: self-isolation of symptomatic people, physical distancing, and  shielding (physical isolation) of the high-risk population. We adapted model parameters to better represent uncertainty about what might be expected in African populations, in particular by shifting the distribution of severity risk towards younger ages and increasing the case-fatality ratio.

ResultsWe predicted median clinical attack rates over the first 12 months of 17% (Niger) to 39% (Mauritius), peaking at 2-4 months, if epidemics were unmitigated. Self-isolation while symptomatic had a maximum impact of about 30% on reducing severe cases, while the impact of physical distancing varied widely depending on percent contact reduction and R0. The effect of shielding high-risk people, e.g. by rehousing them in physical isolation, was sensitive mainly to residual contact with low-risk people, and to a lesser extent to contact among shielded individuals. Response strategies incorporating self-isolation of symptomatic individuals, moderate physical distancing and high uptake of shielding reduced predicted peak bed demand by 46% to 54% and mortality by 60% to 75%. Lockdowns delayed epidemics by about 3 months. Estimates were sensitive to differences in age-specific social mixing patterns, as published in the literature.

DiscussionIn African settings, as elsewhere, current evidence suggests large COVID-19 epidemics are expected. However, African countries have fewer means to suppress transmission and manage cases. We found that self-isolation of symptomatic persons and general physical distancing are unlikely to avert very large epidemics, unless distancing takes the form of stringent lockdown measures. However, both interventions help to mitigate the epidemic. Shielding of high-risk individuals can reduce health service demand and, even more markedly, mortality if it features high uptake and low contact of shielded and unshielded people, with no increase in contact among shielded people. Strategies combining self-isolation, moderate physical distancing and shielding will probably achieve substantial reductions in mortality in African countries. Temporary lockdowns, where socioeconomically acceptable, can help gain crucial time for planning and expanding health service capacity.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.04.28.20083295,2020-05-02,https://medrxiv.org/cgi/content/short/2020.04.28.20083295,Modifiable and non-modifiable risk factors for COVID-19: results from UK Biobank,Frederick K Ho; Carlos A Celis-Morales; Stuart R Gray; Srinivasa Vittal Katikireddi; Claire L Niedzwiedz; Claire Hastie; Donald M. Lyall; Lyn D. Ferguson; Colin Berry; Daniel F. Mackay; Jason M.R. Gill; Jill P. Pell; Naveed Sattar; Paul I Welsh,University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University Of Glasgow,"BackgroundInformation on risk factors for COVID-19 is sub-optimal. We investigated demographic, lifestyle, socioeconomic, and clinical risk factors, and compared them to risk factors for pneumonia and influenza in UK Biobank.

MethodsUK Biobank recruited 37-70 year olds in 2006-2010 from the general population. The outcome of confirmed COVID-19 infection (positive SARS-CoV-2 test) was linked to baseline UK Biobank data. Incident influenza and pneumonia were obtained from primary care data. Poisson regression was used to study the association of exposure variables with outcomes.

FindingsAmong 428,225 participants, 340 had confirmed COVID-19. After multivariable adjustment, modifiable risk factors were higher body mass index (RR 1.24 per SD increase), smoking (RR 1.38), slow walking pace as a proxy for physical fitness (RR 1.66) and use of blood pressure medications as a proxy for hypertension (RR 1.40). Non-modifiable risk factors included older age (RR 1.10 per 5 years), male sex (RR 1.64), black ethnicity (RR 1.86), socioeconomic deprivation (RR 1.26 per SD increase in Townsend Index), longstanding illness (RR 1.38) and high cystatin C (RR 1.24 per 1 SD increase). The risk factors overlapped with pneumonia somewhat; less so for influenza. The associations with modifiable risk factors were generally stronger for COVID-19, than pneumonia or influenza.

InterpretationThese findings suggest that modification of lifestyle may help to reduce the risk of COVID-19 and could be a useful adjunct to other interventions, such as social distancing and shielding of high risk.

FundingBritish Heart Foundation, Medical Research Council, Chief Scientist Office.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.04.24.20078006,2020-04-29,https://medrxiv.org/cgi/content/short/2020.04.24.20078006,Supplementing the National Early Warning Score (NEWS2) for anticipating early deterioration among patients with COVID-19 infection,Ewan Carr; Rebecca Bendayan; Daniel Bean; Matthew Stammers; Wenjuan Wang; Huayu Zhang; Thomas Searle; Zeljko Kraljevic; Anthony Shek; Hang T T Phan; Walter Muruet; Rishi K Gupta; Anthony J Shinton; Mike Wyatt; Ting Shi; Xin Zhang; Andrew Pickles; Daniel Stahl; Rosita Zakeri; Mahdad Noursadeghi; Kevin O'Gallagher; Matt Rogers; Amos Folarin; Christopher Bourdeaux; Chris McWilliams; Lukasz Roguski; Florina Borca; James Batchelor; Xiaodong Wu; Jiaxing Sun; Ashwin Pinto; Bruce Guthrie; Cormac Breen; Abdel Douiri; Honghan Wu; Vasa Curcin; James T Teo; Ajay Shah; Richard Dobson,"King's College London; King's College London; King's College London; Clinical Informatics Research Unit, University of Southampton; King's College London; University of Edinburgh; King's College London; King's College London; King's College London; Clinical Informatics Research Unit, University of Southampton; King's College London; University College London; UHS Digital, University Hospital Southampton; University Hospitals Bristol NHS Foundation Trust, Bristol, UK; Usher Institute, University of Edinburgh; Department of Pulmonary and Critical Care Medicine, People's Liberation Army Joint Logistic Support Force 920th Hospital, Yunnan, China; King's College London; King's College London; King's College London; UCL Division of Infection and Immunity, University College London Hospitals NHS Trust; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; King's College London; University Hospitals Bristol NHS Foundation Trust, Bristol, U.K.; Department of Engineering Mathematics, University of Bristol, Bristol, UK; University College London; University of Southampton; Clinical Informatics Research Unit, University of Southampton, Coxford Rd, Southampton SO16 5AF; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; Department of Pulmonary and Critical Care Medicine, Shanghai East Hospital, Tongji University, Shanghai, China; UHS Digital, University Hospital Southampton; Usher Institute, University of Edinburgh; King's College London; King's College London; University College London; King's College London; Kings College Hospital NHS Foundation Trust; King's College London; Kings College London","BackgroundThe National Early Warning Score (NEWS2) is currently recommended in the United Kingdom for risk stratification of COVID outcomes, but little is known about its ability to detect severe cases. We aimed to evaluate NEWS2 for severe COVID outcome and identify and validate a set of routinely-collected blood and physiological parameters taken at hospital admission to improve the score.

MethodsTraining cohorts comprised 1276 patients admitted to Kings College Hospital NHS Foundation Trust with COVID-19 disease from 1st March to 30th April 2020. External validation cohorts included 5037 patients from four UK NHS Trusts (Guys and St Thomas Hospitals, University Hospitals Southampton, University Hospitals Bristol and Weston NHS Foundation Trust, University College London Hospitals), and two hospitals in Wuhan, China (Wuhan Sixth Hospital and Taikang Tongji Hospital). The outcome was severe COVID disease (transfer to intensive care unit or death) at 14 days after hospital admission. Age, physiological measures, blood biomarkers, sex, ethnicity and comorbidities (hypertension, diabetes, cardiovascular, respiratory and kidney diseases) measured at hospital admission were considered in the models.

ResultsA baseline model of  NEWS2 + age had poor-to-moderate discrimination for severe COVID infection at 14 days (AUC in training sample = 0.700; 95% CI: 0.680, 0.722; Brier score = 0.192; 95% CI: 0.186, 0.197). A supplemented model adding eight routinely-collected blood and physiological parameters (supplemental oxygen flow rate, urea, age, oxygen saturation, CRP, estimated GFR, neutrophil count, neutrophil/lymphocyte ratio) improved discrimination (AUC = 0.735; 95% CI: 0.715, 0.757) and these improvements were replicated across five UK and non-UK sites. However, there was evidence of miscalibration with the model tending to underestimate risks in most sites.

ConclusionsNEWS2 score had poor-to-moderate discrimination for medium-term COVID outcome which raises questions about its use as a screening tool at hospital admission. Risk stratification was improved by including readily available blood and physiological parameters measured at hospital admission, but there was evidence of miscalibration in external sites. This highlights the need for a better understanding of the use of early warning scores for COVID.

KO_SCPLOWEYC_SCPLOWO_SCPCAP C_SCPCAPO_SCPLOWMESSAGESC_SCPLOWO_LIThe National Early Warning Score (NEWS2), currently recommended for stratification of severe COVID-19 disease in the UK, showed poor-to-moderate discrimination for medium-term outcomes (14-day transfer to ICU or death) among COVID-19 patients.
C_LIO_LIRisk stratification was improved by the addition of routinely-measured blood and physiological parameters routinely at hospital admission (supplemental oxygen, urea, oxygen saturation, CRP, estimated GFR, neutrophil count, neutrophil/lymphocyte ratio) which provided moderate improvements in a risk stratification model for 14-day ICU/death.
C_LIO_LIThis improvement over NEWS2 alone was maintained across multiple hospital trusts but the model tended to be miscalibrated with risks of severe outcomes underestimated in most sites.
C_LIO_LIWe benefited from existing pipelines for informatics at KCH such as CogStack that allowed rapid extraction and processing of electronic health records. This methodological approach provided rapid insights and allowed us to overcome the complications associated with slow data centralisation approaches.
C_LI",infectious diseases,fuzzy,100,100
bioRxiv,10.1101/2020.04.28.066977,2020-04-29,https://biorxiv.org/cgi/content/short/2020.04.28.066977,"Controlling the SARS-CoV-2 outbreak, insights from large scale whole genome sequences generated across the world",Jody Phelan; Wouter Deelder; Daniel Ward; Susana Campino; Martin L Hibberd; Taane G Clark,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine,"BackgroundSARS-CoV-2 most likely evolved from a bat beta-coronavirus and started infecting humans in December 2019. Since then it has rapidly infected people around the world, with more than 4.5 million confirmed cases by the middle of May 2020. Early genome sequencing of the virus has enabled the development of molecular diagnostics and the commencement of therapy and vaccine development. The analysis of the early sequences showed relatively few evolutionary selection pressures. However, with the rapid worldwide expansion into diverse human populations, significant genetic variations are becoming increasingly likely. The current limitations on social movement between countries also offers the opportunity for these viral variants to become distinct strains with potential implications for diagnostics, therapies and vaccines.

MethodsWe used the current sequencing archives (NCBI and GISAID) to investigate 15,487 whole genomes, looking for evidence of strain diversification and selective pressure.

ResultsWe used 6,294 SNPs to build a phylogenetic tree of SARS-CoV-2 diversity and noted strong evidence for the existence of two major clades and six sub-clades, unevenly distributed across the world. We also noted that convergent evolution has potentially occurred across several locations in the genome, showing selection pressures, including on the spike glycoprotein where we noted a potentially critical mutation that could affect its binding to the ACE2 receptor. We also report on mutations that could prevent current molecular diagnostics from detecting some of the sub-clades.

ConclusionThe worldwide whole genome sequencing effort is revealing the challenge of developing SARS-CoV-2 containment tools suitable for everyone and the need for data to be continually evaluated to ensure accuracy in outbreak estimations.",genomics,fuzzy,100,100
medRxiv,10.1101/2020.04.23.20076521,2020-04-27,https://medrxiv.org/cgi/content/short/2020.04.23.20076521,"Geo-social gradients in predicted COVID-19 prevalence and severity in Great Britain: results from 2,266,235 users of the COVID-19 Symptoms Tracker app",Ruth Bowyer; Thomas Varsavsky; Carole H Sudre; Benjamin Murray; Maxim Freidin; Darioush Yarand; Sajaysurya Ganesh; Joan Capdevila; Ellen J Thompson; Elco Bakker; M Jorge Cardoso; Richard Davies; Jonathan Wolf; Tim D Spector; Sebastien Ourselin; Claire J Steves; Cristina Menni,King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Global Limited; Zoe Global Limited; King's College London; Zoe Global Limited; King's College London; King's College London; Zoe Global Limited; King's College London; King's College London; King's College London; King's College London,"Understanding the geographical distribution of COVID-19 through the general population is key to the provision of adequate healthcare services. Using self-reported data from 2,266,235 unique GB users of the COVID Symptom Tracker app, we find that COVID-19 prevalence and severity became rapidly distributed across the UK within a month of the WHO declaration of the pandemic, with significant evidence of ""urban hot-spots"". We found a geo-social gradient associated with disease severity and prevalence suggesting resources should focus on urban areas and areas of higher deprivation. Our results demonstrate use of self-reported data to inform public health policy and resource allocation.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.04.22.20075663,2020-04-27,https://medrxiv.org/cgi/content/short/2020.04.22.20075663,Ethnic and socioeconomic differences in SARS-CoV2 infection in the UK Biobank cohort study,Claire L Niedzwiedz; Bhautesh D Jani; Evangelia Demou; Frederick K Ho; Carlos Celis-Morales; Barbara I Nicholl; Frances Mair; Paul Welsh; Naveed Sattar; Jill Pell; Srinivasa Vittal Katikireddi,University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow; University Of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow,"BackgroundUnderstanding of the role of ethnicity and socioeconomic position in the risk of developing SARS-CoV-2 infection is limited. We investigated this in the UK Biobank study.

MethodsThe UK Biobank study recruited 40-70 year olds in 2006-2010 from the general population, collecting information about self-defined ethnicity and socioeconomic variables (including area-level socioeconomic deprivation and educational attainment). SARS-CoV-2 test results from Public Health England were linked to baseline UK Biobank data. Poisson regression with robust standard errors was used to assess risk ratios (RRs) between the exposures and dichotomous variables for: being tested, having a positive test and testing positive in hospital. We also investigated whether ethnicity and socioeconomic position were associated with having a positive test amongst those tested. We adjusted for covariates including age, sex, social variables (including healthcare work and household size), behavioural risk factors and baseline health.

ResultsAmong 428,225 participants in England, 1,474 had been tested and 669 tested positive between 16 March and 13 April 2020. Black, south Asian and white Irish people were more likely to have confirmed infection (RR 4.01 (95%CI 2.92-5.12); RR 2.11 (95%CI 1.43-3.10); and RR 1.60 (95% CI 1.08-2.38) respectively) and were more likely to be hospital cases compared to the White British. While they were more likely to be tested, they were also more likely to test positive. Adjustment for baseline health and behavioural risk factors led to little change, with only modest attenuation when accounting for socioeconomic variables. Socioeconomic deprivation and having no qualifications were consistently associated with a higher risk of confirmed infection (RR 2.26 (95%CI 1.76-2.90); and RR 1.91 (95%CI 1.53-2.38) respectively).

ConclusionsSome minority ethnic groups have a higher risk of confirmed SARS-CoV-2 infection in the UK Biobank study which was not accounted for by differences in socioeconomic conditions, measured baseline health or behavioural risk factors. An urgent response to addressing these elevated risks is required.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.04.21.20073049,2020-04-24,https://medrxiv.org/cgi/content/short/2020.04.21.20073049,What can trends in hospital deaths from COVID-19 tell us about the progress and peak of the pandemic? An analysis of death counts from England announced up to 20 April 2020,David A Leon; Christopher I Jarvis; Anne M Johnson; Liam Smeeth; Vladimir M Shkolnikov,London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; University College London; London School of Hygiene & Tropical Medicine; Max Planck Institute for Demographic Research,"BackgroundReporting of daily hospital COVID-19 deaths in the UK are promoted by the government and scientific advisers alike as a key metric for assessing the progress in the control of the epidemic. These data, however, have certain limitations, among which one of the most significant concerns the fact that the daily totals span deaths that have occurred between 1 and 10 days or more in the past.

Data and methodsWe obtained daily data published published by NHS England up to and including April 25 in the form of Excel spreadsheets in which deaths counts are presented by date of death according to age and region. Simple descriptive analyses were conducted and presented in graphical and tabular form which were aimed at illustrating the biases inherent in focussing on daily counts regardless of when the deaths occurred. We then looked at how a less biased picture could be obtained by looking at trends in death counts stratifying by individual period of delay in days between occurrence of death and when the death was included in the daily announcement.

FindingsThe number of hospital COVID-19 deaths announced daily overestimates the maximum number of deaths actually occurring so far in the epidemic in the UK, and also obscures the pattern of decline in deaths. Taking account of reporting delays suggests that for England as a whole a peak in hospital COVID-19 deaths may have been reached on April 8 with a subsequent gradual decline suggested. The same peak is also seen among those aged 60-79 and 80+, although there is slightly shallower decline in the oldest age group (80+ years). Among those aged 40-59 years a later peak on April 11 is evident. London shows a peak on April 8 and a clearer and steeper pattern of subsequent decline compared to England as a whole.

InterpretationAnalyses of mortality trends must take account of delay, and in communication with the public more emphasis should be placed on looking at trends based on deaths that occurred 5 or more days prior to the announcement day. The slightly weaker decline seen at age 80+ may reflect increased hospitalisation of people from care homes, whereas the later peak under the age of 60 years may reflect the higher proportions at these younger ages being admitted to critical care resulting in an extension of life of several days.

Competing interestsAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years other than LS who reported grants from Wellcome, MRC, NIHR, GSK, BHF, Diabetes UK all outside the submitted work; no other relationships or activities that could appear to have influenced the submitted work other than LS who is a Trustee of the British Heart Foundation and AJM who is a member of the Royal Society Delve Committee.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.04.18.20064774,2020-04-22,https://medrxiv.org/cgi/content/short/2020.04.18.20064774,"How many are at increased risk of severe COVID-19 disease? Rapid global, regional and national estimates for 2020",Andrew Clark; Mark Jit; Charlotte Warren-Gash; Bruce Guthrie; Harry HX Wang; Stewart W Mercer; Colin Sanderson; Martin McKee; Christopher Troeger; Kanyin I Ong; Francesco Checchi; Pablo Perel; Sarah Joseph; Hamish P Gibbs; Amitava Banerjee; LSHTM CMMID COVID-19 working group; Rosalind M Eggo,LSHTM; London School of Hygiene & Tropical Medicine; LSHTM; Edinburgh University; Sun Yat-Sen University; Edinburgh University; LSHTM; LSHTM; University of Washington; University of Washington; LSHTM; LSHTM; IAVI; LSHTM; UCL; ; London School of Hygiene & Tropical Medicine,"BackgroundThe risk of severe COVID-19 disease is known to be higher in older individuals and those with underlying health conditions. Understanding the number of individuals at increased risk of severe COVID-19 illness, and how this varies between countries may inform the design of possible strategies to shield those at highest risk.

MethodsWe estimated the number of individuals at increased risk of severe COVID-19 disease by age (5-year age groups), sex and country (n=188) based on prevalence data from the Global Burden of Disease (GBD) study for 2017 and United Nations population estimates for 2020. We also calculated the number of individuals without an underlying condition that could be considered at-risk because of their age, using thresholds from 50-70 years. The list of underlying conditions relevant to COVID-19 disease was determined by mapping conditions listed in GBD to the guidelines published by WHO and public health agencies in the UK and US. We analysed data from two large multimorbidity studies to determine appropriate adjustment factors for clustering and multimorbidity.

ResultsWe estimate that 1.7 (1.0 - 2.4) billion individuals (22% [15-28%] of the global population) are at increased risk of severe COVID-19 disease. The share of the population at increased risk ranges from 16% in Africa to 31% in Europe. Chronic kidney disease (CKD), cardiovascular disease (CVD), diabetes and chronic respiratory disease (CRD) were the most prevalent conditions in males and females aged 50+ years. African countries with a high prevalence of HIV/AIDS and Island countries with a high prevalence of diabetes, also had a high share of the population at increased risk. The prevalence of multimorbidity (>1 underlying conditions) was three times higher in Europe than in Africa (10% vs 3%).

ConclusionBased on current guidelines and prevalence data from GBD, we estimate that one in five individuals worldwide has a condition that is on the list of those at increased risk of severe COVID-19 disease. However, for many of these individuals the underlying condition will be undiagnosed or not severe enough to be captured in health systems, and in some cases the increase in risk may be quite modest. There is an urgent need for robust analyses of the risks associated with different underlying conditions so that countries can identify the highest risk groups and develop targeted shielding policies to mitigate the effects of the COVID-19 pandemic.

Research in contextO_ST_ABSEvidence before this studyC_ST_ABSAs the COVID-19 pandemic evolves, countries are considering policies of  shielding the most vulnerable, but there is currently very limited evidence on the number of individuals that might need to be shielded. Guidelines on who is currently believed to be at increased risk of severe COVID-19 illness have been published online by the WHO and public health agencies in the UK and US. We searched PubMed (""Risk factors"" AND ""COVID-19"") without language restrictions, from database inception until April 5, 2020, and identified 62 studies published between Feb 15, 2020 and March 20, 2020. Evidence from China, Italy and the USA indicates that older individuals, males and those with underlying conditions, such as CVD, diabetes and CRD, are at greater risk of severe COVID-19 illness and death.

Added value of this studyThis study combines evidence from large international databases and new analysis of large multimorbidity studies to inform policymakers about the number of individuals that may be at increased risk of severe COVID-19 illness in different countries. We developed a tool for rapid assessments of the number and percentage of country populations that would need to be targeted under different shielding policies.

Implications of all the available evidenceQuantifying how many and who is at increased risk of severe COVID-19 illness is critical to help countries design more effective interventions to protect vulnerable individuals and reduce pressure on health systems. This information can also inform a broader assessment of the health, social and economic implications of shielding various groups.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.04.19.20071639,2020-04-22,https://medrxiv.org/cgi/content/short/2020.04.19.20071639,How best to use limited tests? Improving COVID-19 surveillance in long-term care,David RM Smith; Audrey Duval; Koen B Pouwels; Didier Guillemot; Jerome Fernandes; Bich-Tram Huynh; Laura Temime; Lulla Opatowski,"Institut Pasteur; Institut Pasteur; University of Oxford; Institut Pasteur; Clinique de soins de suite et readaptation, Choisy-Le-Roi; Institut Pasteur; Conservatoire national des arts et metiers; Institut Pasteur","BackgroundLong-term care facilities (LTCFs) are vulnerable to COVID-19 outbreaks. Timely epidemiological surveillance is essential for outbreak response, but is complicated by a high proportion of silent (non-symptomatic) infections and limited testing resources.

MethodsWe used a stochastic, individual-based model to simulate SARS-CoV-2 transmission along detailed inter-individual contact networks describing patient-staff interactions in real LTCF settings. We distributed nasopharyngeal swabs and RT-PCR tests using clinical and demographic indications, and evaluated the efficacy and resource-efficiency of a range of surveillance strategies, including group testing (sample pooling) and testing cascades, which couple (i) testing for multiple indications (symptoms, admission) with (ii) random daily testing.

ResultsIn the baseline scenario, randomly introducing SARS-CoV-2 into a 170-bed LTCF led to large outbreaks, with a cumulative 86 (6-224) infections after three weeks of unmitigated transmission. Efficacy of symptom-based screening was limited by (i) lags between infection and symptom onset, and (ii) silent transmission from asymptomatic and pre-symptomatic infections. Testing upon admission detected up to 66% of patients silently infected upon LTCF entry, but missed potential introductions from staff. Random daily testing was more effective when targeting patients than staff, but was overall an inefficient use of limited resources. At high testing capacity (>1 test/10 beds/day), cascades were most effective, with a 22-52% probability of detecting outbreaks prior to any nosocomial transmission, and 38-63% prior to first onset of COVID-19 symptoms. Conversely, at low capacity (<1 test/85 beds/day), pooling randomly selected patients in a daily group test was most effective (9-15% probability of detecting outbreaks prior to transmission; 30-44% prior to symptoms). The most efficient strategy compared to the reference was to pool individuals with any COVID-like symptoms, requiring only 5-7 additional tests and 17-24 additional swabs to detect outbreaks 5-6 days earlier, prior to an additional 14-18 infections.

ConclusionsGroup testing is an effective and efficient COVID-19 surveillance strategy for resource-limited LTCFs. Cascades are even more effective given ample testing resources. Increasing testing capacity and updating surveillance protocols accordingly could facilitate earlier detection of emerging outbreaks, informing a need for urgent intervention in settings with ongoing nosocomial transmission.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.04.16.20067504,2020-04-21,https://medrxiv.org/cgi/content/short/2020.04.16.20067504,"The effect of inter-city travel restrictions on geographical spread of COVID-19: Evidence from Wuhan, China",Billy J Quilty; Charlie Diamond; Yang Liu; Hamish Gibbs; Timothy W Russell; Christopher I Jarvis; Kiesha Prem; Carl A B Pearson; Samuel J Clifford; Stefan Flasche; CMMID COVID-19 working group; Petra Klepac; Rosalind M Eggo; Mark Jit,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; ; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine,"BackgroundTo contain the spread of COVID-19, a cordon sanitaire was put in place in Wuhan prior to the Lunar New Year, on 23 January 2020, restricting travel to other parts of China. We assess the efficacy of the cordon sanitaire to delay the introduction and onset of local transmission of COVID-19 in other major cities in mainland China.

MethodsWe estimated the number of infected travellers from Wuhan to other major cities in mainland China from November 2019 to March 2020 using previously estimated COVID-19 prevalence in Wuhan and publicly available mobility data. We focused on Beijing, Chongqing, Hangzhou, and Shenzhen as four representative major cities to identify the potential independent contribution of the cordon sanitaire and holiday travel. To do this, we simulated outbreaks generated by infected arrivals in these destination cities using stochastic branching processes. We also modelled the effect of the cordon sanitaire in combination with reduced transmissibility scenarios representing the effect of local non-pharmaceutical interventions.

FindingsIn the four cities, given the potentially high prevalence of COVID-19 in Wuhan between Dec 2019 and early Jan 2020, local transmission may have been seeded as early as 2 - 8 January 2020. By the time the cordon sanitaire was imposed, simulated case counts were likely in the hundreds. The cordon sanitaire alone did not substantially affect the epidemic progression in these cities, although it may have had some effect in smaller cities.

InterpretationOur results indicate that the cordon sanitaire may not have prevented COVID-19 spread in major Chinese cities; local non-pharmaceutical interventions were likely more important for this.

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSIn late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in Wuhan, China. In response to the outbreak, authorities enacted a cordon sanitaire in order to limit spread. Several studies have sought to determine the efficacy of the policy; a search of PubMed for ""coronavirus AND (travel restrictions OR travel ban OR shutdown OR cordon sanitaire) AND (Wuhan OR China)"" returned 24 results. However other studies have relied on reported cases to determine efficacy, which are likely subject to reporting and testing biases. Early outbreak dynamics are also subject to a significant degree of stochastic uncertainty due to small numbers of cases.

Added value of this studyHere we use publicly-available mobility data and a stochastic branching process model to evaluate the efficacy of the cordon sanitaire to limiting the spread of COVID-19 from Wuhan to other cities in mainland China, while accounting for underreporting and uncertainty. We find that although travel restrictions led to a significant decrease in the number of individuals leaving Wuhan during the busy post-Lunar New Year holiday travel period, local transmission was likely already established in major cities. Thus, the travel restrictions likely did not affect the epidemic trajectory substantially in these cities.

Implications of all the available evidenceA cordon sanitaire around the epicentre alone may not be able to reduce COVID-19 incidence when implemented after local transmission has occurred in highly connected neighbors. Local non-pharmaceutical interventions to reduce transmissibility (e.g., school and workplace closures) may have contributed more to the observed decrease in incidence in mainland China.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.04.15.20066407,2020-04-20,https://medrxiv.org/cgi/content/short/2020.04.15.20066407,Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays,Emily R Adams; Mark Ainsworth; Rekha Anand; Monique I Andersson; Kathryn Auckland; J Kenneth Baillie; Eleanor Barnes; Sally Beer; John Bell; Tamsin Berry; Sagida Bibi; Miles Carroll; Senthil Chinnakannan; Elizabeth Clutterbuck; Richard J Cornall; Derrick W Crook; Thushan De Silva; Wanwisa Dejnirattisai; Kate E Dingle; Christina Dold; Alexis Espinosa; David W Eyre; Helen Farmer; Maria Fernandez Mendoza; Dominique Georgiou; Sarah J Hoosdally; Alistair Hunter; Katie Jeffrey; Paul Klenerman; Julian Knight; Clarice Knowles; Andrew J Kwok; Ullrich Leuschner; Robert Levin; Chang Liu; Cesar Lopez-Camacho; Jose Carlos Martinez Garrido; Philippa C Matthews; Hannah McGivern; Alexander J Mentzer; Jonathan Milton; Juthathip Mongkolsapaya; Shona C Moore; Marta S Oliveira; Fiona Pereira; Elena Perez Lopez; Timothy Peto; Rutger J Ploeg; Andrew Pollard; Tessa Prince; David J Roberts; Justine K Rudkin; Veronica Sanchez; Gavin R Screaton; Malcolm G Semple; Donal T Skelly; Jose Slon-Campos; Elliot Nathan Smith; Alberto Jose Sobrino Diaz; Julie Staves; David Stuart; Piyada Supasa; Tomas Surik; Hannah Thraves; Pat Tsang; Lance Turtle; A Sarah Walker; Beibei Wang; Charlotte Washington; Nicholas Watkins; James Whitehouse,"Liverpool School of Tropical Medicine; Oxford University Hospitals NHS Foundation Trust; NHSBT Birmingham,; Department of Microbiology, Oxford University Hospital NHS Foundation Trust; The Wellcome Centre for Human Genetics, University of Oxford; Roslin Institute, University of Edinburgh; Nuffield Department of Medicine, University of Oxford; Oxford University Hospitals NHS Foundation Trust; Department of Medicine, University of Oxford; Department of Health and Social Care, University of Oxford; Oxford Vaccine group, Department of Pediatrics, University of Oxford; Nuffield Department of Medicine, Centre of Tropical Medicine and Global Health and Public Health England; Nuffield Department of Medicine, University of Oxford; Oxford Vaccine Group, Department of Paediatrics, University of Oxford; Nuffield Department of Medicine, University of Oxford; NIHR Oxford Biomedical Research Centre; Department of Infection, Immunity and Cardiovascular, Disease, The Medical School, University of Sheffield; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford; NIHR Oxford Biomedical Research Centre, University of Oxford; Oxford Vaccine Group, Department of Paediatrics, University of Oxford; Oxford University Hospitals NHS Foundation Trust; Big Data Institute, University of Oxford; Department of Health and Social Care, University of Oxford; Oxford University Hospitals NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust; Nuffield Department of Medicine, University of Oxford; NHSBT Basildon; Department of Clinical Medicine, Oxford University Hospitals NHS Foundation Trusts; Nuffield Department so Medicine, University of Oxford; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford; Department of Health and Social Care, University of Oxford; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford; NHSBT Oxford; Worthing Hospital, Worthing, West Sussex; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford; Wellcome Centre of Genetics, Nuffield Department of Medicine, University of Oxford; Oxford University Hospitals NHS Foundation Trust; Nuffield Department of Medicine, University of Medicine; Nuffield Department of Surgical Sciences, University of Oxford and UK QUOD Consortium; Wellcome Centre for Human Genetics, University of Oxford; Nuffield Department of Surgical Sciences, University of Oxford and UK QUOD Consortium; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool; Nuffield Department of Surgical Sciences,  University of Oxford and UK QUOD Consortium; Imperial College London; Oxford University Hospitals NHS Foundation Trust; NIHR Oxford Biomedical Research centre, University of Oxford; Nuffield Department of Surgical Sciences, University of Oxford and UK QUOD Consortium; Department of Paediatrics, University of Oxford; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool; NHSBT Oxford; Nuffield Department of Population Health & Big Data Institute, University of Oxford; Oxford University Hospitals NHS Foundation Trust; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford; Health Protection Unit In Emerging and Zoonotic Infection, University of Liverpool; Nuffield Department of Clinical Neurosciences, University of Oxford; University of Oxford; Department of Health and Social Care, University of Oxford; Oxford University Hospitals NHS Foundation Trust; Oxford University Hospitals,; Wellcome Centre for Human Genetics, Nuffield Department of Medicine; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford; Nuffield Department of Surgical Sciences, University of Oxford and UK QUOD Consortium; Oxford University Hospitals NHS Foundation Trust; NHSBT Oxford; NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, University of Liverpool; Nuffield Department of Medicine, University of Oxford; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford; NHSBT, Birmingham; NHSBT, Cambridge; Department of Health and Social Care, University of Oxford","BackgroundThe COVID-19 pandemic caused >1 million infections during January-March 2020. There is an urgent need for reliable antibody detection approaches to support diagnosis, vaccine development, safe release of individuals from quarantine, and population lock-down exit strategies. We set out to evaluate the performance of ELISA and lateral flow immunoassay (LFIA) devices.

MethodsWe tested plasma for COVID (SARS-CoV-2) IgM and IgG antibodies by ELISA and using nine different LFIA devices. We used a panel of plasma samples from individuals who have had confirmed COVID infection based on a PCR result (n=40), and pre-pandemic negative control samples banked in the UK prior to December-2019 (n=142).

ResultsELISA detected IgM or IgG in 34/40 individuals with a confirmed history of COVID infection (sensitivity 85%, 95%CI 70-94%), vs. 0/50 pre-pandemic controls (specificity 100% [95%CI 93-100%]). IgG levels were detected in 31/31 COVID-positive individuals tested [&ge;]10 days after symptom onset (sensitivity 100%, 95%CI 89-100%). IgG titres rose during the 3 weeks post symptom onset and began to fall by 8 weeks, but remained above the detection threshold. Point estimates for the sensitivity of LFIA devices ranged from 55-70% versus RT-PCR and 65-85% versus ELISA, with specificity 95-100% and 93-100% respectively. Within the limits of the study size, the performance of most LFIA devices was similar.

ConclusionsCurrently available commercial LFIA devices do not perform sufficiently well for individual patient applications. However, ELISA can be calibrated to be specific for detecting and quantifying SARS-CoV-2 IgM and IgG and is highly sensitive for IgG from 10 days following first symptoms.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.04.14.20065417,2020-04-17,https://medrxiv.org/cgi/content/short/2020.04.14.20065417,Clinical academic research in the time of Corona: a simulation study in England and a call for action,Amitava Banerjee; Michail Katsoulis; Alvina G Lai; Laura Pasea; Thomas A Treibel; Charlotte Manisty; Spiros Denaxas; Giovanni Quarta; Harry Hemingway; Joao Cavalcante; Mahdad Nousardeghi; James C Moon,"University College London; University College London; University College London; University College London; University College London; University College London; University College London; Ospedale Papa Giovanni XXIII, Bergamo, Italy; University College London; Minneapolis Heart Institute, Minneapolis, Minnesota. USA; University College London; University College London","BackgroundCoronavirus (COVID-19) poses health system challenges in every country. As with any public health emergency, a major component of the global response is timely, effective science. However, particular factors specific to COVID-19 must be overcome to ensure that research efforts are optimised. We aimed to model the impact of COVID-19 on the clinical academic response in the UK, and to provide recommendations for COVID-related research.

MethodsWe constructed a simple stochastic model to determine clinical academic capacity in the UK in four policy approaches to COVID-19 with differing population infection rates: ""Italy model"" (6%), ""mitigation"" (10%), ""relaxed mitigation"" (40%) and ""do-nothing"" (80%) scenarios. The ability to conduct research in the COVID-19 climate is affected by the following key factors: (i) infection growth rate and population infection rate (from UK COVID-19 statistics and WHO); (ii) strain on the healthcare system (from published model); and (iii) availability of clinical academic staff with appropriate skillsets affected by frontline clinical activity and sickness (from UK statistics).

FindingsIn ""Italy model"", ""mitigation"", ""relaxed mitigation"" and ""do-nothing"" scenarios, from 5 March 2020 the duration (days) and peak infection rates (%) are 95(2.4%), 115(2.5%), 240(5.3%) and 240(16.7%) respectively. Near complete attrition of academia (87% reduction, <400 clinical academics) occurs 35 days after pandemic start for 11, 34, 62, 76 days respectively - with no clinical academics at all for 37 days in the ""do-nothing"" scenario. Restoration of normal academic workforce (80% of normal capacity) takes 11,12, 30 and 26 weeks respectively.

InterpretationPandemic COVID-19 crushes the science needed at system level. National policies mitigate, but the academic community needs to adapt. We highlight six key strategies: radical prioritisation (eg 3-4 research ideas per institution), deep resourcing, non-standard leadership (repurposing of key non-frontline teams), rationalisation (profoundly simple approaches), careful site selection (eg protected sites with large academic backup) and complete suspension of academic competition with collaborative approaches.",health systems and quality improvement,fuzzy,100,100
medRxiv,10.1101/2020.04.09.20059865,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.09.20059865,Forecasting the scale of the COVID-19 epidemic in Kenya,Samuel P C Brand; Rabia Aziza; Ivy K Kombe; Charles N Agoti; Joe Hilton; Kat S Rock; Andrea Parisi; D James Nokes; Matt Keeling; Edwine Barasa,"University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme; Kenya Medical Research Institute, Wellcome Trust Research Programme; University of Warwick; University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme and University of Warwick; University of Warwick; Kenya Medical Research Institute, Wellcome Trust Research Programme","BackgroundThe first COVID-19 case in Kenya was confirmed on March 13th, 2020. Here, we provide forecasts for the potential incidence rate, and magnitude, of a COVID-19 epidemic in Kenya based on the observed growth rate and age distribution of confirmed COVID-19 cases observed in China, whilst accounting for the demographic and geographic dissimilarities between China and Kenya.

MethodsWe developed a modelling framework to simulate SARS-CoV-2 transmission in Kenya, KenyaCoV. KenyaCoV was used to simulate SARS-CoV-2 transmission both within, and between, different Kenyan regions and age groups. KenyaCoV was parameterized using a combination of human mobility data between the defined regions, the recent 2019 Kenyan census, and estimates of age group social interaction rates specific to Kenya. Key epidemiological characteristics such as the basic reproductive number and the age-specific rate of developing COVID-19 symptoms after infection with SARS-CoV-2, were adapted for the Kenyan setting from a combination of published estimates and analysis of the age distribution of cases observed in the Chinese outbreak.

ResultsWe find that if person-to-person transmission becomes established within Kenya, identifying the role of subclinical, and therefore largely undetected, infected individuals is critical to predicting and containing a very significant epidemic. Depending on the transmission scenario our reproductive number estimates for Kenya range from 1.78 (95% CI 1.44 -2.14) to 3.46 (95% CI 2.81-4.17). In scenarios where asymptomatic infected individuals are transmitting significantly, we expect a rapidly growing epidemic which cannot be contained only by case isolation. In these scenarios, there is potential for a very high percentage of the population becoming infected (median estimates: >80% over six months), and a significant epidemic of symptomatic COVID-19 cases. Exceptional social distancing measures can slow transmission, flattening the epidemic curve, but the risk of epidemic rebound after lifting restrictions is predicted to be high.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.04.10.20059121,2020-04-14,https://medrxiv.org/cgi/content/short/2020.04.10.20059121,"ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: a Mendelian randomization study",Dipender Gill; Marios Arvanitis; Paul Carter; Ana I Hernandez Cordero; Brian Jo; Ville Karhunen; Susanna C Larsson; Xuan Li; Sam M Lockhart; Amy M Mason; Evanthia Pashos; Ashis Saha; Vanessa Tan; Verena Zuber; Yohan Bosse; Sarah Fahle; Ke Hao; Tao Jiang; Philippe Joubert; Alan C Lunt; Willem hendrik Ouwehand; David J Roberts; Wim Timens; Maarten van den Berge; Nicholas A Watkins; Alexis Battle; Adam S Butterworth; John Danesh; Barbara E Engelhard; James E Peters; Don Sin; Stephen Burgess,"Imperial College London; Johns Hopkins University; University of Cambridge; The University of British Columbia Center for Heart Lung Innovation; Lewis Sigler Institute for Integrative Biology; Imperial College London; Karolinska Institutet; The University of British Columbia Center for Heart Lung Innovation; University of Cambridge; University of Cambridge; Pfizer; Johns Hopkins University; University of Bristol; Imperial College London; Laval University, Quebec; University of Cambridge; School of Medicine at Mount Sinai; University of Cambridge; Laval University, Quebec; Imperial College London; University of Cambridge; University of Oxford; University of Groningen; University of Groningen; University of Cambridge; Johns Hopkins University; University of Cambridge; University of Cambridge; Princeton University; Imperial College London; University of British Columbia; University of Cambridge","ObjectivesTo use human genetic variants that proxy angiotensin-converting enzyme (ACE) inhibitor drug effects and cardiovascular risk factors to provide insight into how these exposures affect lung ACE2 and TMPRSS2 gene expression and circulating ACE2 levels.

DesignTwo-sample Mendelian randomization (MR) analysis.

SettingSummary-level genetic association data.

ParticipantsParticipants were predominantly of European ancestry. Variants that proxy ACE inhibitor drug effects and cardiometabolic risk factors (body mass index, chronic obstructive pulmonary disease, lifetime smoking index, low-density lipoprotein cholesterol, systolic blood pressure and type 2 diabetes mellitus) were selected from publicly available genome-wide association study data (sample sizes ranging from 188,577 to 898,130 participants). Genetic association estimates for lung expression of ACE2 and TMPRSS2 were obtained from the Gene-Tissue Expression (GTEx) project (515 participants) and the Lung eQTL Consortium (1,038 participants). Genetic association estimates for circulating plasma ACE2 levels were obtained from the INTERVAL study (4,947 participants).

Main outcomes and measuresLung ACE2 and TMPRSS2 expression and plasma ACE2 levels.

ResultsThere were no association of genetically proxied ACE inhibition with any of the outcomes considered here. There was evidence of a positive association of genetic liability to type 2 diabetes mellitus with lung ACE2 gene expression in GTEx (p = 4x10-4) and with circulating plasma ACE2 levels in INTERVAL (p = 0.03), but not with lung ACE2 expression in the Lung eQTL Consortium study (p = 0.68). There were no associations between genetically predicted levels of the other cardiometabolic traits with the outcomes.

ConclusionsThis study does not provide evidence to support that ACE inhibitor antihypertensive drugs affect lung ACE2 and TMPRSS2 expression or plasma ACE2 levels. In the current COVID-19 pandemic, our findings do not support a change in ACE inhibitor medication use without clinical justification.

Summary boxesO_ST_ABSWhat is already known on this topicC_ST_ABSO_LISevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current coronavirus disease 2019 (COVID-19) pandemic.
C_LIO_LISerine protease TMPRSS2 is involved in priming the SARS-CoV-2 spike protein for cellular entry through the angiotensin-converting enzyme 2 (ACE2) receptor.
C_LIO_LIExpression of ACE2 and TMPRSS2 in the lung epithelium might have implications for risk of SARS-CoV-2 infection and severity of COVID-19.
C_LI

What this study addsO_LIWe used human genetic variants that proxy ACE inhibitor drug effects and cardiometabolic risk factors to provide insight into how these exposures affect lung ACE2 and TMPRSS2 expression and circulating ACE2 levels.
C_LIO_LIOur findings do not support the hypothesis that ACE inhibitors have effects on ACE2 expression.
C_LIO_LIWe found some support for an association of genetic liability to type 2 diabetes mellitus with higher lung ACE2 expression and plasma ACE2 levels, but evidence was inconsistent across studies.
C_LI",genetic and genomic medicine,fuzzy,100,100
medRxiv,10.1101/2020.04.07.20056788,2020-04-11,https://medrxiv.org/cgi/content/short/2020.04.07.20056788,Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust,Daniel Bean; Zeljko Kraljevic; Thomas Searle; Rebecca Bendayan; Andrew Pickles; Amos Folarin; Lukasz Roguski; Kawsar Noor; Anthony Shek; Rosita Zakeri; Ajay Shah; James Teo; Richard JB Dobson,King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; University College London; University College London; King's College London; King's College London; King's College London; King's College Hospital; Kings College London,"AimsThe SARS-Cov2 virus binds to the ACE2 receptor for cell entry. It has been suggested that ACE-inhibitors (ACEi) and Angiotensin-2 Blockers (ARB), which are commonly used in patients with hypertension or diabetes and may raise ACE2 levels, could increase the risk of severe COVID19 infection.

Methods and ResultsWe evaluated this hypothesis in a consecutive cohort of 1200 acute inpatients with COVID19 at two hospitals with a multi-ethnic catchment population in London (UK). The mean age was 68{+/-}17 years (57% male) and 74% of patients had at least 1 comorbidity. 415 patients (34.6%) reached the primary endpoint of death or transfer to a critical care unit for organ support within 21-days of symptom onset. 399 patients (33.3 %) were taking ACEi or ARB. Patients on ACEi/ARB were significantly older and had more comorbidities. The odds ratio (OR) for the primary endpoint in patients on ACEi and ARB, after adjustment for age, sex and co-morbidities, was 0.63 (CI 0.47-0.84, p<0.01).

ConclusionsThere was no evidence for increased severity of COVID19 disease in hospitalised patients on chronic treatment with ACEi or ARB. A trend towards a beneficial effect of ACEi/ARB requires further evaluation in larger meta-analyses and randomised clinical trials.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.04.05.20048421,2020-04-07,https://medrxiv.org/cgi/content/short/2020.04.05.20048421,Loss of smell and taste in combination with other symptoms is a strong predictor of COVID-19 infection,Cristina Menni; Ana Valdes; Maxim B Freydin; Sajaysurya Ganesh; Julia El-Sayed Moustafa; Alessia Visconti; Pirro Hysi; Ruth C E Bowyer; Massimo Mangino; Mario Falchi; Jonathan Wolf; Claire Steves; Tim Spector,"King's College London; NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham; King's College London; Zoe Global limited; King's College London; King's College London; King's College London; King's College London; King's College London; King's College London; Zoe Global Limited; King's College London; King's College London","ImportanceA strategy for preventing further spread of the ongoing COVID-19 epidemic is to detect infections and isolate infected individuals without the need of extensive bio-specimen testing.

ObjectivesHere we investigate the prevalence of loss of smell and taste among COVID-19 diagnosed individuals and we identify the combination of symptoms, besides loss of smell and taste, most likely to correspond to a positive COVID-19 diagnosis in non-severe cases.

DesignCommunity survey.

Setting and ParticipantsSubscribers of RADAR COVID-19, an app that was launched for use among the UK general population asking about COVID-19 symptoms.

Main ExposureLoss of smell and taste.

Main Outcome MeasuresCOVID-19.

ResultsBetween 24 and 29 March 2020, 1,573,103 individuals reported their symptoms via the app; 26% reported suffering from one or more symptoms of COVID-19. Of those, n=1702 reported having had a RT-PCR COVID-19 test and gave full report on symptoms including loss of smell and taste; 579 were positive and 1123 negative. In this subset, we find that loss of smell and taste were present in 59% of COVID-19 positive individuals compared to 18% of those negative to the test, yielding an odds ratio (OR) of COVID-19 diagnosis of OR[95%CI]=6.59[5.25; 8.27], P= 1.90x10-59. We also find that a combination of loss of smell and taste, fever, persistent cough, fatigue, diarrhoea, abdominal pain and loss of appetite is predictive of COVID-19 positive test with sensitivity 0.54[0.44; 0.63], specificity 0.86[0.80; 0.90], ROC-AUC 0.77[0.72; 0.82] in the test set, and cross-validation ROC-AUC 0.75[0.72; 0.77]. When applied to the 410,598 individuals reporting symptoms but not formally tested, our model predicted that 13.06%[12.97%;13.15] of these might have been already infected by the virus.

Conclusions and RelevanceOur study suggests that loss of taste and smell is a strong predictor of having been infected by the COVID-19 virus. Also, the combination of symptoms that could be used to identify and isolate individuals includes anosmia, fever, persistent cough, diarrhoea, fatigue, abdominal pain and loss of appetite. This is particularly relevant to healthcare and other key workers in constant contact with the public who have not yet been tested for COVID-19.

Key pointsO_ST_ABSWhat is already known on this topicC_ST_ABSO_LIThe spread of COVID-19 can be reduced by identifying and isolating infected individuals but it is not possible to test everyone and priority has been given in most countries to individuals presenting symptoms of the disease.
C_LIO_LICOVID-19 symptoms, such as fever, cough, aches, fatigue are common in many other viral infections
C_LIO_LIThere is therefore a need to identify symptom combinations that can rightly pinpoint to infected individuals
C_LI

What this study addsO_LIAmong individuals showing symptoms severe enough to be given a COVID-19 RT-PCR test in the UK the prevalence of loss of smell (anosmia) was 3-fold higher (59%) in those positive to the test than among those negative to the test (18%).
C_LIO_LIWe developed a mathematical model combining symptoms to predict individuals likely to be COVID-19 positive and applied this to over 400,000 individuals in the general population presenting some of the COVID-19 symptoms.
C_LIO_LIWe find that [~]13% of those presenting symptoms are likely to have or have had a COVID-19 infection. The proportion was slightly higher in women than in men but is comparable in all age groups, and corresponds to 3.4% of those who filled the app report.
C_LI",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.04.02.20051334,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.02.20051334,Rapid implementation of mobile technology for real-time epidemiology of COVID-19,David A. Drew; Long H. Nguyen; Claire J. Steves; Jonathan Wolf; Tim D. Spector; Andrew T. Chan; COPE Consortium,Massachusetts General Hospital; Massachusetts General Hospital; King's College London; Zoe Global Limited; King's College London; Massachusetts General Hospital; ,"The rapid pace of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic (COVID-19) presents challenges to the robust collection of population-scale data to address this global health crisis. We established the COronavirus Pandemic Epidemiology (COPE) consortium to bring together scientists with expertise in big data research and epidemiology to develop a COVID-19 Symptom Tracker mobile application that we launched in the UK on March 24, 2020 and the US on March 29, 2020 garnering more than 2.25 million users to date. This mobile application offers data on risk factors, herald symptoms, clinical outcomes, and geographical hot spots. This initiative offers critical proof-of-concept for the repurposing of existing approaches to enable rapidly scalable epidemiologic data collection and analysis which is critical for a data-driven response to this public health challenge.

One Sentence SummaryCOVID-19 symptom tracker for smartphones",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.04.02.20051284,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.02.20051284,Building an International Consortium for Tracking Coronavirus Health Status,Eran Segal; Feng Zhang; Xihong Lin; Gary King; Ophir Shalem; Smadar Shilo; William E. Allen; Yonatan H. Grad; Casey S. Greene; Faisal Alquaddoomi; Simon Anders; Ran Balicer; Tal Bauman; Ximena Bonilla; Gisel Booman; Andrew T. Chan; Ori Ori Cohen; Silvano Coletti; Natalie Davidson; Yuval Dor; David A. Drew; Olivier Elemento; Georgina Evans; Phil Ewels; Joshua Gale; Amir Gavrieli; Benjamin Geiger; Iman Hajirasouliha; Roman Jerala; Andre Kahles; Olli Kallioniemi; Ayya Keshet; Gregory Landua; Tomer Meir; Aline Muller; Long H. Nguyen; Matej Oresic; Svetlana Ovchinnikova; Hedi Peterson; Jay Rajagopal; Gunnar Ratsch; Hagai Rossman; Johan Rung; Andrea Sboner; Alexandros Sigaras; Tim Spector; Ron Steinherz; Irene Stevens; Jaak Vilo; Paul Wilmes; CCC (Coronavirus Census Collective),"Weizmann Institute of Science; Howard Hughes Medical Institute, Core Member, Broad Institute of MIT and Harvard, United States; Departments of Biostatistics and Statistics, Harvard T.H. Chan School of Public Health; Albert J. Weatherhead III University, Institute for Quantitative Social Science, Harvard University; Department of Genetics, Perelman School of Medicine, University of Pennsylvania, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Society of Fellows, Harvard University, United States; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, United States; Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, United States; ETH Zurich, NEXUS Personalized Health Technologies, Zurich, Switzerland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Clalit Research Institute, Clalit Health Services, Israel; Mapping and Geo-Information Engineering, Civil and Environmental Engineering Faculty, The Technion, Israel; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Regen Network, Argentina; Massachusetts General Hospital (MGH), United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Chelonia Applied Science, Switzerland; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; School of Medicine-IMRIC-Developmental Biology and Cancer Research, The Hebrew University; Massachusetts General Hospital (MGH), United States; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Institute for Quantitative Social Science, Harvard University; Science for Life Laboratory (SciLifeLab), Department of Biochemistry and Biophysics, Stockholm University, Sweden; symptometrics.org; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Department of immunology, Weizmann Institute of Science, Israel; Englander Institute for Precision Medicine and  Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Department of Synthetic biology and Immunology, National Institute of Chemistry, Slovenia; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich, ; Science for Life Laboratory (SciLifeLab), Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Regen Network, United States; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Luxembourg Institute of Socio-Economic Research and University of Luxembourg, Luxembourg; Massachusetts General Hospital (MGH), United States; School of Medical Sciences, Orebro University, Orebro, Sweden, and Turku Bioscience Centre, University of Turku and Abo Akademi University, Turku, Finland; Center for Molecular Biology (ZMBH), University of Heidelberg, Germany; Institute of Computer Science, University of Tartu, Estonia, Estonia; Internal Medicine, Harvard Medical School, Department of Pulmonary Medicine and Critical Care, Massachusetts General Hospital (MGH), United States; ETH Zurich, Department for Computer Science, Zurich, University Hospital Zurich, Medical Informatics, Zurich and SIB Swiss Institute of Bioinformatics, Zurich a; Department of Computer Science and Applied Mathematics, and Department of Molecular Cell Biology, Weizmann Institute of Science, Israel; Science for Life Laboratory (SciLifeLab), Department of Immunology, Genetics and Pathology, Uppsala university, Sweden; Englander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, USA; Englander Institute for Precision Medicine and Department of Physiology and Biophysics, Weill Cornell Medicine, USA; Kings College, United Kingdom; Regen Network, United States; Science for Life Laboratory (SciLifeLab), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Sweden; Institute of Computer Science, University of Tartu, Estonia, Estonia; Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Luxembourg; ","Information is the most potent protective weapon we have to combat a pandemic, at both the individual and global level. For individuals, information can help us make personal decisions and provide a sense of security. For the global community, information can inform policy decisions and offer critical insights into the epidemic of COVID-19 disease. Fully leveraging the power of information, however, requires large amounts of data and access to it. To achieve this, we are making steps to form an international consortium, Coronavirus Census Collective (CCC, coronaviruscensuscollective.org), that will serve as a hub for integrating information from multiple data sources that can be utilized to understand, monitor, predict, and combat global pandemics. These sources may include self-reported health status through surveys (including mobile apps), results of diagnostic laboratory tests, and other static and real-time geospatial data. This collective effort to track and share information will be invaluable in predicting hotspots of disease outbreak, identifying which factors control the rate of spreading, informing immediate policy decisions, evaluating the effectiveness of measures taken by health organizations on pandemic control, and providing critical insight on the etiology of COVID-19. It will also help individuals stay informed on this rapidly evolving situation and contribute to other global efforts to slow the spread of disease.

In the past few weeks, several initiatives across the globe have surfaced to use daily self-reported symptoms as a means to track disease spread, predict outbreak locations, guide population measures and help in the allocation of healthcare resources. The aim of this paper is to put out a call to standardize these efforts and spark a collaborative effort to maximize the global gain while protecting participant privacy.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.04.01.20049908,2020-04-06,https://medrxiv.org/cgi/content/short/2020.04.01.20049908,"The effect of non-pharmaceutical interventions on COVID-19 cases, deaths and demand for hospital services in the UK: a modelling study",Nicholas G Davies; Adam J Kucharski; Rosalind M Eggo; Amy Gimma; - CMMID COVID-19 Working Group; W. John Edmunds,London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; -; London School of Hygiene & Tropical Medicine,"BackgroundNon-pharmaceutical interventions have been implemented to reduce transmission of SARS-CoV-2 in the UK. Projecting the size of an unmitigated epidemic and the potential effect of different control measures has been critical to support evidence-based policymaking during the early stages of the epidemic.

MethodsWe used a stochastic age-structured transmission model to explore a range of intervention scenarios, including the introduction of school closures, social distancing, shielding of elderly groups, self-isolation of symptomatic cases, and extreme ""lockdown""-type restrictions. We simulated different durations of interventions and triggers for introduction, as well as combinations of interventions. For each scenario, we projected estimated new cases over time, patients requiring inpatient and critical care (intensive care unit, ICU) treatment, and deaths.

FindingsWe found that mitigation measures aimed at reducing transmission would likely have decreased the reproduction number, but not sufficiently to prevent ICU demand from exceeding NHS availability. To keep ICU bed demand below capacity in the model, more extreme restrictions were necessary. In a scenario where ""lockdown""-type interventions were put in place to reduce transmission, these interventions would need to be in place for a large proportion of the coming year in order to prevent healthcare demand exceeding availability.

InterpretationThe characteristics of SARS-CoV-2 mean that extreme measures are likely required to bring the epidemic under control and to prevent very large numbers of deaths and an excess of demand on hospital beds, especially those in ICUs.

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSAs countries have moved from early containment efforts to planning for the introduction of large-scale non-pharmaceutical interventions to control COVID-19 outbreaks, epidemic modelling studies have explored the potential for extensive social distancing measures to curb transmission. However, it remains unclear how different combinations of interventions, timings, and triggers for the introduction and lifting of control measures may affect the impact of the epidemic on health services, and what the range of uncertainty associated with these estimates would be.

Added value of this studyUsing a stochastic, age-structured epidemic model, we explored how eight different intervention scenarios could influence the number of new cases and deaths, as well as intensive care beds required over the projected course of the epidemic. We also assessed the potential impact of local versus national targeting of interventions, reduction in leisure events, impact of increased childcare by grandparents, and timing of triggers for different control measures. We simulated multiple realisations for each scenario to reflect uncertainty in possible epidemic trajectories.

Implications of all the available evidenceOur results support early modelling findings, and subsequent empirical observations, that in the absence of control measures, a COVID-19 epidemic could quickly overwhelm a healthcare system. We found that even a combination of moderate interventions - such as school closures, shielding of older groups and self-isolation - would be unlikely to prevent an epidemic that would far exceed available ICU capacity in the UK. Intermittent periods of more intensive lockdown-type measures are predicted to be effective for preventing the healthcare system from being overwhelmed.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.04.01.20047357,2020-04-04,https://medrxiv.org/cgi/content/short/2020.04.01.20047357,Detecting SARS-CoV-2 at point of care: Preliminary data comparing Loop-mediated isothermal amplification (LAMP) to PCR,Marc F Osterdahl; Karla A Lee; Mary Ni Lochlainn; Stuart Wilson; Sam Douthwaite; Rachel Horsfall; Alyce Sheedy; Simon D Goldenberg; Christoper J Stanley; Tim D Spector; Claire Steves,"Department of Ageing & Health, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; MicrosensDx Ltd, 2 Royal College Street, London, UK; Department of Infection, Guys and St Thomas NHS Foundation Trust, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Infection, Guys and St Thomas NHS Foundation Trust, London, UK; MicrosensDx Ltd, 2 Royal College Street, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK; Department of Twin Research and Genetic Epidemiology, Kings College London, London, UK","BackgroundThe need for a fast and reliable test for COVID-19 is paramount in managing the current pandemic. A cost effective and efficient diagnostic tool as near to the point of care (PoC) as possible would be a game changer in current testing. We tested reverse transcription loop mediated isothermal amplification (RT-LAMP), a method which can produce results in under 30 minutes, alongside standard methods in a real-life clinical setting.

MethodsThis service improvement project piloted a research RT-LAMP method on nasal and pharyngeal swabs on 21 residents in a high dependency care home, with two index COVID-19 cases, and compared it to multiplex tandem reverse transcription polymerase chain reaction (RT-PCR). We calculated the sensitivity, specificity, positive and negative predictive values of a single RT-LAMP swab compared to RT-PCR, as per STARD guidelines. We also recorded vital signs of patients to correlate clinical and laboratory information.

FindingsThe novel method accurately detected 8/10 PCR positive cases and identified a further 3 positive cases. Eight further cases were negative using both methods. Using repeated RT-PCR as a ""gold standard"", the sensitivity and specificity of the novel test were 80% and 73% respectively. Positive predictive value (PPV) was 73% and negative predictive value (NPV) was 83%. We also observed hypothermia to be a significant early clinical sign in a number of COVID-19 patients in this setting.

InterpretationRT-LAMP testing for SARS-CoV-2 was found to be promising, fast, easy to use and to work equivalently to RT-PCR methods. Definitive studies to evaluate this method in larger cohorts are underway. RT-LAMP has the potential to transform COVID-19 detection, bringing rapid and accurate testing to the point of care. This method could be deployed in mobile testing units in the community, care homes and hospitals to detect disease early and prevent spread.",infectious diseases,fuzzy,100,100
medRxiv,10.1101/2020.03.27.20044925,2020-03-30,https://medrxiv.org/cgi/content/short/2020.03.27.20044925,A Genomic Survey of SARS-CoV-2 Reveals Multiple Introductions into Northern California without a Predominant Lineage,Xianding Deng; Wei Gu; Scot Federman; Louis Du Plessis; Oliver Pybus; Nuno Faria; Candace Wang; Guixia Yu; Chao-Yang Pan; Hugo Guevara; Alicia Sotomayor-Gonzalez; Kelsey Zorn; Allan Gopez; Venice Servellita; Elaine Hsu; Steve Miller; Trevor Bedford; Alexander Greninger; Pavitra Roychoudhury; Michael Famulare; Helen Y Chu; Jay Shendure; Lea Starita; Catie Anderson; Karthik Gangavarapu; Mark Zeller; Emily Spencer; Kristian Andersen; Duncan MacCannell; Suxiang Tong; Gregory Armstrong; Clinton Paden; Yan Li; Ying Zhang; Scott Morrow; Matthew Willis; Bela Matyas; Sundari Mase; Olivia Kasirye; Maggie Park; Curtis Chan; Alexander Yu; Shua Chai; Elsa Villarino; Brandon Bonin; Debra Wadford; Charles Y Chiu,"University of Californa, San Francisco; University of California, San Francisco; University of California, San Francisco; Oxford University; University of Oxford; Oxford University; University of California, San Francisco; University of California, San Francisco; California Department of Public Health; California Department of Public Health; University of California, San Francisco; University of California, San Francisco; University of California, San Francisco; University of California, San Francisco; University of California, San Francisco; University of California, San Francisco; Fred Hutchinson Cancer Research Center; University of Washington; Fred Hutchinson Cancer Research Center; Institute for Disease Modeling; University of Washington; University of Washington; University of Washington; Scripps Institute; Scripps Institute; Scripps Institute; Scripps Institute; Scripps Institute; United States Centers for Disease Control and Prevention; United States Centers for Disease Control and Prevention; United States Centers for Disease Control and Prevention; United States Centers for Disease Control and Prevention; United States Centers for Disease Control and Prevention; United States Centers for Disease Control and Prevention; San Mateo County Department of Public Health; Marin County Division of Public Health; Solano County Department of Public Health; Sonoma County Department of Public Health; Sacramento County Division of Public Health; San Joaquin County Department of Public Health; San Francisco Department of Public Health; California Department of Public Health; California Department of Public Health; Santa Clara County Department of Public Health; Santa Clara County Department of Public Health; California Department of Public Health; University of California, San Francisco","The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has spread globally, resulting in >300,000 reported cases worldwide as of March 21st, 2020. Here we investigate the genetic diversity and genomic epidemiology of SARS-CoV-2 in Northern California using samples from returning travelers, cruise ship passengers, and cases of community transmission with unclear infection sources. Virus genomes were sampled from 29 patients diagnosed with COVID-19 infection from Feb 3rd through Mar 15th. Phylogenetic analyses revealed at least 8 different SARS-CoV-2 lineages, suggesting multiple independent introductions of the virus into the state. Virus genomes from passengers on two consecutive excursions of the Grand Princess cruise ship clustered with those from an established epidemic in Washington State, including the WA1 genome representing the first reported case in the United States on January 19th. We also detected evidence for presumptive transmission of SARS-CoV-2 lineages from one community to another. These findings suggest that cryptic transmission of SARS-CoV-2 in Northern California to date is characterized by multiple transmission chains that originate via distinct introductions from international and interstate travel, rather than widespread community transmission of a single predominant lineage. Rapid testing and contact tracing, social distancing, and travel restrictions are measures that will help to slow SARS-CoV-2 spread in California and other regions of the USA.",infectious diseases,fuzzy,92,100
medRxiv,10.1101/2020.03.30.20047217,2020-03-30,https://medrxiv.org/cgi/content/short/2020.03.30.20047217,"Physical interventions to interrupt or reduce the spread of respiratory viruses. Part 1 - Face masks, eye protection and person distancing: systematic review and meta-analysis",Tom Jefferson; Mark Jones; Lubna A Al Ansari; Ghada Bawazeer; Elaine Beller; Justin Clark; John Conly; Chris Del Mar; Elisabeth Dooley; Eliana Ferroni; Paul Glasziou; Tammy Hoffman; Sarah Thorning; Mieke Van Driel,"University of Oxford; Bond University, Australia; Kind Saud University, Saudi Arabia; King Saud, University, Saudi Arabia; Bond University, Australia; Bond University, Australia; Department of Medicine, Microbiology, Immunology & Infectious Diseases, Cumming School of Medicine, University of Calgary and Alberta Health Services , Calgary,; Bond University, Australia; Bond University, Australia; Regione Veneto, Italy; Bond University, Australia; Bond University, Australia; Bond University, Australia; Primary Care Clinical Unit, Faculty of Medicine, University of Queensland, Australia","OBJECTIVETo examine the effectiveness of eye protection, face masks, or person distancing on interrupting or reducing the spread of respiratory viruses.

DESIGNUpdate of a Cochrane review that included a meta-analysis of observational studies during the SARS outbreak of 2003.

DATA SOURCESEligible trials from the previous review; search of Cochrane Central Register of Controlled Trials, PubMed, Embase and CINAHL from October 2010 up to 1 April 2020; and forwardand backward citation analysis.

DATA SELECTIONRandomised and cluster-randomised trials of people of any age, testing the use ofeye protection, face masks, or person distancing against standard practice, or a similar physical barrier. Outcomes included any acute respiratory illness and its related consequences.

DATA EXTRACTION AND ANALYSISSix authors independently assessed risk of bias using the Cochrane tool and extracted data. We used a generalised inverse variance method for pooling using a random-effects model and reported results with risk ratios and 95% Confidence Intervals (CI).

RESULTSWe included 15 randomised trials investigating the effect of masks (14 trials) in healthcare workers and the general population and of quarantine (1 trial). We found no trials testing eye protection. Compared to no masks there was no reduction of influenza-like illness (ILI) cases (Risk Ratio 0.93, 95%CI 0.83 to 1.05) or influenza (Risk Ratio 0.84, 95%CI 0.61-1.17) for masks in the general population, nor in healthcare workers (Risk Ratio 0.37, 95%CI 0.05 to 2.50). There was no difference between surgical masks and N95 respirators: for ILI (Risk Ratio 0.83, 95%CI 0.63 to 1.08), for influenza (Risk Ratio 1.02, 95%CI 0.73 to 1.43). Harms were poorly reported and limited to discomfort with lower compliance. The only trial testing quarantining workers with household ILI contacts found a reduction in ILI cases, but increased risk of quarantined workers contracting influenza. All trials were conducted during seasonal ILI activity.

CONCLUSIONSMost included trials had poor design, reporting and sparse events. There was insufficient evidence to provide a recommendation on the use of facial barriers without other measures. We found insufficient evidence for a difference between surgical masks and N95 respirators and limited evidence to support effectiveness of quarantine. Based on observational evidence from the previous SARS epidemic included in the previous version of our Cochrane review we recommend the use of masks combined with other measures.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.03.24.20043018,2020-03-27,https://medrxiv.org/cgi/content/short/2020.03.24.20043018,Age-dependent effects in the transmission and control of COVID-19 epidemics,Nicholas G Davies; Petra Klepac; Yang Liu; Kiesha Prem; Mark Jit; CMMID COVID-19 working group; Rosalind M Eggo,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; ; London School of Hygiene and Tropical Medicine,"The COVID-19 pandemic has shown a markedly low proportion of cases among children. Age disparities in observed cases could be explained by children having lower susceptibility to infection, lower propensity to show clinical symptoms, or both. We evaluate these possibilities by fitting an age-structured mathematical model to epidemic data from six countries. We estimate that clinical symptoms occur in 25% (95% CrI: 19-32%) of infections in 10-19-year-olds, rising to 76% (68-82%) in over-70s, and that susceptibility to infection in under-20s is approximately half that of older adults. Accordingly, we find that interventions aimed at children may have a relatively small impact on total cases, particularly if the transmissibility of subclinical infections is low. The age-specific clinical fraction and susceptibility we have estimated has implications for the expected global burden of COVID-19 because of demographic differences across settings: in younger populations, the expected clinical attack rate would be lower, although it is likely that comorbidities in low-income countries will affect disease severity. Without effective control measures, regions with older populations may see disproportionally more clinical cases, particularly in the later stages of the pandemic.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.03.22.20040287,2020-03-24,https://medrxiv.org/cgi/content/short/2020.03.22.20040287,Estimating excess 1- year mortality from COVID-19 according to underlying conditions and age in England: a rapid analysis using NHS health records in 3.8 million adults,Amitava Banerjee; Laura Pasea; Steve Harris; Arturo Gonzalez-Izquierdo; Ana Torralbo; Laura Shallcross; Mahdad Noursadeghi; Deenan Pillay; Christina Pagel; Wai Keong Wong; Claudia Langenberg; Bryan Williams; Spiros Denaxas; Harry Hemingway,University College London; University College London; University College London Hospitals NHS Trust; University College London; University College London; UCL; University College London; University College London; University College London; University College London Hospitals NHS Trust; University of Cambridge; University College London; University College London; University College London,"BackgroundThe medical, health service, societal and economic impact of the COVID-19 emergency has unknown effects on overall population mortality. Previous models of population mortality are based on death over days among infected people, nearly all of whom (to date at least) have underlying conditions. Models have not incorporated information on high risk conditions or their longer term background (pre-COVID-19) mortality. We estimated the excess number of deaths over 1 year under different COVID-19 incidence rates and differing mortality impacts.

MethodsUsing population based linked primary and secondary care electronic health records in England (HDR UK - CALIBER), we report the prevalence of underlying conditions defined by UK Public Health England COVID-19 guidelines (16 March 2020) in 3,862,012 individuals aged [&ge;]30 years from 1997-2017. We used previously validated phenotypes, openly available (https://caliberresearch.org/portal), for each condition using ICD-10 diagnosis, Read, procedure and medication codes. We estimated the 1-year mortality in each condition, and developed simple models of excess COVID-19-related deaths assuming relative risk (RR) of the impact of the emergency (compared to background mortality) of 1.2, 1.5 and 2.0.

Findings20.0% of the population are at risk according to current PHE guidelines, of which; 13.7% were age>70 years and 6.3% aged [&le;]70 years with [&ge;]1 underlying condition (cardiovascular disease (2.3%), diabetes (2.2%), steroid therapy (1.9%), severe obesity (0.9%), chronic kidney disease (0.6%) and chronic obstructive pulmonary disease, COPD (0.5%). Multimorbidity (co-occurrence of [&ge;]2 conditions in an individual) was common (10.1%). The 1-year mortality in the at-risk population was 4.46%, and age and underlying conditions combine to influence background risk, varying markedly across conditions (5.9% in age>70 years, 8.6% for COPD and 13.1% in those with [&ge;]3 or more conditions). In a suppression scenario (at SARS CoV2 rates of 0.001% of the UK population), there would be minimal excess deaths (3 and 7 excess deaths at relative risk, RR, 1.5 and 2.0 respectively). At SARS CoV2 rates of 10% of the UK population (mitigation) the model estimates the numbers of excess deaths as: 13791, 34479 and 68957 (at RR 1.2, 1.5 and 2.0 respectively). At SARS CoV2 rates of 80% in the UK population (""do-nothing""), the model estimates the number of excess deaths as 110332, 275,830 and 551,659 (at RR 1.2, 1.5 and 2.0) respectively.

InterpretationWe provide the public, researchers and policy makers a simple model to estimate the excess mortality over 1 year from COVID-19, based on underlying conditions at different ages. If the relative mortality impact of COVID-19 were to be about 20% (similar magnitude as the established winter vs summer mortality excess), then the excess deaths would be 0 when 1 in 100 000 (suppression), 13791 when 1 in 10 (mitigation) and 110332 when 8 in 10 are infected (""do nothing"") scenario. However, the relative impact of COVID-19 is unknown. If the emergency were to double the mortality risk, then we estimate 7, 68957 and 551,659 excess deaths in the same scenarios. These results may inform the need for more stringent suppression measures as well as efforts to target those at highest risk for a range of preventive interventions.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.03.20.20039537,2020-03-23,https://medrxiv.org/cgi/content/short/2020.03.20.20039537,The Population Attributable Fraction (PAF) of cases due to gatherings and groups with relevance to COVID-19 mitigation strategies,Ellen Brooks-Pollock; Jonathan M Read; Thomas House; Graham Medley; Matt J Keeling; Leon Danon,University of Bristol; Lancaster University; University of Manchester; London School of Hygiene and Tropical Medicine; University of Warwick; University of Exeter,"BackgroundMany countries have banned groups and gatherings as part of their response to the pandemic caused by the coronavirus, SARS-CoV-2. Although there are outbreak reports involving mass gatherings, the contribution to overall transmission is unknown.

MethodsWe used data from a survey of social contact behaviour that specifically asked about contact with groups to estimate the Population Attributable Fraction (PAF) due to groups as the relative change in the Basic Reproduction Number when groups are prevented.

FindingsGroups of 50+ individuals accounted for 0.5% of reported contact events, and we estimate that the PAF due to groups of 50+ people is 5.4% (95%CI 1.4%, 11.5%). The PAF due to groups of 20+ people is 18.9% (12.7%, 25.7%) and the PAF due to groups of 10+ is 25.2% (19.4%, 31.4%)

InterpretationLarge groups of individuals have a relatively small epidemiological impact; small and medium sized groups between 10 and 50 people have a larger impact on an epidemic.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.03.10.20033761,2020-03-13,https://medrxiv.org/cgi/content/short/2020.03.10.20033761,Inferring the number of COVID-19 cases from recently reported deaths,Thibaut Jombart; Kevin van Zandvoort; Tim Russell; Christopher Jarvis; Amy Gimma; Sam Abbott; Samuel Clifford; Sebastian Funk; Hamish Gibbs; Yang Liu; Carl Pearson; Nikos Bosse; Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group; Rosalind M Eggo; Adam J Kucharski; John Edmunds,London School of Hygiene and Tropical Medicine (LSHTM); London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; ; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine,"We estimate the number of COVID-19 cases from newly reported deaths in a population without previous reports. Our results suggest that by the time a single death occurs, hundreds to thousands of cases are likely to be present in that population. This suggests containment via contact tracing will be challenging at this point, and other response strategies should be considered. Our approach is implemented in a publicly available, user-friendly, online tool.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.03.09.20033050,2020-03-12,https://medrxiv.org/cgi/content/short/2020.03.09.20033050,"The effect of control strategies that reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China",Kiesha Prem; Yang Liu; Tim Russell; Adam J Kucharski; Rosalind M Eggo; Nicholas Davies; Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group; Mark Jit; Petra Klepac,London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; ; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,"BACKGROUNDIn December 2019, a novel strain of SARS-CoV-2 emerged in Wuhan, China. Since then, the city of Wuhan has taken unprecedented measures and efforts in response to the outbreak.

METHODSWe quantified the effects of control measures on population contact patterns in Wuhan, China, to assess their effects on the progression of the outbreak. We included the latest estimates of epidemic parameters from a transmission model fitted to data on local and internationally exported cases from Wuhan in the age-structured epidemic framework. Further, we looked at the age-distribution of cases. Lastly, we simulated lifting of the control measures by allowing people to return to work in a phased-in way, and looked at the effects of returning to work at different stages of the underlying outbreak.

FINDINGSChanges in mixing patterns may have contributed to reducing the number of infections in mid-2020 by 92% (interquartile range: 66-97%). There are benefits to sustaining these measures until April in terms of reducing the height of the peak, overall epidemic size in mid-2020 and probability that a second peak may occur after return to work. However, the modelled effects of social distancing measures vary by the duration of infectiousness and the role school children play in the epidemic.

INTERPRETATIONRestrictions on activities in Wuhan, if maintained until April, would likely contribute to the reduction and delay the epidemic size and peak, respectively. However, there are some limitations to the analysis, including large uncertainties around estimates of R0 and the duration of infectiousness.

FUNDINGBill and Melinda Gates Foundation, National Institute for Health Research, Wellcome Trust, and Health Data Research UK.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.02.26.20028167,2020-02-27,https://medrxiv.org/cgi/content/short/2020.02.26.20028167,Estimation of country-level basic reproductive ratios for novel Coronavirus (COVID-19) using synthetic contact matrices,Joe Hilton; Matt J Keeling,University of Warwick; University of Warwick,"The outbreak of novel coronavirus (COVID-19) has the potential for global spread, infecting large numbers in all countries. In this case, estimating the country-specific basic reproductive ratio is a vital first step in public-health planning. The basic reproductive ratio (R0) is determined by both the nature of pathogen and the network of contacts through which the disease can spread - with this network determined by socio-demographics including age-structure and household composition. Here we focus on the age-structured transmission within the population, using data from China to inform age-dependent susceptibility and synthetic age-mixing matrices to inform the contact network. This allows us to determine the country-specific basic reproductive ratio as a multiplicative scaling of the value from China. We predict that R0 will be highest across Eastern Europe and Japan, and lowest across Africa, Central America and South-Western Asia. This pattern is largely driven by the ratio of children to older adults in each country and the observed propensity of clinical cases in the elderly.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.02.14.20023036,2020-02-17,https://medrxiv.org/cgi/content/short/2020.02.14.20023036,The Efficacy of Contact Tracing for the Containment of the 2019 Novel Coronavirus (COVID-19).,Matt J Keeling; T. Deirdre Hollingsworth; Jonathan M Read,University of Warwick; Oxford University; Lancaster University,"Contact tracing is a central public health response to infectious disease outbreaks, especially in the early stages of an outbreak when specific treatments are limited. Importation of novel Coronavirus (COVID-19) from China and elsewhere into the United Kingdom highlights the need to understand the impact of contact tracing as a control measure. Using detailed survey information on social encounters coupled to predictive models, we investigate the likely efficacy of the current UK definition of a close contact (within 2 meters for 15 minutes or more) and the distribution of secondary cases that may go untraced. Taking recent estimates for COVID-19 transmission, we show that less than 1 in 5 cases will generate any subsequent untraced cases, although this comes at a high logistical burden with an average of 36.1 individuals (95th percentiles 0-182) traced per case. Changes to the definition of a close contact can reduce this burden, but with increased risk of untraced cases; we estimate that any definition where close contact requires more than 4 hours of contact is likely to lead to uncontrolled spread.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.02.12.20022566,2020-02-14,https://medrxiv.org/cgi/content/short/2020.02.12.20022566,A spatial model of CoVID-19 transmission in England and Wales: early spread and peak timing,Leon Danon; Ellen Brooks-Pollock; Mick Bailey; Matt J Keeling,University of Exeter; University of Bristol; University of Bristol; University of Warwick,"BackgroundAn outbreak of a novel coronavirus, named CoVID-19, was first reported in China on 31 December 2019. As of 9 February 2020, cases have been reported in 25 countries, including probable cases of human-to-human transmission in England.

MethodsWe adapted an existing national-scale metapopulation model to capture the spread of CoVID-19 in England and Wales. We used 2011 census data to capture population sizes and population movement, together with parameter estimates from the current outbreak in China.

ResultsWe predict that a CoVID-19 outbreak will peak 126 to 147 days ([~]4 months) after the start of person-to-person transmission in England and Wales in the absence of controls, assuming biological parameters remain unchanged. Therefore, if person-to-person transmission persists from February, we predict the epidemic peak would occur in June. The starting location has minimal impact on peak timing, and model stochasticity varies peak timing by 10 days. Incorporating realistic parameter uncertainty leads to estimates of peak time ranging from 78 days to 241 days after person-to-person transmission has been established. Seasonal changes in transmission rate substantially impact the timing and size of the epidemic peak, as well as the total attack rate.

DiscussionWe provide initial estimates of the potential course of CoVID-19 in England and Wales in the absence of control measures. These results can be refined with improved estimates of epidemiological parameters, and permit investigation of control measures and cost effectiveness analyses. Seasonal changes in transmission rate could shift the timing of the peak into winter months, which will have important implications for health-care capacity planning.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.02.12.20022426,2020-02-13,https://medrxiv.org/cgi/content/short/2020.02.12.20022426,Interventions targeting air travellers early in the pandemic may delay local outbreaks of SARS-CoV-2,Samuel J Clifford; Carl A B Pearson; Petra Klepac; Kevin Van Zandvoort; Billy J Quilty; - CMMID COVID-19 working group; Rosalind M Eggo; Stefan Flasche,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; -; London School of Hygiene & Tropical Medicine; London School of Hygiene and Tropical Medicine,"BackgroundWe evaluated if interventions aimed at air travellers can delay local SARS-CoV-2 community transmission in a previously unaffected country.

MethodsWe simulated infected air travellers arriving into countries with no sustained SARS-CoV-2 transmission or other introduction routes from affected regions. We assessed the effectiveness of syndromic screening at departure and/or arrival & traveller sensitisation to the COVID-2019-like symptoms with the aim to trigger rapid self-isolation and reporting on symptom onset to enable contact tracing. We assumed that syndromic screening would reduce the number of infected arrivals and that traveller sensitisation reduces the average number of secondary cases. We use stochastic simulations to account for uncertainty in both arrival and secondary infections rates, and present sensitivity analyses on arrival rates of infected travellers and the effectiveness of traveller sensitisation. We report the median expected delay achievable in each scenario and an inner 50% interval.

ResultsUnder baseline assumptions, introducing exit and entry screening in combination with traveller sensitisation can delay a local SARS-CoV-2 outbreak by 8 days (50% interval: 3-14 days) when the rate of importation is 1 infected traveller per week at time of introduction. The additional benefit of entry screening is small if exit screening is effective: the combination of only exit screening and traveller sensitisation can delay an outbreak by 7 days (50% interval: 2-13 days). In the absence of screening, with less effective sensitisation, or a higher rate of importation, these delays shrink rapidly to less than 4 days.

ConclusionSyndromic screening and traveller sensitisation in combination may have marginally delayed SARS-CoV-2 outbreaks in unaffected countries.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.02.08.20021162,2020-02-11,https://medrxiv.org/cgi/content/short/2020.02.08.20021162,Feasibility of controlling 2019-nCoV outbreaks by isolation of cases and contacts,Joel Hellewell; Sam Abbott; Amy Gimma; Nikos I Bosse; Christopher I Jarvis; Timothy W Russell; James D Munday; Adam J Kucharski; W John Edmunds; CMMID nCoV working group; Sebastian Funk; Rosalind M Eggo,LSHTM; LSHTM; LSHTM; LSHTM; LSHTM; LSHTM; LSHTM; London School of Hygiene & Tropical Medicine; LSHTM; LSHTM; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,"BackgroundTo assess the viability of isolation and contact tracing to control onwards transmission from imported cases of 2019-nCoV.

MethodsWe developed a stochastic transmission model, parameterised to the 2019-nCoV outbreak. We used the model to quantify the potential effectiveness of contact tracing and isolation of cases at controlling a 2019 nCoV-like pathogen. We considered scenarios that varied in: the number of initial cases; the basic reproduction number R0; the delay from symptom onset to isolation; the probability contacts were traced; the proportion of transmission that occurred before symptom onset, and the proportion of subclinical infections. We assumed isolation prevented all further transmission in the model. Outbreaks were deemed controlled if transmission ended within 12 weeks or before 5000 cases in total. We measured the success of controlling outbreaks using isolation and contact tracing, and quantified the weekly maximum number of cases traced to measure feasibility of public health effort.

FindingsWhile simulated outbreaks starting with only 5 initial cases, R0 of 1.5 and little transmission before symptom onset could be controlled even with low contact tracing probability, the prospects of controlling an outbreak dramatically dropped with the number of initial cases, with higher R0, and with more transmission before symptom onset. Across different initial numbers of cases, the majority of scenarios with an R0 of 1.5 were controllable with under 50% of contacts successfully traced. For R0 of 2.5 and 3.5, more than 70% and 90% of contacts respectively had to be traced to control the majority of outbreaks. The delay between symptom onset and isolation played the largest role in determining whether an outbreak was controllable for lower values of R0. For higher values of R0 and a large initial number of cases, contact tracing and isolation was only potentially feasible when less than 1% of transmission occurred before symptom onset.

InterpretationWe found that in most scenarios contact tracing and case isolation alone is unlikely to control a new outbreak of 2019-nCov within three months. The probability of control decreases with longer delays from symptom onset to isolation, fewer cases ascertained by contact tracing, and increasing transmission before symptoms. This model can be modified to reflect updated transmission characteristics and more specific definitions of outbreak control to assess the potential success of local response efforts.

FundingWellcome Trust, Global Challenges Research Fund, and HDR UK.

Research in ContextO_ST_ABSEvidence before this studyC_ST_ABSContact tracing and isolation of cases is a commonly used intervention for controlling infectious disease outbreaks. This intervention can be effective, but may require intensive public health effort and cooperation to effectively reach and monitor all contacts. When the pathogen has infectiousness before symptom onset, control of outbreaks using contact tracing and isolation is more challenging.

Added value of this studyThis study uses a mathematical model to assess the feasibility of contact tracing and case isolation to control outbreaks of 2019-nCov, a newly emerged pathogen. We used disease transmission characteristics specific to the pathogen and therefore give the best available evidence if contact tracing and isolation can achieve control of outbreaks.

Implications of all the available evidenceContact tracing and isolation may not contain outbreaks of 2019-nCoV unless very high levels of contact tracing are achieved. Even in this case, if there is asymptomatic transmission, or a high fraction of transmission before onset of symptoms, this strategy may not achieve control within three months.",public and global health,fuzzy,100,100
medRxiv,10.1101/2020.01.31.20019265,2020-02-02,https://medrxiv.org/cgi/content/short/2020.01.31.20019265,Effectiveness of airport screening at detecting travellers infected with 2019-nCoV,Billy Quilty; Sam Clifford; Stefan Flasche; Rosalind M Eggo,London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine; London School of Hygiene and Tropical Medicine,"As the number of novel coronavirus cases grows both inside and outside of China, public health authorities require evidence on the effectiveness of control measures such as thermal screening of arrivals at airports. We evaluated the effectiveness of exit and entry screening for 2019-nCoV infection. In our baseline scenario, we estimated that 46.5% (95%CI: 35.9 to 57.7) of infected travellers would not be detected, depending on the incubation period, sensitivity of exit and entry screening, and the proportion of cases which are asymptomatic. Airport screening is unlikely to detect a sufficient proportion of 2019-nCoV infected travellers to avoid entry of infected travellers. We developed an online tool so that results can be updated as new information becomes available.",epidemiology,fuzzy,100,100
medRxiv,10.1101/2020.01.31.20019901,2020-02-02,https://medrxiv.org/cgi/content/short/2020.01.31.20019901,Early dynamics of transmission and control of 2019-nCoV: a mathematical modelling study,Adam J Kucharski; Timothy W Russell; Charlie Diamond; Yang Liu; CMMID nCoV working group; John Edmunds; Sebastian Funk; Rosalind M Eggo,London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine,"BackgroundAn outbreak of the novel coronavirus SARS-CoV-2 has led to 46,997 confirmed cases as of 13th February 2020. Understanding the early transmission dynamics of the infection and evaluating the effectiveness of control measures is crucial for assessing the potential for sustained transmission to occur in new areas.

MethodsWe combined a stochastic transmission model with data on cases of novel coronavirus disease (COVID-19) in Wuhan and international cases that originated in Wuhan to estimate how transmission had varied over time during January and February 2020. Based on these estimates, we then calculated the probability that newly introduced cases might generate outbreaks in other areas.

FindingsWe estimated that the median daily reproduction number, Rt, declined from 2.35 (95% CI: 1.15-4.77) one week before travel restrictions were introduced on 23rd January to 1.05 (95% CI: 0.413-2.39) one week after. Based on our estimates of Rt,we calculated that in locations with similar transmission potential as Wuhan in early January, once there are at least four independently introduced cases, there is a more than 50% chance the infection will establish within that population.

InterpretationOur results show that COVID-19 transmission likely declined in Wuhan during late January 2020, coinciding with the introduction of control measures. As more cases arrive in international locations with similar transmission potential to Wuhan pre-control, it is likely many chains of transmission will fail to establish initially, but may still cause new outbreaks eventually.

FundingWellcome Trust (206250/Z/17/Z, 210758/Z/18/Z), HDR UK (MR/S003975/1), Gates Foundation (INV-003174), NIHR (16/137/109)",infectious diseases,fuzzy,100,100
